<SEC-DOCUMENT>0000939767-22-000097.txt : 20220809
<SEC-HEADER>0000939767-22-000097.hdr.sgml : 20220809
<ACCEPTANCE-DATETIME>20220809162437
ACCESSION NUMBER:		0000939767-22-000097
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20220701
FILED AS OF DATE:		20220809
DATE AS OF CHANGE:		20220809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		221148709

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel-20220701.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:d6428e21-a936-4304-bbd0-42287b684d9f,g:54041ba7-ffad-43a6-84f8-cd8da74de046,d:c81896f1bbec43d4802dcc1c5fa2e0e2--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:exel="http://www.exelixis.com/20220701" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20220701</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80L2ZyYWc6MGY1MGU1ZTYwMWZiNGY1OWEzY2M4NmU0MjIwM2U4MjQvdGFibGU6ZjkwNjE0ZjVmYzc1NGZjNmIwZjY1NjhjMjcwZmNiODEvdGFibGVyYW5nZTpmOTA2MTRmNWZjNzU0ZmM2YjBmNjU2OGMyNzBmY2I4MV8yLTEtMS0xLTY2MzI2_8eb0dc8c-fd0e-48ca-a02b-cb08a40fb6d8">false</ix:nonNumeric><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80L2ZyYWc6MGY1MGU1ZTYwMWZiNGY1OWEzY2M4NmU0MjIwM2U4MjQvdGFibGU6ZjkwNjE0ZjVmYzc1NGZjNmIwZjY1NjhjMjcwZmNiODEvdGFibGVyYW5nZTpmOTA2MTRmNWZjNzU0ZmM2YjBmNjU2OGMyNzBmY2I4MV80LTEtMS0xLTY2MzI2_96016921-591c-4603-a04e-267d82deb525">2022</ix:nonNumeric><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80L2ZyYWc6MGY1MGU1ZTYwMWZiNGY1OWEzY2M4NmU0MjIwM2U4MjQvdGFibGU6ZjkwNjE0ZjVmYzc1NGZjNmIwZjY1NjhjMjcwZmNiODEvdGFibGVyYW5nZTpmOTA2MTRmNWZjNzU0ZmM2YjBmNjU2OGMyNzBmY2I4MV81LTEtMS0xLTY2MzI2_652b8559-a1ca-4d2c-9476-0c878f385abb">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80L2ZyYWc6MGY1MGU1ZTYwMWZiNGY1OWEzY2M4NmU0MjIwM2U4MjQvdGFibGU6ZjkwNjE0ZjVmYzc1NGZjNmIwZjY1NjhjMjcwZmNiODEvdGFibGVyYW5nZTpmOTA2MTRmNWZjNzU0ZmM2YjBmNjU2OGMyNzBmY2I4MV82LTEtMS0xLTY2MzI2_0e3a1461-a5c3-480a-937f-a7edb848d243">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80L2ZyYWc6MGY1MGU1ZTYwMWZiNGY1OWEzY2M4NmU0MjIwM2U4MjQvdGFibGU6ZjkwNjE0ZjVmYzc1NGZjNmIwZjY1NjhjMjcwZmNiODEvdGFibGVyYW5nZTpmOTA2MTRmNWZjNzU0ZmM2YjBmNjU2OGMyNzBmY2I4MV83LTEtMS0xLTY2MzI2_2494f9d6-6dca-45b8-99d2-7153a5334f9d">December 31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20220701.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ba4d0f4b0914516a979aaca1c0115f4_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ibd88d103ffe54da794c385cd93721ee7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5f0966f9eca84459ae2dd8ebc3309047_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b9e8d3facdf4864bb7c81214e9ad6f8_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if42cf2e0fa214b5c803a30524005d09a_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i783842d281c14d18a5ab8e977fb76f4a_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ece728364b4cc48c40e024bb487e25_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51494a71ce844aa2aaa75d35e9949848_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i635c229f1f07418d854dc726f5340cb4_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i769896e9287e4183bddc0e89f0dcc56b_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i706119ef90c140f89a64ca72f784f4b0_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69fd855fbc7048eabfa55142b96cda52_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f1dadf8806a47148f339ef9a9717604_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c8dae096ca44ee58f98136af8f519b9_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbbf35553e864a47b12a2d1fd928f98e_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica2525aa6c6841f982350ebfeb7ae4e9_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13f12b5dde5b4fdda7863e2006ddc6da_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabda242f1aa040f1aa8b97a4539b80c1_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31a5dab809bf451896a0f1f8a5a72ca2_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd09d7b967674984a4b4c0e1ecf5c20a_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i083ff5f50112432b974e39cee8bbb3e9_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51ed73dd842a42c787ae6af93fa1f0ef_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61b5acd047f54e5e890f1c61b9bb0bf2_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5e9422226204c1caad9468840b30369_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a7035844a96447d9ece7ea6b0cc2ed8_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e3a8211d9414334ba9e7d2ba62bc3c5_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fb93329607a4f4485821bd6d3b218d4_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i178b1c70ce884adaa05d4e23647aa97f_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic65133c237764501911f938ce005dd62_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i074c0d5d00e94dcd86712e0f3b167c31_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5638bf7f18a54b5eb3f4e9899ee414b8_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c4a65a50aa94cbcaa556bdea637aae0_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc467238ed7e44f8908d4c4197d02952_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id29da21d87ad4d1cbc07082f36dae1db_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33204058d2884277a534f3fe8b2d05c6_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72e65c25cad842b48b3a06036a8dfb11_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ad2cb90ebc241bb8b2f4469a70980a7_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if60b5dd0182e46dca654df547b7153f4_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c00d41f727490497fb324365d70cdf_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cc4df1f70524cf0b42d834be77810ec_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide7e987c180a418585f377e54ea41af1_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d2914ca5204497ab3d3c3eaea8818d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1249b090f0b64f6ba2e504df49cb49cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fbe83b4d13441469af603970b1bfad2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11fbb1f45c2f4280981d038a82ed2190_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb6414045fef4baaab29a829c64218c3_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9ee23437eab47868678f63cbd6ef147_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f4f857a9fc488b86c7e00d7d13b344_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id762b4c844464d9dbd1a5232a5556a16_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7915746f5547460f9caa2e4177cfce05_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e25b57e2a0b4d829b12b77168539aa7_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf90c32a09a4497996f31bce3e8b5d1e_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i646dda3b25974251a53973741e46976c_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95504af18ae84a95a6f5672e2c0962ea_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1ebf17aa8654c809fdc3b7fdf977b94_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i920841e629d44fa39ab93aed91f7add3_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie673862a0ee14b879e59030e6dfa3b2b_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e90a92edb8647439746c5535fbdf9b9_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fa8420126014bf088bb615340e7af05_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>exel:product</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>exel:country</xbrli:measure></xbrli:unit><xbrli:context id="ic8c53c5143b04fa790d554162bdceec7_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exel:segment</xbrli:measure></xbrli:unit><xbrli:context id="ia26f483bdcbb41acbef2e9cd23df368f_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9620d75cbfe442cbdfb2e49f10029ad_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib68714772b36481f8c505e3eef1639c8_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08b267d864364d6ab0b3c49456d3b22b_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25a529c6b1f84c14b8c06c30376f65f6_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0e39c06180045fb8a7047acd09b09d5_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4609cc64ebd4171954966a86b6926ef_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i077dff06f4904d1990415f13a7b882a4_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d0a7ab1f65b4bc786a98d7742cdc82f_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37e0da3271234f2bae53c14f82b39321_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92fba14ea211474d82d9667f1ee43b1c_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i453607a6d2c241139ae0154655e12057_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89f773b17954459496fdb8e6635e500c_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i125702b0bbdb49ea96eac26fc326c134_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia565cbddd5a042f7b2339b3e701e9826_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6183c887d9e429a96461d489c65f056_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f74d8c31ae74b7fa6e4e39449d3df62_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9f47a8d0e664d6d84d3873e23fc60ad_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59b3ee9c868431aaa28932ed170565e_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i335341eb633f4434b8610f4f0d41be82_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id557498866464ef2bdf02ccdb8ede387_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie61a701acae34a7abd58a8f0dc4a3bbd_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie70c7ffb0e364a418f44f5b2fb7046a3_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00cc9c53a3754125afaca64318f35370_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fbfda11dc6c495abc4054a2e60213b2_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9004549ad6404156b209d07af26d7701_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c826af902764b62b9b01c219b888602_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6dde7ba3d13446293bb96e14dad26d4_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i107d673b016341dba6ddac20be0bf0fa_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e8e064972ed4cd69de87474a9c08e9a_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e893865b1a401fa0a584689c74906c_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d38bdc277d847c1bff9aea646f7b5d2_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie870ca4583284e068d8931189e43799a_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14ebf4acc76c40a8862a0cd9494ba17d_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i664afc43ce6141e7926e690257545766_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56c71bd1b9a544559774ad6cf16b1bc8_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79b6e39380ee492b9465c8a189dc79c4_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d728a2065f34c5f99164244a2469b05_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3955701b6f504b6c9492fed7e52d6cac_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8236363288634352a070bfdeae4ada52_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf483295e3441dfb06c39992af1d0cc_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CardinalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57596bbb198e467e913bd95f788460dc_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CardinalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bde2f537a354fcca14f821547b896d9_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc1e3c9b038f4adbb0f8ca47a926170a_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21feba329f3c47ba847cdba72f05f74a_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c8f2e6e66e0483e9df068c8c67f6edd_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09963410ea564c02b8ff6283d62b4527_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e34c2a69d6c44dd87763d280f6add0f_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb5c9264424540c9a4f238323ac0939f_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16714420b2fb49839858d28e6d5059ae_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0b5c39cb3324983afed5da2408dadd7_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47e812ece3e94486a2fe21cbd2277bb5_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i188d6447088e4f92a8f70243be252647_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e97a0d79c07480eb88736adeb90ea7b_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54050f41270d4c0994179a0b71bcbd09_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeea8eb188124f60a0aaeaa7d0940557_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69844ba478ba4fe381bf568853c31297_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i054896b94915439693f85afea696414b_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb0803dcbf5b4e67ad983af158cc6a71_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c3101bd9ba54dbca9144e467e80187f_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaa34646405c478e99b9fd71f2184c6a_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35af551acc24804b0071e3db5e6fe35_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if53bb4fda56c4d03bcefd670f7e34159_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied4e111ae3b74e388273fc644813dcbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i840ea9693a1241dba5f3c957a1971f4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168b07bb58fb45fea0c1251110528099_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7e6ba1cc1ac40ba8c5827e2046e2bd1_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ef9620b8e045d1ad550beff5449fb3_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife8f6fa225be4cf0b820fdededde5d76_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d94301a72254e9d9c581087dcee3084_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a01e54ece8642d5b3a8cd53ce306b40_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i772576eea90d4bb0929cdf808c536289_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exel:TakedaAndIspenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d2515b3d980437d88f874ad96264c8f_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfeb2faa92124a56beca5879006c456c_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a867ee6b32d4d0ca8d6da06a0baf4f0_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02072ae37a364e828c67a1f3675a3358_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d3b05ed939f4eea80b46d18a26cadad_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e7633a25d674d1d9065925fd26afcdf_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8679d3445ee744d6b8bd2814877f2e65_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib163ec7f845e44e9af8e12e633ddeb1e_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id082ca3812d9497f9a5419f7e2935ef1_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib008fa7a2c3348058b33ada2c3c90db2_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e31b2ad1f74418b3fc3f615f610c44_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ba0f6408f78479fa48647723afcaff3_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab7278b18228461aa447d7af1ab75997_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica98cb95722d43bc90dd8fdac8a16248_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5e7e3b485b4ccba1783e0a9e98bce2_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0faaa279485d47858ff462a4fe31d8cb_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1dc5dede6944878bb37ad9f5b90202c_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id28f186b12114729ad0bcf462687594b_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb3c2f628159430fa2b4ba939626da68_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c34c70519cf4ccdb9cf2f1f898c0f47_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib934a263672b49e2b398d9af12ca3f18_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied5cfd9d83994869a3ed269eca638c4a_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id21078b478324339b815339fdc2f5d2a_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bf36077e14546d49a6c6d7f64c0e7fa_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6b3af1cf525438ea1fdab7f2ae1a4b5_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d122b6fe357426c8ad3468c325f4936_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37d0046d01764a6a84fff26e8dc7ad8e_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa76717dc58d47e987e00cef2f0b1605_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d6438a867804b3690c45471a4365f52_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i839cb707d2d1469585661ba26e60dba8_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i395367a2b6f840398cc68008eec67422_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9403b468905b44ddb12619327a4d1331_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0536dbf918041b2a030788539bad217_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ab318d80ac145cfa0dd2bc25b9ffc19_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7d942e3ddd54d17abcf3f8dd59c4d5f_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b5ed8e63d724ab1b37ae2306c7d0aa7_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithBioInventOptionAndLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc05a0f9c9a41eb9f99aed54fd26749_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1989bb1580374884bd42c103f79e3cb9_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3c8d749d7584b6199a2924e8a1e9a41_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03769550f9144c9984b85e0c5923a535_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if453d9270ba64e94a9244e7992459ee8_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1699183c5c004e00bb9e1dd4a3f6355d_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0451da3ec05541229c7b26c8a138441a_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0503cc8f8c754670b0adbd270a4852eb_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieec985d2c22946468e2db7ee7e8fdd66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie325f3ade8d44aa1a927d9ea4b117375_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a744931712846de898f2a9ba07534f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f56488c0f264c679e4506474188a292_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9786b6a841764a17b8436d495f0e5d65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib217aade91424cacbff6d49127cff87f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i534afc4a026f4e9aafc43cba5359abc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>exel:investment</xbrli:measure></xbrli:unit><xbrli:context id="i3c3df4ca36254ec4a53aa642de2052fd_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b987f3b567145a39c76a99080d73be8_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie98d96a4511c47b9976557bf8ed9d3ea_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56e65916b15b411381657ad58dd0a7e7_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4001c4a298441f39a683b1fdcf12c32_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7bf40d8ebf840d0975f8df43474ebcf_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i182702258c9044e19db73717afe1ba2e_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib08fb62625a144fb8b5d4cbf945345e7_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3322c81a75204e04b49bcd282f9082ad_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e2c9be6723b4ecc857b1318d9a40a7c_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd3ad6acbfea40668adabc0d0ae06c0b_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bec5ac658b94646b56ba00d21fd274f_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fa5514df76b4a5289b9dab0ab958760_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e391b43e0914915bee3cd7d5073d918_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fa7e06004bf493583d8ea1de5a444ae_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5552036575a7423281fcbd4cb49bcea7_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80c87c83caf14e26b70ae4c672e30e2b_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f5ca710be364f0da48207b91de352a3_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51a622ef9643442a9a59c6d3cc3663f1_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i619648b30df241fbb45ec26d4592f421_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8287e312ca114e8e93490b2d88392315_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a5daf776b964c24b6e400bd55663894_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec6206d802e34860b2b50b24991812bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i129784cda6eb4132aed1c7cf8bb7db12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76c0e8d11fc14158ad314c1ac66746ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd4a3e3e3a74aebb9eec590702a773b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46639be8a28240e1a86dea7f936b0a6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib916c6956341489bba5b28db02a30837_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d149a9eefd4440a22b0d5b7e870327_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide4306bdd2ea4e91bb97b8be2b61b651_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba54d40c2bc64ef4bdb52d572de09fa5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa0b629b04984a1eac7d47c831d167f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefecc78bc743406c8b43fad567aad8d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0696d13063a422b94ceaf169c4d5572_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb1fcad1a5f14b1ead0a41c83a2d65ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf6cf4c54fd4471291a5a225c2026764_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica317fbf66054d0d9b5755dec32fb97d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc6b02b5522f4c62b5630f7652995697_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f38a828dd704e21b97feddadcce5b63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1aba76e7e4d6469a8ced5f3ac2c0957d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb5ac02de86e497ca09eaa96e8d84aef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i419d7d0e02084f7482be6ce902493727_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38408adaba6d4341adb12d55daf8b48e_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="forward_contract"><xbrli:measure>exel:forward_contract</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i1fe3c38bcffe44d0aa127c4b877c1d71_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e8d1c4ed84a49b6b1de444247607719_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i214511920f1a4c718201e79910fec792_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f26547ff011485ea499fc7321085b2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i401482ee2371429dbb52062b06e78cf4_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62d04e4f28a941478b345f54d2cb7e3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c8787ab89e4ea8aa9bcbba33a74fb7_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeeca34bdde8405b8c686e83477e4f42_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5abd3b9738c4a48916938c34311867c_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1b0173c487e4563b2a6777d58f46013_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a7e658a6084f529242281c7bcea519_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if900f76b28c94ec78c9965e91ee8f0b6_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadffddf5c5c64493b3fa047c4ed4f265_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2bf0f43bb254fcb95413ba3a8c9c810_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cb92aaea0154533ae9a350686b93d27_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia82d6aff031447fab7f99cce91ae6db8_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6524855f344408b90f428815d3ed343_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57d61f3143c347f0bff85037bb757393_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826763d3077e4ad086c22a3ff19ad208_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b7e89015a804623990353f662f9a155_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i288c55ead7e941548dc6ee322e4a325c_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecb5bc2ce4804674ab1ceb6b7109a08b_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ed4735334c844459ed18dbd61c6c4f6_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ccdd8a412d41abbfac65334e30283c_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2768e53f82974b9da558e84e64b5d621_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0034b83355444c65ad6e185cc7ccd058_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd650bcd87a349d786cbed15f8f31bd4_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2669fd364d81445786658c8dc9193396_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i799167078ab64d6d8c88a06ba5578ea4_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847152b60ebc49c7a64cb3e47896adc8_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18d5c27ec4b94608b6a47b96f6900355_D20220525-20220525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-25</xbrli:startDate><xbrli:endDate>2022-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i140a87f9739042bb9715f01f144db770_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b79f2ddeb834dada1c18e98a6a85c1b_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79b56428e2684493a912b70ba5c56f75_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73a59494ab85495e95f7a35120b582a9_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie20c1bc9723141ceb9391ded30c724c2_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i243680f68f274834b859ce0d17c3e93f_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5128decae384f698a9ab00463cbd990_D20220402-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d22c0ab1ce2424b9a59efba14386e0e_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b873c8ba6a4c4f960fbb64be80b871_D20220101-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i985d03e626eb4a299ec7d942d6a3e0fc_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88887d64754a4f1ebb805302f47aa477_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i69d48eac98d64f5887fc5c912672b993_D20220402-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeb8ed4d7cb445b08584aace5ff56694_I20220415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95b2c08d83814c348966a2366c0de8a7_D20220415-20220415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-15</xbrli:startDate><xbrli:endDate>2022-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8db2258b7ae45a995b0f68fabdcd327_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:LeaseExpansionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia312fa6ca0df4ee1be126a7eea55f36f_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2c7ef7fab7345ebadb2ed3327f9af7d_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i188a4a13c6094e2e882585005f7bcf76_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>exel:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="ia392f18685aa4066aa68046de26c42a7_D20220729-20220729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-29</xbrli:startDate><xbrli:endDate>2022-07-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:199.50pt"><tr><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YmRhYzY1ZTZmYWJmNDFkYmJhMzYxNWY3YmM3OGNlOGMvdGFibGVyYW5nZTpiZGFjNjVlNmZhYmY0MWRiYmEzNjE1ZjdiYzc4Y2U4Y18wLTEtMS0xLTY2MzI2_83750b95-878c-4819-b759-2e3c07e99415">10-Q</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YTVhNTJhNzZiMjQzNGFmMmE4MjUyMTE0Y2UzNTk1ODIvdGFibGVyYW5nZTphNWE1MmE3NmIyNDM0YWYyYTgyNTIxMTRjZTM1OTU4Ml8wLTAtMS0xLTY2MzI2_56a7d330-4933-4a40-910d-8c0a3af97826">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the quarterly period ended <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xMTU_b5dadca6-dc37-4e6c-9d3c-dc75fd96f902">July 1, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6ZGQzOTkxMmZiODNjNDliYTlkMjNmMjQ2NzQ1MzlkNzIvdGFibGVyYW5nZTpkZDM5OTEyZmI4M2M0OWJhOWQyM2YyNDY3NDUzOWQ3Ml8wLTAtMS0xLTY2MzI2_39456fb9-3f01-424e-b08d-870ea8952466">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODc1_69e8a07b-4b2c-4f95-bf94-4e534894cf8e">000-30235</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-top:9pt;text-align:center"><img src="exel-20220701_g1.jpg" alt="exel-20220701_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:188px"/></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6MTA4MWQ1NmFhMWI2NGJjODk4ODQ5OTI2M2E4MDk2ZWEvdGFibGVyYW5nZToxMDgxZDU2YWExYjY0YmM4OTg4NDk5MjYzYTgwOTZlYV8xLTAtMS0xLTY2MzI2_0107aa0a-3cd7-4309-b807-e9a0b5178e5d">EXELIXIS, INC.</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.359%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6NGI0NjI4Y2E2NTlhNGQ3OWJiMDYxNjU0ZTM4YWYxZGUvdGFibGVyYW5nZTo0YjQ2MjhjYTY1OWE0ZDc5YmIwNjE2NTRlMzhhZjFkZV8wLTAtMS0xLTY2MzI2_2fa01dba-8316-4737-8966-98c5b00196d6">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6NGI0NjI4Y2E2NTlhNGQ3OWJiMDYxNjU0ZTM4YWYxZGUvdGFibGVyYW5nZTo0YjQ2MjhjYTY1OWE0ZDc5YmIwNjE2NTRlMzhhZjFkZV8wLTItMS0xLTY2MzI2_2b3a904e-38df-4c4c-b1ba-73a0ff898b84">04-3257395</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODc4_948315e4-f2b3-4faf-a4fd-57fef2f25de9">1851 Harbor Bay Parkway</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODc2_3930f64e-d3ab-4689-8794-839d25e3cc54">Alameda,</ix:nonNumeric> <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODc5_cb358fd9-3b82-42ab-b458-e6dd1dc0669d">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODcy_72915540-7040-4ba5-af3b-e01432f688d3">94502</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODgw_06b2b55b-57c7-49d3-88c0-c7a5d43fe0fc">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODgx_aab18f63-c511-4c9a-9c21-d0878959bcc8">837-7000</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YzM1ODZlNTJlMTdhNDgxYThiNTAxMDc4MzYxYjZjMTkvdGFibGVyYW5nZTpjMzU4NmU1MmUxN2E0ODFhOGI1MDEwNzgzNjFiNmMxOV8xLTAtMS0xLTY2MzI2_681a8400-8570-448f-86e5-d624a0d39e9b">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YzM1ODZlNTJlMTdhNDgxYThiNTAxMDc4MzYxYjZjMTkvdGFibGVyYW5nZTpjMzU4NmU1MmUxN2E0ODFhOGI1MDEwNzgzNjFiNmMxOV8xLTEtMS0xLTY2MzI2_d8bbb195-2567-48f5-ae2c-aae3586bd080">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YzM1ODZlNTJlMTdhNDgxYThiNTAxMDc4MzYxYjZjMTkvdGFibGVyYW5nZTpjMzU4NmU1MmUxN2E0ODFhOGI1MDEwNzgzNjFiNmMxOV8xLTItMS0xLTY2MzI2_a82749bd-37e0-409e-93db-e00c4b0c2efa">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160; &#160;<ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODcz_1a00782b-3a81-4587-9089-c1d50fb0b248">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODc3_2b66e962-1c86-4a74-8d80-90770d8e1bb0">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.208%"><tr><td style="width:1.0%"></td><td style="width:31.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.169%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YjAwMjFjZjNiNjlhNDRkYjg5ZDgyNzUxMDI5ODFhNTkvdGFibGVyYW5nZTpiMDAyMWNmM2I2OWE0NGRiODlkODI3NTEwMjk4MWE1OV8wLTAtMS0xLTY2MzI2_6b8ec4bb-7ea0-4449-a780-91a2ceacd8f3">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YjAwMjFjZjNiNjlhNDRkYjg5ZDgyNzUxMDI5ODFhNTkvdGFibGVyYW5nZTpiMDAyMWNmM2I2OWE0NGRiODlkODI3NTEwMjk4MWE1OV8xLTQtMS0xLTY2MzI2_cc72b796-822f-4aca-b374-fc199be3c7c4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YjAwMjFjZjNiNjlhNDRkYjg5ZDgyNzUxMDI5ODFhNTkvdGFibGVyYW5nZTpiMDAyMWNmM2I2OWE0NGRiODlkODI3NTEwMjk4MWE1OV8yLTQtMS0xLTY2MzI2_1e2400f5-9d38-4c64-b8e7-702526f28177">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act.    </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl83MTQ2ODI1NTgyNDc4_8b5a525f-671f-4087-9961-18fee34293ae">&#253;</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of August 1, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i0ba4d0f4b0914516a979aaca1c0115f4_I20220801" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8yMTk5MDIzMjU3NDU3_c44a1b07-a249-46cd-81df-16b1720838ba">321,831,784</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div></div></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_10">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_16">Condensed Consolidated Balance Sheets (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_19">Condensed Consolidated Statements of Income (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_22">Condensed Consolidated Statements of Comprehensive Income</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_22"> (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_25">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_28">Condensed Consolidated Statements of Cash Flows (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_31">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_67">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_82">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_82">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_85">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_85">36</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_88">PART II - OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_91">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_91">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_94">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_94">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_97">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_97">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_100">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_100">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_103">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_103">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_106">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_106">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_109">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_109">58</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_112">SIGNATURES</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_13"></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item 1. Financial Statements</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_16"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNy0xLTEtMS02NjMyNg_19bfcb81-142f-4f23-b2a9-adf0e0d88347">627,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNy0zLTEtMS02NjMyNg_8865e94e-016e-41f6-aa14-47afad62aab3">647,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfOC0xLTEtMS02NjMyNg_ca7c90be-6623-4a60-ac0f-b31c8dfa3f9d">907,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfOC0zLTEtMS02NjMyNg_a77877d6-aac1-4f3e-8747-3e79d01a6a74">819,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfOS0xLTEtMS02NjMyNg_5b3ad5c8-04bc-4ea8-8e5d-24a0eeff4879">235,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfOS0zLTEtMS02NjMyNg_ef29fbd6-5fdf-406c-8d96-9ec88ac35420">282,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTAtMS0xLTEtNjYzMjY_63582be7-24fb-48b4-9951-01cb4a73c04f">33,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTAtMy0xLTEtNjYzMjY_4cafbc4c-7542-4ce5-a542-bceb67daad12">27,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTItMS0xLTEtNjYzMjY_3b56f311-8089-4014-8230-ec62f603d7b3">48,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTItMy0xLTEtNjYzMjY_d6c56dfd-27c5-42ee-8fe2-b3e502004d7b">57,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTMtMS0xLTEtNjYzMjY_3fac1066-9d79-447b-b0e3-d1f9d399d65f">1,851,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTMtMy0xLTEtNjYzMjY_5823a28a-faa6-44f1-92b8-8838f8611918">1,834,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTQtMS0xLTEtNjYzMjY_84cdf4fd-aeba-4533-ad2a-92bb0acf9ac6">463,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTQtMy0xLTEtNjYzMjY_0af4fc5d-7b76-45f9-b01e-98474395d6d3">371,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTUtMS0xLTEtNjYzMjY_fdf95ff6-8cc5-4b94-b5e6-4a4d718d5a9f">108,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTUtMy0xLTEtNjYzMjY_633ea256-675d-463c-9b8d-fb794b7d9dd3">104,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTYtMS0xLTEtNjYzMjY_8d61425d-c61d-4d37-89b2-4ab02339bd2c">113,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTYtMy0xLTEtNjYzMjY_1ad31182-23d1-47d5-acf3-0928e843311a">111,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTctMS0xLTEtNjYzMjY_a401a7bd-a7e6-4aa4-bdfb-f2c6fd1f9396">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTctMy0xLTEtNjYzMjY_3fa40114-aa80-4392-b6ec-c7191fd90f63">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTgtMS0xLTEtNjYzMjY_37abef52-8a5f-4d9c-91a0-6011559dd4d9">279,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTgtMy0xLTEtNjYzMjY_59b80a61-8821-4821-b8a5-d9a8989e247c">131,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTktMS0xLTEtNjYzMjY_22877636-99c8-4576-9af8-b50a3810ecca">2,881,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTktMy0xLTEtNjYzMjY_479ca2fe-8c48-49ee-bf54-1183f68ba831">2,616,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjItMS0xLTEtNjYzMjY_0379eb38-8ad9-4274-baef-91c86a1aeb49">19,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjItMy0xLTEtNjYzMjY_8b2e30ef-20ae-4fd0-8bf6-1c8a5b607a14">24,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjMtMS0xLTEtNjYzMjY_c7a41599-45e7-454f-9521-6a04e95e8b98">61,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjMtMy0xLTEtNjYzMjY_0020f45f-551b-4573-8417-089ca3102530">61,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="exel:AccruedClinicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjQtMS0xLTEtNjYzMjY_c5b66671-9f80-49fd-9600-aa26ab8af7a2">76,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="exel:AccruedClinicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjQtMy0xLTEtNjYzMjY_4698906a-8b50-4692-9443-24c0a0061682">77,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates and fees due to customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjUtMS0xLTEtNjYzMjY_739a9f7f-c923-40d8-9b71-36aaf7d495d0">43,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjUtMy0xLTEtNjYzMjY_4ea1bd1e-a0f9-43ac-8d2f-8d1d12e68dec">33,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="exel:AccruedCollaborationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjYtMS0xLTEtNjYzMjY_8b6c71aa-67dc-43cf-874a-b5b0c8cd31d8">29,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="exel:AccruedCollaborationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjYtMy0xLTEtNjYzMjY_af68a339-b80c-41e3-bf8f-0c2cda7acfaa">86,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjgtMS0xLTEtNjYzMjY_e5c364c4-ad65-4d16-8751-90b1e22c9151">72,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjgtMy0xLTEtNjYzMjY_5a39fda2-2952-41d1-94b5-498731188b3f">53,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjktMS0xLTEtNjYzMjY_c45fc55c-00b8-4fc8-960f-e973130a68a0">304,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjktMy0xLTEtNjYzMjY_da0ecc89-aff4-485e-a1cc-d83f82f6f6d9">337,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzAtMS0xLTEtNjYzMjY_16b83b1e-cca4-4127-b3d4-4dbe26406779">7,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzAtMy0xLTEtNjYzMjY_4b1701ee-a717-40c4-bfae-0a9be665b4f0">8,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzEtMS0xLTEtNjYzMjY_a7cbcda4-9c73-41b3-ac80-6d2686fcb665">161,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzEtMy0xLTEtNjYzMjY_3772a0fe-3a89-46ae-8358-228a3289bc8e">51,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzItMS0xLTEtNjYzMjY_b64befe4-a43f-4be1-8fae-7591b02f851a">17,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzItMy0xLTEtNjYzMjY_e19411dc-01ef-474b-a123-5265ccdf9b6c">8,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzMtMS0xLTEtNjYzMjY_240b6d97-8fe8-400b-853a-9569a5ca7c4d">490,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzMtMy0xLTEtNjYzMjY_d7bc0cd8-f3cc-444d-a687-f2cdebd0ef4c">405,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzQtMS0xLTEtNjYzMjY_c8431c7a-841a-49d9-bc94-ed296833cd5e"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzQtMy0xLTEtNjYzMjY_7f3ddbb8-d7f1-4125-b9e8-2398f5c6f6dc"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3MWZkNjZlNmNkNmY0ZGMxOTkwMjRmZmRhNWQ0YWJkNl8yMQ_37a2a733-94ea-4a73-9ca9-800f0dd91840"><ix:nonFraction unitRef="usdPerShare" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3MWZkNjZlNmNkNmY0ZGMxOTkwMjRmZmRhNWQ0YWJkNl8yMQ_f8c853bd-4344-4ebb-92c9-3b67cd4b1996">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3MWZkNjZlNmNkNmY0ZGMxOTkwMjRmZmRhNWQ0YWJkNl8zNQ_82c07820-3690-4a1b-8c96-45a14f5ecee1"><ix:nonFraction unitRef="shares" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3MWZkNjZlNmNkNmY0ZGMxOTkwMjRmZmRhNWQ0YWJkNl8zNQ_a7e2cc08-e078-460e-95d3-923ea93945e9">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3MWZkNjZlNmNkNmY0ZGMxOTkwMjRmZmRhNWQ0YWJkNl82MA_4848bfba-37e3-48d0-b688-b97312ca408d"><ix:nonFraction unitRef="shares" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3MWZkNjZlNmNkNmY0ZGMxOTkwMjRmZmRhNWQ0YWJkNl82MA_81df911c-052f-4e67-a7ef-7705946eff98">no</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMS0xLTEtNjYzMjY_d24e5b9c-1e3c-4c33-8a65-476e8163380f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMy0xLTEtNjYzMjY_490d9a01-aa52-488c-8325-f7e6a9feb57e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV8xOA_66d2638f-aff9-4570-afc2-c71c4ae05e4b"><ix:nonFraction unitRef="usdPerShare" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV8xOA_7013e3b7-aedc-42b2-88c1-2c3164f56f7c">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV8zMg_689d981f-63f0-497f-a786-c9aa601a09a6"><ix:nonFraction unitRef="shares" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV8zMg_6bbdee3d-9b06-4f72-a018-bff2a180d1c4">400,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV83OA_25bd77ba-d025-4561-9aa7-d64699ade10a"><ix:nonFraction unitRef="shares" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV83OA_2a3faa8b-f747-4fe6-bd5b-82e91ac1463b">321,800</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV84NQ_8b04eddb-66c1-4f05-9d9d-cd5cf92d3795"><ix:nonFraction unitRef="shares" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV84NQ_9386c90a-1562-4d01-a535-8d03d009b4f4">318,842</ix:nonFraction></ix:nonFraction> at June&#160;30, 2022, and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMS0xLTEtNjYzMjY_2ffa19fd-24d5-4a01-a215-01c9387147c1">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMy0xLTEtNjYzMjY_163d7669-3391-4fc4-a5a9-de5621f160c5">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzgtMS0xLTEtNjYzMjY_e3c2975c-e04b-45ff-b368-d80119c07bfe">2,477,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzgtMy0xLTEtNjYzMjY_e59c7add-a34b-455c-b03b-fdacfbe9b5d5">2,427,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzktMS0xLTEtNjYzMjY_f5bc62b0-9033-44cb-b6a9-ebfbe08e9db4">8,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzktMy0xLTEtNjYzMjY_145c99ed-738d-439c-a407-8ba3ac5b28d5">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNDAtMS0xLTEtNjYzMjY_57d19b2f-c213-4d82-8eca-92ffa8986733">77,262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNDAtMy0xLTEtNjYzMjY_21b69d4c-8d60-491c-be77-9e51f190e8b3">216,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNDEtMS0xLTEtNjYzMjY_76bd214d-bc00-43b9-83e6-8f7fe6174243">2,391,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNDEtMy0xLTEtNjYzMjY_d3d219bf-b445-4fda-a67c-5c061b10d557">2,210,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNDItMS0xLTEtNjYzMjY_da1bb0bb-e8cc-4dd9-ab1a-1563c80524cf">2,881,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNDItMy0xLTEtNjYzMjY_eea580c9-86d2-4210-8d60-bf0badd83815">2,616,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.230%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0966f9eca84459ae2dd8ebc3309047_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMy0xLTEtMS02NjMyNg_ab99a420-fba9-4fb9-b4c5-43c4ce898b55">347,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b9e8d3facdf4864bb7c81214e9ad6f8_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMy0zLTEtMS02NjMyNg_89538a1b-c165-46bc-b3b8-db9bb89ef27f">284,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42cf2e0fa214b5c803a30524005d09a_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMy01LTEtMS02NjMyNg_f37a8b4c-4328-4619-b331-602115637778">657,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i783842d281c14d18a5ab8e977fb76f4a_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMy03LTEtMS02NjMyNg_d3a1c7bd-f9bd-48a0-b564-f635ff8d6317">511,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ece728364b4cc48c40e024bb487e25_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNC0xLTEtMS02NjMyNg_54e2d3c0-12aa-4703-9768-44920a6b1abc">57,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51494a71ce844aa2aaa75d35e9949848_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNC0zLTEtMS02NjMyNg_b172593c-1251-4021-a6ac-052c97a42d45">39,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i635c229f1f07418d854dc726f5340cb4_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNC01LTEtMS02NjMyNg_8ec419c0-c420-45c9-997f-98ae329aee81">89,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769896e9287e4183bddc0e89f0dcc56b_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNC03LTEtMS02NjMyNg_cd1fbac6-dfa0-4964-aafa-0862e7ce3a70">67,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706119ef90c140f89a64ca72f784f4b0_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNS0xLTEtMS02NjMyNg_0d131684-825e-422e-add0-90cf8eb290d3">14,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69fd855fbc7048eabfa55142b96cda52_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNS0zLTEtMS02NjMyNg_82c7fcbb-246f-448f-b440-aea632ead1e1">61,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f1dadf8806a47148f339ef9a9717604_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNS01LTEtMS02NjMyNg_6d7c376b-d861-4e49-b79a-baac2466d660">28,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8dae096ca44ee58f98136af8f519b9_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNS03LTEtMS02NjMyNg_6d636893-f6d5-43ed-b70b-659eb45a2c8f">76,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNi0xLTEtMS02NjMyNg_c80fcfbb-855a-44d8-86c4-b86d91d0f387">419,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNi0zLTEtMS02NjMyNg_a3763580-c3ac-451d-a801-3d9349e5ccd4">385,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNi01LTEtMS03NDQ0Ng_9501cafb-2c81-439b-a543-359dbfa2ff6f">775,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNi03LTEtMS03NDQ0Ng_8e27bc1f-ed90-4a74-a729-f63f24422384">655,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOC0xLTEtMS02NjMyNg_eaedb216-3c77-4fde-89d4-d170ca914352">13,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOC0zLTEtMS02NjMyNg_3bcdab5c-6944-44ae-8a13-ce749eb67bb5">14,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOC01LTEtMS02NjMyNg_0f02e9c0-6d89-4275-9b70-d80e59697bcf">26,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOC03LTEtMS02NjMyNg_dd8704d2-8195-426f-9acc-8945f2c57cc1">28,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOS0xLTEtMS02NjMyNg_117e7d14-31e0-4fde-849f-9cb4707b4b05">199,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOS0zLTEtMS02NjMyNg_f5da91e1-8adc-40c1-b0b4-d2049dc25b94">148,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOS01LTEtMS02NjMyNg_57af5610-ea89-4c2d-a2fc-6631e8f0d518">356,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOS03LTEtMS02NjMyNg_eeffebcd-94c4-4e28-bc8f-bb73304cb5eb">308,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTAtMS0xLTEtNjYzMjY_7e3d0b7c-f501-40bc-82f9-f058404aa575">122,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTAtMy0xLTEtNjYzMjY_20db476b-e45b-4b86-ab7e-a3f4680b365c">98,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTAtNS0xLTEtNjYzMjY_009a7ff0-58fd-45db-99eb-1a6b982b1c9e">225,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTAtNy0xLTEtNjYzMjY_c0700819-9a05-45a2-8449-b70030889469">200,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTEtMS0xLTEtNjYzMjY_3b7509f9-d48a-43d5-8807-386496a09def">335,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTEtMy0xLTEtNjYzMjY_f350a84e-bc78-4e3d-a8b8-56e4c3638a77">262,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTEtNS0xLTEtNjY0Nzg_baf34292-bf4b-4cc7-a52a-cac8c5d63289">608,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTEtNy0xLTEtNzQ0NDY_fb079a37-70a4-47b1-b76a-033afc068565">537,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTItMS0xLTEtNjYzMjY_22d07c06-4a59-4e76-a6dd-111808f32f63">83,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTItMy0xLTEtNjYzMjY_5b9c7ad3-4934-44c7-a1b4-91d798a708ba">123,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTItNS0xLTEtNzQ0NDY_0f2fdc28-d94a-4884-8ab1-f5d665d643fa">166,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTItNy0xLTEtNzQ0NDY_397bd662-045a-4a67-9518-b4df494f0866">118,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTMtMS0xLTEtNjYzMjY_c4157451-ae4b-4c78-ab87-a70ec4164a51">4,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTMtMy0xLTEtNjYzMjY_7e669a30-ad3c-43df-9bfe-4066efe78682">1,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTMtNS0xLTEtNjYzMjY_c4d5a1e5-b729-40d2-bb92-9f1edec1f304">6,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTMtNy0xLTEtNjYzMjY_68c8ddd1-78e2-42a1-adbd-eff06b1d057c">4,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTQtMS0xLTEtNjYzMjY_d83b5bdd-8162-4a12-8c6f-8ccc0ed7535c">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTQtMy0xLTEtNjYzMjY_102404d3-b78a-43c6-b368-297477cf7723">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTQtNS0xLTEtNjYzMjY_b09d0591-ac96-46df-8acd-f31fccf23525">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTQtNy0xLTEtNjYzMjY_420b8405-e920-4ba7-bed4-abfe2d2e9589">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTUtMS0xLTEtNjYzMjY_b116eb7d-993d-4362-ab13-632aa19e871c">88,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTUtMy0xLTEtNjYzMjY_8566b328-e47e-4a12-85de-dead6062abac">124,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTUtNS0xLTEtNzQ0NDY_959bc730-97a0-481c-87fb-1d153bf1abd5">173,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTUtNy0xLTEtNzQ0NDY_b500f13f-ad54-41e0-a8d8-cbb3de57e2ac">122,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTYtMS0xLTEtNjYzMjY_62c94936-a08d-462b-96e8-598472bde2c6">17,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTYtMy0xLTEtNjYzMjY_a69585a1-fd2f-4658-ad4d-f4fc897c5bb4">28,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTYtNS0xLTEtNjYzMjY_f0ac088b-2ea7-4511-bfbb-b122c46bfca2">34,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTYtNy0xLTEtNjYzMjY_7e1ec53a-4ab2-406a-a59d-12f7d69a551e">25,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTctMS0xLTEtNjYzMjY_22b565e4-79ae-4394-bc39-6e3eafa4f1d8">70,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTctMy0xLTEtNjYzMjY_b00120d0-4258-4474-81e9-f6bf0ae652bb">96,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTctNS0xLTEtNzA2MDQ_d4e0aecb-f8e4-4b12-9291-66efcfc2b7e2">139,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTctNy0xLTEtNzA1Njc_faa857f9-f4a4-4031-8d5c-18dab089760b">97,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTktMS0xLTEtNjYzMjY_73b876d2-397f-4e65-b1b6-a72e73fbe7c9">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTktMy0xLTEtNjYzMjY_5d849c8f-6ce8-4c81-b862-bcd9e133d36e">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTktNS0xLTEtNzQ0NDY_d3b64321-7185-4b34-92d8-9ed35ee2c8f7">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTktNy0xLTEtNzQ0NDY_d8ef433a-9e08-4d4b-a425-4df3f5020a16">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjAtMS0xLTEtNjYzMjY_675af6d1-1e0b-4a15-b1fa-75adb0d6fa71">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjAtMy0xLTEtNjYzMjY_9545e8bf-f6d4-4e21-957a-01c6590a670a">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjAtNS0xLTEtNzQ0NDY_a3aa1835-39f5-468f-ae3b-3ccafb77fdd4">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjAtNy0xLTEtNzQ0NDY_8107ad84-1790-46ec-96a7-f039b35663ea">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjItMS0xLTEtNjYzMjY_3bbc6ab2-4163-4267-84bd-fd362adf9742">321,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjItMy0xLTEtNjYzMjY_03cec34f-f2f0-4c05-a74a-845c05870899">314,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjItNS0xLTEtNjY2ODM_61c237a4-71dc-4217-9549-f6d7dc38c8c9">320,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjItNy0xLTEtNzE2OTc_0b0bc54c-c39c-4f04-a0fd-f422dc3294cf">313,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjMtMS0xLTEtNjYzMjY_d00a008d-4228-4f23-a000-31a7ec9961e9">324,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjMtMy0xLTEtNjYzMjY_10185306-4704-4c24-a40a-a2ba63316601">322,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjMtNS0xLTEtNjY2ODM_8755ddae-b220-49b1-986b-851b850a2ba0">324,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjMtNy0xLTEtNzE3MDA_a396b780-bbde-47fc-92bd-2b34714c99b3">322,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_22"></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfMi0xLTEtMS02NjMyNg_22b565e4-79ae-4394-bc39-6e3eafa4f1d8">70,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfMi0zLTEtMS02NjMyNg_b00120d0-4258-4474-81e9-f6bf0ae652bb">96,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfMi01LTEtMS02NjMyNg_8c92ec01-6ee3-4f85-b5ff-54ecac9ea976"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfMi01LTEtMS02NjMyNg_9111fb56-e88d-4a24-b99a-f359b2e1da02">139,245</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfMi03LTEtMS02NjMyNg_0f34aff6-c7df-4d8d-a0bd-5033f95cbe01">97,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses on available-for-sale debt securities, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC0wLTEtMS02NjMyNi90ZXh0cmVnaW9uOmEzZGU5NjZkMTYxYzRlMDBhNmNjZDk5MmNjNjU2NDU2XzIxOTkwMjMyNTU2NTE_1383f293-336b-4416-abb9-7106cb2b59d7">639</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC0wLTEtMS02NjMyNi90ZXh0cmVnaW9uOmEzZGU5NjZkMTYxYzRlMDBhNmNjZDk5MmNjNjU2NDU2XzIxOTkwMjMyNTU2NTc_f50cccd1-6699-4600-9a6e-00af0fb41d4d">257</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC0wLTEtMS02NjMyNi90ZXh0cmVnaW9uOmEzZGU5NjZkMTYxYzRlMDBhNmNjZDk5MmNjNjU2NDU2XzIxOTkwMjMyNTU2ODc_75179167-1332-43ea-8e70-d91bd916e12a">2,295</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC0wLTEtMS02NjMyNi90ZXh0cmVnaW9uOmEzZGU5NjZkMTYxYzRlMDBhNmNjZDk5MmNjNjU2NDU2XzIxOTkwMjMyNTU2Njg_ed43f78f-f427-4ab3-a4ca-94d2ccfecd0a">756</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC0xLTEtMS02NjMyNg_4a15d7eb-1652-467e-bb1a-4c354d712112">2,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC0zLTEtMS02NjMyNg_7eee9a90-13a4-4e5c-8fd4-1951560c27ea">755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC01LTEtMS02NjMyNg_158490bf-33b7-4ddf-9a45-0cd74d501598">8,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC03LTEtMS02NjMyNg_7e29e976-8b7f-423a-8882-e444a8af576a">2,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNi0xLTEtMS02NjMyNg_905b1a90-b291-48db-93a6-9096fd56a5c5">68,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNi0zLTEtMS02NjMyNg_7d0cc15a-1c58-4d48-8805-49a57114fb78">95,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNi01LTEtMS02NjMyNg_31363685-a8ad-42eb-9cd2-dddf60e034df">131,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNi03LTEtMS02NjMyNg_3187c932-35fc-41ac-9051-5952e414b5cc">95,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2022</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbbf35553e864a47b12a2d1fd928f98e_I20220401" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjMtMS0xLTEtNjYzMjY_43b09e8b-923a-4c6d-9349-8fda73efe0db">320,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbf35553e864a47b12a2d1fd928f98e_I20220401" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjMtMy0xLTEtNjYzMjY_c0b1cbd9-5af3-488a-9b9a-e4238e97b145">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica2525aa6c6841f982350ebfeb7ae4e9_I20220401" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjMtNS0xLTEtNjYzMjY_1a524518-e7ea-40f3-af86-e75ae74e8818">2,448,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13f12b5dde5b4fdda7863e2006ddc6da_I20220401" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjMtNy0xLTEtNjYzMjY_f32bc323-128c-4613-b86f-aa4152e0addf">6,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabda242f1aa040f1aa8b97a4539b80c1_I20220401" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjMtOS0xLTEtNjYzMjY_98bd8db2-53a3-45e6-8d3e-f5d442fefdbb">147,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a5dab809bf451896a0f1f8a5a72ca2_I20220401" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjMtMTEtMS0xLTY2MzI2_e9f6dcad-e4df-4382-9c3b-94093e26132a">2,293,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd09d7b967674984a4b4c0e1ecf5c20a_D20220402-20220701" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjQtOS0xLTEtNjYzMjY_ca63c3d9-67f1-4083-ad19-c90bb4df1cac">70,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjQtMTEtMS0xLTY2MzI2_08c647a0-d6b1-47f4-94fb-03ad4c583233">70,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i083ff5f50112432b974e39cee8bbb3e9_D20220402-20220701" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjUtNy0xLTEtNjYzMjY_3a047100-fd31-461d-8a52-e7a69227275b">2,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjUtMTEtMS0xLTY2MzI2_5aaf8d1c-1723-4c25-9203-f4aba074463b">2,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive plans and stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51ed73dd842a42c787ae6af93fa1f0ef_D20220402-20220701" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjYtMS0xLTEtNjYzMjY_fda1cf80-0802-43d9-9d95-22b54d66d5f8">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ed73dd842a42c787ae6af93fa1f0ef_D20220402-20220701" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjYtMy0xLTEtNjYzMjY_4f6da46d-d842-4c62-89df-3c6336546fad">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b5acd047f54e5e890f1c61b9bb0bf2_D20220402-20220701" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjYtNS0xLTEtNjYzMjY_74b988d3-eb4c-4def-b40f-e53a00db3bcf">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjYtMTEtMS0xLTY2MzI2_8e58c080-28cc-4008-84b1-fe7e31e0c740">10,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b5acd047f54e5e890f1c61b9bb0bf2_D20220402-20220701" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjctNS0xLTEtNjYzMjY_977e335d-4c37-4f3b-b851-afa8838760c3">6,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjctMTEtMS0xLTY2MzI2_2aea9c20-57e2-40de-b3ea-eb0b8341859a">6,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b5acd047f54e5e890f1c61b9bb0bf2_D20220402-20220701" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjgtNS0xLTEtNjYzMjY_165ebaa9-1af1-42f8-9d41-3b0ef752dafa">24,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjgtMTEtMS0xLTY2MzI2_d3b324a1-7f35-467d-946f-fcdbf71d70d2">24,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5e9422226204c1caad9468840b30369_I20220701" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjktMS0xLTEtNjYzMjY_48a751a0-abd1-4cb2-8ea0-16c972961ca6">321,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e9422226204c1caad9468840b30369_I20220701" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjktMy0xLTEtNjYzMjY_0eff0597-5690-4b61-a896-da23cceb2254">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7035844a96447d9ece7ea6b0cc2ed8_I20220701" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjktNS0xLTEtNjYzMjY_c3d04d8c-75c2-48d7-9c7c-faf1c368612b">2,477,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3a8211d9414334ba9e7d2ba62bc3c5_I20220701" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjktNy0xLTEtNjYzMjY_27f839df-b47f-46bd-a0ac-34820d1d9db8">8,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb93329607a4f4485821bd6d3b218d4_I20220701" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjktOS0xLTEtNjYzMjY_52f618f3-cdd7-4931-abd8-6d2a41c9577f">77,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjktMTEtMS0xLTY2MzI2_41f2ec31-d414-433e-8385-c0e43124ed57">2,391,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></div></td></tr><tr style="height:31pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i178b1c70ce884adaa05d4e23647aa97f_I20210402" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTQtMS0xLTEtNzEyOTE_5fdaf07d-109a-4ab6-8409-9441d97816b5">313,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178b1c70ce884adaa05d4e23647aa97f_I20210402" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTQtMy0xLTEtNzEyOTE_b1e28ed0-17fc-4e7f-80ab-adf8c05efa3e">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65133c237764501911f938ce005dd62_I20210402" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTQtNS0xLTEtNzEyOTE_54a5889d-db52-4646-9909-df465a956887">2,354,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074c0d5d00e94dcd86712e0f3b167c31_I20210402" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTQtNy0xLTEtNzEyOTE_28ac12a2-e2c0-40d9-bee7-6920bb0d3e25">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5638bf7f18a54b5eb3f4e9899ee414b8_I20210402" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTQtOS0xLTEtNzEyOTE_a34b369a-a08a-416d-8404-19d02f7854d1">445,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a65a50aa94cbcaa556bdea637aae0_I20210402" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTQtMTEtMS0xLTc0NDU4_fad09ad3-d13f-47bf-9213-7b23295515ec">1,911,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc467238ed7e44f8908d4c4197d02952_D20210403-20210702" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTUtOS0xLTEtNzEyOTE_0e88011b-9cf8-497c-b546-cc483973fc87">96,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTUtMTEtMS0xLTc0NDU4_05620abd-cc2d-4748-9a71-28edb453be8e">96,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id29da21d87ad4d1cbc07082f36dae1db_D20210403-20210702" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTYtNy0xLTEtNzEyOTE_d7d1772b-ae92-4105-9d7c-416551836935">755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTYtMTEtMS0xLTc0NDU4_b29c664f-6750-41d5-9ee3-a0646e09470c">755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive plans and stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33204058d2884277a534f3fe8b2d05c6_D20210403-20210702" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTctMS0xLTEtNzEyOTE_d2ddaf0d-d3b0-4532-b245-246fc4b389aa">1,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33204058d2884277a534f3fe8b2d05c6_D20210403-20210702" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTctMy0xLTEtNzEyOTE_77f03cc2-fe39-470d-ab31-75c69ba8b0a1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e65c25cad842b48b3a06036a8dfb11_D20210403-20210702" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTctNS0xLTEtNzEyOTE_7cc0df35-1c99-4ce8-b992-472dc2755dd5">11,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTctMTEtMS0xLTc0NDU4_5ca66caf-d70a-4660-8ece-f30a6b5127f5">11,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e65c25cad842b48b3a06036a8dfb11_D20210403-20210702" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTgtNS0xLTEtNzEyOTE_17d1ce13-4baf-4bd2-9332-6da67eb91445">2,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTgtMTEtMS0xLTc0NDU4_4e03d8e7-5862-49f7-8ca3-15459a9d73bf">2,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e65c25cad842b48b3a06036a8dfb11_D20210403-20210702" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTktNS0xLTEtNzEyOTE_2a60ba3a-34a7-4976-8777-fa3f0e966788">28,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTktMTEtMS0xLTc0NDU4_f5bafda3-8d92-4310-9df1-d9d926af23d8">28,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ad2cb90ebc241bb8b2f4469a70980a7_I20210702" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjAtMS0xLTEtNzQ0NTg_eff8a5c8-6aaf-4719-867b-47d8c173c19a">314,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad2cb90ebc241bb8b2f4469a70980a7_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjAtMy0xLTEtNzQ0NTg_bd0f4a79-5cbd-4f00-b4af-7b5959814318">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if60b5dd0182e46dca654df547b7153f4_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjAtNS0xLTEtNzQ0NTg_438f181c-9112-4082-b59c-18fecb0f4d12">2,390,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c00d41f727490497fb324365d70cdf_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjAtNy0xLTEtNzQ0NTg_7678cc99-ebe9-4126-a16d-d0a1c2222517">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cc4df1f70524cf0b42d834be77810ec_I20210702" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjAtOS0xLTEtNzQ0NTg_641afabc-5c94-4d74-88d6-d0e20879d202">349,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide7e987c180a418585f377e54ea41af1_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjAtMTEtMS0xLTc0NDU4_95ff564e-a1d5-45d4-9eff-a40018365cf3">2,043,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continued on next page</span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38d2914ca5204497ab3d3c3eaea8818d_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjMtMS0xLTEtNjYzMjY_e3b6b80f-c665-48c0-ab6e-416589c74339">318,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d2914ca5204497ab3d3c3eaea8818d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjMtMy0xLTEtNjYzMjY_2d70b47e-2653-4f78-9654-935f8bfd3f51">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1249b090f0b64f6ba2e504df49cb49cc_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjMtNS0xLTEtNjYzMjY_3b6e53c8-4f7f-4d81-8b97-2bd3257d358e">2,427,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fbe83b4d13441469af603970b1bfad2_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjMtNy0xLTEtNjYzMjY_5872be56-f838-4fc2-b81a-87691a3e5c66">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11fbb1f45c2f4280981d038a82ed2190_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjMtOS0xLTEtNjYzMjY_4b2058f3-a7cb-4b27-8274-61508a2c2eb9">216,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjMtMTEtMS0xLTY2MzI2_65e438b6-255c-4455-a290-1583e4beacdc">2,210,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6414045fef4baaab29a829c64218c3_D20220101-20220701" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjQtOS0xLTEtNjYzMjY_58c80d64-9146-4776-82a9-fef210783de1">139,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjQtMTEtMS0xLTY2MzI2_8d3c9acc-f6e9-4843-a8f8-01aecb47bed2">139,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9ee23437eab47868678f63cbd6ef147_D20220101-20220701" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjUtNy0xLTEtNjYzMjY_aaa42bb7-6071-48a4-b3bd-99fdefb10045">8,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjUtMTEtMS0xLTY2MzI2_4e97236a-6ea3-4237-abd2-eabbf123367f">8,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock under equity incentive plans and stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0f4f857a9fc488b86c7e00d7d13b344_D20220101-20220701" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjYtMS0xLTEtNjYzMjY_43fcb96e-f327-46c3-b1d7-82e5a67076cb">2,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f4f857a9fc488b86c7e00d7d13b344_D20220101-20220701" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjYtMy0xLTEtNjYzMjY_e0e453be-17e4-45f2-929d-f9dea5180445">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id762b4c844464d9dbd1a5232a5556a16_D20220101-20220701" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjYtNS0xLTEtNjYzMjY_495f49b4-3aca-4744-b83e-cf8652ae4cf7">15,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjYtMTEtMS0xLTY2MzI2_94b222ab-28cf-4bb6-8216-4ee10d3ad3b5">15,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id762b4c844464d9dbd1a5232a5556a16_D20220101-20220701" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjctNS0xLTEtNjYzMjY_652b6fc9-cbca-4c07-8ac5-a2fcc5000787">11,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjctMTEtMS0xLTY2MzI2_e3061c0c-46d2-4e84-87b7-a363192c7c77">11,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjgtNS0xLTEtNjYzMjY_c721ed13-f320-4bcc-8fa5-c7de145b88f9">44,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjgtMTEtMS0xLTY2MzI2_7903a0e5-78d5-4a32-8846-01149d92fc66">44,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5e9422226204c1caad9468840b30369_I20220701" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjktMS0xLTEtNjYzMjY_1a44d247-972d-425e-b447-722e68c78366">321,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e9422226204c1caad9468840b30369_I20220701" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjktMy0xLTEtNjYzMjY_20c7c90d-d2c3-41ec-b5d9-218b66e00d10">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7035844a96447d9ece7ea6b0cc2ed8_I20220701" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjktNS0xLTEtNjYzMjY_70de1daf-2e19-447e-b724-b7600b97684a">2,477,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3a8211d9414334ba9e7d2ba62bc3c5_I20220701" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjktNy0xLTEtNjYzMjY_76544bd3-6b65-4214-95be-87c3f7ddebd4">8,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb93329607a4f4485821bd6d3b218d4_I20220701" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjktOS0xLTEtNjYzMjY_c160e4ae-8005-45f5-8fe0-ca5b00481474">77,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjktMTEtMS0xLTY2MzI2_4bddad9e-d516-43ba-9c1a-45bc1bf1860c">2,391,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7915746f5547460f9caa2e4177cfce05_I20210101" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTQtMS0xLTEtNzEzMjE_4565b655-93e8-4781-a755-3a39dd06202c">311,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7915746f5547460f9caa2e4177cfce05_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTQtMy0xLTEtNzEzMjE_e7cca817-6da2-4054-b350-fbb7b2a1c9d1">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e25b57e2a0b4d829b12b77168539aa7_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTQtNS0xLTEtNzEzMjE_a4215fe9-4905-44b3-8942-218c12b1790d">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf90c32a09a4497996f31bce3e8b5d1e_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTQtNy0xLTEtNzEzMjE_00577c95-d4c3-45ab-ae67-de48ae930947">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646dda3b25974251a53973741e46976c_I20210101" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTQtOS0xLTEtNzEzMjE_eefbb59f-9e18-4901-8884-851eb182e176">447,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95504af18ae84a95a6f5672e2c0962ea_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTQtMTEtMS0xLTcxMzIx_a362bd35-4025-49ab-a23b-efb5e3419a4f">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1ebf17aa8654c809fdc3b7fdf977b94_D20210102-20210702" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTUtOS0xLTEtNzEzMjE_14367449-91f5-4d10-b5f6-0df6bafd44b4">97,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTUtMTEtMS0xLTcxMzIx_4693d6de-2e5a-484a-99c2-836a850aed0b">97,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i920841e629d44fa39ab93aed91f7add3_D20210102-20210702" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTYtNy0xLTEtNzEzMjE_401e2fc7-647d-4c6b-9c18-baf7cd65e83b">2,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTYtMTEtMS0xLTcxMzIx_f519b55f-3f23-4c7b-9db6-d2f251933ceb">2,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock under equity incentive plans and stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie673862a0ee14b879e59030e6dfa3b2b_D20210102-20210702" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTctMS0xLTEtNzEzMjE_31d6a981-e5c6-488a-9c4f-80bb90a1cff9">3,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie673862a0ee14b879e59030e6dfa3b2b_D20210102-20210702" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTctMy0xLTEtNzEzMjE_43087765-3e1e-4ffe-b1b8-f39255ec04f8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e90a92edb8647439746c5535fbdf9b9_D20210102-20210702" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTctNS0xLTEtNzEzMjE_45f67c06-b1ac-4648-8cc3-e023c9d3f89d">15,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTctMTEtMS0xLTcxMzIx_0168123c-e544-432b-9251-8d130dbd7ee9">15,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e90a92edb8647439746c5535fbdf9b9_D20210102-20210702" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTgtNS0xLTEtNzEzMjE_2c6afafd-6a0c-42ad-8b37-9ae581835a9c">9,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTgtMTEtMS0xLTcxMzIx_c3a64765-00ac-4c8c-941c-06b07676afd7">9,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e90a92edb8647439746c5535fbdf9b9_D20210102-20210702" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTktNS0xLTEtNzEzMjE_6f25252d-0abc-4da1-afd5-6a3759bf7535">62,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTktMTEtMS0xLTcxMzIx_a8e38539-a984-4d43-af62-2383b8e4cc5e">62,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ad2cb90ebc241bb8b2f4469a70980a7_I20210702" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjAtMS0xLTEtNzEzMjE_7c87b782-b13a-4dee-9a8b-56be24f42e13">314,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad2cb90ebc241bb8b2f4469a70980a7_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjAtMy0xLTEtNzEzMjE_f5fe487d-cdad-4fd5-94a1-855a48f3cafc">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if60b5dd0182e46dca654df547b7153f4_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjAtNS0xLTEtNzEzMjE_4fd0b173-38ac-4338-b47f-5f9060a5fbf8">2,390,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c00d41f727490497fb324365d70cdf_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjAtNy0xLTEtNzEzMjE_6c481c94-3e86-4c72-921a-c06b54ec444f">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cc4df1f70524cf0b42d834be77810ec_I20210702" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjAtOS0xLTEtNzEzMjE_6eee706b-a555-44d6-a769-a6be118a4ad4">349,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide7e987c180a418585f377e54ea41af1_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjAtMTEtMS0xLTcxMzIx_300aafdc-798e-4760-a890-7ee0dca30eea">2,043,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMi0xLTEtMS02NjMyNg_339ad039-b045-4ac2-9af2-c4e1b4a5e2aa">139,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMi0zLTEtMS02NjMyNg_faa857f9-f4a4-4031-8d5c-18dab089760b">97,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNC0xLTEtMS02NjMyNg_a46d9af0-7968-4d58-b0ad-0ac5158df4da">9,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNC0zLTEtMS02NjMyNg_317f08bd-8b4e-4abe-b7c0-12ce2235828e">6,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNS0xLTEtMS02NjMyNg_1af202b8-aeed-4ce9-85f3-f65bb1e6b233">44,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNS0zLTEtMS02NjMyNg_0ab673d9-fab2-48a0-b115-4c61e153206e">62,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNi0xLTEtMS02NjMyNg_c54774da-f9d5-4431-9a1f-2f427aeed98e">6,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNi0zLTEtMS02NjMyNg_bec3616c-a2b3-4a16-ad3d-785604600999">2,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNy0xLTEtMS02NjMyNg_701b57d9-a967-406e-8ae4-8e1c57e9b27b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNy0zLTEtMS02NjMyNg_a6f12b5e-8cab-41f3-9ae4-f4f7a2f7d274">22,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfOC0xLTEtMS02NjMyNg_58d7f4a7-6644-4078-bb7e-22e571879e10">4,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfOC0zLTEtMS02NjMyNg_a2b5a753-9463-42e5-ab89-c6876aac7866">22,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTAtMS0xLTEtNjYzMjY_edb3197e-631a-4034-8703-a59b08412ffb">46,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTAtMy0xLTEtNjYzMjY_ed9bc2d2-b647-4773-9657-dcb5431109aa">12,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTEtMS0xLTEtNjYzMjY_dfb25ac4-d11a-402b-b17e-90d6939fc33b">8,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTEtMy0xLTEtNjYzMjY_adcbf91c-d808-4ed0-b5d9-13d7fd683f39">8,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTMtMS0xLTEtNjYzMjY_325bcd55-2f52-4b64-b30f-4775052f0dec">26,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTMtMy0xLTEtNjYzMjY_4eec4589-68af-417e-aa38-795545c0d84b">12,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTUtMS0xLTEtNjYzMjY_39231ece-fda1-41a7-a6f6-c4115470b49c">1,831</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTUtMy0xLTEtNjYzMjY_3b708b9d-3401-4e30-855e-db6cf3ac1d85">9,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" sign="-" name="exel:IncreaseDecreaseInAccruedCollaborationLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTYtMS0xLTEtNjYzMjY_d1657d23-eea6-430a-b8fa-28438565899a">53,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="exel:IncreaseDecreaseInAccruedCollaborationLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTYtMy0xLTEtNjYzMjY_8302a193-f70a-4c7c-bae6-7eac518477a6">2,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTctMS0xLTEtNjYzMjY_d845b512-fe70-4447-a059-4d0a4c216dc8">17,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTctMy0xLTEtNjYzMjY_88befe76-8f89-4410-b105-e8acf9eab2d8">25,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTktMS0xLTEtNjYzMjY_f1c2cbf3-1445-43dc-a27f-137694e02e9c">178,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTktMy0xLTEtNjYzMjY_f6a682ae-1eaf-4028-9859-71b17b573992">221,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjEtMS0xLTEtNjYzMjY_11379f92-7341-4fca-86a6-a72cdf39e074">17,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjEtMy0xLTEtNjYzMjY_d38305a2-f63e-45b2-b4f6-cc0f295a12a3">33,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjMtMS0xLTEtNjYzMjY_f45fcb46-1715-4f96-938b-8eff580e975b">692,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjMtMy0xLTEtNjYzMjY_98deb5fe-8a93-42aa-81d5-7921fb14ea0a">688,903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjQtMS0xLTEtNjYzMjY_16eb9389-d99b-4099-a9b2-4f65643dc209">500,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjQtMy0xLTEtNjYzMjY_5cc6090d-2a98-4e80-883c-3f443120a8d7">714,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjUtMS0xLTEtNjYzMjY_7e09e5e6-445b-4f7f-bade-5283d9f375cb">209,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjUtMy0xLTEtNjYzMjY_e4219a55-e2ec-4b6a-af7a-e96bd57c5536">8,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjctMS0xLTEtNjYzMjY_04dcf3e6-52f5-4837-9f90-7e5419d911aa">15,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjctMy0xLTEtNjYzMjY_c31fd1fd-d513-4c00-88bd-861f6443d7c9">15,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjgtMS0xLTEtNjYzMjY_854c4583-5e21-48e8-b263-5e70dc1cd1fe">11,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjgtMy0xLTEtNjYzMjY_c5fd73f3-6f73-457d-823a-14cf82eb4dbe">9,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzEtMS0xLTEtNjYzMjY_462dc09b-f1a4-4cb3-8a93-296f7d00c9fc">4,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzEtMy0xLTEtNjYzMjY_0629c4d4-6d41-4c51-8389-95b24658b9e4">6,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, and restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzItMS0xLTEtNjYzMjY_d5952327-9949-4915-a814-e7c64de751d0">26,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzItMy0xLTEtNjYzMjY_612c6eb4-6db3-44e1-aebc-47969c9db2b4">218,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzMtMS0xLTEtNjYzMjY_ade2a21d-889c-450a-9d50-3014e013e3d7">663,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95504af18ae84a95a6f5672e2c0962ea_I20210101" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzMtMy0xLTEtNjYzMjY_b5f59b5b-ba4a-479d-afd8-475b9eb13ced">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzQtMS0xLTEtNjYzMjY_51ce5545-f43e-4d2f-8fe6-c5f129fecc0b">637,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide7e987c180a418585f377e54ea41af1_I20210702" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzQtMy0xLTEtNjYzMjY_2e90eb04-35ab-4cd5-83b5-da4e27fa87d5">539,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzktMS0xLTEtNjYzMjY_8f5f8689-656e-4c7b-ac1f-bc866500972c">120,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzktMy0xLTEtNjYzMjY_0859cf2d-1026-4775-8df3-75d4f4fefe97">4,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred for purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNDEtMS0xLTEtNjYzMjY_87fc28a5-5fe6-49b2-a2bd-a72f60692503">3,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNDEtMy0xLTEtNjYzMjY_fd305131-28b1-4aaf-baa6-3cc93ad3cc1e">5,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred in asset acquisition</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:LiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNDItMS0xLTEtNjYzMjY_a679f8f9-77db-48d2-a134-e2a35a4a3914">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:LiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNDItMy0xLTEtNjYzMjY_fc74a12d-be77-4680-8698-6826565a17be">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred for unsettled investment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="exel:InvestmentsPurchasesIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNDMtMS0xLTEtNzgyMzU_cbe69cbd-940e-4660-be36-376a4c38dca5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="exel:InvestmentsPurchasesIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNDMtMy0xLTEtNzgyMjc_82de8be3-4672-414f-a93e-5b246d158b6b">7,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_34"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzQ5Mw_66f6b8cd-e7e7-4ef2-a07e-21acebebd900" continuedAt="i1cc90187b80c46aa9f8945c789ee27a6" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i1cc90187b80c46aa9f8945c789ee27a6" continuedAt="i7027836330cd4867968a3c4d1c36faef"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for patients with difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, <ix:nonFraction unitRef="product" contextRef="i8fa8420126014bf088bb615340e7af05_D20220101-20220701" decimals="INF" name="exel:NumberofProductsinCommercialMarket" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNjkx_8b4c274b-7ae8-4256-904f-c7b831fa3a6a">four</ix:nonFraction> products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in <ix:nonFraction unitRef="country" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="INF" name="exel:NumberOfCountriesWithDrugApprovalExcludingTheUS" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfMTA2Nw_488a817b-da5c-421f-a0a5-0bc8ccf2dccf">62</ix:nonFraction> other countries as: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other <ix:nonFraction unitRef="product" contextRef="ic8c53c5143b04fa790d554162bdceec7_D20220101-20220701" decimals="INF" name="exel:NumberofProductsinCommercialMarket" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfMTc0Ng_dd7ce175-a1c0-4aa4-aeb0-b03686179304">two</ix:nonFraction> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. a member of the Roche Group (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzUwNw_928ba7ca-e816-49ba-9672-bd2b47a5fb49" escape="true">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzUwOA_b0355de0-71d4-4db5-9109-cd5027b256a2" escape="true">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;18, 2022 (Fiscal 2021 Form 10-K).</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:FiscalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzUxNA_bbfd38a5-08e8-4bf5-8ace-1533ce08c5f6" continuedAt="i1f848c17d77b4a9690bc3e8df11eaaf0" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1f848c17d77b4a9690bc3e8df11eaaf0">. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the fiscal periods ended July&#160;1, 2022 and July&#160;2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the fiscal periods ended June&#160;30, 2022 and June&#160;30, 2021, and the year ending December&#160;31, 2022, respectively.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzQ5OA_8767c009-4d66-4e95-9692-42d659bfa96f" continuedAt="ibbbfe7ee137a44a1863e4ff25cdb5b02" escape="true">We operate in <ix:nonFraction unitRef="segment" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNDY0Ng_3ce46f1e-b8aa-4fe8-ac6c-742b75e2b9c5">one</ix:nonFraction> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief </ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><ix:continuation id="i7027836330cd4867968a3c4d1c36faef"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibbbfe7ee137a44a1863e4ff25cdb5b02">Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</ix:continuation></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzUyNw_00ccbb80-b40b-43f9-a11e-1e75016ccb8b" escape="true">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzUyOA_0de0d69d-3c71-4b0b-a3f0-d2883dfea2d2" escape="true">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies during the six months ended June 30, 2022, compared to the significant accounting policies disclosed in &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzUwMA_fbd3ad78-90dd-4a57-bafd-361fce8d0076" escape="true"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDcxMQ_f8adccac-3f2a-4708-9dff-a2b30def5b68" continuedAt="if10a73e2e53c4ce59c914ded94eb0c04" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="if10a73e2e53c4ce59c914ded94eb0c04" continuedAt="i47c38bf688cb4145abfda972a08c4d59"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDY5OQ_f10dd80a-9e79-479f-849e-d658f00348ea" continuedAt="ie1a8cd0980f84acba888dc3cf79fc6e8" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia26f483bdcbb41acbef2e9cd23df368f_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMy0xLTEtMS02NjMyNg_934f39cf-c7b1-4bc9-9a5e-cab3f6f8006e">483,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9620d75cbfe442cbdfb2e49f10029ad_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMy0zLTEtMS02NjMyNg_0e4e6601-5995-49d8-85f4-23fcb49c36ba">380,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68714772b36481f8c505e3eef1639c8_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMy01LTEtMS02NjkyMg_65b0cc11-00af-459f-bec2-218e4be8492d">931,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b267d864364d6ab0b3c49456d3b22b_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMy03LTEtMS03MTczOQ_1a270589-bffd-4752-aa13-3d73ccb42f53">694,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a529c6b1f84c14b8c06c30376f65f6_D20220402-20220701" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNC0xLTEtMS02NjMyNg_addeb7b6-30b6-4775-b27d-d060dcd976c8">136,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0e39c06180045fb8a7047acd09b09d5_D20210403-20210702" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNC0zLTEtMS02NjMyNg_ee5a0a6e-c040-44f1-929e-bf3d3daa6a5a">95,956</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4609cc64ebd4171954966a86b6926ef_D20220101-20220701" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNC01LTEtMS02NjkyNA_d0cb5151-32a8-4e21-88ad-bd4eea14ce61">273,968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i077dff06f4904d1990415f13a7b882a4_D20210102-20210702" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNC03LTEtMS03MTczOQ_4ec68c22-634b-4d4c-b861-fcb73cc7ae86">182,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0966f9eca84459ae2dd8ebc3309047_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNS0xLTEtMS02NjMyNg_ab99a420-fba9-4fb9-b4c5-43c4ce898b55">347,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b9e8d3facdf4864bb7c81214e9ad6f8_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNS0zLTEtMS02NjMyNg_89538a1b-c165-46bc-b3b8-db9bb89ef27f">284,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42cf2e0fa214b5c803a30524005d09a_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNS01LTEtMS02NjMyNg_d2f73c6e-689d-41aa-b460-935756084a0a">657,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i783842d281c14d18a5ab8e977fb76f4a_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNS03LTEtMS02NjMyNg_d3a1c7bd-f9bd-48a0-b564-f635ff8d6317">511,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ece728364b4cc48c40e024bb487e25_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNy0xLTEtMS02NjMyNg_54e2d3c0-12aa-4703-9768-44920a6b1abc">57,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51494a71ce844aa2aaa75d35e9949848_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNy0zLTEtMS02NjMyNg_b172593c-1251-4021-a6ac-052c97a42d45">39,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i635c229f1f07418d854dc726f5340cb4_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNy01LTEtMS02Njk0OA_8ec419c0-c420-45c9-997f-98ae329aee81">89,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769896e9287e4183bddc0e89f0dcc56b_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNy03LTEtMS03MTc0MQ_cd1fbac6-dfa0-4964-aafa-0862e7ce3a70">67,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706119ef90c140f89a64ca72f784f4b0_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOC0xLTEtMS02NjMyNg_0d131684-825e-422e-add0-90cf8eb290d3">14,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69fd855fbc7048eabfa55142b96cda52_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOC0zLTEtMS02NjMyNg_82c7fcbb-246f-448f-b440-aea632ead1e1">61,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f1dadf8806a47148f339ef9a9717604_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOC01LTEtMS02Njk1MA_6d7c376b-d861-4e49-b79a-baac2466d660">28,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8dae096ca44ee58f98136af8f519b9_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOC03LTEtMS03MTc0MQ_6d636893-f6d5-43ed-b70b-659eb45a2c8f">76,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0a7ab1f65b4bc786a98d7742cdc82f_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOS0xLTEtMS02NjMyNg_e485d677-d7f7-4dfc-bcd7-406a3bad5279">72,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37e0da3271234f2bae53c14f82b39321_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOS0zLTEtMS02NjMyNg_c7acb7fc-c366-47db-aeb4-eb9b1185dcc8">100,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92fba14ea211474d82d9667f1ee43b1c_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOS01LTEtMS02NjMyNg_bc4fc075-86bb-4599-8d57-575cf0c1a814">118,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453607a6d2c241139ae0154655e12057_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOS03LTEtMS02NjMyNg_0459220d-b76b-47fd-a44d-b176473d97a8">143,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMTAtMS0xLTEtNjYzMjY_8df2e6f3-404b-4c7f-ae21-3bf9e6f12963">419,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMTAtMy0xLTEtNjYzMjY_3688643d-9080-41d7-b8fa-ac241462f983">385,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMTAtNS0xLTEtNjYzMjY_c08cce14-fb21-4e80-abbc-dbb89e703312">775,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMTAtNy0xLTEtNjYzMjY_779e4024-9c2d-4053-bd06-9e6787fe043a">655,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><ix:continuation id="i47c38bf688cb4145abfda972a08c4d59" continuedAt="i609a4412026848a1818bfaa8641889d8"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDY5Ng_6cd794cd-4791-4bed-a795-cf2b116e15bb" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89f773b17954459496fdb8e6635e500c_D20220402-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMi0xLTEtMS02NjMyNg_c297dc8d-c69c-403c-8a20-1dcc89fac7be">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i125702b0bbdb49ea96eac26fc326c134_D20210403-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMi0zLTEtMS02NjMyNg_0c54f926-0428-47b5-b2ee-1d3fa3895754">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia565cbddd5a042f7b2339b3e701e9826_D20220101-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMi01LTEtMS02NzA3Nw_56d79662-6b73-4347-bf97-0d2f188cc7ef">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6183c887d9e429a96461d489c65f056_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMi03LTEtMS02NzA2OQ_5fdf9062-5ff0-4cd2-9e48-b13ca4915e82">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f74d8c31ae74b7fa6e4e39449d3df62_D20220402-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMy0xLTEtMS02NjMyNg_72bd9dcf-7671-488a-9141-3ec5a201363f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic9f47a8d0e664d6d84d3873e23fc60ad_D20210403-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMy0zLTEtMS02NjMyNg_f8d01442-8fe2-4927-a3d0-86b858afc884">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie59b3ee9c868431aaa28932ed170565e_D20220101-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMy01LTEtMS02NzA5Mg_20f79615-ebc0-4f8d-913b-986c0217ce8f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i335341eb633f4434b8610f4f0d41be82_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMy03LTEtMS03MjQ3NQ_05a60241-824a-4b09-9054-873e2de23b6c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id557498866464ef2bdf02ccdb8ede387_D20220402-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNC0xLTEtMS02NjMyNg_3f03c8b0-f6b8-44fd-aede-0a5a7e48fdf8">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie61a701acae34a7abd58a8f0dc4a3bbd_D20210403-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNC0zLTEtMS02NjMyNg_b1c913ad-84fa-4e6b-babf-59a1196a7f9b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie70c7ffb0e364a418f44f5b2fb7046a3_D20220101-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNC01LTEtMS02NzA5OA_d151246d-8233-4902-8d9c-da5a969cc20f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00cc9c53a3754125afaca64318f35370_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNC03LTEtMS03MjQ4Mg_f567f3eb-39ec-4a55-a72b-887adbfb564b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2fbfda11dc6c495abc4054a2e60213b2_D20220402-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNS0xLTEtMS02NjMyNg_40f6805c-7da9-4b2d-91c4-d5b04f89fb2b">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9004549ad6404156b209d07af26d7701_D20210403-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNS0zLTEtMS02NjMyNg_4f494818-cedc-4a8b-8b95-b5f2354e2627">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c826af902764b62b9b01c219b888602_D20220101-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNS01LTEtMS02NzEwNQ_89d6265d-6139-4250-b1e3-83eb2ccd9fb9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6dde7ba3d13446293bb96e14dad26d4_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNS03LTEtMS03MjQ5OQ_fc543e77-ac45-4cbb-80dd-f80f68cd0272">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i107d673b016341dba6ddac20be0bf0fa_D20220402-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNy0xLTEtMS03ODI5OA_60599333-a466-4821-94cf-27ce0d77b140">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e8e064972ed4cd69de87474a9c08e9a_D20210403-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNy0zLTEtMS03ODMwNA_5821978f-e18f-43ab-a236-c2939ae83dba">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i30e893865b1a401fa0a584689c74906c_D20220101-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNy01LTEtMS03ODMxMA_c8bb3052-334d-4ee5-8674-9531f21ce5ad">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d38bdc277d847c1bff9aea646f7b5d2_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNy03LTEtMS03ODMxNg_4dac9b24-c28d-4c39-942c-2f777f7c78c4">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie870ca4583284e068d8931189e43799a_D20220101-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfMS0xLTEtMS03ODU2NA_ac56013f-e900-4dfd-987f-b7a431de4165">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14ebf4acc76c40a8862a0cd9494ba17d_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfMS0zLTEtMS03ODU2NA_ecab156f-922f-4860-b1f4-5413eb0eddd4">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i664afc43ce6141e7926e690257545766_D20220101-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfMS0xLTEtMS02NjMyNg_7d6eb9ae-9eed-4e1c-ad28-377f69b4bbb6">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56c71bd1b9a544559774ad6cf16b1bc8_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfMS0zLTEtMS02NjMyNg_63857344-49fb-4515-a498-0d5e721fed76">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79b6e39380ee492b9465c8a189dc79c4_D20220101-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfMy0xLTEtMS02NjMyNg_0007bffb-a369-4b2a-80ab-68c2501de08c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d728a2065f34c5f99164244a2469b05_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfMy0zLTEtMS02NjMyNg_712c4553-4905-4a24-8d0f-aafe50bd8941">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3955701b6f504b6c9492fed7e52d6cac_D20220101-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfNC0xLTEtMS02NjMyNg_c7cd3a47-773c-4348-bbb9-72090bd73cc1">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8236363288634352a070bfdeae4ada52_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfNC0zLTEtMS02NjMyNg_511db237-4063-471e-a807-b8d3e7a6e010">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedf483295e3441dfb06c39992af1d0cc_D20220101-20220701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfNi0xLTEtMS03ODM0NQ_4ecfe09a-b520-445d-a57c-edcba9664a46">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57596bbb198e467e913bd95f788460dc_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfNi0zLTEtMS03ODM2Mg_cdaca7fc-5ca9-42d2-b4b3-2d8e2db10e4a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDcxMg_88741920-a14c-4181-9367-a8265111c4f7" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bde2f537a354fcca14f821547b896d9_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMi0xLTEtMS02NjMyNg_99b544aa-3e24-4652-8d42-c5858d784d56">349,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc1e3c9b038f4adbb0f8ca47a926170a_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMi0zLTEtMS02NjMyNg_89bcbf83-40bc-4011-acdc-de10bb041fc1">287,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21feba329f3c47ba847cdba72f05f74a_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMi01LTEtMS02NzE3Mg_c7510a90-c9b1-4a90-9c80-cdf578600e84">663,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c8f2e6e66e0483e9df068c8c67f6edd_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMi03LTEtMS02NzE2NQ_cbe7b501-d079-4a89-9a5a-5a8c68390a06">517,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09963410ea564c02b8ff6283d62b4527_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMy0xLTEtMS02NjMyNg_bf6183b2-46b7-454e-ab72-bcd949eb39a4">62,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e34c2a69d6c44dd87763d280f6add0f_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMy0zLTEtMS02NjMyNg_402ffb06-ccef-4fcf-940f-dd6b1f9cdfc2">90,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5c9264424540c9a4f238323ac0939f_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMy01LTEtMS03MjQzOA_74399a9a-82c4-42f1-9fcd-65a6f98217ec">96,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16714420b2fb49839858d28e6d5059ae_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMy03LTEtMS03MjQ1Ng_3fe74428-3b59-4f5b-86fd-a4a924e48862">124,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0b5c39cb3324983afed5da2408dadd7_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNC0xLTEtMS02NjMyNg_8acb847e-a6e5-4c19-a653-3f73dfd8b3f1">7,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e812ece3e94486a2fe21cbd2277bb5_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNC0zLTEtMS02NjMyNg_d8e4b5b7-6577-4919-95dd-4c651f7d7b7a">7,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i188d6447088e4f92a8f70243be252647_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNC01LTEtMS03MjQ0Mw_e456b6cb-0a8d-40d2-aaeb-81d65ab6fea2">14,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e97a0d79c07480eb88736adeb90ea7b_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNC03LTEtMS03MjQ2Mw_41da0918-bb5f-422f-ab71-001a1ba1b84a">13,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNS0xLTEtMS02NjMyNg_25bf34f6-3cfa-4b8f-9001-2495db2180d2">419,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNS0zLTEtMS02NjMyNg_f902a076-4d02-4315-8ff2-2c4d51326d9e">385,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNS01LTEtMS03NDQ4Ng_08732e9f-63c2-4f53-8d11-33cdbeadb855">775,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNS03LTEtMS03NDQ4OQ_ef0c198c-4060-485b-9417-7fea08d2a45b">655,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDcwMQ_038aa3fe-2678-40d5-9c50-43a438d74da0" continuedAt="i218c6a59ac27400786916d1165f04000" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.</span></div></ix:nonNumeric><ix:continuation id="ie1a8cd0980f84acba888dc3cf79fc6e8"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54050f41270d4c0994179a0b71bcbd09_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMi0xLTEtMS02NjMyNg_17448b49-4cfa-4f86-aec8-4dbd3829a2bd">339,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeea8eb188124f60a0aaeaa7d0940557_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMi0zLTEtMS02NjMyNg_eb619d42-2acc-4059-838f-3343a10f21da">275,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69844ba478ba4fe381bf568853c31297_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMi01LTEtMS02OTI1NQ_3902a12d-9ff6-4ec6-90e0-4064e5174954">641,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054896b94915439693f85afea696414b_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMi03LTEtMS02NzM3OQ_54105d4f-b963-478a-bde9-c8e436574658">499,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb0803dcbf5b4e67ad983af158cc6a71_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMy0xLTEtMS02NjMyNg_752f4310-387a-4a58-8cc8-62fde4522de9">7,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3101bd9ba54dbca9144e467e80187f_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMy0zLTEtMS02NjMyNg_f3c8327c-d25e-4006-9247-7d4722c4b988">8,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa34646405c478e99b9fd71f2184c6a_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMy01LTEtMS02OTI2MQ_acd95000-f2f2-4cd2-bb81-bbfc330eb12b">15,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35af551acc24804b0071e3db5e6fe35_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMy03LTEtMS02NzM4Ng_ef173931-9771-4fff-9bf3-454929cce41e">12,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0966f9eca84459ae2dd8ebc3309047_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfNC0xLTEtMS02NjMyNg_aa4c8ad1-bdee-453a-961f-0b051243df60">347,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b9e8d3facdf4864bb7c81214e9ad6f8_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfNC0zLTEtMS02NjMyNg_34814c9c-a8e4-4684-bd23-06442e628ad0">284,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42cf2e0fa214b5c803a30524005d09a_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfNC01LTEtMS02NjMyNg_0653941e-9e36-43dd-ad6f-3c3ca1f3d349">657,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i783842d281c14d18a5ab8e977fb76f4a_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfNC03LTEtMS02NjMyNg_40f4864e-2a94-4935-84ea-220f65d7e118">511,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><ix:continuation id="i609a4412026848a1818bfaa8641889d8" continuedAt="if66dea93de4240b8b723096cfa76bc31"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDcwNA_168632ef-23a6-4576-943a-0a525d4f52df" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:41.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53bb4fda56c4d03bcefd670f7e34159_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMS0xLTEtMS02NjMyNg_26d7f536-6284-4daa-b730-44050a8da861">14,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied4e111ae3b74e388273fc644813dcbf_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMS0zLTEtMS02NjMyNg_b7741113-1ada-4f03-a5cb-f81843223849">8,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840ea9693a1241dba5f3c957a1971f4e_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMS01LTEtMS02NjMyNg_e7b46a4a-a858-429b-a783-62aab02352d0">24,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMS05LTEtMS02NjMyNg_d64ff527-2a58-480b-b7dc-3cf7812be8a0">48,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168b07bb58fb45fea0c1251110528099_D20220101-20220701" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMy0xLTEtMS02NjMyNg_a5e40fe1-a033-498c-8f66-f8da189497dc">175,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e6ba1cc1ac40ba8c5827e2046e2bd1_D20220101-20220701" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMy0zLTEtMS02NjMyNg_416fa9b3-1e12-42f5-9229-1ebcb107bbcf">24,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ef9620b8e045d1ad550beff5449fb3_D20220101-20220701" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMy01LTEtMS02NjMyNg_894dc81e-20b1-45b2-9ba0-2483af251b89">72,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMy05LTEtMS02NjMyNg_086f192f-8383-4d9d-8082-308f6bb32f20">272,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168b07bb58fb45fea0c1251110528099_D20220101-20220701" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNC0xLTEtMS02NjMyNg_00ba85f7-a8df-4017-9487-8ce2efe647f2">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7e6ba1cc1ac40ba8c5827e2046e2bd1_D20220101-20220701" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNC0zLTEtMS02NjMyNg_192203b0-c311-4c09-83ce-eff90402ca72">168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37ef9620b8e045d1ad550beff5449fb3_D20220101-20220701" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNC01LTEtMS02NjMyNg_34c08371-debd-4c7e-acfb-c30836a6fd6a">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNC05LTEtMS02NjMyNg_54b24f5d-0968-4df4-83eb-8aca8748554f">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i168b07bb58fb45fea0c1251110528099_D20220101-20220701" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNS0xLTEtMS02NjMyNg_c24d45d1-e1d3-4185-90d7-e068bd247088">171,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7e6ba1cc1ac40ba8c5827e2046e2bd1_D20220101-20220701" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNS0zLTEtMS02NjMyNg_3a913d05-d44f-44c4-8a5b-d3c241320def">22,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37ef9620b8e045d1ad550beff5449fb3_D20220101-20220701" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNS01LTEtMS02NjMyNg_e65bcd75-4011-412c-b303-740c67b48a7b">64,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNS05LTEtMS02NjMyNg_1f0815b4-16f7-4699-97b9-4897c2c5622b">258,532</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife8f6fa225be4cf0b820fdededde5d76_I20220701" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNi0xLTEtMS02NjMyNg_87cc6178-b6da-45c7-9ed8-4d493c39bbc5">19,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d94301a72254e9d9c581087dcee3084_I20220701" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNi0zLTEtMS02NjMyNg_a8b41e44-b270-4859-b2fd-274223944f02">10,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a01e54ece8642d5b3a8cd53ce306b40_I20220701" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNi01LTEtMS02NjMyNg_423ac126-f991-4bcc-bc0b-f6debf4a35b8">32,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNi05LTEtMS02NjMyNg_7f2082a0-0ca6-48b9-bb14-23705aca5a30">63,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="i218c6a59ac27400786916d1165f04000"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule, and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDY5MA_699f5ab3-7f42-4290-abd3-42e10ae04136" continuedAt="i8dbcaaeff7b247189c87e438742eafba" escape="true">Contract assets and liabilities were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i8dbcaaeff7b247189c87e438742eafba" continuedAt="i6d983e9fdcfe4b8d86cb63c601583e72"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfNC0xLTEtMS02NjMyNg_771aa6cb-8e84-49db-8bde-be72e0b8214b">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfNC0zLTEtMS02NjMyNg_e12a0854-27cd-4f5b-920c-20ebdec8bc03">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfNy0xLTEtMS02NjMyNg_ad160e44-6177-4f51-a3ed-6b6c5540c9a7">7,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfNy0zLTEtMS02NjMyNg_cbed0832-02f3-418d-99d8-4a42bbb4cb01">7,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfOC0xLTEtMS02NjMyNg_2c06545b-1700-4f29-9557-b086116f63ba">7,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfOC0zLTEtMS02NjMyNg_28ae8ec1-47c8-4979-b275-674be8e30e21">8,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfOS0xLTEtMS02NjMyNg_00f1d0fa-07bc-4fdf-92f4-17e8bfdbd3b5">14,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfOS0zLTEtMS02NjMyNg_845b4c82-7c4e-438e-a33f-8468c7179cb6">16,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:continuation id="i6d983e9fdcfe4b8d86cb63c601583e72"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022 and 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNjA0NzMxMzk1NzYyNg_e22d48bb-613a-4f4c-9b57-252fffdc7e52">4.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfMzc1OQ_dcc3805a-fad7-4a3b-afe7-784776c74a58">4.8</ix:nonFraction>&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNjA0NzMxMzk1NzcwMg_727261bd-122f-42b4-af1c-9ed1981da84c">59.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNjA0NzMxMzk1NzY1Nw_48e640cd-b2f0-4b27-8334-aede01aeec62">91.1</ix:nonFraction>&#160;million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech and the recognition of license revenue for the achievement of milestones during the three months ended June 30, 2022, allocated to the license performance obligations for our collaboration with Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i772576eea90d4bb0929cdf808c536289_I20220701" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNjA0NzMxMzk1ODg3MQ_03c7f06e-03ed-4020-aaa6-20967f450989">89.3</ix:nonFraction>&#160;million of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he co</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mbined transaction prices for our Ipsen a</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Takeda collaborations were allocated to our research and development services performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if66dea93de4240b8b723096cfa76bc31">included in Part II, Item 8 of our Fiscal 2021 Form 10-K for additional information about the expected timing to satisfy these performance obligations.</ix:continuation></span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjI2MQ_b7177724-c00d-4404-a49e-2395a20de71b" continuedAt="i4d93e50ba6874b01a0620465f4ab5ba7" escape="true">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="i4d93e50ba6874b01a0620465f4ab5ba7" continuedAt="i49cfcd6b162343e0ae085839f5ba4336"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaborations, in-licensing arrangements and other strategic transactions to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading pharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K, as further described below, for additional information on certain of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjI3NQ_1d6476d6-6aef-41a3-b9ff-a7d7e6b66636" continuedAt="ib71239080f694985a2859a8137ab68c7" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2515b3d980437d88f874ad96264c8f_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMi0xLTEtMS02NjMyNg_d22a3023-8b64-4c79-a58e-dda94ddb265d">51,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfeb2faa92124a56beca5879006c456c_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMi0zLTEtMS02NjMyNg_45cee8b9-3632-42b2-9e58-5ccab454043e">33,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a867ee6b32d4d0ca8d6da06a0baf4f0_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMi01LTEtMS02NjMyNg_cfc29c42-e660-44ad-abb8-c2ba31e3eaff">75,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02072ae37a364e828c67a1f3675a3358_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMi03LTEtMS02NjMyNg_2abb8f93-8ce1-4a51-b31a-224a7f647421">56,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3b05ed939f4eea80b46d18a26cadad_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMy0xLTEtMS02NjMyNg_87a261f6-2835-48b4-9aa7-37d593623f9d">11,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7633a25d674d1d9065925fd26afcdf_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMy0zLTEtMS02NjMyNg_c8545dbf-f6a9-4a34-9388-237b565cd31f">57,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8679d3445ee744d6b8bd2814877f2e65_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMy01LTEtMS02NjMyNg_988b423f-660e-48ab-abe1-5915e204dd13">20,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib163ec7f845e44e9af8e12e633ddeb1e_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMy03LTEtMS02NjMyNg_5f6c66ab-1afa-4a37-a29c-41279bd5718b">68,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id082ca3812d9497f9a5419f7e2935ef1_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfNC0xLTEtMS02NjMyNg_659a2977-cd21-4927-bc9d-29fbe5e806da">62,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib008fa7a2c3348058b33ada2c3c90db2_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfNC0zLTEtMS02NjMyNg_5b33f68d-7dfe-4199-ae98-ebdf3710f89a">90,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e31b2ad1f74418b3fc3f615f610c44_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfNC01LTEtMS02NjMyNg_8a059a90-a25b-4f84-9935-b9eb3b88f4ff">96,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba0f6408f78479fa48647723afcaff3_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfNC03LTEtMS02NjMyNg_db7af3ad-89bc-425b-a8ca-1a9a7d8b2f03">124,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="id082ca3812d9497f9a5419f7e2935ef1_D20220402-20220701" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MzU1OA_625f9327-cefd-442e-bf5f-24fa8153a399">25.7</ix:nonFraction>&#160;million in revenues in connection with two regulatory milestones totaling $<ix:nonFraction unitRef="usd" contextRef="id082ca3812d9497f9a5419f7e2935ef1_D20220402-20220701" decimals="-5" name="exel:RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfOTM0NTg0ODg0NDc0Nw_33df874d-0678-4bfa-a072-f488d7fcd242">27.0</ix:nonFraction>&#160;million upon approval by the European Commission and Health Canada of cabozantinib as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="iab7278b18228461aa447d7af1ab75997_I20220701" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTU0Ng_34baa429-0dbe-4226-8700-1707e031407c">51.9</ix:nonFraction>&#160;million of the transaction price for this collaboration was allocated to our research and development services performance obligations that have not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><ix:continuation id="i49cfcd6b162343e0ae085839f5ba4336" continuedAt="i19ca93008334458f80aded7c240cd6d6"><ix:continuation id="ib71239080f694985a2859a8137ab68c7" continuedAt="ideb1c470639c40aeb75d0f97cf0a2607"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica98cb95722d43bc90dd8fdac8a16248_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMi0xLTEtMS02NjMyNg_8ef7a9c4-221d-4d24-a843-74f535f1466e">2,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5e7e3b485b4ccba1783e0a9e98bce2_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMi0zLTEtMS02NjMyNg_3899dd1c-a0bc-45b8-9ad5-6e8a1dd1994c">2,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faaa279485d47858ff462a4fe31d8cb_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMi01LTEtMS02NjMyNg_6b8b0dd6-bb7c-4f27-a20a-1d45b9b50b97">5,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1dc5dede6944878bb37ad9f5b90202c_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMi03LTEtMS02NjMyNg_fcf51b9e-bbb9-4b22-9724-caa1cfbe4660">3,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28f186b12114729ad0bcf462687594b_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMy0xLTEtMS02NjMyNg_f356732e-79b5-4ffc-b21d-018399ddd4b9">3,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb3c2f628159430fa2b4ba939626da68_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMy0zLTEtMS02NjMyNg_42dac5b8-385b-48ca-af0b-c86a4d96832f">4,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c34c70519cf4ccdb9cf2f1f898c0f47_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMy01LTEtMS02NjMyNg_a2763096-5908-4b97-90e6-6634bf6b702f">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib934a263672b49e2b398d9af12ca3f18_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMy03LTEtMS02NjMyNg_6cb3c2cd-9700-43e4-a05b-a2a22969973c">8,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5cfd9d83994869a3ed269eca638c4a_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfNC0xLTEtMS02NjMyNg_7386e6e4-6db1-4c58-979e-336b6fc0e34d">6,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21078b478324339b815339fdc2f5d2a_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfNC0zLTEtMS02NjMyNg_003d66c5-d1c7-4816-b0c1-8b71854c885f">6,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf36077e14546d49a6c6d7f64c0e7fa_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfNC01LTEtMS02NjMyNg_d64d0303-73e9-45b8-a369-85c3fdb4f132">12,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6b3af1cf525438ea1fdab7f2ae1a4b5_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfNC03LTEtMS02NjMyNg_a5df0da3-f913-454c-b961-718cd6db9929">11,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i9d122b6fe357426c8ad3468c325f4936_I20220701" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTU3OQ_a7ec0594-7d1c-43d6-854b-75f18a0fd57e">37.5</ix:nonFraction>&#160;million of the transaction price for this collaboration was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a <ix:nonFraction unitRef="number" contextRef="i37d0046d01764a6a84fff26e8dc7ad8e_D20220101-20220701" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfMzEyNg_b0fe9b9f-2f50-4e03-8925-0c0971263378">3</ix:nonFraction>% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib sold by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and in connection with sales by our collaboration partners are included as a reduction of collaboration services revenues. Such royalties were $<ix:nonFraction unitRef="usd" contextRef="iaa76717dc58d47e987e00cef2f0b1605_D20220402-20220701" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTY1Nw_9acb6edb-58de-4602-8fd1-f62064509024">14.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5d6438a867804b3690c45471a4365f52_D20220101-20220701" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTY3Mg_92c03704-3605-4920-893a-44715a32dc0a">27.7</ix:nonFraction>&#160;million during the three and six months ended June&#160;30, 2022, respectively, as compared to $<ix:nonFraction unitRef="usd" contextRef="i839cb707d2d1469585661ba26e60dba8_D20210403-20210702" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfOTM0NTg0ODg0NDc2OA_99241059-dc72-4983-88ce-ba5ba37ecf37">12.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i395367a2b6f840398cc68008eec67422_D20210102-20210702" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfOTM0NTg0ODg0NDc4Mw_6aa87e4a-0ce5-4934-a37b-28c95dba95ea">22.2</ix:nonFraction>&#160;million in the corresponding periods in 2021.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients.</span></div><ix:continuation id="ideb1c470639c40aeb75d0f97cf0a2607"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9403b468905b44ddb12619327a4d1331_D20220402-20220701" decimals="-3" name="exel:CollaborativeArrangementIncomeLossFromAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMi0xLTEtMS02NjMyNg_fe9eca41-2531-4717-b571-cd57369d6885">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0536dbf918041b2a030788539bad217_D20210403-20210702" decimals="-3" name="exel:CollaborativeArrangementIncomeLossFromAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMi0zLTEtMS02NjMyNg_42cbda30-8c4e-4bd2-88fb-c6853a7a74a8">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab318d80ac145cfa0dd2bc25b9ffc19_D20220101-20220701" decimals="-3" name="exel:CollaborativeArrangementIncomeLossFromAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMi01LTEtMS02NjMyNg_e47e2925-430a-4b7f-ae4d-03aec837c0a6">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d942e3ddd54d17abcf3f8dd59c4d5f_D20210102-20210702" decimals="-3" name="exel:CollaborativeArrangementIncomeLossFromAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMi03LTEtMS02NjMyNg_d8bf2548-11ff-4a0b-bfba-52f44bf80ae8">3,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9403b468905b44ddb12619327a4d1331_D20220402-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMy0xLTEtMS02NjMyNg_ea142799-2fd0-413f-9f90-8eec8b72af08">889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0536dbf918041b2a030788539bad217_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMy0zLTEtMS02NjMyNg_a61f5d67-d3cf-498e-992f-501d298cee9d">782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab318d80ac145cfa0dd2bc25b9ffc19_D20220101-20220701" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMy01LTEtMS02NjMyNg_cf0b2244-600e-4698-a728-b84fac0e3f04">2,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d942e3ddd54d17abcf3f8dd59c4d5f_D20210102-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMy03LTEtMS02NjMyNg_50634b66-e52a-4b2e-8cb5-3a15a93755f6">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, development, regulatory, commercial milestone payments and royalty payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then, in most instances we will assume the responsibilities for all subsequent clinical development, manufacturing and commercialization. In conjunction with each of these collaborative in-licensing arrangements, we were subject to upfront payments and will make payments for potential future development, regulatory, and commercial milestones as well as royalties on future net product sales.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><ix:continuation id="i19ca93008334458f80aded7c240cd6d6"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we entered into an exclusive option and license agreement with BioInvent International AB (BioInvent), upon which we paid BioInvent an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i2b5ed8e63d724ab1b37ae2306c7d0aa7_D20220601-20220630" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfOTM0NTg0ODg0NDc5OA_7fbff42f-c62a-4258-bb83-de644c8a53b7">25.0</ix:nonFraction>&#160;million. Upon option exercise, we will pay BioInvent an option exercise fee, and BioInvent will be eligible for additional payments from us for future development and commercial milestones, as well as royalties on future net product sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of June 30, 2022, in conjunction with each of our collaborative in-licensing arrangements, and an asset purchase agreement entered in 2021, we will make payments for potential future development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="ibfc05a0f9c9a41eb9f99aed54fd26749_I20220701" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTkwMQ_264c7227-54c3-41fa-a1cb-985a77cb6fbf">321.8</ix:nonFraction>&#160;million, regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="ibfc05a0f9c9a41eb9f99aed54fd26749_I20220701" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTkzOA_7757aaa3-57e9-4448-93d4-d20d7491fe21">453.7</ix:nonFraction>&#160;million and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="ibfc05a0f9c9a41eb9f99aed54fd26749_I20220701" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTgxNg_dd6490db-4049-4cb5-8a02-da8f6a176e70">2,070.7</ix:nonFraction>&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales.</span></div></ix:continuation><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjk4MA_f79edd9c-f68d-4579-93b0-d2766cc6387e" continuedAt="i715bfa94119147e187b60a1f8d3dc275" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i715bfa94119147e187b60a1f8d3dc275" continuedAt="icec8deb7a9214a4dadd3d3e30e5f4b50"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjk3MQ_d28b3994-19eb-4d45-9aca-21fb03c80fa7" continuedAt="i9020cab30f6e4f14a40bcedd4ac59c99" escape="true"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjk5Mw_6ad53ba7-9d0f-4cdf-88b9-4adebc66f25f" continuedAt="i63854f5d42a7468790523aa91913b81d" escape="true">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i9020cab30f6e4f14a40bcedd4ac59c99"><ix:continuation id="i63854f5d42a7468790523aa91913b81d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExZDM3OTE5N2U3MjQ0YzViMzU0MWQ0M2MwZWI4NzZhL3RhYmxlcmFuZ2U6MTFkMzc5MTk3ZTcyNDRjNWIzNTQxZDQzYzBlYjg3NmFfMS0xLTEtMS02NjMyNg_19bfcb81-142f-4f23-b2a9-adf0e0d88347">627,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExZDM3OTE5N2U3MjQ0YzViMzU0MWQ0M2MwZWI4NzZhL3RhYmxlcmFuZ2U6MTFkMzc5MTk3ZTcyNDRjNWIzNTQxZDQzYzBlYjg3NmFfMS0zLTEtMS02NjMyNg_8865e94e-016e-41f6-aa14-47afad62aab3">647,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExZDM3OTE5N2U3MjQ0YzViMzU0MWQ0M2MwZWI4NzZhL3RhYmxlcmFuZ2U6MTFkMzc5MTk3ZTcyNDRjNWIzNTQxZDQzYzBlYjg3NmFfMy0xLTEtMS02NjMyNg_4d972b51-f931-4153-8420-81063d1b65e4">10,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExZDM3OTE5N2U3MjQ0YzViMzU0MWQ0M2MwZWI4NzZhL3RhYmxlcmFuZ2U6MTFkMzc5MTk3ZTcyNDRjNWIzNTQxZDQzYzBlYjg3NmFfMy0zLTEtMS02NjMyNg_8317dac3-6afa-455a-a941-a5d5305c231c">16,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExZDM3OTE5N2U3MjQ0YzViMzU0MWQ0M2MwZWI4NzZhL3RhYmxlcmFuZ2U6MTFkMzc5MTk3ZTcyNDRjNWIzNTQxZDQzYzBlYjg3NmFfNC0xLTEtMS02NjMyNg_fbbd5b18-6a13-4dad-9538-73e0f83059ce">637,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExZDM3OTE5N2U3MjQ0YzViMzU0MWQ0M2MwZWI4NzZhL3RhYmxlcmFuZ2U6MTFkMzc5MTk3ZTcyNDRjNWIzNTQxZDQzYzBlYjg3NmFfNC0zLTEtMS02NjMyNg_ade2a21d-889c-450a-9d50-3014e013e3d7">663,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, restricted cash equivalents included $<ix:nonFraction unitRef="usd" contextRef="i1989bb1580374884bd42c103f79e3cb9_I20220701" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfNzIy_a72db169-a52d-460b-8747-43dea587550c">9.2</ix:nonFraction>&#160;million of short-term investments, which is collateral under our January 2021 standby letter of credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our January 2021 standby letter of credit will remain effective through August 31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjk1OQ_b79e7896-b4c3-458a-80ae-5d5c6eca1a2c" continuedAt="i4dc850d1cfd74c5995d56c2011721365" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c8d749d7584b6199a2924e8a1e9a41_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMy0xLTEtMS02NjMyNg_fa44f24d-cf88-44ac-ac04-150c0bfe730a">880,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c8d749d7584b6199a2924e8a1e9a41_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMy0zLTEtMS02NjMyNg_f1fb3637-1800-44ff-9f4e-dd92abf6285e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c8d749d7584b6199a2924e8a1e9a41_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMy01LTEtMS02NjMyNg_7db85ba8-122c-4049-9097-0323e2565217">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c8d749d7584b6199a2924e8a1e9a41_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMy03LTEtMS02NjMyNg_8962fd8a-2457-4828-9362-8ba4ec17d287">880,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03769550f9144c9984b85e0c5923a535_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNC0xLTEtMS02NjMyNg_9e8615f5-7599-4cb7-9a36-bf6908a26974">573,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03769550f9144c9984b85e0c5923a535_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNC0zLTEtMS02NjMyNg_06577316-10ae-4003-9f15-bf8f5f82acbb">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03769550f9144c9984b85e0c5923a535_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNC01LTEtMS02NjMyNg_b0959377-c4d7-4b41-abd5-1f3bff76a946">9,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03769550f9144c9984b85e0c5923a535_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNC03LTEtMS02NjMyNg_94eb3f1f-c287-4859-baa0-99549321e452">564,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNS0xLTEtMS02NjMyNg_c45ecb23-9c00-4c0e-9834-2ab2e67e78e6">255,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNS0zLTEtMS02NjMyNg_d28ff075-e086-466b-9674-cf0d4cd09e3a">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNS01LTEtMS02NjMyNg_574967c5-9ce4-4090-9331-83d447f86761">2,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNS03LTEtMS02NjMyNg_e6db0e1c-3d3b-4c9e-b635-98859acc1373">253,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if453d9270ba64e94a9244e7992459ee8_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNi0xLTEtMS02NjMyNg_57b1da5d-e65c-4728-a5b5-91936cbda8d8">12,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if453d9270ba64e94a9244e7992459ee8_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNi0zLTEtMS02NjMyNg_33ef8e3c-5b8e-483e-86e8-664ded5e9245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if453d9270ba64e94a9244e7992459ee8_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNi01LTEtMS02NjMyNg_dbba8af3-fa33-4a96-b5f4-ef1971523ec8">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if453d9270ba64e94a9244e7992459ee8_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNi03LTEtMS02NjMyNg_30e2c4da-beed-4872-b918-21278d2460a1">12,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNy0xLTEtMS02NjMyNg_8da9843d-64a9-4a54-9dcf-1311972c0a43">1,721,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNy0zLTEtMS02NjMyNg_c42b498c-ced7-45dc-b668-0a35bea86fde">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNy01LTEtMS02NjMyNg_14f45879-b120-46e5-864c-76d4fa6b405a">11,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNy03LTEtMS02NjMyNg_5dcba171-c18d-4810-b2ac-44a43c389f32">1,710,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1699183c5c004e00bb9e1dd4a3f6355d_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOC0xLTEtMS02NjMyNg_76937132-3841-45cc-a141-cccba84d9b2e">80,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1699183c5c004e00bb9e1dd4a3f6355d_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOC0zLTEtMS02NjMyNg_d49530d0-f784-4cf6-8cd7-e749b760402a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1699183c5c004e00bb9e1dd4a3f6355d_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOC01LTEtMS02NjMyNg_82c2e1cd-35a2-4270-9b10-47ee7393db78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1699183c5c004e00bb9e1dd4a3f6355d_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOC03LTEtMS02NjMyNg_d71f5819-b760-4b4b-9be4-eabc793eab8e">80,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0451da3ec05541229c7b26c8a138441a_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOS0xLTEtMS02NjMyNg_ca3193ba-7140-447c-8c09-7d30885484ec">87,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0451da3ec05541229c7b26c8a138441a_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOS0zLTEtMS02NjMyNg_79ad8128-a07d-4ad2-8259-236417965e83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0451da3ec05541229c7b26c8a138441a_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOS01LTEtMS02NjMyNg_b8dcfd70-3721-4d5c-99b8-5f118f5414c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0451da3ec05541229c7b26c8a138441a_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOS03LTEtMS02NjMyNg_44bb3a8a-bd0b-4cfb-8713-8e65046146e4">87,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0503cc8f8c754670b0adbd270a4852eb_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTAtMS0xLTEtNjYzMjY_adfe7264-708a-4255-a5c4-adffcf79dfcd">130,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0503cc8f8c754670b0adbd270a4852eb_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTAtMy0xLTEtNjYzMjY_38cd7a97-7011-4793-a8e4-72a78b111e08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0503cc8f8c754670b0adbd270a4852eb_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTAtNS0xLTEtNjYzMjY_0e0028ec-e6b9-44a3-8eaa-47e2df342d45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0503cc8f8c754670b0adbd270a4852eb_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTAtNy0xLTEtNjYzMjY_a8c41264-7f2a-4050-89e9-302132a792fd">130,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTEtMS0xLTEtNjYzMjY_5e36f143-aa6e-4731-8209-566e9aa97b4a">2,020,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTEtMy0xLTEtNjYzMjY_aa048344-ab26-4bdd-8d0b-305e8587313d">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTEtNS0xLTEtNjYzMjY_33ebf661-3417-4511-9721-2c5f62a8e226">11,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTEtNy0xLTEtNjYzMjY_706af30a-7763-4ecd-a45b-c92492730a8e">2,009,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><ix:continuation id="icec8deb7a9214a4dadd3d3e30e5f4b50" continuedAt="i25351ab4c1ff43c19c530506d80111d9"><div style="margin-top:9pt;text-align:center"><ix:continuation id="i4dc850d1cfd74c5995d56c2011721365"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec985d2c22946468e2db7ee7e8fdd66_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMy0xLTEtMS02NjMyNg_93774163-d203-40d2-b034-18e4ffc2494f">945,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec985d2c22946468e2db7ee7e8fdd66_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMy0zLTEtMS02NjMyNg_dfa84e86-a6c3-4dee-8cee-a167fe56c574">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec985d2c22946468e2db7ee7e8fdd66_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMy01LTEtMS02NjMyNg_9a906da9-7491-48bb-85fc-24b3a49088fc">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec985d2c22946468e2db7ee7e8fdd66_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMy03LTEtMS02NjMyNg_5c64ce9b-156f-44cd-bbfd-15de9a1dd7ad">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie325f3ade8d44aa1a927d9ea4b117375_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNC0xLTEtMS02NjMyNg_49500bc5-c842-4d6d-b022-b6897f60ede9">541,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie325f3ade8d44aa1a927d9ea4b117375_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNC0zLTEtMS02NjMyNg_af160f9f-c015-4461-96b6-5a830a29ccf9">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie325f3ade8d44aa1a927d9ea4b117375_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNC01LTEtMS02NjMyNg_90a8c0b8-af95-4e0f-8e89-39772d1a1699">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie325f3ade8d44aa1a927d9ea4b117375_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNC03LTEtMS02NjMyNg_e58b7217-c88a-427b-9b6a-7c67d5acb2ad">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a744931712846de898f2a9ba07534f7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNS0xLTEtMS02NjMyNg_0b06bbb0-c05f-43b5-9606-743a475190e2">33,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a744931712846de898f2a9ba07534f7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNS0zLTEtMS02NjMyNg_c9b180f7-853b-4659-a4d3-503907660e54">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a744931712846de898f2a9ba07534f7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNS01LTEtMS02NjMyNg_a9c79331-3377-4178-bf19-c6ccf2887442">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a744931712846de898f2a9ba07534f7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNS03LTEtMS02NjMyNg_4a786adf-77f0-4297-95c3-6fb4a27261c1">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f56488c0f264c679e4506474188a292_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNi0xLTEtMS02NjMyNg_7f0964ba-fac0-42b2-acc9-44f5b92d956a">12,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f56488c0f264c679e4506474188a292_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNi0zLTEtMS02NjMyNg_e52de9ec-b4b2-404b-92cf-ca6da3f5cf31">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f56488c0f264c679e4506474188a292_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNi01LTEtMS02NjMyNg_d46e9b36-5f77-495a-9b38-9594697d56dc">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f56488c0f264c679e4506474188a292_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNi03LTEtMS02NjMyNg_5809558f-6b30-4e22-9184-9c98f318d0bb">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNy0xLTEtMS02NjMyNg_f60ae5d8-b210-46ba-b806-37c648d189b9">1,534,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNy0zLTEtMS02NjMyNg_97c8f6c9-c72a-4225-a70a-ce7e3980267c">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNy01LTEtMS02NjMyNg_8a17de7e-ff78-4d3b-abd1-69dc801b6ba2">1,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNy03LTEtMS02NjMyNg_bb17296f-c0fc-4dbc-9931-c4c411f23463">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9786b6a841764a17b8436d495f0e5d65_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOC0xLTEtMS02NjMyNg_f22b8ceb-d9c9-40c2-8545-ea83909ab356">135,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9786b6a841764a17b8436d495f0e5d65_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOC0zLTEtMS02NjMyNg_66adc7d7-63e4-4f77-b1cd-9782f7e45fd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9786b6a841764a17b8436d495f0e5d65_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOC01LTEtMS02NjMyNg_f219ea74-4d7e-4502-b50d-f0f0a6431e83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9786b6a841764a17b8436d495f0e5d65_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOC03LTEtMS02NjMyNg_372852f8-8df2-411b-b277-ada2174283a0">135,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib217aade91424cacbff6d49127cff87f_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOS0xLTEtMS02NjMyNg_3acc9338-9465-489b-9aa9-dde38da0fea9">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib217aade91424cacbff6d49127cff87f_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOS0zLTEtMS02NjMyNg_9304d13b-1abb-45bd-9a88-97232ca95bcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib217aade91424cacbff6d49127cff87f_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOS01LTEtMS02NjMyNg_493a658d-7cd4-41f3-ab59-c579b45c4eb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib217aade91424cacbff6d49127cff87f_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOS03LTEtMS02NjMyNg_650590f9-46a3-488c-a262-879248cd88d2">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534afc4a026f4e9aafc43cba5359abc6_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTAtMS0xLTEtNjYzMjY_22d4e3c7-6dd1-4d20-86fe-a671722bcd60">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534afc4a026f4e9aafc43cba5359abc6_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTAtMy0xLTEtNjYzMjY_64b99e2c-6756-4fe1-8efe-0f8a18f4d893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534afc4a026f4e9aafc43cba5359abc6_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTAtNS0xLTEtNjYzMjY_038fc5a1-42fc-4b92-82c0-88e093935ed6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534afc4a026f4e9aafc43cba5359abc6_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTAtNy0xLTEtNjYzMjY_d3d52e7d-9229-4819-b9b3-1a6d6b775885">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTEtMS0xLTEtNjYzMjY_632264c6-9a65-4579-9820-015526dc4dc9">1,855,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTEtMy0xLTEtNjYzMjY_52adad0b-8681-479d-857d-f7853b06e689">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTEtNS0xLTEtNjYzMjY_6281f110-4315-4cc1-a37f-631c73a748de">1,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTEtNy0xLTEtNjYzMjY_d2e54e93-b05d-4f59-a3d6-57ba83fecd99">1,854,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $<ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMTM0Nw_70167168-53fc-4600-870a-94427fc13713">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMTM1NA_debae1dd-acfc-48ad-aac5-43057d1d4b16">2.9</ix:nonFraction> million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2021, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three and six months ended June&#160;30, 2022, and 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjk2OQ_b7a6fcca-6597-4d95-bc3c-c804cf95e06a" continuedAt="i346f19fc29c24f0fb68b322837a4b958" escape="true">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i346f19fc29c24f0fb68b322837a4b958"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03769550f9144c9984b85e0c5923a535_I20220701" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfMy05LTEtMS02NjMyNg_ee7dca15-0374-4503-82c3-9436c5aa1113">540,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03769550f9144c9984b85e0c5923a535_I20220701" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfMy0xMS0xLTEtNjYzMjY_80056c38-4373-40d0-9ded-4de0f7be10aa">9,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfNC05LTEtMS02NjMyNg_2098d5f1-dc25-4b9e-92b4-9fb73ac1a314">237,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfNC0xMS0xLTEtNjYzMjY_e5222663-709a-474c-8832-45a6d441b88d">2,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c8d749d7584b6199a2924e8a1e9a41_I20220701" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfNS05LTEtMS02NjMyNg_e614b6d6-0d68-49ff-bb20-8cc2b5216235">14,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c8d749d7584b6199a2924e8a1e9a41_I20220701" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfNS0xMS0xLTEtNjYzMjY_dc1c5347-b2a8-4888-8111-0fdf5c64fe26">107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if453d9270ba64e94a9244e7992459ee8_I20220701" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfNi05LTEtMS02NjMyNg_bf01d936-c7b9-492d-9464-0b2b7d1432bd">12,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if453d9270ba64e94a9244e7992459ee8_I20220701" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfNi0xMS0xLTEtNjYzMjY_88cebd36-2c69-497a-92db-52bb661cff23">202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfOC05LTEtMS02NjMyNg_19ad45ed-4241-44d0-8349-b97e04c6c061">804,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfOC0xMS0xLTEtNjYzMjY_c443a9ea-1055-49f5-87c1-cc88773670a1">11,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.227%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie325f3ade8d44aa1a927d9ea4b117375_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfMi05LTEtMS02NjMyNg_5e43e571-4dfe-4d17-bfc0-989648ef4d1e">385,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie325f3ade8d44aa1a927d9ea4b117375_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfMi0xMS0xLTEtNjYzMjY_db5911ef-3ad3-4a43-a374-57390ba723b0">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec985d2c22946468e2db7ee7e8fdd66_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfMy05LTEtMS02NjMyNg_ffc5b662-23b3-4804-b66b-5e10473a493b">43,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieec985d2c22946468e2db7ee7e8fdd66_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfMy0xMS0xLTEtNjYzMjY_da89d428-9e5e-4d29-9f7f-53a5c3013813">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a744931712846de898f2a9ba07534f7_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfNC05LTEtMS02NjMyNg_6076c889-211e-463e-93e0-ef0b0ab99b74">18,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a744931712846de898f2a9ba07534f7_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfNC0xMS0xLTEtNjYzMjY_37de9619-b4f4-42ba-9a60-a81a0aab64b5">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f56488c0f264c679e4506474188a292_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfNS05LTEtMS02NjMyNg_1dcd3c5f-f9d2-42e1-b885-4559ea02f80a">7,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f56488c0f264c679e4506474188a292_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfNS0xMS0xLTEtNjYzMjY_678d4e5c-aec4-432f-a3ac-af3a24a50f90">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfNi05LTEtMS02NjMyNg_0e8c9318-09da-4e37-b465-8b2bb80ede76">454,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfNi0xMS0xLTEtNjYzMjY_35e79441-7592-4a6a-b3a0-5e0dd49e9611">1,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="investment" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMTk4NQ_c78404fa-cf69-4090-8cfe-a8408b730de9">237</ix:nonFraction> and <ix:nonFraction unitRef="investment" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMTk5Mg_199011f4-24cb-47fa-a949-8e7d09ab0170">133</ix:nonFraction> investments in an unrealized loss position as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2021, respectively. All securities presented above have been in an unrealized loss position for less than twelve months except for six corporate bond securities with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="i03769550f9144c9984b85e0c5923a535_I20220701" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjI0Mg_c77f48db-04f5-40b4-a9ee-7c2bc932317f">18.1</ix:nonFraction>&#160;million and an aggregate immaterial unrealized loss as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the six months ended June 30, 2022, and 2021, we did <ix:nonFraction unitRef="usd" contextRef="ide7e987c180a418585f377e54ea41af1_I20210702" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjMyOQ_0cf331be-ab89-4ea9-baad-9b80f1045ace"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjMyOQ_8cdffa13-7f38-4989-a393-a6c0d310fb58">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><ix:continuation id="i25351ab4c1ff43c19c530506d80111d9"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjk3Ng_85fb5aaa-cd66-43c5-9c2f-b7d6d5d83a7b" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOmJmYmE3MGU4OTA4ZDRhMjc5OGE1YjhhNmZlZjcyZWE1L3RhYmxlcmFuZ2U6YmZiYTcwZTg5MDhkNGEyNzk4YTViOGE2ZmVmNzJlYTVfMS0xLTEtMS02NjMyNg_92daa4f7-82b1-4f5f-8ece-75cc8609f03a">1,253,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOmJmYmE3MGU4OTA4ZDRhMjc5OGE1YjhhNmZlZjcyZWE1L3RhYmxlcmFuZ2U6YmZiYTcwZTg5MDhkNGEyNzk4YTViOGE2ZmVmNzJlYTVfMS0zLTEtMS02NjMyNg_fdb8bc97-f904-4b67-a088-4d4e286dba4e">1,168,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOmJmYmE3MGU4OTA4ZDRhMjc5OGE1YjhhNmZlZjcyZWE1L3RhYmxlcmFuZ2U6YmZiYTcwZTg5MDhkNGEyNzk4YTViOGE2ZmVmNzJlYTVfMi0xLTEtMS02NjMyNg_990e4f0b-8125-4448-a3fd-9586b4f737cc">456,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOmJmYmE3MGU4OTA4ZDRhMjc5OGE1YjhhNmZlZjcyZWE1L3RhYmxlcmFuZ2U6YmZiYTcwZTg5MDhkNGEyNzk4YTViOGE2ZmVmNzJlYTVfMi0zLTEtMS02NjMyNg_4d72b77d-0ec1-4204-881c-d1278c94974e">365,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOmJmYmE3MGU4OTA4ZDRhMjc5OGE1YjhhNmZlZjcyZWE1L3RhYmxlcmFuZ2U6YmZiYTcwZTg5MDhkNGEyNzk4YTViOGE2ZmVmNzJlYTVfMy0xLTEtMS02NjMyNg_df09c419-5c3d-49d2-820f-5bae951b28c4">1,710,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOmJmYmE3MGU4OTA4ZDRhMjc5OGE1YjhhNmZlZjcyZWE1L3RhYmxlcmFuZ2U6YmZiYTcwZTg5MDhkNGEyNzk4YTViOGE2ZmVmNzJlYTVfMy0zLTEtMS02NjMyNg_005cf349-0aaa-4ab0-b72f-e54d3b01dc72">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMjM2MQ_5a2e6723-6701-44c7-82f7-81fd0a30c557" continuedAt="i4cd7936dfba34587a7610f313d3b4d43" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i4cd7936dfba34587a7610f313d3b4d43" continuedAt="i4dea2e51cbe54d36b8624248dd568f81"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMjM3MQ_5d95f07a-669d-43c6-9722-de19bbc8dcc0" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c3df4ca36254ec4a53aa642de2052fd_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfMi0xLTEtMS02NjMyNg_574fca52-d516-407c-9b90-df620ede977d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b987f3b567145a39c76a99080d73be8_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfMi0zLTEtMS02NjMyNg_a5dcf1a0-ca7b-45b3-a42d-18e474b29cd3">880,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98d96a4511c47b9976557bf8ed9d3ea_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfMi01LTEtMS02NjMyNg_30949088-5039-4c3b-95fc-9aed3ea5969a">880,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e65916b15b411381657ad58dd0a7e7_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfMy0xLTEtMS02NjMyNg_2ff3ad00-29eb-4872-b7d1-7a266e4d57d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4001c4a298441f39a683b1fdcf12c32_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfMy0zLTEtMS02NjMyNg_28ef8975-5a16-412f-9d6c-783222fdfe44">564,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bf40d8ebf840d0975f8df43474ebcf_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfMy01LTEtMS02NjMyNg_c4628812-c55d-48c8-9839-817783b0b17f">564,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i182702258c9044e19db73717afe1ba2e_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNC0xLTEtMS02NjMyNg_6868ec4a-c23d-49f0-8563-1c9629da7a46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib08fb62625a144fb8b5d4cbf945345e7_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNC0zLTEtMS02NjMyNg_a0b8b355-fa1d-46a6-bc3c-c395717726db">253,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3322c81a75204e04b49bcd282f9082ad_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNC01LTEtMS02NjMyNg_7b08923f-1ff5-4bb3-86b0-523022f48d31">253,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2c9be6723b4ecc857b1318d9a40a7c_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNS0xLTEtMS02NjMyNg_cdfdbb92-e60f-4fce-8c8a-8978d229f84f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3ad6acbfea40668adabc0d0ae06c0b_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNS0zLTEtMS02NjMyNg_2a792a8a-e333-4fc7-ae66-aa88891f691b">12,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bec5ac658b94646b56ba00d21fd274f_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNS01LTEtMS02NjMyNg_2e5ebc46-13f2-4843-b1bd-b91f67f94f1e">12,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa5514df76b4a5289b9dab0ab958760_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNi0xLTEtMS02NjMyNg_b1f3aa47-3dd1-4076-9e91-b3a81760bd37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e391b43e0914915bee3cd7d5073d918_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNi0zLTEtMS02NjMyNg_f3c08709-78f5-4790-8d05-a36f350f40fb">1,710,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa7e06004bf493583d8ea1de5a444ae_I20220701" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNi01LTEtMS02NjMyNg_005c88b9-68b2-4387-8beb-459f45060d8b">1,710,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5552036575a7423281fcbd4cb49bcea7_I20220701" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNy0xLTEtMS02NjMyNg_8091d076-58c9-4a26-bfdd-736ce0774bc4">87,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80c87c83caf14e26b70ae4c672e30e2b_I20220701" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNy0zLTEtMS02NjMyNg_654dbfe9-4d2c-4e78-9aca-92cb264d01ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f5ca710be364f0da48207b91de352a3_I20220701" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNy01LTEtMS02NjMyNg_87ca8dc6-b25f-46c2-97a0-ad32e1baf81b">87,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a622ef9643442a9a59c6d3cc3663f1_I20220701" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfOC0xLTEtMS02NjMyNg_a6d16575-1ea9-42e0-8976-e84ec49d45a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619648b30df241fbb45ec26d4592f421_I20220701" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfOC0zLTEtMS02NjMyNg_f8e9e66f-5db8-4485-a25b-839ccfe80d25">130,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8287e312ca114e8e93490b2d88392315_I20220701" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfOC01LTEtMS02NjMyNg_fd44d2bb-f5ea-439a-9b47-eb67489d9ec6">130,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa5514df76b4a5289b9dab0ab958760_I20220701" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfOS0xLTEtMS02NjMyNg_31796abe-9b91-44d0-96f3-b0758326d54f">87,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e391b43e0914915bee3cd7d5073d918_I20220701" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfOS0zLTEtMS02NjMyNg_00619629-a1e7-477b-bd8c-72f054fe9d04">1,840,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa7e06004bf493583d8ea1de5a444ae_I20220701" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfOS01LTEtMS02NjMyNg_d91fa70e-2178-4d60-b16a-430ee3eb9a2b">1,928,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5daf776b964c24b6e400bd55663894_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfMi0xLTEtMS02NjMyNg_ad33ccd5-3a45-42e5-8140-d7c38da7baaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6206d802e34860b2b50b24991812bd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfMi0zLTEtMS02NjMyNg_73835ee8-9465-4a9f-ba80-000d32d88a41">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129784cda6eb4132aed1c7cf8bb7db12_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfMi01LTEtMS02NjMyNg_e6da35a1-b698-4ab2-9a7b-928fcc4fe0af">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c0e8d11fc14158ad314c1ac66746ff_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfMy0xLTEtMS02NjMyNg_bba4fe1d-5c16-4d56-a1bc-76c6bd8fee93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd4a3e3e3a74aebb9eec590702a773b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfMy0zLTEtMS02NjMyNg_2ed0f626-febd-432c-b2c0-d8889b080410">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46639be8a28240e1a86dea7f936b0a6a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfMy01LTEtMS02NjMyNg_e798372f-a772-42a9-9e14-0aaee46d7a01">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib916c6956341489bba5b28db02a30837_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNC0xLTEtMS02NjMyNg_617f308e-13e9-4850-8c8b-80178a62d133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d149a9eefd4440a22b0d5b7e870327_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNC0zLTEtMS02NjMyNg_cbb7a111-9fdb-4b2d-b423-7ff53e370a09">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4306bdd2ea4e91bb97b8be2b61b651_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNC01LTEtMS02NjMyNg_303a3bdd-2920-4122-b47b-6238706cea9a">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba54d40c2bc64ef4bdb52d572de09fa5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNS0xLTEtMS02NjMyNg_38b4c303-097a-48f8-ade7-11ff272f9c10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0b629b04984a1eac7d47c831d167f6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNS0zLTEtMS02NjMyNg_23ff1fe3-e044-4de9-ab33-99eee2082c29">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefecc78bc743406c8b43fad567aad8d0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNS01LTEtMS02NjMyNg_8cb6d738-0bed-4402-8ec9-de940b1d93f0">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0696d13063a422b94ceaf169c4d5572_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNi0xLTEtMS02NjMyNg_b127a4f1-d124-4218-a1aa-d93d5e9ced13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb1fcad1a5f14b1ead0a41c83a2d65ca_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNi0zLTEtMS02NjMyNg_9877d15c-8b6e-49a4-9339-a75528c8cd57">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6cf4c54fd4471291a5a225c2026764_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNi01LTEtMS02NjMyNg_4f89f161-4ad9-4a74-bb7a-775ab007a547">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica317fbf66054d0d9b5755dec32fb97d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNy0xLTEtMS02NjMyNg_a774ee82-4b9d-4ce6-8459-27fdedd811cf">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6b02b5522f4c62b5630f7652995697_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNy0zLTEtMS02NjMyNg_6e765308-da06-4416-a357-24502ae60a78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f38a828dd704e21b97feddadcce5b63_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNy01LTEtMS02NjMyNg_047b8fd0-495e-4e12-816c-4ba7063f8631">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aba76e7e4d6469a8ced5f3ac2c0957d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfOC0xLTEtMS02NjMyNg_403fa39e-e976-44c0-b42b-a73387ed0c7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5ac02de86e497ca09eaa96e8d84aef_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfOC0zLTEtMS02NjMyNg_3478a623-206c-4a8b-90a0-3ee83cb366b8">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i419d7d0e02084f7482be6ce902493727_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfOC01LTEtMS02NjMyNg_32c7829d-b95d-4660-9cc9-e41b578fa701">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0696d13063a422b94ceaf169c4d5572_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfOS0xLTEtMS02NjMyNg_ea120c34-7cf5-43c4-89b5-0e7b384f9fe7">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb1fcad1a5f14b1ead0a41c83a2d65ca_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfOS0zLTEtMS02NjMyNg_f1b4262e-f304-4ea5-90fc-80d913b2f099">1,652,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6cf4c54fd4471291a5a225c2026764_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfOS01LTEtMS02NjMyNg_5ddd1bcc-a8b8-40d7-a9d3-da38ecf0013c">1,719,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><ix:continuation id="i4dea2e51cbe54d36b8624248dd568f81"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had <ix:nonFraction unitRef="forward_contract" contextRef="i38408adaba6d4341adb12d55daf8b48e_I20220701" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMTgxNg_7165d4a5-e062-42c1-9063-3586e8f2c902">one</ix:nonFraction> forward contract outstanding to sell &#8364;<ix:nonFraction unitRef="eur" contextRef="i38408adaba6d4341adb12d55daf8b48e_I20220701" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMTg1Ng_b95c4d89-e687-40e9-b56b-0ae92ebc000d">9.3</ix:nonFraction>&#160;million. The forward contract with a maturity of <ix:nonNumeric contextRef="i1fe3c38bcffe44d0aa127c4b877c1d71_D20220101-20220701" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMTkwMA_f3117c44-6c39-4f34-8caf-d89df1b34e43">three months</ix:nonNumeric> is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the six months ended June 30, 2022, and 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="i1fe3c38bcffe44d0aa127c4b877c1d71_D20220101-20220701" decimals="-5" name="us-gaap:GainOnDerivativeInstrumentsPretax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMjE3NQ_ab9c9443-79c1-40f9-b282-3f065ef04123">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2e8d1c4ed84a49b6b1de444247607719_D20210102-20210702" decimals="-5" name="us-gaap:GainOnDerivativeInstrumentsPretax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMjE4Mg_054f0336-411e-442e-962a-1b2ebce84a22">0.3</ix:nonFraction>&#160;million, respectively, of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.</span></div></ix:continuation><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RleHRyZWdpb246N2UxNjNjMWI1ZWNkNDI5MGI2YTkwMmY2MWJmOGE2NzFfNzk_cbc90fdd-9766-49a0-8250-37a1a74494a3" continuedAt="if5d8393d76f8433eae26303bec578290" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="if5d8393d76f8433eae26303bec578290"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RleHRyZWdpb246N2UxNjNjMWI1ZWNkNDI5MGI2YTkwMmY2MWJmOGE2NzFfODE_f03e8984-a24d-4223-9143-7c78b66c6824" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:64.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfMS0xLTEtMS02NjMyNg_f3a63dab-7c1f-49f4-8657-7babc9ff18f7">9,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfMS0zLTEtMS02NjMyNg_89ff4d9f-c489-4a19-b6ab-bd299f030fe6">8,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfMi0xLTEtMS02NjMyNg_1af22974-f7f9-4d5a-84f0-c806ff617db1">35,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfMi0zLTEtMS02NjMyNg_fe88a52b-ac39-49d4-96fc-09b1ce3051b6">27,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfMy0xLTEtMS02NjMyNg_93f8cc23-69f4-4bb8-b2f7-41eff0dcebf8">13,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfMy0zLTEtMS02NjMyNg_b26787a5-0eed-4a61-8e08-5229a224b83a">12,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfNC0xLTEtMS02NjMyNg_d09bf265-abff-4d5b-a0a3-602b64a9a716">58,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfNC0zLTEtMS02NjMyNg_99e996f8-9c97-4978-aaac-bf4ac9a08659">49,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214511920f1a4c718201e79910fec792_I20220701" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfNy0xLTEtMS02NjMyNg_d8a39321-5094-4840-8b60-662c936d409c">33,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f26547ff011485ea499fc7321085b2a_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfNy0zLTEtMS02NjMyNg_678298c8-4c3b-49c3-9e76-1014908dd9f8">27,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i401482ee2371429dbb52062b06e78cf4_I20220701" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfOC0xLTEtMS02NjMyNg_ef8a3ebf-dd78-4bae-99b7-8b5c9c4a3050">25,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d04e4f28a941478b345f54d2cb7e3f_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfOC0zLTEtMS02NjMyNg_80d03c08-3335-4e7c-b636-acbf6b200fc4"><ix:nonFraction unitRef="usd" contextRef="i62d04e4f28a941478b345f54d2cb7e3f_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfOC0zLTEtMS02NjMyNg_9e577fc5-ac06-4671-b098-e988d8e6857a">22,018</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfOS0xLTEtMS02NjMyNg_4dbbb592-bc30-4341-96ae-0d6549c6d33a">58,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfOS0zLTEtMS02NjMyNg_adf0a59c-7234-4823-8701-701dc3d625a8">49,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/>NOTE 7. <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMzQ1Mw_540c8d2e-ef12-40b9-bd30-b203c7057aaf" continuedAt="iff885ee6bd0b4ea08b65ee6529ea9d6e" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="iff885ee6bd0b4ea08b65ee6529ea9d6e" continuedAt="i8776862f07de41b5bf5690e7272f5a9e"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMzQ0MA_a4f48c62-74ea-4378-965c-a7dd6cac7c1f" continuedAt="iab000c0863c74d26aea6c1253ca5b141" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c8787ab89e4ea8aa9bcbba33a74fb7_D20220402-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfMy0xLTEtMS02NjMyNg_f5d20ec7-14aa-4af6-aac1-e4413b761615">9,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeeca34bdde8405b8c686e83477e4f42_D20210403-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfMy0zLTEtMS02NjMyNg_58adf20c-a926-4526-aa77-3193c35ce3cb">13,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5abd3b9738c4a48916938c34311867c_D20220101-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfMy01LTEtMS02NjMyNg_f0fcefe1-9881-49ac-9a48-3888da02af26">18,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b0173c487e4563b2a6777d58f46013_D20210102-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfMy03LTEtMS02NjMyNg_15cda061-1b89-4ce2-90bb-e2bd4347f012">26,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a7e658a6084f529242281c7bcea519_D20220402-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNC0xLTEtMS02NjMyNg_4693c7f3-1090-45f7-b0c4-0d0e2af54c3f">15,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if900f76b28c94ec78c9965e91ee8f0b6_D20210403-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNC0zLTEtMS02NjMyNg_5af37e10-de76-4416-a18d-686c839aa6b4">14,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadffddf5c5c64493b3fa047c4ed4f265_D20220101-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNC01LTEtMS02NjMyNg_30a8f525-d9bf-4fa3-9c53-41e8d5db94d9">25,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2bf0f43bb254fcb95413ba3a8c9c810_D20210102-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNC03LTEtMS02NjMyNg_e1241553-c7f8-4682-b699-fae5303ba9cf">36,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNS0xLTEtMS02NjMyNg_3d062357-a0bd-4899-930c-97de234b2830">24,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNS0zLTEtMS02NjMyNg_d1072ccc-9145-4c9a-8374-f6dcdb843a92">28,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNS01LTEtMS02NjMyNg_2da3bee2-1545-43ac-ab74-4ee899cd33b5">44,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNS03LTEtMS02NjMyNg_556bc1ba-f83e-4181-93f4-71b14b157cb8">62,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><ix:continuation id="i8776862f07de41b5bf5690e7272f5a9e"><ix:continuation id="iab000c0863c74d26aea6c1253ca5b141"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb92aaea0154533ae9a350686b93d27_D20220402-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMi0xLTEtMS02NjMyNg_01ed3d8e-24dd-439d-b712-fb650f3d2555">3,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82d6aff031447fab7f99cce91ae6db8_D20210403-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMi0zLTEtMS02NjMyNg_837b43a7-c00b-43b7-b2e0-1b51e5d9aef4">5,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6524855f344408b90f428815d3ed343_D20220101-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMi01LTEtMS02NjMyNg_5d4a57bb-ec04-4f9b-983d-baa22f686778">7,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d61f3143c347f0bff85037bb757393_D20210102-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMi03LTEtMS02NjMyNg_aadc7edb-43a6-4140-91e3-235fa7896655">10,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826763d3077e4ad086c22a3ff19ad208_D20220402-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMy0xLTEtMS02NjMyNg_577a1e62-ab36-4238-ad5b-0854d56df957">18,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7e89015a804623990353f662f9a155_D20210403-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMy0zLTEtMS02NjMyNg_d6464aa6-d9d4-4c80-9882-4a9c6194b82d">15,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i288c55ead7e941548dc6ee322e4a325c_D20220101-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMy01LTEtMS02NjMyNg_6a2688d2-ed41-480b-a64c-1923d368057b">32,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb5bc2ce4804674ab1ceb6b7109a08b_D20210102-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMy03LTEtMS02NjMyNg_a3d42d5c-d2d3-4604-8ad5-2ffc19ed1bde">27,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ed4735334c844459ed18dbd61c6c4f6_D20220402-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNC0xLTEtMS02NjMyNg_544d18a8-c1d8-4854-bffe-74fee7c91a11">1,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ccdd8a412d41abbfac65334e30283c_D20210403-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNC0zLTEtMS02NjMyNg_53d013aa-dba8-489f-b457-e0efdc3de1d5">4,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2768e53f82974b9da558e84e64b5d621_D20220101-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNC01LTEtMS02NjMyNg_5fc99d67-0609-4a17-b1e6-fba487c1a76c">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0034b83355444c65ad6e185cc7ccd058_D20210102-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNC03LTEtMS02NjMyNg_684d0c3f-4868-48e1-9af7-eb355ec3d31a">22,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd650bcd87a349d786cbed15f8f31bd4_D20220402-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNS0xLTEtMS02NjMyNg_3ae455e4-f44e-4316-a2b1-b000371d9034">620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2669fd364d81445786658c8dc9193396_D20210403-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNS0zLTEtMS02NjMyNg_272fd47e-e274-4094-9460-5accf1594472">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799167078ab64d6d8c88a06ba5578ea4_D20220101-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNS01LTEtMS02NjMyNg_b70e2586-6c3d-4f7d-96c8-14fc7958de6a">1,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847152b60ebc49c7a64cb3e47896adc8_D20210102-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNS03LTEtMS02NjMyNg_8ebfc8a4-0c78-4bfc-85cd-17b8000205f6">2,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNi0xLTEtMS02NjMyNg_b649521c-fc0d-4b67-9cc3-477f837b7956">24,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNi0zLTEtMS02NjMyNg_708be835-959f-4134-9eaf-1b0acc82f5b8">28,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNi01LTEtMS02NjMyNg_565a92e2-5d10-44d3-a090-75cce951512c">44,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNi03LTEtMS02NjMyNg_d3c62c60-da5e-475d-bc57-e24691390f5f">62,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 25, 2022, at the 2022 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The amendment and restatement increased the share reserve under the 2017 Plan by <ix:nonFraction unitRef="shares" contextRef="i18d5c27ec4b94608b6a47b96f6900355_D20220525-20220525" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfOTM0NTg0ODg0MjIxMA_1c191912-2842-4c17-8f43-42138f5c3589">28,500,000</ix:nonFraction> shares. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTIyNA_ad8eb50d-ea47-4e29-82a7-fc29951d7e4a">31,687,133</ix:nonFraction> sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan. The share reserve is reduced by <ix:nonFraction unitRef="shares" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNDg3_78fd4182-5bbd-4b21-9a4c-afcf73988bcd">1</ix:nonFraction> share for each share issued pursuant to a stock option and <ix:nonFraction unitRef="shares" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNTQ5_b19d4c2e-703e-44a3-ba77-61b59039a8c0">2</ix:nonFraction> shares for full value awards, including restricted stock units (RSUs).&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, we granted <ix:nonFraction unitRef="shares" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTEwNw_f06496d7-58cf-47b9-a293-1386313fb910">587,762</ix:nonFraction> stock options with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTA4Mw_4361a151-fffc-4c6b-a9c1-f0932e0b6569">19.99</ix:nonFraction> per share and a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTExNg_5f0af3b0-8c94-4861-b560-a8214ca06e9b">8.36</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were <ix:nonFraction unitRef="shares" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTEyNA_8f0100b8-ae1f-4348-8b28-4e77121e099a">12,307,775</ix:nonFraction> stock options outstanding and $<ix:nonFraction unitRef="usd" contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTA5Mg_6bfddceb-5ee0-4202-963c-511deb15295e">23.6</ix:nonFraction>&#160;million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we awarded to certain employees an aggregate of <ix:nonFraction unitRef="shares" contextRef="i140a87f9739042bb9715f01f144db770_D20220301-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfOTYy_960a88f9-44d3-4b79-83e0-b050f331c948">1,003,482</ix:nonFraction> (the target amount) RSUs that are subject to a total shareholder return (TSR) market condition (the TSR-based RSUs). The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 1, 2022 through January 3, 2025. Depending on the results relative to the TSR market condition, the holders of the TSR-based RSUs may earn up to <ix:nonFraction unitRef="number" contextRef="i140a87f9739042bb9715f01f144db770_D20220301-20220331" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMTQwMQ_23c6c6e0-582b-41ec-9e4f-1f3062e53899">175</ix:nonFraction>% of the target amount of shares. <ix:nonFraction unitRef="number" contextRef="i8b79f2ddeb834dada1c18e98a6a85c1b_D20220301-20220331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMTQzNg_c6cdf530-0e3b-4e3d-bb53-bec259eb30f9">50</ix:nonFraction>% of the shares earned pursuant to the TSR-based RSU awards will vest at the end of the performance period, and the remainder will vest approximately <ix:nonNumeric contextRef="i8b79f2ddeb834dada1c18e98a6a85c1b_D20220301-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMTU4Nw_c63a4201-f255-4e3a-bebc-a6083044a1af">one year</ix:nonNumeric> later, subject to employee&#8217;s continuous service. These TSR-based RSUs will be forfeited if the market condition at or above a threshold level is not achieved at the end of the performance period on January 3, 2025.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMzQ2NA_213f8a93-27f0-4e1a-a96d-72097e88f9a6" continuedAt="i5a553a01c2cb4ca0bc3a8bd3da54b8c7" escape="true">We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i79b56428e2684493a912b70ba5c56f75_D20220101-20220701" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMTkxNw_a90a492d-49ea-4392-a264-30206d11466f">33.17</ix:nonFraction> per share for the TSR-based RSUs:</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i5a553a01c2cb4ca0bc3a8bd3da54b8c7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:90.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i73a59494ab85495e95f7a35120b582a9_I20220701" decimals="2" name="us-gaap:SharePrice" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg5ZWQ2MjFhMzc3OTQ1M2E5ZWE5ZDE5MjcwNWQzYTIyL3RhYmxlcmFuZ2U6ODllZDYyMWEzNzc5NDUzYTllYTlkMTkyNzA1ZDNhMjJfMC0xLTEtMS02NjMyNg_11a3e7bf-53b6-4a74-8006-492c066ee2e9">20.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i79b56428e2684493a912b70ba5c56f75_D20220101-20220701" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg5ZWQ2MjFhMzc3OTQ1M2E5ZWE5ZDE5MjcwNWQzYTIyL3RhYmxlcmFuZ2U6ODllZDYyMWEzNzc5NDUzYTllYTlkMTkyNzA1ZDNhMjJfMS0xLTEtMS02NjMyNg_fe22f684-9fcb-4d99-9f04-5c13629e48df">46.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i79b56428e2684493a912b70ba5c56f75_D20220101-20220701" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg5ZWQ2MjFhMzc3OTQ1M2E5ZWE5ZDE5MjcwNWQzYTIyL3RhYmxlcmFuZ2U6ODllZDYyMWEzNzc5NDUzYTllYTlkMTkyNzA1ZDNhMjJfMi0xLTEtMS02NjMyNg_efc43a36-9de3-4b27-9b21-bcc6861348ae">1.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i79b56428e2684493a912b70ba5c56f75_D20220101-20220701" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg5ZWQ2MjFhMzc3OTQ1M2E5ZWE5ZDE5MjcwNWQzYTIyL3RhYmxlcmFuZ2U6ODllZDYyMWEzNzc5NDUzYTllYTlkMTkyNzA1ZDNhMjJfMy0xLTEtMS02NjMyNg_f69d2d41-5d38-465c-a9e2-29f236903c56">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#8217;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, we granted <ix:nonFraction unitRef="shares" contextRef="i288c55ead7e941548dc6ee322e4a325c_D20220101-20220701" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTEzNg_117e615c-2b58-4d8e-91ef-1921a8fe1dcb">4,585,618</ix:nonFraction> service-based RSUs with a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i288c55ead7e941548dc6ee322e4a325c_D20220101-20220701" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTE3NQ_f169d473-5936-44cf-bb90-e0b6c5ff5281">20.64</ix:nonFraction> per share. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were <ix:nonFraction unitRef="shares" contextRef="ie20c1bc9723141ceb9391ded30c724c2_I20220701" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTE0Nw_a75c2b87-84ea-4c79-826d-5866b39c4c43">11,496,162</ix:nonFraction> RSUs outstanding, including the TSR-based RSUs, and $<ix:nonFraction unitRef="usd" contextRef="ie20c1bc9723141ceb9391ded30c724c2_I20220701" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTE1OQ_5ea3b95d-eb23-4a89-b2cb-d8c208278cac">207.2</ix:nonFraction>&#160;million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and service-based RSUs granted to employees during the six months ended June 30, 2022 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were&#160;<ix:nonFraction unitRef="shares" contextRef="i243680f68f274834b859ce0d17c3e93f_I20220701" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTE4Mw_828c54ca-79c1-4e3f-ac37-7ff76b2bde9f">5,662,157</ix:nonFraction> performance-based restricted stock units (PSUs) outstanding and $<ix:nonFraction unitRef="usd" contextRef="i243680f68f274834b859ce0d17c3e93f_I20220701" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTE5NA_877a8332-d516-4437-9411-57be11d22edf">113.5</ix:nonFraction>&#160;million of related unrecognized stock-based compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_55"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81NS9mcmFnOjFkMjcwZjFkOTI5NDRhZjhiYThlOTAxYTNjNzI3ODNhL3RleHRyZWdpb246MWQyNzBmMWQ5Mjk0NGFmOGJhOGU5MDFhM2M3Mjc4M2FfNTcy_0adc98a9-b85b-4fab-9a0e-e86380e2b67f" continuedAt="ieb0381e2e00a4210bf5ded43048f3773" escape="true">PROVISION FOR INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieb0381e2e00a4210bf5ded43048f3773">The effective tax rate for the three and six months ended June&#160;30, 2022 were <ix:nonFraction unitRef="number" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81NS9mcmFnOjFkMjcwZjFkOTI5NDRhZjhiYThlOTAxYTNjNzI3ODNhL3RleHRyZWdpb246MWQyNzBmMWQ5Mjk0NGFmOGJhOGU5MDFhM2M3Mjc4M2FfNjA0NzMxMzk1Mzc1MA_e5a269ac-acf7-4528-a4a6-9b10f4f61099">20.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81NS9mcmFnOjFkMjcwZjFkOTI5NDRhZjhiYThlOTAxYTNjNzI3ODNhL3RleHRyZWdpb246MWQyNzBmMWQ5Mjk0NGFmOGJhOGU5MDFhM2M3Mjc4M2FfNjA0NzMxMzk1Mzc1Nw_e17ae4d4-e448-43bf-a000-cb8e0148cbd6">19.9</ix:nonFraction>% respectively, as compared to <ix:nonFraction unitRef="number" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81NS9mcmFnOjFkMjcwZjFkOTI5NDRhZjhiYThlOTAxYTNjNzI3ODNhL3RleHRyZWdpb246MWQyNzBmMWQ5Mjk0NGFmOGJhOGU5MDFhM2M3Mjc4M2FfNjA0NzMxMzk1Mzc2NA_1ec79055-b0f0-4358-81aa-6ede95d72eca">23.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81NS9mcmFnOjFkMjcwZjFkOTI5NDRhZjhiYThlOTAxYTNjNzI3ODNhL3RleHRyZWdpb246MWQyNzBmMWQ5Mjk0NGFmOGJhOGU5MDFhM2M3Mjc4M2FfNjA0NzMxMzk1NDE5OA_a03b99e1-dfa2-4328-8cd7-a2b149601b30">20.5</ix:nonFraction>% for the corresponding periods 2021. The effective tax rate for the three and six months ended June 30, 2022 and June 30, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, which were partially offset by state taxes</ix:continuation>.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RleHRyZWdpb246ZWMwM2YxYzY4YTg2NDliOGJiYzJmMDIwMmMyYzhkZDZfNzU4_161e9d94-baac-49ad-b02b-09f66c8d02f2" continuedAt="i6722e05568ad4740901897970acc78fb" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i6722e05568ad4740901897970acc78fb"><ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RleHRyZWdpb246ZWMwM2YxYzY4YTg2NDliOGJiYzJmMDIwMmMyYzhkZDZfNzM3_af2bb77d-413a-45e7-9ea7-c34a25c059f6" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"></td><td style="width:49.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.437%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy0xLTEtMS02NjMyNg_881b3da1-ebb2-49c6-9707-9599cab693d2"><ix:nonFraction unitRef="usd" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy0xLTEtMS02NjMyNg_8b77dadc-542d-4dc3-b017-3b6f2aad1164">70,672</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy0zLTEtMS02NjMyNg_6908009b-b2da-4422-bc27-444441551caa"><ix:nonFraction unitRef="usd" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy0zLTEtMS02NjMyNg_be7a7ce8-a249-4657-8acc-88ad1a987b10">96,092</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy01LTEtMS02NjMyNg_8c92ec01-6ee3-4f85-b5ff-54ecac9ea976"><ix:nonFraction unitRef="usd" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy01LTEtMS02NjMyNg_9111fb56-e88d-4a24-b99a-f359b2e1da02">139,245</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy03LTEtMS02NjMyNg_3a27da23-12bd-47d0-a386-7db7a7366258"><ix:nonFraction unitRef="usd" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy03LTEtMS02NjMyNg_91e8988d-0d07-48ba-9a18-942768747cc9">97,693</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNS0xLTEtMS02NjMyNg_3bbc6ab2-4163-4267-84bd-fd362adf9742">321,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNS0zLTEtMS02NjMyNg_03cec34f-f2f0-4c05-a74a-845c05870899">314,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNS01LTEtMS02NjMyNg_61c237a4-71dc-4217-9549-f6d7dc38c8c9">320,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNS03LTEtMS02NjMyNg_0b0bc54c-c39c-4f04-a0fd-f422dc3294cf">313,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNi0xLTEtMS02NjMyNg_bd290fb1-1404-4fd4-8df8-03c0278f8ad7">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNi0zLTEtMS02NjMyNg_f4849350-91a5-4391-b2fb-5e71d810b3ea">8,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNi01LTEtMS02NjMyNg_1edd98b5-a1ff-4e1d-bcfb-d8b9b833b147">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNi03LTEtMS02NjMyNg_ecdc74e3-6f14-4990-a35f-da4029074148">8,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNy0xLTEtMS02NjMyNg_64f66061-30c5-43fc-9f9e-8c42bc7db708">324,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNy0zLTEtMS02NjMyNg_10185306-4704-4c24-a40a-a2ba63316601">322,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNy01LTEtMS02NjMyNg_a6e31f3d-09a7-4b0c-a18e-b1d7b809a93e">324,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNy03LTEtMS02NjMyNg_a396b780-bbde-47fc-92bd-2b34714c99b3">322,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfOS0xLTEtMS02NjMyNg_d49676ef-cd91-499c-8cdf-e3f9fee6b6c0">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfOS0zLTEtMS02NjMyNg_23662b5e-28db-4af9-adab-e6919dc2dac0">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfOS01LTEtMS02NjMyNg_438ba54a-127e-4165-bb5b-7100b8b8862b">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfOS03LTEtMS02NjMyNg_e93ffded-50dc-4745-8fb5-680ca55aff4e">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMTAtMS0xLTEtNjYzMjY_35833eaa-6771-441e-9311-6d4b47888a58">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMTAtMy0xLTEtNjYzMjY_ec10cefd-d609-4a17-852e-558abf511554">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMTAtNS0xLTEtNjYzMjY_29a0e004-045a-424f-838d-1d382d7706a0">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMTAtNy0xLTEtNjYzMjY_777cf0f7-8213-4462-a253-f6b8104c5130">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, unvested RSUs, including TSR-based RSUs, PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RleHRyZWdpb246ZWMwM2YxYzY4YTg2NDliOGJiYzJmMDIwMmMyYzhkZDZfNzQ5_6227d32b-038f-4425-988f-f526bdf1a3a7" continuedAt="i6585dd8fbc3641c782c51f4efda5f3e1" escape="true">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i6585dd8fbc3641c782c51f4efda5f3e1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.213%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5128decae384f698a9ab00463cbd990_D20220402-20220701" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjIzN2I0NTNjN2NmMDRlYjBiMTliN2UzMjYwNjk1OWNlL3RhYmxlcmFuZ2U6MjM3YjQ1M2M3Y2YwNGViMGIxOWI3ZTMyNjA2OTU5Y2VfMi0xLTEtMS02NjMyNg_7295643b-4484-4b41-97a7-f93475a92fec">14,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d22c0ab1ce2424b9a59efba14386e0e_D20210403-20210702" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjIzN2I0NTNjN2NmMDRlYjBiMTliN2UzMjYwNjk1OWNlL3RhYmxlcmFuZ2U6MjM3YjQ1M2M3Y2YwNGViMGIxOWI3ZTMyNjA2OTU5Y2VfMi0zLTEtMS02NjMyNg_7d01f985-d1fa-481d-b5cd-c584453262e5">12,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25b873c8ba6a4c4f960fbb64be80b871_D20220101-20220701" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjIzN2I0NTNjN2NmMDRlYjBiMTliN2UzMjYwNjk1OWNlL3RhYmxlcmFuZ2U6MjM3YjQ1M2M3Y2YwNGViMGIxOWI3ZTMyNjA2OTU5Y2VfMi01LTEtMS02NjMyNg_e052c378-7bb7-40c1-96d9-7affdd3df261">15,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i985d03e626eb4a299ec7d942d6a3e0fc_D20210102-20210702" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjIzN2I0NTNjN2NmMDRlYjBiMTliN2UzMjYwNjk1OWNlL3RhYmxlcmFuZ2U6MjM3YjQ1M2M3Y2YwNGViMGIxOWI3ZTMyNjA2OTU5Y2VfMi03LTEtMS02NjMyNg_b8d5dc1a-79ea-4488-9d5b-e4b5201de21a">11,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfODk2Ng_2fd64099-7150-4900-9a39-aaf23578706b" continuedAt="i9deeec9d8a1c470dbd95419d409cfe16" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i9deeec9d8a1c470dbd95419d409cfe16" continuedAt="i08b3d988d89b4d12a693ac0585eb0348"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Build-to-Suit Lease and Headquarters Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the office building (New Premises) associated with our October 2019 build-to-suit lease agreement (Build-to-Suit Lease) was substantially completed. The New Premises is <ix:nonFraction unitRef="sqft" contextRef="i88887d64754a4f1ebb805302f47aa477_I20220430" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTU2NA_858aadc0-eefd-42fd-8b29-12a85d2f71af">220,517</ix:nonFraction> square feet and is in Alameda, California, adjacent to our existing corporate headquarters. The Build-to-Suit Lease term is <ix:nonNumeric contextRef="i88887d64754a4f1ebb805302f47aa477_I20220430" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTU3Mg_fe61f3da-74c3-42f7-a6e1-067d83329d0d">242</ix:nonNumeric> months, includes <ix:nonFraction unitRef="segment" contextRef="i69d48eac98d64f5887fc5c912672b993_D20220402-20220430" decimals="INF" name="exel:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTU5NQ_b8c3d0d5-bd9b-4300-928a-f64dd31bd687">two</ix:nonFraction> <ix:nonNumeric contextRef="i88887d64754a4f1ebb805302f47aa477_I20220430" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNzY5NjU4MTQxMzk4MQ_eb130e80-20b9-4a2f-a9c9-1d4985e6ab80">five-year</ix:nonNumeric> options to extend the term of the lease and a one-time option to terminate the lease after <ix:nonNumeric contextRef="i69d48eac98d64f5887fc5c912672b993_D20220402-20220430" name="exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTU3Mw_b03eb977-a6bb-4c0b-8abf-7210aa8bcfea">180</ix:nonNumeric> months. In addition to the monthly lease payments, currently estimated at $<ix:nonFraction unitRef="usd" contextRef="i69d48eac98d64f5887fc5c912672b993_D20220402-20220430" decimals="-5" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTU3OQ_d29ac847-26e5-47a5-8a04-5f0d4fb11169">0.7</ix:nonFraction>&#160;million, subject to an annual increase of <ix:nonFraction unitRef="number" contextRef="i69d48eac98d64f5887fc5c912672b993_D20220402-20220430" decimals="2" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTU3NQ_413a1595-9699-484e-a692-9ffaf498bbdc">3</ix:nonFraction>% during the Term, we are also responsible for paying operating expenses related to the New Premises. On April 15, 2022, the lease commenced for the New Premises. We determined the classification of the lease was an operating lease. Upon commencement of the lease, we recognized a right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="ieeb8ed4d7cb445b08584aace5ff56694_I20220415" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNjA0NzMxMzk3MjQxMQ_4bd40645-ffff-417b-ba50-a837c2d1de98">160.9</ix:nonFraction>&#160;million inclusive of $<ix:nonFraction unitRef="usd" contextRef="ieeb8ed4d7cb445b08584aace5ff56694_I20220415" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNjA0NzMxMzk3MjQ0Mg_a57ab080-7e5f-46a7-9a66-02c0748ee308">44.9</ix:nonFraction>&#160;million for the cost of the tenant improvements in excess of the allowance provided by the lessor and an operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="ieeb8ed4d7cb445b08584aace5ff56694_I20220415" decimals="-5" name="exel:TenantLeaseImprovementsAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNjA0NzMxMzk3MjQ3Nw_527fe8cf-03f6-438c-8a30-e73c13ca9036">116.0</ix:nonFraction>&#160;million discounted over <ix:nonNumeric contextRef="i95b2c08d83814c348966a2366c0de8a7_D20220415-20220415" name="exel:OperatingLeaseLiabilityDiscountedPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTg0Mw_899c8812-b7e3-47ad-aba7-7898abf61343">180</ix:nonNumeric> months using our estimated incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="ieeb8ed4d7cb445b08584aace5ff56694_I20220415" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTYzMA_9a4d5853-0786-4318-b457-a608ee14d818">4.9</ix:nonFraction>%.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><ix:continuation id="i08b3d988d89b4d12a693ac0585eb0348" continuedAt="ib5a7da647f4943458a5a28ad97ef3d1f"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we entered into the seventh amendment to the lease for our corporate headquarters located on Harbor Bay Parkway, Alameda, California (the Alameda Lease). The May 2022 amendment to the Alameda Lease (the Seventh Lease Amendment) provides, among other things, for the expansion of the premises under the Alameda Lease by <ix:nonFraction unitRef="sqft" contextRef="ia8db2258b7ae45a995b0f68fabdcd327_I20220531" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNzE0NjgyNTYwMzc5NQ_cd07013f-133c-4ed3-827a-3d7ea597f1b4">34,745</ix:nonFraction> square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Expansion Space). The term for the 1751 Expansion Space will run coterminous with the term of the Alameda Lease for the existing space. In connection with the Seventh Lease Amendment, we remeasured our lease components under the Alameda Lease relating to the existing premises using an incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="ia312fa6ca0df4ee1be126a7eea55f36f_I20220531" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNjA0NzMxMzk3NTU4MQ_2cc4164d-1e04-4e42-a848-85c849a8b7c3">5.0</ix:nonFraction>%. As of June 1, 2022, we have taken possession of the 1751 Expansion Space, and accordingly we have adjusted our right-of-use asset and liability by $<ix:nonFraction unitRef="usd" contextRef="ib2c7ef7fab7345ebadb2ed3327f9af7d_I20220601" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNjA0NzMxMzk3NTU2Nw_01a8f2e7-5178-43ae-a5c0-d576df5c1ffe">4.3</ix:nonFraction>&#160;million.<br/><br/>For more information about our Leases, see &#8220;Note 11. Commitments and Contingencies&#8212;Leases&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. These <ix:nonFraction unitRef="lawsuit" contextRef="i188a4a13c6094e2e882585005f7bcf76_I20210430" decimals="INF" name="exel:LossContingencyNumberOfLawsuitsConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg2Mjc2Nw_980a7e62-3a03-4e5c-ac55-6da4cc9a95ec">two</ix:nonFraction> lawsuits, numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties have narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN has, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claims 1 and 2 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial occurred in May 2022, and a judgment is expected during the third or fourth quarter of 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><ix:continuation id="ib5a7da647f4943458a5a28ad97ef3d1f" continuedAt="i84ec0440a5894c25b2ed73e038bea9fa"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the February 2022 MSN ANDA Complaint) arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. In the February 2022 MSN ANDA Complaint, we are seeking, among other remedies, equitable relief enjoining MSN from infringing these patents, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of the patents identified in the February 2022 MSN ANDA Complaint, the latest of which expires on January 15, 2030. The February 2022 MSN ANDA Complaint is a new case, numbered Civil Action No. 22-00228, against MSN involving Exelixis patents that are different from those asserted in the consolidated Civil Action Nos. 19-02017 and 20-00633 described above. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are invalid and not infringed. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would also infringe certain claims of each patent, if those claims are not found to be invalid. A bench trial in connection with the February 2022 MSN ANDA Complaint has been scheduled for May 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 (the July 2022 MSN ANDA Complaint) arising from MSN&#8217;s further amendment of its ANDA Filing with the FDA. In the July 2022 MSN ANDA Complaint, we are seeking, among other remedies, equitable relief enjoining MSN from infringing this patent, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of the patent identified in the July 2022 MSN ANDA Complaint, which expires on February 10, 2032. The July 2022 MSN ANDA Complaint is a new case against MSN involving an Exelixis patent that is different from those asserted in the consolidated Civil Action Nos. 19-02017, 20-00633 and 22-00228 described above. MSN&#8217;s response to the complaint is due on August 9, 2022. A trial has not yet been scheduled in connection with the July 2022 MSN ANDA Complaint.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Pharmaceutical Industries Limited (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Parent), asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. On February 11, 2022, this case was administratively closed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). We have <ix:nonNumeric contextRef="ia392f18685aa4066aa68046de26c42a7_D20220729-20220729" name="exel:LossContingencyNumberOfDaysToFilePatentInfringementClaim" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg2Mjc1Mg_e8efba3e-e0f5-454c-b055-734e21c83cdc">45</ix:nonNumeric> days from the receipt of the July 29, 2022 notice to file a patent infringement claim against Teva relating to the newly challenged patent.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><ix:continuation id="i84ec0440a5894c25b2ed73e038bea9fa"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div></ix:continuation><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_67"></div><div style="margin-top:15pt"><span><br/></span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (Exelixis, we, our or us) current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Risk Factors&#8221; in Part II, Item&#160;1A of this Quarterly Report on Form 10-Q, as well as those discussed elsewhere in this report. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and the consolidated financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the Securities and Exchange Commission (SEC) on February&#160;18, 2022 (Fiscal 2021 Form 10-K).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for patients with difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 62 other countries as: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc., a member of the Roche Group (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo, Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan is to utilize our operating cash flows and cash and investments to expand the cabozantinib franchise by potentially adding new indications in areas of unmet medical need. We will also leverage our operating cash flows to continue advancing our diverse small molecule and biotherapeutics programs, exploring multiple modalities and mechanisms of action to discover new oncology drugs. So far, these drug discovery and preclinical activities have resulted in four clinical-stage compounds: XL092, a next-generation oral tyrosine kinase inhibitor (TKI); XB002, an antibody drug </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conjugate (ADC) that targets tissue factor (TF); XL102, a potent, selective and orally bioavailable covalent inhibitor of cyclin-dependent kinase 7 (CDK7); and XL114, a n</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ovel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 (CBM) complex</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Franchise</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA first approved CABOMETYX as a monotherapy for previously treated patients with advanced RCC in April 2016, and then for previously untreated patients with advanced RCC in December 2017. In January 2021, the CABOMETYX label was expanded to include first-line advanced RCC in combination with OPDIVO, which was the first CABOMETYX regimen approved for treatment in combination with an immune checkpoint inhibitor (ICI). In addition to RCC, in January 2019, the FDA approved CABOMETYX for the treatment of patients with HCC previously treated with sorafenib, and then in September 2021, the FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen and Takeda. We granted to Ipsen the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda we granted the rights to develop and commercialize cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of the cabozantinib franchise in other potential indications, and we work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the European Union (EU), the United Kingdom (U.K.) and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. In addition, in March 2021, Ipsen and BMS received regulatory approval from the EC for CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC, followed by additional regulatory approvals for the combination in other territories beyond the EU. Most recently, in May 2022, we announced that Ipsen received regulatory approval from the EC for CABOMETYX as a monotherapy for the treatment of adult patients with locally advanced or metastatic, RAI-refractory or ineligible DTC and who have progressed during or after prior systemic therapy. With respect to the Japanese market, Takeda received Manufacturing and Marketing Approvals in 2020 from the Japanese Ministry of Health, Labour and Welfare (MHLW) of CABOMETYX as a treatment of patients with curatively unresectable or metastatic RCC and as a treatment of patients with unresectable HCC who progressed after cancer chemotherapy. In August 2021, Takeda and Ono Pharmaceutical Co., Ltd. (Ono), BMS&#8217; development and commercialization partner in Japan, received Manufacturing and Marketing Approval from the Japanese MHLW of CABOMETYX in combination with OPDIVO as a treatment for unresectable or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest-of-world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could potentially benefit from this medicine. We continue to evaluate cabozantinib, both as a single agent and in combination with ICIs, in a broad development program comprising over 100 ongoing or planned clinical trials across multiple tumor types. We, along with our collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator sponsored trial (IST) program. The data from these third-party clinical trials have helped advance our development program for the cabozantinib franchise by informing subsequent label-enabling trials, including COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib in previously treated patients with RAI-refractory DTC, from which positive results served as the basis for the FDA&#8217;s and EC&#8217;s approvals of CABOMETYX for DTC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building on preclinical and clinical observations that cabozantinib in combination with ICIs may promote a more immune-permissive tumor environment, we initiated numerous pivotal studies to further explore these combination regimens. The first of these studies to deliver results was CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of CABOMETYX and OPDIVO compared to sunitinib in previously untreated, advanced or metastatic RCC, and positive results from CheckMate -9ER served as the basis for the FDA&#8217;s, EC&#8217;s and MHLW&#8217;s approvals of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC in January 2021, March 2021 and August 2021, respectively. We are also collaborating with BMS on COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. In July 2022, we announced results from COSMIC-313. The trial met its primary endpoint, demonstrating significant improvement in blinded independent radiology committee (BIRC) assessed progression free survival (PFS) at the primary analysis for the triplet combination, reducing the risk of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disease progression or death compared with the doublet combination of nivolumab and ipilimumab (hazard ratio: 0.73; 95% confidence internal: 0.57-0.94; P=0.01). At a prespecified interim analysis for the secondary endpoint of overall survival (OS), the triplet combination did not demonstrate a significant benefit, and therefore, the trial will continue to the next analysis of OS. The safety profile observed in the trial was reflective of the known safety profiles for each single agent, as well as the combination regimens used in this study, and no new safety signals were identified. We intend to discuss the results with the FDA to determine next steps toward a potential regulatory submission for the combination regimen for patients with previously untreated, advanced intermediate- or poor-risk RCC, and detailed findings will be presented at a future medical meeting.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our exploration of combinations with ICIs, we also initiated multiple trials evaluating cabozantinib in combination with F. Hoffmann-La Roche Ltd.&#8217;s (Roche) ICI, atezolizumab, beginning in 2017 with COSMIC-021, a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with a wide variety of locally advanced or metastatic solid tumors. The data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the initiation of COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC, and three phase 3 pivotal trials in collaboration with Roche, CONTACT-01, CONTACT-02 and CONTACT-03, evaluating the combination of cabozantinib with atezolizumab in patients with metastatic non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (mCRPC) and advanced RCC, respectively. CONTACT-01 and CONTACT-03 are sponsored by Roche and co-funded by us, and we announced the completion of enrollment for the two trials in November 2021 and January 2022, respectively, with results from both trials expected in the second half of 2022. CONTACT-02 is sponsored by us and co-funded by Roche, and we anticipate completing enrollment in the first half of 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our small molecule discovery programs are supported by a robust and expanding infrastructure, including a library of 4.6&#160;million compounds. We have extensive experience in the identification and optimization of drug candidates against multiple target classes for oncology, inflammation and metabolic diseases. The first compound to enter the clinic following our re-initiation of drug discovery activities in 2017 was XL092, a next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer&#8217;s growth and spread. In designing XL092, we sought to build upon our experience with cabozantinib, retaining a similar target profile while improving key characteristics, including the pharmacokinetic half-life. To date, we have initiated two large phase 1b clinical trials studying XL092: STELLAR-001 and STELLAR-002. STELLAR-001 is a phase 1b clinical trial evaluating XL092, both as a monotherapy and in combination with either atezolizumab or avelumab, an ICI developed by Merck KGaA Damstadt, Germany and Pfizer Inc. We have established recommended doses for single-agent XL092 and XL092 in combination with atezolizumab and have begun enrolling expansion cohorts for patients with clear cell RCC, non-clear cell RCC, hormone-receptor positive breast cancer, mCRPC and colorectal cancer (CRC); the dose-escalation phase for XL092 in combination with avelumab is ongoing. STELLAR-002 is a phase 1b clinical trial evaluating XL092 in combination with either nivolumab or nivolumab and ipilimumab. We are enrolling patients with advanced solid tumors in dose-escalation cohorts, and depending on the dose-escalation results, STELLAR-002 may enroll expansion cohorts for patients with clear cell and non-clear cell RCC, mCRPC and urothelial carcinoma (UC). To better understand the individual contribution of the therapies, treatment arms in the expansion cohorts may include XL092 as a single-agent in addition to the ICI combination regimens. We also initiated STELLAR-303, the first global phase 3 pivotal trial for XL092, in June 2022, and other phase 3 pivotal trials may follow in late 2022 and early 2023. STELLAR-303 is evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic non-microsatellite instability-high or non-mismatch repair-deficient CRC who have progressed after or are intolerant to the current standard of care, and the trial aims to enroll approximately 600 patients worldwide with documented RAS status. The primary objective of STELLAR-303 is to evaluate the efficacy of the combination in patients with RAS wild-type disease, and outcomes in patients with RAS-mutated disease will also be evaluated. The primary endpoint of STELLAR-303 is OS, and additional efficacy endpoints include PFS, objective response rate (ORR) and duration response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1. as assessed by the investigator. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies. The most advanced compounds to emerge from these arrangements are XL102 , the lead program targeting CDK7 under our collaboration with Aurigene Discovery Technologies Limited (Aurigene), and XL114, Aurigene&#8217;s novel anti-cancer compound that inhibits the CBM complex. Based on encouraging preclinical data, we exercised our exclusive options to license XL102 and XL114 from Aurigene and initiated phase 1 clinical trials evaluating XL102 and XL114 in January 2021 and April 2022, respectively, and we expect to provide clinical updates from the phase 1 study of XL102 in the second half of 2022. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond small molecules, we have also launched rigorous efforts to discover and advance various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, ADCs and other innovative treatments. ADCs in particular present a unique opportunity for new cancer treatments, given their capabilities to deliver anti-cancer payload drugs to targets with increased precision while minimizing impact on healthy tissues, and this biotherapeutic approach has been validated by multiple regulatory approvals for the commercial sale of ADCs in the past several years. To facilitate the growth of these programs, we have established multiple research collaborations and in-licensing arrangements and entered into other strategic transactions that provide us with access to antibodies, binders, payloads and conjugation technologies, which are the components employed to generate next-generation ADCs or multispecific antibodies. We have already made significant progress under these arrangements and expect we will continue to advance our biotherapeutics programs throughout the remainder of 2022 and in future years: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Ryvu</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into a collaboration with Ryvu Therapeutics S.A. (Ryvu) in July 2022, focused on the development of novel targeted therapies utilizing Ryvu&#8217;s STING (STimulator of INterferon Genes) technology. The collaboration is intended to expand our portfolio of biotherapeutics by combining our tumor-specific targeting approaches with Ryvu&#8217;s proprietary small molecule STING agonists and STING biology know-how. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">BioInvent</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into a collaboration with BioInvent International AB (BioInvent) in June 2022, focused on the identification and development of novel antibodies for use as oncology therapeutics. The collaboration is intended to expand our portfolio of antibody-based therapies and will utilize BioInvent&#8217;s proprietary n-CoDeR&#174; antibody library and patient-centric F.I.R.S.T</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> screening platform, which together are designed to allow for parallel target and antibody discovery. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">GamaMabs. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed an asset purchase from GamaMabs Pharma SA (GamaMabs) in May 2022. In the transaction, we acquired all rights, title and interest in GamaMabs&#8217; antibody program directed at </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anti-M&#252;llerian hormone receptor 2 (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMHR2), a novel oncology target with relevance in multiple forms of cancer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Iconic.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We in-licensed XB002, our lead TF-targeting ADC program, from Iconic, Inc. (Iconic) in December 2020 and then initiated a phase 1 clinical trial in June 2021. We expect to provide clinical updates from the trial in the second half of 2022. In December 2021, we amended our exclusive option and license agreement with Iconic to acquire broad rights to use the anti-TF antibody used in XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Invenra</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have expanded our collaboration with Invenra, Inc. (Invenra) several times since our first engagement in 2018, most recently in August 2021 to include an additional 20 oncology targets.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">WuXi Bio.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We expanded our access to antibodies through arrangements with WuXi Biologics Ireland Limited, a wholly owned subsidiary of WuXi Biologics (Cayman) Inc. (individually and collectively referred to as WuXi Bio) in March 2021. We are focused on leveraging WuXi Bio&#8217;s panel of monoclonal antibodies (mAbs) against an undisclosed target for the development of ADC, bispecific and certain other novel tumor-targeting biotherapeutics. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Adagene</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into a collaboration with Adagene Inc. (Adagene) in February 2021, focused on using Adagene&#8217;s SAFEbody&#174; technology to develop novel masked ADCs or other innovative biotherapeutics, with the potential to develop ADCs or other biotherapeutics with improved therapeutic index.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">NBE and Catalent</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into collaborations with NBE-Therapeutics AG (NBE) and Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc. (individually and collectively referred to as Catalent) in September 2020. These platform collaborations allow us to utilize their site-specific conjugation technologies and payloads to construct ADCs using the antibodies we have sourced from our arrangements with WuXi Bio, GamaMabs and Invenra. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements have led directly to the advancement of two biotherapeutics development candidates, XB010 and XB014. XB010, our first ADC advanced internally, targets the tumor antigen 5T4 and incorporates antibodies sourced from Invenra. It was constructed using Catalent&#8217;s SMARTag&#174; site-specific bioconjugation platform. XB014 is our first bispecific antibody, which combines a PD-L1 targeting arm with a CD47 targeting arm to block a macrophage checkpoint, and was developed through our collaboration with Invenra. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report, we are currently advancing more than 10 discovery programs and expect to progress up to five new development candidates into preclinical development during 2022. We will continue to engage in business development initiatives with the goal of acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report on Form 10-Q, the COVID-19 pandemic continues to have a modest impact on our business operations. While the pandemic has created operational difficulties and complexities, we have thus far been successful at devising solutions designed to mitigate its impact. We will continue to monitor new developments that could pose additional risks for us, including the spread of the Omicron variant and its subvariants in the U.S. and other countries, and the potential emergence of new SARS-CoV-2 variants that may prove especially contagious or virulent. Despite our COVID-19 pandemic mitigation efforts, we may experience delays or an inability to execute on our clinical and preclinical development plans, reduced revenues or other adverse impacts to our business as described in more detail in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. We recognize that this pandemic will continue to present unique challenges for us throughout 2022, and potentially into 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Quarter 2022 Business Updates and Financial Highlights</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we continued to execute on our business objectives, generating significant revenues from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for the quarter and subsequent to quarter-end include:</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In April 2022, we announced the initiation of a phase 1 clinical trial evaluating XL114 as a monotherapy in patients with non-Hodgkin&#8217;s Lymphoma.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In May 2022, we announced that Ipsen received regulatory approvals from the EC and Health Canada for CABOMETYX as a monotherapy for patients with previously treated, RAI-refractory DTC.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2022, cabozantinib was the subject of multiple data presentations in NSCLC, UC, RCC, head and neck squamous cell carcinoma, and DTC at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2022, we announced an exclusive option and license agreement with BioInvent to identify and develop novel antibodies for use in immuno-oncology therapeutics utilizing BioInvent&#8217;s n-CoDeR antibody library and patient-centric F.I.R.S.T screening platform. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2022, we announced the initiation of STELLAR-303, a global phase 3 pivotal trial evaluating XL092 in combination with atezolizumab in patients with metastatic non-microsatellite instability-high or non-mismatch repair-deficient CRC who have progressed after or are intolerant to the current standard of care. The primary endpoint of the trial is OS, and additional efficacy endpoints include PFS, ORR and DOR per RECIST v. 1.1. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In July 2022, we announced an exclusive license agreement with Ryvu to develop novel targeted therapies utilizing Ryvu&#8217;s STING technology. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In July 2022, we announced results from the phase 3 COSMIC-313 trial, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n which the triplet combination of cabozantinib, nivolumab and ipilimumab met its primary endpoint, demonstrating significant improvement in PFS versus the doublet combination of nivolumab and ipilimumab at the primary analysis. At a prespecified interim analysis for the secondary endpoint of OS, the triplet combination did not demonstrate a significant benefit, and therefore the trial will continue to the next analysis of OS. We intend to discuss the results with the FDA to determine next steps toward a potential regulatory submission for the combination regimen for </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients with previously untreated, advanced intermediate- or poor-risk RCC</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and detailed findings will be presented at a future medical meeting.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In July 2022, we filed a patent lawsuit in the United States District Court for the District of Delaware (the Delaware District Court) against MSN Pharmaceuticals, Inc. (MSN) asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#8217;s further amendment of its Abbreviated New Drug Application (ANDA), originally filed with the FDA in September 2019. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of U.S. Patent No. 11,298,349 on February 10, 2032. This is our fourth case against MSN and involves an Exelixis patent that is different from those asserted previously in consolidated patent lawsuits that we filed in 2019 and 2020 and the separate lawsuit filed in February 2022. For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net product revenues for the second quarter of 2022 were $347.0 million, compared to $284.2 million for the second quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Total revenues for the second quarter of 2022 were $419.4 million, compared to $385.2 million for the second quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Research and development expenses for the second quarter of 2022 were $199.5 million, compared to $148.8 million for the second quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Selling, general and administrative expenses for the second quarter of 2022 were $122.8 million, compared to $98.5 million for the second quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Provision for income taxes for the second quarter of 2022 was $17.8 million, compared to $28.8 million for the second quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net income for the second quarter of 2022 was $70.7 million, or $0.22 per share, basic and diluted, compared to net income of $96.1 million, or $0.31 per share, basic and $0.30 per share, diluted, for the second quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Results of Operations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outlook, Challenges and Risks</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to face numerous challenges and risks that may impact our ability to execute on our 2022 business objectives. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. However, we cannot be certain that the clinical trials we and our collaboration partners are conducting will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if the required regulatory approvals to market cabozantinib for additional indications are achieved, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. As is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets. In addition, healthcare policymakers in the U.S. are increasingly expressing concern over healthcare costs, and corresponding legislative and policy initiatives and activities have been launched, aimed at increasing the healthcare cost burdens borne by pharmaceutical manufacturers, as well as expanding access to, and restricting the prices and growth in prices of, pharmaceuticals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achievement of our 2022 business objectives will also depend on our ability to maintain a competitive position in the shifting landscape of therapeutic strategies for the treatment of cancer, which we may not be able to do. On an ongoing basis, we assess the constantly evolving landscape of other approved and investigational cancer therapies that could be competitive, or complementary in combination, with our products, and then we adapt our development strategies for the cabozantinib franchise and our pipeline product candidates accordingly, such as by modifying our clinical trials to include evaluation of our therapies with ICIs and other targeted agents. Even if our current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in NSCLC and mCRPC or evaluating XL092 in combination with an ICI in CRC, produce positive results sufficient to obtain marketing approval by the FDA and other global regulatory authorities, it is uncertain whether physicians will choose to prescribe regimens containing our products instead of competing products and product combinations in approved indications. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic versions of CABOMETYX tablets that are the subject of ANDAs submitted to the FDA by MSN and Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva). The approval of either MSN&#8217;s or Teva&#8217;s ANDA and subsequent launch of any generic version of CABOMETYX could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risks and uncertainties associated with drug discovery operations, especially on the global level. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these challenges and risks are specific to our business, others are common to companies in the biopharmaceutical industry with development and commercial operations, and an additional category are macroeconomic, affecting all companies. For a more detailed discussion of challenges and risks we face, see &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Convention</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the fiscal periods ended July&#160;1, 2022 and July&#160;2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the fiscal periods ended June&#160;30, 2022 and June&#160;30, 2021, and the year ending December&#160;31, 2022, respectively.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues, discounts and allowances, and net product revenues were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,029)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273,968)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in net product revenues for the three and six months ended June 30, 2022, as compared to the corresponding prior year periods, were primarily related to increases of 19% and 25%, respectively, in the number of units sold, and to a lesser extent a 3% increase in the average net selling price of CABOMETYX for both the three and six months ended June&#160;30, 2022, as compared to the corresponding prior year periods.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project that our net product revenues for the remainder of 2022 may increase, as compared to the corresponding prior year period, for similar reasons noted above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;included in Part II, Item 8 of our Fiscal 2021 Form 10-K. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in discounts and allowances for the three and six months ended June 30, 2022, as compared to the corresponding prior year periods, were primarily from higher utilization in the 340B Drug Pricing Program. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and allowances as a percentage of gross revenues have increased over time as the number of patients participating in government programs, as well as the discounts given and rebates paid to government payers, has also increased. We project this trend will continue and that our discounts and allowances as a percentage of gross revenues may increase during the remainder of 2022, as compared to the corresponding prior year period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues generally include: (a) the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the related period that the milestone would be achieved and a significant reversal of revenues would not occur; (b) royalty revenues; and (c) the profit on the U.S. commercialization of COTELLIC from Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues, which are allocated between license revenues and collaboration services revenues, were $26.2&#160;million and $26.9&#160;million for the three and six months ended June 30, 2022, respectively, as compared to $12.9&#160;million and $13.5&#160;million for the corresponding prior year periods. Milestone revenues by period included the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">For the three and six months ended June 30, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$25.7&#160;million</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenues recognized in connection with two regulatory milestones totaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$27.0&#160;million</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the approval by the European Commission and Health Canada of cabozantinib as a monotherapy for the treatment of adult patients with locally advanced or metastatic DTC, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">For the three and six months ended June 30, 2021, $11.8&#160;million in revenues recognized in connection with a $12.5&#160;million regulatory milestone we determined was probable of achievement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenues increased primarily as a result of increases in Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan. Ipsen royalties were $27.5&#160;million and $52.1&#160;million for the three and six months ended June 30, 2022, respectively, as compared to $22.8&#160;million and $45.3&#160;million for the corresponding prior year period. Ipsen&#8217;s net sales of cabozantinib have continued to grow since Ipsen&#8217;s commercial sale of CABOMETYX in the fourth quarter of 2016, primarily due to regulatory approval in new territories, including regulatory approval in the EU for the combination therapy of CABOMETYX and OPDIVO received in March 2021. Royalty revenues for the three and six months ended June 30, 2022 also included $2.7&#160;million and $5.1&#160;million, respectively, related to Takeda&#8217;s net sales of CABOMETYX, as compared to $2.1&#160;million and $3.4&#160;million for the corresponding prior year periods. Takeda royalty revenues have continued to grow since Takeda&#8217;s first commercial sale of CABOMETYX in Japan in 2020. As of June&#160;30, 2022, CABOMETYX is approved and is commercially available in 62 countries outside the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech was $1.7&#160;million and $3.8&#160;million for the three and six months ended June 30, 2022, respectively, as compared to $2.2&#160;million and $4.0 million for the corresponding prior year periods. We also earned royalties on ex-U.S. net sales of COTELLIC by Genentech of $0.9&#160;million and $2.5&#160;million for the three and six months ended June 30, 2022, respectively, as compared to $0.8 million and $1.7&#160;million for the corresponding prior year periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and milestones can vary significantly from period to period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Services Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, and product supply revenues, which are net of product supply costs and the royalties we pay on sales by Ipsen and Takeda of products containing cabozantinib.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development cost reimbursements of $17.3&#160;million and $34.5&#160;million for the three and six months ended June 30, 2022, respectively, as compared to $62.5&#160;million and $80.9&#160;million for the corresponding prior year periods decreased primarily due to Ipsen&#8217;s decision to opt in and co-fund COSMIC-311 development costs in the second quarter of 2021, which </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included a cumulative catch up for Ipsen&#8217;s share of global development costs incurred since the beginning of the study and through the end of the period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues, for the 3% royalty we are required to pay on the net sales by Ipsen and Takeda of any product incorporating cabozantinib, were reduced by $4.2&#160;million and $8.0&#160;million for the three and six months ended June 30, 2022, respectively, as compared to $3.5&#160;million and $6.9&#160;million for the corresponding prior year periods. As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments have also increased.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our collaboration services revenues may decrease for the remainder of 2022, as compared to the corresponding prior year period, primarily as a result of decreased development cost reimbursements related to Ipsen&#8217;s opt-in and co-funding of COSMIC-311 and the related cumulative catch-up in development cost reimbursements recognized in 2021 for which no similar event is projected to occur in 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of goods sold and our gross margin were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,481</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,884</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,684</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,082</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty payable on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring, excess and obsolete inventory, and other third-party logistics costs. Cost of goods sold for the three and six months ended June 30, 2022, as compared to the corresponding prior year periods, decreased, primarily due to lower period costs, partially offset by an</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increase in r</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oyalties as a result of increased U.S. CABOMETYX sales. We project our gross margin will not change significantly during the remainder of 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully burdened research and development expenses on a project-by-project basis. We group our research and development expenses into three categories: (1) development; (2) drug discovery; and (3) other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies, including in-licensed technologies, to enable the rapid discovery, optimization and extensive characterization of lead compounds and biologics in order to select development candidates with the best potential for further evaluation and advancement into clinical development.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses by category were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.898%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other drug discovery</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total drug discovery</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,063&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,481&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,152&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primarily includes upfront license fees, development milestone payments, program initiation fees, and research funding commitments associated with programs in preclinical development stage</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primarily includes personnel expenses, consulting and outside services and laboratory supplies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the allocation of general corporate costs to research and development services, and development cost reimbursements in connection with our collaboration arrangement with Roche executed in December 2019.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he increases in research </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development expenses for the three and six months ended June 30, 2022, as compared to the corresponding prior year periods, were primarily related to increases in personnel expenses, clinical trial costs, and consulting and outside services, which were partially offset by decreases in stock-based compensation. Personnel expenses increased primarily due to increases in headcount to support our expanding discovery and development organization. Clinical trial costs, which include services performed by third-party contract research organizations and other vendors who support our clinical trials, increased as compared to the corresponding prior year periods primarily due to higher costs associated with the XL092, CONTACT-02 and CONTACT-03 studies which were partially offset by decreases in costs associated with COSMIC-313, COSMIC-021, and COSMIC-312 studies. Consulting and outside services expenses increased primarily as a result of the continued growth in our discovery and research activities. Stock-based compensation expense decreased as compared to the corresponding prior year periods, primarily due to lower compensation expense associated with the completion of expense amortization for certain performance-based restricted stock units (PSUs) granted in prior years, fewer stock options granted and higher forfeiture amounts. License and other collaboration costs increased for the three months ended June 30, 2022 as compared to the corresponding prior year period, primarily due to an increase in upfront license fees related to a new in-licensing collaboration arrangement in the second quarter of 2022. License and other collaboration costs decreased during the six months ended June 30, 2022, as compared to the corresponding prior period, primarily due to lower upfront license fees from business development activities. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. These factors include enrollment in clinical trials for our drug candidates, preliminary data and final results from clinical trials, the potential indications, and clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focusing a significant amount of our development efforts on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we project that a substantial portion of our research and development expenses will relate to the continuing clinical development program of cabozantinib, which includes over 100 ongoing or planned clinical trials across multiple indications. Notable ongoing company-sponsored studies resulting from </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this program include: COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge; and CONTACT-02, for which Roche is sharing the development costs and providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action, with the goal of identifying new product candidates to advance into clinical trials. We also continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets, with the goal of utilizing our established preclinical and clinical development infrastructure to further characterize and develop such acquisitions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our research and development expenses may increase for the remainder of 2022, as compared to the corresponding prior year period, primarily driven by our ongoing clinical evaluation of cabozantinib, the initiation of new clinical trials and expansion of ongoing clinical trials evaluating other product candidates in our pipeline including the June 2022 initiation of STELLAR-303, our first global phase 3 pivotal trial for XL092 and current early-stage trials evaluating XL092, XB002, XL102 and XL114, as well as anticipated business development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of the risks and uncertainties with respect to our research and development activities and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.899%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,073&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,368&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,933&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,625&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,495&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,846&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel expenses, stock-based compensation, marketing costs and certain other administrative costs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in selling, general and administrative expenses for the three and </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022, as compared </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the corresponding prior year periods, were primarily related to increases in personnel expenses, marketing costs, business technology initiatives and legal costs.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Personnel expenses increased as compared to the corresponding prior year periods, primarily due to increases in administrative headcount to support our commercial and research and development organizations. Marketing costs increased as compared to the corresponding prior year periods, primarily due to increased spending in support of the commercialization of</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the combination therapy of CABOMETYX and OPDIVO for the treatment of advanced RCC.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The decrease in stock-based compensation expense for the six months ended June 30, 2022, as compared to the corresponding prior year period, was primarily due to lower compensation expense associated with the completion of expense amortization for certain PSUs granted in prior years, fewer stock options granted and higher forfeiture amounts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our selling, general and administrative expenses may continue to increase for the remainder of 2022, as compared to the corresponding prior year period primarily driven by our continuing commercial investment in CABOMETYX and the growth of the broader organization.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-operating Income</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income was as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.792%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in non-operating income for the three and six months ended June 30, 2022, as compared to the corresponding prior year periods, were primarily the result of increases in interest income due to higher interest rates and higher investment balances.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.792%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and six months ended June 30, 2022, differed from the U.S. federal statutory rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, which were partially offset by state taxes.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had $2.0 billion in cash, cash equivalents, restricted cash equivalents and investments, compared to $1.9 billion as of December&#160;31, 2021. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, net product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary cash requirements for operating activities, which we project will increase for the remainder of 2022, as compared to the corresponding period in 2021, are for: employee related expenditures; costs related to our development and discovery programs; income tax payments; cash payments for inventory; royalty payments on our net product sales; and our leased facilities. Our primary sources of operating cash are: cash collections from customers related to net product sales, which we project will increase for the remainder of 2022, as compared to the corresponding period in 2021; cash collections related to royalties earned from our commercial collaboration arrangements with Ipsen, Takeda and others and the achievement of certain development, regulatory and commercial milestones; and cash collections for cost reimbursements under certain of our development programs. The timing of cash generated from commercial collaborations and cash payments required for in-licensing collaborations relative to upfront payments, initiation fees, milestone payments and cost reimbursements may vary from period to period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have cash requirements related to capital expenditures to support the planned growth of our business including investments in laboratory facilities and equipment. We project that we may continue to spend significant amounts of cash to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including additional research collaborations, in-licensing arrangements and other strategic transactions that align with our oncology drug development, regulatory and commercial expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity based on market conditions or strategic considerations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of $10.7&#160;million and $16.7&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a standby letter of credit as a guarantee of our obligation to fund our portion of the tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which are recorded as restricted cash equivalents and presented in other long-term assets in our Condensed Consolidated Balance Sheets and will be reduced as we fund our portion of the tenant improvements. As of June&#160;30, 2022, restricted cash equivalents included $9.2&#160;million of short-term investments as collateral under our standby letter of credit for our portion of the tenant improvements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash equivalents, and investments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working capital</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The increase in working capital as of June&#160;30, 2022, as compared to December&#160;31, 2021, was primarily due to the favorable impacts to our net current assets resulting from our net income during the six months ended June 30, 2022, which was partially offset by purchases of long-term investments and estimated tax payments made that are classified as long-term. In the future, our working capital may be impacted by one of these factors or other factors, the amounts and timing of which are variable.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash and cash equivalents primarily consist of cash deposits held at major banks, commercial paper and other securities with original maturities 90 days or less. Restricted cash equivalents and investments relate to our letter of credit agreements and are invested in short-term marketable securities. For additional information regarding our cash, cash equivalents, restricted cash equivalents and investments, see &#8220;Note 4. Cash and Investments,&#8221; in our &#8220;Notes to Condensed Consolidated Financial Statements&#8221; included in Part I, Item 1 of this Quarterly Report on Form 10-Q. The increase in cash, cash equivalents, restricted cash equivalent and investments at June&#160;30, 2022, as compared to December&#160;31, 2021, was primarily due to cash inflows generated by our operations, including collections of amounts due from customers, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collection of a $100.0 million milestone payment from Ipsen, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by operating cash payments for employee-related expenditures, our development and discovery programs, and capital expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow activities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities is derived by adjusting our net income for non-cash operating items such as deferred taxes, stock-based compensation, depreciation, non-cash lease expense and changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities for the six months ended June 30, 2022 decreased as compared to the corresponding prior year period, primarily due to an increase in cash paid for certain operating expenses resulting in net unfavorable changes in operating assets and liabilities, which was partially offset by an increase in cash received on sales of our products and from our commercial collaboration arrangements, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including collection of a $100.0&#160;million milestone payment from Ipsen</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in cash flows from investing activities primarily relates to the timing of marketable securities investment activity and capital expenditures. Our capital expenditures primarily consist of investments to expand our operations and acquire assets that further our research and development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased as compared to the corresponding prior year period, primarily due to a decrease in cash proceeds from maturities and sales of investments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and an increase in purchases of investments, which was partially offset by a decrease in </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital expenditures.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in cash flows from financing activities primarily relate to proceeds from employee stock programs and taxes paid related to net share settlement of equity awards.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased as compared to the corresponding prior year period, primarily due to an increase in withholding taxes remitted to the government related to net share settlements of equity awards, which was partially offset by an increase in proceeds received from the issuance of common stock under our equity incentive plans.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022, we entered into the seventh amendment to the lease for our corporate headquarters located on Harbor Bay Parkway, Alameda, California (the Alameda Lease) for the expansion of the premises by 34,745 square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Expansion Space). The term of the 1751 Expansion Space is coterminous with the term of the Alameda Lease for the existing space.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the office building (New Premises) associated with our October 2019 build-to-suit lease agreement (Build-to-Suit Lease) was substantially completed. The New Premises is 220,517 square feet and is in Alameda, California, adjacent to our existing corporate headquarters. The Build-to-Suit Lease term is 242 months, includes two five-year options to extend the term of the lease and a one-time option to terminate the lease after 180 months. In addition to the lease payments, we are also responsible for paying operating expenses related to the New Premises.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes outside of the ordinary course of business in our contractual obligations as of June&#160;30, 2022 from those disclosed in our Fiscal 2021 Form 10-K. For more information about our Build-to-Suit Lease, and our other contractual obligations see &#8220;Note 10. Commitments and contingencies&#8221; in &#8220;Notes to Condensed Consolidated Financial Statements&#8221; included in Part I, Item I of this Quarterly Report on Form 10-Q and see &#8220;Note 11. Commitments and contingencies&#8221; of the &#8220;Notes to Consolidated Financial Statements included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liabilities; valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market and/or performance conditions; and the amounts of deferred tax assets and liabilities including the related valuation allowance. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the six months ended June 30, 2022, compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Part II, Item 7 of our Fiscal 2021 Form 10-K.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_82"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks as of June&#160;30, 2022 have not changed significantly from those described in Item&#160;7A of our Fiscal 2021 Form 10-K.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_85"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the effectiveness of controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_88"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_91"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. These two lawsuits, numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties have narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN has, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claims 1 and 2 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial occurred in May 2022, and a judgment is expected during the third or fourth quarter of 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the February 2022 MSN ANDA Complaint) arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. In the February 2022 MSN ANDA Complaint, we are seeking, among other remedies, equitable relief enjoining MSN from infringing these patents, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of the patents identified in the February 2022 MSN ANDA Complaint, the latest of which expires on January 15, 2030. The February 2022 MSN ANDA Complaint is a new case, numbered Civil Action No. 22-00228, against MSN involving Exelixis patents that are different from those asserted in the consolidated Civil Action Nos. 19-02017 and 20-00633 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">described above. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are invalid and not infringed. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would also infringe certain claims of each patent, if those claims are not found to be invalid. A bench trial in connection with the February 2022 MSN ANDA Complaint has been scheduled for May 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 (the July 2022 MSN ANDA Complaint) arising from MSN&#8217;s further amendment of its ANDA Filing with the FDA. In the July 2022 MSN ANDA Complaint, we are seeking, among other remedies, equitable relief enjoining MSN from infringing this patent, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of the patent identified in the July 2022 MSN ANDA Complaint, which expires on February 10, 2032. The July 2022 MSN ANDA Complaint is a new case against MSN involving an Exelixis patent that is different from those asserted in the consolidated Civil Action Nos. 19-02017, 20-00633 and 22-00228 described above. MSN&#8217;s response to the complaint is due on August 9, 2022. A trial has not yet been scheduled in connection with the July 2022 MSN ANDA Complaint.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Pharmaceutical Industries Limited (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Parent), asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. On February 11, 2022, this case was administratively closed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). We have 45 days from the receipt of the July 29, 2022 notice to file a patent infringement claim against Teva relating to the newly challenged patent.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_94"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to the risks discussed elsewhere in this report, the following are important factors that make an investment in our securities speculative or risky, and that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">impair our business operations. If any of the following risks or such other risks actually occur, our business and the value of your investment in our company could be harmed.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications and the continued clinical development, regulatory approval, clinical acceptance and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Pricing for pharmaceutical products, both in the U.S. and in foreign countries, has come under increasing attention and scrutiny by federal, state and foreign national governments, legislative bodies and enforcement agencies. Initiatives arising from this scrutiny may result in changes that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The timing of the entrance of generic competitors to CABOMETYX and legislative and regulatory action designed to reduce the barriers to the development, approval and adoption of generic drugs in the U.S. could limit the revenue we derive from our products, most notably CABOMETYX, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">We are subject to healthcare laws, regulations and enforcement, as well as laws and regulations relating to privacy, data collection and processing of personal data; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, uncertain and subject to change, and may not result in regulatory approvals for additional cabozantinib indications or for our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">We may be unable to expand our discovery and development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our other product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks. For example, we rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and we are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S. In addition, our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Data breaches, cyber attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications and the continued clinical development, regulatory approval, clinical acceptance and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. In this regard, part of our strategy is to pursue additional indications for CABOMETYX and increase the number of cancer patients who could potentially benefit from this medicine. However, we cannot be certain that the clinical trials we and our collaboration partners are conducting will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if the required regulatory approvals to market cabozantinib for additional indications are achieved, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. If revenue from CABOMETYX decreases or remains flat, or if we are unable to expand the number of labeled indications for which CABOMETYX is approved, or if we or our collaboration partners fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow revenues from sales of CABOMETYX depends upon the degree of market acceptance among physicians, patients, healthcare payers, and the medical community.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase or maintain revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, foreign and U.S. government healthcare payers such as Medicare and Medicaid, commercial healthcare plans and the medical community. Market acceptance for CABOMETYX could be impacted by numerous factors, including the effectiveness and safety profile, or the perceived effectiveness and safety profile, of CABOMETYX compared to competing products, the strength of CABOMETYX sales and marketing efforts and changes in pricing and reimbursement for CABOMETYX. If CABOMETYX does not continue to be prescribed broadly for the treatment of patients in its approved indications, our product revenues could flatten or decrease, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our competitors may develop products and technologies that impair the relative value of our marketed products and any current and future product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is competitive and characterized by constant technological change and diverse offerings of products, particularly in the area of oncology therapies. Many of our competitors have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage. Further, our competitors may be more effective at in-licensing and developing new commercial products that could render our products, and those of our collaboration partners, obsolete and noncompetitive. We face, and will continue to face, intense competition from biopharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing scientific and clinical research activities similar to ours.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. Even if our current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in NSCLC and mCRPC or evaluating XL092 in combination with an ICI in CRC, produce positive results sufficient to obtain marketing approval by the FDA and other global regulatory authorities, it is uncertain whether physicians will choose to prescribe regimens containing our products instead of competing products and product combinations in approved indications.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain or increase our sales, marketing, market access and product distribution capabilities for our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with maintaining and continuously improving our commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and precommercial-stage, oncology-focused biopharmaceutical companies seeking to build out and maintain their commercial organizations, as well as larger biopharmaceutical organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly scale the size and experience of our commercialization teams to market and sell CABOMETYX successfully in an expanded number of indications. If we are unable to maintain or scale our commercial function appropriately, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including foreign and U.S. governmental payers, such as Medicare and Medicaid, and private health insurers. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and may limit reimbursement for newly approved products and indications. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. Accordingly, market acceptance of CABOMETYX and COMETRIQ is dependent on the extent to which coverage and reimbursement is available from third-party payers. These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting, or alternatively for patients who rely on our co-pay assistance program, implement co-pay accumulators or maximizers that exempt such co-pay assistance from patient deductibles, which has increased and could further increase the costs of our co-pay assistance program or cause patients to abandon CABOMETYX or COMETRIQ therapy due to higher out-of-pocket costs. If third-party payers do not provide or increase limitations on coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations may suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governments in the U.S. are considering legislative and regulatory proposals to change the U.S. healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Similarly, among policy makers and payers, there is significant interest in promoting such changes with the stated goals of containing healthcare costs and expanding patient access. The life sciences industry and specifically the market for the sale, insurance coverage and distribution of pharmaceuticals has been a particular focus of these efforts and would likely be significantly affected by any major legislative or regulatory initiatives.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, efforts to repeal, substantially modify or invalidate some or all of the provisions of the Patient Protection and Affordable Care Act of 2010, as amended (PPACA), some of which have been successful, create considerable uncertainties for all businesses involved in healthcare, including our own. Although such efforts have not significantly impacted our business to date, it is possible that the PPACA will be subject to additional judicial or legislative challenges in the future, which may have a material adverse impact on our business, financial condition and results of operations, and we cannot predict how future healthcare reform measures of the Biden Administration and federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the healthcare industry. It is also possible that additional governmental actions will be taken in response to the ongoing COVID-19 pandemic, and that such actions would have a significant impact on these public health insurance programs. While we cannot predict how future legislation (or enacted legislation that has yet to be implemented) will affect our business, such proposals could have the potential to impact access to and sales of our products. Furthermore, the expansion of the 340B Drug Pricing Program through the PPACA (the 340B Program) has increased the number of purchasers who are eligible for significant discounts on branded drugs, including our marketed products. Because we participate in the 340B Program to sell a portion of our marketed products, changes in the administration of the program could have a material adverse impact on our revenues, including the implementation or revision of the program&#8217;s Administrative Dispute Resolution Process, which is in part intended to resolve claims by covered entities that manufacturers have overcharged them for covered outpatient drugs. A federal court has preliminarily enjoined the 340B Administrative Dispute Resolution Process with respect to the plaintiff manufacturer in that specific challenge, and other legal challenges are ongoing. The Office of Management and Budget initiated review of a new proposed rule titled &#8220;340B Drug Pricing Program; Administrative Dispute Resolution&#8221; in November 2021. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some manufacturers are currently involved in ongoing litigation regarding the legality of contract pharmacy arrangements under the 340B Program, which may affect the way in which manufacturers are required to extend discounts to covered entities through contract pharmacies. Effective July 2022, we implemented a 340B Program &#8220;integrity initiative,&#8221; pursuant to which we will request all hospital covered entities (i.e., hospitals that participate in the 340B Program) to provide claims-level data for CABOMETYX and COMETRIQ dispensed by contract pharmacies. A covered entity that elects not to provide this limited claims data and that does not have an in-house pharmacy may designate a single contract pharmacy location within our authorized specialty pharmacy network. We believe this initiative will provide much-needed transparency and promote compliance with program requirements, and at the same time, should not restrict patient access to our medicines. The U.S. Department of Health and Human Services (HHS) has notified us that it is reviewing our policy, and we have responded to HHS&#8217; request for information. Since 2021, at least nine manufacturers that previously implemented similar contract pharmacy integrity programs have received enforcement letters from HHS stating that those manufacturers&#8217; actions restricted contract pharmacy transactions in violation of the 340B Program statute, which may subject them to repayment of overcharges and civil monetary penalties. As mentioned above, certain of these manufacturers are now in litigation with the government over the legality of these programs, and depending on the outcome of such litigation, we may be required to modify or suspend our 340B Program integrity initiative program. Further, it is possible that HHS could seek to implement administrative proceedings to recover overcharges and/or impose civil monetary penalties against us regarding our 340B Program integrity initiative. If such proceedings were implemented against us, a negative ruling could have a material adverse effect on our business, financial condition and results of operations. Due to general uncertainty with respect to this litigation and in the current regulatory and healthcare policy environment, and specifically regarding positions that the Biden Administration may take with respect to these issues, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. If enacted, we and any third parties we may engage may be unable to adapt to any changes implemented as a result of such measures, and we may have difficulties in sustaining profitability or otherwise experience a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. Initiatives arising from this scrutiny may result in changes that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continue to be U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying drug prices to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits; implement additional data collection and transparency reporting regarding drug pricing, rebates, fees and other remuneration provided by drug manufacturers; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid; eliminate the Anti-Kickback Statute (AKS) discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers; and revise the rebate methodology under the Medicaid Drug Rebate Program. For instance, President Biden issued an executive order in July 2021 supporting legislation to enact some of these drug pricing reforms, and in response, HHS released a Comprehensive Plan for Addressing High Drug Prices in September 2021 with specific legislative and administrative policies that Congress could enact to help improve affordability of and access to prescription drugs. While we cannot know the final form or timing of any such legislative, regulatory and/or administrative measures, some of the pending and enacted </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legislative proposals or executive rulemaking if implemented without successful legal challenges, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biotherapeutic product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. In particular, the obligation to provide notices of price increases to purchasers under laws such as California&#8217;s SB-17 may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of these drug pricing transparency regulations, and our associated compliance obligations, may increase our general and administrative costs and/or diminish our revenues. Implementation of these federal and/or state cost-containment measures or other healthcare reforms may limit our ability to generate product revenue or commercialize our products, and in the case of drug pricing transparency regulations, may result in fluctuations in our results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., including major markets in the EU and Japan, the pricing and reimbursement of prescription pharmaceuticals is generally subject to governmental control. In these countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partners Ipsen and Takeda may also be required to conduct a study or otherwise provide data that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, cost-control initiatives, increasingly based on affordability and accessibility, as well as post-marketing assessments of the added value of CABOMETYX and COMETRIQ as compared to existing treatments, could influence the prices paid for and net revenues we realize from CABOMETYX and COMETRIQ, or the indications for which we are able to obtain reimbursement, which would result in lower license revenues to us. Upcoming legislative and policy changes in the EU are aimed at increasing cooperation between the EU Member States. Such initiatives, particularly the Regulation on Health Technology Assessment adopted in December 2021, may further impact the price and reimbursement status of CABOMETYX and COMETRIQ in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The timing of the entrance of generic competitors to CABOMETYX and legislative and regulatory action designed to reduce barriers to the development, approval and adoption of generic drugs in the U.S. could limit the revenue we derive from our products, most notably CABOMETYX, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Federal Food, Drug and Cosmetic Act (FDCA), the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve a New Drug Application (NDA) under section 505(b)(2) of the FDCA that relies in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug, where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. Both the ANDA and 505(b)(2) NDA processes are discussed in more detail in &#8220;Item 1. Business&#8212;Government Regulation&#8212;FDA Review and Approval&#8212;Abbreviated FDA Approval Pathways and Generic Products&#8221; in our Fiscal 2021 Form 10-K. In either case, if an ANDA or 505(b)(2) NDA applicant submits an application referencing one of our marketed products prior to the expiry of one or more our Orange Book-listed patents for the applicable product, we may litigate with the potential generic competitor to protect our patent rights, which would result in substantial costs, divert the attention of management, and could have an adverse impact on our stock price. For example, MSN and Teva have separately submitted ANDAs to the FDA requesting approval to market their respective generic versions of CABOMETYX tablets, and we have subsequently filed patent lawsuits against both companies. For a more detailed discussion of these litigation matters, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q. It is possible that MSN, Teva or other companies, following FDA approval of an ANDA or 505(b)(2) NDA, could introduce generic or otherwise competitor versions of our marketed products before our patents expire if they do not infringe our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Therefore, regardless of the regulatory approach, the introduction of a generic version of cabozantinib would likely decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. There are also equivalent procedures in the EU permitting authorization of generic versions and biosimilars of medicinal products authorized in the EU once related data and market exclusivity periods have expired.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government has also taken numerous legislative and regulatory actions to expedite the development and approval of generic drugs and biosimilars. Both Congress and the FDA are considering, and have enacted, various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Ensuring Innovation Act, enacted in April 2021, amended the FDA&#8217;s statutory authority for granting new chemical entity (NCE) exclusivity to reflect the agency&#8217;s existing regulations and longstanding interpretation that award NCE exclusivity based on a drug&#8217;s active moiety, as opposed to its active ingredient, which is intended to limit the applicability of NCE exclusivity, thereby potentially facilitating generic competition. The FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; healthcare costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs. In addition, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the Creating and Restoring Equal Access To Equivalent Samples (CREATES) legislation, purports to promote competition in the market for drugs and biotherapeutic products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biotherapeutic products, including by allowing ANDA, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biotherapeutic product samples. While the full impact of these provisions is unclear at this time, its provisions do have the potential to facilitate the development and future approval of generic versions of our products, introducing generic competition that could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare Regulatory and Other Legal Compliance Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal and state healthcare laws and regulations, which laws and regulations are enforced by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper business conduct or inaccurate reporting, we could be subject to enforcement of the following, including, without limitation:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the federal AKS;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the FDCA and its implementing regulations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal civil and criminal false claims laws, including the civil False Claims Act, and the Civil Monetary Penalties Law;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations, as amended; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state law equivalents of each of the above federal laws;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Open Payments program of the PPACA;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and local laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and federal pharmaceutical price and price reporting laws and regulations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, medical professionals employed by national healthcare programs) and its foreign equivalents, as well as federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These federal and state healthcare laws and regulations govern drug marketing practices, including off-label promotion, and also impact our current and future business arrangements with third parties, including various healthcare entities. If our operations are found, or even alleged, to be in violation of the laws described above or other governmental </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations that apply to us, we, or our officers or employees, may be subject to significant penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, imprisonment, reputational harm, additional reporting requirements and oversight through a Corporate Integrity Agreement or other monitoring agreement, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Furthermore, responding to any such allegation or investigation and/or defending against any such enforcement actions can be time-consuming and would require significant financial and personnel resources. Therefore, if any state or the federal government initiates an enforcement action against us, our business may be impaired, and even if we are ultimately successful in our defense, litigating these actions could result in substantial costs and divert the attention of management.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer patient assistance programs and donations to patient assistance foundations created by charitable organizations could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of Congressional interest and enhanced government scrutiny. The HHS Office of Inspector General established guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations that provide co-pay assistance to Medicare patients, provided that manufacturers meet certain specified compliance requirements. In the event we make such donations but are found not to have complied with these guidelines and other laws or regulations respecting the operation of these programs, we could be subject to significant damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. Moreover, in December 2020, the Centers for Medicare and Medicaid Services (CMS) finalized changes to Medicaid Drug Rebate Program pricing calculations regarding the provision of co-payment assistance to patients that may be impacted by private insurer accumulator programs. Although the portion of this rule dealing with manufacturer co-payment assistance (and related support programs) was struck down by the U.S. District Court for the District of Columbia in May 2022, this ruling is subject to appeal, and it also is possible that CMS could issue new rulemaking or guidance that would affect the amount of rebates owed under the Medicaid program or otherwise limit our ability to support our patient co-pay assistance program. We also rely on a third-party hub provider and exercise oversight to monitor patient assistance program activities. Hub providers are generally hired by manufacturers to assist patients with insurance coverage, financial assistance and treatment support after the patients receive a prescription from their healthcare professional. For manufacturers of specialty pharmaceuticals (including our marketed products), the ability to have a single point of contact for their therapies helps ensure efficient medication distribution to patients. Accordingly, our hub activities are also subject to scrutiny and may create risk for us if not conducted appropriately. A variety of entities, including independent charitable foundations and pharmaceutical manufacturers, but not including our company, have received subpoenas from the U.S. Department of Justice (DOJ) and other enforcement authorities seeking information related to their patient assistance programs and support, and certain of these entities have entered into costly civil settlement agreements with DOJ and other enforcement authorities that include requirements to maintain complex corporate integrity agreements that impose significant reporting and other requirements. Should we or our hub providers receive a subpoena or other process, regardless of whether we are ultimately found to have complied with the regulations governing patient assistance programs, this type of government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory landscape for privacy and data protection continues to evolve in the U.S. and other jurisdictions around the world. For example, the California Consumer Privacy Act of 2018 (CCPA) went into operation in 2020 and affords California residents expanded privacy rights and protections, including civil penalties for violations and statutory damages under a private right of action for data security breaches. These protections will be expanded by the California Privacy Rights Act (CPRA), which will be operational in most key respects on January 1, 2023. Similar legislative proposals have passed or are being advanced in other states, and Congress is also considering additional federal privacy legislation. In addition, most healthcare professionals and facilities are subject to privacy and security requirements under HIPAA with respect to our clinical and commercial activities. Although we are not considered to be a covered entity or business associate under HIPAA, we could be subject to penalties if we use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">governing the collection, use and transmission of personal information. For example, in the EU, the EU General Data Protection Regulation 2016/679 (GDPR) regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also places restrictions on transfers of such data to countries outside of the EU, including the U.S. Should we fail to provide adequate privacy or data security protections or maintain compliance with these laws and regulations, including the CCPA, CPRA and GDPR, we could be subject to sanctions or other penalties, litigation, an increase in our cost of doing business and questions concerning the validity of our data processing activities, including clinical trials.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Growth of Our Product Portfolio and Research and Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval of a product candidate or of an approved product for a new indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and late-stage or other potentially label-enabling clinical trials may fail to confirm the results observed in early-stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events, during or as a result of clinical investigations, that could delay or prevent commercialization of cabozantinib in new indications or of XL092 or other new product candidates. These events may include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lack of acceptable efficacy or a tolerable safety profile;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to identify and maintain a sufficient number of clinical trial sites; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lower-than-anticipated patient registration or enrollment in our clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additional complexities posed by clinical trials evaluating cabozantinib, XL092 or our other product candidates in combination with other therapies, including extended timelines to provide for collaboration on clinical development planning, the failure by our collaboration partners to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">reduced staffing or shortages in laboratory supplies and other resources necessary to complete the trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials or delays, variations, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing Russo-Ukrainian War has had a modest impact on our clinical development operations, particularly with respect to patient recruitment, potentially delaying our ability to complete enrollment in a timely manner. In addition, this conflict has had and may continue to have an adverse impact on the ability of clinical sites and their patients to adhere to trial protocols for in-office clinical visits and other procedures, our ability to supply clinical sites with cabozantinib or other study drugs and to pay clinical sites and investigators for work performed, as well as our ability to collect data and conduct site monitoring visits, all of which could undermine the data quality for patients enrolled at these clinical sites. The need to shift enrollment of patients away from these clinical sites or close certain sites entirely, or to replace patients in affected territories should investigators be unable to continue treating and monitoring them, could further impact our anticipated timelines for completing the trials and achieving clinical endpoints, as well as increase our clinical development expenses. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are further delays in or termination of the clinical testing of cabozantinib, XL092 or our other product candidates due to any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our collaboration partners to fund a significant portion of our clinical development programs. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for financing the further development of the cabozantinib franchise, XL092 or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to pursue the further development of the cabozantinib franchise, XL092 or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions in accordance with our stated timelines or at all. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or otherwise may not result in an approvable product. The duration and the cost of clinical trials vary significantly as a result of factors relating to a particular clinical trial, including, among others: the characteristics of the product candidate under investigation; the number of patients who ultimately participate in the clinical trial; the duration of patient follow-up; the number of clinical sites included in the trial; and the length of time required to enroll eligible patients. Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, uncertain and subject to change, and may not result in regulatory approvals for additional cabozantinib indications or for our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities associated with the research, development and commercialization of the cabozantinib franchise, XL092 and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as well as by comparable regulatory authorities in other territories. The processes of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or supplemental New Drug Application (sNDA) can be submitted to the FDA, or a marketing authorization application to the EMA or any application or submission to comparable regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for XL092 or our other product candidates. For example, the FDA launched Project Optimus in 2021 as an initiative to reform the dose optimization and dose selection paradigm in oncology drug development, which was driven by the FDA&#8217;s concerns that the current paradigm for dose selection may result in doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating pivotal trials. Through collaboration with the biopharmaceutical industry, academia and other stakeholders, the FDA&#8217;s goal for this initiative is to advance an oncology dose-finding and dose optimization paradigm that emphasizes dose selections that maximize efficacy as well as safety and tolerability. In support of this initiative, the FDA may request sponsors of oncology product candidates to conduct dose optimization studies pre- or post-approval, and the FDA also continues to develop and finalize guidance documents and implement initiatives regarding the development and clinical research of oncology product candidates. Recently, in part due to questions raised by the process underlying the approval of the Alzheimer&#8217;s disease drug Aduhelm</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government authorities and other stakeholders have been scrutinizing the accelerated approval pathway, with some stakeholders advocating for reforms. Even prior to the Aduhelm approval, FDA has held Oncologic Drugs Advisory Committee meetings to discuss accelerated approvals for which confirmatory trials have not verified clinical benefit. Such scrutiny, among other factors, has resulted in voluntary withdrawals of certain products and indications approved on an accelerated basis. Moreover, also spurred by the Aduhelm controversy, the HHS Office of Inspector General has initiated an assessment of how the FDA implements the accelerated approval pathway. In addition, members of Congress have introduced proposed legislation to revise the statutory accelerated approval pathway, including with respect to the FDA&#8217;s ability to rapidly withdraw products and indications for which effectiveness is not confirmed in post-marketing studies. At this time, it is not clear what impact, if any, these developments may have on the statutory accelerated approval pathway or our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications or approves one of our other product candidates, including XL092, for use, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the product and could impose requirements for post-marketing studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib, XL092 or our other product candidates in any new indications. Failure to complete post-marketing requirements of the FDA in connection with a specific approval in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib, XL092 or another product candidate in the approved indication. Regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Further, current or any future laws or executive orders governing FDA or foreign regulatory approval processes that may be enacted or executed could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to expand our discovery and development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we have invested in substantial technical, financial and human resources toward drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. Notwithstanding this investment, many programs that initially show promise will ultimately fail to yield product candidates for multiple reasons. For example, product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apart from our drug discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates and technologies. However, the in-licensing and acquisition of product candidates and technologies is a highly competitive area, and many other companies are pursuing the same or similar product candidates and technologies to those that we may consider attractive. In particular, larger companies with more capital resources and more extensive clinical development and commercialization capabilities may have a competitive advantage over us. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to in-license or acquire additional product candidates and technologies on acceptable terms that would allow us to realize an appropriate return on our investment. Even if we succeed in our efforts to obtain rights to suitable product candidates and technologies, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products and technologies will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target company, or retain key personnel of the acquired business. Furthermore, we could assume unknown or contingent liabilities or otherwise incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our financial condition and results of operations. If our drug discovery efforts, including research collaborations, in-licensing arrangements and other business development activities, do not result in suitable product candidates, our business and prospects for growth could suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Financial Matters and Capital Requirements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our other product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we reported net income of $70.7&#160;million and $139.2&#160;million for the three and six months ended June 30, 2022 and $231.1 million for the fiscal year ended December&#160;31, 2021, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of development, regulatory and commercial milestones, if any, under our collaboration agreements; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements; other collaboration revenues; and the level of our expenses, including those associated with our extensive drug discovery, clinical development and business development activities, both for the cabozantinib franchise and our other product candidates, as well as our general business expansion plans. Our expected future expenses in particular may also be increased by inflationary pressures, whether resulting from the effects of the ongoing Russo-Ukrainian War or the COVID-19 pandemic or otherwise, which could increase the costs of outside services, labor, raw materials and finished drug product. We expect to continue to spend substantial amounts to fund the continued development of the cabozantinib franchise for additional indications and of our other product candidates, as well as the commercialization of our approved products. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including research collaborations, in-licensing arrangements and other strategic transactions that align with our oncology drug development, regulatory and commercial expertise, which efforts could involve substantial costs. To offset these costs in the future, we will need to generate substantial revenues. If these costs exceed our current expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of the cabozantinib franchise and our other product candidates, and increasing drug discovery activities, as well as through the execution of business development transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing macroeconomic conditions and financial, business and other factors beyond our control. We do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and we are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon the regulatory, commercial, medical affairs, market access and other expertise and resources of our collaboration partners, Ipsen and Takeda, for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaboration partners dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaboration partners depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, the operations of our collaboration partners, and ultimately their sales of CABOMETYX in their respective territories outside of the U.S., could be adversely affected by the degree and effectiveness of their respective corporate responses to the COVID-19 pandemic, as well as by the imposition of governmental price or other controls, political and macroeconomic instability, trade restrictions or barriers and changes in tariffs, escalating global trade and political tensions, or other factors. If our collaboration partners are unable or unwilling to invest the resources necessary to commercialize CABOMETYX successfully in the EU, Japan and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established clinical and commercial collaborations with leading biopharmaceutical companies for the development and commercialization of our products, and our dependence on these collaboration partners subjects us to a number of risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; decision to terminate our collaboration, or their failure to comply with the terms of our collaboration agreements and related ancillary agreements, either intentionally or as a result of negligence or other insufficient performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to control the amount and timing of resources that our collaboration partners devote to the development or commercialization of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may stop or delay clinical trials, fail to supply us on a timely basis with product required for a combination trial, or deliver product that fails to meet appropriate quality and regulatory standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our collaboration partners that result in the delay or termination of the development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may experience financial difficulties that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; inability to obtain regulatory approvals in a timely manner, or at all; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to comply with legal and regulatory requirements relevant to the authorization, marketing, distribution and supply of our marketed products in the territories outside the U.S. where they are approved; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, and our product development efforts and prospects for growth could be delayed or disrupted, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our early-stage product pipeline, we have augmented our drug discovery activities with multiple research collaborations and in-licensing arrangements with other companies. Our dependence on our relationships with these research and in-licensing partners subjects us to numerous risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; decision to terminate our relationship, or their failure to comply with the terms of our agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our research and in-licensing partners that result in the delay or termination of research activities with respect to any in-licensed assets or supporting technology platforms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our research and in-licensing partners may experience financial difficulties that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; failure to properly maintain or defend their intellectual property rights or their use of third-party intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our license to develop these assets or utilize technology platforms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">laws, regulations or practices imposed by countries outside the U.S. that could impact or inhibit scientific research or the development of healthcare products by foreign competitors or otherwise disadvantage healthcare products made by foreign competitors, as well as general political or economic instability in those countries, any of which could complicate, interfere with or impede our relationships with our ex-U.S. research, development and in-licensing partners; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations related to Good Manufacturing Practice and Good Laboratory Practice.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not be able to expand our product pipeline or otherwise realize a return on the resources we will have invested to develop these early-stage assets, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government, third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical trial or data security protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib beyond currently approved indications or obtain regulatory approval for XL092 or our other product candidates. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to help advance our drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We lack our own manufacturing and distribution capabilities necessary for us to produce materials required for certain preclinical activities and to produce and distribute our products for clinical development or for commercial sale, and our reliance on third parties for these services subjects us to various risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing or distribution facilities for chemistry, manufacturing and control development activities, preclinical, clinical or commercial production and distribution for our current products and new product candidates. Instead, we rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we continue to expand our supply chain through secondary third-party contract manufacturers, distributors and suppliers. To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party contract manufacturers may not be able to produce or deliver material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical development and commercial needs and applicable regulatory requirements. Although we have not yet experienced significant production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic or the ongoing Russo-Ukrainian War, our third-party contract manufacturers, distributors and suppliers could experience operational delays due to lack of capacity or resources, facility closures and other hardships as a result of these types of global events, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our preclinical, clinical or commercial products. If our third-party contract manufacturers, distributors and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing, distribution and supply arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude meeting commercial or clinical product supply requirements for us or our partners, which could delay product development and future commercialization efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA). If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party scientific advisors and contractors we rely on to assist with our drug discovery efforts do not perform as expected, the expansion of our product pipeline may be delayed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with scientific advisors at academic and other institutions, as well as third-party contractors in various locations throughout the world, that assist us in our research and development efforts, including in drug discovery and preclinical development strategy. These third parties are not our employees and may have other commitments or contractual obligations that limit their availability to us. Although these third-party scientific advisors and contractors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as scientific advisors and contractors or otherwise limit our access to these experts, or that the scientific advisors themselves may now be more reluctant to work with industry partners. Even if these scientific advisors and contractors with whom we have engaged intend to meet their contractual obligations, their ability to perform services may be impacted by increased demand for such services from other companies or by other external factors, such as reduced capacity to perform services, as we experienced in the early stages of the COVID-19 pandemic. If we experience additional delays in the receipt of services, lose work performed by these scientific advisors and contractors or are unable to engage them in the first place, our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Information Technology and Intellectual Property</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data breaches, cyber-attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and our third-party service providers, such as contract research organizations, collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our collaboration partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cybersecurity efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber-attack. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber-attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt critical business operations, expend key information technology resources and divert the attention of management. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the aggregate impact of cyber-attacks on our operations and financial condition has not been material to date, we and our third-party service providers have frequently been the target of threats of this nature and expect them to continue. Any future data breach and/or unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information or sensitive business information of our collaboration partners, which may lead to significant liability for us. A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others and result in harm to our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents including the GDPR, subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cybersecurity systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our third-party service providers may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, we received Paragraph IV certification notice letters from MSN and Teva concerning the respective ANDAs that each had filed with the FDA seeking approval to market their respective generic versions of CABOMETYX tablets. Should MSN, Teva or any other third parties receive FDA approval of an ANDA or a 505(b)(2) NDA with respect to cabozantinib, it is possible that such company or companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and the resulting generic competition could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. They may also be negatively impacted by the decisions of foreign courts, which could limit the protection contemplated by the original regulatory approval and our ability to thwart the development of competing products that might otherwise have been determined to infringe our intellectual property rights. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in the EU, have compulsory licensing laws based on related EU rules, under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the Russian Federation has and may further limit protections on patents originating from &#8220;unfriendly countries&#8221; (including the U.S.) in response to sanctions relating to the ongoing Russo-Ukrainian War, and in general, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We also rely on trade secret protection for some of our confidential and proprietary information, and we are taking security measures to protect our proprietary information and trade secrets, particularly in light of recent instances of data loss and misappropriation of intellectual property in the biopharmaceutical industry. However, these measures may not provide adequate protection, and while we seek to protect our proprietary information by entering into confidentiality agreements with employees, partners and consultants, as well as maintain cybersecurity protocols within our information technology infrastructure, we cannot provide assurance that our proprietary information will not be disclosed, or that we can </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense. In addition, we may be subject to claims that our employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that they used or sought to use patent inventions belonging to their former employers. Furthermore, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs and divert the attention of management and key technical personnel in defending ourselves against any such claims or enforcing our own patents. In the event of any third party&#8217;s successful claim of patent infringement or misappropriation of trade secrets, we may lose valuable intellectual property rights or personnel, which could impede or prevent the achievement of our product development goals, or we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations, Managing Our Growth and Employee Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the COVID-19 pandemic has had a modest impact on our business operations, in particular with respect to our clinical trial, drug discovery and commercial activities. For example, to varying degrees and at different rates across our clinical trials, we experienced declines in screening and enrollment activity during the early days of the COVID-19 pandemic, as well as delays in new site activations and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. As the COVID-19 pandemic continues to have a significant presence in various parts of the world, particularly with the potential emergence of new variants that may prove especially contagious or virulent, the impact on our clinical development operations could continue or grow more severe. We anticipate that a further prolonged, or more severe, global public health crisis could limit our ability to identify and work with clinical investigators at clinical trial sites globally to enroll, initiate and maintain treatment per protocol of patients for our ongoing clinical trials. Disruptions to medical and administrative operations at clinical trial sites, including staffing and materials shortages and the implementation of crisis management initiatives, have and may continue to reduce personnel and other resources necessary to conduct our clinical trials, which could further delay some of our clinical trial plans or may require certain trials to be temporarily suspended. In addition, increased costs connected with our efforts to mitigate the adverse impacts resulting from the COVID-19 pandemic on our clinical trials could cause the expenses we incur in conducting those clinical trials to increase considerably. Depending upon the duration and severity of the COVID-19 pandemic, we could also experience delays in planning and conducting new clinical trials of the investigative product candidates entering and advancing through our development pipeline, which could increase the operating expenses associated with these trials and adversely affect their timelines for completion and ultimately our ability to obtain regulatory approvals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both drug discovery work in our laboratories and outsourced drug discovery activities have fully resumed following temporary suspensions during the early days of the COVID-19 pandemic; however, we may be unable to maximize the potential of these programs due to the imposition of increased safety protocols, and should the effects of the COVID-19 pandemic become more severe, we may have to again scale back or suspend activities in the future. We are also reliant on laboratory materials manufactured and distributed from areas impacted by both the COVID-19 pandemic and other natural disasters, for which supply has become limited. If we are unable to obtain the requisite materials to conduct our planned </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug discovery activities, we may be required to redirect the focus of, or even suspend, such activities. Should the COVID-19 pandemic be further prolonged or grow in severity, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines, which could have a material adverse impact on our prospects for growth. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, it remains possible that the evolving dynamics of the COVID-19 pandemic may require further modifications to our standard sales and marketing practices, including shifts from in-person back to primarily telephonic and virtual interactions with healthcare professionals. Such changes in our commercial operations could negatively impact the flow of important information regarding our medicines, which along with obstacles to patient access to healthcare professionals, could diminish sales of our marketed products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These continuing or future effects of the COVID-19 pandemic could materially and adversely affect our business, financial condition, results of operations and growth prospects, and exacerbate the other risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations, in particular as we continue to expand the cabozantinib franchise into new indications and grow our pipeline of product candidates. This growth places significant demands on our management and resources, and our current and planned personnel and operating practices may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We continue to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, including as a result of the COVID-19 pandemic or otherwise, or we are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial, scientific and pharmaceutical operations personnel will be critical to support activities related to advancing the development programs for the cabozantinib franchise and our other product candidates, successfully executing upon our commercialization plan for the cabozantinib franchise and our proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials, and our operations can produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge, or any resultant injury from these materials, and we may face liability under applicable laws for any injury or contamination that results from our use or the use by our collaboration partners or other third parties of these materials. Such liability may exceed our insurance coverage and our total assets, and in addition, we may be required to indemnify our collaboration partners against all damages and other liabilities arising out of our development activities or products produced in connection with our collaborations with them. Moreover, our continued compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be held liable if any product we or our collaboration partners develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. We maintain limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib. However, our insurance may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and may in the future be highly volatile.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been highly volatile, and it may remain highly volatile or fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of FDA or other regulatory approval or non-approval, or delays in the FDA or other regulatory review process with respect to cabozantinib, XL092 or our other product candidates, our collaboration partners&#8217; product candidates being developed in combination with either cabozantinib, XL092 or our other product candidates, or our competitors&#8217; product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the commercial performance of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products, including royalties paid under our collaboration and license agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">adverse or inconclusive results or announcements related to our or our collaboration partners&#8217; clinical trials or delays in those clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing of achievement of our clinical, regulatory, partnering, commercial and other milestones for the cabozantinib franchise, XL092 or any of our other product candidates or programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to make future investments in the expansion of our pipeline through drug discovery, including future research collaborations, in-licensing arrangements and other strategic transactions;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to obtain the materials and services, including an adequate product supply for any approved drug product, from our third-party vendors or do so at acceptable prices;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib, XL092 and our other product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib, XL092 or our other product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of new products or clinical trial data by our competitors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of regulatory applications, such as MSN&#8217;s and Teva&#8217;s respective ANDAs, seeking approval of generic versions of our marketed products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in our relationships with our collaboration partners, including the termination or modification of our agreements, or other events or conflicts that may affect our collaboration partners&#8217; timing and willingness to develop, or if approved, commercialize our products and product candidates out-licensed to them;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of an in-licensed product candidate or strategic acquisition;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in earnings estimates or recommendations by securities analysts, or financial guidance from our management team, and any failure to achieve the operating results projected by securities analysts or by our management team;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the entry into new financing arrangements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">developments in the biopharmaceutical industry;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additions and departures of key personnel or board members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the disposition of any of our technologies or compounds; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">general market, macroeconomic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors could have material adverse impact on the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Likewise, as a result of significant changes in U.S. or global political and macroeconomic conditions, including historically high inflation, as well as policies governing foreign trade and healthcare spending and delivery, or the ongoing Russo-Ukrainian War, the financial markets could continue to experience significant volatility that could also continue to negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been initiated. A securities class action suit against us could result in substantial costs and divert the attention of management, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">a prohibition on actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">advance notice requirements for director nominations and stockholder proposals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_97"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_100"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_103"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_106"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_109"></div><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:8.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.833%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000076/exel20210526ex31restatedce.htm">Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000028/exhibit31amendedandrestate.htm">Amended and Restated Bylaws of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/3/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel2022630exhibit10110q.htm">Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel2022630exhibit10210q.htm">Cash Compensation Information for Non-Employee Directors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel2022630exhibit10310q.htm">Seventh Amendment dated May 16, 2022, to Lease Agreement dated May 2, 2017, between SCG Harbor Bay Parkway Phase I, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20220630exhibit31110q.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210630exhibit31210q.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20220630exhibit32110q.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="ic81896f1bbec43d4802dcc1c5fa2e0e2_112"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic81896f1bbec43d4802dcc1c5fa2e0e2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-top:5pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher J. Senner</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief&#160;Financial&#160;Officer </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Duly Authorized Officer and Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exel2022630exhibit10110q.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if11b18ed800b4fe4abe1adaf150b1f0d_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Exelixis, Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">2017 Equity Incentive Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adopted by the Board of Directors&#58;  February 23, 2017</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended by the Compensation Committee&#58;  March 22, 2017</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> Approved by the Stockholders&#58;  May 24, 2017</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended by the Company&#58;  December 18, 2017</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended by the Compensation Committee&#58;  March 18, 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> Approved by the Stockholders&#58;  May 20, 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended by the Board of Directors&#58;  April 1, 2022</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> Approved by the Stockholders&#58;  May 25, 2022</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">General.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.62pt">Successor to and Continuation of 2014 Plan.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Plan is intended as the successor to and continuation of the Exelixis, Inc. 2014 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">2014 Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Following the Effective Date, no additional stock awards may be granted under the 2014 Plan.  Any unallocated shares remaining available for grant under the 2014 Plan as of 12&#58;01 a.m. Pacific time on the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">2014 Plan&#8217;s Available Reserve</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will cease to be available under the 2014 Plan at such time and will be added to the Share Reserve (as further described in Section 3(a) below) and be then immediately available for grant and issuance pursuant to Stock Awards granted under the Plan.  In addition, from and after 12&#58;01 a.m. Pacific time</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the Effective Date, all outstanding stock awards granted under the 2014 Plan, the Exelixis, Inc. 2000 Equity Incentive Plan, as amended and restated (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">2000 Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Exelixis, Inc. 2000 Non-Employee Directors&#8217; Stock Option Plan (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">2000 Non-Employee Directors&#8217; Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Exelixis, Inc. 2011 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">2011 Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and the Exelixis, Inc. 2016 Inducement Award Plan (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">2016 Inducement Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will remain subject to the terms of the 2014 Plan, the 2000 Plan, the 2000 Non-Employee Directors&#8217; Plan, the 2011 Plan or the 2016 Inducement Plan, as applicable&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that any shares subject to outstanding stock awards granted under the 2014 Plan, the 2000 Plan, the 2000 Non-Employee Directors&#8217; Plan, the 2011 Plan or the 2016 Inducement Plan that (i) expire or terminate for any reason prior to exercise or settlement, (ii) are forfeited, cancelled or otherwise returned to the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (iii) other than with respect to outstanding options and stock appreciation rights granted under the 2014 Plan, the 2000 Plan, the 2000 Nonemployee Directors&#8217; Plan, the 2011 Plan or the 2016 Inducement Plan with respect to which the exercise or strike price is at least one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the option or stock appreciation right on the date of grant (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Prior Plans&#8217; Appreciation Awards</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with a stock award (collectively, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Prior Plans&#8217; Returning Shares</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will immediately be added to the Share Reserve (as further described in Section 3(a) below) as and when such shares become Prior Plans&#8217; Returning Shares and become available for issuance pursuant to Awards granted hereunder.  All Awards granted on or after 12&#58;01 a.m. Pacific time</font><font style="color:#0070c0;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the Effective Date will be subject to the terms of this Plan, as amended from time to time.</font><font style="color:#0070c0;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Eligible Award Recipients.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to Section 4, Employees, Directors and Consultants are eligible to receive Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.52pt">Available Awards.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Plan provides for the grant of the following types of Awards&#58; (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Purpose.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Plan, through the granting of Awards, is intended to help the Company and any Affiliate secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Administration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.62pt">Administration by Board.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Board will administer the Plan.  The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Powers of Board.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.6pt">To determine (A) who will be granted Awards&#59; (B) when and how each Award will be granted&#59; (C) what type of Award will be granted&#59; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Award&#59; (E) the number of shares of Common Stock subject to, or the cash value of, an Award&#59; and (F) the Fair Market Value applicable to a Stock Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.66pt">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards.  The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.72pt">To settle all controversies regarding the Plan and Awards granted under it.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.93pt">To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.87pt">To suspend or terminate the Plan at any time.  Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#8217;s rights under his or her then-outstanding Award without his or her written consent except as provided in subsection (viii) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.93pt">To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and&#47;or to make the Plan or Awards granted under the Plan compliant with the requirements for Incentive Stock Options or exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law.  However, if required by applicable law or listing requirements, and except as provided in Section&#160;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A)&#160;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&#160;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&#160;materially increases the benefits accruing to Participants under the Plan, (D) materially reduces the price at which shares of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Stock may be issued or purchased under the Plan, or (E) materially expands the types of Awards available for issuance under the Plan.  Except as otherwise provided in the Plan (including Section 2(b)(viii)) or an Award Agreement, no amendment of the Plan will materially impair a Participant&#8217;s rights under an outstanding Award without the Participant&#8217;s written consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.99pt">To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A) Section 162(m) of the Code regarding the exclusion of performance-based compensation from the limit on corporate deductibility of compensation paid to Covered Employees, (B) Section 422 of the Code regarding incentive stock options or (C) Rule 16b-3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.05pt">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that a Participant&#8217;s rights under any Award will not be impaired by any such amendment unless (A) the Company requests the consent of the affected Participant, and (B) such Participant consents in writing.  Notwithstanding the foregoing, (1) a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#8217;s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#8217;s consent (A)&#160;to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code&#59; (B) to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code&#59; (C)&#160;to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code&#59; or (D) to comply with other applicable laws or listing requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.09pt">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(x)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.03pt">To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.52pt">Delegation to Committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.6pt">General.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable).  Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable).  The Committee may, at any time, abolish the subcommittee and&#47;or revest in the Committee any powers delegated to the subcommittee.  The Board may retain the authority to concurrently </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.66pt">Section 162(m) and Rule 16b-3 Compliance.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Committee may consist solely of two or more Outside Directors, in accordance with Section 162(m) of the Code, or solely of two or more Non-Employee Directors, in accordance with Rule 16b-3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Delegation to an Officer.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Board may delegate to one or more Officers the authority to do one or both of the following&#58; (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Awards, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself.  Any such Stock Awards will be granted on the form of Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation of authority.  The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 13(w)(iii) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.5pt">Effect of Board&#8217;s Decision.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.75pt">Repricing&#59; Cancellation and Re-Grant of Awards.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither the Board nor any Committee will have the authority to (i) reduce the exercise, purchase or strike price of any outstanding Option or SAR under the Plan, or (ii) cancel any outstanding Option or SAR that has an exercise price or strike price greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Awards under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.86pt">Minimum Vesting Requirements.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  No Award may vest until at least twelve (12) months following the date of grant of the Award&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that shares of Common Stock up to five percent (5%) of the Share Reserve (as defined in Section 3(a)) may be issued pursuant to Awards which do not meet such vesting requirement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Dividends and Dividend Equivalents.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to an Award, as determined by the Board and contained in the applicable Award Agreement&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (i) no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares have vested under the terms of such Award Agreement, (ii) any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of such Award Agreement (including, but not limited to, any vesting conditions), and (iii) any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to the Company on the date, if any, such shares are forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such Award Agreement. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Shares Subject to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.62pt">Share Reserve. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.72pt">Subject to Sections 3(b)(i) and 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed (A) 73,953,064 shares (which number is the sum of (i) the number of shares (453,064) subject to the 2014 Plan&#8217;s Available Reserve, (ii) an additional 24,000,000 shares that were approved at the annual meeting of stockholders of the Company held in 2017, (iii) an additional 21,000,000 shares that were approved at the annual meeting of stockholders of the Company held in 2020, and (iv) an additional 28,500,000 shares that were approved at the annual meeting of stockholders of the Company held in 2022), </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">plus</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (B) the Prior Plans&#8217; Returning Shares, if any, which become available for issuance under this Plan from time to time (such aggregate number of shares described in (A) and (B) above, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Share Reserve</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.93pt">For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan.  Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a).  Shares may be issued in connection with a merger or acquisition as permitted by Nasdaq Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.87pt">Subject to Section 3(b), the number of shares of Common Stock available for issuance under the Plan will be reduced by&#58; (A) one share for each share of Common Stock issued pursuant to an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant&#59; (B) 1.5 shares for each share of Common Stock issued pursuant to a Full Value Award granted under the Plan prior to May 25, 2022&#59; and (C) two shares for each share of Common Stock issued pursuant to a Full Value Award granted under the Plan on or after May 25, 2022.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Reversion of Shares to the Share Reserve.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.6pt">Shares Available For Subsequent Issuance.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If (A) any shares of Common Stock subject to a Stock Award are not issued because such Stock Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or is settled in cash (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Participant receives cash rather than stock), (B) any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (C) with respect to a Full Value Award, any shares of Common Stock are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with such Full Value Award, such shares will again become available for issuance under the Plan (collectively, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">2017 Plan Returning Shares</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  For each (1) 2017 Plan Returning Share subject to a Full Value Award or (2) Prior Plans&#8217; Returning Share subject to a stock award other than a Prior Plans&#8217; Appreciation Award, the number of shares of Common Stock available for issuance under the Plan will increase by (x) 1.5 shares for each such 2017 Plan Returning Share or Prior Plans&#8217; Returning Share that returns to the Plan prior to May 25, 2022 and (y) two shares for each such 2017 Plan Returning Share or Prior Plans&#8217; Returning Share that returns to the Plan on or after May 25, 2022.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.66pt">Shares Not Available For Subsequent Issuance.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any shares of Common Stock reacquired or withheld (or not issued) by the Company to satisfy the exercise or purchase price of a Stock Award or a Prior Plans&#8217; Award will no longer be available for issuance under the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan, including any shares subject to a Stock Award or a Prior Plans&#8217; Award that are not delivered to a Participant because such Stock Award or Prior Plans&#8217; Award is exercised through a reduction of shares subject to such Stock Award or Prior Plans&#8217; Award (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., &#8220;net exercised&#8221;).  In addition, any shares reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award, or any shares repurchased by the Company on the open market with the proceeds of the exercise or strike price of an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award will no longer be available for issuance under the Plan.  In the event that a Stock Appreciation Right or a Prior Plans&#8217; Award that is a stock appreciation right is settled in shares of Common Stock, the gross number of shares of Common Stock subject to such award will no longer be available for issuance under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.52pt">Incentive Stock Option Limit.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 50,000,000 shares of Common Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Individual Award Limitations.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.6pt">A maximum of 5,000,000 shares of Common Stock subject to Options, SARs and Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date any such Stock Award is granted may be granted to any one Participant during any one calendar year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.66pt">A maximum of 5,000,000 shares of Common Stock subject to Performance Stock Awards may be granted to any one Participant during any one calendar year (whether the grant, vesting or exercise is contingent upon the attainment during the Performance Period of the Performance Goals).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.72pt">A maximum of $10,000,000 subject to Performance Cash Awards may be granted to any one Participant during any one calendar year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.5pt">Limitation on Grants to Non-Employee Directors.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The (i) maximum number of shares of Common Stock subject to Stock Awards granted under the Plan or otherwise during any one calendar year (beginning with the 2017 calendar year) to any Non-Employee Director, taken together with the (ii) cash fees paid by the Company to such Non-Employee Director during such calendar year, and in both cases for service on the Board, will not exceed $750,000 in total value (calculating the value of any such Stock Awards based on the grant date fair value of such Stock Awards for financial reporting purposes), or, with respect to the calendar year in which a Non-Employee Director is first appointed or elected to the Board, $1,500,000.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.75pt">Source of Shares.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Eligibility.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.62pt">Eligibility for Specific Stock Awards.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Incentive Stock Options may be granted only to employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code).  Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;6.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such term is defined in Rule 405, unless (i) the stock underlying such Stock Awards is treated as &#8220;service recipient stock&#8221; under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from or alternatively comply with the requirements of Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Ten Percent Stockholders.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Provisions Relating to Options and Stock Appreciation Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Option or Stock Appreciation Right Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option.  If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option.  The provisions of separate Option or Stock Appreciation Right Agreements need not be identical&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.62pt">Term.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of seven years from the date of its grant or such shorter period specified in the Award Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Exercise Price.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award on the date the Award is granted if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Transaction and in a manner consistent with the provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code.  Each SAR will be denominated in shares of Common Stock equivalents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.52pt">Purchase Price for Options.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below.  The Board will have the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment.  The permitted methods of payment are as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.6pt">by cash, check, bank draft or money order payable to the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.66pt">pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.72pt">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.93pt">if an Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued.  Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.87pt">in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Exercise and Payment of a SAR.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such SAR.  The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date.  The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.5pt">Transferability of Options and SARs.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine.  In the absence of such a determination by the Board to the contrary, the restrictions set forth in this Section 5(e) on the transferability of Options and SARs will apply.  Notwithstanding the foregoing or anything in the Plan or an Award Agreement to the contrary, no Option or SAR may be transferred to any financial institution without prior stockholder approval.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.6pt">Restrictions on Transfer.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  An Option or SAR will not be transferable except by will or by the laws of descent and distribution (and pursuant to Sections 5(e)(ii) and 5(e)(iii) below) and will be exercisable during the lifetime of the Participant only by the Participant.  Subject to the foregoing paragraph, the Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws.  Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.66pt">Domestic Relations Orders.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2).  If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;8.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.72pt">Beneficiary Designation.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.75pt">Vesting Generally.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal.  The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate.  The vesting provisions of individual Options or SARs may vary.  The provisions of this Section 5(f) are subject to Section 2(g) and any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.86pt">Termination of Continuous Service.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates (other than for Cause and other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date three months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after such termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Extension of Termination Date.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company or an Affiliate,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if the exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.  In addition, unless otherwise provided in a Participant&#8217;s Award Agreement or other written agreement between the Participant and the Company or an Affiliate, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#8217;s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;9.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.6pt">Disability of Participant.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after such termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.48pt">Death of Participant.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company or an Affiliate, if (i) a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii) the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service (for a reason other than death), then the Participant&#8217;s Option or SAR may be exercised (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#8217;s death, but only within such period of time ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement.  If, after the Participant&#8217;s death, the Option or SAR (as applicable) is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.79pt">Termination for Cause.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as explicitly provided otherwise in a Participant&#8217;s Award Agreement or other individual written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Option or SAR will terminate immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.6pt">Non-Exempt Employees.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Award may vest prior to such date).  Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt employee dies or suffers a Disability, (ii) upon a Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant&#8217;s retirement (as such term may be defined in the Participant&#8217;s Award Agreement, in another written agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company&#8217;s or Affiliate&#8217;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six&#160;months following the date of grant.  The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.  To the extent permitted and&#47;or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee&#8217;s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;10.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Provisions of Awards Other than Options and SARs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.62pt">Restricted Stock Awards.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  To the extent consistent with the Company&#8217;s bylaws, at the Board&#8217;s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the Company&#8217;s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.  The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.6pt">Consideration.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.66pt">Vesting.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to Section 2(g), shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.72pt">Termination of Participant&#8217;s Continuous Service.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If a Participant&#8217;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant that have not vested as of the date of such termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.93pt">Transferability.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.  Notwithstanding the foregoing or anything in the Plan or a Restricted Stock Award Agreement to the contrary, no Restricted Stock Award may be transferred to any financial institution without prior stockholder approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Restricted Stock Unit Awards.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical.  Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.6pt">Consideration.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award.  The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;11.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.66pt">Vesting.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to Section 2(g), at the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.72pt">Payment.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.93pt">Additional Restrictions.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.87pt">Termination of Participant&#8217;s Continuous Service.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement or other written agreement between the Participant and the Company or an Affiliate, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.52pt">Performance Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.6pt">Performance Stock Awards.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A Performance Stock Award is a Stock Award (covering a number of shares not in excess of that set forth in Section 3(d)(ii)) that is payable (including that may be granted, vest or be exercised) contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Stock Award may, but need not, require the Participant&#8217;s completion of a specified period of Continuous Service.  Subject to Section 2(g), the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee), in its sole discretion.  In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.66pt">Performance Cash Awards.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A Performance Cash Award is a cash award (for a dollar value not in excess of that set forth in Section 3(d)(iii)) that is payable contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Cash Award may, but need not, require the Participant&#8217;s completion of a specified period of Continuous Service.  Subject to Section 2(g), the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee), in its sole discretion.  The Board may specify the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole or in part in cash or other property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.72pt">Committee and Board Discretion.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) retains the discretion to reduce or eliminate the compensation or economic benefit due upon the attainment of any Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;12.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.93pt">Section 162(m) Compliance.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Unless otherwise permitted in compliance with Section 162(m) of the Code with respect to an Award intended to qualify as &#8220;performance-based compensation&#8221; thereunder, the Committee will establish the Performance Goals applicable to, and the formula for calculating the amount payable under, the Award no later than the earlier of (A) the date 90 days after the commencement of the applicable Performance Period, and (B) the date on which 25% of the Performance Period has elapsed, and in any event at a time when the achievement of the applicable Performance Goals remains substantially uncertain.  Prior to the payment of any compensation under an Award intended to qualify as &#8220;performance-based compensation&#8221; under Section&#160;162(m) of the Code, the Committee will certify the extent to which any Performance Goals and any other material terms under such Award have been satisfied (other than in cases where the Performance Goals relate solely to the increase in the value of the Common Stock).  Notwithstanding satisfaction or any completion of any Performance Goals, shares subject to Options, cash or other benefits granted, issued, retainable and&#47;or vested under an Award on account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of any further considerations as the Committee, in its sole discretion, will determine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.87pt">Section 162(m) Transition Relief.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding anything in the Plan to the contrary, any provision in the Plan that refers to &#8220;performance-based compensation&#8221; under Section 162(m) of the Code will only apply to any Award that is intended to qualify, and is eligible to qualify, as &#8220;performance-based compensation&#8221; under Section 162(m) of the Code pursuant to the transition relief provided by the Tax Cuts and Jobs Act (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TCJA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for remuneration provided pursuant to a written binding contract which was in effect on November 2, 2017 and which was not modified in any material respect on or after such date, as determined by the Board, in its sole discretion, in accordance with the TCJA and any applicable guidance, rulings or regulations issued by the U.S. Department of the Treasury, the Internal Revenue Service or any other governmental authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Other Stock Awards.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock may be granted either alone or in addition to Stock Awards granted under Section 5 and this Section 6.  Subject to the provisions of the Plan (including, but not limited to, Sections 2(g) and 2(h)), the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Covenants of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.62pt">Availability of Shares.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Securities Law Compliance.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan the authority required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award.  If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained.  A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;13.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.52pt">No Obligation to Notify or Minimize Taxes.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising a Stock Award.  Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Miscellaneous.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.62pt">Use of Proceeds from Sales of Common Stock.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Proceeds from the sale of shares of Common Stock issued pursuant to Stock Awards will constitute general funds of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Corporate Action Constituting Grant of Awards.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant.  In the event that the corporate records (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect terms in the Award Agreement or related grant documents.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.52pt">Stockholder Rights.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">No Employment or Other Service Rights.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.5pt">Change in Time Commitment.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;14.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extend the vesting or payment schedule applicable to such Award.  In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.75pt">Incentive Stock Option Limitations.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.86pt">Investment Assurances.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i) to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and&#47;or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award&#59; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock.  The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws.  The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Withholding Obligations.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state, local or foreign tax withholding obligation relating to an Award by any of the following means or by a combination of such means&#58; (i) causing the Participant to tender a cash payment&#59; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award, provided that notwithstanding anything to the contrary in the terms of an Award Agreement, the Company will have the discretion to determine the basis upon which the number of shares to be withheld will be calculated&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of the Stock Award as a liability for financial accounting purposes)&#59; (iii) withholding cash from an Award settled in cash&#59; (iv) withholding payment from any amounts otherwise payable to the Participant&#59; or (v) by such other method as may be set forth in the Award Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.6pt">Electronic Delivery.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Any reference herein to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;15.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.48pt">Deferrals.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants.  Deferrals by Participants will be made in accordance with Section 409A of the Code.  Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate.  The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.79pt">Compliance with Section 409A of the Code.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code.  To the extent that the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and, to the extent applicable, the Plan and Award Agreements will be interpreted in accordance with the requirements of Section 409A of the Code.  Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded and a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount will be made upon a &#8220;separation from service&#8221; before a date that is six&#160;months following the date of such Participant&#8217;s &#8220;separation from service&#8221; (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment may be made in a manner that complies with Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.6pt">Clawback&#47;Recovery.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law, and any other clawback policy that the Company adopts.  In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company or an Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Adjustments upon Changes in Common Stock&#59; Other Corporate Events.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.62pt">Capitalization Adjustments.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust&#58; (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c), (iii) the class(es) and maximum number of securities that may be awarded to any person pursuant to Section 3(d), and (iv) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards.  The Board will make such adjustments, and its determination will be final, binding and conclusive.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;16.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Dissolution or Liquidation.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in the Stock Award Agreement or any other written agreement between the Company or any Affiliate and the Participant, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.52pt">Transaction.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The provisions of this Section 9(c) will apply to Stock Awards in the event of a Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written arrangement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.6pt">Stock Awards May Be Assumed.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event of a Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Stock Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Transaction.  A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of a Stock Award or substitute a similar stock award for only a portion of a Stock Award, or may choose to assume or continue, or substitute similar stock awards for, the Stock Awards held by some, but not all Participants.  The terms of any assumption, continuation or substitution will be set by the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.66pt">Stock Awards Held by Current Participants.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event of a Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Transaction (referred to as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Current Participants</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full (and with respect to any such Stock Awards that are subject to performance-based vesting conditions or requirements, vesting will be deemed to be satisfied at the target level of performance) to a date prior to the effective time of such Transaction (contingent upon the effectiveness of the Transaction) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Transaction), and such Stock Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Transaction).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.72pt">Stock Awards Held by Current Participants in Certain Control Acquisitions.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event of a Control Acquisition that was not approved by the Board prior to the consummation of such transaction, then with respect to Stock Awards that are held by Current Participants, the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full (and with respect to any such Stock Awards that are subject to performance-based vesting conditions or requirements, vesting will be deemed to be satisfied at the target level of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;17.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performance) to a date prior to the effective time of such Control Acquisition (contingent upon the effectiveness of the Control Acquisition) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Control Acquisition) and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Control Acquisition).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.93pt">Stock Awards Held by Persons other than Current Participants.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event of a Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Stock Awards will terminate if not exercised (if applicable) prior to the effective time of the Transaction&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will not terminate and may continue to be exercised notwithstanding the Transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.87pt">Payment for Stock Awards in Lieu of Exercise.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding the foregoing, in the event a Stock Award will terminate if not exercised prior to the effective time of a Transaction, the Board may provide that the holder of such Stock Award may not exercise such Stock Award but instead will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A)&#160;the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Transaction, over (B)&#160;any exercise price payable by such holder in connection with such exercise.  For clarity, this payment may be zero if the value of the property is equal to or less than the exercise price.  Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company&#8217;s Common Stock in connection with the Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">Change in Control.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The provisions of this Section 9(d) will apply to Stock Awards in the event of a Change in Control unless otherwise provided in the instrument evidencing the Stock Award or any other written arrangement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.6pt">If a Change in Control occurs and within one month before, as of, or within thirteen months after, the effective time of such Change in Control a Participant&#8217;s Continuous Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to a voluntary termination with Good Reason, then the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in accordance with the vesting schedule applicable to such Stock Awards as if (A) with respect to any such Stock Awards that are subject to vesting conditions or requirements based solely on such Participant&#8217;s Continuous Service, such Participant&#8217;s Continuous Service had continued for twelve months following the date of termination of Continuous Service, and (B) with respect to any such Stock Awards that are subject to performance-based vesting conditions or requirements, vesting has been satisfied at the target level of performance.  Such vesting acceleration will occur on the date of termination of such Participant&#8217;s Continuous Service, or if later, the effective date of the Change in Control (if the Participant&#8217;s termination of Continuous Service occurs prior to the Change in Control).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.66pt">If any payment or benefit a Participant will or may receive from the Company or otherwise (a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">280G</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Payment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Excise Tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then any such 280G Payment (a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;18.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Payment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be equal to the Reduced Amount.  The &#8220;Reduced Amount&#8221; will be either (x)&#160;the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y)&#160;the largest portion, up to and including the total, of the Payment, whichever amount (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction will occur in the manner (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Reduction Method</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) that results in the greatest economic benefit for the Participant.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Pro Rata Reduction Method</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding any provision of the foregoing paragraph to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and&#47;or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows&#58; (A) as a first priority, the modification will preserve to the greatest extent possible, the greatest  economic benefit for the Participant as determined on an after-tax basis&#59; (B) as a second priority, Payments that are contingent on future events (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., being terminated without Cause), will be reduced (or eliminated) before Payments that are not contingent on future events&#59; and (C) as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code will be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;If a Participant receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 9(d)(ii) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, the Participant agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 9(d)(ii)) so that no portion of the remaining Payment is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of the first paragraph of this Section 9(d)(ii), the Participant will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Participant and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control will perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company will appoint a nationally recognized accounting or law firm to make the determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Participant and the Company within 15 calendar days after the date on which the Participant&#8217;s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by the Participant or the Company) or such other time as requested by the Participant or the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;19.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Termination or Suspension of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.62pt">Termination or Suspension.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Board may suspend or terminate the Plan at any time.  No Incentive Stock Option will be granted after</font><font style="color:#0070c0;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the tenth anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is approved by the stockholders of the Company.  No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.11pt">No Impairment of Rights.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Suspension or termination of the Plan will not materially impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Effective Date of Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Plan will become effective on the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Choice of Law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The laws of the State of California will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Definitions.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used in the Plan, the following definitions will apply to the capitalized terms indicated below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.62pt"> &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405.  The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.11pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Stock Award or a Performance Cash Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.52pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Award Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.11pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.5pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Capitalization Adjustment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.75pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">will have the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term will mean, with respect to a Participant, the occurrence of any of the following events&#58; (i) such Participant&#8217;s conviction of, or plea of no contest with respect to, any crime involving fraud, dishonesty or moral turpitude&#59; (ii) such Participant&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company or an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;20.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate&#59; (iii) such Participant&#8217;s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate, or any statutory duty the Participant owes to the Company or an Affiliate&#59; or (iv) such Participant&#8217;s conduct that constitutes gross misconduct, insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate.  The determination that a termination of a Participant&#8217;s Continuous Service is for Cause will not be made unless and until there will have been delivered to such Participant a copy of a resolution duly adopted by the affirmative vote of at least a majority of the Board at a meeting of the Board called and held for such purpose (after reasonable notice to such Participant and an opportunity for such Participant, together with such Participant&#8217;s counsel, to be heard before the Board), finding that in the good faith opinion of the Board, such Participant was guilty of the conduct constituting &#8220;Cause&#8221; and specifying the particulars.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.86pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.6pt">a sale, lease or other disposition of all or substantially all of the assets of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.66pt">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors other than by virtue of a merger, consolidation or similar transaction&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.72pt">a merger, consolidation or similar transaction in which the Company is not the surviving corporation&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.93pt">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing definition or any other provision of this Plan, the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.11pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.6pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.48pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the common stock of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.79pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Exelixis, Inc., a Delaware corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;21.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.6pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consultant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services.  However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(m)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.78pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Continuous Service</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service.  To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#8217;s or Affiliate&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(n)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.11pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Corporate Transaction</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.6pt">a sale, lease or other disposition of all or substantially all of the assets of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.66pt">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors (a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Control Acquisition</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.72pt">a merger, consolidation or similar transaction in which the Company is not the surviving corporation&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.93pt">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing definition or any other provision of this Plan, the terms Corporate Transaction and Control Acquisition will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;22.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(o)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.09pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Covered Employee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; will have the meaning provided in Section 162(m)(3) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(p)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.11pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Director</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a member of the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(q)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.11pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(r)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.28pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the effective date of this Plan document, which is the date of the annual meeting of stockholders of the Company held in 2017, provided this Plan is approved by the Company&#8217;s stockholders at such meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(s)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.76pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(t)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.38pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Entity</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a corporation, partnership, limited liability company or other entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(u)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.11pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.87pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act Person</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company&#59; or (v) any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(w)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.6pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Fair Market Value</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, as of any date, the value of the Common Stock determined as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.6pt">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.66pt">Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.72pt">In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;23.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(x)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.03pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Full Value Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Stock Award that is not an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(y)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.86pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that one or more of the following are undertaken by the Company or an Affiliate without the Participant&#8217;s express written consent&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.6pt">reduction of such Participant&#8217;s rate of compensation as in effect immediately prior to a Change in Control by greater than 10%, except to the extent the compensation of other similarly situated persons are accordingly reduced&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.66pt">failure to provide a package of welfare benefit plans that, taken as a whole, provide substantially similar benefits to those in which such Participant is entitled to participate immediately prior to a Change in Control (except that such Participant&#8217;s contributions may be raised to the extent of any cost increases imposed by third parties) or any action by the Company or an Affiliate that would adversely affect such Participant&#8217;s participation or reduce such Participant&#8217;s benefits under any of such plans&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.72pt">a change in such Participant&#8217;s responsibilities, authority, titles or offices resulting in diminution of position, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith that is remedied by the Company or an Affiliate promptly after notice thereof is given by such person&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.93pt">a request that such Participant relocate to a worksite that is more than 50 miles from such Participant&#8217;s prior worksite, unless such person accepts such relocation opportunity&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.87pt">a material reduction in duties&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.93pt">a failure or refusal of any successor company to assume the obligations of the Company or an Affiliate under an agreement with such Participant&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.99pt">a material breach by the Company or an Affiliate of any of the material provisions of an agreement with such Participant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding the foregoing, a Participant will have &#8220;Good Reason&#8221; for his or her resignation only if&#58; (a)&#160;such Participant notifies the Company in writing, within 30&#160;days after the occurrence of one of the foregoing event(s), specifying the event(s) constituting Good Reason and that he or she intends to terminate his or her employment no earlier than 30 days after providing such notice&#59; (b)&#160;the Company does not cure such condition within 30&#160;days following its receipt of such notice or states unequivocally in writing that it does not intend to attempt to cure such condition&#59; and (c)&#160;the Participant resigns from employment within 30&#160;days following the end of the period within which the Company was entitled to remedy the condition constituting Good Reason but failed to do so.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(z)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.78pt"> &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Incentive Stock Option</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an option granted pursuant to Section 5 that is intended to be, and that qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(aa)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Non-Employee Director</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;24.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Regulation S-K</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K&#59; or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ab)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.19pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Nonstatutory Stock Option</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any option granted pursuant to Section 5 that does not qualify as an Incentive Stock Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ac)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.6pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Officer</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ad)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.19pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Option</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ae)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.58pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Option Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant.  Each Option Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(af)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.83pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Optionholder</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ag)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.94pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Other Stock Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ah)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.19pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Other Stock Award Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant.  Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ai)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.68pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Outside Director</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Director who either (i) is not a current employee of the Company or an &#8220;affiliated corporation&#8221; (within the meaning of Treasury Regulations promulgated under Section 162(m) of the Code), is not a former employee of the Company or an &#8220;affiliated corporation&#8221; who receives compensation for prior services (other than benefits under a tax-qualified retirement plan) during the taxable year, has not been an officer of the Company or an &#8220;affiliated corporation,&#8221; and does not receive remuneration from the Company or an &#8220;affiliated corporation,&#8221; either directly or indirectly, in any capacity other than as a Director, or (ii) is otherwise considered an &#8220;outside director&#8221; for purposes of Section 162(m) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(aj)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.56pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Own,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Owned,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Owner,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Ownership</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ak)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.87pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(al)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.68pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Performance Cash Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(am)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.86pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Performance Criteria</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the one or more criteria that the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) will select for purposes of establishing the Performance Goals for a Performance Period.  The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;25.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Committee (or Board, if applicable)&#58; (1) earnings (including earnings per share and net earnings)&#59; (2) earnings before interest, taxes and depreciation&#59; (3) earnings before interest, taxes, depreciation and amortization&#59; (4) total stockholder return&#59; (5) return on equity or average stockholder&#8217;s equity&#59; (6) return on assets, investment, or capital employed&#59; (7) stock price&#59; (8) margin (including gross margin)&#59; (9) income (before or after taxes)&#59; (10) operating income&#59; (11) operating income after taxes&#59; (12) pre-tax profit&#59; (13) operating cash flow&#59; (14) sales or revenue targets&#59; (15) increases in revenue or product revenue&#59; (16) expenses and cost reduction goals&#59; (17) improvement in or attainment of working capital levels&#59; (18) economic value added (or an equivalent metric)&#59; (19) market share&#59; (20) cash flow&#59; (21) cash flow per share&#59; (22) share price performance&#59; (23) debt reduction&#59; (24) implementation or completion of projects or processes&#59; (25) customer satisfaction&#59; (26) stockholders&#8217; equity&#59; (27) capital expenditures&#59; (28) debt levels&#59; (29) operating profit or net operating profit&#59; (30) workforce diversity&#59; (31) growth of net income or operating income&#59; (32) billings&#59; and (33) to the extent that an Award is not intended to comply with Section 162(m) of the Code, other measures of performance selected by the Committee or Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(an)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.19pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Performance Goals</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, for a Performance Period, the one or more goals established by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) for the Performance Period based upon the Performance Criteria.  Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices.  Unless specified otherwise by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Committee (or Board, if applicable) will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows&#58; (1) to exclude restructuring and&#47;or other nonrecurring charges&#59; (2) to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated Performance Goals&#59; (3) to exclude the effects of changes to generally accepted accounting principles&#59; (4) to exclude the effects of any statutory adjustments to corporate tax rates&#59; and (5) to exclude the effects of any items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ao)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Performance Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period of time selected by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to and the payment of a Performance Stock Award or a Performance Cash Award.  Performance Periods may be of varying and overlapping duration, at the sole discretion of the Committee (or Board, if applicable).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ap)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.19pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Performance Stock Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Stock Award granted under the terms and conditions of Section 6(c)(i).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(aq)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.19pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means this Exelixis, Inc. 2017 Equity Incentive Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ar)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.36pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Prior Plans&#8217; Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any stock award granted under the 2014 Plan, the 2000 Plan, the 2000 Non-Employee Directors&#8217; Plan, the 2011 Plan or the 2016 Inducement Plan, in each case that was outstanding as of the Effective Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;26.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(as)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.84pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(at)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.46pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Award Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(au)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.19pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Unit Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(av)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.95pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Unit Award Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant.  Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(aw)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.68pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Rule 16b-3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ax)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.11pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Rule 405</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Rule 405 promulgated under the Securities Act.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ay)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.94pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(az)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.86pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Stock Appreciation Right</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">SAR</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ba)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.19pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Stock Appreciation Right Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant.  Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(bb)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.68pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Stock Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Stock Appreciation Right, a Restricted Stock Award, a Restricted Stock Unit Award, a Performance Stock Award or any Other Stock Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(bc)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.09pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Stock Award Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant.  Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(bd)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.68pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Subsidiary</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;27.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(be)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.07pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Ten Percent Stockholder</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(bf)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.36pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Transaction</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Corporate Transaction or a Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:83%">&#160;&#160;&#160;&#160;28.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">265742914 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exel2022630exhibit10210q.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i080b8923a6684501abd56a411eaaec08_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-18pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CASH COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-right:-9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cash Compensation for Non-Employee Directors </font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Board of Directors</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$55,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional Chair Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$31,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">12</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2,500</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Audit Committee</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$12,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional Chair Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$13,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">13</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compensation Committee</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$10,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional Chair Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$10,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">13</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nominating&#160;and Corporate Governance Committee</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$5,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional Chair Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$10,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">14</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research&#160;&#38; Development Committee</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$5,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional Chair Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$10,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">14</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,000</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meetings for which minutes are generated count toward the meeting threshold to determine when Meeting Fees are to be paid.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee paid for all meetings in excess of eight meetings.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee paid for all meetings in excess of seven meetings.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee paid for all meetings in excess of four meetings.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-v1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exel2022630exhibit10310q.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i759c8edf492c4270a1aa5990fa1f42e8_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SEVENTH AMENDMENT TO LEASE AGREEMENT</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS SEVENTH AMENDMENT TO LEASE AGREEMENT</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (this &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is made and entered into as of May 16, 2022, by and between </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCG HARBOR BAY PARKWAY PHASE I, LLC, a Delaware limited liability company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Landlord</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXELIXIS, INC. a Delaware corporation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tenant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.87pt">Landlord (as successor in interest to Ascentris 105, LLC, a Colorado limited liability company) and Tenant are parties to that certain Lease Agreement, dated May 2, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Original Lease</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which Original Lease has been previously amended by that certain First Amendment to Lease Agreement, dated October 16, 2017, that certain Second Amendment to Lease Agreement dated, June 13, 2018, that certain Third Amendment to Lease Agreement, dated April 1, 2019, that certain Fourth Amendment to Lease Agreement, dated August 30, 2019, that certain Fifth Amendment to Lease Agreement dated January 16, 2020, and that certain Sixth Amendment to Lease Agreement, dated December 11, 2020 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lease</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Pursuant to the Lease, Landlord has leased to Tenant space currently containing approximately </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">254,690 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">rentable square feet (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Original Premises</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) described as (i) 37,544 rentable square feet comprising the entire building located at 1601 Harbor Bay Parkway, Alameda, California, (ii) 59,335 rentable square feet comprising the entire building located at 1701 Harbor Bay Parkway, Alameda, California, (iii) 58,417 rentable square feet comprising the entire building located at 1801 Harbor Bay Parkway, Alameda, California, (iv) 57,476 rentable square feet comprised of the entire building located at 1851 Harbor Bay Parkway, Alameda, California, and (v) 41,918 comprised of Suites 100, 150 and 225 of the building located at 1751 Harbor Bay Parkway, Alameda, California (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1751 Building</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.25pt">Tenant has requested that the remaining balance of the 1751 Building, containing approximately </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">34,745 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">rentable square feet described as Suite 125, Suite 200 and the remaining balance of the 1751 Building shown on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A-1 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereto (collectively, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expansion Space</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), be added to the Original Premises and that the Lease be appropriately amended and Landlord is willing to do the same on the following terms and conditions.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;NOW, THEREFORE,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt;text-decoration:underline">Expansion and Effective Date.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.09pt">Effective as of the date that is the later of (a) June 1, 2022 and (ii) the Expansion Delivery Date (defined below), (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expansion Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Original Premises is increased from approximately </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">254,690</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> rentable square feet of the Project to approximately </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">289,435 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">rentable square feet of the Project by the addition of the Expansion Space, and from and after the Expansion Effective Date, the Original Premises and the Expansion Space, collectively, shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Premises</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, as defined in the Lease, and as used herein.  The Term for the Expansion Space shall commence on the Expansion Space Effective Date and end on the Expiration Date unless sooner terminated in accordance with the terms of the Lease, as amended hereby.  The Expansion Space is subject to all the terms and conditions of the Lease except as expressly modified herein.  As used herein, &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expansion Delivery Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the date on which Landlord tenders possession of the Expansion Space to </font></div><div id="i759c8edf492c4270a1aa5990fa1f42e8_4"></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tenant in its current condition and configuration (normal wear and tear excepted) free from occupancy by any party and in good, vacant, broom clean condition.  The Expansion Delivery Date is anticipated to occur on June 1, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expected Expansion Delivery Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Following the Expansion Effective Date, the Premises includes the entire 1751 Building, as shown on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit&#160;A-1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto, including the addition of approximately 4,129 rentable square feet described as Suite 125 (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Suite 125</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) on the first floor of the 1751 Building, (ii) approximately 25,655 rentable square feet described as Suite 200 (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Suite 200</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)  on the second floor of the 1751 Building, and (iii) approximately 4,961 rentable square feet (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Balance of the 1751 Building</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">consisting of the remaining balance of the 1751 Building.  During the period beginning on the Expansion Delivery Date and ending on the date immediately preceding the Expansion Effective Date, all provisions of the Lease relating to the Expansion Space shall apply as if the Expansion Effective Date had occurred&#59; provided however, that during such period Tenant shall not be required to pay Rent for the Expansion Space other than the payment of Operating Expenses and other charges for services requested by Tenant with respect to the Expansion Space pursuant to the applicable provisions of the Lease.  Any delay in the Expansion Delivery Date shall not subject Landlord to any loss or damage resulting therefrom.  If the Expansion Delivery Date is delayed, the Expiration Date under the Lease shall not be similarly extended.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Landlord acknowledges that portions of the Expansion Space are currently occupied by a tenant (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing Expansion Space Tenant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) pursuant to a lease (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing Expansion Space Lease</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with a term expiring May 31, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing Expansion Space Lease Expiration Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Landlord shall use commercially reasonable efforts to cause the Existing Expansion Space Tenant to surrender and vacate the Expansion Space on or prior to the Existing Expansion Space Lease Expiration Date with the Expansion Space in its current configuration and otherwise in the condition required by the Existing Expansion Space Lease.  If the Existing Expansion Space Tenant does not so surrender the Expansion Space by the Existing Expansion Space Lease Expiration Date, then Landlord shall use commercially reasonable efforts to cause the Existing Expansion Space Tenant to so surrender and vacate the Expansion Premises, which may, in Landlord&#8217;s discretion, include promptly commencing and pursuing unlawful detainer and eviction proceedings if the Existing Expansion Space Tenant fails to timely surrender and vacate the Expansion Premises.  Notwithstanding anything to the contrary in this Amendment, if Landlord fails to cause the Expansion Delivery Date to occur for any reason by the date that is one hundred twenty (120) days after the Expected Expansion Delivery Date (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Outside Delivery Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then Tenant shall be entitled to an abatement of Base Rent for the Expansion Space following the Expansion Effective Date in an amount equal to $1,735.41 for every day in the period beginning on the Outside Delivery Date and ending on the Expansion Delivery Date.  Landlord and Tenant acknowledge and agree that the Outside Delivery Date shall be postponed by the number of days the Expansion Delivery Date is delayed dure to strikes, acts of God, shortages of labor or materials, war, terrorist acts, civil disturbances, governmental orders, and other causes beyond the reasonable control of Landlord.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt;text-decoration:underline">Base Rent.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  In addition to Tenant&#8217;s obligation to pay Base Rent for the Original Premises, Tenant shall pay Landlord Base Rent for the Expansion Space as follows&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Base Rent for Suites 125 and 200&#58;</font></div><div style="padding-left:41.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.423%"><tr><td style="width:1.0%"></td><td style="width:25.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Period</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Rentable Square Footage</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Monthly Rate Per Square Foot</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Monthly Base Rent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Expansion Effective Date &#8211; Month 12</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,784</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$3.50</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$104,244.00</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 13 &#8211; Month 24</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,784</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$3.61</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$107,520.24</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 25 &#8211; Month 36</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,784</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$3.72</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,796.48</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 37 &#8211; Month 48</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,784</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$3.83</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$114,072.72</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 49 &#8211; Month 60</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,784</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$3.94</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$117,348.96</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 61 &#8211; Month 72</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,784</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$4.06</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$120,923.04</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 73 &#8211; Month 84</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,784</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$4.18</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$124,497.12</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 85 &#8211; Month 96</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,784</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$4.31</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$128,369.04</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 97 &#8211; October 31, 2031</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,784</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$4.44</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$132,240.96</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything in this Lease to the contrary, Tenant shall be entitled to an abatement of Base Rent solely with respect to the Expansion Space in the amount of $104,244.00 per month for the first six (6) full months following the Expansion Effective Date.&#160; </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Base Rent for the Balance of the 1751 Building&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  </font></div><div style="padding-left:41.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.423%"><tr><td style="width:1.0%"></td><td style="width:25.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Period</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Rentable Square Footage</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Monthly Rate Per Square Foot</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Monthly Base Rent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Expansion Effective Date &#8211; Month 12</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,961</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.25</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$11,162.25</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 13 &#8211; Month 24</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,961</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.32</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$11,509.52</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 25 &#8211; Month 36</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,961</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.39</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$11,856.79</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 37 &#8211; Month 48</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,961</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.46</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$12,204.06</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 49 &#8211; Month 60</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,961</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.53</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$12,551.33</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 61 &#8211; Month 72</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,961</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.61</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$12,948.21</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 73 &#8211; Month 84</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,961</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.69</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$13,345.09</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 85 &#8211; Month 96</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,961</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.77</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$13,741.97</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Month 97 &#8211; October 31, 2031</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,961</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.85</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$14,138.85</font></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything in this Lease to the contrary, Tenant shall be entitled to an abatement of Base Rent solely with respect to the Balance of the 1751 Building in the amount of $11,162.25 per month for the first six (6) full months following the Expansion Effective Date.&#160; </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All such Base Rent shall be payable by Tenant in accordance with the terms of the Lease, as amended hereby.  Only Base Rent with respect to the Expansion Space shall be abated pursuant to this Section, as more particularly described herein, and Base Rent for the Original Premises, Operating Expenses for the entire Premises (including the Expansion Space), all other Rent and other costs and charges specified in the Lease, as amended hereby, shall remain as due and payable pursuant to the provisions of the Lease, as amended hereby.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt;text-decoration:underline">Additional Security Deposit</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No additional Security Deposit shall be required in connection with this Amendment.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt;text-decoration:underline">Tenant&#8217;s Share.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> For the period commencing with the Expansion Effective Date and ending on the Expiration Date, Tenant's Building Share for the Expansion Space is </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">45.32%</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and Tenant&#8217;s Project Share for the Expansion Space is </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.94%</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Accordingly, Tenant's Building Share is increased to 100% of the 1751 Building and Tenant&#8217;s Project Share is 74.45%. </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt;text-decoration:underline">Rentable Area of the Premises</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective as of the Expansion Effective Date, the last paragraph of Section 1.1(d) of the Lease is hereby amended by replacing the Rentable Area table set forth in Exhibit A of the Lease, as previously replaced, with the Rentable Area table attached hereto as </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A-2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt;text-decoration:underline">Improvements to Expansion Space.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.09pt">Condition of Expansion Space.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Except as otherwise provided in this Amendment and the Lease, Tenant agrees to accept the same in its current condition and configuration (normal wear and tear excepted) free from occupancy by any party and in good, vacant, broom clean condition, but otherwise &#8220;as is&#8221; without any agreements, representations, understandings or obligations on the part of Landlord to perform any alterations, repairs or improvements.  Notwithstanding the foregoing, Landlord agrees that the roof and the base Building electrical, heating, ventilation and air conditioning, plumbing, fire&#47;life safety and other systems located in and&#47;or serving the Expansion Space shall be in good working order as of the Expansion Effective Date.  Except to the extent caused by the acts or omissions of Tenant or any of Tenant&#8217;s employees, agents, contractors, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">representatives or invitees, or by any alterations or improvements performed by or on behalf of Tenant, if such systems are not in good working order as of the date possession of the Expansion Space is delivered to Tenant and Tenant provides Landlord with notice of the same within ninety (90) days following the date Landlord delivers possession of the Expansion Space to Tenant, Landlord shall be responsible for repairing or restoring the same at Landlord&#8217;s sole cost and not as an Operating Expense.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.09pt">Responsibility for Improvements to Expansion Space.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Any construction, alterations or improvements to the Expansion Space shall be performed by Tenant in accordance with the Lease and this Amendment, including the provisions of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt;text-decoration:underline">Tenant&#8217;s Personal Property.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tenant is in the process of purchasing certain furniture currently located in the Premises (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Personal Property</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and owned by the prior tenant in the Expansion Space.  Landlord has agreed to allow the Personal Property to remain in the Expansion Space prior to the Expansion Effective Date.  Landlord (i) shall not be liable for any loss of or damage to the Personal Property, (ii) disclaims any ownership of and responsibility for the Personal Property, and (iii) makes no representation as to its nature, suitability, quality or condition.  Tenant acknowledges that it is relying solely on its own investigation of the Personal Property and not on any information provided by Landlord.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt;text-decoration:underline">Other Pertinent Provisions.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Landlord and Tenant agree that, effective as of the date of this Amendment (unless different effective date(s) is&#47;are specifically referenced in this Section), the Lease shall be amended in the following additional respects&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.09pt">Parking.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Effective as of the Expansion Effective Date, Tenant&#8217;s unreserved parking spaces shall be increased by eighty-nine (89) unreserved parking spaces at no charge to Tenant for a total of 853 unreserved parking spaces for the Premises.  Except as modified herein, the use of such unreserved parking spaces shall be subject to the terms of the Lease.  Landlord agrees that if all or any portion of the parking lots serving the Project are restriped in a manner that creates additional parking and such additional parking is not needed to satisfy the parking requirements for the BTS Site (as defined in the Fifth Amendment), then such excess parking spaces shall be automatically added to Tenant&#8217;s parking rights under the Lease until Tenant&#8217;s allocated parking at the Project is in accordance with the Targeted Parking Allocation (as defined in the Fifth Amendment).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tenant&#8217;s</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insurance.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Tenant&#8217;s insurance required under Section 9.2 of the Original Lease (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tenant&#8217;s</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insurance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall include the Expansion Space.  Tenant shall provide Landlord with a certificate of insurance, in form and substance satisfactory to Landlord and otherwise in compliance with Section 9.2 of the Original Lease, evidencing that Tenant&#8217;s Insurance covers the Original Premises and the Expansion Space, upon delivery of this Amendment, executed by Tenant, to Landlord.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.5pt;text-decoration:underline">Miscellaneous.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.09pt">This Amendment, including </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A-1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Outline and Location of Expansion Space), and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A-2 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Plans Showing the Premises and Table of Rentable Areas of the Premises), and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit B </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Tenant Alterations) attached hereto, sets forth the entire agreement between the parties with respect to the matters set forth herein.  There have been no additional oral or written representations or agreements.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.09pt">Except as herein modified or amended, the provisions, conditions and terms of the Lease shall remain unchanged and in full force and effect.  In the case of any inconsistency between the provisions of the Lease and this Amendment, the provisions of this Amendment shall govern and control.  The capitalized terms used in this Amendment shall have the same definitions as set forth in the Lease to the extent that such capitalized terms are defined therein and not redefined in this Amendment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;3</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.09pt">Submission of this Amendment by Landlord is not an offer to enter into this Amendment but rather is a solicitation for such an offer by Tenant.  Landlord shall not be bound by this Amendment until Landlord has executed and delivered the same to Tenant.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.09pt">Landlord and Tenant each hereby represents that each has dealt with no broker other than Kidder Mathews, representing Tenant, and Cushman &#38; Wakefield of California, Inc., representing Landlord, in connection with this Amendment.  Tenant agrees to indemnify and hold Landlord and the Landlord Related Parties harmless from all claims of any other brokers claiming to have represented Tenant in connection with this Amendment.  Landlord shall pay Kidder Mathews and Cushman &#38; Wakefield of California, Inc. a market brokerage commission pursuant to a separate written agreement.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.09pt">Each of Landlord and Tenant represents hereby that the individuals executing this Amendment on its behalf have the authority to execute and deliver the same on behalf of the party hereto for which such signatory is acting.  Tenant hereby represents and warrants that Tenant is not (i) the target of any sanctions program that is established by Executive Order of the President or published by the Office of Foreign Assets Control, U.S. Department of the Treasury (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OFAC</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; (ii) designated by the President or OFAC pursuant to the Trading with the Enemy Act, 50 U.S.C. App.  &#167; 5, the International Emergency Economic Powers Act, 50 U.S.C. &#167;&#167; 1701-06, the Patriot Act, Public Law 107-56, Executive Order 13224 (September 23, 2001) or any Executive Order of the President issued pursuant to such statutes&#59; or (iii) named on the following list that is published by OFAC&#58; &#8220;List of Specially Designated Nationals and Blocked Persons.&#8221; </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.09pt">Pursuant to California Civil Code Section 1938, Landlord hereby notifies Tenant that as of the date of this Amendment, the Premises have not undergone inspection by a &#8220;Certified Access Specialist&#8221; (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CASp</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to determine whether the Premises meet all applicable construction-related accessibility standards under California Civil Code Section 55.53.&#160; Landlord hereby discloses pursuant to California Civil Code Section 1938 as follows&#58; &#8220;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant.  The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#8221;&#160; Landlord and Tenant hereby acknowledge and agree that in the event that Tenant elects to perform a CASp inspection of the Premises hereunder (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Inspection</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), such Inspection shall be (a) performed at Tenant&#8217;s sole cost and expense, (b) limited to the Premises and (c) performed by a CASp who has been approved or designated by Landlord prior to the Inspection.  Any Inspection must be performed in a manner which minimizes the disruption of business activities in the Building, and at a time reasonably approved by Landlord.  Landlord reserves the right to be present during the Inspection.  Tenant agrees to&#58; (i) promptly provide to Landlord a copy of the report or certification prepared by the CASp inspector upon request (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Report</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), (ii) keep the information contained in the Report confidential, except to the extent required by Law</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or to the extent disclosure is needed in order to complete any necessary modifications or improvements required to comply with all applicable accessibility standards under state or federal Law, as well as any other repairs, upgrades, improvements, modifications or alterations required by the Report or that may be otherwise required to comply with applicable Laws or accessibility requirements  (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Access Improvements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  If Tenant performs an Inspection, Tenant shall be solely responsible for the cost of Access Improvements to the Premises or the Building necessary to correct any such violations of construction-related accessibility standards identified by such Inspection as required by Law, which Access Improvements may, at Landlord&#8217;s option, be performed in whole or in part by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;4</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Landlord at Tenant&#8217;s expense, payable as Additional Rent</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">within ten (10) days following Landlord&#8217;s demand.&#160;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.09pt">This Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of such counterparts together shall constitute one and the same agreement.  Execution copies of this Amendment may be delivered by facsimile or email, and the parties hereto agree to accept and be bound by facsimile signatures or scanned signatures transmitted via email hereto, which signatures shall be considered as original signatures with the transmitted Amendment having the same binding effect as an original signature on an original Amendment.  Neither party may raise the use of a facsimile machine or scanned document or the fact that any signature was transmitted through the use of a facsimile machine or email as a defense to the enforcement of this Amendment.  In addition, the parties agree that this Amendment may be signed using electronic signature technology (e.g., via DocuSign or similar electronic signature technology), and that such signed electronic record shall be valid and as effective to bind the party so signing as a paper copy bearing such party&#8217;s hand-written signature.  The parties further consent and agree that (1) to the extent a party signs this document using electronic signature technology, by clicking &#8220;sign&#8221;, such party is signing this Amendment electronically, and (2) the electronic signatures appearing on this Amendment shall be treated, for purposes of validity, enforceability and admissibility, the same as hand written signatures.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;5</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Landlord and Tenant have duly executed this Amendment as of the day and year first above written.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LANDLORD&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TENANT&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCG HARBOR BAY PARKWAY PHASE I, LLC,</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Meghan Concannon&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;  Meghan Concannon</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Vice President</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dated&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6&#47;2&#47;2022&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXELIXIS, INC., <br>a Delaware corporation </font></div><div style="padding-left:2.77pt"><font><br></font></div><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Dana Aftab&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Dana Aftab                                        </font></div><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Executive Vice President, Business Operations</font></div><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dated&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">6&#47;2&#47;2022&#160;&#160;&#160;&#160;</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;6</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><div id="i759c8edf492c4270a1aa5990fa1f42e8_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A-1 - OUTLINE AND LOCATION OF EXPANSION SPACE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">attached to and made a part of the Amendment dated as of May 16, 2022, between <br>SCG HARBOR BAY PARKWAY PHASE I, LLC, a Delaware limited liability company, as Landlord and EXELIXIS, INC., a Delaware corporation, as Tenant</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A-1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is intended only to show the general layout of the Expansion Space as of the beginning of the Expansion Effective Date.  It is not to be scaled&#59; any measurements or distances shown should be taken as approximate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:329px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;A-1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><div id="i759c8edf492c4270a1aa5990fa1f42e8_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A-2 &#8211; PLANS SHOWING THE PREMISES AND TABLE OF RENTABLE AREAS OF THE PREMISES</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">attached to and made a part of the Amendment dated as of May 16, 2022, between <br>SCG HARBOR BAY PARKWAY PHASE I, LLC, a Delaware limited liability company, as Landlord and EXELIXIS, INC., a Delaware corporation, as Tenant</font></div><div style="text-align:center"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:528px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;A-2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:503px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;A-2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><img alt="image_3a.jpg" src="image_3a.jpg" style="height:549px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;A-2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><img alt="image_4a.jpg" src="image_4a.jpg" style="height:471px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;A-2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><img alt="image_5a.jpg" src="image_5a.jpg" style="height:476px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;A-2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><img alt="image_6a.jpg" src="image_6a.jpg" style="height:864px;margin-bottom:5pt;vertical-align:text-bottom;width:567px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;A-2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><img alt="image_7a.jpg" src="image_7a.jpg" style="height:826px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;A-2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Table of Rentable Areas of The Premises</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.967%"><tr><td style="width:1.0%"></td><td style="width:30.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Building</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Suite</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Building RSF</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Premises RSF</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1601</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37,544</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37,544</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1701</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59,335</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,140</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1701</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">125</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59,335</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,355</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1701</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">115-200</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59,335</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">51,858</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1701</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">150</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59,335</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">982</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1751</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">150 - 225</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76,663</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,169</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1751</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76,663</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,749</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1751</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">125, 200 and Balance of 1751 Building</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76,663</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34,745</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1801</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58,417</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58,417</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1851</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">57,476</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">57,476</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total RSF of Premises&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">289,435</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;2055-03147&#47;01183146&#59;3&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;A-2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><div id="i759c8edf492c4270a1aa5990fa1f42e8_13"></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT B &#8211; TENANT ALTERATIONS</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">attached to and made a part of the Amendment dated as of May 16, 2022, between <br>SCG HARBOR BAY PARKWAY PHASE I, LLC, a Delaware limited liability company, as Landlord and EXELIXIS, INC., a Delaware corporation, as Tenant</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As used in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the &#8220;Premises&#8221; shall be deemed to mean the Expansion Space, as defined in the Amendment to which this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is attached. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tenant shall have the right to perform alterations and improvements in the Premises (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tenant Alterations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) pursuant to this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and the Lease, provided, however, that the provisions of Exhibit B to the Original Lease, as modified, shall not apply to the Tenant Alterations.  Notwithstanding the foregoing, Tenant and its contractors shall not have the right to perform the Tenant Alterations in the Premises unless and until Tenant has complied with all of the terms and conditions of Section&#160;7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of the Original Lease, including, without limitation, approval by Landlord of the final plans for the Tenant Alterations and the contractors to be retained by Tenant to perform such Tenant Alterations. Tenant shall be responsible for all elements of the design of Tenant&#8217;s plans (including, without limitation, compliance with law, functionality of design, the structural integrity of the design, the configuration of the Premises and the placement of Tenant&#8217;s furniture, appliances and equipment), and Landlord&#8217;s approval of Tenant&#8217;s plans shall in no event relieve Tenant of the responsibility for such design.  In addition to the foregoing and except as otherwise provided in the Amendment and this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Tenant shall be solely liable for all costs and expenses associated with or otherwise caused by Tenant&#8217;s performance and installment of the Tenant Alterations (including, except as otherwise provided in the Amendment and this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, without limitation, any legal compliance requirements arising outside of the Premises).  Landlord&#8217;s approval of the contractors to perform the Tenant Alterations shall not be unreasonably withheld.  If Landlord fails to respond to Tenant&#8217;s written request for approval of plans and specifications within five (5) days, Tenant shall provide a second written notice to Landlord.  Failure of Landlord to approve or disapprove any submission of plans and specification by Tenant within five (5) days following the second written notice shall be deemed to constitute approval of such submission.  The parties agree that Landlord&#8217;s approval of the general contractor to perform the Tenant Alterations shall not be considered to be unreasonably withheld if any such general contractor (a)&#160;does not have trade references reasonably acceptable to Landlord, (b)&#160;does not maintain insurance as required pursuant to the terms of the Lease, (c)&#160;does not have the ability to be bonded for the work in an amount of no less than one hundred fifty percent (150%) of the total estimated cost of the Tenant Alterations, (d)&#160;does not provide current financial statements reasonably acceptable to Landlord, (e) does not execute the Responsible Contractor Policy Statement provided by Landlord, or (f)&#160;is not licensed as a contractor in the state&#47;municipality in which the Premises is located.  Tenant acknowledges the foregoing is not intended to be an exclusive list of the reasons why Landlord may reasonably withhold its consent to a general contractor.  Notwithstanding the foregoing, Landlord shall not withhold approval of any architect, contractor or subcontractor that is currently or has previously performed alterations in the Premises and was approved by the Landlord executing this Amendment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Landlord agrees to contribute the sum of $1,737,250.00 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amendment No. 7 Allowance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) toward the cost of performing the Tenant Alterations in preparation of Tenant&#8217;s occupancy of the Premises.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Landlord agrees to also roll over all unused allowance (which, as of the date of this Amendment, equals $855,190.01) under Amendment No. 6 between the parties, entered December 11, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amendment No. 6 Allowance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) toward the cost of performing the Tenant Alterations in preparation of Tenant&#8217;s occupancy of the Premises. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The unused Amendment No. 6 Allowance and the Amendment No. 7 Allowance shall hereinafter be referred to, collectively, as the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Allowance.&#8221; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Allowance may only be used for the cost of preparing design and construction documents and mechanical and electrical plans for the Tenant Alterations and for hard and soft costs in connection with the Tenant Alterations, including, without limitation, permit fees and project management fees.  The Allowance shall be paid to Tenant or, at Tenant&#8217;s request, to the order of the general contractor that performs the Tenant Alterations, in periodic disbursements within thirty (30) days after receipt of the following documentation&#58; (a)&#160;an application for payment and sworn statement of contractor substantially in the form of AIA Document G-702 covering all work for which disbursement is to be made to a date specified therein&#59; (b)&#160;a certification from an AIA architect substantially in the form of the Architect&#8217;s Certificate for Payment which is located on AIA Document G702, Application and Certificate of Payment&#59; (c)&#160;contractor&#8217;s, subcontractor&#8217;s and material supplier&#8217;s waivers of liens which shall cover all Tenant Alterations for which disbursement is being requested and all other statements and forms required for compliance with the mechanics&#8217; lien laws of the state in which the Premises is located together with all such invoices, contracts, or other supporting data as Landlord or Landlord&#8217;s Mortgagee may reasonably require&#59; and (d)&#160;a request to disburse from Tenant </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">containing an approval by Tenant of the work done.  Upon completion of the Tenant Alterations, Tenant shall furnish Landlord with&#58; (i)&#160;general contractor and architect&#8217;s completion affidavits&#59; (ii)&#160;full and final waivers of lien&#59; and (iii)&#160;as-built plans of the Tenant Alterations.  In no event shall Landlord be required to disburse the Allowance more than one time per month.  Notwithstanding anything herein to the contrary, Landlord shall not be obligated to disburse any portion of the Allowance during the continuance of an uncured default beyond notice and cure periods under the Lease, and Landlord&#8217;s obligation to disburse shall only resume when and if such default is cured.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;In no event shall the Allowance be used for the purchase of equipment, furniture or other items of personal property of Tenant.  If Tenant does not submit a request for payment of the entire Allowance to Landlord in accordance with the provisions contained in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> by December 31, 2024, any unused amount shall accrue to the sole benefit of Landlord, it being understood that Tenant shall not be entitled to any credit, abatement or other concession in connection therewith.  Landlord shall be entitled to deduct from the Allowance a construction management fee for Landlord&#8217;s oversight of the Tenant Alterations in an amount equal to one and a half percent (1.5%) of the Amendment No. 7 Allowance.  Notwithstanding anything to the contrary set forth herein, Tenant shall be entitled to apply up to $173,725.00 of the Allowance as a credit against the next installment(s) of Base Rent payable by Tenant under the Lease, as amended hereby by delivery of written notice to Landlord no later than December 31, 2024.  Tenant shall be responsible for all applicable state sales or use taxes, if any, payable in connection with the Tenant Alterations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;In no event shall Tenant be required to remove the Tenant Alterations at the expiration or earlier termination of the Lease except for specialized trade fixtures and equipment installed by Tenant and designated as such on the plans and specifications submitted by Tenant for Landlord&#8217;s approval (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Specialized Tenant Improvements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and designated by Landlord in writing for removal concurrently with Landlord&#8217;s approval of such plans and specifications. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;If, during Tenant&#8217;s construction of the Tenant Alterations, Tenant discovers within the Premises any Hazardous Materials for which Tenant is not liable under the terms of the Lease, then Landlord, at Landlord&#8217;s expense, will remediate such Hazardous Materials to the extent required by applicable laws and to the extent necessary for Tenant&#8217;s use of the Premises or construction of the Tenant Alterations.  If such remediation delays substantial completion of the Tenant Alterations beyond the later of the projected date of substantial completion reflected in Tenant&#8217;s construction schedule (which Tenant shall have delivered to Landlord) and the Expansion Effective Date, then Tenant shall be entitled to a per diem abatement of Base Rent for the Premises for each day that substantial completion of the Tenant Alterations is actually delayed as a result of Landlord&#8217;s remediation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;This </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not be deemed applicable to any additional space added to the Premises at any time or from time to time, whether by any options under the Lease or otherwise, or to any portion of the Original Premises (as defined under the Agreement) or any additions to the Premises in the event of a renewal or extension of the original Term of the Lease, whether by any options under the Lease or otherwise, unless expressly so provided in the Lease or any amendment or supplement to the Lease.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">4864-6791-2730, v. 5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exel20220630exhibit31110q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6011b52a7af1455da45d1ccee26ee2f1_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael M. Morrissey, Ph.D., certify that&#58;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.22pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;9, 2022 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exel20210630exhibit31210q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i12a79bdc1f3c49fd897f351c604529f7_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher J. Senner, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.22pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;9, 2022 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exel20220630exhibit32110q.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4c6d9426e7b540289bec5c232fc318a9_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.92pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended July&#160;1, 2022, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.92pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Witness Whereof, the undersigned have set their hands hereto as of the 9th day of August 2022.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>exel-20220701.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d6428e21-a936-4304-bbd0-42287b684d9f,g:54041ba7-ffad-43a6-84f8-cd8da74de046-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20220701" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20220701">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20220701_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20220701_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20220701_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20220701_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2104102 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2305301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails">
        <link:definition>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails">
        <link:definition>2407403 - Disclosure - Revenues - Revenues Disaggregated by Concentration Risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
        <link:definition>2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedbyProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
        <link:definition>2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
        <link:definition>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails">
        <link:definition>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivities" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities">
        <link:definition>2112103 - Disclosure - Collaboration Agreements And Business Development Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables">
        <link:definition>2313302 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
        <link:definition>2414408 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
        <link:definition>2415409 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
        <link:definition>2416410 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
        <link:definition>2417411 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails">
        <link:definition>2418412 - Disclosure - Collaboration Agreements And Business Development Activities - GSK Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
        <link:definition>2419413 - Disclosure - Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails">
        <link:definition>2420414 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestments" roleURI="http://www.exelixis.com/role/CashandInvestments">
        <link:definition>2121104 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsTables" roleURI="http://www.exelixis.com/role/CashandInvestmentsTables">
        <link:definition>2322303 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails">
        <link:definition>2424416 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails">
        <link:definition>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails_1" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1">
        <link:definition>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
        <link:definition>2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails">
        <link:definition>2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2128105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2329304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2430420 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativesDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails">
        <link:definition>2431421 - Disclosure - Fair Value Measurements - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2132106 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2333305 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2434422 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2135107 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2336306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2437423 - Disclosure - Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
        <link:definition>2438424 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2439425 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEstimateGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails">
        <link:definition>2440426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxes" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxes">
        <link:definition>2141108 - Disclosure - Provision For Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails">
        <link:definition>2442427 - Disclosure - Provision For Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>2143109 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>2344307 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>2445428 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails">
        <link:definition>2446429 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.exelixis.com/role/CommitmentsandContingencies">
        <link:definition>2147110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2448430 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exel_AccruedClinicalLiabilitiesCurrent" abstract="false" name="AccruedClinicalLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" abstract="true" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim" abstract="false" name="LossContingencyNumberOfDaysToFilePatentInfringementClaim" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" abstract="true" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" abstract="false" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_IncreaseDecreaseInAccruedCollaborationLiabilities" abstract="false" name="IncreaseDecreaseInAccruedCollaborationLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesofCVSHealthCorporationMember" abstract="true" name="AffiliatesofCVSHealthCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_LeaseArrangementsAxis" abstract="true" name="LeaseArrangementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_CardinalHealthMember" abstract="true" name="CardinalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductSalesDiscountsAndAllowancesMember" abstract="true" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_RoyalPharmaMember" abstract="true" name="RoyalPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NumberofProductsinCommercialMarket" abstract="false" name="NumberofProductsinCommercialMarket" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithGenentechMember" abstract="true" name="CollaborativeArrangementwithGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_IpsenMember" abstract="true" name="IpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LeaseExpansionMember" abstract="true" name="LeaseExpansionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OtherLongtermAssetsMember" abstract="true" name="OtherLongtermAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AccredoHealthIncorporatedMember" abstract="true" name="AccredoHealthIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementWithBioInventOptionAndLicenseMember" abstract="true" name="CollaborationAgreementWithBioInventOptionAndLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" abstract="false" name="RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ResultingFromDiscoveryEffortsMember" abstract="true" name="ResultingFromDiscoveryEffortsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CotellicMember" abstract="true" name="CotellicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_TenantLeaseImprovementsAllowance" abstract="false" name="TenantLeaseImprovementsAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductGrossMember" abstract="true" name="ProductGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" abstract="true" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_AffiliatesOfAmerisourceBergenCorporationMember" abstract="true" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" abstract="false" name="NumberOfCountriesWithDrugApprovalExcludingTheUS" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LeaseArrangementsDomain" abstract="true" name="LeaseArrangementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CometriqMember" abstract="true" name="CometriqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ChargebacksAndDiscountsForPromptPaymentMember" abstract="true" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_InvestmentsPurchasesIncurredButNotYetPaid" abstract="false" name="InvestmentsPurchasesIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_LossContingencyNumberOfLawsuitsConsolidated" abstract="false" name="LossContingencyNumberOfLawsuitsConsolidated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" abstract="false" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductOrServiceAxisAxis" abstract="true" name="ProductOrServiceAxisAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_AllowanceForProductRebatesMember" abstract="true" name="AllowanceForProductRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" abstract="false" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductsDerivedFromOtherCompoundsMember" abstract="true" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_TSRBasedRestrictedStockUnitsMember" abstract="true" name="TSRBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithTakedaMember" abstract="true" name="CollaborativeArrangementwithTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithIpsenMember" abstract="true" name="CollaborativeArrangementwithIpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AccruedCollaborationLiabilityCurrent" abstract="false" name="AccruedCollaborationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" abstract="false" name="LesseeOperatingLeaseOptionToTerminateAfterPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" abstract="true" name="ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_TakedaAndIspenMember" abstract="true" name="TakedaAndIspenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" abstract="true" name="BuiltToSuitLeaseAndHeadquartersLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" abstract="false" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_ProductOrServiceAxisDomain" abstract="true" name="ProductOrServiceAxisDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CabometyxMember" abstract="true" name="CabometyxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementIncomeLossFromAgreement" abstract="false" name="CollaborativeArrangementIncomeLossFromAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OperatingLeaseLiabilityDiscountedPeriod" abstract="false" name="OperatingLeaseLiabilityDiscountedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_AffiliatesofMcKessonCorporationMember" abstract="true" name="AffiliatesofMcKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>exel-20220701_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d6428e21-a936-4304-bbd0-42287b684d9f,g:54041ba7-ffad-43a6-84f8-cd8da74de046-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b6362c34-daaf-4e1e-b63b-0977635d8aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b6376f82-e095-4f33-93f5-339f0e1d9f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b6362c34-daaf-4e1e-b63b-0977635d8aba" xlink:to="loc_us-gaap_AccountsPayableCurrent_b6376f82-e095-4f33-93f5-339f0e1d9f95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_db0b56af-72a0-42c1-8be7-f942df5ea5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b6362c34-daaf-4e1e-b63b-0977635d8aba" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_db0b56af-72a0-42c1-8be7-f942df5ea5f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_08db32eb-71f7-4c70-bd68-1bb9a272c8d1" xlink:href="exel-20220701.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b6362c34-daaf-4e1e-b63b-0977635d8aba" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_08db32eb-71f7-4c70-bd68-1bb9a272c8d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_cd3679b7-cf3f-474c-9d18-d670f59e9eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b6362c34-daaf-4e1e-b63b-0977635d8aba" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_cd3679b7-cf3f-474c-9d18-d670f59e9eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_03c584d0-6c08-4952-aad4-ccfb15b31da2" xlink:href="exel-20220701.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b6362c34-daaf-4e1e-b63b-0977635d8aba" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_03c584d0-6c08-4952-aad4-ccfb15b31da2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b745a04b-a1ab-499c-8789-54ceef3a1709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b6362c34-daaf-4e1e-b63b-0977635d8aba" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b745a04b-a1ab-499c-8789-54ceef3a1709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2858e8fb-23e1-4c08-8af8-91a21d99da11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_fb3ccf8b-6817-4e84-a1f9-24692f8523a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2858e8fb-23e1-4c08-8af8-91a21d99da11" xlink:to="loc_us-gaap_PreferredStockValue_fb3ccf8b-6817-4e84-a1f9-24692f8523a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0d952d7a-3a18-4190-be63-3b11c844ad2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2858e8fb-23e1-4c08-8af8-91a21d99da11" xlink:to="loc_us-gaap_CommonStockValue_0d952d7a-3a18-4190-be63-3b11c844ad2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f222b305-e73e-408d-8745-d2d1267c12f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2858e8fb-23e1-4c08-8af8-91a21d99da11" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f222b305-e73e-408d-8745-d2d1267c12f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d4284514-1374-4093-9a95-0e655622d865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2858e8fb-23e1-4c08-8af8-91a21d99da11" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d4284514-1374-4093-9a95-0e655622d865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13b0459a-cbe8-47c1-a7ff-84bed5535f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2858e8fb-23e1-4c08-8af8-91a21d99da11" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13b0459a-cbe8-47c1-a7ff-84bed5535f42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d0d48a83-d114-4c6a-b3de-47fb25c5eb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_51edd998-9c80-40fe-98ef-cc844827a658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d0d48a83-d114-4c6a-b3de-47fb25c5eb6a" xlink:to="loc_us-gaap_LiabilitiesCurrent_51edd998-9c80-40fe-98ef-cc844827a658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bc6a276b-c013-476d-b0fc-be1adcffa3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d0d48a83-d114-4c6a-b3de-47fb25c5eb6a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bc6a276b-c013-476d-b0fc-be1adcffa3d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1814aed5-f409-474c-9c70-4346ca5053c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d0d48a83-d114-4c6a-b3de-47fb25c5eb6a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1814aed5-f409-474c-9c70-4346ca5053c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d7ccfc0b-3d15-443d-b22f-1e036abf28ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d0d48a83-d114-4c6a-b3de-47fb25c5eb6a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d7ccfc0b-3d15-443d-b22f-1e036abf28ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9144a074-b3bb-4112-88d9-8c3df3b9b306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_77f6f1c2-a363-42d8-bdd6-30c136fd4748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9144a074-b3bb-4112-88d9-8c3df3b9b306" xlink:to="loc_us-gaap_AssetsCurrent_77f6f1c2-a363-42d8-bdd6-30c136fd4748" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_c6650d1f-3fde-47c7-adce-4e290ee404ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9144a074-b3bb-4112-88d9-8c3df3b9b306" xlink:to="loc_us-gaap_LongTermInvestments_c6650d1f-3fde-47c7-adce-4e290ee404ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_931e76c3-6764-48a5-8c2e-97ae5af59e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9144a074-b3bb-4112-88d9-8c3df3b9b306" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_931e76c3-6764-48a5-8c2e-97ae5af59e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_73564a9b-ebcf-4eed-a427-8a0a2610962d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9144a074-b3bb-4112-88d9-8c3df3b9b306" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_73564a9b-ebcf-4eed-a427-8a0a2610962d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1a0432fd-732a-4c11-9400-f8664fe9d757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9144a074-b3bb-4112-88d9-8c3df3b9b306" xlink:to="loc_us-gaap_Goodwill_1a0432fd-732a-4c11-9400-f8664fe9d757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cf999d71-5ea9-41cf-bb7a-83e72a83b67f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9144a074-b3bb-4112-88d9-8c3df3b9b306" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cf999d71-5ea9-41cf-bb7a-83e72a83b67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dcf66b91-0490-441a-b2b2-e368ba55784d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_5544ac2b-2716-4361-8bcc-5d6515298a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dcf66b91-0490-441a-b2b2-e368ba55784d" xlink:to="loc_us-gaap_ShortTermInvestments_5544ac2b-2716-4361-8bcc-5d6515298a0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_7e2ceffa-ea05-4887-84c3-e061003780b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dcf66b91-0490-441a-b2b2-e368ba55784d" xlink:to="loc_us-gaap_ReceivablesNetCurrent_7e2ceffa-ea05-4887-84c3-e061003780b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_675f2c9f-040f-4028-b5e8-7f48276e9efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dcf66b91-0490-441a-b2b2-e368ba55784d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_675f2c9f-040f-4028-b5e8-7f48276e9efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_192545ba-5167-4c83-b347-4faf86efe927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dcf66b91-0490-441a-b2b2-e368ba55784d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_192545ba-5167-4c83-b347-4faf86efe927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fb91ef37-368f-41d2-8408-27672d27b90e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dcf66b91-0490-441a-b2b2-e368ba55784d" xlink:to="loc_us-gaap_InventoryNet_fb91ef37-368f-41d2-8408-27672d27b90e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_58ce80af-e1ce-479a-aec4-bd31c25b942f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f1176e67-b8aa-412f-963b-c77de0e9e193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_58ce80af-e1ce-479a-aec4-bd31c25b942f" xlink:to="loc_us-gaap_Liabilities_f1176e67-b8aa-412f-963b-c77de0e9e193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f7952422-0a23-49c9-b8c8-7ec51a958112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_58ce80af-e1ce-479a-aec4-bd31c25b942f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f7952422-0a23-49c9-b8c8-7ec51a958112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3bcd2ce6-d179-40de-b0cb-b5e32f746e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_58ce80af-e1ce-479a-aec4-bd31c25b942f" xlink:to="loc_us-gaap_StockholdersEquity_3bcd2ce6-d179-40de-b0cb-b5e32f746e45" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6dddd33f-57ab-44c7-b5f8-1dd2ba1f379f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_5ef201d3-48ec-43f6-a7d4-fdc61f8044cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6dddd33f-57ab-44c7-b5f8-1dd2ba1f379f" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_5ef201d3-48ec-43f6-a7d4-fdc61f8044cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_52337647-d3b6-4f1f-be92-855cc3bdf777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6dddd33f-57ab-44c7-b5f8-1dd2ba1f379f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_52337647-d3b6-4f1f-be92-855cc3bdf777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2beb97bc-7dbc-4225-9347-c08cf343312f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6b706553-d965-4976-84cf-c8421746537d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2beb97bc-7dbc-4225-9347-c08cf343312f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6b706553-d965-4976-84cf-c8421746537d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_95903b09-f8b5-473e-8abb-252601515b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2beb97bc-7dbc-4225-9347-c08cf343312f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_95903b09-f8b5-473e-8abb-252601515b97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ef6be58d-e2aa-4e20-a0ce-cdfe956cdccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2beb97bc-7dbc-4225-9347-c08cf343312f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ef6be58d-e2aa-4e20-a0ce-cdfe956cdccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a67ed203-7e20-4625-b616-91de3b4c2d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_72999dca-e855-451d-a6ec-1f71f4bd2d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a67ed203-7e20-4625-b616-91de3b4c2d76" xlink:to="loc_us-gaap_CostsAndExpenses_72999dca-e855-451d-a6ec-1f71f4bd2d4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f3b4151d-6053-4d86-ba01-208cb735c267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a67ed203-7e20-4625-b616-91de3b4c2d76" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f3b4151d-6053-4d86-ba01-208cb735c267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_ee9ece49-f062-422b-affc-7a31af49dec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_54b6894c-98f5-4d7b-8521-8cce7cf71c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_ee9ece49-f062-422b-affc-7a31af49dec3" xlink:to="loc_us-gaap_OperatingIncomeLoss_54b6894c-98f5-4d7b-8521-8cce7cf71c34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_9bc3ae50-aa30-4e81-9435-a08748f32963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_ee9ece49-f062-422b-affc-7a31af49dec3" xlink:to="loc_us-gaap_InterestIncomeOther_9bc3ae50-aa30-4e81-9435-a08748f32963" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4a1a9616-a86d-45c3-a3dc-8d93b424f376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_ee9ece49-f062-422b-affc-7a31af49dec3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4a1a9616-a86d-45c3-a3dc-8d93b424f376" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d041c81b-ce6f-4351-b135-9f006413aa59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f1fb04cb-2611-4fd3-8797-b9370b92ba10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d041c81b-ce6f-4351-b135-9f006413aa59" xlink:to="loc_us-gaap_NetIncomeLoss_f1fb04cb-2611-4fd3-8797-b9370b92ba10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78682fd0-5353-44db-8532-bc049fc15c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d041c81b-ce6f-4351-b135-9f006413aa59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78682fd0-5353-44db-8532-bc049fc15c0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_995ba3a0-0167-4566-9e3f-f28c2068a063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30377710-55fe-4d87-bd0d-deeee589b005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_995ba3a0-0167-4566-9e3f-f28c2068a063" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30377710-55fe-4d87-bd0d-deeee589b005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ea79473f-4c49-4cee-a5ee-6adba089f091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_995ba3a0-0167-4566-9e3f-f28c2068a063" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ea79473f-4c49-4cee-a5ee-6adba089f091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4dd13ef8-d076-4975-9c74-a6cdeacf0e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_995ba3a0-0167-4566-9e3f-f28c2068a063" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4dd13ef8-d076-4975-9c74-a6cdeacf0e35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a5dfeb28-16cd-4317-82c4-0aac39534cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:to="loc_us-gaap_NetIncomeLoss_a5dfeb28-16cd-4317-82c4-0aac39534cac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_951d7ea7-ae10-451c-afeb-cc42967f63ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_951d7ea7-ae10-451c-afeb-cc42967f63ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_50f7784d-6ead-4a17-bea1-8378f39e2226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:to="loc_us-gaap_ShareBasedCompensation_50f7784d-6ead-4a17-bea1-8378f39e2226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_02b04c34-1bfe-47a7-a0cb-527c6728b73b" xlink:href="exel-20220701.xsd#exel_NoncashLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:to="loc_exel_NoncashLeaseExpense_02b04c34-1bfe-47a7-a0cb-527c6728b73b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b90da08d-a88f-42ec-8662-181fed14e1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b90da08d-a88f-42ec-8662-181fed14e1ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8f672bff-17c5-4ed4-8216-36faa2a3c668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8f672bff-17c5-4ed4-8216-36faa2a3c668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0cfb830f-9859-4c76-89ee-b65bd02b1dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0cfb830f-9859-4c76-89ee-b65bd02b1dd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_566502b9-0eef-4ad8-ba22-0a2d7bbe4885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_566502b9-0eef-4ad8-ba22-0a2d7bbe4885" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_eb1710e7-1803-44e0-8a8f-24f9df2f0dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_eb1710e7-1803-44e0-8a8f-24f9df2f0dc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_81c5017f-c358-4cd4-9341-6dd492d0e5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_81c5017f-c358-4cd4-9341-6dd492d0e5cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_6525d7ec-a3a7-420f-8ef3-14061e0cccd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_6525d7ec-a3a7-420f-8ef3-14061e0cccd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_31a31a62-a6d3-4659-97b7-fe3d71307475" xlink:href="exel-20220701.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb74fcbc-194e-43fc-a1de-f7f283ea58fd" xlink:to="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_31a31a62-a6d3-4659-97b7-fe3d71307475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ccd6733-8cd6-4991-afd7-6fa15e5226ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_418d818c-0e3c-49d8-8d49-f743ec5e4c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ccd6733-8cd6-4991-afd7-6fa15e5226ec" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_418d818c-0e3c-49d8-8d49-f743ec5e4c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_20071cf7-6477-4661-ac18-363ac75dca6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ccd6733-8cd6-4991-afd7-6fa15e5226ec" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_20071cf7-6477-4661-ac18-363ac75dca6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d3ed53c3-3ea1-4f4a-9fac-2574706ffd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ccd6733-8cd6-4991-afd7-6fa15e5226ec" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d3ed53c3-3ea1-4f4a-9fac-2574706ffd90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_295b3cf2-4157-4813-ac89-f22dee88d086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_12577caf-630d-4dda-9b12-1f39ca4de292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_295b3cf2-4157-4813-ac89-f22dee88d086" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_12577caf-630d-4dda-9b12-1f39ca4de292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_61ff3187-1496-4f1e-a527-b6ce7aca7ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_295b3cf2-4157-4813-ac89-f22dee88d086" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_61ff3187-1496-4f1e-a527-b6ce7aca7ec2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d8823ec8-106e-46c2-a815-6315f8ef5fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c27e715-b1be-4068-9232-d7795f0f603e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_d8823ec8-106e-46c2-a815-6315f8ef5fe4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c27e715-b1be-4068-9232-d7795f0f603e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b31b3a63-d237-4ae7-8628-eebd1f6ade0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_d8823ec8-106e-46c2-a815-6315f8ef5fe4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b31b3a63-d237-4ae7-8628-eebd1f6ade0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e264033c-95d7-4394-9a9b-9f30270e7c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e425b457-9e21-46c6-8ad7-5c3642ca9067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e264033c-95d7-4394-9a9b-9f30270e7c29" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e425b457-9e21-46c6-8ad7-5c3642ca9067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ffa5d821-4b05-45c9-947b-fd3c69ef290e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e264033c-95d7-4394-9a9b-9f30270e7c29" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ffa5d821-4b05-45c9-947b-fd3c69ef290e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_be23873a-c8db-4cc0-84c2-8b6157242734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cff7852a-79ad-4306-85ea-c1c7bca35c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_be23873a-c8db-4cc0-84c2-8b6157242734" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cff7852a-79ad-4306-85ea-c1c7bca35c11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dc98638b-c103-4e97-8b76-8862582f5cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_be23873a-c8db-4cc0-84c2-8b6157242734" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dc98638b-c103-4e97-8b76-8862582f5cc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9567d5f6-69f6-4eab-99a9-2f486909effd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_be23873a-c8db-4cc0-84c2-8b6157242734" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9567d5f6-69f6-4eab-99a9-2f486909effd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_ab59b157-4150-43e9-b07c-98c618ccf026" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_0f2bbece-ad18-4081-bc9d-97fdf486fce4" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_ab59b157-4150-43e9-b07c-98c618ccf026" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_0f2bbece-ad18-4081-bc9d-97fdf486fce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_de13862d-cc7f-40db-a7e3-f06a56c631b9" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_ab59b157-4150-43e9-b07c-98c618ccf026" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_de13862d-cc7f-40db-a7e3-f06a56c631b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f0aa39be-5b84-4038-964b-aa6cd8c26609" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_ab59b157-4150-43e9-b07c-98c618ccf026" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f0aa39be-5b84-4038-964b-aa6cd8c26609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_1efcaa59-c586-47b0-90f4-a90d25f5be59" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_a55b3a24-6203-409e-9495-8865999dde85" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_1efcaa59-c586-47b0-90f4-a90d25f5be59" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_a55b3a24-6203-409e-9495-8865999dde85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_ab8c8ae3-6033-4789-b4c1-155b30e2086c" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_1efcaa59-c586-47b0-90f4-a90d25f5be59" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_ab8c8ae3-6033-4789-b4c1-155b30e2086c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_5b6db1cf-d39f-480c-9829-7377a426037f" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_1efcaa59-c586-47b0-90f4-a90d25f5be59" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_5b6db1cf-d39f-480c-9829-7377a426037f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5fa5a541-99d9-4398-b345-ee00b2db1a92" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_7e28e6cf-ac9b-473d-a070-e9c4d15624af" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5fa5a541-99d9-4398-b345-ee00b2db1a92" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_7e28e6cf-ac9b-473d-a070-e9c4d15624af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a29dc0c6-1339-41a5-af12-f39c1a2d51e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5fa5a541-99d9-4398-b345-ee00b2db1a92" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a29dc0c6-1339-41a5-af12-f39c1a2d51e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6aabaa75-5a22-4e37-a7ec-2f33779ac4a3" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8e39c559-6f7d-4f6e-836e-04181758c1e3" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6aabaa75-5a22-4e37-a7ec-2f33779ac4a3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8e39c559-6f7d-4f6e-836e-04181758c1e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2091083d-9161-4b02-bf09-eb5facfc993d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6aabaa75-5a22-4e37-a7ec-2f33779ac4a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2091083d-9161-4b02-bf09-eb5facfc993d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_a6c80cbc-5e97-4a42-93b2-21123dd534e1" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2dfe9f16-c836-4f34-8bf9-5393378f021f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_a6c80cbc-5e97-4a42-93b2-21123dd534e1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2dfe9f16-c836-4f34-8bf9-5393378f021f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_381303e1-3484-4178-a2ed-7e028e787ace" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_a6c80cbc-5e97-4a42-93b2-21123dd534e1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_381303e1-3484-4178-a2ed-7e028e787ace" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9963291c-90f3-46fd-a738-18fc92c48801" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_f140b6c7-f53b-4094-a2d0-05b12bfdd99a" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9963291c-90f3-46fd-a738-18fc92c48801" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_f140b6c7-f53b-4094-a2d0-05b12bfdd99a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_73e73169-e89e-48f1-ae54-e29859eaafd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9963291c-90f3-46fd-a738-18fc92c48801" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_73e73169-e89e-48f1-ae54-e29859eaafd2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1254aca1-24a7-46d6-b21d-d68ad8026a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3548fac9-b00a-43c9-9807-d8bba99f829d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1254aca1-24a7-46d6-b21d-d68ad8026a15" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3548fac9-b00a-43c9-9807-d8bba99f829d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ecade60c-0668-4d3a-ac85-3ebaf373de00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1254aca1-24a7-46d6-b21d-d68ad8026a15" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ecade60c-0668-4d3a-ac85-3ebaf373de00" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2de6b2ae-85b2-4d86-9ad8-db2eed3523a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_983d43be-5c77-49fd-88c3-d21b3e043270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2de6b2ae-85b2-4d86-9ad8-db2eed3523a0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_983d43be-5c77-49fd-88c3-d21b3e043270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_794afc74-3c0b-4ec2-9f61-eb5890f6bdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2de6b2ae-85b2-4d86-9ad8-db2eed3523a0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_794afc74-3c0b-4ec2-9f61-eb5890f6bdc2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_a4fa6631-2047-4dc7-8f14-525e09c292d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_1b7bfc87-6967-437c-b7ee-02c547011641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_a4fa6631-2047-4dc7-8f14-525e09c292d7" xlink:to="loc_us-gaap_InventoryRawMaterials_1b7bfc87-6967-437c-b7ee-02c547011641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_99ed0483-9ba2-42d5-b286-8e4deed9c269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_a4fa6631-2047-4dc7-8f14-525e09c292d7" xlink:to="loc_us-gaap_InventoryWorkInProcess_99ed0483-9ba2-42d5-b286-8e4deed9c269" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_6147c474-7a45-4069-a73c-3b18c1ec6e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_a4fa6631-2047-4dc7-8f14-525e09c292d7" xlink:to="loc_us-gaap_InventoryFinishedGoods_6147c474-7a45-4069-a73c-3b18c1ec6e56" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a17f2b00-398e-48a1-9033-8b311ccec236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5699ab3-7dd3-4a82-92f1-3d34c047eba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a17f2b00-398e-48a1-9033-8b311ccec236" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5699ab3-7dd3-4a82-92f1-3d34c047eba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3fd9ce58-65c5-4093-9c9f-acf909685d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a17f2b00-398e-48a1-9033-8b311ccec236" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3fd9ce58-65c5-4093-9c9f-acf909685d44" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>exel-20220701_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d6428e21-a936-4304-bbd0-42287b684d9f,g:54041ba7-ffad-43a6-84f8-cd8da74de046-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended" id="iba46e9e112e44e45bf48a776f9a47753_CondensedConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a8afc332-3cf0-4b4f-8571-e86db830e59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_RevenuesAbstract_a8afc332-3cf0-4b4f-8571-e86db830e59d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f9f0fdc-5c7c-4ef4-911f-632e8a074126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_a8afc332-3cf0-4b4f-8571-e86db830e59d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f9f0fdc-5c7c-4ef4-911f-632e8a074126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1f54dfe9-7f7e-4a8b-9bbc-092074c7ba64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1f54dfe9-7f7e-4a8b-9bbc-092074c7ba64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8450c925-3f4a-4e91-ae69-024e2b7e18b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1f54dfe9-7f7e-4a8b-9bbc-092074c7ba64" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8450c925-3f4a-4e91-ae69-024e2b7e18b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6f36d4b7-133d-4a0b-ba5f-6a5ca4835a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1f54dfe9-7f7e-4a8b-9bbc-092074c7ba64" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6f36d4b7-133d-4a0b-ba5f-6a5ca4835a3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a119a6e6-f079-4adf-800b-2e8a62bbd7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1f54dfe9-7f7e-4a8b-9bbc-092074c7ba64" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a119a6e6-f079-4adf-800b-2e8a62bbd7a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_617c35f2-1ae7-45f4-a02f-68fb3063dbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1f54dfe9-7f7e-4a8b-9bbc-092074c7ba64" xlink:to="loc_us-gaap_CostsAndExpenses_617c35f2-1ae7-45f4-a02f-68fb3063dbb5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d5be22c0-6cdd-4c9e-8673-94d49dc12401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_OperatingIncomeLoss_d5be22c0-6cdd-4c9e-8673-94d49dc12401" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_e3230798-c6a0-4370-8215-50ad0bdb9aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_InterestIncomeOther_e3230798-c6a0-4370-8215-50ad0bdb9aee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_67631406-2b4b-4e67-8a4a-f9b76c1c1274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_67631406-2b4b-4e67-8a4a-f9b76c1c1274" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_dab6c640-0fe5-47a4-84bf-5901e3f1595c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_dab6c640-0fe5-47a4-84bf-5901e3f1595c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a288189d-76a6-4ac6-bf02-2f19e8a849f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a288189d-76a6-4ac6-bf02-2f19e8a849f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_29f8e706-fa84-429e-8faa-40ae694fcece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_NetIncomeLoss_29f8e706-fa84-429e-8faa-40ae694fcece" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a750dd4e-a9ce-4cd7-956c-d613246fccd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a750dd4e-a9ce-4cd7-956c-d613246fccd0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1be82de3-6675-4999-ba35-bb7623fd4f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a750dd4e-a9ce-4cd7-956c-d613246fccd0" xlink:to="loc_us-gaap_EarningsPerShareBasic_1be82de3-6675-4999-ba35-bb7623fd4f4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f9f769b1-ee7e-469b-9ae2-3cb0bdabef72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a750dd4e-a9ce-4cd7-956c-d613246fccd0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f9f769b1-ee7e-469b-9ae2-3cb0bdabef72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_777659b6-80c7-4196-b09f-18109e984012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_777659b6-80c7-4196-b09f-18109e984012" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0157cd6a-807b-4492-a3b8-2b272616f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_777659b6-80c7-4196-b09f-18109e984012" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0157cd6a-807b-4492-a3b8-2b272616f1df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e623a544-c25a-4d8d-918b-666f401c37e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_777659b6-80c7-4196-b09f-18109e984012" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e623a544-c25a-4d8d-918b-666f401c37e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a9e33bbb-a4ab-4957-865e-929532f7d959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_StatementTable_a9e33bbb-a4ab-4957-865e-929532f7d959" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1eefb963-dfd3-4d5e-8ce2-062d53a9cdff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a9e33bbb-a4ab-4957-865e-929532f7d959" xlink:to="loc_srt_ProductOrServiceAxis_1eefb963-dfd3-4d5e-8ce2-062d53a9cdff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1eefb963-dfd3-4d5e-8ce2-062d53a9cdff_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1eefb963-dfd3-4d5e-8ce2-062d53a9cdff" xlink:to="loc_srt_ProductsAndServicesDomain_1eefb963-dfd3-4d5e-8ce2-062d53a9cdff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d89d1c03-4303-43cf-8846-6d57583ab4a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1eefb963-dfd3-4d5e-8ce2-062d53a9cdff" xlink:to="loc_srt_ProductsAndServicesDomain_d89d1c03-4303-43cf-8846-6d57583ab4a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fdc99877-0f12-4725-a6c4-31f2c31603fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d89d1c03-4303-43cf-8846-6d57583ab4a0" xlink:to="loc_us-gaap_ProductMember_fdc99877-0f12-4725-a6c4-31f2c31603fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_e0816237-0ad7-46fa-ba85-69cd3d60194b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d89d1c03-4303-43cf-8846-6d57583ab4a0" xlink:to="loc_us-gaap_LicenseMember_e0816237-0ad7-46fa-ba85-69cd3d60194b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_cba2cae0-eb9e-46c4-bbe9-a3c75e4cefe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d89d1c03-4303-43cf-8846-6d57583ab4a0" xlink:to="loc_us-gaap_ServiceMember_cba2cae0-eb9e-46c4-bbe9-a3c75e4cefe4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i194358b520d047a893c5009d1425003e_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c37eba1e-f7a7-4513-99bf-af1a6caa09f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c37eba1e-f7a7-4513-99bf-af1a6caa09f5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7fa24d96-b23a-41d3-bfa6-b3427bd9bac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7fa24d96-b23a-41d3-bfa6-b3427bd9bac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2bd3698e-f662-48a5-9de6-9a4306f9e211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_StockholdersEquity_2bd3698e-f662-48a5-9de6-9a4306f9e211" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_207d663f-6199-4953-b61f-66d87a571390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_NetIncomeLoss_207d663f-6199-4953-b61f-66d87a571390" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_99a9c893-88c8-4586-8aa3-3e4f756c0706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_99a9c893-88c8-4586-8aa3-3e4f756c0706" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_64a74bb7-7ac1-4a2f-b66f-ebb6e42b3003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_64a74bb7-7ac1-4a2f-b66f-ebb6e42b3003" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4f435ee3-769e-4b37-bf45-6e3789227425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4f435ee3-769e-4b37-bf45-6e3789227425" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5236f51b-be81-4f23-8731-1a109589fe97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5236f51b-be81-4f23-8731-1a109589fe97" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3a3cb49d-c6bd-4c8d-8faa-4066f122584a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3a3cb49d-c6bd-4c8d-8faa-4066f122584a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5cb81dc9-76f8-42fb-9677-3d4c6530ad65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_acb6ed47-c10b-406b-859e-48832354d8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f03056a6-6564-446e-a089-e9355b1f7703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c37eba1e-f7a7-4513-99bf-af1a6caa09f5" xlink:to="loc_us-gaap_StatementTable_f03056a6-6564-446e-a089-e9355b1f7703" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fb64a12b-da8d-42e4-bcc1-aa2a13a3a28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f03056a6-6564-446e-a089-e9355b1f7703" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fb64a12b-da8d-42e4-bcc1-aa2a13a3a28f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fb64a12b-da8d-42e4-bcc1-aa2a13a3a28f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fb64a12b-da8d-42e4-bcc1-aa2a13a3a28f" xlink:to="loc_us-gaap_EquityComponentDomain_fb64a12b-da8d-42e4-bcc1-aa2a13a3a28f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dba2ca2a-be7a-4315-aaef-f5410d841635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fb64a12b-da8d-42e4-bcc1-aa2a13a3a28f" xlink:to="loc_us-gaap_EquityComponentDomain_dba2ca2a-be7a-4315-aaef-f5410d841635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ca469644-780d-48e3-89e2-3e99e25d13b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dba2ca2a-be7a-4315-aaef-f5410d841635" xlink:to="loc_us-gaap_CommonStockMember_ca469644-780d-48e3-89e2-3e99e25d13b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_62dd90e7-0546-4c79-98a0-5d6470b1bfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dba2ca2a-be7a-4315-aaef-f5410d841635" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_62dd90e7-0546-4c79-98a0-5d6470b1bfeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b2e1a57f-0651-4f27-96b6-aceaa12d016b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dba2ca2a-be7a-4315-aaef-f5410d841635" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b2e1a57f-0651-4f27-96b6-aceaa12d016b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9f37451d-513c-4e31-8232-4a0367cb5e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dba2ca2a-be7a-4315-aaef-f5410d841635" xlink:to="loc_us-gaap_RetainedEarningsMember_9f37451d-513c-4e31-8232-4a0367cb5e4f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="ifb7b831525ad48febc43874b1a3b9e15_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_a7e71976-6163-4209-912f-60e7fc41900d" xlink:href="exel-20220701.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_c7399311-7957-4f82-ad00-439d86049cfa" xlink:href="exel-20220701.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_a7e71976-6163-4209-912f-60e7fc41900d" xlink:to="loc_exel_NumberofProductsinCommercialMarket_c7399311-7957-4f82-ad00-439d86049cfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_481baebb-bbe5-4cb1-b394-4640174ea937" xlink:href="exel-20220701.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_a7e71976-6163-4209-912f-60e7fc41900d" xlink:to="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_481baebb-bbe5-4cb1-b394-4640174ea937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_02bda12e-6106-4dd1-baf7-e0219171df00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_a7e71976-6163-4209-912f-60e7fc41900d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_02bda12e-6106-4dd1-baf7-e0219171df00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_4f481e5f-cbb1-450a-976d-72fa5d220ca7" xlink:href="exel-20220701.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_a7e71976-6163-4209-912f-60e7fc41900d" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_4f481e5f-cbb1-450a-976d-72fa5d220ca7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a1735830-55e3-49af-957b-88be96ea3d3e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_4f481e5f-cbb1-450a-976d-72fa5d220ca7" xlink:to="loc_srt_ProductOrServiceAxis_a1735830-55e3-49af-957b-88be96ea3d3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a1735830-55e3-49af-957b-88be96ea3d3e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a1735830-55e3-49af-957b-88be96ea3d3e" xlink:to="loc_srt_ProductsAndServicesDomain_a1735830-55e3-49af-957b-88be96ea3d3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_88e95b87-5360-4a69-a2f6-63ca35967950" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a1735830-55e3-49af-957b-88be96ea3d3e" xlink:to="loc_srt_ProductsAndServicesDomain_88e95b87-5360-4a69-a2f6-63ca35967950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_a0c472fa-3dca-45ae-8444-3564f78b9694" xlink:href="exel-20220701.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_88e95b87-5360-4a69-a2f6-63ca35967950" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_a0c472fa-3dca-45ae-8444-3564f78b9694" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_d0b97f31-8c11-418f-9ef2-8f0bb5ba6a31" xlink:href="exel-20220701.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_88e95b87-5360-4a69-a2f6-63ca35967950" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_d0b97f31-8c11-418f-9ef2-8f0bb5ba6a31" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended" id="i5500ff2307ef46958df0d238b5a7694f_RevenuesRevenuesbyDisaggregatedCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8524a30d-98e1-4485-b827-e9df507f2d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0bc1bf2-3fbe-4340-83ad-07c5c6b876d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8524a30d-98e1-4485-b827-e9df507f2d66" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0bc1bf2-3fbe-4340-83ad-07c5c6b876d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7b7951f0-bc36-4202-88c4-28ce63aba743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8524a30d-98e1-4485-b827-e9df507f2d66" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7b7951f0-bc36-4202-88c4-28ce63aba743" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5ce92fe7-9bce-4924-bafb-3561be6d1994" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b7951f0-bc36-4202-88c4-28ce63aba743" xlink:to="loc_srt_ProductOrServiceAxis_5ce92fe7-9bce-4924-bafb-3561be6d1994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ce92fe7-9bce-4924-bafb-3561be6d1994_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5ce92fe7-9bce-4924-bafb-3561be6d1994" xlink:to="loc_srt_ProductsAndServicesDomain_5ce92fe7-9bce-4924-bafb-3561be6d1994_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5ce92fe7-9bce-4924-bafb-3561be6d1994" xlink:to="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_4ce8303a-4cc7-4dd4-80b5-50ea2f9846b2" xlink:href="exel-20220701.xsd#exel_ProductGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:to="loc_exel_ProductGrossMember_4ce8303a-4cc7-4dd4-80b5-50ea2f9846b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_d9b46b7b-ecb8-4623-b21c-0dd168294d2c" xlink:href="exel-20220701.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_d9b46b7b-ecb8-4623-b21c-0dd168294d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f2f1aaf9-f030-4e0b-8cef-9acb4eadb669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:to="loc_us-gaap_ProductMember_f2f1aaf9-f030-4e0b-8cef-9acb4eadb669" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_822377ab-db87-4cfa-8d28-6af3d3c825f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:to="loc_us-gaap_LicenseMember_822377ab-db87-4cfa-8d28-6af3d3c825f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ba775239-6e0a-4a03-a550-9785e888246f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:to="loc_us-gaap_ServiceMember_ba775239-6e0a-4a03-a550-9785e888246f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_04bcca46-aaec-495f-82fe-59cbca3dddaf" xlink:href="exel-20220701.xsd#exel_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:to="loc_exel_CollaborationMember_04bcca46-aaec-495f-82fe-59cbca3dddaf" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="extended" id="i7ae3621da2f84bef9c008d0a662e6aa1_RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5eb89d28-2adf-4384-af04-1cf6d44fa4da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bfa0dde5-35a6-4c9c-8fa9-5ddd7b72c8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5eb89d28-2adf-4384-af04-1cf6d44fa4da" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bfa0dde5-35a6-4c9c-8fa9-5ddd7b72c8e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_1e67363f-1cca-4085-86e4-b6da15059ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5eb89d28-2adf-4384-af04-1cf6d44fa4da" xlink:to="loc_us-gaap_ConcentrationRiskTable_1e67363f-1cca-4085-86e4-b6da15059ba5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ff8c520b-5d81-478a-8c70-c51f20dea81c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1e67363f-1cca-4085-86e4-b6da15059ba5" xlink:to="loc_srt_MajorCustomersAxis_ff8c520b-5d81-478a-8c70-c51f20dea81c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ff8c520b-5d81-478a-8c70-c51f20dea81c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ff8c520b-5d81-478a-8c70-c51f20dea81c" xlink:to="loc_srt_NameOfMajorCustomerDomain_ff8c520b-5d81-478a-8c70-c51f20dea81c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ff8c520b-5d81-478a-8c70-c51f20dea81c" xlink:to="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_1e2feb62-f11c-4ec8-9e51-d11df3e6b30f" xlink:href="exel-20220701.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_1e2feb62-f11c-4ec8-9e51-d11df3e6b30f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_de828a01-3df8-4902-a2d4-d54cd5899880" xlink:href="exel-20220701.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_de828a01-3df8-4902-a2d4-d54cd5899880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_940733a3-03ec-4934-8eca-3f543e1a873b" xlink:href="exel-20220701.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_940733a3-03ec-4934-8eca-3f543e1a873b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_1d48c131-27dc-4a6d-badb-e38d10545489" xlink:href="exel-20220701.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:to="loc_exel_IpsenMember_1d48c131-27dc-4a6d-badb-e38d10545489" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember_5195f74c-981d-424e-809f-2d9248c88116" xlink:href="exel-20220701.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:to="loc_exel_AccredoHealthIncorporatedMember_5195f74c-981d-424e-809f-2d9248c88116" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CardinalHealthMember_27567317-14eb-4924-9bfe-1504e21c4f5d" xlink:href="exel-20220701.xsd#exel_CardinalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:to="loc_exel_CardinalHealthMember_27567317-14eb-4924-9bfe-1504e21c4f5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5d838af7-86ef-4db0-b3a8-b5223beaa2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1e67363f-1cca-4085-86e4-b6da15059ba5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5d838af7-86ef-4db0-b3a8-b5223beaa2a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5d838af7-86ef-4db0-b3a8-b5223beaa2a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5d838af7-86ef-4db0-b3a8-b5223beaa2a7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5d838af7-86ef-4db0-b3a8-b5223beaa2a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64651765-f7b8-49d8-a8ef-250217efc703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5d838af7-86ef-4db0-b3a8-b5223beaa2a7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64651765-f7b8-49d8-a8ef-250217efc703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f5b83c43-1e33-40f4-8358-13237ac79194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64651765-f7b8-49d8-a8ef-250217efc703" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f5b83c43-1e33-40f4-8358-13237ac79194" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_75a594e4-46c8-458d-8908-6f410baf3aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64651765-f7b8-49d8-a8ef-250217efc703" xlink:to="loc_us-gaap_AccountsReceivableMember_75a594e4-46c8-458d-8908-6f410baf3aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0ffc5f5b-c176-4a3a-962c-d4915762dc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1e67363f-1cca-4085-86e4-b6da15059ba5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0ffc5f5b-c176-4a3a-962c-d4915762dc1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0ffc5f5b-c176-4a3a-962c-d4915762dc1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0ffc5f5b-c176-4a3a-962c-d4915762dc1c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0ffc5f5b-c176-4a3a-962c-d4915762dc1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ef92889d-2ba9-42c6-bdcb-95863eeffaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0ffc5f5b-c176-4a3a-962c-d4915762dc1c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ef92889d-2ba9-42c6-bdcb-95863eeffaf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_f35f086f-9e26-4f1c-87d6-d7a67da0e386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ef92889d-2ba9-42c6-bdcb-95863eeffaf7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_f35f086f-9e26-4f1c-87d6-d7a67da0e386" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended" id="i6560417dd1a34ac89d5a8611430ed4c0_RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ab9c64e1-695f-4c64-9485-140b5265efd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_43ec3a4d-ca98-4f89-9807-5b3844eb17f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab9c64e1-695f-4c64-9485-140b5265efd4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_43ec3a4d-ca98-4f89-9807-5b3844eb17f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6318ffbf-7e7b-4cba-a1bf-b0b5cccc9a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab9c64e1-695f-4c64-9485-140b5265efd4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6318ffbf-7e7b-4cba-a1bf-b0b5cccc9a7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5bd5e323-3091-42a4-8175-56fedec2c0a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6318ffbf-7e7b-4cba-a1bf-b0b5cccc9a7c" xlink:to="loc_srt_StatementGeographicalAxis_5bd5e323-3091-42a4-8175-56fedec2c0a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5bd5e323-3091-42a4-8175-56fedec2c0a4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5bd5e323-3091-42a4-8175-56fedec2c0a4" xlink:to="loc_srt_SegmentGeographicalDomain_5bd5e323-3091-42a4-8175-56fedec2c0a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cde76ae6-48a5-4a23-9c83-6e4bbdf9fbf5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5bd5e323-3091-42a4-8175-56fedec2c0a4" xlink:to="loc_srt_SegmentGeographicalDomain_cde76ae6-48a5-4a23-9c83-6e4bbdf9fbf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_70866ba0-d4b9-439d-83e6-94a1817489fb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cde76ae6-48a5-4a23-9c83-6e4bbdf9fbf5" xlink:to="loc_country_US_70866ba0-d4b9-439d-83e6-94a1817489fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_a96842d4-39a5-4690-8d33-689c0951014c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cde76ae6-48a5-4a23-9c83-6e4bbdf9fbf5" xlink:to="loc_srt_EuropeMember_a96842d4-39a5-4690-8d33-689c0951014c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_d3f45a76-e66f-416f-9e8c-3a42acc62574" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cde76ae6-48a5-4a23-9c83-6e4bbdf9fbf5" xlink:to="loc_country_JP_d3f45a76-e66f-416f-9e8c-3a42acc62574" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended" id="i699774c33fa9425a95d7ea3156290bef_RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0e65f8ae-46f2-4c73-bf6a-de746701a09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b31d4a4e-e44f-4bdf-b60b-647c91bbe2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e65f8ae-46f2-4c73-bf6a-de746701a09e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b31d4a4e-e44f-4bdf-b60b-647c91bbe2a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_04141a61-484a-4c6a-9886-21c141775c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e65f8ae-46f2-4c73-bf6a-de746701a09e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_04141a61-484a-4c6a-9886-21c141775c03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ede1b97d-5875-44c0-be4e-e781cd626077" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_04141a61-484a-4c6a-9886-21c141775c03" xlink:to="loc_srt_ProductOrServiceAxis_ede1b97d-5875-44c0-be4e-e781cd626077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ede1b97d-5875-44c0-be4e-e781cd626077_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ede1b97d-5875-44c0-be4e-e781cd626077" xlink:to="loc_srt_ProductsAndServicesDomain_ede1b97d-5875-44c0-be4e-e781cd626077_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_143e2495-dcea-41f0-a059-c4728e4e95df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ede1b97d-5875-44c0-be4e-e781cd626077" xlink:to="loc_srt_ProductsAndServicesDomain_143e2495-dcea-41f0-a059-c4728e4e95df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_54367c23-eefa-4f59-85d0-6d7c1750d1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_143e2495-dcea-41f0-a059-c4728e4e95df" xlink:to="loc_us-gaap_ProductMember_54367c23-eefa-4f59-85d0-6d7c1750d1c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_d1409cbc-3b24-4a47-b14e-0529ccd12407" xlink:href="exel-20220701.xsd#exel_CabometyxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_54367c23-eefa-4f59-85d0-6d7c1750d1c9" xlink:to="loc_exel_CabometyxMember_d1409cbc-3b24-4a47-b14e-0529ccd12407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_20eaa1e2-6610-4929-9078-f913bc3c910b" xlink:href="exel-20220701.xsd#exel_CometriqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_54367c23-eefa-4f59-85d0-6d7c1750d1c9" xlink:to="loc_exel_CometriqMember_20eaa1e2-6610-4929-9078-f913bc3c910b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended" id="i106545e4a5314552977c216306161597_RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a45a4529-e5ec-4192-9ae0-005e2f9bda84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aedd5820-eb56-48e0-8471-f849ff25aaae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a45a4529-e5ec-4192-9ae0-005e2f9bda84" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aedd5820-eb56-48e0-8471-f849ff25aaae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_81c3b93e-055a-428b-b9a8-bff291409784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aedd5820-eb56-48e0-8471-f849ff25aaae" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_81c3b93e-055a-428b-b9a8-bff291409784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_d603f077-c61f-4804-a98b-b69cca7c5864" xlink:href="exel-20220701.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aedd5820-eb56-48e0-8471-f849ff25aaae" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_d603f077-c61f-4804-a98b-b69cca7c5864" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_60e2f6b5-b35c-403a-9f05-8d03b2bcb5ca" xlink:href="exel-20220701.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_d603f077-c61f-4804-a98b-b69cca7c5864" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_60e2f6b5-b35c-403a-9f05-8d03b2bcb5ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_8914df32-01d8-4b81-8cf6-6543b66b7d01" xlink:href="exel-20220701.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_d603f077-c61f-4804-a98b-b69cca7c5864" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_8914df32-01d8-4b81-8cf6-6543b66b7d01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_ae227012-950b-4eb9-88c6-09bab41d817b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aedd5820-eb56-48e0-8471-f849ff25aaae" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_ae227012-950b-4eb9-88c6-09bab41d817b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8ecfecff-9bde-48ca-adb2-682c597b05d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f56af4f6-6840-427a-a0fa-584c1b94ac2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a45a4529-e5ec-4192-9ae0-005e2f9bda84" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f56af4f6-6840-427a-a0fa-584c1b94ac2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7af2dd99-ef16-4d5b-bd7b-48478689bc19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f56af4f6-6840-427a-a0fa-584c1b94ac2f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7af2dd99-ef16-4d5b-bd7b-48478689bc19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_7af2dd99-ef16-4d5b-bd7b-48478689bc19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7af2dd99-ef16-4d5b-bd7b-48478689bc19" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_7af2dd99-ef16-4d5b-bd7b-48478689bc19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_bcba3ebe-56c2-4d7d-badf-90e4b5816a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7af2dd99-ef16-4d5b-bd7b-48478689bc19" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_bcba3ebe-56c2-4d7d-badf-90e4b5816a20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_d8f1f259-b8fd-49b4-baef-cea517d1e762" xlink:href="exel-20220701.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_bcba3ebe-56c2-4d7d-badf-90e4b5816a20" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_d8f1f259-b8fd-49b4-baef-cea517d1e762" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_2422ab4d-895f-4144-beb0-a535194d0edc" xlink:href="exel-20220701.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_bcba3ebe-56c2-4d7d-badf-90e4b5816a20" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_2422ab4d-895f-4144-beb0-a535194d0edc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_51fef06d-e0a9-495c-b783-17e8e1584134" xlink:href="exel-20220701.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_bcba3ebe-56c2-4d7d-badf-90e4b5816a20" xlink:to="loc_exel_AllowanceForProductRebatesMember_51fef06d-e0a9-495c-b783-17e8e1584134" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended" id="i8328cb5e82f4409dae0ffca0eecffcb0_RevenuesContractAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_95b5fe8e-2201-4255-88de-e29789516631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_95b5fe8e-2201-4255-88de-e29789516631" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_328acfc4-de47-45e2-ad89-c1ff9dd98c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_95b5fe8e-2201-4255-88de-e29789516631" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_328acfc4-de47-45e2-ad89-c1ff9dd98c6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_f1a57f9b-f3a3-430f-b183-708c6c701041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_f1a57f9b-f3a3-430f-b183-708c6c701041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a82b9534-c562-474b-a024-7a6eb38b098e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_f1a57f9b-f3a3-430f-b183-708c6c701041" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a82b9534-c562-474b-a024-7a6eb38b098e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c710dcd3-9406-46a9-ba6f-fc298636cd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_f1a57f9b-f3a3-430f-b183-708c6c701041" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c710dcd3-9406-46a9-ba6f-fc298636cd1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c618f277-7ecd-4bc1-a5c6-bc97a67370f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_f1a57f9b-f3a3-430f-b183-708c6c701041" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c618f277-7ecd-4bc1-a5c6-bc97a67370f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_3ccbf9dd-e18e-498f-be2e-d572032a4dfc" xlink:href="exel-20220701.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_3ccbf9dd-e18e-498f-be2e-d572032a4dfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_37d058ba-d281-4996-8978-222ad2533446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_37d058ba-d281-4996-8978-222ad2533446" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_8483a51e-13c2-4fbb-9c51-d30b6f0ba471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_8483a51e-13c2-4fbb-9c51-d30b6f0ba471" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8055b1c0-17b6-4e65-a400-516206c44421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8055b1c0-17b6-4e65-a400-516206c44421" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7198b88a-8c8c-4d7d-8b25-d8543c4f68a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8055b1c0-17b6-4e65-a400-516206c44421" xlink:to="loc_srt_CounterpartyNameAxis_7198b88a-8c8c-4d7d-8b25-d8543c4f68a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7198b88a-8c8c-4d7d-8b25-d8543c4f68a3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7198b88a-8c8c-4d7d-8b25-d8543c4f68a3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7198b88a-8c8c-4d7d-8b25-d8543c4f68a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22469b0e-c1d4-4e8e-9815-124531bf8502" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7198b88a-8c8c-4d7d-8b25-d8543c4f68a3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22469b0e-c1d4-4e8e-9815-124531bf8502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaAndIspenMember_f4b08acc-5089-44ab-b2e0-cff0fe529056" xlink:href="exel-20220701.xsd#exel_TakedaAndIspenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22469b0e-c1d4-4e8e-9815-124531bf8502" xlink:to="loc_exel_TakedaAndIspenMember_f4b08acc-5089-44ab-b2e0-cff0fe529056" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended" id="i416288fb35fc413b927ff1a485e1666c_CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6a2e980-50bd-43d5-9063-5012698c08e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a6469b8-0ca5-49b1-baeb-0c77a6d64c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6a2e980-50bd-43d5-9063-5012698c08e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a6469b8-0ca5-49b1-baeb-0c77a6d64c4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a7683fa-e008-4ebb-abd7-433881553bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6a2e980-50bd-43d5-9063-5012698c08e1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a7683fa-e008-4ebb-abd7-433881553bdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7f49d73e-e8ad-4153-989a-94450b6735ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a7683fa-e008-4ebb-abd7-433881553bdd" xlink:to="loc_srt_ProductOrServiceAxis_7f49d73e-e8ad-4153-989a-94450b6735ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7f49d73e-e8ad-4153-989a-94450b6735ba_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7f49d73e-e8ad-4153-989a-94450b6735ba" xlink:to="loc_srt_ProductsAndServicesDomain_7f49d73e-e8ad-4153-989a-94450b6735ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2456bed1-838b-4a62-966a-2fc20e29b2cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7f49d73e-e8ad-4153-989a-94450b6735ba" xlink:to="loc_srt_ProductsAndServicesDomain_2456bed1-838b-4a62-966a-2fc20e29b2cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_5865f6b3-2f3c-4ff6-ac03-25948ec167d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2456bed1-838b-4a62-966a-2fc20e29b2cf" xlink:to="loc_us-gaap_LicenseMember_5865f6b3-2f3c-4ff6-ac03-25948ec167d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_3a45c578-5b79-401c-a9b5-5fee4f3ade60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2456bed1-838b-4a62-966a-2fc20e29b2cf" xlink:to="loc_us-gaap_ServiceMember_3a45c578-5b79-401c-a9b5-5fee4f3ade60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d6aa8afc-7997-4f0d-b45c-10b01e5c05b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a7683fa-e008-4ebb-abd7-433881553bdd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d6aa8afc-7997-4f0d-b45c-10b01e5c05b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d6aa8afc-7997-4f0d-b45c-10b01e5c05b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d6aa8afc-7997-4f0d-b45c-10b01e5c05b0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d6aa8afc-7997-4f0d-b45c-10b01e5c05b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c6bd8ac-2589-479c-94de-0b4c432bbed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d6aa8afc-7997-4f0d-b45c-10b01e5c05b0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c6bd8ac-2589-479c-94de-0b4c432bbed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_ae262b83-fb84-4bfe-9c39-b8e55f43e411" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c6bd8ac-2589-479c-94de-0b4c432bbed3" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_ae262b83-fb84-4bfe-9c39-b8e55f43e411" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended" id="i0610798c800748eda6edc0366e50d75e_CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b14e830d-dd9c-4e95-958d-7776a88db704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9848a724-5930-4e8c-8f8e-ec205b52bf62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b14e830d-dd9c-4e95-958d-7776a88db704" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9848a724-5930-4e8c-8f8e-ec205b52bf62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_13528f8b-9c03-46d8-bd64-3e9842737679" xlink:href="exel-20220701.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b14e830d-dd9c-4e95-958d-7776a88db704" xlink:to="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_13528f8b-9c03-46d8-bd64-3e9842737679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_93feea17-b741-463b-ab3d-8338cc639de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b14e830d-dd9c-4e95-958d-7776a88db704" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_93feea17-b741-463b-ab3d-8338cc639de7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1b2c6c6f-dea7-40ac-b3ca-04f24c425187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b14e830d-dd9c-4e95-958d-7776a88db704" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1b2c6c6f-dea7-40ac-b3ca-04f24c425187" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b889b6ae-a2ad-4f7b-9d21-e6ded6635cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1b2c6c6f-dea7-40ac-b3ca-04f24c425187" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b889b6ae-a2ad-4f7b-9d21-e6ded6635cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b889b6ae-a2ad-4f7b-9d21-e6ded6635cd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b889b6ae-a2ad-4f7b-9d21-e6ded6635cd7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b889b6ae-a2ad-4f7b-9d21-e6ded6635cd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24c4bea7-dd59-43ff-b7b1-e10e96d63fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b889b6ae-a2ad-4f7b-9d21-e6ded6635cd7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24c4bea7-dd59-43ff-b7b1-e10e96d63fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_a140b2bc-a20d-478a-9e21-6f343c4d12b4" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24c4bea7-dd59-43ff-b7b1-e10e96d63fdf" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_a140b2bc-a20d-478a-9e21-6f343c4d12b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended" id="i67e68b44d06c481ea54f776664b46008_CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d101165b-efd2-4117-a311-2c6e19db63c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c5fe414-2b3d-4867-905e-8ba6909e3a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d101165b-efd2-4117-a311-2c6e19db63c2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c5fe414-2b3d-4867-905e-8ba6909e3a8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b36a0053-4b8f-4347-8475-9bed85e85411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d101165b-efd2-4117-a311-2c6e19db63c2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b36a0053-4b8f-4347-8475-9bed85e85411" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_644243c9-50d6-4538-948f-8994549f0ebc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b36a0053-4b8f-4347-8475-9bed85e85411" xlink:to="loc_srt_ProductOrServiceAxis_644243c9-50d6-4538-948f-8994549f0ebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_644243c9-50d6-4538-948f-8994549f0ebc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_644243c9-50d6-4538-948f-8994549f0ebc" xlink:to="loc_srt_ProductsAndServicesDomain_644243c9-50d6-4538-948f-8994549f0ebc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aafcf407-b1cb-4d08-8449-45035d91b52c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_644243c9-50d6-4538-948f-8994549f0ebc" xlink:to="loc_srt_ProductsAndServicesDomain_aafcf407-b1cb-4d08-8449-45035d91b52c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_64790d43-ee36-4472-90c6-0b05298f3469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aafcf407-b1cb-4d08-8449-45035d91b52c" xlink:to="loc_us-gaap_LicenseMember_64790d43-ee36-4472-90c6-0b05298f3469" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_bb57d976-a710-4b56-b9ca-be44466ce1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aafcf407-b1cb-4d08-8449-45035d91b52c" xlink:to="loc_us-gaap_ServiceMember_bb57d976-a710-4b56-b9ca-be44466ce1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_20768fe7-5833-4725-8e97-f3ea03e5544a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b36a0053-4b8f-4347-8475-9bed85e85411" xlink:to="loc_us-gaap_TypeOfArrangementAxis_20768fe7-5833-4725-8e97-f3ea03e5544a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20768fe7-5833-4725-8e97-f3ea03e5544a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20768fe7-5833-4725-8e97-f3ea03e5544a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20768fe7-5833-4725-8e97-f3ea03e5544a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0768c92-e3d8-4e80-bf7f-b7f07dd18702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20768fe7-5833-4725-8e97-f3ea03e5544a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0768c92-e3d8-4e80-bf7f-b7f07dd18702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_8d885cd4-5cac-4730-9ade-1cfc9c34bdeb" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0768c92-e3d8-4e80-bf7f-b7f07dd18702" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_8d885cd4-5cac-4730-9ade-1cfc9c34bdeb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended" id="if2935f600c0344f4830b3664f11d7b88_CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24576b56-1397-493c-bf80-57f6d8fea7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_774dfe5b-c25c-40b9-8d75-54dfce951f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24576b56-1397-493c-bf80-57f6d8fea7ed" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_774dfe5b-c25c-40b9-8d75-54dfce951f61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b016b1-875c-4c51-81f7-9419ccaad5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24576b56-1397-493c-bf80-57f6d8fea7ed" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b016b1-875c-4c51-81f7-9419ccaad5e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a95c9b4c-d841-4afd-b4de-6e1abbf25f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b016b1-875c-4c51-81f7-9419ccaad5e0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a95c9b4c-d841-4afd-b4de-6e1abbf25f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a95c9b4c-d841-4afd-b4de-6e1abbf25f91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a95c9b4c-d841-4afd-b4de-6e1abbf25f91" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a95c9b4c-d841-4afd-b4de-6e1abbf25f91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_559b4a2b-2be7-45a6-810d-6bc347bc25ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a95c9b4c-d841-4afd-b4de-6e1abbf25f91" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_559b4a2b-2be7-45a6-810d-6bc347bc25ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_c8e009d5-89a5-437c-82e8-bb85f961bd17" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_559b4a2b-2be7-45a6-810d-6bc347bc25ac" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_c8e009d5-89a5-437c-82e8-bb85f961bd17" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" xlink:type="extended" id="i0e728829d7514beb818e778207a5d0c8_CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0df5c4ec-9d8c-4dfd-80c3-eb301f2aa8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_210d432b-9d6b-4217-a8b9-f38d54124ce6" xlink:href="exel-20220701.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0df5c4ec-9d8c-4dfd-80c3-eb301f2aa8d8" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_210d432b-9d6b-4217-a8b9-f38d54124ce6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_1da0cc4c-540f-45e3-99c0-ced9abdf8f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0df5c4ec-9d8c-4dfd-80c3-eb301f2aa8d8" xlink:to="loc_us-gaap_RoyaltyExpense_1da0cc4c-540f-45e3-99c0-ced9abdf8f62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0290ec64-2550-4d19-a027-0bd8ae77c0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0df5c4ec-9d8c-4dfd-80c3-eb301f2aa8d8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0290ec64-2550-4d19-a027-0bd8ae77c0f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ddab1b24-d3ea-4241-97c2-555b57a7dd55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0290ec64-2550-4d19-a027-0bd8ae77c0f9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ddab1b24-d3ea-4241-97c2-555b57a7dd55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ddab1b24-d3ea-4241-97c2-555b57a7dd55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ddab1b24-d3ea-4241-97c2-555b57a7dd55" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ddab1b24-d3ea-4241-97c2-555b57a7dd55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_230430de-a541-4a2f-acb9-2974ef4156aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ddab1b24-d3ea-4241-97c2-555b57a7dd55" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_230430de-a541-4a2f-acb9-2974ef4156aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4be81a35-fe16-4478-9d47-8a1a84be3862" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_230430de-a541-4a2f-acb9-2974ef4156aa" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4be81a35-fe16-4478-9d47-8a1a84be3862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyalPharmaMember_15668883-c142-4f43-a060-8fb2344230bf" xlink:href="exel-20220701.xsd#exel_RoyalPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_230430de-a541-4a2f-acb9-2974ef4156aa" xlink:to="loc_exel_RoyalPharmaMember_15668883-c142-4f43-a060-8fb2344230bf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended" id="if5f7b4af7f924a4c8671e09e81905dbb_CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42a9ced0-4182-4fd3-9e76-23e8ee57ddd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_f5882c19-cd8a-491c-837b-3e839ed09406" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42a9ced0-4182-4fd3-9e76-23e8ee57ddd7" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_f5882c19-cd8a-491c-837b-3e839ed09406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d08e54f2-7dc6-43a2-bc21-05d51f662ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42a9ced0-4182-4fd3-9e76-23e8ee57ddd7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d08e54f2-7dc6-43a2-bc21-05d51f662ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba5ae75-c07c-4d16-8f79-2d70ec49b0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42a9ced0-4182-4fd3-9e76-23e8ee57ddd7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba5ae75-c07c-4d16-8f79-2d70ec49b0f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3ffb88bf-3d93-4d96-816c-e31696bb611c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba5ae75-c07c-4d16-8f79-2d70ec49b0f8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3ffb88bf-3d93-4d96-816c-e31696bb611c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ffb88bf-3d93-4d96-816c-e31696bb611c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3ffb88bf-3d93-4d96-816c-e31696bb611c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ffb88bf-3d93-4d96-816c-e31696bb611c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e516ad4-988d-401e-a2ac-087f968616df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3ffb88bf-3d93-4d96-816c-e31696bb611c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e516ad4-988d-401e-a2ac-087f968616df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_8b6f2131-216f-455e-8260-a0a1ef55b670" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e516ad4-988d-401e-a2ac-087f968616df" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_8b6f2131-216f-455e-8260-a0a1ef55b670" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisAxis_f0d7ae8b-1142-4eab-991c-10f7d8860526" xlink:href="exel-20220701.xsd#exel_ProductOrServiceAxisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba5ae75-c07c-4d16-8f79-2d70ec49b0f8" xlink:to="loc_exel_ProductOrServiceAxisAxis_f0d7ae8b-1142-4eab-991c-10f7d8860526" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisDomain_f0d7ae8b-1142-4eab-991c-10f7d8860526_default" xlink:href="exel-20220701.xsd#exel_ProductOrServiceAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_ProductOrServiceAxisAxis_f0d7ae8b-1142-4eab-991c-10f7d8860526" xlink:to="loc_exel_ProductOrServiceAxisDomain_f0d7ae8b-1142-4eab-991c-10f7d8860526_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisDomain_3fb58753-7f95-4161-91f2-7ca6d06bc3e5" xlink:href="exel-20220701.xsd#exel_ProductOrServiceAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_ProductOrServiceAxisAxis_f0d7ae8b-1142-4eab-991c-10f7d8860526" xlink:to="loc_exel_ProductOrServiceAxisDomain_3fb58753-7f95-4161-91f2-7ca6d06bc3e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_05607bcd-e415-4545-b71e-c978f87e1ebc" xlink:href="exel-20220701.xsd#exel_CotellicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProductOrServiceAxisDomain_3fb58753-7f95-4161-91f2-7ca6d06bc3e5" xlink:to="loc_exel_CotellicMember_05607bcd-e415-4545-b71e-c978f87e1ebc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="extended" id="icf508643adcb4f3889087d3561ed311b_CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_2d2ae5bf-c11d-4a09-af90-03de546b2389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_70c2eecd-9a93-4524-927f-77a1fe4c5589" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2d2ae5bf-c11d-4a09-af90-03de546b2389" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_70c2eecd-9a93-4524-927f-77a1fe4c5589" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_4958c75f-1509-4320-8831-4a4cce12a928" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2d2ae5bf-c11d-4a09-af90-03de546b2389" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_4958c75f-1509-4320-8831-4a4cce12a928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_50c965a6-b8d9-40fd-890a-d3838ba19de7" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2d2ae5bf-c11d-4a09-af90-03de546b2389" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_50c965a6-b8d9-40fd-890a-d3838ba19de7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_c1d086bd-f095-46a3-8520-2ab62de0fec6" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2d2ae5bf-c11d-4a09-af90-03de546b2389" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_c1d086bd-f095-46a3-8520-2ab62de0fec6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_a613593c-abda-49bd-8d4f-d3f414313f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2d2ae5bf-c11d-4a09-af90-03de546b2389" xlink:to="loc_us-gaap_AssetAcquisitionTable_a613593c-abda-49bd-8d4f-d3f414313f97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_de79f8bb-2919-471c-890b-1868150c8e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_a613593c-abda-49bd-8d4f-d3f414313f97" xlink:to="loc_us-gaap_TypeOfArrangementAxis_de79f8bb-2919-471c-890b-1868150c8e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de79f8bb-2919-471c-890b-1868150c8e95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_de79f8bb-2919-471c-890b-1868150c8e95" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de79f8bb-2919-471c-890b-1868150c8e95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a7a7eab-fe73-448a-89c5-be09eb4f237b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_de79f8bb-2919-471c-890b-1868150c8e95" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a7a7eab-fe73-448a-89c5-be09eb4f237b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember_1cbad9c7-ddeb-42bf-bbb8-b6e408f15074" xlink:href="exel-20220701.xsd#exel_CollaborationAgreementWithBioInventOptionAndLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a7a7eab-fe73-448a-89c5-be09eb4f237b" xlink:to="loc_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember_1cbad9c7-ddeb-42bf-bbb8-b6e408f15074" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_7b93acc7-755f-40de-a994-4df93a7e0696" xlink:href="exel-20220701.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a7a7eab-fe73-448a-89c5-be09eb4f237b" xlink:to="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_7b93acc7-755f-40de-a994-4df93a7e0696" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended" id="i976b334937074f59a8adafdb030c1e94_CashandInvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_cc008c71-790f-4349-9b33-14b4c8c52551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_cc008c71-790f-4349-9b33-14b4c8c52551" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_598cc7fd-895d-4dd8-a466-960bb94f2938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:to="loc_us-gaap_InterestReceivable_598cc7fd-895d-4dd8-a466-960bb94f2938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0cd76806-d32f-44d2-8c53-8738e944ce43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0cd76806-d32f-44d2-8c53-8738e944ce43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_5f48af6e-ecc4-4929-a1da-37d2c1fbe086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_5f48af6e-ecc4-4929-a1da-37d2c1fbe086" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f00f99cc-92df-4309-9523-b290acae49e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f00f99cc-92df-4309-9523-b290acae49e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09a2bb1b-9279-4b2f-ac1b-29264c0b3ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09a2bb1b-9279-4b2f-ac1b-29264c0b3ac6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_895c0c95-101d-4588-829b-8d213a3cf0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09a2bb1b-9279-4b2f-ac1b-29264c0b3ac6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_895c0c95-101d-4588-829b-8d213a3cf0e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_895c0c95-101d-4588-829b-8d213a3cf0e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_895c0c95-101d-4588-829b-8d213a3cf0e8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_895c0c95-101d-4588-829b-8d213a3cf0e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35fe91d1-15fe-4853-ab5e-66d760958ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_895c0c95-101d-4588-829b-8d213a3cf0e8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35fe91d1-15fe-4853-ab5e-66d760958ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_3f263e62-f441-4e1f-b724-b14ef56d53b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35fe91d1-15fe-4853-ab5e-66d760958ba0" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_3f263e62-f441-4e1f-b724-b14ef56d53b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_861084b0-0ea6-4bde-8fd7-f58086d60f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09a2bb1b-9279-4b2f-ac1b-29264c0b3ac6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_861084b0-0ea6-4bde-8fd7-f58086d60f5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_861084b0-0ea6-4bde-8fd7-f58086d60f5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_861084b0-0ea6-4bde-8fd7-f58086d60f5a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_861084b0-0ea6-4bde-8fd7-f58086d60f5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4a5b484-c6ab-483f-a17f-4fee47ac37da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_861084b0-0ea6-4bde-8fd7-f58086d60f5a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4a5b484-c6ab-483f-a17f-4fee47ac37da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_e01d50d6-30cf-4a6f-9c02-7fa99f809fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4a5b484-c6ab-483f-a17f-4fee47ac37da" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_e01d50d6-30cf-4a6f-9c02-7fa99f809fdf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended" id="idc12e41817904ad1b7b000bd5f6b4280_CashandInvestmentsInvestmentsbySecurityTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74a16c20-225d-404b-a999-a157734e3983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74a16c20-225d-404b-a999-a157734e3983" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7b833fe0-ce95-4327-9cd9-3e4b0f11627f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74a16c20-225d-404b-a999-a157734e3983" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7b833fe0-ce95-4327-9cd9-3e4b0f11627f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c1a7eeef-8c5c-436f-9766-efd23445e9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74a16c20-225d-404b-a999-a157734e3983" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c1a7eeef-8c5c-436f-9766-efd23445e9f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ac817160-34ac-4e67-a3c8-05b0ea995c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74a16c20-225d-404b-a999-a157734e3983" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ac817160-34ac-4e67-a3c8-05b0ea995c56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_60b15f71-cbe1-499f-ad70-1f79ec311db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74a16c20-225d-404b-a999-a157734e3983" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_60b15f71-cbe1-499f-ad70-1f79ec311db8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_072ddd66-7755-4a39-9feb-6356355e17ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_072ddd66-7755-4a39-9feb-6356355e17ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_6751fb10-0d26-4285-b5be-c21743491650" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_072ddd66-7755-4a39-9feb-6356355e17ba" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_6751fb10-0d26-4285-b5be-c21743491650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_0e082edc-7750-4f7d-8f92-6beb9b565ce1" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_072ddd66-7755-4a39-9feb-6356355e17ba" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_0e082edc-7750-4f7d-8f92-6beb9b565ce1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_bbcb5a71-240a-40dd-b041-f52a0d7798f2" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_072ddd66-7755-4a39-9feb-6356355e17ba" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_bbcb5a71-240a-40dd-b041-f52a0d7798f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_494358df-6eac-451e-81ab-76636d735596" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_072ddd66-7755-4a39-9feb-6356355e17ba" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_494358df-6eac-451e-81ab-76636d735596" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_aee8bf42-605e-4ba0-b8dd-b493bf68ae18" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_aee8bf42-605e-4ba0-b8dd-b493bf68ae18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07fecc6f-8205-4409-ba85-25804824ed94" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07fecc6f-8205-4409-ba85-25804824ed94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22f7e157-2333-4cc2-bc89-d4eb3fe85b1c" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22f7e157-2333-4cc2-bc89-d4eb3fe85b1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_fd9b0910-9bbf-4468-96a2-9c8bcda30d3d" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_fd9b0910-9bbf-4468-96a2-9c8bcda30d3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_694ba58c-2aab-4a72-8335-ec0fef3fc6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_694ba58c-2aab-4a72-8335-ec0fef3fc6e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3a323e8b-5d34-4626-8cf3-2046af78ee76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_694ba58c-2aab-4a72-8335-ec0fef3fc6e8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3a323e8b-5d34-4626-8cf3-2046af78ee76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a323e8b-5d34-4626-8cf3-2046af78ee76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3a323e8b-5d34-4626-8cf3-2046af78ee76" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a323e8b-5d34-4626-8cf3-2046af78ee76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3a323e8b-5d34-4626-8cf3-2046af78ee76" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_16723d02-037a-4a80-9da5-56dd7ea0ac00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_CommercialPaperMember_16723d02-037a-4a80-9da5-56dd7ea0ac00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_82c7228a-cbed-4174-b964-201f305c6ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_82c7228a-cbed-4174-b964-201f305c6ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_917bbe54-0f7e-41e2-9231-12e958095e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_917bbe54-0f7e-41e2-9231-12e958095e29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_1fcdd410-e590-444b-be86-1655a2f25468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_MunicipalBondsMember_1fcdd410-e590-444b-be86-1655a2f25468" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_a4dc3989-5153-4530-868d-d8f2824e9eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_CashMember_a4dc3989-5153-4530-868d-d8f2824e9eb5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3cdeb11a-71a5-4bb7-b25b-0035f06bd912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3cdeb11a-71a5-4bb7-b25b-0035f06bd912" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f6cc0bf0-87f3-4581-bf5e-9d2d83737e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f6cc0bf0-87f3-4581-bf5e-9d2d83737e10" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended" id="i2a64ee686d104713bf08027f8bdf60e4_CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_619971dd-a244-453a-9a35-19606b63f404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_42c049d0-535f-444d-914f-2275a0934e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_619971dd-a244-453a-9a35-19606b63f404" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_42c049d0-535f-444d-914f-2275a0934e9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1de71bb6-62f0-4154-b698-5f0600f48695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_42c049d0-535f-444d-914f-2275a0934e9b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1de71bb6-62f0-4154-b698-5f0600f48695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_83c7f6ca-613f-4e3d-b2b1-1a915138ef82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_42c049d0-535f-444d-914f-2275a0934e9b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_83c7f6ca-613f-4e3d-b2b1-1a915138ef82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5efe59b3-1998-49ca-b462-f7a0b91306a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_619971dd-a244-453a-9a35-19606b63f404" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5efe59b3-1998-49ca-b462-f7a0b91306a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6356a1a4-0c24-4d7b-b30b-734cefb6c0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5efe59b3-1998-49ca-b462-f7a0b91306a7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6356a1a4-0c24-4d7b-b30b-734cefb6c0ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6356a1a4-0c24-4d7b-b30b-734cefb6c0ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6356a1a4-0c24-4d7b-b30b-734cefb6c0ea" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6356a1a4-0c24-4d7b-b30b-734cefb6c0ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84cd2119-f299-48e1-abe4-13356d8caefa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6356a1a4-0c24-4d7b-b30b-734cefb6c0ea" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84cd2119-f299-48e1-abe4-13356d8caefa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_86b0b1af-2717-4278-9ae9-29fe0da1c0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84cd2119-f299-48e1-abe4-13356d8caefa" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_86b0b1af-2717-4278-9ae9-29fe0da1c0dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_647c4d17-75c8-42df-8165-640d5254a7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84cd2119-f299-48e1-abe4-13356d8caefa" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_647c4d17-75c8-42df-8165-640d5254a7b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ac00e233-74ee-4752-b438-87ea66f622a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84cd2119-f299-48e1-abe4-13356d8caefa" xlink:to="loc_us-gaap_CommercialPaperMember_ac00e233-74ee-4752-b438-87ea66f622a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_ef335e72-0904-4bcc-9a66-be97ebb27bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84cd2119-f299-48e1-abe4-13356d8caefa" xlink:to="loc_us-gaap_MunicipalBondsMember_ef335e72-0904-4bcc-9a66-be97ebb27bd5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="iff80fbf4874643d7a99d7c2c67f0d899_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55784351-caff-4543-9b99-ff4708c553c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e406a243-cf7b-4e85-b557-6572690bd6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55784351-caff-4543-9b99-ff4708c553c7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e406a243-cf7b-4e85-b557-6572690bd6e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368e38c7-c343-41cf-b938-a0bae32c9358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55784351-caff-4543-9b99-ff4708c553c7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368e38c7-c343-41cf-b938-a0bae32c9358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_46b772e7-eb86-4e5b-91f4-f781940fd8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55784351-caff-4543-9b99-ff4708c553c7" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_46b772e7-eb86-4e5b-91f4-f781940fd8ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fe71326-af57-4649-a97e-aa3c85e8eef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55784351-caff-4543-9b99-ff4708c553c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fe71326-af57-4649-a97e-aa3c85e8eef1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4a985c75-246a-4f15-adec-3912f8d70f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fe71326-af57-4649-a97e-aa3c85e8eef1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4a985c75-246a-4f15-adec-3912f8d70f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a985c75-246a-4f15-adec-3912f8d70f86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4a985c75-246a-4f15-adec-3912f8d70f86" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a985c75-246a-4f15-adec-3912f8d70f86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4a985c75-246a-4f15-adec-3912f8d70f86" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bfb20e16-70c6-4c3f-8704-8cecf242d182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:to="loc_us-gaap_CommercialPaperMember_bfb20e16-70c6-4c3f-8704-8cecf242d182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_f543b919-4f05-4c87-acbf-3de2f853be0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_f543b919-4f05-4c87-acbf-3de2f853be0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_b5b20c33-7a78-40d6-974e-6786844d241b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_b5b20c33-7a78-40d6-974e-6786844d241b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_04e039de-1b88-411b-9a4c-e5643b8405de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:to="loc_us-gaap_MunicipalBondsMember_04e039de-1b88-411b-9a4c-e5643b8405de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2ea56f90-514f-414d-a4d7-ac4c5c73a19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2ea56f90-514f-414d-a4d7-ac4c5c73a19a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_89d049ec-b3b0-49f2-aed8-6f2f3d3fc0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:to="loc_us-gaap_CertificatesOfDepositMember_89d049ec-b3b0-49f2-aed8-6f2f3d3fc0d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_816c1834-053e-4665-9f5f-2f7730b68693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fe71326-af57-4649-a97e-aa3c85e8eef1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_816c1834-053e-4665-9f5f-2f7730b68693" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_816c1834-053e-4665-9f5f-2f7730b68693_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_816c1834-053e-4665-9f5f-2f7730b68693" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_816c1834-053e-4665-9f5f-2f7730b68693_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f325e72-e954-4afa-a646-5b90feb1526a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_816c1834-053e-4665-9f5f-2f7730b68693" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f325e72-e954-4afa-a646-5b90feb1526a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6e93b665-55e4-4b84-a917-bd845926daac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f325e72-e954-4afa-a646-5b90feb1526a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6e93b665-55e4-4b84-a917-bd845926daac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c65da225-2024-41e8-9696-288762f6c0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f325e72-e954-4afa-a646-5b90feb1526a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c65da225-2024-41e8-9696-288762f6c0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fee75144-8ce5-4eaf-bc45-19fd21d57652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fe71326-af57-4649-a97e-aa3c85e8eef1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fee75144-8ce5-4eaf-bc45-19fd21d57652" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fee75144-8ce5-4eaf-bc45-19fd21d57652_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fee75144-8ce5-4eaf-bc45-19fd21d57652" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fee75144-8ce5-4eaf-bc45-19fd21d57652_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0220f4b8-73b2-4d7c-b4d5-ab5e8628a34d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fee75144-8ce5-4eaf-bc45-19fd21d57652" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0220f4b8-73b2-4d7c-b4d5-ab5e8628a34d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f4505210-2054-4026-8f27-d43429144439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0220f4b8-73b2-4d7c-b4d5-ab5e8628a34d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f4505210-2054-4026-8f27-d43429144439" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended" id="i9035a3d5fd894cec911a9e4f37c6453e_FairValueMeasurementsNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd2b3cc-4a34-439b-b36f-0ff64720f32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_e5800083-5c9b-494d-ae05-2986a7c4e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd2b3cc-4a34-439b-b36f-0ff64720f32d" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_e5800083-5c9b-494d-ae05-2986a7c4e54f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_3238e5b1-f1f4-4008-98fe-6b4ad8e65e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd2b3cc-4a34-439b-b36f-0ff64720f32d" xlink:to="loc_us-gaap_DerivativeNotionalAmount_3238e5b1-f1f4-4008-98fe-6b4ad8e65e2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_08f48616-512b-4612-813a-57a56f9ab94d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd2b3cc-4a34-439b-b36f-0ff64720f32d" xlink:to="loc_us-gaap_DerivativeTermOfContract_08f48616-512b-4612-813a-57a56f9ab94d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_9103a783-ad57-469e-a787-3b602aa6d4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd2b3cc-4a34-439b-b36f-0ff64720f32d" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_9103a783-ad57-469e-a787-3b602aa6d4ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec54894-e3e6-4003-a07d-708ce3282ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd2b3cc-4a34-439b-b36f-0ff64720f32d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec54894-e3e6-4003-a07d-708ce3282ec0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_04f6978b-7a17-48b8-bc70-b0ce6081a8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec54894-e3e6-4003-a07d-708ce3282ec0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_04f6978b-7a17-48b8-bc70-b0ce6081a8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_04f6978b-7a17-48b8-bc70-b0ce6081a8c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_04f6978b-7a17-48b8-bc70-b0ce6081a8c1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_04f6978b-7a17-48b8-bc70-b0ce6081a8c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_17e8959b-31f4-4830-89ea-a533c45d10e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_04f6978b-7a17-48b8-bc70-b0ce6081a8c1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_17e8959b-31f4-4830-89ea-a533c45d10e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_a8723a07-47c5-4f3a-b3fc-cacee579c80b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_17e8959b-31f4-4830-89ea-a533c45d10e6" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_a8723a07-47c5-4f3a-b3fc-cacee579c80b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended" id="ib7dc22402d6d45efbadf421b33a358e9_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_4b27541b-8a8a-4f3e-849d-bd529a13d487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_c54fa4d1-9533-4038-85e0-e33187c5cff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_4b27541b-8a8a-4f3e-849d-bd529a13d487" xlink:to="loc_us-gaap_InventoryRawMaterials_c54fa4d1-9533-4038-85e0-e33187c5cff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_57c65c5e-3380-468f-82f9-24658fd08ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_4b27541b-8a8a-4f3e-849d-bd529a13d487" xlink:to="loc_us-gaap_InventoryWorkInProcess_57c65c5e-3380-468f-82f9-24658fd08ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_43d78867-85c0-44af-b453-edfcf565c29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_4b27541b-8a8a-4f3e-849d-bd529a13d487" xlink:to="loc_us-gaap_InventoryFinishedGoods_43d78867-85c0-44af-b453-edfcf565c29e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_3d5da9c1-d4fa-4631-9ed9-7ec62aaddc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_4b27541b-8a8a-4f3e-849d-bd529a13d487" xlink:to="loc_us-gaap_InventoryGross_3d5da9c1-d4fa-4631-9ed9-7ec62aaddc9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_b3944355-7a29-486d-8def-c3c4e777b715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_4b27541b-8a8a-4f3e-849d-bd529a13d487" xlink:to="loc_us-gaap_InventoryCurrentTable_b3944355-7a29-486d-8def-c3c4e777b715" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d431c103-3e53-465b-95f5-0d3e6701a8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_b3944355-7a29-486d-8def-c3c4e777b715" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d431c103-3e53-465b-95f5-0d3e6701a8b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d431c103-3e53-465b-95f5-0d3e6701a8b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d431c103-3e53-465b-95f5-0d3e6701a8b5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d431c103-3e53-465b-95f5-0d3e6701a8b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_33ce9487-0345-467a-9e3a-e4c5e6e1c3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d431c103-3e53-465b-95f5-0d3e6701a8b5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_33ce9487-0345-467a-9e3a-e4c5e6e1c3b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_350040e1-5dec-4b88-95dc-5c73b3d3c1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_33ce9487-0345-467a-9e3a-e4c5e6e1c3b4" xlink:to="loc_us-gaap_InventoriesMember_350040e1-5dec-4b88-95dc-5c73b3d3c1de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_05b22833-de82-48c5-9b72-76a967440c7e" xlink:href="exel-20220701.xsd#exel_OtherLongtermAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_33ce9487-0345-467a-9e3a-e4c5e6e1c3b4" xlink:to="loc_exel_OtherLongtermAssetsMember_05b22833-de82-48c5-9b72-76a967440c7e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" id="i5819e2287f324987ab1840ee592270fc_StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c02f5f1a-9951-485e-99d5-92965a0da6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2bede1a8-16a2-49f3-ad87-bcf3006f4ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c02f5f1a-9951-485e-99d5-92965a0da6fc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2bede1a8-16a2-49f3-ad87-bcf3006f4ef8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b9bac01b-b2d6-468b-9dc3-109ed0dfe1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c02f5f1a-9951-485e-99d5-92965a0da6fc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b9bac01b-b2d6-468b-9dc3-109ed0dfe1d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6c91cd74-5a24-45e6-a0de-27d5e966784d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b9bac01b-b2d6-468b-9dc3-109ed0dfe1d5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6c91cd74-5a24-45e6-a0de-27d5e966784d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6c91cd74-5a24-45e6-a0de-27d5e966784d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c91cd74-5a24-45e6-a0de-27d5e966784d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6c91cd74-5a24-45e6-a0de-27d5e966784d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e1f9e03b-636c-43d2-a06d-1f56cc634828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c91cd74-5a24-45e6-a0de-27d5e966784d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e1f9e03b-636c-43d2-a06d-1f56cc634828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4ddfa1fa-da08-49aa-8c8a-6a54114b9c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1f9e03b-636c-43d2-a06d-1f56cc634828" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4ddfa1fa-da08-49aa-8c8a-6a54114b9c68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_791057f0-bc1e-4e8d-bb7e-b91f0c2ace47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1f9e03b-636c-43d2-a06d-1f56cc634828" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_791057f0-bc1e-4e8d-bb7e-b91f0c2ace47" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended" id="i6d4c63179e6641e78628a9fc0dda07d3_StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c4ef7b9-fe66-4838-9404-1e415eff79a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b2315023-9549-4526-ba81-d3fb58eebe86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c4ef7b9-fe66-4838-9404-1e415eff79a3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b2315023-9549-4526-ba81-d3fb58eebe86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6488497-c2df-4ffd-9a0c-2aadca49caa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c4ef7b9-fe66-4838-9404-1e415eff79a3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6488497-c2df-4ffd-9a0c-2aadca49caa7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_122f3b4d-a317-4c4b-a418-25209a4a0e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6488497-c2df-4ffd-9a0c-2aadca49caa7" xlink:to="loc_us-gaap_AwardTypeAxis_122f3b4d-a317-4c4b-a418-25209a4a0e42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_122f3b4d-a317-4c4b-a418-25209a4a0e42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_122f3b4d-a317-4c4b-a418-25209a4a0e42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_122f3b4d-a317-4c4b-a418-25209a4a0e42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79979ac8-7a1e-4ec5-af82-404c295e232c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_122f3b4d-a317-4c4b-a418-25209a4a0e42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79979ac8-7a1e-4ec5-af82-404c295e232c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_974eaa2c-0cc5-46fd-9964-e44c1c0d8fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79979ac8-7a1e-4ec5-af82-404c295e232c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_974eaa2c-0cc5-46fd-9964-e44c1c0d8fe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8e7c12dc-2056-4b16-a18e-21e88a165624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79979ac8-7a1e-4ec5-af82-404c295e232c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8e7c12dc-2056-4b16-a18e-21e88a165624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6dca358b-2077-4746-b2e5-0c97c56275ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79979ac8-7a1e-4ec5-af82-404c295e232c" xlink:to="loc_us-gaap_PerformanceSharesMember_6dca358b-2077-4746-b2e5-0c97c56275ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_aeff31b6-0872-47e3-823b-cf08ea02385c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79979ac8-7a1e-4ec5-af82-404c295e232c" xlink:to="loc_us-gaap_EmployeeStockMember_aeff31b6-0872-47e3-823b-cf08ea02385c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i08b85c079229443eba80a01938701f12_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a6630c41-f738-47f2-8ed8-5a5e01deba57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a6630c41-f738-47f2-8ed8-5a5e01deba57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ad569042-bf9e-4252-bf65-9007730b0721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ad569042-bf9e-4252-bf65-9007730b0721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_ea6fc440-2237-48ff-b7d3-886acfd659fe" xlink:href="exel-20220701.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_ea6fc440-2237-48ff-b7d3-886acfd659fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_847f81ca-63a4-428b-9e12-2a7a701c1a58" xlink:href="exel-20220701.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_847f81ca-63a4-428b-9e12-2a7a701c1a58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_795c1f09-cbe0-4aca-90e8-43c2c2142bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_795c1f09-cbe0-4aca-90e8-43c2c2142bc8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9b3b0a22-a491-4bd7-a8c9-bb3408369822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9b3b0a22-a491-4bd7-a8c9-bb3408369822" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20a86dd6-72ff-45ab-9fbf-4a9ad47e19ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20a86dd6-72ff-45ab-9fbf-4a9ad47e19ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab5fe723-593c-4702-ba20-e64bb788cc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab5fe723-593c-4702-ba20-e64bb788cc7d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6749dff6-d9cc-4184-b811-39450fddd42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6749dff6-d9cc-4184-b811-39450fddd42e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_531bc322-89f8-4b8b-8e74-3ea6f4d44a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_531bc322-89f8-4b8b-8e74-3ea6f4d44a58" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_d6aece03-2c9a-4aea-b5f0-1f98873d5120" xlink:href="exel-20220701.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_d6aece03-2c9a-4aea-b5f0-1f98873d5120" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ce9132dc-93bf-4015-8a97-afc300bd2e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ce9132dc-93bf-4015-8a97-afc300bd2e7d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_da7acccf-7485-46e8-847d-71cf896410ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_da7acccf-7485-46e8-847d-71cf896410ac" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec704f03-d0dd-4856-8554-68968d3d76a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec704f03-d0dd-4856-8554-68968d3d76a1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bf70c39-97ca-4126-a38d-021c5f9b5b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bf70c39-97ca-4126-a38d-021c5f9b5b6e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfeb539-0c6d-4ac7-98af-7a26028afed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfeb539-0c6d-4ac7-98af-7a26028afed2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ec4adb1f-17e5-49a4-bb5a-ccdc628aa4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfeb539-0c6d-4ac7-98af-7a26028afed2" xlink:to="loc_us-gaap_AwardTypeAxis_ec4adb1f-17e5-49a4-bb5a-ccdc628aa4cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec4adb1f-17e5-49a4-bb5a-ccdc628aa4cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ec4adb1f-17e5-49a4-bb5a-ccdc628aa4cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec4adb1f-17e5-49a4-bb5a-ccdc628aa4cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09afa0a0-05c9-47bb-8b03-dc12d5a6ca15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ec4adb1f-17e5-49a4-bb5a-ccdc628aa4cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09afa0a0-05c9-47bb-8b03-dc12d5a6ca15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_caef0d47-2d20-428a-a306-bb7beb1eacfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09afa0a0-05c9-47bb-8b03-dc12d5a6ca15" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_caef0d47-2d20-428a-a306-bb7beb1eacfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_f3834b3a-378f-46b9-a89b-9da01a5224f5" xlink:href="exel-20220701.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_caef0d47-2d20-428a-a306-bb7beb1eacfc" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_f3834b3a-378f-46b9-a89b-9da01a5224f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_764f2fed-c752-4f6d-9a4f-b30d0b8230e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09afa0a0-05c9-47bb-8b03-dc12d5a6ca15" xlink:to="loc_us-gaap_EmployeeStockOptionMember_764f2fed-c752-4f6d-9a4f-b30d0b8230e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_096f10fa-69a5-4b79-98aa-4f0133c995bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09afa0a0-05c9-47bb-8b03-dc12d5a6ca15" xlink:to="loc_us-gaap_PerformanceSharesMember_096f10fa-69a5-4b79-98aa-4f0133c995bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_3634f0e8-1bb8-46dd-a449-ec303b2cc043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfeb539-0c6d-4ac7-98af-7a26028afed2" xlink:to="loc_us-gaap_VestingAxis_3634f0e8-1bb8-46dd-a449-ec303b2cc043" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_3634f0e8-1bb8-46dd-a449-ec303b2cc043_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_3634f0e8-1bb8-46dd-a449-ec303b2cc043" xlink:to="loc_us-gaap_VestingDomain_3634f0e8-1bb8-46dd-a449-ec303b2cc043_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2609e3c2-f903-48df-a577-718af91ff3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_3634f0e8-1bb8-46dd-a449-ec303b2cc043" xlink:to="loc_us-gaap_VestingDomain_2609e3c2-f903-48df-a577-718af91ff3ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6d4db749-f908-41d8-a4da-1ac688820116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2609e3c2-f903-48df-a577-718af91ff3ab" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6d4db749-f908-41d8-a4da-1ac688820116" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended" id="ifefdff1bab5246d7a43ad92a791475f8_StockBasedCompensationEstimateGrantDateFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70417684-354c-4243-b88e-0d413aee2216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_11d0c8c6-4340-4625-9def-78adf3998219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70417684-354c-4243-b88e-0d413aee2216" xlink:to="loc_us-gaap_SharePrice_11d0c8c6-4340-4625-9def-78adf3998219" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_e4df82e1-b277-4ba4-b9eb-b24c9e980ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70417684-354c-4243-b88e-0d413aee2216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_e4df82e1-b277-4ba4-b9eb-b24c9e980ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b6245a9f-b78a-40c7-83fb-cb92a8f63e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70417684-354c-4243-b88e-0d413aee2216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b6245a9f-b78a-40c7-83fb-cb92a8f63e04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_33f1f197-06d1-44d1-a8e6-f56c37c059b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70417684-354c-4243-b88e-0d413aee2216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_33f1f197-06d1-44d1-a8e6-f56c37c059b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77c95c2a-66fb-48c3-8dfa-5aeafc96fed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70417684-354c-4243-b88e-0d413aee2216" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77c95c2a-66fb-48c3-8dfa-5aeafc96fed9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0a2eeda7-ca29-4ceb-bd4d-9c77e7109876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77c95c2a-66fb-48c3-8dfa-5aeafc96fed9" xlink:to="loc_us-gaap_AwardTypeAxis_0a2eeda7-ca29-4ceb-bd4d-9c77e7109876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0a2eeda7-ca29-4ceb-bd4d-9c77e7109876_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0a2eeda7-ca29-4ceb-bd4d-9c77e7109876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0a2eeda7-ca29-4ceb-bd4d-9c77e7109876_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77a99ad2-6c8d-4a91-9ee6-188229180e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0a2eeda7-ca29-4ceb-bd4d-9c77e7109876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77a99ad2-6c8d-4a91-9ee6-188229180e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_39769144-41e0-406e-a705-4b2c0d244c2e" xlink:href="exel-20220701.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77a99ad2-6c8d-4a91-9ee6-188229180e17" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_39769144-41e0-406e-a705-4b2c0d244c2e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="extended" id="i619bde3dc9d84f548c958404d2ce7ff4_NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_602ac94c-7a57-46a5-aabc-90593c772ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8a1310be-1463-4317-ab08-d92025865c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_602ac94c-7a57-46a5-aabc-90593c772ca3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8a1310be-1463-4317-ab08-d92025865c50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e23ab118-4e5f-4c40-b9c9-4dedefe704eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_602ac94c-7a57-46a5-aabc-90593c772ca3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e23ab118-4e5f-4c40-b9c9-4dedefe704eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6371ab57-d49f-46a3-bc1f-948c8dc14038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e23ab118-4e5f-4c40-b9c9-4dedefe704eb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6371ab57-d49f-46a3-bc1f-948c8dc14038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6371ab57-d49f-46a3-bc1f-948c8dc14038_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6371ab57-d49f-46a3-bc1f-948c8dc14038" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6371ab57-d49f-46a3-bc1f-948c8dc14038_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f38a2f7e-eef2-4fe2-aada-9b6618808da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6371ab57-d49f-46a3-bc1f-948c8dc14038" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f38a2f7e-eef2-4fe2-aada-9b6618808da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_1ef6236e-03bb-4d25-9570-199dadd217a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f38a2f7e-eef2-4fe2-aada-9b6618808da7" xlink:to="loc_us-gaap_StockCompensationPlanMember_1ef6236e-03bb-4d25-9570-199dadd217a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i02033d89e93b40438672c6eccbb45d9a_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_44911a82-3582-4aa8-9904-fc7dc4d5c324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_44911a82-3582-4aa8-9904-fc7dc4d5c324" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e0c0e9a8-c362-47af-ae50-f3d048449ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e0c0e9a8-c362-47af-ae50-f3d048449ca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_0a20539c-d82f-4b4c-8fc9-8edb2584761a" xlink:href="exel-20220701.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_0a20539c-d82f-4b4c-8fc9-8edb2584761a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a06d005d-9f88-401a-9bfd-ce434dfead4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a06d005d-9f88-401a-9bfd-ce434dfead4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_b7c0c9c6-8259-467e-895d-322315a2c03f" xlink:href="exel-20220701.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_b7c0c9c6-8259-467e-895d-322315a2c03f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_123c3bea-39a4-4a7a-9010-4fd928fae851" xlink:href="exel-20220701.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_123c3bea-39a4-4a7a-9010-4fd928fae851" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_9b01b7ad-c6f1-4395-87d2-2ff90965aff1" xlink:href="exel-20220701.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_9b01b7ad-c6f1-4395-87d2-2ff90965aff1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_21177784-ca13-4d86-8c9d-a1a89e5d298e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_21177784-ca13-4d86-8c9d-a1a89e5d298e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_c2b1d6cc-102c-47e1-959e-dc998d69d099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_TenantImprovements_c2b1d6cc-102c-47e1-959e-dc998d69d099" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_877051e0-10a4-46d1-b1ab-45fbac47362e" xlink:href="exel-20220701.xsd#exel_TenantLeaseImprovementsAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_877051e0-10a4-46d1-b1ab-45fbac47362e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseLiabilityDiscountedPeriod_e04dede5-0eec-4680-94fa-310ff06734ce" xlink:href="exel-20220701.xsd#exel_OperatingLeaseLiabilityDiscountedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_OperatingLeaseLiabilityDiscountedPeriod_e04dede5-0eec-4680-94fa-310ff06734ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9d530129-cc83-4d76-9fce-056f5926cdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9d530129-cc83-4d76-9fce-056f5926cdf8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_d0f357b6-5f62-4c71-a767-58eec27d1d61" xlink:href="exel-20220701.xsd#exel_LossContingencyNumberOfLawsuitsConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_d0f357b6-5f62-4c71-a767-58eec27d1d61" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim_21185479-0527-43f8-80e3-ec4251d990e8" xlink:href="exel-20220701.xsd#exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim_21185479-0527-43f8-80e3-ec4251d990e8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_e1757265-0f0c-4227-aa9d-973dcd8f46d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_OtherCommitmentsTable_e1757265-0f0c-4227-aa9d-973dcd8f46d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis_f3885fea-4565-4c5f-9200-ba6b5be294b5" xlink:href="exel-20220701.xsd#exel_LeaseArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_e1757265-0f0c-4227-aa9d-973dcd8f46d6" xlink:to="loc_exel_LeaseArrangementsAxis_f3885fea-4565-4c5f-9200-ba6b5be294b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_f3885fea-4565-4c5f-9200-ba6b5be294b5_default" xlink:href="exel-20220701.xsd#exel_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_LeaseArrangementsAxis_f3885fea-4565-4c5f-9200-ba6b5be294b5" xlink:to="loc_exel_LeaseArrangementsDomain_f3885fea-4565-4c5f-9200-ba6b5be294b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_39c5dd88-13d6-4a78-a3a2-6986a5462f5f" xlink:href="exel-20220701.xsd#exel_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_LeaseArrangementsAxis_f3885fea-4565-4c5f-9200-ba6b5be294b5" xlink:to="loc_exel_LeaseArrangementsDomain_39c5dd88-13d6-4a78-a3a2-6986a5462f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_ca6a56d5-5f21-438c-96c0-23c17d3a00ea" xlink:href="exel-20220701.xsd#exel_BuiltToSuitLeaseAndHeadquartersLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_39c5dd88-13d6-4a78-a3a2-6986a5462f5f" xlink:to="loc_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_ca6a56d5-5f21-438c-96c0-23c17d3a00ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseExpansionMember_3478b0a5-7642-4e70-97cf-b04b6a52bbdf" xlink:href="exel-20220701.xsd#exel_LeaseExpansionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_39c5dd88-13d6-4a78-a3a2-6986a5462f5f" xlink:to="loc_exel_LeaseExpansionMember_3478b0a5-7642-4e70-97cf-b04b6a52bbdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3c5730a0-3b54-4d2c-9f00-862ffe734c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_e1757265-0f0c-4227-aa9d-973dcd8f46d6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3c5730a0-3b54-4d2c-9f00-862ffe734c05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3c5730a0-3b54-4d2c-9f00-862ffe734c05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3c5730a0-3b54-4d2c-9f00-862ffe734c05" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3c5730a0-3b54-4d2c-9f00-862ffe734c05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ecd170d6-71e9-4a28-b3a5-b65beab6082b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3c5730a0-3b54-4d2c-9f00-862ffe734c05" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ecd170d6-71e9-4a28-b3a5-b65beab6082b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6584b5ce-0958-4298-9fa8-0bc6c1889ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ecd170d6-71e9-4a28-b3a5-b65beab6082b" xlink:to="loc_us-gaap_SubsequentEventMember_6584b5ce-0958-4298-9fa8-0bc6c1889ac7" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>exel-20220701_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d6428e21-a936-4304-bbd0-42287b684d9f,g:54041ba7-ffad-43a6-84f8-cd8da74de046-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9c810ab9-aeb3-4992-aeff-3b0e35122ff8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f0da96b6-421f-4205-b8cc-28760a9e084e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_db4c0ffd-5099-44b5-8fa9-2d61f76faa45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_1f8a49bb-3cd1-461b-a5eb-1540c686b5c7_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits on U.S. commercialization</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:to="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_9c5aa00b-cd64-47e0-958f-a6c923a6fec3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_547c0d92-4826-4a3f-b735-fab0bdde400b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8422e67a-1826-4482-a992-48574b0b8608_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_212459ed-72be-4964-8cb1-2c3684dc4cc8_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of lease property (in square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_59440405-3835-4618-9747-4974f01da24f_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products derived from other compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:href="exel-20220701.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IpsenMember_d31efd9e-ad53-4cc7-918a-b81fab16a7be_terseLabel_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Pharma SAS</link:label>
    <link:label id="lab_exel_IpsenMember_label_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_documentation_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember" xlink:href="exel-20220701.xsd#exel_IpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember" xlink:to="lab_exel_IpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2ca13c29-e06e-4267-8d86-55e0664cea2c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_5bb70f2f-fa86-4b69-889c-faa028fb59bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductOrServiceAxisAxis_54f83ec1-2648-4c37-974c-c8d1b2dfa8d1_terseLabel_en-US" xlink:label="lab_exel_ProductOrServiceAxisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Axis]</link:label>
    <link:label id="lab_exel_ProductOrServiceAxisAxis_label_en-US" xlink:label="lab_exel_ProductOrServiceAxisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Axis]</link:label>
    <link:label id="lab_exel_ProductOrServiceAxisAxis_documentation_en-US" xlink:label="lab_exel_ProductOrServiceAxisAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisAxis" xlink:href="exel-20220701.xsd#exel_ProductOrServiceAxisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductOrServiceAxisAxis" xlink:to="lab_exel_ProductOrServiceAxisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_02093be4-6a3f-4685-b478-1494b226d24a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OperatingLeaseLiabilityDiscountedPeriod_5365aab2-98c8-4911-9760-dd9ee5c10136_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseLiabilityDiscountedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability discounted period</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilityDiscountedPeriod_label_en-US" xlink:label="lab_exel_OperatingLeaseLiabilityDiscountedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Discounted Period</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilityDiscountedPeriod_documentation_en-US" xlink:label="lab_exel_OperatingLeaseLiabilityDiscountedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Discounted Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseLiabilityDiscountedPeriod" xlink:href="exel-20220701.xsd#exel_OperatingLeaseLiabilityDiscountedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseLiabilityDiscountedPeriod" xlink:to="lab_exel_OperatingLeaseLiabilityDiscountedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_caf7968d-1bc7-4bcd-a511-aefb8ee7e15a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c5c4b04a-d0db-4c84-82de-097ab869253d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_43f8809d-22ef-42f8-9447-1946b6e241db_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate development milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4565fb65-55ea-4cfb-b639-f7963c6266ce_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9e6a6465-67c4-4724-afb1-7f3fe4cb3f1c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate incremental borrowing rate (in percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02a6d41a-1bad-4995-a355-9ee04218bb0e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_c08f7fdf-5f66-4061-8c32-7cb4bc9b32bb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_25011af2-76c7-4c6c-9454-7b7fc6c10bac_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OtherLongtermAssetsMember_9f6979b9-5422-449f-9af6-bca47fafadc2_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember" xlink:href="exel-20220701.xsd#exel_OtherLongtermAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember" xlink:to="lab_exel_OtherLongtermAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_71218b78-dae0-4bab-95f4-e9380f2d865a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_aa482e50-3db8-4532-8628-04c8b3a29a34_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ffde5baf-c54e-479b-a646-fafab5769cdc_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a5f8cb98-c916-480b-8f95-4811724b462f_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_eaa4aec1-2ae7-494f-975f-31642c503687_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:href="exel-20220701.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fdfc70f7-fe3d-4230-a9e4-a3b5d5cb3d15_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2f609246-d694-4d1d-b849-3fd17ab1b99e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2c3c6c62-34fd-4b45-86d8-60e9b0b0a82c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a5dbdab2-65b0-4d65-8963-b7fa0034f80e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_dcc4e927-c2a9-41b8-84cd-d3411a5277fa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_ef4ad6cd-4926-448b-a45e-ee1f69fde1c1_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember" xlink:href="exel-20220701.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember" xlink:to="lab_exel_AllowanceForProductRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_eb4292fc-dcca-4001-9b22-7bb7e0313249_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b4fdfcf5-bc10-4c49-ad0d-5388cf9dbadc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_ecf6678d-e634-4ede-b08b-70daa275e34e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_247a5ebf-e24d-4f12-a4f4-44b82d1bb81f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c805a62d-d73b-44d8-a344-80f8f180731a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting award percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_e5676016-0eb9-489d-866c-70ea26e671da_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_ce10f93b-c0e1-4872-ad32-f19f143c425d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_9053bb6b-f358-4514-bc70-ac1707b0f7e9_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivative instruments, pretax</link:label>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_label_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Derivative Instruments, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:to="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd418875-36f0-47a7-9e15-3eaa170bbb84_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_06d73f30-663c-476c-a22b-dd70c0a9459c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fee94f01-6ef8-4a57-a396-429defa862ac_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_633a78b9-278b-4ab8-bff0-040faf3fae0e_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate regulatory milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_b369caa7-33a7-4ae0-ba47-92b42e02139f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_fd2f10c5-6e55-415e-bf6c-615a9e693dee_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_79f295ab-247c-443b-8662-e4e0fbd7d8ec_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_60928323-ad8d-44bc-86ad-b788cfd14a41_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b3169a01-59af-4e77-9e09-973ac7cc9ae2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a3bd1390-2e45-49db-a8b2-6cfda474a300_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_9d85c9ed-bdaa-475f-9923-55dce633aa5e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ffdcd73e-a067-47a6-af81-1ffd8ae6977d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationMember_82afc632-f34b-4de6-b21b-5f62419ec434_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_label_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_documentation_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember" xlink:href="exel-20220701.xsd#exel_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember" xlink:to="lab_exel_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_26652e1f-4f4b-44cb-b564-c7fdd59cdf21_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1a2e0913-bb23-4476-9c5d-10c0c48f703a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_71835f86-1d00-45e9-baa0-71d2960fdc79_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_36d9d23f-4203-400d-bdaf-6a1117cb6eb4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_98e8f80f-826b-4332-98a4-3b5c6467ea73_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_28c1b3d7-9135-419b-aa50-5aae480435a7_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2823fe54-597d-4d51-9d57-8109a73ccc53_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_7acd2d5f-5e61-4695-a680-888938ef31b0_terseLabel_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer, regulatory milestone probable of achievement</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_label_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer Regulatory Milestone Probable Of Achievement</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_documentation_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer Regulatory Milestone Probable Of Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" xlink:href="exel-20220701.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" xlink:to="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75666f74-ffff-4288-b1e0-44d32fb43e6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_01481c10-a88c-4db5-8a48-d201e94b5bb7_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7d23ab57-5970-44c1-85e8-81f78b0bd5b4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6e37ab2d-5107-42f6-aeff-00484a22505f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2443721b-39c8-4496-822d-0809f9c61958_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7a46ca3c-4836-401f-bf37-49cefc52d933_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_5f4cfafc-3a6c-4e74-abe8-4461d84b2939_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_49345afc-ee99-460f-98af-f325f0913f4b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_27f28eae-4701-43e0-a176-57ab603198d4_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b011164f-c622-4e06-b932-09b10914ca62_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ac462220-0227-4f77-8700-0755bde2ecab_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_add0a979-619b-4515-8ed0-ed46b11b9199_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fac0255c-04fb-4bf9-870d-30df37736813_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_8d07661b-b6c7-4e7d-9424-ba90a7229903_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after stock option or stock appreciation award (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:href="exel-20220701.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_2d4938a8-9f7b-482f-80b2-1ed696cbfc9e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_bd59ad24-7a21-49eb-ad7e-6297d871b3a4_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:href="exel-20220701.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7418b165-f805-4877-9a21-9095ae1d2b71_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_dbe1f235-680e-4a2c-a0c6-d9c7b5c881b5_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:href="exel-20220701.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_66739fc5-5640-4373-be21-e9f09a2e8f78_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseArrangementsDomain_281473e6-0157-4bc3-94d9-ba4e0ae67f2f_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_label_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain" xlink:href="exel-20220701.xsd#exel_LeaseArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsDomain" xlink:to="lab_exel_LeaseArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyalPharmaMember_9e08f172-8547-410d-9a73-0b8042341d6f_terseLabel_en-US" xlink:label="lab_exel_RoyalPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharma</link:label>
    <link:label id="lab_exel_RoyalPharmaMember_label_en-US" xlink:label="lab_exel_RoyalPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharma [Member]</link:label>
    <link:label id="lab_exel_RoyalPharmaMember_documentation_en-US" xlink:label="lab_exel_RoyalPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyalPharmaMember" xlink:href="exel-20220701.xsd#exel_RoyalPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyalPharmaMember" xlink:to="lab_exel_RoyalPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d75c78cc-c8f6-44b0-a563-218d49e9c6f7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_0e6658e1-0f23-4d42-a90d-e302b041fd3a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_77b7806d-e3ab-496b-8bf5-6c32ecda30dc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3b98ac7c-f3a2-474a-9c24-3c05a2c7334d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_04d423b8-6afa-446b-9c50-8022ab83e2d2_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base rent, lease not yet commenced, annual percentage increase</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:href="exel-20220701.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_2d027d70-f17d-4b1e-9169-239f053eeb1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_e230dc81-7d75-4253-9869-9be33b66131e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_32c2da00-5633-4c53-ad5b-e46e4f9f23fb_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_789e407b-3d99-4297-bc51-84503a85e247_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ef3e1a78-bb1f-496c-bbed-0fa416a3e528_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3747ee3b-bc65-49e3-9e7f-134907d9ec91_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_46ec9d15-4c52-47fc-aebb-b3613675703c_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_883606cd-55ad-45d9-9aef-0ab0428e4f45_terseLabel_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</link:label>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_label_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member]</link:label>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:href="exel-20220701.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:to="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_495a95a8-e20d-4f40-875e-a29a27fc0bad_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_506b58da-da41-4158-9809-d6a7998de75c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_127a4e5a-2b10-4476-9c3a-fd143051bc7e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_ea5bcc70-a8be-43f1-a89a-f2f158555087_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:href="exel-20220701.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4eefd3f6-6a67-448d-ac9e-763bb44a689e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_215e670c-2ec6-4caf-8750-79f2e6ab0dea_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b7482e69-29ee-4eb1-86aa-009f8f07869e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_6f49d6ef-ac3e-4b03-a7fe-2a50e8158ab9_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_d48233ee-793d-4eb9-b170-b78f2b7d7427_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_f78333af-e04b-43ea-bf0d-4442a1573b30_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_83b546ae-3178-463c-892c-c9dfc222eab1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_ef9ea98e-46ed-4fa4-b6c8-24505e23a0f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382577d8-6785-42c4-b0ae-1016d80f5be0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_c4f713c6-9f3d-4d93-be03-2c7efeacbb2f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember_a0b0de63-f1f6-4131-9d9e-b59bc8ec598d_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with BioInvent, Option And License</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember_label_en-US" xlink:label="lab_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With BioInvent, Option And License [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With BioInvent, Option And License</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember" xlink:href="exel-20220701.xsd#exel_CollaborationAgreementWithBioInventOptionAndLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember" xlink:to="lab_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_6434c747-b83a-4efd-b746-75e29805e00a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_35a48923-1963-47d8-915a-e322f7e019f6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_eff6d3a3-c16e-4685-8770-ce9275f4ae1d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_55687a01-0407-4745-94f5-da46f1403f04_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NoncashLeaseExpense_9047ec02-e4bc-4b49-8b66-decb055b9080_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense" xlink:href="exel-20220701.xsd#exel_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense" xlink:to="lab_exel_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f38e4dc8-50a4-41ad-a0cb-14f92541ec33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab58331c-1d6b-4474-8948-f707e65e6ec0_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_83844bdb-05d2-4820-87ed-64936829e49d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_69a7c906-6d04-4628-8dc2-737cbd945bda_terseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inclusive of operating lease liability</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_c15fef55-d5a8-4cf8-9cf5-308aca63cd20_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_b740faaf-7e42-4abe-875a-d52e6c884023_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a9894aa8-b10e-4d4b-aebd-b859351f289b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f337ab3e-920e-4c21-ba23-0e4fe6e67fb0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e6f5c39d-b50a-4460-9c4c-26765cd8a903_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_84630e85-1b90-494a-8db6-129d46a7c8a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_22992778-639d-4470-bec3-816a32aa5f39_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c93ab852-8be3-4161-9640-371fa497866e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_9007a0f2-4adc-47cf-a456-9ad919be9f2b_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Company's common stock on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_ae9df4a4-0a3d-4a81-97f4-e9f1fef8be45_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_449779fd-4889-4c2d-b547-ad42082d97c3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_71915820-bf8f-4f87-bcde-52dbb4352966_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_d3b23f85-7392-4ea9-b768-e509b9f898cb_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8a03e2ea-b41e-4a59-a16f-39d31d62da47_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_d5945f0d-caf3-447d-89a2-4fe85d319a7c_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a48c1422-7e98-4e62-8290-fea3c410417e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04cc9bd6-8585-401f-a795-3274f51298a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_532547bb-507b-4f16-8480-4499fde70c40_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59570618-99f0-43e5-96de-c6896a3cc671_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ff44653e-53f6-4abf-b9bc-b257b644cbab_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1ef6f551-3826-4f8e-b055-c01d9936eb46_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37fc1416-fa85-4ab9-83f3-d5b59face32c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1edab2a8-804f-4d49-a625-ac9769463f26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_46201cdd-a469-4ee3-bdb9-c1b9d8f3f639_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_9a796de6-d9eb-4b68-a5b8-0bc9b0ce697f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_e0535bcd-4c47-4b9c-beab-3ad35b933cde_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_b3f552f5-99bb-4e6a-a42b-2263de530eed_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_4226ba32-5b26-4701-879a-0fbc8c5d783f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_46485a39-db3f-4ab2-9485-3f4940493749_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in share reserve under 2017 plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1568896c-473e-4891-94d7-e6b03601f8f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROVISION FOR INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_7e7adeb4-c558-4897-b757-5be82ba838d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019d3244-168f-4ecf-96cb-75a923b91db3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bbbae6c7-90ef-412a-b74c-9466993ce452_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_2f5f60e0-bdea-4562-a5ab-75205a827c14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_4b191d76-718d-4f89-afb7-211716fd56e0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6555ec37-7a3a-4855-b188-cbf13e072be6_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3f94f3cd-3e6b-4f22-a977-3bcaa2b19f6a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9dc90b39-ca23-44c1-b1bc-96f24e63445a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d0afa005-d68f-4137-92c8-0b4e05fd2302_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_71f49837-6f8d-4de8-97a1-2c5604d261b0_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f5da109e-0c2e-41e1-b98d-9b173d761e2d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_63e96074-d88f-4873-9520-edc1c8c1b695_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b4afea93-54f4-49c6-bcfb-f500fd6ecf1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_6ad92792-ae18-4042-a431-972eacebcb2c_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5c4eaa01-b6f8-41f8-a04c-3889289bbde7_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_82462410-c933-4fee-aa86-2a928ea45454_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_13ec49eb-3ef8-4ffd-82d6-9caec065cf5f_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:href="exel-20220701.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4a1c2c4f-7dae-42fe-a129-9f11721ea078_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_620ab555-7812-4799-bdc5-2832b09ab78b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_699ed41b-153c-4db6-8086-ac4f20e3989c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_eaadefef-813d-489a-b860-6a44ba37d64b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_d348d6a3-a703-41c6-928c-85d4ff7117b9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive plans and stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_e1d31f11-3cb4-477b-b959-06618ef94f30_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend the lease</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="exel-20220701.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12418d72-0bde-450b-914c-d13ea8844616_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a3a2f48f-0854-4faf-89ff-3ed1d17d73df_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_51daea1c-4829-485d-9634-eeff6c8a100a_terseLabel_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_label_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_documentation_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TenantLeaseImprovementsAllowance" xlink:href="exel-20220701.xsd#exel_TenantLeaseImprovementsAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TenantLeaseImprovementsAllowance" xlink:to="lab_exel_TenantLeaseImprovementsAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_40bfef6f-d61f-418b-a744-b000efe66c75_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_51a94651-ec03-41cf-bebc-70656bf29005_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease option to extend period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_148cb8bf-1829-4f5f-a89a-f5f62dcf0ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_df851e2e-7909-4881-a0f4-362a1563dd1d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_828b0e65-3042-4383-8eb8-3569e5fb94a4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_42867f47-3bc6-4e09-b7ae-a20d67f1ac21_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_68f1a678-1c6e-483d-bc4e-2ab0c1b735da_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CometriqMember_15b453c3-8f24-4599-b9ef-031436fb2e76_terseLabel_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_label_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_documentation_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember" xlink:href="exel-20220701.xsd#exel_CometriqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember" xlink:to="lab_exel_CometriqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_c9f0199e-4acb-4e9a-bdc6-9fcb3217d00b_negatedTerseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_924d4ff2-66d2-4ba0-abd3-4bd9a958bbbd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues Disaggregated by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1cdba2a9-17e5-4f8d-b1d1-6fdb95dba241_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_3ad0d12d-e9ee-4229-85c5-6e41724025e2_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_870a7f75-4d8f-4e34-a363-0e852c47297b_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5b520be0-c677-4909-8e6e-885dbd968823_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_4b38dd7a-79ff-4ed2-855a-fed51ca59ba1_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting from discovery efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:href="exel-20220701.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_acaf2f04-1468-4eb3-b549-63563f75a729_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_c59406ad-fd2c-424d-bf6c-e3008e9f4d86_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_49f6b48f-8a25-439b-b65b-91ae86f83b99_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a61d1b85-a46f-4765-8638-539df76e3209_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseExpansionMember_53b01e7e-acd8-4572-ad7a-6809d0728647_terseLabel_en-US" xlink:label="lab_exel_LeaseExpansionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1751 Expansion Space</link:label>
    <link:label id="lab_exel_LeaseExpansionMember_label_en-US" xlink:label="lab_exel_LeaseExpansionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Expansion [Member]</link:label>
    <link:label id="lab_exel_LeaseExpansionMember_documentation_en-US" xlink:label="lab_exel_LeaseExpansionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Expansion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseExpansionMember" xlink:href="exel-20220701.xsd#exel_LeaseExpansionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseExpansionMember" xlink:to="lab_exel_LeaseExpansionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4dbe3e65-0761-42cf-bc35-f827c718c294_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_66d3ee04-9c53-4ca2-aa15-4b14aad55fb4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0fae60ee-eb1c-4806-ba07-e3fedd2d11b3_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_8648cca3-61ef-4dd6-87c0-dc21985b825f_terseLabel_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries with drug approval, excluding the u.s.</link:label>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_label_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries With Drug Approval, Excluding The U.S.</link:label>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_documentation_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries With Drug Approval, Excluding The U.S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:href="exel-20220701.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:to="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductGrossMember_cd434c5a-6d39-4edf-8771-f0b364fd7bf8_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_label_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_documentation_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember" xlink:href="exel-20220701.xsd#exel_ProductGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember" xlink:to="lab_exel_ProductGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a6cd8e1a-f8c0-4d12-9821-b62b2387bad5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_97511ab9-1c5e-442e-ae06-c3c0b1d68e0c_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_23f910a6-ce6a-40c4-b639-fcc5e08b5f9c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_fadb6d3e-8979-4c90-bd22-e7fb11b788fe_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_d9149673-328a-4f17-a40a-86cbded15237_netLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8c2c95ac-2021-4369-867c-8532cbedb3e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_2a5607ec-1f20-4143-af31-64a1bc5eb5be_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c0f7e122-1309-4792-a620-f3f31864bd25_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CardinalHealthMember_14c95462-ad2e-4565-afba-b9fc2198379b_terseLabel_en-US" xlink:label="lab_exel_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health</link:label>
    <link:label id="lab_exel_CardinalHealthMember_label_en-US" xlink:label="lab_exel_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health [Member]</link:label>
    <link:label id="lab_exel_CardinalHealthMember_documentation_en-US" xlink:label="lab_exel_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CardinalHealthMember" xlink:href="exel-20220701.xsd#exel_CardinalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CardinalHealthMember" xlink:to="lab_exel_CardinalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2aed1f46-f208-47aa-8a40-1e20a8692d4e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c1a8ed86-e38d-4499-b2b6-27c995744796_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_e58d873f-0ba5-47c9-a156-ba9c1ebcc0f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_8286f275-26c0-4df3-9ef7-36ff98d90d90_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, upfront payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5c8c23c3-fcca-4c91-a990-097ce3264414_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fa65b363-490b-464d-b170-1d0ec860d248_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8da23b35-b33c-4c8b-b519-cc74934ba724_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_294afc0e-9737-4814-a37d-aa99c7bd248c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0704a092-7511-4194-8526-8bd86384df9a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a98649d6-84d5-4700-93dc-6c3f2a4e7ee6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0e400cf3-30ca-4d46-9049-b4b3d8cf9628_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_ebc5e95f-6f3c-4984-a9fa-90e5adb91a06_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_a2a56dd6-8997-480a-ad7e-ed917bce1b67_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_92bb563e-3c38-4585-83b9-9625b1f0a242_verboseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_fedf8ac6-5489-4b29-8750-145d418fadbe_netLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_0653666b-b985-43dd-a2de-44637fdd6038_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_baff80a0-cabf-4d7e-80d4-0d2726380c84_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CotellicMember_25ec151e-fe11-457b-898e-3ffaba476b09_terseLabel_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic</link:label>
    <link:label id="lab_exel_CotellicMember_label_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_documentation_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember" xlink:href="exel-20220701.xsd#exel_CotellicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember" xlink:to="lab_exel_CotellicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8a0fe21b-f204-423f-a9ff-0fd168eb9861_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_00d4128e-c618-4663-8e53-e6d2ce90ab03_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f860d32-01aa-41a1-aa10-1f31edc0d2cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_615f77ef-3b48-4518-b969-2a2bd34cf023_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_981338d6-eb69-4a4d-8a35-52dcffbc9d59_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_edab4263-8322-400f-baff-d6f6b91206c2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8ec5eb3e-f3ef-44b5-b6fc-126aaa10a73d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_64bf7811-0681-48a1-9ee6-758f957cb234_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4693a06a-39fe-48cb-ba84-f0ecda80cd68_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_c4982949-0b05-4f72-ad29-c5ce3610ee77_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_18797649-2fd9-4a7d-bdbc-694b364cc070_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bfa67808-338a-44e8-9ec8-0ac455179be4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a975ce48-d6f9-4a86-81a6-3e45ae1e037f_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7bedac20-b768-42c5-8209-98799d54d5b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_c850909c-8eb3-4ccf-bdfc-dc0e183f1e15_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred in asset acquisition</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_717283c5-b0f0-4900-86b9-7ac3d7c09b3b_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:href="exel-20220701.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_48c6dcb4-f124-499c-9ecd-66412ae5d12a_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue recognized, including revenue from deferred revenue beginning balance</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="exel-20220701.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3e3c6654-cae4-4731-8493-736cba8fb970_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a23546ad-34fb-48ef-9926-fded427f6945_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_17480749-86c2-4f46-8ef1-b4d0794715c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_cd199868-75c3-4591-80ac-27a5a29730bc_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31c91ffe-e6be-4519-a0ee-6e982877d7b8_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:href="exel-20220701.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4fe466ec-6c67-45bd-b108-ff87fbd9cc11_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 321,800 and 318,842 at June&#160;30, 2022, and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_da03221b-75cd-44ca-93ab-86fd1e925720_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:href="exel-20220701.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_36c160eb-20a5-4c5a-8ee2-e7d4102771e3_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:href="exel-20220701.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7742b4f0-66eb-4fd6-9d57-d607d7c005e2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8a2106e4-10c9-45a6-bcb5-700ee92cec31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_ea620c8f-2e9c-4e5e-96e8-88d1eb4c3761_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated monthly base rent under Build-to-Suite leases</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:href="exel-20220701.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_fd0d6f10-e40b-4470-bac9-4809968fd3ae_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a0c3a149-e294-425b-860a-21f5d6d093e2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_013041ea-ac28-4673-bcf2-1e618e4057dc_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a75a0f1-eefb-48c2-96ac-378e193238df_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_64c6c0cd-d5b4-41b8-bf3a-9d1c76a88087_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_088bf764-a59b-491c-bed3-8207f09022fe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e52bdb4b-e5c7-4060-9fec-b53a9e7584d5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income, Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_35b291d7-13b6-4a98-bf1d-4dd8bdd5ae7c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_89ff801b-467a-431f-bc11-8f50b92bbc05_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_b568f275-7b73-47d7-84bd-4a6c64fab1a9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_b066b17f-981b-4d3d-ad42-2e7944cc7fb7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_be50b5e9-f0a0-4d82-af95-de2a8586da04_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1b943e61-05f9-47cd-8919-59ac1a207dd2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_03f6a8e0-a875-4702-b223-500878d7a569_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbb59ff0-f549-41ac-8df4-d74eea73d70d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b332dc01-412b-42ad-8d78-2afca3724087_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_72e76a11-9835-46ed-95c1-1e58bd6e0296_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_517a9f43-3a59-458b-b23d-7b05033898b5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d539bbef-6e35-4615-bff1-73c31cfed4a4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_96704c0e-e426-4bd9-a19d-0ebf322bd0d8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3b40d01d-18c2-4568-b8d2-a8def5f62035_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6485aaf1-9741-46e5-a369-41c7382263b8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f201ba38-94be-4e6e-b6a8-f5c1393de9d6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9ae2581b-b2a4-4d5c-ac26-e0540d48b2f6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_93793d10-5810-40df-84ba-04bcebf622db_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_34fd7ee5-2845-48f1-86b0-2e687c006708_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_41fc9e93-ba41-4211-8246-6543727ba9b5_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Collaboration Liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Collaboration Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:href="exel-20220701.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:to="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_0ec2953c-644d-4fd8-8b0e-80ce415d0ee3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_946ac459-e3b3-4962-a99b-96683ae3e682_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_17fb8dc7-f81c-4990-9552-e770b36aad0e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d3de1f14-7073-4306-9fdb-c5927b5eb631_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_903a36af-dcb9-4e75-99c3-74bfa6f619c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_5faa0981-885b-41cd-bedf-f6242ac7000c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_4f5d1d73-a895-49de-aca7-602bd08ea900_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0dab15b0-a13f-4c3d-b05a-ed6b09084630_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ecfa2c80-c2e4-426b-930e-51c2e040a6a7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_ee06255e-41e0-46d0-a3b7-93058225ca21_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket" xlink:href="exel-20220701.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket" xlink:to="lab_exel_NumberofProductsinCommercialMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_945bce7d-8248-41ac-a7af-0093606a8976_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_aef17b73-469c-4ad4-b26c-e57c1076e46b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_b26dc1f9-006d-4a95-905a-a2e4cc4fac29_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductOrServiceAxisDomain_77b02d19-c734-4d59-b8fc-eed04bcce070_terseLabel_en-US" xlink:label="lab_exel_ProductOrServiceAxisDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Domain]</link:label>
    <link:label id="lab_exel_ProductOrServiceAxisDomain_label_en-US" xlink:label="lab_exel_ProductOrServiceAxisDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Domain]</link:label>
    <link:label id="lab_exel_ProductOrServiceAxisDomain_documentation_en-US" xlink:label="lab_exel_ProductOrServiceAxisDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisDomain" xlink:href="exel-20220701.xsd#exel_ProductOrServiceAxisDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductOrServiceAxisDomain" xlink:to="lab_exel_ProductOrServiceAxisDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3f028aef-7bb1-410c-a408-04cb9494725b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_195207e9-58ac-47ee-b030-7997003cfe73_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_cd29f634-1ddc-4b74-b969-74badd4fdcb9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_13c32e6b-cb68-407f-a71a-2224dc3e608e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4793415c-d61d-49a0-a657-7bdd5811c72a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e89c4430-f504-466d-a363-50772734d2a9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e7c40ca6-0197-48f9-952c-98acc2a059ca_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CabometyxMember_bc07a25f-bae2-428a-9914-19c5cb52ee3e_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_label_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_documentation_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember" xlink:href="exel-20220701.xsd#exel_CabometyxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember" xlink:to="lab_exel_CabometyxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_0c8af6ad-bc21-45a8-81a8-5b762c6a9af6_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_43815fba-80b5-4e11-bffe-674b642ea04f_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after all other awards (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:href="exel-20220701.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_964231e7-cc15-4dbf-9b5a-5893c86dbd7e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_38296ceb-e5dc-411e-8f1b-b707f8e451be_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_a5c1215d-7812-4af2-97c4-f349c3197012_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_84ad27ce-c4f4-4324-a9b6-696220e8ac6f_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e7cfd7ce-3deb-4ac3-b19f-d00e58b65c90_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_cc59e0c1-124c-47ab-9c1d-e5d904577d87_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8b52b11a-372a-4564-8e36-cdf94952fcd8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenues recognized included in the beginning contract liability balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_05d815ff-f7fa-4834-8142-cfa79c7172cd_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_b72e324c-ab61-425e-98a8-52b7341a577c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7ddfcef2-ddfe-48a3-baa8-883cb778d61b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_6cca9dec-cd4b-4e37-9a53-b3d6ef588332_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_265ef81c-122e-4cfc-926e-0a312b65782c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4a2da279-99aa-4bba-ad60-5d027d809bbb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_cc1582cf-022a-4775-980c-4aa02038f6a5_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:href="exel-20220701.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_3d3ac49f-57bf-49b8-93d0-e861543d9759_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_2733f20b-5ba1-4fbf-a22d-f23ece5d6ecf_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration Risks</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_3b7094f2-1ad8-4e30-97a2-ea6a7f20b68d_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:href="exel-20220701.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_d0520c95-751f-4383-9dbd-74be70b3067e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d9adcfc0-7254-4413-b2a6-6f0829098eae_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_090c8372-ba1e-4435-982d-916cfbe35c40_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_6cc96624-271d-4263-840d-94cdbba2f883_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6ade586b-0122-4e86-9354-17db74a93689_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_2eb07e08-dd9d-4bf4-b1bc-e4e21b661efe_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to terminate lease (after period)</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:href="exel-20220701.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:to="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_9a64693e-35e0-494d-9264-f2783027f6c5_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts for Prompt Payment and Other</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:href="exel-20220701.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_97eade32-b704-4a2b-87c9-517a421d2286_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7666e87e-8dc1-420f-b766-3c645487ace9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_1ee5df70-2ff1-4dcc-9c5e-7278a16e7cc4_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:href="exel-20220701.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b96b8b11-750e-4c3e-ab1b-6d549cd6ff65_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:href="exel-20220701.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_90d8d00a-7585-4c7e-b57b-4eeab8d222c7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_af1f4f4c-213c-4db4-b57a-6d9e77c1b165_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at June&#160;30, 2022</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_02c57e33-9867-4924-9d43-88f8950f3479_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6c12ac63-0214-4f8c-88b1-d49501c69d07_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35cee785-53b9-4b38-a187-a7d92e40f936_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dc18f0e1-0d24-4d9b-94e2-1ad68f5b3c80_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1be30032-7f7d-41e3-887f-794e7b7d30bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fe0eb9dd-73b3-452e-aa69-9ba6a502a69e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_64172d13-996d-41dd-ad96-a6663f1f242a_terseLabel_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="exel-20220701.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9563356f-7caf-4579-b068-f95d1c4baa86_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2d4b9f91-71e2-4bd9-9b5e-302301718e7c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7ebfdc80-52f3-4c30-b369-e52aca149aab_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_3474af75-e19a-471e-9cfb-d9df62cb199a_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5a4fc0a2-4137-4556-9310-8768a59f0240_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_058f2f04-a529-46b0-8ae6-ce0d976970fb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_086fcf36-6a31-44c8-a61f-fedd0fc2476a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_b037e2d3-7195-4a96-9f2b-5a7e6486fb12_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_955e03b0-b868-4ab6-b681-00f582e849d0_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8ecc7378-9924-4eac-b59a-d843f4770f2e_netLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a8cb3a42-abb1-4244-bfc9-a969e5dfc01f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e084f1b1-bd3d-4a9b-8fa5-d30015593657_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9b43ccdb-c945-42c2-8f4d-fe5dd7f031c7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_3f5425b2-7f4a-41d4-9962-76fdc7050ec6_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_add5aad1-e272-4393-bc09-177b46ba54e5_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_ba9e15c6-23a8-4939-a0fa-7b34ff479cd0_netLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_0c47fed1-d4be-4c5f-8bf1-6331e6734653_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e5e66d36-f0a1-4d6d-b8b4-5d4744eccf5c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a36d7b8b-39a3-43c4-b990-3006e0a9094a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6676932-ee07-4a83-88db-086af9c3119a_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f0b2e24a-ad7c-4467-a3f2-362050b2e0fd_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues on ex-U.S. sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_faefde96-cf70-490f-85f9-a496d783ab6c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_82b5cc2b-fc17-4146-ab3b-3fc9329b1ccd_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ec646baf-037f-40a5-95f6-61c4d71cc4d5_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0e0751ac-eae6-4d7b-8984-9cf94973a897_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_22daf424-1b88-4a58-80d3-5f4aadecab8c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_74ed996c-9f9c-46bd-b1d2-6dc892d995a9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_53f6165b-dc21-48e8-ab79-2bbd81b6cf12_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_66e60540-8392-4b60-8007-9f56580add62_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential to vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:href="exel-20220701.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:to="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9d3bdebc-3203-4c5c-ab88-e4438a6a9b3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a480b9e4-46aa-4298-8d08-a9e81660c977_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f9949184-eca6-454e-95b8-b1f6b70fad97_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_bbcfc2f1-1a54-430c-889b-46c38238731e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_ae066ca8-ff8b-4c5c-a3b6-af89e1bcc921_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_59611275-71fc-47af-9b93-b9014c165e19_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5bbe5300-6c18-4eaf-ad6d-13d0d564c8da_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LossContingencyNumberOfLawsuitsConsolidated_ebaf4f7b-a0f5-410f-b583-8100f7d17efb_terseLabel_en-US" xlink:label="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_exel_LossContingencyNumberOfLawsuitsConsolidated_label_en-US" xlink:label="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Lawsuits Consolidated</link:label>
    <link:label id="lab_exel_LossContingencyNumberOfLawsuitsConsolidated_documentation_en-US" xlink:label="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Lawsuits Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:href="exel-20220701.xsd#exel_LossContingencyNumberOfLawsuitsConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:to="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6b473f27-c825-4ba8-aa53-c514e802a307_negatedTotalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fe6c05b8-afec-4f1b-a471-8f5d52d7f2ba_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ebf5ee07-5948-4899-9bfd-8ee4ed7a93ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_6b7e735e-8e6c-4486-8c48-8ef370a36dc9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3ebf1517-9d13-48e1-886b-25d6d64005db_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_93eb255f-1e83-46ad-9bfc-db390dc11148_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income, Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_df3ccd91-8d5e-4d50-ad56-e5e4907ac517_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a1c2c58c-0282-4674-808c-21ca54371759_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_57736310-8cf1-456d-9cad-309ac59870bf_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_856b209f-7812-4c65-b753-3058499dfe07_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2737d4d4-b11c-48b9-b4fe-665c3adc27f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9b5ca7e7-b1c8-4631-bc13-d20f8633a719_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_93c3e746-90b1-4f72-964e-9eec3c7fe87e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3c63ea0b-61f5-4fe8-a6e3-a34188c4c8ed_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_c6fbdd25-eaeb-4dfc-a0f8-54e8d88b7129_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid_4edc133c-d9d2-4431-8431-bf0ad9bfe1b9_terseLabel_en-US" xlink:label="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred for unsettled investment purchases</link:label>
    <link:label id="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid_label_en-US" xlink:label="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Purchases Incurred But Not Yet Paid</link:label>
    <link:label id="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Purchases Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:href="exel-20220701.xsd#exel_InvestmentsPurchasesIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:to="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_e9f847bd-b358-448b-a030-c420f987fc81_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TakedaAndIspenMember_85099ebe-3b14-4bf0-ab72-7c2cd65de58d_terseLabel_en-US" xlink:label="lab_exel_TakedaAndIspenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda And Ispen</link:label>
    <link:label id="lab_exel_TakedaAndIspenMember_label_en-US" xlink:label="lab_exel_TakedaAndIspenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda And Ispen [Member]</link:label>
    <link:label id="lab_exel_TakedaAndIspenMember_documentation_en-US" xlink:label="lab_exel_TakedaAndIspenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda And Ispen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaAndIspenMember" xlink:href="exel-20220701.xsd#exel_TakedaAndIspenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TakedaAndIspenMember" xlink:to="lab_exel_TakedaAndIspenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_104d581d-a5f1-4f8b-b70e-56533bcd73d0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_b5e876f3-f11d-4a02-bbb7-47faeb8f41c4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_570ebe71-c8b0-4979-8428-c89f0bd1e043_terseLabel_en-US" xlink:label="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease And Headquarters Lease</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_label_en-US" xlink:label="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease And Headquarters Lease [Member]</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_documentation_en-US" xlink:label="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" xlink:href="exel-20220701.xsd#exel_BuiltToSuitLeaseAndHeadquartersLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" xlink:to="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_854ea47a-bbb6-4fa8-afb1-514922afd973_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_eaa8d05a-2489-41cf-ac7c-de73f775cdf0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_01f06c63-93e1-4831-acf8-189c653175c7_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_6118b447-9f6f-4e41-9055-78b2bc85242e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_36463358-ebf9-455b-8a61-4ef81a546c19_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_25732a3e-15d9-49e7-aa25-eacdd81de449_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseArrangementsAxis_e317c628-c87f-422b-b676-f5621fc7e8e6_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_label_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis" xlink:href="exel-20220701.xsd#exel_LeaseArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsAxis" xlink:to="lab_exel_LeaseArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_13a7e566-cd33-4124-94b8-eb4c84debf0a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_16408b1b-a7c7-44b5-8410-391183ee6389_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized losses on available-for-sale debt securities, net of tax impact of $639, $257, $2,295 and $756, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_b07134f5-ca7b-4e6e-89d6-98960e116ab5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_807e720f-2eff-4eaf-a845-e13bfc43f197_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e256ac2c-e53b-4a6f-afe2-870f23542f3e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_f88f102d-803c-404f-bb3f-1bd65620d8e9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1d7cf611-26c0-44f9-a68f-d3f992f5b590_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_4c57967d-749e-45c0-85e6-041c4cc5952f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim_302cd446-546f-410d-9ecb-103cf01af522_terseLabel_en-US" xlink:label="lab_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notice period for file a patent infringement claim</link:label>
    <link:label id="lab_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim_label_en-US" xlink:label="lab_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Days To File Patent Infringement Claim</link:label>
    <link:label id="lab_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim_documentation_en-US" xlink:label="lab_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Days To File Patent Infringement Claim</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim" xlink:href="exel-20220701.xsd#exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim" xlink:to="lab_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_d066397b-8036-4d86-9433-f27f667916d3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_eacf91fd-e69c-466c-840f-c21667fe6cf3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_e4290bf8-2fbc-4fea-a29c-7d253fcc0b67_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_492397d8-3c51-4828-9511-1544c94cb984_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_739ebc96-6f87-4f5b-89c9-b45eabd0540a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_10884b40-608a-4f68-9e92-2bd0be8bc2c3_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_d843d75d-187e-4110-84fb-3a33f03a91b8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets:</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_7f33f55e-972a-4b30-a099-24c237811dab_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember" xlink:href="exel-20220701.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember" xlink:to="lab_exel_AccredoHealthIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_020d17e4-abf3-49ca-95c4-7fe6c43b3676_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:href="exel-20220701.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a250cf42-cd95-413e-8789-691bf386bf6f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_91e775d2-125a-4927-89db-1d22219b7302_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_ea546b4c-ae31-410b-bb0d-cd47b120726c_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_6dae35ff-54dd-447a-a9b1-52f3066332d0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0033accf-c13d-4bfc-9682-c9daf9087f51_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_39545eff-0e89-432d-9af6-afaf13eda2fe_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_b5d79865-5410-458c-aed8-395457e319f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_c15a4983-fe9c-4872-b81f-c1818db8936d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb0dc3be-8c35-4f30-8117-2ebbf213b684_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_67f92e71-0309-42eb-a200-7f14965d7abf_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_6b4c69ea-3f67-4b1f-82af-f2558877e947_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_83ced3d7-0b69-49aa-9bb8-8b5a810b4ced_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_53f06232-a25c-47b3-89e2-4ddf2ce11069_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_90a4382d-367a-4975-b764-ede7b46b0376_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f78ad0aa-3151-4350-b1e0-1e01ca8ca4c0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd9cff2b-732d-412a-8653-4eb418cc2056_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5ed460c1-e2fc-4c7b-bc09-d57eacb5d829_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3fa73af8-bd4c-4045-8cf4-34de8624e047_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7d8268b5-d2a8-408e-a166-1677fb3d5b81_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TSRBasedRestrictedStockUnitsMember_16c9e7e6-9b25-4255-a2bf-5743360e0537_terseLabel_en-US" xlink:label="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR-Based Restricted Stock Units</link:label>
    <link:label id="lab_exel_TSRBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_exel_TSRBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember" xlink:href="exel-20220701.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TSRBasedRestrictedStockUnitsMember" xlink:to="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cf1a58cb-b1e3-4676-8032-8b8324e5841e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_005d0d16-76a2-4281-ae0f-2af17d485a84_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_c16fe568-37cf-4cf8-9cb0-f80d82899c06_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_120f2fef-59d9-4abd-9d79-066a0ad980c3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_48354afe-a389-4efa-b881-74e94fef068c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0b5532d1-177b-4a21-8a13-de5473e996ba_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_ad2012b7-895a-4982-b2e5-819ea3a713b6_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>exel-20220701_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d6428e21-a936-4304-bbd0-42287b684d9f,g:54041ba7-ffad-43a6-84f8-cd8da74de046-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20220701.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b687c9a0-799b-4258-962e-51ded613c54e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_DocumentType_b687c9a0-799b-4258-962e-51ded613c54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_18dddd69-f11b-4166-8e7c-a431fa0dc44e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_DocumentQuarterlyReport_18dddd69-f11b-4166-8e7c-a431fa0dc44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8e0979a8-c8ae-4179-903f-e53fbe958c3f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_DocumentPeriodEndDate_8e0979a8-c8ae-4179-903f-e53fbe958c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c0d1d0bc-608a-42db-826f-bb9450daf5d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_DocumentTransitionReport_c0d1d0bc-608a-42db-826f-bb9450daf5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_842b0d35-bd18-42dc-9c80-e4a9d6d6ef98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityFileNumber_842b0d35-bd18-42dc-9c80-e4a9d6d6ef98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3346faf6-a248-4b37-9775-8ccd9bd8ad6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityRegistrantName_3346faf6-a248-4b37-9775-8ccd9bd8ad6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9e1938ed-4976-465b-ae5f-dc8e8554c8a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9e1938ed-4976-465b-ae5f-dc8e8554c8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fcb99ccb-75a9-46bd-9640-287d4c40e4b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityTaxIdentificationNumber_fcb99ccb-75a9-46bd-9640-287d4c40e4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0e6052ce-23c1-4429-867e-a34b94d7a534" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityAddressAddressLine1_0e6052ce-23c1-4429-867e-a34b94d7a534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_edfb8e75-40da-4308-9611-e68279733273" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityAddressCityOrTown_edfb8e75-40da-4308-9611-e68279733273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b68b102a-8d2c-482a-a8f3-2e4b24e8cc26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityAddressStateOrProvince_b68b102a-8d2c-482a-a8f3-2e4b24e8cc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_64c45bef-5e6b-4407-8abf-cbbca5556909" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityAddressPostalZipCode_64c45bef-5e6b-4407-8abf-cbbca5556909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_00ac8c1e-fc61-4f51-8050-21b99fb9f854" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_CityAreaCode_00ac8c1e-fc61-4f51-8050-21b99fb9f854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b08b61f3-493f-43cb-8a5f-9f563cbde9d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_LocalPhoneNumber_b08b61f3-493f-43cb-8a5f-9f563cbde9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_68a60fd9-ec66-4a9b-8678-92e8f787f076" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_Security12bTitle_68a60fd9-ec66-4a9b-8678-92e8f787f076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_79e49f7d-67c2-4b81-9913-37ee7c1f9e74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_TradingSymbol_79e49f7d-67c2-4b81-9913-37ee7c1f9e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_eb6de43a-ee85-48ec-8b7a-076c5d923f00" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_SecurityExchangeName_eb6de43a-ee85-48ec-8b7a-076c5d923f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_416b9344-f196-49c1-9c4a-9bb7e11f5c26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityCurrentReportingStatus_416b9344-f196-49c1-9c4a-9bb7e11f5c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2d4514aa-41b6-428a-8045-a7598a01b778" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityInteractiveDataCurrent_2d4514aa-41b6-428a-8045-a7598a01b778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f9b8d8c5-84af-4884-8af8-928e80ffbef8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityFilerCategory_f9b8d8c5-84af-4884-8af8-928e80ffbef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ea8f8af7-dc73-4f7b-998b-622e8b27197a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntitySmallBusiness_ea8f8af7-dc73-4f7b-998b-622e8b27197a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2d9a622f-1354-44e1-90e8-ec083a3781bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityEmergingGrowthCompany_2d9a622f-1354-44e1-90e8-ec083a3781bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ba71a919-cd38-4bee-8350-0115d9dc25f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityShellCompany_ba71a919-cd38-4bee-8350-0115d9dc25f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b9a05442-93a2-40c8-9644-583ba96100d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b9a05442-93a2-40c8-9644-583ba96100d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c8af7149-b698-4874-959d-4af8f08f2b22" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_AmendmentFlag_c8af7149-b698-4874-959d-4af8f08f2b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2b83700a-7aff-4dae-b287-85acb784ec7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_DocumentFiscalYearFocus_2b83700a-7aff-4dae-b287-85acb784ec7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1935e3d0-1937-4451-b4b0-8dc3ca50aab4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1935e3d0-1937-4451-b4b0-8dc3ca50aab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_434c0164-fbf5-49df-b3b6-baac8bab8d29" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_EntityCentralIndexKey_434c0164-fbf5-49df-b3b6-baac8bab8d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8365cbb0-04e9-4987-bfd7-af731ca60d0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a74a69a9-fb78-484d-ba6a-38ae24cbd3c5" xlink:to="loc_dei_CurrentFiscalYearEndDate_8365cbb0-04e9-4987-bfd7-af731ca60d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f3fc579a-5649-4e87-9bb3-2938875e329c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3ded4bde-d811-4c24-b9c9-2b17515e8a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f3fc579a-5649-4e87-9bb3-2938875e329c" xlink:to="loc_us-gaap_AssetsAbstract_3ded4bde-d811-4c24-b9c9-2b17515e8a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bc9b52f6-4ba4-4db4-98a0-265cbce38295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ded4bde-d811-4c24-b9c9-2b17515e8a65" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bc9b52f6-4ba4-4db4-98a0-265cbce38295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c01af632-420b-4b8c-bc2c-aaef3eb1c305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc9b52f6-4ba4-4db4-98a0-265cbce38295" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c01af632-420b-4b8c-bc2c-aaef3eb1c305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_0b1dec7d-dd87-460a-a52c-13337a5006c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc9b52f6-4ba4-4db4-98a0-265cbce38295" xlink:to="loc_us-gaap_ShortTermInvestments_0b1dec7d-dd87-460a-a52c-13337a5006c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_e3d84670-f6ac-46bc-ae29-083821ff7759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc9b52f6-4ba4-4db4-98a0-265cbce38295" xlink:to="loc_us-gaap_ReceivablesNetCurrent_e3d84670-f6ac-46bc-ae29-083821ff7759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7c55f587-419a-427d-b488-b8c4d23f711b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc9b52f6-4ba4-4db4-98a0-265cbce38295" xlink:to="loc_us-gaap_InventoryNet_7c55f587-419a-427d-b488-b8c4d23f711b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d4b1003a-15f8-4a38-9df4-8135e9adcc24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc9b52f6-4ba4-4db4-98a0-265cbce38295" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d4b1003a-15f8-4a38-9df4-8135e9adcc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_85ce0c01-fd79-4957-abfb-88c7e99ce065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc9b52f6-4ba4-4db4-98a0-265cbce38295" xlink:to="loc_us-gaap_AssetsCurrent_85ce0c01-fd79-4957-abfb-88c7e99ce065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_5bf0da6d-af23-4f3a-b0c0-2f00fe80c80b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ded4bde-d811-4c24-b9c9-2b17515e8a65" xlink:to="loc_us-gaap_LongTermInvestments_5bf0da6d-af23-4f3a-b0c0-2f00fe80c80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a35ca842-9e0d-4d50-adb7-67c6cd289e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ded4bde-d811-4c24-b9c9-2b17515e8a65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a35ca842-9e0d-4d50-adb7-67c6cd289e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_029e1604-7e05-4c38-aae0-65a40afc64b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ded4bde-d811-4c24-b9c9-2b17515e8a65" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_029e1604-7e05-4c38-aae0-65a40afc64b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_097a9043-5049-4c48-84b2-baf5b0d2d9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ded4bde-d811-4c24-b9c9-2b17515e8a65" xlink:to="loc_us-gaap_Goodwill_097a9043-5049-4c48-84b2-baf5b0d2d9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f0f30e50-131e-4fd5-b0fe-8683482b588d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ded4bde-d811-4c24-b9c9-2b17515e8a65" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f0f30e50-131e-4fd5-b0fe-8683482b588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9f488174-37f5-42fc-8b0b-95f4745a55f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3ded4bde-d811-4c24-b9c9-2b17515e8a65" xlink:to="loc_us-gaap_Assets_9f488174-37f5-42fc-8b0b-95f4745a55f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ede6584-6b59-41be-8c50-3548763de455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f3fc579a-5649-4e87-9bb3-2938875e329c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ede6584-6b59-41be-8c50-3548763de455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e33a64ee-5f42-4d42-aeb1-8a9cac10c381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ede6584-6b59-41be-8c50-3548763de455" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e33a64ee-5f42-4d42-aeb1-8a9cac10c381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_22dc781a-44ae-44de-b799-21a8b2845bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e33a64ee-5f42-4d42-aeb1-8a9cac10c381" xlink:to="loc_us-gaap_AccountsPayableCurrent_22dc781a-44ae-44de-b799-21a8b2845bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1fd0705e-e765-4ea5-a660-42e4404d55ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e33a64ee-5f42-4d42-aeb1-8a9cac10c381" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1fd0705e-e765-4ea5-a660-42e4404d55ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_c8a37387-337b-40c2-bbbb-5651515ec046" xlink:href="exel-20220701.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e33a64ee-5f42-4d42-aeb1-8a9cac10c381" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_c8a37387-337b-40c2-bbbb-5651515ec046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_52a77e6b-2aa1-42ec-ab7a-ab1732509d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e33a64ee-5f42-4d42-aeb1-8a9cac10c381" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_52a77e6b-2aa1-42ec-ab7a-ab1732509d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_6ef8f19f-5278-4d5b-b14c-8370237fe669" xlink:href="exel-20220701.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e33a64ee-5f42-4d42-aeb1-8a9cac10c381" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_6ef8f19f-5278-4d5b-b14c-8370237fe669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cfba037f-ed29-4145-bddb-5fbf98bad520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e33a64ee-5f42-4d42-aeb1-8a9cac10c381" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cfba037f-ed29-4145-bddb-5fbf98bad520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_57383bec-96cc-472e-a450-ba7efe0ed7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e33a64ee-5f42-4d42-aeb1-8a9cac10c381" xlink:to="loc_us-gaap_LiabilitiesCurrent_57383bec-96cc-472e-a450-ba7efe0ed7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8f8ec703-1117-4fb3-a3ed-05ec6f3569d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ede6584-6b59-41be-8c50-3548763de455" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8f8ec703-1117-4fb3-a3ed-05ec6f3569d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ccbab885-18ff-425a-bbb2-e3b25571ef09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ede6584-6b59-41be-8c50-3548763de455" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ccbab885-18ff-425a-bbb2-e3b25571ef09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_116a6a56-d9c5-4831-9d89-dcb25e6cd2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ede6584-6b59-41be-8c50-3548763de455" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_116a6a56-d9c5-4831-9d89-dcb25e6cd2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_122f1ea7-c564-4648-84a3-ae173915045f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ede6584-6b59-41be-8c50-3548763de455" xlink:to="loc_us-gaap_Liabilities_122f1ea7-c564-4648-84a3-ae173915045f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_18f4884a-43d6-435b-8d70-112840c024d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ede6584-6b59-41be-8c50-3548763de455" xlink:to="loc_us-gaap_CommitmentsAndContingencies_18f4884a-43d6-435b-8d70-112840c024d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_05bbce39-a6cb-43a7-a06d-da9a52ec765d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ede6584-6b59-41be-8c50-3548763de455" xlink:to="loc_us-gaap_StockholdersEquityAbstract_05bbce39-a6cb-43a7-a06d-da9a52ec765d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bede7bfe-2176-4018-a12a-256082f51bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_05bbce39-a6cb-43a7-a06d-da9a52ec765d" xlink:to="loc_us-gaap_PreferredStockValue_bede7bfe-2176-4018-a12a-256082f51bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_875d7a60-80fc-4485-8dc2-56a857100a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_05bbce39-a6cb-43a7-a06d-da9a52ec765d" xlink:to="loc_us-gaap_CommonStockValue_875d7a60-80fc-4485-8dc2-56a857100a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3c03abcf-09a4-40e3-914a-e121b82257b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_05bbce39-a6cb-43a7-a06d-da9a52ec765d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3c03abcf-09a4-40e3-914a-e121b82257b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27cf2e80-57ce-4c66-98f2-2003bad19766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_05bbce39-a6cb-43a7-a06d-da9a52ec765d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27cf2e80-57ce-4c66-98f2-2003bad19766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6a4c2fc-04a3-4fd0-bb63-946cf28290b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_05bbce39-a6cb-43a7-a06d-da9a52ec765d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6a4c2fc-04a3-4fd0-bb63-946cf28290b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a9e92b87-0cd8-4460-8738-34e3756c4d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_05bbce39-a6cb-43a7-a06d-da9a52ec765d" xlink:to="loc_us-gaap_StockholdersEquity_a9e92b87-0cd8-4460-8738-34e3756c4d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1e714dc-6ad4-4d22-935e-816f77403c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ede6584-6b59-41be-8c50-3548763de455" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1e714dc-6ad4-4d22-935e-816f77403c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f40c0d15-604e-465f-a8f0-7a417d8f4666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2613d56-4fc5-4937-979f-92fea9c2b29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f40c0d15-604e-465f-a8f0-7a417d8f4666" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2613d56-4fc5-4937-979f-92fea9c2b29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_fac28b44-5312-4e6b-baf4-92358acda182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2613d56-4fc5-4937-979f-92fea9c2b29c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_fac28b44-5312-4e6b-baf4-92358acda182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3b64f9d7-f916-4fe7-ae4c-e9de90a1107e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fac28b44-5312-4e6b-baf4-92358acda182" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3b64f9d7-f916-4fe7-ae4c-e9de90a1107e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f4fc1a6-20fa-40da-9072-1b5e206285ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3b64f9d7-f916-4fe7-ae4c-e9de90a1107e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f4fc1a6-20fa-40da-9072-1b5e206285ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_653244bc-97cb-46ac-812e-4cbf00cb5d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3b64f9d7-f916-4fe7-ae4c-e9de90a1107e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_653244bc-97cb-46ac-812e-4cbf00cb5d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e8408933-35dd-40de-be4b-394d6e636512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3b64f9d7-f916-4fe7-ae4c-e9de90a1107e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e8408933-35dd-40de-be4b-394d6e636512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f24e6574-470b-4ee8-b95a-04f7a3a728a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fac28b44-5312-4e6b-baf4-92358acda182" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f24e6574-470b-4ee8-b95a-04f7a3a728a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_88e26ce7-c70c-4c68-ac86-f5f1e2e3cc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f24e6574-470b-4ee8-b95a-04f7a3a728a3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_88e26ce7-c70c-4c68-ac86-f5f1e2e3cc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20ffe5e3-3668-4ba4-b52d-bc16448ac2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f24e6574-470b-4ee8-b95a-04f7a3a728a3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_20ffe5e3-3668-4ba4-b52d-bc16448ac2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_af2cc874-d9dc-49ab-a852-0c5e5c9cb6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f24e6574-470b-4ee8-b95a-04f7a3a728a3" xlink:to="loc_us-gaap_CommonStockSharesIssued_af2cc874-d9dc-49ab-a852-0c5e5c9cb6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fdc68b78-bb33-40ef-9eb1-02b6b1529047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f24e6574-470b-4ee8-b95a-04f7a3a728a3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fdc68b78-bb33-40ef-9eb1-02b6b1529047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d8bbd77d-1de7-403d-b963-bb5b98c2a230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a9e33bbb-a4ab-4957-865e-929532f7d959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8bbd77d-1de7-403d-b963-bb5b98c2a230" xlink:to="loc_us-gaap_StatementTable_a9e33bbb-a4ab-4957-865e-929532f7d959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1eefb963-dfd3-4d5e-8ce2-062d53a9cdff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a9e33bbb-a4ab-4957-865e-929532f7d959" xlink:to="loc_srt_ProductOrServiceAxis_1eefb963-dfd3-4d5e-8ce2-062d53a9cdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d89d1c03-4303-43cf-8846-6d57583ab4a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1eefb963-dfd3-4d5e-8ce2-062d53a9cdff" xlink:to="loc_srt_ProductsAndServicesDomain_d89d1c03-4303-43cf-8846-6d57583ab4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fdc99877-0f12-4725-a6c4-31f2c31603fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d89d1c03-4303-43cf-8846-6d57583ab4a0" xlink:to="loc_us-gaap_ProductMember_fdc99877-0f12-4725-a6c4-31f2c31603fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_e0816237-0ad7-46fa-ba85-69cd3d60194b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d89d1c03-4303-43cf-8846-6d57583ab4a0" xlink:to="loc_us-gaap_LicenseMember_e0816237-0ad7-46fa-ba85-69cd3d60194b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_cba2cae0-eb9e-46c4-bbe9-a3c75e4cefe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d89d1c03-4303-43cf-8846-6d57583ab4a0" xlink:to="loc_us-gaap_ServiceMember_cba2cae0-eb9e-46c4-bbe9-a3c75e4cefe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a9e33bbb-a4ab-4957-865e-929532f7d959" xlink:to="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a8afc332-3cf0-4b4f-8571-e86db830e59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_RevenuesAbstract_a8afc332-3cf0-4b4f-8571-e86db830e59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f9f0fdc-5c7c-4ef4-911f-632e8a074126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a8afc332-3cf0-4b4f-8571-e86db830e59d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f9f0fdc-5c7c-4ef4-911f-632e8a074126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1f54dfe9-7f7e-4a8b-9bbc-092074c7ba64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1f54dfe9-7f7e-4a8b-9bbc-092074c7ba64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8450c925-3f4a-4e91-ae69-024e2b7e18b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1f54dfe9-7f7e-4a8b-9bbc-092074c7ba64" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8450c925-3f4a-4e91-ae69-024e2b7e18b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6f36d4b7-133d-4a0b-ba5f-6a5ca4835a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1f54dfe9-7f7e-4a8b-9bbc-092074c7ba64" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6f36d4b7-133d-4a0b-ba5f-6a5ca4835a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a119a6e6-f079-4adf-800b-2e8a62bbd7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1f54dfe9-7f7e-4a8b-9bbc-092074c7ba64" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a119a6e6-f079-4adf-800b-2e8a62bbd7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_617c35f2-1ae7-45f4-a02f-68fb3063dbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1f54dfe9-7f7e-4a8b-9bbc-092074c7ba64" xlink:to="loc_us-gaap_CostsAndExpenses_617c35f2-1ae7-45f4-a02f-68fb3063dbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d5be22c0-6cdd-4c9e-8673-94d49dc12401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_OperatingIncomeLoss_d5be22c0-6cdd-4c9e-8673-94d49dc12401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_e3230798-c6a0-4370-8215-50ad0bdb9aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_InterestIncomeOther_e3230798-c6a0-4370-8215-50ad0bdb9aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_67631406-2b4b-4e67-8a4a-f9b76c1c1274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_67631406-2b4b-4e67-8a4a-f9b76c1c1274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_dab6c640-0fe5-47a4-84bf-5901e3f1595c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_dab6c640-0fe5-47a4-84bf-5901e3f1595c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a288189d-76a6-4ac6-bf02-2f19e8a849f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a288189d-76a6-4ac6-bf02-2f19e8a849f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_29f8e706-fa84-429e-8faa-40ae694fcece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_NetIncomeLoss_29f8e706-fa84-429e-8faa-40ae694fcece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a750dd4e-a9ce-4cd7-956c-d613246fccd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a750dd4e-a9ce-4cd7-956c-d613246fccd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1be82de3-6675-4999-ba35-bb7623fd4f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a750dd4e-a9ce-4cd7-956c-d613246fccd0" xlink:to="loc_us-gaap_EarningsPerShareBasic_1be82de3-6675-4999-ba35-bb7623fd4f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f9f769b1-ee7e-469b-9ae2-3cb0bdabef72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a750dd4e-a9ce-4cd7-956c-d613246fccd0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f9f769b1-ee7e-469b-9ae2-3cb0bdabef72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_777659b6-80c7-4196-b09f-18109e984012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af14c2a4-1c82-4c6b-b699-20d8938ebac0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_777659b6-80c7-4196-b09f-18109e984012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0157cd6a-807b-4492-a3b8-2b272616f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_777659b6-80c7-4196-b09f-18109e984012" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0157cd6a-807b-4492-a3b8-2b272616f1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e623a544-c25a-4d8d-918b-666f401c37e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_777659b6-80c7-4196-b09f-18109e984012" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e623a544-c25a-4d8d-918b-666f401c37e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4721c856-fcd2-44c2-acb6-2246c0d2576e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_893a3120-ca6d-49f4-adab-84184b5b68d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4721c856-fcd2-44c2-acb6-2246c0d2576e" xlink:to="loc_us-gaap_NetIncomeLoss_893a3120-ca6d-49f4-adab-84184b5b68d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5f7af2fd-27d1-452d-b4ba-906871010ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4721c856-fcd2-44c2-acb6-2246c0d2576e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5f7af2fd-27d1-452d-b4ba-906871010ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e5d699cc-c12d-466b-9093-7926b421e2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5f7af2fd-27d1-452d-b4ba-906871010ac0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e5d699cc-c12d-466b-9093-7926b421e2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c5e11559-9230-4c27-85bb-679873016d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4721c856-fcd2-44c2-acb6-2246c0d2576e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c5e11559-9230-4c27-85bb-679873016d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e2b4fef8-b53e-4443-87bb-8f453f2e3068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_a05bc885-d4fd-4961-bbd3-bda6c2f5910f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e2b4fef8-b53e-4443-87bb-8f453f2e3068" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_a05bc885-d4fd-4961-bbd3-bda6c2f5910f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b3d98806-56a1-42d1-9718-26ee451f5131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f03056a6-6564-446e-a089-e9355b1f7703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b3d98806-56a1-42d1-9718-26ee451f5131" xlink:to="loc_us-gaap_StatementTable_f03056a6-6564-446e-a089-e9355b1f7703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fb64a12b-da8d-42e4-bcc1-aa2a13a3a28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f03056a6-6564-446e-a089-e9355b1f7703" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fb64a12b-da8d-42e4-bcc1-aa2a13a3a28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dba2ca2a-be7a-4315-aaef-f5410d841635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fb64a12b-da8d-42e4-bcc1-aa2a13a3a28f" xlink:to="loc_us-gaap_EquityComponentDomain_dba2ca2a-be7a-4315-aaef-f5410d841635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ca469644-780d-48e3-89e2-3e99e25d13b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dba2ca2a-be7a-4315-aaef-f5410d841635" xlink:to="loc_us-gaap_CommonStockMember_ca469644-780d-48e3-89e2-3e99e25d13b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_62dd90e7-0546-4c79-98a0-5d6470b1bfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dba2ca2a-be7a-4315-aaef-f5410d841635" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_62dd90e7-0546-4c79-98a0-5d6470b1bfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b2e1a57f-0651-4f27-96b6-aceaa12d016b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dba2ca2a-be7a-4315-aaef-f5410d841635" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b2e1a57f-0651-4f27-96b6-aceaa12d016b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9f37451d-513c-4e31-8232-4a0367cb5e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dba2ca2a-be7a-4315-aaef-f5410d841635" xlink:to="loc_us-gaap_RetainedEarningsMember_9f37451d-513c-4e31-8232-4a0367cb5e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c37eba1e-f7a7-4513-99bf-af1a6caa09f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f03056a6-6564-446e-a089-e9355b1f7703" xlink:to="loc_us-gaap_StatementLineItems_c37eba1e-f7a7-4513-99bf-af1a6caa09f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c37eba1e-f7a7-4513-99bf-af1a6caa09f5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7fa24d96-b23a-41d3-bfa6-b3427bd9bac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7fa24d96-b23a-41d3-bfa6-b3427bd9bac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2bd3698e-f662-48a5-9de6-9a4306f9e211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_StockholdersEquity_2bd3698e-f662-48a5-9de6-9a4306f9e211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_207d663f-6199-4953-b61f-66d87a571390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_NetIncomeLoss_207d663f-6199-4953-b61f-66d87a571390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_99a9c893-88c8-4586-8aa3-3e4f756c0706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_99a9c893-88c8-4586-8aa3-3e4f756c0706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_64a74bb7-7ac1-4a2f-b66f-ebb6e42b3003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_64a74bb7-7ac1-4a2f-b66f-ebb6e42b3003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4f435ee3-769e-4b37-bf45-6e3789227425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4f435ee3-769e-4b37-bf45-6e3789227425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5236f51b-be81-4f23-8731-1a109589fe97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5236f51b-be81-4f23-8731-1a109589fe97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3a3cb49d-c6bd-4c8d-8faa-4066f122584a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3a3cb49d-c6bd-4c8d-8faa-4066f122584a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5cb81dc9-76f8-42fb-9677-3d4c6530ad65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5cb81dc9-76f8-42fb-9677-3d4c6530ad65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_acb6ed47-c10b-406b-859e-48832354d8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_79ceb07d-df98-4c75-a401-0d7f51764f5b" xlink:to="loc_us-gaap_StockholdersEquity_acb6ed47-c10b-406b-859e-48832354d8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20220701.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_db869d55-54be-4853-9041-395e3d006ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5737aed5-1366-4f9d-b169-71f327cbdbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_db869d55-54be-4853-9041-395e3d006ca8" xlink:to="loc_us-gaap_NetIncomeLoss_5737aed5-1366-4f9d-b169-71f327cbdbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_487fd149-7dea-4aa1-99e0-7279210743a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_db869d55-54be-4853-9041-395e3d006ca8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_487fd149-7dea-4aa1-99e0-7279210743a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e7ac9317-e9c1-4bfd-8d73-5ba0555a816b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_487fd149-7dea-4aa1-99e0-7279210743a4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e7ac9317-e9c1-4bfd-8d73-5ba0555a816b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_df3546b7-1111-425d-99aa-7ca8d2d4a673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_487fd149-7dea-4aa1-99e0-7279210743a4" xlink:to="loc_us-gaap_ShareBasedCompensation_df3546b7-1111-425d-99aa-7ca8d2d4a673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_caa4bd5d-fbec-4496-b164-3c3ad61f713e" xlink:href="exel-20220701.xsd#exel_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_487fd149-7dea-4aa1-99e0-7279210743a4" xlink:to="loc_exel_NoncashLeaseExpense_caa4bd5d-fbec-4496-b164-3c3ad61f713e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d4a6482b-0132-43dc-a3fc-ded405111295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_487fd149-7dea-4aa1-99e0-7279210743a4" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d4a6482b-0132-43dc-a3fc-ded405111295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_925869f3-11ec-4de3-82df-879b7226d326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_487fd149-7dea-4aa1-99e0-7279210743a4" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_925869f3-11ec-4de3-82df-879b7226d326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2ff30f1-b112-4aa6-b573-44f9b00924d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_487fd149-7dea-4aa1-99e0-7279210743a4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2ff30f1-b112-4aa6-b573-44f9b00924d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6fc854fe-96b5-4529-a712-6ca37977e9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2ff30f1-b112-4aa6-b573-44f9b00924d2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6fc854fe-96b5-4529-a712-6ca37977e9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4f5ae5ae-d8d4-4d39-9714-44b87061ff41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2ff30f1-b112-4aa6-b573-44f9b00924d2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4f5ae5ae-d8d4-4d39-9714-44b87061ff41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4ed786b6-3535-4eeb-b1b6-013fb42800d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2ff30f1-b112-4aa6-b573-44f9b00924d2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4ed786b6-3535-4eeb-b1b6-013fb42800d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9d30592c-26ba-4513-979b-6e5a23903771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2ff30f1-b112-4aa6-b573-44f9b00924d2" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9d30592c-26ba-4513-979b-6e5a23903771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_ac1cbf0f-2516-4bb3-aa93-80ea22493801" xlink:href="exel-20220701.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2ff30f1-b112-4aa6-b573-44f9b00924d2" xlink:to="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_ac1cbf0f-2516-4bb3-aa93-80ea22493801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5c31552f-b3eb-4ea0-a7f0-c18f1a7acdae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d2ff30f1-b112-4aa6-b573-44f9b00924d2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5c31552f-b3eb-4ea0-a7f0-c18f1a7acdae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9b63c819-5c2e-4dc2-9453-58953c14e8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_db869d55-54be-4853-9041-395e3d006ca8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9b63c819-5c2e-4dc2-9453-58953c14e8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d608ad28-ec56-4fd6-a55b-0dfa106730c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_db869d55-54be-4853-9041-395e3d006ca8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d608ad28-ec56-4fd6-a55b-0dfa106730c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ba715846-fba1-42ed-81ce-e6b19407678a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d608ad28-ec56-4fd6-a55b-0dfa106730c8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ba715846-fba1-42ed-81ce-e6b19407678a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_0a7acf8c-618f-41d9-8435-41c58283d161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d608ad28-ec56-4fd6-a55b-0dfa106730c8" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_0a7acf8c-618f-41d9-8435-41c58283d161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_2b09b5bb-0ed2-428e-a9d7-86a8e391f91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d608ad28-ec56-4fd6-a55b-0dfa106730c8" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_2b09b5bb-0ed2-428e-a9d7-86a8e391f91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41c38a85-e541-458c-b683-3349cf3f697d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d608ad28-ec56-4fd6-a55b-0dfa106730c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41c38a85-e541-458c-b683-3349cf3f697d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c67656c-109f-4c4a-b008-be9f5a8b3d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_db869d55-54be-4853-9041-395e3d006ca8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c67656c-109f-4c4a-b008-be9f5a8b3d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_345564af-76c4-4f65-a82d-a8699548a1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c67656c-109f-4c4a-b008-be9f5a8b3d6a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_345564af-76c4-4f65-a82d-a8699548a1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_74c23ae7-80e6-481c-844b-35e88b382d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c67656c-109f-4c4a-b008-be9f5a8b3d6a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_74c23ae7-80e6-481c-844b-35e88b382d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f31f9ac-fc6f-47ff-b9bb-05f4ee66ca48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c67656c-109f-4c4a-b008-be9f5a8b3d6a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f31f9ac-fc6f-47ff-b9bb-05f4ee66ca48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64ac7a67-b117-45e0-a5d7-1f73c7762f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_db869d55-54be-4853-9041-395e3d006ca8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64ac7a67-b117-45e0-a5d7-1f73c7762f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c222e796-ca0d-47df-8a8e-092a4f0aef1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_db869d55-54be-4853-9041-395e3d006ca8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c222e796-ca0d-47df-8a8e-092a4f0aef1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a70ef1a2-c8e3-4307-969c-9ba8dff7cf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_db869d55-54be-4853-9041-395e3d006ca8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a70ef1a2-c8e3-4307-969c-9ba8dff7cf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c2e80951-4e18-4b4c-a2ac-e79730db05d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_db869d55-54be-4853-9041-395e3d006ca8" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c2e80951-4e18-4b4c-a2ac-e79730db05d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_7731cecd-8112-4f2e-85d2-ae47c712c053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c2e80951-4e18-4b4c-a2ac-e79730db05d2" xlink:to="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_7731cecd-8112-4f2e-85d2-ae47c712c053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_46ee1f44-a2bb-4408-878b-825eb90ae818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_7731cecd-8112-4f2e-85d2-ae47c712c053" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_46ee1f44-a2bb-4408-878b-825eb90ae818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_bf638763-7d74-4a53-83c4-760b868277e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c2e80951-4e18-4b4c-a2ac-e79730db05d2" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_bf638763-7d74-4a53-83c4-760b868277e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6b1665e-3705-4dd0-8584-b33cfa3f96c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_bf638763-7d74-4a53-83c4-760b868277e7" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6b1665e-3705-4dd0-8584-b33cfa3f96c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_acad592d-8c62-4257-a251-49a7d05d5969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_bf638763-7d74-4a53-83c4-760b868277e7" xlink:to="loc_us-gaap_LiabilitiesAssumed1_acad592d-8c62-4257-a251-49a7d05d5969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InvestmentsPurchasesIncurredButNotYetPaid_bd2d9565-e1f0-4394-b838-75e9cedcb534" xlink:href="exel-20220701.xsd#exel_InvestmentsPurchasesIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_bf638763-7d74-4a53-83c4-760b868277e7" xlink:to="loc_exel_InvestmentsPurchasesIncurredButNotYetPaid_bd2d9565-e1f0-4394-b838-75e9cedcb534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20220701.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fe2993cd-9f1f-4aa5-a1ad-5bc24e087ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_5b3c87cb-0b59-4cbb-9d3c-e27de78060f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fe2993cd-9f1f-4aa5-a1ad-5bc24e087ae5" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_5b3c87cb-0b59-4cbb-9d3c-e27de78060f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20220701.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d23afa21-9606-486f-bf41-082f0e5fb8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_9c087211-909d-4f1d-9dc2-7245265dab26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d23afa21-9606-486f-bf41-082f0e5fb8dd" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_9c087211-909d-4f1d-9dc2-7245265dab26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e0a731cb-a059-4874-b0d2-364debbc2a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d23afa21-9606-486f-bf41-082f0e5fb8dd" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e0a731cb-a059-4874-b0d2-364debbc2a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_454bb096-f72b-4f24-9606-d2eb1f3ee2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d23afa21-9606-486f-bf41-082f0e5fb8dd" xlink:to="loc_us-gaap_FiscalPeriod_454bb096-f72b-4f24-9606-d2eb1f3ee2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_632c2149-3f1d-45f1-bccc-1572e747027c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d23afa21-9606-486f-bf41-082f0e5fb8dd" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_632c2149-3f1d-45f1-bccc-1572e747027c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_43d2a08a-3666-4b92-84ff-6dbc005cfa62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d23afa21-9606-486f-bf41-082f0e5fb8dd" xlink:to="loc_us-gaap_UseOfEstimates_43d2a08a-3666-4b92-84ff-6dbc005cfa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_958f3329-f822-4bca-a0bf-05658c07cc02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d23afa21-9606-486f-bf41-082f0e5fb8dd" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_958f3329-f822-4bca-a0bf-05658c07cc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bc026395-b2a9-4a58-9770-f4db6f8a8da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d23afa21-9606-486f-bf41-082f0e5fb8dd" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bc026395-b2a9-4a58-9770-f4db6f8a8da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_bee39556-9e2b-4c9b-a60d-403ff1266a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d23afa21-9606-486f-bf41-082f0e5fb8dd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_bee39556-9e2b-4c9b-a60d-403ff1266a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a1100301-c068-4786-a6ee-35666e54088b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_4f481e5f-cbb1-450a-976d-72fa5d220ca7" xlink:href="exel-20220701.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a1100301-c068-4786-a6ee-35666e54088b" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_4f481e5f-cbb1-450a-976d-72fa5d220ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a1735830-55e3-49af-957b-88be96ea3d3e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_4f481e5f-cbb1-450a-976d-72fa5d220ca7" xlink:to="loc_srt_ProductOrServiceAxis_a1735830-55e3-49af-957b-88be96ea3d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_88e95b87-5360-4a69-a2f6-63ca35967950" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a1735830-55e3-49af-957b-88be96ea3d3e" xlink:to="loc_srt_ProductsAndServicesDomain_88e95b87-5360-4a69-a2f6-63ca35967950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_a0c472fa-3dca-45ae-8444-3564f78b9694" xlink:href="exel-20220701.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_88e95b87-5360-4a69-a2f6-63ca35967950" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_a0c472fa-3dca-45ae-8444-3564f78b9694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_d0b97f31-8c11-418f-9ef2-8f0bb5ba6a31" xlink:href="exel-20220701.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_88e95b87-5360-4a69-a2f6-63ca35967950" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_d0b97f31-8c11-418f-9ef2-8f0bb5ba6a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_a7e71976-6163-4209-912f-60e7fc41900d" xlink:href="exel-20220701.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_4f481e5f-cbb1-450a-976d-72fa5d220ca7" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_a7e71976-6163-4209-912f-60e7fc41900d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_c7399311-7957-4f82-ad00-439d86049cfa" xlink:href="exel-20220701.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_a7e71976-6163-4209-912f-60e7fc41900d" xlink:to="loc_exel_NumberofProductsinCommercialMarket_c7399311-7957-4f82-ad00-439d86049cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_481baebb-bbe5-4cb1-b394-4640174ea937" xlink:href="exel-20220701.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_a7e71976-6163-4209-912f-60e7fc41900d" xlink:to="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_481baebb-bbe5-4cb1-b394-4640174ea937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_02bda12e-6106-4dd1-baf7-e0219171df00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_a7e71976-6163-4209-912f-60e7fc41900d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_02bda12e-6106-4dd1-baf7-e0219171df00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20220701.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_60539937-1511-46d1-8078-7da8e55d64e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_01c0f2f8-f8c1-460c-a8a6-ce8a1ce60476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_60539937-1511-46d1-8078-7da8e55d64e2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_01c0f2f8-f8c1-460c-a8a6-ce8a1ce60476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_41edc4eb-9377-4d97-9b99-af82df64da13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b11f4228-feb2-4096-8950-257cdf4cd9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_41edc4eb-9377-4d97-9b99-af82df64da13" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b11f4228-feb2-4096-8950-257cdf4cd9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_956b1b5e-3c9c-443d-b361-0a80dbe23bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_41edc4eb-9377-4d97-9b99-af82df64da13" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_956b1b5e-3c9c-443d-b361-0a80dbe23bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_e41c2daa-d5f2-4820-a9b4-f67492f8fe0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_41edc4eb-9377-4d97-9b99-af82df64da13" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_e41c2daa-d5f2-4820-a9b4-f67492f8fe0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_56a34790-d0ad-4a8b-aa74-1df13701ec88" xlink:href="exel-20220701.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_41edc4eb-9377-4d97-9b99-af82df64da13" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_56a34790-d0ad-4a8b-aa74-1df13701ec88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_cdf5eecc-6335-4d8d-bfc0-4800d3694fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_41edc4eb-9377-4d97-9b99-af82df64da13" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_cdf5eecc-6335-4d8d-bfc0-4800d3694fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2e438812-33bb-4c83-8103-f5fd721975e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7b7951f0-bc36-4202-88c4-28ce63aba743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2e438812-33bb-4c83-8103-f5fd721975e2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7b7951f0-bc36-4202-88c4-28ce63aba743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5ce92fe7-9bce-4924-bafb-3561be6d1994" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b7951f0-bc36-4202-88c4-28ce63aba743" xlink:to="loc_srt_ProductOrServiceAxis_5ce92fe7-9bce-4924-bafb-3561be6d1994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5ce92fe7-9bce-4924-bafb-3561be6d1994" xlink:to="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_4ce8303a-4cc7-4dd4-80b5-50ea2f9846b2" xlink:href="exel-20220701.xsd#exel_ProductGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:to="loc_exel_ProductGrossMember_4ce8303a-4cc7-4dd4-80b5-50ea2f9846b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_d9b46b7b-ecb8-4623-b21c-0dd168294d2c" xlink:href="exel-20220701.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_d9b46b7b-ecb8-4623-b21c-0dd168294d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f2f1aaf9-f030-4e0b-8cef-9acb4eadb669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:to="loc_us-gaap_ProductMember_f2f1aaf9-f030-4e0b-8cef-9acb4eadb669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_822377ab-db87-4cfa-8d28-6af3d3c825f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:to="loc_us-gaap_LicenseMember_822377ab-db87-4cfa-8d28-6af3d3c825f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ba775239-6e0a-4a03-a550-9785e888246f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:to="loc_us-gaap_ServiceMember_ba775239-6e0a-4a03-a550-9785e888246f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_04bcca46-aaec-495f-82fe-59cbca3dddaf" xlink:href="exel-20220701.xsd#exel_CollaborationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e2e9085e-890e-4d36-adfb-2b2231675029" xlink:to="loc_exel_CollaborationMember_04bcca46-aaec-495f-82fe-59cbca3dddaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8524a30d-98e1-4485-b827-e9df507f2d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b7951f0-bc36-4202-88c4-28ce63aba743" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8524a30d-98e1-4485-b827-e9df507f2d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0bc1bf2-3fbe-4340-83ad-07c5c6b876d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8524a30d-98e1-4485-b827-e9df507f2d66" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0bc1bf2-3fbe-4340-83ad-07c5c6b876d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6d9db017-9dfa-4bbd-8133-5c8baf64e244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_1e67363f-1cca-4085-86e4-b6da15059ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6d9db017-9dfa-4bbd-8133-5c8baf64e244" xlink:to="loc_us-gaap_ConcentrationRiskTable_1e67363f-1cca-4085-86e4-b6da15059ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ff8c520b-5d81-478a-8c70-c51f20dea81c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1e67363f-1cca-4085-86e4-b6da15059ba5" xlink:to="loc_srt_MajorCustomersAxis_ff8c520b-5d81-478a-8c70-c51f20dea81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ff8c520b-5d81-478a-8c70-c51f20dea81c" xlink:to="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_1e2feb62-f11c-4ec8-9e51-d11df3e6b30f" xlink:href="exel-20220701.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_1e2feb62-f11c-4ec8-9e51-d11df3e6b30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_de828a01-3df8-4902-a2d4-d54cd5899880" xlink:href="exel-20220701.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_de828a01-3df8-4902-a2d4-d54cd5899880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_940733a3-03ec-4934-8eca-3f543e1a873b" xlink:href="exel-20220701.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_940733a3-03ec-4934-8eca-3f543e1a873b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_1d48c131-27dc-4a6d-badb-e38d10545489" xlink:href="exel-20220701.xsd#exel_IpsenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:to="loc_exel_IpsenMember_1d48c131-27dc-4a6d-badb-e38d10545489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember_5195f74c-981d-424e-809f-2d9248c88116" xlink:href="exel-20220701.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:to="loc_exel_AccredoHealthIncorporatedMember_5195f74c-981d-424e-809f-2d9248c88116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CardinalHealthMember_27567317-14eb-4924-9bfe-1504e21c4f5d" xlink:href="exel-20220701.xsd#exel_CardinalHealthMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_862bdd6b-3f63-4361-bd53-371d5f2653a0" xlink:to="loc_exel_CardinalHealthMember_27567317-14eb-4924-9bfe-1504e21c4f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5d838af7-86ef-4db0-b3a8-b5223beaa2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1e67363f-1cca-4085-86e4-b6da15059ba5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5d838af7-86ef-4db0-b3a8-b5223beaa2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64651765-f7b8-49d8-a8ef-250217efc703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5d838af7-86ef-4db0-b3a8-b5223beaa2a7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64651765-f7b8-49d8-a8ef-250217efc703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f5b83c43-1e33-40f4-8358-13237ac79194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64651765-f7b8-49d8-a8ef-250217efc703" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f5b83c43-1e33-40f4-8358-13237ac79194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_75a594e4-46c8-458d-8908-6f410baf3aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64651765-f7b8-49d8-a8ef-250217efc703" xlink:to="loc_us-gaap_AccountsReceivableMember_75a594e4-46c8-458d-8908-6f410baf3aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0ffc5f5b-c176-4a3a-962c-d4915762dc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1e67363f-1cca-4085-86e4-b6da15059ba5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0ffc5f5b-c176-4a3a-962c-d4915762dc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ef92889d-2ba9-42c6-bdcb-95863eeffaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0ffc5f5b-c176-4a3a-962c-d4915762dc1c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ef92889d-2ba9-42c6-bdcb-95863eeffaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_f35f086f-9e26-4f1c-87d6-d7a67da0e386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ef92889d-2ba9-42c6-bdcb-95863eeffaf7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_f35f086f-9e26-4f1c-87d6-d7a67da0e386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5eb89d28-2adf-4384-af04-1cf6d44fa4da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1e67363f-1cca-4085-86e4-b6da15059ba5" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_5eb89d28-2adf-4384-af04-1cf6d44fa4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bfa0dde5-35a6-4c9c-8fa9-5ddd7b72c8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5eb89d28-2adf-4384-af04-1cf6d44fa4da" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bfa0dde5-35a6-4c9c-8fa9-5ddd7b72c8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8f3a9d4d-0d34-478f-a337-423ddafbb8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6318ffbf-7e7b-4cba-a1bf-b0b5cccc9a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8f3a9d4d-0d34-478f-a337-423ddafbb8cb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6318ffbf-7e7b-4cba-a1bf-b0b5cccc9a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5bd5e323-3091-42a4-8175-56fedec2c0a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6318ffbf-7e7b-4cba-a1bf-b0b5cccc9a7c" xlink:to="loc_srt_StatementGeographicalAxis_5bd5e323-3091-42a4-8175-56fedec2c0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cde76ae6-48a5-4a23-9c83-6e4bbdf9fbf5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5bd5e323-3091-42a4-8175-56fedec2c0a4" xlink:to="loc_srt_SegmentGeographicalDomain_cde76ae6-48a5-4a23-9c83-6e4bbdf9fbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_70866ba0-d4b9-439d-83e6-94a1817489fb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cde76ae6-48a5-4a23-9c83-6e4bbdf9fbf5" xlink:to="loc_country_US_70866ba0-d4b9-439d-83e6-94a1817489fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_a96842d4-39a5-4690-8d33-689c0951014c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cde76ae6-48a5-4a23-9c83-6e4bbdf9fbf5" xlink:to="loc_srt_EuropeMember_a96842d4-39a5-4690-8d33-689c0951014c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_d3f45a76-e66f-416f-9e8c-3a42acc62574" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cde76ae6-48a5-4a23-9c83-6e4bbdf9fbf5" xlink:to="loc_country_JP_d3f45a76-e66f-416f-9e8c-3a42acc62574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ab9c64e1-695f-4c64-9485-140b5265efd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6318ffbf-7e7b-4cba-a1bf-b0b5cccc9a7c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ab9c64e1-695f-4c64-9485-140b5265efd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_43ec3a4d-ca98-4f89-9807-5b3844eb17f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ab9c64e1-695f-4c64-9485-140b5265efd4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_43ec3a4d-ca98-4f89-9807-5b3844eb17f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ec47a50c-81c3-4860-86e8-fad6641618a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_04141a61-484a-4c6a-9886-21c141775c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ec47a50c-81c3-4860-86e8-fad6641618a6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_04141a61-484a-4c6a-9886-21c141775c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ede1b97d-5875-44c0-be4e-e781cd626077" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_04141a61-484a-4c6a-9886-21c141775c03" xlink:to="loc_srt_ProductOrServiceAxis_ede1b97d-5875-44c0-be4e-e781cd626077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_143e2495-dcea-41f0-a059-c4728e4e95df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ede1b97d-5875-44c0-be4e-e781cd626077" xlink:to="loc_srt_ProductsAndServicesDomain_143e2495-dcea-41f0-a059-c4728e4e95df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_54367c23-eefa-4f59-85d0-6d7c1750d1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_143e2495-dcea-41f0-a059-c4728e4e95df" xlink:to="loc_us-gaap_ProductMember_54367c23-eefa-4f59-85d0-6d7c1750d1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_d1409cbc-3b24-4a47-b14e-0529ccd12407" xlink:href="exel-20220701.xsd#exel_CabometyxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_54367c23-eefa-4f59-85d0-6d7c1750d1c9" xlink:to="loc_exel_CabometyxMember_d1409cbc-3b24-4a47-b14e-0529ccd12407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_20eaa1e2-6610-4929-9078-f913bc3c910b" xlink:href="exel-20220701.xsd#exel_CometriqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_54367c23-eefa-4f59-85d0-6d7c1750d1c9" xlink:to="loc_exel_CometriqMember_20eaa1e2-6610-4929-9078-f913bc3c910b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0e65f8ae-46f2-4c73-bf6a-de746701a09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_04141a61-484a-4c6a-9886-21c141775c03" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0e65f8ae-46f2-4c73-bf6a-de746701a09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b31d4a4e-e44f-4bdf-b60b-647c91bbe2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e65f8ae-46f2-4c73-bf6a-de746701a09e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b31d4a4e-e44f-4bdf-b60b-647c91bbe2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2822828e-c9ba-46cd-891c-423d5e711b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f56af4f6-6840-427a-a0fa-584c1b94ac2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2822828e-c9ba-46cd-891c-423d5e711b86" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f56af4f6-6840-427a-a0fa-584c1b94ac2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7af2dd99-ef16-4d5b-bd7b-48478689bc19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f56af4f6-6840-427a-a0fa-584c1b94ac2f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7af2dd99-ef16-4d5b-bd7b-48478689bc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_bcba3ebe-56c2-4d7d-badf-90e4b5816a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7af2dd99-ef16-4d5b-bd7b-48478689bc19" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_bcba3ebe-56c2-4d7d-badf-90e4b5816a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_d8f1f259-b8fd-49b4-baef-cea517d1e762" xlink:href="exel-20220701.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_bcba3ebe-56c2-4d7d-badf-90e4b5816a20" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_d8f1f259-b8fd-49b4-baef-cea517d1e762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_2422ab4d-895f-4144-beb0-a535194d0edc" xlink:href="exel-20220701.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_bcba3ebe-56c2-4d7d-badf-90e4b5816a20" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_2422ab4d-895f-4144-beb0-a535194d0edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_51fef06d-e0a9-495c-b783-17e8e1584134" xlink:href="exel-20220701.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_bcba3ebe-56c2-4d7d-badf-90e4b5816a20" xlink:to="loc_exel_AllowanceForProductRebatesMember_51fef06d-e0a9-495c-b783-17e8e1584134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a45a4529-e5ec-4192-9ae0-005e2f9bda84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f56af4f6-6840-427a-a0fa-584c1b94ac2f" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a45a4529-e5ec-4192-9ae0-005e2f9bda84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aedd5820-eb56-48e0-8471-f849ff25aaae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a45a4529-e5ec-4192-9ae0-005e2f9bda84" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aedd5820-eb56-48e0-8471-f849ff25aaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_81c3b93e-055a-428b-b9a8-bff291409784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aedd5820-eb56-48e0-8471-f849ff25aaae" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_81c3b93e-055a-428b-b9a8-bff291409784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_d603f077-c61f-4804-a98b-b69cca7c5864" xlink:href="exel-20220701.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aedd5820-eb56-48e0-8471-f849ff25aaae" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_d603f077-c61f-4804-a98b-b69cca7c5864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_60e2f6b5-b35c-403a-9f05-8d03b2bcb5ca" xlink:href="exel-20220701.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_d603f077-c61f-4804-a98b-b69cca7c5864" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_60e2f6b5-b35c-403a-9f05-8d03b2bcb5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_8914df32-01d8-4b81-8cf6-6543b66b7d01" xlink:href="exel-20220701.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_d603f077-c61f-4804-a98b-b69cca7c5864" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_8914df32-01d8-4b81-8cf6-6543b66b7d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_ae227012-950b-4eb9-88c6-09bab41d817b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aedd5820-eb56-48e0-8471-f849ff25aaae" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_ae227012-950b-4eb9-88c6-09bab41d817b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8ecfecff-9bde-48ca-adb2-682c597b05d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_aedd5820-eb56-48e0-8471-f849ff25aaae" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8ecfecff-9bde-48ca-adb2-682c597b05d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0eb0058e-f1b0-4c90-b296-281eb0798046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8055b1c0-17b6-4e65-a400-516206c44421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0eb0058e-f1b0-4c90-b296-281eb0798046" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8055b1c0-17b6-4e65-a400-516206c44421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7198b88a-8c8c-4d7d-8b25-d8543c4f68a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8055b1c0-17b6-4e65-a400-516206c44421" xlink:to="loc_srt_CounterpartyNameAxis_7198b88a-8c8c-4d7d-8b25-d8543c4f68a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22469b0e-c1d4-4e8e-9815-124531bf8502" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7198b88a-8c8c-4d7d-8b25-d8543c4f68a3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22469b0e-c1d4-4e8e-9815-124531bf8502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaAndIspenMember_f4b08acc-5089-44ab-b2e0-cff0fe529056" xlink:href="exel-20220701.xsd#exel_TakedaAndIspenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22469b0e-c1d4-4e8e-9815-124531bf8502" xlink:to="loc_exel_TakedaAndIspenMember_f4b08acc-5089-44ab-b2e0-cff0fe529056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8055b1c0-17b6-4e65-a400-516206c44421" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_95b5fe8e-2201-4255-88de-e29789516631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_95b5fe8e-2201-4255-88de-e29789516631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_328acfc4-de47-45e2-ad89-c1ff9dd98c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_95b5fe8e-2201-4255-88de-e29789516631" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_328acfc4-de47-45e2-ad89-c1ff9dd98c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_f1a57f9b-f3a3-430f-b183-708c6c701041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_f1a57f9b-f3a3-430f-b183-708c6c701041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a82b9534-c562-474b-a024-7a6eb38b098e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_f1a57f9b-f3a3-430f-b183-708c6c701041" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a82b9534-c562-474b-a024-7a6eb38b098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c710dcd3-9406-46a9-ba6f-fc298636cd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_f1a57f9b-f3a3-430f-b183-708c6c701041" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c710dcd3-9406-46a9-ba6f-fc298636cd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c618f277-7ecd-4bc1-a5c6-bc97a67370f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_f1a57f9b-f3a3-430f-b183-708c6c701041" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c618f277-7ecd-4bc1-a5c6-bc97a67370f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_3ccbf9dd-e18e-498f-be2e-d572032a4dfc" xlink:href="exel-20220701.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_3ccbf9dd-e18e-498f-be2e-d572032a4dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_37d058ba-d281-4996-8978-222ad2533446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_37d058ba-d281-4996-8978-222ad2533446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_8483a51e-13c2-4fbb-9c51-d30b6f0ba471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9d662530-18a1-435d-9fc7-b13a5e904b93" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_8483a51e-13c2-4fbb-9c51-d30b6f0ba471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivities"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e36e0d29-5c66-4d14-9df3-656d62e3c9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f3662d5a-d82e-4ac2-a396-9e055ef6cf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e36e0d29-5c66-4d14-9df3-656d62e3c9ba" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f3662d5a-d82e-4ac2-a396-9e055ef6cf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e0cd26a-672c-47c8-823c-22262e43b2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_ec8a63de-c216-4ce2-a39f-599c2a10c1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e0cd26a-672c-47c8-823c-22262e43b2fe" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_ec8a63de-c216-4ce2-a39f-599c2a10c1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a61ed815-201d-4b93-ac35-09e6ac0582c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a7683fa-e008-4ebb-abd7-433881553bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a61ed815-201d-4b93-ac35-09e6ac0582c6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a7683fa-e008-4ebb-abd7-433881553bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7f49d73e-e8ad-4153-989a-94450b6735ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a7683fa-e008-4ebb-abd7-433881553bdd" xlink:to="loc_srt_ProductOrServiceAxis_7f49d73e-e8ad-4153-989a-94450b6735ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2456bed1-838b-4a62-966a-2fc20e29b2cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7f49d73e-e8ad-4153-989a-94450b6735ba" xlink:to="loc_srt_ProductsAndServicesDomain_2456bed1-838b-4a62-966a-2fc20e29b2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_5865f6b3-2f3c-4ff6-ac03-25948ec167d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2456bed1-838b-4a62-966a-2fc20e29b2cf" xlink:to="loc_us-gaap_LicenseMember_5865f6b3-2f3c-4ff6-ac03-25948ec167d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_3a45c578-5b79-401c-a9b5-5fee4f3ade60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2456bed1-838b-4a62-966a-2fc20e29b2cf" xlink:to="loc_us-gaap_ServiceMember_3a45c578-5b79-401c-a9b5-5fee4f3ade60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d6aa8afc-7997-4f0d-b45c-10b01e5c05b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a7683fa-e008-4ebb-abd7-433881553bdd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d6aa8afc-7997-4f0d-b45c-10b01e5c05b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c6bd8ac-2589-479c-94de-0b4c432bbed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d6aa8afc-7997-4f0d-b45c-10b01e5c05b0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c6bd8ac-2589-479c-94de-0b4c432bbed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_ae262b83-fb84-4bfe-9c39-b8e55f43e411" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c6bd8ac-2589-479c-94de-0b4c432bbed3" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_ae262b83-fb84-4bfe-9c39-b8e55f43e411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6a2e980-50bd-43d5-9063-5012698c08e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a7683fa-e008-4ebb-abd7-433881553bdd" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6a2e980-50bd-43d5-9063-5012698c08e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a6469b8-0ca5-49b1-baeb-0c77a6d64c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6a2e980-50bd-43d5-9063-5012698c08e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a6469b8-0ca5-49b1-baeb-0c77a6d64c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c7828c6-0525-46dc-a39a-32ab515c841b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1b2c6c6f-dea7-40ac-b3ca-04f24c425187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c7828c6-0525-46dc-a39a-32ab515c841b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1b2c6c6f-dea7-40ac-b3ca-04f24c425187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b889b6ae-a2ad-4f7b-9d21-e6ded6635cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1b2c6c6f-dea7-40ac-b3ca-04f24c425187" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b889b6ae-a2ad-4f7b-9d21-e6ded6635cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24c4bea7-dd59-43ff-b7b1-e10e96d63fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b889b6ae-a2ad-4f7b-9d21-e6ded6635cd7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24c4bea7-dd59-43ff-b7b1-e10e96d63fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_a140b2bc-a20d-478a-9e21-6f343c4d12b4" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24c4bea7-dd59-43ff-b7b1-e10e96d63fdf" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_a140b2bc-a20d-478a-9e21-6f343c4d12b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b14e830d-dd9c-4e95-958d-7776a88db704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1b2c6c6f-dea7-40ac-b3ca-04f24c425187" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b14e830d-dd9c-4e95-958d-7776a88db704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9848a724-5930-4e8c-8f8e-ec205b52bf62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b14e830d-dd9c-4e95-958d-7776a88db704" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9848a724-5930-4e8c-8f8e-ec205b52bf62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_13528f8b-9c03-46d8-bd64-3e9842737679" xlink:href="exel-20220701.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b14e830d-dd9c-4e95-958d-7776a88db704" xlink:to="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_13528f8b-9c03-46d8-bd64-3e9842737679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_93feea17-b741-463b-ab3d-8338cc639de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b14e830d-dd9c-4e95-958d-7776a88db704" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_93feea17-b741-463b-ab3d-8338cc639de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86f1a709-ef42-43ee-8a3b-18f34461f1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b36a0053-4b8f-4347-8475-9bed85e85411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86f1a709-ef42-43ee-8a3b-18f34461f1a4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b36a0053-4b8f-4347-8475-9bed85e85411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_644243c9-50d6-4538-948f-8994549f0ebc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b36a0053-4b8f-4347-8475-9bed85e85411" xlink:to="loc_srt_ProductOrServiceAxis_644243c9-50d6-4538-948f-8994549f0ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aafcf407-b1cb-4d08-8449-45035d91b52c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_644243c9-50d6-4538-948f-8994549f0ebc" xlink:to="loc_srt_ProductsAndServicesDomain_aafcf407-b1cb-4d08-8449-45035d91b52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_64790d43-ee36-4472-90c6-0b05298f3469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aafcf407-b1cb-4d08-8449-45035d91b52c" xlink:to="loc_us-gaap_LicenseMember_64790d43-ee36-4472-90c6-0b05298f3469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_bb57d976-a710-4b56-b9ca-be44466ce1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aafcf407-b1cb-4d08-8449-45035d91b52c" xlink:to="loc_us-gaap_ServiceMember_bb57d976-a710-4b56-b9ca-be44466ce1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_20768fe7-5833-4725-8e97-f3ea03e5544a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b36a0053-4b8f-4347-8475-9bed85e85411" xlink:to="loc_us-gaap_TypeOfArrangementAxis_20768fe7-5833-4725-8e97-f3ea03e5544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0768c92-e3d8-4e80-bf7f-b7f07dd18702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20768fe7-5833-4725-8e97-f3ea03e5544a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0768c92-e3d8-4e80-bf7f-b7f07dd18702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_8d885cd4-5cac-4730-9ade-1cfc9c34bdeb" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0768c92-e3d8-4e80-bf7f-b7f07dd18702" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_8d885cd4-5cac-4730-9ade-1cfc9c34bdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d101165b-efd2-4117-a311-2c6e19db63c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b36a0053-4b8f-4347-8475-9bed85e85411" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d101165b-efd2-4117-a311-2c6e19db63c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c5fe414-2b3d-4867-905e-8ba6909e3a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d101165b-efd2-4117-a311-2c6e19db63c2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c5fe414-2b3d-4867-905e-8ba6909e3a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74ebdf35-2142-46ad-b142-5bfba5b2eb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b016b1-875c-4c51-81f7-9419ccaad5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74ebdf35-2142-46ad-b142-5bfba5b2eb8b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b016b1-875c-4c51-81f7-9419ccaad5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a95c9b4c-d841-4afd-b4de-6e1abbf25f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b016b1-875c-4c51-81f7-9419ccaad5e0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a95c9b4c-d841-4afd-b4de-6e1abbf25f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_559b4a2b-2be7-45a6-810d-6bc347bc25ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a95c9b4c-d841-4afd-b4de-6e1abbf25f91" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_559b4a2b-2be7-45a6-810d-6bc347bc25ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_c8e009d5-89a5-437c-82e8-bb85f961bd17" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_559b4a2b-2be7-45a6-810d-6bc347bc25ac" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_c8e009d5-89a5-437c-82e8-bb85f961bd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24576b56-1397-493c-bf80-57f6d8fea7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b016b1-875c-4c51-81f7-9419ccaad5e0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24576b56-1397-493c-bf80-57f6d8fea7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_774dfe5b-c25c-40b9-8d75-54dfce951f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_24576b56-1397-493c-bf80-57f6d8fea7ed" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_774dfe5b-c25c-40b9-8d75-54dfce951f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64c869e4-ac36-4a3a-8f9d-a70d984b6c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0290ec64-2550-4d19-a027-0bd8ae77c0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64c869e4-ac36-4a3a-8f9d-a70d984b6c53" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0290ec64-2550-4d19-a027-0bd8ae77c0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ddab1b24-d3ea-4241-97c2-555b57a7dd55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0290ec64-2550-4d19-a027-0bd8ae77c0f9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ddab1b24-d3ea-4241-97c2-555b57a7dd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_230430de-a541-4a2f-acb9-2974ef4156aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ddab1b24-d3ea-4241-97c2-555b57a7dd55" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_230430de-a541-4a2f-acb9-2974ef4156aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4be81a35-fe16-4478-9d47-8a1a84be3862" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_230430de-a541-4a2f-acb9-2974ef4156aa" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4be81a35-fe16-4478-9d47-8a1a84be3862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyalPharmaMember_15668883-c142-4f43-a060-8fb2344230bf" xlink:href="exel-20220701.xsd#exel_RoyalPharmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_230430de-a541-4a2f-acb9-2974ef4156aa" xlink:to="loc_exel_RoyalPharmaMember_15668883-c142-4f43-a060-8fb2344230bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0df5c4ec-9d8c-4dfd-80c3-eb301f2aa8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0290ec64-2550-4d19-a027-0bd8ae77c0f9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0df5c4ec-9d8c-4dfd-80c3-eb301f2aa8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_210d432b-9d6b-4217-a8b9-f38d54124ce6" xlink:href="exel-20220701.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0df5c4ec-9d8c-4dfd-80c3-eb301f2aa8d8" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_210d432b-9d6b-4217-a8b9-f38d54124ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_1da0cc4c-540f-45e3-99c0-ced9abdf8f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0df5c4ec-9d8c-4dfd-80c3-eb301f2aa8d8" xlink:to="loc_us-gaap_RoyaltyExpense_1da0cc4c-540f-45e3-99c0-ced9abdf8f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6f0680ae-ebb1-4d6d-94f4-155df62ded7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba5ae75-c07c-4d16-8f79-2d70ec49b0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6f0680ae-ebb1-4d6d-94f4-155df62ded7a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba5ae75-c07c-4d16-8f79-2d70ec49b0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3ffb88bf-3d93-4d96-816c-e31696bb611c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba5ae75-c07c-4d16-8f79-2d70ec49b0f8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3ffb88bf-3d93-4d96-816c-e31696bb611c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e516ad4-988d-401e-a2ac-087f968616df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3ffb88bf-3d93-4d96-816c-e31696bb611c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e516ad4-988d-401e-a2ac-087f968616df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_8b6f2131-216f-455e-8260-a0a1ef55b670" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e516ad4-988d-401e-a2ac-087f968616df" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_8b6f2131-216f-455e-8260-a0a1ef55b670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisAxis_f0d7ae8b-1142-4eab-991c-10f7d8860526" xlink:href="exel-20220701.xsd#exel_ProductOrServiceAxisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba5ae75-c07c-4d16-8f79-2d70ec49b0f8" xlink:to="loc_exel_ProductOrServiceAxisAxis_f0d7ae8b-1142-4eab-991c-10f7d8860526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisDomain_3fb58753-7f95-4161-91f2-7ca6d06bc3e5" xlink:href="exel-20220701.xsd#exel_ProductOrServiceAxisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProductOrServiceAxisAxis_f0d7ae8b-1142-4eab-991c-10f7d8860526" xlink:to="loc_exel_ProductOrServiceAxisDomain_3fb58753-7f95-4161-91f2-7ca6d06bc3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_05607bcd-e415-4545-b71e-c978f87e1ebc" xlink:href="exel-20220701.xsd#exel_CotellicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProductOrServiceAxisDomain_3fb58753-7f95-4161-91f2-7ca6d06bc3e5" xlink:to="loc_exel_CotellicMember_05607bcd-e415-4545-b71e-c978f87e1ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42a9ced0-4182-4fd3-9e76-23e8ee57ddd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ba5ae75-c07c-4d16-8f79-2d70ec49b0f8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42a9ced0-4182-4fd3-9e76-23e8ee57ddd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_f5882c19-cd8a-491c-837b-3e839ed09406" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42a9ced0-4182-4fd3-9e76-23e8ee57ddd7" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_f5882c19-cd8a-491c-837b-3e839ed09406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d08e54f2-7dc6-43a2-bc21-05d51f662ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42a9ced0-4182-4fd3-9e76-23e8ee57ddd7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d08e54f2-7dc6-43a2-bc21-05d51f662ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d00693c2-f20d-43a5-9c03-bd0689fba147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_a613593c-abda-49bd-8d4f-d3f414313f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d00693c2-f20d-43a5-9c03-bd0689fba147" xlink:to="loc_us-gaap_AssetAcquisitionTable_a613593c-abda-49bd-8d4f-d3f414313f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_de79f8bb-2919-471c-890b-1868150c8e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_a613593c-abda-49bd-8d4f-d3f414313f97" xlink:to="loc_us-gaap_TypeOfArrangementAxis_de79f8bb-2919-471c-890b-1868150c8e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a7a7eab-fe73-448a-89c5-be09eb4f237b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_de79f8bb-2919-471c-890b-1868150c8e95" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a7a7eab-fe73-448a-89c5-be09eb4f237b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember_1cbad9c7-ddeb-42bf-bbb8-b6e408f15074" xlink:href="exel-20220701.xsd#exel_CollaborationAgreementWithBioInventOptionAndLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a7a7eab-fe73-448a-89c5-be09eb4f237b" xlink:to="loc_exel_CollaborationAgreementWithBioInventOptionAndLicenseMember_1cbad9c7-ddeb-42bf-bbb8-b6e408f15074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_7b93acc7-755f-40de-a994-4df93a7e0696" xlink:href="exel-20220701.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a7a7eab-fe73-448a-89c5-be09eb4f237b" xlink:to="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_7b93acc7-755f-40de-a994-4df93a7e0696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_2d2ae5bf-c11d-4a09-af90-03de546b2389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_a613593c-abda-49bd-8d4f-d3f414313f97" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_2d2ae5bf-c11d-4a09-af90-03de546b2389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_70c2eecd-9a93-4524-927f-77a1fe4c5589" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2d2ae5bf-c11d-4a09-af90-03de546b2389" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_70c2eecd-9a93-4524-927f-77a1fe4c5589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_4958c75f-1509-4320-8831-4a4cce12a928" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2d2ae5bf-c11d-4a09-af90-03de546b2389" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_4958c75f-1509-4320-8831-4a4cce12a928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_50c965a6-b8d9-40fd-890a-d3838ba19de7" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2d2ae5bf-c11d-4a09-af90-03de546b2389" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_50c965a6-b8d9-40fd-890a-d3838ba19de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_c1d086bd-f095-46a3-8520-2ab62de0fec6" xlink:href="exel-20220701.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2d2ae5bf-c11d-4a09-af90-03de546b2389" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_c1d086bd-f095-46a3-8520-2ab62de0fec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestments"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ea4faf5c-141d-4c57-886c-c33126a541fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_74f2044a-53bb-4f0c-be07-41faa576f5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ea4faf5c-141d-4c57-886c-c33126a541fc" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_74f2044a-53bb-4f0c-be07-41faa576f5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_788d9101-9263-4c79-86b8-863fa2897400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9ee3e635-3b30-460c-98c9-9856e367d8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_788d9101-9263-4c79-86b8-863fa2897400" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9ee3e635-3b30-460c-98c9-9856e367d8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ab329197-fc2c-4701-b562-151ea0fe58b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_788d9101-9263-4c79-86b8-863fa2897400" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ab329197-fc2c-4701-b562-151ea0fe58b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_67d05392-3aa3-43be-8682-afcfce4c0adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_788d9101-9263-4c79-86b8-863fa2897400" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_67d05392-3aa3-43be-8682-afcfce4c0adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_b203a0d9-1e91-46aa-a56c-cfe285081375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_788d9101-9263-4c79-86b8-863fa2897400" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_b203a0d9-1e91-46aa-a56c-cfe285081375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_665dbf42-f332-48a9-91b4-0aacdbf09200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_788d9101-9263-4c79-86b8-863fa2897400" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_665dbf42-f332-48a9-91b4-0aacdbf09200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_20233826-6ca7-49d2-8d1d-5e62749c9a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_8ac9b322-4b65-43a8-acb5-db6e4a20b93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_20233826-6ca7-49d2-8d1d-5e62749c9a68" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_8ac9b322-4b65-43a8-acb5-db6e4a20b93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_277b4cb6-68e9-4f3c-920e-a0a0a9eeb02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_8ac9b322-4b65-43a8-acb5-db6e4a20b93c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_277b4cb6-68e9-4f3c-920e-a0a0a9eeb02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_319e1231-b8fe-4866-a556-699504dd2b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_8ac9b322-4b65-43a8-acb5-db6e4a20b93c" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_319e1231-b8fe-4866-a556-699504dd2b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf403653-b012-4c40-b25c-1ed7a53d94be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_8ac9b322-4b65-43a8-acb5-db6e4a20b93c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf403653-b012-4c40-b25c-1ed7a53d94be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9abb93ec-0851-43dc-926b-2c6c616c9155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09a2bb1b-9279-4b2f-ac1b-29264c0b3ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9abb93ec-0851-43dc-926b-2c6c616c9155" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09a2bb1b-9279-4b2f-ac1b-29264c0b3ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_895c0c95-101d-4588-829b-8d213a3cf0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09a2bb1b-9279-4b2f-ac1b-29264c0b3ac6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_895c0c95-101d-4588-829b-8d213a3cf0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35fe91d1-15fe-4853-ab5e-66d760958ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_895c0c95-101d-4588-829b-8d213a3cf0e8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35fe91d1-15fe-4853-ab5e-66d760958ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_3f263e62-f441-4e1f-b724-b14ef56d53b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35fe91d1-15fe-4853-ab5e-66d760958ba0" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_3f263e62-f441-4e1f-b724-b14ef56d53b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_861084b0-0ea6-4bde-8fd7-f58086d60f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09a2bb1b-9279-4b2f-ac1b-29264c0b3ac6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_861084b0-0ea6-4bde-8fd7-f58086d60f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4a5b484-c6ab-483f-a17f-4fee47ac37da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_861084b0-0ea6-4bde-8fd7-f58086d60f5a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4a5b484-c6ab-483f-a17f-4fee47ac37da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_e01d50d6-30cf-4a6f-9c02-7fa99f809fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4a5b484-c6ab-483f-a17f-4fee47ac37da" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_e01d50d6-30cf-4a6f-9c02-7fa99f809fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09a2bb1b-9279-4b2f-ac1b-29264c0b3ac6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_cc008c71-790f-4349-9b33-14b4c8c52551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_cc008c71-790f-4349-9b33-14b4c8c52551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_598cc7fd-895d-4dd8-a466-960bb94f2938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:to="loc_us-gaap_InterestReceivable_598cc7fd-895d-4dd8-a466-960bb94f2938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0cd76806-d32f-44d2-8c53-8738e944ce43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0cd76806-d32f-44d2-8c53-8738e944ce43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_5f48af6e-ecc4-4929-a1da-37d2c1fbe086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_5f48af6e-ecc4-4929-a1da-37d2c1fbe086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f00f99cc-92df-4309-9523-b290acae49e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a401c7b-4b3e-4d6f-b942-3f157bc2598e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_f00f99cc-92df-4309-9523-b290acae49e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1ef38e1f-481c-415b-9823-93d625e06601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_694ba58c-2aab-4a72-8335-ec0fef3fc6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1ef38e1f-481c-415b-9823-93d625e06601" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_694ba58c-2aab-4a72-8335-ec0fef3fc6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3a323e8b-5d34-4626-8cf3-2046af78ee76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_694ba58c-2aab-4a72-8335-ec0fef3fc6e8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3a323e8b-5d34-4626-8cf3-2046af78ee76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3a323e8b-5d34-4626-8cf3-2046af78ee76" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_16723d02-037a-4a80-9da5-56dd7ea0ac00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_CommercialPaperMember_16723d02-037a-4a80-9da5-56dd7ea0ac00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_82c7228a-cbed-4174-b964-201f305c6ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_82c7228a-cbed-4174-b964-201f305c6ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_917bbe54-0f7e-41e2-9231-12e958095e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_917bbe54-0f7e-41e2-9231-12e958095e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_1fcdd410-e590-444b-be86-1655a2f25468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_MunicipalBondsMember_1fcdd410-e590-444b-be86-1655a2f25468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_a4dc3989-5153-4530-868d-d8f2824e9eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_CashMember_a4dc3989-5153-4530-868d-d8f2824e9eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3cdeb11a-71a5-4bb7-b25b-0035f06bd912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3cdeb11a-71a5-4bb7-b25b-0035f06bd912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f6cc0bf0-87f3-4581-bf5e-9d2d83737e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_857104a0-6064-4eed-a514-36af95ae3a2a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f6cc0bf0-87f3-4581-bf5e-9d2d83737e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_694ba58c-2aab-4a72-8335-ec0fef3fc6e8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74a16c20-225d-404b-a999-a157734e3983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74a16c20-225d-404b-a999-a157734e3983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7b833fe0-ce95-4327-9cd9-3e4b0f11627f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74a16c20-225d-404b-a999-a157734e3983" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7b833fe0-ce95-4327-9cd9-3e4b0f11627f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c1a7eeef-8c5c-436f-9766-efd23445e9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74a16c20-225d-404b-a999-a157734e3983" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c1a7eeef-8c5c-436f-9766-efd23445e9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ac817160-34ac-4e67-a3c8-05b0ea995c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74a16c20-225d-404b-a999-a157734e3983" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ac817160-34ac-4e67-a3c8-05b0ea995c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_60b15f71-cbe1-499f-ad70-1f79ec311db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74a16c20-225d-404b-a999-a157734e3983" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_60b15f71-cbe1-499f-ad70-1f79ec311db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_072ddd66-7755-4a39-9feb-6356355e17ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_072ddd66-7755-4a39-9feb-6356355e17ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_6751fb10-0d26-4285-b5be-c21743491650" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_072ddd66-7755-4a39-9feb-6356355e17ba" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_6751fb10-0d26-4285-b5be-c21743491650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_0e082edc-7750-4f7d-8f92-6beb9b565ce1" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_072ddd66-7755-4a39-9feb-6356355e17ba" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_0e082edc-7750-4f7d-8f92-6beb9b565ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_bbcb5a71-240a-40dd-b041-f52a0d7798f2" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_072ddd66-7755-4a39-9feb-6356355e17ba" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_bbcb5a71-240a-40dd-b041-f52a0d7798f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_494358df-6eac-451e-81ab-76636d735596" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_072ddd66-7755-4a39-9feb-6356355e17ba" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_494358df-6eac-451e-81ab-76636d735596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_aee8bf42-605e-4ba0-b8dd-b493bf68ae18" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_aee8bf42-605e-4ba0-b8dd-b493bf68ae18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07fecc6f-8205-4409-ba85-25804824ed94" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07fecc6f-8205-4409-ba85-25804824ed94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22f7e157-2333-4cc2-bc89-d4eb3fe85b1c" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22f7e157-2333-4cc2-bc89-d4eb3fe85b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_fd9b0910-9bbf-4468-96a2-9c8bcda30d3d" xlink:href="exel-20220701.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0829d2be-a0c5-400a-9590-9285784b14d1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_fd9b0910-9bbf-4468-96a2-9c8bcda30d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_219eabfe-5c2b-440b-88ae-7ee603b7b71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5efe59b3-1998-49ca-b462-f7a0b91306a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_219eabfe-5c2b-440b-88ae-7ee603b7b71d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5efe59b3-1998-49ca-b462-f7a0b91306a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6356a1a4-0c24-4d7b-b30b-734cefb6c0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5efe59b3-1998-49ca-b462-f7a0b91306a7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6356a1a4-0c24-4d7b-b30b-734cefb6c0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84cd2119-f299-48e1-abe4-13356d8caefa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6356a1a4-0c24-4d7b-b30b-734cefb6c0ea" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84cd2119-f299-48e1-abe4-13356d8caefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_86b0b1af-2717-4278-9ae9-29fe0da1c0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84cd2119-f299-48e1-abe4-13356d8caefa" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_86b0b1af-2717-4278-9ae9-29fe0da1c0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_647c4d17-75c8-42df-8165-640d5254a7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84cd2119-f299-48e1-abe4-13356d8caefa" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_647c4d17-75c8-42df-8165-640d5254a7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ac00e233-74ee-4752-b438-87ea66f622a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84cd2119-f299-48e1-abe4-13356d8caefa" xlink:to="loc_us-gaap_CommercialPaperMember_ac00e233-74ee-4752-b438-87ea66f622a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_ef335e72-0904-4bcc-9a66-be97ebb27bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84cd2119-f299-48e1-abe4-13356d8caefa" xlink:to="loc_us-gaap_MunicipalBondsMember_ef335e72-0904-4bcc-9a66-be97ebb27bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_619971dd-a244-453a-9a35-19606b63f404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5efe59b3-1998-49ca-b462-f7a0b91306a7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_619971dd-a244-453a-9a35-19606b63f404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_42c049d0-535f-444d-914f-2275a0934e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_619971dd-a244-453a-9a35-19606b63f404" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_42c049d0-535f-444d-914f-2275a0934e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1de71bb6-62f0-4154-b698-5f0600f48695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_42c049d0-535f-444d-914f-2275a0934e9b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1de71bb6-62f0-4154-b698-5f0600f48695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_83c7f6ca-613f-4e3d-b2b1-1a915138ef82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_42c049d0-535f-444d-914f-2275a0934e9b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_83c7f6ca-613f-4e3d-b2b1-1a915138ef82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3caff64c-4496-4272-8529-7bea48f06f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0b6a2be7-e328-4a8a-a533-e7cae287ac62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3caff64c-4496-4272-8529-7bea48f06f7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0b6a2be7-e328-4a8a-a533-e7cae287ac62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_db25673c-5db4-4a7e-a126-e4d29771e144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3caff64c-4496-4272-8529-7bea48f06f7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_db25673c-5db4-4a7e-a126-e4d29771e144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb066787-2bf9-41c9-b802-b4039e1a0d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3caff64c-4496-4272-8529-7bea48f06f7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb066787-2bf9-41c9-b802-b4039e1a0d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20220701.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_329772a3-41c3-48ad-b4a7-af7746dc0ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_fb58a944-f37d-4839-8521-dbcb973e5416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_329772a3-41c3-48ad-b4a7-af7746dc0ebd" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_fb58a944-f37d-4839-8521-dbcb973e5416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20220701.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d29e5af7-b0c8-45ff-9963-d0278041e251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4465e449-07a0-4c80-ac49-2d837645f135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d29e5af7-b0c8-45ff-9963-d0278041e251" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4465e449-07a0-4c80-ac49-2d837645f135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_531d7040-8c8d-444e-b00e-c88153c3061e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fe71326-af57-4649-a97e-aa3c85e8eef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_531d7040-8c8d-444e-b00e-c88153c3061e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fe71326-af57-4649-a97e-aa3c85e8eef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4a985c75-246a-4f15-adec-3912f8d70f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fe71326-af57-4649-a97e-aa3c85e8eef1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4a985c75-246a-4f15-adec-3912f8d70f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4a985c75-246a-4f15-adec-3912f8d70f86" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bfb20e16-70c6-4c3f-8704-8cecf242d182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:to="loc_us-gaap_CommercialPaperMember_bfb20e16-70c6-4c3f-8704-8cecf242d182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_f543b919-4f05-4c87-acbf-3de2f853be0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_f543b919-4f05-4c87-acbf-3de2f853be0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_b5b20c33-7a78-40d6-974e-6786844d241b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_b5b20c33-7a78-40d6-974e-6786844d241b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_04e039de-1b88-411b-9a4c-e5643b8405de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:to="loc_us-gaap_MunicipalBondsMember_04e039de-1b88-411b-9a4c-e5643b8405de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2ea56f90-514f-414d-a4d7-ac4c5c73a19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2ea56f90-514f-414d-a4d7-ac4c5c73a19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_89d049ec-b3b0-49f2-aed8-6f2f3d3fc0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_860bb741-c233-4681-989d-5f40e17542f3" xlink:to="loc_us-gaap_CertificatesOfDepositMember_89d049ec-b3b0-49f2-aed8-6f2f3d3fc0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_816c1834-053e-4665-9f5f-2f7730b68693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fe71326-af57-4649-a97e-aa3c85e8eef1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_816c1834-053e-4665-9f5f-2f7730b68693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f325e72-e954-4afa-a646-5b90feb1526a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_816c1834-053e-4665-9f5f-2f7730b68693" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f325e72-e954-4afa-a646-5b90feb1526a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6e93b665-55e4-4b84-a917-bd845926daac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f325e72-e954-4afa-a646-5b90feb1526a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6e93b665-55e4-4b84-a917-bd845926daac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c65da225-2024-41e8-9696-288762f6c0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f325e72-e954-4afa-a646-5b90feb1526a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c65da225-2024-41e8-9696-288762f6c0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fee75144-8ce5-4eaf-bc45-19fd21d57652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fe71326-af57-4649-a97e-aa3c85e8eef1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fee75144-8ce5-4eaf-bc45-19fd21d57652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0220f4b8-73b2-4d7c-b4d5-ab5e8628a34d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fee75144-8ce5-4eaf-bc45-19fd21d57652" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0220f4b8-73b2-4d7c-b4d5-ab5e8628a34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f4505210-2054-4026-8f27-d43429144439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0220f4b8-73b2-4d7c-b4d5-ab5e8628a34d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f4505210-2054-4026-8f27-d43429144439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55784351-caff-4543-9b99-ff4708c553c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fe71326-af57-4649-a97e-aa3c85e8eef1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55784351-caff-4543-9b99-ff4708c553c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e406a243-cf7b-4e85-b557-6572690bd6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55784351-caff-4543-9b99-ff4708c553c7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e406a243-cf7b-4e85-b557-6572690bd6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368e38c7-c343-41cf-b938-a0bae32c9358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55784351-caff-4543-9b99-ff4708c553c7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368e38c7-c343-41cf-b938-a0bae32c9358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_46b772e7-eb86-4e5b-91f4-f781940fd8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55784351-caff-4543-9b99-ff4708c553c7" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_46b772e7-eb86-4e5b-91f4-f781940fd8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_430989f5-387b-4a60-a54d-bb8ab6ad1dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec54894-e3e6-4003-a07d-708ce3282ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_430989f5-387b-4a60-a54d-bb8ab6ad1dd3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec54894-e3e6-4003-a07d-708ce3282ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_04f6978b-7a17-48b8-bc70-b0ce6081a8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec54894-e3e6-4003-a07d-708ce3282ec0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_04f6978b-7a17-48b8-bc70-b0ce6081a8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_17e8959b-31f4-4830-89ea-a533c45d10e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_04f6978b-7a17-48b8-bc70-b0ce6081a8c1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_17e8959b-31f4-4830-89ea-a533c45d10e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_a8723a07-47c5-4f3a-b3fc-cacee579c80b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_17e8959b-31f4-4830-89ea-a533c45d10e6" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_a8723a07-47c5-4f3a-b3fc-cacee579c80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd2b3cc-4a34-439b-b36f-0ff64720f32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec54894-e3e6-4003-a07d-708ce3282ec0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd2b3cc-4a34-439b-b36f-0ff64720f32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_e5800083-5c9b-494d-ae05-2986a7c4e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd2b3cc-4a34-439b-b36f-0ff64720f32d" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_e5800083-5c9b-494d-ae05-2986a7c4e54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_3238e5b1-f1f4-4008-98fe-6b4ad8e65e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd2b3cc-4a34-439b-b36f-0ff64720f32d" xlink:to="loc_us-gaap_DerivativeNotionalAmount_3238e5b1-f1f4-4008-98fe-6b4ad8e65e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_08f48616-512b-4612-813a-57a56f9ab94d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd2b3cc-4a34-439b-b36f-0ff64720f32d" xlink:to="loc_us-gaap_DerivativeTermOfContract_08f48616-512b-4612-813a-57a56f9ab94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_9103a783-ad57-469e-a787-3b602aa6d4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd2b3cc-4a34-439b-b36f-0ff64720f32d" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_9103a783-ad57-469e-a787-3b602aa6d4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20220701.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b5863f41-c2ba-4ad5-87f8-419b1e09c73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_6c6f225a-b776-468e-89bc-279b77e2c12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b5863f41-c2ba-4ad5-87f8-419b1e09c73a" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_6c6f225a-b776-468e-89bc-279b77e2c12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20220701.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1d8408d2-41bc-4aef-babb-8187b43cc496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_818a39d5-f580-42e6-9d4b-e0ab325b9451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1d8408d2-41bc-4aef-babb-8187b43cc496" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_818a39d5-f580-42e6-9d4b-e0ab325b9451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5a4de1cf-06d3-478c-b690-15e353afb36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_b3944355-7a29-486d-8def-c3c4e777b715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5a4de1cf-06d3-478c-b690-15e353afb36c" xlink:to="loc_us-gaap_InventoryCurrentTable_b3944355-7a29-486d-8def-c3c4e777b715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d431c103-3e53-465b-95f5-0d3e6701a8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_b3944355-7a29-486d-8def-c3c4e777b715" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d431c103-3e53-465b-95f5-0d3e6701a8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_33ce9487-0345-467a-9e3a-e4c5e6e1c3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d431c103-3e53-465b-95f5-0d3e6701a8b5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_33ce9487-0345-467a-9e3a-e4c5e6e1c3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_350040e1-5dec-4b88-95dc-5c73b3d3c1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_33ce9487-0345-467a-9e3a-e4c5e6e1c3b4" xlink:to="loc_us-gaap_InventoriesMember_350040e1-5dec-4b88-95dc-5c73b3d3c1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_05b22833-de82-48c5-9b72-76a967440c7e" xlink:href="exel-20220701.xsd#exel_OtherLongtermAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_33ce9487-0345-467a-9e3a-e4c5e6e1c3b4" xlink:to="loc_exel_OtherLongtermAssetsMember_05b22833-de82-48c5-9b72-76a967440c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_4b27541b-8a8a-4f3e-849d-bd529a13d487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_b3944355-7a29-486d-8def-c3c4e777b715" xlink:to="loc_us-gaap_InventoryLineItems_4b27541b-8a8a-4f3e-849d-bd529a13d487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_c54fa4d1-9533-4038-85e0-e33187c5cff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_4b27541b-8a8a-4f3e-849d-bd529a13d487" xlink:to="loc_us-gaap_InventoryRawMaterials_c54fa4d1-9533-4038-85e0-e33187c5cff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_57c65c5e-3380-468f-82f9-24658fd08ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_4b27541b-8a8a-4f3e-849d-bd529a13d487" xlink:to="loc_us-gaap_InventoryWorkInProcess_57c65c5e-3380-468f-82f9-24658fd08ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_43d78867-85c0-44af-b453-edfcf565c29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_4b27541b-8a8a-4f3e-849d-bd529a13d487" xlink:to="loc_us-gaap_InventoryFinishedGoods_43d78867-85c0-44af-b453-edfcf565c29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_3d5da9c1-d4fa-4631-9ed9-7ec62aaddc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_4b27541b-8a8a-4f3e-849d-bd529a13d487" xlink:to="loc_us-gaap_InventoryGross_3d5da9c1-d4fa-4631-9ed9-7ec62aaddc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="exel-20220701.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_773938cc-4cc3-47fe-9524-e7df102e825d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_42510ac3-a5b9-4e9c-8d93-4149529161b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_773938cc-4cc3-47fe-9524-e7df102e825d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_42510ac3-a5b9-4e9c-8d93-4149529161b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="exel-20220701.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad7e1c32-2252-4b54-b48c-536d0da1e7df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_577c91fc-ab7a-417a-ab3e-34f5a951de86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad7e1c32-2252-4b54-b48c-536d0da1e7df" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_577c91fc-ab7a-417a-ab3e-34f5a951de86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_2c04d596-30d8-4e7a-bac2-40d296eaa17b" xlink:href="exel-20220701.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad7e1c32-2252-4b54-b48c-536d0da1e7df" xlink:to="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_2c04d596-30d8-4e7a-bac2-40d296eaa17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bb7f8eb-3203-4ae7-aef4-35deb732b26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b9bac01b-b2d6-468b-9dc3-109ed0dfe1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bb7f8eb-3203-4ae7-aef4-35deb732b26c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b9bac01b-b2d6-468b-9dc3-109ed0dfe1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6c91cd74-5a24-45e6-a0de-27d5e966784d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b9bac01b-b2d6-468b-9dc3-109ed0dfe1d5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6c91cd74-5a24-45e6-a0de-27d5e966784d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e1f9e03b-636c-43d2-a06d-1f56cc634828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c91cd74-5a24-45e6-a0de-27d5e966784d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e1f9e03b-636c-43d2-a06d-1f56cc634828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4ddfa1fa-da08-49aa-8c8a-6a54114b9c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1f9e03b-636c-43d2-a06d-1f56cc634828" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4ddfa1fa-da08-49aa-8c8a-6a54114b9c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_791057f0-bc1e-4e8d-bb7e-b91f0c2ace47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1f9e03b-636c-43d2-a06d-1f56cc634828" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_791057f0-bc1e-4e8d-bb7e-b91f0c2ace47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c02f5f1a-9951-485e-99d5-92965a0da6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b9bac01b-b2d6-468b-9dc3-109ed0dfe1d5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c02f5f1a-9951-485e-99d5-92965a0da6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2bede1a8-16a2-49f3-ad87-bcf3006f4ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c02f5f1a-9951-485e-99d5-92965a0da6fc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2bede1a8-16a2-49f3-ad87-bcf3006f4ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e4f4e5-2431-4d13-8a2b-f117a5a17b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6488497-c2df-4ffd-9a0c-2aadca49caa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e4f4e5-2431-4d13-8a2b-f117a5a17b29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6488497-c2df-4ffd-9a0c-2aadca49caa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_122f3b4d-a317-4c4b-a418-25209a4a0e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6488497-c2df-4ffd-9a0c-2aadca49caa7" xlink:to="loc_us-gaap_AwardTypeAxis_122f3b4d-a317-4c4b-a418-25209a4a0e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79979ac8-7a1e-4ec5-af82-404c295e232c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_122f3b4d-a317-4c4b-a418-25209a4a0e42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79979ac8-7a1e-4ec5-af82-404c295e232c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_974eaa2c-0cc5-46fd-9964-e44c1c0d8fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79979ac8-7a1e-4ec5-af82-404c295e232c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_974eaa2c-0cc5-46fd-9964-e44c1c0d8fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8e7c12dc-2056-4b16-a18e-21e88a165624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79979ac8-7a1e-4ec5-af82-404c295e232c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8e7c12dc-2056-4b16-a18e-21e88a165624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6dca358b-2077-4746-b2e5-0c97c56275ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79979ac8-7a1e-4ec5-af82-404c295e232c" xlink:to="loc_us-gaap_PerformanceSharesMember_6dca358b-2077-4746-b2e5-0c97c56275ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_aeff31b6-0872-47e3-823b-cf08ea02385c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79979ac8-7a1e-4ec5-af82-404c295e232c" xlink:to="loc_us-gaap_EmployeeStockMember_aeff31b6-0872-47e3-823b-cf08ea02385c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c4ef7b9-fe66-4838-9404-1e415eff79a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f6488497-c2df-4ffd-9a0c-2aadca49caa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c4ef7b9-fe66-4838-9404-1e415eff79a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b2315023-9549-4526-ba81-d3fb58eebe86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c4ef7b9-fe66-4838-9404-1e415eff79a3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b2315023-9549-4526-ba81-d3fb58eebe86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_151a9e98-a0d4-4e31-b8bf-adc703ef2da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfeb539-0c6d-4ac7-98af-7a26028afed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_151a9e98-a0d4-4e31-b8bf-adc703ef2da4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfeb539-0c6d-4ac7-98af-7a26028afed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ec4adb1f-17e5-49a4-bb5a-ccdc628aa4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfeb539-0c6d-4ac7-98af-7a26028afed2" xlink:to="loc_us-gaap_AwardTypeAxis_ec4adb1f-17e5-49a4-bb5a-ccdc628aa4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09afa0a0-05c9-47bb-8b03-dc12d5a6ca15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ec4adb1f-17e5-49a4-bb5a-ccdc628aa4cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09afa0a0-05c9-47bb-8b03-dc12d5a6ca15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_caef0d47-2d20-428a-a306-bb7beb1eacfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09afa0a0-05c9-47bb-8b03-dc12d5a6ca15" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_caef0d47-2d20-428a-a306-bb7beb1eacfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_f3834b3a-378f-46b9-a89b-9da01a5224f5" xlink:href="exel-20220701.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_caef0d47-2d20-428a-a306-bb7beb1eacfc" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_f3834b3a-378f-46b9-a89b-9da01a5224f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_764f2fed-c752-4f6d-9a4f-b30d0b8230e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09afa0a0-05c9-47bb-8b03-dc12d5a6ca15" xlink:to="loc_us-gaap_EmployeeStockOptionMember_764f2fed-c752-4f6d-9a4f-b30d0b8230e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_096f10fa-69a5-4b79-98aa-4f0133c995bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09afa0a0-05c9-47bb-8b03-dc12d5a6ca15" xlink:to="loc_us-gaap_PerformanceSharesMember_096f10fa-69a5-4b79-98aa-4f0133c995bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_3634f0e8-1bb8-46dd-a449-ec303b2cc043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfeb539-0c6d-4ac7-98af-7a26028afed2" xlink:to="loc_us-gaap_VestingAxis_3634f0e8-1bb8-46dd-a449-ec303b2cc043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2609e3c2-f903-48df-a577-718af91ff3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_3634f0e8-1bb8-46dd-a449-ec303b2cc043" xlink:to="loc_us-gaap_VestingDomain_2609e3c2-f903-48df-a577-718af91ff3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6d4db749-f908-41d8-a4da-1ac688820116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2609e3c2-f903-48df-a577-718af91ff3ab" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6d4db749-f908-41d8-a4da-1ac688820116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfeb539-0c6d-4ac7-98af-7a26028afed2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a6630c41-f738-47f2-8ed8-5a5e01deba57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a6630c41-f738-47f2-8ed8-5a5e01deba57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ad569042-bf9e-4252-bf65-9007730b0721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ad569042-bf9e-4252-bf65-9007730b0721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_ea6fc440-2237-48ff-b7d3-886acfd659fe" xlink:href="exel-20220701.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_ea6fc440-2237-48ff-b7d3-886acfd659fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_847f81ca-63a4-428b-9e12-2a7a701c1a58" xlink:href="exel-20220701.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_847f81ca-63a4-428b-9e12-2a7a701c1a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_795c1f09-cbe0-4aca-90e8-43c2c2142bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_795c1f09-cbe0-4aca-90e8-43c2c2142bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9b3b0a22-a491-4bd7-a8c9-bb3408369822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9b3b0a22-a491-4bd7-a8c9-bb3408369822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20a86dd6-72ff-45ab-9fbf-4a9ad47e19ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20a86dd6-72ff-45ab-9fbf-4a9ad47e19ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab5fe723-593c-4702-ba20-e64bb788cc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab5fe723-593c-4702-ba20-e64bb788cc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6749dff6-d9cc-4184-b811-39450fddd42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6749dff6-d9cc-4184-b811-39450fddd42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_531bc322-89f8-4b8b-8e74-3ea6f4d44a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_531bc322-89f8-4b8b-8e74-3ea6f4d44a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_d6aece03-2c9a-4aea-b5f0-1f98873d5120" xlink:href="exel-20220701.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_d6aece03-2c9a-4aea-b5f0-1f98873d5120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ce9132dc-93bf-4015-8a97-afc300bd2e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ce9132dc-93bf-4015-8a97-afc300bd2e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_da7acccf-7485-46e8-847d-71cf896410ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_da7acccf-7485-46e8-847d-71cf896410ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec704f03-d0dd-4856-8554-68968d3d76a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec704f03-d0dd-4856-8554-68968d3d76a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bf70c39-97ca-4126-a38d-021c5f9b5b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4fe87e66-4a44-41d9-a3a0-33aa6755ab12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bf70c39-97ca-4126-a38d-021c5f9b5b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d2f19cb-c6d8-47f4-8a78-d682fc3c7591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77c95c2a-66fb-48c3-8dfa-5aeafc96fed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d2f19cb-c6d8-47f4-8a78-d682fc3c7591" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77c95c2a-66fb-48c3-8dfa-5aeafc96fed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0a2eeda7-ca29-4ceb-bd4d-9c77e7109876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77c95c2a-66fb-48c3-8dfa-5aeafc96fed9" xlink:to="loc_us-gaap_AwardTypeAxis_0a2eeda7-ca29-4ceb-bd4d-9c77e7109876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77a99ad2-6c8d-4a91-9ee6-188229180e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0a2eeda7-ca29-4ceb-bd4d-9c77e7109876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77a99ad2-6c8d-4a91-9ee6-188229180e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_39769144-41e0-406e-a705-4b2c0d244c2e" xlink:href="exel-20220701.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77a99ad2-6c8d-4a91-9ee6-188229180e17" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_39769144-41e0-406e-a705-4b2c0d244c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70417684-354c-4243-b88e-0d413aee2216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77c95c2a-66fb-48c3-8dfa-5aeafc96fed9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70417684-354c-4243-b88e-0d413aee2216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_11d0c8c6-4340-4625-9def-78adf3998219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70417684-354c-4243-b88e-0d413aee2216" xlink:to="loc_us-gaap_SharePrice_11d0c8c6-4340-4625-9def-78adf3998219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_e4df82e1-b277-4ba4-b9eb-b24c9e980ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70417684-354c-4243-b88e-0d413aee2216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_e4df82e1-b277-4ba4-b9eb-b24c9e980ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b6245a9f-b78a-40c7-83fb-cb92a8f63e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70417684-354c-4243-b88e-0d413aee2216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b6245a9f-b78a-40c7-83fb-cb92a8f63e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_33f1f197-06d1-44d1-a8e6-f56c37c059b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70417684-354c-4243-b88e-0d413aee2216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_33f1f197-06d1-44d1-a8e6-f56c37c059b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxes" xlink:type="simple" xlink:href="exel-20220701.xsd#ProvisionForIncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e8db0b38-b901-49fa-a44f-fda50ffe476b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2a8f04d6-b26a-467b-81f3-4fa055e620ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e8db0b38-b901-49fa-a44f-fda50ffe476b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2a8f04d6-b26a-467b-81f3-4fa055e620ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#ProvisionForIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_43d13622-e16a-4fd4-8acb-ca2a701745a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_42915750-f003-415e-8e81-39ac1d07315a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43d13622-e16a-4fd4-8acb-ca2a701745a2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_42915750-f003-415e-8e81-39ac1d07315a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20220701.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e20619d8-a76f-4d31-942c-f28a397f9f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8c5a5f22-5d0f-4102-af77-9bfa85bf98fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e20619d8-a76f-4d31-942c-f28a397f9f82" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8c5a5f22-5d0f-4102-af77-9bfa85bf98fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20220701.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_94040997-7bcc-4c83-89b4-4654443d86e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b32060b4-d49f-4706-b2fa-4bb47ba7200e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_94040997-7bcc-4c83-89b4-4654443d86e9" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b32060b4-d49f-4706-b2fa-4bb47ba7200e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d06e99c3-ccc9-4e67-ac8f-ed2c61182e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_94040997-7bcc-4c83-89b4-4654443d86e9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d06e99c3-ccc9-4e67-ac8f-ed2c61182e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_07a2b0c5-2420-425e-95e3-60d8e7ec5ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_9fa2f092-c197-47eb-914e-7a20bd49a5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_07a2b0c5-2420-425e-95e3-60d8e7ec5ff0" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_9fa2f092-c197-47eb-914e-7a20bd49a5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2fdae0ec-a234-4fb5-bf96-4123e1c45669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9fa2f092-c197-47eb-914e-7a20bd49a5c1" xlink:to="loc_us-gaap_NetIncomeLoss_2fdae0ec-a234-4fb5-bf96-4123e1c45669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_20446183-776f-446c-8587-900ef564d7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9fa2f092-c197-47eb-914e-7a20bd49a5c1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_20446183-776f-446c-8587-900ef564d7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_87693537-08a4-4533-bf5f-61972423687c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9fa2f092-c197-47eb-914e-7a20bd49a5c1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_87693537-08a4-4533-bf5f-61972423687c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6abdc9e6-9053-4f64-ba6f-964183c5c106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_07a2b0c5-2420-425e-95e3-60d8e7ec5ff0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6abdc9e6-9053-4f64-ba6f-964183c5c106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b948d3f7-4f7d-4e17-89da-920a00dd01dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6abdc9e6-9053-4f64-ba6f-964183c5c106" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b948d3f7-4f7d-4e17-89da-920a00dd01dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_80c58576-349e-4e03-8de0-41fdf8c2ff00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6abdc9e6-9053-4f64-ba6f-964183c5c106" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_80c58576-349e-4e03-8de0-41fdf8c2ff00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b22bded-5fed-44b8-8166-e4d00e88452d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6abdc9e6-9053-4f64-ba6f-964183c5c106" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b22bded-5fed-44b8-8166-e4d00e88452d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_45f78c99-f198-4d3c-8e5c-0b86d4ff327c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_07a2b0c5-2420-425e-95e3-60d8e7ec5ff0" xlink:to="loc_us-gaap_EarningsPerShareBasic_45f78c99-f198-4d3c-8e5c-0b86d4ff327c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1c5de462-f268-40b4-943d-777aec61c043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_07a2b0c5-2420-425e-95e3-60d8e7ec5ff0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1c5de462-f268-40b4-943d-777aec61c043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b04b1dbc-ad50-485a-b8d1-9a77b2dae1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e23ab118-4e5f-4c40-b9c9-4dedefe704eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b04b1dbc-ad50-485a-b8d1-9a77b2dae1df" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e23ab118-4e5f-4c40-b9c9-4dedefe704eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6371ab57-d49f-46a3-bc1f-948c8dc14038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e23ab118-4e5f-4c40-b9c9-4dedefe704eb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6371ab57-d49f-46a3-bc1f-948c8dc14038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f38a2f7e-eef2-4fe2-aada-9b6618808da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6371ab57-d49f-46a3-bc1f-948c8dc14038" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f38a2f7e-eef2-4fe2-aada-9b6618808da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_1ef6236e-03bb-4d25-9570-199dadd217a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f38a2f7e-eef2-4fe2-aada-9b6618808da7" xlink:to="loc_us-gaap_StockCompensationPlanMember_1ef6236e-03bb-4d25-9570-199dadd217a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_602ac94c-7a57-46a5-aabc-90593c772ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e23ab118-4e5f-4c40-b9c9-4dedefe704eb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_602ac94c-7a57-46a5-aabc-90593c772ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8a1310be-1463-4317-ab08-d92025865c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_602ac94c-7a57-46a5-aabc-90593c772ca3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8a1310be-1463-4317-ab08-d92025865c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20220701.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d30d2b36-d3dc-4f8e-9384-f5b7a81bcba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_08769878-8d8d-47e6-bf55-853ecfa1a5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d30d2b36-d3dc-4f8e-9384-f5b7a81bcba5" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_08769878-8d8d-47e6-bf55-853ecfa1a5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="exel-20220701.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3ab1aa3a-e3ed-41f7-99c0-e5223b33e40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_e1757265-0f0c-4227-aa9d-973dcd8f46d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3ab1aa3a-e3ed-41f7-99c0-e5223b33e40f" xlink:to="loc_us-gaap_OtherCommitmentsTable_e1757265-0f0c-4227-aa9d-973dcd8f46d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis_f3885fea-4565-4c5f-9200-ba6b5be294b5" xlink:href="exel-20220701.xsd#exel_LeaseArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_e1757265-0f0c-4227-aa9d-973dcd8f46d6" xlink:to="loc_exel_LeaseArrangementsAxis_f3885fea-4565-4c5f-9200-ba6b5be294b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_39c5dd88-13d6-4a78-a3a2-6986a5462f5f" xlink:href="exel-20220701.xsd#exel_LeaseArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsAxis_f3885fea-4565-4c5f-9200-ba6b5be294b5" xlink:to="loc_exel_LeaseArrangementsDomain_39c5dd88-13d6-4a78-a3a2-6986a5462f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_ca6a56d5-5f21-438c-96c0-23c17d3a00ea" xlink:href="exel-20220701.xsd#exel_BuiltToSuitLeaseAndHeadquartersLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_39c5dd88-13d6-4a78-a3a2-6986a5462f5f" xlink:to="loc_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_ca6a56d5-5f21-438c-96c0-23c17d3a00ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseExpansionMember_3478b0a5-7642-4e70-97cf-b04b6a52bbdf" xlink:href="exel-20220701.xsd#exel_LeaseExpansionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_39c5dd88-13d6-4a78-a3a2-6986a5462f5f" xlink:to="loc_exel_LeaseExpansionMember_3478b0a5-7642-4e70-97cf-b04b6a52bbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3c5730a0-3b54-4d2c-9f00-862ffe734c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_e1757265-0f0c-4227-aa9d-973dcd8f46d6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3c5730a0-3b54-4d2c-9f00-862ffe734c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ecd170d6-71e9-4a28-b3a5-b65beab6082b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3c5730a0-3b54-4d2c-9f00-862ffe734c05" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ecd170d6-71e9-4a28-b3a5-b65beab6082b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6584b5ce-0958-4298-9fa8-0bc6c1889ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ecd170d6-71e9-4a28-b3a5-b65beab6082b" xlink:to="loc_us-gaap_SubsequentEventMember_6584b5ce-0958-4298-9fa8-0bc6c1889ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_e1757265-0f0c-4227-aa9d-973dcd8f46d6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_44911a82-3582-4aa8-9904-fc7dc4d5c324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_44911a82-3582-4aa8-9904-fc7dc4d5c324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e0c0e9a8-c362-47af-ae50-f3d048449ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e0c0e9a8-c362-47af-ae50-f3d048449ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_0a20539c-d82f-4b4c-8fc9-8edb2584761a" xlink:href="exel-20220701.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_0a20539c-d82f-4b4c-8fc9-8edb2584761a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a06d005d-9f88-401a-9bfd-ce434dfead4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a06d005d-9f88-401a-9bfd-ce434dfead4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_b7c0c9c6-8259-467e-895d-322315a2c03f" xlink:href="exel-20220701.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_b7c0c9c6-8259-467e-895d-322315a2c03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_123c3bea-39a4-4a7a-9010-4fd928fae851" xlink:href="exel-20220701.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_123c3bea-39a4-4a7a-9010-4fd928fae851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_9b01b7ad-c6f1-4395-87d2-2ff90965aff1" xlink:href="exel-20220701.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_9b01b7ad-c6f1-4395-87d2-2ff90965aff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_21177784-ca13-4d86-8c9d-a1a89e5d298e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_21177784-ca13-4d86-8c9d-a1a89e5d298e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_c2b1d6cc-102c-47e1-959e-dc998d69d099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_TenantImprovements_c2b1d6cc-102c-47e1-959e-dc998d69d099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_877051e0-10a4-46d1-b1ab-45fbac47362e" xlink:href="exel-20220701.xsd#exel_TenantLeaseImprovementsAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_877051e0-10a4-46d1-b1ab-45fbac47362e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseLiabilityDiscountedPeriod_e04dede5-0eec-4680-94fa-310ff06734ce" xlink:href="exel-20220701.xsd#exel_OperatingLeaseLiabilityDiscountedPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_OperatingLeaseLiabilityDiscountedPeriod_e04dede5-0eec-4680-94fa-310ff06734ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9d530129-cc83-4d76-9fce-056f5926cdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9d530129-cc83-4d76-9fce-056f5926cdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_d0f357b6-5f62-4c71-a767-58eec27d1d61" xlink:href="exel-20220701.xsd#exel_LossContingencyNumberOfLawsuitsConsolidated"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_d0f357b6-5f62-4c71-a767-58eec27d1d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim_21185479-0527-43f8-80e3-ec4251d990e8" xlink:href="exel-20220701.xsd#exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6d33e6f6-36e8-4700-9b3e-1a46ce091f28" xlink:to="loc_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim_21185479-0527-43f8-80e3-ec4251d990e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exel-20220701_g1.jpg
<TEXT>
begin 644 exel-20220701_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
MV,VF_P#I5%7]%=8U#2F%%%%9EA1110 4444 %%%>'_M\?MHZ3^Q+\$)O$%Q'
M#?:]J3&TT33G?;]KN,9+-CGRHP0S$?[*Y!84;@;'[5O[:?@']CCPHFH^,-4V
MWETK&QTJU EO[\C^Y'D87L78J@) )R0#^:/[0/\ P77^*7Q$O[BW\#VNF^ ]
M))*Q.L27VH.O^U)*IC&?18P5S]XX!KY#^+7Q=\1_'3Q]J'B?Q5JMUK&M:F^^
M:XF;H.R*.B(HX55 "@8 %<Y\WM6\::6YBY-GJVL?MV_&K7+UKB;XL?$*.1NH
MM]?N;=.I/W(W5>_I_(56_P"&UOC)_P!%:^)G_A4WW_QVO,OF]J/F]JOE0KL]
M-_X;6^,G_16OB9_X5-]_\=H_X;6^,G_16OB9_P"%3??_ !VO,OF]J/F]J+(+
ML^C_ -D7]KKXL>)?VK_AAINI?$_XAZAI^H>+=*MKJUN?$=Y+#<Q/>1*\;HTA
M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
M186,?B.^A;_7./\ ES4_W5(_>$=2 F0 X;V+_@I_^WJO[.GA!O!_A>[7_A.-
M<@S)-&<G1K9N/,/I*XR$'4<L<?+N_)^21IY&=V9F8Y9B<DGU-?@?BQQ][*,L
MCR^7O/2I)=%_(O-_:[+3J[?UAX ^%'MYPXHS>'N1=Z,7U:_Y>-=E]CN_>V2N
MVBBBOYO/[("BBNO^ _P9U7]H+XN:'X1T=?\ 3-9N1$9"I9;:,<R2MC^%$#,?
MIZD5MA\/4KU8T:*O*3226[;=DCGQF+HX6A/$XB2C""<I-[))7;?HC[2_X(M?
MLI_VAJM[\5]8M_W-D7T_0%<?>D(*SW _W5)C!Y!+R="HK]&ZP?AC\.=+^$7P
M_P!'\,Z)#]GTO0[5+2W3N548W,>[,<LQ[DD]ZWJ_N#@_AVGDF5T\##XEK)]Y
M/=_HO)(_S%\0^,:W$V>5LTJ74&^6"?V8+X5ZOXG_ 'FPHHHKZ8^)"BBB@ HH
MHH *\I_:F_;0^'_['OAA=0\9:PL-U<(6LM+M0)K^_P <?NX\CY<\;V*H#P6R
M0#QW_!1?]O#3/V(/A&+J%8-0\9:X'AT/3WY4L,;KB4 @^5'D< Y9BJC&69?Q
M ^*/Q4\1?&KQS?>)/%.K7>M:UJ3[Y[JX;+'T50.%4#@*H"J!@ "KC&^K)E*Q
M]E?M!_\ !>+XE>.[RXM? 6FZ7X'TO)$5Q)$M_J##U+2#RER.PC)!_B/6OG'Q
M!^WM\;/$U^;FX^*WC^.1NHM-;N+2/_OB)E7]*\D^;VH^;VK912,N9GIO_#:W
MQD_Z*U\3/_"IOO\ X[1_PVM\9/\ HK7Q,_\ "IOO_CM>9?-[4?-[4[(+L]-_
MX;6^,G_16OB9_P"%3??_ !VN@^$7[9'Q>U+XK^%[>X^*GQ(N+>XU:TCEBE\2
MWK)(IF0%6!DP01D$'C!KQ+YO:NG^"O\ R6/PE_V&;/\ ]'I19!=G]'U%%%<I
MN%%%% !1110 4444 %%%% !1110 445\A_MG?\%A/A]^S+)=Z)X=:/QUXPAW
M1O:V<X%C8.,C]_.,@L#UC3+<$$IP:+7"Y]<75U'8VTDTTD<,,*%Y)'8*J*!D
MDD\  <Y-?+'[1/\ P6*^#/P'>>SLM7F\<:Q#E?LNA 30JW^U<$B+&>NPN1_=
MK\JOVGOV^OBA^UM?2#Q5XAFCT@MNBT;3\VVGQ>G[L',A'9I"[#/7M7C7S>U;
M1I]S-S['W#\;?^"\?Q4\=O-;^#]-T+P/9,Q\N58O[0OE7L"\H\K\H@<]Z^5/
MBI^TI\0/C?,[>+?&?B3Q CMN\F\OY'MT/7Y8L[%'LJ@5Q/S>U'S>U:**6Q',
MP^;VH^;VH^;VH^;VIB#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]
MJ/F]J/F]J #YO:NR^&O[17C[X.2JWA7QGXG\/JN/W=CJ4L,3X[,@;:P]B"*X
MWYO:CYO:D!]A_"/_ (+@_&[X>/''K5UH?C2S4@,NIV*PS!?19(/+Y]W#?0U]
M7_!3_@OG\.?&+PV_C;P[KO@NX?AKF C4[-/<E LH]<")OKZ_D;\WM1\WM4^S
M3*4F?T;_  D^/?@OX\Z-_:'@WQ1HOB.V50TGV*Z622#/02)G?&?9P#775_-3
MX8\5ZIX(URWU31=2U#2=3M6W0W=E</;SQ'U5T(93]#7V3^S3_P %QOB=\)G@
ML?&L-K\0=&4A3).1:ZE$O'295VOCDXD0L3_&*SE3[%*IW/V-HKQ']EK_ (*$
M_"_]KFVBB\,Z_':ZXR[I-$U+%MJ"<9.U"2)0.YB9P.Y'2O;JS- HHHH ****
M "BBB@ 9@BY/ '4^E?F+_P %&/\ @L[=#4K[P3\'+Y8(8"UO?^)XQF21P2&2
MTSP%'_/;DG/R8P'/>?\ !;O]N*Y^%'@NW^%?AF[:WUOQ3:FXUFXB;YK6P8E1
M"#V:8AL]"$4_WP:\-_X)&_\ !,JV^/4EO\3/'UKYWA&SN"-)TN1?EUJ6,X:2
M3U@1@1M_Y:,"#\JD/I&*2YF3)N]D>._LN?\ !-;XM?MN73>(EC;2]#U"8RS>
M(->DD_TXDY9XP09)V)S\P^4G@N#FOM7X=_\ !OQ\.](L(SXH\9>+M<O5'S_8
M!!I]NQQ_=9)7X_WQT_"N[_X*3_\ !274OV"M:\,^'_#_ (1TK5I-9L)+B.:Z
MN6BAM%C81J@B11D?1QZ8[U\<ZO\ \%\OC/?W.ZVT?X?V,0)VHFG7+G&>,EK@
M\CVP/:J]Y[$^ZMSZE\1?\$"O@]J5@RZ?KGCS3;H#Y)/MUO,F?]I6@R1]&7KU
MKY8_:=_X(;_$CX/V-QJG@N]M_B%I4 +O;V\)MM3C4<\0%F$N!_SS<NQZ)4F@
M_P#!?+XR:=?K)?:+X#U&WZ/$;"XB;'^RRS\'Z@CVK[6_81_X*P^$/VR-97PW
M?:?)X/\ &C(6AL)K@3V^HA02WD2[5RP +%&4$#H7P2%[R#W6? /[#O\ P53\
M=?L>Z]#X<\4G4O$W@JWD^S3:9=L?MND;20?L[/RNT]8G.WC V$EJ_8SX5?%7
MP_\ &WP!IOB?PQJ5OJVB:M$);>XB/!'0JPZJZG(92 5(((!%?*?_  5(_P""
M9&F_M->$+[QIX-T^&S^(^FPF9XX5"+XAC4<Q2#_GN%'R/U. C<%63XS_ ."0
M'[;]Y^S7\<H? OB&[DB\%^,+H6LD<Y(72[]L)',,_=#-B.3H,%6/W.4[25T/
M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
M@JQ^WY_PM?6KCX;^#[[=X8TR;;J]Y"WRZI<(?]6I'WH8V'7H[C(R%4GY7B_B
MK#9#@'BZ^LGI"/64O\ENWT7G9/[KP]X$QO%6:QR_#>[!:U)VTA'J_5[175^2
M;7DW_!0;]MN^_:]^)NRRDFMO!>ANT>DVA!4SGHUS(/\ GHXZ _<7 X)8M\^4
M45_%N:YIB<QQ4\;BY<TYN[?Z+LDM$NB/]*,AR/!Y/@*66Y?#EI4U9+\VWU;>
MK?5ML****\\]8***^C/^"9G[*O\ PTS^T+;2ZC;^;X6\*;-1U3>N8[AMW[FW
M/_71E)([HC]\5Z64977S+&4\#AE>=1I+]6_)+5^2/'X@SS"Y-EM;-,8[4Z47
M)^?9+SD[)>;1]W?\$K/V5?\ AGO]G^+6=4M_+\4>-%CO[H.N'MK?!,$/J#M8
MNPZAG(/W17U%117]S9+E-#+,#3P&'^&"MZ]V_-N[?FS_ "[XDX@Q6=YG6S7&
M/WZLFWV2V45Y15DO)!1117J'AA1110 4444 %?,O_!8K_E''\1O^X;_Z<[2O
MIJOF7_@L5_RCC^(W_<-_].=I51W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S
M>U'S>U !\WM1\WM1\WM1\WM0 ?-[5T_P5_Y+'X2_[#-G_P"CTKF/F]JZ?X*_
M\EC\)?\ 89L__1Z4@/Z/J***Y3H"BBB@ HHHH **** "J^K:K:Z#I5S?7UQ#
M9V=G$T]Q/,X2."-069V8\!0 22> !5BOSE_X+G?MM2>%M#@^#OAV[\N]U:);
MOQ'+&?FBMR08K;/8R8WL.#M"#D.13BKNPF[(^4O^"FW_  4!OOVS_BJUEI,]
MQ;_#_P /3,FDVIRGVU_NM>2K_>;D*",HAQP6?/S#\WM1\WM1\WM72E96,-P^
M;VH^;VH^;VH^;VI@'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?
M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_/S_ ,% _P#D
M]SXJ_P#8S7W_ *-:O(/F]J]?_P""@?\ R>Y\5?\ L9K[_P!&M7D'S>U=4=CG
M#YO:CYO:CYO:CYO:F ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM
M1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM
M0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-
M[4?-[4?-[4 'S>U?M+_P0Y_Y,-T__L-7W_H:U^+7S>U?M+_P0Y_Y,-T__L-7
MW_H:UG4V+I[GV!1116!J%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!\"_\ !9/_ ()W_P#"X/#<_P 5/!NG[O%6BVX_MJT@3YM6M4'^M 'WIHE&
M/5HQCJB@_DI\WM7],M?C]_P6&_X)X?\ #/WC.3XC>#['R_!/B&X_T^U@3]WH
MMXY[ ?=AD/*]E8E> 4%;4Y=&9RCU/AOYO:CYO:CYO:CYO:M3,/F]J/F]J/F]
MJ/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #Y
MO:OIW_@F'^P+=?MH?%O[5JT-Q#X!\-RI+J]P,I]M?AELT88.YQRQ!RJ<\%ES
MY'^R[^S7XA_:Q^,NE^#?#L>+B^;?<W3J3#I]NN/,GD_V5!Z=68JHY(K][OV>
MO@)X=_9F^$FD>#?#%K]GTW28MID8#SKR4\O/*0!ND=N2>@X    &<Y6T148W
M.NTG2K;0=*MK&QMX;.SLXE@MX(4"1P1J JHJC@*   !P *L445@;!1110 44
M44 %%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P! MZ_2
M"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S>U'S
M>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S
M>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1
M\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1
M\WM0!]I_\$'?^3W+O_L6;S_T;;U^R5?C;_P0=_Y/<N_^Q9O/_1MO7[)5SU-S
M6GL%%%%06%%%% !1110 4444 <+^U!_R;3\1/^Q9U+_TEEK^=3YO:OZ*_P!J
M#_DVGXB?]BSJ7_I++7\ZGS>U;4C.H'S>U'S>U'S>U'S>U:F8?-[4?-[4?-[4
M?-[4 'S>U'S>U'S>U'S>U 'IO[%/_)Y'PE_['+1__2Z&OZ&*_GG_ &*?^3R/
MA+_V.6C_ /I=#7]#%85-S6GL%%%%9EA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
MZ/2D!_1]1117*= 4444 %%%% !1110 4444 %%%% !6+X^^'6@_%3PO<:+XD
MT?3==TFZ&);2^MUGB;T.U@<,.Q'(/(Q6U10!^>?[3?\ P0/\->*WN-2^%NO2
M^&+QR772-4+7-@3_ '4E&9HAU^]YN?:O@7]H/]@WXK_LQ2S/XJ\(:E'ID)/_
M !-;-?M>GL.<$S1Y5,X)P^UL#I7] U#*'7!Y!ZCUK15&B7!,_F:^;VH^;VK]
MY_CK_P $QO@K^T!YTVJ>"['2M2FR3J.B_P#$ON-QZNPCQ'(WO(C5\@?&?_@W
MNO(7FN/A[X]M[A.?+L?$%L8V4>]Q""&)_P"N*_KQHJB(Y&?FO\WM1\WM7O?Q
M?_X)B_'+X+-(^I> -8U*SCR1=Z,%U*)E[L1"6=!_OJO3\:\)U#3KC2;V2VNH
M)K6XA;;)%*A1T/H0>0:I.^Q!%\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #
MYO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:C
MYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J]4_8W_ &KM=_8Z^.&F^+=':2:U5A;Z
MK8;]L>I6C$;XSV#<;E;^%U4\C(/E?S>U'S>U+<#^DCX:?$?1_B]\/]'\3^'[
MQ;[1M<M4N[2=>-R,,X(_A8<@J>000>0:W:_,3_@@I^UFUOJ.L?!_6+K,=P'U
M?P]YC?=<<W-NOU7$H X&V8]Z_3NN:2LS=.Z"BBBD,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /Y^?\ @H'_ ,GN?%7_ +&:^_\ 1K5Y!\WM7K__  4#_P"3W/BK_P!C
M-??^C6KR#YO:NJ.QSA\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #YO:CYO:
MCYO:CYO:@#] OV?O^"%7_"]?@?X5\9?\+2_LO_A)M,@U'['_ ,(UY_V;S$#;
M-_VI=V,XSM&?05V/_$.G_P!5B_\ +4_^[*^TO^"?O_)D/PJ_[%BQ_P#1*U[!
M7/SLV458_,W_ (AT_P#JL7_EJ?\ W91_Q#I_]5B_\M3_ .[*_3*BESR#E1^9
MO_$.G_U6+_RU/_NRC_B'3_ZK%_Y:G_W97Z944<\@Y4?F;_Q#I_\ 58O_ "U/
M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '\_/_!0/_D]SXJ_]C-??^C6KR#YO
M:O7_ /@H'_R>Y\5?^QFOO_1K5Y!\WM75'8YP^;VH^;VH^;VH^;VI@'S>U'S>
MU'S>U'S>U !\WM1\WM1\WM1\WM0!_0+_ ,$_?^3(?A5_V+%C_P"B5KV"O'_^
M"?O_ "9#\*O^Q8L?_1*U[!7(;QV"BBB@84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"?M)?M"^'OV
M7?@_JWC+Q+<>78Z;'B*%6 EOIR#Y<$8/5W(Q[ $G !(Z_7M=LO"^B7FI:E=0
M6.GZ?"]S<W$[A(X(T!9G9CP% !))Z"OPY_X*7?MXWO[:?QB9=/DFM_ OAV1X
M-%M&^7S^SW4@_OR8& ?N)A>I8M48W9,I6/*?VE_VBO$/[5'QDU;QIXDFWWNI
M/MAMU8^386ZY\N",=D0'ZL2S'+,2>"^;VH^;VH^;VKH,0^;VH^;VH^;VH^;V
MI@'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4LD30MM960[0V",<$9!_
M$$'\:^H_^"7?[ -U^V5\5_[2UB&:'X?^&9D?5)L%?[0EX9;.-O5A@N1]U#V+
M)G['_P""O7_!-JV^)_@ ?$/P#I,-OXB\*V2PW^FV<00:E81* IC1>/,A0< #
M+1C:,E44QSI.Q7*[7/R4^;VH^;VH^;VH^;VJR0^;VH^;VH^;VH^;VH /F]J/
MF]J/F]J/F]J #YO:A6VG(X(Y!':CYO:CYO:@#]D/^"0__!0T?M+> E\"^++[
M=X\\-VP\F>9OGUNT7@29_BF08#]V&'YR^/M6OYM/AM\1M:^$7CS2O$WAV_FT
MS6M%N%N;2YB/S1N.Q'0J1D,IR&4D'()%?O'^PM^V3HO[:OP2M?$5CY-IK5GM
MM=;TU6YL+G&3@'DQORR-SD9&=RL!A.-M4;1E<]HHHHK,H**** "BBB@ HHHH
M **** "BBB@ K\W_ /@XA_Y$SX6_]?FH_P#H%O7Z05^;_P#P<0_\B9\+?^OS
M4?\ T"WJH[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J
M/F]J/F]J #YO:OTS_P"#=/I\8O\ N"_^Y"OS,^;VK],_^#=/I\8O^X+_ .Y"
MHJ?"5'<_3*BBBN<V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .%_:@_Y-I^(G_8LZE_Z2RU_.I\WM7]%?[4'_ ";3
M\1/^Q9U+_P!)9:_G4^;VK:D9U ^;VH^;VH^;VH^;VK4S#YO:CYO:CYO:CYO:
M@ ^;VH^;VH^;VH^;VH ]-_8I_P"3R/A+_P!CEH__ *70U_0Q7\\_[%/_ ">1
M\)?^QRT?_P!+H:_H8K"IN:T]@HHHK,L**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KYE_X+%?\ *./XC?\ <-_].=I7TU7S+_P6*_Y1Q_$;_N&_
M^G.TJH[H#\-/F]J/F]J/F]J/F]JZ3G#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH
M^;VH /F]JZ?X*_\ )8_"7_89L_\ T>E<Q\WM73_!7_DL?A+_ +#-G_Z/2D!_
M1]1117*= 4444 %%%% !1110 4444 %%%% !7BG[>W[4,7[*W[/6I:S!-&OB
M#4LZ?HL9PQ-RZG]YM/58U!<]LA5/WA7M=?C?_P %,_VJO^&F?VA;F+3KCS?"
MWA3?IVE[&S'<-N_?7 _ZZ,H /=$3OFO@?$;BK^Q,IE.D_P![4]V'=/K+_MU:
M^MNY^L>#? KXFX@A3KQOAZ-IU.S2?NP_[?>EOY5)]#YWNKJ6^NI)II))IIF+
MR2.Q9I&)R22>22>]1T45_&+=]6?Z0*R5D%%%% !1110 5>\-^'+_ ,8>(++2
M=+M)[[4M2G2VM;:%2TD\CD*JJ.Y)(JC7ZC_\$JOV!_\ A3>@P?$3Q=9JOBO5
MH<Z9:3)\VD6[K]\@_=FD4D'NJ''5F ^JX/X5Q.?8]82CI!:SETC'_-[)=7Y)
ML^#\0^/,'PIE4L?B/>J/2G#K.7Z16\GT7FTGZS^P)^Q78?L@?"T1W'D7GB_6
ME2;6+U1D(1R+>,]?+3)Y_B;+<<*OOE%%?VEE>68?+\+#!X2/+""LE^K[MO5O
MJS_-G/,ZQF;XZIF./GSU:CNW^22Z)+1+HDD%%%%>@>2%1W%O'>020S1K+#*I
M1T==RNIX((/4'TJ2B@$VG='XO_\ !1#]DJ3]E'X[W%K90O\ \(KK^Z^T:3DB
M-"?GMR?[T3$#N=A0GDFO Z_;S]MW]ENS_:Q^!&H^'V6*/6K7_3-&NGX\BZ4'
M )_N."4;V;/517XFZWHEYX;UF[T[4+>:SOK&9[>X@E7;)#(A*LK#L001CVK^
M._$SA'^Q<S=2@K4*MY1\GUC\NGDUV9_HGX*>(2XER14L5*^)H6C/O)?9G_V\
ME9_WD]DT5:***_-S]E"BBB@ HHHH *]@_8C_ &I+S]D[X[:=X@5II=%NO]"U
MFV3GS[5B,D#^^A =?=<=&.?'Z*[,OQ]?!8F&+PSY9P::?FOT[KJM#S\VRO#9
ME@JN QD>:G4BXR7D_P FMT]T[-']"&AZW9^)='M-1T^XAO+&_A2XMYXFW1S1
MN RLI'4$$$'WJY7P+_P1I_:^_MW1)OA/KUUNO-/5[KP_)(V3-!RTML,]TY=1
M_=+] @K[ZK^X.%^(*&=9;3Q]'[2M)?RR6Z^73NFGU/\ ,3CCA'$\-9S6RK$Z
M\KO&7\T'\,EZK1]I)KH%%%%?0'R04444 %%%% !1110 4444 %?,O_!8K_E'
M'\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\ TYVE5'= ?AI\WM1\WM1\WM1\
MWM72<X?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM73_!7_DL?A+_ +#-
MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
M2Z&OZ&*_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6%3<UI[!1116984444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7S+_P6*_Y1Q_$;_N&_^G.TKZ:KYE_X
M+%?\HX_B-_W#?_3G:54=T!^&GS>U'S>U'S>U'S>U=)SA\WM1\WM1\WM1\WM0
M ?-[4?-[4?-[4?-[4 'S>U=/\%?^2Q^$O^PS9_\ H]*YCYO:NG^"O_)8_"7_
M &&;/_T>E(#^CZBBBN4Z HHHH **** "BBB@ HHHH ***K:IJ=MHFF7%[>3P
MVMG9Q-//-*P6.%%&YF8G@  $DGTI2DDKO8J,7)\L=SYI_P""J'[57_#/'[/\
MND:7<F+Q/XT$EA:%&Q):V^,3S@]00K!%/!#2 C[IK\@J]<_;9_:7N/VJOV@=
M7\2;I5TB(_8M'@?@PVB$[,CLSDEV'9G(Z 5Y'7\7>(?%+SO-I5:;_=0]V'HM
MY?\ ;SU]++H?Z2>$/ JX8X?IT*RM7J^_4[\S6D?^W%IVOS-;A1117PI^I!11
M10 445]#?\$]?V(;S]KKXF>=J"3V_@G0Y%?5;I<J;ENJVL;?WV_B(^ZN3G)4
M'T<IRO$YEBX8+"1YIS=DOU?9+=OHCR,^SW!9-@*F99A/EI4U=O\ ))=6WHEU
M;L>N?\$H?V!_^%E:Q;?$WQ?9AO#NG2DZ+93)E=2G0X,S C!BC8$ ?Q.#V4AO
MTZJGH>BV?AG1;33M/M8+*QL(4M[:WA0)'!&@"JBJ. H   ]!5RO[3X1X7PV0
MX".#H:RWG+K*7?T6R71>=V_\UO$#CK&\59K+,,5I!:4X7TA'HO-O>3ZOR22*
M***^H/APHHHH **** "OS<_X++?L@?V#K,7Q8T&UQ9Z@R6NOQQI@0S\+%<$#
ML_",>/F"=2YK](ZQ_'?@?2_B7X-U3P_K5JEYI6L6SVEU"W\<;C!P>Q'4$<@@
M$<BOF>+N&Z6>99/ U-);Q?\ +);/TZ/R;/MO#WC3$<+YW2S.E=Q^&<?YH/XE
MZ]8_WDNA_/W17HG[4G[/.J?LO?&O5_".I;Y5LW\VQNBNT7MJQ/E2CZ@8(&<,
MK#/%>=U_$.,PE7"UYX:O'EG%M-/HUHS_ $VR_'X?'8:GC,+)2IU$I1:V::NF
M%%%%<YV!1110 4444 :_@3QQJGPT\9Z7X@T6Z:SU71[E+NUF7^!T.1D=P>A!
MX()!R":_<']EK]H72_VH/@GH_B[3=D;7B>5?6H;<;*Z4#S8C]"<@GJK*>]?A
M/7U!_P $M_VOO^&;_C8NAZQ=>7X1\82):W9=ODLKC.V*X]AD[7/ VMDYV"OU
M+PLXP_LC,OJN(E:C6LGVC+[,OT?D[O8_#?'3P]_UAR;Z]A(WQ.'3E&V\H;RA
MYO[4?--+XF?KY1117]='^?(4444 %%%% !1110 4444 %?,O_!8K_E''\1O^
MX;_Z<[2OIJOF7_@L5_RCC^(W_<-_].=I51W0'X:?-[4?-[4?-[4?-[5TG.'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5T_P5_Y+'X2_[#-G_P"CTKF/
MF]JZ?X*_\EC\)?\ 89L__1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\B?^"_'PLMO"O[
M2_AOQ1;1I&WBS1O+NL=99[9]F\_]LGA7Z1U^NU?EE_P<.^*8;OXB?#'1%9?M
M&GZ=?7SK@9"SRPHI]>3;M^1]ZNGN3+8_.?YO:CYO:CYO:CYO:N@Q#YO:CYO:
MCYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J_0#_@WOT]I/V@O'5UN79#X>2(CN2]
MS&1_Z ?S%?G_ /-[5^D/_!N[X?\ /\5?%/5MO_'K::=: G//F/<.0!T/^J'N
M,CU-1/X2H[GZB4445SFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S\_P#!0/\ Y/<^
M*O\ V,U]_P"C6KR#YO:O7_\ @H'_ ,GN?%7_ +&:^_\ 1K5Y!\WM75'8YP^;
MVH^;VH^;VH^;VI@'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!_0+_P3]_Y,
MA^%7_8L6/_HE:]@KQ_\ X)^_\F0_"K_L6+'_ -$K7L%<AO'8****!A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M7/\ Q4^*&A_!;X>ZMXI\27T>G:+HMNUQ=3OV4=%4=69B0JJ.22 .M 'G?[<7
M[8NB?L6?!*[\2:AY5WJ]SFVT732V&U"Y(X!QR(T^\[=AP/F90?P;^)_Q,UOX
MR?$#5O%'B.^EU+6]<N&N;NXDZNQX  Z*J@!54<*H &  *]$_;@_;$US]M+XW
M7GB;4O-M=)M\VVBZ:6RNGVH.0#V,C?>=N[<?=50/'OF]JZ(1LC&4KA\WM1\W
MM1\WM1\WM5DA\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U?<
MG_!'G_@GA_PT#XSC^(WC"Q\SP3X>N/\ 0+6=/W>M7B'N#]Z&,\MV9@%Y <4G
M*RN"U/HC_@C7_P $\/\ A3OAB#XJ>,;#9XJURW_XDMI.GSZ3:..96!^[-*I^
MJH<<%V4??-%%<S=W<Z$K!1112 *\P_:[_98T#]L#X*:EX/UU5A:;]_I]\$#2
M:;=*#LF3\R&&1N5F&1G->GT4 ?SB_&_X+^(/V>OBEK'@_P 469L]8T68Q2J.
M4E4\I(A_B1U(93W!'TKE/F]J_;?_ (*H?\$_8?VP_A;_ &UH%O"OQ"\,PLVG
MM@*=4@&6:T=O?)9"> Y(X#L1^)E[93:;>36]Q#+;W%N[1RQ2(5>-@<%2#R""
M""#R"*Z(RN8RC8C^;VH^;VH^;VH^;VJR0^;VH^;VH^;VH^;VH /F]J/F]J/F
M]J/F]J #YO:OU)_X(O?\%$3XGT^S^#OC2^SJ%E&5\,WT\G-S$HS]C8G^)!GR
M_51MXVJ#^6WS>U3Z1J]UX?U:UO[&YGL[VQF2XM[B"0QRP2(0RNK#E6! ((Y!
MI2C=6&G8_I>HKYC_ ."8W[?-K^VC\(_LVK2P0^/?#<:1:Q;J @O%Z+=QK_=?
M^(#A7R, %<_3E<NQN%%%% !1110 4444 %%%% !7YO\ _!Q#_P B9\+?^OS4
M?_0+>OT@K\W_ /@XA_Y$SX6_]?FH_P#H%O51W)EL?EU\WM1\WM1\WM1\WM72
M8A\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U?IG_ ,&Z?3XQ?]P7_P!R
M%?F9\WM7Z9_\&Z?3XQ?]P7_W(5%3X2H[GZ94445SFP4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_ ";3\1/^
MQ9U+_P!)9:_G4^;VK^BO]J#_ )-I^(G_ &+.I?\ I++7\ZGS>U;4C.H'S>U'
MS>U'S>U'S>U:F8?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U 'IO[%/\ R>1\
M)?\ L<M'_P#2Z&OZ&*_GG_8I_P"3R/A+_P!CEH__ *70U_0Q6%3<UI[!1116
M984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S+_P %BO\ E''\
M1O\ N&_^G.TKZ:KYE_X+%?\ *./XC?\ <-_].=I51W0'X:?-[4?-[4?-[4?-
M[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5T_P5_P"2Q^$O^PS9
M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
MHHHH *^*/^"R/[57_"N/AA;?#G2+C;K'BZ/S=1*'YK>P!(VGT\UP5S_=CD!Z
MBOKWXB>/=+^%W@;5O$6M7'V;2]%M9+RYDZD(@)( [L>@ Y)('>OPS_:&^-NJ
M?M%?&+7/&&K%EN-7N"\4._<MI"/ECB7V1 ![D$]2:_)?%OBK^S<L^H4':K7N
MO-0^T_G\*]7;5'[_ /1^X$_MG._[5Q4;T,*T]=I5/L+_ +=^)^:BGHSB:***
M_DT_OD**** "BBM;P)X&U;XF>,=-T'0[.;4-6U:=;>UMXQ\TCG] !R23P "2
M0 35TZ<JDE""NV[)+=M[)&=:M"E!U:K48Q3;;T22U;;Z)=6=;^S#^S=KO[4W
MQ;L/"NAKY?G'S;V\9=T6GVX(WRMZXR !D;F('&<C]K/@E\%]!_9^^&FF>%/#
MEK]GTW38]H+?ZRX<\O+(?XG8\D_@,  #AOV(_P!D#2OV/OA)'I$/DWGB#4MM
MQK6HJO-U, <(I//E1Y(4<=6; +&O9J_KWPWX%CD>$^L8E7Q%1>]_=7\J_.3Z
MO35),_SW\9O%*?%&/^J8*36#HOW5MSRV<VOPBGLM=')H****_3#\3"BBB@ H
MHHH **** "BBB@#Y>_X*D?LA_P##2'P2;6M'MO,\6>#XY+JT"+\][;XS-;^Y
MP-RCD[EP/OFOR$K^AROR1_X*M_L@_P##/_QF_P"$HT6U\OPIXRE>=%1<1V-Y
M]Z6'T"MS(@XX+*!A*_GOQEX/NEGV%795$ONC+_VU_P#;OF?UU]'#Q"LWPKCI
M=Y46_OE#\YQ_[>\D?*-%%%?SN?U\%%%% !1110 4444 ?K;_ ,$I/VOO^&@/
M@S_PB^LW7F>+/!D202,[?/?6?W8IO=EQY;GDY",3EZ^KZ_![]FSX]:M^S5\9
M-%\7Z2S-)ITN+FWW86\MVXEA;V9<X/.&"MU K]P_AK\1=)^+?@'2?$NAW*W>
MDZU;K=6T@QG!_A89X93E2.S CM7];^%7%_\ :V7?4\1*]:BDGWE':,O5;/SL
MWN?Y_P#CQX>_V!G']HX.-L-B6VK;0GO*/DG\4?*Z7PF]1117ZJ?@X4444 %%
M%% !1110 5\R_P#!8K_E''\1O^X;_P"G.TKZ:KYE_P""Q7_*./XC?]PW_P!.
M=I51W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\W
MM0 ?-[5T_P %?^2Q^$O^PS9_^CTKF/F]JZ?X*_\ )8_"7_89L_\ T>E(#^CZ
MBBBN4Z HHHH **** "BBB@ KG_B;\5?#?P:\(W&O>*M;TW0-'M?]9=7LPC3/
M91GEF/95!)/0&O/_ -M']LOPS^Q3\)Y/$6N_Z9J%TQ@TG28I0D^IS#&0"<[4
M7(+O@A01P695;\1/VH?VL_&O[77Q!DU[QAJ;W&TL+*PB)2STV,_P11YP.V6.
M6; R351C<F4K'Z%?M ?\%_O#?AR[N+'X;^$[KQ(\9*KJFK2&SM6/9DA ,KJ?
M]HQ'VKYJ\3_\%Q?CSK][YMKJ'AG0X\D^39:.CH/QF,C?K7R!\WM1\WM6R@C/
MF9]9:'_P6R_: TFXB>X\1:+JBQXW)<Z+;JLGU\I4/Y$=:]Y^"/\ P<'70O(;
M?XC>!;=H&.)+[P],R-'T_P"7>9CN[_\ +4=.G/'YJ?-[4?-[4<B#F9_1+^S]
M^U)X#_:B\,_VIX'\16.M1Q@?:+=28[JS)[2PL Z=P"1@X."1S7H%?S:_#OXE
M>(/A)XMM=<\,:QJ.@ZQ9G,5W93&&10>HR.JGH5.01P0:_13]DG_@O4T4=KH_
MQATEI#PG_"0Z3",G_:GMA@>Y:+\(^]9RIOH7&?<_3:BN3^$/QT\'_'WPRNL>
M#?$>E>(M/;&Y[28,\)/\,B'#QM_LN ?:NLK,L**** "BBB@ HHHH **** "B
MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
MQ)^'>K?"3Q]JWAO7+9K35M%N6M;F/G&Y>C*>ZL,,I[J0>]8=?I?_ ,%D?V0?
M^$Q\*Q?%+0;7=JFAQ"WUR.-.;BT'W)SCJT1.">?D8<@1U^:%?Q+QEPS5R/,Y
MX*>L=X/O%[?-;/S3Z'^FGASQK0XHR2EF5.RG\-2*^S-;KT>DH^376X4445\J
M?=!1110 4444 %?=G_!&_P#; _X0_P 5R?"W7KK;IFMR&?0Y)&XM[L\O!ST6
M4#*C^^",$R5\)U8TO5+G0]3M[VSGFM;RSE6>":)BKPR*0RLI'(((!![$5[W#
M.?U\FS&GCZ'V7JOYHO=/U6W9V?0^5XUX3PO$F3ULIQ6TU[LNL9KX9+T>_=76
MS/Z%**\4_8-_:KM_VL_@-8ZS(\2>(M-Q8ZU N!LN% _> =DD&&'8'<O.TU[7
M7]PY;F%#'86&,PSO":33\G^JV:Z,_P P\XRG%97CJN78V/+4IR<9+S7;NGNG
MU5F%%%%=IYH4444 %%%% !7S+_P6*_Y1Q_$;_N&_^G.TKZ:KYE_X+%?\HX_B
M-_W#?_3G:54=T!^&GS>U'S>U'S>U'S>U=)SA\WM1\WM1\WM1\WM0 ?-[4?-[
M4?-[4?-[4 'S>U=/\%?^2Q^$O^PS9_\ H]*YCYO:NG^"O_)8_"7_ &&;/_T>
ME(#^CZBBBN4Z HHHH **** "L3XC_$/1_A+X$U;Q)X@OHM.T71;9[J[N).D:
M*.PZECP HY)( R2!6W7Y'?\ !:3]OG_A</CA_A7X5O=WA?PW<;M8N(7^74[Y
M"1Y>1UCA.1Z-)DX.Q#51C=BE*R/FC]MK]K?6/VS/CMJ'BO4?-M=-3_1='T]F
MRNGVBDE$XX+MDLY[LQ[!0/(OF]J/F]J/F]JZ%H8!\WM1\WM1\WM1\WM3 /F]
MJ/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#7\#_ ! UWX9^(8=6\.ZSJFA:I;_Z
MN[L+I[>9/8,A!P?3O7V/\ ?^"[/Q2^&R0V?C'3])\?:?'@&64?8;_'_76-2A
M_P"!1$GUKXA^;VH^;VI<J>XTVC]H_@W_ ,%N_@I\2HXH=:N]8\$WS\,FJ6;2
MVY;_ &98=XQ[N$Z=J^F/AS\<_!?Q>MUD\*^+/#GB)6&[&G:C%<,H]U5B5/L0
M"*_G$^;VI8)WMIHY(W:.2-@RLIPRD<@@^M9^S1?M&?TR45_/'X*_;*^+/P["
M+HOQ(\;6,,?W8!K$[0#H?]6S%.WI_6O2_#O_  5Z_:&\.A57X@37D2]4N]*L
MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@  !C    -$" (   "1CO'9    "7!(67,  /.:
M  " D0&*8:,>  !__TE$051XG.S=!UP49\+'<7H'L0 B54#%WGO!KL&"!;LH
M*G:Q]X*H044941%[0T2Q:S1&8Q(;B<9+SLN]=WG?O)?D+J=WFDN\EC<FE\N=
M[P-SV1!V=F=@F[*_[^?_N8_'EN?9V9G9F7^V.#P#        K,C!UA,
M  " ?:&0 @      @%512 $      ,"J**0       !@5112        L"H*
M*0       %@5A10       "LBD(*        5D4A!0       *NBD (
M (!544@!      # JBBD        8%444@       + J"BD       !8E44*
MJ8\!  !>')8X' (  ( 1%%(  ,#>6>)P"    $;PD3T       !8%844
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M0@JHS+2<L]V_?__UUU^WSGQ@B)%"*B<GQ\C'*BFD4"F)%;NHJ,C(%2BD
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M5'336/E-4E8>'; YR5J%E+RMF7)S"BD E95DCD+*U]=7]Q_8 D)K-N[$.Z0
M"BE""+%!Y$*J9NW06M'A@>'!\L%)2 B%E/YX)>3S6PHIV"&)0@H ;$TR7R'E
MZN;:LF?'Y?F;Z[9LM//=4Y:8+? "L<B)%H44(808S9:WCFR_?;S[J/ZY=T]F
M7MGO'U"-0LK >!12L&\2A10 V)IDOD*J5E38]MO'5AS-HI "GE%($4*(+2(7
M4CU&]]_SWMG-KQ^DD#(\'H44[)M$(04 MB:9KY *B0G?_;,SRXYLHI "GE%(
M$4*(+:)[A]2N>Z>WW2ZH&EB=0LK >!12L&\2A10 V)IDOD)*'//-D);QD3U
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M'F#H"JGJP0%C5TP?M62R>I9.29PWP=G5F8_L$4*(8BBD-(]'(07[)E6TD*K
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M)/WP?>':TS8^KFE<&[,74G(;-6O;2OV+**0 5&ZF%U*/'S_V]_</BJA5K6:
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MM(8F-6]MX+X*L_@6=I!/ T1$?"ZM@I3GRSW$712O;I[<U+S1> 0I,#8"00H
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M)0$1J\7MMF##LHR;9VB@MBANI>"8,'&C3?:?.6_=DB-_/$4#M5&"E,WC$:3
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M2 $HAB"%B*A&.4CM.GUHX*BA^R_EI+Z73Y!J:KQGL?/H +HC.$F0:E-Y[P.
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M@?3T],:7+!*D#([P^P$ -C8B,WZR_\S9J_Q;4-\@Y3-B<$JE6?<-93EM@A0
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M-SEM.R]B - .D%=40>DE>W5U=1X>'N(#^_CV3W__1$S!_A&OOU;PQ>6VF"U
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MM Q22>59N;45;3=6WOW*38=B-J7%^$U[G2"%J$R"E,WC$:00E4J0:CQM@A0
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M^Z:\>P[:(.]Y%_%""T!KK7O5RZA,/^MB6WZO24C1\"@^14+JR+D3WLFA;LP
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MD%(%>BZ3G.=(:Y!-$A);G3W#,9PYE']DE LI8E04.5>4HI#BR(3$Q.?P@MP
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MTRI=\G3@@/D1 DC!M9EUM4(N?>U4?\6M9K_+D5%%*?(]?1YW-[R\3KYE3]M
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MAW=BJ/^5J-TF^Y)K\Q%(H=':, (IM?>'0 JM(^L+D%(<.[8,5@JD.-T\][@
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M0<T%Y,?U:JV%0 JM+&O)!J0:YABP+T%5CGFZ$ OD-Y(OD/L*W(982_[)8Y4
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M=U1I"ALSO1:,F90&I K[ZY/K\UTNN6=W5_!T$9+"F@*DZ.P>9/.)-3G;M7=
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M[^;VZ&,/*6'YK9;*SQSZ$S$"*5D.G+M@ J-$"30980J!% J%4C=I\6FM*9!
M2GOO[J"L&&C<[$\=0R"%XA8/D&(N3E??Z"0F ^&?.T^86<LS_NE1\$O:_7R"
M^$8)0.I\;$!\34[TE;3.+Z_)"QNI#Y"**DW-Z:XD@=3(M_=Z7DR$YB<$9L5T
M/Q\76)E0U/8GHQZ1OH'9L; !;6%038!4S\O)P6]NP[F#JT*^T_,AD$*C-<ML
M(/75+:>+[A7C;<&Y<=MV;$<@)22_E==R-7R?1*]C(Y"2Y<#)@@F;1T^8X;$[
MA4I1')""!-=DA:)P!%(HE :)NRF0#DC]^../>_;NL75V.&!_<+OVCMW[]AP]
MYSSTB[N**"U*0\4-I.!5@=)7YQGE6S38R(ZK_4K2'Q?8L>OY1%QE5F9'&1%4
M6PE RBW$.R@G-H]1W2\_#*&>0.J0JV/G%]?\TZ-""Q([OA@3 0JAM&V/1T+R
M$N!-CWJW3Q% RCLAZ%S$Q9Z7D\WW!R1TUY?7O>("'3U=H/QP$N5840BDT&@-
M,R=&H8/;">OC]EMW;+-RM+,Z=LC4U/1/__=/JOXQ%",$4NA/P@BD9#EPLF#^
MZ9%@R?=MF&/ \ZY[J+>"@!2DMB;#+E D!%(H%$IV(/5/__A/9@?-!W]Q!UHV
M6R<'>(V'EU($4BAND4 *7NQ+1YM<_3VJ;WX(0K0VOV*C@4LIX:V/AF%!"4#*
MYN3AI+K<ML>CDO?D$FLU!%)9'65ZIH:^J>'1I:E];VX1<^J),'-INN?EC;#\
MA/#"9$4 *=^4<%NGPZE-A4EU>6G-1>FTXJ3ZO+C*3&[#^8('*E@%&\!F*4WL
M* J1I2FG L_#&91C12&00J,US!P@Y7C.N7*BW=S!INWQ2,?SZP=MK?_P^S^H
M^L=0C!!(H3\)(Y"2Y<#)@CFXG1 =.HK?!:RZ7;HZ"@)27<_&PRA)!&R"]'G*
MUGBGCUCEGQX)6=/E<1F(+1(=@10*I0F2"Y RM3S0]6*\:+#QX+%#+K[G$$BA
M>$0 J=KI'MK"H*O_.>YIVM9JQNNIS/8K"34YL#SX]6U% RD3&_/TUA)VRC^7
M0SASPFH(I'*Z*S[;M#&BZ/+ V[GA7]R#BA7KT6_O=SV[[AGE!XV&K9.#G'M(
M)0:[AWIW?7$MMCS#XHBU@;EQ9-%EZIV^AGEFPQP#/F&Y:*#>Z:(;K+(X8A-7
MD=GV9-0SVB\X)^YTT 4$4FCT)^T5(%787V]VR*INEMYPEV5E<Q"!%%]^"*30
MJC "*5D.' I&A$N06@H"4FFT8@(V$2GS)'XI);R 50>KX).8]0^!% J%(H1
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MZ2]O]+^;7U.RHCWX]6UX'E 3()7=56%^V+KK^02EKRZKLSRMI3B]I412MY;
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MBZ&%J8F-.;Q<L3]EMJFMI:&EJ<[^O353W?%5V5MW;+-RM+,\8F.A]K8\:GO
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M];;0I!W5-SMXPX+_K+QR8M6V];N*4X_?ZA1<9#<2JLCCT[E%=((4>4#9^:;
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M(1,47:(H;XV2_&(UQ_)!GJV[8R0GCKS(Q*JLV+)TQH<DUJALP?E0HO_$&E(
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M^\SF#UK4W-;.#D%*#(Q_3T"H5*NNM=JZ.T;G)9*C0&Q9AE> #^-#HA1!"@#
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MGEWL^OEURJW(,\<=/I#>6(P@)75_"%)0S4VK+YQCH+=X[;+LM@K&!Z,H$:0
M "R!S W(D4<FR28K(];)NHFB@I2UBUW'5U</G:MW6^*%( 6 EL/XC Y"R#:%
M02J]L=C0U'A]?$3P[G!*U\5N"8Q:;VIKD=-^9*ZY,?E0MFX/]59$#_]%!UL.
M(TA)W1^"%%2Y"94<F6X'+EWRL<=SN??RS6OVE.QG_*4I2@0I  !+4+M+]@1!
MZOD0@A0 X V"%(1P@J-!JNF0OI'ARLAU*\+7+J<R8&NP[X:5)C;F.1U'#4V-
M_$.#5FRAWHH\L_.B>0=/EB-(2=T?@A14N6MB0E/K"A1H5FL%^>[5I OW$*0
M "R!'%T3*CDR23;Q7NTGZR:*"E*Z!GK;#L:7]',1I   C,_H((1L<_22O>H<
M]Z4++O_[9P/_]W[_[^Y)]\+_'V[_\HJ=AU/^J6/V'LX]WWQ\_O_]A'(K\LS)
MQW/3N;AD3_K^$*2@RA4&*5MW1P6>)T4^SS#^NA0H@A0 @"6H79 BS#'0+QU
MD ( ($A!",<K#%(9O)(Y!GH^P<N]5_N328MT%Z]9-G_%8AT=':<%[N37A:N6
M>J^AWHH\,_G F]6*,Z0H=XD@!56K,$B-#2YPG A2  "6H)JYP8<'J9<O7TZ;
M,I5L:&AJE%*;7]+7@" % &!\1@<A9)O"(+6?6V1L:;;M8-S6C-U;TG=12AX6
M4Y <R8DEOVY-I[N)]QI_S@FL(46Y2P0IJ%H1I"A%D ( L 1U"5)_^\??XP]E
MD TM'6TZOL2BY@   8S/Z""$;//=7?:\/7N^^;CS^5#'5U>5(7GFN,,9N,L>
MC5TB2$'5BB!%*8(4 ( EJ$N0^NOWW\<6II$-S>VM> _[$*0  &\0I""$$Q0&
MJ>2:/*<%[BW/!IL>G%/2CL@S1^<G930=0I"2NC^L(055+H(4I0A2  "6H"Y!
MZN7+E].G3A.>(84@!0 0POB,#D+(-A&DI(,@!35?!"E*$:0  "Q!78*4:%%S
M!"D @ C&9W000K:)("4=!"FH^2)(48H@!0!@"0A2  #UA?$9'820;2)(20=!
M"FJ^"%*4(D@! %@"@A0 0'UA?$8'(62;"%+209""FB^"%*4(4@  EH @!0!0
M7QB?T4$(V2:"E'00I*#FBR!%*8(4 ( E($@! !1(=EN%O%;FG:HRL;:8) Y3
M:XN"KF/D!S\D=@OYS\"H#1W/AQB?SD$(62B"E'00I*#FBR!%*8(4 ( EJ$N0
M$MUES\K9KNWS2PA2 + 3YT7SY-?;PVF!F^,XO=R<%[J[>'L('T-^\(TM35=L
M"4:0@A"*%4%*.JH.4F]&YIH(4E"5(DA1BB % & )ZA*D_O2?_^GALV"2C@[Y
M+)K?57VHKP%!"@ 6PCEQ>*R9_-+DX[GT3:W-3ZT38TIMOO !G);#B]<N6Q3D
MU_GB&N/3.0@A"T60D@[.D(*:+X(4I:(@-?9T= 0I (#J49<@]?K-C[77.W6F
M3AFY:L^V=("+( 4 "QEWJ9V.CH[30O</.FWJ?<FSN2[VC,I.:/W\$N/3.0@A
M"T60D@Z"%-1\$:0H'1NDA%]!D ( ,(+Z!*DWC9_V"H.4B;4Y@A0 [,1[M?_,
MV;/<?.8O6+E$9_)D8TNS$T\ND!_5D\\N*LR?7N1_=IY[_PSCTSD((0M%D)(.
M@A34?!&D*$60 @"P!'4)4G_]^_<QV?MTIDR>I3M[0\*VDGX$*0#82.\W']NX
MV!^^P&O]Z:7I,V<86YHUW#_#>]3?2#X3*E"F)W(00M:*("4=!"FH^2)(48H@
M!0!@">H2I%Z^?#ESQDS!HN9.MBU/!K&H.0#LI/7S2^2'M*#[./=>[VB0NM?+
M&^YC?.H%(=0214'*U,8BN[TRDU^:V:P<^:5!.S8A2%'M#T$*JEP$*4H1I
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MM.1M%X<L;QSNDS(DD:47&B4__V2!<HY-XK8'V\IK[W13#JQIN,\O+$CR\W_
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M;NV8TXX;,'"?V<MO4DB)2,!)OV1OWII[!H\8VK-7SQ,_>NH;;[Q1ZMUP'H[
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M:-C@WGW[+'DA4>H=<'Z.P(!V%%) V!12$"L**1$)/AU^96_@T$$**: L*:2
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M]*LOVGO0/@HIH/PHI(#@N60/8D4A)2+!)W4/J;O7)6J?7S%L] B%%%!^%%)
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M0FKQFA?G9ZFZ*F8D7NOX&G9LW7!?MDFGSUN<K*@Z%E*M154TS>RU6V)UTA@
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M)>IF5;?[P;[I\U9V^#T^   (F4(*    @*)22 $   !05 HI     (I*(04
M  ! 42FD     "@JA10     1:60 @   *"H%%(     %)5""@   ("B4D@!
M    4%0**0    "*2B$%0(R\\Y]N[<XI]>H! ( B44@!$",EKYP44@  \+9"
M"H!82?8^MZQ=UMVBD ( (%844@#$B$(*  "Z X44 #&BD ( @.Y (05 C"BD
M  "@.U!( 1 C"BD  .@.%%( Q(A""@  N@.%%  Q$D0AM:VA;EJ/3IQ2U["C
M:U=CM[!E[:R*Z-5.FI'X0_=XN5L:UB;J9IW2]D94SZI+/+ZV84NI!P8 T!TI
MI "(D2 *J3^MG75T[ NI'5O6SJYH?KD5L]:6OO+9^DK=]$G9WXZ*V6NWA/]^
M  #L+(44 #$25"$5B^(IIQVO)69TES.D6M^1BNGS$NLVM8QF^Z9U3R7J9E7'
M^VT" ,A%(05 C"BDV.-V--0U7Z?7':HQ ("RH9 "($844NQIJ8L'I]4U;"OU
M8   RH9""H 844BQIRFD  !VA4(*@!B)4R&5*DHR+R7;_EKBHHIV]]M.SK/B
ME+H-.][>L;7AV97SIE>TWB-]5MW:AJW9EK2U86UB9;O?E6N:>-6Z3=NSCZ1Y
MP#LVK7N\;E9UR_23FN^ZM#W+S)ONP;0J;>;1E \\GKI!T]NI7]E+CCGCQ4=+
M22R>5=WZ(GI45,]:G(A>1ZZUM'-C:S^+EDOV*JIGK]F4MR)L&7:RO=K2L/:A
M>:F[H5<WK^ELSVE8^WBB;6 M+Z?=VF@_HN@=3+1[(0]DF[CI+E=I;W33+;!6
MYIXI ,">I9 "($;B5$B]_?:./R1F3,K\H;=LMP-/%5(O;DC,3BL^6E5?L[9]
M-=,ZDVPJ9M1M2/_ANU3ILW#MBPNG9SZKXJ+$:QUZGRT;ZK+./NTLI)R%U/9-
M+V5;2DOG<M^&=N7:+HPM]WINZHF6Y^FP4H74NE\DVG5Y+<OKV&JUS3S3I.EU
MKV046+E67?N)=[RV=G;FTI.K:.%+!=1P  "[22$%0(S$JY!JJXTJJN>]U%I&
M9'UZ2R%U;/6Q%4V5Q/PU#<E&:4M#:S]5,2/Q6MKBFDX+:CZC9FU#JGO:TK!F
M?DNGTV[FJ7.U6@J/>6N2YP&U39]EYLD.97Y]2SO3=/+2XEFG7-76K&4OI'9L
M73>_NG4Y;3]YM[5A;>L90^V7M=-CR[Z>-ZV9W78V5J>G5K4,^^CJZ@G-4S[3
M<O;9U@VM_53[,]IV;*@[Y>CI\QY(.[UKQ]:&9UK/J^IPG6#KN6_IU5BTZA+-
MYT&U]9)_63?O]*:IVIV3M:5Y'544^)(! ':30@J & FJD,JJ8TN5:BA.G[?N
M+VE]3?)?,^>9>=U9ASET+C5Q>E&25OIT/--J6T/=M(QBI77Z]B=V=92UD&JJ
M;YK_MN.94.EC.WK6VC_MZMARVK'II?O:G?&4XVRIEF$WO56SU[:O?5(G0U7/
M7Y?U&LGT:5NKQG8O?^M+\W(T2DV566N=U]+W93OYJ[4*=#\L *#+*:0 B)'X
M%5+M:XY-+S87%NDG3+6?9]:SKCJ]6U,'V1J-SF[[W3I]MI*H\\OELHTJV]PR
MG]*C8M;:UM.Z=G9LG>MPWZMLK5-G*W-G[H_>4KVESZ? I[<4;6DKH?/9 @!T
M"844 #$25"%5\*_L=;S?4Y83<#J=9^JTHZP51H=I]T AU7:F3_-]MI_-?DOU
M+,U.ZSE-.4^MRGR9>[:0:GE>\P6"J5JJ_9EEG=^+O? E9FF.\K[\]"=V3B$%
M '0YA10 ,1+/0BKM:K6,?J20>:8JC(SK 3>M>RJ1_CMM;7:OD.IX5Z9L/RJ7
MI=EI?15Y"ZFV";JBD&H97^KFXNTNH"NHD.KX:/./!C[0]GM\V9NCO"\_.:]"
M"JE=>\D  #M!(05 C,2UD&J]B763]O?,+F2>60NIW#_3MD<*J69;&M8FTDXU
M:G]_J^Y>2.48STX74MLWK;VF.N=ZWO5"JI#SW0  NHY""H 8B64AU7HC\XKS
M9EV6K#LR[\VTLY?LI6[XW?$7Y?;,)7L=;&U8TW(:5EK_TGTOV<M87/K,=_*2
MO=:_:?^C@6_OB4OV=J+0! #8\Q12 ,1(' NIEOLQ-3<7.7^%K;-Y9OE!M]QG
MV71)(95UA%F:G=2".K^I>:$W B_Z&5*9OU&8NV/:]9N:%W8B%0! %U-( 1 C
M\2ND6B_6:[F1>>O94ATOW$N=R]/^LKCT.60YS2>SD$I=7U:20BIM8!T;M[?3
M;NJT1\>V8T/=Z3/FK6G8FOE(Z[WDVZVEUA%F^0&^U*W<V][9G.51ZSVV"GWY
M.S;5SY]Q??-,VCX#T^M>R1PV $!Q**0 B)&8%5*IZB'M1N8[_I"8,2GCPKU4
M(=7<2<VJ6]O07*'LV/32_)9KY:KGO9167J2*DNGS7VKIKW9L6I=HN[_Y[I0^
MT<Q/F3[O@;2[F&]I6),<1^>7[+V==I)1VJMH-[8.+V1/%%+)D\6FSUNY-E5+
M;6GZG;V6'PIL?X%D6R'5]!8VC;'Y-P2;"J.6>Y:GWW4^-;Q)T^?79UO1'5Y^
MZE+*Z.4O;[V4LG7MI5JMU&>@XQ67S7>I;QJXDZ< @"ZGD (@1H(JI'))M0FM
M%^NUKV#2SMQI.X^F=9[5LQ9G^]&\BNGW;=C:_@R=UIETF+!ZUO7-1<QN%E+9
M7V"[8>2Z]JVM1,N45NOLXM@R[=BZX;Y<R^M1/3O1T/X<LM9A5\^Z/=NOYF6<
MM=16'G68\V7SFF[WGOGR<]ULOOV<M[Y2EV7IK=Q>"@#H>@HI &(DB$(J=19,
M#BV%5.MD+1?KI4N=1I2J6M+/NMK>? 9.:UM1/:ON\76;LM43.S:M>[QN5G7K
M4JMG+4XTG>Z3/&.HT$*JM:!I7_IL;5B;>""]KVE__E'Z$[/>C&G'UH9G$VUC
MZ]%\+E)B;4/FS\KM_-BR:EH7&0/.NM[2A]W^7*=H!69?TTTS7]QROE7R'4D\
MV[#U[\WO;]:7W^'7"7.]]FBRQU>VZQ\G39_W0*)IYNHH *#+*:0 B)$@"JFN
ML+._W,>NZO17]@  XD,A!4",**1R4$@5BT(* *"90@J &%%(Y:"0*A:%% !
M,X44 #&BD,I!(54L"BD @&8**0!B1"&5@T*J6!12  #-%%( Q(A"*H>60JIB
MUMK,'V-C3RK\E_L  (*FD (@1A12  #0'2BD (@1A10  '0'"BD 8D0A!0
MW8%""H 844@! $!WH) "($844@  T!THI "(D63OTVU3ZM4#  !%HI "($9*
M7CDII   X&V%%     !%II "    H*@44@     4E4(*    @*)22 $   !0
M5 HI     (I*(04   ! 42FD     "@JA10     1:60 @   *"H%%(
M%)5""@   ("B4D@!    4%0**0    "*2B$%    0%$II      H*H44
M $6ED (   "@J!12     !250@H   " HE)( 0   %!4"BD     BDHA!0
M $!1*:0     *"J%%     !%I9 "    H*@44@     4E4(*    @*)22 $
M  !05 HI     (I*(04   ! 42FD     "@JA10     1:60 @   *"H%%(
M    %)5""@   ("B4D@!    4%0**0    "*2B$%    0%$II      H*H44
M     $6ED (   "@J!12     !250@H   " HE)( 0   %!4"BD     BDHA
M!0   $!1*:0     *"J%%     !%I9 "    H*@44@     4E4(*    @*)2
M2 $   !05 HI     (I*(04   ! 42FD     "@JA10     1?7_ UR&&%W1
/KJF<     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
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MWI9'M?.':*LL+<8#9.K)8W&AZD,Y=^-OI)E ^UFLI9!P@>^"[[110MI2@:/
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M:7B:J>K]4+O6H(.\8X(K-;CZCKN$<7.UPV[%U]&]+Q-@V$FUSB.*6@TUO4V
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MF7&O$7T-C6PZJOQ(WNG&A3(4!@3W<B%NDJJDE>SG@0$#M[+BGB]">EMPVLH
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M/,+Q%/+(B4.'?CEPZ-C^PS5Y=/_APY4\<O2 CT=!LQX[> 0S[#MZY,#Q8X>
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MS.5YNPY?+C7O*+SU:>[^+;]<//O0?-OAN5)J/5!X=<J250V?>1Y<]L# (($
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M[!.YV"=J\9R(Q3-#XF<$Q<X*B?4)CYL3$CUUWJ(1D]Q!S \!,PO:8/Q$(#1
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M3JJH@]*J(;6HRIL594UR'(J*9A5-W,F4:=ERD,%F@<8BT$#O6&!F\>1V'%"
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M#=%)IM0. 'H-99K(3&DSDEMAUE@Y\EXXDN%E&S@Y,TT,WVZBBLWH5E(; 28
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MI6LIVRC-^G*IO0RE;K0,Y$=L%!0N>=:2$R#TVP"H^+>406.",$-WL$)WHSL
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M!@$Y#!><*U#QZ!%9:B7A\20 26JID)C1<BE\<P6H(/A24 )/Y0>DSRJ!I_7
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MP![$J(+[4T5*6V(1F;.$%K?(DBV&LBH%*N !ZP=S?WOTU8]:A0[HU"UD//#
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M@ " Q!RSHC3E009)CNY.(B7(IQ"W*-)^$;:*L)"#=A?$ $)U%A%LFH#\>F
M">(!,+_ #=*SE)ZH@>+C 9)QA<-[,&]1/T3C7+$Q^/$D)Z9WGA7<:^[  U@A
MYCX(#;<3A-S%'7B D[\(B91"&JU=8?;$0/WOK&AC9G2J%^W]SPKG=AC\%%K'
M'VK>_)$GQ[PCFJU4.Q$/B/5Y0BT:.-1LAU*?&:N!F$6DH_.2"0_ ^;04>^.0
MQ8JH&GBE:MA<27K2?[YAQ=J( S  F]%:!UX<44A31Y]EM$O--KG1 0LI\$ V
MYH$"I"P*32Z!QHIYX.F6;3N&]ADT>89<&< #K#)JQ HWE-S&F@?VEP!]D<G^
MR>U\4&AP4Z%M!JBG)L<6 (CS]A\.=DV#9<U?F28]0.Z., 9I +&%RC%I$*L%
M;9PDN2+(80IG8K =%?![]AZ)E0D^C@45MNP#3%$(V"5%T)1T7E3:_BG'J>J"
M54,BH)OB\  9;1-CST=(YS @H<-">HRLF?2RR1EQW#"Z'YBI*V$L*DBM5_KS
M@,""RWZC%9(JB"8\\,7"H:]\T*I[?\(#,V*^D"Y)#N !ML/)1T@Q^ 'U-<8#
MM'>32XP/&H00U4H0(E.JM<<:L^*,,"7XID*^9<4G/U%/3GZO96C(@YW:]QHQ
M8A(?\4!&%)4O,N8I#"X56,]LTH8VM6 A'<MVLI2TF9B8(";;#L'$.IN8<A >
M@/0&E!WQP,1/>9T&CFS=KO^P82]\%!4O3[0@'@A/R9B>8F5Y(.8V/, 1KBT+
MF 1;2*#'3$Z:!R "P<O39_.T.2)]7JRY(%KGFA;W2^^QK_RK0Y>0@8->?/M]
MW@\)T7BCI,F0A-\0%U_NUMD(#W#BFUV05Y>.B:?G,VVI0X^,SB$WNZ+3LZ<O
MTCWU:637)YYNWGW0@ZU"NG?IHXB4[=^TJ[8<_%40#]RJJX9T^('Z[/_JK[^?
M!\!="!RV;A1=R["FC)\ ]8D?:O6OH4\^FIAJN%!7?O!64=[10PDK5RY:N<YV
MY*)UWR73JNTY&_\X?N[<M;**[:=OI&X\H=MPRGGB9LZ%"NVF$_-M*].6K]E_
M[OS5VMJMI\]0V?D:9V[.]D,K3MVP';GF.%J2NN7\]/BE7?H^]F3O4&VLZL"F
MPVL/UB1O*TO,V;G,F[?C\-XK5;>.EM7G'"W1;3N]<,O>13MWZ0X<T&W985Z[
M:^6^RV=+:XKJZO==+?7L/6O;>;;PX*4T[[IWI\WLW^.188\^.?7S,(4F,<:>
M(;*D*_19)-^HDD*4;.<9LGA);@%4Y'6H=(XX"HE3!=N56Z#+E:6LE:6MEY@+
M>;^:1T^:TJP#XH'082]/^7#N0I7)@Q1]*;8\JHRN&+,'P0 (^B%(8LP0:]NP
M-,0#D+&$0@M*)C\I'<F]\H!,G2/6Y@GU!7Q#?B14@G0K+2[A$N,;PN@^(\<_
MU+XKRP.QNF15FE.<YHDP(A[P"/2Y,EV>0IN+> "4//2$TSS@D)F<N!([.0?%
M^SWZF=Z3&![@G).1-3%XD?)3@S@BA=S,D"DR2+)$D/#4 >D^0?<%'HC2IDSZ
MXIM>_WGC7]WZ=PT=/NF-&< #VF4\7<I,?<I,*IVOLT4G.>*!!SQR,SB?0"0N
M)WZ WKG);M>(R8+L;<'"U17(*D_V9CA.QEDXD?AX &, YYB<8R[ I8A8'O!3
MQ/TE4.O%PM7:[YD'?'D_N/?EA8SOF$9H(6W#H6!8^V?%YP7$"L$#'P^8\HC0
MR4F)B8!["YQ/ 2YBF8>)FB#YZ<!(S<3:LI]+NT4%]0EP"XP(!AXB01HVEP?H
MWO!=#QH&N@;! $Z0E1=M 1[@EA=@=9% ^1_C 0<GARF! 8=$9Y.;W'%IRV,L
MGAB3/38M6VAP/R_ZJN/@44W^W:QILV:#1HY^5SQ;I<F*25XEU.7RU;"1*XQ.
M%66+T]JCD?9@SN*GN/D6"'P7:T!?)$?(H(CKLL#W!@?I<@X+_82]-:(]$#TU
M&@GJ>=29>*WC:^Q1238!Y$1WL#R@TKN5NFPYE2<S+I>8\T5FMU";^9;LZX='
M3FS1!GC@S1DR19)=P?( IR?9/B%M".Y\6K%FTJ-QU1H27 0OQ!,@\#%GAX/[
M'-$K24-3 D\&<!K$/,D5%@FX;>-V%[?!3)M]6CA9N,B$898=>@7&[('C"G!>
M!R6= I4^1&>%D S=4<200BMY^/9Q#Y N)8N;;V(SG\O>8\"#!NW!QT/0>_ J
M)@4JN$XY$6VB(:9YP)(E,+L%)LP#QH(88Q[B@??G+!SR\GLMN_7KV"UDP@LO
MA,5]*4](E9'C=K;!A ?\#YX@Y6B#/*"FLZ/BH *7  =B@6,/NF6-7:YWQIG<
M\29XVRCC\BA3X<<_ZD?Z\8 R<JF59R@0&O/EE$N)RUQ(_5,"<(75F,5X@OEJ
M4(#BB\G0G(TZ%D=IVR1@AG)(#$X1%$OV8BN<+6R!^KD9PJZ#1[7I\/"P8<]_
M&!DG2S"+4ZP1J=89J9EA*?9[X@'LULL(Y_<BHT-H0I(E-+JAJH A5VC(1_@=
M8\J7)F2^*?^AV\CGFK3K%#+PD1??^0!X /O@0>(-DJ$(@RZ7'MFY0:80EP?H
M'*]8A#@YE814Y,#7*R#,"2TI:&W/4J"5*B,'\<"3GT1T?'S\0]T&-FT=&MJM
M7ZQ0=6CKOKJ*VJKZ^I*ZZO*Z&E(<*U"C_5_\]7?S0 V.(  >*"J^9LU,FS 1
MUR=NTW3P$T-^5"_>?N'LZI/'[;MV)F_ZW77PX-:RRBU%-9Z=Q]WK_MBT]^#.
MX^?S]YRS;#R=MO/*VJLUVROJ\XY?TZW8IL];E[_KX+:SEY<?.&Q:O3ISP^_;
MSE_:7U6[]D9%]JF;YG6G/Y#\TK;;@/$#^J9\_<WF-2<U!65QF9=U!2>/'#]W
MLZRXK*K\]*V*;:65><7EB2=.RS9LB%A>\,V6K>XSE_:655ROJ:RNO76M].;O
M1Z^:UAW5K=@WWY+]RN3/^_09/N+)9]X-$\B3U"IKAMB<H=!EQ2?EQ27E*"BG
MT&R+,#C"D[)XB0Z9QAEG]'QA\<XQ>Z(IDKX7\T#J>HD)\8!IU&N3$0^T">GQ
MV"M3/IC[J\KHCK-XI9#2SJHR9)'4U]&-B*K!X %&W20++NP$.BC9 PLQU,]R
M"C56P@-HX;A7'I!H<X7Z?!Z5%V'R"I,]A =>%W!Y0/Q5@B$.\X HS0T\H/?G
M =@@75*C4V*R(Y$B'L >P[!K@@Z=A9V5R9D0H[C@+03?"\='*$@:UAO >3W0
M7Q]+%H[$0CS@9GF M@_\Y_6&><"0+M!GQJ@=LY)<,7JO ML'9*8<=BMEA:0#
M9]L0(+Z=[[:B\!E), \PJC_W9Y]]@+828$,!/GH/4.6Y;.#[+Y9@]9>]YJYX
M@'/CP7<A!_L^B=#P$V)_@//X.PE)0$2H0&',8<5WOY2_$L^% ;T?U8! 70+@
M!U(#F/2GCRLX[\/M'^"!H/MJ3.C>".HB]$A"@2I<-X/H<RQ)@I[42._YWI#1
MD.[, W<:$?8]01=GZP\8<(2Z[VU]/$"0@%0Y0#P0GU88:_%$$QXPNI\3S>WP
MR)--'FS>M#GPP#3)[&BM*S9EM0CL V!749B<T09[O,X1@QC G,5+=O/,+BCV
M#.?'+E#H WC 7S=J\+FF'R7LW \%W0S  ^ 3CSWU!5H[^ LUS ,%A <$VLPI
MB >P?:!GO\&(!^0)-O30D3-X[D?#S\S)?<-"^RK0/, %"=J-AXQO@'[/_2^C
M(OM^&?P;^I=0OYD  +O4D_^2B=1@=]%W@86KJ7,_#E\))(-7'A N#Q \H,]H
MR"$]>]*$S_BY[207D!OG-HD[< W<74-"+X,,#^![P0DGV#H/E$-FM'-Y@&_R
MBH 'EL<8\Q$/O#?[U\$O36O!X0%%8EJC/, XIHIQ]#:$$"1:2>P$$9]1"(\U
MAP>P,P_A ;-[EAG>(9+*CS0N!QZ8,JUEC]"F73KU>^JIR9(87J*-9UC.IW*E
M.J=<8Y5IK!+(%!PTK_#48E$$: 3G\Z%Y0$?S@ J7IH9G!V+-@0?$D($4*>4>
M2'M >&"FJ-O0T6T[#!@^[ 7$ ]*E)E%R!N*!Z2F9,YGX@;OE@09%!^=K03Q0
M($6C8 8>> /SP /M.H<,'/3"V^_SOE\*9:V-7GQ' %=2.#B L6:F(F=S">(!
M+*R!%_J$/'=DSI!EC>6!Z/3LSQ?I1GX<T0'SP$.M0WMT[Q\OCCFR_0#A@=*Z
M&L0#]^T# 5__  ]4U517UF,>R,Q,G_@TU"-KV;K%P&&/*K^=9UVW/67]=MOV
M_>O.G#]85GJBINI8==W.Z[?R]Y_2%_RQV/V[:=WAG,,W-EVI.GBK]E15S9&R
MJDT7B])W'/\U]X\%K@WF/_:LN'AA]XWK9VZ57:BM/E97M[6H*G7CB:E1W[3L
MT'?DP$%+OY^?L_;4O)QB4=H%_>J+YZY5(B2\55-YOJKD2.VMS=55R><NJ39N
MF9Z=/W?+3M>UDMUUU9?KRFIKBDI*BC8<O9RP^M!/>?OB]-[1KW[:*638(\.?
M>?,SOGA1HB+5*C9F*G2>^*3\N*1<&>7D)5O#S+8P+:17E^M<L\S>+U-RYB9G
MQX)/FT>HSY4'\T /X('W@0=< 3Q 0HK1]P#!I<H"-TB_IXBCE,@I0@X^'A"H
M,_XR'N"K>C\Q+H@''/?" R2VDMDY<"P!$;+<X.,WO#(VS@.L^&V$_P4/O/+Z
MO[HVR@-Q:L<<C2N6RKX-#P1T?H $[WD-BF\C--T;#TB9" '65<:GW?Z_R@/D
M.-_+9L[Q'>IC3FB0!P))@-P(TGIQ%3:5.3_:4D"$]CO"Y1=\G?"7\H <'SUB
MC8J8[^@S7:S,>2'0OY'>\[WAW\8#Y-!7%OC.=^:!&,P#SPCFM!_T!.*!9BU;
M#'YJ['O2+V+UZ)HUX)FCA[=%/!!#>( B/.#BF\%&)X68"L8K!L</$'V:#=5@
M'^=@A9+I6% H(6$KA%SC&%D='7 ))9 ;X@'4*J0L"@Q9?+65\$#K]IW[#'AT
MRDR%;&EF  _XY$X\0"=AA'** 3Q %K0[\4"P-*@Q8QX@I@/NTT?^&Z!\^RV#
M]\(#<JS0<X5<X_LO_E#&UXB.<^!:IZ/I&4Z20##V@6 >"+[K(*&9ASDV)E,4
M:\;@Q(]^EM^)!Z;-7O#?\X#&AF" +E'L+X0'F,KK#?- A#XOTN#C@6;=N@P<
M._9M^2R!VH%X(%+K%21:)8EIXL1ED+LV>%Z1J<7A 6*@\/$ ':,"/$#*/&.N
M@+B"V_% %.(!H]!,>, ZT_SW\D"LN4">:)^LF!?RU/,/M/?Q &1>(3R C2W2
M>^8!L!($\P!X#V);%M(K)%J'S 3^0I@'(CN-F-BLVR/  R']XR6Q1^_SP&V_
M_F8>J*VNJ2E'@GY37'P=>&#B.+ /M&@]8/ 3O)B?$QS;$[Q[;-O.[KY6<;FN
M^EKMS4O5-P]7U;K/W(SQ[(RRK/MMU<&UYXI/5U85UY25UQ27U)8=K:Y==JQ$
MZMPU75?XW=I]RV]6':^I*ZFHJ"@O*ZVK/%Y^*V73GM?"8YMW'-#KX6'R;W])
MV78Z:4_Y3[\7+UU[+GO'V<,7;UZM+CM??6[/M2,K3AQ-WW<R<>?17_XX\/,?
MA]4'SWIOW#A:6UI>=>W,^=..G<<6;CFU>->E.8Y-3TT5-.\R+'3 V)<_B!(N
M5*O2[!+T.&FS9R4LCU?G20W.B)3T&:F9X2:TY[G11A5O=']A=G]A\<X&OV'(
M+Z1@X@?X"\VC7L/^0CUZ/O;*6X@'E$97+/  Q \@-H@VN2&OJ YRF06(7.^0
MD>*^#0JC&9"5EU$NT9)*\P#Z?L\\H*%Y("K0/J#L-8*)'XB4?)5HC-.EJ%()
M#S@9?Z%\A0X2+OG["_GL R!$B](SR32X?HHX[HWF@<9-JT3\-D+*EQ'/7UR-
M\4!/B!] //#XI#=GRK]=&JU+Y^M3PJB4,$.Z4&^+TV3-T7@0#\C-.5#UQ@2)
M"(.W,;]%S5\"KVQ(:!,YAP>")8 'B$,1Q.8RA06"]/A[D[OD@>#&!PB)'VCL
MS8,!($AH'B _ P!@D6AQ/%D0#[#Q P$A$-P;D2&L0CQ 1R#D*Q%<X;H' ?8!
M-O0"\0RI)G:W$C#ZM([E5= /(YW8D1R-1T,.D*!W:$P"M780A@<8)2_X54%R
M%SS@#(@?H'G Z(Y+71YC=D>;;#%I7N !_IQV Q$/M&C1JM6CHR=\(/\RWN"=
MG;Y>;BJ44+GX?AG[ ,,#2&F#[$PX#Y@/9K :313'!I_E@"ZE%07"%5J<4!_[
MP$#Z70K'")E\/!"-> #"47+%^CR^WLO3VWA)&8@'!CSU3-N.7?L_,FQJN$J6
MT#@/W$GHNP ]FP0_^)H*=P1+,:UJ_RF!6W81/VFZH^@%'_Q_)+1>&]17_CQ
MA-X=.&^.^],%[T\QF788P;_ANOC#9>1*\B:TH8D4E4^! #8VABWP6>",8.#=
M!0F+(H&W0,8:Z,6E@##W1OR%3/ERQ .S%CR">: 3S0-?W88'B+ \T)B ^[X6
MLG,RF92Q]@P\8)/K'/'  VAI\O' DY.GM>H1VKQ[UT'CQKVCF"W4.'F&@@B-
MF[=TF7!)BF!IF@AJ P>.$;E3+@R0$'#604M&*CR8@0?@]UIB6X.D0\$\T'7H
MF+8=!PX?_N*'O'C, ^F1P ,9,\R9?P$/@+^0,Y@'B+^0+-%&\T"'SB&#'GGA
M'8@?B,73@^8!4KT;[WIWSP,0/* !'F![@RRM9'65ZITB=2;:UE68!Y[Z-*KK
MR&=:A@QIUJ9'3\P#Q#Y075]_LQYII?=Y(/#K;^6!FMK:RIJ:6TCJZ^L0#U@S
M,\:/!QYHUJS-P$?&2F=K37EG]/GGTC=>_OW4S7-E-TMJKE^ON;ZCY);E5/F7
MVZ_/V7@A8>O9W"-G3]RX4E5SM;[FPHVRBQO.7UNZNRANW65EX:G9&TXF';J\
M^7)926E%_:V26V57CUP[KUN]]J69DA:='FG=>_BTN3\:#Y[,+:OU%M=8]E_7
MKCOAW'9^Z[GS.R[L*-BYW+9FM6?KX36GBU>=*TO;<W'QUA/FXV<WW+A\_,K9
M3?OWZ3;O3CIZQ5%6K=EQ[A7>MRU#1W7H]=1S[T:(?M/%+G-)C5DJ;6Y\0F&<
M.A\IN.$IRV8LRXQ*]4K-.2J#-Y;*BJ><LTWNN6D%<:DK9.9"1=J=>4"BMD8C
M'C"Z$ R@_\JTM@"!& .MSXX9*/BD2D:,OT;P.<&GDD@7S_IG>8"-'[@+'C#2
MBI08VQ#)P0PCI.XOSDD7M!(%R%_$ \,GO3F#X8'4,"J5X0'G'(W[/@_<_>W\
M21X@1@ )-A1@AU$P$^.3(<@3*L:UC;EZ_.UX@/E-8*DU/50>"(@?^ MY@#Y/
M9<YN972)J^R8Y%P()TC-5Y$RM,'O$RR!6CO(_S@/M!T /-"J=9OAXY[Y6/7-
M;%/.%]:-2LLJJ2%/AGG 9Q\P(1Z BE%R,TZUJ<L2:&S\I$RT9,FP9[S,Z.<!
MWQ@/D+,#"78^AB3Z:H=$XP P,. "NB0[OMG)B2<&'I!HLP7:G$BM.T)KC4Q8
M-EGVU<!1S[;KW'W D,??B8J!^ '$ T'KR=W(/\,#H,5R-$*.T!HJT8J"Y:YX
M +\_ZY-Y&X&7@[<W77Z8]EEBG8NP8P^9S\$M\<D=>\.$PRUP[(T8YUK%]TAK
M?L"9L$A"?>+_-WF V <RQ FIHL1E8E#E R<5R'T>N#<>(+YS,(AB"/](1[N\
M<IEWQF+]F.F"D%'/M^GY:(MVO7J&/!POOL\#=_CZ&WF@!M<CJZZMJ ;[3%U1
M47&FU39^+/@+/=2L]6,C)LS[S?S[ONLK=Q:Y-]]P;+VRXL25/>4WM]\L]9ZX
MG+;_DO-$6=Z9\JS]9ZV;=A?N.W*TN/A,>>F&$Z<T:[;_N&JO9M_E9:=*$K:?
M^FG%+NNN8P>NEYRY6;S[S*GU!XY1.1O?"H]MV75@BY"^D5_,VGCJP/&ZH@-U
MY:MOW$P[>$G[^T5J_:GDC;O2UFS)6K_[CP,7SEZO.%=T:_?I*\OWG')N/9RQ
M;5?:CD/F':>,>P_G7;NTO[XN[]C%]R1SV_<:WK'OB&>G10@6Z&.3T?;CENES
M%=KE<EV^V.2*LE@CDIW\9*0LYD**";TS&NF1!N>LE+S8U!52RTK%LO52["\D
M^,TRYO6IS1$/A(02?R&27XCF 0/F ;U#&@0## _@J*8&A9,"#TXB<092>$C0
M!HS3)@@AF;2+Y.P#I5G/26I&07049&6&:N1P"@OU!Z N"1S3"BE/E,$5878*
M4UP*BTNPV#R)']/K\?'-VW?K/6CH1SS!W$1=K#Y5:G:A'H@PY488<OC8B05R
M@$ 2?=@&(.,X*0+ @0'B-D"T!(($M.#J/^B[&-L$H6V,T8#<(VA:' G8>#BY
M/N'6R$:(! X"03 SX*0$?(UUTJQY/5]ZXX&N/;OV'#!IRH?R;Y=$:^T"G2.<
MLH<;;$(J(T:3-EMCC45W8<Z3F'%^(8ZFB/N37L(:%?:8C5AO@C="7V\087D@
M%TFCSD*,T 7>&_$%NB<A;Q+T/EZ2<Y/.O,FI5RJ%1/(PIEQA ,P3(&)<EP"?
MBKEP3E6LM>#LT>!'1*OF6-='.RZ:>%J7 *+'H*HQ_*QVPG^U4#<-ZA+@ WY6
M2$E+4M#>)WB3 X&B>+YLXF(M)(W!)ZQN7TD'LL?KT3P!\1NR1D;-;_39*W'0
M,)Y[L&L2S0-XP()Y(*T "2YW1;\M&73\;O2CX?_1#?  /"^X2K%,SWPHMD)P
MWX=5T;CO"3R 3W-QI3](-XE^2;]G8/UC$+'.@>XQ)F6Y"O*^.V+2<D2F[&?X
M<]OT']GDWRU;MVD[8L)SGT1_-]N4^X5U@RIYC=Q<@-J@,MAC#)FQE%UE<$B-
M+I'9*TG.E5ERI48O>J(1[4<E9" D(.DI4=OP0- >@X'/#B,^'H"#@TRA.E,"
MJIA3:7!! F6DC5G<(G.6R.24&D%S18N/G,H6:[-Y6F^XUA6FS0Q/2']3_LV
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MV_8C)CS_:<SWL\VYL]/7RLPK9."+Y4$P$&/(B#;8%$8'%%E#.C=B:4N>!/,
M4O)X"9F")!L:?98'&C,+<+N7K!)H9>"K,P5JJU2;J= YHO59*@0 B 22L_AF
M%]^(YAXPGAR"3Y#RD1VE\X;I7#.U]K#$C#?DW_8?_4+KSCWZ#ADYE3]+J<E"
MF@0]T$$*=+#0T\E_R0T0TL_D>ACZ@.<=KT+D,K^A";Y?<B)NA-$AG<;E :(@
M$CTR^(7P$4&W$_"A?NTA2,"<0Q/5$P(D&!Y #PN !P1S0X@\Z*.@LM/\@+->
M@G-_\$XD X2#7]+_93B'>X-D\I,EFLQA_.:8![")F/A$@>$4SQ8H;P*5PD$D
MZ#U-.;C*2C84O3'GRM7+ILW^Z9&7IK;HWKM3]ZX37GHV;-8<>6(RX0%H#^F-
M1GB E)B V\$UC$F=:;[6SM/8(*$MW OJ*^ !(>424F@Y DM^G"%K%M0?P/F%
MC"O /C#E_98]F?Q" F5D@I5O+! 9T7,$^4;E.AOP@/_V3<\Q'"E!EJE 'B#Y
MM;!!1D;S@(/P %0+@:,!M"IZ$0]\]FO2F)G"=H^.:='YD:&/O_P!_PMI0K+
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MRY ^G4*ZC7OAF9EQLQ5)P -0N H[F-%C0<<38]MUXSS 4H$ S 5.G/S>#3R
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M_S.3WYGY[2*("B \P!Q!@C48Z0/F/.PU!']"2DB4VL%3.P@/L"Y#A <DV":
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MD\*8JX)THA#LR K)A BJ##Y7^SN$G9S<$63G,YF!/L$>2D0OQYH6?5K/7A;
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M HV'#Q[)]WD@4,N_>_'Q@ _J\/0P08I/L<$KI"!N.#+1CI" IT&[LI^)@)5
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MA%HN,ZZ4FU9+J-4R7=[M>4"$>8#.UTF2*>$\8V)29!HS/(Z%@")W9,GZQW@
MNRI!WY) :C&'3^A,J>SLNFL>:(YX8 SF@45FL2Y=:/B_B ?8=1ZL/63!1PS
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M@H$8K$9#?6*& 91(D&*-8 #G%R)[ [-DTYH!SM",DS-0$"F(EPFR](-FB1B
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MWF,4L&K#"8J4/8G1DV!BM*2"-P7P@#F?F BX<?JT^QV%C0F8!Y1ZKQ(1 O!
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MO(1^P-.XX2.NV^QJOK%C'.WH'9=3)(C\E5 <UDM\P^V;;)S#5QH^25I&SIM
M,]BRFDQA5YC5G/<$) A""'*9C*//8=L:/FI50UIT.21OP9B!52X?0K":'];5
MR,PG.BX\%V9H!M;A@"Z"7D+.2M%?<^0ZM! YE!9O6*)M](RXMH-&_ZMEQV8M
M6CV*XXD)#T0DN@60W\,=9W3$&JPJ@TU.V<5Z!T_KX*'-G@(>( \[N1%RU^2_
M]R12RBFA,.#IW#@R"CUK5JDA76;.D)LSE4:H_:+4V!50?A5=GRNU9$O--L7B
MY*FB6;W'C&_=N<O@ </>"X\1J^U2@S\/$ <29C@(&Y#52>RO)-&3*L#AA)D_
MA#_I468JL(I9'O#OZ@ >8"85GF_D9*3Q!4?"X0&V&0%"KT6,T9@[Q.R4()]+
M"(1,+6)Q K!D>0"?ZY-;"UA^R7_):^4X9@#Q0-32='2_Y"/P^],\(,8UZ0@/
MD >*^U8-"CGJ(ATK@C1!+I'.*T)(8,@7FE:*S2NEYA4R,&L[Q0G)[\WY>2CP
M0)^.W;J.?^'9F7&S90D6M!^1>&*"S7)L'^ GXNP]/A[ O8%'1,*L46QJ!%BL
M-$AE)_F%W"*HAPT\$&UPQ>H=.)[8(3#1/##Z[0];]>P!/#!Z]%M2S ,F+@\$
MYA?"VSJ=X(BD8X*1Q4N*$N>G@D'D3E1Z"-"0X?Q"\-TOO] XGK3=DT^WZ#WL
MT3&3/A1^*5MBD5 90E,FWY@IU&?*U;:8!+LJ$0PFD516!.7BZ]PXE2IN#S%6
M:.D"",$SBA;*+J+L?(,STN2*,+JC#(!G<D.!3(=X(/6MZ)\8'NCW[!2()Y;
MCN/U;4",HS+P@!IX *WV<-9CRB41QF Q#CK&8O<RV Y(?B&=5Z'/EFG 7RA&
MOSS6O%*1DO?QK_K1X>(NXY__5^^!#[3K1L<30_S S;KZ6U5UI57UMZKK*^_S
M /?K'^&!BHK:^OK2XG*7PSU^]!B<;[3)T)&#?USZ2^Z&#=\LT;S\0<3KGZF4
MWYMD7VL^$'[S_$>J9SZ?.S4N,>I7ZXQYNJFJ[T7?Z+Y:E!$W7QO]]9)OODY)
M6K#2E+1.8_)\O43]N6KV:V&BC^=\IUV]?F=)Z;;SY]+SO>_-^+!IZ^;-V[3]
MXNMY%RZ772NNN5A2?>1*^?J#5PIW7W+OO)2YZZK]8(GW5-G:*Q6[;U8?OEFU
M^US)FET7\K8<\_QQ(FOG)?ON:YY]%W=>*"JNKMM[8+]$+.C?KT?? 7U>F39-
M^4O"[!0P?_,-R^^>!T2650+32H$^G[_0 O8!A@?>COM1KG/$)6<34P""@1BS
M!W1HG9V360A["NGL4HU-HFF$!W#U;[)PD)6"Z 3H"1>@9S[)*=%")+&<J=Q!
ML@R!EP46R#@4S ,:EU2-[0,Z:Z3!%F%>)DBVRHRVJ(6&_T1$]QR&>*#7PT-'
MOAL6%KUPH5*3$H56%M-R?LKJ"&,^U".#A$@..<@]\P"<@K _X)_Q7D6G;B1_
MNIM=A-E+R+:'/8[(<1UMOW9')5A?4?T /-"M:TB?7I/?AOQ"\1"CEA=ES DW
M.J.T*;*E6L4BO30Q0ZS/D9@*0!_%=6=O+W@#_B]Y0(RT"HC\IGWBN107# -_
MD@= MS;ER"UYRN0"F1EHAUZC-4[T)Y()[BYY@-7XT;W(S%XIPE%\1T3IIQ-X
M^_, _2JD'VCI\R%8Z/$\(<*]A<9Y@(Z*@7IDV'\F4/"($)7WMN)S> @>4)8'
M\#7T2T!_XNK0C! >@.K%\&Y$K00A:IG?"WU'I/"&,*N#WI,@@8S4\26YB7!T
MA R-IAHJUZ)7J9(A>#HF.4^.%P0R\8(;1A13HO*2#Z*;BN^]H2L1BF=')Q>J
M4#MU5J3<SUAJ'1<VJ_W@L?]JV:%IBY9#1XW[+.;[V:8<X($$X &5*7M6LBO>
M;%-25K$V@Z?.B$RR16J<H'!@ZR52. !%3&CL<(9*/7;5"'IL;R-!/( Z-E-N
MRHA=YIAM=<>G9,6;LF*0XI5HDR0ZE,:\6;95<=9L\7S=FU&J@<\^WS$T=.C
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M=!*W]7]1#R1I00\P5"ZNRB5 YR<S/WK5]MYCIC9NT;YC]QZOS9B[\KT='/
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M=/,PCW^ T@-,G4</@'^@OA[ U[%!/8"O0LV3Z[GBWF$$'"]J=)NA[6&6I_3
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M \:X>O3K3U%G(JR!WT3K^PE/6URJXXS<S) :$]/SD"18N3-[DN@#3[R07_X
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M8@J&SE[2?_*"87/CIS#7+EJ7,6_=ME'QS&XCWFP6WK=1:(?@YLT&1?2)07I
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M-.%Q- :6*H>IR,;(82GSV. B\(#C!5=CXJ'G$Y+JT+.:#V^IT60)HY47X&1
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ML.R"L,$Q]V!FUD,A2$3Z4W-+4W*@:@U0!'PW\G&P$)2.0;NGA7;7GEOQ1?0
M%'ZQ^0.'Y2 ]8!/I[<FZ J$:VJ8FR@I>9ZSM,#2J49M6C5LV[S-R[#SQNVRE
M+4[A6)QI2R"+65G%O"P'#Y0_XA^61)4I3FE*4%OH6B<39QRR5"X>62;0[^&0
MI6RUFZ4I99/E3'(/BT1KRGAD*9\L@>HQB-P "T>DH9"N<B<I2^F*4HZJ!%%
MD:9$!,^7D4\:(!Y)48BV29#F3>6E#)@RO=_T.6\+4Y)D&C9I8"AS!6BL( RS
M5Z_K,V92<&AXHU8M@H,:]>[:;<8[<0Q9#CP%<"> ^9_B\4#$P8"-B1=NH0VW
M*P8/5&M-LB]5_P<>9 **BGJO@K?()O41;/H54HUOO;VH/6+ ZQ8 "8'#,W W
M";@_/0\(_EK?'07%:G%[;_\;!OZ%!O#U !J@(3U0ZT'P!PR\:,!$%]U[ UCQ
M,M(&T+E%@),]/&$D^)ZO+P8:T@-V]+M\A8TGMR+P00\4"%4UVXMJ]K ."@30
MT;(!B-06H=I*;0;*4%7"5Y?RD)($QV817VF*7KMCP+\6-0_KTZYKUY%OOK%,
MLHHKS>:C$4];R,%]$O%(A=NA@-CS#+8P?I+%'*V+K2VF$\XD%:+(3KK&@80!
M"VHBXRNKQJX5=$N %Z5 1-J2M38Q@5A^]O)-LJFB#\;35X]-2!DR/Z[3L+&!
MG3LU"VT=VJ_WP(F3QB]+G,Y?-V_5MB7ORF@?Z\69EA3LNZ/4(R4UX6936ID*
M,UT)>H"EP>853SEF.Y.TTTA[DM9.@V(^!30OZ*2505K0:Z+6GJ!UTG1.!FE>
MMETVCD;I@0&]QKP=S5J;NBLG%>V\QI)(FI.T2!78F.B0E6ZDL1EJ=QQ9%$LZ
MDM3H.2IB*8O0*T-1R%#  AM*B);R5>5\]*HN%1 E L+-DCOHF6:.PH382W)^
ML2C?S=(7KMAMF+U6/H&]:5S\JE%+18-GQ+?O$Q48TBXLLO>TZ*7,S=(7T0/@
M"J:JS$$=/^QK@N<(FDX@R<J$CA:6NGJ ZD*@*>0IBSC2(K:B2)CC7IE.#%N9
MT#8J*J![]T9MVH2'=U\G$O[ZPX_/$"^M?G(/],#C9]5/:FIB_O/W7]$#E5X]
M\+O9;!X[=BSH@::M>P\8SDQ[7UW\N;KLQ]POSN[[[=J)!S>N/;ESH?+N5S?N
M9OU\?7W9Z0W%)W1?7?SDQ,U35Z[=O7>YJNK&E;N_?WG^OOK[6VO*SHD+3^[<
M?[G\EXJ3OS^Z^OCA;U5W#SZX?^#F0_W!WQ9RMK4(&=:B22^A<-/1"_=./ZG^
MX4&U\]@5;?G!DA^.'KMZZ=CY"_N_.^+XY)#SF]\^^:WB^]O5[N._:SX]G/7]
M5WNN_/;U_>NNW\[D?'G:=>SN3_>JRXZ=?8>3W#JL3^OPOA.CXU,S#._F[6>K
MBFE$F5</6(5$+E>;A\0 0UO (A'/0YP[GT?DLTDS0^N@/U\/+%J[,Y4H6J-W
MB94V@=0LD%FX&4;TFJRV(TB4!4(TC&::>!GY&$9^ID4H*Q#*[!AHP89?T68%
M(H5=K'"(Y ZAW(Z _A4I'&(*2F<R@JI0HBI$_R:K"U-)5XK6E8PAT19+2 27
M"(JX6[GZ/$%6-BTS<V9JRBOO+ F?-KO;C 5]HN->6<&?Q%HU+B8VM.^@P%9M
M@IH%MVC6(K1-A\X=.XT8.VHAB_XVFSDL-J%?S,J>LY>_ND0P-V479Y=EC;X<
M_1!0*](NS"D29*/YS[NKM8#VV88.E@)?:D$G 9T03GH^:U<>>Y>!EV%":T1R
M*SHG$I4=0:0H0/\^!S8*GJ^26N!?!?IF$U]NYL&\[D#CBTAE%61FQ21OP'J@
M1_/(0>/FKV1^F)$*>B"?KX(6$'SH_V#!OET[%;*"?9<-ZP&*4_I \3"?)/ 0
M4[F5+C4RI$:8]8GGZ@$!CHZH\1+X\'?U )]T(5!Z  *W/$8RKPD**G["&HK0
MPRLL>&0 I19>!)27 /N=,:?!]$6 :XU#\ DN:TA-?GRJ1R_()"IJ%I$AW"4#
M>@A ?+# ZQP0Z]P(M?0 '/MSXH((" _S ),M=-JYN)2[#U#13^8!IE_4_OCI
M :CABR<A#)\>\/$\,(YZ&)XG.=YSQ?WQ9WH 1"9<:T#]=S%JF)\ 1_/C* Y(
M&$C)*5F55X8 )00PRX3-\#9"'"8DA+93-8G[+Z@'ZLAIH(->=IB:Y4@F$/.V
M)LGM$]@;.@R):M2R!>+6_<=/6+1NJT#OIFG+5FK<C.P]["PWERS@PS!HXVJ1
M_G=P=(6<+!<OR\W7E_"UI0A"7;E(7R[0P;) 5R[(VLO7[^7I]R*1(,HJ%^O*
MQ%#5H A\(Q"E74@G2M!XRR#*V$0)3^,2$2X):1=KC4(TS$*\A!L1EZ7;M>,2
MN?VFSQX=E[1B9R8_UYRDR4U0YC#4B&#ES$E=UR=J8F"K+@%!@<&- _ITZCHC
M.I:1F85X'DN.B3@N,T#5]Z3(&>5*\CWI'N&'U\,=B\N40?U-J8E2E=A8BQU0
M=?DZ7$JX@M25J@F5\:2&HZ^BX_(&; A)\GB<(,X0FL[6,OGC0)&Z>J!!(#T@
MJ*T'^%X] )VPE+BK%X;'^Z'")G#*X.(UM2!)@(9KSZ/A#6/C8=D#2KN>&&A(
M#Z U#CZ4KK8A\-$T!QZ#NJCC4O#@.7I J(8R%7PDV]"T N8#)!W!I\37N239
MQ>C=1>MWOS3]G98]^G7HWGWTQ DK4M;PY;GB+)<PRP5]$@DTAB,F:F5"6)>5
M Y&9V/)"% MU;E%VF2"KE*XIC)/;XY#(U!1#&4W2Q=:YH$ 6#"80!YM,.%;K
MBU;KG"DJ,WNG=O'JCR?&\H?.6-;_[9A>$^>$OOI:8%ADX]"VS;JT#>X:VB(\
MO,LKHP9/CQD>31NSE#N5N7;%AEV<3(-(5YR<!<\O&(EP"1"N$@>;@5 !K>)]
MA:$XD;"MU-J6ZVPK -:5>AN%6+TU7F^)TUM79ME79#GCLIWQ>G/,+MD8.K?#
MB''!/0;T'35Y$6O-JEW9JU46@<I,)RWQ68XX?6$\8B/:\D3MOEC]GJ79)<MT
M[D1U&5.QARW?PY*7,Z5E3%DY2U;.D>_E*SX5*#\3*#_E*_<+5?M%FD\XLK*D
MG04<N3DEMT"<ZXA7Y,W9*'N-^_Y+BP2]9B1VG;"H;=2T%H/>#.S8-S"X38_(
MWM-C_K(>@-!6JGVU"LJIHR>4EFE$CPEZ0NOH 0I,N8TC=PI4;HZJ2)2+](!Z
MR.)E+88,">C2I4G;=A$1/=Y-23UW[.=G58\JGSV^\[2RLOK)L^JG_^@!_[__
MM!ZH?/*T"O1 ]9,[=V^;+<:Q8W$_LL!F0T:,V2PE#IR\Y#IV/N^KXX;O?CIP
M_N*IAU6'KMTU'SRM^/2X[N"%HE_OEIR\93]X>M^QDZ=OW[Q<^>2;WQYD[;^4
M47*._/::Z<1M^R]W7#_>_.S$I>/7;YRLJ/CB]\J"7W]7?OGKTN1=[=H.;AL8
MNE:<>O'RY=^KGUVMKO[AVFWG-S]:#GQO_^(7]S>7]GY_Z\"Q6]^<O?/3[0=G
M'U8<OWAS__=G+%^>T'UW2G/L7-8OEYPGKQZ\?/_*X^I#OYYGBI.[149V"H]X
M>]X[JW82'^24<%6%-*(T7KL_25O&(0N$A(%+FAA:.U-K9Y,V/FD2$/E\33Z'
M,#-)!T/G9F<WK =BTG:ER(M7JTO%F0YANDTB=0K3"]!KJJ(X55&4(G>B]:(,
MNP_B#(<DLU"2640A65J<+'-12)&[4S'00K(<K2F&=S%29"[/6S*7)!/]ZTY5
MNE-4+HFZ""%94YQ"N)(U+G:ZE9F9)\S*Y6G)^1O6O;PXNMM;$SN\,3%BUL+1
M#'',)H5 :5R2^E[D\-%-6K9JU*1)8-/ EB'-.W=H/VG*).'&]VA;-LU9LVX\
M6S0H)J'/C-AQ*]*6OZL1(=VBL+.D8._GZ>P\K9V/V+RL* 7M7BT42:0.B;2
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M^]:X+VJ 0\-]EYZC,GNU 75HZ%IX(N+P+0V'^0)ZP.-#0 L^WD_MAC\HD=
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M7U,$]!'$%-'.I^:4KLHK3\DI ?%3?V?^##Z*6?\M'RAVZ.&7$,<"_:&2L8N
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M8O#"F."^?9N$AK9HWR&R1^0&2=J9H[\\K7I<]>S9O6=/*H"E_J,&:OW]1_4
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M-FDB;^,'(H6"I209RIP5.[2(,0R8GCAD%O.-V#6Q&\E4G4NB+4S*S$E(S^:
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M"8J<6&7>,I7Q'8UUL:9@B=JV0E.0H"E@J"TLE8FE1C"S5&:DEND*(TV63X/
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M@-(.Z &&R+R5DN,:L'F0Q^Q!8Z8 /> SW6_'KKV$8V5P7)75$R5P&D4SZ7]
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MQL*I,Q?9X3D3_M7-=_X4GSF3O69WP7OV%*_9[MYS/?W =^<CP T/O_D>OO/
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M^8?M'#'->\ (QP$#AXQQ&K,W:.<;M:TO'CY_TO'R;MN+1YTO_]4#O?[]M_4
MD ,=3Y\^[>QL1WI MRP YA=R=')9L&+S,8GFO>OWWKCZV/#Q;=.'E]__^=9W
MO]W[Y/JOIL^NR3^Z:;G\XK6[G0V7?JG\X-/FSS_]]NJ52]=_>>^+GZK>^4KS
MQ86FVW??>?BT_N)]^9N73.^=__S&Y6\>WFF]?MUPX9KB_$7<<?$DCQ7#![G'
MQY#?_>S\M?9'%SJ?OOW@=\NEZX9O+JL_^%KV^H>Z]S]J_>[;CV_?^N[QTPLO
MVK]YTG[FPDU^W>L'R[7DK*(H7,Z6Q/3-J?N7[22Y+MCDY#[+T67JY)D+5H7N
M(QT39&N;*)I&HJJ5J(!Z@"PS4:45-*F.+C+3RDSTT_H,GNF@I":C3+\WX]3"
M*+K[*TG3MJ1Z;$H=O33*<?K:4>Y^(\>/&35AW+1Y"U<$1VV.2=L2D[8M'A^!
M9^PB<T)2*$')I- T:B^$I='"<!CH&,+!*_H3^&(4B;V3Q(H@,, 'P!%V)!*W
M)Q""DDBAJ=305'I(*@,BA1$*D H1EL(,3V&%IS#"4JDAR:0="<3ML>2P!$YH
M<LZ6A/V;XS)WDHZ0CXARA.8#\D:.!)8DI$G.X/B-NX^I@UA' ^.2MT?M#(^.
MW9U"W4O*B,W(2RL2$*05.+D^36:D*FK3E8VYJD9N6<5>SJ$M282M*;A0 B4$
M1PY)I8!?#$VF8 A)(@.$)I/#4BCAJ50[P)XN)%%#DV@80A*I ,'@-8D:ED0'
MYX\A-)D.]D# #]!Z NX,3V'NQ',B<>PNX+$-%MP@<2.IF7LX!Y./%%%/2UD"
M+4M<R9896#)H>4?UR*IACC-8Q@LN;_R%'OA;3M =_QL]T)>%0W3Y"]DE 1A2
MD1X 0V0+1WT& !R$(D9Z0(K9!WJ+ 1JLIM?WX/\8?ZD'(/JU#T ]  /6>\N
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M9":FPIQ949^NK>.H:MBJ&I:RFJF 8-G E)M QZ-UA\1 EQK!9SA@5%+7PJ_
M]3DS56H$AZ6"O\K,3"R'-%PVL]"E%B9RB.>J&])5M1R%B277,V0ZNJ22*M21
M^7HZSYS!J\DJM^SG5^?PS-P2/;581RS6D\IJR*)FBNQ5BJR5*34?$&M.2!4%
M4M4QL?:PQ) I,5*%E7AQ)4%A(BLM5'E-IK+IF/;5XXKF;)Z>RU-GR2HR%95T
MH8(J4#*E>I;<S))7L\"Y26$)=/ *WK(5EBZ MP@<N&UA0U]8#)A'+/1)Q4S8
M5H"=MCU<91T7^<MB@"1&49>I:<BN:,[4-&;"Y:C&+&TC?*MMRE#79RMK<F3&
MPTK3$4W-?KDQ7:+/5EERJQJS-'4P38?$3 83K0#<3PM,"0KGFWH*\MNFHLK$
MD K8G4RZBOO8)FPKG^L]P6- >@ N=2._>1NP]*/=P%0T8GDYZ;+Z+G\A+% !
M1?UB)0LP(&& MJW92[& 78QSU\.C*9L82J0'L+H'76408.F#;L?O 12K8 -T
M4K("ACA;48=D"=P@PT'<>A,P7PC;=@WR\\&LO5:@V(!Z&G3 :.@72"I 8%<!
M;AI+";@4"AC <H/"X%KHMM&O^[65P??DY2A!$ H;L"^ZVXP#MO5::Q*AKLPS
MF#_2GUL)( VU@6K3 Y!G@R]VH<X&Z^I^-Z71X[2M_ \U,.PD,>?U;L "HR&#
M[*%VL+@(VVEC7+^O$NB!+JD#7>,@Y##&%"9?AYDHD6N*T,B$V2KKHHLJ I(X
MXV<O'#ABZ* 1PV8$K([.R -=C"IK2BXW$X!R$!O9(AU'J&4+*EG"*J;(R!!5
M R5  ;Q?6,V1U&;*&S(5C5QI'<R;SC<Q!"8FS+:.<3O4H<353+&1*]'ME^FR
M9'KP)Q)X])IS=%5+S#'1DKUIH_T7#W&=ZK-BPV[F?KA>(-!31698S11T!]0F
M$45HA'I ?(8I>8TI/0LZ$4T.]( ))U>GR$2I4C%>6D$&++_/<Z3;7?[0@^Y/
M#S0P$+FW!YE@WOS=.GZ7)(#'L8T#&!A(#UASX"+8DPOU;0G6@W3I ?0LL H#
ML*W6@O$<T&)"N0XP_MCCXJA#I9$'3N\^7)Y8**>)8/@38.2 J^%*-(!&0_<A
M636N3!M7((LMD,85RM+*M!CO!WLB#Y8&9Q=MSRP(RRW9G2?8=807=:@L/.=4
M4.:);=S\[=S\L.S"?7G\M-,J,E]'%E01^7HBWT 20,L/60!C )B2&J;80A48
M@&8@E%=0!'J@4L"O[SG*#TH_OH5Q.#C]>'0>'TPT0!+@2BOVY8O 3^P^S-][
M5!1W7)94J$H]K<65 #&@1V*@6_P #$V&&?>1'H!F 10Y ,4 ?#JP0EP-45)+
M@[5!:U(*Q,',C)7[8I:$ABT,W+%\:^2&R/BU,?A5\835<7@,:Q*(ZQ))&Y/)
MFU/(@0#)Y, D\M8D\C:$[4FD;7&I@?L2MD8G[4@D!">3MR<0MP(D4S>E,3>1
MLV*/EK%%>JZL&LP1G(H&NK8A#:A6=!-(1:J=C,,KHA+G!>U<'+%G^9Z$,&H6
M^:2$)3;CQ>9D(,/D-1FR^H-24XY0S2SDQV<="28P-\43 +:ETH((C&TXRJ8D
M_(:8Y#6[XU>$[UT1O&MER.Z5$;$KHQ+7[$W=$(W?%$?:DD#9FD3;ELS8EL+<
MFLP,3&)L2:!MCB-OBB%LCL9OC24$)4'7@' <(S2%%I1 W!Z3MCTF-2@V-2B>
M$)1 "4H$( <E$8.2"#L2T[8G)&^-3]J4F+@A*7%]8OSZQ(2-R4D ZQ,3UR<D
M;(R/VY*0L#4N<5M,XK;8E$TQ*1L2<$%T;NRQ$II4GZ&%$R6)KP-Z@"FOS=(V
M9RJJ4_+*UNXCC/.>,]S1>?K,&4%[]A&.E=)AF$<#60)03X%FP'JR%75D6.L3
M :OP(\-F-.@:!)HZ&N%AP!A*H@##QBABVSPB!8!.I$ 2P/Q"%6^PU&?2]6<2
M2R3S(O<X^TP?-'+TH"'#L?B!-VM;GS]\_K@=Z8&7+]O^S2_4\]]_40^TM[6U
MM3]K[WC<U@$+"M]_<,5D42Y?L0#I@8'39LTZ*A)<?/K@1ONS[^_?.W/Y3O$[
MU\D5WV08OJ_]ZM[UIR\>M#^\V_;[M8ZG7SY[8;GRQZ'6'UA5YWEOW'S_ZM-;
MCY[]]NSQ+VU/;[9W7+S_XIUO+FMJFV7&VI:/O_GBYH.O[[8=$9DG35LPTF%R
M)C[[QM>7GSYY<OO)_0]O7[%\^ZWDG>]XYZY)WKRK_N"7JD\NO/GSI1__N//5
MM9_E5=4I^ .143G$=$VAX3/39[?>O73SK?-?YIPX[C]OX42'B9[#)R_R6!"Z
M-99[3)2K;:9#?XQFO/0L4=1*XS6P2BVT$@.UO(K-KR >+]^>RO#?&.F[)FQ9
M)&$GYQ2YU)1=\6IZ17-XUG&W@ U#QTP:-GR4TP1WSZ7KMU#W@^&8I:JEB(Q$
M014=YG. EGJF LS*U621D2PR4"4FL,T W!165('E.;J#)#:1877D&@!8W%N*
M<H^ CXE-)(D9[+22#Y0U!99?D=>"/8@$P/4_BL0($U%+C"21$<>KPI?H:*5&
M%E %HIHL<1U78*&7FVCE)KH0=+\FLK2%*FT$8S%'J,L2:W.E%;DRW7ZYF0M.
M0*@GB:HH4A-<7)19 #_(43;LE]5PA0:NJ"I=9F!+JRA\-9FG 2J%)H45<,"U
M@!\E"/1P 1*6?K17QH&U<F"Y'%@BQX+>6@$& BI,Y6&AR5":EQZ$!DW D%W5
M0O'3%199#7X.6_*$.\$7%=!$SE0"&@T9#TMFR9!7'U#5YFH:LA1@I+;L5]<?
MK&K)UC:RE?"P6(IZE$V_#M)6. !!G@?NI)6N(4J'D08[)^B.OA,\!J0'K$!^
M"W#X0Y[<D/4B8/07D(8F6)V@)^-$+DQ@"L2^TH!]$6D#= 04) J.0(.U@6VT
M$N;3!,RCJ]:!O>X!&GSKT?#:#R@PE-D*^]A-@3+ RMIAC61L&P[T/?0 9$B(
M%5%AD:\:9.VUVGS1+467TT-:]$ W5@2!^#J@4)!% 0H%G@(%UNZUUK#LI0?H
M4JQA_+4>P Z.F!R*3H;DK/>'(=#]1S2Q/Q+?4T'9."5H)PIH>+$!O$5Z0/FG
M>@#VTYZ1IC28NA[,=HT<((2ZT,A6-++  [7I :82Q=LA/6!EG"@=1X\?PCQ2
ML!$ TR=R>_B$33O9 #,+ :6M;N* 0TDL@-"0^.:(PY)9D6D.4_T&#!DX>-B0
MF4M6[6,?!BR?(FE,+JLF"&IH(C-'4)7!JTSGZ[E"H W,#)$%F@($L' 21V+)
M!/I<49\NJV5+JIE"$T,(]( )')P)98 5++&)*S%DR0P9,@,8<"B@H6K.@>>>
MD%^^<F_2./^%0US<O5>LVL7D0A,BD.LB"Z!9L#N =FA-2 7T0"-=VLR E<A;
MF%#NUI"D)H)$AQ.K<2(U05P%QI9>#Q&[#_] #\"=?Z8'8$.RZ0$X,O<:![#!
MJM<3L3;"_M4F$@-=>@#P8*;4S)+!%1,6F!0 FS\F"LLLV$3)71I'G[<;/W\/
M<7DB<SL[;_>ATET'2W<?+$TJE#%06'#**474H9+@S). XF_EY.T\5))0*-N+
M6@PA  "  $E$0523Q]_,.+(HAN83DN@9%#=S-V%Y:OH:7/:J1.["O>09.U.F
M[TR:O0>W"L<-SRG$E:F9L ( F#+T.$$53J!/$^KQ**EHXG'I5LKAM:D9@?3#
M@/?3A/JTT^K-M$.SHW!^(?'^$4D!<=0@]M&D BFN5+/[4/D:?/:<W:39NXE+
M$UBO4 ]%Y9:EGM8 Y<F"P0FPA$*_>@!544!* *4H@#<')N"J(4MJ08_( KV
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MT#O 96*J&,Y_:&4:7J^LOE?Y)Q9*[<) L@J<,T?3# !M)N@"&9C+D+UEVO0
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MOV@JM@OOK@?JH>\'>G#0_@/M S6P_4"C4)>ZL\]#=C>/OC?Y+_1 CZK/4!)
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M ?3D.F!/I8K7O0AV+U<[(]C,RX%UC=#!RI* :<]C? !4+<4+H5$D_3HYS?M
M>)<I!._B6HSW *")_@'&!U@1/: $@/Y5V&()$PQ F\";(!A!1+D93) ,4$HT
M%5H1X$XZ.2(_\DVSXH (O( /4+0&O"G47PDT\)!;2$*!A+BP^'HB44'U%?B
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MKZIZZ=[\86],?V+8R/'SY^PQZ(D/P'7&I<Z8S 6SKHT)<P)PK@#.]ID0[!A
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MK2I0+LV7+3PH7E(@7U&D7B72K9&4K).5;Y!7;I"6K2O4K3V@6+]?MCY7NNZ
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MX34H],_E [@K)U22  <SF,LDH0(2MX/R1?@ <ZPG^(#4"EBPF=(&@@ 4R&D
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MS TVG5@-1[I9C;N=A20Q2/=5^  W41,)KRS=A7\6_P?R 7M,90.]A,%U&F=
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M 'FVXRK#?MC.=C6&%055KB#..GCA#AL:._2-0&AAE?E!Q:E!RUG\&E.K!LB
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M8!2C15DZ&#(;>3@?0*%=K=@:*#:W88^AA(&02UV%<Z8OG P^$"/Z%$5+"H6
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MSR\Z:6H3T(0PMSYNG!AH0:GAQ <P,IM+>N$RC!D?P @-#Y8+I-T]R0?4:7R
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M-SZ _A-FJV,&X!0@FQX(Q_^96CR'O@6^-Q$OCH85BIAB!F.*RT\G Z@*4OD
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M-70=</Z!)!_@FI1](?] @@_ 1PIKFHMJ6Z341@,FF['Q*HBNGG.09DIR[:2
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M]O)PES[<G2N3S&J#.XW(&$\<9<!C=\%$#F+B(%4\<5NE"Y" O_+^ -J^%$*
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MHY% R_F!3FT@M>Q >)(9I,3+5]UXZ["[[IDT?;9A\X%UP>YJH)T8/] APA3
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MB=$H \<VN6<P#,P!V-0C9:2,0+PN/OT41?'F0<3LPP I9C=O,;[@&Y32J Z
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M %(",[EX*3H&+0 O%K[18U[(J!K,!."O4HL "VWF4@_E;1&H^8 L3_E[=/#
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MWCW16/P?_OX??_[37_WTI[_RAF++M+8W-39AAV/=N?,!E;E,RI5S?F,(J16
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M&,DHQMLU&#R0T :B>E_,Y$V8W>T6=]J,P8?=QF"OV'RPPI.89'[GCJ=?O';
MH'ON>VC*C#?+-NS3.]+EGH.K/$ &>A6L='8O=V27-626-:27-V16.I$2 %8Z
M,V6N9"47'G9'=9Z8WA75.:-Z1ZO)V;K\W?J75]M&S%@U:66-9GN@&AKIQ&05
MIJ8NK3<Q65P_^+F7+K]CZ-6WWGK-33?<.."&L>.>B\=;3YQ$ Y6,U4M\H,3K
M@OB XB^$U<>.'X<WQXX=^^*++[[\\LN3)T]^=OBS#__A>]MW[5BX:/'++TQ\
M]977WIR_\N7)L\=,G/EFI<VRV_W5^$ ^LF*P"V .(=3OU=^(],8:[JEJ/G11
M^ #)BYPPPE4<W(\KP0=0GH*9J_ !R<GX(O$!97M7T:FT06&F0EV,4GR BOM*
MJX-J/M!F<F*>)<'?5A+&8+L:!N5-H$,?2!O E/%C;G[L3_).1C[@[5!0Y4UA
MP3+07MX+Y0.L]M3:B%;[>/<#S)H\\XCEN#F8ZH,/Q,[,!Z3G7L0'C, '0CWF
M0">&8KO@=A*B*ZZK#2Y_]\"BC;N7;-JW:EN#Q=F\+M1F=C2NW.Y:OM59L3>@
MVQ^NV.O7U(8,]4W:_6%=75AT-5D\+59OU.)IA?>&^E#Y'D_%'I?A@,_D"&KW
M^U;N<BW;Z5RVT[5LEV?%GL"J_<VX3.)+5@0Z-$&*T:3=, JVQG5!P9W0-[0:
M'%%X8VIHU>Z+&.JC,"0J&Q++=X7*]@;U!X+&6E^5,[RY,;FY*65NB*S>X2S?
M[34T-)G @/,GT;\.E(TC@4MQWHPAV*4/9(GOY;J%]2CUCPIRDM:\S#F^E%[F
M VIN0) RTG*&3?4$Q)/("_]]\0&RDV0^P!MQ*CZ 3CL>T.5GX0-X%Q>)#T!3
MUT;??ZOM.QL2?[>F]3TK-9O;=GY\0%6'. ?D [EVY@S3,_&!DF3@?/@ "S$2
M,G]F/H!9R'QGX ./77WS;0\\.V9Q]0:[I\GJ2_PWX@/L@X'I$ZA<3" #)AH5
MM< R9+CRRBY8^2.P+]ONZ^ #)<'1U<IM*K?VE^(#DC"7$DRGU*$%Q7R 5?#%
MX@/R"7%OF?D J _0'0"@Y5\G'U "BW.@CR5NZ@QCQB!G/RO!!^0@^/-!"3Z@
M];=K FW:0$S%!U)F3]8$?"#08XQTKVQH>='PUL#ASU]UXVW#[KYWXK0YE6_5
MVGQ@C!TR!@^: KT*#/YNG:]3XT5W(*TWH_=E#+X,IN_#E.*@55NM[E:K)VKW
MQNV^6$V@;7TDO2&<7+EYW[C%FF=FK9PCO&W9WVCWQ/6.9F "8DN/SMM&?.#%
MRV\?>N7--U]UP_7 !\9=X@/G\+H(? "8 /,!WB7@W*.__>UOO_^#'X0:(YNW
MO&.V6*VB??/&K=NV[5^RROCR]/G !\R[7.?K+U0"H.E#/6>%$.I&[XYPK[WY
MD/V"^0#;A04R!:4\DX%\G2I\S7R ;"]II1;OA1)EHA4ENR6</Q\ XR->$OI@
MNZX4M)AM(*TCMQ#>)<"%,>(#U=X.!37>U!I_&F#_&O@ @G:9\4Z#&9;=!#2M
MV#SB-1Z5LQ"'%W/NB&(AB%#T(MLH:C[ ^P/(!SS(!TSNA!ES+$;-#8U"74BH
M"POU82N6QVX!/F"LBYCJFZW>1'40Y&84R("N-E2Y+RBZ6]:$VZO\<:NWU>Z/
MVWPQP1$QU(5,CI#%';;ZFRW>%L'3(GA;S8&$-=)A"4,G=U1ZVE=Y$JM\;9IP
MVM0($C:+.AM=P]D.2!B=,7B#L1F>MO*=_A7;_7I'$B@Q+J('X<A64WW Y@YO
M;$INCF:J S'!V63SQ==&TC5-65MC)UA^5=ZT%2L?=PBNM,Z7U08R:C[ D"WX
M+(,,7P";\FDE6)92U"$,@911<I1/,T, U:+W(K "%T?"R:!]:BDPX*^"#T ;
MP-:O:3D$E #^5C5B?N2_:3XP]HH!_?KF S&<"U\;'QCTP&-7W7S+O2.?FV]=
M:W&&X4+D+_3?@@_(HEA2!P+Z$U*V4$=<[[K$!PJ/+P(_+(3HH6_P+_Z060%N
M%/R9^ !&"RA\P!H&P@]#MZ-DQNJ+@Z)-@-SW1?]UAC'S%^$#9JPHG"$^T&L(
M=RVO:WI!OV'0\.>OO.'608/O?/:%5]XT;BS;&5J]*[ARAU^-Y=N]2[>[%V]W
M I9L<R[=ZEBQS;E\BV/)VP<6K]^];-V.E1MVK]ZXMVQ3;?D[M;KM#G&/S[#3
M,4UK?6SRG*=?7[QTS?;UWGB5#\AVHQZT9/2@WH]\X(YG7[Q\T) K!PRXJM]U
M-]S4[Q(?.)?7!?$!?IV27\K^P*]^]:N#!P_NV;MGP]L;:^OV)Y,=/_[!__.;
M7__?7_[B-YY0;%&Y\$:Y:-I^/O'$?2'8*:"Y?U8@'S"'#]I;WK,W'<0@Q?/G
M VRFD BF#"1JOV'Z+?^JH(5X_-?'!^1E5#P;>II2>CLP@,@PXLMA+KF+P0=,
M_CB:_L%D*:2T0>0#9.0A)<#[*LD'?&G U\$'6 D1'^BTX>UG&2#!>6D'9+K>
MC=L"<DR8%%0@2.$$I47\&?B M#\09'^AN*ZA55_?+#0T61P(,T&HCP W$!L:
MK>X8D %<,75'X:_%$S<Y6G4'(E9??'U3JB;49O/':D+M58&$R=$H.)NK@_$U
MX80]V"IXF@RN)H.[V>2-"H$VHQ\NW;;:$5OAC (?T#5FS4T]YG G9I_TM(D(
M- 6 G,!'6R!5 [9F7>OJ7>&* S&=N\, ]C<0(6>CT1FV^9OA$M6A!% .D[/1
MY&RQ!]JK(J#SLO @X&'5>#)5[HS@Z-"X4EJJNI#7,[1XS]8P@R. *1T-VD!2
MBB'B PB_G$PS#',VBY0 \Y F->YV@-:-Z35X896AI^@7,V5XA#/_]^<#K&OY
MH\@%!&C J 7%WQ8?^$ON#PQZX/$K^]]R]XB1<TPV4YU?<+62)PG&#^0,W+\4
M'Y!'% T ]L-&0XW^2C)?N,0'^@;9_:B5E-AB,V64AB$*5X2/><$#7R,?R.T/
MX&RBL!RCM_UKV1]0<<ABX.@JH@1G&#.&OP0?$#$\'4[>+81Z38T]*QI:7C9M
M'/PTYA>Z^9;;[W_TJ>&3YCX]>_7(.2N>GKTLAUG+1LQ:\JU9BYZ8O1#PY,R%
MPV<L&#EKT<B9"Y^<,O>Q%U]_[/GI3[XT<\3$.2.GS!LY;?YSKR\>.W?YR-<7
M#!OUPLV///W$*[.6K=VVP1]?&P:FW6P*M]OC[QD#R2GBACM&/?^-@7=<T;__
ME==?V^_&ZR_Q@7-Y700^P/'$7*CXL\\^^]=__5<N5+QM^[98(O']'_[@H]_^
M]MB1H_083F5Z#Y9;+/,J=*:M^];[HE6!-C&0,@0S^E!&CT7@68:BR<M+@VS4
MLN%;K*C(7ZCS+ AT"GZPLSMMC;W5+8?6-!^JCO1: YV8F!++C;4+F$H/537+
M:);7N,\K^^+S+.*9B>\#)?A #J16"V -8EBS%7.3XT=, $K["6:2YLJTERY4
M)+,*Y!<* A5PQI((0R]#-QEJ<"$Y+M-,1C^#I2V[VD,/ #!B#V<[IFU!^XGR
ML104#5!@1'?PDI"=0VAS@/<'6%%95*!PX8P-;Q^NB!'8Y@#&?&.T-_$',RVF
MHK,3 KV>K%12P(;V4X;#Q/FT]$,\'G-B2,A@SU/V=_R5DK,R#/89/!>04U@Y
MB%)'(VLR(NV1<HGF)1?*[]["SI<JU":Q+#%&AN .#/Q*YXQ7U+56'FC6U349
M&YJ-#2U&1XO9%1/=,<'9(KABP'RJ&[NK&[NJ(IU5$2R5;7 F-'4MHJ^M*I*V
M!D&%)^SAM#V<TCM; /!F?;2GN@F,X)C.V6+TQL0 QF\8O&UL9V-JFE!6"%.:
M?]P@2D*74@IP[%N#JTV#.<X35>&N]<V'JL+=)LJ#:<#8LH3&T2KX$G!RN#2\
M 9C];49HJJ_-$L Q:?6EJP+9FD"GW9<Q-K3I&C#%!,8#$- KS(_4 MI@YFI<
MN71 <CTC-G>8%;!&01Z;-;/U#+9O0,K4I'% >S"?!O2JP9-28,2Z'S =:'XI
M)Z3X-C22*)^C04[KB;)";@.\AV,P?J A#L>P)&$!4C!Q^GK*Q5 F)EK\DDU/
M\TO>&5 L/-2^>$>4H9PE"6W3*2")0;(%?J("] E(%?2;PH]I]K_B(@-2XG <
MG'D$51FN*)&8%12 A(P:9G\*)PY"6K\H0)& )3Z AD6G/022!&\*XXFK=@\;
M]?(5_6^]XIKK'WYJ]"+KVS6!E+VQ5P_6AC\K>-(65]KJ3EFP8$+<X(_I PE]
M**D/I4OS 1_:Y6J0A,R(WHS)W:WW]&H#!W6-!PV-W09?V[)W]X]?4#[PH:>N
MN&G0G8\_-4LG"/M=HJ-1WQ UN-(4^)B6 <*-D85341+D0IB5\C(,->,J&B=G
M'BJ*92D=3-E%6=I(SXBSU.,X+Q4;RC^7<A/1^C>9>A2EUL;&HG*8,@RPZWR4
M7$$F PHPAYN[!%CV2B .H PM[@%UD_#\I>*5B0Q0NBHEHS0F<<*:,\1#^@1G
MN"J "$#J(B4=$MTIDS-%)0AB1E<,,U-[TS8_)AZU@0H &>C&M8"<$2PO(N3U
M/]V"]#UG#BAZ9.JGAH]&/@D>3#-(SCK:(<<0%UY1N:@R&1G*EP0X!O,!%$%%
M751\0)82>:N-Q4WE=IKD:$:E8<B+<GP@H_=@C#)E6LLEN<IO7AZHHR0VJW0C
MJW6 @?9R#=ZDP9?4^Y(&8$=T(X*'([SAO])BN$MLZ2KSM$ZV;QHV^I5OW'C[
M55?W'S!@Z&VWW]=_\#W]A@Z[?NC0?BK Q^N&#KEFR.!K"=</'7+]L&']A@Z^
M]K:!5]]TV]4WWGYM_Z'7W7K7];??>_V0^_K=]6#_!QZ_X=Y'OW'KD"L'W?GH
MA"G+-KR]SA]>%VZU!5JLD0Y[]) 0Z)@N;!@Z<OSEMPZ\HO\-EU]_Y74W73-V
M_'.Q6 O%$__Q$A_HZW5Q^ "\P-P_>?+DKW_]ZV P6%Y>+HIB.IW^OY]\<O3$
M<: +)X\?/WGBY.$O#K=G4^46XWRMQKAEYUIGH]W;AA36E]%X<;%0[\&2>R99
MC]JH&"2NM_7)!\X!I,A!!]LCW55-O6N:#E:'>VQ@"E.(DLG5#F^X^!&*#W+4
M$^GJ9[XN*C,U#9"A]L\Y VP$7/ HDE!GAEHHJ&'@=!9N657([ (KB?"NJXP<
M'U L+0_F8\'X2R>N(@A4>:04"AM3W#99B["I+=DZ4J<%,8^[*-EVI%S9%%"(
MD'I1A/[7@IP0S2^S[*)-A1&P&A>:+^IN5R_9TE*Q#%5-!A:=2KIE[A\:'DJO
M2KW7!UC!()V0=#PV@T^K<;1I&^)Z1\S@1!A=<4SOZ),K+02S5<V'UD3?7]/Z
M7E7S02 28 J#$4PN,2DA ,.^#=Z80[1^[XZ;0^FJ9ABNW2#:#!C=F^2-#A.6
M3<A8J7*0/=P-_ ?ORT-D0-5(N$$-!M0FX."UT??7Q3Z /E&,#&@MM-S>"-8S
M,/"DB%OA6=PGP112'3 =K#[<J+%#U_DSZ(8!Y_$2#4"7L+0AD-)ZL;Z8#J8J
MA_PRU'Q I7+8U$"^)SD4(2M&ZUQ._\_*S(@<(*O Y$4(WDXL@D,/'<^&6A.M
M)1TG%\KC U(SS/2L\38IJR,-/&D$%C_0<X0T.)D/*!2(')G0HJ4Q+! ?X'D$
M5$2/Y83E+13UX.3M%*2I]%ME25[. RA=CJXKC796SVSZTW8';2]([%0]D@M0
MZD9PQ!:(LK."^$ W\0$<L<0']@Q[YI4K;KK]BFMN #ZPV+9Q33!I;^K4^V%N
M9@1/QN+JLKF[+.A4!GR@51^(Z4-M^A ZC/$YB_E @8RB]0O@ ST&SWNZX"%M
M8Z\VDM7YXDNWU(Y;6#'PD5&7WS1XV*,C9E8:Q-H&BS-L<+3J/6DLI*@:0@(F
M34>(7DQP7@P,5"TTA@H[[1R1DR&R1:CC5!/$#%E,P1MIR5^UWL^_Y9_SY"4)
M(YFGS'[96%3-J7P^0&FCL%!C/A_ ?<(B&$LM;Z/#'D]5Q00D(4E9K?/Y !OQ
M$A\ $4= @Q[W)[&ZQ9GA[0,>K$=+R:#@T6?-[JS1F30XHL@'W$FS)VOU]=@#
M -"8)?B ^EZD6V ^P/][GGP C7)<PN.B(G@ _I=R.37.B0^@DVHI%&YE8".)
M#R@K#M*B'JWT"^H])=FO0:#2U[G>R.<#BGKB_0&>=&?E XJ\Y:FA[J+"@U5[
M2MQ[\!-+I-,6Z]$&$]/7;;UGPLS+!]Y[V=6W7G75+===/>#*:VZXK-^UE_6[
M1OI[_;7RFZLON^XJPM677<__>S6^O[K?95?U_\8UMWZCWZ#+!PRY?."P*X9\
M\YIO/GCU70]\X[:[^MW]X-,S9J]XYYUJG[\JT&CUM8!&LT??AQM\S?SV7<^^
M=.7 .RZ_J=]E_:ZX]N9KQA$?.'[\J,('P"9%N_42'U"]+@(? !H _0MOCAPY
M\H__^(_KUZ]?O7JUR^7Z^;__'/@7X 0<</SX'T^=_O2SSZ+)MC+1N$"G,[RS
ML[HA;'7'T;W2EZYT8ZTBG:?]XO.! *I&FF-H'=J#E,5,3KZ)F3%]F2KT23@_
M/M 7SI$/*+A8?( 7&!#J]SA=92_,,_ !7M>D/ 9J37.^8*U&9Y#X0''_B&P+
M2HL09X;DGH'2D--)J;P^\)FJLDRRW%1!-CV5M5AVK&*)3[VD;D-.A=!USP"E
M>UEVLYAF]8E2V--N C5,P!K,\-&-6ED *1GJY,JF;!9(!@%EM6.?)8IM0 BT
M-TTE9E-8+HV*IEE":2Z=1A>5Z6B S"FB3[E580)W%%\%CN?FR5O)\IX/9:W!
M--O!M/0>U_DP#,/BQ^TL&)R2QX4/HY:!"7 T,$S5<D<,_AK@Y%(.?L[P0WP
MO?YRRTO\*/,& S586I64#H,^S# '4$/P9HW>/"U8F@](;CRJ)\[6<,'DS>\B
M!AOZ9P'O+9#EC;2'G/'0H)>\^^2!)'<[:6MN6-%Z =D95LJCBF:]S(2-LOE8
M8@+*5R<=G['+4A&^E\P7/*QX^D@]KX9X,?G I"MN&I3/![I4?*#3YN[\JGR
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MF</UO*65;PI(HWD'#5:?TT2E8[ F/85R*5_J&Z*ZAE:C,\:U98H!WV/&LSX
M)[%@>9EL5;"[)GRP*MAK\75A-0E75G!UFQP'38Y#HNN0Z.X17!FC6R709)$B
M@6:$&B@TSI$/2 , @=_G)!7-W'S;O?"Z!7L(>3RA-!] \9Y["BBXE!.JQ04T
M'JUM.;^Y)/&(#.#"!":\SAMO?!<BER2B4$E!M=S 6E[=;#7XY[PX2/5;T&4
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M/U7YA>A+3 <D9?U7^ #G^Y=# OA+RH0&1EC<Z$:#S.A.Z%T)T#)8>TNJ:Z:
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MG@9J"DNS RVAU(Y )IE/TIC) WY);_#N"!@.(<>X@^2WA7MMX8-F%%GP6/$
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MME[TQJ%B!J%]:^SVB U!!1YQ%*'I4!P, :>6%!*R4)*4C40R2F8)T$0!MZZ
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M&$DU.&% 8 KST3AT6&:,*8T#2AH:BIB0B35:8PWV@0;;  _.L0R(D,P@/'A
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M9T33-]C*?-UJ_U;A^%K@'*MSCP(:G:-\^ZC0-@+Z#?2 T#P""6!A9G<$-,@
MI 20&*#AA!$1\'MZ5$K#^QI1Z@=!:4#.B+O"HLZ0M">BT \HT4_O*?T(U3ND
MZ!V2]0SRNL/UW4&>+D0" $M)=!2N'4.M*)8$I+U*'+9 B ^NX[E-TKP0_B/'
MUI(D#")JXDCCG]"OQ3&IQ6.!;'@FZ@$#^@H%GH2(B2.^,&R2'D!IF,+[V7XM
M/MK(=48<$2+SV#CRG1E-C^.X-,,R9D3*C$(QJ-</R>W?M'J_;7RIWWGZTH(5
M:V8D)\_X:L:"N?.O7+CXS?L/O__NNX\__/#=O_[^7S]^_X=?X@],_/RU]<#'
M/Z+Y 60O](___%M?".F!64E)<V9\-7-FRL*,U=M.G*EN?Z)FO$VN0<K&.L*/
M=XULGQJ7!%-HC0(M3I^P)(78#B7&2>'LA:+87FA4ZT#LA'2-I)Y(I],#%!?&
M#QD6X_D!I >P!D#L'Y,)*F%^ -,+;(-K0:;5['5P?T^Z7C04AU<-DG/B 3L2
M;SV]'L"=$(7,%<*"/I](YU=;00\, 0\0]?6#'FAQCH \ .8Z00]@NT\ T@,H
M)>R00)RO("08B\O'=Q+: EPGI1/MA5@]@!>ZP4^?LSC_J9CR%J9B\B/\5$S4
M [!%:[F,?F!79&4YZ"C(P[O>#W?[/VB!3G$:@ 5QJLV@UQ&_9KR4?B;]/UD/
M6"=JX&GU -=\LQ5DZA6^''$?EPG7)]STDYBB!Q0<QU7BM7<J%'(+)8\4/!DV
MA4=Z0.\G\P,*O 0(SJ2PV=Z$+"7[4_(3>5<DH_5$3D]-U91$4KC;8]W"$A\#
M6&:0*HQK=%P#<"J(7;B/IL(DAA"D%DBY%(<Z <C(&IO$#FRZ'&-?S10]@,<%
M6 -(DCSV_ 2F3@J)'$<G /E$YE+PI.4 %$ZR;!0J/@E&"^V B@MR]*?U@(5]
MRRCS45@]Y)R-PB'8Y$QTLOI"C16:'VAR?ZUQ?:NR#&AMT6;W&/3ZIR1/-^X\
MOGCQRB4+,W?L.W9#U2[OL<@9G\P2T3C&--8/3>:Q5M-(FW%8"X]FCT@=\+I]
M6E-_D]ZMT;M8Z!#:&/\#9_219^AA__!=9TS6;3NOO+_E]-4EVP^D[CJ4<^+\
MK@LWBR_=VG&NNO!4U>;2,YN.5A:=O'+X2MU%D4;T\$U+%WW?Y+A/.]N,CC:C
MZZD]TJYW7Z?N[3M;<Z2JL:;YF?P=W6KQMCA#"H>?;W;4]AA.4MK5Q4<7;RS<
M7GFQYM%C2J=KLEA:;"X-[58:O$I#0&V*M3"C[;:O[]H!'P#W'("Q5MN@EHEJ
MZ)C&/!B'VCPP#6B\Q?Y2$D_6P%?+<)-EJ-DZW&(?;7&,$;0"G._;7!_NNK]N
M[__0ZAUM]@Q#GZAQ0E\34UJA!0Y(3#Z)$4%L\(KT_6)04"8_Q814YH@:*'A?
M4-SIK7UN/4V]S#LO6GO\UMZ;BMI'W:T&3YO!T])G;]/96WNM=6U/B\HO+LTO
MWE9YA?^LL\WB4=-VRF15,/9FEX_?V;?W9NVRK<6;#AZ[1K4W=SD>FJ+MIJ];
MZ?^EU?P_M3*_;K&,-%D"359GDXW1VLQ*QB4W>:0&ET3O%/4ZA3U.<:]'80@V
M&:--^JBZ-ZSL#E!=/EF'5_+6(W[KKG_*G)4_+[Y*;;\BK52^%'1Z*4-4V.45
M='N4=%C8Y3I<JUVVJR*]^%3)397P*:WI]:IU/JK/(^MS2?I<0IV3;W#R32Z!
MWB?2(S]C+'0185]8K(](#%$2G&0Z8-O@.$PHL"[Q[B4UA"38!$6$Y3> W^.M
M?^MH>&81/K9*G]JHY\Z6SN!C9NRQ\^L6YYC4/L1W#0J<@R+'H,0V*(/&C<$C
M#L:HU(!L9A"P\0Q 8HB)33&0T&BV ?G(C\D,&+JHHC>D[/)3G2A_Q&_<XM<N
MR1NWHLNGZ@M3O1%Y9T#ZVBMYY96\\?/?^7D]0<$$/< R)5R166=Q%&Y()RD!
MTJJ@P'9XS9N<C+-@DT4YF;#%+H^1'Y&)_B2FMF\$Y,K<U\G47\[-!GP"D_L+
M]!2?U0.3@!OP ;3FDY4$) '#:"K/,B8PC_"84:7G5W?[OVY\TKWM^)FY:5E)
MLV<FS4A:,&_^E4N7O_GZF]___O<__/CC[__U]W_X_ON/D\GL?_3/WU /_--O
M_6'OX<-[OTI*FIF4-&/&G 7IJXN.5UYK?:BD/5IG3&[!X1@3U"=;0#^A!T@G
MER &$O7 5)#U S]=#V"NS^D!Q%T^J0=(G9RH!W#U&]!B\U\M'BA%W(O$L3*@
MY4&)M_Z\'H =M))&[U=98FIKE-?IJ'ZBO_W*+,5.W( ?*#A[(58/& /C>H![
MJ'&J] DDWI?@,WH #RM^ 2W[0DQY"U/Q)8_P.4S1 ^Q7<UC<YZU]8[GYW,CK
M<C;9!]O[WT-.(F,,"RC)*%[ C?"WTP.)B.N!28TCR?R?0P]@-CS=Q3^%3^L!
M<ASX]^VWCNO/S+=>VQJ[^]'4%O8. 648&#;L*+Y #^ 5.!QO1H^)ITI(+_+3
M]0!I3SZA!_!]N5D1] C81DAD"/![.3V IWU(C9CZ+B;EV.?UP/@40?Q\HD:P
M89[&3DP3T0I(O'[.#YE6^\YQ\Y6YH=,AUGF14QWD)P!'>F)^ROJ!1#V _3$0
M/4!R9JH>4,3U@/M;Y%_('F/U@.C)QFW'%B_,6I:R+#]O1_G5FJOJ]NK[+ZL?
M==8\-MQ^:*J[;VR\J^>UZVKO]U8_Z;SZ].V-1R_OM+^H:WU^)XZ6Y[6M+WCW
MWXJ>=$M>Z*5O3(+GNNO:)X>K^:OWE"6OST]>F[LHNW#YEJW+<XN6;BY8M#XG
M9<7Z.>EK%JS:E)Y=E+N_M.1R=9504MO4TMC^H*'M27WK"^FSOKJ[KP]5->0<
MK"RYRA<][U7K'6JS6VWS*9U!@<7=8+"<;[X'?'?AZNRUN_:7WJJYK)#7M+?5
M/W@*R;O1\NIZ\]L;K3UW[AGJ'YH:'ADQ#(V/ ;K:!UVWVCMNMKV[U0X[73<Q
M;MT%=-^ZAW&? [O?A7;N=M7<[69QK[OF?L^=^SVU#WKK'NGJ'NL):A_I:LG^
M$T/]L[[Z9]UWGG36/.S >'N]_>5%S<-*>>MI:<LI:<M)"0+LG):U5LK;SDCO
MGA'?JQ3>.R6\5U;7LN.2:,V1:VN.7MM_4UG[J*])[VW6>;3=CM8^5[O>)7C4
M47SV>GK1_EWG;TC>]+59/7(#(]+3(A.CM+L;.GKVU=2G;M^[>M>ABMMB\8,>
M^5.F\9ZE_IZK_KZC_KZY[D'?G0=O;C]X<O->^_6VEJJFMLN:>U<T]Z]H'U[5
M/K[:]+2ZY<7M]K?U[1UUK6]N-[^ZH7YV5?&H2O;PLNS!)=F]BGIU\87:O!-7
M]E3QJEM?J_N [ON%;ZRB#IO&X)=U.$IJ5$L+2I;D'-YQHJ9*^+"NZ5U=2V=-
M\]N;S?!>7EQI?GJY]>GE]F=7VU]=;W];W=X1Q_4V_/7NNQMWW]VZUQG'S7%T
M8703P-N![?6V=Y>UKRZI7UQ4/3NO?'I&_OBT].$IR?T3@K:26O6Q&L6Y.NUU
MP=T[LB=\[6OI_1[)D[Z&)[W53[NO/N^^]JS[QM/N6T^[;S_NOOVPL^8^W+KC
M!D[ )%R[Q^(Z?(54W>V\V?[N1FO'S:97MS3/;ZB?5ZN>7E,]ODH]NBQ]4"6[
M?UG^X#+UZ(K\\179DVN*Y[?;NGDO+>(>+R@6U.<2UW8<W4<MAAV-OTRO!SB[
M5I;JQ/4 Q\6EV+N#$ \ZL'2+:Y&FMF_LI3@]@-I2Z[#2.J:TC@+4]O< I66$
M>(C^!";W%Z3=FWJ73P$WX$@/<%,$K!Z0(>N^,8G]@]3SJR;_WZGIZ 5)V]IM
M^V8M639C[IRDV3/FSY]_&?3 -W$]@$)F(3<XOWP2/G]#/?#/2 \<POZ%0!+,
M2)HS/VU5X;'35UL>*DQNM2,J1:OL@3&P_AQ)T9?A]2O_@^H!4MSA('*$ZOD
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MK'D+YE^Z=/EKK > M2)SH3]\_^,O@F#BYV?6 _$CL 4]\ /D.*<'?OO/_S4
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MJ<OG+EXR>_[\62GS9J1 '[\H:>&BKY8MFIVZ9'9:ZJS4%;-3UZ>L@]NQI@
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M4Y<TJLKJJ1.U\HH[LM.W)95WQ*?JQ"<;Q2=YLM-\ZBQ? :CD*4XW4@#8.4/
M5\91V:@XW2 _62\MKQ6=J.43'+_- \!.>9W@5(/X=*.$X%0#PNE&:25/6@E?
M>:*3#<+R.GYY+0;LU N.-PC*&@3'&@0GZ@4G[O#*;S>>K1==$2JNBQ17^9)+
M#9)S=>**&N'Q&LE9<5O-O7?2M[:[S, #QS?-YF\5Q@\JXWNM<:3)$&G6!YL-
MP6934&,**,T!N34@<X2DKHC".Z!TA1LZS974O?U7!+O/UQVJXI?5R"OJE*?J
MU16-JN-\U3&1\KB8.B&2GQ3+SXADIQN%%0V-AZY<SMFS.VW%ZD5+,M?D[3I8
M=?,D>BAX'=)*O@1P5B@[)Y*?%<C."&6P/2^B;C6U4Z_>M>N91[3MKMZF?6=5
M=SCOZ</-79YJQ?/]%_@[3MX^<)Y_](JDK%I>7J,Z5=M4V=!\CG_WG/#>&5[K
MJ7K5J7K9J0;I))RLEP JZA)0+TZ *([R6LA#?D6MD&0[E)RS NJ<B#HO4ER0
MJ"Y*5;!SZ-+U=47%B]+6+%ZV:E/.]H/'SYRX?NM8?>-1'O\P7W"$)RAMA#?"
M/UXO@ ()SWN:+SLED!.<Y$-YYE O@3+ 04AV*NK$E0WBLXWBRGK1Z7I198.H
MLEYX\@X?7NOQFKHC5Z_M*#^UJ?C0FD)0Q65;S]RXV/*",B,?##@R(XHU08*3
MP$Z\@:*^3 ]P#0(Z/FZ($;<"&@=N)+E!D#C&+V@,)^H!LK8[[E]HJAY@@5M%
M+ _(2H,1XM)W_(0)&&\GV02P>F"(_;L5.>J5V;#G*-NPD!D060>T_1]:'+$;
M;4_SCU:DI&8FS9DS8^97"Q8LJ*JJ^N:;;U@]@-</)/+87SX__DWU %H_T'_P
MT.X924ES9\Z>G[QH<=HJK >>M-J"+:Y!.5ZQI\)=5+R7(@0%EVPRH_T7ZX'Q
M(3W, SZK!]@^\M-*@#UA.CT Q +T0)OWVR;7>_0K&:G%53%^66*&I"1Z !&@
M3^L!=K@TK&!B6ON0W!BX^K#GB+!M=ZWJB*B]ZD&W1.]+G!;XDWH #Q*PS(8\
MW4_3 UR>)%*-GQ-<Z_9SZ@'T7B;;6*-X9/9!E2G4\,)\5OF\I+&E7/*@YK%>
MH?-KS3$-6KJ-H+$. (BY-HH;C\!9C' 36>0U):;DI^D!+B!&W&2.#-A@&?-G
MZ@&VJ'\!IF;=I&=)!/YU&CV &*T5>[5W# MZ/9?O=YV@'I5([IUO>]/8Z5 R
MR$6F2.<3Z@/D#7[R+@EZ0(8<^PR22380&S)LTX\[L/%7P/9>^'S2PTFXL+ZH
MK2"!S+&]'Q'D).HV=QT\U\29!9*E/L1B)]X#H1S&"2-/1ZX6!V'5G]8#Z,7%
MP5:<J7J M SX59(EU*3P$$!&W7YK.]WT"C(3LK3VM84L$^)WN_@];HU]L,D]
MHG4-$\3UP/A\(ZK:W+.P#1$N)S8V&$)"(1Q/*JZ#,;3:P3$J,T/YCS;;PTIK
M1* /'!/=S\)Z8,Y7L[84%%P5BA3ONB1=?;7/.^N?Z?A/C<(G1L&37OZSSL87
M;^I?OJQ[\Z;^75=CIX[?J1>^0Q!UZL6=:(OV.W3"CC[^FYZ&5UVUSSMJG[ZM
M>]91]^)=P\LNWLMNWHL>WO,>P<M>T1N]X%4?[ A?Z82O8%_/?]G'?][7^+2G
MX6D/_X5._,8HZC +W]DDG4[9.X>LTR'K\XAIG\06$MHC]990@[6?\H1:W</B
MEXZ2<Z*LU87+LU;D'=AUNN[FG=:F^D=/:Y^]N?.RM[:#!M2],32\U/%?](F>
M]TB>=XM?=HO>=(L[>J7O#/)W)H"L V"4=1BD;Q%@7_Z.!3D.D+S5B]_TB=[T
M$ A?=0'0==[V2-_IXI!UZN2=>AD OL(%$?3P7P+Q&YWH39_@C8[WNH__N@]E
MPHL>X8L>^5M#<Z_UOLYVO\O4\D:G?MFG?FUH[K:W&7QMQF KP!1I94:TS'LE
M/:HVCS8SHRUTK$D?U.H#6F-00X=43$AN#4GM(;$S+'$A-U!2NE_TSL)_;A \
M[N,][.$_ZA$]AP=AI)T648]%J+>(C!:)T2(UF&5])D6O46ND^<^>'KYX,7WU
MAI1%Z3G[2JXW/Z!ZS*I>JT9G5_0RL*_L992]%JK;+(5,>V="=DI]5HW>KC4X
M6HS.9I.[R>#5ZOV0*F5OO^2ME?_")'AI%K^QB%];8"M[:Y._<U"=3D672]'M
M4G0YY1U6>0<C?Y<(,VPI0*>%ZK*. [ZR8*@N(]5E()!CP!%EMTG50ZMZ:76?
M6=4'2:5A"_M4E_ZBO'G3WK(YR]<M2M]\\/AE0?-3[3NC0L>(#6:^SBSH,XOZ
MS))>L[R'@2=2]EB4?7:ESDF@Z'-0O78">9=U8E(968<90+VCE9VTJLNLZF8T
M?59MGU4%E^J$GW3"%QWU]Y[?T#RJDM\[*VD_+7]0_50GI=$8"FKE,$=G>0)'
MUDFC37Z:5@^0L8_Q[@,?B?L=0C\AL"TJ^94<1$T]:0TP2'O"W0NQ?P+B=93X
M=YK"[Y'?(=;1$Z@%&AGY )LG"P\^N_[X3^L!&8;4-B*UCX(DD#E&FOK?MSH'
M>$\[#YR[NGCEVJ19LY%_H04+KEV[]NM?_YJU%_I%#TSW^2OJ@8_??X_LA3@]
M\(___(^^D.? P6+0 _-FS5Z0PNJ!6VU/VNS01D,/&B;4AZ4UW"P!*GF8'\O_
M CV@H%&(8@6.WI?(># =^1-ZX$\",S!L#HX[<K)^ "42J(-K#+8*8I[$SL3%
M^WX\C8"=D"(NB!*#$\;5MT1P="<L-89DQJ!4Y^-WN>K?6N^\9NH[;,)>#UHZ
M'+<1^H0>B).#1 H23PQ[TXEK)4D[@G)^&E*+GAJ3AK\*4'K@D8V(<$/.$%^3
MD).H%?OLNH5I<F\Z/1"WK  Z==?S_KY[#%0![XVM\;65TOF08T&XJ9GU+T14
M 5%<,A..WL(UNT!M.6XZ@=VBFW+R;Y(&&!<#I,#@_&=)/*>"R"P!>DQ\!507
M\$^32@6Z%_[[Q-(X/GLS+2;GSW0_)3[+Y!SF*@Y)6R)(,#XE:&-S6*SW0<D$
MS@I;&2J?(:G!+\3.1L?U *E]4_@Q2@DWU@6_JKD%/"B6IX'XNDT($8TSG[P+
M8/E(;V 7W:2*$:)/B#O;I.!("$1QH330Z$G):=BT[SU:Y<SE'IL;N%]4LIZ%
MQR.C(3& BB5),^KGINJ!Q(J6^'8F/'+\G,2O>)^\7"#W(KVOH=/1\,X.L@K'
M)QY!(0A,02C H %(>2;S R2VAIQAE=+X4^#1P?'W18K-%%&7")1I]A$)'=78
MHBT.:*)#0D/PA.3AZJ)#R0N6S4F>6[![3VU+6[O-H77T2XQ.N=&GTH<TNI!:
MYU,97$J3C6*L4HM-S-A%M%-L<DJ-+@"<B6!RR<T>A<6GM/H5C!?VI28W'!<;
M'&*]7:QW2/5NF;X?PP-;J:Y?INM7&/U*4U!)!]$6RI4Q * , ;G!3^E]E,ZK
MZ/-1/?VR;H^DUR,T^L2VL, 1K;>")/#*W>$6]XCTC:?THC1C=>&R%:NVE1ZN
M5LG5G9U:DT5F<O"-KD93?P/MY9D\(J-;:G#)=0Y%GY7JL\CU%KG1IC ZE28W
M0&5TJTP>%8WVE6C?#?LL\%<U'#%!#CB4)CN!PF!%,-I@7TT[50E 7^%,(YSC
M4NC[E89^A:$?^S^%'0^E]U &%+V!A;Y?H?>H3;Y62^B!-?C(Y+ZGL[?W.>X9
M^Q]9(X_L P^L W>9:),QI#%%U<R@ O>)6F:PB8YHL1[0&(,JM+HL*+$$1=8@
MWQKD6?U\BT],H^MK^CR:;K?RG0.@ZG8IX>YTO\SBDSK\,G>0<H?D3K_<VJ^R
M>MK[_=+N[I)KU>EK-\]=FE50<O+VX]<::Z#9'@-.IK&&U$Q 8PG"5F'RR7#<
M"63W8O931J_"U*^DO4K:IZ3]"I-?9O!*]!ZQWB,Q]$MI'\4$E98@"G= HWD,
M%<U"#5OC!"@QU":D<+3F<!,3B0.^8D0TYI"&\6@8%X'6XFZR>IHL",VV?@PO
M.F+U--N]L*^F79>;'JW?=_*KQ>L6I.<=/=>@?&Z\:PYH;4$*5),]*+,'*5M0
M:0VJ+4$M$VQB0EI+1&N-$6A0KQ%!8.#684@8![0/254: @J#3VGRJLU^K278
M;(NTV*.MCEB;<Z#-$6VQA;20+2@,GX??Z:QYQ=1UNJ0L!6>['K;1BT\(T&21
MU?1Z8!Q$3I SQ]M/(@82;(&X^0321$]H$TC[S+(%1.X)B"I(C$&6"!D^06)"
M88QE6 \HK=!RCJEL/X\>D-E'98XQF7., L;E'FMVQ/C/NHY<JDY;OWE&<G)2
M$M(#U=75O_G-;T / !T%/?#QXR_N1B=__KIZ *TGYO3 /_S3/_8'7/OV[R)Z
M8'Z"'FBW0_<V#'J ]%6DV"%6P8V)_MO4 Z1KCX-8A*/$8YO=^ @Z&8'CB/@$
MCA6_".%#;&*XD=W$:LSVZ%!+#0%A7[^HKU]!AYOL0\T.R $T:*TT<P&)OU@/
MQ+\BQ(G@SZL')C8B/PDH![A&2D:6E5M04G&2/N?7:%+6H=S[M!Y06(#JA9KM
M0_?[/[0[1U1T1&&$]CW2!&TZ$XG[&_UKZ &*X_<H;5@)LR/-%CP'PLT1H:OA
MZQ"*/.&Y_DWJ :AB8E-( N0,>CX<Y0V50QIT;$"B0P$TR*@\N3Y*+3L]-?D6
M\5X*G\:.%,CB<8(3NBX$<M#(#9L16U@N>2H<YWA<#W .N=%CXKJ&&P'6*P!Y
M1_''Y/($<6ODU((8""4 )YZ<^1/UP!<"90A*G@I[N"(+A#169+I&*KL*#MK0
M N+X>N*?H <(XJ]ORMTATQ2V(9$QK+$B/:"TAD7&4(7TT;KM1^<OR4A>L#A_
M_\&:]GO-=I?:Y1>;?3)H?.@!#0+(Z8#"VB^W>R0VCX#Q--*>1J.'I^\'-.H]
M#7IWH\$C,OOE]HC".4 Y8C);1&()B9@ W^3E&_L%)I_8%!2CD' 1L1'=%XED
M(UO1V.6&;"U#!4,$E5'OE_5Z93U>JM<G[_-!>1,: T+0 \Z!>OM O=4O=8>U
MKA'A*_?A\^+4E05+LU;O.G[L3G-3J][49N^7VWSU9F^-V5=C"=1:_#R+3VCV
M2DW]<H-+9G!(#'8)VH*><0-D ).'0&KT2 WH( N\#\?EZ%>7G)X F<DY"5*C
M0VJ$B]O%!IM8[Q;KO 20?A)E0FKPH=ASIA"!'"$HIY'&5M-^K=ZMZ7-J=&ZM
MH;^9#K8PX19SI)F.:(R8>C(ARA($>JT"8FH*:0TAC2&D-J( BS)S2,R$!-90
M Q.H-7MKT0MR RE7]GG4/5YU3[^JQT/UN"6];J'!PS=[&ZV^!GN@T1%JL 4;
M&)^0\2J=/O[;KB-5U1EK<Q>DK2XX5EG]^+64"5#0*]D&I'!]HU]L"@ $>B^O
MS\W7]4OP5X","<LM81D3E-)^">T3T?T"NI]G<M<97;5&9P/M$4#^PUUH+T!D
M\DJ,_5)COPS4@MXOU0?CD&!(#2&Y,2Q'T=#&(<>0&5"0 :G))379I28' /(<
M7@0%,+LIA@/>5U@\"L8C,[K.:9^LV7?FJ\6;YJ47'CS'$S\UJ0T^B<G+8_R-
M3(#'! 1T0&@*2$@8>VC3D.>#"($4Q_\BPQ,2N/4XPBC<@3XH0H$.?) G(M"K
M=$!B#D%N4-:H CHFD/=VH!/0+D5E#+144;X!1'A82A8U3=$#F+@3_!0],$4,
M3*<'< OY"3V UG0EZ(%) 1^FTP-X N&OI@?DCC$YU@-J]VB3/<I[VGGDXO6,
MC=DSY\T#/9"2DE)55?7MM]\2/8"<C?[PR^J!R9^?60_$/U/]C?Z7__<?W#[G
MWGT[DY"]T*QYR0L7I:XJ/%IQJ_UINR.,] #-ZH%XST1Z++9H_@5Z "\I)GH
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M[+/BMC02  7/2)$*H:,QA"+ XD!D>L!F@?4QB0_004F;=)#&A]R4E9WV,?D
M>DOXS !G0AC&=L)=,+T:9BMK\!.A*28>$-&5#Z -BD$7*K@B@B]@?.N!1 D[
M<PA[,F8T!O+MP?P,9A>%7LT@K'R 1#])?UD[CX)),#:#S2\AN6Q\P$ZE,&U<
MG:>'1Y:E@RF]<_+@CLF#7+<./LG9XO$NB0J>HW )=V5#6V>IR0?L74JYVQJ<
M%#^$7%1=AT,OS,NBOTCTF_R6I7L=L/ !)&G$!UH#^=G^T1GH*^2NB2)P@X%1
MS(L5RS:X=$.$*@#PX5W.YX,/8N<#:O2#-/K,G<(4P1]V\0%*6(2..%Y!&D7H
M@67/,SQ$>7+4^_B,=" /!DXL1B+)< L:D2(?+7!0@I"L8&@"ZZG+L"YLO),/
MA#B3AEVP,'!1G [X2>2]-)0DOE2D$"5OQ3F)O M/MT.#35CX@&R\.2'%5.%Y
MPE/%;(]%Z,GQ!>):V?[!E)8N#>0JT6PMF&D\&?W%C7=NOGCQM1<N6G+SG0\\
MU[\WEIX(Z<6>?5-]^RK^#QK!]UO!]QO^?17O4*%W9+(G@7R@+]/PI-N>U"S
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M]DQ5MP,FRKUC)4^^Y!LM!;,ES0 .7(JGD:Y@WRK Z@:10OM]&",T8D$2?E<
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MOMKV]VL]']3ZANN>$8RX\.+A :!V%<\(O0!1,%+V8E U W<T\,@*/37*^8Q
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MA^*T"Q^@^+WV )A?V,(*\($[7PA?LN;6*Z]?][7-WWHFMLOW0=)O3/9ERWU
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M\/"?_O2'W7MWK?K\VL7+EZ]_\.&7=__HC;':WND#_?E9#6QTM(!Q&JF8G,Y
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M/C.5 ,9_LY? B3 5A>P 6^"*"/W'"ILP1BI>"&O/B1(Z7&V:/QE-UV,94>X
M2Z'Q<6%,#L&7HFUUC#ZJJE)HF@)Y4,F*,F&>9* _>?+[P?A+5CP)+.^ A=L3
MA<%D<1!S_S?"QHQ/G^U+S3CYP)9OO_SFOAA,UU3%/UP()DI1],PT@LFR;[@
M"(P4PREH!HY(G!X0BVGP6I"LQAK,8PH-(0QI)E@WC^46,IO:EC*+8LU:/F/2
M +4N6-^)0QUB&P7O!0+\!Z^_<\NF[RR^9MW2:]<]].0/MOWRG3YCXE6C\DJJ
MV3/<]G_0#+U?]0T5/8EI;PKS)G&(/]NR2A4B)Y0"&;U [*].HR%!6W4B 89I
M[SJVTH15C0WC*UO7->DCSN-)MCA]5^D+AE"7*@?7V> #OI$2'BD6MH1Y(V8(
MV'Z3#U#+67\Y]/(\D%M^]&@"N(6JDD&3442?I E#Y\7C1FN',;,STQJ UN9J
MS[^3V+ ML/SNAR^X>LW%EZ]\X+[-E:G:L<,G3YT$/G#B*/.!\_E&[3_GB@^<
MHI_CQX\?/GSXY(DC'YT\_-')0W_ZXQ_VO+%[]1=O7++ZAB]O>>3E/3_>G2WO
M',.=G@C8RGD\YHL6GLMA[0!_+ [*;'RN?ZS-E$#9_4 #XGGX;XOY %.%();_
MJ)#3P+R(4*460\T-UK5"@';_V&EAV@3,-Z04LRX#VUWL.XCN"\X#4]A9WY$F
MCKDL.SZ.[LPWJJ NZP"+/PL90!% QI;KXBYPAU"F$:=0X-X0$LV26)#%01"C
M2X6TPO J/GU+UK.\N\T$E[<3<+?$C8Y-0OE+@AMD*Y7:)=$O[%'9-K3;L'FJ
MVW$$2;RB><I.&WF21-F(<O)+"F=(4X^>@G\[)ZI.*2^)B8G(-PM(^C>P9%BF
M#5 ;^1%C%OB EA5IA40X$)\MSL[":^  6 LV6<?* _!?/F# K$"!W@QASES@
M+3.*#XACH%B$DB8SCP4K%=>I&W</FT.OE)][*-WYA?BH'('T'X;889]3$KK3
M#+KU^A:(B6V!:!Z/A?LZ+LCUS@/*>[T<^\$3P[;V.RX6=2_X(JX%*FBHZ**:
M,Z1]G>UW/PY>2DP_<3(O2LX3WJ2@R08B%#=30*B"_ 3AB28.6KT5;QKL@(*6
M*<?R<[V)^B.!UV^X8\.%EU^&?.">>U_8M6<P/QF9J/1E2CZ<D[/Q](&!U/Y8
M>DY+MX/IAB]3I_H#P#SMG%8N<S7B\X''E.82Q5XWT!!/%:%AGN&IOJ%)$/+
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M$(KYWAOQI<=ZTM-]6-VY%4W.#"1GY^$#?" ->@D4$'27\E&[<5;X0"Q30X<
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M#_BQ!A\F=@"-[P7R 6E3AC&I/U;_!3X0317 F@]D&MZ.?&#S8\^]_B[P!_0
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M\1P^#H9\T-%V)6IY%]FJTIQ-LD/V&-MSF&?)R0JP?\CZ=R&LMT,R[">4%:P
M7H"ASWR @=%$.L(1+"1"C)@/C.Z/9IW^ :0$(,K351Q$#-6PE6)P/8*CD\7Q
M )Y%+H%@3FS5X0M4,^X^7""LBW<A0\-?T2R'=V,J6Q0;-%119"$7Y+D=%GR
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M/A!4?$"O..L#L(/7&GQ/3@".@T>O2S>IU8D/X'7D0@X+@2_B]=V084)6XKT
M)M#IUMQU;(N3.>[L0!M2&"SD&2H"&0!B0+L>F/:GG_*814<Q9:+SCATQ/Q_
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M'PAGZ3B!W@[8@X7<3."OFP]T6THX(<-GN(@^(?C!/SD?T)@2&ZB>V9Y@0+<
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M\,05!I\T/=54=M"&#D:,^")=QYUG&A029:-7X"NPQ8S%TN6MK?\]8[A6<C=
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M]V1J?>GJ]D3) Q(FCWQ ,RH<+R3YP+I;']CX@]@ \X&^+!AS0%IF0A@@WN[
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MDD_B'[#S :?IWQ%F4L*_<CZ 9PF>B @^<-'E7?A JK7#:._,MP;&*MKHM-\
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M=03):]P"5_):H].E5(H(@_AQVC#E4"XLLA2M!P $:-ZBL";*9QUBWE]!N!J
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M[C[)ZDH1YRW0@B<,3_7E9_ =2\1HDNOI17\T&-#P/$!X6UB06_!+,@:U21O
MWQ=I6H0-OGF@MY^^M=P3_20)7=3IDXK7@W6?Y ^E/?V8A-3;4]_^!#YU) J(
M@IDH]$Z@D39CQU4N#_!M?*]R4=\]6R(/@'\IE=XI2;H%ALZ)634,F.,8,]N(
M$A-?XCA#]DFS2V!&:93P@.!VPRU Y8WJ7%WU[N09;[S>VUEG#F_3W)B^?,.@
M(:,'%*1Y0.L*U^%:L'&MI5-O[M*9<>R>L?M53I^"#=!X(0;'+LCIV'3AI]U[
MTMI$6GH$,+T[%W5H(%.:!TB42+C!G;SHZSGOBIXUMYVS^51WK=O59SX_H=AI
MN"!_9*]W^/2M'JW%K7/YC1UA8WO(P/D-UC9]JUMG=>ML7HV]0PT.*QM5>SI5
MGFZ%"T.5>O-<>:.'=@_!0%@2"X!-;)4D^DD\0#U1K..D[HL^'*W[3&;:4)*:
M,ZJV1%0T 1??,.&X%FG="$(0LN6KWH^O"84-F<J6A#>H("ZCTAI2VH!/@L \
M.EO$: ,>2!CM*;VS2^OJ8=R/ 0D8=\^Q.XX5AT^.G#$COWCL[*\V'3I_!^R\
MPN:K:VV#3Y4S""0@M_J4-O_;\$ :=)TIFNB/?PAX1WR '_56,T5RX]CPUC)J
M.JG@M"9FU/2TA8$_$0]2$$4"N36PJ^'ZC"\V#1H\9M"'!:.+QX^<M6# S(_S
MIG[RX90E R:N'%3Z14')IP7C%Q1.GIT_9>Z "0L^&K_@H\D?#YBUM/^TC_.&
M3\[+&YGWX<BB\?,^VW:T[EISO3NF@1;6XF>:.Y3-[< ;"GS=V2XUNM$$!DCX
M$-\I+H1O8<I17!2"!!31J88\_R!7T$%C.K8I1CV(ST%H1\1S"0&'8EM#_BID
M.!4"JC62?WFS).4J^R%G%OML4TQ/G?[.6_* M F@$^T<F']"8P?_)")G T?O
MF]<I=5.^6-]O=%GAB)+-&W:FHMTD7NC5TZ<OGCY[\>(5C@](/-GW/^^,!^#G
MQ?,7SYX"$KSXW0_/?OWLZ6]?/?O?_]W?:0V:,:-'#"T<O'3I2KF^\8J%:["Z
M%<VNFB9OG1GL!0Z\OB,>T!$>0.?>E4[VS(=E$[N9+IH_+P^XD0?DSBZ]IZ?R
MTOT)*[[XJ*BH8'CAB#'#2LI&SYH[=^F7&Y;O/+CD\,F5-9K=E^\H[6T&=Z">
M"Y[S)!K=T-X$Y2T)A?E;M?-?J%S=<C:H8$-*-OP&*9PAN2/(RQGH0T&E,ZAR
MAJG4&),38;@H\ #F'Q"D<Z>TB 1)-9=0L#$Y&X-/%4D"B(D=R9BLSA[1D2 ?
M+94MU*LT1%I,TIR6WL;'".GM(8,M2(5+8-J#&@>*@8MD THZE,$B#"BYB-P1
MEMM"T!8R+3%52T)IZ99;>N2MG4IP0<Q)O36N1^\_6SI'6(,\$#0X<'! ARO8
M ^'$:KE$E2MYVI6L<B6JN5@-%ZWEHC)75.F*@@77LWX]UZ9W>?0N+R"!C@OH
MV AO;<5@&,FP;*Z;]09EL838:4IM*^XDIQ L)MI6:J-[[7JAPB)*U_0ESH'8
M,$@EM<7O6J+OSM!E5EOIJMC$3\JPZ=)..Y18W6B-(_U>I-=3Z!@3_U?Z_-]2
MPO//."]M%_F_DN%$7F1I C+1")<0P:X$24-(D4#9Q_B AA^9[$4_S@-$1BY)
M96#121(%,&#DNE 2'@ 8,'H[*1+H7?Q:%F1$Z,>5Q0/$204/$H,YM2P8Y$0C
M\$!;I\P2V:Z].6/%QORA8P84C)#P0$1F#8%#J;-V&2S=>DM*:P-7#YQL/U1>
MA2NB="48E_#DL]Z(\"HI&&A(7="[.XW>+GH[63E\,N838_Z&<#T7/]?6V>@,
M-9C;SMH#NB;W7N/EI4>JEE74[#][0]WBTEK;#%S X UI/'!)[6I[F\;:IK-X
MM58O;&CL/BW4:W>" 1YP=RK8A$HR;T'* V0X@F2S$6>OD@$!?E;K[\L#% F(
MTIWZHJ.&!Q%& T2! 52VAA1DB71:WQD2<0[_A1: K.)'"C,^7O@"65R,[QC.
ME1H;,I3*AJM_8(U#SSC,.'  !,-?D0?BN$:; ]K0QQK/8\;=K?%T'[_K6'GD
MU*B9,_.+BV=]N>G@V3LJ+#.^VE9O;0LTZQTR2T>=N5WQ=CQ 8<! BC?FSZ7S
M<Q#"(T@IM*^:#)ADBI@%.SZQK'+%"&,CM#\E2\2-)LEAB<3%IX$'=IJN3%VY
M;F#!J*$#A\^8O6#^NLU3-^T9O_' E(T5,S><FKNV;N&ZFD6;*C[>=FCA]O+9
M6RNF;2V?LJMB^L'CD[;L&SI]R4?YI1]]-&94R9Q5&P_777G8X(VI72&%I4/=
M[-.8@VI[1.G(&.RE5H4:/0(\0H^#@ 1R,P\#*'-(AJE@X9IQ-$F#LV[H:F5P
M\7$=]FC026)I]YJ((I PDN# ^#'2P\*;4WS.=/:(.:0B87OX 'L;1,V5R /D
M7L0GC,>7%K.TP9=(<H5OQP/2;Y(OPWY<J<8<@K*D=D;K[!V5]YHW,8897VWJ
M/ZIL<%')]LU[>A*/GWV/<4)/GS[_X=FS9Z]>DOD#[Y$@_?,.>>#E2^2![[Y[
M^ML?GO[VQ?/?O7K^O_U;Y(%QQ6-&#B]:OGQ5G:[^FLU]Q1,TL0&9&4R&3V4+
M_Q%X -L;DMD=._9:^9F@&453Z/V%!HE^7TMY@"1Z)\4Q_I-X@.% W29/5_FY
M6^.7K/AHV.#"H0.&#1\P?.B :=.G+5^SZ>/-NZ9NW#5AVX'YQVHV&,X?O]>L
MM[<U.H/U3A]C\2F:XVKS7VJ<?\6XGF#$#BYSDS&^F3W<Z8@H[6&),!.V*.P%
M<?!2D^ ?C/_!*.$8!K]R&.,KBG&A8$/%)N1L'*1@^74!Z0@U/ J=+6JP1F@.
M-:)P'^*_@&NUV,-40@IJTJ "&]@B>ES2!7_%,%P'7AL0CIP#111L1.'$F"6&
MC6K!(;#&58^BRD=1K:7+Z'RBLW0IFV*JIKC6FM!BSNE>I&%#6C8,;& @":"
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M"F:-"&?K2L/TA1[B.%8H-M;@CM9[4U Q@0>F+U\_:,BH 8.&SU^U%GB@T1W
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M'WHU%HQ=462.":"')\S!H,\APW'O@P?T#HQBS198#+&F$UR$FU+SJSX%Y98
ME9CV_F?B 1[.L<22;BQZ 6IT@C%_Y5OP0%S+Q1@VHL)UA7TJ6P=C"6A;H[J6
MI*8EJ6B.:MW=9Z*_,OJ_93Q1X($5AP^/F#%SP)C26:LWEI^_972&3,Z(WAH
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MM@8OL?'S@#K.L-81UF!$4%2<40J?<.]T9G8N#ZC[X %HDC#*B\7DIU+ILGB
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M1*3C4PS%Z]V=T%["KXP-ETO\PWE UU>.D3>+6A\VFP<TW&,-\L"WO?  /W\
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M.8(\P%P''NB?7]1_4$:\D +<94=*8TYI6Y,Z2T*//!#6>2+:MIC:$Y>Q49G
M UH2U\YG:R5->^YSTQ >D&9>H@XZB1J*8<PA!@OA=>)"5_:@WAW5L &UK=WH
M"C5XHHIF]S;#I7G[3DS=<O#C(S6;M)>J[CKJ;:&S]L@91Z2!C9JXJ,$5UX'C
MZP1'!ZHD=MC#)_CE=(A Y($T*H!K+OKH/ G$R*L1$EUDI+O(GC] ;XHGWMR5
MN7+BA=)@0'*=41X01:/JE?QB9,1[8W'J"TZLI)%^$A2AY3G+MQ,]/*RJZ<>>
MT'!Q#0<'#//Q0@Z_UA;26^(&$B^DL74R8*;:NK4=CW6^Y/%[#X '1LZ8.6S"
MU$6;=I>?_QHG7P'H-G=HFCL,ED"]+6PP!TS68(,] G85?M69_4RK3V/U:^U!
M!AZX)4SG# #B&KE.@ $CUP4E7,H#=)0@S0,Y1>6GB;;CI <$HX\L47B,<C0R
M81P<L$>!!_:<O[5@\^Z19=/&EDSX?/OV$]>O53NX$T[_27NLSI+2M:1,9JR&
MC"NF]<3U+B@88:TW#CQPHLGVR9XC!:,F]OM@<&G)5. !U95;/\H#4FLCO<[L
MO[Z]G#@ZE+Y?VF]%>4 " X0':'Q_%AG^--'RIB%=(6A/).:%;Z0H.4C> C'O
MO1C_7B7B >WJPO$!8:P;^U;(4LW09!BPMZA3[XT?O].\XO#)D=,7]LL''L@?
M,FC$Z4,G__9?_/6+W[WXX>6K?WCV_6]?$,\TVY_]9_WSI^&!PAP>,'F3JC\+
M'B#Z WE@4-'@PH*\@L(/BTK'+=^\\^39K[6M?IVK6]/V+=/>H_%$3!VA4[?O
M+=ZU;^B,F8,F3!DV;?&PR9\.F[1\V*1YPR9/&S9Q^K ),T!#QT\?7#H5-+1L
M&NZ9B#M!PR?.' I_G3"]:/*L$5-F#YTXO6#<I$%CR@:-F0!?'C9Q)FA(V;3!
M)5.&E$R%#?@F_%?1)/CRG!&39@\MG3%DW+2A)3-&3)@S<N*\$1/F#BV9.;AX
MVM!QTX>5S(#]0TJ)RF8.&3]S\(29^9-F#)P\G6K0I&F@_"DS"J;-+IP^NX!J
MVJQ"^'7&G,$SYPV;/7_XS'E#ILXLF# UOVQ*P?@I^40%XZ<6BH+]I9-%#2N;
M.F+\]&&E4P>.G3B@>/*H>4L6[SRX6]MP^L8WLH<6QNHQ>J#1]6\U7ACWQ?J\
MB9,^+"[-+YT\=-*LH9-FPBD&E4R"8\+Q\TNG%(Z?-A@>VOCIL($[RZ84EDXM
M+)V27S*E<,*LTB5??E%>4WN]^:(K>:6MYRS;:;0!#W3J[9TZ!TKK (\9YV=G
MVS7:#2Q,\"+S'WA3#L6LONT)" <*2%@Y-<KH,=.YIU*Y25^IY,A\0_[S\0 ]
M)O74>0--MK6D7^</X 'TVOD&AD\$0?KXZ01'TA3E7,D?Q -PXW!\&O+T9\<#
M&%X%#; M#-8,[!MX>R3ZKI>1@7?. Z3-INR*DW:$9;_$B00-'5(>B/S)>8!2
M"L,E5%Q"R<95_'**P%1ADSNNL_FUYK9SGNA93^S8C::EE;*I6P]]=HJIN/ZH
MML5;[XXW.*.JAQ[%?9>ZM0/'+MSD:)0'+,&Z5A\(7']Q..)=\ !?Z7)F$E/I
M<F"@+QZ@O>9JNC(Q>:0ZR2.E_I.T #,_@0?@2J(,&]9@A%A0ZPSJ'1$PAB9K
ME]'^6.?H5K%)!1M7<$F5.U)Y^^[2 _N'39E26#Q^X89=QR_?;7"$&VT1?8M/
MW^PSFH,-UK#)$JRW!@VM?LW#-NVC=L #@S6H,7>H6MJ5K3Z5.93) S@M_MWR
M !&4>1W6E)3!F<(,U Y\AL:VQR;?+QA/Y_[+]^9NW#FT>&+1J.)5V[95W;VM
M;/-5>:*GG/$Z6Z>NM=-H!I:(*=B("A.FAW5L1->>5+9'=U^_,WO3[D$CQG_T
MP9"RDJGK-^U17[G]7ST/I$6N7]JKQ;=H.6_M7?/ \D,G1DQ;0'B@X#T/O,W/
MGQ,/F/YI\X 0+]2C9CLQ0!9Y(*)G8QD\T  \\&7^B*'Y@Z"$#IPT?]Z68]6R
M:TWJ9A^FN_$^47N[%5S(T!YBS([=2MW\=1M*%BXMGOOIV%FKQ\W\O&36XI(9
M<\9.G#%\[*3\X<7]"D;D?5B0ES< ]4%!WH>%^/E!/@KV?S3XHX*B@F%C1XR9
M6#)^^J3)<Z9.FS]E^H*)4^>53)A9,F'&^"ESQT^=6U0\"8\S<.B@86,&CRP=
M.&SL!X6C^PT94S!JPJ@)LTJF+2B=OJADVD+8*)N^8/STA:#2Z0M*9RPLG;FH
M9.;"XAD+Q\V87S)C7LG,^:4SYY?-G#=^YOSQLQ>6S5I0,@MVHL9-GXM_FKU@
MS+0YA<43^H\<.[ALXNCILTKG+"B;N[!XUKRQ,^>.FS6O=,[",B+8#[^"QLZ8
M-V+2="@G_08-R^L_N&!4R:2%2]<>.5YU^9:^E;W8%KT43)D\$:4C6&?Q';AZ
M;^'!HZ.7+!LQ:PX<8>+"I1,7+BF=N[!D]ORR>8O&S_L8C@R?X^=^7#9W41G\
M"IJ[<,S4607%X_,&C\PK&#5DRKQE.X^<OG3_(I>XVO[X##05UH3( P@#/ ^@
MWYQ1'J EQKY5;(E)B2(IC(CEA6_2'#74]^)CIDG66B-&:#S.$*:J[/II/"#.
M4LTII4S.'JKL@PAU08_Y%D4>P,SEOP</T&A.?HXRSDE(3__-N9(_D <PP3^=
M__!GQ -B5QF>U\%[EL3;(XY@#@\8"!+D\ #F5OYY>8#<*7:]:UA$ H !4QO.
M,&[HZ#'VR0/#W\@#2<(#$9TGJFV+_UP\H'<G,)S)E52R";DC*K."IQ[6.B,F
M5[S!'==;P 'MN.B.U]L"N_57YNXZNF#?B4/G;L.5F]J3)D]"U=)Q^K:MZJY=
M96[7DM7*<=ER)_'X[2$<'[ $&$<$\\#V/CX0^1EX@%9 5\:B$^1<.%DBBP?P
M.'WP@!97D$R@G%BIT;QXNG$HTDL>Z>_) _QE  _ \X'7IW=%#%S8Q,;J'9T-
M]NYZYQ,CUZ-U=ZG=*8($P:-WOUE543%B^HQ^16-*/_YT[6GUX;-WCYRYM\]P
M8X_V&GSN-]S<H[VZ6WMUN_+B5L7Y@_6WY?<XHRVD,_M5S6W*EG:U.?@GX &L
M@[BJ ^8V=79B>E/:GPUELN.QKKW[\/6'<S;MS!]56CA\]/+-6T[>OJ5H]]6V
M)VI<G7)'M\[2J6_%/$ZU]F"=(Z!V!.%Q,9[HT1;V,[6Q9.6:_L-*/NHWM&3<
MU'5;]JFO_7B\D-3:I-,AY!C&GZ _!0_0 B86/&&0BD8B9;^"GY4'@@(/)#'B
MT1L_EL$#A3P/_/*OGQ,>^,?W/-#;SSOD 9IO]#GF%\+Y \ #;G_;RL]7]N_W
M0>&@0?GY0P:/ 1[8>A+1.6KTII3V".8;)9UDHL#@8O^9,V9RI8RN%(9CVG 9
M,GCK5/K>I,M<3""S.4R'<V#.&=S LI46[^638'&J'%.2Q0,:MHMAN]4<J$?%
MP782._P<$4ROAMDJ.FF^496M<W?#_?'+U@T:/GS@@ ^&CQFY9/VFRH;+S$.W
MJL4OMT84SJ3<$:LQMZN</J/#I[YCJ3!=W%ZKVWK:L+/JS.[JQMU5NAW'91OW
M'?]T_9ZYR]9.F+VDJ'1&?E%9_M!QA<-+AQ25#1E>,F1H\=#AXX8,*RX8.G;X
MF$E39B_]=,WV'?N/'SZAJ#RM.GQ<MO=(U8[]QW8?/G7PA&)/9?7*]3O&S_YD
MQ(29XZ;/'S_KD^+I"T?-_+ALT:<+UVS]<F_EMJ.UNTXJ=H).R'>=E(%VGI!M
M/R';=D*V];ALRW'9YN.RK175N\JK]AZKV551M?7 T0T[#WVU=>_G&W>N6K^-
MZK-UVS[?N..S#=L7K?RJ=-J\L=-G+UBS?G/EB0,RU;XZY?93-9N/5VT[6;.K
M2KZG6K&[2K&S6KFC2KFS2KGMA'SUGLH90%##BP<,'#QMYNS->P_*+]XT6=H8
M2[N.@V(#_FO[B0<.N2.HYB*'KCU8)].N/U&[IUJYOY;96ZO>=5J^\Z0,C@E[
MX'-W#4BYLUJQ TY4J]I;JUQ[X,B4I2L'%4_(&SQZQ*0Y*[<?.G'A3KT]>,:5
MJ&?C1IP_D##9P+-)XGH%;*>*[62<(,&[)26$-L8T8A*]:B$L1T7R+M-<+MAU
MAU':CQO:OZW'I$D]\$G5T/$M'4/ _1A6A*/8TA*(V[34D0XM*GX^*$N&O,%B
M.G')!9R!@->&(KWR23*:@>)_Q2RH.->9, F<JPN%;CWLZ<'4M,@#$6BN=+@>
M4#?C '<<K'EO52"+!\BT!!K-2189P!5MU,(T %TO\\E^A =$'P7]?HP+(O.&
M'1C7I"?01?=3'M"0ZZ'#+]G*:5HRE/EE\?(R_E'Z)_&-Y*A76T$O3!0^*VJ=
MX+&PZ:45,6N-9.U%J0TTX& C=3<I$N"O=.D5'@]8E+@T@9%#888626DA)8<J
MDPJ$600,MKC@$U > &^XT]36;?1V-72@?ZE"'DC4N\"[!:<_L15X8.&J_OE#
M^@\:LN"S-2<O7&MT^W6>L,*!/,  #^#\@93>1N8\>)):;U+MYN</P%FT)/&N
M 9=WQ.F&.A)OEOO<-)0'TH*J%#>XDT;TU%-JX %[M,X2DEN#6C;:X$F><2=,
M9G^]V7<>_/M[S@W5QD6[3ZRK-M3>LC2"K7#%U;9 [2-/]0-6WNS1LT&C*Z)U
M!'7VH-8>Q*5SV8B*Q8@= \[EZ#)YH'[!:X7"C[,+" ]@,ARMDR<!C9!KJ)<>
M??+BL#,+>$":/("X:-0:D-7H>!$VP)O%P'V2ND"4%J$1!!N"]T]$5K^ALTZQ
M+Q;[%SP]8%[0AK3UP/$SIL\2(2&(J5JR>8 ^<+A"V 9@B\$CU;%1 Q=#T.)B
MC6SBC+/SC+.[P=G3X'[<T/9$[^F4PW-S^F0MUNV,;NJJ+_/+IA9.F5NR8OVL
M+4?F;*V<OO[@E*_V35FS;_)7^R:NWCWIR[UEG^^:^-6>%>6*RDL/#98 ((&F
MM4/=TL'@^  \TC@68RYE@GN!1P0/C?" H(SY [U*J)O4=*!(JEPRJ3I3Q,^.
MXYH#EK *4,2)T^MAIZPE<.PN=^1K6_EMVV;]A2FKU_<;,2Y_1,G2S3LJK]ZH
M9MVU[3&%MUO)]FBLG>K6&!B?:JN_AB3)4+&A.IMOU]5[<P\>&SIGR8=#BC_J
M/ZRX9,J:;?N4U^\T>GQJ=X?,T:&TX;JK@O--?>4<.3-%=J)OS4=X"I,$Z'[)
M#!#QK^0@V<:-Z84':(1G7SR0??PW2TTF^ J,04L:P@8.%POQ;!FUFR]RF0>1
MWB.]$7)A%"W2/,"GQHXJK- $!&7F@ HJHQ,=2%-;I[XM47F[>>GADT73%WU8
M,"8O;_"0_*+31T[^S5_]]=/?/?OAQ<O_\NP[X(+GN!S9^TG%Z9]WR@,O* \\
M??4:>>#7_^ -=JQ:O6I _WZ%^?D%!<,&CRF;MW;S\4M?-WHB)I)?B,D9C97T
MP22PV<.!<NPFT=&NLKXZP/H6H8CL'CC2H$+SB3UJ-,T9/RC?1QNOQ<L0>0#V
MI#"?/4<%O\+51HR.D-$>-"#,0+GOT;"/-<['^\\T3UZQ9<"0$0,&]"^=-GU#
M157-;8O:$E3^_^R]=W0;9Y;HJ;9REI5L63EG45;.DJT<K)Q%B9(8D7-D4+)R
MH"0&A JH L" G!@E=_>$-_/V_;EG=\_9/?O"S,[[^VV8;EL2+7OO_;X""("2
M+'?;W3W3YKF'!R0!L KUU?WN[T9'4-$84+K"*E>HHJ%9Y0K "ZVNB+ZN2?G
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M(P]PLR=^#IQ91MK\4[6.18&@OL'8S3*8^F) +P_P;9A&C-%G*</' / I=H,
M&[PQ7PB?0 3G9I#X )7,$R0 2+\6GH9<D6>QI8N;Z0G2FTLROJE^IZJ?%+'E
M2?I-WLX#Y.6]S\]\L&1[H)M*+X.]*2$G6] %E??F]/TI#V0]$U^>9:^_46C9
M1M\+@9<LG8Y/PB99K\H^-G+*N-2Q&%2R)M%VI T2B!<<?_E>@@YI( &)!\B<
M%LH#%B]J.70BI)O69\PF'/5**PBQPU4JD^=FR.<!]#1C;IL?0P=P8UJ\[6 C
M*IW1\H;8'M6UJ<O7#AK^1A[H-'/=%O:9E7T.#P@/=&B *+QM(#J!:%=BF^:
M2O;2RI(W\0">.XTPP(70>U-ZK#!.F(6XC8O:V99J3Y.-%2_=N+O^W*6I6W=.
MV;ICVK;=4[;LG+)IU]0M>Z9\MF?RUIT3UFP:,6_IT*ES/UFR9L/1\^<J;\H:
M>!DH1C&F%F'!@%[M,#(IK'] MS1Q)_-1'?;;B6(_4'HD]"I0$]8#YX*S457.
M( CP UX(3!E"HR=[K4HW1?X*Q^^2[46\JME"$DM(/"?K?7+>,"-9^@<WJ5RC
MF2X XC#.B/0.Z"=F43V:?&U6?X>57&L]$]6[(V8W)DR"V-PQJSL&,&#F$B;B
MM%+R43D/UC!L4C$UQO9)D(J/6[BHE<5,2[@B%C:"UX6+EMYS;RDV+CE6LEUN
M/W?]:>D#5EGGLW 1&R QAK9(J4FZ8"9]Q5'[4>F-PKV=!\Q"I]7;A>ED(HG,
M<,@#L%O!<:H\>3R F<EH7;@CVH;@^2OU:T\I)Z[9/W'-GO6G*L[;[ZONNS6U
M;E6M0_F@07&W0?>$LPNARM:DH3E.0E()M2>9$?A1*R9A893=YW9=-,Q;L7/<
M^/G#AGPTL/^H,1.F;#IX3'$?>4 %^Q37HA(BN)^ZL<MS7]._KT@P@.4K.'/#
MD XR:TG/8MJZ&G]/.LS*G3C'O9<'L(NT=(/#74R#0O0>SUH#65HZ2T-F\T >
M/6;RS?)Y()TOI,9&&IC58R0M]=":=V$?:ESJN<LU7RUGE#-1^W1QPF_49,X
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MMI!3PP\MO;3@.]H38"EB6EI[E;_#ZG]&YA-_.6OU)IHO].?G@?0)$N")H67
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MYH$;?P /X(P_HS>E%W$X,9K1L!4Z@H $1@9OHMZK)L4'8GHFK'<'M>X@)N3
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M:5(;](V2;4QG\T"O)LU^+5E7F:V.2(IDT&*V>O9;D30;&E$%D08(9,4'L R
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MOT7Z/@U_Q,*S?*.?*A,]'5></EIZ5*0\C\:7<@1SW#VQ3,(])J%1)."B.F=
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M\X#_*YF[;:_IR2=;3O<;-05X8/GBV467SAGNU"H=4<(#OY7S[7HV:&::=%Q
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MI@WJ*Q-W'1]:L'GLXDU3YJZ=,'8V\L"@82,F3UY]\&#9[;L6P:]TBV5.+_"
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MY#+F9._D2[8QG<T#;[,L];UF4X8'R(]OR%RG5:HD7R@- +V! FG ,&4 J;J
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ME 9+(#K.WQ0^/2P;_-&\P4.&+5^VX&)9L>TI8_1URWV_+1._4L GPP8MC-_
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MK:_#0%PF:C)S$8,,H'])\R),;B$E$*B\LM*"M6_A 6I*YDC:8L[B 8SOY_*
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MZ4>@,>"!'__\/W[\X?\%'OCW__-?@0=6KBY*S<NMK#UZ\\[3+M)&7FH=D]A
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M;];N.9:64UA[<+_?[?CIQS__YW_^]:>?_^"!Z7_^QCP0^_[/0&'  S__R/#
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MDE)G+4Z?E9HU*R5]5E+:K$69\Y>O77_D2D/7:ZG*)0=UB2YU$J")R@*.#7E
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M*^$K P&L+*1W<L!,5#LZU,X.#=C!7LS9_:T\$%FZGH$',,0EW$@XKJ/P##Q
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M!,<9RP-@"4DL 2G,*5BM%6[R@ P^9O7+L-I]@-7GK+[4LF 9PP/7.5)I#_(
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M3,<#P]\KAKYO?*"IJ,'^ W-FS\U?L^Y8NYBG1A[ *ADD51H?;^+)1><FMAW
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M!5ESA3UBT>[P6C6I*41)8 8>H(9^1"+Q2,24CWG_EW@ !R>&:N@I_(+?(#8
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MVLV#;(M#:'0IM6ZEQB,&W83ID@&\H*9HC!!!@FC!4.JD(O8B_I<6YXD]#+I
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MH(X@=B_^53*%!R(69&1M'O^D-=8(#(R2ZHU3#$$TBT&0?,;)"H)+:O%WJMW
M ZNW'5J0G#%G ?# @>O=CX2& 9[9R4)/?4AJ^=1E_NZ.Y=LNV[AB," =] H&
MO#R;CVM!4R/V68B]D^.L_T2)'#,Y[" )=,$ )P$IDD,BXVEL#!,9'UDBE>"%
M\V&C>CV&_P&3W'H[M+6>E;JR)"5S:0P/3 (/L'2$X<&HTMG%^F&>_A_- [&?
MYVL(13,#-=,083!A6**/&W4IQ.X7[:<P:1#&P _'W \!O.()IQ#' U(#YO+Q
M34&N:9S*M:>:S1<;EZPJ7IR?4WGT9 /A <FT/( ^@2@/"/0.D=$E,<&4QUPI
MM&Z)N4_J^-E9O4,@[/X1F"5Q:^%#2AS\7RT  \0FIFV2!1J70.WBJ]Q\K9]C
M&FTV^,^^LU9TR)=LJUV45YJ35[1US^XSS0W'VYJW7:DOKSU77'4TOV!G5O;F
M[))=*[8>*MES:&7UMLS2DD5%>4DER].*"[-R<_/2,G(6IA5DYN[8MO/"[5OG
MI*S=S5<J#M:4;JC:<O#$]3N/Y0-NY5" JQ[H[#4+M<.L#Z83@GOKS]]<=^;&
MP5O"*Z+[-Q2/&J3W+_"[C[;+SXJ?MK^UT2!JN-MA3&"(:*YCK'^ 6LR16S%,
MF*0:;Z1?!P:,16J\3LD^$J'U0A=TR,(*,>YQ!HE1GF1"(9&EX047*I&*VW0%
M*BHQ7R=:-[JP$G$F,%HZ0:;R &G&S)P:S%_D 4&7EY.KMO.U=KR=0'0C'(V#
M!RIB\'N)/GCSWKN* Z>S5JP^>?S8>-#_%^Q*_$=]H1E__HD\4-L@_YKR@-@\
M+K9,2*SC,_) & :^A >H,41-A[!,SP-$S](L EPABP@-'(IY)YX'X.LR-.9@
MCASC_VX> %L?'F\)Z7KV.1XP!%F&4(=NE*7#R %>_U!]]_.JDQ?2BDKF968M
MSL_/*"Y9O+P >&!.1E;%@2.W[S[OUL-A^(FS-:P:R*-%YDL/Z&+\C86-_3)]
M0&YP=;[3'F>+5NW:_U568?*RDEVUEUGRE_*79M'[ :'&WJ$9;M,XV%IX>L=X
MZB"WU\WOL8M4#KG>(S=XY; OK>/6XP^;+S4OVU:[[=+-BSSY_H9;:PZ=K#A^
M?MV14VFE:V:EI<Q+3RG?7GV-+Y#TF80&?X=VE&4<%UH_4AZ0:(>[=(X[)J_"
MZ@<>Z'AC/7Q#GEV*/+ H):5XW9JSK6V<_K\%#V#^P*C XK_Z3>_:JS$\<+53
M\J)?;!S\!1Y 8XX1-++#IBUS!Q*MB@:E(4A,U2D3,YF;_S8\$%T+1/N8X0&:
M>L7H<6+U4M-9&'F!QQS  +QPZCR^P/I= 8P<"/L'>"3\!OO5D\ A+C:#9 0;
M0U+_ +.U*3P@I&$JI+= Q$"A-HW$]#?E@;#PF-4L.KO0P%,RQ\3X3&(%,08#
MKNCE2R"!* ],(S2TB?( /5EX$_,]OHP'2)[2##Q SH+D)V!T;X0'HOZ!1(O_
M\S(=#X37@_$ Z&H(Z<02I$$F<88@VF=&DJ:%2^93>*!D:^V"Y'3@@?)=!QJZ
M'PGT-H[1WFEP"]&S^FV7Z;MN\R>E-20?\ ,/" =]/!MV*<:*6S$6:LS-3 \O
M4>)Y@-Y+9"6;"IK^D<X,J,UBRC)*R&^\R<WP),)G'%(3#&RPZ?7 MFNLI<6E
M:9GI&^-Y .,_,>A(,R+4A7G \'?@ >P8P.1IS,0#,5]AODAM_<AV8M^)_20U
M_1,VPGR>?"7Z6D0: I*K\%D>T,?RP!B!@0G* U7GKZ>N7)F<NZSB\/%K#UZ3
M ?&"H2;4N:FYB5,/&J#Q/(!]9@QD&C*$.Q.3WV#"<OI'.GL&.WN'F/8(-)Z6
M7NZ$P?_50GF +BT3 1X0J. =/]<8O*5V'WVB*JECI:[?DY)9G)F64UBXLF1C
M1>Z&]8M6E<W+*5VP9$UJ\MKTU(JTK V+<LN3<DL69N<OS%HZ+VOQ[&4+YZ0G
M+5R\('W^_*RY\[,7+EJ1G;VZLGSEKHJ,RI5+BG)R"@JJ]NQKZ+H#/" ?&6=K
M1SKZK$*=G=<_<$;RJ.CPQ=1UNW(VU!1M/E"VH[9\UY$UNX^OVG6R^D);_;T/
M,)@*6PA&@]4WS%4[Z-@F\@ NHI-[+WQ',4GD0@):S/D2'H!''J":5E+!I'RR
MF,5G^A.CYJ>98%/T)UEY 1T5'YD9[L@Y#0^$%774(4#S/&,D$082>"!<"(NZ
M,G#)R8?^+O1[T-O)"3P@U(ZPU7:><4PR\!U?Y;DB>5JRO38M=\61P[6C/@_P
MP!_U1C_S\\_C@3V'&A1/Y3J7##,'QL76"8EM0F;%>-#?PP.1:3O. H@(5@0*
M+X<P-@J9%!.$^O=C>Y:1B1Q#2_'K),IH0FH.T6HJOYT'5':8&-CP&W@ V^40
M'L!8888'I,@#;A&F1 ?:M<$V[1B'5,@&=59_[^7ZHV<6%JQ<D+TLO7A5=MF:
ME.7+9Z>E)F7G5!\YT?'PY5V#2PZZ6X/)"5%-P6@'-ZIFS.OR"-0>H<HMT3H$
M*DM=U\--Q\XFYY<D911MV7VF7?Q,\=(LZQD2J>W-[\W-O0,\# *9$&I"PGZ?
M1.61:5P*G1NN(\" 7#W2=/_UIG.-.=L.[FMH:W_X_#)?LN'XV=(#Q\L/'5]>
M59VV8GE*;L:Z[54- J&TSR30>5M5_G;=F,CVZ8[]N[OV4)?%+?Q@O?U4U?"T
MKZUWH/VUY6B3 GA@UH),R@-G6MO8?5:V[5.;Y6.;\3?Q !:8@[LE)+)@/G'=
M2\(#1< #6<6K-E^\TB%\WB<R#'0P\4)V@<&I@'-4NT7:, ^0@.RH@<@LND=+
M=D960?ADS9ZD/<5.U3@Q_TH>B-RT"4)L;EIZ*,(#C-,V5H]'K&?Z%. SQ5B-
MD; *LCA'EL")P4U5><P23LRB.]DXVL33V?3X_C0!XL0V1;LYFGH1;X+'6^0S
M\$ DAC4L] CCYR'ZK^EX@&PJ0*L1T(3OZ/$DG,Y,@NQ'VGF2>P =!5_& Y'@
MG*EG%YDO<=BC\4(1$6%^\ QQ03/)=#PP5:+_I0](@BU(%PX8'I"9W#)K@*7Q
M,#RP.&-N4MJZW0<;[SRF/, R>L2V2> !A>&3TC A-P6E%J_8YA8,8$LRCAD=
M-3'6;2P/S"318Z:W$[%TL2("&HAD]03N7AFM/($VT)3T2FK.XNUM@:'V"G1V
MJ<D+%QIX8&M]9WIQZ=)E&9MV[KK.ETG[!H$'6/I0IY:XF[##T;! -\35#_^=
M>&"*\3T##X1M=SSEN%9E(&0<XH!ABIY)A('(P,:R0?A]7(=*/(4X'I 9L2&/
MP!SBF0$&)CC&4/W7ZJKSUU)7KEB4D[F^]FC=W6]H: JU66F[,8SYP92 J3Q
M0H:B/! 9"L(#6$FO?X3" %Z.A '_M4(BRAC!=TA7,L8X!MY0NX1JK#4"$]QM
ME>O4$^WZ:[RL]7O3EA:E?)6:O&!ATM+4><NRYF8OGY-9-'=Q<=*"DH4+2N8M
M6C5GR<JY687S,G/FIR_Y*G/QG.SD.5F+YJ<FI24E9<Y+REJP,#,Y)34K?5[^
MDMFYR0MRTO*+BW<?/]WT\(EDP"<:GF#I7)VJ81P3]="EKN>K:L_-7;YNWK+5
M"S)7+<Q<F911."]CY?R\=2MVG3G%?PS#*+>-P>#0D2$V?=36%\;RP-3S#=^-
M2&61P"'X#.:/3>4!4&6@@FA5"1H7.F4>"8<2<<-=[:?C@7@E/*W\6AZ(G"!!
M&C>&TM'D>P1%M]@(" 2WEEVH&^%H'7Q32&":N/7"=*!)D+5F2TI6WN%#!\?\
MR -_Q7@AL$U__AELU+_^P0-3?OX)/)"_LB I([.\YE"CXBF8DECG[I=YP(_3
MX102F(8'IDS5"18 E4C.GSC<)S*LG>-%0ISIG^$!+,IA"0GU@=^5/Z""*2K
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M_Y'[:WB ;\9XH34S\T"G&91+(@^,@8A,1,(6,,  5^OC:+P18:L];%)HB/!
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M,B7PA5@>$2ZH)][RIF!#O\CP0W2@B!,@WM43K5T;XTLDGI-8E@CO5X]]&,D
MXF\J> SA;F7T($F6-D,(- DA3 L^B=XCUSL5.H=,YY+"H>+4.4YX8*SNB6K3
MN6LI*U8LRLW:<.1XPX,WR*5D;4M$D[E)/C')<"6YK3H7UHHA_<B0!%!+,R-
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ML\?*ZK7QP42S^.[9Q^_9)Y4#8WA@9 U;:0L!E(*]Q54[./T8-,]%TV2*L07
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MNV\86Q'36Y$^-0P;A]&+_DE'& 5N";^0%$SC&V'0F+A3]+%,QP/\J>&7Z#%
MIT&X2%KT*]2U2YK6TX1CR@.11I!&IKM91! &L'TDX0'2/B\L0&YPF7S,_<D4
MVJ:W$/KG077+0<GC>LTH?^!3J]9W5/2L 'A@<?;BE'3@@?&@[Z\___CSSW_P
MP(P__R@>^.D__OS#__6O__:_  _D+R](R\K>?N@8]]'+I]; ?6M(81R3Z(,2
M,.STHR 2(OC:, 8B0QD%D4XC&%F8*#)C0$EZ[DXGXQ%1@!A#<MB^?C0B=._X
MVC &_U48)^1$% 84F6%<J@])=6.T9C,<E<(P*M>C4N:;X2%'=YO$.*;0CW7I
M0EW:";EF7**=E)J_4]J_4XQ\:GBH6E]S+FE1YIRY"PK*JX]U*%F](V)27DV@
M=</,@3P SP^):(SP@)BLXK"T  ,CMS6.#H!F#&SPLUY;+@L?'Z[G'+C0LO_,
MS>K]9[-+-LY.R9N]M&#)ZLKLC=N7;]F]\\*U*WSYF59>6<V1Y*+RTMV'_G_V
MWBLXKB--%P10*&]0%E7PWGLZT'OOO0AZ"U/>PM*+%)TH42()4]["FW)PI-0]
MN[%O^W9W]^G.?=B9N;MQ8R-V8DS+2[W_GZ<**(#4C+I[U+&[5^#'$UEY\F3F
MR3IU\O\R?W.Y\]Z=7M<%\\W"=5O22JH:]ARZ8.AL4IFJ-NY4E-7GUZW-KUHC
M2"_@*PK6[3W:UG7_G,92O64W/[\L69J9MV;#VM--E?L.IJ]>6[7[X(ZFR^4;
MMO.RBE)$BHS*^N,W5->[[FPZ<EI:4I->7I]=VRC(+6=(<YBR'* !^=4KLLMJ
M)+E%I6O6-FET/:_M]]SC7;910Z_?]-K7_-'+;9?U>1L.LHOJZ5G%_+QB<7YI
M=FE]<=6:C*QB.H-'YZ05UJTYWF8TO71:0&0$:=4Y:49WXU&S?=YD?8L  N:8
MQXESJ4:-V8/K52 9&SPH=!J0-$;(ZMW8I:<O5S5=@+NC,:5Y12L/-;4IG[S6
M#OA5 X,&.X96N#4P=:]WZD[_5+M]2N>>TGBF="ZR\.P8CV-"1Y2%U!0? (;C
MG"1Z.*%VD,519QJXW(06I V0X+TALQ^D\ZC)%]%#54[40<+,0-0R.-T^. U'
M^ @E?PYD[XO @X#.J&RC+7W#&*4.WHS>J#DPVS$T#[ $9DV^J-$7@18!1E\8
M 95#NRC'+P%5.22@GP@7 <Q/\;,HW\<![2:4'],X1PB&"49T[E&#=QRWZ4@/
MJ2T[H!#4M13Y 7YB(IV!H\$3TF%S\)TN8'0!>D2,&\ IK0L^CID#4YU#X:[!
M4+M_RN09-T FNI5X#PPPR[K'S=Y)BV^J/8X./R (.7"MT3UF6@3(TV,&UQA<
MJ', OZ+N:T3M&%8[AK3.$3V4]T^:_)-F_Z3%#\225.A!%F%QC';:1WL<X\!R
M;WN"=SRA!=QV 1^( "NXZ8[TD!V#3I"34!A",Z$%F-P1BW>Z T1,_TR[CPHX
M$,+="<('#""OXU8,WE$<8^_"Z$)0MV"TC9BL(^9W8+*-F5 $07WN1!B7\0&B
M&Z"Q3:FL4PM\X-[XWQ@]\P?TC_,:MC,XLA2F<!D?(/8#LY:!68MMQN ,:=SC
M*L^(!K_326*UDJ C]"?R@47I-C&'6NJF)![D";'8BXGH\$21#]@FNCQ3/9Z)
M=D]091O?T-+.+JNA*])KMFR^UG.[QS9HL0./BFCMH>97(S<^"]SXS-ORN:_M
MI5_].J#O'\+!M(\:;*-D,1)]\'=X<8<*&H6/E$<=]/="A8 E0A@E#>-6!D9E
M)EL](!8#9W@O'R"+XD1=GHH-!V+]HIM1LMX?"_)-(:YM1>T5+$:_3AC>!5$O
MAA@?H/95"!_ 6$[]**83/D"QCA@?:,>PXA0?")IL4\@''!,WG9- =[O1M&].
MZYQ5.:95CIFS'V$\,E%Q,2\;^,"^LW<^ACNE-NYPVXTH#E'CHR%#A'R NOT$
MA99$Q+<U%K2MJ)"T?S8?P-!:E/;+@C8\9;B/Z]EDD(U4-&CTLQG20'E76&F?
M.M3^44'C+C97SF$*J]>N/=UIT;B<NI$IC3^L=T7:!X+MO>.ZON'6@4"K+6"P
MC71:)SN!N8'4ZYB"'X+* 71K$CZ:;?#=Q70F#:YI/9 !][0655ZGU>@2(T@<
MYX_B]K5K4FV?:.D=;^T-*OM"ESZR;6NZEE-6QA*P"ZIK3JC-YEZO:6!0_=*K
MZQ]K>SW2W#NN<<X8 U^: E_H\1N)J&U30&65KX=AJ*D@ [%',<ZOWL7"XX'4
M.B%N8TSAAZSB+WLM4"L%"^O]L55_RHYKX:IWWB14S+*801=E#!9SS?>.?PBL
M@1"2Y7Q@*LZ-J8<?CM1=A(C+T8EV]R2^5[W3IN'?*5W3!]J?Y:S?E\25<8$/
M[-HY-QW^Z<?OT7X XQ/_Q@?>\_?7XP/??O=/__O?_>=NX ,Y.6)%YOH]!W4/
MGC\.1#\<?'/3"P+W; <*UM$.>R01G?9HEV.:0N<O!HKCSMGWPS6S#-W0KCW:
MB6TAXNU&H$4XU>V<Z7;% 0S!@86A@,41:G<$.^VA;GNHRQZRX",.8AS\J,+M
MSDBW??JF;>:6;:Y[8+;#.M_I_J)GY,ONX3<7[_76;#[*YDAH*8S<BH;];9W
MXPD!F-1;88X)4Z$<$_<'S(0/@$R@M([>&!B^81M7.L,Z5U0/[[@7@=:'_<T]
MGS1W/KMJ^/#@6771BNTT:6&*K$!<UB"K6BDLK2Y<LVG#D5.-^X[**QJ8BKR*
M#=NO=]Q^9'5K[CRLV;:3G96KJ*C9</#HYD/'"^M6YU76UZW?5M>X19Y3(E+D
MK=NU_X:QX^"YR]F5=71I1E*:6%Y54[5S5^'FS>D-*XHW;:G;L5M25,:0*E+2
MI,*<@MTGSUPQ6+8>/B'*+1)D%>0  :A<(<DO2R^JR*VJSRJIX,LST^19\&X]
M=?VZ\=&SSL_MNN?6YH>?-[7?W7*VN7#C?G[)JA1Y09)(3I?*TS)S%+G%&=DE
M0J$BA<9F\B5EJS:<4IN,+^UFYS *BZYQU$Z!EZQC7F]_"X"$T3F'OIX\H02$
MS=YH!\A8@6F]=U)E'U4!UW)@Q&N+-WCEX]Z&,Q>Y>>4IS/3<XM4'SRK;GO2J
M!P+*@2&]?;S#$;PY$+S;%[S='S3;@VKWE!(H@7-2YXC#B6I=6CO,-.-JZQA
M:Y^ 7F&L# _1B4>3=Y!WI[0 =U '_?&!: YD(*1U3JF!*CAQK\/@"YO\45-@
M&HX&;QARW@]@%]XXH%I/4 M\P#X.9$ %?8!WJ!OC8  E !A]P%&AH9BR')0G
MEX2@&^^"5(X)C6M*X\)>(;#;0<0[/<&2T'_'A ;X@&N4^)H<4:/E* A_HUK/
MF,XSJ0/B07$/]Z36/:%Q0>$)8".6P9GVX5E@/M KJ%SEF% [QK5NP!@%#7JD
M6<1"?@R>,8-OPN2?,OMPPP?(@&XI]" -+\ ]9O0@'X#")N\D!;,/Z0$DX)3!
M/98 :CMB'"[4.D<U3KPOXC9G1.W$16Z==USOFP 8O!-&[P16!7"#'(DS>KMM
MM,L^?M,U>=N-?."N+W+'&[[M#MURAF\Z(X >5Z3;%>ER13I0T7\QYGK,B9 [
MA+I>_FET+N3#QP8>)'C&X.F"(^HLN29^]C;CB/7?#>E1HWW4;!NUO .S'76H
M2 22I7B7#Y# 0QIT-H+&P5W>R)W1W^'^@/9Q7OUV!C>=EL@'G",8C\P[;W+,
M6:S !T#8@L=I3.V!YP&Z-&7"NUZB!/^G\X&8]+R 1&(05_I:!*ZP$#]U.L>4
M&OB %_F V36EM(ZO;[:P2JOI<AGA W=Z; $3,GG@/Z&6UZ-MO:/*WA'EJZ'F
M%YY+C_O/W'E^M/W!0<.=(Y8'31^^:OG,;T!'<#&%)1V)%PL2V(*2AHFRB$W0
M:T(^0$PAM=0"^5(^0/7?0O8'.N)1+XG<CY*0%N-DH15R(A^@&,+/N9"*\8$%
M[D2)@W&)D!+$<7_ BOL#1)5\@HC@"_I"R"BHS0&#=<IHG6RW(1^XY9J\Y0GW
M &-QSVD=,TK[M-(QC7S@U$5A<1$_)Z-N[P'<'W!,$94JLD-"MKMA?%2OARFO
M^2BG4HO69&/G73X0IP%+7(Y2 _NG\@'*3TXL>BX5<!>5QY /H+Z[*[I@T!)S
MT89S:P3X0)MMXI#E8<&:'0RVC$D75#6N/]/5I75Y=<-AE3>J=40M?2'+ZW%M
M[U!+O[_5ZM=;ASKZQSK[)RP#N):'404<X_!:TZ'B8I R-*+<#QC<4;T[HJ6
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MPOHUAZZW:3[YW.SVZ;U^E3>@\@^K?&,J3TCICK2Y(RIO2.D'R@227W01WFF
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M!V0@-96>#'P R("0QQ9PF (V@P?<@9$JX++$(EZ:$/5UB*Q/8W(8##XC!?@
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MVX-+\>[ 4O@3^ ".><S%4R(?0/]",3X0:VN!#P!YLWAF.I 2Q- 1^_E,$R9
M^  ZA9^C^( 90XL@'S Z(_#BU3GG#E)\@"=C"B6[=NP@? "XP \@EW[[W0_?
M_O ;'UC^]VOQ@9\P/O&/WWWWW5=???7=]U]_^]T_?_W-/_[]W__MW3LW<W/S
M^"+9RLV[-?<^?N -FZT3S2\";7UC)E_4/!@Q#(8,@T& /A#4!:8HZ =#^L&P
M <]&C$-1@#X0UOJ"J#CNB5!0>:-J$,T#,YK!61VJ9[PQ!.8-@5G#X(PA$"77
M0@TAF%P3$#0-!HU4IC_X+@S^L XUO^?>P8S.#WV(8B(PIQF<4PU%E<.3;<,C
M;4-#JL$1;6 "G;IXT#94Y9MJ#8RU#0\JAP:/W7]4N&4G4R1*93$S*^L/:GNT
M S_+!] %(;SQT?5JM .-F(=O>H?N#PYVV_K/=EBJMFUE*Q2I(*X+1.(T<1J'
M)^"P>6P&BY&2FIJ4F@I2/IT#<CR'2>.P4KD<&H=-8S%I;":-RT[E<YEI BY<
ME,:CL^EP#9O#8M#IS-14 8\K$8EX' Z3R6"QF2"2IS)34Q@T8!%T+HN1QDD5
M<5*$[&0!(XD+4CJ3";Q!P&,)N$P^2.^L5 Z3P6/A1QZ"+4AC"?A /]AI/ :7
MF<JATSFI'!Z#G\:!LRD\ 4TH2TZ3)0LDR0)QDE"4(A&FRH1,*9\EXN(6!YW-
MH?/9='Y*,ILMD%6NW7Q69[:\[K,X70:/5^_QZWR#&O^@*C#4YD?C#8-OW.BB
M? *2\$ $Z$ #MZ=#1(EKLMTQU>F"\8P:!R8- R.7'[]J;+HF+*BET149V?6;
M#URX?.\3C0N-E37.45/_1/?+X,V7P8[7:-ZD=*%*O1&G[1@Z/" V3;>[(B0"
M4;#'/WMO],O;0V_A;:7'Z6'"C'&+PF0Q(V(A'C\L"&J+%G*F+1CI8IHD4"PP
M$2' :,/P?) #K[\NWWR/_VVW_PT4H_QD+\!@A9)A$[52N."]T8FF.&8'5@5G
M%P"%$\LO $UWX"ITVTJI9BX14Z@^='KFVF$ZB2,VESAB3J#C]1 = QOEDR0$
MK>--Q6X-7MQXFS!;8)SY@:"N'[4@M'WH4AJ(&52%[@063(,2L+0);!$'BMP@
M^8B!F3K=V,,.-\P-,U L<7RP,V2*0KLT6Q@JO!GX\L[P[V\%ONAP3>-0(.6F
MCE0"T[&)+3Z9D: Y:%P;GP71)3RZO(B#<OFB)\ YDNHPL27H],[!-YB -_!5
M=GCF8)[6]@]I^[W:?A] T^_3#?@-]B&3<P3U$KU3)L\DB4 W'CNZ,-(%OBB(
MV $/&XB;W8&Y6\-O;P;>F&UA7>^$80!$4C2$Q8G6&=7;(SIKB.IAO,-3FOY)
M"AB*E8#X\L,R)BO*?+>]84"7:\KB&-=AB+TABW/\IB=TQQ6Y[YZY%Y@SVD8/
MZWN*5FQBL66I3&'UIIV7[CPT.@)_!A^@EL/)9#\#E !>@$:BB$_Y25S&!XCD
M&J)TTPUD59YXZT?%& -QW6/ P'-_"A\HJZ%G9-;MV-UZ^\%=JZ^S/V#!IL,:
M:QB$W8[ [V^/_+['$]5^[CG5\7BWLONPY?'59RZC;;*31!Z RE$MF_@81>V7
MN!1+*051;H7:R2TGW.8L)>XG_LKBH_%+^4#BCY=H5"_].2]&*::B#J.SS@6!
M&[D6D?6I$8L--37:2ZV<8QL+U+Z',]3I#/8XD0_TN()=GJC)-:NUXYY;(A\0
M9F>NVG_XXKU/"0N:5/>.D-D-!P2HA8Z$:(BY9 5@B&+B132!F1 KV"@%:@#Q
MD<!]JC^?#Q#-DUA@1",5;(M0@@6E%%S_QLR@QC9!',1A-$:5;>AH^_V2M3N8
M+ D]A5VY9NVIKJX6N[O9,W'='E(.1$VOHQU]\#J=TJ!]_[C1,4:,]6,;&GK\
MG>+=$=-J=(7Y2_@ _& UCMDVVTR+-:*T1Z\\=^^\VE;04,N5\O/K:T_K3;=L
M;N0#_5Z38\S@B6@\LTK/O-KW5N.;U[IG,+*!/:2U3N+.0/^886#"@*\FU#2C
M]@>HK8!ECU#L(_62C+L)6H9W!Y;"+^(##NH52OR'QF(:+%4HBA6+-T<5(Q9-
M1FI;XUW2BS_P$)E 9\P.?.=CB&LW[@]TN+&W)N];M6WZ@.E)5N.>I#0%6Y*^
M:\?V^>GPCS]\__4W7W\-_[_Y[NOO?B!\X#="L/CW:_$!RGC@VV^_^^:;;X 4
M_.&K__M?_O7_^KN_^\_W[MW.+RA,DV6LWK%?^_#%1X,S^,(ENTC =TGHGV$*
M,1]_!!K7B 8CVHP!-(X1E7T881M6+JH5C;;9$4KGF!+(/<8M6G Y,H[AA&(N
MTD?@\ACLPUK[L,XY@AX)O1,&G+'0.V$BB)_$,-HC+H7&C7Y=-!XTS425:V^T
M%?77QUI\@\U^7ZO/K_(,:_"=,MYF'VN!:7)PS#0UT1Z<///1TZ+-V^E\?@H]
M-:.R9K^F6S,P9GE'7RBV=8M+7_C$8Z0%-*V>O!F8N!,8-+U\<4S35K*^D94N
M9?!Y$K%$)I3PF2 ]IS+H-& "M-3D9%IR2FHRD &^5*(H+,BKK"JHKLDM+Y?F
MYK(D$II (,C(R"@J%&5ET+G<9+B,R:(Q6$P61RQ-SRLHRLS.Y?#3DE/IR0Q&
M"K (#H<E$@DS,^0EA8K*4DEY45I1+C<[0Y"ID!?F9Y449Q85IN?E27-R1)F9
M?'DZ3R9-4V2DY^9G%9=EEY1E%1>+L[)8XC2T2!;QT[,5A>7%N>45BLJZC-HU
MZ94K>;DE-&E6LC2#KLAD9F6P%%*6!+@*G\WF,^D\6@HG%89,DEG<T+CWW.7+
M-^\T/WW6\N)%Z\M7K:]Z6U[U-K_J:WG5W_;2JGPQT/+L];5'KZX][%W U8>]
MUQ_U-3^QMCZU*9_U*Y\.J)XY5!\[6S"G[TS/ARN.GD[+*:71)#)I\<H-^PZU
M&9L>/KWP[+,;GPYHGKN,3SR6QQ[C,Z_J,]^-E[X;+]S-'SM;G]I;G]GBP'3S
MDP$X:EZXC:\#^L]];<_LUS[JO?K@U?6/>F\\[H>ST!R@&8%IZ R4:7OF;'OJ
M:GWJ;'YL;WGJ!-QX#!=:KW\TT/S(!OG*9V[U)U[-IS[5)Y[F)W!JX/I'UAN/
M;!2@3 M<^,31^M31]A2K0D"=SZ"'<(,.//L^-"-LY(@@-<!5+N7';N7'KB4@
MF:KGGK9G[@50^=!B*S3QQ$ZA%>& VFY\9+WVH/_:PP' #=);J%GSB5?UL1L^
M7K[W^LK]WBL?]EZ^__K2W5< ^'CM0=_")<MP]4'_U0=]%*Y\V'<%$_W7'PY<
M?VA%D+&Z]K#_&F9:H?[KCVS7'ED7</4CZY6/^B\_Z+M,7?@1P ;WJR(W!1V^
M^F'?Y?O0F3X"2/1>N=\'F5<?]E]YV'^9PH/^2P_[+C[H/7__U?E[+R_<>W7Q
M?@R0/@^X^_+LG<^;;K\X<XO"9V=N(RX\Z+W^Q';CB3T!CN:G#NCDI0]?7[SW
MXN+=CR_>?0ZX=.^32_>>7[C[\;D[S\[>?M9T^]F9.X@F^'CWX[/WGI^]^_SL
M[8_/=#\]W?D$T?7D[,V/+][[#!ZSZX]P0+#/'^)M0B?/W/G\S)W/FNZ]/'OO
MU5GHV]V7V//[K\[=>]ET!SKV8@%-T,];+T[W?'*L\]F)]D>GVS\ZW?'H@^XG
M%^Z]:/G89AP8,MM'+?;16Y[@?4_TH7?VECO<\JECZQ55=L5*-EO*8(MK-N^Z
M?/<CDW-0X_X3^  %2DKN\@%EFNWPXBHRAEXA@:MPO7\I'Z $1$H7!01*,^$#
ME+BO)^Y3*-6=/XD/,#*S&G;M;;O[T5V;OZ,/^0 (-,J^*>5 V.B>[PY\<=L_
M>],=-+ST-3^U-3]W:_M&B=H/JMF@.A#QI F4P$A\ML3$Z+AR#CJ6P!@%,0Z
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MPMJCYP%0^=IC%P'0Q.I#9U<?.;>.?(PW?1[RUQR&_F#)A4R\BKKPZ.6U1Z_
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M_PP^$+OD3^$#>N0#"X_TG\@'!L('S4\I/L 2RQI7KQKTNK[ZP[^@ <$//_Y
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M>U)6KM^=>?&6J.UY(S4B,3DEE%]&13'3N,;R7D.]4U-1#1W4,MY&JZ^1#6B
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MM=-VF9$2T [9:$AB#S607JDY).<BB673R^VHZ/(,6?^3] #T&=1ML&D9@/0
M, J2V]O'!JAIY<EQ=*1A8H'"&)<O:"[+_R0^J0?X^(V%^+P>X") D)TJR'5.
MGYKR:0'(#C,B(T?D3$A@\-[ 'V\[E;-XTZY%R^*6+UU:5)#[5[_[YH<??OCE
MEU^^^_ZG'W^S#RSX^_?3 __'=__-'1F[>.7<BN5+UZU=E[A^PZ&CF3F%5??P
MQANJENM88P'>4J[JJ%1UU.B>E&#-F3>+]I_)N5!05:7IE'1UBYYT"QZ_G0?A
MXS?BSE<Q/'XE[GHM>OQ*U/FJOOU%=4M7=7-775-7?5-7;7-75>N3LO8GI1U=
M)9V=I9V=91V=%>V=56T==1U=#1U=Y83VU+5[B=OV+UVU>7G"UL1->S=M35J[
M[NL5\9LV;SL(8J!!KE>WO51UOE(_>:-\\D;8]J1(J;LJ$*85%J87%^=@\J*6
MUNK'3ZK:.O/DBN/W\[8>/Y%X-'532OJZ \FK]Q[<?"AE]Z'4'4F'-^W=NW7W
MWOW[C^S?EW;H^.5;8FW-*S/H :TUW#(R!9)  U,FYS>I<TRHK.-*3@\H3#"1
MN,4F/^@!(34I(D/2@6&\VZ1\U4<\[\:?]<I>&&5O&:Q_1-XW7/><*M2_.56&
MI^8+KDO;:YZ;%<8QT /M;*!YR/D(;SUR.F?YVIUKMB6E9]^^F%^1=:,TY?R#
MU L/T[.+3MTJNU90=^=!PXW<FLMW*\_=+CM^_6'JU?R,&X6G\BO.U8ANJ)K*
M7P[@C NG1PN:'Z?D%WZ=?6G?^4OI.7>NE]?4Z%H>2HGTZW>^/G%F[ZD+R9=R
MCER^D7+]]M[SEXY<OW7U4=7QG+M'3V6#'E \>:LULE+2)K2,"BB?C)F4&"-%
M;>9+-:VIMX1)5ZKWW:K:>Z_D1&EE]J-RT -+EJ].6+7Y:,KIPCI,UFN0,0XI
M,RQAG1@SK"5=30:?C@SC3%C*!F6,ET"UVV)0&UUJPYC:X-*"*#)Y-,8QM7&4
MA\HPHC*.:$RC6J-+8W"K $:/$N9UUJ^TAQ0 %I5 U[- !7Q-C+^%\;?"J\77
M;''IJ5$-XU; X:Q1W#X!4TCETYZ4&W>7;M@4MW%S5LYM07-GDX%1#[)8OTU#
M>;1,0//'@"HLTCX-X]>P :W5K[5ZU8P'H&&].IM?S7@5YE',-"R?!FQCY AN
M'E581@EJ3$FY>!"6,1[H+>U6S0&\A0\5%J O,&@.2SD@&F1RRLPC&#5&,&Y@
M/S/0T!X-Y58#"3#SNW5QF-TSG)Z6=>G8,1WCTC$>'>MOM(8TE+_AK?5L-9%X
MY/C*S1L.I1XHK*W%WY+(?DVC C0*RMUH9EM(B]9B)]!9>;2T2\NXU:QW 3R?
M@Y:!GXSQ0"? NO2LN]'F@5>M>51K&=581N$[>AO0E^&BKK<IA94)^U+CUVU.
MS\RJD:BUKQAUKTO1.ZPRC1+TL)9FVRQTF\79Q(1T[(06^*5Y5&T>4<&UPR63
MH[C1B1D<"N,P81I1F<>@3:!EH'UTT#VL?AV<JF5,;1K5D&,QF%!/@SZF-G!]
MC!R;A@M>=:1+0[KPH5'9X+"< VX857)N VJSARN1$="Q@29[L-'NATMHM ,E
M=6NH8<(\HF:CA#%XOUZ[>6?2EU\NV[IS]]7[A3 (-+'<2A[:OZ.1<6IM+IW-
MV\AZFFA7(P6G-$P,6A4#K&K(KC,-ZTTC.N.P%D@\!S4YK((O6$:4K%O!N/);
M7AQ]6)M<4)6KZ5*:1EJLOB9JK-WN;[.%!"^,YTN%B8<R%JU<NVA9_-*5B<<O
MW91TO&J!UJ8\G],#"L;#T:P(L'RN,E24SP<_FQR&8Q*(M#%A4 LH:1LG&-
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M=:EEHGM-+W!RY/%P^+7WFPY'M**][WA^]=H#Q[Y( #VP:OFJ#2>S;\FZ8GH
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MU-24^)7MXL.&=7N25VS=E9)]LUS=KNRCE<819&>'FV@.JL@ #[49N3#],82
MC'Z," _-+**(]<)_D6&5*?3G@0PI@7?^,2A,041,J:B6'M?3$[.@QG74.&A%
M4(S('<L"JC7($=FP&DBS*5+YU'JR6+PZZ4A<XIJ#*8<>BN6XT8W;?R=B_DIL
M?J\TA9H-HZT&I][@!O8/4)L":F-@YO24QB! !2+!A*Y.\RFH+2%N'IT/5$O5
M$M):T(:&!E8=QDA?\1,RK42TZDC:RBU;3IT^+\7;6WH]"G*JAHQ44T$1<!W3
M<+/)V4+Z=-0[%?T[#?U>3T5UH"BH*("+*QT'0&O@Q@!F\,/%JJ#QZ7$=.ZFW
M3NF8"7B+DS.6F<^"ZWM!9$E P9JPDQC@S%44LE,1).S<KS('-'1(9XWHK"$M
MX]=9 SI[4&$+"6T3LM'_A-M^=T_6L6G/H<7+OMJRZ^MK]PNU3\TM[#="YGT]
MZ%X:!;^VL!$]2EZ)*#5*I6)&"7SDR#Z \LP0? 82M/*'AAJ,"BC8L(SR22P>
MPA92.2+"P>%[C:].U:K22J67!/K*SGZ-T:4RN NUK]/O5*W=?_S+U=N^B$O\
M_X$>2+EXO:JU2\T,BYDQD2THI,,"(](#.N.X?BBH-7J!!RO,(W)J3$Y[44/]
M.;3O7ZD'>.- S&XP"V[/T\O\_T9Z8-J3!)%(E"@6QCV+6TNY-#3*AL?'$__%
M]8"2MR%PQ@2YT8V21TW7?E9Q1A(U5R<!1\[WGV:<OX+Y>H 'C=+40&]$KTP
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MLO/RE2],>ON'&OM4!1,06;UJ%(4<UK)A#8O\*Q!1-L>2/.(P./"!#23*=:A
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M9HO,A<P:DC)!9""F/P%@WKRS$T!&<9XA,)LR(5 1.!O&Y@"YXZ,E)6#GZ%<
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M(8T]JH7^$],#7'P+E]QPH1Z(Q29"$Z%$-RA#/\K''XL=A.$(.9?/Z@'>N+I
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M5I%!M0F9?'$R*#=S05],2/;']  ?:L+W$W2O62[WU\=Z@/,PY MLS^U(,WH
MA6+'] "#],!,:-"\QI\;0H" P@/X*'#>=+\@TH #RI(T9S&%J[*'0J%P+@Z!
M^P(?E\+;!V!V=BFI407E4=DG9.;@+>+)EI.7%ZW;NFC)LI5QRX1UU7_WM__E
M^^]1?J$??OSII]__I@?F__T%], O7)@VBLR8407P[Y??__//O__YNQ__Z1]
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M,69*1'T04U-R2T@#XI^T*\DQ3J+P2W?S:<W,3#:WDNOGP:='1,N?*(B3=RJ
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M.>*,!PB**$ K]RC=(4A3U \Y<,(CH+!ZE4A1!'2V4*,]I&,#^.!P_3-39<=
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M,+BIN;#&'C%@:&7RFC-^I[NWU9G1&$.:MJYW&[3S5F\;/G'&:V,FK]KV"_,
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M<.US["5BP1I!<KCK\QD=Q3R XKMDIOVI/%!2F8W8(&JRG[T*#RA>B0?2$BN
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MW;).EZS3(S<"&, =&VEV9Y1MOL,?RJ;.7S-LS+3IJ[8<%QE$;1YX0QIDB<<
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M%,UQ&5'G<%0:=/AC:3+@@48N>%)_9_'6@Z/'31OYQIAEZS>^KU$WLIS($Y'
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MY@&="VP0'B@\241\?_4_T !\\8'K!3R ;96*M^[Z+XUD=1R2!_"_Y"4"1E#
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M)2(RA4GR-/PA68?P!1FLL#04#TA?Q@/FF,Z,/""SPUG(JL$<67A/RE>4Q[
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MRO, =E3%&9#!^M\)4H(]J7>#_$KVXX$"$L#R0!0DCK,&&Z#B1@Y<8Z#C^_$
MP\'$&E)P0> !QIME/%\SSF^!![2FE/PSU^$/!=,6+ $>6'/P2/6-NYJ?QP/4
M>"I _\#@/%!L*-Q)1%G?"P;P  ZO-2XV1[$V'''U4O<"5=7%;UZ\-]^/!XBF
MP< VN@:CU@$IYLRH7%E-UV--US<B:VR?0%<./#!IW.+*)1_(Y(PU*'4^KK<]
M:K#URFQIP@-^'7K/>D!28.9NWP82L7SJ<WXSJ>\3T2TH7'(PAHKW2Q3^D'33
MY'D 5"Q&ZWD3-6;'3K&R?.W64>5OK5Y+>< IYWP-]NY!>, .)R*KL>>T=A*:
MB*A?H,<X0XJWY/V*_8(/!Y\Q"EXI.MM0A"#?$WR+HCR+TD(Z?3Q =L>QXC#,
M UQ(;8\PKIPZ^.]D[J_?!K&R<=.(*>,K%KRY\[WWA5^8 <. !T36! PUY0%2
MOAF1 .&6B#R&UGD<F@>*G1YTAE23??=2'D@<E]]YLW+GR-&37Q\^#GB@X=9G
M3>Z0KCNI=*48>U;-YG2F+$(R&Y<Z@B)G0.0,2AP1F9TD>Q15R!G*J&C#SL0T
MV(-4XZ&@KG>E]9Z,U@U#%(6I3((S1I1Q @_$Y>BPC>ML<>QG8@[HV)#\H>L]
M]>TE1\]-6;?CK9W[-YXZM_O]JYN/G5VX8=>8F;.'C1T]<<Z,]0?W?]1T36,-
M2&W)!C-87 3X#8+>U*6Q^K"BCCVJA7<F$2FDV [I[57H\$4,=Z.)^).8@F+2
MEY<>,Y50Q,7!DQA]LI^HY7>R!]3Y*364L\5#1"HP1J0F,,R4 ",I$_!NN/^=
M;TI-Q30:/0"&=$B0DA6';-CC+CYY39$T)_VYD%3IEKP%N[/IK$$#&]1984#0
M^2;GLG(6:#EW]6/;YM-7)BUX:\R,J:N !ZY]H21_5:@FI"!.,/A13&JM4G<*
M_:=]9N?_*37^7_?A2H1<O?S0T25R4,/!) D#)$:(_'F^H"I>4188-+RT8-PP
MW9S%AMETML%1-6-S:X4M*>'B-2;_(=6-^5L/EHV?-NJ-T:O6K[^H9106$^/L
M4MC\C#FD[8BI.X '4@VV1".LJG"Q6?.E3DE[9O(Q\6SB4@Z7D".&K5=1PO+Q
MGR7Y Y0'['&1/5UOS]1A>X<4\H! ,G==Y<@I4Q:NV'*IL?7ZPRY=1Y>PW2ER
M!&MMW?4<3*H@N*-*2XST)^[/ S*\M+"U$>52N*I)O-8+>2 OI?BZ3T,;XAGN
M,Q*?=E^,*^&!_!Y-,0^0#:,D4?^(3TA0#IC_$0^(J^0G\( <]PVCZ$ZW)N06
M/'?  UI'4(?1PDAT<D>NOC-Z2'I[.O+ U!$3)NW=O3,5"P,/H#1]]AQXX,EO
M/##@ZP_+ W_]%TJ5O&+.K-'39U8=.%K=>J\)9EL7;H,15HZIG?_:>$"#B)P6
MF%-"<U+M^49DBNZN44Q>LFQ0'L"Y@\@L4"=P66,G2.(?>$4>D#KB0GM*S*7%
M;$:,]4:CTCX>0).R06H2C%8,:KF@WA[0V?Q:U@<&#S36;I7%JS)[5&;XWJ6V
M=*FMW1KR6RWK)P^ZM98NK:E+9^G6V0)Z3\30%=,X@PJK5V9R-]ZWOJV]N?%R
MX]H+=<>85G&'O;4[WNR%I=0'OY6;W 9WN-D3T=JZ#6S7=5>DB0O*VEVR=@_"
M@-DO-P=P[N824D=&2N*=9+;$V1MM*XY_,'S*W+(1$]:N7'>U7M!B,AN"4:DO
M(7"]$@^@OO>@*B+GB^>! A60936*$S>'@P_7B0[KWF8 "=38LI'G ;(4$><
M&Y#; G)G!'A W?6-VO6G:MO7P .R3YV'+C1.G;^X;.ITX(&:FW<UK.>?Q@/\
MK$JL*'^@7S( ">;)JWR^6-! *];WO*$30(%&W+4%&4V*#I7\R= \0&4-77KE
M9.\-6_*Y,FI/3HL\\+70$J4\,&+"V(4K%YV7RK _L>MQG:VWGLU)V12HBF8V
MH,>LH5[&T4."/4J] 7GUGW<H\\G0A6?Z(*'T(S,DQ)R<,AC/#"8 >.+5)ON.
ME_) 47TA!9=6VS(:CJKVOJNEH,;HO)%ODX(Y3N25@\\8Q9<<#59$D8T_XCXQ
MG;6*)S'TI),S17"4U!OE(BIK (!9X<Q0'CBENC5_T^81$\=.GC-CQ[OOB;^R
MZOS?BIV/A):8TA+ Y"6\[.'PLEJ2J(#;M%:4E?PD.9B12)5B=!F4!Z(R+GE"
M<??-RATCRB:]]L;8RNW( \V>L-Z78N"N<?9H;3T&:Z^!A3%)R%T1J2<L]43D
M[KC2E:356E]F\']IT7V,O\<;F91GU6,T*9H._TL2](3('!": T %(#) 6X!$
M4#GB>IC\L8E8M-D9D[>Y3DI;YN]]NWSM]A7[C^XY=^78%='>TY>7;-PU9OK,
M864CQ\^HJ-J[YZ*VF3%W2VQ8;[2F,]+8B<I)9?;I;<%F5ZS%DVIR)[5X'C$V
MB2&QYL42BIJ"1%3S"ML:AK4)9AZ#-]O4E6OR9C%6A$Q!_.MYCP=OROR&*Q5D
MA9!%RH=Y*W9)D7+;?&!5HM2U@B%#)-*L-"V*\  E>3A4.$YA1[>PO4O2Z<-P
M-?QM\;]#)TSA:-6VN):-ZMF0WAK46D-:N"P=6;D]!SR@=O36?>[<=:%NQO(5
MD^?-67?LU.5;#W!=)F6=Z(J&P5$%$4]WEZF@+'8P%EW_#!D0>=X[P?MA3)C&
M0-^SV'\RF!$J(+D$--Y)8L;S@LGE9BQC7Z0L,0@08R8):ZG9I!8@WY63.5-7
MC=W[Y:US-^T;,;9BU/ Q59LV7=9KE%8S\@#K9TQ]/%!OBS>P89$E@*#(^XO@
M^@F0'A1XNP$)Z!Q1H'IZ8%)+F 1J%O- 0(4\$)+:8F)'1N#*U3LR0FM"],!U
M4B"=4[5R9'GYPI5;+M0VM=[W:-L\C0_M KN_VNJM9?UB.RP3$84YJC0EE*:T
MPIR5F[,RG@?",M+G%"YF44>WH,T+IQM)=8@<#'HQ%Y^(08U>(?@83A/M&%,T
M1>-F3;[L=8$'9#2]#3>,8-E"MQ[<LU(V#!BO=L.DG2 E7W\"#Z 3&%C"D9*S
M6#P G@'H,K@B!A<L^B2.R-73:(H?D=^9MO' L+$5(R=-.71@7SH>^?'94U"I
MSW[C@2&^_E \\ 3CA?[SW_P5HU:4SYHY:NJTJOU'JEMX'E!A/6/ 1&ST"QC0
MW/4([%\##]@B&CM<UAF!.?VJ/&!/D$D39N=2'K#%R%8H!LI+VDD_LDW;QQ$>
M.$%YP.J3VF-"+BFR85EHJ8U$$'(AN3U(#!Z$9%P0G^%"$JM?;.Y2@.)G?1HN
MH'.$#,Z(WA&"QRK6QP 56'WP0(V;^@&M'0P[?6@=<+(B>G?4X(GJ7?#1@G)+
M5\-#F["=4UC<TD[[Y;M?'9+J-ERLWWQ%\'[S7:7% RI!:_<KS&Y)AT/286>L
M7CVF$?M:[/YKSI".]<L[W$H3_+L@8PW* 0E@!K?%@0?DKEZ5YQ%(H@]N=:P\
M_L&(R7-'CYRT?O5ZX(&FSDY=("+I!A[H+?" TA$5NR-B)]^\G6P^\?U!0=S#
MJJP;D@=B,@ON(>'KB>SHXP%4EGG_ ,\#H("#,CAL1YCQ9M1=WZK=_U;+?:LW
M9^2?NP]?$$R=OV3TU.EK#QZIO7E/^T_@ ;I_CU,YV>2@N<+$T#G 1UZ6\ #9
M=,E+^8%61 )TGN7G92>IID^[GN6+Z]/Z^B7:>B@>P#4['\E--Q?)9U2YLQKO
M(W778^"!0^*F&97K1DP8,W_9@C,BL1+.K_MQ _>H@<U)K,@#+5S0X$RJW(]4
MSEZU(Z,J3A7@R017&NIWIDM%P4K<"!23"L?,3PM)!K?Y,TK,L(]5&^T[)4S%
M^NVCIRZJ6G^X5G93U^Y2.OR-CNY&5U#HC)3P *8TP+T,2,#+XB(%5N !F!RP
MF;K>W6OP],(#['%N[S]14"L5V7V2]Q5Y0$WZD3$6G@<8__\F<3XZI;XU;\.F
MX1/'3'ESQJ[3I\7W6;W_3R7( W%XF9X+&]PIO3>G]^1Y@ A6)#<$C/Y'2$6;
M&O]=R:'RW_%@TLW=H&L3C",FMZ=.*N_-K=J9YX']]3<_;7*'-%T)!38KZ-%Q
MO4WLHR8;C$E2X8[*O!&9-ZKP)!AW2EU:/'H(P_$A](7Q0AC*3^9S&BG*?Q8;
M.@>0!TQ^,+K7"-_A\'1NH/J8P15K=<<4#^TGQ8:Y.XY-6+%^[J8=RW8>7++U
MP)R5&\?-6/#ZF''#1KT!/%"Y9_<%M4%I](K9>(TQ=K4C!#P@-?G5UD"S/7S-
MD[CF33=AI =N%F# *BQ >#!]1A<+9;X.!)'747@22*#5_PBLN;L'IB MF8*H
M&E:1J*>"%2U2?0&NO/4M2;PSZJ6&(5[TXBE<423X1T%:(M#54TGB^W'#'J-Z
ML'\"*&EZ*>(:FN^71_]<PR5T<(/8PM0_ *L;8\_(.>"!+/! PQ?N?9<$\ZK6
M3%OTUL:3[UZ]UZYUPP>!,XB-;W$Z)7'S-!V%?L"^6P/WH2D@\?XK>J%2GP"_
MXT!\"T O@O8NC$$B2("?J#12J(@3,. 6_D34Z8._:FSS@L$#$9Y6F.HQ1XAJ
M )C\Q2;2TQU0F4UHN90![FAOK\*=N6KR[9&US%J_^_6RR2->+ZO<M.F*0<NP
M%N !.2R1E <ZDV)KJIY+-+"(IL1E1+B%\@ )(8//J'<F@ ?47$1)W!2#\P"'
M^<02-BH!$G#W-#BS0G-<=-]]2B";7;ER5$7%PM7;+M0VMS[P:-L]@C:'T!ZH
MMG;5LCZQ';1U6&&**$UQA2DM-V5E_7B !&[!T#4^],!W">F,,1 #"M8W$>4?
MET)I7TL-Q&,R%=-5B:Y$Q%W0-V.7\ "MAL(!@(4I#ZA<28T')GSX$SX[KK#C
M,S0/$**#LXPNP33P@-04 QS2</$F=ZS)#>.,J07  T)SXJCR'N6!T5,JCAXZ
MF$O&?GSVY#<>>,'7'X$'ILR<,:*\HFK?X3X><*65,)^"R':D\CSP6._N@:7H
M7SX/ .EF2;Q0BH\7J@8>&#Q>"*</Y 'B9"SB 9@QT4%&;BJX R5MKM-]/%!)
M>4!I[2[B ;0\#P0*)N,"<C![$!Y(@!_,72#H%99N!>M7LGYX(#-[)2:O-&_P
MH\S<);-TP7<Y/+!VRUB?S.:7<WYX(#:YZ[]D/[K7(;QO55O<DH?6L\VW=U:+
MJDY?WG2Q_L/KGVA9KY[S:=DNE=G%F)PJ$WQW*8T.M<G5S 5:[$&-I1N6897%
MKV9#('=D)A]N!;$QJ1UY0.U]##?\A[<[5QW_$'E@Q,1UJ] _H._HT'0'Q5WQ
M @]H@0?L$9$K+'*&L3D+<307> "WZ%[* S3%#58^5Y+R +X>D_GR/(!7%TR7
ML B%@ =DCK#2DU%YOU45>. SY &,%ZJ8ACQPZV.MS:OD?AH/,%@\)TF#*0O;
M)+S1>/H!B;\,,9!KQ37R^[V&&GTW!>$!#<DT0'/C=ZT'&Q5C>[(!QT.M'P_@
M*DZC7#AT9)$X!.(.=J;5GE[&B[O4QQ77YV[<,G+RN'G+YK\O% /O*;Q?-]H?
M-[ ]R -L^.?P@'P@#^1-A;(#CX=$O6<I#]08[:2^T([1TY>LW7BT5G9+U^EA
M7$&!TU?, SK" S+@ 7M6A2Z"$A%/+QB:B5C@ 8 !XLSL>44>*+(AJEH5\P"?
M38O9<G"#**TAI2NK]/V9Q(GY W,W;!P^:4SYO%G  R+@ =^?2ER/1=8$H-=
M'E#AG@)>YX0'BC19877G9[/"1\9YDK!0BL$K)]5$>$#EC .3G&(^GKMF%_+
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MS[S.675Q5M>YYDV>:5M@W/&6E_%(>/A7SYMZ0CO$J@M8U6!\>S+&@)&'.@I
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M$QEW!7HX,"@-AN>JB6N'^T#"7@17;V_H//S)(RUD1$4?8RF<Y&4K6683&3>
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M!PZQ+G;T'[_<CX?L"7>(;6+QFE@ZY^!0+>S"!*D>"'<F8H(99WUVX;OY, ^
MK;;#T'ZBZSX*UOX=3;%Q=9 =Y>&!W-M,/N(!#HZ7VN<!8E$/DHK K+QCGP?H
M.AO3Z& :$0\H;G-%Z5=O^J?D!J?EY=1<OM+6VT)B=+"%=^G\&^/TJ\/DJV/4
MFS3V':ZH6?2DF3_;P'K8P'K4*GC6+)B[Q9BYS7S8PGO:S'U41Q:<N<^H[*/7
M##$OC[+JJ>QF%J>1Q:IET,[2J-5TQAD&]P)==(TZ?9WRJ([RN);RJ)8R4T>9
MO$Z=N$X5U%+8U\C,JV/,NC'.=1+OVACG\A#]?#_Y=-=P25-O66OW^8$'EQ^,
M7WI JNP<R*QKCJJZ%G'J2FIM4V7?^#6:\ [_\5W!TQO,B:MD[C6ZH(X[5<N?
MJ>--7^=.7>=,WF1/U7,>7AYE9U^N]X](\_6-R<H]TSK"8<NTO#4'>]7&TCGX
M*C>"@4G, R2C:]R\3C-M<(W>'$%8Q&H^'Z=</,@#A#5&K.W S"C! X>$WO'P
M +;VT,5U<-2K;+61J3;1-6MDK7M<LTW6[C(U6]1%<^T0,R*[PB\ZLZ*V;?SQ
MXK32*5)OLN3K#/D&$^<!Y.+B>D)TJR/(Q)E >#B]#]CQ>.Z?<+7DH+O+N.>1
MR0,&7^<!,/$]&P0/,%5NJLP.^1RP^PUA4N_;],2W0*YHN8/NR5SN();.T2A%
M\,#^FL"^4?XU'L#V-WX*)K2;$]"J"$6V4#MP("#;/6.TTM^\NSYXO^#&C3,]
M_4.O%B9,;K;.15%8*7([+JW@I*/#UF^SS;LL\R[3L,7$902.?N^1\_4T%$8L
MXMK!P1S,3D,,PSS]!JPIZQ$/; Y+5BY0IJ(JK@;$9I17HSO]\838QM/M4?1;
M9,,Z,J\1#TPJ+2)(,_*1H?XE2_,)5QGS&,V'5PD(VQV^%)T^X=E"] ;X,/:U
MGU3T3Q#>Y[8 _R^Z6*B):"HHL\"1N[D2%U>&\&:7N;I'UMH:.%/)Y6=]0J,C
M4](OM+23WBYQS2Z*SD55K?.4.Q.:/9$.]9^>V@A<W'=A>8[\\*$2Z(*Z,G#S
M($1X'D-'!/40$):@L7R-K5CCZ[>XAKV.J;>YYRX%A@6="/"+3<\JN5)[IJ6K
MNN-^1>M@>0MZ]D>*&X>+&H>*[_25W.TJN]M9?K>[HK'W5&-_9=/]RF9"_4A5
M+0-5+?!K>7-_:7,?H;(6V"Z^VUO8V%78T%%8WY9_JR7O1E-.;6-V;2-ZS;O>
M5'2[M?1.9T5SSZG6>^BUM+&SJ+ZMZ'9;45-+86MS87-3>5M;95M[>?W=@BMU
M"665H>E9H4E)P0G)P4GIH<E988EI(9'1_@'^0<$A\1FY11>NG6YLK6[K/M7>
M5]'67]Y\K_1.3WE]5T5#)U)Y?6?)K=;"Z\U%-UN+Z]M+&MJ+Z]N0"F^W%MQL
M1D=2UMA5U7KO3$O?Z:;>JL;NRL:NZKL]IYM[\:\]58V]E0V]IQIZ*FYWE]_J
M1J^GZKLKZKM+ZSO0WHIO=Q3?[BR^W5U2?Z^B<?!,^]B9#E)YTW#A[;Z"^GO%
M30/E;0_*V@:02EH'2YL&3C7UGT;[O]5VJJZUO*ZCXF9O6<.]@OK.O/KV_/J.
M?/3:T)EWJRVKKBGC2E/6U9;LVK:<VK;<ZQWY-SKSZ]JS+C<GUS0DG+Z=7'TC
MK:HVL^I*[MGKN1<:TLXV9)YK*+K27%+767B]I[#^?FG34%E3?_F=SM([[45W
M>_:%KDM)T[W"AL[,ZZU)-[JR&WKS:QOC"RM.1,0<"PT/RBY(OW*S^&YWT9WN
M@OJN(M2,+7T5K?TEC6B?'47H9.L[L;I*&KI*[W27-O:BIBYIZ"ZYW56*!,T"
MV\6W.HINMA?> *&-HIL=);<Z\0>(S_24WKY7>KL/J?Q6?\6M@8K;0V5W1DJ;
MQDI:1TM:!@I1@UQKR#I_+:7J?$QQ==:EVW6#C+Z)5_0/&K[6+K)L3]J^GW']
MVQGGOV,9=^[+5SKG54TS[\[<HR>?;PPMOA!ZZG+LU3MQ-3="$XK\_6-"0Z/+
M+E[LF131%2JHIP'AVMN"Y2W1LILM=U+5=IK.SM:BP1K'A1\1GE:'J83/81X*
M[/0%2[+[/+#&4=J8$#NW1=;ND#3;#&3IOM/?&:$FEQ3Y1T3FE9P?(C]ZLFR>
M5JXR%$:ZR4HUVZDF!UUG!QZ0.SARJ#_ DNTR,0_@"L$.)DX;!4O<.&$4D>B)
M2R2Y.B(V!/4212$]SI_0V>*,HM!O'.@ZB%YEO_LEM#]7<E0X=S 8])#$2;<]
M8?PX8=Q#>X!P%TQ'GH$8=>F>X'C/#HEH(NS3ZXF*\122 W\A\,)%/,"0(=!R
M P\8G, #6EA!\O+ T]CJ*\="POPC(VY<K]W=6O_]/_^ C%-<?P#QP#__S -?
M_/RU>.#7__5W/_SW?_B'OWWT>#H])R<\/KGB\HTAP9,9A>VQ84>DW8*"VRJ7
M2+\Y9=Z=_M?E <\Z YCFX YA_ ,\@&]6\$<$9T0@YBVN:G.?!P3(B-3ML?2_
M8!J^%]G^/7K(KSW@1&7]81[ :QH>'N!H'>#M@WH<DYNCMY.6% T,0>;%FP%)
MN8&QF3$9Q8EYY8GYY:EEIU,KSL27G(HN+(TN+DNHJ$H^?3:YYE)\U86HDM-1
MQ:?C*\['5U^*/WTY_?*MS(O7$RO.1A56GLRO/%E0'598%9%7EE!4FEI^*K&\
M,J:B^N2IJN"*TR'E-:&E%\*+KT047HW(NQR1=S$B[WQ$?DUX_NGP@JKP@HJP
M@O*PPE,11=51I6=BRL]&EYV)+*J***@,RR^/+"Z+JZI,.'TFKNIT>'&9?T:N
M3U+F\<1TO_3<T.+*J,ISL=478JK.19:=#B^I#"^M#JLX$WKJ=&A%=6@YVJZ.
MJ#@377DNLOQ,8&KN-_[1 0$)^847NLE"KD*/8("Y8CW$ VK7N,$Y;G;3S9M\
M\S9V>_TI'MCOO+S3I7A2&3N>';@9/O, 867RM$ZN=HVC-;$T9IIZC:1VC:HW
M29H=IF:;MK1R_0$K,J?"+RJC[&K+R,,/4W+'$1Z _> 5)X^'M(#(ZH/G]9&9
M#I,Z<B?:QBE!,2KL^],3EO'A3#LL[#E#U'_!V=P@B)PLM=&07:O%^=WP/Q(B
M@ %M@.LJ9%4B9JKV*YL294T/."-]D;?GB/%*# \"S3H2%W7NNET6,F0-6S.K
MV[.K;MJK]Q>[>E+/72QOZAI\]F'&M#YIVN+KUW&1K%V.!D8LFL(%&&#8!H==
M;\#T%U_]XSP 38JNH\>&]B9;Q+B%^PK#)L^PB>"0;=@86C:?)T]$EEWRCTXI
MK;SP@/%0L+C&U>Q1=-MDPP;F =M/\,!AT]FS"G' JCZ((OOZ\WE "(XZZ)9
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M**#)U4RM@P8N>3NBY>W)Y0VNPDW7..A:*%K/5B%^_AQ2O"_ONO3GIX]XW'!
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MYMGK?C&9W_G%G/"/.1X0_:U_Q/'@"-^PJ!-AT<=/1GP7%OE=>-3QR&C_I-3
M5-07I_K$)?LG9P2A(3,]&PVBOO%)/A$Q)Z(3@I*S@E/S_./34(?N%Q+B'Q02
M&!0=%)$<$)]Y(C'G>&SNB>A"O\@2O[#BX.""D.#<D)"<H-#,@) TO^"D$\'Q
MQX-B?$Y&^81'G@B/](V,]HV,.A$>Y1<9XQ<5$Q 3%Q"7$!B7Z!\=?R(<?2S2
M-SP&'9Y/:)3/R1B?L%B?L)CCH3''0Z*_"X[Z-CCR6 BAB&/!$<="(X^%1GV+
M/A >>RPPXMBWZ*@22\JO]M$G.7(=TV2AFRPLK?T(#ZS3(6P1 Z$7(#UIRZ$?
M_.POY.V_B#D/PI?ZIW@ N_=\Y@&V9H6NL9(U[E'U-N:!+9IXY0;B@>R*$Q&I
M!1<:!D2O)Z2V"?4F6PXI^0A_(=P;$HNM8"]"MWB0![QEB:'XP!>16$IXI>/.
M^J!]3%3JI2N@F,L?RP.XQ 'AT.F=>H'9%[R-/3X/V]_[_D@'S<?]R7)H.NQN
MQ]%NLW0[R%H5(!XP;\UHK4/3<V6W[I[,+TNNJ;U-$9#?*9EB,T=NG3+L/EW[
MFYF57Z Q #*"RYP0.TL<U1'3G[#^OWB3B7G .T01// 9L0[R -^PQ3-M P^(
M3>?)HLCR"_XQR:55YX$'%JQL]1Y9NT,Q;-'TZX=X0/5+EOHC3[V%_86^Y($#
MIC]8_(=YX)#^)!X@QDOO#N$.02,Z\ #V$>?(7'R)FRMSL;3H#E\?59DQ#YP_
M'A(;D9QUOJ5K_(WX( _,  _L0*RD)R#^)WC 8ZG@4?GS^@#DOL33*/L\0(>*
M@:N(!VC*]5;1J\)+UT*C3H8$GHB*#(]+2TLJ*DD^=2:I\F)BQ97XTJM("657
M$LO/)Y6=3BJK2BFK3BT_FU9^+JVT)J6T&JL**;FX,K'P5'QA>6Q1.3+9D**+
MRZ*+RF)**N++JY(JSZ16G4FMK$ZNJ$PLKT@H+8]'?RTH#,_*"4G+"$G/#,W,
M"LO)B<S-C\[+CRDH3"RK2*RJBCM='5=5'5=9%7^J,JGR=$K5Z>13U2F5U>EG
M3V><.Y=Z]D)"Y9FXXM*X_+RPQ/C@T,#8J+#DI/C(Q!C_F(B@Q(3@I)3 ^*3@
MY/30U(P0K),I2.EA*6F1:9E1&=G16;E1V5@Y>=$Y^=$Y>7%YA4F%):E%92E%
MI2F%9:F@TK3B\K3BLK3"TO3\TO2\DO2\TC10249^659!>69A16I197)1%=:9
MY,*S*84UJ87GTDLNIYRZ&EU^(;R@*JKD3'SE^<CB*K_D;)^XE+"4[+2<XIR\
MDISLO-SLW,+"DJ+2RJS"4TEY)7%%)7!&6/$EI?%H [V37QQ74(K:-J'D5$)I
M95)Y=>*IZL2*ZJ32FK3B"RDY55&Q&7Y^H=]]Z^?O?S(B,BDMLZ"@N#*O%!W&
MF=22"YFGKJ:5GD\MJ$K(*XTJ*#JHZ*+BN.+BA-**^+*:!'1!B\]DE)S)+3^;
M77XZ#7U1:45"22E2(KY>\87%"<4E:#NYK"*YW*NRBJ2R\D00;*>5G<I$YT*H
MK"JSY%1J05EB;E%\=GY\ED=QF?FQF7G1:=GAR>G!"1E!\=F$0F)S0F+R@F+R
M_&/S?9#B$6)EGDQ*"8V*# [T#_+]+MCGFS#?$[EI&:T=?:*7\[-:LTB_0M.9
MJ:L.BGU[;&5]3 U)5VGSIKI^;ES1E:#4\MB**VE7F^*JKP7&99_PBP@(.)E5
M<>H.G3XN5C @EF^;(]^=6-Z96M[D(5-5[6#@ 9JM/)0S:E_[/'#P8?\J#W T
M&S3UUJAB8TR-^NI=^GM=_3 YO:(L,#(J,[>J]X$(\\ :1:P94QD9:\ #XQ#R
M9X7(HGT>D$.=.-QU0XUAPOXAP@,(,#A* C_& S!%A9U+&<1L$5[BQDZ2'AXX
M"@ _Q@/[IT_,I!"-X&V-+W@ 1NH#/16TU0$>L&._(X@V@74,)1&WN<%5.H1:
M^Z3!SM?:&2H[2[=-EA_D@;!K5R\3//###S_\^M<XT\WO?_\S#WSQ\]?E@;__
MV]EGCW.+BD[&)1:=O8)XX*G6[>4!*UM.\,#'F;7O9U8_?84'CMCNA^QX+P]X
MI($@'O@3\8]_W$Y@/W\6#^#;U DWL68;V8X'>8"SSP..__3G\0!$$:C1C>Z<
M-&Y,Z)SD]XKZ<5[6V5O^T=G'CD<=^R;LV/&(;_W"CP>$^8:$^X=%^X5%'4=6
M=4#(=Z'AT=FY.6?/%5RZG'?N0N'E*\57:U,KJT[$QAT+#@E+1H-"=67MS=)+
M=3D5IW.+2F-C8T*.^\6=B,F,R2LL.)M??BVCZ$INR<WBTKNEA7>J<VZ?R;EQ
M.O=Z55YM9<&5\OP+1;DU^=F5.;D%V7F9V3E9H-SL[+R<W,*\W(*"G+S2[-Q3
MV3D56=GE.;D5!065A475>?D561E%&2EYZ<FYZ2EY66D%V>F%J8DY4>$)P8%1
M08&10? :%1 <%1@2?3(\/BPJR2\X^IOO0@,"$XK+KO1215#-8-7&,*\=X0'"
M7VB=8]CP>'#"/;!.^'%^C0<\DQ XO/+0I??J*SS T5HX&N !AM9&T:V/:79(
M&O 7\O! 5OEW:-P^<Z.7^TRXO 8\H-AB*;<)W\I]RXR8 H&[Z"@/'*A)?% X
M7P21HN$/\ #E#_$ 6-4>;W+"$"0&)[RJ^T?SP&>AYTZW#FG^M=ML>"ZV1!HG
M9T'3R9PLO-H0E%5R,K^Z^'8WNNUOD29;.'.C+]53NKVGEK\1Z;89$DCX#:ZB
M.*'$H5/[FOY('B R"L!:XA<\4'$^(#:QK/K\,/.18,&&C'Z2>I=BV/FS> !6
MS']:?P8/X%'08Z!#I(?:38=X##=7L<Z7(1YPLK3("'"/JDR(!Y+++QX/B8](
MRKG0TO,OY &OH-379Q%!]JC/-( ;&$MIXRBM//TF7;71(GR9>^Z27XB_O]_Q
MS*R,2[?K[PX-MU)9+31!,V7R[OA$XYBH<5QTE\1M)C&:QZ@MH[2644;S"//.
M&.,VF4[H%HEZ8XQ2-T*J'1ZO>S!V8PAT?7#T^L#HK0>D.V.T9@JSC<ILH]!;
M2-2[XY3&4=*=X?$;]Q]<[KIWOJWK0GO7Y<Z>JSU]M??N7^\;N'%_Z,[(^%T2
MK8%";R#3&] &TCBM<9QZ![V2:'>IM$8ZJX'*OD5BW!PA7^GJS3E].C(E(:T@
MZ_3UB^=;ZRN;;Y_M:3_7VUW=WE;=UE[3UG&VM>-<:\>%EHZ++1V76SIKV[KK
M.GNO=_?5]?0CU7;UU7;=N][55]__X.XPJ7&<4D\B(S5@-5*HC53XTF8*$K4%
MO9+169#ODBB-8Z3Z!Z-WADA-0Y2[(.K=(4;C +UQ@-$TQ&X<Y=0-,ZX.D&\^
MH-6/T,ZV]"17U)S,S$^O/'NEI:-Y<+!MH+]MX%[GZ(-.,KD%-<O(>.,H$HG0
MW3$0VF@:(;>,4-I&Z6UD1CN5W<[@-M-8=\BT>@K[#HU_Y=YP5LUY_ZC(8[X^
M@7$Q1>?.W>SI:AY]T#@V=FUH]-HP]<8XJW:86C=$NCDT5C\T[-4(>FU &AY!
MU^+V W+](.7. +7Q/K5I@-H\1&D9H;:1:6T46BN%AB\<#5V[5C*MG<KHH#$[
MZ!ZUTUD=#+2!#HS12J4W4ZEW:32D)A#]+I5:/TZZ.3)R_<&#ZT-#7CVH&QJZ
MU-=7T]YQIJG][)W."W>ZD"XV=%^ZW7O^=F]-?5]E?6])0V?QW:;2AILYYZJB
MT^+\@[[S]_\F--@G(R.YJ:5#,/OZD5S#4:A)2NV888VTMDE:W:(;-Y'=3'JC
MO?U 5'"I+>=RR^7[C";>DXOW*4G%9P)#8WQ]@U(*BV^,DT?F90S(;[O#D^].
M+N],+V_RT>BO=C U=K8*@LN/PL 1'B">;L^D^)_" ]6]PQ./#_, S>P<5Z[\
M17G LSX@]\S<<S$/$!81[D^^!( _R ,'>SSO!FZ* \+_^_GS;,@*Y6+(')]Y
M %R;G.#=A'F @UX5B =L7AYPL/0_P0.__34"@I]YX&L_?RT>^,U_ W^AO_O/
MCQY/9^3F(AXHNU@WQ'_R2&E_8MH3(4M%X<3^0EN(!QXB'K#\R3P ]MQ^XC;P
M#(%L7T1,,$Z13NSAC]@)813J_B1_(4_\ +KI>6 *; HUZR*U2ZAR81[8Q3SP
M2\0##!7X"T5GY2,>B"S(:V +F3_& UH7!UP2(5Z>KW$(-4Z1QC6M7Y_4.6D+
MFA;VHXJ;77&Y9T+C\D.B<T)C<L+BLB+B,V)2,F/3<V(R<D/C4WS"8X+BDPO/
M7[PS.-C#8'33Z+T,9@^#>;6SXV1JVK'0T/2*\OK^O@$.M_G!Z+6[K;<:FPH+
M\L)] ])#4LX67+A[IZ^YEWJKD]+2)^A[\/C^_4<CW3-C75,CW1/#O<+A^\+!
M06[??69/'ZV]=[BUI]^K^VV]2/VMW0--'2-WV\:;VL=;.L<[>JD] XSN?EI;
MUTA3V_VFYMZFIMZFEMZV]OZ.CH'ZAHZ:FFO%):>+BJJ*BJL+2ZKS2ZH+RFM*
MSUPJKKX0GU5T/##&UR\VM^!<YSB?IS *;"[FBI6IM1V('W"3C.YQDYMJA)3&
MQ$7<%^''B0,EOS"&/";1%S'E7GW) URMP\L#9@\/@*_G+D.]15LRWQAB1F:6
M?1.:E%%5V\5\PE]:%:%[!L& >A<"S0],Q.*["#PI$0\05CL+XG'==&SW?U5@
M 2N_]!?:[[+1^P=XP([0@H-3EQ[D <(U?_\=SN$6(#IW".'ZP@2'>@4X,]*!
MSQ^TCP$&].O@\*/;X>AV('A.;F6^5=SC/K[4-I1[H2&]YE9A;7O9[7M%-WK*
M[@S<&)U\,*?FR]:%JDV> FJ""M!S!('.?RH/@!LNP0-"'-GL357IX0$^ZCV
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M.[6X('CWFOGJ!?7-&\:"F"N6\Q;EO 79OOA8H@7%Y()Z>DDW+=5/*TQ3:K-
MH6<L*\D2-46NZYE[5=;6&I">="S$-S0O[5)O^\CL%'WAQ?B'5_VO7_6]^3#P
M7GS_[>+0^R5T4IP/R]P/R_A5PIN7<MXOL]XN,5[/4YZ](4/C+)!GQ:19,?7Y
M$O>]=')9.2E1B\0J+"624*P4+,GYBS+>HHR[1$C.%RL$8@4Z<M:"A+(@'EM<
M BTLCGQ8&/DPCU['%I;&%\6DI66/T/;BTLC\XH.W'T:?OR4]?4M] J(]?D=_
M]('V>('R=&GLZ6+_[/O.9R_:9B8O#_2DE!<>#SUQS.>8;^!WR6F)MYI:68^?
M3TJ43(ER3*H94:Z.ZMRCNG6*?IVBL/4_7;X^R*^\??]B%Z5O^BUM4=/*F\DY
M?2DD+-;7-S"MJ*2!RB MJ9E:U%,!#TPM[\PL;PJ0H:QVL-1VCLK&5:+7K_CA
M')F'\MK*A^,'>&HTN& >4.[S@+X!>* T*#(J*^_TO9'))V(S\,"R=EQM8EA<
M5)/CC^*!P_HQ)(#X@0.=\#X5,+%9#\[]WCS+Q&3''\,#7NW/.'S9\^"9LJ/[
M\71<^RL)^[.N= AUPW$.D*O4PP-<-! H' *-;4)O%^@<S#^&!W[XF0>^\O/7
MXX%__MT_(AZ8F!0DI:>'Q2557KTU)'@Z);4\U&]/H5%<MR74;B >F#+O_?D\
MX,E4#5ZP; C)71?J-B&L'BK,;V&K[LM_.:K_27B HW6QD?6)UP<$:H=(1<@N
M4-E8$M/0W&+#"*^F_E[%Y::*"W?*+S24GKU1<O9:V86ZBBLWRZ[<R*X^'YU3
M'%M0=NYNR\C$E.#M6_Z;-_S7;P1OWO9SN>F5U3YQ<1EGJAM'A\<?/^YF<&YV
MW6OJZBDI+@KP\8V-3#UWL;Z/*AA^^*I_Y@WIN8+W?H7_TC3YU#C]Q# QJQ,^
MT_!?J+FO%<S74L:K9?H+&>.Y$O0"Q'RAH,W)R$^EXX\DI$=2\A,Y;4[.?"%G
MOI337RQ3GKXG/W[%>/*2.?N2,0NO2*29IX.\B7L,+HC)[6%R.AF<#A:GDRMH
M(%&*KM[TCT@^?CPJ*^=,%UG 5QFY%CO=9&$ #ZP3/  3/$;WJ-%%TCL94"6
M<-ST3'M #PCK+="=?4W_G_% 1$;)L>"$U(HK;;09SH)9I-S@J7?YND]\[<Y^
M2!GAL@\A4$=X@*: *M2P#+I??W=?7\NT\^?P !03V.9!0!BRW;&P\4H<WA?K
M V""_R$>@#32^G6FAP>V^9IU@<S*F]?2YY8>"%YV4*;KA[C7^YA7>J@US2-5
MC0_.=E"OC\QTB19(KPWL90<?(P%/M7GTJX_J7\P#9P+BXLI.GQUA/10NVEG*
M[TFJCV3]WO\,/,#%TV L["D+I9%PDB@FNF1ZN%X"U:9 YN+*[2R=C;[B\/+
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MN#(W1[;!DFTQ9)OH#H?JI1HG!P$89!8ZI".']Z,\@#8XR/[!*=?Q PL\@"L
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M=R3%7%+$)<2VN,(>T3I"!E=([PJK[6'"#GN>(O!^02D<H)$_).QH,038@/S
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M#$G-@]=N/:V7:$^V:ZX;'VK>.+KARJ%B<C,8??!FT+"FPR'2KC_/ [P;+?!
M.IX'G'OGD'(<#XPZ]!_E 7[F#WN6P7ODPE0*^-!\W=+1^J1I'G!@Y FN!O!?
MA$(,^!/P@"(M_")X%N8@VYA@NQ/;02@&P#4,B6B?S X0ZV\Q.YM>TQ?O/MMZ
M0U1P[/2V1NGEAV;@ 9P.SVC\@<K$D/ !)/Q_JL2XJ2C2XP<C7-H[YV,%-=C
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M0?#(@5+X_('WG>P_H'$\X-=2/A454#!@.1.M-/8G5MO?2I_;CS2VY55NF+X
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M'GN&>%YU6EYTZ-K.&YKK]\R2-R[1:[NXWZFU![2VP 7=W9+JO5.G+ICT*?#
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M$39?PV^G SHZH$W+C\XN[5=37A7)BQHOGX;Q:QF@B #VDN.%)QV?@>7\/.0
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M!P@NR-=7CJJQVAV?06A/*.PQ)7II.$,\JE&PY-D@AKU@^#YE!#\O(OSV/1C
M^!!^\D8-AAZSQ$)"'TJ"\PMU+>2V@-06DMHB<EN4L$>QO0[E49-N ^/I<D9N
M#Z9N>X8-V$T"*RN/GT3_42008GOD?+MB8<I_]%>\YRVT'<"9<BD]5H$'UP?X
MBM'\.]--S?2N89T36Z%AL5J:YP'!_O)%WT<UZN6CHX^T@$)_%+X:C#[+MR!
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M!C,")X4*C J/\!@/>,;$,Y*6[\JL%EQ_E ?;P GB7U$CDN$&W[/,JZ9]6C8
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M+9N_BPL8:*^&\FIM01W6X8X0/ _PT80_B0=P:A;C@H2@26QD2]#!T<'O#_,
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MJGY&;/GE Z?J3UR]D]/2F]%X-_/JW8+6WE,=#TO:[A<T=19<:3O==.=J+VE
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M?'-P;$HLU;(6=/0E*VG9.2IU4S6KO]<_L+/0#G<Q#,#MZ9!5C3?D4KKY<I=
M[D3BRZ&1&5>%^,')4CE9&C=#"PY&L@%$T4-O)BA1@-?8V7XKS#^&U=M!?&M
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MX&%0>\F+ECL3LPA.KM*F'CR3TJ5V#K;,_[5^_V?A^H('U"YD?./Q0C2%%_'
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MLGMBV3VV#$@@P'@ &ALKP61'IC9" @;47\)A #J%@4&_;1FC3T1[B_:?+G7
M>&5:0\;W#>ZSDB[BR;:!HKN$LP.<@K9'!_)JXL]<O40<H\Z;65('8]G.ED/[
M@L]@X$_$ ]N1>P &Z+7HE";.FZXQ'V>W/$QK[*XCB(AS1CZR++^"@3^.!ZQ<
MN84EMU/D;H+41UST\F2K3PQ_-:W:(HXM7VH;*:YJ.GNMHYU )CQ]REQ<YACT
M;*N%;; *U':)!GVHFR)W,!0N/)\$(0%0EA3C@5!Z.GXM0PH!VA#HH4#Y7=[3
MW/.7(P\E[PF/R,TK>- _.OYL?GK>+%DR2Q36"9V=NZR\(Q!4W&K/:[C0T-DV
MRN=)7KR>>/V./3G3-31:7'4A_GC&@>34??%'(XXD'$A.BDP^>N!XRI'<G#-7
MKO5SQ/0G'PA3;X:G7S]Z_.KATQ?]SUX,/G_QZ/'3:X/#)TZ=WA<;AVS8O9%1
MX4C[PR/W[C\4=S3O]#G$ ZP/4I$>D0R4BY5H-OESO@?L#Q>[&/7=E-N,2?I[
M)=:)R,&4VIC+%J84Q)):03(;1_ZIV.@G0?27'?IO**P\I65;5J[2PI&;V7(3
M5V'>$4>)R\*!EMXF_K9V;_^8N'(3>A4N+O8^;+F1*36PE@WL)1-[R<A>0AMZ
M]I*.O:SE2+6\93U_R;!;G 4-\X-R4N-BOM,T#K*J[@QT\Z8$4@-'9B4OVT@R
M%YJ;$,X]>C(/]84R3NX_?#@B-AKG =+///#[_OYR// OO_SG@-?YM7] HK5\
ML][HCPO/',"WO^2!+P4IAJ%9^0_A@1UA+\?[&^"?^-D^_.?\ _S/>" R+#(B
M-BV[NK6;/O/^A<H^LV3BOU6(Y_2(!YBOE8V#G/SK]Z\,\@DS<N9;*^V=C;[@
MH2L0W >(<_H6$C<+\<"11,0#Q;4-M^D<XLLYQI*1(_/PY%ZVU$J>4PR_E@V_
M,HV^<Q+G7<1%!Q9P8F>H'#2E]?[SV;./",G5M=%9N3$I)^(.I\0>/!1W,"XR
M(GQ?1.31M.S*JZV]PDG*LG9H23\P;QI>L)/F7;0Y-W7>05PRCTH-(W+#B-0P
MNF 8G342WIN([SZ)_-Y"F[,S%IS,12?T35P$L99<[&4W"^1D2QU<.11?Y\BP
M 6O9PEJVL&4VOLH9:E"O]@N@^+2#I=#>?_RDN+TE,O/XWB,)<2D9*<?S4Y)R
M$PZ=3#J2GY)2FEO<</GVT,#,.[)4CW:)I+&153:*S(:OJ.T(3:*$6</(>_WH
M!SUAUDB:A\A1L!*P;#PT4W9-OC]U=R2^XLK>W,JDVI:Z$6[/S(?160UQ04^>
MUS-F#8PY/6W>P)HW2=X9)UX9A&_@P:%E0X]2WZLV#,M-Y'?:UC[N\<SJ^/C"
MTQ6M7<3QX9?R$;EE5&6G*EU,-*]O=^5D*GUT!93N@2B@KT250=6@4$N![?"A
M;4<!5!-B:\#B)R[:!S\8A^?->.; Z+R5N&@C+SO!P_"I]N@?R .A^D58UO(J
M&Q:0?&A/" O6D5GSR*P%O2UD&'_! ]OB8/7+H80Y9!&L0CESS1IASG:=/''B
M]*5]4<EQA]-JVSM'7K^AZ\TTDXN"K$/-BE"^*I%[^1HSTZ!CZ$UL,+:\.VG$
M/Z;M[,.0Q8"'_$*5=&P6QX(#(3I?J/4*T<2/!A,MH& HGYC.3JZZ& W^@6NX
M?X!G=!&T%K+10S>@Z3\(]4;ED$A !]>'GZWP_ZG] Z%X(61TCNG\$IEC4/BF
MJ*8M+"X[YOCIBW>)[%?*::437?YC"Y;'<L]KX^HK4W!:;F4]FW] $9Z_V'KL
M1&[JR=SS+4T#8OX FU5VKB;^4-*Q$SE7;W<S/RP(?O8/?"[</X!;HNBL&#>N
M\%1X@4O7P/.E\ML/(S(+]J>F%U]N'!J?&9,;.,L&!)F(NAFZ-9IFC0[=$OX(
M'E!X17*/6.J96/),+GG&ESR298]0YN'+/5@C, ]?X86Z0&JL6[,&7LM3>04*
MJ!RZVSC&PX? I[%LN_]XJ8$\5M1%1"102Q!UCKT;>*F\SGR<5-M^M+KU,FF<
M],% 6[#@5,#!<BW^M#R 5:F'9"HL?P!*":$Y%(VEC8R9K):^8U?NU SS2?,F
M-&]^#0/XQWWYYM_4USR Q0LQ9':RS$51!#F:+=[R"F_.RWICOTM\?/Y*[[E+
MG:V]HZ3)&='2DDBC$5HM7(>#9;9#R2:9E;IL)<N0C>$18E7F$!*@XXG768+?
M:^=:WED6U 40L]WAS.2>OQAY&/% 9$9F=E-K9^\PJYLD[B *VJBB6VQ),X5Y
M]L[=[/H+)RI/5UZ]U#G0/\1@CK X]T<(EVZVI1<61R<F11Y)V!,=&Q85'183
M'18;M>]H;'SFB:+:^M:'(UUD7@>!?9/(:B8SKU,9331&"YW13*&=:[^5G%^P
M/RX^+#P":5]X>/C>O>%A>^-B#N>65+8_(G/GY.-&#\2RJH,3^N\GY.N#PJ5S
M+</9U3?/M/1>&^6VLZ=:Z),MM+%6FO FC8_41A>TTX7M#.%MSE@7?ZI;,'U/
M,(4);<QT\2?O<L?O<) F[G(G<77QIN[R)F]S)FZSX?$=H0>1[G#1XV-W6&-W
M6>.XNM@3]SB3/ZTN3NC-0^_/G>QDCW4P)!TTR2WJV"TJNA7?HHDZ:<(.*K^=
MRFVC\-HI EP=-/0O<3.!<Z6?>I,DN/J07G2E\W33W1[>U+C2(E([J5+;Z**-
M ?V@_'W3'Z"^4%K&WM@X9&UN\P#I9Q[XZ;\_"P^@!_\=^_NWW_SF5_\:XH%_
M^J=_M%CTERY?B(P)WQ\?%9YP.+NJNH<OGC$ZGSHW!"8H30T-[6'N6><8-KB&
M3:YABV?:XIL_[I; \IW0\CW/]!$]APU/_B0H.*A98:@##&V095SE6C=Y]BVN
M;9-GV>0;UT7Z]3'#AMBT*3!O\LP;'-,:QP#+M%S(!@YP-% .@J[W4?1^LC%(
M-:TS+%L<R_=<$_JL[[F&[SCZCYBV6+I-IGJ=H43:H*LV:6JD-88JP(29QLY2
MF3DZ&]_@Y.G<'&BNCG9FDZG_@:+=8I@^4I8=-PC\]%-G]\<>WA,='Y.2>;'U
MON3%\JS6_4QJYK^5"><U$TH+=U'3SAXOO?FP[$9_RP/^0_K+ ?;+A[P7?6,O
M'DX\ZV+SZN[<.7'J='1RRL'$8]FEY?4MG3?[R;>(HMODR;ODJ3M$R<TA=M,@
MNY4HOL68OLV9N<U!U][4/>[$??[$ ^%D-T=4W_,@N[HF*3\_#KU)_.'X0X>.
M)AR)CCNP]T!D?,J)4[67;PX1[_$DG9SQ=M;$+=9,)_MQ)_?)+=[C6[R9#MYT
M!V^R@X,NYJG;[.D[K*F[K$D0$]3%0N\_<Y_WN%?P]('@V4/1<Z1^\8L^X?,>
MWI-N[O0][N0]_F2W (T(:'R1=+)$'4SA;;;X'G^B5S3S0/RD3_3D@7"FAS=^
MD\0XVW[GV*FRJ.34Z,2TY(R\C-Q3Z2=+4XX7)![+33I><+*TJJ;Y3AN!V<6;
MO"=YVC/U^L[8\W;NXUOLI[O5SIRY29MJH4[<I$]T,*?1=[G+?7*/]_0>]VDW
M]VD7YW$+45!Y>R#MPO784]5)59>*V^Y6]0[5/2+4/QR]^&#DZL.1ID'"S5'J
M;3+[ 5TRP)Q\R$8'<ZI#.-4LF6H9F[XUAH[/6%5K3V+FF9@C.=DE=9=N/^J@
M"COY4YVBZ=NBQW=$3^^(GN&Z*WK6*7S:P9NYR9YLX4XV\W9KJI4_W2J8;A<^
M[10\1[HMQ"1XWL%[VL9]W,Z;:1=,M[ F+Q-%M<."^E'A19*H@<B_3.3?9$X_
MF)XC(&Y1.!@:#UL+H5S0MDP'R<%\35"@"0C EO5!UB:RM[#D4;YZE:]"=M(:
M7[?),VRQ]1^9NN]HFM611?.#QW/W!2^[>:\?/5/39%XV5MX'ZR3JXVKQFIYH
MVD;V[BKT!@&?QHK L"I&%YIVE35GO4.?R:]N#4_(C<DHJ>L9),W*^&8WT^@B
M(6!3.5E0YL_+-;B9!CM=9V=H7% A6P7IO%\*R[W&!0V8$>= QBHR4E>YT$O+
MQU)XH:S^CB&+55+G0?E4P"&.<149H_V+^EJJ*.G<E>BD]++**A)?,JDR<_6>
M885C6.DE*/U,N5LHLPN1E:/V(5R!6"RE%[P-QA40U*CU86FC'@" 70GK8#V$
M!)S !8M_1:"''%RTP8,&3T' $G .K'"17:OUBS2^*5U@4N8<X;\N.ML<=B ]
M)O74E7MDUFOEF,PJ7K;PE\Q"N7U,ZQY3N\9D]O$%B^B5AL1_TS4J[*(*B!-/
M12_?C](XE147CL:GI!_/;^KHY;^33EH##)UG5.$F@W<H"'Y+=8"G0J@#XF&/
M".!,P#K002E;3% D"AVQ54RA0P='#YE$4.#%#QLZA(L!E@+9A5[@ ;43G?F%
M=0TQAX_NB3A44M,\.CD[K@M*C)L("%GJ52Z4^' C&.!IT*^,G2U:9.A[06"F
M?^J.MTN?2F!!;C':T,.O#*T2=.L"V.< U/O'37!D(L,;HA/#A[TS>CYB5-A5
MK@Y]'/JO![)R-;#!17!H"DXY-F>L&WS(A76)#7[:@K%AB!534AV>55S2U#XR
M\TJB@&8LE$4S=,O20"E;8$+(B<*\4BIP28%YK70SD%28( XP)+R1%IPAF" _
M7@&N +[<+5IV299 XF672.H62EU(?)F+HX"E ;R+"%;(RX?.=BZ<X5Z6VL7&
MQ-&XH5L%Y+N[[DY^.--+R^D8/-W':!*\Z'^EHLR;Z?.6-N[SE/J.P^>:+@RP
M'SV74N>,C 4+6X9X  ' 3CD'-U/A82K0 0Q]"BZ.TH?$5?FP?L\^+.<!J^VS
M2Q@2N+?EP8J0NMD*)Q+ZE\2X"NLI4W.U(X)S ^PVX2NZU,[3^;'&;2"H/K=+
M.WV(V1I(C<"%??3.7L'.8.EGZ#R$V1E=\FCG&3(W7>ZE*_TLA-::S9%GAKOL
M][?HKR]VL>K;1KM&18SI#V.S2M&2DB-7,-1:FLY$U=EH:CMER4R=-T$95HT/
MX27>HA1=MC@@;;,'?"($%*A]0DU@3+\J5GGNLZ?RSS=$'4D-VQ<='9^8=K(X
ML_AL:EY%0O:9H[F5B87GCA:<B<W(C4HY%I68>#3]1&918>ZITNSBXA-YN8GI
MZ0>/'MT?$[,W.CHL/!(1Q9ZHB+#(O6&PSA]S*"/C6.'I8R5GDXLKDXHK$DLJ
M$DLKDTY7)B.=JCR<6QB9E!QV, :],&P? H'P/7OVA87MBXR*SRRL:']$Y<^K
MITP^B<$O5 =F#-\]U7TW-"XKNM03F59V,*,LN;0N]4P]VKV$O-,)>06)^7FX
MT%R?5)"?7%286EQTHJ0XO:3X1$E)6NGIM%-E:(9-*2U+*2D[5E*>6E*QK<IC
M)14I164IA9\IM;C\6'%Y2N&9I/S327EER7F5R7D52"D%9X\5G@,55!XK*#]6
M6(:44H"_Z@S:3BTJ/U94F5)T/J1B='LNN?!L4D%E4EY%4FYE4FX%;(#*$_/+
M$PK*DPK/)A>=3RZJPE2=7%R=D'_N4$[YT=R*^(Q3,1FG"NM;>UA3XB6S1(U.
M;R=9ZD*GAT"__N#I?%%+1V1ZQI[XN*BX@WO#P@Z$[Z>22/_MO_W]K__]-[_]
MC__XS>^@SM#__(^?:>"SOS\+#R#\^BWVA[=^P'G@__CO_VBQ&BY?J8V*V;__
M4-3^Y"/'*RMO49EC2M-3QSK?$" IW22EGZI>H6M6&;IUZ#>DWV ;-CG&K9 0
M Y@^<K%;EF&3KEVC0=87=",":=9HZE6*,DB4^8@*'T478%@VF/8MAFV3C:Q_
M9+6H5\8TZVAVX>K76(8UAF$5UJNT4).;JT"CI)NN<9&TGA&]=] 0&#:N$<U;
M=,L/+.B$^CU3_Y&!#'K-)A)-O4Y5K-'DZS3%)E6Y14%2K=/0'"RWLV5&CMK
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MLJ_ \:5+L>$CL*H!PJ.;T&1"_4>A_IJOO^1JW:E(H,L0G#($7RN<P^DZGQ!
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M0#T14(<%!^@?Q&HG#&&L/!,C9V(%]#$6(E _ !7!5=C9<@M'!N3H$0^%(S4
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M#OB'"KY4*3A4B_:UPEV]8/>(?V@1*-#7MY S$4S/Y! CUGG$LJRRB9%CD=S
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M=<R&&%E*(U-I9"@,=+F!ICBB*8QTA8$AU[$1/0SJ#[ZU;V'MGC!WC]PPWAL
MS%TC]]#$EUKX4AL/A2.#$7)A% <M'&]A:,_@O/F#$]K[(^I[ W7?R$"L'#B+
MZ8RC! =EIDJ.I]_KIM[KYB1F<"OQU!\YR@\ K@I4/K*1#TSY%5U^104E<LT"
M[>H/0@W@BJLX8QY8F;LFUJZ)C<)Z#W;O&.PDJ/P(]S)[)LZ^A7M@ =K #6?/
M#.""QGTKY #^%RS#V3<#>(=6H0R8'TZH=E#$<'3:)8 BP<&30(T!X!Y:V6[
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MZP&."F:&0H/)P,D# )B!"YA],NO TOO"QY.XW/J0W/JT>_T5@_3J4?8]VO+
M\_?3;Q'ZOHZQJV?L&7@*JSM6*<PS (,%05!AX.;[R<$<.+L49B1 Z_]I/2!
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M82_%ES5YA).BLVZW CWP3B\$^_/)C\7MU.YV=^;K+@%P]U0NF'94X6#"W$E
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M$TF'T0)R/-OK&%R&QQ4-,H+ATKLWH?;$"6(J$ 8 ;USC2[P"7,5(H)\JEI)
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M12#]L=H\=L'JD9/G;=I7W62]?M'0L>74I<UU5\^UW;'RL?9@UBQF*%]<Y8[
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M=YU-=SS-=WS-=SA TUUOX[W>Q@>/KSY\6/_PP>6'CRX_>'+Y@?/R \_E!UY
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MBZB9J)J-D5],#(7\*T"U!ZP36#]A0 ^DB4].V<J!,RGQ8D)[ B;2".@8\4>
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M@&-Z A 2)CZ!;G4>Z,:0UAW6>R)&7PR&=!/2B[@!!( G0GOA5H\#*$1,XT5
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M90#'%> JI$!+4+C<&-=X,$L,!F+B @H)-Y(-/@RF1Y2++0*!PUQA>$@%%-(
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M>R!G\X,"3YLD8.K)^L?" >OMCQKT*T\W O93'8K'HAGN#5]<YXT:F119W"$
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MZ('72?8@WE0"?X8>P$QGY;F!*!-2X);)P(2-=AX2.V[GDPXA9A63)BFG!S$
MEP-7?',.X#?NR!&5=>;:S6]-F/Q3](!,$''->.">(??/GZL'<H0<(VLT"9B
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M\DRR?147PK-J '8X='4"O=5!HG O=,(76OX+K? Y0OR55GBA9OL4[FRK*Z7
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MJ![@08REC$(>Q8" /CDFJ> (EG3NJ*P'?C%ARO1E*X\V*.E'OI^D!\@-@WJ
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M'L#8929K\J4=[O0=KG3?WZ^X]F3MQR?'35LV=L:J#X\W7+G'HGT 9  Y0FL
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M,*Z4@M4P!J[-7Y&2MSPU?UE:_O*T_!7IA2LRBN U5ZXO7K$>S/VBY5F%H!6
M!*AB6O!K 6AY5O&*K(TKLXI79^>O*2A(R<]-7)>Z=,7*E2L2TU+79ZW/SUB?
MEY:=GYI7LKJ@=/F&3<MR2E9D;UR9LREQ0UGRABV)N64K-Y2NS"N+"\XWE*Z
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MCMX=6 =M+@\(K+AX3T<<TJ8,O<'%[&[-?EGH S/K!X\/PG&NEQ<3*H!'QL(
MRYLY9VJI@G4NM$8_X '&.X@_XW@CH8:ECE&0>(8'I*C0C((R:U!F"\FQ>$LL
MGO\'C5U,6X2.*.]X -<IQ%8ZU2#Z*<$U?\@#=)FP'VVK<V$ :V#!A3G'9"[H
MRZ-TH#!JMMG_3GD@PO  V_Z697\C<DWQ+9YZJ3)[Q^[/DU)SMNZZP)>+7A%R
MDT^!'E/C?%.(.^3D:5U !=!/)1::!\Q^%35# DR5#\R2C+NR8'P+,7X]@,(
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M95.\M$J?F05/C9QG!NZ,V$]TK$?P^D.SZGPPT'$?U?5@B/U8SWFB9\^(\]0
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MDJOFF<(J%T!M#-=R:"2(FUFN<;5[ GA 24Y*R+'VU]1IMB)W\[XUJ85[CS<
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M-8Q%*JT!OL4OL:.S#<?B$V+*VB"Z[)O1I0IN%U_GX>L]\(A0ZV:_)'D#%,"
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M,7%%SH;]YZ]+GYIZ]4'.H+O3$NRRAK&^A\G736!-!E"GU8,G-B\P  <7PGW
M/'P"]W $A%]DP>TR@<[-'P(8@!,O7XL2Z.#Q "8_A L#*]P8%!N!;*&;!-3.
M4/>@8=^MML32\N4Y)=M/-;:I[BOUE)ST\"DOFPJPR!"(;0OQ;73Z*5,82Z';
MHDKTKT;1F4LPGZ$<#?00EG;]2!CT3X?MT>M!$9D9M^51%MP)5%@B2K@Y)D %
MW+;E8=W)@,#B93\W-W3)"[<=7IZ6E[MUU^D;+8UB2;U">>W!4^Z0%6TMF(DL
MPU)=3*B-<O3A;F.0YXC)@^-BTGNU_V')H5.K,O+W5AUY^73@3__T+_[G?_UO
M_O*O_NH__9>__X=OOOKZAU]^3QNM'_@+_3,/_+?__"8\\/4W_P_PP-_\[5^I
M^]6Y&TLR2TH/U3>S[[S60 ^!6=,VKG!,*YU3ORT/J&B/U;AHLX^9U:0PG3C'
M>YRC?>YQ$3%\5CVX?O_9I:F9!;\?'J"C\6(BX %SA(_^IF!.^976 %8S<(Q)
M[6]XMNENR[C \1;W!VZQ4XH*/UN]+*U\ZPF.BFL,,JOF3-BB=,8-0^6>8'A
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M<>+4#J\&44S@O0;^GJAV$A$G"0&O#BBUDZQUT[2;G^4!I@H+%E5M,Y MP .
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MH5V%Q[NO#Y[K \$_.33!]<&FL:T??.!C[2\\./BP]P_A6<7F6 [N(GAT$$@
M\>[0M6]HVF_HNK=LR -NQKRRJH\8F9)V,B#@6G9>,VN$@T4*D:1K-"4,6CLL
MS(UA;V"-"QM;M2[6[0@->YVOD<S:WHL1&<%7;N07-P^*9@0* !7K!!C_MB%
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MPF+]0F,.*?9(2.R1X)@C0=%^ER+]@B*@+EWUNQ1^)"@"R"\PW.]BV)& ,+^
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ME0/SR;BX"/#E#K'6-6S8%.N<?'2#H[)R$#@#P-? (7RQUB'2 $YPC!C<0O#
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MUH\;-.5T[4;OC"2_">8;/1T:G?^D@?IBCC U4]#6>P/P0$M?<EE#N=[2=0
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M@N:>P-@T_["8NT\:\&,O.\7C=YH[TROK;S=TW:AX=KMYL'UXEB4W@R,E2<S
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M.SP$V*D=NF:'KMUE:N![+K*-%5[U.BK?LWKP%&$S Q )N+ZP>"<+2SE"5]F
M&'!  @-TU Y,& ^0@,8ETKB!!*A3 ,' !00@@:^&/,#R\< J!;$"'TG7;##4
M&S3U!D5C(^EL%*V5BEI8B(7G6W7@U3H'2[S#0YT\+!WXQ][H0UOS+^0!&#N$
M]>*^6)3]OX7&>M];PX;L+_+ H=J'G^$!K%V&L4F J520K+B(E8>L<1$;:%7I
M,(?/-DT->4!LWN'KG'7LT8BLVWZG_2]'QY6U]Y)F9("^?/L)=@"ZC?UAT0_+
M.<$QT4\LCN\0#J[RP3'^.AY@ZP%2NCFHBZ5PTE0."F+KG945MO4')V3XAUW+
M+:WNX(CK&;P[S5TWG[;<J>_,J&S.;X7K!T2 &#5VBLQ"4:R!KHL.%P_8/^ !
M[5NR<8]LW&6:]^@8#\3=?7 V).IB1').;5?G*SG7X!&9]]@:)\PW"F.]7(S]
M&A'>V_5@!0@X#WQHB*'UQ&9^( ]X+SKX#<^PP\;JT4+(5\+U&WQ86<DF4J[R
M94:NQ,"1Z)E+6MH\PEQ4\V0&H=)R(('"Q)>;N%+X&;[*)-*N"C1FX!Y8<BU7
M9>2KS3R LDKH)]@*+1#X/4NN8<HUW5,S.2W=%Q*RSX<FWGY8CQ^>Y:I7Z7HK
M1;O&U</JU&-*QYC"(00]D\Y--GAH>@\;XYG/Z! />'&.NQ_?"&#^L'R@^#>+
M%_+>-O\*/+!_"-YRPERLK 0#2W<&<TEAY:@/?^VGM[17G]^-_>B@3QN'+P'S
M@3[# UK@_Y#J 7+4C;03@1>B,F\VT(6P[*X:AE;#:.E#/. ];UCTZ2:LT&S8
MXP$*59I)"DOGG":[!7<F.NYL6&AV65GWV 0;,3 T5I;.CIM'*HB"C/*6\/3[
ME^.S0Q*S+L4F7HR['GD[_WY7;\^+:?**DKBLX*(&OM;,1O5 8H-5J%OC*+&"
M99JU8</&L'Y#K+6.F9W#NG4 M#?+:_TCHL^'A645%G6R! *9D:_Q$%6NGF5;
M[X(5M[A&6C2S9881C7%,HQ9*I-2IF0ZNN+AC(/%!16!R3D#"S?SZ'OPK.4]C
M9VOM1(5E0&HB@BY,Y>"")D[AHLHVP(/&D-NZGDN:^"]J&</59'X-D5M/YC=0
M>/5$5AV>]HS,K.CHRWQ8FEE<4=5/H<^H)LU[+VV_%2NMK31^1'*:W_&OOOKZ
MJW-!%RY>#;\0<2TP+C7Z5E'R@]K$HJ?7[U?D/&WK$;\0R0S,!42H, RK5[ER
M'5-F8"@,=(6&ID#IB!9&V"(VX-U)"BL016FEP:P[:RQDC8, 9@-4L$J:490/
M4,.S<H\&AP:G9CSNP>$FIZDSB\PE*4^.<)4:F@P%IW=@03JXI"+*#&3Y*D%F
M&92:!Q5K1.TFV;B-TWH&$1<L(:_RL)6;G$7;H&BYI(V:]* FON3)S>;VPMZ>
MHLZ.S)*2T.OQ7AXX=NJK^+2$5@(!^$C:"L 56[_,.:!T4M5.GM;)6-(UL)[?
M;2??[V(\$\TR%#:! 31<CD;!9-+#TK,1T4<OG$_(NM5)Y0D7=&*8%0JF0&6@
MVPQ89WT=$U9C\=,G%],7>4!F9<LV@ $ 32)NV7"_CW;I1I[?N4#_*U%WJ^KH
M_S][;QX4Y9KO>>(.RJJ@@"*XXH8B HJ@(JB(J+CO*,B>ZYO[GN"^>]R 7-[]
MS07(?<]DT7.JIJ=[_KH3<6.F;\2-B5FZ9Z9[;MW:NJK.HA[G>=X$1?14G:I;
MIV]'=!'?R$@@R7PS>=_G^7Z>Y[?<?Z1&:7[_(-\8Z3+$  \@<-KZX)M9&(A/
M<-/GG;BF7FL3OOPS/ #SB<&4)[>_;'L^M/TB)[5@9<;BM*K:W<TR-2S71D3Y
MY+B0?"G'0GKSL-X\J, \(B(L@BN>GQNLW@]94U_WPZ]\[Z?F]S#P61X MP(#
MW!SH>&)K?4A>N6UJOCG0?G> _\@L?T'I3%8=($S"(Z6#0BK"08/< 9_<'-(3
M8971+7I*(X]0R4,#<O/Q)9YD3<GVM"7+CITY__-_^^^ 1_W#-U__X>L_?/?M
M-V_??/ON^]?O_L8#4[Y^*AYX\^;-U]]\\X=OOOGVS>MOOOG]V]>___[MU__[
M__;O16)!SO+EN2L+:XZ>%]_NOP$<B=GWG@?D;$/0. ]H[3'( [88M%G 9,!X
M(>!N(UJ8/!!3DR/ 8:L_\$!$; V)K0'Y8$CO&E';0TUW7JRK/STCJR A+3>_
M9-<Y48\&=6@(CPKU*LV>N!0FC]+D46,^'1G4PF1EKX;V:^@@S%*@0A \Z#$U
M\:4"_YD,_5)L'!<-C(H,8U+32_ MD-3\I0S(]$IN?*4R?:E%?]Z#_9M>[.<]
MZ)<ZTTNU<5PQ,"HSC,J-XTKLI08;TV C"GQ$2HY*J5$9,2)#8W)#6&*$987B
M-6KBK?[B]1S!9!G?$Y#C$ SD<&O/+R%@!Q A[A:17F#IQ 3;VBF>GPK=/X"!
M$!#D 2*@)0 8!-2$3TG Y $I;*@.04)$N-@AS(.0;@'IXE%.'N,6,&Z$=,H(
MIY)TRZ%3!,84=D.3P[\%..%GDX8_SP/L>#01"?/'Q(Z&[ H!'!38L'+8.97M
MF1IA TLFYO)I/""+QR=,?8DX#[ EB3ZCCWNAOP\6FL(#?L@#*-QCF<X#5%@$
M>  8"RIXW?6R=RAZ3GT;\D!22L:R@IHS38 '>@8CNJ%1<'X"\Z1F [WB1BV>
M!O!^M)WJWCYV.5-X(#Y&LV%.\7%S&@],QMN VX@<?$H?\P /<P >.-#"6;:I
M+"5[Q::JVB.MG -7NTJ/GR]N.%UZ]'Q1_9E=E[@=]P:NV\-Z2U!L=HAQMYCT
M26"[UDD>B,<+T6. !X1VP ,C[/[ K?<\4 YYP B\G79P1$;!KF1_@@?8ULOO
M>6 R6 A,8)#-@#^&W6T)]L3&O'*S6P;F1<.PPCBD ,;.-*Q&G5K"HR<\.B 2
MR,TJ?M\#?J6%&U8N+;!<@SZMS:,@AV7$D(IV::U>K=6CL;C?2\TXE?20@K:W
M/'Q:=K$EO; D-7O=]KTG.O6/Y/B0V.(0TL,*QJLG_1]X@ X*+&&$@<6Y/SW5
MH:;R 'L+M_7@RGH$V(AXE".;*<YVFK.$?F0^,3L]LTPX?0:=Y(&/SZB?@@?@
MN[#"7X$S$ PU\7^N_!.C_^DI_4'Q+:_IAP%?9?I%^A?Q@)8. !XXT86LV+)E
MW@0/Z#[P +S8/]B@^!@R&94745I&  ](T2&^>;CE"0UX(''YJJ3%6:7U=6TW
M;RM)FY1R**T^SE.LME64O^- 8L[Z>8M6I.2LFI^=EYB[+'-3T98CQT[(U>T/
MGXD,^(TAKY89:G_X_.*UNU?O?=%Z[^GEW@=7>AYTWGDN>&P"XC\R2EZ0LN=D
ML^I6V<'C:4OS4Y9D%^_:<T6JUJ%#>ON(A(EQ\3!,(<!#0H.#_P05/'B"W'L@
MOOM =.M!A^9&8X>@N.YXYH;RM-7%.XXU==\?T%A\X'3EF@>[C39@N %CR\U>
MF<DG-GIEJ*_C(5G/U6\]?G5U[;$5E0<+MM>NV%Z[<GO-JNW5J\IW%5;L+B@N
MS5RU9EE1<>6Q,Y<5-Y''A.2YE7-WX$0GLF)SR>P%23,39\Y)29R3GC8S(W-^
MWNJ\DEWYVP]D%E5E%>_:7'_FBOJNVF"1/,,!EO=2#IBU;+))4)L$LTAP!K:)
M)8<0S,DU.CE&)Q=0 5Q(]H !1T:Z58Q/27L!%? >&@ZV\7*+2V<MR<[;NNT\
M(M$.F/08V4-;](Q533)BE. ;T:Y^8[<11\AA">,1$"[8;MP\W$GYNJVA3B;8
M202$6$B.1X!M4+QP=??TUU\6K=O;N'QWW?K&$V7GSY:=/+%NUZZL52OFIB8#
M'IB3.&M-4>$%+E?VU(@,V#H''.TF7[O9R\4]<MJG)5SM-Y_7MH@JSG0=Y?4*
MGEKUEJB"])U6WEI74S=_V?*$E)0U6[<U"Y6ZYY9>(J8D7DF)5Q(R!GA 0GE8
M>25@4(4):9_11SP ZY"Z99A;CK,\8/(JJ;#&/LH=L ,>6%BT'?+ 4L@#HDD>
MX!DBG0-1CA&&&TSC@?CL!O6#:?2?V1_X\%L2F(J0F R+J(C4-G[UJ;WL?%=R
M_HJ,)>E5^W9?56A%_7:$C/TE/,".6M/',?C##WG&DT@ ZXV^?U.L)GA :'3S
M^IV<%\/<OF%!OT-L<$H,0](!NQIUZ F7EG0K"*^$"B%43$2-*)CQ7ONKN\ZO
M[CI?]3(!N+KTG.#UWCO2U+:TL"@Y,Z?^R+&QEU\"NPI\Z3=??PUYX/6W[]Y^
M]^YO]86F?/V$//"'/WS]>_"YOWGS^O77[[[_]NO?__*K5['39TZF9V7EK"S<
M57^J4W-?9W1JT( "@#ZXL(%')-A5U8]X( H'=!@S$U"10< #:C*L(B( !J;Q
M@,@21!B?S!;0.F,([CPDO99=L3\A,S^M8./.H^?YMU]<HWUJW*-&?1JS_[VT
M:$"/!WM(8*.#6@HNL0,;K27#6C*BHT9TU+B6_$I-_$R)?2DWC4N-8T RTTNY
M&4IA?@5E?*4TO-087^G-/^M!?W8-_:K7_%)O'-,:QE0#(_*!J,(PHD;'M=BH
M&H_)"3"(C$BI$;BZ8 Y+#0&Q$;8ABRM>TG&2!P)*'/* C(WYDU(!V(N*\@HH
M+X_R\6F?D((%LQ$8*0A[>:H P)!A'2N6!$(:/*A&_3!-%G/)8=Z/"R8SD7#\
M CP@HMP"RL6EG=V,DV-Q\]B<"@DLB,;F&!%Q 5O AN:SL89_A <^'8D^H_A@
M!'="H"_\.-\71I6\']0^';FF*[X]^N-XX,,BQ)_B 5F<!Z@(X $Y$[[N?-EC
MCYY5WEY67)&0E#H_*W=+;<,9^?7N9[30[ *F$)R?O8YQ<*).\@!T:3^2!R;P
MYL?Q0)R=%'0$')6,@3P@1V',)1]S=#PQUK<+"HHK%F3E+]M04G*P<=.!(WD[
MJG.W[<K?45M065]^NJWUUHL>2T!#>Q'CD @#, EYX$.\$,L#(FI48!T1V&)B
M6TQJASRP>E?-@DD>:($\$ 3O5,9V*8;G)P!4=L,G#F_2/\H#D_\"V!]'SFZ%
M*=B]+S8$SB\W \%JW$K<KP(H2P5UEDB/-:ICP)7NEP'\@*4M/*Q@!Q^9R2,U
M0VI56L!A>!#SD,!H%V,.6+*#@D7]Y!1PL> 6?.N4T\-R>K#EB^?E3:T9Z[:E
M+"DLW=W8JKX'?(R(<0AAO!  #]]UU'?]S^>!N/Y:/#!Q5DSBHNP]!L.?3S^C
M_LH\,+F*#\5N<TT< /69Y(2)ATT\>/KI#37M3V!@Y(<AXCW;_R4\  S],_PD
M1[02\,#"]!7;RL])] J3(\X#8KCK.)T'8#\$^'F"0XVJP3B&#0M01\M3NNP2
M)S%O96+FPI*Z_6TW;DB->.<S<_M3M.7.\Z,\95G#^57%U2O6E:\I*ENYJ;B@
M:,N:'14EAQL/<X07-=?;;S^6#Q"==Y[4MO(V'SV[]=BYK8WG-AXX451W:OOQ
M*]67.'N;N+LO=($[^RYQ=QZYF+>A=%92VIP%J87;RL[RQ"J#%?" PCZ.,".(
M951L&>$9'>=U=_=>:"D]4%]:4U=9?[RRX>36VH:EF[<G+5N;NJ*HXOBE[OM]
M@'@5C)MKMG6;; +, 7-8C2ZIT:-  Y(!UP7MLVTG.M(V5LU8L@9FTJ?EL5J6
MD)XS,WW)K(59"2FI"4F)B9F+\C=O+:T_47FF=<?IMJT-Y]95UF:M6).8E@QX
M("%QUJS4Y#F92U+R"W.V[%RZK29C8^7"HJI-=6>:U/<T)KM\@%&9;&IL4&:P
MB@PVD=DFQBPBG!&B%K[9SC4.=QE<748/!_7Q<#\"_B_@PZ<#:GM8;0N#(4CX
MA;&^C;NTN&1V5N;231O.='6J'C]6O>A3#1B5!K-LP"3J-PKZC)U/7W0\-R"X
M76'W2VT!'NGJ(IT=I*>#\;4SOJD\( <\T#MPZ(JXZ,"IG1=:SVCT%WMT)T3"
M72=/%FPN2LI(FS%GQKSDN>N*-US@\V3/38AQL-WH:L>"'7B@"W,AI$M+>_B/
MS T=BJJ3G8=;58)[Y'5K3&^-G-?<!3R0N#0O8<&"55M*+O/EVF=,#ZR-#GE
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M7'>1T]DD1"X*1.?YDC,"R2FA[*1(?H0G.H+(+]QXQ#$P(EBBP\UG/!S:T\D
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MW(J9@/3C&3=^'TY@I$^.^U0L#T"32OL1)L!G_!S&U\GXVBV!#HN_FP9($!"
M489=;E?!MP#>3E3'"O" "@W)C5ZIP2DQ.:2H4TYXE+1/8?'#$@JT%Z%=/!K
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M5^2!^$H\^)#A'\(JM# I.1[  V-X+'!P^"GV!]B'L<']D\N*$RLR#,R(>/^
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M%5:!5P??,C&==4P/8&!P1#L()G@P,0/N!),<F+;],C;\^D.C0<*C8-LC:*"
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MQ/VWS>X>U*TEW2K:H[($X>;^IP#PIWA S:Z6Q9%@8E*?+.P57_J:?NK_2!Z
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M(+=W565=4DY^TI*\-96UNYHX%5<DFT_SEN\Z45"V[\#Y-MZ]%[ \+NK1F5U
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MAVM<<$SQP1T#&%D+8\=E;,2%D@P!>\HV<8.YAC(:T!2;;TK!=J=*X*>AX,[
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MQ,O&/H%G"RO(L'*B@2Q<.U9:?, %R6VCG2\<NUKDJ87E"4D9"0FS4E)2XCP
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MZX^6>6H:6T/AG^ X)UC.,9%W!H.SKT7FGII%89]0V2<T]C&5;21S@ Q$MI[
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M>S+;>C/!"SO[LKIZL[IN@]WR.X>+NX:R&EJ#4M)LO3RMW=R"XQ,RRRO2RBJ
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M"T[/<HZ,M0^-#L[(+^L9&J(LD!YS[XH/-@].-P^.Z6Q)-V$^K:G?+[O*+:7
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MVM_?QM_;SL_3SL_+WL?#WLO# <C7R]'7Q\['V\K%S<+:P>*&C:V]LYN/OUM
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M 0^<,OD&HD2'D>FP4CWQRGHV6<;7]O25,?TMO=K',EOPYJEP\_ _]:KP\"5
M K"F7,48?/3-X3#Y!S#P@6#XP==XX+<+^N=\0 +?B0?^"?K@5'SPS<TEF:_:
M0""*S%2NT1Q&"4[C]:C'5^D93%,-9AX@RH\I,B,PW3Z:'\ K?D*1O\1N*]O0
MM+",?"L/WU#  Q@*BRV[\A<2ZP&1?E5XQ%2!D6RN3:X GV@$=#$O/V>JSJ>W
M)24CL]Z12<X>_C&IV3F5M5E5]>7= Y/+JTR!A,P5$3@BDE"^H-:N:(])'%7%
M,#D\MSZOOFF,B)ZB42KZQ^)N=0=DE;H%!MG;6[FZV&47%O3,H+NPC+I)?&YS
M=VI9>45[QSACB<Q6$?BPB*3)96@?\@ /6)]Z8","'B!)CW!2S=2N:NR1LI&X
M7C PW(J=F'GZ@*HVDN1G TL[>0U]?OZA3K9V\;'Q5?5=657=SA%Y%NY1UCX1
MWB'1$?'I$4GY0?% N0$QF5YAR<[^,;;N(8[>D>XAB>XA":Y!,4Y^D0X>83:N
MP1:. 7:^T8$997&U[;&WVD(*JT)RRN(*JN-SROTCDFP=?&Y:NEI;NX%&U=K)
MV<;=Q=;;W=[?SRXPV,8_Q"X@U"4\QC,ZV2,\T<4_QLD[TM$SPL$MPLXURMXE
MQMHN_*9-L)M/<G[-[2GFHT7^X=K>R8KR9%%X3-LV4':/2#PC,-VP(F!3:B:W
MV)6S2/_,;"=OO^#@R+3<XH*&UH*6KJQ;;5%YY7[)V:&916"[O'NXI*T_K[Z]
MJ*6[O&>PK/UVT:VNLI:!3@)SEBO RO;P(L #:B B6T/:UA.W#=@=[>SV'HJ[
M3Y-J*7Q9%QH7EY;E[Q44'Y_3-(J9?2P ?1D-YC/0@68*]'HX4[(-T@<\ &X5
M.#\@UF 4^AF)NI$T%YE9:._@;FOMD)B=VT^F$P!IB$Z)_.=DSG,&^XS.!Y=/
MAU+J, J8\Q[R +BLX'(#4Y5[ 'I)#.< V,0?E1W$\XTD(1P=($O/B=)+O.PY
M7OY\_*FR?)(8F%UJXQ7D%QI9V]I&O'M_D:<D[2@16S+$M@K#.\ (#E B-5*T
M_Y7$4"CQ 0SI%AN@1 :4Z @M!C*B14:<Y(RB>L'8?TF6GB+9ZJZ%)TE=$^'U
MMW,&D#4SU 8$I7H"538Z4S:%+IDA%$T3BR?PI=.D%OK:]#,I2:;'"@]GN$J$
M0(T1ZG B T%L),&*+F=4Y1E)=DJ0',,<H'"0'MCE<'X 4 &T^V'8 )P6,,/
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M$VOIZ6WM&^";G%$S/(5_N,ODR!D\)4VH)K_G ?G_##QP'2C\M8!@A@(.ZO_
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MK-"(!VTRG,<[A\$/XE.BR/A-'H!QPV)89<@<80PC*,P!QW#[0QZ ,K6-<(H
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M&@#Q--$AF;]/$QXN*(T+^R=TN0XOW,?P5#C>/EFH06V)6_"LK)ZQ6V@6<O>
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M%FY7"EIX'/O"S ,LT(DHC[#[1_\,'GA^S0.*BBE2<$ZYM7N D[MO0GIV3>=
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M$3@CR%Y^'SQP<LT#)]/;@NJIV9#D5#L7)SL/9Z= 3WL_#RM/%RL_#^L@'ZM
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M+9)$386![T:V]) M _SOG+)U#O-'24]HDH^5P(4>^)@T_VXPY2=L^0D+?<H
M5*=TU>G$YE[Q-,\CJ=#9*S0WOQS'># GU(&OIA7'T\IC@OR4(0;/H(X#6_LQ
M47E"4IIH<MCLD:8+ 9]Z\SIZ(#BYA<0!HT3_'#$+ "6 XE(/?&0?@&* IWG+
M4<.L&D@.'S/HR)()$P3!XEP7]0K0.(1+[7&E!Y#)-O@8(N3^@[[ELH>ARZY&
M4+".' CY"S"\ZA-F?VVWU\&\3)MV 7-?9^[Q4%\IM)S"]^@!M!O\0 ](+_0
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M!L;#ULTW/"FSM*VS=F2Z<IA>-7*_"?^JG?*BG;303IDS@SS709GKI,YW02R
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M$28=U]-DT-R$M)9CZ!@F@P9K!O20A@#?4M&+@]X"L\4&3C@!4"7[YLL%<Y)
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M]HRA.FKE/ W*K[" $_9.\1G90V0&<UW*DH'.^9 D.B*(X(P/00S&:P-!N@]
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MR0Q,I8FM/@1@0G<4 P(C"KK<0)7M@\U(HCV2:)<LW@, *T3A#D&X0T;*^M+
M-@HS0'N&2\4^6:ZG "$A,M)$!V:(#^AB$T,"6M<!70)-X0 ,H&#AL'<(1SX4
M9N>0JREA",G1)1CHBO@0[.WREE$OL\@AE3AQ&]M="ZM9@[2 .WT!5;U)?1.I
M V-^%=5V42E./K$^_FDP22/S)= /!.71M/R !)JB]( K.D#U %YQ#%H(4W[.
MDJ.T^WMQ=H'3:P3WBN->UP]  WQ@'U">0CVPH@5ZP#>]P,G3-R,S'T=_M"
MK?='$^+S,<DA5JIC2#0S$NV,S,!2OJ.JOZ"JWB'E2DY^X+@?TFNS?>!Z0.T9
MZO>//N:7W[*4, \I6FX,"@;0MZ"YQ9!$'"@_OC#EH7K ;!E =@+%&]*30%PH
M!X2R7]@Q/L%UD7!UB9!8IBL-<(5KQ 7M*_[U>N ZKBN!2R#'O;(/D.6@/1S2
ME0<\E6Y.O3NGUO%@2=13ZM9; );JE+RF;,,S0E*R+9R] A(S.[ ,WL;6??!8
M03V@1UQ!](A,0CVI(. 1%4<TD8$D@,6 IP%S$F@HPFWJ^A9A64U<WZ4(##0A
M?'RH @-A;1>[K"5L[%!@Y=I]HFA_:GVWFOPHI6VTN'^J!<?,;!^(J&UKG7U4
M.4EQ"\^X;1/@YA;3V#8^MRJ=5VB9RJW1E\N%_:.N4<DW'-QO.'O:^ 0Z!H38
M>@?<PKC?='"V</:P]O"V\?2Q\@JR"XC$1,0[1R?:AT;9!T5%9I9TCI*IKX0L
MI0XGE%=1&+ZI.;<<W%W]PNYTW24]WZ#R=R=$^GOB@PG1"9%_0MT$0YMI6F*<
M4!CZ-U0E]/L!U5T6@<DW; )O60=8V@5:.@98.'C?L'>_X>9YPQ/ R\;3S]K%
M][:;_VV?D%L^03=</6^Z>MIX^%DZ>5C98&RL[*TM;>P<[%P\73W# OU3$\/+
M2],ZNPL')W)[Q[(ZA@I[1BL'L=4#N-+VD8RJCIB\JM#4TM"$LM"XLL"8(J^H
M3/"X)]?4Y30U)Y7>B<VK*F@8JAVB54\PRR?I)3A&Q^.EH15!X23!/3']AJV+
MC;-/:%9!V>CXO4</J*O+^.?/6HF$_,Z.S,;&_/;VBM[>^L&A02)IFLEI[AL(
MC(JWQ+A#;W[O@-M^8;8AB9CH3*?(-&O?: NW8+O :,^4+$Q2BG-Z6FIG:P>=
M7C\X&A$5[^Z$B0)Z8(2*7]ZF2D!'#;.^8M>U8$E#]8 <*@&6#"YA[P?:/&@S
M,+^^J87[++"@ZI:[[TU[#- #PV0&:UW,DNI)$A-!?(1'+,!0#P"Z+-$#0#UP
MX6<+PP:@MRV<UJ$AH2QF7/2?EWJ  /7 Z?B2(K\?ZQ:7"0[G%19;TMB'>_""
M*U+3A0:*\"U5\B.J]!R(&8(83M6C@$>4[%/ > H>6,!>U$<4]2%YZX"Z961N
M&3G*?;94RQ I6#+5K'IG7K/+$,N[9N^#EAI:65\TA&UG+'0P'M03.+4X9B.)
MVTR=:Z7.M!)8K01&-VUVY/XKXI*4+=[C(@'Z!+D.I]C'R0^QLK-IV1NL\BU!
M^QE9]QESZYBUKKE'?9B24V/OX'?#PM'"WNF6D]--)X>;SDXW75UNN;O?]O2R
MA*W=W]H[R-HGV,KO"M9^P3;^P=;^R!)Y"V#E&V3M%V3C'V(7$&H?&&$?&&T?
M% ,!5I!UA^!8QY!XQY $QY!$ (?@1(>@! #[P'BGT%2WZ$*O^%*/V!),<*:-
M:Z2EO>^-FW88C/NE'D YYR5WO:"Q?WK!UQ])#Z OL#'0 P*!H+^_?VEIZ;H>
M^-Y=_08Q'7S]]=<P6Q%,5@0+&4!]\-UWWWS[[3_\]*=_^;__E>G=\8OUI?ZQ
MD8S"DI"X=/_H]-"D@NRZSA[V_*QL9TG_^3/-6Z[(2.'OT.1[+"VLMDV2&HB2
M?:KB@*$^0O0 H/Z'5.4Q577Z$6C*4\95/-\EX& /QTC4DQYEV&@_@HR=U_4
M(@F08>D3/<!$,I>S%6=<^2E/>C(C.09Z@"4Q$$4[.,D.:]O$T>JZ[C^)J6YV
M](MU]HI.S*[J)?/HFPKRBJR+^2BS8SBDI"&\K"6IH3^[:ZQBE-)%?SC];)W)
MEW/$*K98PY;L@C&2*469WQ^*#PP(U^P#'_$ =%!'X@J.Y]10#^0TMF*" AW]
M?3)K:D9F'[*$VPR$ZEWH@1,ZS Z&Z &(BVG(:P>%OIM2(^ Z0 _,J(^X"B-=
MJ)U^+>Z>>YDW2HMN'8EM'HEK' S*K7 ,"+7".-EC''T#_./2TG+NU.:U]&6
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MH!*X, C =-I,)(,> "H)_G ]@'87'#4,4D(!LQ>@(3W_7](#T%GHF*($[=G
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M>N#\FAYX WKM:AS7*RG[)NBDD[,Z8#RQBH[DE4.+C**IZ^#0(C=!<J8^9EX
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M1\V<%X$%-= ^X(B)R\X9IM"X*WR6>)LHW<=*3%CQ(1[FC3@ ?3L%Z@'==3U
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M"W?/F\Z.,3E9@Q0J<X7/ 'H )M\\P(F/B.(3DN24 ABM%(QH<-[J(_O -3V
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MN5GX>%L&^3I'!P9EQ?G&A]@[.[IBW-,SBOKP+.**E"S209HNA$ORA5$7.O!
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M;V?ZQ)]P\O)+33U)9-T8$:WUJKZ+DS_!*58I<BU;,C,HFMG" PR$!WIG4!Z
M#(;PP'HTX-?@ 6@;=][R%GC[;!PKT!OJRWC@=]M&O6[6NTBX_#H/6")DX(6Z
MF0>L$IF^M9#H)MMX84,QC?1=H5EJSOX.VX($2,B0]:Q!]R/* R2NFLK7]<\^
M'E!_V#TU5T2_&E?9&%=V\2R1CID64Y6+1/D*3?6PZO+]L--%.]W]$!YP#4LX
M7D^YPKBGI$_-PUXK8AT-WN-;]V&[F;\"S*G0,V#TH-GH8KB40.%#. $*&/*
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M5#!=8^#O"X 'K-&JR*H9[/>"K+6_@P=*:,-!Z9D[W3QVV-F&)\37D4A,V']
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MQO[91TSE@]KK_+06\N'SETXW=[7>'.N?-])5IC:.NHNOJQRX%YE3NLLK$/#
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M\?N>03ML'7;N=PU-.%Y+&:+?4]*F8/X #?;__GUX .Z2;B,,H%4'$ .( GA
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MX.L;&T<F$\OK; /#=GOZ',HX#7B !G@ "HL'9/%#(&I)(BW" S"O&E8<0JD
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M&DL=THU?"E%[5J5H7DY&5Y0W!I!0848I&EZRO-[B6@&3PI%B+^:3:R4-= ?
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M5_  GME_1:CO44(>P,@>$X#^%JL'A/-] AU#M$(!/ !TOV01\  @ 6A(3@*
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MEW\ SQP8ACSP(4;R0;?T$0&H7O%"OV"VEZ^!C=7$#^G0)[#($B^A><DH#_0
M'I"MLN7K/,!$?K*5JX '^N<>]2C6*#!_ YX+Y)Q^E8O@Z_$ <E31<#)S'5ZS
M@2M!;.Z]M>7&1X\ >M59;#W_Y.OQ .1/:]R1E0>@BD(T![JW&S\4?@5P98KT
M="0R$%ZQX(95K)'%QN:;O")B[\FZCI3R2\>**V***XZ473I<5GNHM"ZNHCWE
M(OYT"[.4=J.:?BOS$O%P9M7QLK:6OKM]O(4^L;9/L3BD?C@POX;GJ$H9UP\7
MU-H$'=MA'[AC?Z!G;$9N%Z-S3(R;GL5,J,@<#4VX;3Q!CQ7,#]9L,K[VRW@
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MG\]O;F[F<KG_]F__]O:/XX&G3Y]^_/''0.X_?_[\V;-GGWWVV3/+XSGR "\
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M/94(U%D_PHP6J#1_IY$!RUGK"\%<;:38J!06"-K. ]O?CMHV'H#Y V#/P5L
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M!L3Z :FQ3[[(D@$(GVN\QLEH('DGYCI$I+L>/1-95%]$O]8YJ82MG>#E9&#
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M>Z)KJ+2?AYM>I(M6RZE7@N*.V;K8>87YGJFI;[\C1'F@\[X"QYG_73R 3)1
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M?1ZAUL_5^3@Z#T=KY^B,7+U.8  D !Z@_>V1]0/VR/H!U.L>.L$#UD@97S]
M\X!^$)/Z3_! %<,#R4D92XI.EXON/NQ4V:3OX0$FS[*0V7^T<V#\1.@Y/L:8
M;!-H3#0.4X*-B1?")@H'9@@*S*-7'YDV7ZA.R,G.R$HX<OQ@HZ*54 WPS)^S
MS;_@D4-"D!R: 6D?!?<FK\_5K!MM,/V23XX)>\QE?/G2[;L^Q'BA54<KZUD/
M5"*UA]='IRP'^($[R^"F%P-@'>*W!Q%\1O\ 4DK$L+R2UL-3#7)Z'9S(9:1Y
M "<B&1D300*<W]1C2C&9WH>)R/0.#!DR>J7F(8$AF@?2DM(RKUPH^\LO7J*\
M QD(4A'^X7+BG^.%WGK\*_" 3J<#'NCM[?WUKW_-O,A,TO_T77T_#@#?104(
M1;_(/'!AP-=? R%$8T#4;G[X0>_OS>LWWW[Y_>LO?X^>)4Q7^_K;W_[Z5__+
M\$CP6?>SFL:ZK;MWIB]9DK H)V7YFH*#)<<JFLOY;<UWNA2J_ANDOX,,R4'
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M)<2^HJ*T)<MF)R^,R<Q=O+YPU]FK%=);TN?&#I"S6K="YU5BD:8PI\?+[P%
M#XDLOU0Z_OVM@<\[>LFKS<+EF_;.3LU+7+EESZ7ZVCLOQ!J[U$AG/8.N1^.?
M2*<%,"#4V$&ACJ<*G3H>_T2;X $849A((50M,)K2<>J3-ULDONB]/( SRM#Y
M4I\IC&/<^T;@@=3%*^;'I6S<<[!&<>,'>$""&Y/'\^,\0/KE.%,;Q% -H[_N
M;H0'/HI/7;EU5QF;+U*3(G(8>4#[DL#I_T%ZA73$F%.0DJ@:Q_40G(5/IO<
M#^#^$0D\"E0_81$Y2I"C(G)$"L*+#!,:YWE19^ZV/< #"Y>O+JFHYSW3 @]
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MAS$8QC[6WC_:9ANA>0#CE"*H8 -.0.E,MS0?$Z4V_0;\"19IJ)/012,!;<
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M^5MGS$]*3,\]<NH"<>=!1Y]5TN,1J5X"#_#47L(PZ?>.( %=!B?*%?"63<#
M#_  )B :YX&*:!XX?@1X0 !G87K),G[&TX>%&O1'R>"0>FT"]2!;]PX>6+AZ
M;4E5$_>16JKQ$"JO2(,^ 1G>IPP/#(HP%=*4<809=";KDS*G@Y>1MDC@$TY9
M3H[IZ,.A>4"B"TFT8:DV(--ZY#J'5#<@-CK%E)^K]Y=V]JX_7Y^4O_V#N)3D
MA>F7R\[]^6<C.*O[YMN?>>!]CS]A'ICZ'^_7_>][_0<>WT_PP'>O?_\]KB*
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M9='*]7/FQ\R;-R<A-7GIELV[+UP\QY?4W'I4?[>K^M;SVCLOZN]U-7[:V_0
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M]+4/J;IG QR-7VH)26T. 6G@Z(PLE8W3YZ -28 '-EXZ'0/WI_. UB'43_)
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M^X$'"C:NK.6Q%3TFJ7D4_0/( T,_P@.,%*9%O](ZA$8O7Q8S'!*)LP_*:!C
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M&1CXX;W]"S^BSH\.$Z(-V0!3D-(D $?^YKNOOO[ZRZ^^ AY &*#+HGWS]9?
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M&* P1..7#JX2JA9T8@1PGS2Z3#& C4FC$Z3@Q"<95)K"S/( #!#"&F%AH3'
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M7E=_NK)RW;Y]J4N7KUA7>.A4^?&K5;M.G=URI/A,33/[<3??U,\S.>!<@#W
M".T P(!8BU,S K6;T/BD&I_@F?ETHRBO8'-<7-+B)2N.7JUK?*01@AZEJVN/
MIX) 'F F\J-5IH#.0<3NM0EZ+>UJVZ<Z^R.U[7X7V?%$+WRH;7J@N=SY8G]3
M^[+3=9G%%U=>J-S%%I3=>E#W3-_PG&SNMK!5 SRXU":/@/3RC&Z. 0F-"V"
M;.#&E<I,1B"M"^?XH)>VAB360,TCU>[KC3!VSHA)25R84WSR@NS&D\XNF[#+
MR=6&69H03^T58Q(1NIWKX9B9&F2X(= BF[W+,#G/=.-I!WF1PP#9C7.+ F.
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M9YI3,C;.6Y"[KK"D0GA3VF>5F3 B7*H-*M1#8')M:)P')F& Y@$O@7K=S<"
MT.@F0  9_"*M#R>,=708O9;A 5\;Z6S^],G>BQ>1!V+BEV_86MK$%O;VB2PV
M#FD36-Q\DYNK=?! J$'O8Z+!P^*#KX _^=!-&]P(&V8O1B98,5!!;/I<:/@S
M@>G/ &PDEE_(K5^T6C]OLXRU4\/MIK!,[;I$W,PKW#<S)3US[;H3=4V\IVH%
M##]8T2QR]20(3CYZXI_Q#[S#IO, 8TI3J"U2<6Q8#CQ@'A:18:$QR#,&N,80
MF@F-1PX)S,.$=51D'15C0G=X'I-8QF";H$8%IK  LU'YA 8OF( V9ILP3=>@
M:._B ?17*$Q!J8%I)\@#,O3J#$NT84*-7-=*O6PWOX)#E>@"A,:#*>%!<4([
M5)E%&IO4X.JP#=VTCX%L59)#_"['">Z=Y<<JUIRJ/R]^*'CA4("^5_MX*@];
MZ^=I_)@:0H<Q;&+2)R2QBQ=K_?"*1 _[#,"V2.T# QY0F,.M_2-*V[","C(#
MPWMX & @#+^L&-.3N[DFO\ R++6-2JE@RS.JN$665WAP=DK>HI6[SE5(B'NF
M5FU0;!KF4<,\RXC0,B(A1^7&485Q1&X:D9(C$FI("BK<[$?=:<$-VE$PP0,X
MW447ZH[<;F*3!]T4$2P)2J@@B'@\MFD7/\HF>0 5.<  J&%;4 *JSN03&#VH
M&(Q>7'M#!:3FH)0"(D*+B@H+B>A4L$SP6*32IP9&33KK%!7% [CAHV'I+1NG
M!1\:W)OTB4PS+YW-*6+T>!S)Q"*@*XGRU3!RP_49:K6,*H#!3,"T89%A1*D?
MA08CIX9J'ZD.5K5DK2N,SUF^X6AQRZV[]ZB!#IU%UF-4:*VM)I>"=,G-;KG9
M(X=[D\*X*4PTCE4%<,5_J]''N 4ZS:$;UC!8NY7A 1_R@!H#*:%C9!N<'-+#
M,P=Y5)!/!;D&'TOMXJA<0CVZUX0&-^*!#HC4T=+;SU+9^>A5& 2.E1GA -Q*
MRJ.DO K2(S>Y90:71&<'#)#I[$J34VX8$(+,[=+RNK1$MY;_K+>F\\ZABIJ,
M#5L_2LE8L"AW_>&2O>65*P^<67/DXA7Q_7:-L^'N\_S3I:N.G[@DY)^Y=C5O
MY:KXS*PU!_:>93<<OG8I;?G2N?%Q\V/C4M*REZW>LN7 B0M\:<NS)\4RP8J3
MQ=M/GZWEBJMJN9LW[8^+STY:M'+/F<OL^\];32#@^IOZ;$U:%YK&#E3 !=%O
M<O%)MP!Z.<H+S]#X>087W^ 4FMP$Y1>8@W OM&@< KU=9K37?MIS1G+GG.C.
M1?'=4G9K8?&5Y-PML^+R9L])G_MQS,<?S)H]:UYZZJ*-:W<<.'KQ>*/TI/CN
M:<G]Z[?[FI^:N=W]_!Z[4 4 YH)> GH *7H1@>0'<89>W<_O,PO4%I[:PM+8
M&K3V:IVK4N^L,CCJ27N3V<XQ]=<_?%Y<79.W=O7\V'DIZ6D;]^P]?.'*[C.E
M*W?MRRC8F+VI<.W^PP4'C^1LV;9\V^[3E^J)C@?\6P_.-+3L.7?A?#/# \ _
M;C[>'4Q?!_T>W"]A,*%Q2*P/R?L&>4^TQVM9V?D;8F(79N>M/WJMN?F1EIZB
MQI([D;B@<1-&BTXF @?7AMGA=*1J6WNOK?.YN?VQ4?;$('ANX':3 (KM)NBF
MW!4/^G8WBW-.E*\Z=^44T=[\1"/5.UHI;ZL9.HI!H"^.U@;&U=EYB 1.>.;3
MAALZ)]\P"+^7! '8T_BP:__5ZHPUFSY<D)2<GG/LU 7%S6>W>^R"7GNC=K!)
M#X.:&R^RT26EW#(**[L36)[,+M#V\S4VOJ;_78;!7=.<!@ZX4WA Q3JG4.L0
M(0_8^7H7V^2Y^EBS_4I]0O:JU-2<@T6GZA4W>;UDL\[?J!MFX3(#!_" 3.V4
M:3V$(4CSP*LI/)"ZIN!H=2/KH8H XE*YH5M )$#1[Z4] ]-X@"X52B-!I,H8
M^@U0]Z,KX'T\0/\OD[LB*&9"'S%JT4.'GM*UD$D_1^LZU_%H[=FKL2L+9BR(
M25FXL++LTI^/?O;MMZ^_?/W-;]]\\]5WK[_]F0>F/?[9>0"$_D3@$,CB7__Z
MURJ5JJZN[L&#!W_U5W_%8,"W= @^;$_?V[^=QUOG_&,/YOU,E-0WWWS]F]_\
MYK_]M__^#__P?__G__)K?VB$+Y9MW;DG,S<O86%&;'I63L&FP^57&EIO$X_[
M.(_4+.AW>OM!$ M,(RVZH>J>0'5?J,4XQC./<HU!+O9E6&P<L1[C.%T$^A!Q
M#F^JD3X9A3YWC%?!N L?:#@A>E2A9P&M[Y=@O/BX8:D_'UT3R@/OG# 1$\T/
M_;X!"5Z,<C8HUX>ENB&IZ24(:#[U.4\S4GO#N/<,*SES\]R8I06%)ZX);HE[
MK'15-;=$ZY6K G)54*8!K1G PL:,^!@WD#L8Y&/"J7TA1@UYL-2:,8!UG35^
MB187U$J1!WQM%G\KY6IZ\'3/Q4NQ.3D?QB0L6[_M7!-;T*LBK ,<RLZW>GDF
M-P>Z/)T3I+^(B8*P!$04C!F#/+V+:P"9Z!&8O835+[*&"?,(WS3&T7_&,7S!
M,WU!4%](S)_+S9\IJ#&E:5AI"$EZ[1?YK;F;=GX8EY2Z?%71]3K6(Q56*H!N
M:/S2B1$)X/H$I!AX$Y29WF%28^ M@^N@1T<G3GX;X+)$8N+%QI (UP\$>(8@
MVQ">,)8QS#$-\<@1'C7$HT)\*B2@@!#0^-00GT[B1&",4##:,.#D/49WHY,'
M X;+,ZBP@@S#Z6!->ZR*#<<V)#>.B+1AH3HH,XRVFC]KLWRF($?%NB"A0=B3
MDR$%Y5> D#+[.ANW>0  @ !)1$%4E)2OU1Q0PI]&?QL9YKZP'VVYE7>T<M7)
M^C.B1_SN085A2*P)\E4>GMHC4+F)OD%1WR"A@?$84! &#/C%@V@8DA0$6B T
M?H*N!BHW#REL(PKKL(0,,F%4(A"F4:=#&/U"&%&HH P8SQH$><TS>#A&/]\\
M+.T?;>T?%FD=YXD;RW<>FY6\+&O9KK/7)))/S)VZ8:EQA&L:9IM'>&:L.R$Q
MC(CU(R+]L$ _Q-/C=X&&D)%^N1F.(0!WT\3-Q80,,1MHN+S>2QA]<"3 8(AA
MS(%%;;_#HD)WHNX(] ],0 Z2@(5!BP!!!@4@M5%MA_@&K,')-^(KA E:#@Z-
M8"( :3",IP(N"M![HW=K]H/A[? NH[^1B5]ZCQE]4>;%=0XDQN3 J"S0HHF-
M0PJ@Z('/E;970F.(I?=QL74-R:E1..RJ)^J#=9S,C3L6Y"XM*#K2=.OF7<K:
MKB,EO7JYUJPT.60F%#I2RB-%'P6N9\ A7XOS$>@B,/E;R4"[.=1A"3/6:@DI
MS$&YR2_7>R0:%Z$&@>7B&MT<TL>F0F!<*L0Q!MDZ'P]N-%Q6/B*BP@1<+GV
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M:7*Q#;W(EC'/94M:$-^H5:PB/S!OW89\!N17='K3X-C60SM!W>&&QK*F!DD
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M.U#2ONG/@-QN8@?T.W9[9W9[WF*G:V;;,+O=-?^J=_'-E>>;+4,C&7F7>?(
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ME:J0N'5KVK_W-W_SP2<??_#;CW_YT:^!<7XN%.Z?TG^X'MA+>WL_^N@CU_C
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M-]EP>[RD>RBYH%$4E8EW#\/)@BGR"(9/%%,>SO *97@&,[V"F?(@ICR0Y1/
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MLWU#.7[AG\$WC.T=S$*?G(.9/B$ EB*4[1O&4H2Q?$(QA'P&1>A;^(1RY"$
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M($,2 81$H8 H$)*$8K)(2A;+*!(WFM2=[N;!</>"KHHC#^!Z!_%]0X7^X>*
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MM;F_4XL'.]W;LM-OVCUR>X?'[FCW^ -MG^S>8_3+4^(7+-X0G^U<R!;\0GJ
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MOCU\ZO2),]\>.O5-62CXAXD3NO3N;5B<]M[''^T[?G3_\>/[CQX_<.3$P:.
M8P>.'-M_Y/#7-?MW[?]ZUX%]>XX<WG_LV,'CQ[\^6//A9Y__\<_O>/Q!M\<;
M#%14!*N#OBU>=U5^;DE*:MKPD4/ON>^.7_W?+;?>_9M[6K5X;,"@"0OEVDW6
M9*;09"W460NTUB*-M4QM]:@9GPICT92K':4:>ZF6+=6QI0:VS BPE1FM)7IS
ML<%<G)13E)I=E):%2,DN,N44&<Q%NIQB;4X)@.QPXC98RO7F,IVY%/<2090
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MNV[]OUL[/M1V37KZ\4.'X,L/OP%U5^JYR-^2B4S2 Y))=K-;/3\P3\=BKY#
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ME)G10?KH:Z[9ZGDB6$N6-0NK%(29 <KAJ"00BJ;'T7E)]M]@0B<*)OZTCE]
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MH'BX,D("SC>&5"^J!82JDA+YU0+B:_$DQSZC27;L[3<.(4/2"^%.I-F2(#9
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MF#83/<!6:]BM6L=V/4@"QS8#-T4 G -=ALC\P+_17XC,!E R'0%GD*:_D7I
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M&5BWAH29TA%)P$T.X'9FX?W(J!X0Q  <T.-(/1!;3Y( +G0!R+ID1Z7!66&
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M7U@/$/!^+Z0RX93B$7%:59) 1S86( @0$"G%> B\T1!YO-QP4#U )8'"ZA;
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M5_%PK !D44X.@M](%-3PZ@KH\T*&@DI#?J4^%SA6$'B;@O$JD)<38H>4F@P
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M_[67KM9=E/1 @R;I <DDDTPRR?[7+5H/[#.E)K=HU_;.9K_K,_[IV6GI*J9
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MP#]Y@#C900%+C)>,-]C[Q5]#>2"T**S.>2"@D5&N3+0N@=)8C]?Y\B]0S?"
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M^O3LV:UG7\(#3VY(DJ><TXO45BGMDM-.N:Y:1E?(Z#(90H(*N<X&'KE*!PR
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ML!\ZJUV1J)RV:=_,+0?7"7)3+YJ/E5PY5O:Z7&=/+ZX24K8TRII47)E27"F
M]T1KD=!VN=&E@"H97; MTH*<7(DIEP0_39D.K<0G-#C%J&+PBMJS#<YLO3.3
M=F:7ULG-UJVYIR8^L[9'Y.BPW@-[]1HX?C3PP/%//_I3:U,SRC.&>,#3X77C
M]&.\,<;S &^\\<8;;P^FD3]2  -NM]OK97B@M?'V3Z_41N_ /-"[1^_^_?N%
M1TY<],3&9$7:!:,$?!TFK@:\V&H)78%5+46S@7&P!)82!U(K4>R$ X7Q@!,&
M7B8CN\0G*>64H8Q 2"A5*$X0A*1S@&38N5'H74IM-?# [#4;^XZ>%#EU[NJ8
M^+0S^9E4N4I3GJ&NSE1;55J[G+(S2 #>FQY=18B0 )P_/P^0]7UQ_?VN<  /
M:%'0"/'V2"H;]+5K'@B5'*VA6ZLRU2$>P*$LJ*.]4Q[0H*3^9#DM=,60HAC=
M&P\$X4T0ZGR[ EUS%*^OMH!7"C7$/, ,DA 8"/+OI2%<Q(H]F'M\Z!ZFD"YX
M +TJQ+\//)XMC8GG\0GC 7QV<@DI7F3 3P(<D<>$8Z((_Z"U#E0^K@N>:<"Y
M!2X/0/U5AIHL4UVFL4ZNLPH*3(GGJ?ASFL37J*0+NI1+>I7!>LKRD^.55Y(O
M&%:G9DW9$#MA[:XY.^,W*UX6%I3GF.JS3?7BXNK4O#)$)CHTLB345(LU55)M
MM4P'C&%7ZAT*^%VCK%+@%DS:6&@#R%FN \9&@CL5T3:QP2XSV)1Z:Z[>GD,[
M5'J$(E)C]>;L$Q.>7MTC(@IXH&?O0>-'/WPBY\1GGWS6UMS:X?'B>"$\1,#S
M ,=X'N"--]YXX^W!-)1$! <+^7@ &?# &U=JHG=L!A[H[>.!28N>V)2B%%PT
M29!_[$)";K=%K*\4TR +N.!2SJJWL*% <LI1-RUVGI!CA^7SI;"3YY)2-40R
MM&Z 3P@&X!2X"CC0-< #^[-?GK5V8Y\QCT1,F_ML;'SJV?P,7;E2"TA0G:%!
M/*! SA"'!_1V$8T"A]CQ :Q.EL%BA7_J#T;_9WG @!;,8KQ/W.L<S -XD:_O
MA0=DG4P49B2C:T./[T0<'D!..>4@\?IL]WG@4PMPCKDPP%57/-"5NN*!('%K
MXC\^D >PNT^Z\ /+\?$ =TB!W""'!RSH1-I!Q@> "N1=#(DP]3%PYP^X5,;:
M;'-]IK%67%PA+"B1:ZMDFDJIID)27):69TJ]:$@^1T?GG'_JH'C2VMV//!_]
M5+Q\>];9^'.T1%,-OR\ SVD%Y<EYI4*U!54>:HA2<C%9N3#TVF!#AF" 10(B
MQ ,*S ,R/(,<O?\&J)Y=H;?E&!PY>H?2X%26N,3&ZDW9)\8_O:9[Q.BPW@-Z
M]!XX;@SF@8\_;6MJ 1[H8'@ C1D&>[0_8N-Y@#?>>..-MP?3OC,/B'0U(MHI
MTEM%^BHLJUCODNA1&#KC"[+A(DPR&>2L(&&7G=FF'$%=]:QD>#JO"'A 7R,W
MU"JTU3'9+\TD/#!][JK8^)2S^4I=N>*[\$#PM5CQ/$#$A/&@IL-1^R1P']T%
M$N-D_^MX(."4N_& KZK<4S@\P$XYZ(H'Y/?/ S(T,E:CU+MD6EMZ7KE"8SUJ
MKI>I+4GG](=>*MZ;<V%#^O$5^R7SMQR>_.S.2:MW/1DG/7Q&(Z,L"@/@-+RN
MMC1-57)A.0C/EL83)/#49!1Q!]+8Q1J\$2PX 'ZA +]=@-/PDL-O:+K!F6YT
MB8SP(!Q9!A=(:70J2EQ"8_7&G)/C5JWM/A+Q0#<?#Z!XH<;F#K>'YX%.C><!
MWGCCC3?>'DS[IWG )M)78]E8'@@-%Y%2  ,HF"=(B >ZZJU'(PF(!\3Z&IFA
M5A[* Z\B'I!KRY6::I7&JN1Y((0$OCL/D,>']I )ULP4B/1BJ"W<",ZSR:DA
MSP-<'E"@O+=V47&5,+\"36LIMNY2G7L\5C1_1]*"'<ESMAQY=/W!>9OCENU)
M>2XE>__)?'%QA<KH5)I<4H,CG;8)M)94356:U@*OKE2/RT?OI$NB=8HU#J':
M!A(!%> DN5S! ?#;A,/#:L6Z.B%=EV:H$1AKA<8:B=Z58:C---0H@ =*>1[X
MCL;S &^\\<8;;P^F,7^E  70$@0DQ5!'<Q/P0&T,\ #)+X3F$P,// D\@.</
M6,%#%2.1F0!H]3&4?04\LT 8\+N#X'5I;61D $VX!#P@HP3,]%]G9P(/$LIW
MB<"_ 2305,7FO#QSW29_O-"YP@Q]I4Q;(5=7*;16-$N!*<V7<X;IV.;.)PZ:
M/,!FZ$=?\0$H2,8_?X")2N_:,0WL)B="/&"J59G1_ $IX0$-GC] L3P [CN:
M9\S,)^Z"!YA.>N9"H>W#O1$D-G-HL*-_KV); _F4<@08-7)45;1\@5AK%ZJM
M:875@B)PEVW(0\4+&DA\E<%3S F6L %CWXT'4*LR+>\[D6F9+LKQ'\;R -E@
M]X>*PPQ<L3P@YL0+=3I_@"NQ <$ '(.2;J$;!XAU((=>4P4<&_=2\<(=B</F
M/#/TT17CG]HR:^/^Q=$I:U,RHW-?2WM-+R^N5&@M<K24 ;RN0+#PSCNE0)(@
MO& <61T"6EA,(1B ]D\KL@B*H:IV]+JB&?!^H5@XND9"UXCI6OC%$=(N(:H,
M_%:Z,HVU:#T0HTM97BLV6S;GG)SPS!HRG[AGKT$31C]\*O?DYQ]_BGC X\4D
MP/- L/$\P!MOO/'&VP-M\(>JS>-U Q!XVCO:FYIN__1J7>R.+4/[]^[1XZ&>
M_?KV"X]X>,'RC<D*P463#*6?Q^OU!GIC4E^_<B?N()Z-JC2B+)S8M0KVJ!CY
M?7H'"INF$ \(T86<,G4EX8'>49.&/_+HRMT'D\_D9= 5P /P(\0#(=[AM_)
MX*"!"W>R.KCSB1F1U)-<[]PG-,66[4WWB?  R4LC]8T/!/$ [G?'^4;Q[%76
M?PTLW-> W$9&3>>K20 /^+>Y*RK<?;Y$5Y+I@ ?P\(*A#CYQXQ!GU)I>C!9Z
M(YXHIP%1JV(>J,4N;,@+X'M#.A'G9<#M"?=H$[$^/=>S]VT$E8!FI;/827B
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MJU!K2]<Z0"+PVXK+H[->G+%F0Z\HQ -+-N\]<NJU#%U%* \0$0_>IZ#,FR@
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M\<8;;[P]T.;C@39/J[?#T]+:^)^_^&E<].YA_?L\]%!8]]Z]>@\>%C%U#O!
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M\O#<U=%).=EG#2<**C(+RL3%94E4>1P-JDR@+0*4JJO3I_!/\0"92"/7.96
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MF:!CT)VB)2,Z:R7LS8LH.YY][G]G@"'%@(+&>J7ILHHC0$3\SN X(E\A@3R
M"D337:AJ*%RDK\7S!WXJ+WU#IJ[8+%",GK\H+#Q\S-P%&U.DJ1?T@"("K4-(
M.4BN7H7!J3(X,M$G3JM*\@N%/D'.HPP2"PGH;8'VT<-7JU0'50+2=BDH!Y"
M2E>NI"N51A?P@ 1XX%C1HUOBPF<O#1LT;$149/SA_;_[#?  ^)9D0BF*!N?S
M"P79#Y$'O+Z!@O???__"A?,"@:#&5=_<#(^P'5S\EO:6K__^Y]_^X:U?O_7V
M'Z]_]-ZGG[Q]_=K;'UQ[]Z,/__#1A^]\<.V=:]=^?_W:[S]\[_<?OO_[ZQ]@
M7?_]]8_^@/7^M>O7_/K@_?>OO??>^^^^^]X?WGWO]W]\'PLVWOW]NW]XY]W?
MO_WN[W_WQS^\^<<_@GY']-\^O??N6^_] >N_WWK__7<^@*M\2/3.!]??_N"#
MMZ]=(WH'Z]WWD-YY[]J;[U_[]7OO__;]:V^_?_WM=Z^]\]\?_/J=W__LOW[U
M]A__^\]__UL;7D:['<\H8)H7JRL+;LT0"SZA:PL^\__<[J4^9'\['B(@XPQD
MP &<_M_][G=965E[]^[5:K5D?(",/Y#Q@:X*Y(TWWGX4%L@#G_[IXZQL5=2X
MJ,$1X8^O69.8D:.ZI)47E @+*]&<2UVMA,)I=E"_*7:.=5:9'F23Z5E?C0EZ
M8;P6CD-#W!>5N2Z[](K*4 ,8D)97EG3>G'JI5*ZS9QAK4_-*MRM?61$GF[LK
M9=JFP_/V")X7'-V;\=)>^;%=BMS])TZG7BB6%AF4NK(,'P^(*&O@^@/WP0-,
M< 6.%PI<HP!%DOA2BSK$6O^L7S1#FCC9H>YF%Y+@II RG?UL4! B!"X[$9&=
M))0HU!L.<,%#%.P^^IQ(Z8^>!S@.-&P# #!S3KCO#'IA4)HI1(9$OA?&%3 6
MQ"Z8P*QC;9?I &4M<J!?0UV:\2>IYI_)2GXB+BK=D"H;]=C"L.'A8^<OVI@J
M23FO$VHL:1J[0&L7(21PR-%R?C8E;5.@]8-1Q8)^7[CRO8%([#.%6U8::]#P
M IJ>#F6B=<>X/*#263/U%1F&*K1XG/F*D*[;EELP:].AX;,6APT8 CR0F'#P
MK3?_LZ/#[6U'O:X\#W1J/T0>8,<'KE^_GI^?)Y%(:FLO-[>XV]'#;/-V>*Y]
M_,'YHD*1*DMUZN63>?DYK[Z6=>;5G+/G,EX^HWCQ)?G)%Q6@%T]BP<9+BE,O
M*TZ](C]U1GGJ3-;Q5W*.(>4>?R7W!%+.\9=S8.?QTSDGSF"=SC[Q<N:QD\J<
M8[+LH^*<HZ+<8R QZ.@Q\;'C1)+CQZ0G0,<E\/7H"<FQ4Y+C+TJ.OP0;XJ,G
M14=/"'-/"'..IV<?3<O,255E"Q0Y D5NBB([09EU1)Z1*,](462F2E1B98XD
M,UN1>U1K,OWQ^O56MQMN'4<B=1*GA/7/-OB_M;&O'!E#8+O_X?/--]_,S,R,
MB8G1Z_4DWRCA 8(-P07QQAMO/RKC\ #\R_'QQ]=5&8I18T<A'EB[-BG[:%8A
MK5*7B]75*/L^@0'<90Y>,DZ,"/YQE4A;#1LD3R(3_8R<F("YF(Q#K'=FEM3G
ME%Y1ZEV$!Y(OE*075$@UUJ0+YDWR5Y;%"A;L2EP<*UI^6+5)<3;QK$Y1:,XJ
M-JN*]$J-,4-7FJ$K4]'E+ ^@J"2\+#%X=43WS@/L\F2^("*TS6XP2X^AVV17
M#4-K!< &N9<@1[9S82</(826P2%6[*"!Q+<.L0BW$A-9Y)M@P/6&>1Y@COD.
M/(": B</I5'J*N:=81:TKD$Q9BB%+@H>XRQ@YWLK.*W')3ITU\BM!X?>JM [
M)<9Z@>F-M))?2,VO"_/-+R2)(^?,"QLV?.S\Q1M2)<FO40)U=:K:EJ:Q";6H
M>C*=34[A6",44\<NU1SR!+%PI%/ N@3P>@ )9)5>SBZ[DF&J@]N7T#:)CP=D
M%(H7RJ"MV8:J3&.UW."4F^K3M#6;L_)F;CPX?.;BL/Z#PZ-&)B7&O?6[_VIO
M;_5X6_%\4)X'.K$?$ ^TX46CV/$!L \__+"PL%"E4M5?N=K4TH8/1CE$__.W
MOSZ2+ERX:MV3FW=M24C=<"CQN7UQ:Z,//K,KYJEMNT$KM^]9N6,7%FSL7;%]
M[XIMT4]MCUVQ+7;5YIC5FZ*1-L>LV1+[W+;]+^P\N&'WD8U[$C;N2<2?\1OV
M'%Z_Z\"Z';&KMT4_LR/ZZ9T^[8J&2Q"MVAV]:@_6[IB5.Z-7[HAY>N>^IW?N
M7XFN$O/DUN@GMNQ=MG'7DO7;%SZ_9>':S8M6;UNT>OO\U5L?6[-ISNKU\U>O
M7[)FX])5+SRQ>OWR9]>N7/>"4)7QQB]_>:NQ"<U(0%.F/62@(% ($KBM]V,S
M]I4C+PE\DN6'61Z(C8TU& R-C8T=G/$!G@=XX^W';EWQ0"3B@>2<8]F%^DQM
MI01E"L(+,'%X  <Z@W]<)=* 2$XA+.RRA/HWX.R"UY)AK@,D4-!.*),L2RRG
M'**BZIW9YQ?%I,_9&O?$ ?$6Y=D#K]"I^172XHH,=5FNIC1+8U)I39ET629=
MKJ(K5'254F]!/* +Y %P[_2HK_?^>8#  .(!'!"%]B >T/AY0(A7JOH./("1
M(-B/)SP@8U<EP^WFYP$C2D 4Y UWP@-DI (KU(E$^GYY@'NYKGF !#O=:Q,%
M"IW>E7S%WBL/<*OJ:PH) @ _#+ \($:30[@3QSEPR.6!@"JA(!^FCQ_S0+H9
M\T#)Z^GYIN>31!&SYZ+Q@06+-Z9*D\_KTM665+55H$4Q2^@50HZ[1:JIEI!!
MIY#?%ZY8'F#'!^ -49D1#X  #&0L#]!V''KG(CR08ZS.-%J@>C)C?8K&N2GS
MTLR-!X;.6!36;U!X5&1R4MP[;_T*>,#M:>%YH"O[%_- .^[B;><L0T:^DA^]
M__[[!04%V=G95W_R1F-+*SG#ZW'_Y!>_B$Y,6;YYU^9D2<+Q,X>/OA*C/+9+
MG+E=J-J:KMPNS-@MR?S_[)T'>!37N?>Q \9@TXM$,1T;,+U7TTR7Z A1) $2
MJ&TOLWU7#21Z$2I;9V9[[[NJ&!RGN,1.;,<WR1=_+G&+<Q,G<<"F"7WOF5DM
MBP2.R\V-_67?Y_\,,V=GS\S.K);_;TYY]PBE>X2R/4+Y'H%B-T^1P57L G$4
MNUF*3$IHA:W<QRW)$58<%%7EBD_FBD[FBH_GHO7*7/'1@Z+R@Z*R''%9MJ2K
M2K.E)=E2%258+\N65N3(CN7(*G,DE5FB8_NPBCW"LMT\5097N9,MW\F29S!4
MNQBE.UBJ[6S%=I9D-UMR@*?(XRH.%/,W[-R]:/7:0\6L0&/SIY_][=I--!3A
M-AKN<H-6VQTD:KSR+:H#W']ZQ+\VMZGTP_#-@>4KK[PBD\GH?&2)_842AQUW
MKB@9R4C&?T@D\ "LO?WV_Y%(L-01*?U3!B_=L+Y(42JOQ>5H!B'PK$%> @]0
M-L4G,'@%N$=@\%#KG4U,)T/#I_RNB.KD(#&&A6CB=K^4#$N($/.B+8U?.2NS
M>$D.9Y?D9,$Y$T\;P PAJ<&G,KC+#(Y2PJ$D'0K"+B,<$MPAQITBW(T17@$1
MH/(E=XB,T,G(J'QD_X0'OEKP25':6BU*6QOG :X6I5CNY.R_G:C^'F$QE10Y
M3AH8?7$H&$ATO=@#>*#K=>ZL_PD>H!^'QUSU_>I/Y(%.!KUK;=].#V* 3H>[
MRP/WG@V-(S   (  241!5"<" ZH>JGT ,4!GP1WO\AV@=&]_H=B-HUDN+"*#
M$C+& T+@ ;I]P':)6V])+Q:DS)C3;?"04?,6;F5AS L$?)%8N@ 'D2'U<9!Q
M]R$D@#^BKA?V7M$\0+6\Q2ZXB!JDC@:?F*-T:FW468CJN2<F(F(\(C8$9:1?
M:?(HS#Z)*2PT-A1K@UL4%Z=L/M!WTMQNCSX^:-A01E'>&[]\"4P!-8-CD@?N
M']]K'GCKK;>JJZNE,EG+E2M?W+H%+]!W[_(+/SW XNUD"H6UQ EW8Z4]+-,[
M1/46J<XN-SB5A+O$Z"XQ.4M-KE*3I]3H*2$\2H-'IG?+="ZIUBW5>N(2:]VB
M>H>PUH'5N"@YL1H[5F,3U=DD:KM4 [))--:XQ#%9Q%JS6&NB9)%H;%*M RJ7
MZ=PRK4>B=HOJG,):N^"BE9)%>-$FKG%+:OTBM5>L<8OK[2J-[23IK;.&SQML
M#)$\+6,? Y,T7/GQG_]Q[8O;MT$WVV[=:;].J^T.Z,L[[2 TSCCQO[7_S(A_
M;9(\D(QD).-KQ?\6#R!/0\TX!%Y-0DVK(M2#XP_*S0W  P<J-4MRL=E[&!F2
M$YC&+35&4,=]K5^B1SQ0CCO+2$>)$9# J2!=4M*9Y %:72]R9R5Y@-+_3SR
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M7WSY95O;ERCC<5<>N)[D@7;JBQ'_VB1Y(!G)2,;7BOORP'"*!S9NH'B H'C
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M.,ORBM;D%6W,8VP^S,[DR/*/G>.K21'NP QV3&<7Z]U"W ^V&QP2RKZD1SR
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MH((C4-4Y7*1UEIH#"J-7HG.*M'9!O9EQ5E=X6L.^0 C5#J"",EM498W I\,
M?G#J!G5QV%]7U!VA$F\E\$"LBQ<U9OK>]H%$85UK^W9*8(!$\7$_A_1R*!Y
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MC'*(")ML!/&(!K[6NT]V<M*JK3U2Q@V>.'WU_B.L<VK@ 8[6RM+ H3VH,8%
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M//GDDX ?4/_KK[^^9LV:;MVZ+5FR!,B$?F!/CQ_(S\]7*I4OO_PR_5Y "X%
M (> V@ MH%HP[NO7KP?\Z-NW+RS!ZP\<.!!((-Y]"$X -0U=N?+FFV\"_"Q8
ML" U-14.!" !I!%/=Y#( ^7EY0 ,!H,AWE\HD0<2KD0RDI&,_["XMWW@PX\_
MDI>J!HP<UGO<J)GIF_8IE!ANXI+. MQ9: X4F()%1A_#Z&*:["RCA4("&\\
MMB\DU#2+-)<H/2?24H(5S25,W2Q4-]'"U$TBV$W;(M&U2K0M,@TE;8M<URK3
MM<JUK5)MLP!OX.)1+MX$$A"-0K5WO^3$Y)7;'DD=3_' 8>;9>C'I!!Y@:FP<
MO1OUV:!X0*3S2[5^J2X@T0=1^P#JQ]\5!F*3_W32/7;_N^N>]H$@!V0,WLL#
MX%8]8M)/S^K#OFC./V7(/X$7'">+3I#9\O-+]A:,7+!ZXHI-SQYD+,[,6WV
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M,WH.(3,%):8@9@X*K$&^#0FSAOXG>*"54E<8H'F@18J&#C^(!Z@$9-^&!]#
MB9LW;[W[[OMG3I];O?+9I4O 3B]=N'#AHD6+%G<$K$,)F.99LV:!_]9H-%TG
MU8E?9'KSG7?>D4JE*U>N7+=NW<F3)__XQS^"H=?I=&EI:5 "1G_CQHV5E95@
MXH$<P)JO7KT::H8E./NWWGH+ZGGUU5</'3HT??KT[.SLAH8&.MT8W#[@@;U[
M]V9E946CT4@D<OCPX6W;MCD<#M@!>&#BQ(E3ITX%=-F_?_^*%2O@LRRGXIEG
MGH$/ D "2+-Y\V9@$C@WF4QFM5J]7F]961F\!!\30.CX\>-P2NU=> #V2?)
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M>I<(]TH(-#H90R,E$I  X1;B 2 !^F$\S0,T$M =AR3F,$;ZA82/;X!7T0G
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M$5", ""UR3#(>C])11J_/\ ^C40%M %_82+5$HC+&1>4-BC21_4 9&H)4(C
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MP!LC3+<1HZ&I$1J:H;Y8NT9.9BW^Y7^2Q7VXQ.)/^C[&]M"(BY$UXD)I4(D
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M&( ,C$@2R+0^I ?V%K[[[)(578>,2AT^?N;R#=L/G:2T=M@?8.SY:@=/XQ9
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MD,P\402EA@"-LUYRJ'^[B+^%*-K.H;10'1E4 ?,8>B":%#5NM&0FT?Q+#3B
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M0^8PT@,2\.K^1>D!)V+_9  DTN"GI =P> "(&5.5 K@U!!"C88 >*+4_@7H
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MEX^L75AWI/D\=?\)1?MAR@0=3HF)4%Q,P\7 %ZHR^94]/EC>1T@ $70$LX;
M-5)\F$3N'X@4@I0M!!YQSH^Q/H+QHF9Y00 2E-E/F5VPPY=5T#-V/>.$GIMV
M4;2'8GP:+D )0<(>QNU1W!['; G,%L<=$;4S<.ZKA^L/GJH85U==-6?[P4;E
M'1-I\\EL+CGGIIA((0\T"<$SM/T,S3>YO.W!R$E6.'2W^]P#V!! \9A5/>;(
MQT[JG@>_[3IK>+SZN&SAD3/UFD[%(UIK<>+=@N(AW7[/K'S$4"8[V*)'TEG
MF7LHLX<P>0BS#[,$P.]3;0T#J6#R= AU=O/+NWV*;J^RVR-*U>/!S#Z=$-$+
M<8J-86RDI<>QE>B8\OF.XNF?#!HVJJ9ZAE:F^_7_#'G@U9OG+]Y\^U+D@5<2
M#^2$Q -22"&%%%)\Z)$[/_"GO_XUUM9:7#2\>-R8Y5LW-QJ-UVRN2ZZ0QA:B
M'#&5$%'P8:405-F H7=B-@<N. G> ZP8SD<P(0JDYB-*+JQDPW(FJ$!2<B$H
M%BBL%F*D(ZEQ)2E7G'1$<+ KSJ]@?$K6IQ8"N VXO0!E]RM=?IG;W^[PJ#G/
MV8MWYV_</WSLM+%U"S:=:FR\_5!IM<MH0!H^W!;)SB>6>"!;_S)Y !/Z#*ZO
M.SQ?MS[QK#@A'SZM[F>CBF;,KSW4=(ZXUT,P(35TKF+I4K1/.J2D@S*3K^F!
M_?P]H?F14V[V X$GX.6YN_R%^VSC?5K4A0?6"P_IYD=LZV.NO9N7/>9E#VWM
M]^WM=VWM=SG%/5KUR((]-F-/+.K'5M5C!KASQ6->_IAK>\@V/6 ;'W"-#X7&
M!_;&!\[&AX[&1_S9!^9]ALN+=S:45,X</VEQ_0DE_H#7.L(JP:>DO9J!>*!1
M")WAG"<X[JS7(WOZM"D6.^/PMCD"2L&O%ER4W=-ACQJM<<5MYT'\]K(3;2L:
M6X]>O87W\%JSD^IQ$#UVU4,6@('.ZM:9G;H>AZ['J>UQ43UNRN0%5*.Q!C6
M@AC8B0^*CI#BBJ">@+K;CW7[\&XOWNW!>R \4!9?IQ#NM"=T0B]E2[2;W=L!
M#VS</G+*[$%#RB94U^IDNC]"// :\,#K;U^^EGA@@)!X0 HII)!"B@\]LG@
M_&?KS_[T3W%<732J9'A5Y>+-6\[H.KLXC\$6QO@0[HRK'%&5,ZQVA3"W'W=Y
M<:>/= 0U]BCE2%".).GL!2+L2=R6 ,($M)(!5G*,I03<-O#<CEX*O,T1QP1
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MHDV[I56_M=FPI5G_>1NU7JY>>N;<U$\_+RJ?4C5VSO;Z\ZI;9D+PM3M\,F>
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MO$_%H?I":1Z@S$&J)]@_/_!#>0#IGY4'4KOZ0_, 7$24QP-B$@7!P*F/O$'
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M$)7' RD?_'W*V'31>&4+>N@LPRVN]Q#5;\%_$ \ 92XAFP?R[M"SL [2]_
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MYDDL9YGF@0&5PP-:VG.ZXQK,)ZZ<4%PU9<G6^K.=UW56AY[YR7A 7&KRHWD
M+NE1%?" UI;0"''Q#3]*;^,!=!JP\T"6'<]2G,BT5B@8)9$'\J2VP%2$?U8>
M$%<<0>]N]6/ >?=X%-TN>;=387(K+1ZER:/L<??+Y%:;O;C%AUN!!0^DQ$"!
M[>"#LL<.^1.7LL>C-H/W!$A %["K70C6XD1?D_A-X>#H0IRR)S5 P#HS$0)<
MIAGL! JW #X)8G!>"^8&$'20!,\!#W2[%8\<RL=.5;=+W>/!+%X<UK,*8$P
M+HI#:]6HM_# (97( V,G+5ZV7Z&0/WJDYFP*P:7@W JK&V>">B%I$)[JV*2&
M@=5=,T/77_FJ<)R1"GD EA)Z"P\8N82!3QB<O4;( _[ZKBLS=]67SIXSJ'C4
M>(D'WB\D'I!""BFDD.)##\@#&29X]9L__Q.-#B\?6UY>4[UZ\[9&JN.*U7-9
M2&B9!,GU$5P_#\#U0K"481AVO )B0I@UJ#3YY&CY-?#9,.$2YM1F"1:TB0+7
M F$@AP>RYP=RU@ME\T#1N,D+-N\ZW7$5\@#GT;$^+>"! NK(-U)I TJAU?RP
M)BD7PYD(P !T#SB P1O5X4*/]6ZA^D+]=^)1@7]@IOWPUC)B(303DN(!/%5J
M$X[2#]1 CC#ML]&5PJ/#2Q-09G"^(/R('RD<)='T%VZ$"XUR!_!=>C</H-SN
M%)#D9EP03)  +M_L59G<[8]LK0\%N<F%T<CT ^N?$>U/]]\-]2>9"% D&P0&
M767V9D@ _')T0DQG0T(P)@I^Z3:XFDCO[#.Z^HR.7J.0T(&?(A.FZ! 0^!EK
MX2\SJA'@HQ8M9B/9$&'QXR8?8?93=$#+AG1"U.!(Z!P : $  QX($1PJ4RMF
M7P@QF3W6Q(<!#U"I]4(K!Y6.G;1HV3Z90O;@H9KC%8)3R;G55J^&C1KM3PVV
MIQ27))F<KG I'AAHJ$4"R7!.1A  ( ^(=6-3Q4:UL/- O(-/=MAZC>X^HZ]/
M#7B@\W+=CCVE=9\,&E$R85*MCNCXX__CC]'_#[Q\]?J[5V^>OWKSZM6;?#?[
MKSPD'I!""BFDD.+##_3?JU?HR8M?_=%_4*K;R\>6E5>/6[QVW>$F&7FGN],:
MT#$QBDD2;"_.)D@FKJ5C.FM49PUKF! A9@\#>T?#6[; WBE[X#U=P@K,>DC#
M]@O=N(5V'^8)Y*019]<72N<3"W&=+:YG?6>[;LS?NFM8U:0159/G;]YYLN.J
MGG4:[7Z#$-3!V\#Y/)"QMKFF&67W H\(/#H7(X&!$W-8+2&"_F%M!]**B UB
MTVUB \"YXE:?VN)365/UA<!II!I[<1 8< 8.U( BH+-,Y6%G">XD?0EIYYWK
M%)%QA^5]Q-F/'*%#9]ULSE(:#^"89'V$@E,9<#Y!S$#(]Z,#:B >2!TW?;:H
M/1G"C_3E(.H(8E:_FO8!*<QN()75AX%AA,W+0FD%<0;>C >< "4^9P)HHQ^\
M7PEXP +^!,8J3$(W#Q@2-C> 8\["UEWBA:16*(EI!CQPS_"[ S]7S.)3F[Q
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ML\8:%GF @/6%4CR@%WD E0\BV2 )D<!/6'W %L/;NO#F/;RSFQ'8 N_U(C8
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M+NOJ_^(H<;V0U8]; UA^_D#Z5/,''*6G?Q\/[!1Y8'3-0#R0$'D 9B;\ 7B
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MW ^SA+E01EHAHK?%  !TNGH[77T9&9U)G0V8\HB&#6<+SB?P$520%.PG3/'
MW"1U0H+J<1TENV9OW#9TW)2*Z?._.'Y!?;>G2_!I&3?%^C1<4 /+Q<!%'1@7
M$45D+'L!#$!QJ#J[*%2R'3RA"@JZ0XE+30JW][^AO[4"*F$)*PCE-0T0EZTK
M+0'4 !CVW(5]=M$3E15X7.C[,T+.'MWOAS  >SGG.-JL_(%,Z9O,???L*J+9
M$DTY=.'ICX@OH5,?Z/VB!G2B&16^OU X[/  #X2CUFS IY+I7(+TH44D*-0
M/)":2X&LE9+8.PRV=,@"PM3I97()<B6^ ?::8,1DCS#%0)%TB #G"89H !X8
M2&D>P&')4?&KAP6L<"&N="1DS@1ABZONVW9=P*MF+_NHO&;JXM7[V]5X-^0!
ME<V.<>X.>[Q+Z--8HH0YBM-QG 6*901+OL)3!6/8+PQ^[^#JHF(9I0(>B%*"
M6"HJ08FM)_BXCH_IA;B>A>5]]:[>BZ%?Z-VQO?J+X]=L^&ALS4<C1Q>/K*B;
M6G?K\HW?_=EO7GSSS9M7+^!Z(=A^0(*!G)!X0 HII)!"B@\]( ^\>O[B.?@O
MUK???=L;B^W?L:N\J'3XL-)AQ6.&CYXP9<F&/6TZY2,';"X&7"F3P*U)TMI'
M6?NT- "#J)8):%F_EH76'-W=1_?+^;#8O,D(E<Q(;P<6/ )7;]-!C2@&=H."
M&<;P>5#'A[0V:!;ABO,>G_P.<Z!=6_?IYJ%C)X^>,F]3PUGEC<>=M$=G=9.T
MAV+\&MB/%CI4C(^H^10/I$H&%<+  (I3T/3#^C#]RBY6\WY"Y "]9IY[1CP0
M ;88S@^8? HSD@GU1495\Y$M3JG_4WS:Q4+#!QD&WOY''EV\N9[9>>H$H'?,
MLL)9YX^G>2!C9[$\'LC^2%KY#CC/#1=<?J'@K A:BT] JPI[@8%'N!'P #3Q
MXD[ZKSU+.4B ,H;3ZC^'U&/>%$=J9%"U'[@E/43]2 ";%L,.8AI1#!1%APG4
M< !VE.N'@=QF<'DC@'PYQD=Q\9M"?(CS,:4-MB0#/( ]L.]N)*IG+?MH5/6T
M1:L/ !YX8B$=+H7-KF:=!B'2R2>TYBAEBI'6)$XG,"8F"O( &R? $R :/:8$
MAA1\+_"OD ? J"+!7QV<'8*_=E*(DT(2"%(!;/D7U0DQ+>)SG2MY,?1S@RNZ
M7W]IXIJ-'U6._UG)Z*+2,7739W]Y_?9?_>ZWKYY_\^;U<X $8F*Q%-DA\8 4
M4D@AA10?>J1XX 7D@6^_[8W&]FW=63ZL9/C@DF'#1P\?53-UT;KZ%HWJ@0![
MQ/)1R -T+T$_):W/-/13+1/7L2$]&]"Q01T;!H*M7I%T7$3/ X5U2'HDV#&
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M\NJJAG-SMC8L/]2X2]EU]MH3V1VSXO9#[*N'QD?6*Q;G5=9[F?5U6CUZLQO
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M/XZC60+P<9$'(!*DJ0 FZ8KV]P^@?!Z 9_4OB@?$L\H>3%$B%?Q$/ !+6@W
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M2TIJ%Y74+BR;N;!B]I*J)>OF[3E63W:U/: IUD_R 8P#"A$#\0"\V?_#>6!
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M8/B]\@!J$L[5 >_ED >\X'-\4 +E^60*=]X+3A#.Q,#I1K HJ@&FDT&AT0
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MJ-+_-^(!6+H4+VAE@0L#P[MC1[S!#F_4(OU,OUY*=/J\RQ^>*4?W#K[_4_
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M!.1HX;#D,E5Q0?N(7:_0+@N,IK"U*1]F..SAB^<!?.*"N>:PP3@K1GB)LO"
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MBP$I@0 &L%&2BY%</P6$JHXB-PQ%,) '<$I)PF3STT:%YE50GP<B <I%P52
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ML['+T72=>;M!6;U@Q=BBJC%CB\<"'A#G$P\O1!X00PPQQ!#C!8R4?Z? _Y[
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M54*[B7>2:,]S-#0/H$_P/%J8%Y3& P"$ )R K\"JG?J>05W/(#BCY_! <BC
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ME&G-,K5!7&T0J<UBPBZA8+X0FP?$=%BBA_E"4L@#<$HQRJ'W(A[P0\?\TWD
MYOED\P#PUE*X/_/H';M\  DEU8[B\S; !O!P/3#HWE(TA0"TCZ;VYN&!]IRE
M+).*$WCP>7&!K:S\?KB^*AL&P#]!(P!"X,-IG .#+QM/A!"AB<49+?P="/"
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M@:X][KZKQ[WW])PQ>8;Z[/EKWW_7UM8"E&R-P\E$F4L.<,'Q !=<<,$%%_^
MD?4]U8KP +QH:&@@"-W,63.[=;MGT:*%-KOMRI7OX_$X^&TBD6AL;/SLBZ]"
ME]XM?_/$JLT[)C^QL.?8*=T>F#1XYIS)2YZ?_]K>C66'A.?T,IV=!U<<LD-3
M!6PH'109(U)SG<Q:*S$&!138Z),:X(-2O/;E[I/4R\JC"_=(G]A2NKQ8L?WP
M*8G6(-4:A6<)\1FBK,;XNLYV0&LIKS$HM:8*H[/,YI&9W6*#4ZIW(QZ XP,B
M"DI"A6146$%'@.1T&/" &!:11;GRR#'C#/X?%,,#E!]C 'R:CFO?IAZK(^L)
MLY[2)=CX6@=/8^=K[24UU@)8.M<N@^M[1N 008T#V%.<I0->[SUC+CIOP_,-
M(!(@#&#.R]0Z8,1:Y!2J_0K10JA8"&_P4=FF%O. F(*C'.#B4RMIPK)K^-1,
MUE .#S"F.5=HW"/M^]/;TV=,7RKS3]2-[$MB UC^6\L<%8&-$UZ9(5AFJ2NW
M75"::\%G!A(@3,=R@3Y$P-!.-?!^X9!+=N)0JEJ<Y^;G2^!3\]5.R /5=O"Z
M5.,J/&L%EET&00Z@'> !BT#G5(++,P*R]10"V"-]>ZC +C6P['XQ7:LR7RPS
MU<.$(MI36FW:=4RS5GGDJ:V\2<^^,G/U:\^7J/8>.BL[8U#6V.4:CU3C$6G0
MC'/*5Z+W%5'>$L+/TP8%VI! R]21**UQ%YZW%U1;"]6V$L(AT'LDIJ#4'!(;
M_4*]%_Q39/!)3 &9)22WA97V"/@I,GC%!N\^5_TA9]UKRL-C'YK?]=X!MW7M
MT:U;KYX]^LZ8/+/F;/75*Y=;6Z/)UFB\-99H:P-*LO\?T>F#XP$NN."""R[^
M 2/K>ZHUQ0/-S<UFLWG.G#F]>O5:MFR9R^6Z<N5*-!IM:FH",-#2TA)/)+]O
MN/[[/_^GR>,3E.];N.JE$=-F=1MZ?[<18P;/>&3VLVM>Y,GWO'$6+IJNMLM(
M#S"= GV(KP\)#!$A\$R&D% ?Y-$!/K!<M$]I#BM,@3VGB>=$57.W%#ZUK>0E
MV;ZBD^<4.EJIHQ751(6&/D1:#A.6_>=IU3E*I367&>P2O56HMXF,3HG!+:$]
M.%^HG0?(L(** *5Y -L[Z$V1(V=;SXZ4X@'&T;8+#2]@LYC+ Z5J&Q#@@>)J
M&QP?('W KT-OJO,BRPN' H KQ8N-WH '\@HQ #->@5$*BQED:+?=++_+\ #,
M>P$MP J[2) '<+7F#G@@/24Z+;PEEP<P:\'NS;I@W($9%X;>A6P>8(HH9W1^
MCBD']Z@RUP(D4)@BX/;Q^XB'>O";E<T#.1,)?AP/@*-*:QS%Y^W@IQ"\<6IG
MX3D N@Z^#C8%>* 8\(#6+J.\,O#.JET%-8[=.O=.TEM$@#X/*^F03./BGS;L
M/5JSY>")%V15BPHE#V\JG+QZT^15F^;O$&S>=U)XSJC2.54ZCXKP*PB_#"V?
M*@2P0<'<(1ZL+1T2Z<(B'9/V!NM>5]N*:VPE.CN?=(KT7IDY*+>$I$:_&/
M[18!0C#Z9.: PAI6V2-*6UB,>*#"5?^ZJVYSY=&QCR^YO=?@+G?UN*='W]Y]
M!LZ8,K/ZS/FKWW^73$9C\<:6>)3C@=S@>( ++KC@@HM_P,CZJL*Y0V![(I'X
MYW_^Y[U[]S[XX(,OO?22P^'X[KOO6E THHC%8HEDLBG:_.F77[[S?_Y9:S 6
M2Z6/+ULZ<MKTOJ/']A\W:=P3BQ9NVKE!NG_'ZR<*C];PJRTBX/[I8#'A+29\
M?$-8;*XKU4? :Y'>5^&(5-@"NTY6+RH03EZ]?OI+&Y;LY6U0E6_?]_JVRJJM
MJHJ=955%50<+R_9O$RI>DU04'#XMJJ9Y&CV?,HM-+K'1+88U$%(\@,H/2XF0
MG P#R2@X@Y;]7!_;4VPB;T8H=R65BL,6?/SL8_, $)XDC0HSNZ$I1WX4K^&3
M<LE,O@UVV$)8T3F;!U)*739;.&$)W1&>BI 6'B5 %Y:1M),6M,@(2]+"ICE7
M^/)PE658DPO9:%10V8D9AMTAZ7L1P:RD[*M-=WCFE71TIYG=GBEX%D0CN _Q
M2=/4D7.*GX$'<)LH*PD6C^.I7?C=!#!07&T'A%!2XRS5.$O4-K[6+M*Y1*"+
M@%/7N/>2WCUZO]@<EM/>O6_6O%"LG+=NQYPU&Q];MW'FRQLFKGEUTMIM#V\M
M7B:LV'SX'*_&*J,\2LJOI (J*JA$"YO* $-2_E+24TQX  ^(R+"$C*!I,! F
M4?ED!X!/ 8 !RB/1^^2FH,+,\("0<HMHC\3@DYD""DNXS!916<,2O5=D\"J=
M=>6NVDV'3DY8MJKKT%%=[NU]YWU]>_89.'/:@S5GSE^Y_&T\WM38=+6YI0GR
M %J"F(MT<#S !1=<<,'%/V!D?U>QOJVN7+GB\_F*BXN+BHIL-MN77W[9W-P,
M."$>CP,JB,5:$K&69#R6B+<T-C=^?_7[/_[Y3WJK05RF6+EN[>1'YPR9-&78
M] ?'/[YHQM+GY[VR;;W\0.EYLYCVE>K<Q5JW /" I;Y$'RG2^<1&?Z4SK#2[
M-Q\^,6?+KJ$+E@YX<L'H9<].>?:YZ<^NG+IL^90ERV8M73%WY0MSGUDU<][B
MZ0M7/+VE8.>A4R+")#6[I!:/R.P1&5@\@.</(!AHYX%4]G^[W<SPHS<2LM'9
M*3'(<^/77C8/I&# B7YFKNO/JG_,:@0M;\^Z,$:I60H9HF$9->R&L>-'>3)I
M,1DR>6$@?;KL+;F[H>U"-!J %]3'97IQP804#S"HTRYT(]D7G!JUP"#$5O;]
MINXZ%Q[2PKT'3X1:P!>?WHA[DE'F_LR-XW_BQ54[NO%,X2N!V?QHM2B$'W [
MZ!G  T7G;*4UL+PT7P=^Y1!JG4*PC\9=JO,6TH$22T1F#_//T<_M%8^?N[37
MJ"D#)\V:M'CI[/6OS-E5\+2X?.VATWO/&X%-5YK"<M!7I!](1OAEL"O02 [A
M!7\O0 ((6F&9/B*A@T(X:P)0&80!6/B/=$MH."]? 7C !#K<)X)$ZI+0'ID>
M3NM76<+EUHC"#-X(CQ#L::]5.&HWGZB>L6YS]TDSNO0;<MN]?;KW[/_PK$>)
M&NV5[[^-MER_UO!=8_-U;GP@-S@>X((++KC@HK-$^COK_???KZZNKJRL=+E<
M7WWU%>:!9#()D" &F*"Y.1:-ML;C;:UP"G);6^S;;[[\_;_]UNEW5QP^N.J5
M5\;.FGW/X&%W]!W4YX$),Y:N6BTHWWM"PZLQEZIM/,+-I_W%1*!8YP4\4&8+
MB4G;AOU'G]Q1^,"RYP8\OG#PDPN'/SEOY)/S[G]RWN@GYT]X:M&D)Q?=/^O1
M^X:/OF?PZ#%/+'M!H.*K]0J[3VKS"BT>H=$CU+/SA0 &1.2,8"Y-VIMF&] ;
MZX;V-*4,'H 5E^$+%^8!["EQ"T(2U@_.G<,J1DE$S*-TUJESO35CKY'334\#
M8 2GR<+'WAF\D:W<7^5N20D/$< %]9DYN$SZD-:=]MEL'A"A=7BR+QB-8^!'
M]1TR $MXDL8/=3@CQO23[:8_W4Z*!YA!C#2$Y#9R8V'$XL$<(::2-'Z;TD,$
M/)3H+P1O-^D4$6XQ+'[L*=%Y"ZA J26B<M<+SE.+-^[I/W;6[3V'#)DTXXGU
MZU?+I:\>.;KS/,G7.Z4F0%!PE2J!QL=7>P4:#^[MU( ,DZ\%=I#JPW)CK50?
M F\97PL@Q,[7V0%V2DBWE/;*#7ZE*:@T!F2HK(>8<$LIKUSO5QJ#999PA17F
MXTDICYCRR6QU<D?]CO/TXWMY ^?.[SI\3)=NO;OWZ#__B44VDZ7AVO?1EH:&
MZY>;HHT<#^0&QP-<<,$%%UQTEDA_;7W^^><6B^7@P8->K_>[[[Z#.4)H? #R
M0 P00:PE&HM%8U$(!DWQED8X5-!\]?*5K__]/_]D=MIVE11/GS.W]["177OU
MO6?HJ%&/+WAJ\XZ7I!6O'3RQ^Z2V1&T5TGZ),20SA926L)AT[3RF?DEUZ.D"
MT=S7"N9LVO7$:]OG;]NY9%?AR@+>"T6"Q1MWC)N[\,X!([O<W;?_Q(>>WE94
M\)9:9O6(;5Z!Q<,W>01_'SR0J8[=-DL_C@=X3 )/2N UFEE[0QZX%4$SG?-P
MG?7B?YP'<I5N)V7]F8YE5H7"/7PK[6,>P+E2T)>3/IR:!?N?&2I!XQ*P/#:T
MX#)PE,X+>& OX2LRA<L#ER2$9>EK1?U'S[RK]\@ICR_:()>7JL\+]2:1P2DV
MN@6$L_B<K?"TM?@M5^DY+Z_:4Z)V(CE*T?02H1:8>YB%!:M*PUG4(0D->M[)
M)P /6(6$0TJZY;17:?"7F8(JQ -H>5:WC/(J]'Z5,5AA"5=:P@ 5I*1'2OJ4
MYCJ%K;Y09ULFKQR[?-5]XZ;>=D_?OKV'OK1J;7VXMJ6Y,9YH:HY>BW+S!_(%
MQP-<<,$%%UQTHH KD+:V AZPV6Q5555.I_/RY<N8!%"R4"P>!V"0C,=;8_$D
M9(-H4U/CU>L-WS4U?A=KN19MN?K9%Q]'+M0>.'9TT^[=<Q8]/6+RE'[C)PQZ
M</:XA4OFK-NTLE3VVH&3)=4F,05GTRJ US&&@8\I.6?:>Y+8=52]XXVSV]\\
MO?OXF=*W-.+SE.P\O5G^^M2GG[]KR+@NW0<.F?+8\MW\HC,:J<DEM+CY0":O
MP #7&^T\/, \O,^<Z?NS\0!.OTD-;F1)E$[%^?OF 3'*7TK78V879H;[8\[)
M:80MV Z:3RS0HMD1-/3E<#DLRH^[G3FI'A;3D-,^.;R%H( .%M&!(G-8Z;LH
MU%D6;R[J/6+:'3V&SIR_?-?!PS*C06*R"BDK3VLIJ;:4G+&5GG$*SOJ$YP,"
M6)W 7:)QE6K@2K6P'++.*Z7\,GT(P$"9M4YI#L.E;&FW@(0\( (\0+CEE%>I
M]Y<9@RI# +S&M=O:>< <KC2'P:_@M'["*Z-#4GVHE'*MV7]DQHNO#)@\NVNW
M 2.&CBW:5?+;7_]K:R+6VMJ22#;'6^,<#^0&QP-<<,$%%UQTHL!?6U]^^:7#
MX9#+Y4:C\=MOOT48 $<&P$^4-]0*O$(\D42,<+VQZ;MKU[ZZ?OV_8RU76EL;
MD\FFJPV7/_[LHU__[E\L3FO9P7TO;'IUTMPY_<9-[#]AVNBY"QY^<>/B/<(7
MI >W'M+PSSM5AG"9J58!V(#VRRF/4&OCJ2TBTJ$T>,OT'EF-90VO;.1C3]\^
M=%RW$9-F+W]Y2]41&6V3F=U\O9UG= J,'H$Q(- C&"!#4C(D(^ 4 BA8BZ#]
M"7':<8ISS&A'@CM#=^C-JC/ 4BX)W!(/Y#?*69?->L*=VH?EOS-L]$TX72ST
MO#\[J29EIGWPC#E  F<MH\(+.#<)4P$VQ]!_TPP&M%]PF@=0-S)*H47N_?Y<
M/  ;1_9=88JTRQC!:S'!4]Q$+^&KA;0#DY$"<D-89:Y5F>MD,&\'[@ N6 X8
MPQB4&X-*0U"I#\*B!.8ZH;6VV!*2VFMY9XV+-A;>-VQ2E[OZ39Z[:-N^@V**
M%AI,?-HL(&V @>5$4$&$Y;J(5 >0.""$&5 P"0KS&+@7.6C6%"FSUE?8+Y19
M:Q4F8.C](LHM))PBF"_DD5$^A3Z@,H:4QJ",!A?L@:6=*9],'U :0V7F2+FI
M5JD/R<&]H 2S4JVSA'*\<OC$@R^_.G#J[#ON[3]V]-0*Q;[W__P7\*<?3S0G
MD\W)-L #,!&0XP%V<#S !1=<<,%%)PK\M?755U\!'I#)9 :#X9MOODF1 $0!
M\ -_NZ$,HN98O"$:N]P4_;HY^DU+R_?QQ'54U2@)E&AMNG+MF[]\]%^!^DCY
MH4//OK1N_(R'>X\<W_W^"7VG/C1ZWC./KMV]1O)&\2F3@O I2*^<],HHCTCG
M**FVEM;8Y91/17E*CA/S7MW;:]+#]XR:.F'>,VOY*DD-769QBPUV'F7E&QR
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M3#QS%[<N=@?BIJ!PGAA+M]1+:5K#3;$[08SSD?!&X,CUD ?@PJ_FB-!>"WA
M9@X+3QE7;N,/F_;8O2/&S5KZ[/:J@U)2+[%:Q7:'S.)1&4/E^KHRNDZACV &
M2'4XY)9TL3GP&MA]/,2!BJ#!?*=T;AC&'@7"'L@#!)JV#HN"!R0&<"RZ0BH
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M[]A^VG',$595&UX15TU:^%RW4=,&3G[TR=6;]E0<J=28 0\(=4;  P*] _&
MIX3T%!#>$K5'I/')B9""C$B)$"SFJFOW=NA)-F-D\QKQ&PKX0F#Q/3<MKU2?
MF=^/_1G+Q+.])EM9^^3=']K<'.7NCP5_FZI^P!+S4#^7!_ _88:,/BR#8I)8
MX#-L^"P_IY "<XH<SYWJ:FAA=8 'X$+^D =0H66T#[2SF ? =A%RM_A765>;
M?2Z6TF,OV=V(A2ZCO9V;HX*.^CS/1@H/VL '\/ 9/( 90Y!O"958@@IS!/#
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MI;L1*M]G%781I"94G=H8E)L"0  &E.80$'@!\$"B;R^"(=7[,"1D\$"U8:5
M,6'QBM[CIMS6L__XJ0\>/'CDXX\^07^PT204QP-Y@N,!+KC@@@LN.E'@KRW
M P:#0:52 1[X_OOO?_1W62N>4AQ/Q%MB5RY?_N;KOS9<OQ)+-$43UQN:O[_>
M=#G:<BT6;VR)-;:T-"628&M#??W%#9NW#1PY:N#H!YY\;N6>BDJ5FE+I["K"
MJR \4L(MT;E%I$L(1+F%>H_( !=29)LYQK!BY?  -E7M'HLM]K3CCGE E)[$
M:0QC@PY\&UQ/4X,>>R,>P&=AU'YX!@]DEC1FW##>$S7HYJ-'^ P/P+I@L!H
MO(N;YP%TR_#:4/8_8]E1$C^>&P"-.)ZKD!+K:C,Z)VMC5L>V8T"FTGV.+X8I
MT\8TQ=P(=KVXH]@GRBMVQ^;^-G?G7.N?5S\3#W@%=*#$4%]B?EMI>YM_DEJP
M?GNO,1.Z#A@T;=&2K16'Q&H+X@&_G HH='Y9C5M2XY+HO%(*6/D\_89[)GTZ
M?-?@[0,?/(4II# 'H4S,3[DQ 'A JO<B^;  #X"?\%.G]\E-(:4E5*HV/2]2
M35KZ;)_Q4V_KU7_"M-EOO''\DX\_17^O+1P/=!0<#W#!!1=<<-%9(OVUA7E
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M/@RI\0%&*%\(,4 &#^!/E]S@5YK#Y?;Z"D>]D+"]**^:MF+5@,DS[N@] /#
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M/""BO3S2Q=,Y>5K'WI.Z5:7RZ<M7]9\R\[:^ \?,>ACR0'I\(![E>"!O<#S
M!1=<<,%%9XGTUU::!QP.QT_A@080UQK>??L=7G')Z9.G/OOT4[@]F8PF8O&V
MMN9$_-,OOO!X@GMVE4R9\G#/OB-'37SHF?7;>8=/OJZW[C,[Y 8KGS3S")N0
M<HDIK\(05)GK5.;:F^ !^/R^'080#V#]+#R ;5F:!])&#=;8(N'S;YS\DR7,
M W(C7!TRS0,B$F9^B^'J]?EX )T+"VY'*P7Q4L6&Q2B/2&Z,X$H([9:1I?8K
MS'SDS]ZS8Q[(O@4D=\<\P.1-@4X EZ1$[Q2;!\"O8-T#C0M/<<[MV%RE#3&X
M)'COB ?@6ZF'513@<$%.4\S'(/5A8/=&'K%YH..AAG1OX)$-K!OP@$@?+#QR
M=L&&S?TF3  \,&G^PHV*?:5G],75SI)JMZ#&)54[%!J'3.,0:5R\&D])#1P4
MPN\I<ST$GB?0?KKV&P3[H)2MU&@ 9@ WJLX!BQ_#MX8 '>4246X1[>&3KA*=
M@Z<#).8H.$6\P%?.7/'"H.FS[Q@X9-Q#CZ;SA5KCS<EH8VNL)<GQ0$YP/, %
M%UQPP46GB\\^^PSP@%*I=#J=UZY=N]7OLO0W8"(!RQ+_TSOO\DM*3QX_\?%'
M'X$MT5BL&<X@;DW"/=O^_!\?[*\Z,O?QI5-GSWMFW?:=B@.2L[H*@U5IL@MH
M2Y'.5*2S"4@WK.)D@"OD  $[*$;F&/K:G'PA['U3VZ&U@LH$@'8'3,/EB<2W
MR@-X^BGT;>W.$AMNY@DZ:V>8^8.?B /33S&U8\6IXL1BRBVA/&AZ+FXDP_EE
MG92!#18JI.\E#2?9?K<#P3;Q_CFK ^&FTF?)%BM?" L84_B46@\P#$$+NC I
MFD* UTIBNA=9:CPO CUHSVFY ^&+!/OSU"[  V +9 PZR-2 @VLZ9;Q]N3=[
M W74VQTJ PP0#U#9/ #SA8SADN/53V_<TG_"Q-O[]QO_Y%,;Y%5%I^F"L[;"
MLX[2<W;1>:NTV@JG$*@A#_#4<.0'7CQ^.^@@@V0Y;P$SQJ)V"-1V(9) #1JQ
M S9CWI$T#^B< L(I(%W%6EN1QB: 4Y#=16]1JWCR*4M6]I\\H^O H1,?G?O&
MZ3,H7Z@U$6V,7;\::VI,Q).)9%N2FU+,"HX'N."""RZXZ'3Q$WD !S@J"91(
M_NY??U-95G[LR)'?__[W34U-T3CD@5@2N([61+SUU__\>Z&@[.FE+Z[;5JQX
M\WS9.5I%FU5FN\1@+29,!5IS$>'@DQX1?!;^ SP [5TJU3LWC21EE]&$X[\A
M#[#LHQ?64*/<4"1,Y@8PP"PN=%,\@!\,,SO@VV'NG352D6MY\PJV^7/Q )I"
M /-5:#B% &=28<%+2DV!Q4^[T8/V% QT_#R>K?\M/ "@3D ' 0\4&2_*S77\
M4YHEF[8-F#CIMGY]QSWQY";E?OXY4ZG:7:KVBC1NN1;F"RE@!X(V03NPY_&@
MBLI2IS+7*8QP: 7FN:5F?:2G:,.>A*,T<"A  D=I''@^,:8R)9 AH$!C4'@^
ML8!V"V@/6L+(5WB:7%$@'OO4DE[C)M\V8-#$1^<</O761Y_!^0.)%L #U^+-
M3>!OEN.!K.!X@ LNN.""BTX7/PL/)$"@M(/W_^LOU6?.OG'H4%UM[=???!V-
MM0 >:$G$8XG6;[^Y:C*Z7GYYR]/+UA1(JHZ1CD-&5[G9+C-;!7I+,64N)*U%
MA)-'> 2$7WH3/"!!3E= H.?0&F96+GI"C[)*"#_D ;;]_7_/ S#-G3D*S2$F
M' +"B48&/*F%1V^6!Q#,M!MN# !,^[<" Y*?FP?00D.0!YAI&ZBDFBB=^ 13
M>G#_(XR!'<5@6[IS;J#_)3P +L/#IP)%@ =,OU!:+XC>TBU];<> R9.[].X]
M>L[<+>4'93JGE Y+Z(A2'ZXT!/>;@E6F4)FQ5FZHDYGJ5&CIIPK[Q4K'):!R
MVP65I1X(;"RS7@#"_U08:V'^&^AJVH^6=?(S&& (E)O#%99(I;6VTEI78:M3
M62-*2T1EKU/:(U)S2&(*2@W^PK<@#XR?OPSP0)?^@\8]_.C!DZ<^0O.)D_&F
M>//U1$L4\D"BC4L98@?' UQPP0477'2Z^.D\  Z))^* ",#KOW[YE=-FWU]5
M19'D!Q]^$&UIB29B+?%X+);\\/U/CQXYN^R9EU:LVE0L/WQ8;3MD\)49W6*#
M0VAR\LVN(H.SB'3R";BN/["J-\4#A \[16 ?TPMW0C;0POVS[>_?B ?P#EZ!
MSL77V-$T8B?  *G>CW*';HH'1 P/9+MV 5Z6%/OFFU9J_\SLJ1_% PP5 ![0
MHPG?Z T"I\!S"5()0F@"- GSB&#[S&0&+ZHSG7.*3&$> -T">4#M @?^1!Y@
M=]0->CN_&![ F?V8!\(R,B!#;YR "I30M:6F2^7V2^*SU+*M.P=-GGQ;SQY#
MI\]852C8<?C<]J/4UJ/TSF/4WN-$X4E=X4EBUW%JVQ%JRQ%JVS%R^W%JYRG]
M[M-&H)TG]=M/4-M/T#M.ZI%H\*N=I^CM)\EMQXGMQW0[CNEV'H="+[2[3NAV
MGR3WG*3V IVB]IRB=YTB=YZF=I\S[#Q';SVAVW)$O>V(>D/ET45;"\?-6](;
M\$"?_N-F/G3HZ(E/\/R!9#39TI2,QY*)5L0#V8:V,P?' UQPP0477'2BP%];
MGWSR"4W3"H6"S0.W]+V63";A^$ B ?;__OOOWWG[[7W[]AT^?/C7O_XU:!"@
M0BP6NW:EX5?O_8M,MN^Y%U[;5JA2':$.UW@/:(,J(B31A\26L- >+C%[2VB7
MD'1*")<,3B&(R.%R.F%@$+%;Q<_(6?;.#[P:</^E:B>>NIH6'YIFKP27)D@M
MS8D/%V5.X669OSS;(8&DYR>PIR7@H0FF4#&S' V>\RJ"Y8'A?%\X(U;MY&M<
M0IT;KBQI8.H)M#<.KZI]N4G6E2 #BI9.DNF9U81$:&52'KI-$5KW)KNU&YIC
M..N:AI.M\\+ S4_Y16(6.\+I+N - ET'KTWC8B80(QB#ZSZAO!=\\;!CL]O)
M5OH60'<!(UY:XP1-X>O$$S-$.5,1<N]4@CX8:;$_.2+TUL,#40^SFX*7EYY%
MG=D5J7<_*"%KD2(2$@X4B"GPAH:DQDBE\Q?"&N.R;3N&3)[0M5?WO@^,FKIH
MV4,O;GYPS:Z9+^^:M6['@Z]L?6C#UMGKMSVX9NOT55NF/+]E\NHM4U_<.N/E
M';/6[9JU=M>,EW=.?VG']+4[IZ_;/7W=KNGK=DY?OWW&*]NFO[)E^BNOS5R_
M]<%UVQ\$[0"MAYJU;ONLM=MGO[SCT9=W/+9VQR/K=\*-K^R8N6G7M$T[9ZS;
M_O"+VQ]=L^.A%U^;\/2* 5-G=1\ZLDOW^R9,GG'TX+'//X+UR."B7\EH&YQ-
M#"?WI/_>N6CE>( ++KC@@HM.%?AK"_" 7J]7J51NM[NAH0%_G271 \/L _)%
M>O^FIJ8K5ZY<O7KU\\\_MUBM965E9\^>_>UO?WN]\7H\GGC__0^/'GOKY0W;
M-^X2*M[0'*AQ5Y[WE%<'%-I:"5TO-M4++76EQF I7*K?+04&&CI.QKSB=!3&
MD8/M%'S,+TTY:8@$N)Y7.E\(/Y]&?AJ9Z=0\8\8LLA)7J-3ZH?AY?PX/H ?;
M2/ " BS!G;$);A^70'X=&$II*O,;7DEZYJ@AA)8D0N=BO"QS86SWF18TQ^ED
M(;@%ML:@3FH=S.S]<YQQ6AWR )H6S#ACU!LW(_A>H QX.#Z@#\%1&@)G:N'5
M1:&';N<!YOH[:#_?+<#)RG"]4?B>,M"">C*K'014>83>8D;I&<] (CB. =_?
MU$!!>SN(!QAE(4<[#4(20#! AL1D )9J-L#UHRIL$?XY<NF6K8/&C^[:JUN/
MH0/[CI_<=])#?<8_TG?L0WW&S>HS87J_2=/[39C9^X%I]PZ9?/?@27</GWKW
MB&EW#Y]\YY")=PZ=>.>PR5V'3@*Z8]ADI(EW#!M_Q_!Q74>,Z3IB])W#Q]XY
M?-R=P\<#W85^ G4=-N[NH6.[#1W;?=C8>^#V"7>.G'3GZ.EWC)EYY\AIW89-
MN_?^F?>.F=EMU(0[!PZ]X[X^7>ZX:^+$Z<</'/OB@T_A7VTBVM;:T@97&^5X
M(#LX'N"""RZXX*(3!?[: CQ@-!P PJ4  (  241!5!K+R\N]7N^/XX$V-$30
MW-P,>*"QL3$:C?[A#W]XZZVW &.HU>K?_.8W'WW\<?C"I1U%_*5K7MVK/+2_
MQK:?\"FJW3)U0*JK$Y,7A%2]@*[E46$>&102 8G.+R&8Q_GI)[O Y\F8TF A
M+.AN:<9Y9S_3A;Z0/9D8[P_KE&&_*(96F#5NT $/I)\98X_;_M09_$KKY:O=
MI34./#J!55+CX*<L;+M;19X>^^],Y_H#/(!M:SK+A7UYN2;XQKH!#Z =LA.B
M;BQ\=[ 18/?UT.ZG.APU@FX?_$2+#L'WB &;G'8D'?  / 6)G^+[4&%C2'WP
M+6B_8.8R<AM,'\N\<:1/JH<%FX'$<- &.OX4:[6WD]'Y'?( %EP 5$2Z9 :O
MPA*0&;WE9I_HC&;YUFT#QHWN<N^=77OUZ-IO8->^0^^^;VCW>P;><U>?N^_N
MT;U;SQX]^MS;O=_==_7KUFUPGP&C^P\=W[O?_=WN'7QOKV&]^H\"NJ_?_3W[
M/]!S -"HG@-&]NP_HF?_X3T'#.O9?^A]:?6#ZME_6,\!PWL-&-)[X*#>@P;U
M'#BLQX"1/0:.[35L:J_A,^\=-N/NX=,!%=PQ<O)M0Q_HTF?@;??VZG+[71,G
M33]^^/@7'W[:EDPDHHVMR2C' WF#XP$NN."""RXZ4>"OK4\__13P0$5%!>:!
M9"JR]^XX6A$_X'RA>#Q^[=JUSS[[[-UWWZVNKJZJJCI]ZA2EUQ\\<6IC0<E+
M>TM+#[]5J7-4T@$Y$1#KPF+=!;'NHE!W0:"K$Q"U B(L)$)B74@,R[BR/%FZ
MSD"JM@ C/3.9%>^3%C:X4ER7(/.0M&>%.S 3=CO@@8YS2."S?ZV'IW8!'BC)
M%%_K9NPR4Q@!F6]\KO0+ECKB 7P![9DM*9/*F&_6];.:RG;&:<&+R<<#N8W<
MC)#G9JX!&'1TL["K<:VT- #@U^W_S">V%\\=XDB/I3 \EMD.;#;G3M%1+!Y
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M']^0!Z#0@W/HX#LVV9(.>"#WCM+"_<RZYA\0MNFYPATNR1R[N,&EPMT,<-H
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M*LT#T//E\(#D)S  6VP3F1;:&(#U=&^9![)].<,#1L@#X)]@-P$!*Q[\#_-
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M CK6IY6GGP)G;V ]!LZK/!F%I>4!"0@!5 QA8AAFC<-NLGX=']1Q090+&KA
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M I08*%-X0'"MT]!QLQ?UB8GK.VCHJ%&C%\S-LW+<]]]^(_]5OWX%"XZ^E9%
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MAAIJJ/')Q==??VVU6LO+RST>S[???OM6'C3X>!YX+8>R_MM_^:W5;EU6L&S
MP'Y]!_4;D9(</W5&[L8=Z[7TD;M5IZJ%(P_,ASZO/ETCGF/MIVO%XX^9DP]J
M3RNZ7WOFH1D(K)^Z7W/B?NVQ!^9.G7C$G'["%]98+U3;BAY9"Q^+)Q^SQQ^9
M3SRL.?.PMNBQ!:D1#&P#9:G7/.0OW&-TU74XZ]#7-I4^KM?7NE AI!%"YVH]
MYQ\VZN[;C??M9?=LA@<V_)%=7]6H-3>56IP:Q@T?P'-^#1\LY0$_!#2\7\O[
M]+Q'#ULB !YP=DEP(J(+D=PHD-#A[:"<*!S< %[<17&=\SZA*,9)6AP$E(MD
M !NX<=:%0KEA3@Z<'@U')SJ%R>E/F!!&( Q$='Q(ISP5YI3^94K>4<>P@YR>
MU&E_"1X0"#@!-RD_)I=SJWPH#P$)$HL(2* 9"!,<T.*S88QIQ5B@"%SG0CA4
M$)-'2.3WRHX</K-7?/D[LQTZ>2#Z(]%/VT(&>YBR!L&9R E12L:7C!.RWC/K
M477 3%<V41?J=$[8^"/5>="NXWZ$]>]52O8.I?  %R3 7;*$4'/ )(3U#\2U
M1\\G3IX^)"5CYNK-I\KNT(S;)(4H &.6!HRQ$QQ0/<8TX*R3@.<0I4>,![CE
M@MEQT9RQ;D<4_)A<J H!2]Z' DB0@J0M3-HBA#6,2P#M0AC 13&"BV%2"I%"
M &/@S 2#Y"]O;"EO;@.\NA&[F+A@>9\Q2?T&#QNE\L#'A<H#:JBAAAIJ?'+Q
MRU_^TF:S_1$\\.9U=QYX]>H5V!F\Z^7+E__MK_^:,AC'9H_O V+H@ 'QHP>E
MIH^>-F?2NAV+CYY;<QY9=4ZWXJQF;1&VOI185TS E?/(AG>U_IQ^7:%N3:%N
M];DNK;V ;=92.]"R7:AIEX[>IB$V:=!U)?IU);I-&F0[0AZ@*TY6W#AJNKI#
M;]A:2AVNN*5]R*.U==HG-EUM,R($M$+H?(WKU"WQ"/7YO@ME>\]0^XO+CQGN
MG+MI*:VNTW%NO0#S?P  E B!8C%0(OA+!%^IX-/P !*\< ?>T27!@8A.1')!
M\<YW!/! =!'"#_  @ $O#@<N/ @CFW7X_![X=3_"!3N% D?.AU"Y[90.*J2'
MN2*PPYKLK>$3=#F7R1,5ZY$+TD/!FO2<$Y:E9X%!=,,*GG""@=*=#<! (RXV
M@"4F-,M/XL.HI0UEOH"R/,68-HQM 6" LD&YC5>4!V K-)BZ$S7]/=3) Y04
M #!@JHL8;"'@O*/S)91)%-W&,=XW[M"[*XX?#@)$:YAVJO.G'WKOA_3.<95#
MRSQ =K8:^&C!:0."5\X:@FGZ.!_26X*EU5Z2\R,/A(TGBI*GSAR<DC%C]:93
M%7<,K*?<UF:RMI*<%S4W8I9&@G7@</8P?'O7N(0\FM0QU:&+!Y2; ,Y9R0T#
M2 !GJD@!RA:F[1':!G K1$I!7(H $9+\4@0\ )/0C-9 >5-;66.;7O!LPBXE
M+5S99TQRW\'#1\7$ AZP1GD >E:5!WH-E0?44$,--=3XY +PP!\W/O N#W0-
M#OSVGZWVNM7K-L3$QX](&),T:=SH"5D#4U+Z)J8/29\T9OR,U,EYF=,694Y?
M#)894Q=F3EN<-6/IN!E+QDU_1UG3%H^=NBASZJ*,:0L[-7;ZXO&SETV<6S!I
MWK*)LQ>-GSE_[(R\C!EYF;,69,U;/'')RFEK-L_>LF?J^NUCEZS*6K9VX;Z3
MQRKOD)9Z@FG069IT@D\OA4O,[F-7+&N/HE,6;AXWM0 L\S\KW$]>+WHDH:('
MLP40T:L5O"6BKQA(\'7P@%_+^76<MV>^D)(R)'ATO+M3P('I81Z1!Q-D7\YV
M"?ARW.+"H  ,^#'&C\I-<_6L3\?[]7Q SP?U7+A3B"(^K.-[YP&\!P\PX!!1
MP7HUC%.6"PY$ /9@_1@+&[3A H !NZQZ3&B"%IF-8)9GF.7'LK["F&<8VP8W
M B:!,Y6C9EJA B4CZ'VOC"F3@WDO;!MG"QGM85KA 9E;%![HTGNN/>K=NWB@
M8X+!_PX>Z'GH_Q4>X" /$#R<HX*+$42(%-5Z<<Z'/.0WG;R0E#MC4'+J]%7K
M3Y;?-+#N"ONS,NL7-!_$+$X4<"!D,S_!PB)%\BSGZ$R,KK&+=WE N7N=<T5P
M@"*2G[8%C?806%+6@,P#(2!"DCOT@3<"!!7<Y77ARN8O3(U/M9QG@_YB8MZ*
M/J-3^@X>V<$#G,H#/QPJ#ZBAAAIJJ/')!> !29+*RLK<;C?@@3<=*4#P9]UX
M0'GU"B8+ 1X $  M1#192!X<^)N_^>\83B:E98Z(3YBQ=-&Z@WN6[-B4O6#^
MF/$Y(Q+'#8])'1F3-B9^7'S2A-%CQHX8F3(R)A6LC!XS+G9TA\#ZF/&C1F?%
MQ(Z-B<V,&9W1J9&QZ<-'I0T=F3QD9,+@$6,&#HT=,"AVP) Q T<F#8I+'YH^
M(29GYNB9"X?GS.Z;FCU@[)2,I1MV()6DI8$677JF62=X,7M$RWB.5E8MW'HR
M-FUF_Z$9PQ*F3%RT:>-9HO".!15=N-VO$]P:WE4J>DH$3ZG@U<#A K^>"^CA
M7((@7.E-6KY+.B&HEX7PT6?\G4+ SHQ?;_&CE@#&!%$FB#!!/0,G*LBY0!$@
M/=_RGN!VA0=T\&,#\A12Z".A]6=Z%\FX:8N#LCA(BXNT #SP$5R X.04<Z$.
M%T5<M$(D$)J@#>5:<.9+W/(?<,M/<.9'./L,YUIARE!'1<[NOKS33W=7U]-N
MQ6IW](Q3/'WGL_GWS?K_&;UW_A\EV)_82[%>$M;V\2. K&RMJ+VMF(5%I=!'
M_,:3Y^,GYPY,2IJV<LTQXQ72["BSMI59GQF$,/A-X:R+A.,V09(+DUWW]EV]
MRP,8''*1&UVS+HQS$X*'DGP&6\!H"QJL 5J"]QD'2& -PG$#JY^6?+3H*;/[
M+C:V7'+\R-3X12GK6:NIB)]3T"<VM>^@F%$QHP$/V$3^^7?RG_D;&094'G@O
M5!Y00PTUU%#CDXM_"P^\?OT*2&Y+_%*.?_S'?PR%0CMW[AD1FY Q9>JV4\<T
M-RJ++IOV%9U?O?VS!<O6S\HKF)FW=.Z2E7E+5LV8MW3RC+S<F0MFYBV;D;=\
M>H>FY14 39V7GSMW6>[<);ES%T<U;_'DV0NRI\W-F#P]-6=*\L3)*>-S4C(G
M)6=-2<J9E3QK8<J"_(S\-=FKMZ8O71\S?>&(Z8LR5VS?BES$F6:CS8=P3KWH
M(1M:$-9WI.QAWH8CL<G3^O1/[C]B;,;,Y:N/EIZZ]EC/-:$V3RGO*.6:M8)3
MR[MTL(B0#V']P+MCEA!JB>C9UIYBH+1<JZ9#6KY-QS\%T@()3S7=5,JWE7"M
MI6R+G@VC3 1A(GH&($I$PT:T?(M6: 72]:(6.'F@-QX@60]EZ5VTQ6TP.V0D
M<,$MK(]D R0;(C@O+MIPB<<E 2*!T C],7#_S%<X\Q]D?0DG$G#P 38I>BD)
M>M">SAB:8[GT36_;%<.-R5(V*DCP[YT'2,%/RSQ L#X,EJORHW6M2,.S8C%$
M27[L,;?A9.&8G)S^"?&YRU<>H2]B-0U&,6R2V@Q@!\%-\2Y:\-)"@.)"<.)!
MMXGC7>HV*^-='H!UJ"C>;1"])JL?R&CU&R3PV_'A  FL <+JIVP^VNJE)7=9
MG5?F@1^;&KXL9;QK-97Q<Y;WB4WK.VC4J)@XF0<XE0=^.%0>4$,--=10XY,+
MA0?^8+Z0$G*!0AD&%+UL?_[=][__W3=__5=_??7JM:G39\8DI2[>M+GTZJ6K
MHN4R7TL_?%!2>?4T9CR)4B=0_!1.G$2(0\7:?>>+#Y=H3R#$,3UY1$\H.JS#
M#VO10QKT0"ERH%1WH%2K:'^)YK,+Q3O/GMMRZO3ZDR?7GCBY]NCQ-0>.K=Y_
M;,WQPHU%^O4:;'TIOEUOVE1,+3IR?NKV([G;CVY&+B+FIK*Z("ZZ4-%M:&S!
M.=]1X[WYZP[&I4SK-R!QP/#TS)D%ZXZ7GKGQ6,?4(Y)3*SJT@D,ON!#! Z?M
M,@&,"9"6(,6$2.#@+6URGCW04XQ]AK-?X!S0,Y2%0MAG>K#DOD"%+Q#A"[WP
MA5;Z0J-(A,M2\5D)_[2$;=6Q+2C;BD PB.B N+!>B* ?5!A*#*&PW*1L&3O*
M$)&<#SC4#OG@HVO&+7? ]=*,QVAV&A@7Q;A)* _!> D&[..FK?6T7:)L(BE9
M2;&>Y-T$VT(P7Q',CS'V*XQ]BG+@B'Y,]))6#VWWTO8 ;973413!PD&]%.2)
MC@F(L"J1DEP$ELIVQ=I"'OB#2"#O\Z&,H _G"RG/U]_?WO,M'QK?Z)+".3UV
M4,J_1L<'/ 0+/T3/^[#Z5JSIJQ)K*VT+88_Y#2?.CIDTJ5]<W)3\@D-D!5)E
M!^[?(+88Q" E>@R2!YAX6H3M+[HS *P3ROEQ+LH#72,M\AV#G2ZB/.#JX@%;
M0.8!'V7U$Q & J3" Y*'Y!T&T5E1'[K8_*6I\0LMZUNOO90P9V6?47!\("9F
M]/QY<VPB_^+[[^2_<C5?J/=0>4 --=100XU/+OXH'@!;HR,#LEX^?_G]-]_]
MCU__@]_CW[ESS[#8T2E3INS3E%[FV.MVJXEE:(;#&0&W\+2%,Y@M=$TM\;A*
M?^\A$%557<9P)H8W6CA%!C-#UUBH:@M19<:K:_&:&D58537Z^(G^X2/-PT=%
M#Q^=>_CXW+T'9V_=.WOS7M'G3Y!:7EO#E3PPHT\$_2/^Z*7/5Y_#9^\]LU%7
M@5J:+C9&#+#0OKNLJ058J!-EGR]8MS<N.:=?O]$#AJ>,FU.P\;3FW.W'>L:.
MBDVHU*P7'3K>!=P>P@50)H19 H392UG<M,5/FL- !%2(M$0H2PO%M-!,B\$,
M19DC)-C"MI)\*\&WXD(K*K8BBH06N)3:$+%-S[<@7 O*MR+ =K,AE(7M$2C!
M3\NB>%\O$GR4Z*6!IQ3<1B#13XEA'):8!&_TRD^=P4_!;K!!%0DKC;H!!A@M
M'@/$ #?..#'&2<+)S6XCZS2)367V>I/=:K1:C5*=@7=23)BT?$%8  Q\ <Y-
M)_IU(IP"05HA#!CL(8,M1'<(\D"WU*!.D3!E!;92!ML1QJ4W.U#63<#"HT%8
M)^>C>:#[[().-Z]L^?^3!^068'X*-F?P$9PLN (+-X';B\.B0!ZROHUP_*34
M^@5M;P$\L/YXX9B).?W&Q.4L*3B(5^B?V$GP"Q(CE!BB1+_!ZC?6!6D)3B#N
M=LZP504F)R IE5[?Y0%8";<S7XCDO?+G! QROA E^>$4 ED # PV !MN@H&U
M=TTV7T5CJZGQJ9[W;]1?39RW&N8+#1X>,S(F;\XLJ\ ]5WG@!T/E 3744$,-
M-3ZY^"$>Z!:=_^F4-*$70"]?/?_V^;>__?U?_<5?7;U\/7?JS &C8F>M75MR
M\^:=9L<5>P-6PVK-@E9J0.J:<5L#+M:AO$W'BJ6UG,;,8X*-MC4:ZIH[1=N;
MP!;*VDA*#82U ;Y%D;V!L#<2\CIJ:]1;&W5BO9:SZ]DZ4F@LJW/38A/%U%=(
MK@K15737LEE;-N] X49M&5+;<*4I4@9\K>"J:&PID[PGR^XN7+<[/GE"OWXQ
M X8E9<Y8O.KPF1.7;VMK!92O0X4&'=>@89HTL#^N'S7[-8^:"F^R9ZX]OG"C
MIO@Z5W2-.W_54GBI]NS%&B"P<OZRN>0R4WJ9*;["%%UEBZYS%VYPYVYP9\&[
M;K&G99VZR8#EV;O"^7O6PL^E,W?$4[>%4^!'-YG"6Y8+MRTE=\PE=VI*;E<7
MWZIZ7T6WJX&*;S\NO?5(<^M)Z5VVZ)[M[%W;Z=O"F=O,V3M0A7?9PL_!(9CS
M]X72)W:\MME@ 1CC02U.A&G&V&8#[Z+,C;I[7-&M)R6?/RI]^+#DX7W]DVK2
M4F]D@I2YC3!_@;' 088TDJ=4<FDE%PXS4H*T%6* 09;, ]#?*_:Z!P]TC@_H
M+4Z=V0&H /C:/VI\ .NL/M1+O=&>YCZJJ'N.YM]W-]/*6][Y4<=;>F) YU6(
M =@&#H*9(A\!$X2\)%ARRK&\<$2%AUVEJ?JGA.,_EMI^1-E:D0?<VJ-GQDR<
MTB\N8=*2Y0>P2OV3>A)VD @3 NSU1EN#!CO@)7!*<G71;I<<1119W2Y![I@F
MS\96LJT D,!SZQBHD6\X6,(1&UJ2,XA$C\(#1LE=5A\R-;3J  \@UY,7K.N7
MD-EW*."!$0OSX/R![]5\H1\,E0?44$,--=3XY +P@-*/S.UV]^Q'UBW>=,PK
M #  1P9>PSJC[<_;_^G7_[.ISKEMVYXQ"6EIDZ=M+RPAGICONH*W7&&CU:5C
MFS2<0V_SZNI\&KNWQ.8IMKJ+)5>)U:.Q^W3U?EV=7VOW*=) >4MMGA*KN\3N
M*:[S*BH!JO>5UONT]3[P.7J[#WR@7O*@DA=X5DQP <M+\:Y*F[_"ZBM]).ZF
MKBXYH5ES@3Q[N[;<ZJFT>DR2IPRX,4O3,>K:@C7;$Y*R^_>+Z3<D/G["C)GK
M=VS3$H6?/]991#UKTS$VK=FNK6G +6[D4>,1X[V51S5Y.P\OW'EHV<ZC2[8>
MSMNX;_;:W3-7[P":M6;GG+6[%Z[;NWCC_D6;#BS:?'#1MD,+MQ[*VW)P[I;]
M<[;NGRUKYN9]L[;LF[O]X/Q=1^?M/#QG^T'P<N;FO;.W[,W;MF_1SOV+MN]=
ML'77@BT[YV_NJ;S-.^=MV3D/KFQ;N'GKPLW;%V[?OV#7B;F[3LW:<7+F]A,S
MP7+'R=F[3\_<=7+VKE,%)Y%#9?>P)XTTX\5JG)KJ1L32A+,.RM)T]LKC]2?U
M\[8?6K#[P.(#^Q<>V+>IJ+CPQB.#V4=#'H!EA?1\4".Y2R6G1G0@@@N'W87A
M,WY !09;V& /TW)=2\6S=K/1<(EW.'B%!\ 2UB:"38[?,_$?5J?I5Y*.NDF>
M@=#=UBN*PH9<HJ?CE)3G[G)-'KD'66=>?D<N4*?M[KY=&>( QIT6 [0 T[$@
M \B%F\ ZR<MOA.,P'DKN.D?5M>&-/]'8?D1:6TKOFE<>/!DW:>K Q)2<92OW
MXY583:-!@C" LK!_,"GG6<E=YUPHY^H8)8A> KR'TKOUCI2Q@B@PR)<</5NY
MQ7*4OA3Y*=%'2P!ZW33G-/!.D]53WA RUD=*S.YUVBOI2S8-S9C4?]C(T;$Q
MZU>O=#4WJCSPPZ'R@!IJJ*&&&I]< !X0!,%@,#B=SF^^^4;9V"L/O (8( ?@
M@1<O83OBY]^]^(L__4M$2T[(F1&7.F[QQIV%%;>I&NNE.O]51UM98PLF!F#E
M>R&DEUJT4HL&R-JJ@VK3V=K BE;>KD@CM6JD2*D8+A%")6*X6(ITJD@,%4GA
M$BFLD4):,: 3 UHAH!<#>B%0RGA*+2[@F6 JA>37U38<O?IH?:EQZ0G-)HWQ
M[,TJHM9>;O=>; AA5?;]NK)Y*S8GI4P8/&AT_R%Q0Y/')\U:L&#_D<.7;NC,
M@IZUZLT"8I;P6KN)<>KN\IO/X.,7KQL^+G=DUL3X["FCLR8-2\D:DI ^*#YU
M< )0VI#$C.')8T>FCAN9D1V3.2%F[ 2P,CQM_-#4K"%I64/2H0:GRBL9XX;"
M]<S!J>F#D],&):<-3DX?D9$5.V[\B/2QPU+3@(:FI$8EOQR6 K:D#4I-'9B<
M/#@Q<7!"W."$A"')&4,R<@:/G38@<\: K+D#LO,&9,\?-&EA_W%S!XZ;E[YD
MR^8B$_*@CK)X=%5-)8_K]#6-N+D)?V+?CUS)7;ES1/:,8>-S1DZ:.&S"N(Q%
MB[<4X=ACA\'21EB>H6RKG@]H)%>IV*P1FO2P][,+AUV!_50'#T0;C4%GW $#
MLC<EHL4QY38%D ><8*FW@'674J+T?>O?BV2/WCDR\"X/*/V)H^#1[2TR.<"&
MS='I"L NRSP /Z'+7K^K7GD PH =5DHU@HL%/AO"@!NSN, 23M40_/+S^ !P
MW@;12P)S;VM!ZW\,> "7(A=N5B_??SP^9^J0E/0I!:L/X)6$N=ED:P$\H&?@
MX ;X?-BU6@!Z9WQ )A8?+'ZJW,8.1?E!'BA0J 977BJG+=-+1\E4'REX2<%#
MR^ED)M%ELGG*&H)T7?A"M6--Z:7,_&VQV=,'CAR5FI)TZMB1'W_YK/WE<_@W
MKN8+?2!4'E!##3744..3BZ^__KH[#RC_SGKE@?;V]N=RP'RA%\^___[[W_[3
MOUCYNH*"]6.2QF7/6+"G4$\\X(T,?""-B1[<'L:D",Y'**Z%9MMHYBD4^\P0
M%7P)E@;N68>^ $N:?4HQ;2331K!/.]2&65HQIA5E6E VHN=#0#HN"/OUBA%$
MBNB!Z^(#J "-%/!8Q8]L!\KOYI_4SMMW>OTY['CE;9*IO](4ILWUA['*!2LW
M)Z=DCQ@6/WA$0O_8E,&9$W+6;=IGJL0Y*R'4H6:!L$@FKK&"<UZX6E6PKS!M
M;OZH\;F).5,SIL]*RYV>F)T3GS4A?MR$A/$3$[*!)B5,R$F8.#DQ9TK2Y-SD
MR5.3)DU)G# Y/GM2_(1)\=F (B;&@?6).7$3)L9FC1^5D3DL.:E_;&S?F)A!
M8^)'9XY-SLE)G CVG! W8<*8\=FCQX\'R[CL"?"]$R;"=V5GQV1EC<Q('Y&2
M/#PY:7C:V)CQ4T=-FCLR9^&HJ?FC9ZX</6O5J)DKATQ<"'@@9<'&]6<I[3TK
M:7$C-0YM50-F;H9]T![;#V@O3<W?/CQ]2O^$]'Z)"7U&CQJ6G9U_Z(SN?KW!
MTD(P3Q$VHN-]I:*C1&S4"(TR#S@[>""H=!U6>*"[MXX:61$VST*B/""K8^7?
MP /PH;B2*M--LJM^U\W+3] 1N5<:.#HTZ\KP!2 *A1_>(X$?Y@%P=1_@ :_"
M [#;6I0'_+BM15_WHU*9!\[? %^58X 'AJ:FYQ:L/HA?!/?<9&_MP0,8#WM7
MRYV)HR?0<2%RJE)'G=8.-E#FCK]SGIT7WNURNO& "'G :'4;ZP(R#S0#'AA;
ML'WTQ)F#8F(G3AAOHHC_^[_]US>O 0+(XP,J#_06*@^HH88::JCQR<5'\@"(
M5Z]>*3P 5L N[2]?_.KK7UV^>"-[PLPQ*9/R5FXMJKAS7?*62QZ-N?X"TZ2S
M!E I3/ 1(]-26=MZJ;:M=YF?=M?%VK;*FM:*FM;RVBZ5U;0 F6HBM"5"L&$<
MENP,H6R(D%I)^S-,:M6P_E+6!ZB M(8(WEOR2-JJKYCWV<F\SXZO/:L]?ND.
M;JXSF.O.5=Q:MFY'0GSZR&%CAL4D]AD>UR<^-;M@]7Y3I4&J,]H:<$:B6'NE
MU57&.HY0M^=M/3HA?^/<C3O6'CBZX?"QM0<.K]BSKV#G9T#+=^U=L6<O?"EK
MQ6?[5N[=OVKOP=6?'5R]Y\#*7<IN>[JT8W?^]EV+-VV9E)<W,C5U8%Q<_/@)
MTY<5Y&_;L6+79\MW[RW8M6_9CCU+MNT"RWSPWEU[E^_>5[![W]*=GRW:MG/!
MIBUY:]?/7KEF]KHM"W<<6;K_W.(#14L.E>8?TRT[JEVP_\*4C8<R\K=/6G]@
MPP5#R><B#6N, D?K,HJ^BY+?5-5P6'MY=L'N^'$SAZ=F#4A*ZA,_9E3NE-4G
M+B /ZRES&+>T(&Q(QWM*Q:82J4$C->B%1HQS$#QTU3_  X3RE%IVKDJ63I=8
M61\N&=2;.ORN[/4[%4VR?_>XA)P:!&! Q[C #M"LRS.>,:59<F]]TWY ,@_T
M&!_P8!;8\:US?*"3!V#S+\@#7P$>(*3(A0X>D,<'UAPD+I$69UE=&RF&$;D>
M$2G"F<0(ZP1(0(A=)]:=3  #4!U2$*MSA_?/MIL@#] "."N/07 9>8=!<-)V
M'UT?+JIQK-->&;=B9^R$&0-'CIJ:._GVC:N_^-E/ 0N\DON*J_E"O8;* VJH
MH88::GQR\9$\ %XIDP=@NM#K=N BOOOVF[_\L[^X4*A)RY@R+G?AYH/G30^$
MSYM"95;7^5KK:8N]6/+HQ2#%A<N82*4Y?-$<NAA=]JY+EO!%2[C2'*JL#9;7
M!LK,/66J#9C,09,E:+0$*7. 8H(&L=5D?T8"'F#\Y\V^$BZ VUJ,=2VTX#YS
MHVK]>6SNSL-S=AY:<;)X%UYYM/SF(;UQX8H-HT;&CQ@4,V)D0I^AH_N,21J7
MO^I@>669K:Z\KAYGK9305&'W(54-6TLJ9VPZDK?MR%X-I;G^N?;FO>+K=\Y=
MOGFV\GIAY?5S%V^<OW(3Z,R5&Z<OWSASZ4;A);#Q^OG*ZQ<JH K+KYTMOPI4
M6'[U7,6UXDNWM-?NGC5= M8_?L+$@8DI&;/FK3EP[#!J. -VN'CSW,5;9RMN
MGBF_<;;R9N'%6^<OW[EPY>[Y*W?/7KI]LN+Z<</%HYCQH(X^1%PZ=?G)^3O2
MV=O\V=M,X1T6+(]<?+A9=W'Q<6W>H:+U)67G[G &(6 4@T8I<*F^Y49]2WE5
MXZ'BRKG+=J5/F!LW=N+0U-3^*0FI\^9LO: GGC30YA!NB2"P,YJ[5&HLD>HU
M4KU>:,"XYH_A 4(NSQ]->7]7G?,!/@8)Y-VBSKC3$+^CGH_&_QWQ@/?_6QX0
MP5FY#;S3P#73G(.V>>FZ4'&-<X/N6O:JW:,F3.\_/&;Z]*F/[MWY]2]_ 5@>
MCO*]@JT$51YX/U0>4$,--=10XY.+[CSP^]__7OEWUAL/P,UP"L&+YR]?/G_S
MIOTWO_Y[GA76K=^>-G[&O!7;CNDO7C0W7K5[<:[Q7*UTEJTKEEPZT4MR?B,;
M,+$^(^<U<AXC*XM3Y#6R73)Q8!]Y-UA$WT-Q/44S'@/C,UG\1HN?LO@HUF^4
M(N5U;;0UHF-\%\S>$M:/B<"VMAA$'UI3?^+R_4T7L!4GSA<</[_TV+FEA\X4
M[#DZ8T'!Z-%)(X;%#AL9UV_XR('Q"1/R"PX8R@RBW61K!#Q "TUE5L^YV\RJ
MD]BLK2=6'-.<NGB7-EM-7 /-U!.U5KQ&(FMME-E.6^R4Q8Y9K$BMA-1(:)6
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MW/MW;_W]UW_W^M7+Y\^_>]G^$I8/!IRO\L"[H?* &FJHH88:GUP 'N!Y'O"
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MV*>9=^$<K*X#LX^DH D@ 0 P2:[("6OA0W7.?X4O;0&%!\#O!4@&@P <'Q
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M"A[  S(2=/& /#X 3#-T_S2LXB)//(49/G+'62'PT8)U+7N($@,TK/K2.P^
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M3D@;G)C>J4$)4&!E2%+&D)3,(:EC!_>F04!IF;+&#@9*S1R4DCDP.6-04OK
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MRK*JQH;G[]\&TVGN) (YG%%05LKE\04" 9_/Y7";FIL;P K^_X!\./MC@_P
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MF!D@_*EWB?XU$24]9V#(*^VW@X7%LI)W FW] )Q;-SP'K&\Y&SW-=:_&R$G
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M/@ D$ KPKNPB/H^//2< #N$K 9+<#?4_D+3/37NU3_RM]4_3OL0_(YGCI7X
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M[Q#,JWWL^[<B8%&[QP+2AP-_/;-O1/N3^OK9M4_V]?1_&MP,2/T N(@?/GP
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M#'E79+HG-6E;<((;-8T0D4/ )ATC2N8=PRU!!WX LP32#N[2]/]'/]!>[?T
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M/G!K^%7[\.'#L6/'%BU:M&_?OG?OWH'M^'5L:&B07KZVD2P"^0$$ H% _$B
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MS<-ZJ.,>0-8;X+3Y\DF0R4.<0'8+CC0\;7NH.+%<*3CXKO9Q;8=9N(!;10
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M[%=O4S,;U5EOH,'(<;,V>WB<8X):$5DY!%86'*N-B0C:DY'N04W924EVIZ2
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M8\>"YNK4J1/N 8 9  T(FDY%1<7&Q@9XGMK:6BZ7*_W/ ?^? 2$%^0$$ H%
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MU:U[MQX*W104NRHHM%./;K"&4%UZ=.W4K7,/907]?@;FPP</L1PRR,QH@/'
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M@WRI?POY3!$(Q/\PR \@$ @$ H% _ ?(#\&6()\.@?B'07X @4 @$ @$XC]
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M<R%WRRNX;8["$C7R"J^F''!9-7GF0N?=I[)?OV\2'RV7F;#JV9.$$_NW;]E
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M5&9%>?UDVJE3]TZJFH-G+0B,BG]54RN0:2^86UWM\YC0+0YC^O0$-594MYA
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MI^E)%'WG-*O^!N"D5%7[&4_8X)GX\M77G@_@NX2UCV.BMHX99Z*KJJ5OT-O
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MH>CMJ&IMNN3*M8]-XJX,Z5?EY\L;UYKRE)AT"LA1-C:W]1WOH*JJ2:,"H*)
M:<+2G;NVK9SAB-!X$'VLP>Q):XY>.#9WO*TZ*"-%0;1YUCOWIQ2)MQ9&%6;*
MKMW^*O(<!I4&@Q0=?>MYZV/V;PGQ<&8 +$SSR:H$;%Z?5H6M4QEB14]W]9O7
ML0LF&BDC% C7 S#(EK>9,^=,SB>\=<E@$/QY"#U 0$! 0/"7@'U1=_8U/;N]
M)M!UD!XXC^F!<WMFV;(P/8 &^0@$J*D9ARPX<.[\[=NWKQR)6C[>7%4.C848
MV&IC-##$$A.R$1J"ZX'C WI % MT]Y7>.[?>5QD-@@":2 ]D?14_W2TN2-XS
M6 ]$_!MZ *;"" +S9 4&IBY^_M.F3Y\:/#489>KT&=." MS=C)5599DPE4P?
MOGZ@-/_B^N7Z'$6$!F!Q,9\OIV,T;IRUJ:XVE\5%8 2F4M2];%8_>%R*/0GM
M*4G+D.@![+$RFP%#%(J,E+04C@R) D)87D8V@P)PM!V=#CW!XO+6[+QXB1[
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M<6L9G(#9>].S6O'(?KC',? +#N@!M#MR;$[0_.C70S-IH@/]_,X\=T^(A$
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MGRI-H:&J@$(BB3-+4@ Z1"9Q976"0PX]S:QN:VO^GG\S<G. @28?(@%85G\
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MY^*W+ZX>.[C[U,6LZO(.M&!CQ?,3>Z?:.L[<M3.SIK8\X\$2>V>NM P(4JF
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MH1\ &"+D 0      XD(>       @+N0!      #B0AX      " NY $
M .)"'@      ("[D 0      XD(>       @+N0!      #B0AX      " N
MY $      .)"'@      ("[D 0      XD(>       @+N0!      #B0AX
M     " NY $      .)"'@      ("[D 0      XD(>       @+N0!
M  #B0AX      " NY $      .)"'@      ("[D 0      XD(>       @
H+N0!      #B0AX      ""N_P#(?E6*W=48S     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_2a.jpg
<TEXT>
begin 644 image_2a.jpg
MB5!.1PT*&@H    -24A$4@  !!D   -." (   #;,4-D  "  $E$051X7NR=
M!5P47=N'5\1.5%0$!<16$#LP4.S6Q^YN+%*1[N[N[NYNI*21[NZ4AOW.LLKK
MLXL^BKO4=U^__X]WG#ESYLSN(^]].7-F,%@          ( _!T.X @
M    X#< EP          8"B 2P          ,!3 )0          & K@$@
M        # 5P"0 8,;JZNCH[.[N[NWN_0]CBY_3U]0WLU=E/3T\/82,
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M^?FIJ:G$(H$%EP      8.0 EP" D>$_7:*WMQ=Y0D8_A86%!-,D!@"7
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M565,_]QK< G29M2Z!(^&_OS%-$L8F9AW[5FT=!FF_QTL'!P<24E)W_^N P
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M2Q8E#5U-G5AU< GR9-2ZQ%L5[04T2ZZ]Y=.+2#CS\"D:&QTM;7Y^_O>_Z
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M&.K5=*LW[6%CV\O.P71';1Y?W'&KNCTWN.<N67[9(/VR1?G&#[XT'^.GG)3
MK#ES0*_$):N#VZUT[U.%4]R:!WC-[MR^55U>HO_YZVF#O%527VY;%6;7=.Q2
MR6)5R(@K_FJ=4'_>.-\IM1&=H&5"0T,'5EM=!0,N08:,<I> ZQ(   # . !<
M8LQ@:V%]]^PU'2&E)*?P0O_DWYQUC<]8<8G)$S#29M[F2:U6G^M3RW%W 6'[
MND^^4YMSA(OREM4^J;#W(M)+3_-@=K[B%):_<?K E.4'#JNE2$K),%#/?"NF
MPA/1,>F2'M.N4]*2XMJJBKMO"]QZ*_98UH)9*5_<NVC'2QU>R\\793TQ.[GW
M<)O(^Q6NNBF+F3@+LVC=)7XE$0%>ZIV7*1YY3;FB/>6HP!5N!0$I><RN9]/9
M'B@ZQ=SW;L7L?(E9L'J#5))6=-.^AQ+/5%P\_$-YWG#N/GV[J;J$2]YX_M%W
M=#S!-,_LSEV]\]8\?KEL_E6S J.8VIBBKVU=O5$%K79)#?+!50<U<W:K9@G[
ME!M&UZI'U'"ZU^ZZ(X2!N==D"+@$     ) ;<(FQ05Q<G)&*KIFD=H"A,RK!
M?W^F!#YCPB4HILVFWG='T#&M_FMW65-7;-'7FM9NC<BZO69M\V2J#QN4A.2W
MEW5A=^E5"X1T>E9A3U][2#%WY7'C<H/$CEU/%#EU_-_XUDR_87+BF7@?%AM0
M@CUH7'O7I5DGOLTNL;ZNJ>4XKWYTTI?\!NPY^[;'/K@W0CAD=&]^K#'KGN5#
M_SYAI_15YWFX+!.4XOLX1%S/?K1W*L7*>F8MF#TUR-$XKQU[\0DO9NKBU9(I
M,L&U:]>N/7'CJ4E:'Z]-\HI_WO-:)1B86DJ9>G\,:K6(+ R,2M@BE_S4H:SN
MZ[?9U2T=O58)]1KAU<JAU8>T<U9(INM$U:#UYXP+#IG6G7XNA@&7($/ )0
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M.TL:.P]HY>Q0R;+\7%_1A+,+;+]LI)2W/_-LH6#G1OO.7P3OER!QP"4
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M<(G^@$L      +D!EQ@5A(>%JXC(>6K9^1LX9WK$%@6.$Y? 3[..L0ET5K=
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MEY>'=XF!-75U=1D9&<@H?'U]T<^"@@+\)F<[1][[KSRU;--<H_*_5[&08<N
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M:R4-'@W]4>X2J =!$VMN#?T/!N:#OG'OCUVB_PUWJ#=N=7W\)&SB@Y(JX!(
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M?OX205=LI\X@Q_B%2ZQ@847-9LZ=^^/IHZ,SK-M T-7?,WO>O!\=#UP"
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M)0   (!Q [@$6>CNZ4Y-3546D]/X(/?)V@]9!(@$Y&_R-RX!&56!=]4!
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M^G'FX3/&=<P;=K$)F=H@D4 1,K4]?.WV-HXC#X4EI>QPEUD(SVZX BX!
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M]4!IG(CHR5V'C]+%H#WNGQ6S537!WH5B*J=C)J>S8/;?Z*5-*]85!Z:5!K_
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MF*TGK6X@H_']F.$_^O?K'VA):,EN9FSK;7+ENY3*?9MHZSYM7K$>-5(6\K*
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M717IY=T2)6<"$HEN[ !K@MU?0GCTF*5;=_RY:$F?/GUX^?AX>-$#'[@$
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M,-Q? @   .C9@$N 2T!Z0+K()2"L#^,:)UY^?EX^N,8)    Z-F 2X!+0'I
MP"4X)C#W&@   . DP"7 )2 ](. 2'!-P"0   ("3 )< EX#T@(!+<$S )0
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MMGX7#YS>N7;KZ3W'D#\\O'A[^?S%&Y:NIIA[%5)3"RC=?$ [,> 2'!-P"0
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M!#9?XMS>XU0+3P]=6X]G71B"OJ./H>.*^4L8(YB.6;]X5>>Y1-;G3Y^9/S\
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ME)FMF-JSNWIF3^Q<._GJ)BS@$@   $#/!UR"U2X1;NN'7"*;%(^OT$4!E^@
M< DE9\(C"_L;:L^N/]6^H::#GG17Q-1U9:P<E9P[;]'5=M*V2UC8J7F1D4*@
M(;Z<G:N$L27JTEU]LR>VKIVY#FSK@$L     /1]P"=:Y!):7Q+A@*Y]@2Q],
M+? 5.CW@$AT +J'I&WCDUH-^ P?U'SP$/0KVZR<@*-17B!410!$4$NS7O]_
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MI^M<0LF%@ ;6M[0,SCZ2'R(\@NG/H4V.WI70)@7CF_K5@$NT!EP"    Z(F
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M%XH4HA/7?FTOX!*M 9<     >B+@$N 2D!X0EKG$T3N2J 1?K2L"+M$:< D
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M6_]M=E^\IDT*QF]" 7.)YW;860@TB!\]<=)@X1',[^]NT!=1144%\S<4
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MG0)RROODR@L'3BV>MP!U"5R"_8.=7$IR#R49NX18$; )]/AJ_T_ )1@!EP
M    ]@%<@AU=HC8J_]3N(TO^6@@NT8."="+&D>IGXIKN%9E'IDVOQ]?Y[8!+
M, (N 0    #L [@$.[I$363>R5V'P25Z5M"!R_5+BG:@^INZ9?K$=.XJL> 2
MC(!+      #[ "X!+@'IM!11TQ)<@KWT[#.\HPJIG7D/.W )1L E     (!]
M )< EX#\6K![@[01?]JLB72OJ"!+0I)[:"[]CA/XM_]>P"48 9<      /8!
M7((=7>)#2M7%@S#WFNV"]*" DE(;F8]&]FVF(::H+JJ@)"@CW3LRRS<NG\S<
MPF\'7((1< D     8!_ )=C+)=!0M8B:ZJ%KN_3O?U<N7 IKPK))D$64!F4T
MQY>APV$HHZ%Z6[;-J-R65;LKIWQ+1N*\>(B53WEP)KZIWPNX!"/@$@    #
M/H!+L)=+% >DEP2F;URV#O5J\_+U<*\Z-DD1-2W6*<!;WU[COL*@_@,9(^\.
M>*ZHWQA3C&_J]P(NP0BX!     "P#^ 2[.@26U9L0+W:M'P=N 0[!/UBU$45
MJ-Y^C"Q"1'@4=Y\^0H)"PX<,&SIH2'L9.4S82<.B-JH W]KO!5R"$7 )
M & ?P"78T26VK][,!2[!-D&_& TQ1??.W)@Z88JVA/+DL1,>7;X;[Q(48.'5
M06A+.77>LK#@$HR 2P      ^P N 2X!^4'0+P8:RB.76/;WHL#GWK/_F&DJ
MI].245\=D==^<M&QR_5+Q+?V>P&78 1< @    #8!W )< G(#X*YQ/VS8HOF
M+O#6=Y@Y>9K.0Q54@J_9=0&78 1< @    #8!W )< G(#P(NP58!EP
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MMFKON,/*@J=LI!P3:E]_;'SSJ76:WGYJ>O,IO?BMA&O)E)//N"<LZ#- N,^
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MH*+YW6<TGL_*>EE14='ZXO+JIH^>\8W;Y?VX)BR?]^>,AKJ:5N_^2E;Y&^/
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MA@6MLV[C[X>IJ5\/ZLQ_':-E/2I<N'[3O^LW=V*6;MV)=@+=)8:!2P    !
MQX!+L-HEPFR($7;^^+O4,0?W=LY+<4!:6="+[:LVMM[_??@$!>?N6/:08!W=
M^(X^\'[]^G555142B?3T],_T&SJ\:OQ@%T8[(Y&0UZY(9%6\Q59M^D2_LNE-
M<W-B8B)2D=?-S5@%^AR)5XK>':W:%)K50%NU*:FF/9$HJ7YK$4);M2FG'0=
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MUJ$Q78?],\HI*6O'GV? !V)B^I=<E]!HKS4Q&(SFYF:5RO &)A (! *!_*\
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MZQD7^S/.G>N)W5EGA[,N#OKW_R/KB1WX\ZSK0U#GW!VON;@M^19I4($N 8%
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MN95&IU'IU-;VHK4RP;\HK=>]L(-W.@Q:LG?01Y_M.W'FRE,7Z!(=!5T" H%
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MA$ @$ @$@O*^N\2$"1/ +&J 6?\/APX?/F38F,]&W?GS:OGK+'):S\S@H4N
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M@B/B&P1\_9EN>VI3!JV$*# F3I:>80.V6XTX\.+3I3OVG[]VV=4)ND1'09>
M0" 0"*1[H$M E^CY BX1&%HU_D2(Z83E&)->WB^>Z7U3VM0F07MJDZ$IO@:)
M0E+?B&S";+;]QOP*GV]@R9!"U19?AFQ(!T1"861BW<B0WHLDN6-I/*'A9VFB
MLA;_9G_4*8W(TG#8+%Q5!8E$ZEA-Y/+D,<;$M-?$%1./![BD4EN9PI9& A[?
M()>_%09'>QN3 9\,VG!MVH68A"HV&LRJAU+=EE4O "(17\X6ZHB$!G6)10L1
M&_EHPM2?+*^'DZLH"KE"I58I=7?5 "A5;7D-2&I3J4YJDQY\L?IJ>..P?9[]
MIJP<.'C8OA-G8.^U;D&7@$ @$ BD>Z!+0)?H^4)SG,8<],3T_@"\<1]O;[UO
MJA"/;$@7F-LIM4D7@43U(H>W_'(X9N2B!8N6<#ELO0%@=IY0SK'7BH3HS7HA
M/8AT1"2>I=/U6KH[4+=IDLII2Z]%OLPD @>@M9)Q.)S\C4@ W-R?]I[XU8?[
MGD[X[5EX1@6)6-]07]=Q10+%/2!Z\'=7/CKH.W+5D;RB4MU#':35\"TC2+&E
M;&$7<1(*^(L6SL/T'3Y@_=7OG<M*M/O-&22GCH^D-A$,+VW2("*A>I;%6WHQ
MS&S6!DRO/F;]^IB?@CE.G0JZ! 0"@4 @W0-= KI$SU=[)NQ^=XQ)/\0EWNQ[
MC:*](H&(A+$I/D>H=$ZE/\N7[#EQ%X,Q^6+V3 Z[DTO(%.K$"BX0B>1*KMY?
M\W=01Y581I$]T^G4+BW=*. DU525E7_)N!6[$M,RE IY8V.C;F<"P"^E\L-]
MGL-VV@^9MCP@((#04$<@$'0'2.4J^\263W[S-YN]?<"0C].Q*;I'45*J>591
MI,ABELC02Q6+A"NV_-1_Y>D/]CX_\ ")G35(KC;^M:!!/[6I [90 3ZTYWF2
M7<=OF?0QPR#[2PR ^TOH%<QQ@D @$ BD>Z!+0)?H^=+;7Z+#)=K:--H>"40D
MZ$9$ MSOFDJSBZ<V<37W;R-;)<R=.Y?#>;NGF$B&-%O;:YNMC:4VX<ABFQB*
M&Y9F3%>  ^35\V,JY7ZQ16-&C4R*CP%WTNETW3&U5/G) .(GO[KT_GQ.+Q-,
M:%" 7*'0364%;I!8)?[Q0?H'BW_!8/KT[662GI:F<P*$-#2UJ9")IC9UA2N4
M?W/%O^\>CSXSMOWXL[G^8>UZL (\$ E:08/ F$A0N0J75)I] JV%J[E['0F_
MPL!]KPV5UB7L-ESWQ<S\$;H$! *!0"!=@2X!7:+GRZ!+*%7(SM:.L92@'(9>
M,&L'5)[<(YUF&44FT)%U1'=N(WO5+5BP0/VF<P!);4*6-B'-UL::CVLH$MM8
M\I-D*L](2[=4KLZOY_EETBLHJB8B8>1GG^[?O__QX\>AH6\O"]12I5YYHK7G
M?3%#)J*_2WOV_*R[Y[10JHHH9GGF2C;_<1\=T*]?OXY]KS5H:E.]P"("N2+1
MD=JD!SA),DYP,9(Z>?LY#,9DZZ;U>@.0+2^(VM0F E]NI$>BE2-_BJ7?CR(W
M,I$NCAO7W^Q[#5VB2[7O>WTW!#/?'.Y[#8% (!!(5Z!+0)?H^=)S"7\_7S +
M+B:*@$@$YC"-]4@P^ J/-/J]2%(3H[TA =WW>NK4J;DY.4JY3*;4O!$)KL$6
M9T #36H=0T%2FXR(!)B=%S3P_3)I>0W(<B86D[YY\^99LV;-G#GSSIT[Z!@\
M7?H@EA)1*7_RU&?.[%E?S)GSQ1=SP)B @ !T %^LC"YA >>I8FJ" OS&CQ\'
M7F??OGT[7 ));6H0W@UOB2EE&[LB 40BI9+[+)-=3U?M_>47<(9MV[;I#I B
M>^<)ND]MHO,43]-H%E'D9F;[A]:Q[S5TB:Z%NL3&VX&8N;\B+L&%+@&!0" 0
M2">@2T"7Z/G2<XF7OMZ-?,VC.$I@+L/8M0*N4.&&1>;$33KQKZA+].[5:]*$
M<65E%84M;0[1Y$3CJ4W@L> ,[E@:UTAJDURA+L8+?--I8(ZN5"$G:5.K.1P.
ME4JE4"@"/K^M34.@RVRBR;Z9-#I?(96(F0PZ2PL8(Q:+-$A?N#*VE T\(0\O
M5+=I%#)I4% 0>)TF)B:H2Z#[2-P+;XDK8PLDAD5"(E,G57+=4JFM?,2*]N_]
M%=/9)<#+RT=2FVC%!(&Q*Q(<H<(EA7H_^JU(:'1<PLRL'^R]UJOV?HFK7ICI
MV^$:)P@$ H% N@)= KI$SY>.2_0';_SDK2?^Q;*@7(:Q?23X8N639*I-+!E/
MZ[2S->H2&&2:;FKCE>*=)TVJX(IDAB?6C0SIW6Y3FY#U0GB!3SJMI%%HK/&@
MCBJQB2&_S*)3.6!V;L!81%)E5 GK7C@IGR!4:&T$ !0"?9V9&8A+I-7R+2.1
MU"9C(J%0J&/+.!Y86N,;!]B[=R^FLTODU".I385XH\W6/)'2*9EJ&TLA=/[0
M=%S"S/PT=(E.!7.<(! (! +I'N@2T"5ZOK0N43UJ[V.,J=D'<S;^;(>-KY08
MF^)SA,K'R=0'<90:2J<Y,>#6[=O(M]C+;.2Z/\]Y5>829,92F^K?(;6IH('O
MFT$O(0J-K1>J)(OM8BD^F30JU_!^<V*IZG4AZWXD*:=!H+LS7GQ\/'B9)AA,
M7G9&(:G-*HH4922U2:,5B9A2]O-T>CWM[148/9?(K1>\RJ(7&!<)MD#IE$2U
MBZ/4MNI_:->N7T<^M+X??+[V]\.W["\[/X0NT5'0)2 0" 0"Z1[H$M E>KZ
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M5HO$O[[^?^R]!WP<U;GW+VH2@B'4D,:E)5P(:20A">^;7!(N*5Q228"04))
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MB-ITO!]K)-+4IE[, VFX7B&B-A%-HA6H31&&VI3;HXT1HC9I$;5)I/9&V#Q
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MUSUN5_8;.''BQ(D3IXM;%[N7N...NR[[UK._+AQ=>[#Q_5U'WR\??^K@3+7
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MX@/E4!?^$[ALK=2*]=(@BD!@@$J2G3SA$"3&'0(X$9(\I+/ 03X%X 3-$^*
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M]BJ0;_41"1DY&5DY\GI@(#Y26YEE)Y^O?ALB=N"9H+CLI)Z?O^W4AG>!BU[
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M PM7B-Y\L?_4M<TBT"^%(S^S34HQZ7G"$W^< TU&/D$.;E)'B[]!'@$V\.^
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MJ4>5:7HEO;8+48PHU8C]1>\W)V5BM5;H-RTA<G#O+N+P<%WKL 8<8QE3[YR
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MPEL)[O@![J0<[JD<X36!X5XJD=[*$=X?@IV!C7*H.Z4!B: 0\+]*@0X?@EW
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MJ<,T>Z[2Q\_'SET%6F*-?8M6= ..T.P4A[KL5!A?WMK9-Z05A3-"X%M'7ZJ
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MU!:NWG+HCI:.0\@\ 2%F-MXW1FX//EBL6KFROAZ;GIZ.B(TI*D$'9#;JA6"
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MBWMFDT$L7C\6GUO7W3=(?!>*/6&5):R4Z98%O6E!X]K\4M&MK:W!A2T6B01
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MA0L7 -R\>7//GCU0(8R,,'H&!@9&%@X^?F%):VOKU)3D%2M6I*6EW;IU"Y3
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MU<8ERPV*[!/JH@KJE^@5B:@5;#(KBRJ#1G6G57<!R[W6J-2J3KT8O%(HMIP
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MK%-"P[*K9F>>F63E08,9NKJZ#A\^+ $:M<[.$6&AAP[L3RFJ?Q'4QK'V K>
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M/DP[41U>]SD5M,@'XTJZ3$*Q,060$AB/@@:B;C VIK"U&$]T0/9^R:.<K*,
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MUB2NVCBJ5/_.(WEP^KYQCY-WHG)DB9YSV(VP0IV$&I/X:I.((EW@)+$51O]
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MG&S]KCY#^X*?NO^5<9?Z5_=!+Z1WYZR.@^0W,/>0EOKSBI^-[Y7_6%>,@("
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M;FP:+D:U)'HI6P+F+;A44"_T^SPO873O//@Z,#"OQ2?$74M-PLQ!S<A&^<L
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M@9.+Q=)/+CQ?"SM@6)XF?!PYAO.8MCC4I9X<'+:!\H+$DR8,#FCI=X"-$PF
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ML^9!9UC%I[R;G><;OX15?[[YFGR#>\\_)=:\3*QN/P]M1^:#W*;7'5]^V@!
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MI;/SJ[26,XNTIX""+[V *&#L-AG1OYQ[#9<&/ !@F5)O4MC:T_6SH>#2FLR
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M);JQ(UH;JQ$&Z+)2P4_5+]SV*Z[AX&)1L]RA[RBM92N)R=!5!G9G9D56>!@
MEGCQHEW-P$Y@^J(%TGH'M1RG3IZX:.'"MK:VB(B(PX</BXJ*ZNOIIJ=>F+UD
MG:IOL7=Y9T+Q#2T-#3@"(R/CPH4+1X[\:>8,9OS\H_?LD79S<W-R<N+CXX-O
MYHO.EI&6W'U(PR*YS2GST8PEFXD;]Q5+!*6K]N+I(OY< A<N7+C^B7"6&/(V
M?%BBZ.Z9"_6F)_0V[SVQRCKP(+C:YXIUP7$!5S6IQC@/63"AIZ.K^U"#AR7
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MS;YF<S93(ZG&].(=1]*?2A\X4QZ_&]6]\JIX[+ID+<(2$GL6ECUP*>JVAA?
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M,N7=1";HQY3HQE<:E#YT*'E@7]+6I9 YRO]B!@XFN)W/5QF$YFKF7+<*R].
MVWFEN,C:K;.7K)V66&T47Z&/L\3_@;IR>G"6P(2S!*Y>J*O;BH"SQ%"Q7[($
M-<W_"4M$7=2^T1E@YB6[9>_"3;OGT=+18!>H9+3URF<?:)3+'CG^6U4]=ZEN
M=]LLO8" LP0N7+\2X,2%!M.(0NV84KW<&U:#X7'B+P5^9.IETZ@BG<1+ADDU
M1H)"?&NVS)8ZM)Q]!+-;S(D+#299URSQ,4Y#75TY/3A+8,)9 E<OU-5M1<!9
M8JC8+UD"S":PWQ=(ZB>1QH1=N'+*UGV+^ 6XX#T# [)Z#F8SYX^7.;YRE_RR
M70>7_EOM/K0,O T!(3["7\>$Q87K_U4%K;81^5I^*<K@J_6WN_8W LY)JC$.
M2%4)SE8W=);Q2E!T##^R[^1J>)/9;)%W>Y"F'&>)GJLKIP=G"4PX2^#JA;JZ
MK0@X2PP5 Y:8,&$"%)BPJ""XMEOW+MRR=^$VV470M90^=*0L\L$O8 EUJYV<
MW*R2"LN %B3V+)"47[;GV$K94VO@#?L(9O*J.F@,9PE<N'ZI@MLVB9<,H5&*
MJ]#/_;$NRB!4_BW;S&;+J"*=D!R-],MFZ4WF<>7Z"56&*?4F.=<'[Q,5G"5Z
MKJZ<'IPE,.$L@:L7ZNJV(N L,50,6$)0<#P4F(KY]J8/7J4/'+$UAO/1M8<I
MBWSPJZ;=[92A!"<WBYF7K%O,<?O00_:AAQW"#GO$G31VW\?&P41>50>-S5DR
M,1=G"5RX*(3-F@"_W#M1$?SR@L&]=%0>NK1P?(5^>)YF8K510:MM?[N8?RF<
M)7JNKIP>G"4PX2R!JQ?JZK8BX"PQ5(S($DHF6^M>N4-# #T?:#!WU=T+:J2I
MI^S(,9SC)O(*"/$)3.+%)"C$!]^,Y.?D'<W1W^+CY^3B9:.FH<9N!B86!KX>
MG'>CY+Q<-$HLY47APC7,!4Y)VF6ST#R-B$*MU$93<-H&Y]R#7)1\<M$%9+);
MD"6N!G];BK-$S]65TX.S!":<)7#U0EW=5@2<)8:*$5E"T6C+_]@["[ HMC:.
MKY3=@2W&M?-Z/_/:7CNQK]?NH 5%1)!&!10[4!0$">GN[NXPD*4;Z=SOG1E8
MEMV=%160.._S?U:<.7.FSISS_F;.>4](QPB3^HN"VMPF2OZMJX2.G<A+6^&7
M\$O(5EC'7@26Z[M=:6N9!<MHZI\>,J(_\3!LVKO0-/"Z@:<4:TI&F?A+NW8&
MSP,)Z3?H$];> $6\<A #Q]<F4@YC"2QB+.Z[$[^L6_T^P8-,B'551Q-BB9:+
MS.E!+$$(L0323XCLL:(@EN@LUO58PB59&:JSP!S-WZBXJB=F03(CQ@PB'H:#
MYU;%5#P.R;_/FI)1OAEW64\'"0F)$+0W4$'91,H;>DF]L!$R]+[JF@S>%38:
MFU 7J+Y^BQ!+M%QD3@]B"4*()7Z7B+<J#>]66-;^M!BS;4G.3.E;*"@GX""Q
M/E84Q!*=Q;H>2W0$ 1CHNUT9/FH@\3#L.;'</TO#HT.&ED="ZD2""@J>(X=X
M!5/_Z_KND@:>4N]]KK[WO68:<-W 2](\Y ;.&\Q;(7$68HF6"[$$9R&6:'^Y
M)"O#188R0)=/VAU8R)KRAP0Y^&7<9<P6Y$V]398S-L+VDTI@MB;3)BU1:)%V
M,NWE9=GM34]4HR&6Z!R&6*(MQ,02>T_]#<V,U]?;R,M!0OIU@8/BGZEA'B)[
MW_B\MO'Y!Z87GEL+/;<1,O&7=O^LAIZR'Q5BB98+L01G(99H?_E0[[QQ$1=1
MV$G7,RNA7PSB JX@W,K[[\\R9@O2L1?QIMYA3>^*1^YV3E12>/(?TR8MD:CB
MKFMW]BU?/[/IB6HTQ!*=PQ!+M(6"<C7U7"3Z]N]%/ R;]BX$E'>(4P!P]_C2
MT8.Z("%U6$$%!8^/4Z*23:3<>^^KKYW$H1%]ZR)AX"EI'GS#(5X1U6 _(<02
M+1=B"<Y"+-'^"BN\+W5[;U-9I%#.26^)*7_,H3*$8NS^A5.G4'!4(KX]W'UT
M*6.V8)=O;@\MO,]V0]_T._:Q"M/GCF':Y!?MP($#S&YK1S7$$@(4Q!*MJH L
M#4,OJ1GSQXT8/0@D>&R9@9>4D<]5BU!9NYA;V/2W6!]!=*F1D'Y ;OA09L=X
M19, Z>?60GIN5QSCE5P^*@.HDWUV1VJ)$$NT7(@E. NQ1%N+>)]"5(88$GQ6
M#2O4OG9W7U-9I% .GEWIDJ2,E4:2C[3@A$!%ZIRHQ+JJ<1=J=M&W-NQ>P)@M
MF+#\#BAL;+T7@B6FS6EEEMBT:=-7CE945,3LU_XF0RPA0$$LT:K"7ITF*!EZ
M7WWG(0GZ$"@#CZYMU"UHL)^87S+PE'2(4W#]2/J<(R$AL0K\$FC_WCA+O'(0
M-0NZ[I2(S?Z&#9!H;%E9-T%JB1!+M%R()3@+L42;RNT3-BS!.:GA!8H+_D=H
MP7UIC?U-99%"Z3^P]X&S*^'*>Z2HL^2 %5%P3K!:-/@&7G,R[P4;%)&DO&'W
MGWWZ]63,EH)/1,:9)>8OF<3-S<7-\_/BX>$&H^^1CX]O'$?3U-1D]FM_DR&6
M$* @EFA5P=,.C8I_ED9#@*;T.^[XP&N;2#GSD!N&7E+0<AO[21,^$.OF2$A(
M3'+_K.80KVCH+?7611P;8_T)^PK/F@SI)X18HN5"+,%9B"7:3H33_\Y3\K'Y
M)3VW*P:>4CKV(CKVHG#-;]P[V%06<5NY:;8W]0ZL8LX$BFBRRFLGL6=6ERU"
M9=EZ(#YI=YP3E6;.'\>4)X4C2T"%[)RHK*9S7.'Q?QKZI^^\/?43NOWF^!-3
ML8=O;O*/&L:\;Q(3%Q=G]FM_DR&6$* @EF@7>:2HP;/M$*=@X"FIXR *..&*
M?\1@38F$A,0H>';,@F] (VH1)NN.!AVUJA!+M%R()3@+L40;B?CTJN\N^=)>
MQ#3@NF7X39LH.8"!-RX2UA%R8HJ[FLHB;AL$_V3/$KB/!UL]L;@$^; -?$>P
MQ,+E4YCRI'!D"9!3@A)X-4Z)RN'%#UB#-;5$0?EW8\MT4LN]#8W?/N1H]^_?
MEY6555=7#PH*8O9K?Y,AEA"@()9H1P&^NR0IO_>]]LI>U")$UB49ZZK!F@P)
M"8F0^Q=5FTBYMR[8I-=X/V#T1:(UA5BBY4(LP5F()=I*GU0<$Q1?VHD\MQ8R
M])+2<Y, /3*[^-[G*K#$,9%U3641-U*6P#N%ZCJ):QF<-?2Z"C>H55C"#0^)
M81H@;> I91,E_],/@G.R@OO'.XFY+LRN*CO+RLJJKZ]G7OK[#+&$  6Q1/L*
MGC3G)"4CWZLO;47 2?)(0;X1$A*IX $Q\)1\;BV,S6KTLZT4$ID02[1<B"4X
M"[%$6P@<,^<DY0]!,I9ALD\L+DFI[[UQ_^#-!_^>O[[%V$_:FWH;BE]36<2-
MC"6 29P2%%\[BFH;G0<F<<6GBF-*\Q,LX9&B;A^K )QC%7[3DV601LL%+.'Q
MZ6Y"CG-U;1FSM]K<ZNKJXN/C<W-SF5?\/D,L(4!!+-'N\OB"Q4EX82MLY'.5
MB.S$F@8)"0E:.X=XQ7<>4OH>DJZ-W^B16E&()5HNQ!*<A5BB+42\]7_O?=4F
M2OZEK8C*RV.WWYP4DMNA\/2_EW8B9D$R9R0W-95%W-BRA/MG-9=DY?>^5PV]
MI4#Z[E<:AE]_;K:['V4)-SRT%%#$,ZO+\/LK[T;I+%%54\KLK3)8?7U]>7EY
M8F)B?GX^\[K?9X@E!"B()=I=1%A86QPG3 .N_PK*(R%U51$?(HQ\K[WWN09_
M>*:H>9"KK3VYKBK$$BT78@G.0BS1=K*-EM=WE]0V.F_L>^V!R?F9?XZ_=&/;
MWQMG'15:>UYZ2U-9Q(T-2WS"RH]=S*WGUD* '[#JG8?D$XM+C@E*3.7V1UG"
MXXN:=:3<:P<QJ*B=$GYIDI\6L@0!$MG9V75U=<SK?I\AEA"@();X'?+XHNJ:
MK/S23L3$'[$$$A([X<B-C34,NQF8H^67>=<O@U3(:_DY(99HN1!+<!9BB382
MX9N]L!4&$G!)5K:.DM,R./O.75)&ZZ"6P1EP\9O*(FZL+.&1@H&$CKVHH?=5
MIT1%KZ^W[6,5WKA*P+,/.,$8%N^'6 +*O&.\HK[[E1<VPO8QMW[Q$6@A2^3G
MYP<&!G:<F24(0RPA0$$L\3OD_EG%)4G9V%_:V$_:(58!77PD)":Y?U'U3KU]
M155PH^"?.PXOWGYX\8Y_2:6B<RR\^ $1]) U*R0R(99HN1!+<!9BB3:599BL
M 3;P^HJQWS4  R.?:R8!U_TR[S+-54=ISA)NGU2@%K6-E@<4>6DGXA"GX(Z3
M ]"%3;3\<QNA5PZB#O&*]#O5<I;P2%%W2E!\YW%%QT'4(E06W]<O/0(M88F\
MO+RPL+#T]/3JZFKF=;_5$$L(4!!+M*I<DK$I)X/R[C$&.V-5*"YH&Z!2L(F2
M0Q<?"8E)'E_5_+,T5FZ<Q=RFL;,9\\?=U3L-WAZ:>N*'A%BBY4(LP5F()=I4
M<'FM(^6 )0P]I=[[7'WK(F$>? .\B.M:!YK*(F[ $CYI=X$* !C (?D0* /
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M_;L(R-[ 2XHUMQ_56U<)'7M1=L+FR-1SD[ *O\E:H31<);P F 9<9\VVX\C
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M\[*>"YGHFT [!X096JB][]1RYAUT QLTI&^S_W,-[+=6<L!614I_\KL_:M&
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MU";GF*+*&C8]M5H2ZJJ@I,8D,$?)*BV:89A[.[ $.'G+UL]8O64._%?+\,S
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MM\R,]*KJVI"4RB=N>58A>7GY!<0T%-75U9#2WMX>S2_!0>W&$HQQ'.0KO@
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M%X<\S< I*%\KM<GLONN-U5L$5E'7ZJT"RS?,.GANE6^6>F0I95H>!*$L,5.
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ML5GSIB)YX,>K(PHM(%.YF=G8)^X^_A_\ESP-59'?\#Y+1&%?V'O +62^*8G
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M "?XW*W-4%_-G,/NGZ.1VF2*K/U7K@^, 3!\[M:6RY+;V3F9!(4W4 MI$$Q
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M 1C[VJU8B(K=W2**B1>[,3!14KJ[4SI%004)I9NE2QH!Z>Y.$43@/[.CB+O
MU5_19?F^YWUXEIDSLS,[LW.^=V?..=&5CP.R54@AO4WQ_Q"8IQ9;HW>/** +
M%L]X$RT55:%#7@R@,M!Q)V2KV 2+/O%^Y!PG'92G3EZ&@LA6#<I3\\]6>1TE
M8>[.ZQPK$YRO$4A>#*!8L%\!L5/.^[VB5ZH"_M<G78F W0U3(R^,_@9BY54)
M6=B%KF<9=*XZQ4I9^?/WPQ,O7C,W;E,W;K,^0+-,7;DMO?E>OY5 *P_$?HTC
MVV:J UWJM5_<0XIE^)HSIEJ7O,#/03Q,Z(L9G*].!6#G&'&/4 UH%RZ&W9=0
M/1=?IT^ZU[],<(%Z1)GV_N/K$.@%^I>\S$] _ :1[\X@!9U.W3L55Z=_@X=Y
MQ?H%Z'(17J)%NN,_";K^^&>A*D]$QN JG_QI#>L[SK'2@<2;%>2%!PKR.PF_
M'?(W_7GPM/#B7<85Z^>_"A-%E].%#-A 9)R<G*6EI:1I*Z4&N 2I2WS?7J(G
MI$^Y_1] >XDA2%"^JG^6(CJOGGCSOHF1^-IO/6DQ2B,@5\4O4]&:P&_LS.D4
M(Q%<H/J##]D#% (Z7GB?2]T0>CN"Z(3$1WS7MKDCIGT!N0'VM/37DFAN:)'Z
MVTJ=WT)XB09:X1!Y<OKWMI<@7C>4PDHT(LNU(LLT!S?E6L2K(K9'/=I+G*7\
M]A+8EZ5 C1H.01EV%-#W$=^IW]Y> GU*SO%2T@97U)ZQ&SL_E#&ZHF%]B_!E
M&%_2PD,</"T\R[Y[T^XE[SX8H@]_V=IY*$544E(BS5DI., E>G4)Z,<)^#_!
M$K@\U2 B^+AR;V(E+3QYGOGQ.\=)$K*^C(E.^01D8ZFGUWLYVU!A2V^^E\%"
M'LER*.E$.X7OW6#9$:!_4%;G\4Y.U^Z^BB76L ']?>+-]^-]/0%]\7O[<0K*
M5_//4GZD>.K$I6T'6=<SG]PP&#G(NN'PZ8VGK^^T\.2-*-4D#*I^G- W JU!
M^^7=4]=VDN_:X *=0NA$XI4[Z9>AB-=3O[<?)U0)>KV7-W7C5K*X(6M\5<V*
M_46@(%Q5>@5/"\_=VK-^^R)T@GF_EV=8-><'\V3*"7 )< G@MX$NE+X9BJX)
MTLYQ4DZQDDZQ4J^C):P) D^\>-T2I='1'W174FR;<U4<(L6>^CQ"5;[C6W&G
M&$GG6"F7."FD%GZ92N2+ (.+X (U=#3EC*^J/+FI^^J^K.%5'=M[Z$0%5_Q%
M?J]+A!9KH&O+LC7S9LZ9S,2R;O>A5;N9!Q^,Q]9LWL. JC]A]7/Q=7J$P>82
M*.&^PK%_Q,CANYA7[CVRFGP'!P>'5J%3:/:\*8M7T'JGRH>7:/QVER 0/_F@
M/%4CIX>RQFPO@X7P=R$O!H!+_%R 2Q# ):B=P#Q5E&%;>O.9NG 9.7$:O'YH
M[,1I'R:*TC5T524O/U@(*51#><PS/W[MEW?U'3A,G+G,W+AM0T2\TQ3("P.#
M"U3!^V<JH7Q.UNCJ(X53.C9WW9)DX1?$7^<WNT21AD^:PLH-"U#"EXP]"*&)
MI@PZD#\XQT@N9)C%KW0:-X?!Y1+HF%ZXLW?=MD7HDHZ.*?D.#@J0*B2W&-T6
M.+Q\[3S/%#GB*.^_WR4(W7?I\^$F=G^ 2_Q<@$L0P"6H'>S&;BHVM/!3;SX+
M+UYS#]XGGKPHY_9Z+T_(^FZPX<$"/O"97Z:B:X+,\T!!HS><R"(LO?B>^3YR
MB! #EZ .B(=8R394Q-*'SRE6$BK^W\) N,2JC737N0\D-NJ'%*@'YZL-.F*J
M'K]^*TZ_=): \IE!ZA(7[^Y#+A&8JQI9ID6^@X."D *UQ":#6_R'5JR;/Z N
M02!^:(&#\(;\GP1<XN<"7(( +C$$\,]20E4^2K+1%0&]0%=JI!:&;QXXOA4G
M-G$;9)=4Y!)^&8I/??E,7+A<XJ50->.3)N_]7@'MFF^&HG\6:7E@D(+=G<A2
M0M*(OR8O /PL ^02;)Q,L36/!^DQ0OFW?;CH0H;![1)KM](C]PXM4B<O,R@@
MMK36O<G'_ =< OA/P"5^+L E". 20P&\\YP\5;P%-CKBZ-)L%RYBZ<V'JDS?
M=,7!\J,OGJRX)$@]\>)]YOO()4$:59]?6ET3&UX'#)(= 7Z0 &)?3X,T2:5
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M<PFT85ZI\JX)TLYQ4FB;U:UN:5C?1CH4F*O2SS9W0^(2&W<N1F:%+IK@$@
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M<(F_0V">*OH:/R>VE[ )%@XI5 \OTW**Q5Q"SHA-\O$E_(B 2U !X!(   #
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M'A^SFUY=8MF:>33$IMCSZ6>LW4*O:7W;'VNKK8TV9O7FA5OV+D.K"B\%EP"
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M8_JN]$3:?P[PC3VM2;/T, W#H3%')(:O_O>[ B@#7G%HPEF=89NNTBP^,/J
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M4XL^F >6!Z4U?/[\K3;+JVI][%NJZUM:5-V:5/CQIFG,5*X Y!+.[Z&]1.^
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MK&#E5;#V\([(RJUNZ:5-VV\-< D &*2$EVA&56BCO^BU:X+T\P!!<P]>*X*
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MX"ROL%QA17-;6YNLC+2[NSN^GL3\)@V/XC=Q-;$%K7Q&?N.O6#,BEX!QK_L
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MB9'A^G7KT-P+I__5-GO)(F"AYYE75O\YI[)5T#9U*E\XM)?H!W ):@)< @
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MW7MLVSOF[CP"2F=H:(;A+L'&=2"^7B^T4!U=0]'?N%J]:UQ,1)>8"RX!
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M7T:#*)=4:"_1.^ 2/TY CHHO=FN"R]I? .7H 3FD!?H"7 (    8(H!+#%R
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MM+([O6$M 1MLL,$&VW_*YK*6.&RQ ?^,)D575Y<86,YQ8"U!T!*>F:/(_O'
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M#)/@S H9&1D2=WX/JU:M@KHU&WYO+<(C)"0$=6N6&!D903/]A6S?OOUGNMP
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M 9()NLU<Y3^M)6!@_@CV[]^/TQ(_]%T"B#A+2DKF2/0, P,# P,#\_\;6$O
MP,QU?EQ+C(Z.(I'(YN;FN?#2!08&!@8&!N;_/;"6@(&9Z_RXENCN[BXI*4&A
M4+^])08,# P,# S,?P%82\# S'5^7$NTMK;FY^>/CX]#5\# P,# P,# _ O
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MEA#A3/2V9X;9KE\FQT62A(9??)GIU9=%=4!8VY_Z\/12DG409/1M$DHA@=]
MVOU]*SB@*7&P'/?+!T+VIDQ;;2D$$\]*S\CF[VD)S%CUQY!+.]0D.1A)<V 4
M6VQXVCJR#$DJ$@;*,\,N;ULF)C@M*8>@XMJM[A^^M$Z.X=:=&^.H14^:A BK
MO*;%HW>U,ZJ)CH;(2SK F>8RLXQIFCI#X_4YGGJ2%"+BFT*2I]]IABM?^.[
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M7TWWF(TC,;G=R0,:0O0( 9F33SZU@EZ@N[*BK=<L1- Q2!CNLW#UO.'A?N7
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M;04/SN@N%!'4=+E?T O&.N-%GZPW"E+P<N\,CP$#PXF)RD=V1G)T@D:GHAK
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M;0L-99XEC@\K!J9=?^CNEEA'8SDV2J%=9\,^Q3\XIR^T4$##Z5YN)_R<F\O
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M"-G]%^* 6CC8G>IIPL<ZCWH^ZP+B\4M*20@+<##12F\[%%S0,=/Q3VH)J!L
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M[W0EWMTDQ<\F(K-NUX$I]IML7"+$MTS6[,D7?&$V38[CY(_OG=!3%>5X4$6
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MFXU)?#79NGHIOZ#H9M\'!=-[8$_TU[T\8[B0DVWIV9NY ]!O=3!S#UA+P,#
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MO8#(D=>$3U5$QNH*;N^19!:3V1_\J86T*O;7/CNQ@9>)7M[<*QO6$G\ L):
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M%:F'HP,-P+ZBH\%;Q#!! :.:R[)2HI/ROG61?P3"8@>;RU-B/\;G%K>2C.4
MG-S64N V$9M>6O>=BPIF3@%K"1@8&!@8&!@8&!B8?P*L)6!@8&!@8&!@8&!^
M'>/CXUU=7:.C,WQ9^N. M00,# P,# P,# S,KV-@8" W-[>GAV1DXS\66$O
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M?!87D]TZ0AP ;G[($@   #>60,G/289^G+'G;I%MBPIAN_&G[OXYD^GZ& D
MMSAD"0  @!M+(+5*[:+<7[NHZS^-BU)_S<Z92&;[?'0 ^'] E@      @$8@
M2P      0".0)0      H!'($@      T AD"0      : 2R!       - )9
F @      &H$L 0      C?@;*[!ZL:&J*0H     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_3a.jpg
<TEXT>
begin 644 image_3a.jpg
MB5!.1PT*&@H    -24A$4@   ]@   -A" (   "3C82;  "  $E$051X7NR=
M!SR4_P/'SR:$LD4D*:%2TB[MH:%=&MI+-% :MLQ0I$%(2TN#[#TK%0T[F] R
MT]3]O^?Z^?F=^OVKOSC]/^_7NWNYYQ[//7?/>9[W<SWW'(4*        Z' H
MC ,         OQ^$.        )T 0AP      (!. "$.      ! )X 0!P
M    H!- B ,      - )_%"(-S4UO0< @*[,AP\?&%=M    0*?R0R&>GIX^
M9LR8D0  T&71U=5M;&QD7+L!    G<</A7A,3 P%  "Z,O+R\G5U=8QK-P
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M,M\?;SLFLYE>[T9F?LQ4VJ%3BS>,S?IXDEQM.UIG21:]D]^ZKW\4_P0A#@
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M_T;RTD*(MQV3V63^$#=S6\[-PZDT1&;PB#[$'J+\9%:%A877KU^/K[@'  #
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MUOB;[X@3(_-LGKP]=O#HLM:_TE5"//65Z[)-?X?XM7O[[U8Y,_\K$R$.
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M=HX(<0   *"]0(A#"']"A#@   #07B#$(80_(4(<    :"\0XA#"GQ A#@
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MR\DFY"93MV4'7)>:']/QO*U/AI,ZIQ<\_"G)4T?*FZP'>O<5G;%X&$(<
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M?V6:;'I$*C/*Q(B[S-E74.&E+O.R9CO2EZXSJ>;,[DS!ZVA6E_\NXPAQ
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M    2@9"'$(HA6R(]_ZQ';T!IRQ$B ,    E!R$.(91"-L0'#._(A#BVB ,
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M$>((<0   )Q"BA!74U.GE9FIVZQ[^;M6&8]KUT4]Y+HU0AQR7(2X2(0X0AP
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MBUA_-M7B]"7S(J0$C[N_.1JG+_P^.1+BY:8@TS'VOO.X67T5F!"?*OZA!@
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M9]>>234OV;GJ*H,5*<2CA+LD!5ZQW!>A?R1A$[4X/X-7NONH(,1%(L0!
M3L&M$*<"B[AK=RS1V#]Z8TB:M0 M7I@5+,3I11=D\LZD6O@&Z_KQ#<)NVGQ^
MW86;QOD9PM]_$5JR0$>(BT2( P   )R"6R$>)=Q7@3IIQUF=8^>-A0?PB0\
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MCB7>5[C"6(%#7"2S4WB6XX7?78\G&C?1J,<V]#SMX<EY;M*^^@AQD0AQ
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MJI BQ $  ' <A+C\B1"7'+((*T^(,V;P#@HV[@G3"[UA+<CD??-'[RNV"'$
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MV5HJ#AJA4M,  (  241!5"JJRG2Y[<3JE#QWR75P!18A+CED$2+$12+$ 0
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M7.P50X0X    P"D0XK!2&YWM&)EN?S3>:%>([JD4TZATIM$E!ZL8(L0!
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M(Z='*7@C#:FB6HC,>"3&4!S9KS22(RQ:=H+IDBK9[=#RHD.<_9H4>,72+\J
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M40&(VX2)S65$KG!''NL'$\G=/?]P=E9)LZ9[L65454M'3V\O.:NT]95_>>R
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MW9+EX0+S2/H8VE? 7COSQU6/BB!.,V$@3NWY/041D1<#04<U\Q)\Y<BG9_M
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M%EX9@L"?BL_#"N)02"BJ=Y82%!L*#U7XG" +U8%*A9=J[3ZVIK_*PP'B0<@
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MU9";R.3*3G)9>?F\E9MQ8[%54T9 Z)Q7H'#@RP]^S^ R@3Z(&4#I)!"^^J?
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M PIZ;JC;CMLOA6/?S[9H@;B"VFZ]5/G ACWB%D?NRUD[NBJ8!TX8BQ;D*\-
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MYIVA1/TM*EJ"N)F7D&N2W/=N7?\.B!/483 &+>44*_.]9(>H80)QX. //L^
M^;[9TX8/Q&&T8Q4J!B#^@Y6_?P_$(4$ \7?>0CZ4==RI'8:H805QJ)=]E)1%
M@$C =R+#_Q:(ZUK=*R-;/) X@J,QB)-()":FA9"KPJNKI63SQW(G,! ?*6$@
M3NV):<3U%8BS\9XV+^VBA Y1UU*KE"8TC,3'1"YA8['W#I4-Z;!);6[J(.?5
M=)4W=G5U=L+_DOZ-C)M.S=QXANFB.@Y9.V7BXF>>O&\K?7.:8=^VCJ[<BD8"
MJ:F[IU?6KV:]+L$\K5O_I=&V]6LRB<67;&O\B9W@]C&V2B.B+34Y8=;4B6BW
M&6C_'T!\S68VN.H#U(8C;R>AG>!LA2N"723R1LSOG:2_!^)0'>],)<M@4;\<
M5<B%.NL_I92F5Y^"1&;,Z@-Q"*WI;48198/=?EN1Y5H.T5)PB'X 3/T@+JQ^
M5E;O,A1C"<<"V (7/NH$?UM0DJ "#<M@,?<4^>]-^*$&<8WWM^^+'=G(_4,0
MSU5UB);TRE"*_'<ME=%F)&>(Y$X_;X9SG$Q2@R&USZ\*.@\Z->5[790:Q)E8
MY\)8):G^W^8>5:X%N.P4*_U_[)T%6!1;&X 7$,%6,% 4! ,[KWWM;J]Y[4Y4
M&D1"NI%2ND4DI+M3NKN[6SK=_YL=Y2*+B@$_<;[G?9;=V3,S9V;.GGEG.'-.
MG^O]O/9\^: "A;\/+/]OCW^)[X@X'#ZG.%%,\?/EX+"2K[J?P \39M^R=RF^
MQJW[E\''B,J7Y"E_%M(P28I0TDB==6+_.B/?BN$BXF:^O% D^.1.0V[/WOH;
MVU%;MW9[\B]'OT2\L[,S-365@6$VK)5?_DQBX^L[O <7KV"$VB&T["5V&3>(
MQ#>\XI4[@Q\J).($).*(H<%7(LZTY9A.:DU]?5M[1TEM2TW=Q];FQM:VMNC(
M<+IYBY=RO7=-K:^LK;>(*%LF'7??(C>WKHO]?;Y+6M/#V]<I**FH)M#!,BC&
M35O YVZ7UEI3W]32UA:8V[3E5>XQH\*LJK:"\MK4HAK#A*Y99^4VKU^36EAU
MVC#;/K*@H^M355-G26US3%S"U!FS"12]FZ>,!A%?NI;)/D;$.T/:)5%L,,%=
MV<"5XUN6X_-=$;_+=_#;(HZU3C%TX[2-%((WY*O^4X"':=FS3YS\6<3O/SL<
M5*3HFM0[V2_CFBQNZL/S+I!T6Y1L,W&Z1?R1R#$>TBTGEL6SK,.>^V3*D"_P
MEX&<.,2*&+AQ.L9]LX<3,#]ATI5 =XAH7+SV9.^&[3\0<5-O'JBWW5(DR-?;
M?X*+%'EE3\-*Z69,-/'BAI)#GN9G@2Q9!#^#I7VKB.(B_O?!_U288=XTN#;S
MR_[=M4.YA>68!_+UN=[/:\^7!ZO>NN^S"O<,":TKWQ)QK$O$6%'2H10%<P7=
M=X@1_0+V'JX]R/-##I0ZR"0<7'R-&W<NAH^>Z9+D*;^/4URO/(C"E0SL=E-O
M;ES$^P07\36;6+LW>6B*.&P(",FD*>-F,$P91[K7LW'CIIJ:FD^?/O7VYI^)
M?HEX;&SLVK5KJ:FI8:VSY]&M^&L^9&+%^OF0L[!RE< "^<$DH?$U'Q)Q).*(
M(<97(DX]?LJ\)>NV[CRB&+#O\I--ZU>O7K5R\\E;QW52%PKZ,@A%K3]VXZ^U
MJQA8EA(FLTY<?7R_8O#DU4>6K5S-Q# =/]9CZ9GF/[9>II0%<ZU?L^KOZ\)[
M]8MGBR7/DTH[H)VUX^2U;1O6K+ZI./&T$AWKZOVROM/7'IZ_:-F!YV:'.%[N
M/''IJ$$>"[L%]52L-5W/& TB3CM^+)S#%J]@7+1\SB #RKC_G[5>Z5*!W_B/
M-B[B%^YN[W5<(.[R?E/$H1X Q5^Y8?Z"I;/)5_H'85LUEVG!3 H*"CQ+TQDF
M+UDUESS9[\#"QG"'[V!HJ?*W;HJ#"'IGRJS9S#IC]I19<["JCWKLF 5+9B]>
M^8</*!02UB4,KVT>?NOG0"[B</:GFS%I^\'EH$U]BCAV%9$FN?_46E@R^1I_
M"MCS>,U/244Y?_$LMC^T^9"Q _^L]?Q&$?TLXCWN28\90\7RA]8.R[GV=&]P
ML5*?_X+ QQ4R<.>$:[#_]OB7$/^VB(=7JJA9WI^_:-;"9=C600'K"2L; TPG
MSPPY>(TQ_LL_$L=/I.F>^%- 627/ V0/#N*9F]M@,_N\\,-%?/4FENY-'IHB
MWE-(\)@X<>+!@P=+2DA]#OQJ]$O$_?S\>JX8CRET$W8<6K'[V*J=AU<.)OM.
MKH'" :4$+@8F31ZG9<>.1!R)..+_3D\1IV%8-/68Z)Q_%5YZ9&WD-B6LXSWZ
M1%Y$WV'J8S?FHT_U/!+^XGY[CD?Q^C.E8T_EM4RL&)^'33ZK3+5/<-(9Y?F/
M+>FV7:5E6+Q$)H%^WQ/"ZNL7A;6,['T%W2KW:&:]3ZBWCJO5-[<S,=!A-PBE
M/2I.F#)W['WW21?4!675]\L'G%%P%].SG?#4=])?%RAI)W775WB,!A'__P;3
M@AD@XL%%?72'YT,J))#/[B=ZN^.?ZUO?AS[OTXV R"H5?3>.7K,,WX!KE<A*
ME>^(.+SV:6,#$;(&-V)J^SY]0$X<8T7Q)])ZQM8]2X.*^A;QX"(ECQ3)N<R]
MNPT=4@'9\TSKNXCZ8B,3R>F[<OSUY<;PGPU0IM"REWW^/P1[9#9;5LN!G7G1
MS%YSP94;*"E>,,B)J5.7T+J"I_SWWH[GRN<Y)4[B\"N<Q=LQ#V9LVL4FI'JA
M.P_<TO\(*)Z=OQ#;J*5KF&#;^_R9P\\!T+1]U%WRAXN(0TR8,"$G)Z>W-_],
M]$O$@X*"\-OA0R=HQXV=2C=QXB3:T2GB.HZ/)T\=/V7:>$HJRB=B)Y"((_[O
M]!3Q22L/L6HVK].I*6_L^E!,5 AM*VPCYG41*<_I3!I+J,L,#ZD@%K02S5.(
MJU^7:T>WJ016KGU=(AC8=4G!B>&$X(S]3V:?D9RR 7M2C5?E+=9Y.)$84M!V
MWJ*JNU)*:"5:Y1!YC +7/=0RB6MUJ< FYK433=*(SI5$!3.//BNLT2#B\'L!
M>8(3\!W>@X//\Y<7O#.E^U0-4CZQ6U_*9G=ZS64=*AA=HP8SDL_B0[I;9A<E
MPBYRC'QUPQ%%T]M!!0I]MI3UP84L2T98]5_R&?\X=_D.F0?R?^NY7C@<<*YQ
M2Y9X\'59 NV#X]OGA01,]\J0%E0^3[ZNH0-DSSOCFT74)ULFMD[]M>TC\AE_
M'SG#&P'Y\GV>PK"1GK)E[:-%>NV]1T)'/=(DH<KZUJ\CN%C1S(\/4L)/WC-=
M*JE%$WY*./&-KT)*E$#'R7,R<)AX\R2W:G7G :X3$II>JYC?A:_$7EW&+G7Z
M*CD^F=@9!/8\N/C&G=B(R N6_OEGE'^3;XDX(R-C7EY>][GI%^+711Q.:8?.
MK#_V[\;#Y_[Z(QPZN_[XQ8UP2?=]KG/LW;#C\\C5H[9I"B[BT^@G4H&(OT B
MCOC_\_4=\<5+[FJIA35W?&DX5]),?)O4QF69QOK/,Q6O7'QB:E77,Y\FTZ0N
M>&^;U-A.)(H_N4H@4$_?C_5I",N9LNZDE$.RT5LK/6NW.]K!\R\IO'3/4'JM
M+R<GM_;"LW^D;%\X9FY\J&&LI6*IJVSP2LE,^^71>R)K'ANI>V;-VW^7:MSD
M+]75YQ@-(KYJ$TM(J7)BDV9DM>K@ V4 RU)F[QQV SX!)]=><P7FRW_+,_!9
M0$^AWB-?W7 $-O\[&XL35J9,/N- $)#W@SWOGR<'1:OG+%"ZOGE\2=.A#)"O
M:.C0OR*J2#[C[P-:_)V][4.Z#.N]]ZI4X9KA.W/!5R#W?:;TSL1J!JCNR',R
M<."-3+[.H0QL.'P5VH^N;U):M3C$3A(&IK.@WV0HBOBJC2Q0>X("PB[^(T ]
MZYXBH61V1\'DEH+Q+>RU+[3L'IV\LKD[&W#]!.6/?)>-8%#3%/*4B/\[7[41
M)Q#FTHU_;_G.*ZG,)[?=V3?DJIK7@9>11A;V2SDL*/Y1?_'JK5]L=GA2=JBW
MD[^[HY.S:T!*F8MWX+%S5Z=>U&1^:$XQAF8\VP[F.X;_FN4S'V:??4+PC*3U
MZ4O7KVF%'#Y]<<_VS8QL:S;<5STB:(RM;#H;8?9*PJSEA!G+YK*M/7SE\:4W
M><PWM,9,F85GICM&@X@O7\_LD28%)S!?4I>]@T[OO/4!Z>9?3WHGZ NR%0U7
MOM5[W=<;.TC;2[YJ<LCFZIV +#WY+$.*WAGN@X'9A%\[].1IR/E.2O(%#BCD
M&<#XG >RZ619C:Y1Q9O3(!'O'7V*^,H-\[TSI$-*E.$B[(\07:.F:<L^EV4&
MT\*9S-]E'NL,1F9Z@)6-P<"-\_,%[J@!B3AYRI\"EA!<A/6I-,KQSY/#!F,C
MVS^_1N^'-1D7K?UKPP%Y_S/6#1M/W=MXD>^@N ,;*_/8,90LS$RKEBU9]D"/
MX<HKFAGSQ\V<OV3MEN-*?EN/7UUXZ-X2Z?A91_AH9BZ8>4%IW&PV,\OWBB'-
MBCXEM4T=R<4-B27-B44-Z:4-U\VR>#T;=?7T*>GGS^+Q7227SB06.X$O2L:C
ML+&ES34TB6[A.HHQ8[]45Y]CE(CX_Z4?<00"@?@=0,2CJE7O"R 1[ROZ%/$5
M?\WW2)7\@_V(!^;+VX0+R1O?@C/ENT#^M_Y\?6+FQ_<N2, Z5!!X'_;<(ZWO
M$5-',$C$R5/^!-G8__)<DP:P$[3A@B?VVR';/[_*5R+.N'Z/7$!T9F%Q;4MN
M;6=N46E1>75.58OY>WMFUD4.3BYIV07/'/+F",=,Y_(^IA*2EI675=Z8FE=V
M[1$/S71FRK'C**EIJ>GFP9*6W-=]FTELZ"(F5G3]\Z;TA%'!&=.BPT8EV[2+
M#IHW;KRK.'[VXK5R,:M?E:Q3RV%3SK5(;LNH)>[0RIUWWXQZVFCL-06). *!
M&(X@$?]>#(Z(^^7(N29BXT'XPAF]3!FV.;3T!X20.H'Z@W?UA@5(Q,E3]I^0
M$B6XA-NTBVWQ"L91CI#*A? *E3_EXE^)..T4^DWG'MN7-'PB:@24!Q=TQ%=\
M.F=6_(]QWK)G;J=-\B]85;MDM,H%U)U^5U5$&I7LN6OI6?/R[2KQ4__".@^F
MF;5@SCEI</')YU2WZ-=8QM<WM!.CB]N B(*FO=K9+SPK4JH^O7BINVK%<I>8
M_&/&Q09A54GE;75MQ(!BXDQ.+QJ6S6#SGVNK+X%$'(% ((8F2,2_%X,CXKZD
ML0 <8D3?^O.Y)4OT_6@M HGX[XEX>+D*%#"\*_Y1'G=X#T;7J ^(B./!M.VB
M5M@*E?R=>J4;V#4)4]<29F\:MVP?@6$38=K:37_OVKYK#^/*;1>NWGI@F3U7
M*HW =H[NFOY*C3+ZG;=I&9<MD8YGY7:F7GF",'/S]"5;#N[?=_[X@9M7+SXQ
MB9QS\,F:+3MOG#ZP;?U*QH7+V<U3UZ@7G'M;<H-7^LC!?2NW[B5,^V^$MIZ!
M1!R!0""&)KU$W"5)++14^3?/^'^042'B/EAW^G*@X%IV[,[Q+P+R^^AL$N&#
M1/SW?I9A92_?!?+/F#WEOZ(\6N.1T-&H:K4!$O%YLV=P\O#.%PY]9%]I%-ND
M^LY#0>R9(#_?HD-W19[Q*8H_6W'L'H'UPLIC]RYS23**QHE[5RF^5-M]^B;#
M*=%)R_=13YO+(N##>$F%FX='1_:9M(B (#_O[4=<U-O9.=XFR+\R6'7\'F'9
M;<*,M03:&?2\P3*!']4^U(FHF?+P\(@*\HJ]$&$\\)! V[O&1"*.0" 00Q/2
MPYIJ-SCVX76U@1NG4]P+P/?SL*._=>K_?4:+B/OER+FE2!AY<+T/?^[]C4%H
M$4C$R5/V'US$I\_".K9;NX45Q/'HA0W# LCJIEULW3_ ]=L6_FSF3U[9LO/P
MRK$T8_ E#*B(;URY&*H.V_3.ZH:VO'HBW@&X82)QAUF;63;V/KZ5*!).#*_#
MWIO'D/X0B<\X'L"\5..GSCK^G)G;E9)F@M0K$\]*8C/I6[MLHG$ZGI 86T^4
MBR3>4/=D.?Q8S2?_\]0O :M8HUY(-7U!]^[" XDX H% #$W@9!12HB1O=!/.
M5I<>[C+VXK8)%[(*>689_,PB^)E3_(N /'G_;W4 /_",%A'''0LN@ S<..RC
M1?S[&KL+@42</&7_P46<;@8VYJ*XYN74-FWRGC2')BFMVFI6#[K'WY8QN/ZS
MF4]HTC0/Y)]*/Q%?PL")^)A)TY=L/>Q@;Q>44A)>W'5.R>.\J.%+JX#YHA'3
MKVA-OZBNI&\1Z.$4ZNT<$AH:5=P>7]C@[^/EZ&!_\L83&GJF2<OWK39H7J:0
M3K?MRI2;9H0;]NR:GMJ1C=L4H]X[>W@E%/GX!T?$IT27M"L$?SSXIL8CO<$G
MH]X[H_Y#;F-P;I.<?PV]4#S#E=?4H[7[0B3B" 1B..*=B=W\AK,5UJ]7+M8?
M(@@A&+F.XQ,S7U[00K<D"=_O]),XD(P6$?<AG<Z],J0-W;E,?7D\TB3]\_YO
M5S]#%ES$)TX>-V8,%8&"P"&.1/PGZ"GB(FK_QGW4(.])<V@26Z>A;':G6\0E
MM*_\;.9!NTV\>:;03<"7,' B/GG-,18>5[KE.W>)NVW0K1F_BWWFO 5+CMR;
MP^4^CG73F.DLA&E,8Z=C'1=.W'!ND6(>ZXLH:M8M\U@6K6(WF'Z$GW;N"E8>
MYX4"W@OY/?9J96X\<7O!H7NLJI5LW'8;=AS8*^DZ?=-9^F/">XRJ=JK$+1<)
M.*R3<5@W"]B@D@8<,RW?(>) 1=9W(0&)>U8V5P  @ !)1$%4. *!0 QMH#:#
MLY5?KER/<Y.T=Z;T^]#GV@Z/3;UY7!+$_B\N/HI$W(=T&#S3I72=GICX</OF
M?+>7^%')YY$UITV81C^1@I*24_QD7,,KN(@<>416J]J$"\V:.U B+JQZ(:96
MO3^#+ P%0)H536]WB[BDSM7XGSSNT;7JICZ#(>(3V';.$XU>)1'R(:N6TZ%T
M(F>@Y/L8]]C\-?+QS%PNS+P>BP5]F/F\F'B]EHI^6*68MEP^&7S:,S)#,:2%
M9K\ Q1CJL=.9QTR:,6;R#'-G_]S2:C7OW-E2F0>U,Y-R2LOJVZ\;Q-)RAJA&
M$XW>F*]8OSF]N*:RF5C1V'G;JI##L:R\F>@9$C=IVG3"EWW5'4C$$0@$8GB!
M26".K'>6C$NB^+L ?D-WK.WXX#<9'UTB#L#UD%/\"QVGQX8>7%[ITKXYO1.,
M9KKOB%-38W?$N:1._:R0#1<&3L2GD9IG"*F B ^;?R:0BWC"3QYW$/$W/KR#
M(.*4-!/&+CVT636CHIU8V=!^PZI4,J !:A*GP!CZ=4<9>;T=\XC<KC4/'&K2
M:XEI%6UIE>T9I%;BZK%$BLWWQLU?-^>\+)[)O?S&9]XWF26TO(NM6ZJ8>=^A
MNKF+6-%*O&Q1JAU/=+$T6LG&VM;XN8DYMV.Q4D!5?FWG:9,"I@>H'_'>R1 (
M!&*8 B[NER/GGB+Q-H#/T(W3,5;4?W#;BX\Z$?<A/;CI'/_"S)?/P)7#U)O;
M.U,:3,(O5\Z/=(^<//WH ;LC[O1X\M3Q8%3CQM,L7#9[][%5VP\L'WGL.K)R
MX\[%X\:/99@[C6H,Y:4'NWY?Q,/+5<S]^6AHL?)\E^\@_)CM(H6A=.%%:RC?
M'0=I5C"Y13UV#%Q%C*49LW3-O#T_>=QW'5VU?MM"FG'4L^?1CQE#>?_9X0$2
M<0@F)N:0G(]0>YC%?%RMDBT3U 3O"]-B&>DFZCN%P/O*AK92;!JQ@TC4B6Z#
M-Y;)[8M/<4_<<FWN%?5)*_9139@VYYP,[88KA)F;6%9OV[MG#V'>!L*L=7OV
M[.4Q"EIU0W[^VIU[+MQ?>%UUYYZ]QP[NO:;ARWI1>M[*K2LV;B?,_7O"JB.4
MM)];PW<'$G$$ H$8ID!%!R<:]Q1)8T\NBR !KXQ!'<]Q-(JX#VFL3<]42?,
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M-3ENW;;]OL)<5C;*A;OGWM2EF<GRI;KZ'$C$$0@$8@3@GRL'6FSJP]OSMMJ
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MB865M3HGWC^W3<"IV#NC/J^Z[4U4M=:'RM+Z=J?DNG6/M"??,%L@%DU8L)=
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MEZN\]>>CH<4:+9R\LEGYS6UQS<O?04KW&JC/0-]EQ$7</(#?*TT*2CB8XG>
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M>QM>BC_AF5S6\MRE6#^L*JVD=LDU1<+XZ5_MM6$KXJ3'0J1MPI\;>W+!!5O
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M4LB1=8H7>^/#\]:?SRM#^C?E]?_%0(OX"XV+22V:7AE2MA%8AT0]<4F$LJT
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M%#9((V=T4]'TMH$;UJ5@8('\4[$3>/:HQXX1D#]K'RWJ$"OJDB#FFB@.^@N
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MYIC1U$7DM,<Z-PS+:ZIJZM -JU7R+5N\'KM)W!TC4L1]OIP8KI'^58A$'(%
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M^2W-K2^S5HL$7A5\S<7%/8^18<6*%?OW[V=DQ$8G()">UMSWS'3EJS+-X(K
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M',8^:=*6P;\4\1(U1YPPJ!^QVU*UT'PEZQ!^I)O*H$6<F.%;Q@$K[)DD%5Z
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M6"?GIFE&$#X]I^^S-V\,#0W)R,AH:6DIR,DL38W$G5-G/O%BY?>9\\QKDV1
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MY]#UAR*.F=@B7H.(.!,+/;JFUY_M'RH1G\DP%50HI7<IK=E@9'[#OR;FO49
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M,$#$EZR8*Z)V#@!:CXF-DOG-L (DPPSI-H% ()"Q#&BW+?QY^UHS(>4SP '
M1-)(E*@*C8 LN:>2QRDHD(YY@REW!0Y)Z%PD;3G_DQ=:%QZ].#J-'DEUT+]
M$8<B#D4< OD) T3\P(FUF>V&@/Y9#B<D:'+&/^C, X% (*,+:+1CWB/Y3U"
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ME:O[I,D _#/E(HB=D(?PU !%_#M#)>(V88+39TY!Z^%7.-U <%:UO+UP"5-
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MI%4;%T(1'Q5@^D+2R%\ !!%?KJYD=F/5IH5H/8,IC'/I;_ <N/9TWY7'>_^
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MA'H5GW<O7,O"LIM[>KX,G!.!\*&CQROUPWG#' 9N1;(I,S4LKXX[$??/E'/
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MJ^M?1>_E-6.76Y;>]P!/?1X$9*M_RUF_PQ04<=P?!+1>)RF!6Y&0?,UO_4$
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MEH!#)S?L/;HZK=TBKMZ8>&U_.G&U1F#%O.(4@S]J1G[;-:&(_[\BOI$UILH
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MW<N^P_8#*UFY40L!B73>;!L_T7_]1'PQ^7Q\.4L9R#=LYP2;!J[FW*L9P&H
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M?.RZPK$3IRY<.!\9&;YLV3(O+R]\F97- PY1#=J^5=+NY;ZIS1V?^XM#$8=
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M_; B'2#BXFK'T]LM4]LL=)]? R+N$B&7V&A*7 +D=R2V&MQ3Z6[:R35SU@P
MW][E'C&*3F%RKT*D?=,>AQ6C3\'_RE]".#L$ H% ?B;$EO4C$)<S@916"QM?
ML1DX$7\?'"K]H4<CI'YPY%-)RT!E^^"G3ZC!/HVN6ZF;JQU0&I=;?MVU)#ZG
M+/MCX5VW(H/@LLJRTJ"D_)B,PKJJ\JR/Q0IOBG<]+=EN57+3^6-1?BXR.GC)
MK8I=.^]#85=J=:]B:$=D9BD;*^M?#HY+OTC$DY*2P))FSL2]F(K!7),X?%]1
M:/D:IM!\P\0ZJZ@RXZ@RHU^"(=&4_Q!LN0FVW!3RNQ-7;9%8;W7PQ$;\T<NS
MD2VFTCRRQ)AS)8.D^JFL3OO,#CO]EW<86:G=HE12FZV)2X#\CN":)I,UO&.#
M+_#M78DM-XLJ,PTK-(HJ-8VI,(^N, -3B&>$0" 0R$\'=<72?TB9\5\EE)E&
MEYN!"_I$<KJ?OPB0FXL+7\@CYL1M5O\\L26GOF^759&(<WE3S_#0R*>Z'J2Z
MZU-GWU!;SV!=YU!GW^ =]U(S;$-EVT!(7NLVTSP1Q^*<FBY)'["*#>6M@\T]
MP_6=@ZU=_2T]PZ<<RK1#&\!<#5W#817#_$;Q<\C03MH3TR\2\:BHJ(E+53 \
MJVI^@6L50U">=ER-"?$]RC1"'_*[$UUI&%=K,N&).&M4N4%8D2[G"GIQ-:'T
M=JNT-DO=%]<96*E<(N23&LV(2_BG1);I1Y493&4BB=9Y^A%;8QQ>HK=A&R>^
MWG?Q\X I %#[D64&Q/DA$ @$\E^"^]OC/V*BAI6 :ZM!;#7:C(^3W6/](E!J
M'D[$YU^PUXL?:.L;Z1T:3:CHR:SM&QG]I/FA'D@YMJ0[JZY?*: >[[1"+\O7
M&Q<(V)4J!=;'5_1%E?;<>UWCF=FA$=+@FMH*,C1V#U]TK3IB6[+6,/^03<D9
MQW)^VQ*UB$[_I")FYDF*FA(3$S-[-JXS/"Y):9^0U!)B9*4,R%''O:Q)V&OG
M/^-O>@M!(,1\MX^XX.<^XE=^5A_QL.(G,34&R<TF2<TFR5,,_"HE-9E$EJ.#
MNA.O_'0BIEH_K%A[PS8.?+WO/+0*6ZD'(,X)@4 @D"E.7)VA2Y3LH9/K]QQ=
M/<Y!X?4;=W#.G($A(2$Q<PGH&48BBKLONU;(^]>JA]1+^58S:^;>\ZZR3VQ9
M:Y0/C!SOM$F5O6[I;:^26M-K^OJ&1HTB&E]GM8/I>?7]:L%UQY^7@MD#/G:Z
MI;7QFA;<]:X"F1V26UUS!N3<,LAHT+<E)Z;)$?&[CXYXQCW2M+[TH5 [$HX(
M#9G:_,JH*1&E0/H-#9UNGKVU\^BYS5,-@;.;CE_<<E5\_^M$);">Q.L_G8BI
M-@ W&U^*N#Z ."<$ H% IC@I+69/?1Z,BRA!(B&9<=?8)Z\%2:CH>1Q4]]"G
M>JY<!D8J7>Q-=5O?2$%CO]:'>KN$9J/(QL8N=.P>?"IO';SH4DZCFJW@7ZL:
M5%?8U)]9VZ<:6&>*;7)*:1T9_>2;TU'</(#/7-")+!8-Q9#2$BQZ<D3\COQA
MO_3'9NYW0HNT(\N@B$.F-+]4Q,MT06-Q_,(6TGFS=QQ:M?W RFW[5TP==AWF
M 9L_<^8,*Y_[8#V)UW\Z 44< H% I@W)S:8V?J+SYN.ZH1 E$A*2PZKN"75_
MB:M*8)V\?VW_,.Z%3009^?0)N+5J8'UMQY!?;D=V71^"&T'SP>MJ.?^:AZ^K
M;GE6 HD'$X='/SDDMX+9>P9'\?.FU_2E5/5V#"&RKAD+*"<I?"&!B$MJGY#6
M$6;E6AJ0B^^:0KB_O@'A'QH@D%_ =[NF_.3PA1%EH+$P$3BS:<?!E2EM:.SJ
MV%K#J4-6M]6+( EZ9@HSCSM@/8G7?SH!NZ9 ()#?"F)KF@80;^;W""M^$EVE
MG]AH0LS'01O',.EOB?B,&3,RTU+PRMJ+(,5CHVHB9=WH?P%JD5W"KDWXB;HQ
M/5'52.,04MD[EFT\M8\BJA%=9SR:P??\#B2A'AE&$(ND?GZ'AHH^9+B_FXMC
M+ # >)H<$9?2$I;3/PT\)BA7,[;:B##6S+<@? \2 OD5_,KPA9'E^BDMYD?/
M\6X_L!(4!<X.;(7!U"&MS=+.7YR>F=+"\QY83^+UGT[$UJ#A"\=?UMQYB">Z
MRA! G!,"@4 F&?3=1")KF@X0;>EW 5?G=QEJKE%RQ/BFJ6K;72&=-V?6K)FS
M9\^<A0/],@L-Z =$W,/=K;R\#*1G@9F'#;$EI655%>5")C'609F !?<"^ VP
MA<6E( OX+"XI4W!-$;&* WG& ;/K^*2!G"?-8A.RB_;K1=%(!+M'Y9KY9\R[
M&W#!+CTV+IZ#E0DL<08^8B(N38Z(R^F<43816;::,>2C;D*M.7'@OZ\Q(08-
MY/_DRR ^,17F8 IA'LAG?F7XPNA*,U#@\0O;MA]8E=3P-+;*G#C/))+6:F/W
M3H:>F<K*6SR]S98XPW0BH<XRJLQDXW9N?+WO/KP&U B (/K55".V\A^<SJ =
M0*DPBZWZLIPJ"S#]Q\N9!$ C5C&Q$9O::_N'@+^R$!Q+$X#5]!]29D(8N6\"
M,16FL95FGS'%$F7XAQ@13?FO -M%N*7?!AQ^&6VV4EJG*6D6$T-%NW@)Q8*9
MLV: [[2,Y#3T9 #PA8)Z$0D)"6CD*2DIZ7%I,27MC$74='3H]YF+J)=0T0(P
M\ZCFD='@)[(P,3 QTL\G7SI[,0U^EO&TD&(IR E^HJ&E(UE(C2&E(J>FI:"A
MQ<RGFKUD*0W-TMFS9X$ESE] .J[$DR/BLKJGE$S.<?,P!.5JH0/Z$-W3? /B
M6#:0?P4NB$],M1$:QZ<:W.$8@"F$>2"?^97A"R/+#3(ZGAZ_P+=M_\KX.A-L
MA2%QGDDDN=G"QD\,?2+N=3^EQ8(XPW2"('SA[L.K$QO, /BS9LH"#E?B;2$F
M<B)E^C%58ZT!'O!?-$+E5&X62M 0G^,K' 4;L:E "7HX$1Q+$X'5]%]"%+EO
M J!9 /4R!MI$$&:8NOP3]P--&;@BWY3F'[?-KZ99LV?.F3MK]AP4\ 7\ES#'
M?YS $F?.G.PGXEP\#,O6,*Y<SQS\41,WQ#UA+Q_(?TI<G:$K5N[0R?6[C_
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M$1KSZX"YJTV$107:\;0S-.YT[;%GYMN@N*=>;EMGRBE)&!IK>>R8+:\D"0U
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M6'WVI@OU*1184$SNIE-ICL<2[8E;XT_9X]8XBCB"(&P!BC@U*.((AX,BSNZ
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MJR N0>FT@Y,?#W$YRARXN@- F\@R9#$8#R*^>?_"$ZGKJ8MH&>#4=B3!KM>
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M37:!;6R#]_+5Y__:.^^HIK*N_V?&T1F=L8P=050$>Z6(@B@J8T.Q8@,5!$%
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MRE;N4!UNAK<D!7[Y9=L^@^A\[D#O0V7)5G*+%JS@VZ_Y]%TKEDS$YKC<WK$
M\;OH2;?B]JF)HF#+0VR/;?Y;4%[A_/Y5?TO(WG];28-#M^2Z71=8LD7JS'FY
M#8*"![0M<QAQC.!NMN5;G]PV6T#*WV5M7Y3-$-N=<49'^1 "IVXE_#M#A_,
MA#@   #\_'Q7B!-[,QTTA58OVV <7(GE"2CQQNC4G#_^V&(6S @_1BUVN[MM
M_>(-FAZEC/!D'/ZS$"<-52='NCVU]D[,G0J[,=82J07]U"($CU^/14T)\16W
MC3)GQJ]@,HY,L;Z^;,%?V^[:)K5SC'#EK[P5I0_(*>E$5[9#6FZB^>/3L\)S
MYR^5>>B>R0FA#8D'=&FXP2G!Q8@U5TU3OF&A,=$;6$)<Y4T)O#))QQ4XJXEN
M6;B(GY]_Z4*!"T;)W%%31 \Z<NO_P=8(3;DU BLDG\8C9W%K8 OQHZJ^93SR
ME0TLQ(\*(H0NZF;/.FOCPZ4^ZKN6_KI8\HQM<M743D(JKCGQN>+V98CUNS6C
MBF$!0\"6^JCM7/KK$LFS3U.XM@=2($OG2]N6(H3VW(LN85BRHZ;HVI<P;@)\
M4[:;RI'UJY;N4GX04X.:79+^Y_"%C&Q*U(%DDTN;UR[:I'#'S&(*$U6%;4*"
MFVY;?F&$>:<W,39K;CZHE?8-KH6&JXRPOK!CT2*1/3?]WK&SR'"$^#57WNB'
M@ZGN,GR_+3I](QQ^YAAO?/U<EG_.O*U2>A&IS"W%#$C(SV]TI 5_6[SFLL=K
M1OXJ7",C:LK\RZ;)S$7B[IH(@]/;5B'6GKSLFMLX\T$*9DJ(6Y?QJ,'!+(NK
M@H(K1(S#6N!+3VT,N+-[XY)ULA?UN 9NH7M3>CW_9D6-T!;>&YH^\-E1?=?*
MA9M5'0N&9GJF<P$)<<U3\U<)[G?[^+WO!+V[VNW2MF5"&V1N/9AJVMSB_L4#
M2]=O/>,8V0E+?1*:N5E33N,EG$L*4MQM[ZUO2/ C5LF<LDPMZV<_#C##%R[>
MM-LPJ9*IC7$-&?:G-B(0?^S4=B[HF]IWV9L7J[]__IS%BY<LG+/LDKIO!:SX
MZ0-MB9;R2Q>N6K1D_B_+MRE[O84=P. #5%2*LPS_WVO$C]XQYNJF@9;"SB7\
M)RZZY#/V37#1%/'@T"K$FN-*L<S(\O]J@! '  " GY_O"O'>"I_;4HA%RZ7=
MWR,)7'J$A*T,L]V_ZM??Q>4?>4?$ACC=EEPW9[600F!.'YE'E?QG(3[1E_Y$
M40 !B6[QFW9^,;$0<3'>ULK[!1#S%APP\H(#B3-=4U;-^4OJN*'7*]B$B[C<
MXN8A2"5.=.?$J$D((A;P2:@8>8;!AR)<GMP070?5_9?8.>\"1FPVRF!EI.-Q
MP86(WY9+JAA[AC$:# UZJBZ_>1D"L76O?OP7#./'G5+/$>+%C(C(D^/UJ8_E
M=S <U?\2N/ H!<D2XE?%%B$$A2]:>;,Z%!WFKJ>T<^'\W\7DK0HZ9UNR^U\(
M\9>&)]8AEHL>?>@=%LT9*L2']"+D, UZ+&C.?W9=&NK,0M%3>BY!C&,QP?8F
MBN++$0L6[=*QS40R'1MHN,9<IVL'8$NQTP]<@YF607:/+XLM0_RY>*^>71:2
M(;_&1YA"?.U=\W2V^_!H78:]PI:Y<W[?>]\EIV\V7?@?A7@=!I+8$W5O'AP1
M7B%SUK&2]XU&7X'5Z2T+1$0?YS)464NFT9'-"&%)U=@25F.DT?(@@P,K?D5L
M$C=.*F=(<<H@[)K"_ZNPA**E!^/Z,0?O:WI^_X+Y?V[3M?W,$/\3J)I7NC(;
M?D/,%195L?&*9%B%>]BJR>[ZY=>_UEXQCF[H98P3#E\(1TTYJQ_5V,=J%ED1
MJ+9_\6\( <4'[UIF"XX'QQ%7E5J#6".M\"1@ZA*]<C6]MF?%W#5"YX+S^NF3
MM.YJETM;5N\5-TAJY'D@HZ#"U:67;A&Y$E;(,ZW_7T+\WND%*P3$G[YN)\WF
M2TXA(I,<3VU=):1J_(XW2B:U-.3\YB7+CRN%MD,JF]2=Y@\+\<.W/$M8S\(T
M3.L;(SBN^9+CRB\K6+N-.7'$GZ26LU;**2.583:BRWY#K-ZL')K>Q;[^^*8"
M[^OKF*\_Q![:Y3"?%*GXEG=NAY<S%KZWGC9-*F?^@T#!M,<_//;W.A'ED#3>
MFX-88'=ZK<"JD_:O.G@O !#B7  A#@   #\_A*_A2KM^1:P1TDZMYQ;BI.KD
MAX?_0BQ>JA3#7+*<8KRS*D97>LMR=D+"^7]+J^BGS$ACW_W)7V4+8NY&"8><
MIAEOF%F,EB>8*1U:M^PO[LV+<_]>+7)1Q2&["6Z61*P*5!.<[=4UC/1E^T*&
M[\3X8%64\[D]V_FX\PTN7K5E_S^6[PJG$CP.M6=X&!_:N'X9]W:_>8L%)*25
M_1);V8GI*;5)#V06(Y8LO1I=.,+2 6,504].+H/-%QW7?=\)+\<2\EY<%)WN
MU8R8.W_5CJ-W?1.^HQ,('>_<9%;/0^R_YE[,X]#"AEP=^.#$RNFUPO )*T1\
M9=1*[R^(-3A[9,,*[KR>ORQ<O6[/7=.H2M24[*-3, 4Q^F>.;%C.[?\-6^[5
M,(NI9H2FFX0S:^8Y7UXR%_'W3:,/:/9#%XW4E>Q^>@-T#PB?\XAK'9OA+(%O
MB]4[._?W^?QZ?E5<+T.&\T,U]L^=O_=T4!V&1)XH=E!8MV:^^$/?AFD30NI-
M-;N^EN_/'9:1[>-D6DOF TE^Q.H=UR*Y0ID/-$7</['J%\1*N5LO*C$D.B3$
MPR\*,2[#-'Y;P"=[QRN'$WB;AJW-<%.5V\W/8_S'"K[-%[1?%#2P@V:/U(59
M[5KZ&^+8O;!ZSM9 "N9+_'W)-;_\_J>,J=^7OAGY3>GX0I>;![ASE7)8M$I6
MW>!#-WF20OKVZM'6Q7,$E0W2^J950*KU4Q-=.W>=DO7G05;>=QAZ?Z:U\L;Y
M"/YKUKG,%#G?8[@^4$46\<>2K4^BVF81XG02JB%$9=,?:X540].GNV'U5;E=
MW/6[T$;%R&(\E8A.\3G*_SM"0O%Y40?;@CY:DV%Q8M/<7^?LT7+XB(1## T5
M)SS:_\N<U1L?OBOFO%HA(JLC-,3AI]/=IY]^K,0R;Q L^M/3<XRO\[Q+KA&-
MK''0L-4?3<494R:O&5S+4-TT$O+#B_,;Y\T_>R^L@>?]!D1OJM-!OGG0 T-D
M,\_\-X1H0DTN.G@QLG7V+]B_"2#$ 0  X.=GHOJ=D<)6?IEC-CFMW#_IV))X
M,_EU(E)R;E_:X6#=/- GOI7'V6OMW22P<I6PG*Y=8D/O3#D 24"34^NWRUWR
M+X8]0V:'/H%IJTUR-U.17;V2B>A)=0?_K,9O+'=7TD1CG+FLJ# _']_J52P3
M#GPW'@14LA8R(>F#+OT<;G91<BOCV%[QLS:!'XL;1WC7Z>D$?.OG! ^=HUO7
M,\PV[CFJ91__M1;##KT,06G.ME<2XQ??9Y!2.<8YNZLX0.LT/[^(Z!W;C&[8
M(V"B-%KW@BC_FC5\JS@]$Y2_9QCXN;83^[V #A/HC% EZ1UKKQB&5<_J?DUI
MBK-7D^+G7S-CO#(GM!.KV>J#AFUO_.2C?^G@6OC0JC6"1Y4L7R;78)BY0;EA
M6'H_N"C-MCRF;!6:7-//93D^6AJD)[Z=7^*1<RZ7:H0#QCDH[Q?AWZRL%UTW
M72I-$I"I=O>V[]Q]R"ZF$3<ETT?+$BRN;-]]03.^98"$1;\U/+/]V(G["14S
M_5LZ4SS5Y3:(W;7*0HT0VXL=KQ[BESYCF,CR&F<R5AIK<'PWO[#4]<!/ Q0R
MMBQ)5TYR \^<KUPIL'KG'</ _";VDQ0+2F]+0;3;M8.23"OA70?T?2/S.T:X
MQ.]8RSMOA7W;A%2LWK5R258"MB+$[-#F#0+_J'H6P)LZ>: 3*E\:7Q6#+A'O
M-=IRX+R%7W9;+US]V%"NZQ6)?:+J 4E=TX7\Y'A9K,[)72*G;@95<>7@I \5
M^AC)[=Y\R-"G!#MSMK@8;8TSN2F\2_RT1S*2/.."3])&Z[+L+XL)*VK[EZ.F
M'Z3@BKTUCAW8)&\?]6U\HB\G^O:AG0*7'H14<07#)$^TQCN=W2TD<."RU<<:
M"AS?,^/9E2U;I>6<,MB[+&$FT%FA2N+;UPBL/6\?7,J\04C8FJBGDAM%^/=?
M=?M<R_GB$Y#5X1J2.];Q2Q@[9S.32Y&P5:%6!W>(G')F9 KCA=Y1Z'!-=O/Q
M\U89/&_JVN(M+^WA%[UQ/[%KQI/AOPX@Q $  .#GAT["#_9V=:*[APG,2&4L
MJ!-C@]T=2'3/*'$63V<(,@Z+1G9U=B+[L+A952=U C?8TXGL[ATE\M0\$RIA
M;*BWDT4W9A@/)P9B0:>3<$/=J"[V85XP@Z.<)((,:]+80 ^*<0C=C<%-S.)7
M, FO$Q.PO:PJD>@^+'ZZEB$3AOM0G2C4P#A7V#XZ!3_<U]G9A<(,$RAP,9V(
M&^AE-L:A"X/EUGDS@=H>ZT,C._L&QV99RX2@DW'#&#1OK4RZ>P;P).ZZ:1,C
M [VLF>GJ&\3Q3 4/-,+(0 ^7)8G7DDXCC@Z@D)VH0>RT*:/@!KH[OWU#]TP_
M, D/97RX'XE$HH=Q)*X<HC0B?J@/B>SMQY.I="IY%-/=V=,[2)AEL#3H'NOI
MZ.KMQT&69"*V#]V)[AG$\\X?=0(J;__6B1H:H]"ACHX/=$^;<VA(G>BAD8D9
M>A>&/#[0V\.T@F[FD8EIZHU&QH_THI!=F"$\[P,;C3 *35A;5_?T_L#0B6.#
M?3-ZT8GJZ1]C3Q.-BA_J1J)1@[C9^D4F#/8@.U#=P]PA1^#K.=B-[$(/CA!G
MR<G*!8V,&\1T(5$](^.S?CFA2P!5U(D9PG$]7G* 3NY%=: '1J"K1B7@,-#=
MV#L ?<UYC(@X#*KS6P<*,P9_&6DD K:O"XGNQA(8NU#9T,D3 VA4Q[=69/\P
M*[ -W#DLNJNKLWM@C*M..I6$&X!:@JX4^U:B4Z'[MPNZ'T?QLXR"1A[M[X&^
MQ?TXGODGXX=ZH1NU;V"V<_YM "$.          #\ ( 0!P          ?@!
MB ,          #\ (,0!         ( ? !#B          # #P (<0
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M ?JJ3E&Q35/)*F=C!/4EW.W:85FXCNMJS],K1SG2G4)N>FVMY6#B6<).G 0
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M'7 E)X]?=0Y++RS-CG(ZIFK[OI6S=W>L*-15Y?+=N 8TV+,) /P7 (0X
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M1GX"\'U=1=E5:"SW=E4  / S H0X          #P P!"'           ^ $
B(0X          /P _A]N^Z8C>(UOK     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_4a.jpg
<TEXT>
begin 644 image_4a.jpg
MB5!.1PT*&@H    -24A$4@  !&\   -8" (   #UZ5<]  "  $E$051X7NR]
M[XL5V9KON?Z"89AW\\(!+PP.,P7->.]IZ:X#8C>G>TAHJFV$@W"EG;&4:<:$
M.T6+<D?L@NP#^B(1*1PH?.4[7UQW^C/]K>G/JF.IZ8\ZEGGJF+:59;6GIK/
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M??K47[NHZ*:HW(*5\@*>$%* PE:$;HH00H8/+[ERE;FII61$"KP!)88* S/
M;_3K B<K8&!QO$:UU.T?"#?US8L7L#J_^?QS?\NBDB.*XWK\^+&Z)ID0)R8^
M:OK4J4[2GM9)_> OFMTP"KSLS9ZOO^H HINB<JMKINBF"!F4PE:$;HH00H8/
M+[ER%;LI;:O1IALQ2.(TQ'Z(Y? W2"3>"?[DLU__6C8Y.SV-^?93O'!!N<:?
M"(4# 7QW^&)B6KY,!AC\-NFL^-GMVSU;QN34Q/CAU&"HT$T1;7$R/4C!0M%-
M4;G5-5-T4X0,2F$K0C=%""'#AY=<N2K=E I-3-9*J<OJZ3K$)J&1Y^3QXWCU
M2-R+6!TU/[/W[F%"[!8^\30_/]]S5TOF:U00-I0)<4IX*>M)\CFLLTFIYI\^
ME?F=U%>>?DAZ,-JST!?#4K8:1'135&YUS13=%"&#4MB*T$T10LCPX257KA8W
MI59*IC$,.@;W$Q.2L1EGYLH5M5*?W+SYR:U;ITZ<$(\DIDMV]?FC1S\:H>2C
MO9^:L?X>/GB@TU\]?XY=X4_9!*,.ZLS[]^[!PG62U[?TT)[P*M<72>= :ZAP
MK%*^+A6*;HK*K:Z9HILB9% *6Q&Z*4((&3Z\Y,K5XJ;FGCRQ@_MAV 8,.R$&
M1J9[]J:SNG+YLJP\.SL+MR-6"J-9Z+^=Y).^"PL+6 $CF\.YR<Z_>?%"=P6S
M)/]B$'9Q0>B1*!-2DF]?OK0K>WJ5?%<*AWOQ]==XT:N3F"M9*G,$?YLR1#=%
MY5;73-%-$3(HA:T(W10AA P?7G+E:G%3$-J"8*7$=72Z7>-T!#]_ Z-OO_T6
M-NE'UW3S)IS2A7/G9BY?OG3A@OQYY=(E\4AH(%I*>O?)"MHAL-,=R@+&"9WZ
M9'U\&PHLVTD/*R\F'[#J= O_JCNT1LK@[X.+;HK*K:Z9HILB9% *6Q&Z*4((
M&3Z\Y,K5Z*8^?_3HZLS,#V9P/[$EF(8S$8N5XDED0]G#5U]]A08HC'@.=Z3
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MI !T4VT4W13UDQ87%W_VLY_Y<WLIC']"2$5(RCZL>;E8CO8.7;AF;&W//GZ
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MX GIAVN,AVE.24I$TOU_//3/-B2K #OO>0&E .^\NUIL5;A52'7EU!*&BPJ
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M,#SUO8 GI!]NN12\-II3D@*@*UVZ5ZD.?:ZG7\!M^W9X+3D>MNHH%RUAN*@
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M3W13[1-"*V* X:GO!3PA#4>?3.&BPM@HV'Y@]]B6#>'2$H]8^@X'QVN;<LD
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M)&JNN/C9>VPDSR9-(6*S*CL\=N:I:)4KJKV;G3!('Z0IB()1U>W6!S%5VGD
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MK3"D#](4 #0+R5Z6C+V+("3BD/Y9J5*,C(S,S"&2E3Z=-(6(V&"2IGR$- 4
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M  "X0II"1(Q/TI2/D*8  , 5TA0B8GR2IGR$- 4  *Z0IA 1XY,TY2.D*0
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MA25-^0!I"@  7%$7>'7AMWL#B(@83;UU)4WY FD*  !<(4TA(L:GT;J2IKR
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M)VG*1TA3 &FAI:5E='34G!H>NW5.1-)40T*:0D2,3]*4CY"F -)"9V?GP,"
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M#A\^;&ZE$J0I      !H0,RG_O0T)?+4G@-?CA>EJ0\^^,#<1"5(4P
MT+!\_/''CM_G^_[[[YLK5V(':0H      !J8@*?^@N!S4P       ";CX^/O
MOOMN^4#UZJNOFJM58@=I"@      FH%#APZ5>>IO]^[=Y@J5V$&: @    "
M)N'X\>.EGOK;N7.GN70E=I"F      "@J2CUU)^Y7"4BK"(A30$     @*\$
M/O5G+E2)"*M(2%,      . Q]E-_8HJY4%E(4P      T+R\]]Y[,E"]^.*+
MAP\?-F>7A30%      !-S>>??RZ?^B-- 0      A./X\>.OO_[ZT:-'S1EE
M(4T!      !$@30%       0!=(4      ! %$A3        42!- 0
M1($T!0      $ 72%       0!2BIZD=        S8V9D]S@WE1)(I]3 .^@
MM , 0./!U0W<B5Q:2%,EB7Q. ;R#T@X  (T'5S=P)W)I(4V5)/(Y!? .2CL
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MYZ&>HLR_TS]WQ;^]D=WHL?W]V9[EW)NWC61GJY[BU%V+(@*[7\5]KT+W-W\
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M5%&G7.]E0FUP*.WJL57CGZ@>& LL)T&=\N#_<N#JBJ"Y1?UOA=O[-8&%-OC
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M^@GO6[?!>/!O,O=DX/EGSQ1S5RY;]>DGGQIS(7$BEQ;25$DBGU, [Z"T P!
MXU&KJYL:_5S8==^#1E+2Q_2[<<E-]J>D],]0G?./YZG$93PB",D2N;20IDH2
M^9P"> >E'0  &H_JKV[EDU+%,?WT)P/G77"Y6-UX&E"\MN]BU8J]0WOEKI]X
MK.^-5]\P9T,QD4L+::HDD<\I@'=0V@$ H/&HYNI6,2GI8_K9H:C\9ZA$RKIO
MW0:Y[B6S+K,W7B6'#Q^6&S?\W=[?R05$2NS?UL\#ASJ12PMIJB21SRF =U#:
M 0"@\8A\=2N?E,J/Z2=X]YUWRSP9J!#;N7')37*QVG[MKQ&BSIV6']=4O) +
M+%M\O3SXXO6:FLBEA315DLCG%, [*.T  -!X1+BZZ4FI\_:[RHQ^+I_<T^=.
M6D\&VC=_7GWE56/*&Z^]H:*7O<<(['MOG\I1:J*:LO6)K>+7)5>UE4I3(OM]
M^*</S:EN'/KT4*GH**GFKQ-;KKAZQ07*$*&T2$A3)8E\3@&\@](.  "-1]BK
MVPW7WB@CQR4S@T<_EW/M)_?D NK)P,"']U1."[P-]<1C?=_]^W/DZE6.HK[S
MA9UR.Z^]^IJ:J)[]Z[[_)_+&E'+^W 5R&7VB<-4--XL_2@1"\?J"[\PQ@LI#
M/9OE8OK&E3_?_'.UY&6YO_K?NGK4[;Y+9\][Z86=4]NR=BTWJWCV/YXUYHH]
MREGB\,[[9O;.FTJYTZ..FABVM"A(4R6)?$X!O(/2#@  C4?8J]N_WG&WZI'K
M#_B5']-OLM*3@?H=K1G_<*Y\H=^&R@Z>GON$U?1<ZK"W'PK]WM2A3P^IZ?>O
MOW_MS7?8R6=Z+KH\_LM?V=/G7W25B"7R0<'M3V]7FQ)'J);17^ON&=PC%]8G
M7CKK,O78H8J4]KI2.5><?/FK6''V/W]/OA8')N>*C:CES_G'\RXM_)NFYPY,
M+N-(V-*B($V5)/(Y!? .2CL  #0>$:YN>O(1??=G?OU,F3'])BL]&6C?T9)3
MM.ST;Y?-GB=?!WX$*QHJ44@W;]R\_9FI+*0^UG7)S$O[M_6_\=H;8K]JX:>?
M?/K##SY4OVY]8JM<>-&\J]469,(1Z45L2OV!G;=U?O3!1V)'\E>1&^7":E-B
M27&ZQ+HR4*U><9NQP.M[7G]YY\OJU\G<OT/]*O:E9R=Y>U!-$:=4;%G\^LCF
MG\LI>OQS(4)ID9"F2A+YG )X!Z4=   :C\A7-]$IO^&:Y:KC/O-;L^TG]RI^
MADJLHNZE&'>TQ+IW_V#J/MCWOWNAO7HUE+I?]-!/'I(+&)^;>G;@.;G P&\&
M^G_3/_CRH @V<LK<<R^2^41D)Q7V1! 24V;]TVSQ6MV4>W['\V*M?>_MNWW5
M6CGE]5=?GRR$)1&EY+J"^W]XOYPH?Y6OU:]K;[E#_2H2D7RM?Y1+3A'G?%)+
M4_H)O.+"^=-+?"JL#)%+"VFJ))'/*8!W4-H! *#QB'QUTQ^]D^KWG?0[3B)+
MB(6+URX:K,^^HZ6O_B]GS9 O C],526'/CWTHWM^-%T;TT_XJRU/3%II2KQ0
M"]A^^LFG\DN'92)244U&1'MYY6.//CY9"#_Z7]?[4*^<*'^U5[QY^2URECPP
M_;;8I);])K4TI2\@/Q@F_D9]8D4BEQ;25$DBGU, [Z"T P! XQ'AZJ8_N2>Z
M\B*0Z _FB=<O/O=BF<]0':_T+57V#2M].'7[6<$(R$V]]/Q+^L2?;?J9G'[)
MK$LG0Z8IL8 (>],+MX-DF!$)S7CTSO;Y'<]/.J2I0P</V>LN69#-0C*4&G>9
M] 1%FDHUD<\I@'=0V@$ H/$(>W6[?,Z5LFM^V>QY>N]?)!R5D:2!H\8]]>33
M>NXR@I;^]."R1=<;=Z+$NN<4!JAXVAHP,!1R(W?<^H/ Z1=,GS-II2GUR**^
MO#C^IYY\2HZ>)Q/4.?]XGOBKY6-^%YUWB5Q,KOC(YD?T=?>]MV]PYZ"^0*DT
M):+4!?_\O=MOOOV-5]^0$Y4'#QZ4!V;<FU)W]B9)4RDG\CD%\ Y*.P  -!YA
MKVXKK\\/.&'<5M+O.,WZ]@7OOO.NME(6_8Z6?7])7UTJ0I<>M_3511)0PW]'
M0^U%!!4U43V2-^=?OC]92%/M2U?(N>K9N1>??5&MHK8SF<N3YYT]4[S>W/.P
MG/A(80QT=>1JQ2>V/"&GR*'>Y>M2:6K#N@WRM3K:7_[\EW+*SA=VJ@-3W].E
M_I!KYE\W29I*.9'/*8!W4-H! *#QB'!UT[]^5WZ62=UQ,B*01,0,]9A<X%@4
MQ@VK0Y\>NJ^0'RZ9==G ]H'RJT=@\\9\X)F>^\ZHCMLZU*@/PC6KUHIEU-\H
M@LWVI[>+/^K\7%@2WK3DIDT__JE:_IZ[[I6;E0_[R1'>9WYKEKHUI^X4??^[
M<S=U;WK@AP^H=64LE*]+I2DUW(5P8_?&[@=^K'[]X$\?B -3HUR(_-:_K5_-
ME7&7-)5J(I]3F)R<./;Q!Y\<FS G0UIQ+.U'C__MM3^]LW7H.?%3O#9G-R/'
M/QK8TK\_O:?BY!=O//+HT)&3YG0 @&; \>IFHW^621IXQZGB6!2E;ECI3_T)
M19*Q5Z\&_<AU+SSW(KF ^A(GJ9CRS*^?L9>_=/8\M4UUFVAZX0-4"GV4"^7.
M%W?)N?+74FE*+6!XS977RKG&H4H[;KM3SO4N39T8_>C0L::Y*KN<TY-'#^SN
MW_O9B?>V+%VQ8NG*O&W=+WTV/OG7MS:ON+EHBEI>3QF'^E<L[?\L_\NQO=TK
M>X:.:;--QH<V7MR]-[NML(@=?7O!LNSQK%AVT=6W/?:'<KNQF5I]9?L5BY<_
M\,JA<EFI\A\"J<*EM#__ASWW/M^K^\K^(7.A(B:.[=NV?O["J]M$D5N\<N.>
M0U$*;C5,'-O_VN[]1\S)8L8'3RXYZ_HM^[\R9X3DQ!\?7W;S?QS,_EU???;&
MKQ^\[=;;.C9M?2/_AXY__NY_;+KGMNL['WS\K5P#H!.PO&@@/GIARX;;UG2L
MW[+S@Z.YMG;BRS=^?ENA;6E?M_//^C:"&IG)\4-[?_WP^A6W=FSHV_WAT9,G
M_[JW>\WZ77]NFI8; & *EZM;(/H=)^DCFW^NWY72!Y-XJ&=SV!M6^NI2.ZU5
MR8_N+7JV4/C#N^[1%QC8OF-Z+G+<<<L=<LK33SZM+W_W#];IRXN_\<)SYGY_
MQERQBCVZAEKKNV>=(WZ^\.P+:M:M-ZT64_2_3GZ_<-=]#ZHIQJ%.+TY'0V\/
MZ;,VK+]?S1*;G3]W@;&\3(9A VKDTE(^37W2?\/U'5T;>[J%F_N&?M>_XN%(
M'7DOJ71.3QQZY6=KVI;,G[Y1/R<G/W]NS84_^_V)R:_W_6+AAK>TSEKP\G5-
M4VI'XW_<,O^._E!]6WWUDU_LOO.FGJ&CQ4OH5/Y#(%54*NV3K_WI'2-*2=_^
MZ/?FHHJ_[KEO_OTO'<Q5@I-?[OO9ZF6/'_C:7"A6QC_;=N>*;9^8DR>_.O#H
MC;.^_;V%C^XO]YY 12;^U-=Z\Y;]8V)'H[L>N+9CV_ 77XU__OK&^<LVOWML
M\NL#?8MO??CM/X^?/'+@U^NO7;?GRZDU@Y:?_-N!Q^]:LW'PHV/_=>S#P<TK
M[^K[X]\F)\>&'U[SX!L!@5!@-3+B//_YU?6W=/[J=U^,?WWL@^?NN^Q?G_M\
M_.27N]>?_Z/7CE3UMP( ^$C%JYN-<<=I^S/]ZMM@Y0VH ]KHY_98%"XWK.0C
M<W+U#_[T0?FQ*Z!N1"@MDDIIJB@^Y7\=/[AKPV5+.QZX\]K+'AS,=I6^.K3K
MP87S[^R^;>G"];L.C8L>S)I_F7M[S[9AKWO3E<[IWP[LV?O9\;T]Y^OIZ-CO
M-]ZT9N#@R8!N7.#R)=+4L7U/W=:V8''[LHNNW[#KT_'L](6SSE]\P]K^ V]N
M_/ZB%3===%W[XD4+5FX=/CJ1NP/PS)U7+%ZV]*:K+[IYXRL']>4_4KU7?4<G
MWMU\X?J7#D\8._HO$07G_F)8KG)X9T<N%@:LGO_K1H[M>[HCN]]E"^9W9TO"
M^-Z>[UQP\>4WW;7MW;?E'S+^R4N=JS?L^MU+'3?_8I_H=![=V[WHPNZ])W(=
MP04=NX^X'P#$2:72/GG?"X_844IX_POY#Z%:B$*RMBBN'-F];H8H_!/'_K!U
MS46+LL7FHCO[_O#ER>PMF3_TK;PZ5PRN7O/X'XZ=_*1_Z9WYM#\NJXPHTDN6
M+EV^X(H;"\M,!E63:Q8O;LLMDYUR_-TMR^;.F35WF7E+9V+_EGEW;'_[Z97S
M'CN0/3Z]OGPY_/B="RY:MD+4KQ6_>/.0*']'AI]<=W5VRN)KL^W;U&9.?OS,
M\NO[#V5O^OSEM>ZN_@]EKBG4_:+W+XR*'[1\<8$_\>[/KKAMY^%)[528V(U,
MKM9<+O^H2>U-#5'O5I:*9   #4S%JYO!MJ>VJ8?6])M1]JVJ2V9=9H]%88]^
MKL\5&_EAYSUJ]5*C7)SSC^=M?6*KMA[4B;"E11$A3?WYI34_Z/L@6S[&/]AZ
MXYJ=AP_OO/.ZK1]E%SO^T>,_N/.%@Y]M6[]NUZA:S5.<SJG123KRVGUSNG+O
M 8M^S-57S+W\ M&3NV+A=>O^XX#\$)'9J0I,4W_]9.N::Q_]8W8IT3?*WLL2
MTZ^7IW1\:.,%U\BS/3ZZZ_[6=:\=/?+&@W/N>N[S[*231][LOO3VIS_\BUI^
M"OU)O[ESOB=6G/PO:T=_>6W=C??M^8M(R!\]?FO;XW^:Z@H'W)OZ_=/7R#?F
M)PZ_\*_?Z]X[+OZZ&??LSO_Y*WO>^N/@73>NVOK!N.KV9=]+O^;JA?\^_+6<
M\F&( X X*5_:#WWYA9VCE.;2>>S[D[E@\/[@?9?>O_N+[/]\XM/^6RX2^4'\
MTV_*/XHV,=)_8_OFWPT'I:EK;GC\0*Z4_UD4O_OV?&85'FT941//NW?WD1,!
M>2.7Y*_(IJ!/^J^_*1?R5?V:.+JGZXKUK^4^931Q;&CS0I%G/G[FAOERHW]^
MZ;:EVE\T<637A@4/[RN^VS9Q[,-=/4OO?%HDI:\_>'KIVMR]J:,?_6;##1M>
MU^Y-*::6%U7[(OU&TU=O/7C>QKU?[>V9?OG\.1?/7WSCU7.7W[?MC]H)+='(
MY!&I=<OR.3]Y,UL?10W]X>(J;\0! 'A(^:N;S:H;;I:19N:W9AFWE9YZ\NES
MOYD-6C/^_ES[#I)QQZG\X.G"BV=>JH<Q$;34&.4BC\FA\*#.A"TMBDII:NI)
MOZ?V_O4_LVE*7-VO?^83^0S^R?]\^OK-;[VQ>>76_\Q/^/B9E=UO?;)M0P,\
MY>5T3HO2D0@ -U^1[UV-??3"]L(G'[XZN*TSW^L*3%.%SR.M6'K3U><ODJ?N
MY+%/WMGU=,_UET__MNPFYCNF14_ZY?I;;[VA=\)$0%J[8MNPU9'5X]#$L9$]
MFV_H?/J#[$K%.\IV-.>O?.[S[,VK?$*;6EW[V%7^YD!VM(EW![?VK#S_W%DR
M3>7_.GDG8>D%<_(WFN0C26/[_GWYPV^^W;WV%_L^>VO#FEQ'UOD ($[*E_;?
M??Q^J7M38=/4T]NZM>*:^RBF*#;G=:M)XU]\\NFQ_PQ*4U-;^^J-[HMRM:!4
M-<DGMT-?!:6IL>&'E^5NFF6?][L\6S'5BMD\=O5MW;D6;V-/UYU7R^=RQ6Y^
M^_+3W;=<_(T%VE]DWQHZ^-*Z6U8L7KC@SA>SQW[RR/Y'5W]_[K)<O;YNPZ[<
MIZN**%K>?(A7_N%C'^[LV_U1_KV8D?Z5*V6MR5&BD1$+'GKKL8[V97?^>N_G
M^5M=YL8! )J#\E>W0$0N4N/=R8\\Z2-2W+=N@_'I)O&K/D:?_8$BX\MYA]X>
M4D-3R"?]U).!(FX]5=TW31F(4+?SA9W]V_K%3SO@14:<$['-QGLB,4)ID51*
M4_:]*=*4CIZ.B@+ Q+'/OI@:L4,EF< T9=Z;.G+L#T^LN:'[J5W#H_DG VN;
MIB8+'<$1:T?B7R@B]"T//;QN?NYYO!*K2XX,/WK7J@U/[=[WQ7%Y5$5IZKH;
M?C8X^.!--V\;R?8$Q:%>UM/WT[7BJ$X,/73=3W_UL\M^\M97$R$. .*D8FFW
M0U2E-!7\I%]Q<:TF30U]:18>MS0E\OJ<&^7X$Q/['UN8#?QZFK)NZAY[;\O*
MM0\^^<KP%W\IKE9:FIKX;.^ &EUF_/.!N^8__-Y?IVYSB6D'^JY=W9=[_Z+$
M\ON^_OB9&ZXI-*VYMO0&4>-.'OOS9ZHA,?);8",S/KIGXPW7;WHIG[+RJ/P)
M -!45+RZE<(>TT^.EFXL5OXC3_9@ZVJ6/0J%G=.J01S)+3?>>LX_GJ>V+U_7
M) +)(Q>!RISA.9%+2_@TY?2D7Q.FJ8G#+ZR[,/OX7([L0T3+>X;DHSV5[DV9
M:>JSO=WM\D,.$Y_VWYS]J$E1FIJ5?^Y(>]+OJA_)1Z>T)_W*IJF3?WEM_;)U
MN_[3VE'VY=$]/_K>-ZSASNPT-=4)/G%PV]KOFVDJ>P GC[RVX3+Y6)?HW5XP
M_9Q-V81T8F_/.3.F9[=V+,0!0)Q4+.T/[>ZS<Y2P=\]3YJ(%3G[Q\GI[%(HC
MKSD\Z??!2[>UYP9FR V^]QU9!1;.V_AN-F#GG_0;L0J/4YHZ,;3IHO.O:9^Z
M&WQUS]"APHH31U__R>6KGON\\*3?TNZ]?U,/X(EC6]ZF5RM1&;_?L3M[!"<_
M?6[E"GG A73T^R]>6'^%/.#LM.+;2@'+[_OZY,'G5K9O'/IK=N?9@?C:LY_
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M')*DTT;O.7ZMUS9F,>@*.\;8B28Z#*$&R3M/CW:=RXC([QAG>V#54]#; 0
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M>3BG:7"DZ61J9:^PP]Y;M>?DS9%GIKU?M8XY?,]-L7<1WB;Y4N\\ZP&1I@
M(*!A=%.3\>X;>1'K(KXL2G]?DJ9>=Q=O<=]<F]$X.L]O( [<O05I2A9WFT+
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MW@X  /X'HQLHQ]U;D*9D<;<I@.J@MP, @/_!Z ;*<?<6I"E9W&T*H#KH[0
MX'\PNH%RW+UES0T      (# YIZ3E,'<%         ^D*0       !Y(4P
;     #S^#T'5!TL\-H0"     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_5a.jpg
<TEXT>
begin 644 image_5a.jpg
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M<)IRB7DKPQ?4:GS2*?OTS4L]B:14I+S-4@<"0(>HN=1QTVGS+Q:F0+=-CP<
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MY@U?&CYJI?U:&O]^JB9 #^5G%$FI2)G':AT( !VBYIK.8NK3=+:&-@2/ P!
MN80VFRHV[[J3=NQH?I!E?<1(PU+M0#4IHZ/LA,?#-Q<))XX=L] B^>3RI4OV
MXW3S*/S^][^W&O1XPN-&UJ-EP2R$'SFCC\Z>U9BD;\CUISEJ2.'4(BD5*?-8
MK0,!H$/47--9+/AT(F;9%@  LB*TV52Q>=>=)#GH5-H2'B1"2'C04%$[L[8]
M@'3\Z-$?'STZ?^Z<K-$YQ.7?^]]^JR%J[P<?W+Y].VX\L\Z>/JVY2):_?_#@
M=W?OZL%\-'P(:GEY^>?'DI+.(CVC,]5+F>2 ?==9AR(I%2GS6*T# :!#U%Q3
M6&S7WG?5I]O?W#$%P>,  % NH<VFBLV[+B2QX<+Y\YHK=*R=1 CM@9$@5!LD
MKEZYHIGDP8,'FC<D9=E(N8?5FUZ7;]X<-<6<%)"/OOKRRT\_^41RBT?6?'WC
MAA3047:UDIKEP+0CZ,.#!V6/ES[_7'=][J./[*AT(@>_H9V.SB&^-'QL2:*=
MOG:I$Y&4BI1YK-:! - A:BXSW11*4U ;=-OT>   H#C\_=S^.L3F71?2>;T%
MR0\KKK](?PR2I*$3S6G_C'+DT*%'U9P*.O3N^K5K<;-JC)Q$HY,G3MA6;?CH
M[%DYC(;1<3K/^)?7K^M4$!\>.*#K+?*E/4OVD28ZFV$B+3F=2$I%RCQ6ZT
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MLG9\K503 -H$$NG0OHE$4BI2ZK'@NM26 # [8BZ=Q2[]:"SJTS0%M2%X'
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M,4^CH&+S^]E6FH[\K.++-V]:@38B*14I\]A@:#Q; (!N47--9S%OTDF995L
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MCR1#V22N':W0&W;DT"'9W403A9.4BE2T6J74E@ P.VJNZ2RFWDS?*ML&? T
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MX3C ])U(<H*R7DXVK*\=-[A_W[Y0K$$DI2+E;>;M!P"=$_ZV3<0LWIQE6P
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MRU:X3<_2KS[[+)R%U';\Z%%_'5SQG[5_[U[[2):EI$3*-% UB*14I+S-O/T
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M2MV[=^_"QQ];DI1+$0N-$TFI2)G'!HR^ \B #9LVOO'^V^GZ/)&P)$$H70\
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M'YW7[MK5JRO#I*2Y2);;/"*E!Z8!2?=RX?SYE>%(PMIW0W4NDE*1,H_5.A
M.D3,]2__S;\VT\VN=!<=TCS_A,0D.HL  .;/((.DI)U(.@N"!@]]KZM$#HU,
M&F9:OK95THO&'EF0 ".57_K\<PU+FH@L*7VSO*R;-'<?>=F$$WJ<5Z]<L5D<
M-.;),?<TA4,02:E(F<=J'0@ '3*H>E=F1TW:MU6E_EU[WTWW;FS^Q<)VDA(
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MG]Z^?;N/GAR=SNZ/SR,=/"AK]$FJGT.:2VYZG#HA>/LA?)V(I%2DO,U2!P)
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M*14IDA) <9"4  #6+22E0D52*E(D)8#B("D! *Q;2$J%BJ14I$A* ,5!4@(
M6+>0E H52:E(D90 BH.D! "P;B$I%2J24I$B*<T3O;Q<Y/Y8)U=8SZ[O<QS4
M):7U<'E7%ZYPWW"%>\4N+U>X/^SRVD4>D)1*$$FI2'F;>?M!'Z1W-^B6\/N\
M5IG/;]%@1%*R?Z$/N,)]PQ7NE75R$UY=?FY)//EK/" IE2"24I$*-S6S'_2!
M7EXN<G^LDRNL9]?W.0Y&)*4U?WE7%ZYPWW"%>\4N+U>X/^SRVD4>D)1*$$FI
M2'F;>?L!0+:$OY$],:A+2@  L+J0E H52:E(D90 BH.D! "P;B$I%2J24I$B
M*0$4!TD) &#=0E(J5"2E(D52 B@.DA( P+J%I%2H2$I%BJ0$4!PD)0" =0M)
MJ5"1E(H420F@.$A*  #K%I)2H2(I%2F2$D!QD)0  -8M)*5"15(J4NJWH-26
M ) /:M*^K3H@*0$ Y$=HLZEB\P[E)Y)2D8I6JY3:$@#R04W:MU4')"4 @/P(
M;395;-ZA_$12*E+F,>_ U)8 D ]JTKZM.B I 0#D1VBSJ6+S#N4GDE*1,H_5
M.A  ,D1-VK=5!R0E (#\"&TV56S>H?Q$4BI2YK%:!P) AJA)^[;J@*0$ ) ?
MH<VFBLT[E)](2D7*/#88&L\6 "!/U*1]6W5 4@( R ]_\[<F7&S>H?Q$4BI2
MYK$!20F@$-2D?5MU0%(" ,@/WV SQ>8=RD\DI2+E;18<" !YHB;MVZH#DA(
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M316;=R@_D92*E'FLUH$ D"%JTCE8E1D=  !R([395+%YA_(32:E(F<=J'0@
M&:(F[=NJ.DLXKU0" ,B*T&93Q>8=RD\DI2)E'JMU( !DB)JT;ZORYED @ P)
M;395;-ZA_$12*E+FL5H' D"&J$E[M>K+[[R^8=-&!MT! .1&:+.I8O,.Y2>2
M4I$RF]4Z$  R9 Y)26*2A*5T/0  K"YI4EKDS;,EB*14I+S-4@<"0(;TG91T
M(H=T/0  K#HDI4)%4BI2WF:I P$@0_I.2MO?W,$32@  >4)2*E0DI2*E'B,I
M 11$WTE)8M)+NU])UP, P*J3)J4!SRF5())2D3*/#8;&LP4 R!,U:7]6U5GO
MMK^Y8Q3_W=9_^$_^CW_^SU[_%^FV  #0*[[!9HK-.Y2?2$I%RMLL.!  \D1-
MVI]5=^[9E:8CS]_ZN__E<UO_[.__V9^DVP( 0*_X!ILI-N]0?B(I%2GS6.I
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M)*6UR,X]NYY_]47Y6@593@L 0.:$-ILJ-N]0?B(I%2GS6*T# 2!#U*1]6W5
M4EI;;']SQU////WLPG.R(-_LEAW;9"$M!@"9$]ILJMB\0_F)I%2DS&.U#@2
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M)*4B91ZK=2  9(B:M&^K#DA*<R3<A^<&20F@.$*;316;=R@_D92*E'FLUH$
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M("EURWSV4B)OO/^V_(XU\.S"<Y/^$OI[KRUOV;%MU SU8Y%CD+#4YDOTNP:
M_#'/^IM&;-ZA_$12*E+>9MY^ ,5!4NJ6^>RE1)YZYFG)(?K+-HI)^X+\O=>6
M=^[9M6'3QK3P6&3O^G+>-E^BWS4 Y(]YUM\T8O,.Y2>24I%2OP6EM@3('Y)2
MM\QG+R72Q^^8O_?Z90D\;[S_=EJ^&?E5W+)CVV*[+]'O#@#R1ST;%)MW*#^1
ME(J4MYDY,+4E0/Z0E+IE/GLI$?F6=^[9E:Z?A7 3MN7G7WU12,LWLV'31CW"
M-E^BWQT Y$^X5ZAB\P[E)Y)2D3*/I0X$* N24K?,9R\E\M+N5[3'ID/\?=@O
MZUN/T_(-R"8V9J_-E^AW!P#YXPVK_AV0E$H02:E(F<=J'0A0$"2E;IG/7DK$
MG@)*/YH:?Q\.]V3K(&J)[X9J\R6&W0% YGC#JG\')*421%(J4N:Q6@<"% 1)
MJ5OFLY="T:\[73\U_CX<[LF3=F'Y1YO:?(EA=P"0.=ZPZM\!2:D$D92*E'EL
MX/Y(I[8$R!^24K?,9R^%LFOONW)EIIAK813A)NPON^ZK91=6F"ZOS9<8=@<
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M9L=J2W.@3TH-!1JNV"C\632<T:Z][Z:C[';NV95F-J7-Q6_8'0!DB#>L^G=
M4BI!)*4B91ZK=2! 09"4NL7VTGQ)M^S8UCP57M]'&^Y@LV.UZ<,_/@N%I*2Y
MQ<^RT'=26JP;%BA?P:B>O387OWEW ) ;WK#JWP%)J021E(J4>:S6@0 %05+J
M%MM+\R4=^YZ?OH\VW,%FQ]<F84G.;L.FC1).WCK\7DA*BU58L@*R/(>D%&8#
MEZ.2M":[3DLNMKOXS;L#@-SPAE7_#DA*)8BD5*3,8[4.!"@(DE*WV%[&7M+F
M(^G[:,,=;';2VB0%Z>MW13K@L+G V"N6XL_"+Z=(-!JX$8^USU,96D]#;?II
M<P$ R IO6/7O@*14@DA*1<K;+'4@0$&0E+K%]C+VDC;T:2SV?[3^]M4)8VL;
M6V#L%4OQ9S'VC"25V8A'OYS2YN*/W1T 9$6X5^B/L7F'\A-)J4@%IWD' I0%
M2:E;;"^#JI\D+>!+-LMJZP/;15?XVN3$)8J$7ZK: OZMK[Z\9,BT0(H_B[%G
M9/U(H7\I1>MIKFWL[@ @*\*]0G^,S3N4GTA*1<K;+#@0H"Q(2MUB]8_=T=@"
M6D:^ESX(=[#9L=KT$:"7=K\B^'ZS4$"^=RD@*ZV _R7<L&GCEAW;)-M(25N9
MXL^BS1GI\81GEE*TGN;:VNP. /+!&U;].V#T70DB*14I\UBM P$*XC624J?8
MS6'LCGS)6DF;?E"-XNL#W45Z5%-CM4F\V3S\0B7MV!QWOH ](R2?6H'-PU]"
M7T!^/6I?A:3XLVAS1CK?73H/7D#K::ZMS>X (!^\8=6_ Y)2"2(I%2GS6*T#
M 0J"I)0GZ=%*<))0(==*FOLMOZRW#K^GFRR\L#5D@W '\YO4#AILCA:+[E#E
M"[79MW?NV65?;FT!_?739?LE'%4@Q9_%J#/RZ#N4TG<K!=*+G])F=P"0#]ZP
MZM\!2:D$D92*E'FLUH$ !4%2RI-PM/J2(HD]\C7IJ+:QT44'N4E&DG@@A24A
M^%<8^3N85"[?@@8D2R:RN>S('A,*UTT'U_DU5L"_I\CG'"LP*@C-(2DM#L?U
MI>L]6D]S;2UW!P"9X VK_AV0E$H02:E(F<=J'0A0$"2E/ E'ZT>I+5;?FK3X
MTZT\DF3\A=5I#.Q'O8/MVONN(%5)H'IVX3E9UI%OFL=D01\3>LV]#4F6-7?I
MVY#LU\8*R!=JA^J?"/(%+*OH1.&Z[).2+]#PZZ%GD2XW0%("6)]XPZI_!R2E
M$D12*E+FL5H' A2$)27M"FBF>2(RCW93C$6:K;)K^3?]J'/4I*58-1RM9 \_
M"4'SZX"LC,\8X8U&>@?;7#VP)-=?.Z#^>%\;2KYNV:_]N%C]MNCR]N%\#(-J
MS@FM4&N6CW3"ANW5][M]V#MD!:2\%9"SL *6E'0O:8$4.["P/ K=-:/O -8A
MWK#JWP%)J021E(J4>:S6@0"=8+]F<Y"TB4.N2)$HU?"_^X'M54]16LDJHJ/%
M!H5858_3CG;7WG>E?:^75+X(_<K2K3P2?B1FZ"82>'0^.E__('GIDP]"OBI=
MJ07"[X#58(?Z6M7?I==<]VZ5-!?P2:FV0(H=6%@>A<XP(9>E^>II/<VUM=D=
M .2#-ZSZ=T!2*D$DI2)E'JMU($ GZ"^5_;+U*M]UT*ST.&O97O7AY":[JOF3
M'JT^.*3YH>&5M8&7WWE=-_&):''X>]534K(RNFNKI+F 3TJU!5+LP,+R*"0N
MOO'^V\P2#K .\895_PY(2B6(I%2DS&.U#@3H!/LU:U9SFV\LVBH-+>82T1>5
M-F!7+-TV0P;#6<+16-D5L^5:=N[9I4,6]<+RYEF =84WK/IW0%(J022E(F4V
MJW4@P-Q(_X]_4M9,4AJ,>TEK[>37V3*HFO+I68#'/WP5[LDIDJ5M_*'\PC=,
M'JCU--<V=G< D!6AS:8_QN8=RD\DI2+E;98Z$&!N;'?SC$W':VLE*6W8M+'T
M4_ ,>G[S[-K WX?#/3F@4__9J,6Q4^K9OZ-HWAT Y(8WK/DW-N]0?B(I%2EO
ML]2! ',C?:/HI*R9I#3[I<B*-HUU\/?A<$\.^.G(%Y/@%&AS\9MW!P"YX0UK
M_HW-.Y2?2$I%2CT67)?:$J!7QCYNT88UDY2:>PF*0V\IW%B:\??A<$\./+OP
M7 C26W9L"R_/-=I<_.;= 4!N>,.J?P<\IU2"2$I%RCPV<'^D4UL"],KSK[XX
M]AV:8UDS24G?"%3Z61AZ2^'&TDRX"8^Z7#K'>O@_A9U[=HUZ>V^;B]^P.P#(
MD'"O4,7F'<I/)*4BY6T6' @P'_19]E'#A]JS9I+2XO E3NGZ$M%;BK_5H%&R
M*V;+@>W52ZC2]3II>+I>ZQE5FY5I+@  61'N%:K8O$/YB:14I,QCJ0,!YH#V
MGXP:.S01:RDI+5:#K&K;Q,6AMQ2[U?2JN>VH)]D5L^7 ADT;:U\U^_RK+]9.
MB*+UC*K-RC07 ("L\(;]X[V#I%2"2$I%RCQ6ZT" 7GGC_;>EY==5'EAC24G'
M675U<581O:6$&XN<W6LS3'>NFX=^R+"CVE?!^@+Z"Z/+$C/:OUAV; ';W:@"
M*?X^'.[)AEPN^95(US=\5'OQTS+-!0 @*[QAU;\#DE()(BD5*?-8K0,!^D-:
MC=*V:V@[3LH:2TJ+PR2Y\,+6V8<FKB)Z2_$W%HDE@VK2</D%D'\GFLE#"MN&
M8?.P(Y],:H/0=C<Q_41!:&R!GI+2J(XCI;:[*;WX*:-V!P!YX@VK_AV0E$H0
M2:E(F<>\4EL"=(*^@51:>]K&[3;2K+VDM%A=L2T[MFGGTM0],*N+WE+LQO+2
M[E>>77C.XHV<EY_S>BQ:7C>7?V79PD/8D<02?UM+<\[8 G*HS07D-ZVV@$]*
MM052M$"Z[!GU,)*RO>X1)JVGMC9?IKD  &2%>C8H-N]0?B(I%:EHM4JI+0%F
M09JS]MLEC4AIVC8T^*9F328E9=?>=^6B;=BT42]@65;5X[2CE=:\#PRCAHV-
M0D[?]YS(LG7:A!UM=UU&?J>^@$4+WUW3OH!$*8MYOK#]$OH)WWWA%/^%UGZY
M#1/<*;73XH5K4DOM[@ @6]2S0;%YA_(32:E(#=S?9K-?:DN 69#&XO;^)W-;
MPTG)T.=SS*UI@0P)1ROAP>9 E].9=.(*^462370XHJ0L60X1R';D,U4:J!:?
M?,.O'R9G!?R8O=H"V]V .E_ ?@E'%4CQ]UZ_;&P9_=(D(WW54K@FM=3N#@"R
MQ3SK;QJQ>8?R$TFI2'F;>?L!= A)J5O"W\C,28]66OP2EO1N(P%@HN>4%JOX
MH9N'Y]S"COQO0FU2\E&J-@CY<%);8%00ZCPIR24:M)A)7V)2Z+8*UZ26='<
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M*>LG;5E*A<^_^F*Z?I&DU!UV<ZA56KX3XFXJI<4,_;W2,D]NU)GZJSE5>H(
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M2LB]8^\_4O[9A>=JDQA)"0#6&_Z&:;>.V+Q#^8FD5*2"T[P# ;JB?5):K.M
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MZ&1T=M\(QZ:OQJKM ]01=-;#9EA5NIQNF"+U2WZ6WROY]6CY %OF^(L  -"
MOU?\\5Y,4BI!)*4B91ZK=2! )TR1E!:KW@G99-+LH7N9=%\I9HU5EQY,>H29
MD![;J.?*--O4UF"5I+6M$_Q%  !HP-\K]-8Q("F5())2D3*/U3H0H!-*3$J+
MKI):@]B"/58D2:#-/.83T>'I]$3ML:6A:%1\TAK2J[K>\!<! *"!\"=)%9MW
M*#^1E(J4>:S6@0"=,$526O71=XMUH:AVI24E>[:J0SH\G9ZH/;8PT*YA2)[6
MD%[5]8:_"   #80_2:K8O$/YB:14I,QCM0X$Z(1)DY)_[E^V;9@A($7WTGY?
M#5@EM0:Q!4U*<H(2ZM)*9J3#T^F)4<?FO\3F:1ZJ.U"\JNL-?Q$  !H(?Y)4
ML7F'\A-)J4B9QVH="- )$R4E[8ZP86S-W1$INI>6^VK&*JDUB"UH4I(DT! &
MIJ;#T^F)AF/3+L$M.[8U3QWN;T$-M:UM_$4  &@@_$E2Q>8=RD\DI2)E'JMU
M($ G3)24,GSS;*U!;$&3DD2"21^I:D.'I],3S<>V\,)6*=#\.EI_"VJN;0WC
M+P( 0 /A3Y(J-N]0?B(I%2FS6:T# 3JA?5*28A**TH:U-+A;3@:M>VFSK[%8
M);4&L06)27)L<MAI#;/3X>GT1,.QZ5N#A>:)+OPMJ*&VS'GC_;<U,T^'OP@
M  V$/TGZ8VS>H?Q$4BI2WF:I P$ZH652DH;UADT;7W[G]8D^"NA>QNZK#59)
MK4%L09JY$@8F>CUN>SH\G9YH.#;YWN6R:/IMF.O"WX(::LL<.?(T_[3'7P0
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M_+SR@<0<WH%[D)2\1+4QN_DA(I9566V,^D,)0D1?5$6L,-02\E7-I19E#N_
M/4A*7J(W5Z/Y(2*655EMC/I#"4)$7[2+6'B+GU<^D)C#.W /DI*7J#9F-S]$
MQ+(JJXU1?RA!B.B+=A$+;_'SR@<2<W@'[D%2\A+5S.SFAXA85NV!@E&.$!%=
M5A6QPE!+R%<UEUJ..;P#]R I>8G>S(SFAXA85NV!@E&.$!%=UBYBX2U^7OE
M/C:'=^ >)"4OT9N9T?P0$<NJ/5 PRA$BHLO:12R\Q<\K'\C'YO .W(.DY"6R
MC:F6IC<_1,2R*JN-7H4D]I2(B XJZU5A5:LD\RK,X1VX!TG)2_1FIC<_1,1R
MJ]<?'7M*1$0'E?7*+&&A44O(5S6OPAS>@7N0E+Q$;V9Z\T-$K+QZ+4)$=%Q9
MKPJK6L7/*Q](S.$=N =)R4M4&[.;'R)BA37*$2*BR\IZ55C5*GY>^4!B#N_
M/4A*7J+:F-W\$!$KK%&.$!%=5M8K-93*%[6$?%5SJ469PSMP#Y*2EZ@V%M-:
MG=TF$1$KH%Z+$!$=5]:KPJI6\?/*!Q)S> ?N05+R$M7&=.PVB8A8 2E!B.B1
MLEX55K5*,J_"'-Z!>Y"4O$1O9@J[32(B5D!*$")ZI*Q7:4.H?%!+R%=S020E
M'R I>4E,.X"KVI[=)A$1*R E"!$]4HV=[)=R6L)Y8R0E'R I>8G>S.3/PAHM
M(F+Q4H(0T2-+F';RTI@W1E+R 9*2E^C-3/XLK-$B(A8O)0@1/;*$:2<OC7EC
M)"4?("EYB=[,Y,_"&BTB8O%2@A#1(_6Q4P&H)>2K,6^,I.0#)"4OT9N9_%E8
MHT5$+%Y*$")Z9 G33EX:\\9(2CY 4O(2O9G)GX4U6D3$XJ4$(:)'EC#MY*4Q
M;XRDY ,D)2_1FYG\65BC140L7DH0(GJD/G8J +6$\#Z\\^EI38O$7"NV-:MY
M8R0E'R I>8G>S.3/?!LM(F*II 0AHD<6EG:D^<X[OV7%#7>.%=/+G_J\,9*2
M#Y"4O$1O9O)G^$:+B%A:*4&(Z)'YIAW=D/,NV[)V]*Q)W_K.M__CAA]-:UJT
M8ENS/6^,I.0#)"4OT9N9_)FST2(BEDE*$")Z9,BT$VCV>44B^OGR6=_]P?>$
MXQNGBKR49=X82<D'2$I>HC<S^3-3HT5$++>4($3T2'WL5 !J"<J'=SY]S^/W
M_[C^!G-2"WW>&$G)!TA*7J(W,]7:]4:+B%@Q*4&(Z)%&8LE+8][Y+2M&SYHD
M?A4Q280E$9GL63+-&R,I^0!)R4OT9B9_%M;@$1&+EQ*$B!YI)):\5/..;YSZ
MK>]\^[L_^)ZZ#"FGQOO&2$H^0%+R$KV9R9^%-7A$Q.*E!"&B1^ICIP)X>.?3
MYE.A4>\N'YC#.W /DI*7Z,U,M7:[%B B5D!*$")ZI)%8\K*$\\9(2CY 4O(2
MO9G)GX4U6D3$XJ4$(:)'EC#MY*4Q;XRDY ,D)2^1XQ(#NTTB(E9 2A B>J2L
M5VE#J'PH?EZU&N;P#MR#I.0E9LM+8-<"1,0*2 E"1(^4]:JPJE7">6,D)1\@
M*7E),ALET)L?(F(%U$N0PIX,$=%!9;TJK&J5<-X82<D'2$I>8@]-"FNTB(@%
MJ$J0CCT9(J*#RGI56-4JX;PQDI(/D)2\Q!Z:%-9H$1$+T*X_E"!$]$59KU(C
MJ;PI?EZU&N;P#MR#I.0E>I/3FSTB8@6TZP\E"!%]4=:KPJI6">>-D91\@*3D
M)7)<(M&;'R)B!=2+C_TK(J++RGI56-4JX;PQDI(/D)2\1(Y+)'KS0T2L@'KQ
ML7]%1'196:]2PZB*HMY=/C"'=^ >)"4OT9N<WNP1$2N@77\H08CHB[)>5;YJ
M&>\;(RGY $G)2V0#,T8J=IM$1"R'=OVA!"&B+QJ)I6(:[QLC*?D 2<E+9 ,S
M1BIVFT1$+(=V_:$$(:(O&HFE8AKO&R,I^0!)R4ODN,08J=AM$A&Q'-KUAQ*$
MB+XHZU7EJY;QOC&2D@^0E+Q$CDN,D8K=)A$1RZ%=?RA!B.B+LEY5OFH9[QLC
M*?D 2<E+Y+C$&*G8;1(1L1S:]8<2A(B^*.M5Y:N6\;XQDI(/D)2\1(Y+C)&*
MW281$<NA77\H08CHB[)>5;YJ&>\;(RGY $G)2^2XQ!BIV&T2$;$<VO6'$H2(
MOBCK5>6KEO&^,9*2#Y"4O$2.2XR1BMTF$1'+H5U_*$&(Z(NR7E6^:AGO&R,I
M^0!)R4ODN,08J=AM$A&CIVK^@=C3%Z.Y]'2,R>S9$1$=5-:KRE<MXWUC)"4?
M("EY2>!(Q6Z3B!@]5?-W#7M5$1$=5-:KRE<MXWUC)"4?("EYB3TTJ7R#1\2J
MZ&9C=W.M$!%M24H0'I*2E\@&IH>ERC=X1*R*JJ]U#7M5$1$=5-:KRE<MXWUC
M)"4?("EYB6Q@^NBD\@T>$:MB]L:N*H.-/3$B8@TJZV'EJZ+QOC&2D@^0E+Q$
M-C!]]%/Y!H^(55&U_4RHR8SI[44A(M:@LAY6OBH:[QLC*?D 2<E+[*%/Y1L\
M(CJHW@>K!T:Y0$2L964]K'Q5--XW1E+R 9*2E]A#G\HW>$1T4+T/5@^,<H&(
M6,O*>ECYJFB\;XRDY ,D)2^QASZ5;_"(Z*!Z'ZP>&.4"$;&6E?50U<9*HMY=
M/C"'=^ >)"4OT9N<WNP1L<;5^V#UP"@7B(BU;'7KH5Z<S>$=N =)R4OLH4]U
MFSTB.J+>!ZL'1KE 1*QE556L%FHUS.$=N =)R4N,QB;;FUT+$+'6U/M@]< H
M%XB(6&%5'=:+LSF\ _<@*7F)/?1A&(2(:TA*B(A.JNJP7IS-X1VX!TG)2^RA
M#\,@1%Q#4D)$=%)5A_7B; [OP#U(2EYB#WT8!B'B&I(2(J*3JCJL%V=S> ?N
M05+R$KW)J?9F-TM$K#7U/E@],,H%(B)66%6']>)L#N_ /4A*7J(W.=7>[&:)
MB+6FW@>K!T:Y0$3$"JOJL%Z<S>$=N =)R4OT)J?:F]TL$;'6U/M@]< H%XB(
M6&%5'=:+LSF\ _<@*7F)&OKH[<UNEHA8:]HUP:@5B(A8>54=UHNS.;P#]R I
M>8D:^NCMS6Z6B%AKVC7!J!6(B%AY51W6B[,YO /W("EYB3WT81B$B&M(2HB(
M3JKJL%Z<S>$=N =)R4OLH0_#($1<0U)"1'1258?UXFP.[\ ]2$I>8@]]& 8A
MXAJ2$B*BDZHZK!=G<W@'[D%2\A(U]-';F]TL$;'6M&N"42L0$;'RJCJL%V=S
M> ?N05+R$C7TT;&;)2+6FJH4Z \H$8B(U5758;TXF\,[< ^2DI>HH8]J=:KA
M(6(MJ_?!Z@$E A&QNJHZK!=G<W@'[D%2\A)C,,0P"!&E1G&0#R@1B(C55=5A
MO3B;PSMP#Y*2EQB#(89!B"@UBH-\0(E 1*RNJ@[KQ=D<WH%[D)2\Q!@,,0Q"
M1*E1'.0#2@0B8G55=5@OSN;P#MR#I.0EQF"(81 B2HWB(!]0(A 1JZNJPWIQ
M-H=WX!XD)2\Q!D,,@Q!1:A0'^8 2@8A8754=UHNS.;P#]R I>8DQ&&(8A(A2
MHSC(!R=3,O$  $Y 241!5)0(1,3JJNJP7IS-X1VX!TG)2XS!$,,@1)0:Q4$^
M4-C38TED"Y=;MG!959N7+5P^U>95&SE&4O(!DI*7Z,U,;WZ(6.,:Q4$^,+IG
M++ELX7++%BZK=MW DFN7XAA)R0=(2EYB%#79_  B@-V[8%ZJ;:@_D(_9O.63
M+5QNV<)EU:X;6'+M4APC*?D 2<E+\BIJJG%6V,+>M["Y2F)A;UW87"6QL+<N
M;*Z2F/VML[^*(57;4'^@L*?'DL@6+K=LX;*J-B];N'RJS:LV<HRDY ,D)2_1
MFUE([$9;;LTUR =[:1707(E\L)=6 <V5R =[:1707(D@[+DP+]4VU!^P;1$1
MJZNJPWIQ-H=WX!XD)2_):]"CQDE5P5Z?G)J+J"SV^F37G+_BV*N477/^BF.O
MDKYN]I.8EVH;Z@]R;GE$1"RKJ@[KQ=D<WH%[D)2\)*]!CQHG505[?7)J+J*R
MV.N377/^BF.O4G;-^2N.O4KZNME/8EZJ;:@_R+GE$1&QK*HZK!=G<W@'[D%2
M\A(U]"D&H_7:9'E)D7,A)23G>V5Y29%S(24DYWME>4F1<R$E).<;R5=S3I-]
M@C"H3XWYJK:>_H"MBHA8754=UHNS.;P#]R I 4#U4:-YU9=@8>I]L'K 5D5$
MK*ZJ#NO%V>P+P3U(2@!0??31/&/Z8M3[8/5 ;5M$1*R*=A\7(RGY $D) *J/
M/IIG3%^,>A^L'JAMBXB(55'OXQ1F7PCN05("@.JCN@W9B]A]#(94;3W]@=JV
MB(A8%54IUC'[0G /DA( 5!_5;<CNQ.YC,*1JZ^D/U+9%1,2JJ!=A59;-OA#<
M@Z0$ -5''\TSIB]&M?7T!VK;(B)B5=2+L"K+9E\([D%2 H#JH[H-B=W'8$C5
MUM,?L%41$:NK7H1563;[0G /DA( 5!_5;4CL/@9#JK:>_H"MBHA87?4BK,JR
MV1>">Y"4 *#ZJ&Y#8O<Q&%*U]?0';%5$Q.IJU^082<D'2$H 4'U4MZ%W)UB
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M2HB(SJCJL%Z<S<(-[D%2 @"(("0E1$1W)"EY"DD) """D)00$=V1I.0I)"4
M@ A"4D)$=$>2DJ>0E   (@A)"1'1'4E*GD)2 @"(("0E1$1W)"EY"DD) """
MD)00$=V1I.0I)"4 @ A"4D)$=$>2DJ>0E   (@A)"1'1'4E*GD)2 @"(("0E
M1$1W)"EY"DD) """D)00$=V1I.0I)"4 @ A"4D)$=$>2DJ>0E   (@A)"1'1
M'4E*GD)2 @"(("0E1$1W)"EY"DD) """D)00$=V1I.0I)"4 @ A"4D)$=$>2
MDJ>0E   (H@*2 J[YT9$Q,IH5N0$9N$&]R I 0!$$+-#)BDA(E9/LR(G, LW
MN =)"0 @@JB>6'72=L^-B(B542_")"6/("D! $00DA(BHCN2E#R%I 0 $$%(
M2HB([DA2\A22$@! !"$I(2*Z(TG)4TA*   1A*2$B.B.>C56F(4;W(.D!  0
M051/;'32B(A8>?5JK# +-[@'20D ((*HGMCHI!$1L?+J15@59[-P@WN0E
M(@A)"1'1'4E*GD)2 @"(("0E1$1W)"EY"DD) """D)00$=W13DHQKE/R 9(2
M $ $(2DA(KHC2<E32$H  !&$I(2(Z(XD)4\A*0$ 1!"2$B*B.Y*4/(6D!  0
M04A*B(CN2%+R%)(2 $ $(2DA(KHC2<E32$H  !&$I(2(Z(XD)4\A*0$ 1!"2
M$B*B.Y*4/(6D!  004A*B(CN2%+R%)(2 $ $(2DA(KJC7HU5<38+-[@'20D
M((*0E! 1W9&DY"DD)0" "$)20D1T1[T(DY0\@J0$ !!!2$J(B.YH)Z48URGY
M $D) """D)00$=V1I.0I)"4 @ A"4D)$=$>2DJ>0E   (@A)"1'1'4E*GD)2
M @"(("0E1$1W)"EY"DD) """D)00$=V1I.0I)"4 @ A"4D)$=$>2DJ>0E
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M4TA*   1A*2$B.B.>C56F(4;W(.D!  0051/;'32B(A8>?5JK# +-[@'20D
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M4@( B""J)S8Z:41$K+QZ-5:8A1O<@Z0$ !!!5$]L=-*(B%AY]2),4O((DA(
M0 0A*2$BNB-)R5-(2@  $82DA(CHCB0E3R$I 0!$$)(2(J([JIJL8Q9N< ^2
M$@! !#$[9)(2(F+U-"MR K-P@WN0E   (DC,NL^2W7,C(F)E5'58+\YFX0;W
M("D! $00DA(BHCN2E#R%I 0 $$%(2HB([DA2<HU+ERY=N'"AIZ?'?"$=DA(
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MV*N477/^BF.O4J QDE(1!)^)IY+2KC<.=5\8N'JIK^^2GI3"?(&2P2Z2$@!
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MR@^V#]0.[.T  ! ]Z-T@/"2E_&#[0.W W@X  -&#W@W"0U+*#[8/U [L[0
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MJXN*XBO:$M%HL/]46U.]J#S7CYC?UC-8H:1D$-P02H.=E,I%AD\A_Y/%_SX
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MX#+5V<NM,7%K=[:MF?E_P^&24FJ\TOC;HXEA4/^)+?'15?)87&I0I?[7GEA
M:J0U?&9C^Q/Q484ZLS'Y'_KZQ4\=B2^T_U1;?-18OZ3UT_C+:A0X?+0AC<"A
M5?JX*C6T3:Y ZO!%\E6Y&>TCD_H!1BB*W'M[\J^<I1JHJ)_:3\QS++/_E3/M
M9FJL+(]:J%?ECIW:"77DOR3LW4-$A9UM;:V[XA$H+2EE7['D_SM2IY:E7I6)
M*^WL8K56R:UD'*VU&D):F!GL;7\DOBC9<M5!L.2GR-ZN@^I&>E(*WK96$U;O
MGMP"R]O.:?\N26!]"O6"7(A<);4S3&MJ/94L6,EFFUJ'Y,G8R;^O<6IB*M9J
MNX=V%#HH*65>^>2V2J[)8.^1WR8#)TD)(/KD[MT 4A2>E!H>6#7\W];ZU5N&
M_\UID]9A)_NSM#.L4A?VV!VMR96>UN6)_SX&#LZROUH"0FR?H>Q)*>U_V$.I
MGKY^>=/P/X;MFU+8(YX4H9)2_+^V;:UM;<-_H^0&E\.1H+^(2DKZ01L]G*26
MH/^'7@Y&Y7+21D@!! RMS&%N7W?[KN00-HE< ;G,U#Z3"IG6]1Y0+"'V=KEG
MQEM<PXH_I/^Q)*G!L?Z_@&1HD;M6?G_EH;0_]$#R\&SPJVF[06I_SCH.3DM*
MV5?,"NK)Z?=V]5ZRUCG9 .6U6_DD)?M=4ODMWG)SM.N@NJ$O/&03UF-GX"'$
M.-:G4.CKD-P9AH\("?J[.\1'4)>*#06N@]Q54G4UKJQX074L+2EE6OED3Z&O
M2:HR9]U# " 2A.C= )(4D)129T2D_I&9^F]<_>+-)S*$I:"DE-ZG!CYID3JL
M$7]W^_^:V5\M#2&VSU#6I)1^0&FX>U;_<4_>""O],FA[Q)-"_>LT6&,6.9@3
MXY(_)<\:2JRA,723))],.]BEWZDB\(1)N9Z)H63:H#. U,C5-.#Z[^182OB'
MQ#_44Q\J;<"MCR"A-(38V]6II,8?49W$%;B?! VX@__*@;,K@EY-&ULKPOTO
M)G"G#5ZQ9$-._%_C3XF I I.ZKV2Z3$9D!1Y)*7@SV(3W*Z#ZH:>E(*V7D 3
MUM\]&77L4Z^M3Z&PDU)0'5.I3Y@\(T[^%?1=13Z>]>MF$7+D:J==\AJ4E#*M
M?- >F*PG&4L6 $2&$+T;0)("DE+\'@-&]Y_I_[@I@I)26H<49ARC!:& LVNR
MOUHR0FR?H2Q)R;ZZ)GX'"#$XT.^E&W 6F3WB21'JF-)0ZC0;N7TT<R:EP"?C
M?Z; 5;('>1F''4%#J]3- %(G^"5//3)76[UI\GKQ^#A)NUQ!+0Z*)-S>;EUG
MDE3^+0('QVD#[JQ_Y<#=3*&.:-D:+2),A3&34M854W%(-W5267+,K3M\:FL>
M22G@1.5TLK;KH*VG_SGL5],G"&C"Y4A*>NG633\'<D5'GUR?B5N[SZDSEN7"
MD^4T*"EE6OF@SQXP"P!$DW"]&T"< I)2$)G&ZTG2NZ6 [C]CM$B1%H2L@U?9
M7RTEX;9/IH^3NJ=YCEL.V,.1H'Y=DFG+IR6EU&' 84=.JI^<.CID#MV2"\CR
M9+F2TE#:Z4:IJ[<U)S34I[UI,J)/W'KJH^2#K)=[07Z$V]MU$@<WU%7RP\<>
M _>3Q!Z>XZ\<N)LILK^:1M _:"STG3;'B@TE/NSPG212RE&[>;.'A$&'/@(:
M0OBDE*-=!VV?BB>EM (5L#,,7WJDO&5*@W9LQVCCP_O,=8]V?-8^?)Z>L6%S
MK#S'E !JFOQ[-ZA=2I24TLZ#LDGODO.Z]UV<[$$H^ZLE)MSVR9"4DELIYW$/
M^^*$P#%-@E!)*?FO=_W63_JH(ELH*O?9=^;02AO-)(>)]8N;]Z>N8;!&6JE]
M:?%L>V6@6'+O[?9%)G'T6Y8%[B?:.#7'7SEP=D7V5]/)]XX..58L?1G#WPU@
MO1I?_O;D[>F"FIO5$.RLDKVN9FS7074CY[;-WH3S3DI!][[3UR=5*J]K;-F7
MNMK*>-]4Y]*T8F;ZG2$F/-2\=JIVPFT^22G@9%VN4P*H'7+W;@ I\D]*R;&I
MWK^FKE7(^'VO1H>==G)YG"S?IS1\4ZG$J,4,0ME?+3VYMT^<P*04>)/BU)A2
M#R3RQEEI@<H>\:0(E93L?Z"FW7XW6U(*N*.#/+DQY.7@&8<=&896VD#-_A=O
M<C\)^B#FJD()R+VW!\</O8$GAZ<!=W20%Q/F^"NG:DOP/1L"[NB0.5T$-D U
M/DY,K^^TV5<LF:_TRY.2P_>F]A[[_&2YMP?<>""@(>AQ0CN_-+DD?8B?HUT'
MU0U]X04TX3R34O).I.IT:#LIZ?]\23UE)A9U29AZ4C_U<7CCY).45)F=]DA[
M_--S[SN FB)W[U92+EVZ]/*65XZ]>\Q\ 7P@_Z2D.N/DW9_5C6N374[Z&%UB
M==AI=]&5MX75OITPZ'A(AB"4_=72$V+[# 4GI0P'E%+#@M05#LD;]8YL6-6N
M709N;4!%J*1DW-'XROFCSR?C9>ZD9-XE?/B."Z%N,9QQV!$TM#*N4TK= %K^
M95/WNC"VP_#9.YQZ5VI"[.W)$TK3OGEVW\;XWE7_1$=\MTDEI>%[EJ1VFV2#
MS?57#M[-4D<#U#W'97M)O1J\,P1\\^Q^>;0GZ)MGLZ]8ZM8LQEW"X[ON0'(<
M;]XE/-GV\TE*V>\2GJ-=IQ:E!ZWTK!*\;;,TX3R2TF!OYTMF*;.3DM$7!"86
M[;\AZL\Z?"78<"3.+RG%WTO_HBJ^3PF@A@C1NY6,CO:.":,FQHO/?XTV7P,?
M*" IQ0<-73OE;:!D'Q._Q=/P/U##)"6CES*^B3(X*5G&>\3LKY:>4-LG("DE
MOR0D: !WY7SGGK1+&NI7;]%O\! G8 ,F"964ALQK*M3WR2;6)UM2&OXZVNL#
M;E^>^VLK,PX[5!)+-_TMTKX:4GU[:?KY0@$'.:$TA-K;S6J0:,[#WPR;'*P/
M?]EH?*=*_U*!G'_E[-\\:[P:WX7VI'T_<AKF5[7&5T:=/6CLM-E7S/ANV;3W
M-2YA2JN0>26E(7- 'V]EZ=\\F[%=)^8=OBE%(B&8"\^S"9MA0Q'8G--7=<C^
M: F,:[K4=\5:$2C@-(2TVPCEFY1, F8!@&@2JG<KFG-GSS7.N5<6MYD-=W>?
MZC:G !\H*"G5,&P?Y]!/Y8*24HJ]/7!P#%!= N[@FG;F(0!$FE+T;MFX=.G2
MDX^MEQEI]'_?TM'>84RP^_4]SV_ZG?$DN E)*3_8/LX@QSK):^7Y&J5R4(J]
MG:0$#I+ZCG)UUFCR[,H*G<4- -6E%+U;1D0*&O5?HV5,$G%(I";]U>Y3W3,;
M[I:O<I3)"TA*^<'V<09U 8RZD@I*3"GV=I(2.(E]UJAQ4B@ 1)=2]&X!B.0S
M:<P=LJ3<M^"7%_YQ07]5_/K0 ZODJQ-&33S^_G']57 6DE)^L'V@=F!O!P"
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MR7[-DDA0CS6ME?-.&#717GB17+AP02[<\"]=?Y$3B 38UMK&28 Z)*7\8/M
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M WL[  !$CP)Z-_UL.C%,%V%#/UE./'YSSYM9KEFZE.M;F.P#3?HMQ>WS]PI
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MD>9QS=H[7_OZQ+-+[EA[Y*)Z!IPGQ-X.  #@&<7W;B+A3+[UYW+4KDZ-TV_
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MY$*2@P>^?,,WG_/C.=GKYVH7YGDNZ$9C/35I=%8?X#4JYM/S/VKAW6\H20D
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M<20E>Z@/U$&W P#DPW2#.)*2/=0'ZJ#; 0#R8;I!W#Y)"0    #0DI0
G %4D)0    #8BZ0$     'O]!XF:TI6\V&BI     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_6a.jpg
<TEXT>
begin 644 image_6a.jpg
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M:G1PR%EB'A$=Y=?!3\_$E*G5Z&4J1[^Q.B(!Y*-2S,BJ>BZ(P+M//2"?'B9
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M"W5MYVM;S]6T]%:U]%:W]-:VG6><ZN-U7A("I_H$B(LX_,X^P>G+C:=A5I\
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MOS'*O34FN#TNO#,AO"MJNB=JOB=JN2=JO2MJO3/9>GNB!0K?F6B92:N*%E0
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MKA3.G8.<>_D--S)/]&TO/!.=VQ*>R0_9PPG<QPO:+R <: H[T!R6U12:V4@
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M-A*"-<I;("9%6PR.J )I@K=$DJ8(9X)_XRD7D\8H!;9;(KPIS!E5( $9C(^
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ME,$6Z[)$VMUQG7=TT),8\,;[?6Q_ #'@9_I]3+^?UF6 C6-#P;&1P.BP+SX
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M+RPJVR2OV9Y]4<X=2;ITKI93=PZL>O_)-SY\]E;Y*2?=08I+52PE6^F4E58
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MBA@ENQD%1^Y&T%91H=2A>#$)6P(A8Q$%"Z;P@.P/23X"-B)SM9E%+C3N43'
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M)R/'67ML\$[E^?6[7]O^V?KJOGS?N"F1]JEK>*+W^[S]Z>N0=5Q5=/[[JMA
M%GYUW:#L_.CHJHKU@6R]77YZ[8[G=YQ\I&+A*3#J+$[J>7XE<)G^N!R.<0%B
M%KZ+Y&RWM7'/F8_6;'WIU.U#/5@S 5)LSO=(Q:+9D<QHQJ6E%_A5@$9!<Q0@
MOP+?#-3<Y@AH6<$1YNS^:;,K,62E^DQ$UU"PM===UV:MJ-<7U>@+:BTEE>;"
MDN&<&FM)N[>N&:]NQ"IK;"5%0P^*!A]4F@H!T+CUCO(F5V6CJ[(!JZRV%)<-
MYU8-YM8-Y349BP>\33VNVH?-5ZZ6''_0<+&LYVZ'O<I&]T4X$$!N. $L,=2#
M?'/O-8WD8507*]I&%1<K.FC>$9?<8XJ7YO#HE!N:<Z-BE.$""3%L]/:>N7GX
MQ;5/OK7E>6A(V*DO4+&H%\++\GYU8;8(RY$L1[!\"'XX2,@N SZ_SMEC,.K=
M Z5%0NL.]:(B?PRXF8$9LYGH M$_'&S%QT?@6B@%;K*;2>%,VL.D/+2"HTE2
MT;>65XU+0<ZL#E; R%E;9-("XF-<\1+35FNT$X2^.S$8GK&$T2QIZK+#R*/:
M'4][Z;3+,SFDC[0,!QNQ>!]H1Y"P:,XL9+E'7@?9LRX@099]]'D5N[3D(%RJ
M7%MJI=9 FFQAI.EB0/!]P86C]Y)FX4-3$""]10NN\)3%$Q]T,7W>L8'0C!'=
M#<D3X[U$$J=X_YA"C2L,,>-WT48[V>\=&P'9RJ:@\6">M\4NJ%BD>BDD=G'U
M191I5"\&%!@(,F@,1#@;FK*#1Z413LPW98(6'?P$H$7G'AN&#'0*1X\UI;8Z
M1&0;1AH:=60]>HFQ"GKW]F&UH&*W?[;V<L$14Z@=LA%)I&))_I$)=C'JW5OP
MCW\$BZ0GFL;[7P,<J=BLE__B*F 95 F[V&/[D>NVX(Z*."&Z2=$54UL(M  2
M%@TI8W@W+7@IR1<0;;UT]:V1@Y]4/[>V\'L;RO]I;]-/+G:]<*_C@_L-QW-K
M\JL;.CO:AZHK:DX?/;3GXXUWKYYV6X93 I=2%$%$09H7LBLJ=B6LA"\)WS 5
M6_*#-ZN_O;KY+X[H?]$:V1.9*9L01\;1V\1+BCY"!IWJ3W"!,<Z7F682K4&Z
M:'XE)(F08U\VC(0]UEB?AU6'!B^UV,W#H@8]:L0S")>ZR"V"YMT)M "CSTD-
MW:V\N&'/&SM/;*S5%?C'+8F4']7WZOM=[2'-K@N_/O^.*E8*L%(PBP MJ;-3
M+<VO2D_%$U<\OG']O>K/U^]^2?,H\(V#BD7"=_X\E_UNUJZ0BHW$DD&HGM4U
M/P/=UCK(\%<  (  241!5.8]I[>MV?K*J=N'D8H%*9;V48JJ8E,6;9I/Y*RY
MM#'P5<@NJ(RA2B9$9V#6XITV>28--D8WY&_I=%2WF$L;0+8.YI7UWBMHNW&_
M_N*UBE.72S^[6G7Z<N6IB^6?W:H_G]M^_4[3I9OUYZ[7GKU0=OQ<R;&+Y2>O
M5)V"?^\V7[K?>@5XT';M5N/%:U5G;E6?O5-S[F[M>=C;W=IS^R]OW7'ZO9/W
M=M^I/5>F>]!D*>_"ZWL]#>W.ZEI]X</VZ]<J3A2V7C;XZF.<:2SE2LA0TNR@
MY\9DG.%P8A)GDR&D8I/!A! Q>OK.WCRRZIT_O+7YA5MEIY=3L68&K3FG.@6B
MNAQ:?:$X%T%  GX^2RO[^2H_JZ9'E;VDM0$0,=6>K;4'\'%]FZTBO_5ZI2['
M&.T"41N!5@%J&SB14 ,5F\*1E?%KJU@*S5?@1&MJ< XJZ1B%LL2[;.&NZI[[
M91VWAGQ-P4E3=-:&>MB18<R%5K*8\Y$R9B0ZZT;R*W3W>_%:WY0APEF#L^8P
M;U5-B4Y5LRYAZ:$S)_ %*E83-]FCT^;->"Z:6P[TAD&C19<'M<"]:%$)$:TW
M$9UQV:/]'::*=G.Q.=H2G!H&A00O 2JC8@-C*9H522=I;C?6-@P6#7D:0C/#
MM&*A90L(V9A@53OZD82-\2Y5PJH^P>A%I#6J'T-U1W;&. =  DE'7/;$)8^;
M&6P8S+]7]7E>_>5>>W5@W*"IM[B"NMV1\[K:F$>^SHON#[P0:$W%YAS8?GSM
MY7Q0L1V0C4C:"<ZVK(I%)DP!K0JQ#.C%FUTX_SR^3,6BU_5R9&[:8H_M#*Z8
MX"&A2A(\,0&9-D#"TH*-%BT@9%G.C1;*EOS!C(H]L+/ZV7?RO[.Q\KLG=4]5
M^[<9$K==8]V^N(^*CX^/S83\_KJ*DCN7S]04WPOAMK0D*++,\[P@("FK"=D5
M%;L25L*7A&^NBFV)[ [/E*+Y8I$UU$]*WJB"4Q(HUR!:[$?PH%5>>=5Z)"+4
M@10XJFF6SGB*8"6M(E\*JX[VR-)5&9 WK=K-JC;-W8N&A:'%2Y&*I8?N5U_\
M8-];GYS\H*Z_(#!A&4L'XNH4\>KZ0RI+_0ZSR+3^U:EV'B>.NMJ1P]\26.3)
M^B6NC<N1.43VZ!/D*ZDNYA18 HL6Y-1LL4OU/4*]M."4*:_A\N:#;^P[OZEN
MX*%_PIA(^VFT\(_*UU:Q"3E,<4%R-L (48H+=5M;]I[9_O9'KYRZ<Z@':R0%
M-YORTF@V4R>:0!3-4:_98K-TZI>B^2^24'.CL?"N*.]P,/W-QN*KQ9_MO[CE
MD]/K/SGS_LY3[VW[;.W6HVLV'7IS_;Y7WMWSTKK]K[ZS]^6W]ZS:=&SUQZ?7
M;3CRYKO[7T$;][RT9O>J-;M??'OWJG7[7]EXY"W(L.GXFBTGWH$\L&7+L=4?
M'EOS_OY7/CCT^KM[5CVS[J=_7/O$VY\\]]&)=W9=V+SOZD>';^TX<GO'_FL?
M?7IATT>GWMU\[*V3=W>V&?)#D\.CH&)!M7.V&&=E)2?-8<2TBU6ML#3R*PB;
M?+K/[QQ=]>Y3;VYZ_F;I*3O52B(5:V$4>TRT$H(9#207[2QR*M!F"4##C%2+
M+!I+A%9"SOHY9*K\K)I>4[&,-O!%'003@_NIX(SB<3(#9=UW3]S==:WT1)^[
MWC=I!"'KG33XITQ13C5#J@8_4G1"K/Z;0>VC7_ H6+0=]=NZXO I/*8DG+\[
M-&'J-)=?R#EPYL[N9GT1-)Q(WJ'UC614;-H;X>T]KMI[M>>O%!^OTN7 8PU,
MF;P3AN",)<([2 D-WT$2?(DS0[;;0(;'])F&]@M27S696;$0\XGL%?XRH*8R
M:FRC]C;"\P@1K:<=E_VJHO7&>!R:P3VVNKN5Y^Y7G^G%ROR3 [1L8Q7D41!-
MPO7ZQU(4,1OLLW?<J[IZM?!DC>Z!*][+R-9$VIX9Q86LP@Y5?KE0QY3J3_5%
M*I:"E@ T%3C4%4[Q&#EK'X47CH3;PMWW*LY^>G+]P?-;RMMO892.3-ICG#,A
MXZ,*_*@U<RPZQ$(K'1(+*O9<SOYMQ]ZYE'<8J5@1J=AH$E0LDM>4YNJ QK.J
M-E<TS>WR*E8ML=GN+LCNP&89([X(%GD1S)/5\-!0SS_KY2;A\_UO2U'7.<-)
MT4.*>$PKA&B$&0A9*\T[: ZG.!\I!ORBO9>IO:4_M*/ZN35Y_[2AXKLG!YYJ
MH7:'YRJFYKS<')=2J[_1>**KK;FLX%Y?9QU+!M.R)$L2QW&"&D#(KJC8E; 2
MOCQ\XU3L6U7?7M/\;5"Q3=%=H9F2,5&?0/[R04+V1%(N4@;=&4(>L4NKWOD*
M^ OJ8-5-*CO_5ZC8!=#R1:+:-S=/7/&#2L.8H0>UES8?6+WK] ?U X6A2>O$
M7'!4]F0=_4M!5H?E3R\A^99E?G7UK%U]"5]\E"\Z4!S9:#W9U;F&.MP$B\Q:
M2]IN;CO^SJ%+6QN&\@.3QM$TNC/9]_!+8&5?0@E1?""6#+ B07&1;DO;WL]W
MO+WMY5-W]O<ZZZ#*C*= ,V&,@F:B1>N%2MHHNJ5G]>5 M00"*,K9:;3V+ @(
MCYWL+6V_]<FI]:O6_^JI-3]Z[MV?/?_NSQ'K?O[">[]XX?U?OK#A5\]M_/73
MZW_^U+J?OK3UR==W///LAE\^N?:)I][[&?"'=3_]_=HG?K/FA[][^T>0 ;+]
M\?U?/+OQ5[#]MVO^Y:EW?_S;MW[PS\_\7S]\[F]__,+??^=W?_F]/_S5+U[]
MSI-K?OCDFA__?O6/GGKGB:?6/O&[U3_ZW>H?_G[U#Y]>^\3'GZTIZ[SA9G5Q
M!0UR(CA+9-:(;&R\G9@%M8&LYC'>R\HA4[#_W/WCJ]Y[^O5-S]TH/6&G6F+B
M8&+.RBJ.F&A1^Y>MJN>B=NTXLJDCKQLT;RXC^+++P#S+ERMD;D3[<8&6U?0*
MJZ!!,-9H]_V:\SM.O'OR]JY>9TUHVAR>L7C'1OSCANBL#0U0$YRDVL&-6@[S
M/&[)>UQC"1@KX8F4%Q*P*Q! [OA@_<##0Y>W[CVWJ4:7 SM7^]DS*A9Y%*0\
MD*W#4GXI__#1:]OR&B_;R!XX$RB-8=!/(K*\JE9DY *AF9.121ZD*IHY(0NU
MP;.T$;B(3*-H(;.:^$*E**I7FLFC;<F,8X-=Q5&'!M*%VDWPC1M:]$5G[NWY
M_/ZN5E.>?U+'I"Q,RDKP<!\<%.\;3]/$3+!-WWCVWK%#E[;G-ERVQ[KCLG-T
M#@.]BY8"65"QZ(A+5:SZ%!X!OP6"LT,,1X>' L]+.QF]K_7,W3UO;7UZX[[7
M'M9?=%!])!IHZ(2SA>>B_H[FG^/\0X0$JZZ*IW/5@8K]^.C;%Q\>,H;:J045
MRZ$E&"GT+?3>F&]88NA7G-5UI@X[6Z8A@5#;_-GE<VEQ?=RK=5%ARV;Y'JHE
M+_P%0,62\!J1$5JCB]:.PD-3$YJ='H+S142_5W+VL TW]4=W5+_X3L$/WJ_X
M_M'>W]1&/O)+!>-SKJFY&2$U-SG%V6S.TN+"XL('%G/_]%0BK2B2F%&Q*[;8
ME; 2ODY84;%_CHJ-\5#]^%G%YV9'<NHN;SFX9O>930V#1>$IV^1<Z/_W*E:;
M?"":1/4?J-CRKKN?GEY_[-KVQN%\_X0AD?*I5MBE]_!+8&1?7 G&>#^9]#.@
M8I-(Q>XYNWW-QR^=O+VOSUD+U5XB[6$S*M:.9EG_LU0LH-:^3E9VCZ9\H):<
ME*ZV+_>SFSLW[GOUW4]>V+CW%4ALVO_ZED-O?G1TS;;/WME^:MWVL^]_=.K=
M+2?>^>3\QET7-V\^ON:]@Z]M//+FEL_>WOS9&LTT^^[^E]<?>GW#X3=@^P='
M5Z\_^-I;.Y]][OV?@WC]NY__IW_Z_7_^T0M_]]TG_^K[3_^7G[W\C[]\[;L_
M>^D[3SS_CS]^_A]^]-Q__><__AW$OWCENT^]\^./CJ\N;+GLB/4P,EPR-!60
MBB5XT#%V(NED15]<#E"BEY&#AD#?Y_= Q?[QC<TOW"S[-U>QC-IY2JG=RJ/(
M]1F#>P@W4.]O!>VX?O?+1ZY^K,/JU"D"7.%I2WC&2JOI;/6FL4A8/&8OU[3=
M6-I/":X0VH\%8P?J!_) GAZ\A&9S Q6KVF(S4AB4TVC:"U*IPUS^^8-]>\]_
M\*#FO)/J0RH-&8.1\5CU@ECP9T#CJ-!L ^H>LD'[1",.ER[;FY&P\^)5M4RC
MA*KDYN<I6Z+(YUU(-50?RB7#.M%7D"B7T55'9JP=YK+3=W>=NK.C29_CF^AE
M0<4J%DW%DIQG8HYA.:++W'KF]N%=IS??JSH'*I95G/&T$QG@U66'T>P$F7%=
M"WZQBU0LC\2K!DA8T)=1SJ:*2PS^16[]DGO W7#X\D?/K_O%VITO/&RXY$D,
MQ]5V2SSEA09#YJ(TH;SHEP6?0L.FWUU_,>_0]L_67GAX<,3?HLEE]4!V.+1V
M;VED:,?49K!JD<V6L/_]*E9SYIX?F_BOKF+1:#Q%[=M1;RF-UNS 6$$=G"I
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MP@/A+ 6:#_1U^2<NLJY9TEJ5_*H4"]>K=G#9^B%XD)\W/\BJ37W1]*!N,&^
M4\>0]_"TPQSM*%TU/"CIK&64/.B,OUQYY'39=X&E[P64_N)BX_M%S&,3"_E&
M%V?.,6.TV<PFA\WD<-K7*78]K:?73V\#Q3KTQJE.;L?UQHB H@_W5_[]H>:_
MQ7:Q$9/SI4"Q4V@&*(H[(,,1_W06 %E?^TYO^3,?HK0W2K%J.P\W*CSA-*6H
M]>F9N(#H.V=:2&6"*1*V0'5'\29 ]H>UFL7J#X@P7O1#V!]!L826=^A++816
MI5A"J-G&SC++.I_%WC^3DA6%/&W-N2EVK=A=A+TL\O" 9BFQ)/-TLJ2[CUD_
MRF]F*WJE\S2=53AEDX\P^R)O7/C=U[_Y<L>[B>GG1@55<L.(S@Y9RE,:N KC
MN,I"EAG)3&4?M+B]K!IH+Z5H(-,=;!-9[BY9Q*)WG4M1EZ#A1[SBYS_2X[S=
M:^:']\ /\JZO0LT8BIFY+#,3S^J@*0SCA(V!TL@  M-BOY5T6??3BN1+MX[?
M?!9>VIW9S\<42RJJ',@IZ<ZH'G[1SJCL9%8U4TJA1>Q@5I&DG:)Y-/ &\"HU
M(I>?<$78P19@&?*W*EF@RPQLI9FC,'/D1G8[N?+"C:#?;_SEAD._3\V[0IEL
MD9DHF"!92AM=9J$!'*BM3"VRV>5HS""X^W"CA5@"M.Q?KM8N#!H$8<A!)O8J
MR@$X0 [>;:(Q45?"T\C/=_SZP+FOZ@8S)PU#:@=5::.J;'2- PT6XEN XK5B
M3[V>&38HDY4$6B&<6J98(ICGDN".NT%68T/CG5)@1#=%H>!;<BL*Z[K<4<$!
M:55X2SD:=O4*)XLXE:#5U46<(2&"8E4XT!0P+M J4&P;I?3FD["0F+W7'H8"
MJ '%ZES(SS^>XH.DP%%5?86NCHVF"OD)#;LBBF4I#"Q8UA"]5BM45FAP5VX9
MQZZ"Z=C@&_4 E5:^TL)S"P@,U4)PYI />+3>RO2*5H7Z !ZI/),1?<60F:DR
M\YC"0@:@5%N%.OND9)[50Z])?'HQX,)W(3$[<NN369I.C1,5>,!QF1&ND>#(
M%12+GQ'4@>1H!OO8M9!7@[P&Z%M"9B*?RE 2;,@I+)RGPDI'!@,.EL8.';-E
MLQE 6,*6QBT<K7=MP=%]:R0D"W=9UF5:7;$>_>1M4;9Z)?\2BN7/D7KX]>6#
MN84=Z67=&2WDDE%1*T\W)%F 7A:=KAGM%;=7,XK3NN(CJHZ<KO@^L/R#(^6_
M#&_YL(1]7&(H,""*G34[G5;KHM7D<*Q3['I:3S\AO0T4ZYPRS73QNZ\W7CY8
M^.'>\I\=: 2*_:Q9%B5=J%BB6&@J.#('4VEGZ"PL'?%ZU%^X#?9'V#=.L1H[
M3^<4PGX(3UOGKAV)N7NN9<P]NPOXE1A,\D?,-;0VQ?I?HUMOB&)_2"^A6!7V
M3@\<F==P/SHUY%8F\A<KGB,#Q:I?$K@+N]I56_G8&3L3*)8TT=7#J!D3-O(T
MW7(C":A%;YT<9@Y$WKCT[A__X^,-O[CY*(0LKE*:1[30$)JYR@6>RL36H'?N
M#*YNJ(]=UT$K)TO:I89QK1..BT.2$K1*D*O7$"#QBADQ#3Y_CXAVD9CY3G#M
M,F^Y1^D0Y7C_!0G Q<24+=#D!KK:PM:A83 ^?@_.AV6ZO.=)6=+%6T'Q&8AB
M>[GUO=RZ%FII[?"+ZL'G0*Y=[)HN5G7;>#D@[("PB:[NGS31B0,109[0NW67
M0(^B2'"!A&1&.!Q'#??%)M [A+V,VK#XHQ]\^Z]?[WW_=DX4::)5:J+I75 R
MH= R97@T5XVP!@HDUXMB^1AAL?S+V]JECJ!8@&DIBO[*TSG$LXL*C4TRQ.V\
MFA;VZ;9?'@[[IH64-6'HD5D&9)9A %D4<0J%R$*T2N28!Q.)W,/OW(FI<LN@
M@/P6X4Z@MU#91@%OT11U-$O=;32)=H+GKKDYDKB)1%<$S<[Q&K0C?O4KP\OR
M[,'-HW"9%AP8#/M-@PX;%+-;69?/WSR,+ K()4"QA"4H'IQF>8Z[FKB^3P$6
M&A0T<]7 LBNE-B,<)ZQ*L$=5@M@P^ *9H:X@FD&/X9B%-D"; 8.B(*BK"G?
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MR41[,,-MTDQ;-1P9Y47-PPO7#UY/.]Y.R1!,-VOM@S,NFL9,D<Z35$8&"KB
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MCRXI$"G^:&C\4?B$-6=O!)Y%*_&OQ)KK ?!?.,EC$=MAYZ"@2"2\L"/PTM;
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M.NDZ)W?**9AV"!"/OC;%VI?TNB"[EM9\@KPHEAB+U3E$"A.WG5R9D!YQ_F9
M<G9H&_4%IE@1IEB:TD;3.)AK4:Q';J=17A3K_:NO_&[-2_0Z%(L,J1'%RBU
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MC%EI6XG7$/*<(2$-;L[U#AX25.M$S>X6CZ@BW0TY'M."*EZ)ZFNV%X3YBO
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MZPX'^A[TWI%VEWBXHJC/'-X+9#X2&0-*B]F'!0::VQ&_!$H=W%E@.-).H_]
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MQM(Y</@(C@NE%_K;G8+RBP^/;#^\;._QM8^KLX6F7A/T(5](L?3! 9KLY%<
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M&+)-\B=GBS62 HG. #0>19!B._@5%QX<V9JR9%?Z:NBKO S%:LEL2-@)=-Z
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M.GGGP*F[!T_?@YX5T?U#H+/0 </NTR$BTH^Z?R0@Z$0]2+V$/:B9+A,5Z9P
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M#C]OS&6V>=QVE\_J<)-XL0Z?W^;S.V,4&UMBRZLN;PK%=HH[,RH.+G[XHP5
ML97?2QOX1;DV469%6RQ0K-:N4+ND2LQ(!(0DA4\,=JAW!$1\*JB,<(40'H6,
M$**AX$,WD('$X!$#GFJ<?)6#K[!Q9=-LN96CA1ZY5Q*03QHF>(L_T0<DHM(1
MBE4[.4H'BEIDB5$64X 2 L, ]88PGB!"(^Z<>D$B)6HOT9%\XH'_$IR]&XZ>
MH>:$I$(@"3"#A@<JM)ZB$1$SW*"-C3@SP,I<"O^<H[8%4W99,:@X2$%>,6M
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MB4RP[@HHFF(M7LF$7P'U/*78'4>6IV?MJ1UX2E+KH?,5*9QS4ZP>6XK([FY
M&(^"]NW)08,)7V@_?ZZ+B11KMO/-=A'(Y.":'"R3@PFO1@R("W6@2N56])BZ
M;_5>VU>X:77N[Q;F_=N2@G].K'F[A+O+8'MN]W/'74:;QP44.^UP$8IU^M <
MZXIL:V-+;(DM7[>\"13KG[);NT2$8N__:.'3OUQ9^;WT@5]4$(H=<?2:T*-
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M6^L<TCK0+23XB"'%$@Y&T^QW2;%!@VNDD%^#Y!JN:(HUSD.QIB#%ZIQ L8P
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M'A59><VI:(J=1W/;8FGK.!M2A5\G0K'!\YS#+W8N15>L89J[;?[:)C/Z*.1
M\^WM=13P*+!A5EMJH-79^1J,1,M68@XP-LZ<< DD(_U=@LKJWMP6=C$T?H [
M&.D6/4=G\24Y[<A#Z(,4.[>(YS0TGWQ3U]/ZZTEG-B>>V@@K-.N!'BF6)B@*
MIU@ /HG1+3>Y90:74&4=$H^WLPU5 \JB'FEA![^HNC?O3N'5/6D[WEWP\__]
MZW_^R?O_]JLO?[0F_O=G[L;GU5VN[GO8QBWJ%I?W2JH&%74\0YMR:LCLQH1M
M.C+?GQB8@W?ANZ)8:EN-OMU447L._&0>BJW/SCL60;&8"_J[I=CHAW'FD0R&
M1XTP8,]!L<%Q@_DI]N"^XVM.W]U9S[A#*)9O\#"B;+%\LJN7H-A =L#(O_8:
M@KMIC#+!SF@>CP+#ZU,L3>402;$J*U,US:3Q*Y!B_1*X.T"QLHE!Y30#R'50
M7M_"*>Z55(M&>O1NGM$KT'FX!%LC*1:^A3(30;$T$0Q0[*$+.S8E+3IUZT!U
M7YYT?"!$L7I\6M$IF09I#LA%'ORHVI[J]2C6C!1+;;'BD"W6;,=*!LJ/UBL1
M>SG5NL+378E;RSY8^.R?EA7]76K#6T"Q9J18M=?M\-A]A&*=,8^"V!);OLGR
M)E"L?WQZJIW7<;SRT/J"7ZVI^/]65_Y->O\O&D:.:-U%H\X^ T;9E&O<<I57
MJ(%VRR$VVD0!0RFT-$&$I:X")B?)8!DM;,\$046VT/,)PVB3&(0O*^)E.U-%
MXNE]O7#*4:BMC6J&YQ.I?*/:Q1=IWLK:,,\@<N H06> ;T5&M]CLD5D\F$[,
MX!(!Q6)6, =/964! "FM0 ,X;,W5=P 2-3,+AU5-LJEA#8E7&@@U%0H7A2<?
MN?^0(F\-$5*RFP_MJVQ\L*+[44;VWH/GMCZIR>89.O7(RMA8AGL4:#$\ K2F
MT!;*+5Z5Q2?'YMP]H+"VB<<;^>8F@;F#H^OJX#9F/;JP>/,7/__T)^\N?.>3
MU;](.KN^L/5JEZBX7U;)T-1SC:WBT1[%Y*"&A(8EX=G) #WN/V3 "W@41&3"
M#.7#C"Z?T8I(I(F^!%';!+:<1]%;AK;7!\-LT?.D[H_]LKJLW*/K$Q>D9.YH
M9A4!J4!Q0H*9(T9!A+X1Q48HFL5G%!9"+OSS68&0R<S.<!E(E%^S6PJ=+DJQ
M3</%IVXE[3VV^N3MW;5#.8HIH%BNP3.L<:!?K,$=2)5,THZ\E$<!=NJ"ML/9
M3YG@!4_KC,A="(GFFII3T=XI 3D!1CDD-0.'!M(R>7BJ(,6N2_ATZZ&O<LK/
M"PC%ZEUL^%;G@ [G,"W&],Z&SD=' KO"'3>Y2%9M0I9P0<@LKD'XH<[.8FF;
M6[E%[?QBIJ8)<-D A_;RM!X.NA.@V"%AS@B7 "-X0#'&="VX,D+R0D,Q2\G<
M#D7NV+6$RI['DK%^#$I#*!;[;)C-& T$814^)MF*YM?7I%A2*YH<$I-= ;+8
M12-P8@[.J)TW8A.8H6%RB@U^F<S'JS,4G^].VE[ZX5?Y_[2B^._3&M^N$>S3
M395X_4J?Q^IQ>MQ.K\_K)6T@4JS7YX9W,8J-+;'EE98_/L5ZD6*G._A=)ZM2
M-Q2^NZ;B'U95_$UJ[SMUYD-J5^&((T2QBI>EV*@&^+4UA[7FA9J+8F=.;QX%
M*?95%.#+J!-XH>:MK"G%1A_%].U2+([FBRT^V;A?!8(5^ 2C=]GX0(H:&P<H
M5CHQ0#/Q2$;[NX5538R"'G&U8*0'H_>[N6K7*U#LG-(1 ^28'[UOFQB%IVXG
M)9W9?*\TDZENP3%9DBP^BF*AO1<BQ7I49B]2K,$[J'-W:YP]:OL !AZR\B2C
MG*>U#U?N_.J=3__CW45O \5F7-W9(2B03W9))[KE4WV8*\'),6/N5LP#3*VP
M(=/R'X5B7U7A%$LOCI%$?QN0UQ.*_3+Y_+8F9B%T#^ OX&R;[Y9B7RQDUFB1
MLDV9=5;\#2(]B5%@<DN@B(93[+[C0+%[:@<?*"8[1_T 6P&*Q;]).D*O1+%$
M01OPS%<O1;%X#6=/YHNZPL%B3$5"4P?6:<!@0K' IB" U) MMH-?<O9N$E)L
MRJ(0Q09ML1A;8&Z*)7<9 V*0^X[>!<0I%BA3:.F63?3+QON&E'6-S/SZH;QN
M4;EHM!LH%E,Z^X5Z'T_GY<*KP<\W$EG\F(*;7%*!Q2<F=G<AL>^*V[BE1R[M
M!(K-R-Y7WO4(]D\B'@K1S\'.,3EY%@\9XPHOP-\VQ1J18N4@BUT("#OB8(W:
MN*,VD@W!)3'Y%3(OKTY7=+XK*:[TP\7/_L>*XG](;WH'*%:#%*OP>Z8]3K?;
M!10+T.JEMM@8Q<:6V/(:RQM!L1-6:[>HYTQ=QN;B]X!B5Y3_]:&NMRKU^^7V
M9Q9[KQ%M=0IBBQ7$*);J3Y1B:0PCM94K'1OF&7I8F@Z&J@W$TK9S]1UL7>NP
MLFE 5C\H;^@6557WY99U/FAF%[,-[4H[2Q,>Y_]U*9:,-F(&6JV5T\HN.7EK
M_]YC:V\\/\50-<-%H,%Z0C&J2/,?I%B7W.16&C'H&TOC[-6XNK2N/LS@Y6 #
MQ:JG147-3Y=N__)'[_W+VY_\\+=?_7OJE>U]LC*CFZ%W,W4@(  W-TBQF =8
M90LD?Y\U+/NG0[$XSDM2T<+-HAX%*9G;FUE%-+(]19 W@F)G&RQ1,]]BV0Z%
M0)ZQB8;'B_5(0AX%38SB,W>2$T^M.W,WOG;POG2\S>QC&CT,O0OOKRY@5B<4
MZR8!M@(4^P*/@ODD(-/OHLY\MO :SJ98](>92\' PX$TPF$*4*S9"Z?-P8A7
M3I9\<J!#4'KNWH'U)%[L@\H+0DLG\"M\JW>C[V^H#$1X%.C1J8 C&Q^ IZF=
M5];(*" JK!M\5MWWI*;_<57?HX+F&X^J+^767JGL>= GK0*05=B&9-9!R52_
M>+(/7D%2(OGT$(ERT \E"B/+3@Q)QP=E$X/P257ODX/GMJZ-_SP]:P^AV $:
MHAO=#ZQL> 3HG(19!?B[H5B[8 3J?+?4X).)7*Q*U;.S'8EQ91\M??[/*TM^
M0"E6&T6Q/B\L3J_/X?/%/ IB2VQYY>6/3[$>OW_2:NN5])UK/+:E]'=K*_]A
M1=E?'>SXCS)UO&0ZSVSK,6%TTED4:[*)C$&*G2TZBA39 +^VOEV*C3K;US_M
M[XYBZ16@0ZZO?,19 H0%(!"/#'8):LHZ'N?7W\ZKO?FT[E9>W<UGC;=+V^]7
M=#TL:<MY6G?]<576O=+,[+SC-PO/E'<_'-:V ,7J/)@9-3S-[^M0+'%!!EI5
M3C$:AI]#*[@S;>6MPC-L;1LP62!83P1LX< KW%F9P:4 -,$DG"&*=2/%:NV
M.ZJ:GM)5NQ;_Y(-_^_FG/_[UPA^F7MXVK*X:]7,Q2:D7X\D#+I!!9[P+A'BH
M17,V!Q ZB4;8EZ=8$\8'G=G#'X)BD;R)+P0:.!WH%YN5>W13TJ+42[M:.:5
M&_"GX$I26"<ATCCDW^&%#3I3AA19%*,5C)>,P27F-JE^C0+ %X"_X$')/A$W
MT1!+W%J@KQ(2C@_8^$"Q(UZYP2D:\<D-#E$+L_1\SJ$#9S:>O9=0W7^7;VG0
MNX&?&"8/UX1.G%A:B,D0,]8:W2 9D92LATTV"BH0F)8<<;8EF$_C_KY8>O1U
M"48")G]*X^"J;"PED<H^([6#I":F;TF.8B)XR]02"ZO9 QT2EF)J0#D]*!GO
M;><79]Y/WGC@R[C4I8^K+XE'NV$;E74(-C:X,79;< QAUJ6&<P".')37/ZV_
M?O9>\I%+.].N[#Y^/>'$C83TK-VIE^,.7]QVX.S& ^<V';^^]V;!B<*6&[6#
MN0VL9_4@9CZ^LI[5,<E;UK-&5D$CLP >TD;&<^@=-3&!AO.K>W,KNAY=RS^Q
M)7GQTAT?P"'@K6Q\D.;6QD"V5A92+$XVX,\J_-\!Q=JYHS:!!9WOQ5JWF&<;
M*I/EG6Z+WU7^^^6%_[*Z] <908KU^.4^SY37Z?8X?5Z/S^OVN#UVKP_D\GHC
M6]O8$EMBRXN7-X)B)ZRV+F'WB>HC&PI_ Q2[LORO@6)+5?O$DW^:%!MV2G\R
M%!OM28Q"MV#\[<M1;"#,>]3G5-!LJZW< 5E33NGEI-/;=AQ>M2=C_?[36Q-/
M;3UP9EOJY=UIEW<?NK C^?RVI-.;=V>LWIJR%-[FU5\;TC1#HZOS\ G%4I!%
MO1[% F>8O$+I^$!-?Q[L?\>1Y0\J+@DM9*Z)A\Q&FIMBI7J7#"@6&GO@5ZV[
M6^>F%,O1.T2C?EW3<,VF_:M_]?E/WUWXLW<7_?C(Y6T,3?6(GVOTL@P>0%@6
M&;VE5DF2U&U.AB->C- ,SZGH8C"'",7.Z ] L7!!#&0:',*3@S\H:[CR)&-]
MPI>'+\2UL$L44PPC"8X&&R@FAQ53>(D"F!6 R*^E6'*)R,6?%228VAJ)(3!:
MVGFDP61C3.4TYKI36YEJ3*!*?3FX.+.*E@J"DG1&%Y7&QE--<0!M32[,0#OJ
M5P":M++*@6+WGUYW^LZ^RM[;/'.]SCU@]#),7J[) W\0;BO>7^*!#3L1&YR2
MH,3A.P\I!-!4H0QY)%O>O/]40UVW*<AB@0D@+%PTE9VCL#)E5H;<QE386>&"
M#Z530]+I(5@)"-:G!A73@QH[0V-C**<&99/]:MNP?**_DU\"%+OIX()=Z<MS
M:RY+QGH"%(ONOURC&V]E9 >,W&+H'+:PBN$JK4_\\O/UO_QBPZ^ -5?O_63%
MKH^6[OC=XJV_^7+C+Q9N^?7:^$_V'E^=EA5WXF;\\5OQQV[AZXG;"<?O)!R_
MC>OX]E;BR9O[0:=N)9V^<^#4K0-'K^X[<G$GU _;4I; SA=N?A=J#.!:$K0+
M9WUI["R@6(,=76.-KMF%_[NB6+-="!T>M4O(L0Z42G.18BM_OZ+X7^>@6)?'
MZT**=<."%&N+46QLB2VOL;P1%#L^;6WEMA\N2ER5^\[:BG]87?6WR5T_+5/'
M2Z?R+$BQ0DJQ)%XL4NQ\&6A)5?5J./ABO3+% JOAA*UHMP$QIA:+/-NPTXXZ
M](OUK5.L*10=;)9PJB^U&*&)Z(5'-.!TX*"%::YOS5XI4&PGO_K,[4.+MW[X
MP;*?+=CXWJH]GZ_<_?FJW9^M3URP<O?OH<U;&_\YZ*NM[_U^]=N;#WYUM_1\
MO[(A2+%HC@TIE"WL500_05J530S6#ST_?#$.*/9)3;9DK)]:"D/VPC"0Y9%!
M7JG>*2,^CFR]9T#OZ857@X>)">4=(HM7"Q2[[>#Z]Q;]_(.EOWQO\7]0BC7[
MV7HWP^!F&=QHBPV+Q#2W<*9YU+U^0V3$& 5(L4 P1K< $,J(@[;"(7GCY<?I
M<._VG]K4Q"C$R&C$*1:H43S:1U-YT?QY&((C:#A\@>C%)Q[)&'^-KJ#L' U)
MOSRGX*LYI;:QR'@T#D;#"N(L;H\L2RDV5&[#I77P%5,LY10;,SG;N&-^I=DE
M;6:6GKJ9M/?8RA,W=U?WWQ6/MYC]#),/P(Y%;B[A<@>/3EC4V84ZNR@H87@N
ME9"HQ3=D!@[+&LBG<>6H(A 6X\V%N1!0J1T<I8,=8%8'B!TN.5"LC2F9'I9:
MAV4VAM1*!&^G!N53 XJI >EXKW2B#Q#6XH438_6(*M 6F_1%7.K2)[,IUNC&
MNT\JQJC2ZQ; A>T25%[//[$[??7RG1^! &>W'5JR#9[XE*^V)"]<E_#IZCT?
M <5N25FT*V/%WN.K=AU;N2-C^8Z,97%'E^\\M@)UE"ACY:[TU7LRUNP]MA:T
M.V/-CB,KMB8OV9BT<.6NWR_=_L&VE*57'F>T<DJ@R$%Y,WM%V&FQLG0V-L9.
M=LX>OOBN*);88D4:MXAK&RR5!2AV>?&_K$**_7FM,%XW7>KUR_V>*9_;ZW/[
M@Q3K0%LL@*W'&P/9V!);7FEY4RBVA=UVJ"!AY9.WUU7^8$W-_YW2_;-R;:+,
MFC_BZ#.C(3!&L;/T)TJQ&ANO6U1[^=&Q]8F+%FU^?\W>+^-25^\XO'K'H96[
MTE9O/K@8VKSM1Y8!6:[8]?%'*]]:M>>3*[E'N\15"ALS8(O]9A1+8K/CM"3E
M-+.-6YJ>M6?[X:74%AL(@1FT%[X<Q;+(7!:QR:.N'ZC<>F#=>U_]XL-EO_I@
MV5L9V7%,;>U_!HH=EC<!Q2[;^6'\\?5 L?#YN%]N\8D5D\.BD5YX-1"'8Q!F
M=7)CI+,Y%)8LFN9;AD?/2, H/%X>,FXH9<-LA6\VZR=NC &L1IP-^$(@*Y,0
M728/W#CT?#4&7XT>,9$$RC"45>4T&UA69>6,^U4FEZ1^L# C>^_.]&4G;NVN
M&WZ@F.X<]7-,/H;."6+C/ND9.BB5BO0.<5"B<'>%D Q.D1%J!K?40J-VD,!>
M1!*S1XS3_(G"HP?BR:-1G. RB6U,YA>R%%8FH*K2R5'#8P+UI%>@]O)GY.&K
M/#RUFZ="<6&=OM6@GRL'L%4QB;X$9@]_VJ\PN7F]XLK7H%C\W,D7FGL:AI[E
ME%VX]"CM\J/TZ\].W2DZ>[OHS-W2L_?+S]\I/GTM_VA6;AKHZM.,:\^.9N5G
M7'J:?B$W]5)NZN6G:5?RTZ\\)<K+R,H]>C7O^+6G)T#9><> 62\]3,N\?_C<
MW90+]X_<+3E?W9?+5+= SR30PT&+.R-&L;$EMORG6MX(BIV8GF[EM!TN3%R9
M]\ZZ*J380ST_J] ERFWYH\YPBA62>+&2&,4&*79.14\6(9JKX:'Z;B@6OH*=
M\ V]U3WYUY^=R<Q)NYI[ZG[9E9S2R_>*+^:47KQ3=.YVX=E[)1=N/C^3EK5W
MS;[/UR5^>>%A:ANO#!IIO4= _6()PL(K[YM0K,K*ZN!7 )1L/K@(_6)U[8 "
MI(G"<6$:<3V*8J4DFV@XQ3(,+B[F;G IJWO*-B6N>7<AVF(_7OG.B1M[V/IZ
MBY^C=S,!80T$%_Y<*1;P8OFNC^)/;&@<+H +BQ&X'%Q 6*ZA0SS:1T-^4LYX
M&0%N!J+2VGGH'AKNVA'E&TJGXFGMD9\'O&!17,(W3 Q(#&=B V@C6<V<:#35
MDA%\M0TPEZ/&<7Q4:$4QR92,#DK' <1%\@E&4>O]Y//;XM*6GKZSKW;H@7BL
M5><:4%I[9!.@?N7TL)J8>#56KL;*4UOY:JL -0WBJ:>YT8)#PSE@FD *M4$1
M#@Z@J@&-NV%V6;@X5C;\"_0YMK+@3RDFAV3C@^+Q?N'$@&AZ6.I@R9QLJ8,I
ML3.D=B:(KLB=;*6;IW!S%6X.O"J)U*18:NU,V7BO;+Q/[V1;W +%Q$ SZ_GI
MVXD;]G\>HEC32U$L5",8Y0-N^K"ZJ4]:.Z1H9&G:V-K6(54#0]/$-;1R]*T,
M=4._K*974M4OJQY0U ZJZOJ4M3WRZEY959^B!M:I^A5U@_(&V -H4 $_J>N7
MUO6!)+6]DMH!63U+TRJT],HG<!*8?!)>&6HK6V_G&H@O3:0K^;=.L7:)R28'
M!2F6/6+G8J2M"(IM3XBBV++9%.N-46QLB2W?9/GC4ZS7[YVP3K:P6U(*XE<\
M>7M]U3^NJ?G;0ST_K=#%*^RY8ZX>BTND<RH)Q6+M8'3(S%"#1%5& 1Q\=2)\
M@=YLBHVJ7HF(G2 JVC_6K?-&AC>&YQO[PU LBD3:@M9:,C(T(&OJY%?W2QK9
MVDZ6MH.I;F-I6J!9XF@[V-JN7G%#;NW-Q).;MQY:1BE696<;?2(]\"O0#'%
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MAKNES.SFUB*N[H707"LRUPN--5S=2Y:F@J.MY!NJQ.UU\AX:AM_R0*5SY!8
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M(BX\63)J(K=NY"PWHMZA';EHO:P9H>@'(4S1FT4A2(5"084IPOX:R.6&@N7
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MR2 *_FJX\]L&$35'>P")",6*U3:ISM&FLHB 8E,O;5ZS:_J)VXG$+W:8%(N
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M=BA_W[*'GR\K>G=^P;]MJ_GS$W6\R''7Y Y2K$,D=PD53HD62,(F,-EX1AL
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MN<:R'L1*K R[C J*=3A=#:+ZY >)LVZ_CQ1;^&\QBAVY@.$BW[Q35V!D%"M
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MA86\"(*1SN#4U3KX6GLPJ"<5I]- ?!F)R8H8F(E,).09A; $.#!B*$6Q(%L
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M=G3YP[)S='4-@$Y?0&P-B ")-*-,[0CKC:'8R?2-4FPL6<9J)A?[RU$L/);
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M6B<76'G7Z:1/5OU^PYZO<FMO*0;I%A(E%!9'PH[(A*EW<?%E.KY2CY&312(
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M#T;:0D=2/+$).TYGE8P2PD0X46H,0U":X0HGY1(<=>?&3*H,=7UAT[V"IKO
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M#P=X8496#HE+)9#V]U3V/ 5Z XI=OO6CU%-K@>?VG-NT.R,)*&W_Q2WI9S<
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M5%:JQLI&^<-,8VJ35&T6HT-"\\%I6BM%"TOH7U'"-J'>(M3#\6 /Z_%.3FE
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M[..H^WF:?IZV#T8R7&T_6]W#U_?#GJ$Q!-\ZMM_K*^]0IZ*V1(ZN3VJ@0,-
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MTI4=TCFR$H6[HLE0GC8*EJ^.*C.2%6:*VD93V^@K#+'(%JM<2;$K<!;S-N$
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MU^O6??KO=9^N6__UVQ]N??N#K?^S\_A["44!-&6ERC*HL1$59C(*/?NKIUA
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M.+NPX^Z5Q-, G4X^FX)C/.*+0FX77+Z5=S$J]_RU](#@V!/AJ?XME"+1S,B
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M0GQQ2$S^Q6MI_M'W+D9FG_._><3[FFM,_B78@*7K9:A[:*HNLKQ]1-(\/-9
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M$,]2FHD%(0FG_*X[9]9>I2IJU':"=H&LM)!4%JH:9*:H312UD:8V,M4&MMK
M4QL$F/AJ U=GYD_81!.V4?C3E/,<^0Q#-D,#9E4:J5HS$[I_9,>RLC4FNLH(
M'$S#S6.+-JU5%(MARG*^)20S788EGJ5KNINIQ6DU-\/3_"[$>X:E^,857LEJ
MB %^[625CTA;R(KVH;%&P-S$LO"S4>Z^$:YQ!8$#@GMR<R]_LK=AJ"PJ+6K?
M,>=UG[SUW^_\Y=4/_[3ET = L8/"<LD\4"QW?$$POB <M_/U"&0Y3VF._?50
M++R%37[BHPQGLS1@_7$K7&)P#P&*+8K,\ M/]JSLC1-.=:KL1/'\H-)"P<)<
M((,H,KA:H;F*-!:QQB+5F,5:LQ!#1M@GW-#8.BM39Z4O">JLM=(B)Q,TR &4
MQ#.!:>UH21 UW,Z]X.JSR>GTU^=C//*;XDB2%N2Z:F/A]OYE+X*GH5@09:PU
M,B7 Q>OKX,BCC0,Y0+'C=CB;3(V9@=RU<2^%E7M[R2G6A"R^,BM;:N-*;#RI
M#3HF@<(B5)I$2M.HTB*16D>I4X1\<N+Y2B?/XO6'RWYWNO5/*<*=#&,1HEB,
M71T4ZRB.\D+*RT"Q^.PN7E3E59>T+YS+__6 8F>!8GNFX(9B%"%;K 51K-+,
MTYFXOS2*-2.W42S4*_?IM(;/?@(]YO@?J>6$$:OT0RA6M89BL61IJ[7FOUHA
M"\KPJ3 S^SBU-S."G4YO.G+VN]3RR)44JWI>BH6Z; YY-VKMO-%I4B/AWN5X
M3]^(_9FU8:LH%IG'S%2UB:I90;$:0-AY@<J \D% 2QBW"\9M0I61/39)X6M'
M^-IAX?C@V.208HX,W?_$ F_"SM-96"IDEEL=]FB) QC(Z=9$1SE+,598HEB:
MU$AAZ_L 5?-;[\07A=PNN)1><[.L)ZUV. >6H&YV)7>\?PQE_!KL8E=DU$8%
MW3KN??5 9*9W _$.55E!D=>WDBI22Y*/G_5\?^,'_UC_UW]]].=M1SZ*S@T:
MX)>+YX;U"YR)!3[Z%784:PDN-"RGW9JK;XU^D13[2"U1+)QTIF*6KC?S)JP"
MO86G,C);R477TWQ#$HZ7=L;P)]O5=I+$,(3&/]9%BL42(@AT]E&=3:*SR6"I
MMX[JK7 SX: 69:2C 9()M3&UB8:)OE8JS*, AC>XIX$,FV(%:X8$=3<S @_Z
M;?8.=4JKO-'+KA3/DG28W12:D\)(4QKI*A/R(G@@,Q.?P+=,L3!H46 Q"N"$
MDL=:;Z6?.QJP+33^5"NQ8&R2H+$PY/-DZ1Q)C'RX2?(5%*O$M.@;\.!:PU\N
MKD2T^CBAC@"+;H8%.'M6BEU.NZ#%:'5%F%CD#JO##;'PTQ8IE@,@*[/Q,.]8
MOM(D0"!K%DLM(NK4<#XIX7R%DV?1>O>*/_JT_S5]= _35.R@6$=QE!=;?G:*
M72PK*/8UMX8_!O2]FB7:2YZ+U=L[IRP,O1%N$'R9A2]%-PLT1^<71;'(892W
MF'D!/R33]^JG!=FEV5UK#_Z16IDM8I6^CV*Y&,4RA_B-UQ#%[HG*.-_+JEFD
MV(=G=ZV*7KXL#4J?MO8?PX3\"%&>^BY&U?74H'TGOS[HMRVY]#I%VB'#*!8W
M]V(YNAZKE5W@,L4"?T-%,DO%O!79PLF1NL'<"[>/^X3OS:P-Q2AV9 7%,C06
MP B:!M$&4V5@89,"^:IYGM+ 14$HS1R%D2Z>)G$T_11QQQ"_I9=9T\.L&!'6
M\[1]\GF*ULK6VSA:*PNWC:VFV*4H2+B)2VM'CYB5V(0PR3Q9/$<43 X2)<T-
MA+Q[3;$Y]=%5_1F#PGJFNILH;J[H3<^LO54WG,O6]J*'O&8&2=R<WW(G.!I%
MU[^:[)%9?[&T.[)A)+V-7%'>7A1X+?#C;1^]^N$_UGW^CYW'OHB]=V%04"F>
M&](OL/5VC@;+QH1;YM2_5HI]K$P<O86/QBKS+,4L0V\13-A$L$9I8+62BJ^E
M^%R(/5K0&L4=;]?8R3(C 7-$03X ,#A1HQE[/"U*VBS26$>U((M(:P(@!G:D
MP5!',4]6&BC*>:IRGH8MU\A 51@H$HPC\28$-*G G*W[N=774_V!8@-O'BWM
M3*8K.M06N !A!(B\<G%@14+1 !"_(ID6\PPO^L5:4:96U3QCW,K78Q0;G1GL
M'K3C:J)W&[E0-#FLA*^;)8[-C(Q.$\9FB8ABL4<'RU+AV7>7]- %"&UI+;P^
M+\6BX<0*85[%2(LXN_S6$MVJ469@A+ R&R8K1V[E*-"M"2Y;G@I.@7E49A;2
M)H<0Q98[G2Q\[UC%G_TZ_CMS;!]0K&EA'%&LPZ/ 41SE!967AV+Y497A+FE?
MN@#%UO\YH.^U3-%^TER<;J%]VDH=-W+5)K[<RI?:T%*#42P([R3^MU,LRN!E
MY2U^XU/VTS\9R#X+O.):1-@U_]B#_^UI*%;0>"W9'RCV)D:QT"WI['R\?UK;
M#ZWNEA[?#. ?AGY.,D=MIY:')P7L]OC"U6=+4DD$6=*.4>RBT\+S4:P,SY(P
M3U<8F5S=8%5O9O"MHV?"=F?4X!1+U"Y0E!8RHE@+0PVLB0RQ#* !E9&E-G
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M!0:A6-/WHUBEC:T8I"N'62H[AV]X7-2<<OART)XSRU(>G&9J2B=3K-[%0D\
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M5G3D-+-JS\1$O/G/-W[]YB___L5K06%+4HHN=BO*>H<[]#ZFQL7H>]*C?,)
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MZ.5;1L306;+X):)D'9581V7CZA^53Q.UG.+4<0&Y@DRX0]G J&)PM!?4/ZH
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M?D/"E;M'(F*W)Q:=K&7=[NS-[E*45'7EQ:9?61*TZ#=O_M=OWOS5._/^LNG
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MH!#0\)N0P\M#8#I)2+$GD$KWGED_60"U@+ A1[\!]MUU<@UP[:Z(-3 /2T#
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MTC_/W_3VJ9O;2]M36H6%0,R=LA*ZLH*G;Y;UT]0VD=XI-[EZS6ZYQ2.U>(1
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M-KK28J1/C$M ,(C(S:<\(+4V#G5!*9116+JK.^]%WSD<?G[#];2C'8*'9@\
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M[&):'6,4Z_93[)@%[BG<^0-0[&3;ZBR:&>7G6S=Y=N$@,S*0PNVW(_@=&P
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M-'?R3>U]-A9#57^W[&KXY<TG;^XJ:DT16MJ ((TC0IV7IW:S>^TTI9VA]7!
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M6=H^7E/?7QZ<[/N%T<7_>.]7O_O;_W/?X9/<I@":I$VF(ZGW.7#UQ=M\R99
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M*\4J7R$5AK K.M&*?E:).<BB<9V(OC"26!A@YG;=+OAA<*9+3)%?7(E_7$D
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MMO$Q_^#R'__P]W__Y-8?K/RNEW2^A&+%VZA)(-VA2W=H4BT=]R@XG7_K>\H
MD4<QE;Y#2BRS\4NEU*,:X-!1X13%LN1:)M:G_I0 ,5$H4T/\.,/''S2"?/0Q
MR_T9X0X&R,43;RF]T"9S>8LMWN8L L4^9TJVN4L;K(5UAGB+36 TIQ3[Q>:Z
MM! R1>HAY2YE>9,HWB !R$H-/?I_4.\N//?!2_0JBHW.=C5X%'Q_BMU!5P=
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M5?M<Y1Y'M<?%!=@*G(H0=I<)XUA$=X2PL S\/():G&AAL:5M*N):'<SBK![
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M#L7.B(XY+;4#*99*XF5P"3 ,+28+X&/6@"FW8!VZ]J)9E +NZ?&)UHX1>>'
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M]FKO"+-GB,G7M12V/(A*.GGFRL&;J>=+VQ^W2\NHU%.#D[T LCKWM!YJ@I0
M73^A2[!@=O*?$7D>K7'/%J+""\P0V2T%FI3K D?1D)@==2)J[]7[(;7,',4H
MQSPATSE$*BL?.!66C1,2J \L\S1-99U/<NJ3&GCY4E.G?(0E-K6S50U\;3-
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MU("8BFJ&O(*A*&?**YGR:D9?);VO@M97T=531JD35=K9#2KID)9TRDJ9BBK
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MG=VE,(S!2 73SC N/HD!AP@+RT"Q,$Z#B_G*@U-P(=U)/]_54P84:W )C"[
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MB6H6%O>-LJ8I=CJUF $#-KT.Q2K&&*WBPH3LBW[G-V\X\.T:G_DK=GP)O36
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M*=BQ-_\+K]S?^57^[0YW0YOYEL[>1F9WO848!?]K*792VCM$4JI&8DI5H%C
MET-GMYZ[X1<:BQ:XBW''+R6>B$HZ&9T2')-R*CH9'4]#KAWRO^ -Z.E];"50
MU[8CRS<<^&$EPA @W?P5WBC8#[RN]4$47KU[ >Q\T:9/-_HN]K^P _8<'A<0
M=OMH1'Q@U-V3N//D8%#DW9,1"8'P%@@6X"UJ/:7+]TY?3CD=<OW0[J"UP*^
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MQGG&"4 Z+I5?@TJX!><:SCME@X=K0$C<">IY.3QM ]S.G;+2\S?\EF_]<D_
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M11Q[0+$'XV#\@^-%H5CMFJI7V!+5XVS?](%-RQ^!8HNDMS!?+!51K/Z 8G^
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M.V2P[Q#_L)Y%AR=X@?Q;6/\SE'ND-+!E:PSY.A.,.AARV1I=OLY *5,FKMS
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MCU__^-/3;WQTXN5/3K[ZX?&7W_C\-Z]]^C^_./^6=X1M35<&3=(E7V4O6B7
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M7OG@V]>.?/_F+=^O,8IM4FP,JS>I0%0:C&+W$\^/Z$</ZZ])L<\3H"H Z[^
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M>W-\8^P!<UN&BX!B6T>+&P9S">2R'D9C-;'8,=#^S<]>013[S1]N>GU=T/:
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M.$;BMS0,YE?W9+>.EO0PJWI8Y=V,@DYZ7A>]J&.LHK@U,SK[45I9<DI)G&.
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M+@^N1^7X^3]V<'MX,R3))2#>P2O*-C !)0P]S' /B+_W(-DUKC#H<4%@3'X
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MXITS%N^8L7CGS.5[9J_8]Q.<PY7[YZP]O&#-H?E06;;[QR4[?UBTX_N?M\V
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M !;A0<^5#-)+"&GW8J[<B;R86?V<HR%J' +Y,%MF8TFM#*F-J;!S5",\S:A
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MW7GJ'1!Y*2#B>D#$S8 (_]OA5Z\^=+_^V#4R[7(E.9'76Z^T4^46IJ2?K1@
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MW%N/SZW<,6OANB_/7-N;71W/U[0I!FF L!1 6&I>$[V (6N ^]3@$,"=ZWP
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M D/)<>$VUS'\FI :#?)@:F%]$Z5;3Z")J\G=Y9V"TC9V 9%;Q)+72?I(R$G
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M!W=OA:T(S.)F6@&)5TX1U0 -LQ7-8A0.G87]"Q@8X=%\[%R] W 6F7(-R,=
M8!SI-C@0$$OZR&Q%4Z>@ IB8R"V#_?!4!/D .@9G VE&AZ%#,0V8P)3 FK^)
M8F$*%R0(\%0#8#=$X:J;.@2ES8S<.G(&5"0#G2CI$0H^@"RL*!>H%3?QTI46
MW/CJ-/TJ\, (5BH>!0FGV,Z>\A9N(1F%/NA"40*00?0MBD4H^1:G.HD6R1E?
M$QF_L8\3%#O9[#I.P\XY-DSOD.N86+CP35"8 D2Q3+:FE< K ['4K<IAEFZ4
M#_,5)D!V9+=#M\P4D/U]M\._H_X8BK5R9"8 6:YTD"<98$OZZ>)^<D]_AZB?
M).Q#@HJHOP/%B1N+0B!%P7W)>*!?\4 G5,;K4A,9\!1 K=O8+C"TR88H(B.I
MCI9]/_[BL8N;+]P]G%X5Q=6UJ.WPO]-4*"P70V%&.:(_$6%Q:5&, D&/H;.T
M->7V$\\SU_8]3O"#QX+2S#2,"I$%&@OFBJ45<$J#W]W8NP45\N>9NL]W]7&*
MQ:VM @/I57&XQXW]IZ_OBT@-:&(5"OLZX6)&476M;&<O$9,"A89%$3G@3 +9
M7PX^L=EEX>$+Z\-3;]:0,UI918VTPD)":F)-6$S=_5?$)_G,YW6<+ *SK(5<
M6=B<$5$2?"'CZ)'7BP]D?'>J^)L'A!7U$I]><]DTQ4Z7Z?+'EL^=8M7#=9\/
MQ6*I33%-H=BQ<(8?:JZ<^GW--D*!B0/X+"AV_ #P"HKJ907(!H(4 DT"P2 ,
M91<W4O,Z^!4\#0&+"(L&;8P;YR:?.F1ZL2+W62!4W'X#*XMZ.T3Z#FD?!0^5
M!6B+WC-B[Z!Q#AZW06K0BTL.2DZ+LG_Q^T:$QM%N6)\E;R) DT/-);"*D1VW
MCZRS<='2$6!N-/@,-M0/<WO1F&@@/ IN.IU"L5K,<P!6P$RG"&KQCSC.(H2U
MT9&U=8@J'R*+#.TL13V17PP4V\+*YZB;>+I6NJ*>KJRGJ]"4J6KH-K8IX(ML
M=)@J4#PO9((=#^\%8 %SH,+O)72**IHY!5WB2F%_IS-"UA29Z7@ ,J3)+(M'
MA!BW8^'#Z3"'6@461A1N&:!2F9F.N\,BJ^HDC)BXK2;)N<C. 2#0C2#;%<J0
MY$#SN?HV8G<%45#!U;;!"OI1@9-BL;?/GRG%CE]^[^K=E7^W_BB*55B@AR#4
M#(MU#K'>(=(C0R:*<XP"M&$18=5V%A8CUBE8JA_APA27?A07FJ/'0LOA\6)A
M0Y3Y>9C5QB\)2;A\W'>+][VCZ=51'&TSK*/&(LLJ4+1CYRC)WTJQDGYR-2GC
M0>PE[]M'(U[> HJ5F^AP\$J47<QIVH<SH'%@^;<PBH4>YB<B+%KY5R@6F7N[
M#1U L6?]#X+BLH+ABH7O56,8C;^=&)?<C,62&V:(A[K*2*F^]X\!Q0+9AR7?
M*">F-M'S:SIRWE3%A>4%A!1<CVL(RJ+$5#'2&L@%]<22G+K7887WO3-<CKY9
M>B#].[?"KX,)OS1(+_9:RJ<I=KI,ES^V?"X4*]4J\MHR;^:YG\A>=+CP:\]F
M1+&-_8\TP_4F1+$2G44J&Y;\:RGV0YIXDMI0I%)G<_4^O;OMWRLXL F(G"S\
MR-]/MQ^AV G#ZL<H%H]L@&1%R</PG&%:+.>"?) )4IJ@Q0*01:.XH)$3&[MH
MXKI61A$\]-NYI1QEBV(09>?"F4:+_7VX<"H%BL5=8\=MWLAJBU&O\_3B&G.L
MA$V49J9B/ HL%@D![<?&Z;6CG0CU)(#7:E)Z,SV?+*KNUK>KS Q\0!C*<XN2
M V$D#9T$E*N6!A2+8^L4Z899>CL@(%UA0IB+AWW%*1:N1@TV$@OX%9>DOT.H
M;V,K&ZCB*@I(4M7$RBLA)A>UO\II24ROC<UI>M["*Q0/= (<J(:=8>?Q0/0X
M3Z#XG8AN::(^$D5:W<8OQFVQ3FNH,P0L%L 5:<+/>*JPLX2?7MR6#Q]E0[#;
M+GQ$2\\ F:=O9VM:80IUW-, I>P:1,-<4#:*L>P):/B+B29!Z0_0(CPSI\S,
MD&*I$& F7='8Q"QL9A4QE<T Q#H'7V5E*\S _7#JX!_GX'V/?\SM\/<(NY ^
MK'_ X4WYQD^@V+- L2)CE=I&D@X2-3::=AAY%"BM O6P2(WR30A1R&>X,ATH
MP#">U !/,SM%:NAHC6ML-?1:8.RJ@PI<C891 5QUS>Q\W!;K$^2241/#T30C
MV'6@"'1R]-( 10)1#CF#.G^*T/TXPI<.4.K(.8\2KE^Z=R(J):"-4P*7HL[!
M X)TOA- !G[DP(JFF#L0#LK.V__7]'&*U3AXP,=\/3&IX,GIZWO=_?;%93X
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MW#AY=__A:]MNQ9[/:4YHX1>U\ IKZ%E%Q.2LQOCDBK!G>0]B,P,3\T->ET>
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M3IK_J"?G!8HE>A8!]^44B[<&;;&<T3D>4NP$V^14ZH!B.74Q&5>.G-]S_D9
M&3U5/=5FF?-ZF)=V+P  @ !)1$%4%+R*8LFK!(-J.3 @AMS<+]!V@D3Z;HFA
M5XSA67HX0\T5]$<1B2<.G=MR-?%X97LF>X@F,_5@ !9C%PB3GN@7U276]TB,
MO5)3G\S$6*(^.)3$T"72=P"2"K1M(*&N'83;&KI(UXZQ7"R](*FI&PXET,!^
M>(;Q6QBRNIC[%S;L_?![OX\B4X-;!HJ(.QDVZ1B*RX,]B,8ID(\S>>8NIJ:E
M0UI=W/XP+.7D6M\/WUW_QTU'5EU.#GI4'5_8<K^@Z7Y:2>RUQ^?#\D['U5V]
MUY[PM/U!67-V!>U)7D-J7.79$X7?[<E[8VON?^TK^6U4^^H%BB4Q"E8H=J6L
ME-=4_M,4B]E+9N%W/#4],:#HOM=V[539*M_"_SI.^T.:=%/O9*QYKG7*+9MP
MZJPS>HU'KYP;&IP7:\D*&Y,'LY _)QAVNW%MK,VCL,TJ :1&Y@9'YE&V6865
MY""@(I).S _;//+AL0&NJJ574@/B:^C8G,%W <6ZY7)C;U5[5F1*L-^)#3Z!
M:(O-K[LS,-BDG\8TGM S#8\QV4--+0,%'?P2N:6;K.;F0^\.#?J(1VES8ZXL
MBS>?#8F>2"RUEAF)C;C>4A8(I;4/X/A*W+'4G*L]HFKH[2;GAY>&E1T#S2N?
M:4Y)1?BG%GV#]'8!3TUO&2CNX%= &VUP"$?GE)/SZK'Y(8ZJ-2T_ZL#Y+=_L
M?A>T[_2F.WDWF,H6DI-6:9Z1J2=XT,=T"6O;>97LP=;A40[T0.AYAHLVB!<:
M)NY"IST<&T#MS6$(V$7!5\" @:]KSZR(/WOKP.6$P-*VAZI)SOC\$)*W2V;!
MR(Y45"FO,!KY,H3]MU*L$WITZ>BLJE_:<B7N]+<[/_MXW3\^6?_&I]^]\>WN
M#X,C_+/*XQH9>>W\$CJOH)U?T",MY>N:5)/].B='-<5430W 4P=,W\0J"4\*
M.7II3TKN=:@!ZYP<LV]@*#'*ED:M.F<.CC.&)UE:!Q>0SH@24D*3\!(/2^+D
MMR RL_G\V$Q,B7)ZIH1K^)X7"16,$<U BZ'C,:CM#(XW+!XYW$2]4Z1S"!KZ
M\P/#=OH%K[]7<H.AJ%%/#QA=?,TT6SW%,LSP;.@A ,\5CZ]KI?.*&IEY+9R"
M5FXAC5W0(2H7&MJUTSRH^1'X0<W*C)BT$ZY(I!AE%+7<O9IRXL;=L[5]N4,3
M U AZBDN)@\C#&<F$=-^S#WZL7J.8B6+Q/93)%K&J2_1<\9+EVCY\_;#6KS+
MP'^JB8&A42:T,[HIGM+6UR>OA5IM%Y9R-,WRD5[%&$,YWC\TR1R:9*FGV%3Z
M9<J.BR-ARK7Z6=B-%RI$M! 45DC.\P4M1UB4:49@<' ,S@&KAV=V<K53'(M+
MH9V0M;+JKB5>]CV^_>05OY+F5/5DNVVNGZSNPNAU *EF)VE#O.ZJWE;.ZI&;
MW5*9N8\V4)13DW*_..91V>WLJB109MGMQ^7QF26QMQ^$G@C;LR=H3=#E7;"=
M61:75YM"*;<V.;<Z^4EU$J7LJL3LZN3<VM3\QHQ"VKVB!<&8N; IH[ QO:@I
MHYAVMZ3Y'JB4J(1VMZ@Q'7:6M=ROH#\$E;;<+VZZ6U"?EE]_IXAVM[S]T=.&
MM#,W E;O>'OC_D^C[YUKY90,C0] *V>=A9.7:*9Y<AN#HVGMDM;0>*7U[,+*
MWIR'50G!T0&?;__'/]?^]\;#7UZ(/YI>$IU;=Z>8]NAQ35I\P?5;)6'I+;&Y
M_?>J!@IHO>4M/17E;9FI=6&GB[?X/GU[1][O#I3^X6;'FE;T*.B:FYN$_LX]
MYUFAV)6R4EY+^;50[.3D>+^T\P[MRK&"3W?E_J^C=;])%:[O&HLVN)M&[ +;
MQ)!A2C7D'):ZI#(W=WB&IW4(7B:A'B/>X\06-J\D^Q0E$G$0FWL;R<(U/H\Q
M%W682+,=$+:#7\Y4-&!T>J<($!9P4Z3I@.;O<NS174=6[SC\U;D; 04-Z7PU
MG8K9I!IG<56T-EYQ4W]NKZ1R:*3/-$,%).+B,H6%)>&6&9P1LRR(V"JP$X(3
M "0%JI8:NS-+8\]%!20\NDQYB>&W+_30RX7669<4H^UXY*,>*B@8IK/OX)7#
MQP5JNFJ4!9<Y-HMI#MBJEK2"J(,7MGZ[]P/0_C.;TW*C6(IFS&XP(U>/\T3:
MKGY94PNKK'6@#"A6-<:%6B+_)2=,EFX8T%T/[:E48@6T<U/"Z.M*8"R>MNUA
M>=SI&_LOQ1\K[\@$< &ZQ77!DUSB;?9<7_LKH%B<WQR;4S,DS6$Q(6NV??+Q
MMV]^MN'-59O^L7G?%V%QQ\I;'PPH&R6&-LYP0X^XM(V;URXH9*GJI;;NH8E^
M8%,,N>"6TGE5-S)"CX?[I3Z-!(HUNB5:!U^'3R"QI=EYJBG.\.2 :HJEMK-U
M,SP2NHM/DBF@*) EY(%&++00$RTF$#*XJ5&9U^Q-Z;D:>WX68M$2O.CR0;P^
MR"OU64*TU.DU,/,#PW?YGUY_O^PF<ZA>Y^":2*BLP0F&:GK Y!92,[Q#$TS&
M8&UU3];3QI2"YCN-K'R>CJX&M*+&BK.8R,U @!L(0#W-K>C(BD@-CLHX6],+
M%,L&W$<7%P0OO$#+XO3ZO[I'/U8O4NS/T$^E6,'/IU@2 ED[Q=5,<C"+ 8G_
M*C9U],JK.T2E'>*R7ED5<[B!IV\56SID(SVJ"1:T)%1^$UR?Y, <&<0T2X4I
M6%8;%,4NX]0?%HR]@6+UC@&3DVN"C6D.C,"U&"^V)O3&V:W[-QPZNZN@(5D]
MV3$RQUJ@6)YVDH<-A5NQA&)QW(N6@EDY0]F0FG_]Y#7?@Q>V!87O"8G:%Q+I
M?SS<Y^15GY (WZ#073Z!:[?L_WQ/X)JC%[>?BMA[^KK_F>O[X#7DFE](A%]P
MA"^E4R#8$[7_W*V#%V(/7XP]0NE"'+P>OA1S^%+L$0SG<OL8Z JEN&.78X]<
M6E!HS.&+-P^=OW'@;.3^,W"<FP>AC3H?>VC[T=6?;OS;]B.KDYY<[117*=#K
M;$ QV@\_Y"YQ=5U?7G'S_;SZ.WE-Z:6=6>7=V8^J$T]%[_]L^S_>7?^';4'?
MA"8%I15'/ZY*R:U*OUMX^V;6Y:BG%U(;;N;VW:MF%]'[:SKZZZH[GZ357SU7
MNGU?X?M["OYXM.*OMWLVM&MOC#B[O10[NT*Q*V6EO)[RGZ;8>0IDYT=&K&V<
MAMC*,P>??+CSR?\*;/A=NG1CWU2LT=-L@XYS5*$;'QR<4DJ=8MD,>\C.AD'S
M2X0>I9A&U4 < 1?\J(BF80]),$LZU-%9.3JH3?/EYMX!95.WL*I;5,4>HL&?
MF@F.:GP =N;5I$#SM_W@%[N.KKYPZV!!0QIWN$4WQ1L>8_'5+1W\TF96?K>X
M0FKJ-#GX5H 2)Z[>P(6NA *MQ*EK"4DCQ5)>;E0D!.BBX.NRRN(N1!^\\^1:
MCZ@:9_0<(BJ&%R7T@O4*MGE4(@!X#Q5?QD*P6&EAL!2-#&D=9Y FT+1)S3W$
M05;$'&P"BCU\<?LZWP]! 6>WW,F-9$@;#7:Q=E( ",N0-/2(ZCKY-7V2!K&^
M1S/!1R^":1&Z4=K%&/?1+M8YR'(3IP"M>M";+A'RDTLBM?;F-=RY$'LD+#&H
MO!,I=F0..D*.>GQ -X5)<9;RRG^<8DF82?GXO(8A:;T<<WKUED_>__KO'W_[
M]\^_?W.S_V=7X@/K>K(5UEZ+2ZB;&A ;6KM$Q4W,G&9. 7.X46;K&1IGZ0 F
MW-)V8?7->Z&!87MB'UWJD=6J@$[L/*JBJ+HB^ CO% (@@HP+_+I(L<3-@ @Y
MSRLT;5(,BB"[6#\OR2S_:HH5D(EIN&MX'(!@.!E 3-4D!WX@6CNB-FV@*#C2
M[]#%S5E5<1P-S0A XQ%I'9RAR7Z,D#7#1W/LG%3GY D,=*#8!V4W,RMCF]@%
MBA$&\K0;/3BIK&QP)F9<Q#8(WU+5E1V1>BHJXTQM;R[@/E"L:I*MFR;3XN1'
M]Z/OT8_3_T<HUD(NEKB-XD#%NI!&#OY43[&EENZ!X<8N<06=7]PN+.V25#*4
M=5Q-LT!+A]'IH+6?"A%%.:7@. <#R7D#(5/>J L5\C,IEF2UX!@<;+U]P&#G
MP@!8-R%MZ*XX>^WX=SY?[3NU.:\V03W9.3*/F1&>4>P,H5C,<2"A*-;H$%L]
MF-6O750!C\'.P#4[CGT#%(OQ3&(.GXL^</[FP=!;A\]'!9R\XA-T:=?)<!_$
MUFM^IZ_Y \+B*PI!UBO@VJA]IZ,#SMX\ "![_M8AKX!-8P[#H:#9/!>U'YIH
MT+FH $IGH_:?B21,'.&'01*O^)P(VX,*WW,"_KSN&WAE]Z8#GW^QY<U=@6L2
MLJ\T<XJY6CIKF-8MK8'177'+_:RJA/LE,8_*X_(:TVO[GS9Q2_)H&2&W#GR^
MXQ\??/]GOW,;HS,O/FF\\[3Q;D9>S)7XX&.1OD&W_:_FGLF@Q97T9#=VE[5V
M5Y:W9B577SY;LBV@Z'V_XK^<J'LKA;6YVQ S.M.+%+N2]6"EK)375_[C% L_
MXEF@6*O-TL*NBZT^=ZSP,Y^"_SK1_,>[BLU]TW% L:,.H6U\T#@QK)H>4CBD
MRAFNVL'5VP4ODQ!=.9' "+DNC96-'H%(L9C_DZPXP=YE1@S,*C%T 06V\\I:
M!XIZQ=5"7;M8WPE<FU5^.SC"=\?A+_U/K@M/.%;0D-HG@?^VL8>;N@3E@+#M
MO!*^MA7(TN:68D <)^"I$AIW QJ#I=0:*3)]KZ!D<6&N+URJ/",=GQU<I-B+
MMS!A>K^L7D_F:I\M5EC(B+NXAYI8!(HU48%F9A!G]5/ XCU\#7U V=@KKNF1
MU' TK1)K3X>H*B7O^J'SV[[U^6"MS_L!9S>GY%QKYU4H+$R)H;=77-_.K02H
MY:K:I<8^7$I,PN)H)_C:2<19M&?/H.<KSF6CGL,FV$^Y'0^.L8I:[EV,.[KH
M43 VCT$>3 XA)CI?,$29ES@5+)=I.:/\&%$'7Z[E[WPFI-B)>6V_I",LYL+7
M6[[XX.NW/EK[]T_6_W6#SP>AL8=JN[.&1AD3\XK168EV:H"OH74(2IH&\CM$
ME3P='9!=#0,)IXC.+X],.W/@W!;HL%NX)8/C++3%HK$3YP0H?#1YQ.99D @H
M=BG"$HH5F,A\+HDY#[<52 *E!SGYR,$(P8O8ZD58#,D$!$GHEB1"\RZS(^9A
MO$?4'A253A-SY *>DEQN:!9%0R\,2VCL8F"+$Q&[<VH3^/I6RZS8.@<<+"3Q
MQ;AP;A:/"%Z!:X7&MNK>QW=+;CPLOP65(+/U @?CVB,X3_P6]$^ PP*^P$9Y
M1R:,9*ZGA=3T/B$>!1+U% <I=H88GG_"/?IQ^L442\)F$9YS$RV#O&5"CX(7
M+^05>OZ+O.%=89OD4B8.[DYX\G')EVJ<);?V<F%@+"QO8.2!Z)R2JHXL:'\*
M&]+[)+701N%">Q(5%1!6CYX&2,,4&2]4R,^B6"<*U_;9V=II%FR,SPWK)R4-
MW:5GKAU=O_M3OQ,;GE3?5DUTC\Q!D\L BH5'% ;5U.^(3"YANT<DLLT"Q<I:
M>"47;Q_9<FC5X=#M=_(CBUOOE[0^J&A[!%=4U9%9WOJ@N.DNY0E0C X &44-
M&?C:>+<8U)2QJ"+:W<+FNX4MJ*+F>\_4<K\8/DO\!/*($P(HKR851.6.02UQ
M44#5).?"G_6IV;5)=_*C@J_[;]S_V99#7UZ,/9)=G53'R&MD%L K/+?5/3D8
MV:;K,?S9RB_K539TR6OS6^Z>C/+_>//?@&*/A.]Z5)/0 G>JOQ H]GB8_]83
M:[9?^#8X_6!*?70Y([>UO[JMM[JTY5%B96A(X>;]!>_N+_O[V9;W[PEV,2SQ
M8ZZ^N=G)N16_V)6R4EY?^750[-R\;<Q*YS<E-%XZ4?ZU7]E_GZ3_)5VQN6<R
MQN"F3<R()Z;5MFF-WJ%6N11JX #H:$ED[&6BG% Q5O8241/ZN%(5Y^8(R!J<
M JJG 1!4C[.EQN[_E[VW8(_CRO:]/\A[G^?..?<,)IE,.(Y#$Y@D#J.=Q PQ
M6V!&V98LF6790K,,8LFRF)FE9F8U4W6WJ)G>M7:U6K):3IR,9X[O/=K/W^U2
M=7=5==6NO7][U=IKC<@:.EAE( QNQ:FH[;EUN21M3^J:57$?;=SS14KFCJ*&
MB^VLHEY!)6!-K^#>D*2&IVE5CX]8<5XMSN@WX^-X=(=%BO5((Q3KGZ%8['C(
M) P+,<?:_%*)N2^_\MS!,YORBE)'I(WPEB.,<6=HU[?9WF_1-?3*&=,.[1WK
MY(V.,43Z[B%)?0>)A-4IJ*SJO77NQB& UP^^?_G#'U\!Y+IP(ZFJ\U8/KP;4
MP:KLX]<*=+UT*!PZ5CE2+*8J%6""'/P)LID9<B$9D32B(+K)PBM0+'14!\]O
M 8*)^L4"UM/6;G)%(C]ACH_L'#T *-.,@HI]*_8S<Q3[R5FBT/59/R+N/91V
MX/TOWUWTCQ<7?_3LXB5_7O+]BP=.KZOOSU<Y!L?"4D<(+A9?91\"O.@157?R
M[P_*&WF&;OB!0&QMG+*4G,1-![]+N[R[2W!?/<5&0)Q%L80L06B%G6.(G:98
M3"A 8LYSC20Y%D@/<J---T*Q9%Y=9(:<%ZVS9"PA,?G$L"] 2:V+J_/PX,/T
MN"*68D%:)SKI GU:_5*+7Z*9Y#0Q2HYEQATX]U-1<R;?V &<;0V* ;BM1):
MR.R'C7 58P-#BKJZH=O%K=FE;3F-(P4CJB:98TA#,I;1U*['O)U\.#8X U -
M]I_=% FX-DY3+$?O)$\_HC7Y9ZY1['5\!,6RZ:-KAF+1G70NX<VGWTZQ,RLQ
M%FSD_K60= 8&)]_D$F#P:6W7@+"VEU<% H3=D[KNV,4=T! I[<,XG=1+8AW
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MS55W:<8XM-N#$>,R8F@"(['"TD\)K1%;+$ZDLP2EEJ#$'!1'1-*# 17)'<.
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M$L("WKK7=1TI-C.A%L#+,0+XHL'(QSP+>13^Q%+LK]#CIEC8&MSR*ON(S#H
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MB"^?X' 4_5T#M;>K+B;E;]IR:\GZLD6KRI[>5O-LQO"7_>:SXX'!4(B>W;5
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M+U=@[:D:S#]SZ\#AK.VY]](ZI94*-T,'52*HM 940+%BS[#0.RSS<XP!Y43
M,.G1BTW]I8RLI(;5ZTI?_>;F[U86_$=JQP?=NI-1B@V$%CP*%LI">3SER:%8
M&U!L6MV>317OK*W]<T+O,Q?$G[;;_^T42\;N-K]T,CRJ'F=6=EQ/S4I,RXF_
MUY&U0+$/ZO]*BK40BIT(F?JXG8F'$]_X\(V_O?[TTXO^\Z-EBTYD)?2+*JU^
M+A7DFKVL:8J5F#PR@T=B\,*)C5"=QLD>4M3?:<A(R4M(NK3U]+4]9Z[O/7EU
MUZFKNT]>V145_$FO.7-C;W;Q\<J>:P)SIS4HMF%.3LPO8 F2+ /_2HH% <):
M U+M%%<]R<9)8QY^,[/D</JV/2<W0)606 =4$ZQ!,J.K@WMO0%HOMO0;T)T1
M>9<VP<Z(.#, R,('X(O N[VB:OR*M5_KXM;TW3YX?NN1C.W5O;<T$PL4^PA:
MH-A_BVB*I0=F4%>SBTY\O/*U%][_3Z#8\_F'NP3W51-,K.UN@=;)U4QQ:*FG
M6*HIAGQR2&3K'58WM0G*FSC%W=(JKK53Y6$9@B);:-064 /%"MV#?/> U,<V
M!97.H-D;M*H<K$KNY:.-J]<4O_Q-_O]>6_K[\P.?#ULO.$/,<'@"_6(7*':A
M+)3'5)X BB4;)+;8^K2ZW9LJWEU;^Y?XWJ?3Q1^W.TX8_6U3;LFD4V=S&4T>
MH\$_"L1F]X@FG!*'&Y@5 _)C3'X?+MLP%XZ4\LIBA0_0Y_)KE&*CK(GNGL!G
M-K]\,JS1C+/O=]Q,S=J5EI-0T9XEMW7:@UQ[$-I]-IE4(20YP&#O<HM/:?&.
M6KQJ(EA06GP*LAXDFRTS0+9?;@O"!V0ZIT"@[[M=G9ET(2ZO^.2 I$[GY%H#
MF"Z+GE1+))Y7F%(+"2/RT-F$C_!$M,BRF KALV.NON-NPZ6DB]N/7MI1VIHG
MLPY1 =B[PN*7FKR8LR=VRS&*)#Z($?1DL!&1Q-Q?TIQW+",^-7MW;=\=W13/
M$5::W- QHY\Q&2',+SQ[Q".9%AD21#7GPW,Y=1;3Q$:_!Z#!>3.SF(;N;HF0
MK14385,_KV?7T3UO+GG[;V_\]9G7?__Q#XM3<^('Q/>L ;@$7).7;?)P",6*
MC&ZQP2W"1XTNOM;)@7X.7F74P*"TMK8_OZPUM[0EI[#ATIVZC#NULU1WX6Y]
M1D%#1G[5V<NE*5<KTJIZKO'T;48/SP+P 504$%)!$;SBI"X_+Q+3X'%3K-Y#
M4RQ4-AYTS/ !G9O7S"A)RMAQX/2F\M;+(E.OT-C;/%)2UW^G7U0K,?<A>D[/
M'C.@-7?6QLGV 60Q\:Q/)+4.0J5M99<-RAL #NYWWP2*A2%354^^:HR)?K%
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M?\L1DH'HG/(V.!4XY0M_LM[)$1E[^H3W6QG%G9PR[FBK?HH]%I*-A^4.&$)
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M>8EIN5ON=Z?+[0U4:-CL8U !H<DM(K98!>756MQJLXM0+-JY!;\^ZP&?A%S
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M*%] OY'IUY*2RN[["9<# A,V7<M.DFKKS!Q8+![:3\A^@E]ZXV&A<\4HX>3
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MS^72S1IS>[,BB[=ORWMZ1]G_#&WX\\7>#VLT!T<<!1:RVV.Q@V"Q6EIEH@;
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ML%C<44$!MY/W[,$-5M%^'^ZWG2'K+MPY"!:KM4M]%NLKOO)/6WP6^P]9^*L
M\DH0A-UNIRB*89BAH:'\_/S,S,RNKJZE_6+YLOA:_F#Q!/GB\SSP(;9 "W\(
M"BNL.TJ!.U !;IY=MK!+K-8+&#J27/!BEG&'/6!Q&"\6A)4EX0PP#,&PJ-\
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MRM^?ZWBW49>@I\MF:=$4.6"@U5HDLJ"S Q9ZT$PH]3:Y?J'%^AW\^G1J5/M
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M:[?;^<"Q1J/1;#;#'*]W+BK>%?DR=U$?4;Q+SE_]L<6%^<7*W*YZ:RP*0\N
MM-(VBIZAG3,,:P6<S"Q)3=L=EEF;87I6-V/5V1TFVCF-PGNAV @H/(*+(U"7
M!)=SQ#*4V7XOY.'.K^\_]77^__OWL%B=$V6!U]$H';P6? Y]^?5[4&"4B]!1
M"IQ9G@\%*G\2,9K7%HN\Q$"C?J@HD"</Y7F)*X^P6#YFTWS<O_.B)C%>W3P"
MA_HI8I_ G5^1Q=9CBPWQ6BQ(">P2JP2@HJ/D!MQVZ[-8]Q;FK;*PW1%53'R/
M AO*W77R1N3IY BP6#Y>K([H,M)B(]QI!$QE)G31^Y'S_0R+Q:D3^!M#HJ-Z
M-"A]ET)CDS9)"N'3]\5^D7AQ;VG;S:&I!@N'\M]J'0#8]H">&L WML1CL5)T
MDU-R#2D=)T0C5N' 9+O2W"K7-W8.E3?W%;3T%3:*\T!D>X>JU98NC1UT'(6/
M'9\5C4QW:ZP2$]4_Y41]J>'6XIEDT$L33GP ]X >V3.*<Z>SRXH;[_C';MP>
M^!$_NHL/4( ?L>1:.^JA.__$_E)X_W?H\9'JB#ZS73%C5TR24J.S5\M*-$R_
MGAK"%JL9-G>7]]TZ5;]]7]'JK3E_^*YH]8G.;QO,]Z?<%CO7H\!GL;[B*S^S
M^"SV'[+P%X+U-,2"Q8+.6JW6D9&1L;&QV=E9)THY@,K2M?@568_">M^:/]-;
MO#,7;6%NH_-VAD%99U$6,:CP,U'.L'DOEVZ?+X^:SWDVZRV>_8$/!1NUT\RT
MDP5F>. E04_:'(89FW;6IK/:#01E8=@93SRO61<:](52C V#Q7;<"\[9N2'S
MZ4V"?PFL^8^+PO>;]4F/L5C4H\"!NNAI26EU3U;2U?U[X[X\E1+9/EBB W=D
M^Q99K)[I,^*65_C.FR"DH'=H2D@UI$Q#RC%]&+Z.06'A\9<E;JQ"K9Z>[H +
M9 B9JY<^-)3;HR-Z%,1^'@0&_6K\2(M%/^82,B\Z0JK#H>-1@'K8&0+U!N9Q
M]]W$%HO7[0,+J1%F'[\9&9RTG;?8<= ($"QLL09&@5JML-Z9'^MSC^&_O<4:
M/?V,D<7B=F[>8D_?BCZ7&E76GNRU6!W98R#%6$SEOYS%\MU+T/VCI]!O]Q-6
M<:NLZ/2M"+^8SQ(O[2GKN(4LUB4V,^A& HO5.N!![E$6*YL@) #N7= _:A,-
M3G4-6-H5QM:N@7*X5>IZ<KK55</30G3(E +NG[&97KU=;B)1,&:# ^XW]RUG
MA)=$'XIL8)7 ,D.6KM'I'M#?X4EA;LW-O5%??;/_D\L9"1V*4KA+^1L2!)=O
ME_7V3%A\C7X&<Q9+RK2DC+?8:;O" H^(R&+%&J9OSF)-W:6R&\=KMNS)?W;S
MP__\OGC-J>[OFLR9/HOU%5_YQ8O/8O\A"W\56#RZ"^25;XLU&HT='1U-34TR
MF0QT5JO5FLUF6("_:KP"<AXO]-:7U<3Y=?XEOQ'O'!8W WNWPV\?]@$^#L2:
M#YL !2KS7RY:GJ\OFN_]%&^=P2K,%\^>((ME6!)$EN4<#.MP,G8&UV$.1<^2
MU Q!SCB(*0<Q[61L<R&]6!*ET>7HL:G1A\('H7F[-F8]L[7X7T,;_GA5]'&K
M\8C1639+S;?80=0OEAJP.)0X1@&*^Z-QB"N%*,WF[IC/3]Z.Z%27@L7JG3(-
M)9D@Q8 &_< JU=-H>+6!5FA).2@LZ-VX ^$163PE9/B+WR.X.'DF^B74;7ZX
M.^!<DB<P6B2U1KY/Y%R#4Y];1/@?B'%N)Q[>8E&J)[XKY'(6:\0MK%Y@![0.
MJ99W60?*&NJ%_]6;#T& \C YI"-3W96=62=N1H8<_N9R9E+74-68#9Q&CCH5
ML"H3B"P*D(0^ K>HS7G>XW1P'C]"8>>T_G%"N6BQ95=9^I:;);NWF*6K/'8+
M_.4SX?97/BL5S(27$WP&VN3H"W=BRMVYNU"/ HU#J"=Z34Z9>WB<V])^CL7B
MYR6T;PH3C6XVN+)@ELW2@J-7@G:&O'?@[,[2]AM#4_63+HF91=:KM?=-V)5:
M4J6E^^$^UWAZ%,!MK*7Z=%3?F%T\8NWE[X$)_, &]P \F_5KFQI$>>5M&8WB
M?(6^!11VBAGD;=5"JZ "1ST^VXL1 ? 2;'YLMG=DLGO0U*'4MPZ9.T>GNU7&
MMJSR*]^'?[X]\*/+=Q/:^TOT#ODD/&W" R'N(.O]&>%Q%OOHB_(HYOZ#8(M%
M7>0=BFF'VV(UK'@"+)966\!B'5ILL=>/5F_^/G<%6.SNTN=/]WS?9/%9K*_X
MRB]??!;[#UGX"\%K(H@C'Z-@;&PL/S__^O7K:6EIF9F9Q<7%75U=!H.!;Q^%
M9:#"ZZG74&$.&#"?^HM_E\5Z"@M[YWA-E'_7.\>&"V^H_,[ 6_-7]&YJ_KK\
MYWKG\R_Y^=X;S+N'WL.<;['\X>,ED(^Z4. M)]3_?_;>@RV.),O[_0CWWMUW
M=_:]N_NNN3O38[;'[,S3,[OCV[MI.]WJ;GDA"9! $O(&(0GDD4<2\L@[O/?>
M0WGO* K*>RC*VWLBHJHHJ@ A"?5T#WF>?V=G149&1!J4OXP\<<*/O&.18 45
MC]KH]+B=7J\'Y0SX4.\M"O;E@T>(VJ8N8Y5L+UO[Q0-$L5L[?WB9^U&?Z8C>
M5SON9EI=F&+]A&)E)J!8E]C@%.I= !EBI8-=-WAW7]ZZ-;L^/G9]>[^L&L&K
MBS7J9(XX&"!843I9*A<;J!00-BIXQB-7T;#@)Y:7KYL4BC! NF#15_@PQ4:$
M/LHCBHWKH,6 *S3Y!"AP$J83(^JK0R+P"BNP%0E'O$)"^2=+)A]D8X6Z>*/^
MFA$1/C!YQ00:X(D.D-'*+#I=L'=7;O+EHJ-T13.<'  :G0]1K"DH,?AQ<"47
M1JX8)'TB/9!FQ/7@AC7I.AR3/S%;HJ;;<4J-.-L3VS:?PNX6EJ 40!:=*/P"
M P#7T/_PU/7=>7<R&P9N2HS-.L^@SD-#%.MFFOPHYH,!Q5+E3YV[ZZDI%@VH
M0@<.]X#,[!^R!N36H!Q=4\:CW;FK/EW]WYL/+JKLNC!D:;4$N68_>E_2.(0J
MNUCCDF@](M0%BRB612A6C6YR@=+!A3<9-*@1?840Z(",0W)+0 8O/#1I?1NS
MJ(U5S)0W*<=9R&<@XCD !ZYQ<$% HD3HIQ-)':%;G9-G@/)MS++6ZVE[OER5
M\>&%NP=Z^)5:.YHN#LX>&@J&[K2$DYQPSF/OBCE>[BC%DK]E./,6EWC<B3P*
M)BG6,V1V*L>=R*,@3+$E/UM2^+VU-:@OML-\G_*+I8RR>3>*8K^51BY$ ,<H
M %CSXQ[*H:&A&S=N[-BQ8].F36EI:9F9F7?NW!&)1(1Q"0(2-(R6 XE L1,3
M$R1/M%C@RV@* 658AB]_I%Z"O[ )"HF62?:-UD4(-=IF@J>P%?8B\XV1'6-+
M)H!+:H^VD]0(!ENCB;%;<2.A0!=4.'5;R.OQ.9VHCSB YYXE9G :*GGE.\J3
MO[C_X\45_[2EXP>7.!_V&0_/2+%NL=&%OMX"<T0H=OW:W9\<O[Z]3U:M\<*3
MC*]#CK \).)4@-:1+RSJC_2+@.=P]Z3$ +P"; <@ @H(C4&1.22)RA)"_J;D
M 9](L<AE,("F,K*&)C6&)!T+2:Q!X"$14B LLU\(2TB'K5,%^8>B HJ*"A<X
M9 6N(M7%B#0#:A]'7"*%=@)J )2<+LC<<6SMI<(C=$43HEA7E&*E1DRQNG '
M\U.@ T+8A4BQ",*B%'O^SM[&P9L20YAB-8AB6?@]1#B/%&OPP(Y#)N^PU3\R
M%E*,VNB-M#N;<[YXYZN7UV7^J:3MC,S2$J%8D<8AGHEB-2X!&O+E1@[?*."&
M7VKPRTPA^7AHQ!8: 58>M@QR1EIZ!55]PFJQO@<::<(19 FPHLY^\N($*Z3[
M']\VR,? S8>;83PT-!X<@DW57;<S#BQ;N^W3B_=S>OE5&CN74"R:WG8N([J^
M+HH]TKPXN?2_$,56__(X;35%L911]B*,HMAOI9&K )SGP$9P4RJ5YN?GIZ>G
M+UNV[,,//URT:%%.3DYO;R_P8A 3).E !69U8B-?_\$('7IPT"Z2@7@I$)2,
M=KN2NB /V870[3@V@K,H0,#$!%DG' SY;38;*8H43DJ E>A>).0M:0QD@Q6R
M=6QLS($])0CUDC9$:P<81F$*7%#4!-&$S0;_ 5KCHJ!VW /M]MHGG%;+N-4Z
M#I5XW5X_Z@#V*JVCQ?3"K26K,<7^\^:.[U]DOM^MS]%YJ\<]3.M4CP),L1*3
M6VSRBM'@&P>[/NQ1\,GARYL[!:4J%]L(/!I 4=]!..06(EJ-!SD,1$6\8Y4.
MSJB#/>I@J9PLM1M]C=5ZN6%YN"CTI@L]PB/]4NQH[Q3JH'+BP2OQC^KPZ"[D
MVH@]"K2NL#1.EM:%@M*'AWE%Y8Y\>,5=JJC&24UZ%T2_S!(1R# 2OU@\!GQD
MC &\=21_VZ:<%>?OYPS*&T;M%,4^C?ZB%(LGQQ)I'1*53:RQRTQ>1+'*"7H+
M\^ZVPU^^M^3E=7O>+VX]C2@V1"A6/!/%H@%/@'J(7Y$KN=HE5#KX:I=([Y6:
M?$-FWY#))X&[5Z3K[A%4=;!+.:.M&@<'V@EWN&*,KIQ@$9<5;53$B04O 63A
M3P\0%MZ@X.14==W:=FC5NMV++CT\1$9WA7MS*8JEC+*%9Q3%?BN-7 C2DTI0
M#XS+Y9X\>3(Y.7G)DB7OO//.6V^]E9:65E96IM%H"$V.CHZR6"PZG<[!QN?S
M%0H%P")@'VQ5*I4"@0 R,)E,V"H6BV%'J]5J-IMA$_R$\LE>,IE,J]42WH5-
M(I&(CXW'XT$)<KG<:#3")I/)!#EA%S:;#5LA&VR"'0FAZG2ZD9$12(&2R29(
M@68 IT*EP\/#L".T!':42"30<HO%0LJ$-HN$(B$R 9_/Y?(X,IG4:#1 <\P6
MDVQ(RF*S& PF;(#&2*4RE5)E-)H,!J-*I1:+)3P.ER_@=;&Z+M?GIS]8^N7#
MGZRH_;=M73\XSWBW0[-?XZD:\S#'W#*#5PX4JP&*]2*$M;HDJ#O6*S8%) "@
M#8P'.1<WKM[Q8>:IE,J>&\S1)IZFG:=IXZI;D;1M''4K2]D,Z4QE"T?=CM7&
M4K8R1YKIBD;:<,.@O)ZFJ&,J&]CJ)K:JF:5L J'\H)%FE@+4Q!ANH,LGQ9 W
M,!5-'&4K3]7&4[?S5&%Q55!I"U?=S%$VL4<;62.-3$4#$6.XGJ&H9XXT0.(4
M*9J@"B9H&&J9(KJ\$00K[)$6[F@;1]7&48;%'FT%08U\=0=KM(4SV@:%E+;=
M.'1QR];#2?F/#].&D5\LIEAA#,6BT>@&]Q1Z>"(Z+$R*)1_$E386\HN]OCOO
M=F;#8('$V*3SQE,L&MTU%[]8A+#AN0^F$[R*B-030KF1JS#S]2ZY-217.9A=
M_,+]9U=_GORKS3F?EG><&[*V1BE6[1 K[2(UHE@QXCDTK@MY@2.*]0H 9(%?
MY6-,KKJ+)F^F#[>PE1U<52=7V2G0=L%-VRNJJNF[5]-[=W"H =[*S'XIW!XJ
M!P>'H149<2R+L+"CBP&_:,$*\.M$:'@\)-<X>8V##W/.;0*0O5IXE% L<7%!
M0;OP:\ 3]'P4J\7CV)Y L49Z#?<2&MU5]O.E12^MK?KEL<&D=M,]<T@>H"B6
M,LKFU2B*_58:N1"QG^;! /CR\_-W[-BQ8<.&Y<N7+UZ\>.O6K0\>/ !&!/C3
MZ_7 K\7%Q7?OWBTI*8&5RLK*OKX^0%6@0UCV]_=#2F%A85%1445%16MK*U I
M0*I*I0)^;6YN+BTMA1UA4UM;&P BT"V0)50*.6MJ:LK+RR%#55555U>75"J%
MZ@!AV]O;(1T*A$VUM;7=W=W K+ )6!8@M*>GIZFIJ1(;% *P2QI#IF\ _KYW
M[]ZC1X]@!7:$EA"Z[>CH*"TIA?975)2#RBO*.CL[1T84-MNX4J5L;V^#0[Y]
M^_;CQX\A3UU='10+!4*-<!2U-76/'SV&O1]4WC_RX'#*[2^6%/YL=>-_ ,6>
MH[_=ILY2NRO'W!&*]2.*U7NE%I=DS"DQNP#(1(: >-3);N84'KRT:<G&MY)W
M?WKV;N:MJI,WRH]?*SUZM>0($JR4'KU6=JR@XL3MZC-W:\_=K3T+*S<K3]TH
MS[U6>NQ*\>%+A8<N%1Z\6GJDH#(7]KU>=@P$FZ[AY?72XS=*HP4>Q3IRM?@(
MI!14Y-ZL/(%4,2E(+*@X?@,*P;M ^6$5H26D7)NJJ\5'05>*CEXN/ *"E:@N
M/3X"NE)T['I);D'9R8(*T"G035B6(]VL/ WK5XN/P_K=FG-G;N\#A-V8O>Q2
M$?(HF)9B40\91;'3*D*QL"1=W888BCUW.[-^L$!L:-)Y!M'H+L>@UO5L%$N&
M@B5*!!2KL0OE)LZPF:=S2BW!(;63U2<N/W9EX\HM;^PYL:2F-Q^/[D+3"&.*
M%44H5J*!?8$=$<OR",5J/ *)::"=4_:P/O]J<>ZU$K@Y3Q=4GH9;Y4[UV;LU
M>7#;G+^? XE-C$*1OF?4QE;86#(K33Y&5]B8(S;6Z$18R@D4OF#82E-8PSVU
M!GPCX0&%#X[F;]M]+/E:X;%>816BV ":#%F%@L6B,%OQ)SGAG,?>%7.\W)/?
M+K [^Y,IEH<IMO2_EA2]E(PIMLU(42QEE,V_413[K31R%0*!@#,R<1>L Z@U
M-#3<N''C_/GSQX\?S\W-O7;M6GU]O40B >($D&4P&,!V-V_>+,0&? D4"WN1
MZ1* % '['CY\"- )6 D "JBJ5JLA Z JX";L KL#4P+% H..C8V-CX]#'@!<
M0%O8"X@3EI"3X"_0,VR*E@G5 :I"45 7P"B-1H/6 A8#JMZ_?Q]* *B5R^70
MSI&1$0!3J N.I:"@ ) 4")C@+Y0)8'KGSAU@<2@9=H=6M;2T$&Z&96-CXZU;
MM^# H4S 6:@4V!W@& Z$Q6)55E0]N/>@J+CP?N7]HX^.KK^W>%GQSY,:_FUS
M^_?.#+[9IMZG<5>-NQEC$;]8H%BC5SKFDHS;Q4:'4.L2Z (BE9?7+BP[=#GC
MT^3??[3Z-^NS%FW,7KQVUR>KMGT 6KGU3\LWOP?+U,S/-A]:ONO$FETGUN[,
M7;WMV*HM1U9D'%P*F=/V?0%;4_;\&58@)4Z;<I9LS%ZR*1N6BY'@9\Z2#=F+
MT_=_N>' 5Y "&1+WRC@(NRS>>. KR):V+RRT"RYA$Q$43I2S;%,.M&1I^OXE
MH T'ED9%?@*5;LI9GG%PQ>9#*[<<7D4$M+KU2-*VHZMA95/VLBV'5NW,34[+
M6KQXP[LKMWYT[MZ!@:'Z40>.4> +QR@P^&+ D:+8>"&41$>*@^D2 C.&8Q0\
M1!1[)[-^H$"D;]*Z!S2N 95]0.-D&GUHK!X>NC=WBIT>['0N@#.QSB51V41J
MF]C@DIG],I6#"12;>RUC[8YW]YU953=P!2C6%& ;O3S4<6LG%"O5>J0:MS@,
MLJ1[$@56$]*'FVZ4G=IY/#EE]Z)UF5^F[UNR+NNKE#V+X+[:?'#EQ@-+-V4O
MS[FX^5;5F7K:PS9.:3.KN)%1V,0L:F&7P,\V;ECML,XJ;F,5=7+*^H35_:*:
M04G=H*2VFU=QM_+LGF,IVPZMNE9TK$^$^V(C%(O\:TF$N%E<"YZ)8J-"7>;(
M]V-FBG5I%&9&'?\*4&QRR<^ 8E.J?X4\"L+Q8MWHWV^*8BFC;)Z,HMAOI9$+
MX??[B5,IZ8X%& 7^ X($;@,\[>_OYW X,ID,\(ZXJP)9 CL"K4(&(%K8"C1I
ML5A@$[ CP"XDPB:@/2Z7"S^!7\>P 7<"ML(FV!VVPB:=3D><&2 /_ 0VA=(8
MV(!KH2+@9L@#Z$E\&-AL-I/)A+:-CHZ2CF%H&"1"@;W88$=(@5U@1R@3=H04
M. K8!'0+^T)384?@4=@+#@$V$>>'@8$!J!W2C48C+(5"$1PX9!@<'(3"(3/4
M"&7"5G1RN'PFG<GALCM9G==;KFTO6[.BY!?+JO\IO>E?3_>_WJ[9K_/4((IU
M2F(H5@90.V87&^P"M8.G]0LU?D&7I!(H]OWEO_K=QS_\*.DWGZ[]_;M+7WE]
MT4]?^_PGKW[VXS]\^I]O?OE??T[^ [#LYL/+LR]N/'IMVZ'+FP_F;\J^D+[O
MW/J]9U)WGUP+@ LKV1<VY%S<")LBV@@I!\ZG[<\#K<?+L/;EK<\ZNP[IW+K8
M=-"!\^F@_42QFR#]P@9H %21 X5?RB Z=&G+H4N;<_(W9U_(R#Z? 501U<%\
MT!80VG0!;\K'@DT78:^M1Z_M.'IUQX'S&0?.;SJ(?0D 89-W?W[QT2&:O''4
M25'LW$4Z1%'54"G@%SI%?D2Q#7W(+_8<BE$PV1>K<0YJ4:0M/@AY0D?GNWH^
MBC5X9#JG5.>0F3QRLW]H=(+1(R@Y?G73VAWO[#^;5--_66IN,7B9!N1./2/%
MDB#!<-V[!)7'K^U:N>6C#U?]_OUEOWYOV:_?7?JKMQ?_\H.5O_TLY770E^O?
M7KOKLUTG4XY<V7[LVLZC5W8<N;(#=CE1D'GRYJ1.P<_KNT]<VW7Z1N:YV_O.
MWMQW[E96WNW]9PKV[CVQ+GG[GX%B;Y6? L!5VEADZ"%Q*%<[4'R#OPC%:B,4
M.V)A-@BO'FM9FE+V\V6E/US?\.O3[-1NZZ.QD(**M$499?-K%,5^*RT8$TB5
MC'PB Z3(H"LR[HH,A(J.Q"+CMR"GS6:+CK*"K20G69(5-YX,C) QV8L *^GW
MC:N(K)"(!%X<@<L=B;3EC\3D(BF.F)%>I(6Q9<(**9"DD&9$FP<4#C -*\05
MF+C/PE98QHX2BRV9I$">Z, U=$1NCP_.A-\[8ADM8Y=FU:6O+'ME<>7_N[[A
M_YP9>*-3=P#'*&!8$RC6"A0[P=<X^%J?4.7E=8C*CUS;"O#ZUI?_]57ZFVMV
M?IRT_</EF]];LO'MI9O>7I;Q+OQ,V_?%MJ,K3]_)+.^^T<XO:>46M; ?-S$?
M-C(>U-/OUP[<J>F_W4"_W\QZ!.FQ@I1&G VV1@4_T8ZT>[ CJ&[P+JQ'A?)
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M%&,K)(6M*("H&X^[)Y 11Q5S8-"92(+L/I<2IN@O1+&DJ5%%VS-WBC4'6.8
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M1R9<NF&CH)IW[TC[ZM2:7ZRL_&Y&TR_SV2ET<]%$4!D(411+&67S:13%4K8
M#5%L):THW!=;/P>*=4E,P =>L=XO'G&RN@3E5XL.9^>EG;Z]IZSS6C/[<0/C
M077?K?*NZW6#=P>&:L3&[N$Q&HF^/AEA:O)!B"A6Y^41X:^QX6^R<Z;8*9Z"
MZ*'K$Z'@K%AHK@$D(7(VB-02*^R<$%]XI&W(J6 :X3A*L12+/ K<88K=>B0I
M[UYVGQ11+)PB PYB@#)3%!NGIZ)8[%$@-;>8 DR3GZ7S,!'%>C@Z-T?GXF &
M%;X8BL61MK:\F75J557W%9&^#0HQP@N2FU L["@VHMEK<1\J$H\(.XT@(1YU
M<.'^1Z")67,FJ>PHO*O&P4&8ZR*EA44Z6>$VCKV(L11+^F*)O\'72+'PM\,U
MNKA6A]#F%&.*96&*90/%6MRJ<9=%:A"5L>_DM*Y*KOGITK)_3JM[^0)K)<W\
M&"@V2%$L993-JU$42]E"-(UYM*3WT;[RU)3R_TZJ_9>,SN_F\=YO,^6H/=4V
M-]/FE)K=,JU7IO%)]5Z@6(G5)3:Z1#JO2.L7#ML9S<S')Z_O2-N[:,_)M0\:
M\MIYQ7W2JGY9=:^DDC9<)S)V*1U,G8<'3U;B2Q!FV<D'(7%RQ;'K/? 8YL8H
MAF+)DSA&X<^ID6=Y1)%QW G/731/J1<%R4_0I*/A-)IL9XPP'R.$Q<$*U'A0
MN<K);>.6GKJU=_NQ-><?Y/3+@&(YR*4!!S% 8\]=/*-7:/%+P\Z+<8<S'<]%
M,6*21:;;)4X&XC&)'(B1PT;<>9A40H&))2=NFEZ)A4];4>*FJ0K?#&[4^PCG
M"E ,R*PA$B^V8;! 9FXU^AD&'T/CH@/%ZO$5Q!VQY#"?@F+1?3B)G@(TD0&*
M LM330!QPIF7F7Q2H-A.7N&12^E)6][).K6FJNN:2-<!14';"&HC1V=TRQ$G
MF3"V1A0^(L2CN&.5K$1_QBFZ21^=,W;J20[?\.3>CDU'#9CR,YSY:2]B@J:4
MD'"Q(M>+9W(+QIUB&PI= A3+5(?HJA 3*-;DUEB=8V*]I(1UYT#+BC55/_ZJ
MY!]2:[Z?QUA*-S]VA-2AD!^S*T6QE%$V/T91+&4+T53&T<>=]_:6)@/%KJS^
MYXR.[UX0?-!A.D0HUHXI5C\#Q<HGZ(WT!T?R,U9O^W#'L56%+?ET1;W8U"VS
M]DDMO4-C_2-VNMK#T?OX4R@V9FP3 1<$&41N+I$>Z1DI%LUT!1E(%>ZP@&)-
M7EZB9J%8-&C&$U:X-*($BM5X^*-V-E#LF3O[=N8FGW\XA6(U9$SZUTRQ>&1Z
M[*F.5T*!B24G;II>B85/6U'BIJF:(\7J(Q0+U]3H UB/=M@_,\7R9J+8+E[Q
MT4N;DK:\GW4JI:KKADC7B2@6[XXI%AJ 9LJ-U#+=$<UR":8*?5X(-WC*54 7
MPC<KQ2;< +'I\1=KSII20D)K#>'K)3!Y1.-.Z52*I>O\<#AJDVM,:) 4L>\<
M:%VQMOIE1+'5+^4QEC$LA<Z0EJ)8RBB;7Z,HEK*%:$"QCSKN9):L)12["5'L
MAQWF0VHOIE@7D"N*B*GURPP^&?$H,+K$,7VQCTY<VYZV]_,#Y]-K!^Z(C%T*
M.WT4QR@ C3H92A=+C3P$T.?.Z&?6R6<AI+CY1C<O3@8LQ&$X<RS/S2;@5X_(
MC&4"<HV1R2,P>_F),GI1W(#X<K" ADE1J#1/3&D>D=XK0C&&?"*]7ZQV(XH=
ML;.B%'OAX4%$L0XV\CV80K$B2T :^[4W7E,_],_4L-EE("$7YD"QB?L^FV:B
MG+A:9L^&FQW!2A=<%Y$Y( 6L;!QX>.+JSK.W=C?0;LHLF&*]B&)U: 9:1+'H
M/>2Y*99T_VM=/+6=IW42BI4HQFC=O))C^9N3-G^0=7)=5>=-D;:+C/?'%(NZ
M@:$!1C\TGMS5I %B%'TV\1B?2O-W=9Y?LUTX]-<A&7<.V9S2",725"&:-@ O
MATJ#QR(P28IX=W,Z5J74_71)V3^NK_W1!>9*IK4H0K'!8,!+42QEE,V+411+
MV4(T3+&WGY9BM1Z1QB=0V!FM[,*SMS.W'EIV\N:N3F&9TLE$DQ%XN6H/1^UA
M \(J'<Q1.U,YP5+9V7@8=1A,B8QN@='--[EY<3(BA'U>BHV5^?DHUAQ3%$6Q
M<9J-<K[U%%MZ+']KTN:/LTZF5W7>%FF[T2E%386]4/<M:H-?$$.QD=H3C_&I
M-']7Y_DUVX7SB,UNZ;A3'J%8!J%839"K]ROT/@/?(BH6WCO8M2:U_A?+RO\E
MO?8G%YFKF=9B9TA#42QEE,VO411+V4(T3+%W,TN24\K_9V7UOVQL_]YYP0<=
MYH,:3_6$BS7AE)G=<AVB6*G!)S6[)18TNDNB]X@!T48F&&V<HG-WLW8=3[KP
M8#]=46_P\\U!D3$0GDM6Z^&H'$S(-C+.4-I8&@<7]<C&4RP"V3@9$($]"\6B
M"8VP8CMB<5^LT.05)(J,(H\O!PM[)D04WQ<K)!1K\*-Q75KD4<!JYY:>O;-_
M5VY*F&*='(RYDQ1KP%_)R8B<Q.I(^V,18<9LLRJ&8N,^9Q/2B@B.'8T6>@[%
M?N..AYN(R.F=0[99*/;DM5U L?51CX((Q1I\J"MT.HJ5QJ"D@(S<"KM!1PX?
M(S[AUTEO;*V+JW; $LX,7"814&P/O^S8):#8C[).KJ_JO"72X;Y8'+%8Y^:$
M^V)]+Z8O-G+>XI5PQ5^4YG+A/$+X-\'FE$\XY&-PU'ZF)M2O"O4CBO4I#%Z#
MP"(N%=T_W).\OO&7*ZK^?4/#SRZQU[+'2MTA70C(%5&L#_X70!0;I"B6,LJ>
MQRB*I6PA6>3F59N4CSOO[RU9EU+VVY7PF&E[Z9S@3QWF;)V[RNY@VQS#!H]"
MXQO2H1Y$%)T @:Q7:O)*X)D-;-K,?'SZ=N;.XZOR'QY@CS1: J*QD-02%)L#
M0A!P@\;%5MJ92AM3-4'Z8F.Y:D9%NA+#@#+'A_<LC]LYEC"3XDHFO&7 X\$)
M>,'1=7++\NX> (HEH[M4+JXA("83(JB<7+63BYP((_%B$ZM FA>*33AV+ QS
M4T>VX;[,9Q%V)I[3=9RKHA3K"0^W1\0?D,!ZT^"C4]=WG[FUNV[@AM348@HP
M##XF\HMU,?6H>Q4/#8R?]4"&)<&P#GDX!@\7LRQ&WO"8,-23BD(<8$5_:IPL
MP%F3'RZ08&1\L%=8?NSREE6;_[3W9$I55X%8WXGZ7Q$W(_:%>HUXBJSXPWF1
M>K:[XFDURY]25'@$(<_L$4XXAIRV$5B:O2Q]J$<=ZM4$X(0KC6ZSR"0M%ST\
MTI>2UO++%;7_OJ'I9Y=Y:[GC%=Z0$6&K'\U[X \%_9AAXRS^<4L9993-:A3%
M4K:0;!J*_=W*JO]O5HI%X[I,+D2Q9A\@@G#8.MA NY];L&/;D>47[N]C#==;
M_*+QD,0:H5@@'D0&#I;:P58[.&18=^+C,%'??(H%P"+%HH-R\]43G"YN>=Z=
M SN.K<V[G]T_A"G6+T:=M8ABT0Q,%,7.J&\6Q7),?KA2@E%;E&+?SSJ57-U3
M(#%TDO,&2T2Q+GYX2!:Z71,.ZL7HV>Z*I]4L?TI112A6 /SJLHW:'<,61+'=
MZE /IEB5T64A%'L44>RO$,4V_^P2=PU0K"]D"E-LD*)8RBB;'Z,HEK*%9,]
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M)]ZW#Y[*'J3PUACABL(^M;.@U1,S&"(.B''YD;#[)A[7Q4>QEKPBBU^BM+&
M8H]=V;%JV\='K^Y@*5M)+ZS& Q* D&OL7YYBYTGS3;%33B\NT(A&PHDT#FX3
MK?#4C;VG"G97]UR3&%L, 8;60U<Z!M5.!NYG#5,L;HE([Q+K71*]2V8 N:7
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M(EV?&/D>X'I)U0AS(ZP0K2A:=02%\:P$A)71+F*#6ZAS\C4.+J 5$0 3^NE
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MC/2GCMI0'"L4RLK.5CLX6M<DX,8J"KN3,PNX>!HW'S"1".%@1#J?4.<3P0H
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MR.23F;S#1N^PV:\0ZP>*FJYN.;AJ1<8'!\YNJ.V[(S5BO]@ S^#G:-PTE7,
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MGE2[FL<=/)M=;G(JM.YAE5>L\:%.)I.;:W!Q#&Z.WL/1^W@&/U_O$^B]R',
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M@9</%$>Q$&0126/&<&CIXF-,'U>/3K'>^9I'*&U<:+,/0U@@,XRC@.4>[&X
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MO;SSZ(HV1HG9A4].JV7FP:[A\H:!^[UXF=C6;?!RC3"$0$A2+ )9\"DV^L6
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MY4\7LO:6=:4#NBUN2\MONEG>F5G5DUW6>;>D/9U4:7L&$)SH -O)K.R^!Q8
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MG%U[+&7KL1M;CM_<"@0FCEQ/.G1U$Q*8V'SP<N*!RXF'KVT&2'HA<_^YC+V
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MJ(U ^R]L/'!AX\$+FPY>G*T+(1VZF'CH4N+ARTG1.G)Y,]#1RUN@KJ#/RUO
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M1E$L9<O.",(_8A27]6<>J5R[H>R5=;6_/CCX>H%V"]>;:0O2)CS\\2D)P%;
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M&$6QE"TO"TX3 <*C,>#5?7=/5:Y+*GME;>TO=M-?RM*L9[EOVXD.EXL[.06
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M:6Q<E04HEJ^U\]16SH)7NDJQIXZD?E):DQ9"L3HGP^@!BN7B= :$^RD"6?\
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M)PJ8:O2*5#;.,+>MJ"HSM>#(U=JSX\(N8%PH9L#;-'B%1A1<EF="R1%0E-E
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M+'CT@H5BX\HZS?O\ ?*0?&*XUV@)%LRCCZOA\P@9W4@&E\CHFC&Y%$:7'/U
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MEDE!%UHHZX,I5?J0*NG!ZJ6(>Z9%/5."_BG!P)3@\;2HBR)MI,@:J;(.FFR
M-D?KX0\6]>?'-[X7W?A:;-M_RWST>@5[+VN^>0E3K"<888,H]JG_OD@CC;1P
M(RF6M)?-0NMKD&U(L;$!BET&BAW=D&(5+J'"P5,">+GX\QZ1SL&6&$;I,SU4
M:0]K]A%=UMLQ?/?*[3-IEV,R"V+/EAQOZK\AFY\&--'8.<!D@#O/@RG?0(K%
M(]-5#HX*.2!RA<8)8G17;,;G!>7I%%DOT*W.*R3\)E$O'=Z(T24PN85(JZ]E
M@X420[C7NF#QD#@Q<5F(GC!_?QCN, O"WR^+8@-CGO 4@:R?8JGUF86Q!^(_
MR"J,>TQK>(DH%I6!*S_O$2^OS*HM[,?TAIRKB&*SKIYX.%TC7=B 8@/1*HPK
M8H-/I/,@=P+Y(I,Q,] Y4EE6FW>A+/E\Z>D+UY/.7T],OGAXU]&WW_[LGW;%
MOI.0=RBG-!Z>>2[?2[EX-SGWQLFSUX_GW3I94)%26I=UO?'LM8:<@*YCP?*B
MZC0H4%"96E*3 1_1DJJT_/+D_/(S5VLS;S3EEC6>O5J;55R555*34UI[MJ0Z
MNZ@RTZ\J)%@"@@+%U=E7:\^N"3Y69EZKSKY1=^YF_?GB\HP+-TZ?*SV95Y90
M=#^]K"X7%I;5YEZOR2%TK?HL4M79JQ7GKY9?O%J>5UJ=>;TN\49C\JW&K%M-
M^;=:;Y6TW3S;D@D4>[CI^R3%DD;:EVHDQ9+VLEEH?0VR9Z58C5.H<G&5+K["
M*9#;.#-FAMS"0$.271R5E2Y?HBK,#(*KJ)*>BO8": )!A??2VH?NSBQ0=#@%
MU$M"L6X_Q0*A JHJ;6R%E24PC#^DUERYGWHZ[]#U^G/,N0&]1SB_(@695B2@
M>>Q9N+@B75Z1+:U("4?#8 &P&KWH^@1D\HJ0@&4]XD4O6B60U->XWE5WW0F&
M'?ES*^" BX,!\P&=B:P'0+'9Q<>B3G\$B#/$:)Y;HA-CO[Z]%.O/>K#:_XTI
M=@9E*:/6917''3R]/:,H[L%DE=BTWJ, Q_TE?$^-/C'<99BB6H$I=I3365J5
M&Y.\ZZ.(WW^X[\U/(M_Z_,@?/XE^ZYW/__G-[3_^UX]_^G[$KS\]\N^'$C\Z
MEKTG_MS^$[E[3IS=?>K\WJ1+!U/RHU(+HOTJ/ R")8D7#YP\M_=8SN>Q6;OB
MLG9!X=C,3R,2WOLL[JT])]XYG+HC(6__F2N1H,2+!Q/.'X2J>/K"H82\@R?/
M19PZ?R @O/!0?&[$B;/[UBEG[\GLO0DY^Y/S(D$G,O=$)^V(3-A^.&GGB:P]
M27F'8.')['WQF7M.9.[&@ID]QS/V'DN+.)9ZZ%CJP>.9G\>?_2CA_([$O#V)
M>8<3\A).EZ2=J3I]LNF]F*:_BFO_[R3%DD;:EV<DQ9+VLEEH?0VR5;]8)]/$
MN,Z\%-_S84S33^/J?Y#;^XL&X7[:TO7U%#M+4*S*R54Z44<LX5VG=G T3H[*
MQE)8&$HK6^/@J1U<JJRWNKNDM";G6NW9ZW7G'DY5RY?IP"@J*\N 1[N'T\G&
MF!(\Z"JLI+]\&(^NK;+)6L] L2&COM9O!V7P<J+S!82=L['$"],#G);2NMR4
M_!B@6(JL5V%AJ6QP<1#C@I16?^@QC86MMJ!83@$1?@(J"XZSZ^<_#A(.N$OD
M/P/.(S)*S"Y2@1IA.5Q)!+ZKR.L_L.<:Q;69B)BC".QP]F XC'F/"/504NO/
MEIPXFKKK\NWD,6X[RDP;-+H+=1C[X_!O"6']^PHJ''[7_/<N;*UG%^&Y$:K5
M>+%(>A</J'UI12)?I'9/5)RY%+G[^!\3+QYJ&[TK-DUHX%G.SE2AZ*WH=80!
MK@P*.0?77VB$9PR?&&9T#A0@=ISWH*3R;'3B)]OVO?G!WM_N//@'H-B]Q][=
M<^R/G\7^^\>'?[\C\LW=L6_'Y^RY<.OTM;J<6\WG;S6?N]UR'JD93>^TY&%=
MN--Z\6[KQ5M-Y\OJSY;69E^MSBJN3"^L2,LLCHU(^."CR#<C3KV?5GCD:FWV
MS>:\6\UY90WGKM7E7@^H/A>6$+K1</Y&XWFHHO +O5J5A?I? ZK**JW*OEYS
M]D;=.=#5RJS\NRE7;I\IN)L*RXF.V*+R](([:"'2G3-7[B9?064RK]S*S;^5
M4W GM?#>Z>+RTR45J5<K<HLJ\R_4%60VI\:W?!#3]+=Q;7^>]>B-2M9N]GR3
MV:-SNIU>CQ?%T5I!\I$42QII7\Q(BB7M9;/0^AIDJS$*W$P3ZSKK4GSOME6*
M_7F#<!]MZ5H(Q2*/ A1]?:T72N-&4V* MMS"F%UFS)CID@7*"+_]7D=^045Z
M24UV6>/Y7EJ=W$P'F),OT0"#4*_>YEH'')OWR:V5#^/1<-S<8)6PM3;6$PZ
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M%H)B&3H'@"QR(%[PB1>\8MBRTL*0+U'GEND:.YO8"U#LM+ASF-U(E3X0Z4>
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M *Q&+V="TO2@NZBJ(W]@OEIN'0&$!995.L8!9-$72VZ_#;?66GB-RTHHUA+
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MVJA$A'TH;E)1IZ"5PA#[,IH]R :$?7R*-9$<!1H_KX?D*#B0]UEQU?$953?
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M7QI?SIIGK;F)P<Q?W(5NN=%<&VS-"1(,5BTO+],-H"+0%!O=Y.LOQM=BZ\J
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M/GY#LS3MB(AICZY$B@7!O-''@56VH- >$NL]W*;!RM3<CS_:\]KI*_O'1<W
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MI-&UB=_17YO1NW0]Q4:B4*1E[S+Z8H=3DEJ!8K^[O_$_+@^^T:G*D7@:C8S
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MHQY@+#)Y%(S%8$2DMJB,2 Y_5JL)@S'T0FH.8J<WBKS87S B<ZXH[5$YW%T
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M]C3\<'?]C_;4_R2YX6?)C3^#,^)!&GX$VEG_0U8[ZG^TO?Y',$UJ?&9GTT]
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MPY]*@BQ+#@MGH6BU4; <R\ 6@%X=P/&0W,S( -1Z.?57J_..%>V_T5P@,DT
MX\)RV,82E,&^",%!.5<W7%I[[FAA:D7#Q4EYM];#QYIZ!!8<2DIB"4AHLZ"C
MFM87PZ:%B0\D\"06$RP/",T^@='%-;EY5I_0$1!K%V?'!4T72M/V9+][ON3
M**_6X)YUAD16/P]DP1<(J\)7$_ 8$!)8&#(L;>S>EI#XC5AX!@V>(2\E..8
M%[:TA6(B!9/:PPI'2&'RB^6VZ6E9UX2X7: ?@1I!+4Q>D<4/]^2"'5_?RY>B
MZL7( MP 0.U&6 74SN#- /,&K\CL%=E](KM78//P[5ZAPR?^LG+ZQ(M^\6*
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MRW?WMWSO\NCK[=H,H>^>+C1M",A-C!('M(SR]5&>+BK0143ZJ,P04>A#(FV
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MP(-L\#@;/.:&7 (HUVZ]M5MG[<%"%K+'J5B]%6C1VR8!?X &L=BLIUH Y":
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MHP$]" T>K*VSM!.>KV*]4T935^+YWCG&1*36BB:-U[H^\7N)UY^A8CFPBO7
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M;HT=7BS14!CBKZ0Z^TVM4G.+S-:NH$0*6@2. 4NKU-329VSN'6GL&:H7#S>
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M?(*S9P<+9I\0^A)0E-S9)X6SCF?//)8Y[6C&M,",-X"C_&G'^-,#,Z8?Y<^
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M/C1ZV#E8&VK6&H.RNQZ4H/VP$B-;&DL #J0*/4$2$>-M^.GMQFO'DPGBCY.
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M" @(" @(_SX0%8N @(" @(" @/#O U&Q" @(" @(" @(_SX0%8N @(" @("
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M5D9!Y;=Z$9@?V?J.2'(+6YO:JHM*/[]_]_9=6E;AE\KF1OG*ZX@#N;J3,^4
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MD$DD,MA^8' 8- Y/(NKTM U8'QS[ZEE9,WC/H/+^DXCI 5:Z'$TL!2@;%?P
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M[VNUY%+DN^9F484H)RIJ<7\K%AD#7'R0C"D]5LP__BX'W'F^?;VZ?J<'UY:
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M[TZ@4*EX&HN/[C%O,*ABDVYO#PJ@TW54B5H]A@Q8'KGC_,U;%PZ>63=BE*N
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MS><ZOXVI5/\P7QV&OY2A2&[VG7U[^G8SU&JO,W[;QCOIKVBJ0 PY@Y\5^/B
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M2_;C"U=M%BP88VP\;9/E]>>W(Q\^.[KF^('3^Q^]?_?*_\'%?;-F[[7:9GG
M=N;( :/ZC_E]U>[+QUV?/XHK*F%+FSW,$A'4O/[@MO6(Q=(%Z\S7+IIAMG[C
MHN.>)T[LOGK<?*NSR\%3^\\MG3.G_P:SG0]#L]/2HKT\32=.Z=&U30\C7>-I
M4\?U&]NS?;?NAKVG+%VTX^S!\QX^+H?.V,Z8-E2W\R]:;3OU[SK<;N76@^<.
MS5DP96 W?1,3L\.'[D<'13T-.;O*?NZ07J--1HP=,<MD],BY*Q>8FFY:NW3N
MDM5S%_V^<M6RV6LLEJS?N,5L[MQIBQ=:GG1\^BCP\I'3RU>9G_$\Y>]S>_M<
MLP'=?].;,'2MT_F0@GR67)658K<Z4)8D2/WK+P].'['=:>?R-#BU(.]MX),S
M5ELMCASR>_V6@N)Y/$=8'IO@LLW2S';!B=A'171N+>']E:T.6T_:^7Y.*?V2
M_OS<<?-UYA?\G1X]>G'1?/^ZY3--=SN<='3R>^CU^.&=,WLN;%AI:FINMGZ]
MI?4!VU,A3][EE>:'AI]>NMS8>, JQ\,O"\OYC;=5;74[*J3TS**'!T__/FV"
MT:0I,TRF3)HR>I39VHLO'J:GY42Z^FQ=M'21E8W?&P)9E<5JS@8"@?Q$P"P6
M H'\[*BR(@ZW-#+RE*GEG'GS['Q<7Q=G94<E7ERWSV+3FD,NSHX[]UI:3YAU
M8N^1@^>/K9@P8<&8M5<=XVO+U,\O;S8C1%3WYO/5]?9S^QL.'-!3WZ#_B/&#
MYILM7C++=)GQQ-5+3:9-F:O;VZC+I&F6?C[I%+JHJ/3AD3TFQD-G6BXZY>9Z
M8MV^^7T&#YXP;-7Y8P_2WV3E%B>XW=IO8C*J=^?NW71[#M,;:+5L[=Y3QY8O
MGS]Q\#B+#6>?/,RIR2U(>G]UXYX5TT8NMEANNGCSLN&C1P_NK:_7JY]QSX4G
M[*_<?.BWVVZ%<>^NW76ZZ^EH&PX9/V/)-AOS);.7C)@T9KOGL>?1[X)/'/M]
MSJB)F[>ZQ4:4<!C8$YZPU5)GL0@JK6](\/"UF#1IX* ^JTYNOQ<7]?"TI\4X
MXQ&+%QY^^JP*96-190U)ET\O,^[;??S@E2X7DO*R\D()9Y:O-UDZV?2"H^?Y
M"[M^GSYAWH+C-QR#_(+V+K1:8;;PQ,O[60PN@DCJ"?$.B\V'CAZUP,+48LG&
M1?-'3SQ]T/5);-S5TYMFC.S0H^_(%4O./+^;Q:4W/<[TZZV("*IB7Y__?>/$
M.<9+SI_QOW/_QL63-@>.>07YOPP*W+?<?)BVX;#9QGL?W?C,Y2B_L=!B)A (
MY*<"9K$0".2G1Y4426A?/E_=>M;:<ONM=Q%$$:<ZX>-E4[N90X:/&3=Z[+ A
MPY>/,#E[UO&"VZ55DR=/T)UQ<&M 7@:6NS4F0ZHBPLBI>'K@A-GP7KWT.W;5
MZ6G8M]? (8,&#QABU+??D$']^O;IUTW'H%M?H]]/.(04%[/+Z\(OG9T]9\':
M\X>>)"8\/.EI-6)0_Y%=C/;87$G]V$"BY=]^?,1DYFC#3MV[Z_4:KC]B^\K-
MAR^<7&ZV9$B/_G-&K_9T32@MJ$WY?,/JT+S!0T>,'C1TR/CIXT8MF3]MU- )
MO2?T77;U^//D]/<^GEMF&;?KJ--9N[N>?N\^?0<.&S:D=X_^1N/[[O"_$/NQ
M(,'#<>.J*;/V''Z8E<I&Y(U?0,4R60 /H;Q.=-IF.5"W?Y>NOYE83S\6<,-[
MSR7SL:.'+5IXZ.FS&I0+HICO<^YOWS3=Z+=?]0U&+5WA&N3Y(NCAP476$P?V
M,QH_=J+Q&*.! T?,FG_.WSGX]OU=<[=,&#)R^>&=3XMR9:B"1'CC,'_#Q/F3
M]GF>N[K/Q>;WR9..VY_P??KXJ/7*B;W:=M S&&:X\)2-?W8FH]4T5M7W_/*H
MI--+3.>NG+CK^9W46@:EMKJPN*PD^?6C<_OFC1G5J4U7@U%ZL\_NOIU;P)/C
M>>Q_\<:Z$ CD_Q8PBX5 (#\]JIQ(PLC*]+)S.[#K:&C!.SZ*U"6D7%IA-77@
MH.&C1XX9.F3$[R.F7SCO[.AQ><W4*5/[+CFW[T5UJ4@UK3+C4W\]@<3/NW=G
M_Y+)O?1UM/7T#0T-M75[=M/5U>W10T]'5[=[URX=.G7LU&GLNIEG(\)S/F<]
M UGL(K,MUYSCLK(3/ )V338:/%YOZH5CCX@UB BMO/_RR-39(WO\UKY]%Y#%
M+CZY^;3KS8NKMBP:IF^T;*+E';\O]37D+ZDWK Y/Z3Z@:ULMK?:=1XP=MF'#
MBIE3%_>;,G3YM>-/8C\FN5[<-'=T5_W^?0Q[]QO2O\_0X8/[#3#LU&W81'W[
M.Y?COI2]NNYDOF;JG(,G7A3EJ%=*V3?82DF)@IP K^WS1G7LJ-VA4X?!BX<L
M/;CG@/F.-1/'C%EM=BXF'LOF%4A^<.CA>0O&]NG8J7O/OD9#S!W,CAP_M<9D
MXRC=7CVZ=^S<O5-[[;ZCYBR^''CE8>"#77,MAO0UFK;3*K@@$TQ,)+S;O=!B
MT<;Y7K'W0]U#3ILOFGUJ^ZZ+ 1[K?I\]H/TO6FU_T];2_7VF[<-G)6R.JH'-
M\UCE:X1?$9UT9NG:&?.-M_A?C2\G\D1\ 9-7$4%PW[)\=/_NO[;IV+E71\,5
M2_8_?%S,IF%?FX!9+ 3RTP*S6 @$\M.CRHC$M+0T=^O+.[?O>9R5Q$(E5804
MQ]7;35?-VW;R^''K'>NM)DX_>_ST*>=SIL;C9HY<<?I4:/:':B:5)VWV<WYE
M(BM .1]>N]G;C!X^;MR4\;-FSADV8'1?@YZ&?7KU[-.O[^#!0X>,'#Z@UY#%
M(W]W<7\9$AET]M#4V<O7.5V(SLA,\/"SFS)PT/@!9N=/AY>F5U21WGD&'9@R
M942?SEVU#4=,Z+_!<9OCU8!SOZ^;/L-HQJG]?V1GB1 A[4OV]<W[9O<9,&B@
M0>]^(V9,&[]ER^IY,U8,'&-DLL-L[TGG,Q:FJY:.&&UL,G[0D.$S1INLWVRQ
M[/>9_7L:332T#;R2^*4TT>/BVN433'8=>IR7H?ZIFKIK% @]JSKDT &S<;KZ
M/;5[&/0TF&0T9/G*%7,7S!XY8,B"17OO!F56EU9\^.BWZ^",?B/UNW3JTJV[
M?D^=\5.&S)@Q>V@_8_UNNCK:W;IW[]2N:T\CDSGG YS^N!.\=X'YR-%&T_;9
M^B6_)3=4%X9&;9MG/G7!U(->YZ[NO[ICU;291S=9'' [OGC5TO$#C(R&#C+J
MW7/.C-_/.(<DQ^149A10Z%P)_AW9YAL1$=8E?7 VW6H\?-"(-;_O=+H2_"SH
M\1_/?8Z>WC)SK-% /0/#OKW[]-(>/G[5Z9.$FGSL G+3+" 0R$\&S&(A$,A/
MCRJ5$=-2T]VM'!UL[(,SXFBHK"8IV]OZV+$S]H%Q45$W[AP_NGSZF5-'CEP^
MOV+4R"'=#4:,7[EMQ;EG-]XVD*6J/\"KOT4J1^5E!4]=/:PW;S_J?,S%T=UN
M@<6*24,FSA@[:,;\^=;;CIUQ<MRY;?F&&<:[3[K[!MX\X3!^VA+32V<BTC+B
MW/WLI_0VZ-5IX#ACLX,;#OKY7#WL<G#>A"ES1TZ9OW*]V>S5)RQM]EPZM'#.
M-+-Q*^[XI],Y8,F,])* [8=LEH^UW+]YV[931W98G#V_;_N&O=.,1@X<UJ.?
M\423Q?/LCEOOMSVX=L+,^9OG[[X1>.^2T[;9XX;.F;3OT=VTG,I7'I=6+YXX
MR6[_'SFIO,;<3OFO7%@>F^*ZVG+AZ#X39HR?.7/FN%E3C68LF3/%Q&2H0=]A
M0^9N7+_OZ&&'#5MG#QNMWT6G<\?.7;ITZ=:UDYY>MQX]]+MWT^O2I6O7+EV[
M=/Y-JX-.OXG33P6X/'L:=M;,UF2PKH'Q\.GKMKO?]'A^^Z;Y0JO^AD/&31T[
M>93)U!G#%QXUWWSLZN$=QRXXGG2^?/7DCNT;;-:NL]E[8+NE_5F[TY$1.716
M8TM5357(F=FE3PZ<6#)\0#=#_=[#QRQ=M]AFI_WF)6NGC>QO-&O2LK6;UB^<
M.WB(\2P[V\=%*?2FZ2$0R,\'S&(A$,A/CRJ5D7$KJ^,#(Q[<#?I8E<-!$48Q
MZ>T?D82DD+R&FIKTW*AP?Z>0T,=/(B,\3YW<8[EAC;GUSHT7G_N];Z!H9K$(
MR"NI>6\_189&IA1\RLTL20AX\<CC_+4;5\[XW+X=&Y>>7U;Z[G7P?>^3@4]"
M8Q/BG]T[ZWC-._QE1F55;NRKX$O[=]MNL=A@;G-DZ[&[OO?N/'OB><'5W_5F
MT).G]V^Z_7'+[>;#!U?..]V^=#,ME23&OMS)KZ%^"'[V,OAR]*?8I(2LMU$O
MDE]'A@1'>AX]O\]ZXP:[;7NO7GWYAO V^M4#9Z^;CWP(>27E*9^?WW ]Y>'Q
M/#V=V, HCH_P=KMTX=[#E)J*IF\4*/^5"^L^YSQS\;MR[HS[3:];-[T=G1WW
MG[SB>/K<N3TV6]::K5MOMG[#^N5+35>L7KUYVU:[G1@.#@X[[.SM[.SL[7>
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M@4":@%DL! *!0" 0".3' V:Q$ @$ H% () ?#YC%0B 0" 0"@4!^/& 6"X%
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MV!RPX5\0GT2(O8,T5>Z]F'*^L,4BON7736WFUXO&Y L1+BY/B)65"AH5 .5
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MYJ-"3(92C505I+!BE(DGLI@BM?A+D/M2U8+@QCFP^"B7A\M%^5B&BDH%J%R
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MCK$!.BGCHT$E-@H$7 BW/!>Z566(%?!\F-7Y<# K&Z<8.Z7.T< =SE$[7"*
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MCB)MC"9MBB%OCD7W6L!F#$ALC:.%X, ]V#(@?S-4(Y:Z,9JR(0H@K<>))F^
M'""&LB&6MBFQ:6M2<PA.8G-(0NL.():^-8*\X3AQ[0F,X\1U)PCKPXD;@ C2
M^@CRQDB L@%C?21E;21ES2)O+;(FBKH6@$\CR&O"&]X*)[Z)<Y+XATCB&S$-
M?\ VRENPF9*;-BRR*;EI<S)]4Q+LM[!O4]?%49XCEKPVAK0F%B"O7>3-&-(;
ML90WXJFPE?\ Z1C2ZY" S1U/>RNQZ:WDYC5 $OVMQ&4D-+X9OPA,)C6M>4;S
MFL3F-0E-:^"C6.H;,937HRFO8;P>37T]FO8:QN^CJ+][!N6U*.KK4=0WHFG
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MMXA/@0%UD!B]?(-W0._IUWMZ#)X>H[O/Z&:9/"RSEVU&<LD!3W4$^(X 6)K
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M![Y'I$=JR-&Y!W1NIL[- AE%G1;<7).'9_:"L_)-((YS [K9 ?T<Q^2&\RK
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MAN_S&[Y_2+A02K]6W7:KB'JIK.E:"[>T1U[/D-9VB*L9LEKN"%TS\AJCE
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ME:3WR^O_619KQ2S6Z)0*ASO*J+GG\^*OYJ>U#53C%HOU^UQ9O>?Y:8L%?T7
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MO<ABE9:.#F%90]>=3D'YR$3?S+SJ:4 SZ95CXPQ*K"Z1#<<ILCM%CD4FG&+
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M21CP2['!2;QN^ ] 9V8<*LF*"/_8EZG%P2.<IH4-INI H('Z[0!V,_C)5J
M*$@JY-$"28VF!F*7V*^5P<.@2+,GUAHDQ$0K,(S(ZKCJ/:%J%_N+U2\I#N?Y
MV]PZ8650NYU-U4?W:_[3DZZ_B97<INMJ=DY6KRCV:KE:WN'R]BCV&!#VZ.0(
MUGIL47"P!13;*<KWJOOV4=D_F;?^HW/_K_*X#VG:%/G!D/)0+#=0K B%D-FG
M:@[I6CT74^S"ZHY\;7=Q32=>V^>@V5T&BA5BBGUS^_T&(<K4$!K&<_D5NSSV
M_%"!@6*]QOBUBUN0#:@KN<N[Z(WJRK$(SS3BX?,"0XNQH#:7:I D^".):\4G
M;&%ZE0\5+B#:*+<IK338-<3"+]ZV<3!W<8,!% N@B0.4&T, &'PNDM\:A>MH
MDD;QKA"Y(B&//$:*U1Q)^(K1W/H8MTBKB"SW+EJ5;)>SBOUQ$F17GG'<>(:S
M?[@NE^'%\OP10AXHR=0WDQM:P;26VCU9$9WC'I3\LJH[1; \",6N.10@I-A#
M8*'<1QZ7-'JT/X[[!04K4NP)B91XO;R+Z!8Z&"N',ZH]$7=AN*HS,R;7.R;?
M.ZTR)*,N+*'</Z[4)[[<-[+0(R3'*2+?+:4Z**\M)K<U)JTN-+$R(*G*/Z'"
M.Z;$'=9)57ZQI1YQ99Z)5;[1I1X11:Y1I1Y1I>Z1)6XQY9Y)M?ZI#4%)M7X)
MU;[Q53Z1Q:YA^4[1Q>Z)%;XY3>&5?:GU(UFU@QDU@^D=]&+&4N?LUL3L%IK=
M19$V@3C*WOF=B64]0Z5'?HM$BL&"NDC/,(NX/(\>6OFT=IS GQK/-"+"\,K&
MND"Q;]!KAC")R#&5B 6Y&O3&7[BP06L;+PQ)L0]+<V@9R8,\K)](-D^F-TZD
MD+@@V/C:[:\5[+EU,@/]P!%N'5R@9^33) 3KU8N;]-5CZ>JA1+[-7MI@0B=M
MXV1N<8W9/)0?F>D<E>7:.EH ^VR<3*^?2-=.)$2FPT+?\J).Q)>U=B+"$IMV
M6SL6K^-+@S6DR;6<O1QRHM77" YH^!;O(-8:M8I^/K=QLJ ]DG!D UFU88XA
M#WWB+*MZDZ'KLKS/4B*?5JRE73I'WELWF.D>9?'(_L]>L4];)W+GMR;A:,"L
MR,L5[I2J40(>;8'ZD*\Y$FA/1"LG8B*<#2DDM,="S3%?<\S3'G.UQVR-09R5
M$Y[JF#V[-=XXENF3^,PSUKRR+Q$H5G,LP(X4V#@H@,&< %4F>(R91+55(&=;
MS%Y&N7>LU5WK3]S#GK:,%"YN,E?T$I#1CP3^7UWJ5+Q9R/[UM8(_.0JB!@\U
MER)J3B\/<@^WB,_W&N4W E*K$,I+E'JAR:+7%.! H>,I]I!PY88KDWU< Y]Z
MMC[[(""0U>K$6"(LH<FZ0+,G4.])-'NS6OV\XG":O\UL$)>%==O9U7_\J XH
M]G^/E7Q%1V.Q9RGVBF&OEJOE;2]OCV(/CX_UQ\<HR/0A@.SQ@7Y'O3?3+2@(
MK+MG5?'>B_9_=N_[10'G+EV;*-/W*XZ$LOU9N6Y^62>1[[&6=32UGJ4]@,H%
M*'9^=5>VMC>WML]?.V"N'K QQ0JQ_\BS#/1#A0=Q#0F 5R)(+VVQV?,#18T)
M/M'6286^XX(FV39S]1@@5;"\RP%^@@8#>P+'<Q$P1"(15-4AG@:ZPB(NP,@,
M),2CA/,6UAGC@I:,\E#WL&=!27: "- V0\.,8A3I@:?1KY1[7 7RQ<A%,R=(
MT 0LX$ZHII4'!EWP&8Z,8O6HY>,K1XM;D_P2[>(*_7J9-4"Q*\<2#;0-L!NP
M.!HH0E*BE[^&(_\8&2[D=2)-V@\6W#N] %T+E))>H,8"G))H*5VT\NA<]\"4
MEU4]J7R@6("M(P$:A4+M+@>/RD"3AMIXXA6(1']00'N,8O\(2$*^!T<6J?42
MC5ZRL,&D2MK;)HH;1_-:)@K;:,6-U+SZB>PZ2G;52$;90&K5<$8'JVQDIGET
MIKF'6]5"*VIGE;0R"NLH66W,HBYN6>-D3BNCH(=?WCB56TO);*;G-]'S&B9S
M(-')+>WBE4&BA5'0R2YNA,..9[8SBGNYE:/2)JYZ:'9K<F:3*EH=%:Z. +\N
M[-%FMB:XJC[J7 MEIIDA[YK>'%_6L]3'\(_B"!1#.=7ASD%/ -TZ)TLEVC&5
MG@<0H]+S3>V]Z@#Y&S(@+")17)B&:8ZO%0:(2_Q*9/@O87?TJ%.DXTVO4MO&
MBR,R7<(SG!H'LXF7*^0U=H=%)-]A@E :#V>>"CD3-3B7O2SXB0)%@>+!/MV3
MI0$)+U[YWHG)<1M@5F+_ RB?2YOTI2TF_)W6CV?G5NF- WGAZ<Z@FNX,WM*@
M;(L%F"O;9L%3"2+9 "UMT<]J<9NQ"!M-VD62[3+ENX;]9=L,D'P;70**X;3'
M789C;C%@#8+M\BVCMK'0)2,M;3.(\!&8LAVCC-NQX".4%7=^;6J<WY1<[.<8
M]# PR;9I.$>Z,H8\'L SJ$,/H$@]VC):X!EE><_F8^>01S5]:4+%$!QV=I4Z
MK9V0:BA2#5I+U.,2]9A$,S:[-K&P22.9-YQQB[&X18>-\QM4T-SZQ-PZ969M
M'#0+Z4WJS 9%H!YL&,D*2'GA&?NTM#-!H!P"Y@9>)%T7G!D>BCAPP"51N^0H
M @);=<B5[S$ZIXK<(\WOVGSD%?6L@U(,>8.:"H<@(4B*)VRA/^&/$ X8_CKA
M,&E ZK"F2ELSJH)<PY_$YGM0Q,T*^.$Q&I96'/  OF4ZCGR?BT5&IJ%:0#6#
M$OW)H185:O?QH("Q5CGW@!R0P5H12$ND$Z[L"8CPZ*Q4JYM;010K%6S3FR2E
M47UVCHV?/*G[/\PZ_Y<X\0V&K@)9%!SCUXPH\"S1U7*U7"UO;WE+% M/MO[D
M>/_D6'=R?( '9?6'NYK=F3Y!443C8X?:/SAUO^?=_\L"]G=T;;Q,WVNDV 44
MLW&/LZQCJ,F8Z[YD10<4N[2V-[.VSUT[H*\> -VBN#[X!26L1?]_A(=@ 5Y7
M#D&2E2- 5>'B!I.[.%C:FN0;^R*Y*&!"V :M$1HK/1 I]M";1,TQ>K5GF&]Q
M.G$8C6.I=%!'\_!HEH!0+, H<M2Z@Z+=((L%O7AYFS,E[<RL"',+>QJ28M\^
M7@"-[NJQR/C;TP$SXZ6=;KGH].>,T( $ A&!ZE D4E,JNM)#,ESBB_P[IRIF
MUJ8PG:#?+N-ZG[R.5.QS\*C>C]3W4NR;1ON^3XC,\+1K'-L3X_4!=V:=VL>J
MBBWP#$JUJ^Q)Y<C[Y3HV>9T*L*L]%&L 7O7((0-<K"GB S&K6-81AT'\Q6WV
M_"9S?HLEVT5>A):V67S%T*BHL9==V<^O'I;6#TIJ^T15/<**;GXECB5;,2BM
MI\HZ)F6= Z+:-F9)#[^B@U-2-Y$%A#HHK6EC%?8(RD?G&MK91<WT/$AW"\HZ
MV,7=_+*AZ5K8H8-3W,4K'115=3 +V^@%@\*:\9EFNJQG9FM*=2Q0'O,7=8S9
MG4E V*4#QNPVE:/NGYAOI<RU,):[I9MCL@.F\@A=OF!Y.*<ZPCG(+"K;S4"Q
MAWS5D4!YB(PCB:"XC$R BI&\IO\^F]&_*,-P/A(J1BB]A2U6/ZLN-M_++]XF
MK2R@82"KCU[1SZ@<8%810=HD^#C(JAYBUY@TR*PF@J_Z&!7P6_)S$"1@YV%.
M;4%#E$O(XY<^W\7G>?32RJ6:4=GVE'R;+MNFPZ.T>BA9/YJ9T4[5]^6&I#CZ
MQ=FFE 0V].=T4\M[IBJ[)RNZ)LNZJ"6=$\5$'90BD]HI16T3H.)V:G'G5&G7
M5%D7#:F;5M9#@Y^#RH"AT<\IQ5T3)3V393W4,DBTCQ>VCQ6VCZ)UQW@1$=IX
M1JVC^><T8A!T1\^J>2BW:2BWKC<CMR;<,_+I<_>O_>*LH3\@U8QCKA)!-VSE
M2#RMI38/%T"/Y<;]7]VU_E-XAF-=7R;D!S*#K\XDXP6BB\6)<<AA8=M8 >0!
M<@5;8']0]R12)[6D@VBJI(U:U#"<DUSN[Q+^Q#WZ:5E7DE YO'(D,ADQGUH
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MWY^Y?$F*FA17),JP,RDWDF>X9&*L#,<GIP#!1]A(LF?(;:I]<*H]%$)@JEU
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M8$TB&2:T[1S\".04_! $":!D$-H2]- I\"%:8SD&/W0(?N00_- ^Z(&MWUU
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M!P5& HI=VF2!9)L(59>W8?M%*7:YREV>0>@E';+J^^$B09Y0HP)-RQY;ML.
MCU",\!5%V!2<:O?0_C.W2 MH=_G*(;DQA#U<IG2-PECH'N#4 ,@.\FK92WTS
M:]39]:GY+8;R ,U2FMMDS&[0YS:9"UNLZ54:?;ZWFUY1TY]9VIY0T!J=WQ95
MT!&=WQF5VQ65UQ&5WQ63WQE;T!57TI=4/IQ:/IA:.I!<W)=0T!V3WQ4)RNV(
MR&X+RVH+)3.ZLEI"LD'-(3F@EM"LIN"L1E 02C2%9#6%936&9S>%Y;9$%'7&
MU0QGM-.+!@35P^+Z05%M#Z>BFUTV**R=7&QGJ_KX*T- M*+U4?[*,$\](-0.
M"C6#%'%#2HFW>\3C]'+_$4ZM5#VFQ/&NON^]MOI?3+%HQ-U$L7HQ>KN]BRDV
M#%-L5[) -?Q]%&O @O-CL3^E3(.O%_7#*!:3W-D163) B\9E#_F2U?&.J5+_
MY)>V_G<+6^. ]DS>E,]>Z0^G6*.P+>^/U?=,F2(4>^X27B<#G9\1H5@R%ELW
MF.44]L0A^&%A2^R4M V>=W3D[Z%8M'V7C::+[;&'.;7^\39WK3]R#S?OG"A^
M"Q2K/A;"Y0"Y9M:$V@<_C,AVF9"V+A.*Q:^>+ESF69VA6-Z;*?8LPIX5'I25
MK!@I5K!%;Y:41_<Y.C5<-ZO[._/._PU3;.GNB?J*8J^6J^4=+N^,8G7[VTNK
M@D9JFG<QHEB7GO?\A]\K>=<42P(2HIG">WQ@5MIT5W9UA%O8T_A\GQ%NX^S*
ME!J_]8,]Y0COZ,!Y4+^3()!D7C"I)>4H\B2J^D$S*Q3&;"=5W,I='%C<8"(W
M7@?":2VUHCWU\:L;[W_Z=W^X^?_<LOB==[1E0W^F1#4*N85?2=2CT,8 Q8YR
MZ[E+?:;&QD2Q))PF,HL\0D'/27M,1.:O &T <^0V1-KZW;'RNN4:85'0%"-<
M'MHZF=$>"N;7)SD+O4"Q8_P&R-ZT9AS:*@!9<B&0!\.4D7U 21[ *QYPY1 ;
MOG/&&&2&+_939HS?*\*A*0WVD1=E-!E$<U.,0F:4>(Q9@]X@<P"FR>0V2$]*
M6J.R79^ZW?2.>UX_E"U4CZ#7A7J#G1^4@'250I_O&N;7@SBR_J4=UK*.*]M%
M<>&!8I=V.8L[;-D>;WZ329_KK>[/BLGW\D]Z"4SOG6#E&FON&/70(>J^??0#
M^Z@'#M&/[*,>VT<]<HHU<TUXZAK_U#G6'-*.L8\=8A[81]^'M5/<(Z18).?8
M1RZQCUQC'Q.YQ#QRCGYH%'PT<XXV<XYZXA)MYA'_S#_=-J+ );[,.['2-Z'<
M)[;$$])9C6$5_2E-U/PN5EDOK[*'6]%.+VZ>R&NFY((JNQ,#DYX[!MW+J@JF
M2=OAS[9V)"9E=1EQB"[][?^"SO_\^RDV_-\<Q1)S"&0P*H K@G]1*Z70(\;2
MPNUF3GV$9&7<L/,9(ORW0;%5O6DO_.X\][J=71\!#Y?<&._@-12[ARD6UV_
MK-"I]HFQ^M;R#ZZA3SHH1>2'%Z#PIQ(J:BA&[(B (FE)K0B$?GAHAB/Q48 0
M]J>CV._3%<5>+5?+OXKEG5'LOGYG>4/<2L_R+__V9<4'+CWO^PW]"BB6L1HM
MT[?+]8R%78%L;T:Y/X-]^/^,%'MJ8+<O0+.>#R3+Z.TY<B; G.LM:HKWB[--
M+@X8X31.:R84:*R1O[S#6=R@D9%+%"\>&@"H^,@$+#RR*-MD$!>,0&/TF8XA
M=O48OU&D&(6?KQU)X402-:6L-1DH]M?7_N\_W?I_O[/ZHW_\BY;AW-F5B;5C
M,4 >-!LBY3!%T#3 K *<G5^;1"TT?EVKQ;-2L/<<KOH0M<$D\!69R&)\VXC:
M & ^H%@;GV_-7+YX%7 OO3*(.=M%8!'R-K=&I4VW]]$K1CAU0L60:@\-P0)_
M$W->0UAY'1I;106RC<+GD@BZR"O0>9%)$D387O;,JV0<C_>TV3C_0MG4$*(^
MP!YJ/F4[#.*B2(UGKS-F.F/S/"P]OO:)MVX8SA%J1J$! XK5'(NTQR*X?(6.
M.[TZP5CHAM:.)Q]$'L3@TC9HTA7J].K4W"9C?HNYM,,1JL9;*,6!*0[W7G[Z
MN=D'7S_[W:WGO[_Y_#>?6[YWP_*7-ZQ^==WR5S>LWK]N^<%UR_=O//_@"^O?
M?&[UZQN6']RP KWWN?7[H!O/89]???[\O2^LWR?ZTOK]F\]/]:75>X:TU0<W
MK7[SI=5OOGCVP0V+]T!PKCMV?WKH_-ECU^N/7*X]</H4TD^];MJ%WG>+?>J;
M8@.8ZYW\'*CW9?#=5T%W7"(?NX8_,G/\U-SI6E*1]SB_<7YU4H/G[ESFFY],
MQC?=@+#()1PV$^^E5;E'6#H$/2SM2.1CBP(T>=R(2O\J*19GGE L7,[*B1CP
MKF6\P#72PLSY\ZS:,*!8A9ZK/#1$139=Z1LH]L)?VIB?=TRQY*T%2<!Z>FVB
MK#,)GJ9G[E_E-$1"U608<-U#+T-,\(KJ-/P\DJ^@EH,TU!)^<=9WGO_1-!9[
M^OSB)_>L3DOFPEN7LU^=+3U<19P> 5$L1X4]P(R+FI)*_:R]OPE*LQ\5-9U:
MQ%Z"]=.K_L$4>R%[2E23&Z3>Y6EWQ=J=6<W>C'Q?#!3;(JV(Z7<R46R\Y!IS
MOV3GBF*OEJOEG2[OC&+U1WNJ[9DN=EYP]3W[ZM\"Q?H._;*8]RU0[)*^7::G
MS^_RE_:FWRK%'@B1P8 >4^PV<"J3-==7W)S@G_ RO3QD0MBVL,X@_GV@U23P
MJL:^M%:/18">JT?8 Q%JM]#L#0V>KSVM'1_C-_32RBC"9H!@8 (X/L !<J+4
MGFIF_\5O;_R7CV__M[O6?PI*>MDVF@\4"P?$+19W:8O.FN\>8M>,"QHEJE$R
M81F-8AX)-="^(@LY-"2I/1%IC@3 <T0DMI,2>UL4:48+FF-L_>]:N'YI%W@_
MHS*8,=M%<JA%_,<6+ ^B /?T"O9"#U3B:T=B^(H,+9,!&.!1-90M\@J.L09Q
M*F'64VPUR#3MYLT4BS^B+63VB7&[J7F#D\KQC&D2[F%2W!J6[OC(X9IKA'G-
M0*:18KF:8P%0++YV(9"K6#M&G^_BR/KG-VGP<7Z+(5V=G%Z;6MAFX;%8+F]Y
MI*HGTR7<XK;5AS>?_O:!_:=/7&X\=KO^R.W:0_=/L3Y[Z [IZP_=KI/U _35
M]<>>-QY[7C?SOF'A^\5CSVOW7#Z^Z_PGD^XY_>F>XT=$]YW^!'K@_#&2TR?W
M'?]\W^G3NXX??_ORC[=?_ '6]QP_>>1Z[8G[#3/WSY^XP?J&N<<7ECY?OPC\
MSC[L@7W8?9O ;\T\/H<?WK/[DYGK=2O/FW=M_F#F\&ERL?<HKUZJ'B-=H\M\
M\Y/I#,62R8XJG:!WJLHM_!G\?TK:$WB$8L^SW5DL^!FS]U-3++*\Q!2[>B*9
MVYAJGRSQC+5\ZG83.GX M6B8%CU*_Z8H%NB\N"T>$-;*ZW9Q>P)_>7!%#Q6@
MP?SIM12[O(?,Y2%!%;6$ISN:.5SWB;'JGBPUC<4B+C12[.5B,="AZ8Y@7#;I
M\D^0+<%YBAT5-L87>5MYW@I,M1L1-B[M(HHE??5S-_<'4^QIMB_,A#/>8B+5
M+D^S*];L3)^EV.CS%,O0%5]1[-5RM;S;Y>U2+')3<'*('GIXUO>U>_-]O*+P
MNH=.M;]W[?W ;^B716AV%Z+8)3U]#BAV%U&LZD"HUB,7DC\?Q9IF5VC1ZW[1
M\BX7M+3%8LSVY-5%>T=;)Q7YCW ;9[23!-?DVZRE31I0)D$];#_*@(^+FS0C
M_'&U.#:C2#D,%#O,J>4L]BWO<("2-XYG@8/GUF@UW9E/G;[ZW>?_ !1[Y_E'
M 0G(Q0]0KQI[_X%*%BITH6)HA%O7SZADS'8N;$PIL0M)^'9ADR9=H8@UH])5
MRMPFL!I]89MQ1O"1+MMEL65].?41MGYW+#V^=@Y[4M 8+5@>VCB2FE[NPS$!
MD;NH);!&X2AW.&@^+YI&C1JVA<VIQ0TTNVMYFZ/802[9L6G!I=E=FUBFC]L@
MY."6"!DJ;-'/:1.)^(&'#"#/\"@\+]Z^05]<IQ$G\PMK4V+E2 >ER"7TR4V+
MW[STOUO9FP9<3AHJU2$RI= <(XJ%IGUF?9*QV$.1M# 7>Z97)Q:VF7-&<U@R
M',M<Z"_O3/>-M[4+>. 3;QU7Y)50ZA-;ZAE=XAY5Z@J*+G./+O>(+O>,+O.,
M*O&(+':/+'&/*?.*J_2.J_2*K_9*K/5)J/:.*G,+*W0,R;</+7 (A76>?6BN
M'5%8GGUXOH-1CN%YSN'YSF'Y3B$Y#B'92*&YCA$%+E%%;C$E'G%EWO%EWG%E
M7@GE/LG5 >GUP6FU@4F5OO!51+Y+2*9=2(9=4*KM2]_;=K[?Y-2$T*;;T63!
MGX\1B0C%8F^LT&_!%@7\;FJ%:ZB%?>"#TLXDOFJ8A$TZ)89+,'?QF#^5?FJ*
M7<:SX &5H"\$G9\>9I5_\DMK[V^*VN+A(8+_%50F*N1Z[/44>Y:'OO^J_[HH
M%CI[0+%0&[SPNU/5FS:S,K%U/ .//'E(SPW'&M\OR9%W6V3.1).VQ^5Y/'?_
M.C#1MI=6+L<N9@TX^/W%8NBU0OE@*7$W]3+%FB#8<$#L%X+82HV)FF+R/:!W
M 7=G6-" *1:];T%7=&YRVZGS0>PZ \$K- TK^WS40!@;@@OEJ3*ZVC Y<S!)
MC69WB;5 L;J9Y0.)<(L!%!O5Y^A8CRC6HNL_Q$NO,?:O*/9JN5K>\?(.*%9O
MI-C5_<5!45E4DYEK_8=N?1_X#OZBD'.;4.RB@6*E;X%BU7CB,QE')!\5V F.
M?(=#F^[** ]]Y7O?)<0\O3RDNBNC=:2H;:RX93BO<3 ;:2B[>3@'Z+,))7(!
MN0:8551Q"T_6#U (##HN;.R9*@42%:M&- ?"M>/IC9-9$.!@0W_N,^>O?WW]
M[S_\"MG%>D4]J^U-%ZM'H!(GA@KJ?=[,"F6(75/?G]$V7C I:>7+!P3RP2EI
M6Q^CHF$HI[('!9:L&<AL&LMK'B\XU5A^TVA>.[6XLC?5*\[JEM7OOWG^H8W/
M-]DU87SYX/JQ!#4;NZS50Z%VGP^-$V2^931OE%?'GN_A+PWP%OM8<]T WYT3
MQ2TC^<W#^1WC)3V3E;U355T3Y9V4LDY**:C#N&X?+P'!5SU3E;!;%[6\<Z*T
M>[*T9Q*MNR9*@)*-*NZD%'>,%[:/%;2.YH-:1O) K5A0JJ#FH=R&_BQ0TV .
M%$ABH?>WS__XNZ__"^2_9B!#O#*F0 XCL54<"EJ+[!J5>KYD97R05U?5EP8%
MTC91/,2K[V?7]C!J.B<K6L:+0:7MJ?Z)]N9.-Y^Y?1V0_#*U*C"YTC^APB>A
M"M@406I\C7="C6]\M5]LI0^ ;&2I1U2I1TRY5VRE5UP5VB&ASCNQSA=8]E0U
M/DDUP*#>H*2+\DFJ\DNL]$VJ]DVI"4BM#4RM"80$**TN*+,Q-*<Y(KLI'-(I
M-?ZP3F\(@75:72!2;6 * %6Y;W2NBZW/K:<N-^+S/4:Y=?/KR*KDY]5YBE7K
MA-!U@7OJ%?7<)<R\O#N%IQQ2'?$5>JYI(OR_2HI%J&> /. D1+%;]'YV=5BF
MDU/8D_*>U,4=)E"L&CD#.6<!_*^=8M%8;'N"I><MH-CJOO29U8G-DVF@6!17
MY;S+6"0\C$IZZ=!YI@J:0U/MS1RN <6.\NJ)UY1S^^,RT9 P$(=&7\+8\'WU
M"$4QQ($,D6=?'++!8!^/MJ,(A>A0\'/XN'XB63D6*7%8F=43R=1L1W2>^[V7
MG[A%6L!SO;S/ XJ%7KH<AZ*%?8@/8(/@X[%0<R18.1*L'0G7CT0;AZ)U? J3
MD'MCXM+8&!3CC-#/B5;UXO7]Z?7]^57]O%(_+=IFMDY71@\X.37<,*O_.XON
M_Y P#11[95%PM5PM[WAYNQ1++ J.#12[=K T)*F(;K5P;?[(;>#7/H._+.2@
ML5CY81NV*! L[<XH]]'L+C7R'(G=6NU+M+KYE=VEU;V9U7W.ZD]$L<@O 38!
M-,Q>VH<Z3JS8X0'%9E6%O_2^]\3N\Q?>=UQ#+'RB;?SB7OA$/_>*LO2,?.89
M]<P+UDA/_>-MHC)=,BJ"*]J3@-4&6=7]]$H$N(,YPYP:;!( ^12M'4UOGLRI
M]P2 @XX!CS^[^ZL;#]Y_8/OG@ 1;0#<Q[(9?\"GW -R%"^M30^S:4A0M'05$
M $3NI574]F9D586&9SI[QUF[1EBX1SWSB;?Q3[0UR2_AA4^<=5"JG6^\S2.'
MZY_<^:<OS7[]POO;W+H(GFP *G%HEI8VZ5JXS'TA:[:[<2"[NCL5LMI-!>@$
M*BV"+?GU45%9+KZQUIZ1EKZQ+X*2[$.2'8,2[0,3[ (27A'Y8\%7P<D.?G&V
MP#K>,5 ^ME!$WC%6WE&6WM%6WM&64%8>D,]P"P]0Q%/XZ!/SW"?&R@=_2X3+
M\RF4)- \)&!_V-,]W/R%YS?7'OSR^L-?^<1;=TV5S:Q1\9M$KES' 4&CCBCV
M@,]7#K6.%R66^ 2FO(K,=DLK#TXN"XK-\PY.<_)->.F7\,HE[-D]V\\^O?.+
MF^:_?>YUVSWJJ4NDF7/$$]=8<]<X,Y=8,^?8)RYQ9LXQYHY13QPB']E%/'P5
M>O]%\%V;H.]L0^Z\"K_G$/4 ]O%(?.J3]MPOT\8OP]HOP\8_PR80*R#=VC_-
MRC?%J&20M4^2M5^*35#&*S06F^40F/[*/]46UJ'P,=/>+^6%9_PS]U@+6'O$
M/7.--G>+,?>(?^:=^-PGX;E/O*5K^.-[-A_>>OH;O[CGG92B&2V%L,)EOOG)
M=$JQ(BT.R+R\P^FC5:/[&_^BIB^#IQA28A?%)E3Z5TNQQOP?<(%B@8KZ6%5
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M/FUUC_H9;Z"Z?["V2U&1_>S6L2M;]YU9?^/QR6>=&3V:RF[5TTY%>9?J:=]
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M&_JSKJ4=.I,46]B8K!GOHC3/?6XQND5&M]#D%I!4I2)BX4:0(@I2K'E9[N0
M(ED]HF%$(4P<64]$52$*(BQ]FT]>Z-/7+TIK>V'3W?B;L:>3=I6V L6V,4.R
M..%=%Q6]',SD(8IQ5B$^Y7#Y2'6-\ 38(BJ$)\"AR1X,'TN"R#(-< @Q"!<1
M\U2&_MG!)Q;JI0U/MOR1VK0GE^,N;SJ7 A2;,S311P>V JV^',5&]&KPT#/+
M$(2E9SMYAI22-)!2&PAO*W*XK5B< U;/H-ZMDHSW%@K33I=MCLU^X_.<_['Y
MV3_<4O]6Y$EW+IBC%!LMT;**934IUCJM;I5FW7ZV_5#QS_;6?#>^_<>/%9]%
M*79Y <6.^]5#X[R'Q9>W'/G@R)6M%9T9P],"VX(F.*(+O0@4BVE%^/)5"OUQ
MS3YHH5@[T=VC?=8@S&^3EXIT35I[[\@D?VQ:B/9FKVK2/S"S,&QSJX8G^P<G
M^O1S0 8*JR<L0,'S*=;H$ W:NX7#M;E5-X%BW]WPX_AKV\I;'RI-K7!/A7LM
MW(-;Q(75W1E-@GQ8#-^9SC*I-8.W\ @J?5&]',5&4MTB;+>D7C'%7DT[4M7Y
M^*^$8M5+4JS@&T^QS??B;X53[#*U64A<6+2_^J![I?2J 4[%L 8$^T:G>+*Q
MIG9)2:ND2#12-S+5AYMV!?B59/,RS*'K#HK,9(5M([[F>I>0-U2=RE(L+P>N
M>GJ85IMB!T,I=@NAV'^-4FRT1,O7I*PRQ;9(LVX]92CV9)1B5R"&8B?Z@6(W
M'W[_\.48EF*-GJ\_Q:+7 >6#D3F^2-_8+"FJX^>V2(O[M-62L6:5L7/ UCLR
MT6^8%4]X-4"Q(U/\H0F>;E9D)@/R0GMC<8IE[_$T-_K8=+]XM#[KZ;6-^_[P
MAT^_=^#LNHSRQ!Y5!0"9VMS>)7\"" OJ53\%A(6U\+X[BRF(@E@00:4OJBC%
M+J_(?5QD3Y?;4%"1U+*HHA2[0HHU$U?LR7GUQ+P*( _X%2-F3/. 06%%H%N;
M1PZ7&$];V<#/;9,4*XVML):5A-P*5D*N1)-3#" +-;""LPN$_O1S@M[!*J#8
MPU&*C99HB987*:^-8M$OUD$HUN7#*][G<UBF5$WBC!OE08^"1_)/>VQ71KU/
MHQ2[E C%:H8G^U-+KFP^_$'<I2WE'8^'IOCV!:W)RPSD(HI$V*\#Q6(T ^(^
MBZ/^M>-=O.'J%EE)B[2H2_F4IZWI5CQK%I0T\8MXFIK123[TDL$A&9L1TN#G
M9A<2 ^>^M1S%4F,JWDV=8LE8P\/B"VNV_NSG[_V_VX^^?_/Q\8K65 #9?FU5
MN[2D65@ +"LW-AN<0@ :N)-Q8[:;_HHIUNR3C<ZA7^Q5'-W%4*S-CVQ*#=Y$
M.(I\"07=>9<7M^61^\L(C?$D!?&RBF@#HTB4(:"#%&OSR8<G>^IYA&)O[RAL
M2%;;.PUN,LJ-("QU^#;AL"2A&43\8AFW8\;5,MQ+E=F=""=7CLCJM'GTW&;;
MYL:H%,RX,7<XQ;+G@'D)].12+((L 7$CB;.AM'44-=\[=2LV 2@6_6+;8-\M
M2\1;8%8G[R7L7L6D7XV6UVG>R%2?GF2:-1$\A9GP+SPH-O3GUO9F"09K8#Y0
M+_ QRD_D(['AO'(KGI;!/B&QYS >G]$MY8_4I5<D L6>3=Y;R\N!9U<C/F/@
MZ*Y(?OU**)9T+R(LD=4MM[K55M>@S3MD\*BE$[U%HK2$)UMV9KVQ(>=_;*G\
MAUN:*,5&2[2L?ED%BG5X_3Y"L>9)98/PT;6RK?L+W]A=]1_'6W^8+OLD2K'+
MBT.QB5N.? @4^Z3]48!B":=^[2F6""?&YOCJ\4ZAKH$_4BL>:Q(.-]3WY3\J
MO9:<?;:P]JYPJ,'D1N\"Z"L3R=]CF!/3!&:!WG@^Q=+0JI+1ACM9I]Y>_\-?
MO/=O>T]_<COS9$%M$MQT 60%0S4R?9/6BK&!C"X1?7F*/G]1BB6VV#$'OT&8
MC[98#L6:Z0A]1DL9%&7DJW V"A?BX)(4&[)'2^Q.F"+:P AAB"-J0S4Z,71#
M&,46U">K[)UZ,K*>.YC/Z!:9T"]6&&*+9>H/L<6&4"PQ0RXF*857+K\&.@T1
M%D]@0K%A^,MVR,HIEL:'!HI5$8J-O[GC=-*NLI8':DL[7"#+U$/?^U/G 6@,
M7"9]FF>MXJ(V27&'K!0^FP3YH$9^7D5;:D[EC;SJ6^V2$@RW[,.+"$0#EB&\
MDC8S_[+'UR?#D9T+2HM?(=8W955>/W)E\YD[N[_&%!NS,_O-#;E1BHV6:/FZ
ME-=*L4Y"L7,>G]<W[_4Y3!.*.D'ZU=(M>_-_NO/9_S[:_/TTZ<<]UBO$HT X
MYM3J'%&*#=>R%*N,P-:O&\5*62:@[VI'Y_@#DSV#D[TC,WRMK:>!5W#S4?S)
MQ!T LNV2)W"7FIS7COLT<%B!7W4D%2W<AS@Q"A9'.GIC!E:8F%=-+6@D(PTW
M'AU[>]T/_[SA)XD/XTH:[];T9+9+2\0C]8/CW107J ,?K$B#K7)O[7_-%!N(
M%WO\6MI1AF))YW X21(&B!QQ%UM<>)B6H%@+.8[!K]#DB0'U,%Y2Q$ZQBJ06
MJI53++'%=I' &GBZ+N=1$*B'A"D0487M3@B#+D*QU)3+LBQ.LR1*SV%4),4N
M@9[LNE34HV#,*<28(2X14&PQ2[&M#Y3F-BLG_$5X582D8>MT()?2U-K RWU8
M=.'\G3VG;^PX>WL73"3<C#UY=2OHV.7-H(LI^_)K;@/IPG,C/!^"A,.U('9:
M,M80DJ].WR0U-,O-K3)S:ZN\]$')Q4-?;DQ(VE77GSLRW8_$Z284NX1>/<6Z
M)5:7Q$84]"AP#QK<*J!8ZE&P,^?-C7G$HT 5I=AHB9;5+ZM L;- L=YYKW?.
M."ZOX:=>+MZT._<G.RJ^'=?PW53QVBC%+B^68A\67]E\!#T*OJ$42S,(&-QP
MBQ487$ 2F*&G6_XL)>?LJ6NQ*;GG.N45L+\3?HW-H\086[,8+!9N7>00KXAB
M04"Q,PL#<$^]D7[L_2]^&G/HW;+F^]*Q1KF^665J&Y[L-1&O [A5TZ"8U",V
M[([^UTFQ&'?"(QF9XS>*"JX_9OQB-;8.'*(>,*T1R?%D9L7=%GX5V3 J24!2
M:ZALH3O+)G&P>94VKXHC=4#<F6BY7U16-U' \0 7]JB(EP(Z=P+%-O1GW7AT
M^$(*XMW09!]&7_*&9+(P>R46KPCE$9.6RTC$,;JS(0<EY'B%[)J<><^.4L*U
MC#FE?<PNP 1<VN-^?!=O"_0P-6?:O0H0-632WK N[<P:0;$8MEE/PCG+3"U%
M37?/)N\Y=W<?X*QPI&YT&N-G43A>M$+8EMTK'YWBM8J+DG-.;SORWI_6_>"W
M:__CW0T_7K/U9Q]L?@,FJ#[8],;G>WX7=V'#E0>';CX^?CW]*-6UM"-74P^#
MX$GR3O:INWEG[N6?I;I;<#8E_\S=HG/WBB]<?7SLX)<;-\6]<_KVSD9A@0Z3
MXN)E3AXVZ*-"I$A0V(@S'$_REZ!8-SPI2:SP5$-D=<K-3K79,6!Q#1@\:OET
M?X$P]431QAU9/]V0]Z]?//W63=5OA5&*C99H6>WRNBG6.3_O\/B!8CW>.<.$
MG.3NVK0[YR?;G_Q;7/UWTB1K>JU7QKR51I](Y]3J68KU\\S>7K.';W')K,X!
MV]R8?6[4[M3: 6K=?S442_P"Z:UN9(J?7G9MZ]&/XK[<4M:6/C2)%&OV*DT>
MQ;(BN;M654;T)<!0J4"N()HPS((Y5]7C7HUHL#&M^/*9F[OOYI[O5CXC^ZNR
MH#L!#N^(,+VLB&*GYC7BD?JDK/CUNW][^.+&#EDI'5M-K5P6XA1H<."@D[$9
MI%C#7$B  A3:X1952/#7983A8".Z(E)F9)>@(OF5BKO,<EJ:8KEPMI3@UJYW
MB@:G>NOYN=<>';V6?K2F.W-HO&=\'E\6<WH[A&+-'CE'L$>(YD02CMB9B X@
M4U#X+?=0<G9<04"6O7CE5.22#\KDEH4HR"Y$K*=LH+7043:_8G"BNZ;W\94'
M!\XDQ3YI?3 ZP[?Z%7!$(D9W48\"$OJ4Z]C*\?5$CEQ"9N[N>.2$H?%W W>*
MB@(W?A5XGT"R8%!^I6%6.:<!IQO9,]]#^I!M#)Y^:$YF1W>5M3V\>/_ A?O[
M"QI3^@>K1Z;ZX.2G_1Q*L3"--:!/CE<Q/-%7S\M)?'AXP][?__Z3[X(^BGEK
MW<[??!K[J[7;?O[Q]E^ /MG^R\]V_OJ+_7\$TMUQ[ -6VX^\#W.V'WT_]OB'
MN^/7[DOXE&IOPJ>[3W^\,WX-?.X_MQX^MQQ^-^;(>U<?'>U6/S6ZT(>$N,*C
MVT; :!TN[J$/.<E?G&+Q](-==HHM1&;XM7&JS ZMV:4U>C2J66&1,/58WKH=
M&?^Y,?=?-Y7_W2W%;\11BHV6:%GM\IHHUCOO=\Q['?-^MW_![9WWP:?/89Q2
M-DL>WZJ(V9/[TZVEWS[2\-T,Z5J^+='HJ;9ZQ2:'QN@8LG@';/-RRWR_T==K
M\O(Q0K5KP.S469TZFWN0W ;D:)ESJ2TNFMM]\3MWN);(0+L\7*YPL9!5EL@T
MNY08&F!KH'<U\A6UUDSX-9,+ _I9<4YETJZ3GQR^N+FTZ>'0!&]B7FO!H2V*
MYRE\U,MK%MY(2,Q7V".C4SHZ(X#;E=VOMA&[E'"H(27GW,&S&R_=C6L6%ILQ
M/JX:359>M<V#QS<49.5+42PK.K)$.%Q[-^\,W$I/7MO:)BDV.W'8-:;((O=I
MQ(YE7W.'4%<X@2TSMNF%%7I+7N9,CER2$:$B5B%):+D*A)WG4N8B,@#%CG?7
M]F5?33MR/?TH<,S8=/_D@IIR/R.GF"O,S<;**=+!XP$C 4?PKUCGD 05"'6L
M)Y4$38ED:%'PN."H._12&)MA1LKC8*/I?M0,(SKLG6IDEC\R(UA<LX+1.10T
MQNR3:<>[RMM33]^*/7)E4T']G>$9GG5!:?!( .+1XV6J%S0TW3<TW3L\TS<\
MW3<RPV,'UU.Q>SH*&YWM7U2CLYSFS3*"=4G *1%,#$WS!B9ZAJ;Z8,DQAY#6
M3(.MZ@/UTVEX D3SH4]N(0+FML\K;?,*JU].G4TYPMS"UGF%Q2\?GN95]60"
MQ9Y)W@,4*],W(2(3XZXE9(R7-"#X5@G2S0K[U)5Y54F7[AT\>77KJ1O;+Z;L
MN_+@T*5[![Z\NQ\$$^PTZ$+RWO-W]J"2]L T+ PZG[R')K]-N!G+"JI*N!7[
M9<K^R_</7KYW\&KJD:+Z9+FQQ4BBA1@<Z+E!+L.(AS3F48I]9EORL6TIF3D4
MB\*,),%G5-Q]A](\I[$XM2:W9F!&5"9(/YF[;G?F3S?G_L^8TK]-EOU*X7[D
M7K L+""Z$F'XG?#[7[1$2[1\E>5U4ZS'O^#Q+B#%^IV666V',B>Y>L>^_#>!
M8H\V?C=+ME9@2S1Y:FQ>B=FA,;$4N]!O]/<:?7PC_.BX!TPNG<6ELWH&Z:WZ
MKX5B >;\:(@%BC7.20MJ4O:=7G_TRRVEC0^'QI%B7[&!^:L1VDB<,HM+,>[3
MP 1-E0X[15_R"@;KDS(3=IWXY,S-/?5]^4:'-,#N6E@&5C<Y7IAB+5ZI8*CF
M0>'YG2<^BK^^K4F0KY\14%MLN,V5(R[%+JD7OW%^U>*<;\M1;!!G(W<J(#3^
M>:3#D[VU/9E(&/</5G4]'IWD32UH+(1X&&L?&;\?E%=J\C'B#.83D]3';(X,
MN<FK-'E5(#.1Q:>FLOI4-GS5SHQJ#S7ZHKW0YL-FD]19(B:]*C'J,QORB#'5
M'#[W$OD59J^2BFPQZ')#&T/Q;GIA$""RIB_[7,K>HXDQN;6WM9,]..1H7J%S
M"JGK"Q&B.1F8B'N*!,G);V>=5U)A#']2<Z2HA3O(3#3T 1P%OP)7],D-;A'
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M+*ZX8;:X@B7#_@T*HX IJ*P+2A0)XPJ?FO&NRIZ,JX^. LA6=*:K[9UZDJH
M,!0#WP*V!J@:YB#^$@)F15^"L__",I3(">\BB,-,V(K9*ZOLSCAX<<.^<^MR
M:VX+ANK,#JG=HP26U6&R#PDG4BRF>$6/6.*;;O.J)N<'[#Z5R86NTCJ"O)8
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M.NH%><GY9X!B"YON]@U52XW-:GNG=@*]")!$298R^*0^!IKQ+EA%:6WG"N;
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M6:1EXCER0<WUP]%?1US<4=Z6,J4;_D%;+ ">"B.3A1W)A1=.Q.V]4Q SS&Z
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MQ-<>"2U^?R]NL9QWR4;"8HE"E TN&V&Q9@=ZNPNSV"[Z_9NUAT.*_W*P\K5
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M!OR)+=(&H<)B5=&#?AOJ.QXD=9375-Q\[VYA[(V<,U?23IR^>BCXS);C,3O
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MB_5B]</@A5ALP*^@'WJ*7V'YS\2+%2W6DZ-@)8OU-E=O?"Q6-#M:T9%Z)NG
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MHC&/J=%PK("D6$2Q9H)BI_J*F^(=*79Z6412[$:1%$L(V\6*5'W953$7;QX
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MPXO9VB_JK%\0Q>+977/$["[D:6NN%BC6H_; B8(_'\_^#Z#80J#8^3228LE
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M#Z^,8E?,JRM+JZM+JRNF5<O*ZJIQR2!1"\O[TN_FG3F?\_[YNC>!8I]S75Y
ML29$L808J 5=@H>O4&44:8Q\8O$5@(]MZ.$U$FH('8=V<--H;<;8FU(LMFZ<
M7QT!8(4& QH2SX?''L:ZX55SII?YFS[NUY[R&Q!_ [QN2M7;RS98LEVC!<T#
MX5=ARH(@6VED3>H9<F@P3#RIGL66=[4QRZIZ,NH&<OH%M2)U/S3PT%X*5+V@
ML9EAZ2):=5:IM_E=U^W(HL#*<#: @^OR%!TY-=%7[_WP(,:UAUTV/C,X-C.
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M9H%(.]C#JZX;S.M@E;/E77Q-'T/:/BQN'!36T4:;>8INH;I/J.H=FQY6Z-G
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M;4BF/2+&8C_X(?=-[XK?%S)_&%_(,JVH28HE QEV,;P&%%OC>I4<BUTOYZ2
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M"1K34;G:[K[1F@;BK71Z771$EE],WOV<IB=5_1E5/:G%;0GE72DM](+JOG3
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M!)I1J&-PD"@&@A50 PX581G0LPJ9&&&&!5"K0%G*$,*B&3SF1NO@:.RP9>H
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MM,H3(>F)JZ#^AET$/0VHD%!+X?;)5FE0H^"V+CI$,(5[AWI*9K;>CKHE>H=
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MDD,$% O;%VDG./(ACGR0(29-\-I&V<WT>9)\E0%_!<!%:+M$$2^3@3\D*],
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MO_K#__W'S_\GZ.$W+1.9,\MCN@VARB94_5PI%D1\U(9NU:)=M+PQ"YT0Z),
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MV$3:V?CYBJ_XRK^S/$N*M5LV-\R;&U;47T44JUZ5D]CUL2T!_A7OGFIZX=+
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MX3FJ1,%-:<+%<6ALQH0M@YSZ04[= *NV<[JT<3BW8ZJ$(NZ2K%-T#L %#J"
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M"5P]?E-\X:U/3[SYISV_\ O[IG$D5[@X3OC%_K0HUJT?AF)-*,Z&.\ ^FC'
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M32?%SJMGFR9*"(H]W?+ZI9%7LT5'F<MY&ML.BN6KC2*M1>BCV)^$=E"LV@:
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M=M&S_.:1U\VLJO!>434*$X#;C![&:SV<P;_%X\$\\7 # *]3:T/3&\/2+0:
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M6*C8XG%FVK.J0ETCC>*+/.B33<AJ<%<@W^;)-KGH6S:<MUV18D^LW)>H#D8
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M[(@LEZ12_]K^O&Y!90N]I*@Q#@6D;4VN[$[/K@XMI<0/3S9.K=/E.SPILI$
M^!!,;W*YRMY.034@;%5?7LU 4>U@44)YT%V'RW_YX==?W/J30ZAI%35/K!Z
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M]F0[!AA8>]TNJ(["*1:0]/D4"\"*.F*WN',: 1ZN%N^['5'WHMA=F<[AZ8Y
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MUQY]\Y/Y5P:.5QYZWS%VO?ZCV9?PTS'4M+@Y^5^#8I4O--C]QU!L-[\ZL23
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MW& _FV(//6UY6#=@%(L\;7U!U%&L+NG2+R"]&XK5Z"CV9^SH65(_?R,G*!9
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M+QE]^OLO_ONY'__3UM^@LBM;/#< J/$S*!9W@'66*I"0WU/!X4VRH[WBJTJ
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M9+^@+J,BQ#WL@9VOOD/ /;<P$_=P4^=@0P?_>_!S7&#/  "  $E$0533(=#
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MV1W>R.) CZBJD5[<*21S5=T3&XSI;39/W=,IK&R@%P.HC2X-J?<$'%E;&C'
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MZ 0PO<73(=]KOA9UKG@:*U>[C2RR<V9F%[T\-.-)8,J#^J$LJ9YDL/+4&TS
M1(V9A\6U/7Y"X>%FM$J-5KB5A'CN+MPRJM\2+&U+%VT2K9FG6*"P9WK&A$VC
MHB;.7/\T8"XRN+XD\2S^%77V[%T^X?R62(NR=DE%.G+]0'YPJDMTKL\ NUZU
MSC%8T74"-YT:W6A<Q-GV>^I *";@R:OHI(Z?%Z1#%(M%\T44*U_8D&FWA,IM
M]NP.&_#::%(<\BC *?;75^M^X=G^YTJ>NWRU]2C%XO%B'<51'.7'*S\6Q=H]
M9G=W;7#+;UMVMI<LIID-5;>D,:KMB4O#*9>N7WD/O5W N\[0EFE-Y 4;%X_
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MQ7Z.*+;60;&.XBC_+N7'IUCD46#;W5W?L<ZLSW5+&^-[W%SK3SUJ_9DWYE%
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M*K21,VM BD)D[-D2*M>YTZLLQ0I3N<'%PK C_,7M0#"S8HVIV& J-^&8"/3
MH!A;H'9Z$PDA+!)7MW6$8G'IT,!J]#/55CX@[#SPB@VY+LQOB=2;0M@W &CD
MM(!M3FWFX>95.#*P(3R,PZ$H1>AXZFS(K*O>XLVL,7!C*APZW&768!.CLP:7
M(IH0R)<HS)D>LJ0%,!3X%8AV;@-ES84##H"+<HE9A+-K3*!A=/Q?0;%V6VQM
MQ#6WT\@6&W'=0;%_GV)U>"1=>T0Y9$RU7RT6 5#LW!ISB%6;7') L:J_2[$
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MM^4+VS*,[)%9U&"#GR: HP=,.;?G@ 'KA_[ XJYL:5>^L"/%[;M:F]W/ 69
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M.H<BZ\JHBKCL_.F'YW_YQ<WW@5__=O$W9YS>N_KT,[=P@'B?M,KP],KP^**
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M6=#*D/< Q2+['(K  %PB4"S2>QDU(6G.%QZ?NNKZ*1RN'D;5 +>N82@7CM@
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M9"UESID[O@_%3F*>!O_[*183 CO^W'!-5V9DAEM0XL,7N5ZII<]S"1%=$V5
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M-&;!I)$ZR*PK;HQ+*/"-R?:(RG1+*0GHFBA3+%!02XF,%GA3A]*'DB4M@$H
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MP^D[37]ZU/[!B]$+ ]/1B&)W'13K*([R)LN;HMCMU>U-1+'"^KBVIR[5?WE
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MM,HOU[6/0/.96A*$S_A&'+!E.!;-PEY!(Z^]R-,0$S; W_#B6Z)=%KG2>=;
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M4RQ^R^$FVLA7Q@I"3"PNPWKT5V2Z@#UM<!1>O^$_"+(U]($3,5Q8!<&U_@1
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M%,OHJXC.1Q3K&6M+Y1,0I6'__NB:2(:9E\#-,[[6/KPBX Q4 JU&YKC%D7R
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MLJHC?1)?&CNH/7I^T]97'PC2/^VU5X(=<&1(MDL$P1U* %BM/+1@"0P:0?0
M-MU<OLUR]DZT@U6Z=K>OZAQ14MEUZM[NZWK'M9_=L'#5>.*E8^FN9>)TW]1!
MW<)% ^#2U%G=X(VJD;,ZX*FYIY:%E[:EC\X3'[VG?@:V 08VOGJ6GMIFKAIF
MK@]-737TWMR]:W/YLL'Q,YK[5,S. ;]:N#Z\;W7IEN%)P%!#>]57P<@[&)R
M<Z0U?->CY[>43<[<-CJI;GG1Q%$=\!I* %O/J.]54MEY],Y/Q^[\#!DXP_,/
M]EW4/ @Z>_^WDW=_.79GQY%;/QR\_H]#-_YQ7'G'V?M[89>3]WXY>6_'B;L_
M*JGL.*&R]_CM@T>O'SY^2^G<O?.7-"Z?N:=T5GW_0YMS01E/&\39?3.M&,4*
M9/.?@9X_0Y\,E'Y)6W?\5[7Y17\EQ8ZL"F$#&3S3@&+?";=2+ @0%M;BKK4&
MYEE0H]D#E=6<G")Z,L KA9E92$NL9&7SAJCXC#&,\-A#2VSI(G- T=8]0V_K
M*TTH\ :*?1-LE+]!L4-?I5BX M!S'L4"7PND=<WBDB9!(5U4S.@H9W95,#K+
M&9T4=D\5M[^&.T#E#%!Y0W4=XRW2>9Y\60P5L&\.'D$<-!"[Q.^984K&Z.)1
M&BP[)UI!T+&4C#:+1^E00X7#C7Q9O4#6 $O>8!UW$ Y5 ^(.5G.D5?!+<4$>
M%QLK9/91&#UE%<RLP!1[6T\=SQC;TM:T[IE6%+<64!5U#/"QVPU#6YQE-VP5
M4 "P#8H=5G FYKE3<[QQ-(K,ZUOE]ZZ(I*@!ZN^=%=4.%(2UOK $BB7MU"/]
MZE1^B](>-+[$6ET;?_=N:9MBM]-V^E[I/X!BD47!:4/2+JOJG5&2NRW3P1C%
M-@XM,U"\(F0MT(6I VM:_B"*_0)T?KW1^N)F2_^R.X)/C_ -0F_N%C"*':81
MJZ*=@BU,WZB9OKD'SV[W*)M,2F@-CU OS&\4D9LDA8UB<J.X #)04L?/JQ/D
MES,RDHL"/*.?VOD:V/D9O HRM@LTLO+6L?#4?NSUZ#$LWTO+W/WAAC3-W!Z:
MN6F X*.%IY:EUR,K']TGOGK6OCK6/MJX;/QU7H8:OXXP?1%B].*MT9M0<Y=(
M*Z=PRU=O36T##&T##2U\'JG:7-&V5XXB>7,&J^6KHI%5$4ZQ,J!8!5 L(*P0
M-+8@' %]@6+E&&1LXL7(1B2(T=7VH67A)Q2+S2 !(&#3.\I22T(]HIZ]#C1[
M$6!LYOS@OM7E>Q;G39WN.T58N<4\=8FR=HVV 7X-3'OC'FMKZZMG[O+@F9^!
M=^*+"*)[-,DK*A\I+-?-/]7>+<;FN9\!4.QUW6,G5'\!"@1,O/#PP)5'1T"0
M.:6VYZSZWLM:AZ[I';^B<^2\YO[SCPY>TCMZ4?_H)?UC5PR/7S54NF9XXKK1
MR1O&IVZ9G+YI?.JFR>GKQJ>N&"E=T#]Z[M&ATP_WG7MXX+(..B <!Y8 RG>,
M3]][?.&>Q87;1J?@(Q1>TCIT4?/ A8?[0=A@ZM&KCXY R6FU/<>5=P+"XD(@
M>W<W<"J4PPD?O?W3H1L_'+CV]]\N_Q?HX/5_P@8G5."'_*RD^B-0[ E5^+A7
MZ?9!I5O'3JN<N:!^\9S:^:,W#QR[O4O%])AGG&DU-[5WN@7A#J+8]\2S3;%;
M]!'% H8R<8KU_9AB%>\I%K;YD&*I/$+'! T/68*_5,'=2XVNBN"8G1/T!A$I
MNS(\*M<]CN1#K(UI[2X%P(4-</"5H6#(K/X%1L]LLV2\OJ6[*)[L!13KL$ZQ
M5=+?HUBX&F-+$OB7>0/4<GI&:D%P3+97=)9G/,$WD>@/>5 R.3"MZ&UJ<7!Z
M61BY(8DF*>F99 +%2A6\WED6HMA% 2 LLZ^RBDTH:\VL8.90^?E47GXE,[>(
MEI9;'9M2'!)/"D@@!R07!B<7!2<5!B45!B05^H,2"_Q "63?]X*/!7[Q9-^X
M?.]H@@?\=D!8*Y>'AB^4X?E6S<K!7DDA&PS<%&&363^C#:(=PL('3F(4.S'/
MDZU3;+MTL6]D<0BCV/RP5EO+TK.:^;OU\O<YE=W!*):QNC;R;DT![=LVQ6ZG
M[?1=TO>G6 ^BN7GZ&2/R+]8UNZ+;U5IG0H!B!Q<;!Y=:A] H7<?H4O?H<O?H
M?WN*14X9Y[BX14%A?:)#D)G6DVOW+2[H/+UAX?3 *<0B(.E5<.J;MVD.(>E.
MV-(Q+-,92OP37_HEO' -M[9VU7Q@<?&F[O';!B?NFIU5-3\'_(1 RO0,L-2F
MH/":@=)'0M2E=-WHQ$T3M/$=\W,J%N=5+,XJ6YS>U&VSD]<,CUYXM/^2SD%5
ML[/:SVX@$](G5VZ;G %$NV%V^JS.(77;JZ&YKBT]I?UHE(@+#2<:BUT"BN5_
M(\6B-G4%_='X+!.Y GD?FUCK&%V5 +GVS+%[YCD]F&E!WQRG?Q[9$G1/MU5S
MB'Z)]OK/56[KG[JI?P)H[YS&/J"Z&_I*&D^N@AY87WEH<TW_E8K!:U7,5!2V
M.:)L<D;WQ1W V<=N#RW=M9YX/GKL^M#HS;U'F&GL+<,3<(3#-W\$"CQ\\X>C
MMW_&!CA_.G#M'WLO_]?^JW^#$L2X*CN/ $K>W77RP=X3&GM/:OQV6G/?:<W]
M9Q[N/Z-YX+SV(:#;RWK'+N@<.:-UX(SVP8OZ1ZX:*5TQ.'Y&8]_A6S\>OO$#
M' 2^Z-R#?>>Q<X9OV7_U[WLNP5?\';[NA.JNDW=W*ZGL.G;KIZ.W?E)2WGGR
M+O#H3E@%)X9[40!@/81.$AUM/YS>I?_Z]<+_VGW^?^X\\S]VG?T?>R[^+]CR
MT/4?#E[_^Z&;__OP[;\=N?7/(S=V'KVQ3^DVHMAS]RZ<O7OVR(W]1V_NN&UT
MV"W&N(*5U#/5+%\4 <6B^3W;%/M%_9L4VXM1[*9=+,#KN@<#++CTZ)IH;$T\
MC$8W&2W=I;G5D5#?0S.="YH2!<.U^%PQ#&%YPZMP3,X 4.P,73Q6U]Q5&$_V
M_)<H%OY0^(LEPTU5C)S8'&^78*OG[OK6CII/G+1!%J\U+%X_L'%^]/B-AJ&=
MJMD;#;>(IX3J6/Y@/9 K4"RR=EU"Q@-">2/P*Z!J>)9[7+Y_>GE89GE$(CDP
M*-GQI9^)WC/E^^:7M:QO0"4UM+MK\%Q5_[FR@=T=D/[SV[ $0L4%'_4P;\JX
MX.EG (4O[J@8G58S/><<^KBR+:MWAC&PP()KB*/_( )9-"R-B8,-RB(-*;@H
M]@$6_@!-[<+,":8QBH6_K&\%*+9#JI".*.2],Z):*2&,\<2R[(PF:8]>WB&G
M,E5*>_#X<NOJFNS=VCSRL[5-L=MI.WV/]+TH=GE",0L46_05BEUL'5*L4^S8
M?PC%?C@'Z^.C?>F 7]*G1_@&(8J=YXZO=DAG.)6MV6[AUII65U0,3ZF;7P"<
MA8>[R>N[@+.6SAH@"\?[5BX/;=RU'SL],'ZE:OCBCN[3&^IFYZ]I';ZD<>"&
M[G% M#LFIZ_I'[]J 'AZ\KKAB4U=U3]^4>?PQ4?KNJ1S9%VZ1Z[H';UJ<!RX
M%MOR^'6C8[B 7R_J'#BB^N,OE_ZOW9?^IY+JSFMZQU3,SMTV/@4[7H"#Z!\[
M^^C@@V?7WV8[-[07=,VT8*WRND7!R#=3[.B2>'RU?719+$/FL%QH<8%BQU8E
M<FQ:], B7[HL! TN(S\^T'8.KXCZYM@5;3E.;ZUNZYXZ>.6?^R__#:#MX(U_
M[KOR-R \8#L<]0#[  =/W?L5Z'/OI?_GU_/_]\%K_P!&/*WVZZE[N\_>_^V*
M]N%+6H?.:^P'77BX_]R#WT[>VWU<>0<@(T D+M@7#O7;Y?_:=_5O<&3$M;=_
M.GCKAZ.J.X%B 6%!IQ[N._D0,GM//O@-R/6BWE$0<.TQM=U*#_:<TSD$%'O-
MZ,19S?VP+TZQI]7VP D R.*#K(<P&(4E?.-9];U MTCW?X,\$F3N_W9&'0V[
M*JGL/'X''Y3=@73[YR,W?P2BA9]VX.K?X0J X#CH)RCOPL9B?U"Z^^,)9%&P
MY_BM T>N'SIR]>CQFTI*MY0.7-ES\-J/-PT..D<:E#$2NB;I&,7";?F=QF(W
MYV-]K*T[_JOZJ)K_Z_7T8WU,L2L"9G]%+-G[F9^!6[0-A9FY,;L+LXM%4S.Y
M<LRB8)-BJ7QBQP0-R!6?IX]3[,@[(5#OH((C'FUJ$)-)]7%)10&II<$E+:FP
M%X[%^.1]V0H/4:RBK1>-Q0+%%@#%VGIJ.08;Y]='\T:J!S&*'5Q"#A ^3[%+
MB&)%LH:*EBR@6+>0)R^]C)ZZZ#QUU7GFI@?\"K)VTM*RO';UX=$;CTX\=M("
M-FWKK<3=$<B@)_ .F18P>BNS*Z,"DQT#DAT3"X* =(DU<6FEH<$I3D_<=90-
MSIQ7VW]%X\A-W1-W]$_?T3]U1__$;3TE$&3@*:=J=!ITU_@,RL!'K$39X.2-
M1T?O&)R\9W+VFO819<-3KP*,B^G)G1-TZ![ A<7'6;%'#0L3&S.'Q2A6P0.*
M!7A%4G!&%-SQ>4#8K10[-*(8ZYL5UTESPAB65F5GM$B_Z><=<2J]5RX)&EMN
M65T;VJ;8[;2=OF/Z/A2[N+(\KICIFN@L9F>Y$\W,TTX;D7;]YU/LA[MOU=:C
M?47?^D4?"#4J"_R)=YTC"A&CHSP^W^=U@#$RC?4U@,P+7X.7?H9O@LV<0BSL
M@TRAQ/&MF5N$-7Q\Y6]DYZ-OYZWWS$L7MG_FK?<ZR-0QW/)UB/FS ,.G_@;/
M HUL ]%[?UQ/ PRL?76M?7Y'3WQUGO@] MGXZX L/#4>V%X^K[WOQ+U=%S4/
MW#$^_>#)58VGU]2L+ZG97 %^5;&^J.]X+RC+L:@EA=Y5+!RMAY9&AJ9V_3L4
MBTV4YB W[$M"Z3RW:[*U?1S:Z6;)1 NF9OC8,='2.=G*E]7GUR:\\#&^KG4<
M*/;0M7^>4=][5>?H9>W#P*.0!W(%YKNH>?":[K'KNL< 57$<O*1Y<&,*U)X+
M#P_<T%<"H;6($?>>QP9'D1[L^W_9>P_FN)(KW_,#[.Z+C?=B]TV\&4U,Q.[.
MDV:DT:A;ZI9:;=3L;K9W9--[#Q"&%O3P( &")!P)$(X$"(^"][: @BWOO?<&
M5?"N/+ G\Q9 $"#95*M%2J\KXX\;%[>RKJN;F;_,>_*<381@.WYE#U (2_CW
MHSVO?[CW]3_M^<TFH-5#;P*M?GCXS0\.O[GIT!OO'_S=^_M_^^&A-S<?_0-L
M>6OGKU[?\J]O;ONW]_:]]M'A-R'SIKW(,@'.#8[^'CY#.!9AV_KA;F#HW\!I
MP*'AQ. DX<R_/OX."%8^.? F7-UGA^ "D;T!Y(2S#0COBM"[W_T23O(=;&F
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MJUNHG64"^P;>)^ 'S^86VMSKJX7U0GU@(11&*(#F>4';:$G<W? +-P]GEL?
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M?W;HCUM.;(J[=YK,K=7/<AWX88.>U5]*L4_JL?N.9WO>^-L1-JL@#&'7"6>
MC^#^X%N$WTC(Y!/T#G;5S>*K<??/ F!)QVG:>9X1GCTH1(!K/N3:S.J#%0G(
MXA4C$^H5CQ8F-]+J-$'@3B+TL<V+' L@EG7QD)P!F5;#9SAYR#,&'HL%B@76
MA&<2NEA L8"P@;'8/]^B +_0!XJ5&Q8$F&(OPIY)Y!S5%.V'4*Q[G5WL:CR4
MIU<[%L+LQRN%+JMBG%[=DW<F_M"ND(]/Q>U^T)#<PZX>D77V\!K7C,7>Z>0A
MNUA,L7> 8C=M?_N=+6\<NKSC7N.-%MXCBKR2+"CK8!4_Z,I,K(I-JH\I&L[L
ME=1P-'U#@JZ2GH=72)$'JOZXH^&?]K?^MTM]KS5I;L /ZEM>1 X*D&,"CWO)
MZ4&FL4&*#:9@>GDI2+%_-Q1K7YFA/^%3 ,6RE%WW*Y.NW@K)*HD=$3>;%P2O
MEF(5$_0:<OZ%F\< MHI;TOE&"C*[]$BQ!ZYG>6;]JU'LL@I/@4+VHZ9%(4=/
MKNS.B;]W.CQFSY7;H16=V4"QA*E#(%@#'GE=/3'TFA*/Z:JG6&W4TKB[I_:=
M^7)GV,<[PC[:B?3AKH@/=H:]OSWTO>TGW]^+@?78I6^/7]D:$;?K[/7]9Y/V
MA5[;!EN(">.P/!F[,S)A3V3\[HCX71$)N\,3=T<DH>7)^)W'KFT]=/GK@Q>_
M/G)ER_$KVTY>VP7=@,BX?6$QNP$BMYWX\/-];WUY\&T@4>#:T*L[CU_:!E +
MB'GP[-<'3G]UX,Q7L$+HP-FO0.BCM3J/E@<PC#X6QE8D(%1$JUN.7?SNZ,6M
ML )+$!SK^.5MH*,7867[B:L[MIW\Z+UM__FG;;\)C]M7UU^H=-#MV"W&^H?G
MIT>QZ,*=8KN;T-,IUNK$%.N3*:>875S2[=+8I/P+#2./Y--,'0XP@0//2@E9
MO(A?L41FPH3:+P99?4@K$8^13^+'GHF)$5F 5SPH2YBZ!F838MC%3J_$ZAE&
M_6#!I5M'08";4OL0;$<^W7Y<BL6SNWX(Q:X>=,4R>XTGOJ<(/H5""B5=.<&H
M[LDG*#8R=E=A_8UN5M60I+V+75_9EY=3C^QB2WM2VSD/N@6EK:Q'>8VWP^*.
M;-K^SI^^^_V1*[ON-::T\LKZI=4]O-)V9E%I?W9&>VIF3W(I/1M:J!%)-YG=
M5M15<+DF["#IK1V-/]O7^G]?)/^V20T4*_$MS^' 74MH+';)[5UR!RDVF(+I
M9:8@Q?[=4"SAA8 8CH5[PM.2']2FQJ2%93V*&?W;H%B FVMI89=NG2AMSQ*8
M* %?C\C!$Q$[8&.LK+\.Q>+@M]"V$0,YFAEV.[T\)C,"B&U'Z.:(N'T/&^_P
M]/WH9:@'6?1NI%C8:,4TK)WFM-/*8[-.[3_SU=Y3GQTX^\6^TY_M"/M@1]C[
M>TY]M._TYKVG-Q\X^WEH]/:HE$-Q=\/O%%^^3THL;$C)K4FZ6Q$+ZSFDA,RR
MZ*R*V!Q8KT[(!I$2[]4D$+I+0LJIOY[7E%+0G/J@Z?;#QK2BYK22MDS0?=*-
MZ(QP8,H]D9\!4,(EW*M,+&I*>]!XNZ ^M: N-:_F9G[M35@AE _+^L"24&'#
MK<+&6["$;+DU*7DU<&+)H#R\CE2; MD>-M]YU)J!U)(!/1!"<!H/&^%\X*/,
MA\UIL?=.;PO;O&GG;P]?V K9Q.8A._;OMI9R?E(42\QL6[U>AR>@YU"L8TFI
M7^#WBQO3*Q. 8NN'BV53=,T"3[O(UX%PR DM"IS&USMY2"Z>P<-'[BQ\&&<Q
M8JY0++8!P(XO".?$0*YZ;$6P8F_ (=P5$W$WB/S*26I-W_WSR0<OIAZIH^0I
M)D:!8@GO;S^,8N'?,1^BV$YF1>H#1+$_W*)@S<#VVJ@'SZ=8- ER60653U5W
M[NFX@[M"/SZ;L/=1<VH?KW94WM7#;:SJS[_?D'BO-KJL]U8']V&/L PH-K<^
M]63,X4W;WWY_VQ\.7]YYMSZYE8M<R?;PREH9#XIZ,^ZT7$_O3BP:S6Q@E/6P
MFMM'&Q]T%5QKB#C2\,[.IG_>V_+?+_3^%ED4>$3>Y9GE)0_R@K[D]R$W!5[D
MKB"8@BF87E;Z&Z#8]K]QBET=7'FQYOF%*=:Q8<OS!<0PX5-8%H0@6!?J*8\:
MTJ)OAZ8]O#HD;,04JQCW*G!FV0:MW]N/2[% D/)Q6AVE,"8CXLJ=4*!8GK$?
M\A,3X8EVB'AQ_^1.OI]BGW.7D./]IU&LW2\?7T83^?%8D5 ]S:KMSX^(V_O-
MD?>^.O3N\<O;\VIO<G1D^!3.[:D4:W2B+?"I;I;;SV_(*D^XF'KBRNV0A.Q3
M\?<B+]P\=#II=]3- U?3CT9GGHC)#+V>=Q8(M;HWF\RK9JC;.?INIJ:#KFJ#
M%;:^>U3>/*IH9JK;X2,Z2-M)TW4$I.T8U;2#:/H.IJ&+K0O,T.(:^@2F 9JB
MO:(K.^[NJ<BXO='IX:5MF0.B1KZQ'S[B&RD\0S]'W\?5]\$*(?B7K>M]/,%K
MC?"T+3)6+U,#I_=XXA=LX9GZ1=8AL748)+(,P6]'S/V"G<.-XILH\,6JWMR(
MQ ,?[WOKP+FOBYLS))8AZ#5-^.%Y^PE2K S*B&5!8,4^_Z%43OJ4DWXD6!]?
M>]I/H]@^4>.MDNAK69&5??GB"2I0K,X9H%A 6*U+8' +C!XD _(HC->]2"A,
MAB<PO+HB%$3#Z H8#Q &LH11+*)8O!VS+ ]R6MQ\H-A:2MZEV\>NIH<T#A6J
M)JE L:9%!+N$IZT7IUB"+\>@BO,K='/<-EII<D%4_+V(FOY<[2QS?%EN]>&]
MO3#%KC_0AGIFHZ R(8S@979J14=V9,R^7:&?7+AQL*H[:T36RM8-#(C;H:OP
MH/5F?E,B:2"#+"H=D%5W<,MR&VZ=N';@3UO? HH]=&E'5EUR*Z=R2-DT)*OK
M%U>5#V7?:HI/ZTDH8^:T\^L&A;V]K*ZR@9*$CG,G6M_;U?(O>YK_(:KG]09E
MHL4E\"Q-+OM=RRBH#[1K/F0?&Z388 JFEYA>&<5B3UOZ-CX)13VH_CBD];53
ME)_G*K8P9W,,'K+%3;=ZF38OQ^Y%#J0<'B!7W9@+I!USJ\?<BC%<ZQ%"1E28
MM\;6A+,*-*Z$4=J*:1K*CS,3WDFQ 1:"O#&7'/N@56 ^1H(M-D2Q2H=7M2)8
M5]@]"N3Z<>7H"*3PR,'JR00.$1#ZR(Z"?A$A"0+;X2LX[(W(BLX*[P$+OHN;
M<,@L1R=&:(6)Q_T*:"9-\P+#+->R*.3IR,6-=RXD'TG./3\@J#<N\.%PL <K
MD*)3N$8BV$)<N\,KM7L#K04Z ?C4)43YD1X[,R?.9/4"47.%VB$DBUMD1@Y$
MGY#-*S$Y!2+K8'GGW4NIQZ_<":GHSN89*18BT#EVXXK>W>/(7H1_QX"9[%J*
M)7Z+-4+7XA1;G'#R< _EXQX%NBTNX&^$$<#KXUZE';G6(IP,($$3BW9%A+?U
MH",2%%M'*0B+V?W9OC]\NO?W0+$/F^[PS134!OMD0*O(BVV 8@/NV4TN%&=H
MS"LU+O(!*-OI%54]N=4]>?64POJ!PHJNNX4-*04-R>7=F37]]^'?1VWI=0,%
MHXI6S0QSS >P(K-YQ3:/F)@Y;G4+07:O> PVHA?!4IM_13Z)V2,R(HM&OADX
M SG@7'6J)8=[U<>ON_,H^AS\ROD76ZEE'$.?8H*AG>/JY_FZ.9YFEHLCI;%!
MFAF6:HJAG*2#%!,T^01-YA@%2>TCL(2/4)Y9EAIG0QG&J;)Q*BR)CW2PGQFT
M$^T,2[.J:909?33+Z>61KF6%?7K@#WM/?U[2EB$?&P&$16.QZ[I Z\K"BC:"
MX+/D<*]$I%O_T;H]O$+)H#[! >20G^:I)14(\:M/#D(SDU9K #?APP%*)?)?
M!A2KF>5T<:IO%%R\FA%.ZB]03#$-T(]RB0R+0@.>VF6$(A8P)Q";O2)X/$P>
M(2$S"@*'0A*L%7+BYA*@[8@7 __"<PN"QQC)"2#+)[8K)VGU@X71&2=CL\*;
MAA^J)ND./W3D '\%\&02>P"MK] >.XY%%V+!#IZ1@01^H>_P*^#Q:!DMN9%W
M/NY>9$U_GG:6-;ZL0/8/:)^$GG#EMJJU!T)5S9I:: .S!HZ[1FBW1&$7VT9*
MV[+"H_?L#-T<=>,0]"='%1T<P_"@M+-NI*BP-26O)9$TE$66E \H2!V\\OOU
M-X]<V?OV-V^\N_6-@Q>W9]0D-;%+AA3U5 5T.%MJ1@IN-42G=<54<7-[I2U4
M^5"_H+]RI.QZ[]G0CG=WM_S+WJ;_<;'[#\V*ZS87W[LTM;SD7E["LY:7?'AJ
M5Y!B@RF87EYZ-13K6UZ>]7DT4[H63E5274AXQ:;0MM^<'?IE@6HK>_ZNR4L>
M\S)L/IK5Q[)YA3:/S.I26IUJJU-K=6EL;K7-K; %AN)P/;@2R-2&?:FB$1'<
MN%H6A.8%%*W4-,<WSO%-"P*"JXCA0%P#2I&[>"\PEM+B4L*>QP"7O5I86IP*
MLQ.. O_JL72PW>[3./QJNT^)3HFH6W'D5?QF#6/0.@%=N=%KZW&?PN%#L^:)
M^0KP$0"6 0>.0N %-;(3S?:U( ?[,F ^-&\&>3^5$2,-#JQQ[ D?K@+/NV<S
M-9T/&V^=2=J7F'-J4%QOQ ,JQ&2.5=LXI 4D:*B@<7+XI X@)V@7G7!HE(UX
MYXCBFZ\[_\>-!VH7UX1"#4P662NTPT4>ST!^V)AZ-FG_E3O':_IR^:8!PR(*
M<X!"!OB0*P#] @_.')@2ED;X+?"%K\J&6GWD&1[-?,=73;SN!Y(#W(?NQ(1/
M/>%3V:%WX90Z7(HIOV9F63>YI(;?PN3")+HR@<:ZX@+6L(@"SVIFV/4##TY&
M[_I@^VL?[G@=5BJZ<J3V470LKPS?>>*2G[A2*S(E!#X&"&8"" K,@QQ]/S&*
MR=)V#TF:@"_IJDY@W"%)<^-040NU!-;A<#B^@-SNPR/Q7BGJ.:R9L[)1 =8!
MX4X(\3K5ANTBX.&AB!MO/;H6GK O^MZIBM[<5GIY![MZ0-HRJNZDJ;OHFFZ&
MM@N>!!!=W4Y3MC'4[?C?#OB7JFRE*EI&Y<U4>3-L9^NZ6%A,;2<:%5:UT; 8
MF@Z6M@N6-&7KJ*R9IFAE:>&Z>F C?'=(VLA$__:V,1Y%WPOYXO#O#T9]4=5]
M3SE.)<P)B%# WRL"@QZ#X,;W'M^KOR6013\3CO@ %(O)56K%-C.X8Q8HYNL$
ML.584B@FZ&VTLI3\BTDYY]IHY5 0X &&A]"X$A/DR=+WI *=S*=H+?81YJKK
M1+RL4$XRH"Q<2PN+R8QH&BY63[&@2B&ZE(1=$*&U1WGVFQEDM$J8I>IFN2VC
MI<FY%^+OGJ[M+X 2!Y752F2^@+OEOTR/N[MKA.[S6HH]>6W7=R<VG4G<5]:9
M-2!MI^L&^\1MI.'"^RU)V8UQ%0/IW>)2LJRRE5-RKS[ET)6];WW[YCM;WSQT
M>6=6;6(CJY BJ1R6- P+.VH&'J0U7,[LNE+-R>F6- Y)![JYO:7#14D]X6'M
M;^UM_MG^AI]=[7B_4W%SPL/W+\\L+_M0#%K4ROF1@BF8@NDEIE=!L4M^[_+2
MM->IFM TL2KBJX^%E;\?UOYZU,A_%*J_8\UEFKP]-B_-XATU>>B(DQ9%YD6Y
MQ:FQNG0VCVX,*-.KPB[N Y[;D1-X_$X9ZLT)OW+*KY[R*AU0=2XBB@66-<[R
M]#-<X"'4S'@#;0R*480\TBLPE:HL+I75I;(!Q?H0Q0+"&A<!9-46I]:TH#+.
MRTUP#FZEW0<4JQKSX"-Z)&:W&"$4<LRT)LS]HC @V$BT$+C.1=4Q\F8*AR:&
M(O 8)#Y_*PY_%6C#5O#.@E ;GV<@_)*"\ P%N]7/<QG:S@>--T\G[DFZ?WI4
MT;SZJA%!F.NQL+4<V[#(!2 ;\XGM/C'R8.K$[G@65RWG!&;L6VI5:X@6UI^@
M6+-S53Q"0+$6%U]DI92VI9V[<>#R[6-5/3F = "LR@F&?IZ'2'$1S?$R+.#A
MV'F^&?VF^%CP&Q%"+3$:Z4&C5E[4WH,0R,()(%Q0C'M5DSX-+.UNA<.CA/7I
M)=W4$OQ>\+N@_1,@:T%V!8A]X4"Z.?2C0U-=VU=PXLKV][?^YX?;?QL1N[>J
M^[[,3B5P&?(_G6(]Z'99/$)L<2B ,]?,< !!T%#H#$<UR81+LRR*K8L2D66(
MS*L%2<=&$48CWT"H6[5JLQ$8:EH9T K84P:$MZR.>#D?&P7:_3(34*RD"2@V
M-&[WN5O',ZL2LZJ3TLKC<AM32[NS20.%]2./6NEE7>SR'FYE#Z>RFUT!RSX^
MJ5]0TR>H(?-)O=RJ'DX%9.AB5W1S*B$;;.GE59%YU; $P4;X"#)TLLH[F64=
MS#)8=K'*85>-0X6/VNX4-=^JZ<]MI167]:1?O7M\YZD/SZ4<Z*"7ZF?8#GR-
M/TV*M:^\]AES2:WX,48/"7[)0(#L8WF15EE6:J<"Q=Y^>.5FX:5>-LF&@AM#
M;QF%.WY<[M8SW(J"%/MLBBUIRPJ]NG/+L3]%Q.TJ;DVGB%L9NB&*K+.>7ES0
MD7*_):%J*+-75MZOJ&[GE>4TI1Z+.?C>CK<W[7KG1.S^^TW)K=P' [**$4GC
MJ*"K?K#H7LNUW+Z8>D$!&3IRLL$N3N^CH0>)W:$GV][<V_1/!^K_.;KC@Q[E
M[6FO<&EY=@DU;$&*#:9@>C7IU5"L9]D_[5E436J;V!7QI./A%9O".WY[?OA7
MA2J@V"R3M]?FI5N\5).;;EKD L5:G JK"^#2X/ :'#Z]PZ]Q^)$7)P>*M"F'
MZA*QB(L8]51.^]73/I4#:MM%%.<=6AI8&N=0N&UH::#N0W:32R@J$BP=(.33
M5&USJ]&(KQN(5FESPXK"XE):7$"Q:M.\PC@O-3FA4D:907:?@A@K156_![4N
M3Y+?8Q%-&E$7KQD##@PWHBHX$$(I@+;$("*1#;8$2)V@6/SR#HW4(O=5(J:F
MJZ ^^53"GAMY9QGJ=L>2E AVZO"C ==5 8V97-CNS2,:\TD0Q:)7DP%_/02N
MX1>1C]L,8F1T1;"^.BU:-(9?BZ\3BK#J$\O'1RJ[[UY,/7+Y]O'*KFR>L1\@
M4C7%A*4)#SG;$#6BDX=+ ((D?K)587"76G$S"9>,XZ^J)Y948X#X ':+B'LF
M?>HIOQ:!++( D=L]R*/6Y+(*>!?=6W2WT7<#70+<G8#+T<_Q2+UYA\Y_\Z<M
MO]Z\\PV@V(K.;+%UF&B#\6_W%(I]#.YN-* +%$N0,4)P]%N+X#PGE]26!3%7
MW]?'KQN1M0(3H*,3H;"PV<:?+<*&$C\Y\(L;74"QS7=*8\+B]YQ-.0(KF94)
M:65Q=TG7"YINEW3=J^K/;QHM!A(=%-=3%2UT91M-T0I"*WB<%3:.R)H&)?44
M4=V &/FU'98VCLJ:J9!-B;/)6X;%C0.B.OAH5-X\(F^&G!V,TOJ!_$>M=^Z3
M$G-KDHK;[I1V9MRO3XS.#@U+V)%6<@6>-ZM3&!@Y?M+3UK/TOQC%0JV"36#E
M /'&.9X1/17X\<,#_*C HAZR? R5<1P<V$\$!Y9#+ZB+595>$@,4V\FH-"T(
MB>*/^^$K]<9ZAEM1D&*?2[$A5W=\<_3=D]';"QMO]?*;1M44LKB5-%R8VY)T
MKR&FO#^M4U32(ZEH8A5GU28?N;;O3]O?_F#7NT"QV8W7FU@%O<(2"H]$83=7
MD_,S&J_DD*-K>7G=XH8^ ;F%UOZ@+R^^(R2T]<T]B&)_%MVYJ4>5-N,3!2DV
MF(+IU::73[%HW;N\-.MU:J<-K;SJI-J0B,H/P]M_>V;@WW/EWS!F,DV>GC$/
MW>JEFCT,//@G1N_W%P$H-7A$5FUQRU=K1JB"C0L"W1P/:E(#L@V5HID67@4T
MKJ9YOM4I(J9<V+#34/1ZV@W4I9Q:UDPM:<9]B'[,R-)+;O.H;(A<Y6:G%&3S
M &QI'%Z=W:,;<VO&W$"Z*KM?:5]"P>O1V"JNG=&,(E=@Y'4CR.(7W*BV-2.G
M3E#C*VQH(E0 &=$X+N#1/#(M@!6B4D90M1@(=F7SH49B538<B=2&I^7"M8S*
M6P R(N)V7<\]0U>U.?P2H$F['WE_M/LEJ\*AS .#BWBR1<"U) +9P';TT<;3
M7I$$F7@2"(OW/(8%*ZN@/+$,'0F1V#90VIY^X>9A@F+Y)@HQ<0H-5.-+1FSJ
M1VR*O >L1%5=I5BBK0H(GX/#NQ)MU26U+B"0'?>H$,5ZE/"O<59@FL>>!/P*
MV#/>"0)EA,@89(EG PX$M[>R.V=OY.?O?/W+CW>]$1F_KZSCKM \"-^%]H_@
M762*ATX@0+$$X@<HWQLX-S2\B@'%CJQ0\)0UIUAJ&Z4(&[I9U715)^ RX:06
M$_E?1K%X;IG))1J4M::5QP'%1MTZ#N3:,%+<QJSL8%?#L@59%U21!;6 GGP3
M635)T^/ I)IIIA9$6+A.,Y235)EC6#8^HI@8A3R:*0;*,,/2S[(-LQS##$<S
MR5",CT(V]30=\G"-O111;=/P@]K^7%BVTQ\UC3PL[4S/JHJ.SPV_E'ZTJ/46
M\M $S\8*FZZ_BJ?I?SV*1?Y 7%+SO  HUHPM9R;\:NA%!QX29%@"V(JJ"TRQ
M:!T$_;I>;DU&:6QRWH7FX4>J*19Z"T&\'0HX]-C(<"OZ\RG6B-^!$!UCV#,<
MO7&P*#H]/#8SLFFH6#7)1(8KB'$QQ2+#=Z1U1PF\,5AY2[!:3JVX1""*G>.V
M4DMOY$9ABBW4SG* 8A\7YPT42Q00HH>_5NNR/:G'!R44. '<0Y", <5FGKBR
M_>O#;Q^_LB6W]D8[LZ9/W-G")#WL3+]=>3&U_'Q!^_5Z1FX3J[!R,">E)'K/
M^6U_^.9W[V[]_:'+.^]4Q50-9[70\UJ'BUH'*Q^V9"17GKG3=J&,GMG$JFBA
M-E?UU>1T9,6T'@MI?@,H=G_]/T=W?M"K3I_UBY>6YY"7K27L--8?M(D-IF!Z
MV>G54*QGV3_K=>EG39W"NN2&DY'5'YUL>RVR[^=W19\/V5.5LRVZV0'M'$4S
M-Z29@4:7HY[BJR:$RG&L";YB@JV8@*:7!I([:#('#6HQL6U8/D[3SW*L0($+
M0CU\:X*AG6+!OVC6\*J1I0M1[.22>LPMT\UPI6.CDK%1U12;(%>K6VY:E!@7
MQ6,>:),T=H_&M"#738O@!+0S/&!E[1Q',\-23S'1')IQFLP.B$"%<U!.,-13
M  WLM=+.<(!LH(I73[( N7 @*SE^/8UL&RQXPA-\2S%.AZ4.3=GAP;>4$TRT
MJQD4= J$=C6%!$T.'$N%<\)I]W"J,DJOA<7LB+\701'6ZN98^GFV9H:IQG%Z
M5@7_JF<81+QU-?X7;R36\:>$)IEPD@&AH[-7!.OHNTBS3-A/8">S#.W*=CBT
M:HK&U'04M]R^?/O8E3LGBEO21V5M<'/@/ .RCRK'Z7 5<$6P?]DXE?C)8+DJ
ML6U$C#>*K</P7?AUH)U#<V7<,D!8(%>'6TE0K&5>K)OBJ<;AAJ"? +XBM R*
MK,/$L22V$9%U2& >X!DI0*LL;4]N3?+VD(_>^O(7FW?][E3"?N1"P= /32.T
M?V8W\287:ZWAQ&.0A0X&M/%X+!S;.2 +$+<$?EGX.6BJ#C*O=E#4B,(HN!!2
MK[;3&U'C^_5X+%8$1S&[)</RMCMEL2>B=YY-.5+<D34@;1:.#<LGF6([E67H
MHVFZAF3->""VF6?HD=J&X#<U+' M+J'=![T:^00Z6RF:7K;B(7_,*T93@IP"
MTR+/M, SPZ.XR#<N<(%?^48R0]U.C-W"/AFJ=K%U #HG ^)ZH-B;1>>O9AV_
MG'&TI",-L#A(L5"E0-V";>YY@'?HW8Y/99P70CE%4^)FN5!.M;-<*,BH+,\B
MJ6?8/&,_ -^=XFO ?$"Q4&\8%@0(9 F,^]$H%CJ0JT(]2>(C]32K<:@H.N,Q
MQ4(10"9;+H)B5TAQ_6\7$*+8 '&N#,=ZI5 BH.)JHY4EYV&*[2N ,@YU[,KY
M;*#8M5W]-=L?H^T&ZEVSGS5R87^QR-.6$BH!*-1 L5\=>OOHI:_O526TT*J
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MROF0O7LOO_OYV=>_NO#6@2L?'+KV$9PXD#?\G"JHZ!#7MO(K $R!YD_>_@(
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M3"G;^ZHO!!_X^?O_\XTO?Q*9?4-BZQK%8?S-HR+@,YZ.@D;,)V2 +'X42C9
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M9C]W8*9O9$F.30B4S@7%\+QB9!$05N->QK""8C?B>F4)>3RXYG3#,VKW C(
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M=U-B:2-Z7U"]M8CQ8ML5^ 9Y-ZQ+MVO[F7Y+C1+MAZU+EDP$M0=._^M%5,\
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M3UY]-+VOEJUN[U:U=<A)%9WI:77WZ[EI?8Z6'DMCF[0\OR7A8LB)M_?M>NO
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MV5?7E67P\$>7+=X%X\@<LLQQS<//B<0'1(,?EX&+.$++HA%@T3XAM8_#RZ5
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M/ZBZY1VZ(RCZ6.-('D<W@GY!5HY\D8Z<M""[E/48^@?J3T6Q<*V 8N$"0D^
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ML;$KB<HBT=JEDS/L3G)#=.;5J\F!5;UY/ -)ZYC4N\0:NTB#C@"((- XX.L
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M"9 Q!@V-6SLP<X)E"^._08HE\MN 8C_9\=M7/_[9UN_?#KU]JJHCDR4?TEN
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MJJ*;(&P&WA7-$.&*X>YIT7P))Z)YKFZTL#GYVKWS=PNO=9(J@&+1E72B28W
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M,E.;86EXVCUA=),T3K+*1D.CL Z<8E'X\C^(G_[<]",I]LW/_OF3;W_K=_E
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M53R'G R(9\F2.0I<0[F)CCD?((OGR9)Y"N0CS7D$.1YAS@KP3R78OE@^6;Q
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MJC%^9MOI#=?_\D/F<PNKYFUM??VJ: EW)%9O XH5:RRRNZ%8$D_ICTIS([,
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M^U7!ORRN^9_1G2\V*<Z:["I2I 9^I.TAB@U9R!Z)A2CV\;* DT8HUN'$:KA
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MMW\H^6UX]^\2ASYE3:98;%JW#7X7K0Y\-!2BV)"%[!%8B&(?"YLCQ9JF*98
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M*]NWI[Q_].+&E)P=X/2\7>#4*]O!:;D[4W-V@&$"9J*G>'[*\DX&9V^+&N;
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MF@B&$,4BAT/(-,C2HO4,15,LK9=!D:=*L2C_CD]L]8HL@+ S0D"0T:!J>M8
MCRQER_7R,^E7=E^O. L4ZPXK7E:*=:*X6)G2,UC157CTXH;4["V-_=<TGBY/
MF.\*<AT!'DVQ2YHJ$( X+Z1P8HJE8F3-,T*Y<["J^\;NDVM^\=&K/__PV^_M
M_*_UQ]Y<?>#WJ_;]=M7^WRTPS,'^:.]O/MC]*VCYUM:?O;[Q1[\!0EW[&OBW
M&W[X^N8?O['M9V]L^^GK6W[\AZT_>6/[S][:\9]_W/*3WZW[_NOK?_C&AA_]
M<?U__&'M]_^X_OOO;OGQG[;]])TM,.<UH-A?K_K6X0MK6SEWS5[.Z*S<2@B,
M,QR+GV\G<:&-%5,LW\2\5GEN;\:: Z?77WF05C]PLYU;TC!XJZK[:FU?4>/0
M;<I-PW>:1^[&W,J^W\$KH=R.'7O:R2^E')L3F\D0E,VY@B&HC'<GOZ*37\D4
M5'>+:KI$U92[Q34]XMH>"7*OM+9/5H,LKP5WBV&1TC;. W KYWX+M[254];!
M+NUDE[3QJUJD+:V*1J:DM%=X=X![OW^DK)?=7#/8D-F>M[=VS=J:K[U?\S_7
M-GX!4:P)]\4BBO72%$N+UO,23;&T7@9%*(I%&(LHUD^$?8AB?6PS)Y=Q;F?9
MVS&*3>K_087Q@.)1%$N-- >$-4[P]&,<ZXS($U3"_$%I0T')R=3,'=?*SO!T
M':,1.)U++7Y!E&)Q^0/4K?4R4"S*<B]S]I>TYQPX\\FQ"^NJF;ER>YN=8-G\
M8*[=)Z2222429Z(?CV+1JW/QP3C -Y%''\^/\Q.LA&(I_G,%E9Z(VAU6N8(*
M>",43N 3&Z?X0DM/24?![E-KWM[ZBS6'WSR>O>WL[<,9U_:E7]V;<75O:OZN
M5-PCN\"X:_9$SO9CV5L/9VXZE+GIR)4M)_)WIEW?EW'C0.JUO2<*=A[/WP&/
M)PKP8][V$SG;4O)VI.?O3@/G[L@HV'GV^MYS-_:>NKHK^<KF#4?^\,:&'QXX
MN[J%==LXP_+,RBP!GGZ*99CF6E" ^'Q0P=PGPM6\X' @94"Q5.X"0%B8YAD9
M^:6G=J>O3LK:4=99(+0P]9-L]=B0W-4'CU2A.RUX8H1*DD ]A4=XB7)L_GR#
MB1'-^# L'C,\76B69IP]9XYV@J.;Y.JG^(9I@0F.UAD!99-7&&<!E>.9LG&&
M&]VVB1'T=I,<+:QAG&. %4X*Y%ZYPB_1>T?,DWW6T7Z+<\3LD7,L@CN<DF.M
M6S;4?P/UQ39^(:/WM6[#E7%"YR?'"!)'%.#8?#JB@!:M9RR:8FF]#(HL1[$6
M3A[S_&-0+/"3&T[5?BE0K-;#,DWR88YY6M CJ+YR-R7ITK8_$XJ5.OJ*6[/W
MGUH-%%O%S)$!Q08PQ?HX=K_H&5#L?.,7A&+QX"?5Z*QF-*(!BG4&4+^^Q2O2
M3W!Y)F9I9^&)[!T LA=N'Z\9O-DMKV5(*L%=LFJ&N*)35,&05%!S*'>"42&N
M\E9^21/W?B/W7A._N$U<SI!7,Q4U,-$D*&X6E#0)2AKY#QKX#YKY#UKYQ>V"
MDG9^21NWN(WSH%-0W"4IZY:4=O#N-PP67;Y[9//Q-T]D;6KEW-%/#7MFI5:2
MKT<I"]A >]3@K02*10G@8'_ %!LM2(LHUL#(+<[8E?9Q:LZ>FMX;*L\03M>%
M<GBY(_*)6<WXK'IT%KX*)94X%N6.Q::2M5$YN6)V@/',I3S?#'<8XYCC:/"&
M I#:2?5\HXDEC;*(( <EJ)0)FD9Y<Z-)Q\(*9UCI1FEEY8ZPQC1K,LWJG+/B
ML3!O(L"?\$K'_";9F*I,4I/*W+6Y\=L?U?_5NL97TGN^Q]1GC?HUOH G$)BB
M*986K><EFF)IO0R*/%6*M?NEKH!L-*AT$W+KC,@\)0!<&PVIK%Y1C[ Z^TYR
MTL5MU\O/ L5ZPG!JE[RD%*L$=I&[^DL[<@^=79N4N:FV)U_A['"2' ?!P1$%
M8H=?AIQ GXG^,Z%8C%9 :2I/1.V9U;B!KA#%BH!B=4"Q1D9I1T'2E9U).;N*
M._-9QC;9Z #?QN1:.D7.'IB6>@8D[CZ)NU?L0H:9\"CS#"C'AN6>09&KAV=G
M<NU,GJ-+X.SF.[NY=@;;VLFQ,=@V!LO:">;:&'Q[%]_2R<-9K@3F3J&E76CM
MX!J;!Y4U#&'QU<KT?:<_2LO;#A2KG1QTSTJLI,#HY>BFV,89/A!J L6BTF(P
MD\H12]6G!7R$::Z^,Z_DY-Z3:T\6[*_INPF[BHT0P;%@\O( -V/P"D1+42,R
M!D>*=%&ANSBC X<0.:*@B7(FS"^UP"A@(V:T)7@+<5Y;E&UW*:.MBCH:]H.R
M.U,8C0JD$6@/A&/!'E(;(R;CK-8>$8Z&N).$8#H@!XJ5CBK+975I77LV-2"*
M7=_TEQF]KU$4ZR=&"6*:IEA:M)Z7:(JE]9(H&A8;"A%$,( S;4T07HZ%G<<\
MM[/L':#855&*_7ZEZ8#27S]&R,:GM8XI*4KP"6<R/):+@B>4&LE'U5L7VWQB
MNU_B#BK&PFJK5]PMK,Z\G73BXM;K%>=X^@X4%QM$M9'0"9)*LT45WHRCV 4(
M2SXSB@7LDRV@6,2L<UX1Q2)J48T-5?=<.Y&U)35G6UUO@=S5Z0QR'"3'2?#A
M<]G],ONGH=CEG-@^ME3<)Y(M^ A/Y,?Y"59*L?"(NRKA,@ HU@W?)(8DX[2
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MF P'#U"6Q#D64; @M2T58["\H\A+K1 ^(X6V=L2R\Q1K)96ZD$X=4A@)CC/
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M9RF*16&O?C[*JQ7@ P1# ]GH -_&'-0V=8HKFKD/ )';^,4 Q!QS!V"N;&R
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M928./+20@!.,*X!G&^@;P+5(L5D1FPY^$'DF)+<NDZ=NEEM8()F9J:1BQ$F
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MN&X?F]O*K2.I-U#0VKD;L2FWCE Z=Y/HEE> (WZEW3U^_L[1Q"L']QU?N_[
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MUB,&07<5:%H;V?E-W$*^IE5E98U[^%HG5X6Q!Y@FEMK)0(I%^#;SE$0* 'T
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MN/)*[JE35R/N55[J&ZF1F[!N @[PLG/@<0Z?Z.Q4GW\1$07>D^P/^9@[X<]
ML592]<",:;E&;-PQIT //=8LTAG%4^81K7ED0-UQGW7U1/V6W>6_6)?_[1V/
M?W"A?V6/]L:LBU L#NKR(2Q-L;31]F*-IEC:EHGY>YH+[R(>F\NEL8ZWCC6F
M-R<>+%BQ(_>M+06OAY3](*;E[8>CX7Q+\:1=.&-2Z69&U481IKM'BN42D.41
MIQ3.XWW=SE=:^$H3W.$$>L=@[W!UZJTCD:>W9>>?[A^MT3D%6@>P"Z8C5=M
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M*1;NM7J;:,H]W#]4DY(=?2AA,T842&KU?HI%6L5;HS^%UAQ0OK(4"_PDT'0
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M<&5D)]%S[!9*9GM;A269^8DQYT,N/3K1/5RAL+)T+CY,?;3M?XKS_@I05/D
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M"00L=.X&M[- P2^L T0AE'=)/\ZBD*CF/EG0YJ(*WKT@X3M]0K%,><VUXE-
ML8E9H>7=MX> 8NWHVL07]%8F"!G1S@;Y&=$+M?#)$A3K50#%/N5(R<%Z9^9.
M)IY/(8(7.K!)1*\%8XC]4E+%L4CCWATC^PS\JB13N16!6^<4C+M%([-]K8*2
MS+S$F',AEQ^>Z!ZJ ![5NP14="^V-E<V.6#'*.PC%8GA=T%M=Q[%$E]L_V@-
MX"ELB&IASO>,N\=6.UAJ!QO'D%&N:Z\3.OAR+*%Y/6HQBEW0\WUI[^8H]IEZ
M13#%ZNW"2=>PTC&$%,NX%%.U;G?1FUMS_B6BXKO7V1MZIQ[I/7*+Q^5$BL5_
M'I<'%'SGHXTVVKY*HRF6MF5B[L4I-N\Y*)8JO@H )]!T#(S6U_?G/VZ]\Z3C
M?F7[O:N/3NT_MG9GY*I+=T[TB)ZHS3R5F0MWS7&[F% L6V7"(-I_8HH5?RZ*
M'9KL+6F]%75V1WQ&>%5OKDC7]251;!#2+<EV7TS!NQ>DA11[,BOT<<^=84.?
MUZ_IX,AL+!#,R!WS*'9.3Z?8);7DD?H)CU LCK&#1RD27\'&R($ BE40E^<\
MBITO&<%30K'"D9G>5G[QE=P$H%B@SY[A2@!-C V81[$4R#XGQ6H74BPZ7U])
MBM5@L+)PW#U$4>P-QN4CU1OWE_PL)/=?#U=^[SI[?>_40Z!8:R#%PEV.S--&
M&VTOS&B*I6V9F/O+HUBXR\K-7/%X3\]P=4G+K?,WCL0D[X@YL^/HN=T'CJ];
MN_O/(1$?77F0T".L5!C8P*Q4I@+@5X6! UQ+1<$N XH%<AJ>["MLNG[PU):C
M:?LJNQ^*]%TJ$HV*=$53+$VQRY=BU4XA2.<>4CB18F\RTD_4; XO_>6N_*]'
M5OW@!G=CW_2C<;?<AN56"+DBQA*.I8TVVEZ@T11+VS(Q]UQ<K,/M\MCG4VQ(
MWD^W%KP>4O9&3,N?'@#%FLNFG)+Y<;'S;]XVOLS(9LF:"ANO)::'[XU=LR?V
MDT.)FR,2MX2=6!]_87]>]16NM ENEA..P4GG$+ I$*W<P/I<%*MS"%%?35SL
M%Z18O*E;>)*I_H+&:_OCUA].#BEKOPL4JR8ADKB,+[[0U\B232W02Z#8^3LI
MP#?UWM%I/$ KA@PH-BDJ90NAV+L2(U L!\G5SI9:F2^-8G$GYU.L&;-W!>;P
MHF!1&; _),Z!A!/8.5(+)ORB(@I&9_O:YD<4*"P8,DLE"Z-"8Q>G6(OW3*KL
M9&$+2T,HMD-4EO$H+I'$Q0+%:C"Q@] 7]4N"8KVCWS@$89%B50ZN"D>V88/4
MT3V#YI^<KY!BL5?+S7#X?#U0K$ND<@FUKD&Y<Q H]A8S/;YN2T3YK_84?B.J
MYO5;_,W],SD3+IG=XW+[*)8$%- 42QMM+]1HBJ5MF9A[ <4JS=+:H?QS=:'S
M*+;Y3_<EAWFFTBG'L'%>CH)Y-V\D"9M@:**WE5N:4WTE*S<I.^_TW=*T!X\O
MW7]\L;CA6I>@0CK-F/9(9CPCU!@OI9&#0[N6R/6S),5^6<RZ4%^<8JT\R71_
M7GW6KB.?A"9L+&J^ 12+.:&"*39XW<_2RZ+8>5^1;_E(L78N4U9[O>1T5,KF
MA,S]Y=UW@&*)(Y;[3T&Q5DQ_NRC%^EV>ST:Q_6V"TB"*11[]+(KU)_F"SZD=
MF*/8G'B@V#N/SU,4JW<_A6+1':NR<U1V/\4^1\]Y(11K18K5N$0:IU#G')0[
M!KOUK;?95Q(:MAZJ^-6>DF]%U__HMF@K8R9WRB7#D:2$8F%"!G=YZ,%=M-'V
M(HVF6-J6B;D#*-:%F;:<*HNL;K@PM3XL-.^/7HHM?2.FZ4\/AB.XII))QY#!
M$EB[:][-&VYF8P;F\%2?2-?%5[4)%*T"99M0U<Z3MS!'ZSFRII')?KA9 L6"
M)EV8;POOG22OEMJ"P;+/1+%?'<+:OBC%JNR8J50RU9]3F[DM<N6>HY_F-V3#
MV= [Q53) V]$P5*K/TW_#!2+(@C+TSKX+'G=C=*DPV<VQ67L+>NZ-6SH4SIY
MH)<;41!X>JF7W9B7@"3P\D&GMS4EE5&!HEC<2=Q/^;R( M'(3%\KOX2** CT
MQ5)ISI:B6&J[U%X!W@53;&Y"PI70V^7G^D>KB2]6X-V?^1$%*CM+96>J;"S2
M_I('_BSZJBF6.EA,,(RCN_!-B](^V#/>=H=[]433U@,5;^TH^W94TQNWA%N8
MT[DS3KG3X70[D%P='K>=R!E\ZZ.--MJ^0J,IEK9E8MC)",8NH-CPL+QW=^3]
MQ[:"'P+%1C>]>W_X(,=4#!1KM(Q/&.2$8AE!% LWLS$C"T 6[N(3[B&#9VS6
M,SKE'H8;I,K$59MY>+,DJ0D01FU"O4U(RA^(X:X)"+L,*):*1QR=9>367MU\
M\!\AT:M@1J3MPD(##O'<Z*XE5G^J_KDH5N/@,>6UUTM.'3Z[*2%S_^,>KR]6
M#@AK9TM?(L52J<106/WAV2D6)+.Q99A@@:4@Z5WU;J%DNK>%5Y21$Q](L7-Q
ML=X&*=!\7HIU\E4D<X(_U$%%(:P-$):ALC))^JTE#_Q9])52+-6KX81C!0T+
M?\K"GW4,:6R#W?JV6[RK,0U;0DK_8TOI-R(:?I3-VS P^6C&+K-;; Z+R^EV
MV3PNB\=EQ<1;M-%&VXLSFF)I6R8&?<SI<CF<3KN/8M5F>3U2+.:+W9;_DRV%
MK^TH?>-(TU\>#47QC*5 L;-6K=X@)13+"AK=19$$]:?.(9IP#8T[!P% \;YH
MX>OLHG&G&.Z@:HQ9Y"H,F)J JG& 60LL//6"O.ZO',62NE9"F8F=7Y^]^="'
MVZ-6Y=1F"K6=RXMBO1$%5-6#J)0MIZ\=K!JX/V+J)R#( @K\PA$%W*6U^)$&
M4*Q?9.>M6(R#2L7J=W92"J18!2G?A;6[[)@+#+[2.K'VV-!4=S.WT$^QU.@N
MH%L_=))\L<&78#&*96N< I@)I-B^T6JJU)F21.OZL1BKW]E@AD'$)%M9\L"?
M15\UQ>("=K[&SM>9V-,FGLDQK+61' 7<*Q&UZS<4_GA=\?\)K7LMG;FF1W=G
MRCIB,9KM)@=0K)VF6-IH>QE&4RQMK[#Y!@6CX.9A=CL-+IO%;L=W?$Z7WJ!L
M$A>=K]NWH_!7ZXJ^L[[DWW>7O9G0^%&)*'%HIGK2*1ZW2Y5F,1:OIVYOON3G
M%$9HG610MH6K,'/4-K[6(=0Y11J,E^5K[5@05>\<A-N>S,@>G1X8FV%@<EF+
M+T4\":L-E(:4GL)RH[;//8K+6XC+5Y<U4-K/:$2T4-IGJWI :KJ*Y69.8=/U
M'=$?[SFV-K\A6ZCKQ%*N=JP!BW 3S ?S,[PN)F0(7#* 8@/* 1"FI##.*](F
MB5Y (9$$28.\,E<I+?A;ZLP'?RZ@1(J9P0QO8*3Z6L&IV'/;S]V,K&/FC!D'
MR-@I?!V/)0^L+"4&=.(+=TR &B0K1V/C:NV+:D$AMV<27O$%$I"J5- @/"]Q
M-62[?JE(G3F_ "*E9@:R*3G#5*SJX$0G4&QF7F+L^1WIC^)Z)4_@<(!B55BR
M"RXE%\NJ8<U;?U4V[_E7^.)BE3:^S,25FWD:AUAAYG:(*C)R$N,S#MPJ2^D=
M>0+74>/D4V/. F-M"=>R*/E8^3,X_NDB11,"%? K\_TNR)_>!1:VX.OV(/B-
M4Z)^#GPLNF'#IP6U:6#2PC$X)3J[I%O?<H-W,;SVXS5%KZ\N^=JN^M?3^E=U
MJJ]/F8>L)H/=['"YL-:!DXB.BZ6-MA=I-,72]@J;VSLH&(<'V]WN68]CRF4U
MV6P8GN9P3\RJ6D1%Y^KV;"WZV<?%W_RT])M[RG]ZNN'C2D'*Z'3])""I8UAJ
MX:N 9@#+\+VM'^]$*N)KQ#JH6,2+ _,:ATCG$FMQ+01</:E1"8 E-;&E!I:,
M0EBX=V+R)J$:"QTM+@V!D@6X^30A=\ZO'#O7VF=0[")Z1HHEM9H$HP9&<<O-
M\)-;HL[N+&V[#11+40(B*2)[\%K$=;>DEJ18JHCK(CF8",62G/]J2[![V^?D
MQEAD_]$M7& Q"306(8@J9J:V\ <DU=?R3QTY%Y)V*Z:1F2LU#E#X!:)H#%D0
M$-;*)B55@P58J;/S%A/E@/^R!(?)IUI&D W8 ?(F84Y8R]?$0,>MWUEK90]-
M=K4)2K(+DXZF[<K(B5] L7!!!4J+6&6%9[- ;WT0Q?+D9NCA0PHSOT-4F9%S
M,C[]P,W2L[V22MC*TA3K59 +^?DH]BF:W[&#OUT@BF+%1-Z#Q>IQ-N+P-O=/
M6-FS2+$C/4BQJ>%U*]<4O[:R_.O;ZEX[T_5AJRQSTB2RFPU.JQ/0U?=(3><H
MH(VV%VHTQ=+V"EL0Q1H\CNG%*'9;T<\_*?[6VM)O <4F-:RN$)P=F:X#BM4Z
M)#*+@%"L,)!B-12>&MDR(]OKW<'7ZR("LH,3GF$0("R. #.RJ-0\ +CXJMV)
MF$O8:\FWEJ\*Q:JHJ@<3O:6MMX^F[3V5&5'=ER,>[X:C@V/'=Z\DDVC0*J\Z
MQ:;>BFYXE2F6<FE3@;-SZ0+(5R,SO3W#E;?*4HY?W ,4ZX\HF$^Q(I553%/L
M?(J5].B:KW.!8E=]6O+ZJO*O;ZG^;D++7^N&+HT;A Z+R6TG"$O]?T13+&VT
MO5BC*9:V5]@^FV+%1>?J]VXK^L4GQ=]>6_*M/65O)M6O>BQ(ELS43>!8^\4I
M5HV^1K[<A#EWQMU#P*P J4A4=H'>/3CM&9WRC&CMHC$#<V1F % /&!<'-3O%
ME/^2ND$&H-@\O4(4*S.Q1+HNH-B35PZEW3G>R"X>FNHCKF@QGC%?_$#@*L]
ML; 8#UG!._H',_93>?N)J 7FQ;-2?M^OCF(U%CY#4H,4FQ)R_F9TN1:0M0
M@ !)1$%4/<-+L5X@^_(HEMI5OPB5HH(^7["8OX5GI5@*%C68F97CW7D[=\S0
M/S!6<Z\R+>[R/J#8[F"*Y1.*%:JL(LSPY3__5*8M*Q9L@U]*(,5VBI]<R3V5
MD!X*% M,K,( 7#X598OR(2S*%^HPQ[(D8/?S4BS&"01'FP3U0*H_>Q^QJ&])
M:5_?Y_,:%)!<9B(BJDV^+]2! Q0[;F7-.H<IBKW!2PMO6/UIZ>NKRKZVL?+?
MC];]X8G@G'Z&[[2:/0X"KQ[\7\B;.Y8VVFA[4493+&VOL'U%%(LS5)@=XJ-
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M9UPVL\WJL;L]#M?4K+IML#2M,71'Z6_6E/W?=>7?VOWXS:3ZE8_YIX>G:O0
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MB@K<,PC%(G@EWCO4GYUU)KN<UO-0[#-DCZ3V0I&"IV9^]B(GUV#@ K[PMZ8
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M;?C48KL ]UQ<VZ>N*VFG6WNLV3@Z%N8$<EW<GN%N3+%E8Y3U_G%NVS"K"8:
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MJ8L>836S9>,,\?"" ODF42)W)0 !*I@$ O:U:GYE%U!X?G6?NG: [NZK^W/
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M4MV:3 -:EVIA?/645F2ZE0W=ZH9NC4BA7]M 6@<I#*MRJQ0GM:PPK"@,,+\
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MFA<-Y;4D!*2XQI<^[*;6+AU0A,A5C!S&J @"*85P6KCPU9E"KCM".3I2[@&
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M!G$DKQY0J(*![KGJRNY,@+#\AKB<^NCTJK#$DN#H//_P+.^P3.^H7+_8@@#
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M(?"M$/A7".];]0!4*0JH$@=6BX)JA,$UPH<UPI :P>/J]<=/5D.K5L(K5R)
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ML**_S>A(4!1;)*DH+J8-DP'VQP'E5N]CL'G14L?C@0K%!/#!P1+D-C]R)EM
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M\CQ-3]/?)7W#%AL,X)-!(M 403#H\WD]F'L<P]W&$<LURHV<G5MNEY98=-:
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ML7LX5@_'XB&:F5%#(._1O83]B50HU$&3:\8'S7B_!>^SX+U6O,?F?3QV LC
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M&- +_E(S '420?LCH  7-OAJ<!3CPN)%P=JB$!'^Q2:/"#"[A0@/E$C1J2"
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MKC5@C6^^^>;,F3/!.!<M6K1^_7HPXW7KUH'4@L+^Y"<_@;U<OWX=+DDW;MP
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M.8 'AEVF.U+*L3OIJ8SEL?09J34S=W6^>9&[KEB>4Z[:15'MIBAW48BA#::
M2LJ5NQ"JW6&49&8/18V@:L)0-+NGL*=<LY>B0M!4>^G*/73%'H9\-P.-K;"'
M(=W'E.Y_A+U,V4XTE)>TL%*RJU*VEZ7<1]?MOR;*+ZA;G5"R+*[\I774'V75
M_?0,_\W.X;/VH)*PV'"_V&#(/>X9O]O3=_WFS?/GSQT^=# G)R<]/3TI*2G:
M$)N8F!@;&[MCQPYP4+APH'/XD*@1)1:+A4JE@JK"5*5200E<:.KKZW?MVD6^
M'#8X..CQ>&PV6W5U-=AJ:6DI^;H87)C$8O&M6[?.G3O7V=E)WEMKM5J0Y@,'
M#H!WLMEL6!GT5RZ70^%O?O,;T%90V \^^" O+P\T].C1H^0TFF#V\.'#L)>.
MC@X0Y9*2DL+"PJ*B(JA*K]?#'F&_<&Q;MFR!-<&_IUKL-Y[(Y@\RBWH4!'&_
MSQW /2$4+<:C'Y96"K_<TY">0']K'6/!>EK,1O9;A^\D4@:.="II'&N+8*);
M--$E=;9+K:U2VQV1O4ED;T X&Q'V!H&UGF^MX5HJN98*$IZU4F"K%CEJQ<-U
MDN%Z #(D(F?M?1QU4Z@7.QLDPXT1&L@-R6TEP$B]9 0*Z\1.J!9 ZXN=C=)A
M\,46Z6BK#!B),-HJ'VL#%.,=JO$.Y7BGXG'(QSO(U4AD8ZW2X3M"1R,//I&E
M3F!I$%J;^+:&(7O]@+.N?[BN?[QA8**QVUE3*;UUZ<[!_=2<PN*LG<4;"F]E
M;KV9FG<C->^+S#WTK1=:C]($G]_1L_L<+4,C71S'/:Z]FV_MBB*P(83V;I&]
M&Z8"^UV!O5-@Z^3;.SF.SO[ASN[1CGO#'4/V#KZM@PM8T91G[^0[[O(<=SF.
MCGYG>Z^S;<#1QK6U"2UM,G.[PMBN,K8K31T*<Q@YFK8K+.U*:Z?*<A=A[E*:
MNQ26+ID-Z);:NR7.>PA'-R!V=(D=W5+G/>7X@,;%T;F!(9U[$ W*"AKD >WK
M5T90>*: ]:N\@VH<&%+[.4H_1T6@]G'4(*,3O1+G78FC2^JX)['WB&T]0DL7
MW]PIMG;+A_L5PP.*T1[%1"?!7=E$EV2\2SAVES=\E^,$.GG.NSQG%P'*"$:Z
M16,]DO$^T7B?D&2L5X#H(>@5CO>*QGO$$Q'&>D2(>X!@M)L_VC45P1@)E$]=
MU,U%>^\8<K1SG.U<1RO/T<)SM/'L[5Q;)\?:R;/=$X\.R-Q<N9<G\W)%KD'^
M6"]GN)LS?(\[TL,?[1.,]@O'!D@$(WW\D3ZNLP?]#!SW>(YNOCT,S][%<W3Q
MG=V(</D]ON.>P-DC'ND3C_3#[("IO=?8.N2X"Y\4IHT2=GG7S=+.ZW5"QH"U
M0S0^P!GNN6=JZ38V]=E;!H=;!T=:!T9:AIQW.!&&$,TP'70T#SJ:!H<;!T8;
M!\<:!V$ZTC@T3-(PY&SB.)NYSCO<\(;-O.$[O)$6/C#<Q!MNY#D;^<XFOJ.9
MYV@2H'P=WU$C&&T0N5H%GH[>\3LU)MI5P;'"EOA$^J)/;_\LMO2GNVI7U(J/
M64>% 8]G$O-/@LN&L$DTX@]<QI\P_R,OH&0'6;AZP_2IPCY-3U#ZW[-8N\MQ
MDW$S9V?VE\5?&M2F@#<PXK:TRNA'FS<DTE]?RYB=7C]W;_<[%WAQ7RBW%FOV
MEZ@.E"KVE2KWD)0!JKWEJKUEB'UEJOWER@-A5$7W41=1- <>1U&YYA!%?8BJ
M/D13':(K#]*510S% 8;L  ,)ZX''L9\NVTN7[6:B,13V5TH/5"H/5AH.?RG=
ML:MQ?5+9&_&4:;&T9S8V_.RL\/7.D=.VH)SH40 ?WS\9& ^$QO @'C&XT.@(
M&D +Y+*_O[^OKP^\<RB20/6^:L0!\L2"DHV-C8'+DB%=T:DF1-9@,*C5:KO=
M'GWT@V&8V^V>&J(5%L&%:71T%-8GKTWD/;?3Z;02"1:1:U945+S^^NO_]$__
M-&_>O#-GSL!106VP,CXE@6H30VVC%(V5'2*Z\\)!$O&S U AR/3FS9O!8N$C
MPYKW?R%_RW3_,/P!-!JR#S,,RYJDI:?;LS>PWHZES%Q/F;:!M6AWS0?G&^-+
M.W(K.0?JE<=K-2>J9<?8PN-,T2F&^"1#? PA.8X0'Z4)CU $ARG"@Q1A412:
M^!!=>I@I.\J2'P,@$^'(_;ST*$,207J,*3W.DIU@R8'C3-A$?I2$@38YPE8<
M8RN/L^1'V;+#%;)#%;(C%=)C%=(35;)3U?*SU8KSU?*+#U&CN%2GO-*@NEJO
MNE:K?"Q7:Q678;4(%ZMDY]GBLTSA::;@%%MXND)\AB4^39><I(B/E8N/4&3'
M:*J3I=)C9]KSM]Q:N>[X6ZL.O[;V^)MKC[[^:=&2CPXL_O#(XE47WME(67NP
M)>_*X)$2R66*[ 9%?(,JO$:? D-XE> :0W"5SK]*YUVA\2]3!)?*A1?+A.=O
MB\Y^*3I]2W"FG'N6RCD'4(;.4CAG:;SS3.$EIN@R0W21(CY?)CE'$9^C"<\R
M^6<KN6>K.&=K.&>KN>>J>&&@$)7SSE;SSU?SSE=S+U1S+U9S+E9Q"7B7JOB7
MJX17:@17:GF7$=Q+-=Q+]8*KK?(ON[7E?09JC[Z\5U_6:RB[9RSK,I1VZF]W
M&,*T&Q^@PUARUU1ZUUS6:2GK((!,I[D,RIN5-VJ%%ZOY%VIYEVHXEZH&+[+[
MSK)Z3U</7F@07&T27F\476V07JI'7*F37JV17*L67ZL476<+K[.$U]@16,*K
M+,%5IN *DW\%IG3!%1H!G8]*V/RK%8*K58+KU<(;U:*;->(PD*\5?UXO^[)1
M45PO+ZZ5?1GABQI ^D65Y&:5^$:EZ$:%Z#H)Y-GPO7 N40<O4(?.TP;/T 9/
MTP;/T@: \XRARY6"+^IE)4VJTF9-:;.VI$%YJUH*FU\EJ11=JQ1?JY)<)ZD0
MP<%?8?(NT;D7&=R+3.Y%%O<2"9-[@<V_7"V^7B.]42.Y3G -J)5>!V"V0G"9
MSCE'XYRKD%RM4WU1);UVJ^?8N?K"DU5;K[3NH_/.UBBO5,HN4'DGR[@G:*)S
M=,E%NO0R37J%(;["%(5AB*[0A9>I_(L4[H5R[KDR_NE2P:DRX:ERP2D*_Q25
M?XK./\T4GF'"#TEXCN \287D4I7L2HWB:JWL<JWL4JWT2KWD:KWX6KWX2J/D
M8I/D;)/D5*/B3(/Z<JWZ.EUV]1KWZ.&N+7F-*Y,KEJ^B_FH]]6=[ZE^O$QVU
M#0N"+O>DVS_I\TR&W*%)P ,7[.@5[XE(T>MG(#+".5GX\'I/T]/TK4Q_ XO%
M286=),9BG9QT$P1(B[T1ME@5LM@QCZU-SCC2E)E >VTM<W9FX_S]]]Z_R$OX
M7%%P2WV@6%ET6[Z_1+$O2JD2V%NBV$O,@N,6/8SR0*ER/[':H\"B@V7*@^6
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MH:)UBNB*(H9B/T.YCZ[<P]#O^T*V?6]+0AKM;;#8=91GTJI_='1@T1W;46M
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MLD5;RA;GE"_)I2S+I2S-*5^:2UD")9M+%FZ^C=AT>\%&H'@^"<QN(A9M+%Z
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M>BE$5XA>W:+IH16B):$I%CLV-E934Y.=G7WX\&&93(9'.ND^6L,WGD)$UZX
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MBR]';#CAN_:0UX)#@>9[_54/!,G>BC<)J[[52"]&G[3%G1?[.[I85N\Q78'
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M ]TC^PC[2_Z7M%R^KNCK2O\R 0\\"K_ZYKX?[Z_UEWR=A5\"%?TE?YF25Z9
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MVI:6%F]O[_W[]]^\>1.X6&"CF7RS'01/$1 (!/(+T_LL!X% ?BU^GHM%[WE
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M^WN[^'NY^7FZ^KB[>+HYN[DZNZ"X\L%O8?_2L^+PS.6W^-J>^OKZ^G'Q_XH
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M?BV@BX5 (+\[?^?,^G?2_._@I?9",,E_QR_2C+YA]]577R.8[>_2NY"_5XQ
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MO[.-2F*5N?M>7V2FI]1O\! 14(6(B<%RJXNAU07HP#.+S<A,LMYEJ3!(:\B
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M?:^XO?> '%4)NHP3*HL7W[4YLJA\)D#LKQW\7\%6L6S8L/D',MD33JM8$RE
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M(' @LJW)MI<)Y8T]WQ\_CS!7DZ2"0#*2:@<./:^I9HZ-]91\O[]KKZ.\")W
MB\!@D;"%*G:YG# %$"6""G:.>V,NO4I/34W^_/')XTL[=CNHJ@L@N%"""(5
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M_YK_:7S\1ST?#[?D^K_^'SR^C!G^0UZ<J>D)AT5P>?<"/U:QWDG^BVD^<A@
MP--#Q0+ G#6;.3.A\TCW_ W_DSSD/^XY>.1B_]/E9L_X&/]A+YK__'S\1SV9
M_U$  $\+%0L  ,\&*0H +Q(J%@     "#RH6      (/*A8      @\J%@
M   "#RH6      (/*A8      @\J%@     "#RH6      (/*A8      @\J
M%@     "#RH6      (/*A8      @\J%@     "#RH6      (/*A8
7 L^?#&J]BEXH4\@     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_7a.jpg
<TEXT>
begin 644 image_7a.jpg
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M?_#RNKHZL' P<G!Z./O:VMH6+5H4%14%]B]UX_>=F##GY,F3(?OO[.ST=1>
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M%"_0/  1O4?@"8%GQ&FD(+C$$)\-[*8DX[Z"TF@1B@\2DA<(H2\\(NY 9//
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M?D16QH7CAW=MV;2BJ:F,8;KM#G-KJQKB!H;J9,C.3>N67#Y_A&=LD([RG#T
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MR=;VMB/'CBE5*@])> B") A;5_?6+<E'#Q]QV!T$2;IHTL/2!!3%T@B&@;#
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M] B;OA#HUA5VB71J"[KU10",=*CSVAIOMS5F=VKR.M2Y7=I\H%.D2U^(T!4
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MPUP)SP*>^&>IZ2\P,U[LX7=4PC B[BDR_ADR_FF1)ZF$)ZAI3](]<+%/<#'
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MR-"'):BP1^CP 0R4'SE0@@X;0(4^1(;\%H:(L(?IR %,]" ?;.0 1-2C;-1
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M'\Y<S9L0G+&JAW+.5-H'=TS49[36 ,#@.5,)P!J5$G>W?QERE_UYV3^A+O"
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M8]@1CUEF_!_WS 'DUJE46SJCK>!U-<C[S86B]Y>@FJZW@?G3R_[1E-ZS_?\
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M ] 3!C7%C*:HL_S&LO'_6#CBK:384>JT P'V+[V,IZ?Q^;[VC[Y7K[W-BR^
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ML)&.!XA_VJKF6JHX1WFP0015?Z))ZM7>;!-G^A0WF'H)9\9^>KZ@[RG?8U)
M_)MQX1](BG7Q^"^\L&+DJ^K+^TB=F+:KPW'X9PRE$7TQ99,R=AFA*V[59/D;
M2TF#TE=;NG+L!\.?^^.2D>_47#U!F22,5<PVE[)V#%N+D60PL$PLMN]1WU[\
MFWG\.\H8B[I5>?WBZIGBXUO-!9<<DJNAQE+8#OX?'^\O%M@]Y#9C[@'^=TP=
MG+E[,<;P&0#^]1K*5%\GOGA][7!B_-]LD_Y/8,1_A$ZM<S+>0(#B2);"]4,H
M/IP(PS)L O\)>PB6P/^ K0?_U>LF>,?S^%_P&RIS_C<._YT,$:0C 3H<H"/P
M)0AW[K0:/U\T;\'L&;G9&7-F3%V_;NW6+9N?_<??7WEYT!./__GDB>.__,4O
M1HX8/FSHD$$OO9A[(^>UEP9]^N&'%\^<-34WD\&@W^-).7OVYS_^\9[MV^NK
MJY,F3)@_;^Y[[[YSZ."!/;MWO?7F&Z-&CKB2?GG?WCUOOO'/*9,G)4V9[/6T
M/O#:/V%2 'K#S1+:H, :O$E%&N3MLFO6W L^Y0W& (S4L@AO)9;U@OJFP _L
MUW F-6U1(?Z-2DM12G?MG[&K"1QEU@?_M*XDV%00,9?2-FE$5]16=LW?5$H8
M%-X:T=Q/7WWK3S^?]>&@ZO0O" /X!"54<REM41*0%# ;0TGBY+U8(MZ#OLWX
MIPU*SEG!6#643F;(.=NFN-ZNN*;+.=N0D]Q>?@O'?_!/&?^.>L0?RW_'H#T6
MA5.>L7/:1YF[NO#?]TV(YWT\_DE3O5YUI7C[1'+<4XXIWPF/_DGPU#H;[0GX
M28Y@&9I@&!)*%9[6W(,=!A!;="4L8;PE\#]@^[;@GXMTLI$ $_8S8?CB!U%!
M;R308=;5IR2?2#M_^L"NK755%1:C_MB10T<.[MNU;4M)8=[.K9NOI%V2B(H/
M[MM36U516I"_;?VZ@ISK3I/1U^IN=SE2SYW9L&KEI3/)#I.Q3"&' T\?_\+3
MYC8T-Z:<.W/FU F7W0K?3Y\X=NG"N?R;-WP=K6%_VX/%/_;]V[6$04[I98Q>
MP<!/;VUG1;[N6K)3G!'1RZ!JB&PPQP>PBRH>_X:\<^O&OX6SRRP*&I<N5,3@
MG[/*63ND+ <%&O*LTC1/;2'CJ @85/.'O_'FGW\^X_T7+ZV=4Y5YJ.;:X:K+
M^RNO'3.(+E(FF3 " .%]_VT WV;\4^#;V<LB.BFMDS.-,LI1!E_<H@SKS11'
M27JPMA@77>2'O@J/"9\4_$T)XP&M0AQ,I4.6L6OZQ_E?K..<6@;_XOCGWG66
M>-['B#.51XQUCNH;JL.SB7%/N:=_OVWP=X(GUMBH=@'_1"1(4F$"_@D$28)^
ML!, 8XNNA"6,MP3^!VP,0] ABFAM,5>OG^"=]&MNS/?9N;^B,Q:R]GP6\&_3
M $Z0*,*PZKB"*19.\>H;)/@VX_QA"\;_Q\^H8D[1KQ"94?SS)U7Q&)!Q3B7;
M6LUV&-D@X-_+!7ULH(/U>_"3%^%I8?P>O\L:=-L]-B/=Z0%UMM@);YN_U1EL
M;_$X+?"%]'O:[68JT,'X.SI=]DB[FPMX&6'G5D?8VQKRMK+@583]'6Y;H*.%
M#'J#7G?0U^IM<X3][>% .WSQ=[0$O&ZBLY7VMS'^=C;820?#5) @(Q3X 6RP
M'5<9<->SCG+,I?AL[%;<(Z#-*@(97^&K*O25YW54Y+56Y+:7Y3;FG*K+/N&M
MS*,A0_B8.5'ABHCE.&+?ADL/X^K#\.DHQ]"Y<&IW%6-66T2I^V8.T5S>SSJU
M4&O'I0NMPOC!K@$$& Q80II+6(<L4)]GDV6$&B2LLSIBJ=CXV<BAS_Q^U(M/
MK![YS]+3ZV6IN[17#F;O6:Q*V1VH+8A&E3?AA,!8*/8G\!AB%+O#_2LV!6L_
M'L:#$88![JU^?%\61WB4P2.F3$JR64HU2B)-,L:@"M>4AJM%UI(,8W%ZH$',
MF,&-UK+6,I09'#XM Y^6,GY]2RUC55A*TS9/>C?WX"KPPVAL#^BUW ,^WUC>
MQ\I21AIK.FIO*4_.)<?\Q3WC>YT3?^;8-N]BR=7<FX7BO,+\&]=OW;KA=#IH
MF@'\AT,$]@(\("\@MNA*6,)X2^!_@,:Q#$NRB'^7N0;P/_F_N5&/<+-_R60L
MXJRW&),4)X-9U=@E? ?VQ,(I7O&\[U=Q95]LFK$2O(<*7)8&?ZKXBIV,<ZD
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M\8LN^JL+_;6EK>J;GK)\TJCQ:/,:;UWP5A<Q%BUC5'-F+8>5?JCZ:^ G;=*
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MOA/GFV?XH9$JNR1]]:C79!=WTP8II1-''P??'G,7(?ZM"J<\ _"?>W 51@*
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MW9IK6;L6VY57P=O@P]3$H>X.^+]+JWO/C<0=]<#%6OI](EV(O<.-@*>%#2U
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MO15N+(@T%E"Z8LH@QAC _,3"J/@;@=N![9 (I G7AG/;^*H_GY\28=R[T-)
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MM/G]SK)T4BORF*6$4>XU(N.?B7^X<_74/D@^NJZM+!V')(V!SO^Y]#Z+P1_
M&R5IR:W,B#"KJ(H$Z"YB/RV_7F(55%[?OZ8D_H1'2?>7!FZ4B'\L)*CH:\I9
M_^H/8W<OG^YIQ<C!)\TX>")6%V_A5Q3_U,2_]M*T';_]EW,K7RN(.5B9<*(U
M/5KP*$%6E"PJN,EX>+GQ;F3S_4N,C!AF1BPS,Y:9$</)N0K/X1U65CPO[UI;
M05);8;(DYSKXJ157CA_[X%>;7_F^HC 9DQB"]X\9C434 /DB9G\&!5BRZ/U@
M/1_\ZP6>?E;EE>-'WON%,.>:A9EO9>2;FW--33FT=$U9K>D)9U>^>7S9KY(.
M?9QZ=.6#\UL*+Y]LOG55\.B&(">6DQW5?.]B4_JE^K3H^EL1C+O1PLPK@HQX
MYNW(^L2SS:D76/?BQ+G)=3?/E5XZ<&736TD[WSOTSDNI1SX=%)?[!F6D1>RS
MS9541L9CP4PEK'7OW7/;,"L1%CNFK=NGXY_.S0<FM4X"^+]W>D?TU@\&155^
M[1/POUC8R0^'PB"<ZFHNO7*4<?^2;U".AI%-3F47"!PK[+$;[/.IY8-W([4;
M?^#9]*W)]2_86Z-<3NV,VP/X=X4J_H7:<V\A_"^Y+0'_95$;WVTOO@W>O\<B
M)P'MYC; _+/Q;Y3V-V;>.K6IL_(>9B+[DO#?T_AHS2O?C][^X507XZ\2_QB8
M9I'*"Y.W_\<_@P<_(JH8$U5.26L<72V. 38!OON@PC_<[K/*P*TD36+"+"9!
M6/262NMFD1(Z'MG')I7<<7'5E*1FE%_^\,RV;;_[%U'V-4+))@;8F,/XKP7_
M7NSD%[?>CCJWXG?BW.NZABQ _A"K:(13,L(N!MG8>;P'-Z/6O;?KC7_9^^8/
MSZ[^3<K1E:E'-M_<MRGIT*=W3JUY&+X!#(*T8YNNAZV)W_5)XL%5R4<^!3,W
M^>BGJ<?6P_/$_2N3#ZRZ&;;BVIYE9U:^>OR3WWSRTG<O;GU'R<C&PV@0@+L/
MV*8"8O!L$D:)5\7-O+CK?O@.'YP@+ U,!<;^>?S/7B'V[M8'9W=>VO;AH*CZ
MB=[_G#!XT"S!DVZ6D%K>9%>CKB7WT87=K(Q8PBHAYH8_YKQ_@]AKZR7[)2,/
M+IFV_9MG\PN.S=]QLB^%\!]J7V(+X7^)S>OS39.$FW /,PK[]OZ*V/;=Z77_
MS77Y#2_KMD\G)W2!V/79.PMFO#=S2Z.WO"<M3"'U8M(B\]HZ_)0%X+=0@B>
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MX^IE3"OJ;)QB R/7T=7DZ&&XU!RJLCMNVU1;_:BH8D)<Y6QKF)#6.?M8'JT
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M.2:Q$):/2:MA#>-2U*BT>E16XU&RAR65(])JF[!\ O:BHY$*%, 0 <R\!*:
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M\!PP-3]2<OPR[XW_H3)YL2393L B]S5+NJOS^NH+N^H*_,W2'D-60T:$2Y[
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MV0G0Q;P+E%7A424[9/&!)@G<]I1)2H,?-CA14*A[GM?0Y]B00!1>B.""XW0
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MUC' /[/DOT;TGW!H;6/.#9R3]M\/_\(3$2B$_XG*#-<]\!]HEL3N7Q6]8_'
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M-6N5<C;%X$AC 9CO$_]$/)S&@*Z@S'#9M*Q+SSAUK$7#ME:X=!DQ>U?49T8
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M38\!Y3),O/J L.0Q-1'^'?>;&.!!#WI/C:R5\*^C!/@/?VJ'$@#<?Z0>AO]
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MD/]6^">B+8K>FOST4UON[EWY3X__!X7E&+IO_+-6#6U2@N!-L+6*<U<P%O5
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MD#4I<+XKN&+PQJP$9Y=\Z:JAR;3\P N<[]!5S5A5VNCCT;N6=NHS.?C!NLG
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M5@PW_H,'X-(#^W$BOE,/@.PTY)A*XB!B#GHJ.'=9P*J"SY&:0VGL"/:")$F
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MX1^OB4-7F7)Y[^R7KFZ9U:9+]M47]U?D6G*BVA7) 'MO8VE/3;ZI.*8F.R*
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MM'ZZLX>%0(+S!R@N0).1_^@!A,_<'\> \0S#\", ?#Y?964E1/]#HP'8P03
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M@//M?<X^>TNJ)Q7U,\H&=V\'KN&Z!QAN-<=KE\WTMDY(ZF%UG4>$DB1:Q,@
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M.5&*\D1<_\@T<OC],0CQ(7;!I<"R\&/N01:N_>? /W *-;S*&\?#=[XW+FL
M"*=:_CS* Z":]W!SH\]^]I*H-'ZLL]'9SYA2-DYUP]*_WA$%89?"DGP+8^9?
M1X^A/C50[X5%B*D:Q@O5_:@C)[6X&2DQH8--$[RCG7,#'7VUZ7EA!^75*>.2
M^BE9@[.G#55S?=45E[P%3!FAKCEY/&2*0S=A8"_@_[^0,W^>9]]UC.LF<&(2
M)Q W'/PG4#C]_X0&;D$@Z*>: >)D\1\.AP/PSV0R7:0MOV'YS6\/FA__J[=_
M0OQ[C>(1:;U%6#6G8A+#<L"JF;ZV@VM^O_NU7YBYY; 4JTHPU)BG9Y;!I?F.
M+EAZ:+@+L<"RY,,R>M!'?_GD-_^=>_TH/MY#C'8C0_P1;JU#7._+YS+"(FZ/
MD*]L .& 98[@$(5!#(L*K#S")],#T3]9%V$Q^H?%$$G!N-P$_0S?JTPR\+X#
M].P;N]==V_%.5WG"A*A.UYS'2 L;K+NG;<IUL,M!H']DS>\/O?-L2=AA85YL
M1UH88/_5S6^'[UA;%WL&;!FR_I5/7OC!SM=^GGA\TV1OBTL#JQ<O.C&PN[P%
M J,VYG38IK=Z*E),'873\OII63VA8J'][;-RFJ>G=4Y:/R^CN3N;YN6T.25]
MOK=E4EKG[&R<D],F^)4N1;.GJVU&2I]3-@\+:_II&19V&?$5\/]/$_WK!816
M4!-U*F+7NG'YE^.?BOX!_H^\]X>*V-.RVE1U8P[LG"NNH=( ,:L$.*_+U@JN
M3H_!/[P4%G@IJ-7_L+L5V>^ ?%^R"R*UA\7MR0*+<_WM,/7/+$*U_-'.QNG^
M=@?9*G-25#_3W8K#/W;IHL?PI?C'=WS/%?1'0<R^C)P$[F#_B,OC<7K<TW->
M[*M%_\! ? _ #QZ83*9[]^YMV;)%J50BL(JP'_]^^Q+SXW_5AD_@V-3$F/'.
MB=& [V/'?N ^_0L2_]DX #8(&0'_+)#Z,+R MP;17'=;XK%-C.Q(V-H$3BK+
M,*T0)SOBP$XA #.^TJ'D _A8 G["3G1:@::Y(.'P!F'^+<\0%W8$AB7*P08B
M3"]T:WB(#C@9$OAV>H&6432J;/ 8^;":NDTZ+*F[L.F-O6_\2EIVQ\@MT[46
M37>UHAJ^1\7U@!<:Q4 >$-\,=XTHFLY^\?J&/SZ5=?F@$S@K*@ZJ%8UWM@YU
M%,WV^E8YDVUA80.898)-AV'BH<P#*^SRH$"$NI Q!^6K+R3V&B50OJQ ,C&0
MC-KA8\K=H9KY&JENAW!\&';4'>F"C@59&Q$NK*!D4Q):$91)"AL?:T285@3P
M?V'#ZU>WOME?FSHAK-,VYK:GAO;7IFOHV39F*2L]_,!;OPGXZT]N'OBTX,H!
M>OSYG(M[XP(_B=SS849P0$7$\8L;W]C\TC.;__+CU#/;)WM;R2$'.)BQ@'\I
M M$BJ8X\D71H_:2TP:-FH6HFJN/ 5?XF/J8#%XV-:%F8GHL;R'YQY()R:FX;
M-?#<6@ZFYL(F<@8A9H2KPQ$-;!H$\P%74&H)@838$"?G_-["T$.(E@>'6WP]
M>5>9^N>+=TFMW/B16C[X+_ ,,,JO'XW>^^&XG+:(_T?%[N!Y<!U8V9'G-[S6
M2[LW-\@ 4?6$I'Y<1H,]J!PRE"JL1&ZY\N5?0<N.\T&1*9,2V"/8)D.TW DE
M?5Q!Q_1P>@OBW^";@[CO0("_1RV?ZB ,_@N'^N'?K]"KX>/]K"EQO8-?-=O7
M"I%/MF:&?8U)^3HRPPL"6QG!)I]ZMB-B^_RNI]%MWT6#7IAJ2VQEU,1D9K:)
M9=,34[/C$P2&PUR])\O]HVY#*(I2E?YF9F88#,;1HT>;FIJHGD!49@#UTV]^
M6VE^_*_2O 0ZC'JG)H:'$@[-[/XA=O _D9!?S2=O07AYA+4/-73A&@ \)9R0
M!K&%E:P5KQ*DG-K9E!2J;RN!D^OL2D-[B;&C%-;8@2HQ,8I!(&AEEUE(&1G%
MNK8"55..F54J*(@+W_U!Z8UC7=6I^K8"?7LAT%!S;E]#AJ(J>; IV\JK'!'7
M&1A%_,*;T[VM<+@>I@$J'(+JD"]>7?^'[]\YOJGN=HBD+&&H.:>_(1/<?X%Z
MZC-(9?8WY @*XT]^\O+.5W^9>?40,M+IU@D]*CYA5<A*$_OIF69.F9578>&6
M YG9I>"0@*SL<DIZ3BDEX&&8P&;\2AVCR,@N,[!*#*Q2('!J=EXEN%$Z>%4V
M;H6-6^D0U '9>#64'+P:._C)!0]J@< S%GZ-EEUN%M5:I#2SE*875!OXU49A
MC6E!X%?#[>53W/H128.%5STNJ!_EUK;<N7QT[1^B]G[069$P+J@9%];V5*:,
M\:MGI U8/[._YF[(IR]M__/3YSY_)>2SEZ]N?Q=<G- =:\Y\^M*Y#:^%;G]W
MWVN_V/'79[YX_@>9E_8"*GB'N\DQ!E_T#UP<!'):6A9V)'S+V[+BN#%I#:8#
M :O :P'\$.!6^,!K(5L$0;]G^:@&U$I</584AX#3D'E^=W[803)57@K'HK]&
M&C\$/U5IAVSN_! ]R3B!F>_L;:F\<31V_X>CLEJ/C@.^;X_!/Q!F$ B+;EW9
M^C;X$KJU7.!03DL;QD5U&+FLCEK+\+6U8I2"TN)1&<@$0^!M6,73/:W2D@3:
MK1 ;N]S=SX MLLC.!>0>E@S^ T=M1(XYI+B:BPPR<0V74',Q%1NX!;.=+</"
MFC%QE6>(Z34(O'"Q!BSY!;\S]^LV2G&3@+!+O#J.)7*K:^</D.W?Q8[]T:VN
MF'&-E#<TA43&T.KK";CZ#R$S]9]XY=]"[3^JU#]XT-[>3J?3@4_@=#HQLOJO
M'_]^>Y3Y\;]*H_ _.>$8C#\XM^='V('_1$-^Y4K9BO#S'XY_LP15\:]L6WMY
MZYK(?9_>.K(Q\<2V.\>WWCJR"3PFM>'6T2]N']L0'[214L+Q34FGMH(GTX)W
M)IW<<OQO+T;L_?#.B<TWCZRG=/LP7(!WZ\!G*<>W%%P^4'KM2/JI[=51IT:%
MM9X!%JKE>2VR<5E#\/I7/OO#]\YM?.WZKO?C#WU^Y\B&N/T?@U<!W0R$BMWW
M:<R>3R(#/CJVYH^7-[S-R(HFQGIP</.R*!"+K.'VA;R+^]).;DL]L?7NJ6U
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M"?O+L;]@Q,+(/_5@>GH:1/]JM3HY.=ENMU/%  C_X+_?'FU^_*_2?(/_D\,
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ME3,'C.8>LZVZJCHC.6ED9'@>1/.X%U857;S5/-J(A;9^B[, +I=K<'#0X7"
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M9!'_LG/W+90PB=PJ%CB&V2%F5=1):=Y-;4/VI*@.'60!9QJXVKY9#-)O!AX
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MV?1#8L_/G+'OX?;FN3G;'(JY$=SC='N<+K?+Y7*[Y]UNI\?M>=#<7V;49M2
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MAWA>V!MP(T2=M6GK__3#^!.;6+E1#0D7$HYO&FS*AG/M\&!@89Q%;#]4*[[
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M3DZ;%M?.*>GS78WSW4WSO<WNP78/T$ [B("A^EJ1_C9"P_9JN91('X+C!7Z
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M.2#ZG7.-I)J3+@ U)IYO3#[?D1$*-J GG6M-NUP?=XH6!_=9>_-4W>TS]7?
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M6$&(;%-$YF"2G0L6\0^G2, SP,G3"X2%-P^]^[OHO1_5QIYI3+A0<NU(1G!
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MC$B;O(X^PB#_I\(_:H5-@0F _Y%NPJ9 =4+W('.$7Z5KS-4VY4K*$^=T7,@
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M:"1P!I7(6)/'LNE-E[7;OW@]_^YI7"XDH72!R-+(5>9$=@@28-CMQ:S#!C2
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MOG35BFP!9Y!@OHL:LM*]W93!2/9I,V_I]GV(V_W!LOMW6,!:>=J=[,L>RL1
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MW956A=!0DY=ZW>OAR3U."]X^O741V@>BQ%7PBA^N,CN6D("3'I,!Q900&"8
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MG<(";#_>JAX/$ES]CX%XG*#,!&DD2#U)#E&P' L# 4 L#[/OQ(@;@& B&T<
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M:?#A'<B"!W_&!()DP=(_U.2'WC]"7"&PRGE0K[<5&CT8&PKO'MH6<FP7VQV
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MS *9_F@ 9).(1"I(:\F0-%-7%&NM+\(@:$ 0>MP^ZJ+;H)QSTV-#TN4#:.-
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MP7:(-XP##]0/MI8CX* ,-O2VE*5X[<FXX +Q3XP'&#5\>)C@;,KO.48*^%W
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M:RS"1!4HR-AZ6^%ZOY^.?SC->\;*L>GQX9OF3N,?@K_!*&\TRNJ-,L'M!D$
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M[!?8B,+@8.C*'(2@(5Q-(AX2MG$^ ^<IYNP7L#V;T%#2FBV8<P1S-G0ML63
M[ 9LA&/X:C7$OUV#C++J0QOM8]\-]/XK/_@N];!'XD9]/'#8@+%3IH\>,VI
MG][+ERZKJ:J6\"_IFDG"?S,5>X5):G'Q#/]^3(*8%S"""8DX/E(>"!2N'%\[
MI+VGU^V'WGMP[7L/)7W=+:C>S=MDF)+)F4,L>8(Q1S!E"F9-- <%^+'AV=G$
M[2QITPG.;%)Q ?N+H?VYSXQK;;C6B6&^UUCS-7:^VL8QHRH;9KXXI6R-B519
M2)6#5'I)124IKR#EY=1"G4E%%:DH)Y4N4D6W-Z-J(U=M@ND&?+:H_?"Z],BD
MTB94,%>"2865E%O 'JO@T6-[)K&Q8?O@C<2FFS]A 'Q]+[5+6BMNV;3C7P,S
M_%/:V3(C)9G85LCG*60+OU[ZT5-G)W</:Q)H%,(;H/8E]M7K;=%1:B)K+G*6
M8*^95#NA<V-#LPD/B<_9U+%;7M9NF+S15TYJ*TE-%:FI88_@NLCL)TQ\E3"S
M,(T+@S8<T$=J"G@/97\>MN822ZX@VIPG6'(8_BG[V4A'$&E=K E -BTR*JH.
M;+1^]7;E1[>%O_A#9%,?;X7&XK$X*WTUU55NER,8#"*$8K_U5T.Q/UZ2)#%)
M^&^F8J\P22VN2^/?&_#KUT^IZM?:/ZB-?EIWR[9O*D^O".4=@A[G,+E?-C'E
M7!'^[9F".X=& *0\'WL*D:L8N4IBS+M+(IX2SEO*><OX<C#VEA'1-!UG%KRE
MQ%V$G?G8<0$[\WA'+N?,P^X"XBT4+7B+B+N ;4!=@!P%O",?.0N8"\&N(DSM
M+"*.QK878GL!-;(5$ ?-MJ$.(_I>FI+UQWU5\<\;U/Y\%;86"D49G/)XY9F-
MH?1MQ'2*-\I)8PK&&MK*Z; U&]EI"11C3YG@-31R.9AXRII8'[OEC]DD>,S$
M;28N"W%9V2-8\-BNQ-AK0>5Z7*G'525\17ZD/ >Y<K$C%]MR"$W]+:)SZK)_
M%90)#&9P:?R73_B8[W-7Z//?XZT#PN'"<G^YLZ(VX//Y:VNJJZLYCHO]UE\-
MQ?YX29+$).&_F8J]PB2UN"Z!?YZ/5 0#I6LG5_9M%1S<UC*K3^C\2G+A #:=
M(TXUQ3^RZH@Y][+X9[XX49M=1YR9Q)%%H%XWA]ARP?:+1O;<B#V'=^8AUP71
MQ!FUX,J/VG%!L&7!;'LV!;')>%LZ9Y=AIY*X58);S:QD#1)5A/(;F$&MP^8,
M9KJ@$_^$<[!EP:'J;<W$]"F+#MDR>7LF;Z'XU[*I"W_^'?VK@G^8#Y"^1R4V
M:X-%6NPHPD5JE),8SCP0R=E+O.>!_7:8C3#FU>N/*7X*A$8 MBQDR\'V7,&>
MQWP!BK'>]$];7JRC6S9QPQUAWWS!7@BV%0BV?+#XYQ6;QEN\\P)V4^<A=S9R
M9V)7-G;FL)LOF6RZ9''&Y$SZ18+*_^A;:_2A\#8-;U14']CD&?<A&=R.[_D7
MO+E?*%(0Q#3E%Q#B,()IM6._\E=)L3]>DB0Q2?AOIF*O,$DMKDOCOS(4+%X]
ML6I &V^OV\]U>SIIRF>F'3-)Z6GBUL TLE> _WI3'B,;W4M+'!D-#',$1VVG
M5*91 CP2&W/3@\"M=Q6QR8D]G=C3ZIPNU)E A[%T:),(\0% %,8?-"F(6<$:
MT['F]&:9X*2!@D;P-##]TZ6F)AX-<6= F"+V_8,W%8O8G_#5P#_;0"G O?\\
M8LXGY@).DY0V9\+R_SQ_9DJ/&L46F%7(KFTZ*.'%(XCM#"!+I@N4G1IB5$5M
M:NSZ]3]IL[J135K6\H,^TF5:SO(F<Q__A+%9A>@CY3H-MAP9U-BAPPX:)F;2
M+T"CCY[BWRS._-OD+3MUV*2J.;39.OQ?J._?4:^_DFT#@^$+ 1P(80'Q@'_Z
MA8[]RE\EQ?YX29+$).&_F8J]PB2UN"Z-_XI0L&3UQ.I!][A[W;[RB3],?NBV
M_8/>"F?LPPXE CAEX1^I_&]L9-%$K$KD4&.GAEG-+"Z#B5,C.("+0"\S )MB
M6VAL9$W'P'XY9B9VUNC=*B.6=-%L UF##>2"E3))?%;&G$8L*8)+3MQR[ $3
M9NRN,UUVJ; MDUBS&#[E,;#Y:5\]_&-H_9=%3'G87A3*3-DR]+-NK6]:^_FS
ME:D;,2T0FX8TJ9QH<(2ZZG$8F%G%!FB"4L70E:Z1HZ5]!89:]T:FT966/K)G
M:0FG0E>]GV/X1,SBO)'1]I+(KN5I$,!"P(O%!>&+EO4Q@3@FYBTC>P:GEU7L
M7><:_3[7\V]<]S]1_(>YPA ,)BQ@S&/$2_B7=(TEX;^9BKW")+6XFN"?!#C,
M57,1_<:I50/;>OO\[?M';QMYW_4) UZO5>^BN3+%/Z&,O&+\8\C^55!GX%!B
MAQP[ -+$K@1#I@X6K(IH9P%3U$)C8\H82-]IHJF!I-.LP9!!LAGVF)%9BRT
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M4FD[-(/A__ZY#]T0]\#-YT:_SV4>0J9D[-) EWU+_<2X/Q__-/NW9V!/-N^
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MC],V@J19E.. <%RR?XE?&<G^?R+B7YC$<P;L<P;\@S?^43;X% "6Q@F.).#
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M<]"U>8-+Y-YJ_[\: D9@P8/)4"\RM"^QN"_95G20%R7O1P;VQ?WZ !'^?8@
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MF;-LEC; JV6AEV'>:Y:Y+YOF_K=]T2M(P,M(P'_;Y7^PAOZ[+?B_L'B)H0
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MB'_SDGWM1+KVDHVUU3&L 7B\A63M=CMKU+ J!V__W&_/_H6=G).3(]F_1/?
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MQL><LH)559/:2D)?PH T;R98?IAC7? !NL ;V_(U6W<+&'\#BUA9^,8_QN%
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M,AP)&HX&#L,"AJ#RH6C8<$?X,'O$,"1\F&/Q4'OH$&OP(+<L00/-\@$67J;
M_J8 +T]9Y'V-@3)=0!]U8!^57-8L[ZT,ZJ,,DNE"^]*1?;G@/['S_IU>\)]8
MW!16<0OC[&H6,X/?O9UB$8>#M=@X(\)2)$/_]NU?F#W =GJ&E?BMT_J#>0X\
M-2^/59BN6J'SL'!1''$H#V-KJE!V]'A9EK*;K,]]V)3457F\%Z #GAJA+>Z]
M(8;25S^L$>\<QJ9\4JNG//?A\^09ZR+QHO-BV[\ RG)FB@B,#,V]<YU&3(2E
ML?3\N<(U7R.K!M%RF2GP3^9%?\#D+V.+7L;GOXKY]L;FRK#O^J!S>V,+^SC\
M>MG\7T7\>@FB0OH+(H/Z,8L'LA%#.$'A@\6*&,!&>)$1_;#(OHXH&1+9SQ$Y
MT+%D"!DS@HD<@ 7\T;[P)4=P/RHYA-,\P3B'AD$LP.81FL50A+7:.=,+8?]Z
MO5ZR_Q>=UI_*<T!H@GO26011N">_0CE_([3]9L2(8[>++UXM(?$SZ![VSR(,
M';UV>?Z#7 :W4C:CY7%U]<$MJM@9UN536Y9^I(]^T[KL+5OT6]:H=RU+WK-$
M?&0-\[$L^=@</<&T[ /#\G^8E[UO6?X/RXH/P *0*>8]8\Q[YN7OVU9]:%_S
M$=2J#QVK/[*M_ "& ('E-1/L:R>85[^O6S56O>9=S>KQ+2L^U*R<J%OUJ6;Y
M1ZKH<>KU'UOWSZ;N)7+V1IQU&&B'C>%8G.%P@F 1E+/A-)QRSU+T4^W?L[*>
M9U+/$ZMX&P_:QV1<$P.!K^,X+AB\,$\0_"F,]M^[=V_)DB7 _BT6BS3S_X5&
M=+1TB!#GJ8@W>Q;$:?5(Q-]-6\2QV\47KY:0^!ET"_OG6(0B%P0LS+V30Y$V
MB[Z1T#6PRE+V\0WN8197F,H4'66*DYB2)*8TF2D]S91DLB47F-(LIO0L4YK.
ME*8Q)6><*D\'HH$J>)6G,6Y59M"EJ619*EF>1E6D4]7GZ,I,^DD*4W*2+DNF
M2T_1):<9$%)YEBS+)$HRJ*JSK/(F:RIC,#7.V"P48B-I B$H.X(C-CMN(>PH
MX4!Q!XHAJ B,1U@6K+<SA#."^$3K0HC#\&8O0/)O\Q,,'CB]D!$ =P'"A=:
MT/O7Z70FDTG82G0FDGB!Z.(@$? \J+I O-FS($[K14.\3U]DQ'63Z)%T!_LG
M6 9GJ.B5T7?NW20IQ$ZC-LJ.XS;28:)1,X6;<=*$DCH'U6*G##;28J:L>MIH
MHO4.2D^0.I+0DJ3=)1L03MI0T@I%6%&<%V%U8!:,L(%/!VJV(V8[KD4=:M*N
M0LT-#FN]PZ) K'4VB\)JJ;?;FNP.-6+7V6P:&Z*W.(",)H?9:+=;+5:[V6JW
MF*U6L\-L!8)_6FV>@-ZVF0<L .NU6EM7"\L.AP/A 8T#\&D'R5JM%AYA0T]
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M!X$9/$(Z0DS/1*JJJLK+R_/S\U4J%3!^F\TF3?WK'C ,WIBR4#8T*.GAN0W
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M:NN<JLW?5FV<51OGV[##7QD?K-RY6+DSO"D>?(8V; ^N^2$ :DM =5Q@[;9
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MQ*0?0$H[Q*0=8U(/,BE[F)0=3,I6)F6S6XF!+N')@7C*)B)M"Y6Q#81E;7>
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M6"KC6I-#K9*,$5Z2798Y7)MH+KYAKHJUJ;('JN)MXHR1ROC!LI@Q8>I05?Q
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MFQO_2A^&<?CWD?==S2D/L=#(?Z/2H1&--)<F'UW?G'6%ZA:2O2+4<:Y'(_X
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M,O;6W/C7-I95'?Z<P__?.?[1N2A6CXK22HV\]/J,2^K2V.:LR[*D4$7R.="
M-!/ 3VB$;K3H40,UH15,M)>[5O\C]:+A^L*2BWNEMTXS.H1_6L\*+2OW:/CO
MXR60&A[@?US7>'[;DAWO<_B?DO<]_&/BG[*T4(:6OOA@PYZWG:N^/1'P+*WE
M<?CG[*D9A__Y,O;6*"O%V BGIJ&LXN"GSO7_1:WY!IVWG!Q ^">[FQE]$^J,
M?!#^1^J+DT\&B!-/8SH)N*<^Q8HW\SC\/[X _P;Y>&ME]KE=P:O>C-FW(G+K
M9S=W?WEC]](KVSXON;Q?D1HF3PU3IE]0I)V7)I\5)IX6)IVISX[HK;K541K=
M61FKO!V>&N2O3#Z'EO$U(/ C^33^>^2YK@O_E$Y&JT5,3\V0*(70\ B3<E3;
M<&[K%UO?>35NSV>&\AL,6@M821E<-_R5\#]+[OG(]RSWN3Y'_EWH'P3_)/HO
MD!/F9L;2,7;[0M_!]\>7_IMM\P(._YP]3>/P/U_&WAJ'_W]$_,M&F\IO'?';
M^.9K05_^R>_U%[>_]]][%OUBW\>_BMV_LBA\3V;(YM03 2G'_1./K8\YM.K&
MON57=R^%S_.;%IW=\M'9P(6G5OY5E1+&6!2D04P!K;5H\9Z'Q;]62O<*F=Z:
M.^)4QBAQZF4CFOHSFS[;\=Z/8W9]8JZ*!N^?-M71:-RXG,._M_[A\&]LM>5%
MFO:]ZUC];6O@#VDUU_?/V=,S#O_S9>RM45:2!OSK&LNKCRQVK/\)N?8;5-YR
M8J  -S10W4V,KA$U]IK0##%J>EEL0@(/CT+\1B/_4T]ME"2%8GHI.\?,IV29
M"__&Q\<_[/'25\!_G4LL^%DA@*$:  ,U !!JRE:R\D[M_GI@5CR:C.S2+ :Y
MO9.GRHC(#-V6=-S_YM[E2<?69P0'IAW?T)Y_8Z2I;+BA>*2^:*2N<*2N8+BN
M\&Y=P9 J_VYC<;\LVR#+[)-FW3JX6A)WBE#S<34/Q>B%&H!>A +T@E!T7MG,
MH+_NGQNVV8F%*EHG)3LJ^GF)E$$\ULVSZYK.;OSLZ.)?W]R^R%(;1_;4DGH%
MKD-QB-D0OU,<FLE^-A]05&85JEOX/NRLN><KS^UYR??(OP>AP+IL/GODRWMO
M>/LD\@#)IJ(LN_60^)]:\8]"_R9RTHP< $?1=?W>MYU^SZ"A?[W5@'^"PL9I
MVL8P&(=_SN;3./S/E[$QSQ'G  "  $E$052WAKQ_C,3,[37BD!6V]:^2Z_Z=
M+EY-#U>0?>U49Q.C:: TKDC@D^'AW-%^I*S88L6D&&^MS S=(4T^C[%?/;#O
M?TJH]&=9[LO[!^+?YYBO@'_6Q>]K<#O],R_T,&G.I5DX-%=6/(S86'Z45N+L
MYMLZ:L>ZJN^UE8VVEX^UEH\H\O1E\:/-Y5"CHB;#V@"GX3="7CO[,^%ZJ5/-
MPWMYMPZL$L4$X[U\1T\-H1.2!A&[UHL/>&;BA])+(1VJ'_)'CK65#@F2"*/D
M7G<MKFT*"_SLY-+?7]WX;A\OGNBI(0TJI]9%G1E)S?#['T*SY-Y3D?=M^!SP
M%?2@R82^\D[A2<K]C.[JEYR](L*_ZT\7_NU%U_0'WG7Z/S.VX1GD_1-]%(6-
M,;35@W^2H$D._YP]>>/P/U_&WMH4_D6G5EC7OD*L^3<&\'^ODN[K8-3MC+&5
M,2K!-20-*'0, @ X]U TL O[NMO#+776CMJLLSNE26%.K1A'X\E]O(VYF,?A
M_U%$FN0D&_F'@&0'ZNC!>K;(EC$6)=E58V\NPWN%E$Y":<0/Q+\8O'^-P*FN
M9=GO@YS9\'-__)]8\KO+&]ZRU,21O;64J0Y# >\X_/OJGP3_5IJVT^[&?[3>
M#^?]<S8/QN%_OHR]-7*<H!R$T]Q2)3RY;&+E"\2J?Z5SEU&#):2AF6BO!^^?
M5(M1(!? _ZQ+AZ&"0S7149,>LE6<<-85\Q]5$;P*FKF8Q^'_442@[E@YV:\"
M\%.#]:1>@G773C27#$@R=35)]^H+ /R45H*B OCBWZS =1*GAD>H!0D'5TMO
MG2;U8ES#![__4?%/&J0L_I,1_KMJ"7T+X#]H\6_"U[]AJHX!_).F>M)2SS8F
MS]KX__>.__G4WQ?^9VJJ\9_-?X1_2M?H*+ZNW?>V,^#94?_O4=V5-&8F*=Q.
MT0Z*QBCP^BF*)J D>;+%G2<USK[.QN%__@QNC1S#2#ON,+=4\H.6C"[Y(;GR
M7YF\%<R=<MK82G4U,8866B=C!E3,0!TST. 6^/V3G>7@=](&^7!]26)0 #_N
MM%,K0GW_OGV-<S&/P_^C"/6JF%#@/\(@)?02>ULEUE8YWE!D$65T5\8[U#SX
M+4BUR!/8;CK^*3/K_6OXI$:0>&B-/.$,!8GHA+1%CF2>&TN3=SX-_Q*\K>P.
MX-\@&NOA$;IFP/_1SWYU?LV?#>4W*#6?,M?3_8WLD\XZ](_#_Z/(.X7YT]30
M/S;_6?P;FQU%5W7[WW&N^]YX()KX1SL!_QA.,CA)XQ1%,"""Y/#/V3P8A__Y
M,YK%/V'#[::F"MZQ+\:6/H=_^2_.A \G.E/OU-4.B6O&ZFOOJHKO-1>/M)2.
MM)2[=*^U?+2MPJ.QU@J+."OVX-J:Z&"'5LQ85%S?OT>S &RNK'@8N4/)*NP]
M_"%E@;;\5EMV9'=1%!K$UUO+##<R9A76S4?K L_$/VJY,2D(@\R#?T7B6=HD
M(W5"RBRE[L/^:?CQQK\P&=<*)C1"7-MT/O#SXXM_<VW3^\;R&[1&0)NAFMC(
MCI3D\.^E^V;UK/).8?[DC7_"U$3WM5L+KA@.OC>QXEO6+0L8BY1VFD@2HRB&
MI!CP^@'_.$,0'/XYFP?C\#]?1E$T16%.C)IP.EO:\V6[_DJL>-[A]TW%T9_6
M7]]9<_E4\?GC99=.E$4<*[YXL"3B8/'EPR77CY7?/%X1=8(7&P*P+XX\7!1Y
MJ/+F\9(K1R*W+Q7&A]IU8O!-T<)TKNCEG@#F<S$/!9R'&@"[2HU+/N/Y/5^Y
MCO2(G33HDA?^5?<7.R?-+79(OV=4OV?8_XP+L?*Y\X<3 IB/? ]#0@_H?:M>
MHMB[I;32B=;*G+,[FG.O$#T\&O)<*Z)T(DJ/EO4CM6CRGFN.@'NLOFO!7[.2
M-,HPG0!3\^,.KE8DGZ/,,C8F($#=,SY\5KE_1!?^Z3X5I.ELK;PKR<)Z!7;
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MFNNA10X#"W( B%DH0X=EM= A47@%_9.X_P@6]2H*X:S #CGC5"(P50!!=,A
M&$C\"@*@?Y0 :,S\HZ6<G>R8T5/_R'+TK<#&/Y[8\D>T2^:AD/Y#&7YI&F4
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M:V5<:-+$A'2@?9HQ+RQ6-#%(8,+U]0IJ[\3S'B7Y#&).UT%BL"F#3G70J64
MP,<F)6-4,BX=LK5%S1@5C!YF:C4PM-\H"YA!HU4"*%,(0:-\"4R*T$]F,K<"
M0QBE'/PF8'<E[=#1@^U!JRH >Y*DY915#3^!-( I]$$56Z;G42$&6H#?) %@
MZAL# K187 TE?,:!(X!%B+9OP^%>@Q  JC  ]/)EAX19)!S!-3_ !WCZ^5X"
M7[_ -[ $1*%_%?QZ8=0A44![/L'"QG[8B-U#LP&9_2.$M)S^">FBE0*!%@A$
MM&3#%0M +!CGHQ$E?BU'E%WDBPY!&TE8#N" KQ_WI,B#BX 32A!FO-\%:\'R
M_+L1DWY8>,*'%:9_)&GX\I(Z I&3A(P9)ER#"(&3S$+"V0(PX=(B+#R(9:_6
MRQ Q[6"- Y<6I"C:)O7UM4B>GBLZOZNOYO%T9\-L=Q,=/N&2.UW^W$-7U[!6
M5="B8RVM,\77+7%O^M?_X>R6/V>=G0&61/JM\.2V:/J,M6]NB]'_2K4H^F\]
M^K9_[7?]&[ZCW/E//64W@!L8:U=@3#[A;*0<H%OK,/H_P@0+^BA,$\H)=553
M<J(B\[H7E#RKS&<2>PQ"&I>NM8Q911GE/J,\8%?['6J?34G!#.72441?1\H'
MMC8K&*YVL*N5<;>%X-0MP<)/.L:M17 6<E#9'3HXG+)K@Q85G"T UP*!P*P(
MD)4(N H2/\;+1;/1XK7G$!;(C #IARC''/,!AG2+P0QJ,4<O\A"6R0E3(SEY
MN'LOPT(W.(TSS#I$/25*)W8;$771Y0CUX54(]3^R)<BE^>.>H$N+IHXH EA*
M%1'-&"@*4__:Y'Z+U&>61 #_Y;:#4+5<.>:PH'^_! &0O98B:)*^ KB/40SP
M&\7PU@'@]:-(#N.H,Z.TQ^4V#H\JZLW1=!@.@L"U\,7,C>+18AT]VA5@&2(+
M'U](_\NT_P@!?V7ZIS";D +IWRZ;ZVJHNQU7?_?X?'<C/GJ'&L\<?;]?0/\!
MLY8UZ8#^;<=_%MCP?\YL^5/6V1&C_UA[;2U&_RO5%NC?/SNF+6F-^YEOW5\#
M_5=\\"U!:APHHXRU<\XM'+)4^RV*@%GELTJPU!L"K;ZH-9*%9]3^^X3%%P\T
MW#OE!ZW:I<%J=0"89TU*UJ"DC0J?418<:@V.=?CMJCFCU =D,]S.C'0&;"I_
M/^BO<BJLW,.6$*Q*A$4)5\<.6)6X4(W;X;L< 'S# 2@_:)#[!R0!O8R8!Y2T
M%5<$& <07COC:@/]F";+ZERW%Q#6GB/*/6624$@Y2&8<O7E-8D"8Y,0!"WJZ
M ?Q >&0CMP.HT9C-#9.G2L@:-KKBXQE,$HZ6$&&:#'".^F$."PTF-[8&SK0.
MNJ,\: E3;/@,D8O":;GO?K,4@;M)H1OP!7L+G] Q /03I#&S%+9$879 ,#O
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M5L DF>]L&I*6N*4EGCZ!IY<_W]T\U]DTV]8\T]HTV=KHUM0,M3>ZE)5]-6G
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M@TX%W2'W6UI\SA;:JO;WB@,6,=#_T^,;W8)"7T?SN+C4V90[H:BD85;5HT\
MF6$EP&J@04ZUU4VWU6':'YQB5-*L:P??_=[EC?^1>7*+%W:P*0)&\;2N=E1>
M#D3".#4!H]2/Z^5BLLR/8(<ZV/%>UJ4;4U4^.[7E[NZ/ZF_'@\P!U,*8Y7 2
MS%5G1T]#;Q?/5)<!BMKUK?]9??/8/-"_7H(.6?UBMD_L:VV8U=6A[Y55.:HH
M'Y258EH;S,:J"I@QR9TOO$X?P"#&2#P8JKSHY6"6C6NK30U90&;!?F%0+P[H
ML9\A8(Y5M.4&S;+Y?OY8>]UH:\VL033=V^+FY8]*2]'8&\H'$')_PP5:XC?
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M*6-$6N3K;L+H!KT(TS.0L()(^-E\5_.8NJJ[^HDR[_:9U6\::YY1>C$JN&@
MP'(^+'K1*P-VN<\L 1D.>I)^:HM-5@SC-M7;C"F2D),((N2Q+"4?C7D)T7<2
M8_,,(DY00 HGGI4+,(<&AXOB6P3TN$20,'K$LI7OT-(X,+T30;E4&'6R"!%I
M@"(($E=' I)BB#A1>CN:0)"=4E>,R4N&)04N0>Z,M@KX'G8>E95-*2I1?K)B
MG.2TIJ;ZRI',N(W2M,N^?C[C4OI[6W19UQP-F7ZL@ "W@/Z>Z(K8)["WY.@K
M4@0I9^[L?I_W^ P:_ZT*?R]_"%Y[524*A:Y6UB:S";)++N_+BM_84WB7@:?
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M@L?G87RT!?=HO3C8+P*9@,4,AHK9CB:@GR%AT9BH9%)2-B(O \5Q7%4YJJB
M[Z/J\IGN!K])Z-/S* MT1A3L;;$U9QKKT^?;:H')9MMJ.0<(Y!(N'B\LZ RK
M*VVB@MF>EO;RE&,?_,A4GX4BPI VU"MB9N"T?U"IX:[[JI[F7]PWU%HS;Q01
M^L=4RH0YPASL4'*9$TE ( &F22#!>&1(,>M?5(Z_"#"73FAPEB R:.&P>) 5
M0+]?CF $<*$H$-L !C=RSS0,DC59 8.,YJO.EB%1,8R8H?:I6Y@W+"V<@Z%S
M8L(HD%:'A46!;CZ&\+EU\QU-C;?B<T]N4V5>G^MNHET*3V>]K29MA)<;[&C
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MC /(7F2LR[BQX]= 2)C T:I B0>H'?1%H'E26P%M)(.M^OK,Q\<_-XORX:B
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MIFX=6<U-BG)V<+%0/1-0#=Y_O[R@4YC=*R\$U]94=:]3F#5=W>*<'DD>2E[
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MY_LZE10\;ZPZO^[=B,]?LPHSL82,6>XU*MS61G>GQMMGH<?Z?,Y^#+9GY1S
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M,/A7D/"N&7Y&Y8.*==\?3O7PR-@$LOLN@0LV-0+E[XGI(P/B_IA:$AIAZ47
M_\8>=N[?(B=UPGGH_O#XGQ0;;@D"(X/4"YUM-6GAZU/"UI&/P_OW:/C,"+^$
M, H\316%4=OR(C>/J(M&FRK'&JO&&ZN<K=R9XHRWU*#:./C?%NYP!V>HO=K9
M4.VJ5XZWB@:TXH&&ZK[$$Y9U+XY_\,_>?<^Z39P0_D-MT5H(_PO5OEKX=ULD
M %K>K9,I45L12(9'R?KW%<._0=)>GCC:SIG$?\*>98.-E:0-:_L^%OR/MV-&
M^H/O_?K>X;6!^#=A%#IA%'M,$N#'E2T?GU^'%?\8_,LITYR_X2P*FK-_ #7
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MS+G\6=^J_W)G;W%9\RE;/=W> $SU6H4D3A(K&=@@4V<*WE),%7=A 39;HOM
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M ^"?THO@(L3MV&6>CAH3YR[_5D3%I0.\^#!)4I0@(0*>:(KCAVN+21V?QC0
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M(6 #<,6EF-'26V\<J[ZX#[[C@5ZAE56,26D%59UUF69:/KBAX$D'K5(_?.S
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MQT'TK)/L[!3FG5,MMY+JKARLN[2_X?S^K!W+3[Z_).GMY[HKTH,8*O&QXS^
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M)> _9)4Q;AXO.K9Q4%09L? Q5H]5]*7@G\J/3%C$0Z(:2<%%8?Z%22T-LP_
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M_]775_WA>_RT(Z%>$05/_S[M='<3;#-LEX>].!YA:\RZNO:EOWK\AZURN[A
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M5 -&>M@8'K4PDZZ0NR?H:&6MVLH]R]=^^_^EOOF["6GQ5'M#O[)4G'7*UR-
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MZ<Q7PFW9P-> 5S_CDH?<4MK%U1)5X2-IKKC,[9CDA#  )R8!+!4TR"T',2Y
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MEH:-0M^PF.JO&4_9$%SR7^%G'_9O^P';6P*/#:P3>H];_#,TT3Z6+8'_>]4
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MD4ED=(G@GQ@0.%V0Y/$E:?X L1J<&D"B!;DM1'I$./S'^DAB?SIU%!P8.OK
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M$JR%C;:+\!8IU:)"^UL=A 5#+(2]'W/TD/8^TMZ/.P8PP'Z'#;/V898>V G
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M+B(#9C9 D N'3O-?Z?\5_W?VK/;Z])WR@)UH0Q[25(ZJN8B"#9P8 DZH@B.
M437+H62 ^[@:KF<,"/.X=R_&NJPV%2106IZCO@0.#8+MEL&/ /;3(/YAEV7G
M?&$E=+-0\&6K&&D5UZ3<#EBYX/ ';R;M6=-#3Z5:N)BLP"+,[*"G#$@+["J6
M0RO(]O<\,G;DHWU?])3>(A79N(:/:42(6DR"=T=.)V30!\)U?(>2:ZWGX'(I
MI:RBE%(XAEO!Z$L*41[:U+AE?N^-=:2F&*,P?+CKW[#]+#:,_Y_+7E)V< 4
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MRLKD$UOVOOV;$K<#6"T=-TH<>B&F%J)*D5TCMNC%#I,$@PUGA&@S'S/ [K-
MF 'P0TSIJIQR[IB"L,DD^H&,8N?CU9A&@FFKB>8Z4E]-*(3WC^W8_L%?SB^9
MHLVX/<!YVL_)-)0\ZF _ZQ'D80#))A$<TZ=FXR81IN6T"7*-I8_[JO)%S\+V
M3GO[Q >_CU@U)?G,FJ"#2Z/.[KOM<>3QD4/Q[GNBSVR)\=T1>G+]-9=OVVFI
M>%,E+!G7@N@<KEC $CXE9#_@L9Z6%NZV4>S$/]G,QYO_)_S#(8$P)@9TY_76
M%=Y<-]]KTEO2ZQZ8NI0RL0@S;!-$PNA?B.LDI%X"F_(V"Y$F>@<OMU=:;)/1
M^VM*V[DY/<*\Q[X' /Y!5$KIA8@:^#?@-XHQ!5M1_)CY*+3BP0UF<K"J_'%5
M9G3RQ<,W#JQZZ+./^2 PV?^0['E\*SLW[;+'\QMGGEX^'GED0ZK_D>)P7U7>
M T%22$&XCS@M4EGRR-I0#O,)]")4#APO"287TF.#=XS^T_&9[Q1<W.T0IE":
M(E+]K_'_SXP_6*3GE#-7'^I'['\-_ZBQT:&0]O++PW=^<WCR'Q^[+NUG)E J
M.K@LN ;N_OQH^\#95\!9%'#_^)9U;_WZZ:F=F#"7:"S#-?\)_R8A_(UZ;C\C
M[\F1[8='_?G$F-\?G?QKEZF_V37NOW=/_,W%E9.YT9ZI7MNNK9Q^>.+;QR?\
M/?O $LOS&Y3\.:[F8@H!KA1A"BZFHN$JIK/1 OA?8,)T2$TIJ83SIJ%;K*E4
MQ?G?GS_NPKN_*SV\A&SEV"GDIZ_[&\;_L$$;QO^P_6?\@^B_,?Y:W_YQ^/YW
M\,AM%#N"U!?"$:OJ*@JV_JV%&6%&GG,R.AP^"R,G9Y^9H2XW$/\BB']Y>:K'
MMH-O_Z[H\%ZRCDG ]O)5A%:,JR283HH8@22D60JS"%NJR=8:PE1%F*5 :&LM
MTE8'A+;7VUMJP"WX+G@F89*2YFH@',X5K'>TUMA-$JM!:#>*"+F K.<D']^U
M;^P;/HLF*I)N6LI34%[N .L9_'1N8MKJRS$U&R;! 5J#HVVI0E1L"S^_BY=5
M%'/^V*>C N=_4.ZW0YL;(LD,5I:D: N?M^5DF@I25*4/1=EASR).WSNWNQTV
MN*4-LI\TPF5M&,YJ."CL)<?6TM- D"W.C"8T[,'E;E(WI-?P#]@/8$# LDDQ
M9N#U-I9$[%AV>N(;B3N6<A_Z&YA)6 L?A7L' L Y0@O8+R'4/'M=N3@M(L9C
M>]3QS??/[H[WW'/?<T_:I:,!6Q<5A)_#%$P8_6MX$-4P6!<.-%0B"C8L!# (
MJ1:IM:&B\+9?;O#9IT'',Z^YAQ]=+TF-M-73'WB[)/FX9%\]]2SPQ!,_5T%B
MB$-:@C94H(V5\&UMJ8(I'3"?@(\K^;A.BBM$M+O!FT?\R6/VR.++!Q%A&LS[
MTY81JG*(>=CQ"7@V3,CRP7!_<-"B@DG(AP1K]E2O\O]_A'\]SZ%A$28!8FBP
M*ZMZ!17ANU<>GO+')-<E%O8C2DES3FT6.XL;7Y8XOL*_&H@/<)OFM7_/Z#_E
M>NW'!+F4O()X&?V36B9<G]<ZTS)@!@D?MO.#A7]\1,M&FWF.VG)6J$_H-W/N
M;UYX;\_"F(.+KF^8<W'5M(?'5S<^N4Z+.)MP9&7DMA6AJS\K.+'&4A!!J4H(
M-=<AXR!- D3. ?C'8((A^-< 8N':"D1=3"K!'X 8!=ZMF=N4<.7.YY/._./W
M^:[+R Z!E7(,XW_8?AX;QO^P_0?\]R$P^F]*N-E_8#Q^X%V(?V8XH<D'X*24
M$DHEP375<,/>Z(S^X9AY"64$O!&^C/Z!*R $;"/-X$MFCM<^%X#_0[N):CJN
MX=O5/$<3%VO@(8U\NX)GE;-Q)5S#IPS5N%9L:V([%%Q4Q7=H!#;MH/AVG<"N
M%: J ::&MXB2!Z7BH6JX\XTJ&+B:8:\K0K@EE)21=\;%?=(_/*:_D^^UAW[E
MA"#2CQ-UL3[M-C?Q)C\YM#;S3GW6W9J,:&GZ;7%*N#3SCBP]FO_HQD/?/>YS
M1U]?-J$VUA/7%=M5)92ABE0V4/)J$@ZVYY &IJHLX<DEUQ9Z*J:@D7HVT<S!
M#&RXGZV#C7@1F.G-U;(R@MTW"C-O ]K]($U!_SK^P8\ GPDNJ+1(4"._3UX6
MNG71X=&_3][[I2@Q0)(1+*]\9->PL&9PRGP"+BR+2+4 J:^LB+U\8>,7%[<L
MB3NU*]%[_^VC&Z/=-IU8,27[QBFTB4X91)B63QK$L$30*$%47!*\.\ G !Z/
MAM,MRL\./BO+C<L/\TKTW7]YUW)>4HBECG[WU)Y8C^VYUT]7/0DO"O.I3KUM
MEY; '72] %,R'4H&.#O8QK]90C7#%1=<755YY^;" 8$"  "  $E$052F=_[H
M,7M44<!!1)Q):0#X2R'^AZ)_#JIEP%!;SX<U==#E8B *!CB,0<'%_W^6__T(
M_T.I?R*'L<&FDO8(*R+WKW:;\;>L,ZMM_"=X4X5S*>*'^!\L=@!RXA\HQ^^(
MRY@W\GP.XL+G9%,YKJ*#HX)OAS/ZAWX)W/6'>_^#^$<U;(N"AIL$MB9Z191_
M^NG=G?GQ#G$V)BNP5>6V,A[W"+,P>275S,=K"WK8N:R(2T5^>]N+8\%? JI@
M(W(>*A>@3OSC6CJN \XNAP2GKQ/B6A&EJJ*T=8BY#F^MJGUX[=:\B>YO_CKW
MX!=$.\=.6LAA_ _;SV+#^/]EFS/QCX1]""@ >QM)V$@,(6'?,0Q!4 R0WVY%
M^Y%N34UJ9,O1V=B1B?BM;53N)8)S#^.G4J(<2I)+5.<3M;E$;29>E8Z+,S A
M4#HF2,<%Z1@WE>"EX?PT7 B^E4[P4C@!!\^-^TOVSE66PB13<6)MQFW._:ME
MD9=*(BXQ8ZY6W;O>DAQIS;P_4/"X/2-6%G>M]EY0_<,;RH1@=7*HZLG-YI2;
M?3F1G9G!LN00><IM>=K=QB=1]<EA\J004\*UWN0K \D!';$^+3&^YH2;NKM7
M,O:L])TZXN*L4?'K%D5\->_2PJE^BZ<?G3/FZ&<33RZ:<F[%K(LKYU_?M,SW
MZSG'YHYU6SC99\7,HY^//_7U].WC_G)AQ61N[#E4EH]J:3@$0PW<6= )< ,'
M?)HK"N(>^[FT,#,(+9LT\ @#%VWFP-)!/<QE0V '?H&.]33$;8/X630<,2!G
MH'(Z0!VF9F&PR^S0BO<@_L$/0OQ#U FH[MK.NH*';AL\)KV1?V:;79RE+KZ7
M>\>[L>(1 OR&]GI"+4)D;-@?MUE4''4AS'4=Z_[5AJQ89ER0,"E4_/A6M-O&
M\IB+2&,E;.6K!8<$/3 "ML[ED$8QN .]#2VO@_\\-\0[+]@;1/_<I&M1)S;5
M/KN#R=CW3A_,"CJ3'G"\)/)\[HU3X#7[106(K!)6Z,'6#K": WIUL,^CF%#!
M56[FG>NN4T8%KII+#SWMD&23J@I,68HJRC 5 ]>#,)IE4U>":)LR O>%80=8
M!8&UCNW0LQ CUV'@8-!G^EXIH.Z',L! '&;^M\E1?5U_->..Z_J]$WZ;[+;<
M)DS#9&5P/4,/4_^@=,Y"QV;1D("WI.:2"F:>SZ$3D]XN#3A*2/(P62FJIL$*
M#H, +LG -1L>";L&#=["_@&8A@6G,QAX=BV/_2@D[<*1 4$>J6;BSA)!7,7$
M-&RKC$::JU!%)7!_&?'!"6>VF^A/\#:IM:X"4_%)K01F(S:#]Y2)ZUDPL0,F
M;=03^D9*74_I9*BI 3-)%$DA#Y9]$O3A[RJ/?D&:*U"R'_S_O?Y_^G]MKW^&
M#MLOTH;Q_\NV(?3#Y48'">(.TDY1B+,,$(']]GL(I!='N^SM;>69T57'E_>[
MS.[T^KK#?U/GM1T=M_:TQQQLB3E@NGO ?/= ZYW];;?WM4?L:0_?U1ZQ'2I\
M6VO8UI9;6\P1FZ#"MYC"ME9Y+PV>\_N':\8JPEQ9_EL>[IT?M&K"B?GO>,P=
M<6WQY-C/)U1\,]/HLK+[U+::'8O2/W\_;M[?8[]X-V;1^W=6?G1W[:C\K6-;
MSRV1'9W\:,7[]U=,N/?5S >KYB2NFOITXS36KJEFU\G6(Y-56\9QOYN:MWE:
MSI9/(A:^=V'"GZ].?C=JUN2+'XYT?_>-TQ-''?C@K7UCWM[WT5O'/AYY]:OY
M,5N^\5\T8_^';Q[XZ"W7CT=N^> OF\;];=.DMZX?7"U[\0#&T%H>I6([-Z>=
MU6@P Y$MSX][=.%@.R_'F6W.>U7E.$3'%@G5T]#,>AIY=*,\_P'L2 .7?^'^
M/6'@H2IGFWJ(_Y>I 'H>!IOJ<PCP2%>M15%1=N/DE2_&%_GLQJ7/K54YC85W
MI<^C.T39E%Z -'(<#4PXG4_#+;T7$.^]3YP:H2EZ),V(JL^.E>7$)7KOYST*
M=C14P-\(78JAHQI<8P#,PZ##(>C@Y]5DW-.]2&W,N:LMB8\YO:'FV6U'/3ON
MM%OMTP=F6D9==A3SP65U40(F9X*X'X-UB:\.>.@U<243D92\N.A^;?4"=KAO
M)RV#@+F03$!*2L,"(G5L3$VW*RIP>25<9M>QG7WZ0#3,L&LK;$:&P^Q,^U=R
MX22D(6?H!Q<3X-^NI(.SP(RPYW^?N#SFR+I=$W[[\.AB>WT>982MC6!S0RV\
MPD/7_V7U*:7BHEH6J:351YR/_6YN4T(0U52*-!1B.AKN'.1(ZJN<KH,05E3"
MK%(6+ A4P^,GP/$;>)2Y!KA6SX//]DL*OY^C -Y!:T,YG!D!BUKY9?&!#R^Z
MFKE9I%&$-M((%0=.!=1RL&8XLP <'G <,>"$ 7?!*")UU92^EC))"76EZ4%
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M]H,/<3D#5HC!/(;_+?Y)LQ@WBS65*5'N6P"5+34ES@YQ/-(LHLQB$.6_AG^
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MZ%N\W/N'-0)JYR!'9SD#=.!@)2&7;!&1)B'AG"  G458>@ [$,"N1,TBF*8
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M:-:VY4RJVPBJ_A]NVSO%)+QH(-B24P.7Y[\5#LA[D/=#R:8K"F)4 3Y!TB"
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M)D$=$H^>;LF.I+WV5.P#/^#O>)6P,5& _T#??\"^%0O@/V#0%ES.+^$?M@'
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M7%?W3/3UC*LZ9C4]T_)V2UM1=_+)FK-[\P]ORCFP]LC'S]/3(T!80#J5L#[
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M1GG8=E9ZY 0X?P?4V)_IZW;TE/=7IY5'!('LGY-[EI=_7M>2?5U<CQG8A%6
MZ]FHCH4;.)/*UAEEX[BT4=N43\^(%I5F9Q[:L_&/OSSXIY\R3V_%--W?D/W[
MY1%A68!]T$-E_[D'UN5L>\=..SO*R#6T9//R+C5%'U$6Q TS*EU,VC"["KB#
M40'<Q:L=$]2V7PK=_])#H7_[1>N9[=Z^%G)$C#GXF 6*\Q-Z.:&5$H-"0D?5
MY3FD8_QJ567B,*_*TEE@[2J\)JR]PJNZ)FJ ._<.J/!S"_^PVQ \L<E0O0#@
MO^3$=C.]R&<"GRD79/\0^7,^CW^+#(X8,"I),_BJ" @'FQAHOI%\HN6I1[)^
M]4/AGD6(F0.R?RR _X!]*Q; ?\#N!OL&_ \<?=>[]"G: _?$//M+77,<:>CY
M)_&/.:6$2V+LS"\(VS1*]?U_&?]0#]@BG!ED($8>>$)U_<$) A/*=A>S$CS"
M,G(J;H#JOT[_:$&J[4W/AW-Z7,(^6NSJ7W__]-N/76$4WN!7Z)O25)7Q XWI
M-Y3M/I,4,8F].MYU>>M52>.HL-[-JS%T%)GII3.:'N\@L^3HIO@MB\4%E^Q=
MY2YFS55QDT_'08?8IK;"FK,A].23UNY2$(M,R-M ?N]B54ZK.D>YM66G=EJZ
M2F;ZZ*DAGU><W*FI2>^O35=47A:7)]"SSC SSPJS+O#3SW8G'9]0=(#8Q6?@
MC0GK;5VES-33)Y:]'+GVS1E85,\WM.7J6K)L]")K=Z&+688;V)B.-=O;05C9
MDP.==DZ-A=W@-?4RLB^'O/C8D;_\M#UL[3_&/[4&0#J&O$;U9!__\LYE,9\^
M.U@8#@B*FS@N?KVB,LW5589IH9@2Z9# N0-06@<.;/1I6?R,B-.+G@Y^\M\K
MCWP^):M%]=VS0YU>;0\(3;Q#0I^&A_2QL2$N!MZ4B0LB%1>[?$+1/*5J10T<
M?Q"#&WG^EGV8[L_CG](*E.$6*:+C"4'V?RK(R:&A5JJMP-_Z?SO^"2CZ*T<-
M"E(O)"T"PL7!3>WNC)-I#_WT]$_O:0]^$Q^6$*0WL/<?L&_' O@/V-U@ /\$
M 1P\\?GP&PB&H#[BFL<WZA /'7Q]_/.GFO[TD]BW']8VQY-]G8 EB$T"=6;N
MP/^<PUL\Y5 );J&#I VVUP,W\8U-N<6'-XWQZV%!N+\KC)+^G7.7#+.)9G0L
ME!+\ ;D^2-.GU5W#W.HKP@8H8N.20_;#J71S3KJ5/C@62#9CY/E<8G59[,:'
M_NW$RX^,",MQ,W-<T3#0DM&3&SG44> 9XA'#?3,#3&U+CK0\KK<AS2VHGAV@
M>[5,TBZ:Z>^JCMQYZM-7M#69A$$TT<=P<6M&>+4W9:T@.'"R*\5E"9KZ3*^&
MB0RR0:[L9E4Z657,G(MGUB_JK<N:4G6GAJZEG=EM[B@>X=:XV573ZDY$SYM5
M=X^RJVT=Q:;6 A NC"L[;>RJ,5D+:N#:.HNB-KP7NW/I56DS8>0C.O8-6?-U
M61.WX'QK\E$[JPS5,1$S;UI5+R@\QRFXY."WW=!(.M(3]OS7HP#_G>'K\<$>
MW,3T+YG<P7YXP:FZ"MPI11T#7DO_3)\H=LT'04_^>TG0NXBVW6-D7I6WV[LJ
MG S:I*H#@QT$0@1$$BXIYI0@&M8-98NB*.K2^\]L>^#>ND.K434X209N9>-6
M'DS!K2 CEQ(F.+T7Q'8(./\A)HC/8'.F142.]H+/!;Q'E%)N ,$$1LU9F'-J
MMA!N%:-ZKK@HMNKLWA%!+12 ,G&@U+^53]CX.*S\%Y!PHH$8LT@0L\QGEA,&
M(6X3^$8X,Y8V=\FYQ$=_&O'K>UKWO8F/B0ERAL "E?\!^S8L@/^ W1V&DR!I
M@M\%'XK?Q# 40X@K7M]5NVPP]*6K:Y\4O/N'RIUO.EDYJ+05:N[:1.2M#JYY
M_,^Y]59I]X(^?K^;A 0LMA<2!IZI(;?TX*:KO#J A+D!\U8JW:0<UL;;Q>2P
M KA/SYGIIP]SJIT]Y2.\FDDU;"&C\"\F84$^7%? ;;"1SV<&QU%.&7C8B'R@
M*CGXL9]%O??G*Y)*TLY%]'2?@3$JJ6M,/$I/.VON*.7D7FA+/&KNR/<,=F-Z
M%J)EX$8V0(YWD%YW?L_9S]Z0%<0@0UQR3(-9Q%!M4-X*HI!1<2,K_Z*F+F.V
MMQND_J;V0M\@R\VM*SJU:_>BO^D[2V>'>&<W+KZT=8FP\-(HKU9:FC#4E#.E
MZ.BM3A,5Q8X)Z@FCX*J@P4:O'!$V>0Q<PBEQ])3$;/DP<>_*JR :T'$)ZBJ1
M+AG@+CO_7'5T2&]]ZA5)/3TQM/+TME%AD]<@OZ&1U<:>6_/HS_<^=C_CU&9B
MB(&;6',=__-*B'/XAT45(M0APEQ2KUWC,?5.*P7GE[ZY^M??2U_UHD=5-S[0
MX>37WQ2T7)<T7Q$UW)""B(1'.&7@!!";<(Q3:^72;.VY"8N>W?0?]]3L_PQ7
MMQ &!F'CXC II[9.J-'/,*T'J;Q)B&C9TWW=-Q5MP&\HVC ]%XX=HN8QHG#8
MTH+3HT8?P6C/(NJK3FN\=!"< '@-9+^92U+LQ^Q\.-]YKH!1BMCD/IL"LXD1
MEW!ZC'O3TN(HOY#PQ,]//_R]E@-OH5>%*#F-$__RXK\[[Z$!^TY: /\!NSOL
M:_$_%/KRY):_.K:\U9>\&]6W88IV<$-'K/]:_".  6XYR/Z-]!(WOW9"U3$F
M:AB7MWD'&#"G!"_^1_COJTC8\>A/+K[W]!5AN6^@;:JW!='UH%:^LCHE:_^&
MC'UKSZ]_3T5+G%&UP5EY9CYAYL%'F] [U /P'[?I W9:Y)2RBQSM ]'&A+K#
MQ:NQLVCZ]@(7NVI"V8'K>;A)I*R\#"( ?5M1Q;G0K:\_U9D6.=O/B@GZ-/O0
M!EU+WKBLU=)5 I"/&/@WY6W6[E(WNVJF%X8RH_PF1"_ ;>+I0?I08\:E38N2
M]WYV3=X*!P2 -%?+0;4LS, >$]7570I-V+WT<LB*N$UOJ&EQQ' ?;NM'[-K6
ME+B5#_]X^T/?8Y[>0FA9_RW\V_IG#:H)*3ORH]< _C/7O.SM;YHU,,9D;1X%
MW:MA7)>W.#E5<-0A+$T03@\P'-T5;FG]#4%UZM*7=CSP_7^(?Z@$8.#YAE@@
M8G-QJQW4SLB8L&%$4 >5!^$VQ(+M"0K_F%6(Z+F2XKBJLWM&^'6P2>%K\ ]U
M(^P*U*Y$W#+OB&CB*N>&M<5%NYCR]"\O_N'^ML/O(E>%7G(:)0/X#]BW80'\
M!^SNL"_AWX>/>KW7'#+#H==FMS^G^_Q%1=P.S-2)J[MP(Q]D__Z]6[A].[^;
M>X=3"_YS>KISMWNJPQY*VNEYQOKLXOT;Q[BU.*"=E9K;>P?^G5(3L[SJ0HBZ
M%JKDXB8(C[EI]'#1>/[%_L("AX)P*A!87*:< M&)6]I/2]S\T ]B%CUSA5TT
MRB[6-:>9N_*UK=G,S#/1ZQ:'+7FIXF105U)89\*1IIC]P)D9IWJKDJ\*:BP=
M!47'-F;L7JDL3O -<6?U@$!BQ,PW]91VID8(\J/=#!I /B?W B?G?$O\T9[T
M2%UKH;&S+#=\NZ8Q#]4+TP]M+(D(&JC/TC7G*6C)LK)$>7G20$,6>-*:$$9/
M/SW8F.WI9X%X!7=(/3K6,+LB8^]GJ2&K1KBU-T1-5_GUULX2;NXY0<$%)2VA
M.?9@:LB*L.4OYNU?9FK)-'65]K>67^T5T[-3-C[QB^!'[NTZOH$8Z+D-_R"<
MFG.XDP*')CC$F%OJL?6/#TAN"!EGEKR^Y?<_S-OPNG>@94;?,R)NGA"V$2!Q
M-W#=O)I10;UO@ E"D"O\NA%NC<?,'>56Y*YY>\_O?]02OA'O;<6-3,38 _!/
MP (]B/\OQ'PL<'8 ^'Q1/=<SP)CNIR/]#'E9(COG_%1O-SR?^>H$"'5J[++/
MR 4O8Z2?SCL"2T%!]H\9.:B>15CYF)4'\(_;J%G&\'LB!?C'G&K?,,"_>'*,
M<]/8-%H1G?W4KY(?_S']X'O8%9#]SZ"![#]@WXH%\!^PN\.^%O_Z0Z_9ESU<
M]<<?9J]^=H1?@,G;4!W7"S(YDPCD?,#AZ+:O<BC&1\GQ?B%#:YJ7U]7SS VY
M)0<VC@D:  +!'?\._$_KF*A3:J27YA[>V%N;C@+V4R_#37QJ)"ZU:/R5^+<I
M9HQ\=%C67Y&X\3?WI:UX94I6:^_(YF9'M"8<RCRXNO'2H9:HHT<6_5=:\(J:
MT\%INY;%;OTP[_ ZVNF@\I/;6F(/UD>%G%WS1GGX5FMK(:[C@V,2PPJ 3UU7
M$2"WI#!&E!O5EAA><S&T+OI PZ5#@.C\PMCNS'/G-BV6TE)PISIYWYJ+FS^L
M.A]2=2ZDZ/BVG",;+VSZ(&[')WG'-A>?V)%Y8*VP,&9*U0-WS9URU,0;Y5;&
M;OK@V,<O=B>?[$PZ7GUF+_#X;4L2@SXN#M^<MG?%V=5OG/KL5=J)=45AZPM/
M!A6=.22I+V]+C0_^VV_W/G8_S/Z'F%_@WPXO#G1*,!BW0F4AV&PYJ@#9_P3
MOXAQ;NF;FQ_Y4=;:5V>5M5?5S68&;811 P7\G;*;RC8[H^*:H.$:KVZ$43FE
MZB)'96YV6=GV)>=>?90?$TIJ.G$='3$RO@'_!/B@#;R9?CH<V*@72(IBNU).
M8GH>_."@[B^%?__$)H?49^*-JSI:XHYF'USO8%=Z#%Q$RT -;,S,02U<S"DD
MG%)8W>F$DZ,1FWS&)/;9Q5X'?\K%]!A;)BIB6E[Y$^VO#\C#/\&<7(*<)HC
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M@I$WZ@N)=9R8I811"NPUE+6:<M22KEK24T-"YP;"&%YY2%:'B'*+**<46*N
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MMQ"?9@EB,X0<<^;H:0646T5[JJ&C .Q2VJ5$B8GLU;170[L::5<MDJ.&LB@
MN@(-M*.!=M4#FP+3\V@;"O>A)T%H^7 )@_[N,!I]'3RRDG:H&)=%B&)N)BR.
MFGE1"Q]Z,[0+!OTRYHF)$LFNZ$Z!',N>9%.0%@7M:2#LU9A!'C'(0D8Q;D2%
M &B-D-9"QX*+&3E1Z()H9:1!3IB0T.S\F P2N)$R*DGD"570;5*Z4P5:H*/&
MG"%*AUQ#6ZN9W'^QQ'_=0AZ;"Z7\HV'HKQ/&.@ NQC_J_'=4 S/T!9619C[_
M\(8SB=-:Y3F431Q6EV,Z#F[@0B< _E*FFA'*_$/:A+A+@+<(<&<UZ:S!O:J@
MJ41_8OGV1_^X\+9;LF:^$86W)<!O_*-_%O^L(6/QSUI_L!CW8:M&4X#","(<
MCH8!WHYU^#2*Y>^%W[ZGXOW;ZY:_CFE/$=I"TL2C[,Q3]I[DOI<5R@0<*_QC
MA;100LZ11@G*G^]0T>ZZANS#&8FSVJ1YJ#\ >1*(][%,]:A2;:P#V8;R[:-W
MT7?%$OLS=>TN*Z9_N*>76(PB10N?L DPJQ RGK2)(5> #8(9L1D*;7'(@%-&
M."242TZZ9*0==:%3CN[B0PS^4;]";!I"SVF@@D:(86@+&I$0VS,FDAG!@!Y;
M6$1HQ20E$4J5E 4EP8T);D0)<8U5P%2% FL34QT'E1&2,I+%5I#K X]FOJC$
MD44,S"(TE($1_('0#T,ALDE(&_BT4=A;_@"5/D+U#Z7=YVF5$Q8% 3TP>"9F
M!8&&1YC.?%$  '9\241!5$A1.&Z0T@8)_#C%)-:E3;'Q',PUM_4(_95*RB1G
MGE/ L)M+V(6D#7T[0CN\U"8%ZL!'Z7UBHRXN4BS#/XK=F?\EAG\T]$_674D9
M_O5FY$1&FKF< VM2ED]MD^:@CA =#SEP)I2Z&* ZQ6(T_@!>5?@_NB6D5XJ[
MZPA77=2M)*R5^B-+TU]Y8.,]OZI8_#X./3P0!>R\?]9^$6/QSUI_,.H'_),X
M'@R3 1]% U?4&=87;GTW].P]WSWWFY.?O1CB)]/Z<MHD0'%P+!7KE84R_%B1
M8APE(+I0[[W"WU#6IBH4G-YZ;MO"MJKSD',(,PPP?OAXK*L?H2BN"R'V@+F[
MJ/Q/4_<Q+^YCN#:A!Q:7=F/T]@=<Z\ET#W?_*;K*Y;V>BO5J_(C0W]WG4_^T
MT)]ND=!V9;BQ0G!\4^K*:=;B4R%5,:E&#WT(FQ2EB(#L-P@H$RKY0\+3<%4!
M9Q7F;*;L392CBM:5MQU;I9TPC/?VP\8=4TB/ J<QZ,'&W]_7V^+;4-9N2F/Q
MSUI_L!_!__EM[_F?N?.;@0.V#GNP[<)^6EMVC?@'/4E^4 AK8T;SZ80^59&'
M?\Y:=KKJ3%)#SL%0,R>JX;+XOYRN<GFOI_Z7\,_4!X)76!Y55[I%69J"HTY.
MNH=[UL7-:)7GD[&OUHMZ\4_ F\2A(NTJRM)$FQMHJXIN+O4=6^V:/JIFU(N.
M/;.!2PE %-[#\??W];;X-I2UF])8_+/6'ZPO_CLI /'OBA@*MK\?>>%>B/\M
M;][?5G*0-E8"-"9+\@.?F-[F2PAQZ4NFFA]LY15>098Z]W"7LHC2"B,UI4SE
M0"FF8TKH,A7_?C@"T_3_J^/_)T#Q7QO_O;J2']#W+[[X(Y?=?BUB\(_J0>OX
M  T=4$8;*KS"+*?PK+XDN5U9"&)S'] C#R%E%L'HG[(I")N2-C;2QGK:K(3X
M;SVR2O;AT/3'[ZI>,8ZP*VB(?^*&/_R/;T-9NRF-Q3]K_<'ZXK^#HH ;Z\;_
M\_?.>'C CG<'=98?I8T<9CSVI<'ZE11[$F\2$UJ^K_J"DY_I$643.F&L%C#J
M'D!Y8-",-;1D\?\OB_]>]?W(SQ7Z]V-5GAU*U$6$!@I( 1K%*:+L<J\XQU&>
MAM57H#F6J,*0$ T"L$@)JQR'=X6Q 1CJ@$4)=.6.P\M./G;'JM_>4C#C[8A#
M08$((+'X^_MZ6WP;RMI-:2S^6>L/]N/X#PZY&^)_^]L/M</H7UT"T'AL9G!9
MK!UGQJ;U?8FV=.-?$FGDF,I/^QK*Z-8ZW"2*:KEH;IM9C!M%!,2 4Q4?1++X
M_S^"_[A__]H%/X)I>>CI?DL-2O; _#6$E@?#?=PBCM27N\O/M/#.,G,O191)
M0-O0W$O<(L4L,L)03QIJHR9I1'W!?FQYT@._7?*[?R^<_Q'E:\+H" 6B\??W
M];;X-I2UF])8_+/6GPS>#22&!S$BX(7^@)MH#]D*=H^(O'SO@B=O.?C)4UW\
M4[B:0YBE* XSH;QR4+'LO"2*Y!C$,OEZ4= 6R^-KE],N5:"AS,)-]]>4A!LY
MH=K2<%U90%5$V= LM5 SAV+FJO7%_V5TI1VNA<3,GE?'?Y\O[8M_"HUGO*PN
MF;[(3 =@MEOZG,S5=='\^,O*I*1-*E1W\>?Z"I<X:G'O]O[V*UX<](T_=H2K
MRM+= 4#9%*1501@EP=H2E(:YMAAO+ ^J"CV5:6Y.*M%8CA(X:BIIFPSE77!7
M8:XJ8&N@;(U15ZU/7Z$YN7;9W?]OZ=VW<-9^0G2I*#I(XVSG/VN_A+'X9ZT_
MV67PG[OC ^K-@<?&/5"^: 2E.$>C6>D2*C;+BXGL8Q/6*8,(K</M,&2'_H%1
MS"3+DP.(=KNR1915NF=EQ8'5\I1M]5G[FW,/RTYMLU6F$R8Q84"I=9CH_R(V
M]&%PMZZT XO_^(]?73\&[][??L6+\T_C'\JAQ/6"H)I'6.0MLGS>T77"(VN5
MR=]7IVU7G-K,.["J(7-7M*XD6EL<4A;@S9Q(<V50S>W2\$*-,BB?1NAK*G:G
M;]WYZ!V)?__-A14CPFWR" @!XH:W:?%M*&LWI;'X9ZT_V67PG[/]??JCIW)G
M#BV9_5YUTB+>S@3N_C6B$YOY1]9WZ_!ZSO[5W(-KX8K@Z ;1\4W"HQOY1S8(
M3WPO3MXB/;55D;*=LS<QZ>L1FR:]OWGRATDS1V__9L2*,:^<7CW=J\Q'F=O-
MB#=]1_Y?1E?:@<5__,>OKA^#=^]OO^+%^:?QSZ0H0-4!#&+,KJH\OFG!\"'S
MWGURT7M/+?UXZ+*1SW\W?,B62>_F;YYW?O/\W/6S2Y.6YF]=?&;]W#,;YI]=
MN_3LVH2T#0O.;IQ1ON"370_\;O'MOSXSZU7,5QVF<>J&S_MC\<\:,A;_K/4G
MNQC_@'9@G6%'UK;WR#<''A_WP)GQ0\6;9G)W+"G8O"AWRZ+\K=TJV+HX=_."
MPFW?G=^^I&AG0O&N944[$N#&HEU+B_>L*-V[LF)?8N&6Q?MGC3DP;_R>V9^N
M^_+MM5\,2QCYTI$E7[FE.< F1YGJ$<(O8D,<@_O2_:H[]%6,9WV1=D7"R6()
M['HS]L0R%C-E"[HK%_?F*8I3O%M@07W=EQ75G=*G[]#ZR^,?_" 5;4:)@VA4
M0ND*5R#^F->LWOQ]3.&EOA>'Z?OY@?W7A/_>WQ@3RDK$]"$YJB(FJ3AUQ\9)
M[ZW[_(T-XU_?\/D;:\>]NN&+-Y.F?52X=4'1]H5P6;I[:>GN%?E;EQ1L6UJT
M;<.%;>L*=R[/7C>EY)MAAQ_XS>:[?WUA\5NDORJ,DE;&W];7W>+;4-9N2F/Q
MSUI_LLO@/R]I>.C%NY<]^^_[A@_RYNV)*@NCC1S"*"8-(BHFN*X7=C\(,*.Q
M8W CH44)<5$.?).8,HK<PBS!L8VR4]NDI[:6[ULE/+:1?V1]8^XA?T-9K*P.
M@_"+4'%5NE]UA[Z*<>O:\=\#*F8$(J(^:9''U(W_WEH ?11_S%CZWLN*&0-_
ML7I.N _^$>85*#%?+_Y-*LJ(LN<R'XP'\.6.><WZX;?WJ._%Z?NI'U7<ST2C
M/1@/@[0I<9.LK:JH,?=@;7I2[9D=5:G;9"<V\@XFFLX?!6@P(#/R'SI;*(&@
MC#;(@+Z1UM7!'TXVY'4<2Z@9\RSOG0=TN\93[0*<#K)I?UC[98S%/VO]R>#M
M0.)$!"?"[30%'.&VB"-[QRC_D+_->F# KG<&!CDGHNIR7"<D(0MC&7 9=??>
MPQC4RC3H)C%N$#*Y;YFTN%9Y1,LW5J2Z^6<#]64=RO.=U1="C15A=27"OUW!
M)/=%:6Y_H$5<I-B')5??H:]Z\7]%]:"N^Y@RE&K> "-4)2J'8Z^BG=7 605<
M5<"M1'(I**<<"CCZJ)?Z=D9,#N-+I>@6*AO(3(!$I76A%R5BBMLR2W3:,M2]
M;U*B0K<6%4IT8X.G40.@K-7 J*)T4DH7*PQXF9D7/R$TO_2SO5MZ'9U+KDQ,
M*.=_CZ[A+^@^N+%7S)Q/>(?8%+A!C&L%T::*:%,YH>4"+=^OR-<5'&GA91 -
MY91)A*8&V*1H>*E=B7I?C$VTH1XE#&XN:#GZ7=/G0ZM&W._8-9YPEA!T.T6Q
M0_]8^R6,Q3]K_<K@_4 P%D3X]WDPQ[E=DX///;'@@0''WWZ$Y*2$396X3D*8
MJH@^_=(_(D(O]D@+_*HBRB0%=D74(,"M$LI3%8)M/5/AEV(J_/9EQO54W\B[
M3R!.,X$I\ZA>B@H4:65TLXS45U&F6F"KI1Q5A%-!N.2$4Q83YI!BW34"+B/*
M*D'5@2^GWCY\%-/#)2J#*^@6#'8-/&#B A.:!4?K%;2FBE97 X,"F)24605L
MU92]FH(.@59.-XGI1@%*W=]S]?JR_Y_!_Q6%\'_1I?LI^.^NT6 0Q>:%4AH^
MJ>9A&AZ:XP>OFTM).ZK"M666TM/MTCQ*S4?E"6)[PA.+/8DP-].F!C3O7UOJ
M/)3 >?O^S,&_KET[!G?S,!I-68V_K:^WQ;>AK-V4QN*?M7YEX!+\=WDP>];N
M29$7G_CNX0&'W[P/*SV.VR2D04% ]6'\E07#-1FF$;;+\CWB;$PG(%#Y6B'=
M5H\ZDYG0'S!S!?LRXWJJ+^^O@'\T@Y'!/Z6341H9I5-2AFK:C&KFDK8JTJ:*
M$X!!N>4R0B5VX$$N*TM53$R9W6H4TW?W!Z 21Q13M0@]23$J:+V*UE8C_.N5
ML4)!T!&!@AX8J5< M00TB5!_>,_HO[[LOR:<7_K9OF_%ZY_'OU%,Z010J/2P
M48*&+S"C0*(Z7J>BT"/,:A%E1QHY@*D6R*0#0E6/N_%O:D+XAY=.5V'8LRCE
MZ3NVW#F OV0LX:TBZ/"-#_Y9_+.&C,4_:_W*P _X!\#A]V"VS)U?1)X?M.31
M 0=>_Y_ ^8,$*N)>11CDQ,6%VW]<S$-KVJILD>0TYA]V"L[Z:XJA4/5>IB9]
M=_:W:Z'./Z.^O(_3)<\1X/G(28.,T,.EBC+5 &L=[6P$+J@F %><C:2]GG(@
M 7L];4,"MCH:KCL:4#W?F)AU@-ZJ9[8P2T<#<#20MCIX$ HNT<MZX*J#HAPU
ME+T&.*!J@;T6[6]KA*A#:6XM=>A;'(VTJXEV-Y&.>M)2"PPJH)'1!E2:+W;F
M?=E_U0O[4_?O5O<C@)^)?TA]0L.#^$>//XQBN!YN*.]4G;=QTXUE*0[^V5!]
M&6D0HR<C6@&IY1,Z/@E=1C3['QZJ@38UP@M%&7C-28OV/WQ;PN_^[<*\SS!O
M/4%C (^_JZ^[Q;>AK-V4QN*?M7YEX ?\TPC_N#4S:7QTZ/UKGAN0\M'?0A<.
MX188RM<01AF!6OP^I+^2+$K:I@K4EYG*3]LKT[VB;$W^D<:<@R%U)4H2H!<R
MN(T'QG567]Y?5@S)F-J^"AA?4K9JX*B#N*6]6MJK!ZT&*+K-! 5BRU8C\!I
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MUG=Y_'?O=K'Z'NH:U8-_&G7^BX"G&C>(HT9IV:&U:6MG=BD+2#3T3X2H;Q;
M)>H#8&8)4@81\^!?3KM4M%L,/#+*HT;/_I/690_YZZK_'E"TZ!/"I0;HV3^+
M?]9^"6/QSUI_,  ;-!@S =AT H*@P@3900$R ,P!L^#D O+5)P]_]*>2%:]'
M%&FT&;*_BD #LR64409%ZB5(!BEN%$,11@EIEE(6&665]PJB%-'4IJ)L2AA;
MDWJ^_,RVE,2O';R,<$,YB5+MRLB+.__[\H81,QT\IIX<O7UY?S7\QRL>_PKD
M : E&M^ JOZT-((N XC: .XB<!>&.\F(%X3:((#IH!>$72#DH.$RZ("B_'80
M<% !)QEPDWXO%83!NI\*=H% !PAV4H&.F$ X2 :ZJ% G@$<(NJDN!^5S K^+
MZG+2 ?C2"8]#!1VXWX4'VO!@%QX*$B$_$>PBT$2 =BK4AO9O-1,N#6&M97P:
M>6_2XFZAK,S7IA\NKQP5.D+JO3@]U[E'%SL95^D#L# =$G$>PZ7XIUVH\S]J
MDI4?7G=FW4R?(I]05Z#G_7H>, HH P_7<' -%U?SB&:XSH^:12&G-.HNPUR"
MJ+TI6J-R;%LE'_9HZL#?*]=/0L638/A/W? V+;X-9>VF-!;_K/4'8_!/TC!L
MHFB2HH,DY2,!'@$FOU%\<J'_V8$;G[LE>?)CKO-)T=K2B%I HGEQ,#AF9):3
M4"89:9$B,<TZ81*3%PNZ"V8);I$39K0;;1;7YNP]DC#!P<_$-%S*)D>3["_&
M52]F+M4U\?['\7]MHI%4S(,,!>VNH]O5=, $PA8B;,7"%MKO CX/Z/0"GPMT
MF4&7B5F:*1\JS(-J\T!UFD&G#70Z08<;J=-UB3H\S$8GVL<']S33'=:+!3J-
MP&>D?%:\TTGXO$17.]790G5ZR$XG<@Z@N]"F!YYFTEE'VE30H[I,1TC/!+^K
M*\9I='D9I^=BQ1^S][^X-OPS)]:M2]^%GXUJ>?"8X68>9I()3F[)W#BG7983
MK2NFC'Q"RX%+VB1 M0PLS%Q! W0:I)13'FE31=O*,:\(=VF)QMKV?1NMG[\B
M>^<QX[YOX06A(?MO?),6WX:R=E,:BW_6^H/]"/Y%)Q:T//;7-4\-.#7YL?;2
M_91>1-FJ2+N"M$$I8\(M,@PVS4P/+:K18D+57%!O+2-*+XP)-T@(@QANA_BO
MR=ZS:_9H._]L=WXW]$SW(CST ?__#OY-"MHH XYJNJ4>>@"@4T=TZ+ .'6@S
M45X+U6*#\3=HT_2*:E7'A!(%MC2B?$$02!XUH^9+I>G9V$A[&FA/$^W672+X
M5HL:M.A(MY[TF-%WH:K!.LJC 5XU\#93KFK*J2#M,LHN 381;1/U^>'_TOBG
M$/ZY\(!A-0\WRX6GMN9M7Q2JO4#I>+1+#FQBM+1+,$,EKN<1.CX)91!@9F'(
M)@S8+P1L%5V6ZF"=O.W(%L^,#U0CG]$?FDMYZVE T#0[\8^U7\)8_+/6'ZPO
M_OT4PK^QRP#QW_KXW]8],^#H^ >M9[_ODA7XZCA=:FY'$Z>CF0O5V5SIUPE]
M<-G$Z58CQ]]0X6\H[Y6OML174])94]994PK7NZHO< ZNVC[M(X?P'+ K4'D]
MU'-P$1[Z@/]_"?]RVB!%4'16T9YZX&F@/$VDIPFXFBF'EK+K@%,-W'64JX9R
MU5XLVJ%BI*3M"MHN1Q3L%=IRJ6Q05;2] <D&5<^HEK;5T+8Z8*NG[(V4O8FV
MU]+V&F"O @XE<"@@\BD;G[+R@4T [$+:(>[SPV\ _FT]_\6U=/YW'_F27$.]
M0A/_] +:J<)TPJA1RCOQ?4KB-Y:RY#99=GMMH5>5VU9;Z&\NB>@K(SI&<$7/
MQ8U\Z U@]LJH@QNRJ=J4E>HM";(10S(&W\%?/PYOK0,  S06?W]?;XMO0UF[
M*8W%/VO]P2Z+?RS<W?G?^?3]B8\/V/;.G_*7CLU=.^?4RIDG$Z<GKYZ1G(AT
M>NV<<UL6G]V\*&?S@IARMRS,V[JH8/MW!3N60.5N792Y?@[4F?7STM=_F[YV
M=N[F^4<7CM_^S7"/-)<RBBD( QO*LO<#'OJ _W\/_S+2A)Y<(#1:5,""\@$
M2Q5EJB6-=:CR+--[05OEJ':1148QK@R-DB+#I1B8A,#(HPR5E($+!=>!D8]D
MX@(3>KR-<N ;), H0^,,S K*)*>,2 "Z'08I9900)@ENEF!HL(6<-#(G8Q*1
M\+"HQ@\4'UA$3'D"19\?'D_<*^K:\=_[7_0]R$^5A1D]ZJDFF*%_I0?7[)PU
M:O><T<G+OTI;.RUYY>34U5^GK9F6LFIJ*EQ?-2DE<5+*\HDYJ[XN63D]>^VT
MS/534S;.R=F\E#/[R]./_&G#GV_)7SHFVJ:FT-@_(O[^OMX6WX:R=E,:BW_6
M^H/UQ;^/H"#^S4$S_\BWKD%W+7]XP)[A=W,W3BW?D5"\.['TP.KR?6LX^]?%
M5+9[=>FN5<6[ER/M6EZR9T7%_L2*_:N992+GP)K2/2M*=J\HWK>Z9&]BV;Y5
ME?L33RZ9<'#>6(\DIWM$][\P_F/C#=&H>(N*-E?3YAJX DPUP%A+FZK0A/M+
M!BTR,L,]E<R0-Q$P\RD3ES+QH)C1[(PL<)T/S")@D@*41"$VWA Y$*09B3+#
M[2CO/6$1X58A;A.09A5I5J!A%F8F]8U)@!Z-F^ 1X$L%::V"%Y!1;-K"]<0_
M/&;LX&@X8?</O%9=<:*@14H8A-!K(0V2J%F1MS-AQ\R1YS;.+MZUA'=@55E2
M0MGNI>6[EY8E+>'L7%R1M*ALUZ**I,6*I*6U6Y;*=Z\2[T^H.+A:='BS;.$W
MIQ[Z\]H__:I@Y42\PTS"^Y@=^<_:+V(L_EGK/P:8IZ88H$(DCF,@Y,<#N%>U
M?8;JS?M.//CO)=.>=LM/T+5"H%:0-GEOP5_4?*L%N$Y$JH501+, ;^)'&WF1
M)EZXF7^I1)$F0:21&ZGGU&;N/;-FIEN4!8^#BK\Q.?]_!!4_'_]753S[%?%N
M1^]I_."%7/(1RB+O43P^:1LZ($K+$_>+XN=#7HOBCG#]U'-YF<P-ETZ,C#^'
M:W8IKJCNVX:.31.U* FS+&I5%NU<=B9Q>JB^!#?R"8<2-XMQZ!]895"X18YD
MA2]%F*$<,Y22>C%IE.$V::CQ?/V&F4?NOWW5'W\EW#B+[FH =.#&TY_%/VO(
M6/RSUG_LLOA7;)NN'?&D]*,'-9L^[JQ-H^M%0*N$C3) -7]1(TX9>_/]R6-"
MH;.]"LFFND36&MI:#:-J8)36G=O'XO\G*NX(UT__J_B/&L2855F^;_79M;/:
MI-G!^@N8EA=L+ \W<Z(:+A2FY>,ZZ%_R,%UE5,^)&BJB&F%$+_:;!/[F\XU;
MY^Z\ZS^_^Z\!E>N_IGS5)-V%W_@F+;X-9>VF-!;_K/4?NQC_& 8"OBC$OW+;
M#,.H9]03GG7N_=+?F$DWB(%615A1UW1W(VZ2H9%K$'7,>#?@4%%V)0%9B-IW
MIEO[!U4!U"NN('5B&/VGKYW%X%_V?Q__BBOA'_P?Q7]LQN-E$CA>-_QW)XFR
M*"-Z$6Y5\(]L+-Z9X%<5XEH.@'&_7H#*_5EB^889F<5HK(!#23N5M*<9>-5$
M>WW4S&G8.F??O?^U[+\&E*X<A[6*<;HS$G]?7W^+;T-9NRF-Q3]K_<<NQG\T
M2G5UA .$5[5CIGKX$^+A]ZLWPNC_#%TG AH4_:.A;4P[#J-_A U;;*R["MB5
ME%5!F&54GUH P*@$1@5ME%-Z<=VY_2CZ%V?3%EEOP=__H_B_NBQ]X=V7[E=5
MW!&NGRZ#_[[?'M/UP[^)P;]5&=&),+-,?&(SQ#^,_C%-!6$08EI>1,.-:"K#
MS9Q0<P52$R?<S(VH^9A&Z-.J.G6*#J,XT%2DW[F@X/G_S]YY $91)7S<\SP]
MS^Z=GYXFA"(=(EVJ(J+AE$-1*4:DA%Y4>N^("4(0",700DF 0 @)I/>^2793
M"(2T[9N>S?8V_7MO9G?9[(8 "AZ2][O_K;,S;]Y[,UG>_[5YTW&_VU,96Z:0
M39D4HW[H\_Z1_2-8D/TC'A^<[%^OQ326^J)?%A=^V"6XU]\2%PZLSPMB2K*=
M[!_.6H<O_[6V%V&9SHT".#L'V"E@Q'Q&C.P_Q\56[T5.,3PX_2_LG^&&C61L
MY[^(EWG\I_A]ZXQ%T7"Y7T4>^RQH#K=L -ONAS,<V0X# 2TNP"2W,$FI65Y@
MNAFC^&5%P2>#8H>Z";9-I>O3:4;U\!?]0_:/@"#[1SP>T+!,8^"[TG":,A,$
M9B0M1K+)H"@.6)K_?N?#;ST1[MV])O,H<R.;K.3LW[H^/&OV[(O^1'FLV TQ
M6QMP?AM0 9P2+\ZG*K. _8=L6<#:?YZ#_5O%FD1+27-A1<%UT=_?+^LRM_:5
M;JV3\&\+=MUS><CCY'**J]\[B3-.1[DZZUWE:J7WISO6KB1L#0#H]AO_<N\@
MEQ/O6[9:(SMIE)'Q25F^6<Q+/+CEZJYEAL(H2I@&_LJD*(L49H*L4B*XD!0%
M-W)H^#PDGZK,I\1EM+B<DI80UQ.5!S;(IWXDGOR^>.\BNCZ;IE5HT5_$'P.R
M?\3C =?RAW.F*9+!,8K4XC3&*%22Z[^NSAS6\:C[7Z*G]VK*.L&4YUI$? RV
MB1U>#'.O*N2>B",K,DO"#@5OG@_'_F7Y]K%_%\-SE:WUZ=1 _SVR1\YFLE4O
M=[Z0NYWB$MYU$/VN<FV(NUKI_:DM^__C9+-_<2XEXC%R 2'/-TMX"0>W7/-;
M;BZ,IBO30$4$OMQ/F,F=0HG!5[@* E/%8RISF/)LLJJ J;C!5-Z@"U/K]V[*
M>:]?=-\N^9OG4DU%-*W] \HTYS(4T2Y!]H]X/'"Q?QW&VK^HZ/"*E$%O!+H_
MD3C['9T@A!$*<&DASKFFJR_>1<C^[UW(_NWVGTF),^ Z!\)TIBJ-J4@E1=ET
ME8 6%5(E2=(]*T-[O?[S"W])V^!#J6[0M)Y"K7_$'P*R?\3C@8O]ZRTT3BM4
M546'EZ8,>OU$YR?2%@XR%%U@JFSV;QO[=Y'SPV.W7P1LM_]R:/\A6Q;49H8Q
M<IO]VQXE:%,/SOYA7S=G2+;([^#E=[=_&3O#'T[R;VG_O\7U766;A&_MGW<U
MU'M5*_;/Q>DJEW/O?LI=98W!V?YQ:1[L_#^TY:K?,F#_5$4J(^,1P@RN\Q_V
M_XO3*4D:+4YC1&E,50I3D4Q*TFEQ'B4M(&\E*PYM/-_??=LK3^;Z+V<L0HK6
MH\Y_Q!\#LG_$XX&+_1M,-$;5:*N*C_R0.?S-LSW^FO/#<'WA.::,AXD%T/Y%
M=[+_-GH%K/9/563=##]B;?U+>-:Q?V&V<SRMZ,'9_VU+:Y'MWV3_^0YZX/9O
MEXL3WZ=:L?__@9SMGVW]YR8>WAKAN]0@N$8+T^'K &S>S]H_^QXI$5M'K,QD
M*M))N'(BGY 6&VZDEA_8=*CG&\M>^DO2[A](LY"@C>RO^.'B7(8BVB7(_A&/
M!\[V3QE,E(6HTPM+ I?E?]#Q7.^G<I>--%T/I<MSS<*\^[+_VW,#.?L7Y].5
MV;<B D^MGUV='@KG](FR@??#2H!K5,YZ).V?>_$QJP=N_PY/3OY>\W:*P?[5
M5:[GWO64N\H6B;/]X])<8U56S+[UH5L7*K,N495IH-T/F_Y2'G<B" :?$1#F
MLF/_/#CV+P%U@D)"5JHOS;GQRY9]/=Y:U^&YR)T+#-I;!&UF'OJ2_\C^$1!D
M_XC' 7;./UPN';@_31($AID(HPK3ZTVRT@.+FF:]VSBIIV'[!#P]D"Q-):MR
M*3%\^;J+5_%:"+[S!HH69A,5&61E)@'G]O/@.C^BG,(+^W]9^(4L*821Y<,:
M@/7U<<[FYZ(V^Z5_HUIDFVY-SI?F?$JN?8##.LQQ=SE'XB+KI 1:!&V2%/)H
M438G6%N" R7W+5=+ML=Y6ZYAV@Y_SX+9YK9MSW=08(\\'Y?PC!694?YKSFV:
M5Y]Q@1*EDY49[)L@<FWG9L%/80Y3E<=4YC.5?$J<#OXHE/0&4594OG?;_K?_
MN?SYOUQ>]8U!70'[K"B+\^_[0>-<AB+:)<C^$8\#W"M_6/LG*0HG<+.!,39@
M6LQ4>W/O@EM?=A.-?<.R?AR=?I0&S;(JMKT.+<K)TEKZC:W$!R(KTJE*=C27
MLRY13G'H@4/?3ZE..0_?>0-C@^N[N43H*IYS*H^$'.8/WJM<(VD]3JZ5#)^1
M<[B?;-W+]92[R-7+6\1I]>8VY7+*_<HQ"4J4Q<CS"$FNJ2(SVG_M^<WSZS-#
M&4DF60'M']X!ZUF94,)L!D[^SV>J^+0DF9&FT[+K=%FQT'_SA4%O^KO]+7VC
M-ZXN-\,?\$-O_CN7H8AV";)_Q.,!#<LTV = $S1I(3 S;5::]82AL7#WHFLC
M7XWV_*MDR4@\[1A=E4-7Y;-KL-RS_8-V7B6H-$#OIV$AGLU4995</!BT9E9]
MQB5PB"A/@R.[\"Q7FW32;[&]AR]D__>JWV3_6:S +R<'U@"$N90TD9&F,)("
MO"A;ZK^I>/+@]'$>HOUS:%4I25,T[OSC?N XEZ&(=@FR?\1C 71_^ ':34:*
M,-*@"45J="9:H\K?O>S8T%?W=7XB:_80<U8P(Q0P586P8Q;VV'/^9%_FCUVA
M'0J6[-:&/FSKVXK^R@RZ,I,JSR!*4XN"?SFW85Y3SA6B(AV']@_]P,DCV76"
M6=U>8LC%PVQR=3NKK#//72P0'FHAYSA= K@(QLP&MM>$K(L=.3SLD _O#'<5
M#K)'0G$YMTV,=TC=\?:R=X![/@(^(?F .O_;].;6Y7+*_>IV$I)L$IBZ+)>0
M\# 1[]H>V/G?D'61E&12E1E45:9U4HB(K2_"C2RV&R"#$:63\AA&%@]N#B%(
MD?^\6C)]>.F7W6H.^-"-UVE0@T7VC_A#0/:/>"R@X;0_\%L ):>.IK1@$R>,
M6IQN5.7^O'K_B#<V=GPB;O900TXH(RIFJHI)]LWTG#^Q,[-8B;. 0+%N,T6;
M_=O&LV$_?WDZ79YA%L1F_[HC9/W<QNQP2IA-PJ8>CS7"N]C_;VC]VRLESH>D
MMI5N6YD,>(< KFII_W!U&CC#T6;_TGQ&)F"7.VQQ75 .B=XA>[#JP-8>8.N?
MJ *5ITRK@#4".VRCQG,'W=7+_R?VCXFRS16928>V7-BR0)Y\5G<]FBA/@S^;
MV_:? P7M'WA_*B-.)A37&'DLN -T84K]GM4"KVY1_5X5_^Q#-980</+*0R_3
MG,M01+L$V3_B<8#K]P?%)L8P>H;6T#1IQC ]2537%_ZR8?_[;ZWN]$3DW*'J
M_%!"5D1)KA-R/@'MG'7EEF_UY1Y_IX 7BF'3EO,,JBJ#%F:92Y,5*>=J4B_4
MIUTL#__U5GB@OCB1$O+8%P;F4Z!R(!%PHCB)^:0XGQ,[J5[ BHU?"I?CA=,&
M;3;,V1LER:'@<O&W18AS@$@)$+<']EM8!6( N57D6R7/@X*QV1KWLI:2Y[80
MV",%%YA%B]B)D.RL1I@EA8"!,;."V>-!+X>//+ 2">  MC3+*G$F#02-C1WA
MEF3"G;)L-D5X:?"BA)D$G#QA%5V5P0@SP8F,) -*? ?!"'F.HH4Y3K(ZJTV4
M*(<4MY!3>!# 222L^>704&PS'8I]AI/MJ*>%<)JGBWA0;+4&+OTKSL7*LZI3
M0O//^E?%G*S)"&W*C=06QN&@IBCFP5\13"@;3@"$%Y7&B%(P12Q>G0#^H$Q1
MIL)OY>4^+__RTA/7M_M0RC*"QBGZH;_TQ[D,1;1+D/TC'@>XQ_X(!K;^3: &
M0%%FLPG':;-45K)OS=%1K_W4[8G$!<-T1>?Q:CXI*2+%!40%:(_FP,>Q)'Q&
ME,\(\V#C'L[C@W[ M>E)8295E4D+85<V69K:F!%6G73.4!A'5F12E5E450X)
M9Q)PXL%6OLW^:3&?K0'P*5F>5=(\$KY%$+2&X9.$E"276_S?H2$.3@?>GT/)
M6HB4\5CED-)L7)2!5Z6S8Q 9<"X":$!+<RDYSU&D+(^0%C@*EQ5@K'!%H55R
MJ^!^"1\7"PBKP#8K(0\( \8FS;/(\S%%/@:CS2/$N: =3Y1GFH4YG"PB& P'
M^X6YN"@7GB++LRCX%D4^/!&^.Q&<E4<*P2$^)Y <#G(ES<-E.4"8))L3(;Z+
M["'O)))]PMY1+@&R@1,[BF0G\(.Z'0UJ)*!>4I7."-,8(=C(9JIRX301(9SP
MX2#XF[&JBD>69X%? J@SD:(<O"P-*TVQE"36IERHC#JA*XJ%S_XYK/K'+OP'
M8DXC9,GFFE1"5L 4YLI^6AWB^<\?7WDB>_M,1B.D*0L)?\(/%^<R%-$N0?:/
M>!Q@^_YA#0#8OYFA#11H_)LPDC8II#</K X:\<K^SD_FSAINR3@#RG2FH@BJ
M+(\I!\IG*O+A=EDN4YEP6U6)[ HM/*A;V4Q93G/R945TL"4_GBEGYV]7YC$5
MV4Q%*EV:",24IS"5:;!KUZHTV*Z5V9K(0*!9+$J'$@.E,E*@9$:2:'_[#B/C
M@Z8\>TIZ"\DSH&3@K!2Z*I$J!QE(@*I,8H0IC#"5D:0YBI9DDA*^HPA@\*Q(
M60$GXK8$T/[A$C0"(+"!B?.AA'R+D&\6\\T2@5E6:%$ 1T_&%,FX+ F7)!'B
M1(M8P F3%' ;N+@ $Q=80'@@>2$XRRPMP&#]HY"2%-*2(EQ6;)6T&),482 Y
M&1_((LWG1(B=E$-(TQR%R>XB2I3"WI/;<@[ +;WG).CW:7 Y7J@41I3$B)+9
MG>FPEX([ZBC8U0&J7^FT,(.L2,%NQM'@KZ  5< 4^/>59.+78Y3IY_3YX51Y
M(OAST_"/#D^! G'"WTD\+4^";X\4\.0[5I[N_<K&5Y](_7$6K1.3-(:!G_!#
MQK'\1+1;D/TC'A^X/@",IDP4823-)IHRU$EN[E\6]XG;U:$O5"X;1^2<9:>A
M%=&R8EI6"$1)!4"D.!\7YA*2+"AQ%ER5!33-Y?DT]&/85X^59<B2+LC2+I*2
M/$HN@"W@RBR\(@LN(0#:^L#A1/E@F^TP8 5:F;!=SJ?E!90,2$#+B^B:ZW1U
M(:THH*OY='4>+0>I9-HFV;$OJY7SP2F4+!^(9#_A!HA'"CL/*$DN)6-?UF=;
M2(<4YI!"T"SFL>,"N:0$BA)G,55)+20$2H:R?DV&]B9*IN%&"MP6@XI(BE6@
M7@(^.:]B[8JN2J.K,NC*++J*[1(7\1AQ'MN]STJ<R=JD39R)P@U6E>Q7;EQ
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M\(/IG" B]R3)/TT5G"4%9TC^*1A#'JO<4T3J$2+M5R+S")%ZD$P]2*4>)I/
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M+N+<#7$G^[?/\VH];Y]^,X6SA%:/.N3<;8I_?!Y\+.Z"KW>+^^R(2][LCV;
M7-EG(;1DR/;0TPO9K5:3<!Z2OQVGV^B)$Q]@YMM(Z(M%BUJSX=M_'?MOM95X
M;=@[_[FQ?T=^VYUQG#XBE(7.9W]3HQ8'\FJM(_3-F;;),>SO5JN,9WO]V>^L
MQ]\IW?NZKD<79/_0_E/.G0&*.A=:8Z%!%4Z6<+G<^QUJQKO8S '&P 6JU'V-
MZ;N5&3\[JCEC5W.ZGPHH;9<Z=8\J9:\J!7SN40.E^JM2=JL3=ZL3=JL2?VY.
MVJ-,#FA..:9,/F15TJ&FQ(#&A$/*^(--"8'*^ #%A1]5*_^K^N:UYJ^?,QWZ
MAFXH8 @,KO1'8#2!&V@+M'^JE=\7=R&NW#6 $PY1.N,4@+-_4%$ -8"PL+!C
MQX[1;-4!V?\?CKWHV108P/JLQ[C%/^WQW[/19Q1;B'4?]\5X.'?*PVO5B?CD
M\*V?L<5?]_$GR^[6^:_B^=J:3>,6;MUS>XBZ\_*+L;?;6]P8,,O!*]G7-G-=
M!&Z>XQ=OW07.63R.&VY@IZ +0[YERV6/43Y;]@0$!NZV]2CT^3+PNLEN+5PQ
M2BEY?N.YR%K8O]MHGZV[0;OSI\5<GVOGT?Y\I[9_*Q;;<K\C'EX;KHD,;>:M
M6-O648><VTW1-J?,-0>MY<VA4F([T6/<MG >7R#(2PJ8R<WH]/8>=^<D[!FP
MS\:8:FWI=M\0)SCSX#)_YX1LN.3<UD]^3S9INQ6N87[CG;';_X>^/ UMNA[X
M)5=9X:X=AK[]W."T4#DP]-IP'^XKE_,[IGM?U_7H@NP?VG_LN;- $>?/-^.D
MAJ3$T:<+O^Z*S?0T3>ZF6?V!>.>'Y;M&"OV&"WV'5_TT#'S"#?#5[UVQ[V#I
MSF'2+1](-XY7;/A8L<$+2+[^8R#%ND^JUWY2O6Z<8L-_)!O_*]P\4;SY4TZ2
MS>/AQJ;QLDV?2C9])MKT']'&3S0_#-#.>E'I_8SQ\-=T=3:%Z0D*!S)3A ;4
M AC2R?Z=VMS<13D&X#KM[1WXW$Z[W]\5>SR.7\$&SK[PUV0R@3BCHZ-1Z_]_
MAZWH&1905)NZW>FY?SA_/K/LVBK.@>UXC//+L"Z"TH;]4[@L?(GS9 )0["\.
M+J^]0W>QES^O.'P).P;1 MO8[>UGI5H>G1-2#M<+:FG_7#%N#7/'(6J/<7MX
M+9X^X'"UV!;[6\)=?MMY:_NHBX/:IR6ZY*"UO#G8?P,W_]Q>/Z-IZQX[K2;A
M,DYAA3.Y!YCY.R>T=H5WZSFW_[KNQ2;O;/^_\<[8[7]"0+$!_JIKHE; Q_?!
M#9AVLAQ6 .P3/WINS81]5K8!,NM _AW3O:_K>G1!]@_M/_S,&: KH>>!IQG,
MN##Z&&]R1\/L;H8IG0WS^S4M[JI<W$F]L(-JOGOS/#?5/'>@IOGN30O>5,U_
M73/W+=6WG9N_[J.:VKUY"E WY>2N0,V3>ZDG]]%-Z:/_NK?FVS[-,WIII_<
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M)7E%Q;SB$E[)C=R;)7FE-POR^%F9N1G96>E 69EIO)Q,@2"/GP__EU>0EU_
MYV=5%&>7YQ=E9!0E@V/9^:+<FXKT\M*<LN+B&S=O%=TL*2@N*,SG5O7A*'2
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MT>Y ]H] (! (1+L#V3\"@4 @$.T.9/\(Q/^W5P<"     (+\K0>Y) +8T3\
B[.@? ';T#P [^@> G0!_ZO6B 4!ST0    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053457504736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,831,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458413088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 627,000<span></span>
</td>
<td class="nump">$ 647,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">907,938<span></span>
</td>
<td class="nump">819,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">235,400<span></span>
</td>
<td class="nump">282,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">33,020<span></span>
</td>
<td class="nump">27,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">48,281<span></span>
</td>
<td class="nump">57,530<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,851,639<span></span>
</td>
<td class="nump">1,834,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">463,889<span></span>
</td>
<td class="nump">371,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">108,529<span></span>
</td>
<td class="nump">104,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">113,958<span></span>
</td>
<td class="nump">111,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">279,705<span></span>
</td>
<td class="nump">131,002<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,881,404<span></span>
</td>
<td class="nump">2,616,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">19,978<span></span>
</td>
<td class="nump">24,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">61,450<span></span>
</td>
<td class="nump">61,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">76,740<span></span>
</td>
<td class="nump">77,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">43,795<span></span>
</td>
<td class="nump">33,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">29,990<span></span>
</td>
<td class="nump">86,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">72,568<span></span>
</td>
<td class="nump">53,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">304,521<span></span>
</td>
<td class="nump">337,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenues</a></td>
<td class="nump">7,209<span></span>
</td>
<td class="nump">8,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">161,019<span></span>
</td>
<td class="nump">51,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">17,395<span></span>
</td>
<td class="nump">8,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">490,144<span></span>
</td>
<td class="nump">405,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 321,800 and 318,842 at June&#160;30, 2022, and December&#160;31, 2021, respectively</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,477,117<span></span>
</td>
<td class="nump">2,427,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(8,917)<span></span>
</td>
<td class="num">(758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(77,262)<span></span>
</td>
<td class="num">(216,507)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">2,391,260<span></span>
</td>
<td class="nump">2,210,615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 2,881,404<span></span>
</td>
<td class="nump">$ 2,616,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053457521184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">321,800,000<span></span>
</td>
<td class="nump">318,842,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">321,800,000<span></span>
</td>
<td class="nump">318,842,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458592256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 419,427<span></span>
</td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 775,407<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">13,481<span></span>
</td>
<td class="nump">14,884<span></span>
</td>
<td class="nump">26,684<span></span>
</td>
<td class="nump">28,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">199,481<span></span>
</td>
<td class="nump">148,790<span></span>
</td>
<td class="nump">356,152<span></span>
</td>
<td class="nump">308,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">122,759<span></span>
</td>
<td class="nump">98,495<span></span>
</td>
<td class="nump">225,622<span></span>
</td>
<td class="nump">200,846<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">335,721<span></span>
</td>
<td class="nump">262,169<span></span>
</td>
<td class="nump">608,458<span></span>
</td>
<td class="nump">537,006<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">83,706<span></span>
</td>
<td class="nump">123,008<span></span>
</td>
<td class="nump">166,949<span></span>
</td>
<td class="nump">118,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">4,757<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">6,579<span></span>
</td>
<td class="nump">4,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Income before income taxes</a></td>
<td class="nump">88,508<span></span>
</td>
<td class="nump">124,888<span></span>
</td>
<td class="nump">173,737<span></span>
</td>
<td class="nump">122,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">17,836<span></span>
</td>
<td class="nump">28,796<span></span>
</td>
<td class="nump">34,492<span></span>
</td>
<td class="nump">25,180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 70,672<span></span>
</td>
<td class="nump">$ 96,092<span></span>
</td>
<td class="nump">$ 139,245<span></span>
</td>
<td class="nump">$ 97,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">321,117<span></span>
</td>
<td class="nump">314,117<span></span>
</td>
<td class="nump">320,349<span></span>
</td>
<td class="nump">313,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">324,904<span></span>
</td>
<td class="nump">322,941<span></span>
</td>
<td class="nump">324,096<span></span>
</td>
<td class="nump">322,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 347,044<span></span>
</td>
<td class="nump">$ 284,248<span></span>
</td>
<td class="nump">$ 657,342<span></span>
</td>
<td class="nump">$ 511,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">57,526<span></span>
</td>
<td class="nump">39,640<span></span>
</td>
<td class="nump">89,593<span></span>
</td>
<td class="nump">67,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 14,857<span></span>
</td>
<td class="nump">$ 61,289<span></span>
</td>
<td class="nump">$ 28,472<span></span>
</td>
<td class="nump">$ 76,779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053457390944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 70,672<span></span>
</td>
<td class="nump">$ 96,092<span></span>
</td>
<td class="nump">$ 139,245<span></span>
</td>
<td class="nump">$ 97,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized losses on available-for-sale debt securities, net of tax impact of $639, $257, $2,295 and $756, respectively</a></td>
<td class="num">(2,252)<span></span>
</td>
<td class="num">(755)<span></span>
</td>
<td class="num">(8,159)<span></span>
</td>
<td class="num">(2,491)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 68,420<span></span>
</td>
<td class="nump">$ 95,337<span></span>
</td>
<td class="nump">$ 131,086<span></span>
</td>
<td class="nump">$ 95,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053461036672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact</a></td>
<td class="nump">$ 639<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 2,295<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053453184848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 01, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 01, 2021</a></td>
<td class="nump">$ 1,879,113<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">$ 2,321,895<span></span>
</td>
<td class="nump">$ 4,476<span></span>
</td>
<td class="num">$ (447,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">97,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(2,491)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,491)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan</a></td>
<td class="nump">15,487<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">15,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(9,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">62,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jul. 02, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jul. 02, 2021</a></td>
<td class="nump">2,043,077<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">2,390,654<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
<td class="num">(349,877)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Apr. 02, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Apr. 02, 2021</a></td>
<td class="nump">1,911,187<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">2,354,103<span></span>
</td>
<td class="nump">2,740<span></span>
</td>
<td class="num">(445,969)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">96,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan</a></td>
<td class="nump">11,285<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">11,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(2,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">28,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jul. 02, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jul. 02, 2021</a></td>
<td class="nump">$ 2,043,077<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">2,390,654<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
<td class="num">(349,877)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">318,842<span></span>
</td>
<td class="nump">318,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 2,210,615<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">2,427,561<span></span>
</td>
<td class="num">(758)<span></span>
</td>
<td class="num">(216,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">139,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(8,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan</a></td>
<td class="nump">15,832<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">15,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(11,185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 44,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jul. 01, 2022</a></td>
<td class="nump">321,800<span></span>
</td>
<td class="nump">321,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jul. 01, 2022</a></td>
<td class="nump">$ 2,391,260<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="nump">2,477,117<span></span>
</td>
<td class="num">(8,917)<span></span>
</td>
<td class="num">(77,262)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Apr. 01, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Apr. 01, 2022</a></td>
<td class="nump">2,293,851<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">2,448,130<span></span>
</td>
<td class="num">(6,665)<span></span>
</td>
<td class="num">(147,934)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">70,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(2,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan</a></td>
<td class="nump">10,319<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">10,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(6,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 24,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jul. 01, 2022</a></td>
<td class="nump">321,800<span></span>
</td>
<td class="nump">321,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jul. 01, 2022</a></td>
<td class="nump">$ 2,391,260<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="nump">$ 2,477,117<span></span>
</td>
<td class="num">$ (8,917)<span></span>
</td>
<td class="num">$ (77,262)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053453095776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 139,245<span></span>
</td>
<td class="nump">$ 97,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">9,266<span></span>
</td>
<td class="nump">6,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">44,381<span></span>
</td>
<td class="nump">62,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">6,443<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">4,359<span></span>
</td>
<td class="nump">22,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="nump">46,693<span></span>
</td>
<td class="num">(12,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(8,322)<span></span>
</td>
<td class="num">(8,020)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(26,025)<span></span>
</td>
<td class="num">(12,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,831)<span></span>
</td>
<td class="nump">9,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInAccruedCollaborationLiabilities', window );">Accrued collaboration liabilities</a></td>
<td class="num">(53,263)<span></span>
</td>
<td class="nump">2,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">17,903<span></span>
</td>
<td class="nump">25,863<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">178,849<span></span>
</td>
<td class="nump">221,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(17,946)<span></span>
</td>
<td class="num">(33,768)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(692,091)<span></span>
</td>
<td class="num">(688,903)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities and sales of investments</a></td>
<td class="nump">500,356<span></span>
</td>
<td class="nump">714,081<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(209,681)<span></span>
</td>
<td class="num">(8,590)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive plans</a></td>
<td class="nump">15,791<span></span>
</td>
<td class="nump">15,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(11,164)<span></span>
</td>
<td class="num">(9,413)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,627<span></span>
</td>
<td class="nump">6,074<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash equivalents</a></td>
<td class="num">(26,205)<span></span>
</td>
<td class="nump">218,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at beginning of period</a></td>
<td class="nump">663,891<span></span>
</td>
<td class="nump">320,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at end of period</a></td>
<td class="nump">637,686<span></span>
</td>
<td class="nump">539,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract', window );"><strong>Non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">120,363<span></span>
</td>
<td class="nump">4,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred for purchases of property and equipment</a></td>
<td class="nump">3,570<span></span>
</td>
<td class="nump">5,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Unpaid liabilities incurred in asset acquisition</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InvestmentsPurchasesIncurredButNotYetPaid', window );">Unpaid liabilities incurred for unsettled investment purchases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInAccruedCollaborationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Collaboration Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInAccruedCollaborationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InvestmentsPurchasesIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments Purchases Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InvestmentsPurchasesIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053466383536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for patients with difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 62 other countries as: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. a member of the Roche Group (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;18, 2022 (Fiscal 2021 Form 10-K).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the fiscal periods ended July&#160;1, 2022 and July&#160;2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the fiscal periods ended June&#160;30, 2022 and June&#160;30, 2021, and the year ending December&#160;31, 2022, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies during the six months ended June 30, 2022, compared to the significant accounting policies disclosed in &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053461284304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,029)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,044&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,383&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,065&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:41.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,812)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,966&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,965&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule, and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contract assets and liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,722&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022 and 2021, we recognized $4.5&#160;million and $4.8&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022, we recognized $59.4&#160;million and $91.1&#160;million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech and the recognition of license revenue for the achievement of milestones during the three months ended June 30, 2022, allocated to the license performance obligations for our collaboration with Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, $89.3&#160;million of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he co</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mbined transaction prices for our Ipsen a</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Takeda collaborations were allocated to our research and development services performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; </span></div>included in Part II, Item 8 of our Fiscal 2021 Form 10-K for additional information about the expected timing to satisfy these performance obligations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458838128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</a></td>
<td class="text">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaborations, in-licensing arrangements and other strategic transactions to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading pharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K, as further described below, for additional information on certain of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,767&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,727&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, we recognized $25.7&#160;million in revenues in connection with two regulatory milestones totaling $27.0&#160;million upon approval by the European Commission and Health Canada of cabozantinib as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, $51.9&#160;million of the transaction price for this collaboration was allocated to our research and development services performance obligations that have not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $37.5&#160;million of the transaction price for this collaboration was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib sold by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and in connection with sales by our collaboration partners are included as a reduction of collaboration services revenues. Such royalties were $14.6&#160;million and $27.7&#160;million during the three and six months ended June&#160;30, 2022, respectively, as compared to $12.1&#160;million and $22.2&#160;million in the corresponding periods in 2021.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, development, regulatory, commercial milestone payments and royalty payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then, in most instances we will assume the responsibilities for all subsequent clinical development, manufacturing and commercialization. In conjunction with each of these collaborative in-licensing arrangements, we were subject to upfront payments and will make payments for potential future development, regulatory, and commercial milestones as well as royalties on future net product sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we entered into an exclusive option and license agreement with BioInvent International AB (BioInvent), upon which we paid BioInvent an upfront payment of $25.0&#160;million. Upon option exercise, we will pay BioInvent an option exercise fee, and BioInvent will be eligible for additional payments from us for future development and commercial milestones, as well as royalties on future net product sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of June 30, 2022, in conjunction with each of our collaborative in-licensing arrangements, and an asset purchase agreement entered in 2021, we will make payments for potential future development milestones of up to $321.8&#160;million, regulatory milestones of up to $453.7&#160;million and commercial milestones of up to $2,070.7&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053461284304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text">CASH AND INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,686&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, restricted cash equivalents included $9.2&#160;million of short-term investments, which is collateral under our January 2021 standby letter of credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our January 2021 standby letter of credit will remain effective through August 31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721,693&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,425)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710,443&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,020,763&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,425)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $3.6 million and $2.9 million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2021, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three and six months ended June&#160;30, 2022, and 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,059)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804,054&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,425)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 237 and 133 investments in an unrealized loss position as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2021, respectively. All securities presented above have been in an unrealized loss position for less than twelve months except for six corporate bond securities with an aggregate fair value of $18.1&#160;million and an aggregate immaterial unrealized loss as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the six months ended June 30, 2022, and 2021, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053461083344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880,486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880,486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,821&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840,945&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928,766&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652,724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had one forward contract outstanding to sell &#8364;9.3&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the six months ended June 30, 2022, and 2021, we recognized $0.7&#160;million and $0.3&#160;million, respectively, of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053459782896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:64.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,364&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053459063920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,381&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,381&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 25, 2022, at the 2022 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The amendment and restatement increased the share reserve under the 2017 Plan by 28,500,000 shares. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, 31,687,133 sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan. The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 2 shares for full value awards, including restricted stock units (RSUs).&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, we granted 587,762 stock options with a weighted average exercise price of $19.99 per share and a weighted average grant&#160;date fair&#160;value of $8.36</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were 12,307,775 stock options outstanding and $23.6&#160;million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we awarded to certain employees an aggregate of 1,003,482 (the target amount) RSUs that are subject to a total shareholder return (TSR) market condition (the TSR-based RSUs). The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 1, 2022 through January 3, 2025. Depending on the results relative to the TSR market condition, the holders of the TSR-based RSUs may earn up to 175% of the target amount of shares. 50% of the shares earned pursuant to the TSR-based RSU awards will vest at the end of the performance period, and the remainder will vest approximately one year later, subject to employee&#8217;s continuous service. These TSR-based RSUs will be forfeited if the market condition at or above a threshold level is not achieved at the end of the performance period on January 3, 2025.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the TSR-based RSUs:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:90.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#8217;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, we granted 4,585,618 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $20.64 per share. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were 11,496,162 RSUs outstanding, including the TSR-based RSUs, and $207.2&#160;million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and service-based RSUs granted to employees during the six months ended June 30, 2022 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were&#160;5,662,157 performance-based restricted stock units (PSUs) outstanding and $113.5&#160;million of related unrecognized stock-based compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458918096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">PROVISION FOR INCOME TAXES</a></td>
<td class="text">PROVISION FOR INCOME TAXESThe effective tax rate for the three and six months ended June&#160;30, 2022 were 20.2% and 19.9% respectively, as compared to 23.1% and 20.5% for the corresponding periods 2021. The effective tax rate for the three and six months ended June 30, 2022 and June 30, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, which were partially offset by state taxes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458589888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text">NET INCOME PER SHARE<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"/><td style="width:49.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.437%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,904&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,941&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,096&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, unvested RSUs, including TSR-based RSUs, PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.213%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053459065584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Build-to-Suit Lease and Headquarters Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the office building (New Premises) associated with our October 2019 build-to-suit lease agreement (Build-to-Suit Lease) was substantially completed. The New Premises is 220,517 square feet and is in Alameda, California, adjacent to our existing corporate headquarters. The Build-to-Suit Lease term is 242 months, includes two five-year options to extend the term of the lease and a one-time option to terminate the lease after 180 months. In addition to the monthly lease payments, currently estimated at $0.7&#160;million, subject to an annual increase of 3% during the Term, we are also responsible for paying operating expenses related to the New Premises. On April 15, 2022, the lease commenced for the New Premises. We determined the classification of the lease was an operating lease. Upon commencement of the lease, we recognized a right-of-use asset of $160.9&#160;million inclusive of $44.9&#160;million for the cost of the tenant improvements in excess of the allowance provided by the lessor and an operating lease liability of $116.0&#160;million discounted over 180 months using our estimated incremental borrowing rate of 4.9%.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we entered into the seventh amendment to the lease for our corporate headquarters located on Harbor Bay Parkway, Alameda, California (the Alameda Lease). The May 2022 amendment to the Alameda Lease (the Seventh Lease Amendment) provides, among other things, for the expansion of the premises under the Alameda Lease by 34,745 square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Expansion Space). The term for the 1751 Expansion Space will run coterminous with the term of the Alameda Lease for the existing space. In connection with the Seventh Lease Amendment, we remeasured our lease components under the Alameda Lease relating to the existing premises using an incremental borrowing rate of 5.0%. As of June 1, 2022, we have taken possession of the 1751 Expansion Space, and accordingly we have adjusted our right-of-use asset and liability by $4.3&#160;million.<br/><br/>For more information about our Leases, see &#8220;Note 11. Commitments and Contingencies&#8212;Leases&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. These two lawsuits, numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties have narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN has, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claims 1 and 2 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial occurred in May 2022, and a judgment is expected during the third or fourth quarter of 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic </span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the February 2022 MSN ANDA Complaint) arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. In the February 2022 MSN ANDA Complaint, we are seeking, among other remedies, equitable relief enjoining MSN from infringing these patents, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of the patents identified in the February 2022 MSN ANDA Complaint, the latest of which expires on January 15, 2030. The February 2022 MSN ANDA Complaint is a new case, numbered Civil Action No. 22-00228, against MSN involving Exelixis patents that are different from those asserted in the consolidated Civil Action Nos. 19-02017 and 20-00633 described above. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are invalid and not infringed. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would also infringe certain claims of each patent, if those claims are not found to be invalid. A bench trial in connection with the February 2022 MSN ANDA Complaint has been scheduled for May 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 (the July 2022 MSN ANDA Complaint) arising from MSN&#8217;s further amendment of its ANDA Filing with the FDA. In the July 2022 MSN ANDA Complaint, we are seeking, among other remedies, equitable relief enjoining MSN from infringing this patent, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of the patent identified in the July 2022 MSN ANDA Complaint, which expires on February 10, 2032. The July 2022 MSN ANDA Complaint is a new case against MSN involving an Exelixis patent that is different from those asserted in the consolidated Civil Action Nos. 19-02017, 20-00633 and 22-00228 described above. MSN&#8217;s response to the complaint is due on August 9, 2022. A trial has not yet been scheduled in connection with the July 2022 MSN ANDA Complaint.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Pharmaceutical Industries Limited (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Parent), asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. On February 11, 2022, this case was administratively closed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). We have 45 days from the receipt of the July 29, 2022 notice to file a patent infringement claim against Teva relating to the newly challenged patent.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053456685888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;18, 2022 (Fiscal 2021 Form 10-K).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span>. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the fiscal periods ended July&#160;1, 2022 and July&#160;2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the fiscal periods ended June&#160;30, 2022 and June&#160;30, 2021, and the year ending December&#160;31, 2022, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule, and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053457201648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,029)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,044&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,383&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,065&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration Risks</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues Disaggregated by Geographic Region</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:41.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,812)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,966&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,965&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Other Assets and Other Liabilities</a></td>
<td class="text">Contract assets and liabilities were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,722&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458888496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,767&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,727&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053460927872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,686&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,686&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Investments by Security Type</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721,693&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,425)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710,443&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,020,763&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,425)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):<div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,059)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804,054&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,425)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458948576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880,486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880,486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,821&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840,945&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928,766&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652,724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053459058320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:64.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,364&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458967648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,381&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,381&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</a></td>
<td class="text">We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the TSR-based RSUs:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:90.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053459732784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 01, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"/><td style="width:49.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.437%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,904&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,941&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,096&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share</a></td>
<td class="text">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.213%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053457219248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 01, 2022 </div>
<div>segment </div>
<div>product </div>
<div>country</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS', window );">Number of countries with drug approval, excluding the u.s. | country</a></td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting from discovery efforts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products derived from other compounds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Countries With Drug Approval, Excluding The U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberOfCountriesWithDrugApprovalExcludingTheUS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053457309184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 419,427<span></span>
</td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 775,407<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">483,073<span></span>
</td>
<td class="nump">380,204<span></span>
</td>
<td class="nump">931,310<span></span>
</td>
<td class="nump">694,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">(136,029)<span></span>
</td>
<td class="num">(95,956)<span></span>
</td>
<td class="num">(273,968)<span></span>
</td>
<td class="num">(182,949)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">347,044<span></span>
</td>
<td class="nump">284,248<span></span>
</td>
<td class="nump">657,342<span></span>
</td>
<td class="nump">511,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">57,526<span></span>
</td>
<td class="nump">39,640<span></span>
</td>
<td class="nump">89,593<span></span>
</td>
<td class="nump">67,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14,857<span></span>
</td>
<td class="nump">61,289<span></span>
</td>
<td class="nump">28,472<span></span>
</td>
<td class="nump">76,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 72,383<span></span>
</td>
<td class="nump">$ 100,929<span></span>
</td>
<td class="nump">$ 118,065<span></span>
</td>
<td class="nump">$ 143,947<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053455609616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Concentration Risks (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_CardinalHealthMember', window );">Cardinal Health | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_CardinalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_CardinalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053453106208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 419,427<span></span>
</td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 775,407<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">349,615<span></span>
</td>
<td class="nump">287,190<span></span>
</td>
<td class="nump">663,680<span></span>
</td>
<td class="nump">517,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">62,240<span></span>
</td>
<td class="nump">90,921<span></span>
</td>
<td class="nump">96,767<span></span>
</td>
<td class="nump">124,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 7,572<span></span>
</td>
<td class="nump">$ 7,066<span></span>
</td>
<td class="nump">$ 14,960<span></span>
</td>
<td class="nump">$ 13,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053455537776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 419,427<span></span>
</td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 775,407<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">347,044<span></span>
</td>
<td class="nump">284,248<span></span>
</td>
<td class="nump">657,342<span></span>
</td>
<td class="nump">511,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">339,159<span></span>
</td>
<td class="nump">275,614<span></span>
</td>
<td class="nump">641,971<span></span>
</td>
<td class="nump">499,209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 7,885<span></span>
</td>
<td class="nump">$ 8,634<span></span>
</td>
<td class="nump">$ 15,371<span></span>
</td>
<td class="nump">$ 12,251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053457089056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 01, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2021</a></td>
<td class="nump">$ 48,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">272,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(258,532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June&#160;30, 2022</a></td>
<td class="nump">63,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks, Discounts for Prompt Payment and Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2021</a></td>
<td class="nump">14,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">175,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">1,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(171,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June&#160;30, 2022</a></td>
<td class="nump">19,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2021</a></td>
<td class="nump">8,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">24,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(22,186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June&#160;30, 2022</a></td>
<td class="nump">10,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2021</a></td>
<td class="nump">24,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">72,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(64,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June&#160;30, 2022</a></td>
<td class="nump">$ 32,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053453102944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract', window );"><strong>Contract assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 394<span></span>
</td>
<td class="nump">$ 394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">7,513<span></span>
</td>
<td class="nump">7,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">7,209<span></span>
</td>
<td class="nump">7,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total contract liabilities</a></td>
<td class="nump">14,722<span></span>
</td>
<td class="nump">14,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Contract revenue recognized, including revenue from deferred revenue beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">59,400<span></span>
</td>
<td class="nump">91,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exel_TakedaAndIspenMember', window );">Takeda And Ispen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 89,300<span></span>
</td>
<td class="nump">$ 89,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract Revenue, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exel_TakedaAndIspenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exel_TakedaAndIspenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053456991216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 419,427<span></span>
</td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 775,407<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">62,240<span></span>
</td>
<td class="nump">90,921<span></span>
</td>
<td class="nump">96,767<span></span>
</td>
<td class="nump">124,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">57,526<span></span>
</td>
<td class="nump">39,640<span></span>
</td>
<td class="nump">89,593<span></span>
</td>
<td class="nump">67,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">51,168<span></span>
</td>
<td class="nump">33,656<span></span>
</td>
<td class="nump">75,782<span></span>
</td>
<td class="nump">56,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14,857<span></span>
</td>
<td class="nump">61,289<span></span>
</td>
<td class="nump">28,472<span></span>
</td>
<td class="nump">76,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 11,072<span></span>
</td>
<td class="nump">$ 57,265<span></span>
</td>
<td class="nump">$ 20,985<span></span>
</td>
<td class="nump">$ 68,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053457416608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details) - Collaborative Arrangement with Ipsen<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 01, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amount of revenues recognized included in the beginning contract liability balance</a></td>
<td class="nump">$ 25.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement', window );">Revenue from contract with customer, regulatory milestone probable of achievement</a></td>
<td class="nump">27.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 51.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer Regulatory Milestone Probable Of Achievement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053453127200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 419,427<span></span>
</td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 775,407<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,485<span></span>
</td>
<td class="nump">6,121<span></span>
</td>
<td class="nump">12,552<span></span>
</td>
<td class="nump">11,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">57,526<span></span>
</td>
<td class="nump">39,640<span></span>
</td>
<td class="nump">89,593<span></span>
</td>
<td class="nump">67,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,097<span></span>
</td>
<td class="nump">5,065<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14,857<span></span>
</td>
<td class="nump">61,289<span></span>
</td>
<td class="nump">28,472<span></span>
</td>
<td class="nump">76,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,785<span></span>
</td>
<td class="nump">$ 4,024<span></span>
</td>
<td class="nump">$ 7,487<span></span>
</td>
<td class="nump">$ 8,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458965616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 37.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458549568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - GSK Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaboration Agreement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_RoyalPharmaMember', window );">Royal Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 14.6<span></span>
</td>
<td class="nump">$ 12.1<span></span>
</td>
<td class="nump">$ 27.7<span></span>
</td>
<td class="nump">$ 22.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_RoyalPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_RoyalPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053457076048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 419,427<span></span>
</td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 775,407<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech | Cotellic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossFromAgreement', window );">Profits on U.S. commercialization</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
<td class="nump">3,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 889<span></span>
</td>
<td class="nump">$ 782<span></span>
</td>
<td class="nump">$ 2,517<span></span>
</td>
<td class="nump">$ 1,733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProductOrServiceAxisAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProductOrServiceAxisAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053453093632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithBioInventOptionAndLicenseMember', window );">Collaboration Agreement with BioInvent, Option And License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Collaborative arrangement, upfront payment</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember', window );">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments', window );">Collaborative arrangement, maximum aggregate development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments', window );">Collaborative arrangement, maximum aggregate regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments', window );">Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,070.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithBioInventOptionAndLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithBioInventOptionAndLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053457428176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 627,000<span></span>
</td>
<td class="nump">$ 647,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">10,686<span></span>
</td>
<td class="nump">16,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 637,686<span></span>
</td>
<td class="nump">$ 663,891<span></span>
</td>
<td class="nump">$ 539,301<span></span>
</td>
<td class="nump">$ 320,772<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458387472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">$ 10,686,000<span></span>
</td>
<td class="nump">$ 16,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer</a></td>
<td class="nump">18,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">$ 9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053452861504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,721,693<span></span>
</td>
<td class="nump">$ 1,534,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(11,425)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,710,443<span></span>
</td>
<td class="nump">1,533,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,020,763<span></span>
</td>
<td class="nump">1,855,704<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(11,425)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,009,513<span></span>
</td>
<td class="nump">1,854,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">880,593<span></span>
</td>
<td class="nump">945,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">880,486<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">573,343<span></span>
</td>
<td class="nump">541,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(9,059)<span></span>
</td>
<td class="num">(1,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">564,401<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">255,407<span></span>
</td>
<td class="nump">33,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,057)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">253,408<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">12,350<span></span>
</td>
<td class="nump">12,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(202)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">12,148<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">80,747<span></span>
</td>
<td class="nump">135,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">80,747<span></span>
</td>
<td class="nump">135,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">87,821<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">87,821<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">130,502<span></span>
</td>
<td class="nump">119,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 130,502<span></span>
</td>
<td class="nump">$ 119,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458534816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 804,054<span></span>
</td>
<td class="nump">$ 454,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(11,425)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">540,226<span></span>
</td>
<td class="nump">385,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(9,059)<span></span>
</td>
<td class="num">(1,672)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">237,680<span></span>
</td>
<td class="nump">18,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,057)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">43,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">12,148<span></span>
</td>
<td class="nump">7,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (202)<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053460932928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 1,253,553<span></span>
</td>
<td class="nump">$ 1,168,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">456,890<span></span>
</td>
<td class="nump">365,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,710,443<span></span>
</td>
<td class="nump">$ 1,533,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053453254656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,710,443<span></span>
</td>
<td class="nump">$ 1,533,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,710,443<span></span>
</td>
<td class="nump">1,533,668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,928,766<span></span>
</td>
<td class="nump">1,719,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">87,821<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,710,443<span></span>
</td>
<td class="nump">1,533,668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,840,945<span></span>
</td>
<td class="nump">1,652,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">880,486<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">880,486<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">880,486<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">564,401<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">564,401<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">564,401<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">253,408<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">253,408<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">253,408<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">12,148<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">12,148<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">12,148<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">87,821<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">87,821<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">130,502<span></span>
</td>
<td class="nump">119,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 130,502<span></span>
</td>
<td class="nump">$ 119,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053452958528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narratives (Details) - Foreign Exchange Forward<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>EUR (&#8364;) </div>
<div>forward_contract</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of contract | forward_contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative term of contract</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnDerivativeInstrumentsPretax', window );">Gain on derivative instruments, pretax | $</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnDerivativeInstrumentsPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnDerivativeInstrumentsPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053453188096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 9,760<span></span>
</td>
<td class="nump">$ 8,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">35,233<span></span>
</td>
<td class="nump">27,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">13,371<span></span>
</td>
<td class="nump">12,927<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">58,364<span></span>
</td>
<td class="nump">49,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">33,020<span></span>
</td>
<td class="nump">27,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 25,344<span></span>
</td>
<td class="nump">$ 22,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053453057744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 24,622<span></span>
</td>
<td class="nump">$ 28,035<span></span>
</td>
<td class="nump">$ 44,381<span></span>
</td>
<td class="nump">$ 62,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">9,549<span></span>
</td>
<td class="nump">13,667<span></span>
</td>
<td class="nump">18,448<span></span>
</td>
<td class="nump">26,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 15,073<span></span>
</td>
<td class="nump">$ 14,368<span></span>
</td>
<td class="nump">$ 25,933<span></span>
</td>
<td class="nump">$ 36,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053453123744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 24,622<span></span>
</td>
<td class="nump">$ 28,035<span></span>
</td>
<td class="nump">$ 44,381<span></span>
</td>
<td class="nump">$ 62,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,493<span></span>
</td>
<td class="nump">5,902<span></span>
</td>
<td class="nump">7,171<span></span>
</td>
<td class="nump">10,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">18,928<span></span>
</td>
<td class="nump">15,412<span></span>
</td>
<td class="nump">32,001<span></span>
</td>
<td class="nump">27,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">4,698<span></span>
</td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">22,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 620<span></span>
</td>
<td class="nump">$ 2,023<span></span>
</td>
<td class="nump">$ 1,919<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053452739760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 25, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve under 2017 plan (in shares)</a></td>
<td class="nump">28,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,687,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward', window );">Reduction in share reserve after stock option or stock appreciation award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards', window );">Reduction in share reserve after all other awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">587,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted in the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,307,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,585,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,496,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember', window );">TSR-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,003,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember', window );">TSR-Based Restricted Stock Units | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting award percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,662,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053460959024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Estimate Grant-Date Fair Value (Details) - TSR-Based Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 01, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of the Company's common stock on grant date (in dollars per share)</a></td>
<td class="nump">$ 20.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">46.85%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053458476400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">20.20%<span></span>
</td>
<td class="nump">23.10%<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053452717408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 70,672<span></span>
</td>
<td class="nump">$ 96,092<span></span>
</td>
<td class="nump">$ 139,245<span></span>
</td>
<td class="nump">$ 97,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income, Basic</a></td>
<td class="nump">70,672<span></span>
</td>
<td class="nump">96,092<span></span>
</td>
<td class="nump">139,245<span></span>
</td>
<td class="nump">97,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income, Diluted</a></td>
<td class="nump">$ 70,672<span></span>
</td>
<td class="nump">$ 96,092<span></span>
</td>
<td class="nump">$ 139,245<span></span>
</td>
<td class="nump">$ 97,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">321,117<span></span>
</td>
<td class="nump">314,117<span></span>
</td>
<td class="nump">320,349<span></span>
</td>
<td class="nump">313,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">3,787<span></span>
</td>
<td class="nump">8,824<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
<td class="nump">8,819<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">324,904<span></span>
</td>
<td class="nump">322,941<span></span>
</td>
<td class="nump">324,096<span></span>
</td>
<td class="nump">322,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053457221568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share-based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities and contingently issuable shares excluded (in shares)</a></td>
<td class="nump">14,350<span></span>
</td>
<td class="nump">12,285<span></span>
</td>
<td class="nump">15,436<span></span>
</td>
<td class="nump">11,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140053453206176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 29, 2022</div></th>
<th class="th">
<div>Apr. 15, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Estimate incremental borrowing rate (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LossContingencyNumberOfLawsuitsConsolidated', window );">Number of lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim', window );">Notice period for file a patent infringement claim</a></td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseAndHeadquartersLeaseMember', window );">Built-To-Suit Lease And Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lease property (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">242 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend the lease | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease option to extend period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod', window );">Option to terminate lease (after period)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment', window );">Estimated monthly base rent under Build-to-Suite leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage', window );">Monthly base rent, lease not yet commenced, annual percentage increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Inclusive of operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseLiabilityDiscountedPeriod', window );">Operating lease liability discounted period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Estimate incremental borrowing rate (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_LeaseExpansionMember', window );">1751 Expansion Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lease property (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Terminate After Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Days To File Patent Infringement Claim</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LossContingencyNumberOfLawsuitsConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Lawsuits Consolidated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LossContingencyNumberOfLawsuitsConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseLiabilityDiscountedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Discounted Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseLiabilityDiscountedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TenantLeaseImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Lease Improvements, Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TenantLeaseImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseAndHeadquartersLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseAndHeadquartersLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_LeaseExpansionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_LeaseExpansionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>exel-20220701_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exel="http://www.exelixis.com/20220701"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20220701.xsd" xlink:type="simple"/>
    <context id="i1e85cf3adc3143168c5871013115016c_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i0ba4d0f4b0914516a979aaca1c0115f4_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ibd88d103ffe54da794c385cd93721ee7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f0966f9eca84459ae2dd8ebc3309047_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i0b9e8d3facdf4864bb7c81214e9ad6f8_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="if42cf2e0fa214b5c803a30524005d09a_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i783842d281c14d18a5ab8e977fb76f4a_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i17ece728364b4cc48c40e024bb487e25_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i51494a71ce844aa2aaa75d35e9949848_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i635c229f1f07418d854dc726f5340cb4_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i769896e9287e4183bddc0e89f0dcc56b_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i706119ef90c140f89a64ca72f784f4b0_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i69fd855fbc7048eabfa55142b96cda52_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i2f1dadf8806a47148f339ef9a9717604_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i2c8dae096ca44ee58f98136af8f519b9_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ifbbf35553e864a47b12a2d1fd928f98e_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ica2525aa6c6841f982350ebfeb7ae4e9_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i13f12b5dde5b4fdda7863e2006ddc6da_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="iabda242f1aa040f1aa8b97a4539b80c1_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i31a5dab809bf451896a0f1f8a5a72ca2_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="idd09d7b967674984a4b4c0e1ecf5c20a_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i083ff5f50112432b974e39cee8bbb3e9_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i51ed73dd842a42c787ae6af93fa1f0ef_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i61b5acd047f54e5e890f1c61b9bb0bf2_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="id5e9422226204c1caad9468840b30369_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i3a7035844a96447d9ece7ea6b0cc2ed8_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i5e3a8211d9414334ba9e7d2ba62bc3c5_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i3fb93329607a4f4485821bd6d3b218d4_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i178b1c70ce884adaa05d4e23647aa97f_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ic65133c237764501911f938ce005dd62_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i074c0d5d00e94dcd86712e0f3b167c31_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i5638bf7f18a54b5eb3f4e9899ee414b8_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i9c4a65a50aa94cbcaa556bdea637aae0_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="icc467238ed7e44f8908d4c4197d02952_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="id29da21d87ad4d1cbc07082f36dae1db_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i33204058d2884277a534f3fe8b2d05c6_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i72e65c25cad842b48b3a06036a8dfb11_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i9ad2cb90ebc241bb8b2f4469a70980a7_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="if60b5dd0182e46dca654df547b7153f4_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ic8c00d41f727490497fb324365d70cdf_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i6cc4df1f70524cf0b42d834be77810ec_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ide7e987c180a418585f377e54ea41af1_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i38d2914ca5204497ab3d3c3eaea8818d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1249b090f0b64f6ba2e504df49cb49cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fbe83b4d13441469af603970b1bfad2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11fbb1f45c2f4280981d038a82ed2190_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb6414045fef4baaab29a829c64218c3_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ia9ee23437eab47868678f63cbd6ef147_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ia0f4f857a9fc488b86c7e00d7d13b344_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="id762b4c844464d9dbd1a5232a5556a16_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i7915746f5547460f9caa2e4177cfce05_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i9e25b57e2a0b4d829b12b77168539aa7_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="icf90c32a09a4497996f31bce3e8b5d1e_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i646dda3b25974251a53973741e46976c_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i95504af18ae84a95a6f5672e2c0962ea_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ia1ebf17aa8654c809fdc3b7fdf977b94_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i920841e629d44fa39ab93aed91f7add3_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ie673862a0ee14b879e59030e6dfa3b2b_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i2e90a92edb8647439746c5535fbdf9b9_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i8fa8420126014bf088bb615340e7af05_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ic8c53c5143b04fa790d554162bdceec7_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ia26f483bdcbb41acbef2e9cd23df368f_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ic9620d75cbfe442cbdfb2e49f10029ad_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ib68714772b36481f8c505e3eef1639c8_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i08b267d864364d6ab0b3c49456d3b22b_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i25a529c6b1f84c14b8c06c30376f65f6_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="if0e39c06180045fb8a7047acd09b09d5_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ia4609cc64ebd4171954966a86b6926ef_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i077dff06f4904d1990415f13a7b882a4_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i6d0a7ab1f65b4bc786a98d7742cdc82f_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i37e0da3271234f2bae53c14f82b39321_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i92fba14ea211474d82d9667f1ee43b1c_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i453607a6d2c241139ae0154655e12057_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i89f773b17954459496fdb8e6635e500c_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i125702b0bbdb49ea96eac26fc326c134_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ia565cbddd5a042f7b2339b3e701e9826_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ie6183c887d9e429a96461d489c65f056_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i2f74d8c31ae74b7fa6e4e39449d3df62_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ic9f47a8d0e664d6d84d3873e23fc60ad_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ie59b3ee9c868431aaa28932ed170565e_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i335341eb633f4434b8610f4f0d41be82_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="id557498866464ef2bdf02ccdb8ede387_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ie61a701acae34a7abd58a8f0dc4a3bbd_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ie70c7ffb0e364a418f44f5b2fb7046a3_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i00cc9c53a3754125afaca64318f35370_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i2fbfda11dc6c495abc4054a2e60213b2_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i9004549ad6404156b209d07af26d7701_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i5c826af902764b62b9b01c219b888602_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ic6dde7ba3d13446293bb96e14dad26d4_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i107d673b016341dba6ddac20be0bf0fa_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i2e8e064972ed4cd69de87474a9c08e9a_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i30e893865b1a401fa0a584689c74906c_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i0d38bdc277d847c1bff9aea646f7b5d2_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ie870ca4583284e068d8931189e43799a_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i14ebf4acc76c40a8862a0cd9494ba17d_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i664afc43ce6141e7926e690257545766_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i56c71bd1b9a544559774ad6cf16b1bc8_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79b6e39380ee492b9465c8a189dc79c4_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i1d728a2065f34c5f99164244a2469b05_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3955701b6f504b6c9492fed7e52d6cac_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i8236363288634352a070bfdeae4ada52_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iedf483295e3441dfb06c39992af1d0cc_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CardinalHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i57596bbb198e467e913bd95f788460dc_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CardinalHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6bde2f537a354fcca14f821547b896d9_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="icc1e3c9b038f4adbb0f8ca47a926170a_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i21feba329f3c47ba847cdba72f05f74a_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i9c8f2e6e66e0483e9df068c8c67f6edd_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i09963410ea564c02b8ff6283d62b4527_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i4e34c2a69d6c44dd87763d280f6add0f_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="idb5c9264424540c9a4f238323ac0939f_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i16714420b2fb49839858d28e6d5059ae_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="id0b5c39cb3324983afed5da2408dadd7_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i47e812ece3e94486a2fe21cbd2277bb5_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i188d6447088e4f92a8f70243be252647_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i8e97a0d79c07480eb88736adeb90ea7b_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i54050f41270d4c0994179a0b71bcbd09_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="iaeea8eb188124f60a0aaeaa7d0940557_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i69844ba478ba4fe381bf568853c31297_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i054896b94915439693f85afea696414b_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ibb0803dcbf5b4e67ad983af158cc6a71_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i0c3101bd9ba54dbca9144e467e80187f_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ifaa34646405c478e99b9fd71f2184c6a_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ic35af551acc24804b0071e3db5e6fe35_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="if53bb4fda56c4d03bcefd670f7e34159_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied4e111ae3b74e388273fc644813dcbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i840ea9693a1241dba5f3c957a1971f4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i168b07bb58fb45fea0c1251110528099_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ia7e6ba1cc1ac40ba8c5827e2046e2bd1_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i37ef9620b8e045d1ad550beff5449fb3_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ife8f6fa225be4cf0b820fdededde5d76_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i0d94301a72254e9d9c581087dcee3084_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i1a01e54ece8642d5b3a8cd53ce306b40_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i772576eea90d4bb0929cdf808c536289_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exel:TakedaAndIspenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i7d2515b3d980437d88f874ad96264c8f_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="icfeb2faa92124a56beca5879006c456c_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i9a867ee6b32d4d0ca8d6da06a0baf4f0_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i02072ae37a364e828c67a1f3675a3358_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i1d3b05ed939f4eea80b46d18a26cadad_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i0e7633a25d674d1d9065925fd26afcdf_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i8679d3445ee744d6b8bd2814877f2e65_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ib163ec7f845e44e9af8e12e633ddeb1e_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="id082ca3812d9497f9a5419f7e2935ef1_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ib008fa7a2c3348058b33ada2c3c90db2_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="id3e31b2ad1f74418b3fc3f615f610c44_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i6ba0f6408f78479fa48647723afcaff3_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="iab7278b18228461aa447d7af1ab75997_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ica98cb95722d43bc90dd8fdac8a16248_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i1e5e7e3b485b4ccba1783e0a9e98bce2_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i0faaa279485d47858ff462a4fe31d8cb_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ib1dc5dede6944878bb37ad9f5b90202c_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="id28f186b12114729ad0bcf462687594b_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="idb3c2f628159430fa2b4ba939626da68_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i7c34c70519cf4ccdb9cf2f1f898c0f47_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ib934a263672b49e2b398d9af12ca3f18_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ied5cfd9d83994869a3ed269eca638c4a_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="id21078b478324339b815339fdc2f5d2a_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i2bf36077e14546d49a6c6d7f64c0e7fa_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ie6b3af1cf525438ea1fdab7f2ae1a4b5_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i9d122b6fe357426c8ad3468c325f4936_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i37d0046d01764a6a84fff26e8dc7ad8e_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="iaa76717dc58d47e987e00cef2f0b1605_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i5d6438a867804b3690c45471a4365f52_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i839cb707d2d1469585661ba26e60dba8_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i395367a2b6f840398cc68008eec67422_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i9403b468905b44ddb12619327a4d1331_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="id0536dbf918041b2a030788539bad217_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i3ab318d80ac145cfa0dd2bc25b9ffc19_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ic7d942e3ddd54d17abcf3f8dd59c4d5f_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i2b5ed8e63d724ab1b37ae2306c7d0aa7_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithBioInventOptionAndLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibfc05a0f9c9a41eb9f99aed54fd26749_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i1989bb1580374884bd42c103f79e3cb9_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="if3c8d749d7584b6199a2924e8a1e9a41_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i03769550f9144c9984b85e0c5923a535_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="if453d9270ba64e94a9244e7992459ee8_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i1699183c5c004e00bb9e1dd4a3f6355d_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i0451da3ec05541229c7b26c8a138441a_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i0503cc8f8c754670b0adbd270a4852eb_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ieec985d2c22946468e2db7ee7e8fdd66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie325f3ade8d44aa1a927d9ea4b117375_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a744931712846de898f2a9ba07534f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f56488c0f264c679e4506474188a292_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9786b6a841764a17b8436d495f0e5d65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib217aade91424cacbff6d49127cff87f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i534afc4a026f4e9aafc43cba5359abc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c3df4ca36254ec4a53aa642de2052fd_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i4b987f3b567145a39c76a99080d73be8_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ie98d96a4511c47b9976557bf8ed9d3ea_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i56e65916b15b411381657ad58dd0a7e7_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ib4001c4a298441f39a683b1fdcf12c32_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ib7bf40d8ebf840d0975f8df43474ebcf_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i182702258c9044e19db73717afe1ba2e_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ib08fb62625a144fb8b5d4cbf945345e7_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i3322c81a75204e04b49bcd282f9082ad_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i3e2c9be6723b4ecc857b1318d9a40a7c_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="idd3ad6acbfea40668adabc0d0ae06c0b_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i8bec5ac658b94646b56ba00d21fd274f_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i8fa5514df76b4a5289b9dab0ab958760_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i0e391b43e0914915bee3cd7d5073d918_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i0fa7e06004bf493583d8ea1de5a444ae_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i5552036575a7423281fcbd4cb49bcea7_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i80c87c83caf14e26b70ae4c672e30e2b_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i4f5ca710be364f0da48207b91de352a3_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i51a622ef9643442a9a59c6d3cc3663f1_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i619648b30df241fbb45ec26d4592f421_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i8287e312ca114e8e93490b2d88392315_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i4a5daf776b964c24b6e400bd55663894_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec6206d802e34860b2b50b24991812bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i129784cda6eb4132aed1c7cf8bb7db12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76c0e8d11fc14158ad314c1ac66746ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0cd4a3e3e3a74aebb9eec590702a773b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46639be8a28240e1a86dea7f936b0a6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib916c6956341489bba5b28db02a30837_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79d149a9eefd4440a22b0d5b7e870327_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide4306bdd2ea4e91bb97b8be2b61b651_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba54d40c2bc64ef4bdb52d572de09fa5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa0b629b04984a1eac7d47c831d167f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefecc78bc743406c8b43fad567aad8d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0696d13063a422b94ceaf169c4d5572_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb1fcad1a5f14b1ead0a41c83a2d65ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf6cf4c54fd4471291a5a225c2026764_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica317fbf66054d0d9b5755dec32fb97d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc6b02b5522f4c62b5630f7652995697_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f38a828dd704e21b97feddadcce5b63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1aba76e7e4d6469a8ced5f3ac2c0957d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb5ac02de86e497ca09eaa96e8d84aef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i419d7d0e02084f7482be6ce902493727_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38408adaba6d4341adb12d55daf8b48e_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i1fe3c38bcffe44d0aa127c4b877c1d71_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i2e8d1c4ed84a49b6b1de444247607719_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i214511920f1a4c718201e79910fec792_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i4f26547ff011485ea499fc7321085b2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i401482ee2371429dbb52062b06e78cf4_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i62d04e4f28a941478b345f54d2cb7e3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8c8787ab89e4ea8aa9bcbba33a74fb7_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="iaeeca34bdde8405b8c686e83477e4f42_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="id5abd3b9738c4a48916938c34311867c_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="if1b0173c487e4563b2a6777d58f46013_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i96a7e658a6084f529242281c7bcea519_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="if900f76b28c94ec78c9965e91ee8f0b6_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="iadffddf5c5c64493b3fa047c4ed4f265_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ia2bf0f43bb254fcb95413ba3a8c9c810_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i7cb92aaea0154533ae9a350686b93d27_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ia82d6aff031447fab7f99cce91ae6db8_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="if6524855f344408b90f428815d3ed343_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i57d61f3143c347f0bff85037bb757393_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i826763d3077e4ad086c22a3ff19ad208_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i2b7e89015a804623990353f662f9a155_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i288c55ead7e941548dc6ee322e4a325c_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="iecb5bc2ce4804674ab1ceb6b7109a08b_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i9ed4735334c844459ed18dbd61c6c4f6_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i98ccdd8a412d41abbfac65334e30283c_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i2768e53f82974b9da558e84e64b5d621_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i0034b83355444c65ad6e185cc7ccd058_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ifd650bcd87a349d786cbed15f8f31bd4_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i2669fd364d81445786658c8dc9193396_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i799167078ab64d6d8c88a06ba5578ea4_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i847152b60ebc49c7a64cb3e47896adc8_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i18d5c27ec4b94608b6a47b96f6900355_D20220525-20220525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2022-05-25</startDate>
            <endDate>2022-05-25</endDate>
        </period>
    </context>
    <context id="i140a87f9739042bb9715f01f144db770_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8b79f2ddeb834dada1c18e98a6a85c1b_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i79b56428e2684493a912b70ba5c56f75_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i73a59494ab85495e95f7a35120b582a9_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ie20c1bc9723141ceb9391ded30c724c2_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i243680f68f274834b859ce0d17c3e93f_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ie5128decae384f698a9ab00463cbd990_D20220402-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i3d22c0ab1ce2424b9a59efba14386e0e_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i25b873c8ba6a4c4f960fbb64be80b871_D20220101-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i985d03e626eb4a299ec7d942d6a3e0fc_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i88887d64754a4f1ebb805302f47aa477_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i69d48eac98d64f5887fc5c912672b993_D20220402-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="ieeb8ed4d7cb445b08584aace5ff56694_I20220415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-15</instant>
        </period>
    </context>
    <context id="i95b2c08d83814c348966a2366c0de8a7_D20220415-20220415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-15</startDate>
            <endDate>2022-04-15</endDate>
        </period>
    </context>
    <context id="ia8db2258b7ae45a995b0f68fabdcd327_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:LeaseExpansionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="ia312fa6ca0df4ee1be126a7eea55f36f_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="ib2c7ef7fab7345ebadb2ed3327f9af7d_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="i188a4a13c6094e2e882585005f7bcf76_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ia392f18685aa4066aa68046de26c42a7_D20220729-20220729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-29</startDate>
            <endDate>2022-07-29</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="country">
        <measure>exel:country</measure>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="forward_contract">
        <measure>exel:forward_contract</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="lawsuit">
        <measure>exel:lawsuit</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80L2ZyYWc6MGY1MGU1ZTYwMWZiNGY1OWEzY2M4NmU0MjIwM2U4MjQvdGFibGU6ZjkwNjE0ZjVmYzc1NGZjNmIwZjY1NjhjMjcwZmNiODEvdGFibGVyYW5nZTpmOTA2MTRmNWZjNzU0ZmM2YjBmNjU2OGMyNzBmY2I4MV8yLTEtMS0xLTY2MzI2_8eb0dc8c-fd0e-48ca-a02b-cb08a40fb6d8">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80L2ZyYWc6MGY1MGU1ZTYwMWZiNGY1OWEzY2M4NmU0MjIwM2U4MjQvdGFibGU6ZjkwNjE0ZjVmYzc1NGZjNmIwZjY1NjhjMjcwZmNiODEvdGFibGVyYW5nZTpmOTA2MTRmNWZjNzU0ZmM2YjBmNjU2OGMyNzBmY2I4MV80LTEtMS0xLTY2MzI2_96016921-591c-4603-a04e-267d82deb525">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80L2ZyYWc6MGY1MGU1ZTYwMWZiNGY1OWEzY2M4NmU0MjIwM2U4MjQvdGFibGU6ZjkwNjE0ZjVmYzc1NGZjNmIwZjY1NjhjMjcwZmNiODEvdGFibGVyYW5nZTpmOTA2MTRmNWZjNzU0ZmM2YjBmNjU2OGMyNzBmY2I4MV81LTEtMS0xLTY2MzI2_652b8559-a1ca-4d2c-9476-0c878f385abb">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80L2ZyYWc6MGY1MGU1ZTYwMWZiNGY1OWEzY2M4NmU0MjIwM2U4MjQvdGFibGU6ZjkwNjE0ZjVmYzc1NGZjNmIwZjY1NjhjMjcwZmNiODEvdGFibGVyYW5nZTpmOTA2MTRmNWZjNzU0ZmM2YjBmNjU2OGMyNzBmY2I4MV82LTEtMS0xLTY2MzI2_0e3a1461-a5c3-480a-937f-a7edb848d243">0000939767</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80L2ZyYWc6MGY1MGU1ZTYwMWZiNGY1OWEzY2M4NmU0MjIwM2U4MjQvdGFibGU6ZjkwNjE0ZjVmYzc1NGZjNmIwZjY1NjhjMjcwZmNiODEvdGFibGVyYW5nZTpmOTA2MTRmNWZjNzU0ZmM2YjBmNjU2OGMyNzBmY2I4MV83LTEtMS0xLTY2MzI2_2494f9d6-6dca-45b8-99d2-7153a5334f9d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YmRhYzY1ZTZmYWJmNDFkYmJhMzYxNWY3YmM3OGNlOGMvdGFibGVyYW5nZTpiZGFjNjVlNmZhYmY0MWRiYmEzNjE1ZjdiYzc4Y2U4Y18wLTEtMS0xLTY2MzI2_83750b95-878c-4819-b759-2e3c07e99415">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YTVhNTJhNzZiMjQzNGFmMmE4MjUyMTE0Y2UzNTk1ODIvdGFibGVyYW5nZTphNWE1MmE3NmIyNDM0YWYyYTgyNTIxMTRjZTM1OTU4Ml8wLTAtMS0xLTY2MzI2_56a7d330-4933-4a40-910d-8c0a3af97826">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xMTU_b5dadca6-dc37-4e6c-9d3c-dc75fd96f902">2022-07-01</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6ZGQzOTkxMmZiODNjNDliYTlkMjNmMjQ2NzQ1MzlkNzIvdGFibGVyYW5nZTpkZDM5OTEyZmI4M2M0OWJhOWQyM2YyNDY3NDUzOWQ3Ml8wLTAtMS0xLTY2MzI2_39456fb9-3f01-424e-b08d-870ea8952466">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODc1_69e8a07b-4b2c-4f95-bf94-4e534894cf8e">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6MTA4MWQ1NmFhMWI2NGJjODk4ODQ5OTI2M2E4MDk2ZWEvdGFibGVyYW5nZToxMDgxZDU2YWExYjY0YmM4OTg4NDk5MjYzYTgwOTZlYV8xLTAtMS0xLTY2MzI2_0107aa0a-3cd7-4309-b807-e9a0b5178e5d">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6NGI0NjI4Y2E2NTlhNGQ3OWJiMDYxNjU0ZTM4YWYxZGUvdGFibGVyYW5nZTo0YjQ2MjhjYTY1OWE0ZDc5YmIwNjE2NTRlMzhhZjFkZV8wLTAtMS0xLTY2MzI2_2fa01dba-8316-4737-8966-98c5b00196d6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6NGI0NjI4Y2E2NTlhNGQ3OWJiMDYxNjU0ZTM4YWYxZGUvdGFibGVyYW5nZTo0YjQ2MjhjYTY1OWE0ZDc5YmIwNjE2NTRlMzhhZjFkZV8wLTItMS0xLTY2MzI2_2b3a904e-38df-4c4c-b1ba-73a0ff898b84">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODc4_948315e4-f2b3-4faf-a4fd-57fef2f25de9">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODc2_3930f64e-d3ab-4689-8794-839d25e3cc54">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODc5_cb358fd9-3b82-42ab-b458-e6dd1dc0669d">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODcy_72915540-7040-4ba5-af3b-e01432f688d3">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODgw_06b2b55b-57c7-49d3-88c0-c7a5d43fe0fc">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODgx_aab18f63-c511-4c9a-9c21-d0878959bcc8">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YzM1ODZlNTJlMTdhNDgxYThiNTAxMDc4MzYxYjZjMTkvdGFibGVyYW5nZTpjMzU4NmU1MmUxN2E0ODFhOGI1MDEwNzgzNjFiNmMxOV8xLTAtMS0xLTY2MzI2_681a8400-8570-448f-86e5-d624a0d39e9b">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YzM1ODZlNTJlMTdhNDgxYThiNTAxMDc4MzYxYjZjMTkvdGFibGVyYW5nZTpjMzU4NmU1MmUxN2E0ODFhOGI1MDEwNzgzNjFiNmMxOV8xLTEtMS0xLTY2MzI2_d8bbb195-2567-48f5-ae2c-aae3586bd080">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YzM1ODZlNTJlMTdhNDgxYThiNTAxMDc4MzYxYjZjMTkvdGFibGVyYW5nZTpjMzU4NmU1MmUxN2E0ODFhOGI1MDEwNzgzNjFiNmMxOV8xLTItMS0xLTY2MzI2_a82749bd-37e0-409e-93db-e00c4b0c2efa">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODcz_1a00782b-3a81-4587-9089-c1d50fb0b248">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8xODc3_2b66e962-1c86-4a74-8d80-90770d8e1bb0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YjAwMjFjZjNiNjlhNDRkYjg5ZDgyNzUxMDI5ODFhNTkvdGFibGVyYW5nZTpiMDAyMWNmM2I2OWE0NGRiODlkODI3NTEwMjk4MWE1OV8wLTAtMS0xLTY2MzI2_6b8ec4bb-7ea0-4449-a780-91a2ceacd8f3">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YjAwMjFjZjNiNjlhNDRkYjg5ZDgyNzUxMDI5ODFhNTkvdGFibGVyYW5nZTpiMDAyMWNmM2I2OWE0NGRiODlkODI3NTEwMjk4MWE1OV8xLTQtMS0xLTY2MzI2_cc72b796-822f-4aca-b374-fc199be3c7c4">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGFibGU6YjAwMjFjZjNiNjlhNDRkYjg5ZDgyNzUxMDI5ODFhNTkvdGFibGVyYW5nZTpiMDAyMWNmM2I2OWE0NGRiODlkODI3NTEwMjk4MWE1OV8yLTQtMS0xLTY2MzI2_1e2400f5-9d38-4c64-b8e7-702526f28177">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl83MTQ2ODI1NTgyNDc4_8b5a525f-671f-4087-9961-18fee34293ae">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0ba4d0f4b0914516a979aaca1c0115f4_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xL2ZyYWc6YmQzNzZhYjg0ZDFjNGRlZGIwMzU5M2YwNTQwZmJlZDIvdGV4dHJlZ2lvbjpiZDM3NmFiODRkMWM0ZGVkYjAzNTkzZjA1NDBmYmVkMl8yMTk5MDIzMjU3NDU3_c44a1b07-a249-46cd-81df-16b1720838ba"
      unitRef="shares">321831784</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNy0xLTEtMS02NjMyNg_19bfcb81-142f-4f23-b2a9-adf0e0d88347"
      unitRef="usd">627000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNy0zLTEtMS02NjMyNg_8865e94e-016e-41f6-aa14-47afad62aab3"
      unitRef="usd">647169000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfOC0xLTEtMS02NjMyNg_ca7c90be-6623-4a60-ac0f-b31c8dfa3f9d"
      unitRef="usd">907938000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfOC0zLTEtMS02NjMyNg_a77877d6-aac1-4f3e-8747-3e79d01a6a74"
      unitRef="usd">819905000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfOS0xLTEtMS02NjMyNg_5b3ad5c8-04bc-4ea8-8e5d-24a0eeff4879"
      unitRef="usd">235400000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfOS0zLTEtMS02NjMyNg_ef29fbd6-5fdf-406c-8d96-9ec88ac35420"
      unitRef="usd">282650000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTAtMS0xLTEtNjYzMjY_63582be7-24fb-48b4-9951-01cb4a73c04f"
      unitRef="usd">33020000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTAtMy0xLTEtNjYzMjY_4cafbc4c-7542-4ce5-a542-bceb67daad12"
      unitRef="usd">27493000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTItMS0xLTEtNjYzMjY_3b56f311-8089-4014-8230-ec62f603d7b3"
      unitRef="usd">48281000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTItMy0xLTEtNjYzMjY_d6c56dfd-27c5-42ee-8fe2-b3e502004d7b"
      unitRef="usd">57530000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTMtMS0xLTEtNjYzMjY_3fac1066-9d79-447b-b0e3-d1f9d399d65f"
      unitRef="usd">1851639000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTMtMy0xLTEtNjYzMjY_5823a28a-faa6-44f1-92b8-8838f8611918"
      unitRef="usd">1834747000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTQtMS0xLTEtNjYzMjY_84cdf4fd-aeba-4533-ad2a-92bb0acf9ac6"
      unitRef="usd">463889000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTQtMy0xLTEtNjYzMjY_0af4fc5d-7b76-45f9-b01e-98474395d6d3"
      unitRef="usd">371112000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTUtMS0xLTEtNjYzMjY_fdf95ff6-8cc5-4b94-b5e6-4a4d718d5a9f"
      unitRef="usd">108529000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTUtMy0xLTEtNjYzMjY_633ea256-675d-463c-9b8d-fb794b7d9dd3"
      unitRef="usd">104031000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTYtMS0xLTEtNjYzMjY_8d61425d-c61d-4d37-89b2-4ab02339bd2c"
      unitRef="usd">113958000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTYtMy0xLTEtNjYzMjY_1ad31182-23d1-47d5-acf3-0928e843311a"
      unitRef="usd">111663000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTctMS0xLTEtNjYzMjY_a401a7bd-a7e6-4aa4-bdfb-f2c6fd1f9396"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTctMy0xLTEtNjYzMjY_3fa40114-aa80-4392-b6ec-c7191fd90f63"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTgtMS0xLTEtNjYzMjY_37abef52-8a5f-4d9c-91a0-6011559dd4d9"
      unitRef="usd">279705000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTgtMy0xLTEtNjYzMjY_59b80a61-8821-4821-b8a5-d9a8989e247c"
      unitRef="usd">131002000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTktMS0xLTEtNjYzMjY_22877636-99c8-4576-9af8-b50a3810ecca"
      unitRef="usd">2881404000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMTktMy0xLTEtNjYzMjY_479ca2fe-8c48-49ee-bf54-1183f68ba831"
      unitRef="usd">2616239000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjItMS0xLTEtNjYzMjY_0379eb38-8ad9-4274-baef-91c86a1aeb49"
      unitRef="usd">19978000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjItMy0xLTEtNjYzMjY_8b2e30ef-20ae-4fd0-8bf6-1c8a5b607a14"
      unitRef="usd">24258000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjMtMS0xLTEtNjYzMjY_c7a41599-45e7-454f-9521-6a04e95e8b98"
      unitRef="usd">61450000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjMtMy0xLTEtNjYzMjY_0020f45f-551b-4573-8417-089ca3102530"
      unitRef="usd">61969000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjQtMS0xLTEtNjYzMjY_c5b66671-9f80-49fd-9600-aa26ab8af7a2"
      unitRef="usd">76740000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjQtMy0xLTEtNjYzMjY_4698906a-8b50-4692-9443-24c0a0061682"
      unitRef="usd">77544000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjUtMS0xLTEtNjYzMjY_739a9f7f-c923-40d8-9b71-36aaf7d495d0"
      unitRef="usd">43795000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjUtMy0xLTEtNjYzMjY_4ea1bd1e-a0f9-43ac-8d2f-8d1d12e68dec"
      unitRef="usd">33700000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjYtMS0xLTEtNjYzMjY_8b6c71aa-67dc-43cf-874a-b5b0c8cd31d8"
      unitRef="usd">29990000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjYtMy0xLTEtNjYzMjY_af68a339-b80c-41e3-bf8f-0c2cda7acfaa"
      unitRef="usd">86753000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjgtMS0xLTEtNjYzMjY_e5c364c4-ad65-4d16-8751-90b1e22c9151"
      unitRef="usd">72568000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjgtMy0xLTEtNjYzMjY_5a39fda2-2952-41d1-94b5-498731188b3f"
      unitRef="usd">53366000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjktMS0xLTEtNjYzMjY_c45fc55c-00b8-4fc8-960f-e973130a68a0"
      unitRef="usd">304521000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMjktMy0xLTEtNjYzMjY_da0ecc89-aff4-485e-a1cc-d83f82f6f6d9"
      unitRef="usd">337590000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzAtMS0xLTEtNjYzMjY_16b83b1e-cca4-4127-b3d4-4dbe26406779"
      unitRef="usd">7209000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzAtMy0xLTEtNjYzMjY_4b1701ee-a717-40c4-bfae-0a9be665b4f0"
      unitRef="usd">8739000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzEtMS0xLTEtNjYzMjY_a7cbcda4-9c73-41b3-ac80-6d2686fcb665"
      unitRef="usd">161019000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzEtMy0xLTEtNjYzMjY_3772a0fe-3a89-46ae-8358-228a3289bc8e"
      unitRef="usd">51272000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzItMS0xLTEtNjYzMjY_b64befe4-a43f-4be1-8fae-7591b02f851a"
      unitRef="usd">17395000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzItMy0xLTEtNjYzMjY_e19411dc-01ef-474b-a123-5265ccdf9b6c"
      unitRef="usd">8023000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzMtMS0xLTEtNjYzMjY_240b6d97-8fe8-400b-853a-9569a5ca7c4d"
      unitRef="usd">490144000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzMtMy0xLTEtNjYzMjY_d7bc0cd8-f3cc-444d-a687-f2cdebd0ef4c"
      unitRef="usd">405624000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzQtMS0xLTEtNjYzMjY_c8431c7a-841a-49d9-bc94-ed296833cd5e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzQtMy0xLTEtNjYzMjY_7f3ddbb8-d7f1-4125-b9e8-2398f5c6f6dc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3MWZkNjZlNmNkNmY0ZGMxOTkwMjRmZmRhNWQ0YWJkNl8yMQ_37a2a733-94ea-4a73-9ca9-800f0dd91840"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3MWZkNjZlNmNkNmY0ZGMxOTkwMjRmZmRhNWQ0YWJkNl8yMQ_f8c853bd-4344-4ebb-92c9-3b67cd4b1996"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3MWZkNjZlNmNkNmY0ZGMxOTkwMjRmZmRhNWQ0YWJkNl8zNQ_82c07820-3690-4a1b-8c96-45a14f5ecee1"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3MWZkNjZlNmNkNmY0ZGMxOTkwMjRmZmRhNWQ0YWJkNl8zNQ_a7e2cc08-e078-460e-95d3-923ea93945e9"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3MWZkNjZlNmNkNmY0ZGMxOTkwMjRmZmRhNWQ0YWJkNl82MA_4848bfba-37e3-48d0-b688-b97312ca408d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3MWZkNjZlNmNkNmY0ZGMxOTkwMjRmZmRhNWQ0YWJkNl82MA_81df911c-052f-4e67-a7ef-7705946eff98"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMS0xLTEtNjYzMjY_d24e5b9c-1e3c-4c33-8a65-476e8163380f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzYtMy0xLTEtNjYzMjY_490d9a01-aa52-488c-8325-f7e6a9feb57e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV8xOA_66d2638f-aff9-4570-afc2-c71c4ae05e4b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV8xOA_7013e3b7-aedc-42b2-88c1-2c3164f56f7c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV8zMg_689d981f-63f0-497f-a786-c9aa601a09a6"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV8zMg_6bbdee3d-9b06-4f72-a018-bff2a180d1c4"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV83OA_25bd77ba-d025-4561-9aa7-d64699ade10a"
      unitRef="shares">321800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV83OA_2a3faa8b-f747-4fe6-bd5b-82e91ac1463b"
      unitRef="shares">321800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV84NQ_8b04eddb-66c1-4f05-9d9d-cd5cf92d3795"
      unitRef="shares">318842000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMC0xLTEtNjYzMjYvdGV4dHJlZ2lvbjo3NTk2ODNhOGUzMDc0MGQwOGM4NmQxY2E2NmNjNTY3NV84NQ_9386c90a-1562-4d01-a535-8d03d009b4f4"
      unitRef="shares">318842000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMS0xLTEtNjYzMjY_2ffa19fd-24d5-4a01-a215-01c9387147c1"
      unitRef="usd">322000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzctMy0xLTEtNjYzMjY_163d7669-3391-4fc4-a5a9-de5621f160c5"
      unitRef="usd">319000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzgtMS0xLTEtNjYzMjY_e3c2975c-e04b-45ff-b368-d80119c07bfe"
      unitRef="usd">2477117000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzgtMy0xLTEtNjYzMjY_e59c7add-a34b-455c-b03b-fdacfbe9b5d5"
      unitRef="usd">2427561000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzktMS0xLTEtNjYzMjY_f5bc62b0-9033-44cb-b6a9-ebfbe08e9db4"
      unitRef="usd">-8917000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfMzktMy0xLTEtNjYzMjY_145c99ed-738d-439c-a407-8ba3ac5b28d5"
      unitRef="usd">-758000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNDAtMS0xLTEtNjYzMjY_57d19b2f-c213-4d82-8eca-92ffa8986733"
      unitRef="usd">-77262000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNDAtMy0xLTEtNjYzMjY_21b69d4c-8d60-491c-be77-9e51f190e8b3"
      unitRef="usd">-216507000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNDEtMS0xLTEtNjYzMjY_76bd214d-bc00-43b9-83e6-8f7fe6174243"
      unitRef="usd">2391260000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNDEtMy0xLTEtNjYzMjY_d3d219bf-b445-4fda-a67c-5c061b10d557"
      unitRef="usd">2210615000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNDItMS0xLTEtNjYzMjY_da1bb0bb-e8cc-4dd9-ab1a-1563c80524cf"
      unitRef="usd">2881404000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xNi9mcmFnOmQxYmI2NjNlZWE4YjRmNTRiNDg4MDMwNzA2ZTRlOTA2L3RhYmxlOmNlNzNmZmRmYzc1MjRjYjc5MTA5ZGNjNzk1MzJiZmUxL3RhYmxlcmFuZ2U6Y2U3M2ZmZGZjNzUyNGNiNzkxMDlkY2M3OTUzMmJmZTFfNDItMy0xLTEtNjYzMjY_eea580c9-86d2-4210-8d60-bf0badd83815"
      unitRef="usd">2616239000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f0966f9eca84459ae2dd8ebc3309047_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMy0xLTEtMS02NjMyNg_ab99a420-fba9-4fb9-b4c5-43c4ce898b55"
      unitRef="usd">347044000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b9e8d3facdf4864bb7c81214e9ad6f8_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMy0zLTEtMS02NjMyNg_89538a1b-c165-46bc-b3b8-db9bb89ef27f"
      unitRef="usd">284248000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if42cf2e0fa214b5c803a30524005d09a_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMy01LTEtMS02NjMyNg_f37a8b4c-4328-4619-b331-602115637778"
      unitRef="usd">657342000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i783842d281c14d18a5ab8e977fb76f4a_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMy03LTEtMS02NjMyNg_d3a1c7bd-f9bd-48a0-b564-f635ff8d6317"
      unitRef="usd">511460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17ece728364b4cc48c40e024bb487e25_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNC0xLTEtMS02NjMyNg_54e2d3c0-12aa-4703-9768-44920a6b1abc"
      unitRef="usd">57526000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51494a71ce844aa2aaa75d35e9949848_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNC0zLTEtMS02NjMyNg_b172593c-1251-4021-a6ac-052c97a42d45"
      unitRef="usd">39640000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i635c229f1f07418d854dc726f5340cb4_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNC01LTEtMS02NjMyNg_8ec419c0-c420-45c9-997f-98ae329aee81"
      unitRef="usd">89593000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i769896e9287e4183bddc0e89f0dcc56b_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNC03LTEtMS02NjMyNg_cd1fbac6-dfa0-4964-aafa-0862e7ce3a70"
      unitRef="usd">67168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i706119ef90c140f89a64ca72f784f4b0_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNS0xLTEtMS02NjMyNg_0d131684-825e-422e-add0-90cf8eb290d3"
      unitRef="usd">14857000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69fd855fbc7048eabfa55142b96cda52_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNS0zLTEtMS02NjMyNg_82c7fcbb-246f-448f-b440-aea632ead1e1"
      unitRef="usd">61289000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f1dadf8806a47148f339ef9a9717604_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNS01LTEtMS02NjMyNg_6d7c376b-d861-4e49-b79a-baac2466d660"
      unitRef="usd">28472000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c8dae096ca44ee58f98136af8f519b9_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNS03LTEtMS02NjMyNg_6d636893-f6d5-43ed-b70b-659eb45a2c8f"
      unitRef="usd">76779000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNi0xLTEtMS02NjMyNg_c80fcfbb-855a-44d8-86c4-b86d91d0f387"
      unitRef="usd">419427000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNi0zLTEtMS02NjMyNg_a3763580-c3ac-451d-a801-3d9349e5ccd4"
      unitRef="usd">385177000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNi01LTEtMS03NDQ0Ng_9501cafb-2c81-439b-a543-359dbfa2ff6f"
      unitRef="usd">775407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfNi03LTEtMS03NDQ0Ng_8e27bc1f-ed90-4a74-a729-f63f24422384"
      unitRef="usd">655407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOC0xLTEtMS02NjMyNg_eaedb216-3c77-4fde-89d4-d170ca914352"
      unitRef="usd">13481000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOC0zLTEtMS02NjMyNg_3bcdab5c-6944-44ae-8a13-ce749eb67bb5"
      unitRef="usd">14884000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOC01LTEtMS02NjMyNg_0f02e9c0-6d89-4275-9b70-d80e59697bcf"
      unitRef="usd">26684000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOC03LTEtMS02NjMyNg_dd8704d2-8195-426f-9acc-8945f2c57cc1"
      unitRef="usd">28082000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOS0xLTEtMS02NjMyNg_117e7d14-31e0-4fde-849f-9cb4707b4b05"
      unitRef="usd">199481000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOS0zLTEtMS02NjMyNg_f5da91e1-8adc-40c1-b0b4-d2049dc25b94"
      unitRef="usd">148790000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOS01LTEtMS02NjMyNg_57af5610-ea89-4c2d-a2fc-6631e8f0d518"
      unitRef="usd">356152000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfOS03LTEtMS02NjMyNg_eeffebcd-94c4-4e28-bc8f-bb73304cb5eb"
      unitRef="usd">308078000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTAtMS0xLTEtNjYzMjY_7e3d0b7c-f501-40bc-82f9-f058404aa575"
      unitRef="usd">122759000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTAtMy0xLTEtNjYzMjY_20db476b-e45b-4b86-ab7e-a3f4680b365c"
      unitRef="usd">98495000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTAtNS0xLTEtNjYzMjY_009a7ff0-58fd-45db-99eb-1a6b982b1c9e"
      unitRef="usd">225622000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTAtNy0xLTEtNjYzMjY_c0700819-9a05-45a2-8449-b70030889469"
      unitRef="usd">200846000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTEtMS0xLTEtNjYzMjY_3b7509f9-d48a-43d5-8807-386496a09def"
      unitRef="usd">335721000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTEtMy0xLTEtNjYzMjY_f350a84e-bc78-4e3d-a8b8-56e4c3638a77"
      unitRef="usd">262169000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTEtNS0xLTEtNjY0Nzg_baf34292-bf4b-4cc7-a52a-cac8c5d63289"
      unitRef="usd">608458000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTEtNy0xLTEtNzQ0NDY_fb079a37-70a4-47b1-b76a-033afc068565"
      unitRef="usd">537006000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTItMS0xLTEtNjYzMjY_22d07c06-4a59-4e76-a6dd-111808f32f63"
      unitRef="usd">83706000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTItMy0xLTEtNjYzMjY_5b9c7ad3-4934-44c7-a1b4-91d798a708ba"
      unitRef="usd">123008000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTItNS0xLTEtNzQ0NDY_0f2fdc28-d94a-4884-8ab1-f5d665d643fa"
      unitRef="usd">166949000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTItNy0xLTEtNzQ0NDY_397bd662-045a-4a67-9518-b4df494f0866"
      unitRef="usd">118401000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTMtMS0xLTEtNjYzMjY_c4157451-ae4b-4c78-ab87-a70ec4164a51"
      unitRef="usd">4757000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTMtMy0xLTEtNjYzMjY_7e669a30-ad3c-43df-9bfe-4066efe78682"
      unitRef="usd">1891000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTMtNS0xLTEtNjYzMjY_c4d5a1e5-b729-40d2-bb92-9f1edec1f304"
      unitRef="usd">6579000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTMtNy0xLTEtNjYzMjY_68c8ddd1-78e2-42a1-adbd-eff06b1d057c"
      unitRef="usd">4573000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTQtMS0xLTEtNjYzMjY_d83b5bdd-8162-4a12-8c6f-8ccc0ed7535c"
      unitRef="usd">45000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTQtMy0xLTEtNjYzMjY_102404d3-b78a-43c6-b368-297477cf7723"
      unitRef="usd">-11000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTQtNS0xLTEtNjYzMjY_b09d0591-ac96-46df-8acd-f31fccf23525"
      unitRef="usd">209000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTQtNy0xLTEtNjYzMjY_420b8405-e920-4ba7-bed4-abfe2d2e9589"
      unitRef="usd">-101000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTUtMS0xLTEtNjYzMjY_b116eb7d-993d-4362-ab13-632aa19e871c"
      unitRef="usd">88508000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTUtMy0xLTEtNjYzMjY_8566b328-e47e-4a12-85de-dead6062abac"
      unitRef="usd">124888000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTUtNS0xLTEtNzQ0NDY_959bc730-97a0-481c-87fb-1d153bf1abd5"
      unitRef="usd">173737000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTUtNy0xLTEtNzQ0NDY_b500f13f-ad54-41e0-a8d8-cbb3de57e2ac"
      unitRef="usd">122873000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTYtMS0xLTEtNjYzMjY_62c94936-a08d-462b-96e8-598472bde2c6"
      unitRef="usd">17836000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTYtMy0xLTEtNjYzMjY_a69585a1-fd2f-4658-ad4d-f4fc897c5bb4"
      unitRef="usd">28796000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTYtNS0xLTEtNjYzMjY_f0ac088b-2ea7-4511-bfbb-b122c46bfca2"
      unitRef="usd">34492000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTYtNy0xLTEtNjYzMjY_7e1ec53a-4ab2-406a-a59d-12f7d69a551e"
      unitRef="usd">25180000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTctMS0xLTEtNjYzMjY_22b565e4-79ae-4394-bc39-6e3eafa4f1d8"
      unitRef="usd">70672000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTctMy0xLTEtNjYzMjY_b00120d0-4258-4474-81e9-f6bf0ae652bb"
      unitRef="usd">96092000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTctNS0xLTEtNzA2MDQ_d4e0aecb-f8e4-4b12-9291-66efcfc2b7e2"
      unitRef="usd">139245000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTctNy0xLTEtNzA1Njc_faa857f9-f4a4-4031-8d5c-18dab089760b"
      unitRef="usd">97693000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTktMS0xLTEtNjYzMjY_73b876d2-397f-4e65-b1b6-a72e73fbe7c9"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTktMy0xLTEtNjYzMjY_5d849c8f-6ce8-4c81-b862-bcd9e133d36e"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTktNS0xLTEtNzQ0NDY_d3b64321-7185-4b34-92d8-9ed35ee2c8f7"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMTktNy0xLTEtNzQ0NDY_d8ef433a-9e08-4d4b-a425-4df3f5020a16"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjAtMS0xLTEtNjYzMjY_675af6d1-1e0b-4a15-b1fa-75adb0d6fa71"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjAtMy0xLTEtNjYzMjY_9545e8bf-f6d4-4e21-957a-01c6590a670a"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjAtNS0xLTEtNzQ0NDY_a3aa1835-39f5-468f-ae3b-3ccafb77fdd4"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjAtNy0xLTEtNzQ0NDY_8107ad84-1790-46ec-96a7-f039b35663ea"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjItMS0xLTEtNjYzMjY_3bbc6ab2-4163-4267-84bd-fd362adf9742"
      unitRef="shares">321117000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjItMy0xLTEtNjYzMjY_03cec34f-f2f0-4c05-a74a-845c05870899"
      unitRef="shares">314117000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjItNS0xLTEtNjY2ODM_61c237a4-71dc-4217-9549-f6d7dc38c8c9"
      unitRef="shares">320349000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjItNy0xLTEtNzE2OTc_0b0bc54c-c39c-4f04-a0fd-f422dc3294cf"
      unitRef="shares">313295000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjMtMS0xLTEtNjYzMjY_d00a008d-4228-4f23-a000-31a7ec9961e9"
      unitRef="shares">324904000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjMtMy0xLTEtNjYzMjY_10185306-4704-4c24-a40a-a2ba63316601"
      unitRef="shares">322941000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjMtNS0xLTEtNjY2ODM_8755ddae-b220-49b1-986b-851b850a2ba0"
      unitRef="shares">324096000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8xOS9mcmFnOjE3ZTY3NGRkZTZhYjQ2NzQ5NDIxNTRkN2IwNDJhNGY5L3RhYmxlOjk5ZWEyZTU1MmNlNzQxNDlhOTBlZGEwNTAyY2YwYThkL3RhYmxlcmFuZ2U6OTllYTJlNTUyY2U3NDE0OWE5MGVkYTA1MDJjZjBhOGRfMjMtNy0xLTEtNzE3MDA_a396b780-bbde-47fc-92bd-2b34714c99b3"
      unitRef="shares">322114000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfMi0xLTEtMS02NjMyNg_22b565e4-79ae-4394-bc39-6e3eafa4f1d8"
      unitRef="usd">70672000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfMi0zLTEtMS02NjMyNg_b00120d0-4258-4474-81e9-f6bf0ae652bb"
      unitRef="usd">96092000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfMi01LTEtMS02NjMyNg_8c92ec01-6ee3-4f85-b5ff-54ecac9ea976"
      unitRef="usd">139245000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfMi01LTEtMS02NjMyNg_9111fb56-e88d-4a24-b99a-f359b2e1da02"
      unitRef="usd">139245000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfMi03LTEtMS02NjMyNg_0f34aff6-c7df-4d8d-a0bd-5033f95cbe01"
      unitRef="usd">97693000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC0wLTEtMS02NjMyNi90ZXh0cmVnaW9uOmEzZGU5NjZkMTYxYzRlMDBhNmNjZDk5MmNjNjU2NDU2XzIxOTkwMjMyNTU2NTE_1383f293-336b-4416-abb9-7106cb2b59d7"
      unitRef="usd">639000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC0wLTEtMS02NjMyNi90ZXh0cmVnaW9uOmEzZGU5NjZkMTYxYzRlMDBhNmNjZDk5MmNjNjU2NDU2XzIxOTkwMjMyNTU2NTc_f50cccd1-6699-4600-9a6e-00af0fb41d4d"
      unitRef="usd">257000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC0wLTEtMS02NjMyNi90ZXh0cmVnaW9uOmEzZGU5NjZkMTYxYzRlMDBhNmNjZDk5MmNjNjU2NDU2XzIxOTkwMjMyNTU2ODc_75179167-1332-43ea-8e70-d91bd916e12a"
      unitRef="usd">2295000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC0wLTEtMS02NjMyNi90ZXh0cmVnaW9uOmEzZGU5NjZkMTYxYzRlMDBhNmNjZDk5MmNjNjU2NDU2XzIxOTkwMjMyNTU2Njg_ed43f78f-f427-4ab3-a4ca-94d2ccfecd0a"
      unitRef="usd">756000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC0xLTEtMS02NjMyNg_4a15d7eb-1652-467e-bb1a-4c354d712112"
      unitRef="usd">-2252000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC0zLTEtMS02NjMyNg_7eee9a90-13a4-4e5c-8fd4-1951560c27ea"
      unitRef="usd">-755000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC01LTEtMS02NjMyNg_158490bf-33b7-4ddf-9a45-0cd74d501598"
      unitRef="usd">-8159000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNC03LTEtMS02NjMyNg_7e29e976-8b7f-423a-8882-e444a8af576a"
      unitRef="usd">-2491000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNi0xLTEtMS02NjMyNg_905b1a90-b291-48db-93a6-9096fd56a5c5"
      unitRef="usd">68420000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNi0zLTEtMS02NjMyNg_7d0cc15a-1c58-4d48-8805-49a57114fb78"
      unitRef="usd">95337000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNi01LTEtMS02NjMyNg_31363685-a8ad-42eb-9cd2-dddf60e034df"
      unitRef="usd">131086000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yMi9mcmFnOjI0MDhjNTE2ODJiYzRiMWQ4MjBjYzA4ZDRkYTYxN2QwL3RhYmxlOjcwMDQxODYzMjAwNTRiNTI4NDVhN2UzYjY5YjZmMDNkL3RhYmxlcmFuZ2U6NzAwNDE4NjMyMDA1NGI1Mjg0NWE3ZTNiNjliNmYwM2RfNi03LTEtMS02NjMyNg_3187c932-35fc-41ac-9051-5952e414b5cc"
      unitRef="usd">95202000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifbbf35553e864a47b12a2d1fd928f98e_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjMtMS0xLTEtNjYzMjY_43b09e8b-923a-4c6d-9349-8fda73efe0db"
      unitRef="shares">320268000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifbbf35553e864a47b12a2d1fd928f98e_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjMtMy0xLTEtNjYzMjY_c0b1cbd9-5af3-488a-9b9a-e4238e97b145"
      unitRef="usd">320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica2525aa6c6841f982350ebfeb7ae4e9_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjMtNS0xLTEtNjYzMjY_1a524518-e7ea-40f3-af86-e75ae74e8818"
      unitRef="usd">2448130000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i13f12b5dde5b4fdda7863e2006ddc6da_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjMtNy0xLTEtNjYzMjY_f32bc323-128c-4613-b86f-aa4152e0addf"
      unitRef="usd">-6665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iabda242f1aa040f1aa8b97a4539b80c1_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjMtOS0xLTEtNjYzMjY_98bd8db2-53a3-45e6-8d3e-f5d442fefdbb"
      unitRef="usd">-147934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i31a5dab809bf451896a0f1f8a5a72ca2_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjMtMTEtMS0xLTY2MzI2_e9f6dcad-e4df-4382-9c3b-94093e26132a"
      unitRef="usd">2293851000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="idd09d7b967674984a4b4c0e1ecf5c20a_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjQtOS0xLTEtNjYzMjY_ca63c3d9-67f1-4083-ad19-c90bb4df1cac"
      unitRef="usd">70672000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjQtMTEtMS0xLTY2MzI2_08c647a0-d6b1-47f4-94fb-03ad4c583233"
      unitRef="usd">70672000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i083ff5f50112432b974e39cee8bbb3e9_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjUtNy0xLTEtNjYzMjY_3a047100-fd31-461d-8a52-e7a69227275b"
      unitRef="usd">-2252000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjUtMTEtMS0xLTY2MzI2_5aaf8d1c-1723-4c25-9203-f4aba074463b"
      unitRef="usd">-2252000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i51ed73dd842a42c787ae6af93fa1f0ef_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjYtMS0xLTEtNjYzMjY_fda1cf80-0802-43d9-9d95-22b54d66d5f8"
      unitRef="shares">1532000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i51ed73dd842a42c787ae6af93fa1f0ef_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjYtMy0xLTEtNjYzMjY_4f6da46d-d842-4c62-89df-3c6336546fad"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i61b5acd047f54e5e890f1c61b9bb0bf2_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjYtNS0xLTEtNjYzMjY_74b988d3-eb4c-4def-b40f-e53a00db3bcf"
      unitRef="usd">10317000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjYtMTEtMS0xLTY2MzI2_8e58c080-28cc-4008-84b1-fe7e31e0c740"
      unitRef="usd">10319000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i61b5acd047f54e5e890f1c61b9bb0bf2_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjctNS0xLTEtNjYzMjY_977e335d-4c37-4f3b-b851-afa8838760c3"
      unitRef="usd">6225000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjctMTEtMS0xLTY2MzI2_2aea9c20-57e2-40de-b3ea-eb0b8341859a"
      unitRef="usd">6225000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i61b5acd047f54e5e890f1c61b9bb0bf2_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjgtNS0xLTEtNjYzMjY_165ebaa9-1af1-42f8-9d41-3b0ef752dafa"
      unitRef="usd">24895000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjgtMTEtMS0xLTY2MzI2_d3b324a1-7f35-467d-946f-fcdbf71d70d2"
      unitRef="usd">24895000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id5e9422226204c1caad9468840b30369_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjktMS0xLTEtNjYzMjY_48a751a0-abd1-4cb2-8ea0-16c972961ca6"
      unitRef="shares">321800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id5e9422226204c1caad9468840b30369_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjktMy0xLTEtNjYzMjY_0eff0597-5690-4b61-a896-da23cceb2254"
      unitRef="usd">322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a7035844a96447d9ece7ea6b0cc2ed8_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjktNS0xLTEtNjYzMjY_c3d04d8c-75c2-48d7-9c7c-faf1c368612b"
      unitRef="usd">2477117000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e3a8211d9414334ba9e7d2ba62bc3c5_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjktNy0xLTEtNjYzMjY_27f839df-b47f-46bd-a0ac-34820d1d9db8"
      unitRef="usd">-8917000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3fb93329607a4f4485821bd6d3b218d4_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjktOS0xLTEtNjYzMjY_52f618f3-cdd7-4931-abd8-6d2a41c9577f"
      unitRef="usd">-77262000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjktMTEtMS0xLTY2MzI2_41f2ec31-d414-433e-8385-c0e43124ed57"
      unitRef="usd">2391260000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i178b1c70ce884adaa05d4e23647aa97f_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTQtMS0xLTEtNzEyOTE_5fdaf07d-109a-4ab6-8409-9441d97816b5"
      unitRef="shares">313262000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i178b1c70ce884adaa05d4e23647aa97f_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTQtMy0xLTEtNzEyOTE_b1e28ed0-17fc-4e7f-80ab-adf8c05efa3e"
      unitRef="usd">313000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic65133c237764501911f938ce005dd62_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTQtNS0xLTEtNzEyOTE_54a5889d-db52-4646-9909-df465a956887"
      unitRef="usd">2354103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i074c0d5d00e94dcd86712e0f3b167c31_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTQtNy0xLTEtNzEyOTE_28ac12a2-e2c0-40d9-bee7-6920bb0d3e25"
      unitRef="usd">2740000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5638bf7f18a54b5eb3f4e9899ee414b8_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTQtOS0xLTEtNzEyOTE_a34b369a-a08a-416d-8404-19d02f7854d1"
      unitRef="usd">-445969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c4a65a50aa94cbcaa556bdea637aae0_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTQtMTEtMS0xLTc0NDU4_fad09ad3-d13f-47bf-9213-7b23295515ec"
      unitRef="usd">1911187000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icc467238ed7e44f8908d4c4197d02952_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTUtOS0xLTEtNzEyOTE_0e88011b-9cf8-497c-b546-cc483973fc87"
      unitRef="usd">96092000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTUtMTEtMS0xLTc0NDU4_05620abd-cc2d-4748-9a71-28edb453be8e"
      unitRef="usd">96092000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id29da21d87ad4d1cbc07082f36dae1db_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTYtNy0xLTEtNzEyOTE_d7d1772b-ae92-4105-9d7c-416551836935"
      unitRef="usd">-755000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTYtMTEtMS0xLTc0NDU4_b29c664f-6750-41d5-9ee3-a0646e09470c"
      unitRef="usd">-755000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i33204058d2884277a534f3fe8b2d05c6_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTctMS0xLTEtNzEyOTE_d2ddaf0d-d3b0-4532-b245-246fc4b389aa"
      unitRef="shares">1560000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i33204058d2884277a534f3fe8b2d05c6_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTctMy0xLTEtNzEyOTE_77f03cc2-fe39-470d-ab31-75c69ba8b0a1"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i72e65c25cad842b48b3a06036a8dfb11_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTctNS0xLTEtNzEyOTE_7cc0df35-1c99-4ce8-b992-472dc2755dd5"
      unitRef="usd">11283000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTctMTEtMS0xLTc0NDU4_5ca66caf-d70a-4660-8ece-f30a6b5127f5"
      unitRef="usd">11285000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i72e65c25cad842b48b3a06036a8dfb11_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTgtNS0xLTEtNzEyOTE_17d1ce13-4baf-4bd2-9332-6da67eb91445"
      unitRef="usd">2767000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTgtMTEtMS0xLTc0NDU4_4e03d8e7-5862-49f7-8ca3-15459a9d73bf"
      unitRef="usd">2767000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i72e65c25cad842b48b3a06036a8dfb11_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTktNS0xLTEtNzEyOTE_2a60ba3a-34a7-4976-8777-fa3f0e966788"
      unitRef="usd">28035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMTktMTEtMS0xLTc0NDU4_f5bafda3-8d92-4310-9df1-d9d926af23d8"
      unitRef="usd">28035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9ad2cb90ebc241bb8b2f4469a70980a7_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjAtMS0xLTEtNzQ0NTg_eff8a5c8-6aaf-4719-867b-47d8c173c19a"
      unitRef="shares">314822000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9ad2cb90ebc241bb8b2f4469a70980a7_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjAtMy0xLTEtNzQ0NTg_bd0f4a79-5cbd-4f00-b4af-7b5959814318"
      unitRef="usd">315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if60b5dd0182e46dca654df547b7153f4_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjAtNS0xLTEtNzQ0NTg_438f181c-9112-4082-b59c-18fecb0f4d12"
      unitRef="usd">2390654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8c00d41f727490497fb324365d70cdf_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjAtNy0xLTEtNzQ0NTg_7678cc99-ebe9-4126-a16d-d0a1c2222517"
      unitRef="usd">1985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6cc4df1f70524cf0b42d834be77810ec_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjAtOS0xLTEtNzQ0NTg_641afabc-5c94-4d74-88d6-d0e20879d202"
      unitRef="usd">-349877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide7e987c180a418585f377e54ea41af1_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmY1NTUwNjIzYmE4MzQ0NzNiYTQ2Y2YyNTI0MzVkMmJmL3RhYmxlcmFuZ2U6ZjU1NTA2MjNiYTgzNDQ3M2JhNDZjZjI1MjQzNWQyYmZfMjAtMTEtMS0xLTc0NDU4_95ff564e-a1d5-45d4-9eff-a40018365cf3"
      unitRef="usd">2043077000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i38d2914ca5204497ab3d3c3eaea8818d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjMtMS0xLTEtNjYzMjY_e3b6b80f-c665-48c0-ab6e-416589c74339"
      unitRef="shares">318842000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i38d2914ca5204497ab3d3c3eaea8818d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjMtMy0xLTEtNjYzMjY_2d70b47e-2653-4f78-9654-935f8bfd3f51"
      unitRef="usd">319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1249b090f0b64f6ba2e504df49cb49cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjMtNS0xLTEtNjYzMjY_3b6e53c8-4f7f-4d81-8b97-2bd3257d358e"
      unitRef="usd">2427561000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9fbe83b4d13441469af603970b1bfad2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjMtNy0xLTEtNjYzMjY_5872be56-f838-4fc2-b81a-87691a3e5c66"
      unitRef="usd">-758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11fbb1f45c2f4280981d038a82ed2190_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjMtOS0xLTEtNjYzMjY_4b2058f3-a7cb-4b27-8274-61508a2c2eb9"
      unitRef="usd">-216507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjMtMTEtMS0xLTY2MzI2_65e438b6-255c-4455-a290-1583e4beacdc"
      unitRef="usd">2210615000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ibb6414045fef4baaab29a829c64218c3_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjQtOS0xLTEtNjYzMjY_58c80d64-9146-4776-82a9-fef210783de1"
      unitRef="usd">139245000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjQtMTEtMS0xLTY2MzI2_8d3c9acc-f6e9-4843-a8f8-01aecb47bed2"
      unitRef="usd">139245000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia9ee23437eab47868678f63cbd6ef147_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjUtNy0xLTEtNjYzMjY_aaa42bb7-6071-48a4-b3bd-99fdefb10045"
      unitRef="usd">-8159000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjUtMTEtMS0xLTY2MzI2_4e97236a-6ea3-4237-abd2-eabbf123367f"
      unitRef="usd">-8159000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ia0f4f857a9fc488b86c7e00d7d13b344_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjYtMS0xLTEtNjYzMjY_43fcb96e-f327-46c3-b1d7-82e5a67076cb"
      unitRef="shares">2958000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia0f4f857a9fc488b86c7e00d7d13b344_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjYtMy0xLTEtNjYzMjY_e0e453be-17e4-45f2-929d-f9dea5180445"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id762b4c844464d9dbd1a5232a5556a16_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjYtNS0xLTEtNjYzMjY_495f49b4-3aca-4744-b83e-cf8652ae4cf7"
      unitRef="usd">15829000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjYtMTEtMS0xLTY2MzI2_94b222ab-28cf-4bb6-8216-4ee10d3ad3b5"
      unitRef="usd">15832000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id762b4c844464d9dbd1a5232a5556a16_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjctNS0xLTEtNjYzMjY_652b6fc9-cbca-4c07-8ac5-a2fcc5000787"
      unitRef="usd">11185000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjctMTEtMS0xLTY2MzI2_e3061c0c-46d2-4e84-87b7-a363192c7c77"
      unitRef="usd">11185000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjgtNS0xLTEtNjYzMjY_c721ed13-f320-4bcc-8fa5-c7de145b88f9"
      unitRef="usd">44912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjgtMTEtMS0xLTY2MzI2_7903a0e5-78d5-4a32-8846-01149d92fc66"
      unitRef="usd">44912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id5e9422226204c1caad9468840b30369_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjktMS0xLTEtNjYzMjY_1a44d247-972d-425e-b447-722e68c78366"
      unitRef="shares">321800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id5e9422226204c1caad9468840b30369_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjktMy0xLTEtNjYzMjY_20c7c90d-d2c3-41ec-b5d9-218b66e00d10"
      unitRef="usd">322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a7035844a96447d9ece7ea6b0cc2ed8_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjktNS0xLTEtNjYzMjY_70de1daf-2e19-447e-b724-b7600b97684a"
      unitRef="usd">2477117000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e3a8211d9414334ba9e7d2ba62bc3c5_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjktNy0xLTEtNjYzMjY_76544bd3-6b65-4214-95be-87c3f7ddebd4"
      unitRef="usd">-8917000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3fb93329607a4f4485821bd6d3b218d4_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjktOS0xLTEtNjYzMjY_c160e4ae-8005-45f5-8fe0-ca5b00481474"
      unitRef="usd">-77262000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjktMTEtMS0xLTY2MzI2_4bddad9e-d516-43ba-9c1a-45bc1bf1860c"
      unitRef="usd">2391260000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7915746f5547460f9caa2e4177cfce05_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTQtMS0xLTEtNzEzMjE_4565b655-93e8-4781-a755-3a39dd06202c"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7915746f5547460f9caa2e4177cfce05_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTQtMy0xLTEtNzEzMjE_e7cca817-6da2-4054-b350-fbb7b2a1c9d1"
      unitRef="usd">312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e25b57e2a0b4d829b12b77168539aa7_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTQtNS0xLTEtNzEzMjE_a4215fe9-4905-44b3-8942-218c12b1790d"
      unitRef="usd">2321895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf90c32a09a4497996f31bce3e8b5d1e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTQtNy0xLTEtNzEzMjE_00577c95-d4c3-45ab-ae67-de48ae930947"
      unitRef="usd">4476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i646dda3b25974251a53973741e46976c_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTQtOS0xLTEtNzEzMjE_eefbb59f-9e18-4901-8884-851eb182e176"
      unitRef="usd">-447570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95504af18ae84a95a6f5672e2c0962ea_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTQtMTEtMS0xLTcxMzIx_a362bd35-4025-49ab-a23b-efb5e3419a4f"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia1ebf17aa8654c809fdc3b7fdf977b94_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTUtOS0xLTEtNzEzMjE_14367449-91f5-4d10-b5f6-0df6bafd44b4"
      unitRef="usd">97693000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTUtMTEtMS0xLTcxMzIx_4693d6de-2e5a-484a-99c2-836a850aed0b"
      unitRef="usd">97693000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i920841e629d44fa39ab93aed91f7add3_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTYtNy0xLTEtNzEzMjE_401e2fc7-647d-4c6b-9c18-baf7cd65e83b"
      unitRef="usd">-2491000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTYtMTEtMS0xLTcxMzIx_f519b55f-3f23-4c7b-9db6-d2f251933ceb"
      unitRef="usd">-2491000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie673862a0ee14b879e59030e6dfa3b2b_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTctMS0xLTEtNzEzMjE_31d6a981-e5c6-488a-9c4f-80bb90a1cff9"
      unitRef="shares">3195000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie673862a0ee14b879e59030e6dfa3b2b_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTctMy0xLTEtNzEzMjE_43087765-3e1e-4ffe-b1b8-f39255ec04f8"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2e90a92edb8647439746c5535fbdf9b9_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTctNS0xLTEtNzEzMjE_45f67c06-b1ac-4648-8cc3-e023c9d3f89d"
      unitRef="usd">15484000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTctMTEtMS0xLTcxMzIx_0168123c-e544-432b-9251-8d130dbd7ee9"
      unitRef="usd">15487000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2e90a92edb8647439746c5535fbdf9b9_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTgtNS0xLTEtNzEzMjE_2c6afafd-6a0c-42ad-8b37-9ae581835a9c"
      unitRef="usd">9413000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTgtMTEtMS0xLTcxMzIx_c3a64765-00ac-4c8c-941c-06b07676afd7"
      unitRef="usd">9413000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2e90a92edb8647439746c5535fbdf9b9_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTktNS0xLTEtNzEzMjE_6f25252d-0abc-4da1-afd5-6a3759bf7535"
      unitRef="usd">62688000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMTktMTEtMS0xLTcxMzIx_a8e38539-a984-4d43-af62-2383b8e4cc5e"
      unitRef="usd">62688000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9ad2cb90ebc241bb8b2f4469a70980a7_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjAtMS0xLTEtNzEzMjE_7c87b782-b13a-4dee-9a8b-56be24f42e13"
      unitRef="shares">314822000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9ad2cb90ebc241bb8b2f4469a70980a7_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjAtMy0xLTEtNzEzMjE_f5fe487d-cdad-4fd5-94a1-855a48f3cafc"
      unitRef="usd">315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if60b5dd0182e46dca654df547b7153f4_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjAtNS0xLTEtNzEzMjE_4fd0b173-38ac-4338-b47f-5f9060a5fbf8"
      unitRef="usd">2390654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8c00d41f727490497fb324365d70cdf_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjAtNy0xLTEtNzEzMjE_6c481c94-3e86-4c72-921a-c06b54ec444f"
      unitRef="usd">1985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6cc4df1f70524cf0b42d834be77810ec_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjAtOS0xLTEtNzEzMjE_6eee706b-a555-44d6-a769-a6be118a4ad4"
      unitRef="usd">-349877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide7e987c180a418585f377e54ea41af1_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yNS9mcmFnOjliZDA5NDQ4NjZkMTRkYTVhNzliNDk5MmIyODc1OWEyL3RhYmxlOmI3ODBmMWExZWU2MjQxNWU4ZmM3NTU3MzA4NzIyMTQwL3RhYmxlcmFuZ2U6Yjc4MGYxYTFlZTYyNDE1ZThmYzc1NTczMDg3MjIxNDBfMjAtMTEtMS0xLTcxMzIx_300aafdc-798e-4760-a890-7ee0dca30eea"
      unitRef="usd">2043077000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMi0xLTEtMS02NjMyNg_339ad039-b045-4ac2-9af2-c4e1b4a5e2aa"
      unitRef="usd">139245000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMi0zLTEtMS02NjMyNg_faa857f9-f4a4-4031-8d5c-18dab089760b"
      unitRef="usd">97693000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNC0xLTEtMS02NjMyNg_a46d9af0-7968-4d58-b0ad-0ac5158df4da"
      unitRef="usd">9266000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNC0zLTEtMS02NjMyNg_317f08bd-8b4e-4abe-b7c0-12ce2235828e"
      unitRef="usd">6895000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNS0xLTEtMS02NjMyNg_1af202b8-aeed-4ce9-85f3-f65bb1e6b233"
      unitRef="usd">44381000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNS0zLTEtMS02NjMyNg_0ab673d9-fab2-48a0-b115-4c61e153206e"
      unitRef="usd">62688000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNi0xLTEtMS02NjMyNg_c54774da-f9d5-4431-9a1f-2f427aeed98e"
      unitRef="usd">6443000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNi0zLTEtMS02NjMyNg_bec3616c-a2b3-4a16-ad3d-785604600999"
      unitRef="usd">2586000</exel:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNy0xLTEtMS02NjMyNg_701b57d9-a967-406e-8ae4-8e1c57e9b27b"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNy0zLTEtMS02NjMyNg_a6f12b5e-8cab-41f3-9ae4-f4f7a2f7d274"
      unitRef="usd">-22800000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfOC0xLTEtMS02NjMyNg_58d7f4a7-6644-4078-bb7e-22e571879e10"
      unitRef="usd">-4359000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfOC0zLTEtMS02NjMyNg_a2b5a753-9463-42e5-ab89-c6876aac7866"
      unitRef="usd">-22831000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTAtMS0xLTEtNjYzMjY_edb3197e-631a-4034-8703-a59b08412ffb"
      unitRef="usd">-46693000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTAtMy0xLTEtNjYzMjY_ed9bc2d2-b647-4773-9657-dcb5431109aa"
      unitRef="usd">12313000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTEtMS0xLTEtNjYzMjY_dfb25ac4-d11a-402b-b17e-90d6939fc33b"
      unitRef="usd">8322000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTEtMy0xLTEtNjYzMjY_adcbf91c-d808-4ed0-b5d9-13d7fd683f39"
      unitRef="usd">8020000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTMtMS0xLTEtNjYzMjY_325bcd55-2f52-4b64-b30f-4775052f0dec"
      unitRef="usd">26025000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTMtMy0xLTEtNjYzMjY_4eec4589-68af-417e-aa38-795545c0d84b"
      unitRef="usd">12296000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTUtMS0xLTEtNjYzMjY_39231ece-fda1-41a7-a6f6-c4115470b49c"
      unitRef="usd">-1831000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTUtMy0xLTEtNjYzMjY_3b708b9d-3401-4e30-855e-db6cf3ac1d85"
      unitRef="usd">9346000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <exel:IncreaseDecreaseInAccruedCollaborationLiabilities
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTYtMS0xLTEtNjYzMjY_d1657d23-eea6-430a-b8fa-28438565899a"
      unitRef="usd">-53263000</exel:IncreaseDecreaseInAccruedCollaborationLiabilities>
    <exel:IncreaseDecreaseInAccruedCollaborationLiabilities
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTYtMy0xLTEtNjYzMjY_8302a193-f70a-4c7c-bae6-7eac518477a6"
      unitRef="usd">2972000</exel:IncreaseDecreaseInAccruedCollaborationLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTctMS0xLTEtNjYzMjY_d845b512-fe70-4447-a059-4d0a4c216dc8"
      unitRef="usd">17903000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTctMy0xLTEtNjYzMjY_88befe76-8f89-4410-b105-e8acf9eab2d8"
      unitRef="usd">25863000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTktMS0xLTEtNjYzMjY_f1c2cbf3-1445-43dc-a27f-137694e02e9c"
      unitRef="usd">178849000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMTktMy0xLTEtNjYzMjY_f6a682ae-1eaf-4028-9859-71b17b573992"
      unitRef="usd">221045000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjEtMS0xLTEtNjYzMjY_11379f92-7341-4fca-86a6-a72cdf39e074"
      unitRef="usd">17946000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjEtMy0xLTEtNjYzMjY_d38305a2-f63e-45b2-b4f6-cc0f295a12a3"
      unitRef="usd">33768000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjMtMS0xLTEtNjYzMjY_f45fcb46-1715-4f96-938b-8eff580e975b"
      unitRef="usd">692091000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjMtMy0xLTEtNjYzMjY_98deb5fe-8a93-42aa-81d5-7921fb14ea0a"
      unitRef="usd">688903000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjQtMS0xLTEtNjYzMjY_16eb9389-d99b-4099-a9b2-4f65643dc209"
      unitRef="usd">500356000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjQtMy0xLTEtNjYzMjY_5cc6090d-2a98-4e80-883c-3f443120a8d7"
      unitRef="usd">714081000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjUtMS0xLTEtNjYzMjY_7e09e5e6-445b-4f7f-bade-5283d9f375cb"
      unitRef="usd">-209681000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjUtMy0xLTEtNjYzMjY_e4219a55-e2ec-4b6a-af7a-e96bd57c5536"
      unitRef="usd">-8590000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjctMS0xLTEtNjYzMjY_04dcf3e6-52f5-4837-9f90-7e5419d911aa"
      unitRef="usd">15791000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjctMy0xLTEtNjYzMjY_c31fd1fd-d513-4c00-88bd-861f6443d7c9"
      unitRef="usd">15487000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjgtMS0xLTEtNjYzMjY_854c4583-5e21-48e8-b263-5e70dc1cd1fe"
      unitRef="usd">11164000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMjgtMy0xLTEtNjYzMjY_c5fd73f3-6f73-457d-823a-14cf82eb4dbe"
      unitRef="usd">9413000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzEtMS0xLTEtNjYzMjY_462dc09b-f1a4-4cb3-8a93-296f7d00c9fc"
      unitRef="usd">4627000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzEtMy0xLTEtNjYzMjY_0629c4d4-6d41-4c51-8389-95b24658b9e4"
      unitRef="usd">6074000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzItMS0xLTEtNjYzMjY_d5952327-9949-4915-a814-e7c64de751d0"
      unitRef="usd">-26205000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzItMy0xLTEtNjYzMjY_612c6eb4-6db3-44e1-aebc-47969c9db2b4"
      unitRef="usd">218529000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzMtMS0xLTEtNjYzMjY_ade2a21d-889c-450a-9d50-3014e013e3d7"
      unitRef="usd">663891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i95504af18ae84a95a6f5672e2c0962ea_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzMtMy0xLTEtNjYzMjY_b5f59b5b-ba4a-479d-afd8-475b9eb13ced"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzQtMS0xLTEtNjYzMjY_51ce5545-f43e-4d2f-8fe6-c5f129fecc0b"
      unitRef="usd">637686000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ide7e987c180a418585f377e54ea41af1_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzQtMy0xLTEtNjYzMjY_2e90eb04-35ab-4cd5-83b5-da4e27fa87d5"
      unitRef="usd">539301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzktMS0xLTEtNjYzMjY_8f5f8689-656e-4c7b-ac1f-bc866500972c"
      unitRef="usd">120363000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfMzktMy0xLTEtNjYzMjY_0859cf2d-1026-4775-8df3-75d4f4fefe97"
      unitRef="usd">4893000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNDEtMS0xLTEtNjYzMjY_87fc28a5-5fe6-49b2-a2bd-a72f60692503"
      unitRef="usd">3570000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNDEtMy0xLTEtNjYzMjY_fd305131-28b1-4aaf-baa6-3cc93ad3cc1e"
      unitRef="usd">5125000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNDItMS0xLTEtNjYzMjY_a679f8f9-77db-48d2-a134-e2a35a4a3914"
      unitRef="usd">500000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNDItMy0xLTEtNjYzMjY_fc74a12d-be77-4680-8698-6826565a17be"
      unitRef="usd">9000000</us-gaap:LiabilitiesAssumed1>
    <exel:InvestmentsPurchasesIncurredButNotYetPaid
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNDMtMS0xLTEtNzgyMzU_cbe69cbd-940e-4660-be36-376a4c38dca5"
      unitRef="usd">0</exel:InvestmentsPurchasesIncurredButNotYetPaid>
    <exel:InvestmentsPurchasesIncurredButNotYetPaid
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8yOC9mcmFnOmVkNTRjNTg4MTVhZTQ3MTA5YmU3NWI1MGU0Y2NhZGUzL3RhYmxlOmNiM2I4MjMwYjIzYTRmYzhiMGEyZWRhMTI0NWMzZjcxL3RhYmxlcmFuZ2U6Y2IzYjgyMzBiMjNhNGZjOGIwYTJlZGExMjQ1YzNmNzFfNDMtMy0xLTEtNzgyMjc_82de8be3-4672-414f-a93e-5b246d158b6b"
      unitRef="usd">7378000</exel:InvestmentsPurchasesIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzQ5Mw_66f6b8cd-e7e7-4ef2-a07e-21acebebd900">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for patients with difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 62 other countries as: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#x2019;s (BMS) OPDIVO&#xae; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#xae; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other two products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. a member of the Roche Group (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;18, 2022 (Fiscal 2021 Form 10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the fiscal periods ended July&#160;1, 2022 and July&#160;2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the fiscal periods ended June&#160;30, 2022 and June&#160;30, 2021, and the year ending December&#160;31, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies during the six months ended June 30, 2022, compared to the significant accounting policies disclosed in &#x201c;Note 1. Organization and Summary of Significant Accounting Policies&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements adopted by us since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i8fa8420126014bf088bb615340e7af05_D20220101-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNjkx_8b4c274b-7ae8-4256-904f-c7b831fa3a6a"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberOfCountriesWithDrugApprovalExcludingTheUS
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfMTA2Nw_488a817b-da5c-421f-a0a5-0bc8ccf2dccf"
      unitRef="country">62</exel:NumberOfCountriesWithDrugApprovalExcludingTheUS>
    <exel:NumberofProductsinCommercialMarket
      contextRef="ic8c53c5143b04fa790d554162bdceec7_D20220101-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfMTc0Ng_dd7ce175-a1c0-4aa4-aeb0-b03686179304"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzUwNw_928ba7ca-e816-49ba-9672-bd2b47a5fb49">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzUwOA_b0355de0-71d4-4db5-9109-cd5027b256a2">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;18, 2022 (Fiscal 2021 Form 10-K).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzUxNA_bbfd38a5-08e8-4bf5-8ace-1533ce08c5f6">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the fiscal periods ended July&#160;1, 2022 and July&#160;2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the fiscal periods ended June&#160;30, 2022 and June&#160;30, 2021, and the year ending December&#160;31, 2022, respectively.</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzQ5OA_8767c009-4d66-4e95-9692-42d659bfa96f">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNDY0Ng_3ce46f1e-b8aa-4fe8-ac6c-742b75e2b9c5"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzUyNw_00ccbb80-b40b-43f9-a11e-1e75016ccb8b">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzUyOA_0de0d69d-3c71-4b0b-a3f0-d2883dfea2d2">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#x2019; equity.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNC9mcmFnOmQ1N2U0MGE4NWY2OTQ3NjE5MTc0ODkzNjkxZTlkMDA0L3RleHRyZWdpb246ZDU3ZTQwYTg1ZjY5NDc2MTkxNzQ4OTM2OTFlOWQwMDRfNzUwMA_fbd3ad78-90dd-4a57-bafd-361fce8d0076">&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements adopted by us since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDcxMQ_f8adccac-3f2a-4708-9dff-a2b30def5b68">REVENUES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(273,968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule, and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Contract assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2022 and 2021, we recognized $4.5&#160;million and $4.8&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2022, we recognized $59.4&#160;million and $91.1&#160;million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech and the recognition of license revenue for the achievement of milestones during the three months ended June 30, 2022, allocated to the license performance obligations for our collaboration with Ipsen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022, $89.3&#160;million of t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he co&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mbined transaction prices for our Ipsen a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd Takeda collaborations were allocated to our research and development services performance obligations that had not yet been satisfied. See &#x201c;Note 3. Collaboration Agreements and Business Development Activities&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; &lt;/span&gt;&lt;/div&gt;included in Part II, Item 8 of our Fiscal 2021 Form 10-K for additional information about the expected timing to satisfy these performance obligations.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDY5OQ_f10dd80a-9e79-479f-849e-d658f00348ea">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(273,968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia26f483bdcbb41acbef2e9cd23df368f_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMy0xLTEtMS02NjMyNg_934f39cf-c7b1-4bc9-9a5e-cab3f6f8006e"
      unitRef="usd">483073000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9620d75cbfe442cbdfb2e49f10029ad_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMy0zLTEtMS02NjMyNg_0e4e6601-5995-49d8-85f4-23fcb49c36ba"
      unitRef="usd">380204000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib68714772b36481f8c505e3eef1639c8_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMy01LTEtMS02NjkyMg_65b0cc11-00af-459f-bec2-218e4be8492d"
      unitRef="usd">931310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08b267d864364d6ab0b3c49456d3b22b_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMy03LTEtMS03MTczOQ_1a270589-bffd-4752-aa13-3d73ccb42f53"
      unitRef="usd">694409000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25a529c6b1f84c14b8c06c30376f65f6_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNC0xLTEtMS02NjMyNg_addeb7b6-30b6-4775-b27d-d060dcd976c8"
      unitRef="usd">-136029000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0e39c06180045fb8a7047acd09b09d5_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNC0zLTEtMS02NjMyNg_ee5a0a6e-c040-44f1-929e-bf3d3daa6a5a"
      unitRef="usd">-95956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4609cc64ebd4171954966a86b6926ef_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNC01LTEtMS02NjkyNA_d0cb5151-32a8-4e21-88ad-bd4eea14ce61"
      unitRef="usd">-273968000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i077dff06f4904d1990415f13a7b882a4_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNC03LTEtMS03MTczOQ_4ec68c22-634b-4d4c-b861-fcb73cc7ae86"
      unitRef="usd">-182949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f0966f9eca84459ae2dd8ebc3309047_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNS0xLTEtMS02NjMyNg_ab99a420-fba9-4fb9-b4c5-43c4ce898b55"
      unitRef="usd">347044000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b9e8d3facdf4864bb7c81214e9ad6f8_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNS0zLTEtMS02NjMyNg_89538a1b-c165-46bc-b3b8-db9bb89ef27f"
      unitRef="usd">284248000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if42cf2e0fa214b5c803a30524005d09a_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNS01LTEtMS02NjMyNg_d2f73c6e-689d-41aa-b460-935756084a0a"
      unitRef="usd">657342000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i783842d281c14d18a5ab8e977fb76f4a_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNS03LTEtMS02NjMyNg_d3a1c7bd-f9bd-48a0-b564-f635ff8d6317"
      unitRef="usd">511460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17ece728364b4cc48c40e024bb487e25_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNy0xLTEtMS02NjMyNg_54e2d3c0-12aa-4703-9768-44920a6b1abc"
      unitRef="usd">57526000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51494a71ce844aa2aaa75d35e9949848_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNy0zLTEtMS02NjMyNg_b172593c-1251-4021-a6ac-052c97a42d45"
      unitRef="usd">39640000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i635c229f1f07418d854dc726f5340cb4_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNy01LTEtMS02Njk0OA_8ec419c0-c420-45c9-997f-98ae329aee81"
      unitRef="usd">89593000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i769896e9287e4183bddc0e89f0dcc56b_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfNy03LTEtMS03MTc0MQ_cd1fbac6-dfa0-4964-aafa-0862e7ce3a70"
      unitRef="usd">67168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i706119ef90c140f89a64ca72f784f4b0_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOC0xLTEtMS02NjMyNg_0d131684-825e-422e-add0-90cf8eb290d3"
      unitRef="usd">14857000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69fd855fbc7048eabfa55142b96cda52_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOC0zLTEtMS02NjMyNg_82c7fcbb-246f-448f-b440-aea632ead1e1"
      unitRef="usd">61289000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f1dadf8806a47148f339ef9a9717604_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOC01LTEtMS02Njk1MA_6d7c376b-d861-4e49-b79a-baac2466d660"
      unitRef="usd">28472000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c8dae096ca44ee58f98136af8f519b9_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOC03LTEtMS03MTc0MQ_6d636893-f6d5-43ed-b70b-659eb45a2c8f"
      unitRef="usd">76779000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d0a7ab1f65b4bc786a98d7742cdc82f_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOS0xLTEtMS02NjMyNg_e485d677-d7f7-4dfc-bcd7-406a3bad5279"
      unitRef="usd">72383000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37e0da3271234f2bae53c14f82b39321_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOS0zLTEtMS02NjMyNg_c7acb7fc-c366-47db-aeb4-eb9b1185dcc8"
      unitRef="usd">100929000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92fba14ea211474d82d9667f1ee43b1c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOS01LTEtMS02NjMyNg_bc4fc075-86bb-4599-8d57-575cf0c1a814"
      unitRef="usd">118065000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i453607a6d2c241139ae0154655e12057_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfOS03LTEtMS02NjMyNg_0459220d-b76b-47fd-a44d-b176473d97a8"
      unitRef="usd">143947000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMTAtMS0xLTEtNjYzMjY_8df2e6f3-404b-4c7f-ae21-3bf9e6f12963"
      unitRef="usd">419427000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMTAtMy0xLTEtNjYzMjY_3688643d-9080-41d7-b8fa-ac241462f983"
      unitRef="usd">385177000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMTAtNS0xLTEtNjYzMjY_c08cce14-fb21-4e80-abbc-dbb89e703312"
      unitRef="usd">775407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmNjMjdhOTM5MzY4MDQzZTU4NjgzMjJkYjZlNmUyZDdlL3RhYmxlcmFuZ2U6Y2MyN2E5MzkzNjgwNDNlNTg2ODMyMmRiNmU2ZTJkN2VfMTAtNy0xLTEtNjYzMjY_779e4024-9c2d-4053-bd06-9e6787fe043a"
      unitRef="usd">655407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDY5Ng_6cd794cd-4791-4bed-a795-cf2b116e15bb">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i89f773b17954459496fdb8e6635e500c_D20220402-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMi0xLTEtMS02NjMyNg_c297dc8d-c69c-403c-8a20-1dcc89fac7be"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i125702b0bbdb49ea96eac26fc326c134_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMi0zLTEtMS02NjMyNg_0c54f926-0428-47b5-b2ee-1d3fa3895754"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia565cbddd5a042f7b2339b3e701e9826_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMi01LTEtMS02NzA3Nw_56d79662-6b73-4347-bf97-0d2f188cc7ef"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie6183c887d9e429a96461d489c65f056_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMi03LTEtMS02NzA2OQ_5fdf9062-5ff0-4cd2-9e48-b13ca4915e82"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2f74d8c31ae74b7fa6e4e39449d3df62_D20220402-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMy0xLTEtMS02NjMyNg_72bd9dcf-7671-488a-9141-3ec5a201363f"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic9f47a8d0e664d6d84d3873e23fc60ad_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMy0zLTEtMS02NjMyNg_f8d01442-8fe2-4927-a3d0-86b858afc884"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie59b3ee9c868431aaa28932ed170565e_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMy01LTEtMS02NzA5Mg_20f79615-ebc0-4f8d-913b-986c0217ce8f"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i335341eb633f4434b8610f4f0d41be82_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfMy03LTEtMS03MjQ3NQ_05a60241-824a-4b09-9054-873e2de23b6c"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id557498866464ef2bdf02ccdb8ede387_D20220402-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNC0xLTEtMS02NjMyNg_3f03c8b0-f6b8-44fd-aede-0a5a7e48fdf8"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie61a701acae34a7abd58a8f0dc4a3bbd_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNC0zLTEtMS02NjMyNg_b1c913ad-84fa-4e6b-babf-59a1196a7f9b"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie70c7ffb0e364a418f44f5b2fb7046a3_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNC01LTEtMS02NzA5OA_d151246d-8233-4902-8d9c-da5a969cc20f"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i00cc9c53a3754125afaca64318f35370_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNC03LTEtMS03MjQ4Mg_f567f3eb-39ec-4a55-a72b-887adbfb564b"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2fbfda11dc6c495abc4054a2e60213b2_D20220402-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNS0xLTEtMS02NjMyNg_40f6805c-7da9-4b2d-91c4-d5b04f89fb2b"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9004549ad6404156b209d07af26d7701_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNS0zLTEtMS02NjMyNg_4f494818-cedc-4a8b-8b95-b5f2354e2627"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5c826af902764b62b9b01c219b888602_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNS01LTEtMS02NzEwNQ_89d6265d-6139-4250-b1e3-83eb2ccd9fb9"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic6dde7ba3d13446293bb96e14dad26d4_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNS03LTEtMS03MjQ5OQ_fc543e77-ac45-4cbb-80dd-f80f68cd0272"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i107d673b016341dba6ddac20be0bf0fa_D20220402-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNy0xLTEtMS03ODI5OA_60599333-a466-4821-94cf-27ce0d77b140"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2e8e064972ed4cd69de87474a9c08e9a_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNy0zLTEtMS03ODMwNA_5821978f-e18f-43ab-a236-c2939ae83dba"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i30e893865b1a401fa0a584689c74906c_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNy01LTEtMS03ODMxMA_c8bb3052-334d-4ee5-8674-9531f21ce5ad"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0d38bdc277d847c1bff9aea646f7b5d2_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjU0NDE1ZDVlOTEwODRjNDZhM2Q1YmRkOTc2MjczYjg4L3RhYmxlcmFuZ2U6NTQ0MTVkNWU5MTA4NGM0NmEzZDViZGQ5NzYyNzNiODhfNy03LTEtMS03ODMxNg_4dac9b24-c28d-4c39-942c-2f777f7c78c4"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie870ca4583284e068d8931189e43799a_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfMS0xLTEtMS03ODU2NA_ac56013f-e900-4dfd-987f-b7a431de4165"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i14ebf4acc76c40a8862a0cd9494ba17d_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfMS0zLTEtMS03ODU2NA_ecab156f-922f-4860-b1f4-5413eb0eddd4"
      unitRef="number">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i664afc43ce6141e7926e690257545766_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfMS0xLTEtMS02NjMyNg_7d6eb9ae-9eed-4e1c-ad28-377f69b4bbb6"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i56c71bd1b9a544559774ad6cf16b1bc8_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfMS0zLTEtMS02NjMyNg_63857344-49fb-4515-a498-0d5e721fed76"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i79b6e39380ee492b9465c8a189dc79c4_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfMy0xLTEtMS02NjMyNg_0007bffb-a369-4b2a-80ab-68c2501de08c"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1d728a2065f34c5f99164244a2469b05_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfMy0zLTEtMS02NjMyNg_712c4553-4905-4a24-8d0f-aafe50bd8941"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3955701b6f504b6c9492fed7e52d6cac_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfNC0xLTEtMS02NjMyNg_c7cd3a47-773c-4348-bbb9-72090bd73cc1"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8236363288634352a070bfdeae4ada52_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfNC0zLTEtMS02NjMyNg_511db237-4063-471e-a807-b8d3e7a6e010"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iedf483295e3441dfb06c39992af1d0cc_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfNi0xLTEtMS03ODM0NQ_4ecfe09a-b520-445d-a57c-edcba9664a46"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i57596bbb198e467e913bd95f788460dc_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE2OTE3ZmI1OWU4MDQ4MTZhZjljYmRlYTk3Y2Y1NjJlL3RhYmxlcmFuZ2U6MTY5MTdmYjU5ZTgwNDgxNmFmOWNiZGVhOTdjZjU2MmVfNi0zLTEtMS03ODM2Mg_cdaca7fc-5ca9-42d2-b4b3-2d8e2db10e4a"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDcxMg_88741920-a14c-4181-9367-a8265111c4f7">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bde2f537a354fcca14f821547b896d9_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMi0xLTEtMS02NjMyNg_99b544aa-3e24-4652-8d42-c5858d784d56"
      unitRef="usd">349615000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc1e3c9b038f4adbb0f8ca47a926170a_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMi0zLTEtMS02NjMyNg_89bcbf83-40bc-4011-acdc-de10bb041fc1"
      unitRef="usd">287190000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21feba329f3c47ba847cdba72f05f74a_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMi01LTEtMS02NzE3Mg_c7510a90-c9b1-4a90-9c80-cdf578600e84"
      unitRef="usd">663680000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c8f2e6e66e0483e9df068c8c67f6edd_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMi03LTEtMS02NzE2NQ_cbe7b501-d079-4a89-9a5a-5a8c68390a06"
      unitRef="usd">517147000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09963410ea564c02b8ff6283d62b4527_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMy0xLTEtMS02NjMyNg_bf6183b2-46b7-454e-ab72-bcd949eb39a4"
      unitRef="usd">62240000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e34c2a69d6c44dd87763d280f6add0f_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMy0zLTEtMS02NjMyNg_402ffb06-ccef-4fcf-940f-dd6b1f9cdfc2"
      unitRef="usd">90921000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb5c9264424540c9a4f238323ac0939f_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMy01LTEtMS03MjQzOA_74399a9a-82c4-42f1-9fcd-65a6f98217ec"
      unitRef="usd">96767000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16714420b2fb49839858d28e6d5059ae_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfMy03LTEtMS03MjQ1Ng_3fe74428-3b59-4f5b-86fd-a4a924e48862"
      unitRef="usd">124727000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0b5c39cb3324983afed5da2408dadd7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNC0xLTEtMS02NjMyNg_8acb847e-a6e5-4c19-a653-3f73dfd8b3f1"
      unitRef="usd">7572000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47e812ece3e94486a2fe21cbd2277bb5_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNC0zLTEtMS02NjMyNg_d8e4b5b7-6577-4919-95dd-4c651f7d7b7a"
      unitRef="usd">7066000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i188d6447088e4f92a8f70243be252647_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNC01LTEtMS03MjQ0Mw_e456b6cb-0a8d-40d2-aaeb-81d65ab6fea2"
      unitRef="usd">14960000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e97a0d79c07480eb88736adeb90ea7b_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNC03LTEtMS03MjQ2Mw_41da0918-bb5f-422f-ab71-001a1ba1b84a"
      unitRef="usd">13533000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNS0xLTEtMS02NjMyNg_25bf34f6-3cfa-4b8f-9001-2495db2180d2"
      unitRef="usd">419427000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNS0zLTEtMS02NjMyNg_f902a076-4d02-4315-8ff2-2c4d51326d9e"
      unitRef="usd">385177000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNS01LTEtMS03NDQ4Ng_08732e9f-63c2-4f53-8d11-33cdbeadb855"
      unitRef="usd">775407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmRlZWY0N2ZmNTlmYzQzODM5ZGFlYWNiYTUxZDUzNzI1L3RhYmxlcmFuZ2U6ZGVlZjQ3ZmY1OWZjNDM4MzlkYWVhY2JhNTFkNTM3MjVfNS03LTEtMS03NDQ4OQ_ef0c198c-4060-485b-9417-7fea08d2a45b"
      unitRef="usd">655407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDcwMQ_038aa3fe-2678-40d5-9c50-43a438d74da0">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule, and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54050f41270d4c0994179a0b71bcbd09_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMi0xLTEtMS02NjMyNg_17448b49-4cfa-4f86-aec8-4dbd3829a2bd"
      unitRef="usd">339159000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaeea8eb188124f60a0aaeaa7d0940557_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMi0zLTEtMS02NjMyNg_eb619d42-2acc-4059-838f-3343a10f21da"
      unitRef="usd">275614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69844ba478ba4fe381bf568853c31297_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMi01LTEtMS02OTI1NQ_3902a12d-9ff6-4ec6-90e0-4064e5174954"
      unitRef="usd">641971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i054896b94915439693f85afea696414b_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMi03LTEtMS02NzM3OQ_54105d4f-b963-478a-bde9-c8e436574658"
      unitRef="usd">499209000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb0803dcbf5b4e67ad983af158cc6a71_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMy0xLTEtMS02NjMyNg_752f4310-387a-4a58-8cc8-62fde4522de9"
      unitRef="usd">7885000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c3101bd9ba54dbca9144e467e80187f_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMy0zLTEtMS02NjMyNg_f3c8327c-d25e-4006-9247-7d4722c4b988"
      unitRef="usd">8634000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifaa34646405c478e99b9fd71f2184c6a_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMy01LTEtMS02OTI2MQ_acd95000-f2f2-4cd2-bb81-bbfc330eb12b"
      unitRef="usd">15371000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic35af551acc24804b0071e3db5e6fe35_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfMy03LTEtMS02NzM4Ng_ef173931-9771-4fff-9bf3-454929cce41e"
      unitRef="usd">12251000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f0966f9eca84459ae2dd8ebc3309047_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfNC0xLTEtMS02NjMyNg_aa4c8ad1-bdee-453a-961f-0b051243df60"
      unitRef="usd">347044000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b9e8d3facdf4864bb7c81214e9ad6f8_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfNC0zLTEtMS02NjMyNg_34814c9c-a8e4-4684-bd23-06442e628ad0"
      unitRef="usd">284248000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if42cf2e0fa214b5c803a30524005d09a_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfNC01LTEtMS02NjMyNg_0653941e-9e36-43dd-ad6f-3c3ca1f3d349"
      unitRef="usd">657342000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i783842d281c14d18a5ab8e977fb76f4a_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjZiOTQzZjkxYjc5ZDQ1YzJiYzAwOGRjYjZiNmFkMzI5L3RhYmxlcmFuZ2U6NmI5NDNmOTFiNzlkNDVjMmJjMDA4ZGNiNmI2YWQzMjlfNC03LTEtMS02NjMyNg_40f4864e-2a94-4935-84ea-220f65d7e118"
      unitRef="usd">511460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDcwNA_168632ef-23a6-4576-943a-0a525d4f52df">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if53bb4fda56c4d03bcefd670f7e34159_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMS0xLTEtMS02NjMyNg_26d7f536-6284-4daa-b730-44050a8da861"
      unitRef="usd">14625000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ied4e111ae3b74e388273fc644813dcbf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMS0zLTEtMS02NjMyNg_b7741113-1ada-4f03-a5cb-f81843223849"
      unitRef="usd">8875000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i840ea9693a1241dba5f3c957a1971f4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMS01LTEtMS02NjMyNg_e7b46a4a-a858-429b-a783-62aab02352d0"
      unitRef="usd">24825000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMS05LTEtMS02NjMyNg_d64ff527-2a58-480b-b7dc-3cf7812be8a0"
      unitRef="usd">48325000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i168b07bb58fb45fea0c1251110528099_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMy0xLTEtMS02NjMyNg_a5e40fe1-a033-498c-8f66-f8da189497dc"
      unitRef="usd">175564000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="ia7e6ba1cc1ac40ba8c5827e2046e2bd1_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMy0zLTEtMS02NjMyNg_416fa9b3-1e12-42f5-9229-1ebcb107bbcf"
      unitRef="usd">24444000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i37ef9620b8e045d1ad550beff5449fb3_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMy01LTEtMS02NjMyNg_894dc81e-20b1-45b2-9ba0-2483af251b89"
      unitRef="usd">72890000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfMy05LTEtMS02NjMyNg_086f192f-8383-4d9d-8082-308f6bb32f20"
      unitRef="usd">272898000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i168b07bb58fb45fea0c1251110528099_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNC0xLTEtMS02NjMyNg_00ba85f7-a8df-4017-9487-8ce2efe647f2"
      unitRef="usd">1311000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="ia7e6ba1cc1ac40ba8c5827e2046e2bd1_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNC0zLTEtMS02NjMyNg_192203b0-c311-4c09-83ce-eff90402ca72"
      unitRef="usd">-168000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i37ef9620b8e045d1ad550beff5449fb3_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNC01LTEtMS02NjMyNg_34c08371-debd-4c7e-acfb-c30836a6fd6a"
      unitRef="usd">-73000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNC05LTEtMS02NjMyNg_54b24f5d-0968-4df4-83eb-8aca8748554f"
      unitRef="usd">1070000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i168b07bb58fb45fea0c1251110528099_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNS0xLTEtMS02NjMyNg_c24d45d1-e1d3-4185-90d7-e068bd247088"
      unitRef="usd">171534000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ia7e6ba1cc1ac40ba8c5827e2046e2bd1_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNS0zLTEtMS02NjMyNg_3a913d05-d44f-44c4-8a5b-d3c241320def"
      unitRef="usd">22186000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i37ef9620b8e045d1ad550beff5449fb3_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNS01LTEtMS02NjMyNg_e65bcd75-4011-412c-b303-740c67b48a7b"
      unitRef="usd">64812000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNS05LTEtMS02NjMyNg_1f0815b4-16f7-4699-97b9-4897c2c5622b"
      unitRef="usd">258532000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ife8f6fa225be4cf0b820fdededde5d76_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNi0xLTEtMS02NjMyNg_87cc6178-b6da-45c7-9ed8-4d493c39bbc5"
      unitRef="usd">19966000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0d94301a72254e9d9c581087dcee3084_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNi0zLTEtMS02NjMyNg_a8b41e44-b270-4859-b2fd-274223944f02"
      unitRef="usd">10965000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1a01e54ece8642d5b3a8cd53ce306b40_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNi01LTEtMS02NjMyNg_423ac126-f991-4bcc-bc0b-f6debf4a35b8"
      unitRef="usd">32830000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOmM0NmI1NjQ3NjM3NTQ4NTFiMDYzZGVkMDA4OTkwY2IzL3RhYmxlcmFuZ2U6YzQ2YjU2NDc2Mzc1NDg1MWIwNjNkZWQwMDg5OTBjYjNfNi05LTEtMS02NjMyNg_7f2082a0-0ca6-48b9-bb14-23705aca5a30"
      unitRef="usd">63761000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNDY5MA_699f5ab3-7f42-4290-abd3-42e10ae04136">Contract assets and liabilities were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfNC0xLTEtMS02NjMyNg_771aa6cb-8e84-49db-8bde-be72e0b8214b"
      unitRef="usd">394000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfNC0zLTEtMS02NjMyNg_e12a0854-27cd-4f5b-920c-20ebdec8bc03"
      unitRef="usd">1665000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfNy0xLTEtMS02NjMyNg_ad160e44-6177-4f51-a3ed-6b6c5540c9a7"
      unitRef="usd">7513000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfNy0zLTEtMS02NjMyNg_cbed0832-02f3-418d-99d8-4a42bbb4cb01"
      unitRef="usd">7814000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfOC0xLTEtMS02NjMyNg_2c06545b-1700-4f29-9557-b086116f63ba"
      unitRef="usd">7209000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfOC0zLTEtMS02NjMyNg_28ae8ec1-47c8-4979-b275-674be8e30e21"
      unitRef="usd">8739000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfOS0xLTEtMS02NjMyNg_00f1d0fa-07bc-4fdf-92f4-17e8bfdbd3b5"
      unitRef="usd">14722000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RhYmxlOjE5Y2Q5ZWYxNzQwYTQ5MDk5MTFhOTE4YmJiMzdhMzViL3RhYmxlcmFuZ2U6MTljZDllZjE3NDBhNDkwOTkxMWE5MThiYmIzN2EzNWJfOS0zLTEtMS02NjMyNg_845b4c82-7c4e-438e-a33f-8468c7179cb6"
      unitRef="usd">16553000</us-gaap:ContractWithCustomerLiability>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNjA0NzMxMzk1NzYyNg_e22d48bb-613a-4f4c-9b57-252fffdc7e52"
      unitRef="usd">4500000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfMzc1OQ_dcc3805a-fad7-4a3b-afe7-784776c74a58"
      unitRef="usd">4800000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNjA0NzMxMzk1NzcwMg_727261bd-122f-42b4-af1c-9ed1981da84c"
      unitRef="usd">59400000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNjA0NzMxMzk1NzY1Nw_48e640cd-b2f0-4b27-8334-aede01aeec62"
      unitRef="usd">91100000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i772576eea90d4bb0929cdf808c536289_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl8zNy9mcmFnOmZlYTdiOTczMmNlNTQ1ZWY4NzExN2FiZTgzZDkyNzhmL3RleHRyZWdpb246ZmVhN2I5NzMyY2U1NDVlZjg3MTE3YWJlODNkOTI3OGZfNjA0NzMxMzk1ODg3MQ_03c7f06e-03ed-4020-aaa6-20967f450989"
      unitRef="usd">89300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjI2MQ_b7177724-c00d-4404-a49e-2395a20de71b">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaborations, in-licensing arrangements and other strategic transactions to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading pharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;Note 3. Collaboration Agreements and Business Development Activities&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2021 Form 10-K, as further described below, for additional information on certain of our collaboration agreements and in-licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Commercial Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2022, we recognized $25.7&#160;million in revenues in connection with two regulatory milestones totaling $27.0&#160;million upon approval by the European Commission and Health Canada of cabozantinib as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022, $51.9&#160;million of the transaction price for this collaboration was allocated to our research and development services performance obligations that have not yet been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $37.5&#160;million of the transaction price for this collaboration was allocated to our research and development services performance obligations that have not yet been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Pharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib sold by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and in connection with sales by our collaboration partners are included as a reduction of collaboration services revenues. Such royalties were $14.6&#160;million and $27.7&#160;million during the three and six months ended June&#160;30, 2022, respectively, as compared to $12.1&#160;million and $22.2&#160;million in the corresponding periods in 2021.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Commercial Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#x2019;s ZELBORAF&#xae; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#xae; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research Collaborations, In-Licensing Arrangements and Other Business Development Activities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, development, regulatory, commercial milestone payments and royalty payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then, in most instances we will assume the responsibilities for all subsequent clinical development, manufacturing and commercialization. In conjunction with each of these collaborative in-licensing arrangements, we were subject to upfront payments and will make payments for potential future development, regulatory, and commercial milestones as well as royalties on future net product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, we entered into an exclusive option and license agreement with BioInvent International AB (BioInvent), upon which we paid BioInvent an upfront payment of $25.0&#160;million. Upon option exercise, we will pay BioInvent an option exercise fee, and BioInvent will be eligible for additional payments from us for future development and commercial milestones, as well as royalties on future net product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of June 30, 2022, in conjunction with each of our collaborative in-licensing arrangements, and an asset purchase agreement entered in 2021, we will make payments for potential future development milestones of up to $321.8&#160;million, regulatory milestones of up to $453.7&#160;million and commercial milestones of up to $2,070.7&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjI3NQ_1d6476d6-6aef-41a3-b9ff-a7d7e6b66636">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d2515b3d980437d88f874ad96264c8f_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMi0xLTEtMS02NjMyNg_d22a3023-8b64-4c79-a58e-dda94ddb265d"
      unitRef="usd">51168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfeb2faa92124a56beca5879006c456c_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMi0zLTEtMS02NjMyNg_45cee8b9-3632-42b2-9e58-5ccab454043e"
      unitRef="usd">33656000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a867ee6b32d4d0ca8d6da06a0baf4f0_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMi01LTEtMS02NjMyNg_cfc29c42-e660-44ad-abb8-c2ba31e3eaff"
      unitRef="usd">75782000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02072ae37a364e828c67a1f3675a3358_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMi03LTEtMS02NjMyNg_2abb8f93-8ce1-4a51-b31a-224a7f647421"
      unitRef="usd">56107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d3b05ed939f4eea80b46d18a26cadad_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMy0xLTEtMS02NjMyNg_87a261f6-2835-48b4-9aa7-37d593623f9d"
      unitRef="usd">11072000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e7633a25d674d1d9065925fd26afcdf_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMy0zLTEtMS02NjMyNg_c8545dbf-f6a9-4a34-9388-237b565cd31f"
      unitRef="usd">57265000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8679d3445ee744d6b8bd2814877f2e65_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMy01LTEtMS02NjMyNg_988b423f-660e-48ab-abe1-5915e204dd13"
      unitRef="usd">20985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib163ec7f845e44e9af8e12e633ddeb1e_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfMy03LTEtMS02NjMyNg_5f6c66ab-1afa-4a37-a29c-41279bd5718b"
      unitRef="usd">68620000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id082ca3812d9497f9a5419f7e2935ef1_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfNC0xLTEtMS02NjMyNg_659a2977-cd21-4927-bc9d-29fbe5e806da"
      unitRef="usd">62240000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib008fa7a2c3348058b33ada2c3c90db2_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfNC0zLTEtMS02NjMyNg_5b33f68d-7dfe-4199-ae98-ebdf3710f89a"
      unitRef="usd">90921000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3e31b2ad1f74418b3fc3f615f610c44_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfNC01LTEtMS02NjMyNg_8a059a90-a25b-4f84-9935-b9eb3b88f4ff"
      unitRef="usd">96767000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ba0f6408f78479fa48647723afcaff3_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmM3Mjk0ZWMyNWI2ZjRjNzliN2Q0ZjI5NmIzOGEyNDZmL3RhYmxlcmFuZ2U6YzcyOTRlYzI1YjZmNGM3OWI3ZDRmMjk2YjM4YTI0NmZfNC03LTEtMS02NjMyNg_db7af3ad-89bc-425b-a8ca-1a9a7d8b2f03"
      unitRef="usd">124727000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id082ca3812d9497f9a5419f7e2935ef1_D20220402-20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MzU1OA_625f9327-cefd-442e-bf5f-24fa8153a399"
      unitRef="usd">25700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <exel:RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement
      contextRef="id082ca3812d9497f9a5419f7e2935ef1_D20220402-20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfOTM0NTg0ODg0NDc0Nw_33df874d-0678-4bfa-a072-f488d7fcd242"
      unitRef="usd">27000000</exel:RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="iab7278b18228461aa447d7af1ab75997_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTU0Ng_34baa429-0dbe-4226-8700-1707e031407c"
      unitRef="usd">51900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica98cb95722d43bc90dd8fdac8a16248_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMi0xLTEtMS02NjMyNg_8ef7a9c4-221d-4d24-a843-74f535f1466e"
      unitRef="usd">2700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e5e7e3b485b4ccba1783e0a9e98bce2_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMi0zLTEtMS02NjMyNg_3899dd1c-a0bc-45b8-9ad5-6e8a1dd1994c"
      unitRef="usd">2097000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0faaa279485d47858ff462a4fe31d8cb_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMi01LTEtMS02NjMyNg_6b8b0dd6-bb7c-4f27-a20a-1d45b9b50b97"
      unitRef="usd">5065000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1dc5dede6944878bb37ad9f5b90202c_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMi03LTEtMS02NjMyNg_fcf51b9e-bbb9-4b22-9724-caa1cfbe4660"
      unitRef="usd">3398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id28f186b12114729ad0bcf462687594b_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMy0xLTEtMS02NjMyNg_f356732e-79b5-4ffc-b21d-018399ddd4b9"
      unitRef="usd">3785000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb3c2f628159430fa2b4ba939626da68_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMy0zLTEtMS02NjMyNg_42dac5b8-385b-48ca-af0b-c86a4d96832f"
      unitRef="usd">4024000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c34c70519cf4ccdb9cf2f1f898c0f47_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMy01LTEtMS02NjMyNg_a2763096-5908-4b97-90e6-6634bf6b702f"
      unitRef="usd">7487000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib934a263672b49e2b398d9af12ca3f18_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfMy03LTEtMS02NjMyNg_6cb3c2cd-9700-43e4-a05b-a2a22969973c"
      unitRef="usd">8159000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied5cfd9d83994869a3ed269eca638c4a_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfNC0xLTEtMS02NjMyNg_7386e6e4-6db1-4c58-979e-336b6fc0e34d"
      unitRef="usd">6485000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id21078b478324339b815339fdc2f5d2a_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfNC0zLTEtMS02NjMyNg_003d66c5-d1c7-4816-b0c1-8b71854c885f"
      unitRef="usd">6121000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bf36077e14546d49a6c6d7f64c0e7fa_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfNC01LTEtMS02NjMyNg_d64d0303-73e9-45b8-a369-85c3fdb4f132"
      unitRef="usd">12552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6b3af1cf525438ea1fdab7f2ae1a4b5_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOjM0N2Y5NmY3NmQxZDQwZTI5OGU0MDk2M2JjM2ZlMzllL3RhYmxlcmFuZ2U6MzQ3Zjk2Zjc2ZDFkNDBlMjk4ZTQwOTYzYmMzZmUzOWVfNC03LTEtMS02NjMyNg_a5df0da3-f913-454c-b961-718cd6db9929"
      unitRef="usd">11557000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i9d122b6fe357426c8ad3468c325f4936_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTU3OQ_a7ec0594-7d1c-43d6-854b-75f18a0fd57e"
      unitRef="usd">37500000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i37d0046d01764a6a84fff26e8dc7ad8e_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfMzEyNg_b0fe9b9f-2f50-4e03-8925-0c0971263378"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="iaa76717dc58d47e987e00cef2f0b1605_D20220402-20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTY1Nw_9acb6edb-58de-4602-8fd1-f62064509024"
      unitRef="usd">14600000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i5d6438a867804b3690c45471a4365f52_D20220101-20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTY3Mg_92c03704-3605-4920-893a-44715a32dc0a"
      unitRef="usd">27700000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i839cb707d2d1469585661ba26e60dba8_D20210403-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfOTM0NTg0ODg0NDc2OA_99241059-dc72-4983-88ce-ba5ba37ecf37"
      unitRef="usd">12100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i395367a2b6f840398cc68008eec67422_D20210102-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfOTM0NTg0ODg0NDc4Mw_6aa87e4a-0ce5-4934-a37b-28c95dba95ea"
      unitRef="usd">22200000</us-gaap:RoyaltyExpense>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i9403b468905b44ddb12619327a4d1331_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMi0xLTEtMS02NjMyNg_fe9eca41-2531-4717-b571-cd57369d6885"
      unitRef="usd">1682000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="id0536dbf918041b2a030788539bad217_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMi0zLTEtMS02NjMyNg_42cbda30-8c4e-4bd2-88fb-c6853a7a74a8"
      unitRef="usd">2160000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i3ab318d80ac145cfa0dd2bc25b9ffc19_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMi01LTEtMS02NjMyNg_e47e2925-430a-4b7f-ae4d-03aec837c0a6"
      unitRef="usd">3821000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="ic7d942e3ddd54d17abcf3f8dd59c4d5f_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMi03LTEtMS02NjMyNg_d8bf2548-11ff-4a0b-bfba-52f44bf80ae8"
      unitRef="usd">3954000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9403b468905b44ddb12619327a4d1331_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMy0xLTEtMS02NjMyNg_ea142799-2fd0-413f-9f90-8eec8b72af08"
      unitRef="usd">889000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0536dbf918041b2a030788539bad217_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMy0zLTEtMS02NjMyNg_a61f5d67-d3cf-498e-992f-501d298cee9d"
      unitRef="usd">782000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ab318d80ac145cfa0dd2bc25b9ffc19_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMy01LTEtMS02NjMyNg_cf0b2244-600e-4698-a728-b84fac0e3f04"
      unitRef="usd">2517000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7d942e3ddd54d17abcf3f8dd59c4d5f_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RhYmxlOmEwOTYzNDBjNTlmYzQ3Y2RhYzE5MDQ2ZmIzMjYzYzI2L3RhYmxlcmFuZ2U6YTA5NjM0MGM1OWZjNDdjZGFjMTkwNDZmYjMyNjNjMjZfMy03LTEtMS02NjMyNg_50634b66-e52a-4b2e-8cb5-3a15a93755f6"
      unitRef="usd">1733000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i2b5ed8e63d724ab1b37ae2306c7d0aa7_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfOTM0NTg0ODg0NDc5OA_7fbff42f-c62a-4258-bb83-de644c8a53b7"
      unitRef="usd">25000000</exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
      contextRef="ibfc05a0f9c9a41eb9f99aed54fd26749_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTkwMQ_264c7227-54c3-41fa-a1cb-985a77cb6fbf"
      unitRef="usd">321800000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
      contextRef="ibfc05a0f9c9a41eb9f99aed54fd26749_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTkzOA_7757aaa3-57e9-4448-93d4-d20d7491fe21"
      unitRef="usd">453700000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments
      contextRef="ibfc05a0f9c9a41eb9f99aed54fd26749_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80MC9mcmFnOmYwZTJjOTI3MjE4MTRjODZiYThlNTk3NTQxOGFiNmFlL3RleHRyZWdpb246ZjBlMmM5MjcyMTgxNGM4NmJhOGU1OTc1NDE4YWI2YWVfNjA0NzMxMzk2MTgxNg_dd6490db-4049-4cb5-8a02-da8f6a176e70"
      unitRef="usd">2070700000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjk4MA_f79edd9c-f68d-4579-93b0-d2766cc6387e">CASH AND INVESTMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, restricted cash equivalents included $9.2&#160;million of short-term investments, which is collateral under our January 2021 standby letter of credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our January 2021 standby letter of credit will remain effective through August 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,020,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,009,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable was $3.6 million and $2.9 million as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31, 2021, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were insignificant during the three and six months ended June&#160;30, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were 237 and 133 investments in an unrealized loss position as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31, 2021, respectively. All securities presented above have been in an unrealized loss position for less than twelve months except for six corporate bond securities with an aggregate fair value of $18.1&#160;million and an aggregate immaterial unrealized loss as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During the six months ended June 30, 2022, and 2021, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjk3MQ_d28b3994-19eb-4d45-9aca-21fb03c80fa7">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjk5Mw_6ad53ba7-9d0f-4cdf-88b9-4adebc66f25f">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExZDM3OTE5N2U3MjQ0YzViMzU0MWQ0M2MwZWI4NzZhL3RhYmxlcmFuZ2U6MTFkMzc5MTk3ZTcyNDRjNWIzNTQxZDQzYzBlYjg3NmFfMS0xLTEtMS02NjMyNg_19bfcb81-142f-4f23-b2a9-adf0e0d88347"
      unitRef="usd">627000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExZDM3OTE5N2U3MjQ0YzViMzU0MWQ0M2MwZWI4NzZhL3RhYmxlcmFuZ2U6MTFkMzc5MTk3ZTcyNDRjNWIzNTQxZDQzYzBlYjg3NmFfMS0zLTEtMS02NjMyNg_8865e94e-016e-41f6-aa14-47afad62aab3"
      unitRef="usd">647169000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExZDM3OTE5N2U3MjQ0YzViMzU0MWQ0M2MwZWI4NzZhL3RhYmxlcmFuZ2U6MTFkMzc5MTk3ZTcyNDRjNWIzNTQxZDQzYzBlYjg3NmFfMy0xLTEtMS02NjMyNg_4d972b51-f931-4153-8420-81063d1b65e4"
      unitRef="usd">10686000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExZDM3OTE5N2U3MjQ0YzViMzU0MWQ0M2MwZWI4NzZhL3RhYmxlcmFuZ2U6MTFkMzc5MTk3ZTcyNDRjNWIzNTQxZDQzYzBlYjg3NmFfMy0zLTEtMS02NjMyNg_8317dac3-6afa-455a-a941-a5d5305c231c"
      unitRef="usd">16722000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExZDM3OTE5N2U3MjQ0YzViMzU0MWQ0M2MwZWI4NzZhL3RhYmxlcmFuZ2U6MTFkMzc5MTk3ZTcyNDRjNWIzNTQxZDQzYzBlYjg3NmFfNC0xLTEtMS02NjMyNg_fbbd5b18-6a13-4dad-9538-73e0f83059ce"
      unitRef="usd">637686000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExZDM3OTE5N2U3MjQ0YzViMzU0MWQ0M2MwZWI4NzZhL3RhYmxlcmFuZ2U6MTFkMzc5MTk3ZTcyNDRjNWIzNTQxZDQzYzBlYjg3NmFfNC0zLTEtMS02NjMyNg_ade2a21d-889c-450a-9d50-3014e013e3d7"
      unitRef="usd">663891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i1989bb1580374884bd42c103f79e3cb9_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfNzIy_a72db169-a52d-460b-8747-43dea587550c"
      unitRef="usd">9200000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjk1OQ_b79e7896-b4c3-458a-80ae-5d5c6eca1a2c">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,020,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,009,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if3c8d749d7584b6199a2924e8a1e9a41_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMy0xLTEtMS02NjMyNg_fa44f24d-cf88-44ac-ac04-150c0bfe730a"
      unitRef="usd">880593000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if3c8d749d7584b6199a2924e8a1e9a41_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMy0zLTEtMS02NjMyNg_f1fb3637-1800-44ff-9f4e-dd92abf6285e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if3c8d749d7584b6199a2924e8a1e9a41_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMy01LTEtMS02NjMyNg_7db85ba8-122c-4049-9097-0323e2565217"
      unitRef="usd">107000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3c8d749d7584b6199a2924e8a1e9a41_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMy03LTEtMS02NjMyNg_8962fd8a-2457-4828-9362-8ba4ec17d287"
      unitRef="usd">880486000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i03769550f9144c9984b85e0c5923a535_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNC0xLTEtMS02NjMyNg_9e8615f5-7599-4cb7-9a36-bf6908a26974"
      unitRef="usd">573343000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i03769550f9144c9984b85e0c5923a535_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNC0zLTEtMS02NjMyNg_06577316-10ae-4003-9f15-bf8f5f82acbb"
      unitRef="usd">117000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i03769550f9144c9984b85e0c5923a535_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNC01LTEtMS02NjMyNg_b0959377-c4d7-4b41-abd5-1f3bff76a946"
      unitRef="usd">9059000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i03769550f9144c9984b85e0c5923a535_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNC03LTEtMS02NjMyNg_94eb3f1f-c287-4859-baa0-99549321e452"
      unitRef="usd">564401000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNS0xLTEtMS02NjMyNg_c45ecb23-9c00-4c0e-9834-2ab2e67e78e6"
      unitRef="usd">255407000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNS0zLTEtMS02NjMyNg_d28ff075-e086-466b-9674-cf0d4cd09e3a"
      unitRef="usd">58000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNS01LTEtMS02NjMyNg_574967c5-9ce4-4090-9331-83d447f86761"
      unitRef="usd">2057000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNS03LTEtMS02NjMyNg_e6db0e1c-3d3b-4c9e-b635-98859acc1373"
      unitRef="usd">253408000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if453d9270ba64e94a9244e7992459ee8_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNi0xLTEtMS02NjMyNg_57b1da5d-e65c-4728-a5b5-91936cbda8d8"
      unitRef="usd">12350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if453d9270ba64e94a9244e7992459ee8_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNi0zLTEtMS02NjMyNg_33ef8e3c-5b8e-483e-86e8-664ded5e9245"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if453d9270ba64e94a9244e7992459ee8_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNi01LTEtMS02NjMyNg_dbba8af3-fa33-4a96-b5f4-ef1971523ec8"
      unitRef="usd">202000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if453d9270ba64e94a9244e7992459ee8_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNi03LTEtMS02NjMyNg_30e2c4da-beed-4872-b918-21278d2460a1"
      unitRef="usd">12148000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNy0xLTEtMS02NjMyNg_8da9843d-64a9-4a54-9dcf-1311972c0a43"
      unitRef="usd">1721693000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNy0zLTEtMS02NjMyNg_c42b498c-ced7-45dc-b668-0a35bea86fde"
      unitRef="usd">175000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNy01LTEtMS02NjMyNg_14f45879-b120-46e5-864c-76d4fa6b405a"
      unitRef="usd">11425000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfNy03LTEtMS02NjMyNg_5dcba171-c18d-4810-b2ac-44a43c389f32"
      unitRef="usd">1710443000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i1699183c5c004e00bb9e1dd4a3f6355d_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOC0xLTEtMS02NjMyNg_76937132-3841-45cc-a141-cccba84d9b2e"
      unitRef="usd">80747000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i1699183c5c004e00bb9e1dd4a3f6355d_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOC0zLTEtMS02NjMyNg_d49530d0-f784-4cf6-8cd7-e749b760402a"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i1699183c5c004e00bb9e1dd4a3f6355d_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOC01LTEtMS02NjMyNg_82c2e1cd-35a2-4270-9b10-47ee7393db78"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i1699183c5c004e00bb9e1dd4a3f6355d_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOC03LTEtMS02NjMyNg_d71f5819-b760-4b4b-9be4-eabc793eab8e"
      unitRef="usd">80747000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i0451da3ec05541229c7b26c8a138441a_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOS0xLTEtMS02NjMyNg_ca3193ba-7140-447c-8c09-7d30885484ec"
      unitRef="usd">87821000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i0451da3ec05541229c7b26c8a138441a_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOS0zLTEtMS02NjMyNg_79ad8128-a07d-4ad2-8259-236417965e83"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i0451da3ec05541229c7b26c8a138441a_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOS01LTEtMS02NjMyNg_b8dcfd70-3721-4d5c-99b8-5f118f5414c0"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i0451da3ec05541229c7b26c8a138441a_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfOS03LTEtMS02NjMyNg_44bb3a8a-bd0b-4cfb-8713-8e65046146e4"
      unitRef="usd">87821000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i0503cc8f8c754670b0adbd270a4852eb_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTAtMS0xLTEtNjYzMjY_adfe7264-708a-4255-a5c4-adffcf79dfcd"
      unitRef="usd">130502000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i0503cc8f8c754670b0adbd270a4852eb_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTAtMy0xLTEtNjYzMjY_38cd7a97-7011-4793-a8e4-72a78b111e08"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i0503cc8f8c754670b0adbd270a4852eb_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTAtNS0xLTEtNjYzMjY_0e0028ec-e6b9-44a3-8eaa-47e2df342d45"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i0503cc8f8c754670b0adbd270a4852eb_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTAtNy0xLTEtNjYzMjY_a8c41264-7f2a-4050-89e9-302132a792fd"
      unitRef="usd">130502000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTEtMS0xLTEtNjYzMjY_5e36f143-aa6e-4731-8209-566e9aa97b4a"
      unitRef="usd">2020763000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTEtMy0xLTEtNjYzMjY_aa048344-ab26-4bdd-8d0b-305e8587313d"
      unitRef="usd">175000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTEtNS0xLTEtNjYzMjY_33ebf661-3417-4511-9721-2c5f62a8e226"
      unitRef="usd">11425000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjExNzVkMTFjMjc3NjRkYmZhYTdhNThiMmVhMTFjODE1L3RhYmxlcmFuZ2U6MTE3NWQxMWMyNzc2NGRiZmFhN2E1OGIyZWExMWM4MTVfMTEtNy0xLTEtNjYzMjY_706af30a-7763-4ecd-a45b-c92492730a8e"
      unitRef="usd">2009513000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieec985d2c22946468e2db7ee7e8fdd66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMy0xLTEtMS02NjMyNg_93774163-d203-40d2-b034-18e4ffc2494f"
      unitRef="usd">945801000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieec985d2c22946468e2db7ee7e8fdd66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMy0zLTEtMS02NjMyNg_dfa84e86-a6c3-4dee-8cee-a167fe56c574"
      unitRef="usd">42000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieec985d2c22946468e2db7ee7e8fdd66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMy01LTEtMS02NjMyNg_9a906da9-7491-48bb-85fc-24b3a49088fc"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieec985d2c22946468e2db7ee7e8fdd66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMy03LTEtMS02NjMyNg_5c64ce9b-156f-44cd-bbfd-15de9a1dd7ad"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie325f3ade8d44aa1a927d9ea4b117375_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNC0xLTEtMS02NjMyNg_49500bc5-c842-4d6d-b022-b6897f60ede9"
      unitRef="usd">541774000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie325f3ade8d44aa1a927d9ea4b117375_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNC0zLTEtMS02NjMyNg_af160f9f-c015-4461-96b6-5a830a29ccf9"
      unitRef="usd">876000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie325f3ade8d44aa1a927d9ea4b117375_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNC01LTEtMS02NjMyNg_90a8c0b8-af95-4e0f-8e89-39772d1a1699"
      unitRef="usd">1672000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie325f3ade8d44aa1a927d9ea4b117375_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNC03LTEtMS02NjMyNg_e58b7217-c88a-427b-9b6a-7c67d5acb2ad"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8a744931712846de898f2a9ba07534f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNS0xLTEtMS02NjMyNg_0b06bbb0-c05f-43b5-9606-743a475190e2"
      unitRef="usd">33965000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8a744931712846de898f2a9ba07534f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNS0zLTEtMS02NjMyNg_c9b180f7-853b-4659-a4d3-503907660e54"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8a744931712846de898f2a9ba07534f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNS01LTEtMS02NjMyNg_a9c79331-3377-4178-bf19-c6ccf2887442"
      unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a744931712846de898f2a9ba07534f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNS03LTEtMS02NjMyNg_4a786adf-77f0-4297-95c3-6fb4a27261c1"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4f56488c0f264c679e4506474188a292_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNi0xLTEtMS02NjMyNg_7f0964ba-fac0-42b2-acc9-44f5b92d956a"
      unitRef="usd">12924000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4f56488c0f264c679e4506474188a292_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNi0zLTEtMS02NjMyNg_e52de9ec-b4b2-404b-92cf-ca6da3f5cf31"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4f56488c0f264c679e4506474188a292_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNi01LTEtMS02NjMyNg_d46e9b36-5f77-495a-9b38-9594697d56dc"
      unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f56488c0f264c679e4506474188a292_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNi03LTEtMS02NjMyNg_5809558f-6b30-4e22-9184-9c98f318d0bb"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNy0xLTEtMS02NjMyNg_f60ae5d8-b210-46ba-b806-37c648d189b9"
      unitRef="usd">1534464000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNy0zLTEtMS02NjMyNg_97c8f6c9-c72a-4225-a70a-ce7e3980267c"
      unitRef="usd">934000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNy01LTEtMS02NjMyNg_8a17de7e-ff78-4d3b-abd1-69dc801b6ba2"
      unitRef="usd">1730000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfNy03LTEtMS02NjMyNg_bb17296f-c0fc-4dbc-9931-c4c411f23463"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i9786b6a841764a17b8436d495f0e5d65_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOC0xLTEtMS02NjMyNg_f22b8ceb-d9c9-40c2-8545-ea83909ab356"
      unitRef="usd">135653000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i9786b6a841764a17b8436d495f0e5d65_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOC0zLTEtMS02NjMyNg_66adc7d7-63e4-4f77-b1cd-9782f7e45fd7"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i9786b6a841764a17b8436d495f0e5d65_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOC01LTEtMS02NjMyNg_f219ea74-4d7e-4502-b50d-f0f0a6431e83"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i9786b6a841764a17b8436d495f0e5d65_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOC03LTEtMS02NjMyNg_372852f8-8df2-411b-b277-ada2174283a0"
      unitRef="usd">135653000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ib217aade91424cacbff6d49127cff87f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOS0xLTEtMS02NjMyNg_3acc9338-9465-489b-9aa9-dde38da0fea9"
      unitRef="usd">66531000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ib217aade91424cacbff6d49127cff87f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOS0zLTEtMS02NjMyNg_9304d13b-1abb-45bd-9a88-97232ca95bcd"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ib217aade91424cacbff6d49127cff87f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOS01LTEtMS02NjMyNg_493a658d-7cd4-41f3-ab59-c579b45c4eb3"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ib217aade91424cacbff6d49127cff87f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfOS03LTEtMS02NjMyNg_650590f9-46a3-488c-a262-879248cd88d2"
      unitRef="usd">66531000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i534afc4a026f4e9aafc43cba5359abc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTAtMS0xLTEtNjYzMjY_22d4e3c7-6dd1-4d20-86fe-a671722bcd60"
      unitRef="usd">119056000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i534afc4a026f4e9aafc43cba5359abc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTAtMy0xLTEtNjYzMjY_64b99e2c-6756-4fe1-8efe-0f8a18f4d893"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i534afc4a026f4e9aafc43cba5359abc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTAtNS0xLTEtNjYzMjY_038fc5a1-42fc-4b92-82c0-88e093935ed6"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i534afc4a026f4e9aafc43cba5359abc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTAtNy0xLTEtNjYzMjY_d3d52e7d-9229-4819-b9b3-1a6d6b775885"
      unitRef="usd">119056000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTEtMS0xLTEtNjYzMjY_632264c6-9a65-4579-9820-015526dc4dc9"
      unitRef="usd">1855704000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTEtMy0xLTEtNjYzMjY_52adad0b-8681-479d-857d-f7853b06e689"
      unitRef="usd">934000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTEtNS0xLTEtNjYzMjY_6281f110-4315-4cc1-a37f-631c73a748de"
      unitRef="usd">1730000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjAzM2E1MTE0Yjk0NDRkYTZhYjZkYTc2ZjZjZDQxZGY5L3RhYmxlcmFuZ2U6MDMzYTUxMTRiOTQ0NGRhNmFiNmRhNzZmNmNkNDFkZjlfMTEtNy0xLTEtNjYzMjY_d2e54e93-b05d-4f59-a3d6-57ba83fecd99"
      unitRef="usd">1854908000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMTM0Nw_70167168-53fc-4600-870a-94427fc13713"
      unitRef="usd">3600000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMTM1NA_debae1dd-acfc-48ad-aac5-43057d1d4b16"
      unitRef="usd">2900000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjk2OQ_b7a6fcca-6597-4d95-bc3c-c804cf95e06a">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i03769550f9144c9984b85e0c5923a535_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfMy05LTEtMS02NjMyNg_ee7dca15-0374-4503-82c3-9436c5aa1113"
      unitRef="usd">540226000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i03769550f9144c9984b85e0c5923a535_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfMy0xMS0xLTEtNjYzMjY_80056c38-4373-40d0-9ded-4de0f7be10aa"
      unitRef="usd">9059000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfNC05LTEtMS02NjMyNg_2098d5f1-dc25-4b9e-92b4-9fb73ac1a314"
      unitRef="usd">237680000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ia4fc59437ced4e31be6fb74a0da6e9d9_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfNC0xMS0xLTEtNjYzMjY_e5222663-709a-474c-8832-45a6d441b88d"
      unitRef="usd">2057000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if3c8d749d7584b6199a2924e8a1e9a41_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfNS05LTEtMS02NjMyNg_e614b6d6-0d68-49ff-bb20-8cc2b5216235"
      unitRef="usd">14000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if3c8d749d7584b6199a2924e8a1e9a41_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfNS0xMS0xLTEtNjYzMjY_dc1c5347-b2a8-4888-8111-0fdf5c64fe26"
      unitRef="usd">107000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if453d9270ba64e94a9244e7992459ee8_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfNi05LTEtMS02NjMyNg_bf01d936-c7b9-492d-9464-0b2b7d1432bd"
      unitRef="usd">12148000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if453d9270ba64e94a9244e7992459ee8_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfNi0xMS0xLTEtNjYzMjY_88cebd36-2c69-497a-92db-52bb661cff23"
      unitRef="usd">202000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfOC05LTEtMS02NjMyNg_19ad45ed-4241-44d0-8349-b97e04c6c061"
      unitRef="usd">804054000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjE0OWZlN2M0ODU0MzRlNGNhMWVmOTYzZWE0NTk0MzJlL3RhYmxlcmFuZ2U6MTQ5ZmU3YzQ4NTQzNGU0Y2ExZWY5NjNlYTQ1OTQzMmVfOC0xMS0xLTEtNjYzMjY_c443a9ea-1055-49f5-87c1-cc88773670a1"
      unitRef="usd">11425000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie325f3ade8d44aa1a927d9ea4b117375_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfMi05LTEtMS02NjMyNg_5e43e571-4dfe-4d17-bfc0-989648ef4d1e"
      unitRef="usd">385053000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ie325f3ade8d44aa1a927d9ea4b117375_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfMi0xMS0xLTEtNjYzMjY_db5911ef-3ad3-4a43-a374-57390ba723b0"
      unitRef="usd">1672000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ieec985d2c22946468e2db7ee7e8fdd66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfMy05LTEtMS02NjMyNg_ffc5b662-23b3-4804-b66b-5e10473a493b"
      unitRef="usd">43290000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ieec985d2c22946468e2db7ee7e8fdd66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfMy0xMS0xLTEtNjYzMjY_da89d428-9e5e-4d29-9f7f-53a5c3013813"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i8a744931712846de898f2a9ba07534f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfNC05LTEtMS02NjMyNg_6076c889-211e-463e-93e0-ef0b0ab99b74"
      unitRef="usd">18962000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i8a744931712846de898f2a9ba07534f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfNC0xMS0xLTEtNjYzMjY_37de9619-b4f4-42ba-9a60-a81a0aab64b5"
      unitRef="usd">21000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i4f56488c0f264c679e4506474188a292_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfNS05LTEtMS02NjMyNg_1dcd3c5f-f9d2-42e1-b885-4559ea02f80a"
      unitRef="usd">7475000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i4f56488c0f264c679e4506474188a292_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfNS0xMS0xLTEtNjYzMjY_678d4e5c-aec4-432f-a3ac-af3a24a50f90"
      unitRef="usd">35000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfNi05LTEtMS02NjMyNg_0e8c9318-09da-4e37-b465-8b2bb80ede76"
      unitRef="usd">454780000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOjA4MTczOTdjNzAxNTRmOGU5NThiM2IyOTEzMTdmMmNiL3RhYmxlcmFuZ2U6MDgxNzM5N2M3MDE1NGY4ZTk1OGIzYjI5MTMxN2YyY2JfNi0xMS0xLTEtNjYzMjY_35e79441-7592-4a6a-b3a0-5e0dd49e9611"
      unitRef="usd">1730000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMTk4NQ_c78404fa-cf69-4090-8cfe-a8408b730de9"
      unitRef="investment">237</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMTk5Mg_199011f4-24cb-47fa-a949-8e7d09ab0170"
      unitRef="investment">133</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i03769550f9144c9984b85e0c5923a535_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjI0Mg_c77f48db-04f5-40b4-a9ee-7c2bc932317f"
      unitRef="usd">18100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ide7e987c180a418585f377e54ea41af1_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjMyOQ_0cf331be-ab89-4ea9-baad-9b80f1045ace"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjMyOQ_8cdffa13-7f38-4989-a393-a6c0d310fb58"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RleHRyZWdpb246YTMxM2MyZjUyOWRjNDc5ZThlMTk0ZjkyNTUxYjRmODJfMjk3Ng_85fb5aaa-cd66-43c5-9c2f-b7d6d5d83a7b">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOmJmYmE3MGU4OTA4ZDRhMjc5OGE1YjhhNmZlZjcyZWE1L3RhYmxlcmFuZ2U6YmZiYTcwZTg5MDhkNGEyNzk4YTViOGE2ZmVmNzJlYTVfMS0xLTEtMS02NjMyNg_92daa4f7-82b1-4f5f-8ece-75cc8609f03a"
      unitRef="usd">1253553000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOmJmYmE3MGU4OTA4ZDRhMjc5OGE1YjhhNmZlZjcyZWE1L3RhYmxlcmFuZ2U6YmZiYTcwZTg5MDhkNGEyNzk4YTViOGE2ZmVmNzJlYTVfMS0zLTEtMS02NjMyNg_fdb8bc97-f904-4b67-a088-4d4e286dba4e"
      unitRef="usd">1168256000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOmJmYmE3MGU4OTA4ZDRhMjc5OGE1YjhhNmZlZjcyZWE1L3RhYmxlcmFuZ2U6YmZiYTcwZTg5MDhkNGEyNzk4YTViOGE2ZmVmNzJlYTVfMi0xLTEtMS02NjMyNg_990e4f0b-8125-4448-a3fd-9586b4f737cc"
      unitRef="usd">456890000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOmJmYmE3MGU4OTA4ZDRhMjc5OGE1YjhhNmZlZjcyZWE1L3RhYmxlcmFuZ2U6YmZiYTcwZTg5MDhkNGEyNzk4YTViOGE2ZmVmNzJlYTVfMi0zLTEtMS02NjMyNg_4d72b77d-0ec1-4204-881c-d1278c94974e"
      unitRef="usd">365412000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOmJmYmE3MGU4OTA4ZDRhMjc5OGE1YjhhNmZlZjcyZWE1L3RhYmxlcmFuZ2U6YmZiYTcwZTg5MDhkNGEyNzk4YTViOGE2ZmVmNzJlYTVfMy0xLTEtMS02NjMyNg_df09c419-5c3d-49d2-820f-5bae951b28c4"
      unitRef="usd">1710443000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80My9mcmFnOmEzMTNjMmY1MjlkYzQ3OWU4ZTE5NGY5MjU1MWI0ZjgyL3RhYmxlOmJmYmE3MGU4OTA4ZDRhMjc5OGE1YjhhNmZlZjcyZWE1L3RhYmxlcmFuZ2U6YmZiYTcwZTg5MDhkNGEyNzk4YTViOGE2ZmVmNzJlYTVfMy0zLTEtMS02NjMyNg_005cf349-0aaa-4ab0-b72f-e54d3b01dc72"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMjM2MQ_5a2e6723-6701-44c7-82f7-81fd0a30c557">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Forward Foreign Currency Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we had one forward contract outstanding to sell &#x20ac;9.3&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the six months ended June 30, 2022, and 2021, we recognized $0.7&#160;million and $0.3&#160;million, respectively, of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMjM3MQ_5d95f07a-669d-43c6-9722-de19bbc8dcc0">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3c3df4ca36254ec4a53aa642de2052fd_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfMi0xLTEtMS02NjMyNg_574fca52-d516-407c-9b90-df620ede977d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b987f3b567145a39c76a99080d73be8_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfMi0zLTEtMS02NjMyNg_a5dcf1a0-ca7b-45b3-a42d-18e474b29cd3"
      unitRef="usd">880486000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie98d96a4511c47b9976557bf8ed9d3ea_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfMi01LTEtMS02NjMyNg_30949088-5039-4c3b-95fc-9aed3ea5969a"
      unitRef="usd">880486000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i56e65916b15b411381657ad58dd0a7e7_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfMy0xLTEtMS02NjMyNg_2ff3ad00-29eb-4872-b7d1-7a266e4d57d9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib4001c4a298441f39a683b1fdcf12c32_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfMy0zLTEtMS02NjMyNg_28ef8975-5a16-412f-9d6c-783222fdfe44"
      unitRef="usd">564401000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7bf40d8ebf840d0975f8df43474ebcf_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfMy01LTEtMS02NjMyNg_c4628812-c55d-48c8-9839-817783b0b17f"
      unitRef="usd">564401000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i182702258c9044e19db73717afe1ba2e_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNC0xLTEtMS02NjMyNg_6868ec4a-c23d-49f0-8563-1c9629da7a46"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib08fb62625a144fb8b5d4cbf945345e7_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNC0zLTEtMS02NjMyNg_a0b8b355-fa1d-46a6-bc3c-c395717726db"
      unitRef="usd">253408000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3322c81a75204e04b49bcd282f9082ad_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNC01LTEtMS02NjMyNg_7b08923f-1ff5-4bb3-86b0-523022f48d31"
      unitRef="usd">253408000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e2c9be6723b4ecc857b1318d9a40a7c_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNS0xLTEtMS02NjMyNg_cdfdbb92-e60f-4fce-8c8a-8978d229f84f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd3ad6acbfea40668adabc0d0ae06c0b_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNS0zLTEtMS02NjMyNg_2a792a8a-e333-4fc7-ae66-aa88891f691b"
      unitRef="usd">12148000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8bec5ac658b94646b56ba00d21fd274f_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNS01LTEtMS02NjMyNg_2e5ebc46-13f2-4843-b1bd-b91f67f94f1e"
      unitRef="usd">12148000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8fa5514df76b4a5289b9dab0ab958760_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNi0xLTEtMS02NjMyNg_b1f3aa47-3dd1-4076-9e91-b3a81760bd37"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e391b43e0914915bee3cd7d5073d918_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNi0zLTEtMS02NjMyNg_f3c08709-78f5-4790-8d05-a36f350f40fb"
      unitRef="usd">1710443000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fa7e06004bf493583d8ea1de5a444ae_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNi01LTEtMS02NjMyNg_005c88b9-68b2-4387-8beb-459f45060d8b"
      unitRef="usd">1710443000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5552036575a7423281fcbd4cb49bcea7_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNy0xLTEtMS02NjMyNg_8091d076-58c9-4a26-bfdd-736ce0774bc4"
      unitRef="usd">87821000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i80c87c83caf14e26b70ae4c672e30e2b_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNy0zLTEtMS02NjMyNg_654dbfe9-4d2c-4e78-9aca-92cb264d01ea"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4f5ca710be364f0da48207b91de352a3_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfNy01LTEtMS02NjMyNg_87ca8dc6-b25f-46c2-97a0-ad32e1baf81b"
      unitRef="usd">87821000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i51a622ef9643442a9a59c6d3cc3663f1_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfOC0xLTEtMS02NjMyNg_a6d16575-1ea9-42e0-8976-e84ec49d45a4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i619648b30df241fbb45ec26d4592f421_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfOC0zLTEtMS02NjMyNg_f8e9e66f-5db8-4485-a25b-839ccfe80d25"
      unitRef="usd">130502000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8287e312ca114e8e93490b2d88392315_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfOC01LTEtMS02NjMyNg_fd44d2bb-f5ea-439a-9b47-eb67489d9ec6"
      unitRef="usd">130502000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8fa5514df76b4a5289b9dab0ab958760_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfOS0xLTEtMS02NjMyNg_31796abe-9b91-44d0-96f3-b0758326d54f"
      unitRef="usd">87821000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0e391b43e0914915bee3cd7d5073d918_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfOS0zLTEtMS02NjMyNg_00619629-a1e7-477b-bd8c-72f054fe9d04"
      unitRef="usd">1840945000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0fa7e06004bf493583d8ea1de5a444ae_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOjhhMGI0YTFiYmIyYTQ5NzBhMGVkYmExNDUzNjZiNTkxL3RhYmxlcmFuZ2U6OGEwYjRhMWJiYjJhNDk3MGEwZWRiYTE0NTM2NmI1OTFfOS01LTEtMS02NjMyNg_d91fa70e-2178-4d60-b16a-430ee3eb9a2b"
      unitRef="usd">1928766000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a5daf776b964c24b6e400bd55663894_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfMi0xLTEtMS02NjMyNg_ad33ccd5-3a45-42e5-8140-d7c38da7baaf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec6206d802e34860b2b50b24991812bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfMi0zLTEtMS02NjMyNg_73835ee8-9465-4a9f-ba80-000d32d88a41"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i129784cda6eb4132aed1c7cf8bb7db12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfMi01LTEtMS02NjMyNg_e6da35a1-b698-4ab2-9a7b-928fcc4fe0af"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76c0e8d11fc14158ad314c1ac66746ff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfMy0xLTEtMS02NjMyNg_bba4fe1d-5c16-4d56-a1bc-76c6bd8fee93"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0cd4a3e3e3a74aebb9eec590702a773b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfMy0zLTEtMS02NjMyNg_2ed0f626-febd-432c-b2c0-d8889b080410"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46639be8a28240e1a86dea7f936b0a6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfMy01LTEtMS02NjMyNg_e798372f-a772-42a9-9e14-0aaee46d7a01"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib916c6956341489bba5b28db02a30837_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNC0xLTEtMS02NjMyNg_617f308e-13e9-4850-8c8b-80178a62d133"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79d149a9eefd4440a22b0d5b7e870327_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNC0zLTEtMS02NjMyNg_cbb7a111-9fdb-4b2d-b423-7ff53e370a09"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide4306bdd2ea4e91bb97b8be2b61b651_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNC01LTEtMS02NjMyNg_303a3bdd-2920-4122-b47b-6238706cea9a"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iba54d40c2bc64ef4bdb52d572de09fa5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNS0xLTEtMS02NjMyNg_38b4c303-097a-48f8-ade7-11ff272f9c10"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa0b629b04984a1eac7d47c831d167f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNS0zLTEtMS02NjMyNg_23ff1fe3-e044-4de9-ab33-99eee2082c29"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iefecc78bc743406c8b43fad567aad8d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNS01LTEtMS02NjMyNg_8cb6d738-0bed-4402-8ec9-de940b1d93f0"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib0696d13063a422b94ceaf169c4d5572_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNi0xLTEtMS02NjMyNg_b127a4f1-d124-4218-a1aa-d93d5e9ced13"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb1fcad1a5f14b1ead0a41c83a2d65ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNi0zLTEtMS02NjMyNg_9877d15c-8b6e-49a4-9339-a75528c8cd57"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf6cf4c54fd4471291a5a225c2026764_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNi01LTEtMS02NjMyNg_4f89f161-4ad9-4a74-bb7a-775ab007a547"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ica317fbf66054d0d9b5755dec32fb97d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNy0xLTEtMS02NjMyNg_a774ee82-4b9d-4ce6-8459-27fdedd811cf"
      unitRef="usd">66531000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icc6b02b5522f4c62b5630f7652995697_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNy0zLTEtMS02NjMyNg_6e765308-da06-4416-a357-24502ae60a78"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4f38a828dd704e21b97feddadcce5b63_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfNy01LTEtMS02NjMyNg_047b8fd0-495e-4e12-816c-4ba7063f8631"
      unitRef="usd">66531000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1aba76e7e4d6469a8ced5f3ac2c0957d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfOC0xLTEtMS02NjMyNg_403fa39e-e976-44c0-b42b-a73387ed0c7e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idb5ac02de86e497ca09eaa96e8d84aef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfOC0zLTEtMS02NjMyNg_3478a623-206c-4a8b-90a0-3ee83cb366b8"
      unitRef="usd">119056000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i419d7d0e02084f7482be6ce902493727_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfOC01LTEtMS02NjMyNg_32c7829d-b95d-4660-9cc9-e41b578fa701"
      unitRef="usd">119056000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0696d13063a422b94ceaf169c4d5572_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfOS0xLTEtMS02NjMyNg_ea120c34-7cf5-43c4-89b5-0e7b384f9fe7"
      unitRef="usd">66531000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibb1fcad1a5f14b1ead0a41c83a2d65ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfOS0zLTEtMS02NjMyNg_f1b4262e-f304-4ea5-90fc-80d913b2f099"
      unitRef="usd">1652724000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibf6cf4c54fd4471291a5a225c2026764_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RhYmxlOmUyNzVlYTM5OTg2YzQ5YzlhZTNlMmU5YWZlMjJiZTM4L3RhYmxlcmFuZ2U6ZTI3NWVhMzk5ODZjNDljOWFlM2UyZTlhZmUyMmJlMzhfOS01LTEtMS02NjMyNg_5ddd1bcc-a8b8-40d7-a9d3-da38ecf0013c"
      unitRef="usd">1719255000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i38408adaba6d4341adb12d55daf8b48e_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMTgxNg_7165d4a5-e062-42c1-9063-3586e8f2c902"
      unitRef="forward_contract">1</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i38408adaba6d4341adb12d55daf8b48e_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMTg1Ng_b95c4d89-e687-40e9-b56b-0ae92ebc000d"
      unitRef="eur">9300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="i1fe3c38bcffe44d0aa127c4b877c1d71_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMTkwMA_f3117c44-6c39-4f34-8caf-d89df1b34e43">P3M</us-gaap:DerivativeTermOfContract>
    <us-gaap:GainOnDerivativeInstrumentsPretax
      contextRef="i1fe3c38bcffe44d0aa127c4b877c1d71_D20220101-20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMjE3NQ_ab9c9443-79c1-40f9-b282-3f065ef04123"
      unitRef="usd">700000</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:GainOnDerivativeInstrumentsPretax
      contextRef="i2e8d1c4ed84a49b6b1de444247607719_D20210102-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80Ni9mcmFnOjI3ZDIwNTBlYzU2ZTQ3YmU4NDQ3NTE4YTZjYjllZTJhL3RleHRyZWdpb246MjdkMjA1MGVjNTZlNDdiZTg0NDc1MThhNmNiOWVlMmFfMjE4Mg_054f0336-411e-442e-962a-1b2ebce84a22"
      unitRef="usd">300000</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RleHRyZWdpb246N2UxNjNjMWI1ZWNkNDI5MGI2YTkwMmY2MWJmOGE2NzFfNzk_cbc90fdd-9766-49a0-8250-37a1a74494a3">INVENTORY&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RleHRyZWdpb246N2UxNjNjMWI1ZWNkNDI5MGI2YTkwMmY2MWJmOGE2NzFfODE_f03e8984-a24d-4223-9143-7c78b66c6824">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfMS0xLTEtMS02NjMyNg_f3a63dab-7c1f-49f4-8657-7babc9ff18f7"
      unitRef="usd">9760000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfMS0zLTEtMS02NjMyNg_89ff4d9f-c489-4a19-b6ab-bd299f030fe6"
      unitRef="usd">8867000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfMi0xLTEtMS02NjMyNg_1af22974-f7f9-4d5a-84f0-c806ff617db1"
      unitRef="usd">35233000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfMi0zLTEtMS02NjMyNg_fe88a52b-ac39-49d4-96fc-09b1ce3051b6"
      unitRef="usd">27717000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfMy0xLTEtMS02NjMyNg_93f8cc23-69f4-4bb8-b2f7-41eff0dcebf8"
      unitRef="usd">13371000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfMy0zLTEtMS02NjMyNg_b26787a5-0eed-4a61-8e08-5229a224b83a"
      unitRef="usd">12927000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfNC0xLTEtMS02NjMyNg_d09bf265-abff-4d5b-a0a3-602b64a9a716"
      unitRef="usd">58364000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfNC0zLTEtMS02NjMyNg_99e996f8-9c97-4978-aaac-bf4ac9a08659"
      unitRef="usd">49511000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i214511920f1a4c718201e79910fec792_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfNy0xLTEtMS02NjMyNg_d8a39321-5094-4840-8b60-662c936d409c"
      unitRef="usd">33020000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i4f26547ff011485ea499fc7321085b2a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfNy0zLTEtMS02NjMyNg_678298c8-4c3b-49c3-9e76-1014908dd9f8"
      unitRef="usd">27493000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i401482ee2371429dbb52062b06e78cf4_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfOC0xLTEtMS02NjMyNg_ef8a3ebf-dd78-4bae-99b7-8b5c9c4a3050"
      unitRef="usd">25344000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i62d04e4f28a941478b345f54d2cb7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfOC0zLTEtMS02NjMyNg_80d03c08-3335-4e7c-b636-acbf6b200fc4"
      unitRef="usd">22018000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i62d04e4f28a941478b345f54d2cb7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfOC0zLTEtMS02NjMyNg_9e577fc5-ac06-4671-b098-e988d8e6857a"
      unitRef="usd">22018000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfOS0xLTEtMS02NjMyNg_4dbbb592-bc30-4341-96ae-0d6549c6d33a"
      unitRef="usd">58364000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ibd88d103ffe54da794c385cd93721ee7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl80OS9mcmFnOjdlMTYzYzFiNWVjZDQyOTBiNmE5MDJmNjFiZjhhNjcxL3RhYmxlOmY5ZTcxNGNmZjBkYjQwZjhiN2IxYmJiZWZlYzliMDFhL3RhYmxlcmFuZ2U6ZjllNzE0Y2ZmMGRiNDBmOGI3YjFiYmJlZmVjOWIwMWFfOS0zLTEtMS02NjMyNg_adf0a59c-7234-4823-8701-701dc3d625a8"
      unitRef="usd">49511000</us-gaap:InventoryGross>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMzQ1Mw_540c8d2e-ef12-40b9-bd30-b203c7057aaf">STOCK-BASED COMPENSATION&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 25, 2022, at the 2022 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The amendment and restatement increased the share reserve under the 2017 Plan by 28,500,000 shares. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022, 31,687,133 sh&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan. The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 2 shares for full value awards, including restricted stock units (RSUs).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2022, we granted 587,762 stock options with a weighted average exercise price of $19.99 per share and a weighted average grant&#160;date fair&#160;value of $8.36&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hare. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were 12,307,775 stock options outstanding and $23.6&#160;million of related unrecognized compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, we awarded to certain employees an aggregate of 1,003,482 (the target amount) RSUs that are subject to a total shareholder return (TSR) market condition (the TSR-based RSUs). The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 1, 2022 through January 3, 2025. Depending on the results relative to the TSR market condition, the holders of the TSR-based RSUs may earn up to 175% of the target amount of shares. 50% of the shares earned pursuant to the TSR-based RSU awards will vest at the end of the performance period, and the remainder will vest approximately one year later, subject to employee&#x2019;s continuous service. These TSR-based RSUs will be forfeited if the market condition at or above a threshold level is not achieved at the end of the performance period on January 3, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the TSR-based RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#x2019;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2022, we granted 4,585,618 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $20.64 per share. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were 11,496,162 RSUs outstanding, including the TSR-based RSUs, and $207.2&#160;million of related unrecognized compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options and service-based RSUs granted to employees during the six months ended June 30, 2022 have vesting conditions and contractual lives of a similar nature to those described in &#x201c;Note 8. Employee Benefit Plans&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were&#160;5,662,157 performance-based restricted stock units (PSUs) outstanding and $113.5&#160;million of related unrecognized stock-based compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. For more information about our PSUs, see &#x201c;Note 8. Employee Benefit Plans&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMzQ0MA_a4f48c62-74ea-4378-965c-a7dd6cac7c1f">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic8c8787ab89e4ea8aa9bcbba33a74fb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfMy0xLTEtMS02NjMyNg_f5d20ec7-14aa-4af6-aac1-e4413b761615"
      unitRef="usd">9549000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaeeca34bdde8405b8c686e83477e4f42_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfMy0zLTEtMS02NjMyNg_58adf20c-a926-4526-aa77-3193c35ce3cb"
      unitRef="usd">13667000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id5abd3b9738c4a48916938c34311867c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfMy01LTEtMS02NjMyNg_f0fcefe1-9881-49ac-9a48-3888da02af26"
      unitRef="usd">18448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if1b0173c487e4563b2a6777d58f46013_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfMy03LTEtMS02NjMyNg_15cda061-1b89-4ce2-90bb-e2bd4347f012"
      unitRef="usd">26063000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96a7e658a6084f529242281c7bcea519_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNC0xLTEtMS02NjMyNg_4693c7f3-1090-45f7-b0c4-0d0e2af54c3f"
      unitRef="usd">15073000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if900f76b28c94ec78c9965e91ee8f0b6_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNC0zLTEtMS02NjMyNg_5af37e10-de76-4416-a18d-686c839aa6b4"
      unitRef="usd">14368000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iadffddf5c5c64493b3fa047c4ed4f265_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNC01LTEtMS02NjMyNg_30a8f525-d9bf-4fa3-9c53-41e8d5db94d9"
      unitRef="usd">25933000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia2bf0f43bb254fcb95413ba3a8c9c810_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNC03LTEtMS02NjMyNg_e1241553-c7f8-4682-b699-fae5303ba9cf"
      unitRef="usd">36625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNS0xLTEtMS02NjMyNg_3d062357-a0bd-4899-930c-97de234b2830"
      unitRef="usd">24622000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNS0zLTEtMS02NjMyNg_d1072ccc-9145-4c9a-8374-f6dcdb843a92"
      unitRef="usd">28035000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNS01LTEtMS02NjMyNg_2da3bee2-1545-43ac-ab74-4ee899cd33b5"
      unitRef="usd">44381000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjRiMmY4ZWRhZDM0MzRjMmJhNWY3MWUxNDE3ZTA0OTRmL3RhYmxlcmFuZ2U6NGIyZjhlZGFkMzQzNGMyYmE1ZjcxZTE0MTdlMDQ5NGZfNS03LTEtMS02NjMyNg_556bc1ba-f83e-4181-93f4-71b14b157cb8"
      unitRef="usd">62688000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7cb92aaea0154533ae9a350686b93d27_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMi0xLTEtMS02NjMyNg_01ed3d8e-24dd-439d-b712-fb650f3d2555"
      unitRef="usd">3493000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia82d6aff031447fab7f99cce91ae6db8_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMi0zLTEtMS02NjMyNg_837b43a7-c00b-43b7-b2e0-1b51e5d9aef4"
      unitRef="usd">5902000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if6524855f344408b90f428815d3ed343_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMi01LTEtMS02NjMyNg_5d4a57bb-ec04-4f9b-983d-baa22f686778"
      unitRef="usd">7171000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i57d61f3143c347f0bff85037bb757393_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMi03LTEtMS02NjMyNg_aadc7edb-43a6-4140-91e3-235fa7896655"
      unitRef="usd">10596000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i826763d3077e4ad086c22a3ff19ad208_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMy0xLTEtMS02NjMyNg_577a1e62-ab36-4238-ad5b-0854d56df957"
      unitRef="usd">18928000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2b7e89015a804623990353f662f9a155_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMy0zLTEtMS02NjMyNg_d6464aa6-d9d4-4c80-9882-4a9c6194b82d"
      unitRef="usd">15412000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i288c55ead7e941548dc6ee322e4a325c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMy01LTEtMS02NjMyNg_6a2688d2-ed41-480b-a64c-1923d368057b"
      unitRef="usd">32001000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iecb5bc2ce4804674ab1ceb6b7109a08b_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfMy03LTEtMS02NjMyNg_a3d42d5c-d2d3-4604-8ad5-2ffc19ed1bde"
      unitRef="usd">27081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9ed4735334c844459ed18dbd61c6c4f6_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNC0xLTEtMS02NjMyNg_544d18a8-c1d8-4854-bffe-74fee7c91a11"
      unitRef="usd">1581000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i98ccdd8a412d41abbfac65334e30283c_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNC0zLTEtMS02NjMyNg_53d013aa-dba8-489f-b457-e0efdc3de1d5"
      unitRef="usd">4698000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2768e53f82974b9da558e84e64b5d621_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNC01LTEtMS02NjMyNg_5fc99d67-0609-4a17-b1e6-fba487c1a76c"
      unitRef="usd">3290000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0034b83355444c65ad6e185cc7ccd058_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNC03LTEtMS02NjMyNg_684d0c3f-4868-48e1-9af7-eb355ec3d31a"
      unitRef="usd">22645000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifd650bcd87a349d786cbed15f8f31bd4_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNS0xLTEtMS02NjMyNg_3ae455e4-f44e-4316-a2b1-b000371d9034"
      unitRef="usd">620000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2669fd364d81445786658c8dc9193396_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNS0zLTEtMS02NjMyNg_272fd47e-e274-4094-9460-5accf1594472"
      unitRef="usd">2023000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i799167078ab64d6d8c88a06ba5578ea4_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNS01LTEtMS02NjMyNg_b70e2586-6c3d-4f7d-96c8-14fc7958de6a"
      unitRef="usd">1919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i847152b60ebc49c7a64cb3e47896adc8_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNS03LTEtMS02NjMyNg_8ebfc8a4-0c78-4bfc-85cd-17b8000205f6"
      unitRef="usd">2366000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNi0xLTEtMS02NjMyNg_b649521c-fc0d-4b67-9cc3-477f837b7956"
      unitRef="usd">24622000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNi0zLTEtMS02NjMyNg_708be835-959f-4134-9eaf-1b0acc82f5b8"
      unitRef="usd">28035000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNi01LTEtMS02NjMyNg_565a92e2-5d10-44d3-a090-75cce951512c"
      unitRef="usd">44381000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg3NjIzNWRhYmJjYzQyODBiNDJmYmNmOGFiNzJkMjM2L3RhYmxlcmFuZ2U6ODc2MjM1ZGFiYmNjNDI4MGI0MmZiY2Y4YWI3MmQyMzZfNi03LTEtMS02NjMyNg_d3c62c60-da5e-475d-bc57-e24691390f5f"
      unitRef="usd">62688000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i18d5c27ec4b94608b6a47b96f6900355_D20220525-20220525"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfOTM0NTg0ODg0MjIxMA_1c191912-2842-4c17-8f43-42138f5c3589"
      unitRef="shares">28500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTIyNA_ad8eb50d-ea47-4e29-82a7-fc29951d7e4a"
      unitRef="shares">31687133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNDg3_78fd4182-5bbd-4b21-9a4c-afcf73988bcd"
      unitRef="shares">1</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNTQ5_b19d4c2e-703e-44a3-ba77-61b59039a8c0"
      unitRef="shares">2</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTEwNw_f06496d7-58cf-47b9-a293-1386313fb910"
      unitRef="shares">587762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTA4Mw_4361a151-fffc-4c6b-a9c1-f0932e0b6569"
      unitRef="usdPerShare">19.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTExNg_5f0af3b0-8c94-4861-b560-a8214ca06e9b"
      unitRef="usdPerShare">8.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTEyNA_8f0100b8-ae1f-4348-8b28-4e77121e099a"
      unitRef="shares">12307775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="idbb94681ddb446c8ad4b6102bf4f52d2_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTA5Mg_6bfddceb-5ee0-4202-963c-511deb15295e"
      unitRef="usd">23600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i140a87f9739042bb9715f01f144db770_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfOTYy_960a88f9-44d3-4b79-83e0-b050f331c948"
      unitRef="shares">1003482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i140a87f9739042bb9715f01f144db770_D20220301-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMTQwMQ_23c6c6e0-582b-41ec-9e4f-1f3062e53899"
      unitRef="number">1.75</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8b79f2ddeb834dada1c18e98a6a85c1b_D20220301-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMTQzNg_c6cdf530-0e3b-4e3d-bb53-bec259eb30f9"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8b79f2ddeb834dada1c18e98a6a85c1b_D20220301-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMTU4Nw_c63a4201-f255-4e3a-bebc-a6083044a1af">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMzQ2NA_213f8a93-27f0-4e1a-a96d-72097e88f9a6">We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the TSR-based RSUs:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i79b56428e2684493a912b70ba5c56f75_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfMTkxNw_a90a492d-49ea-4392-a264-30206d11466f"
      unitRef="usdPerShare">33.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharePrice
      contextRef="i73a59494ab85495e95f7a35120b582a9_I20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg5ZWQ2MjFhMzc3OTQ1M2E5ZWE5ZDE5MjcwNWQzYTIyL3RhYmxlcmFuZ2U6ODllZDYyMWEzNzc5NDUzYTllYTlkMTkyNzA1ZDNhMjJfMC0xLTEtMS02NjMyNg_11a3e7bf-53b6-4a74-8006-492c066ee2e9"
      unitRef="usdPerShare">20.70</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i79b56428e2684493a912b70ba5c56f75_D20220101-20220701"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg5ZWQ2MjFhMzc3OTQ1M2E5ZWE5ZDE5MjcwNWQzYTIyL3RhYmxlcmFuZ2U6ODllZDYyMWEzNzc5NDUzYTllYTlkMTkyNzA1ZDNhMjJfMS0xLTEtMS02NjMyNg_fe22f684-9fcb-4d99-9f04-5c13629e48df"
      unitRef="number">0.4685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i79b56428e2684493a912b70ba5c56f75_D20220101-20220701"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg5ZWQ2MjFhMzc3OTQ1M2E5ZWE5ZDE5MjcwNWQzYTIyL3RhYmxlcmFuZ2U6ODllZDYyMWEzNzc5NDUzYTllYTlkMTkyNzA1ZDNhMjJfMi0xLTEtMS02NjMyNg_efc43a36-9de3-4b27-9b21-bcc6861348ae"
      unitRef="number">0.0159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i79b56428e2684493a912b70ba5c56f75_D20220101-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RhYmxlOjg5ZWQ2MjFhMzc3OTQ1M2E5ZWE5ZDE5MjcwNWQzYTIyL3RhYmxlcmFuZ2U6ODllZDYyMWEzNzc5NDUzYTllYTlkMTkyNzA1ZDNhMjJfMy0xLTEtMS02NjMyNg_f69d2d41-5d38-465c-a9e2-29f236903c56"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i288c55ead7e941548dc6ee322e4a325c_D20220101-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTEzNg_117e615c-2b58-4d8e-91ef-1921a8fe1dcb"
      unitRef="shares">4585618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i288c55ead7e941548dc6ee322e4a325c_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTE3NQ_f169d473-5936-44cf-bb90-e0b6c5ff5281"
      unitRef="usdPerShare">20.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie20c1bc9723141ceb9391ded30c724c2_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTE0Nw_a75c2b87-84ea-4c79-826d-5866b39c4c43"
      unitRef="shares">11496162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ie20c1bc9723141ceb9391ded30c724c2_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTE1OQ_5ea3b95d-eb23-4a89-b2cb-d8c208278cac"
      unitRef="usd">207200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i243680f68f274834b859ce0d17c3e93f_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTE4Mw_828c54ca-79c1-4e3f-ac37-7ff76b2bde9f"
      unitRef="shares">5662157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i243680f68f274834b859ce0d17c3e93f_I20220701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81Mi9mcmFnOjZlNTdkYmFhZDk3MjQ0YTg5NTQ0M2M5NjEwZTMxYzY1L3RleHRyZWdpb246NmU1N2RiYWFkOTcyNDRhODk1NDQzYzk2MTBlMzFjNjVfNjA0NzMxMzk1OTE5NA_877a8332-d516-4437-9411-57be11d22edf"
      unitRef="usd">113500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81NS9mcmFnOjFkMjcwZjFkOTI5NDRhZjhiYThlOTAxYTNjNzI3ODNhL3RleHRyZWdpb246MWQyNzBmMWQ5Mjk0NGFmOGJhOGU5MDFhM2M3Mjc4M2FfNTcy_0adc98a9-b85b-4fab-9a0e-e86380e2b67f">PROVISION FOR INCOME TAXESThe effective tax rate for the three and six months ended June&#160;30, 2022 were 20.2% and 19.9% respectively, as compared to 23.1% and 20.5% for the corresponding periods 2021. The effective tax rate for the three and six months ended June 30, 2022 and June 30, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, which were partially offset by state taxes</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81NS9mcmFnOjFkMjcwZjFkOTI5NDRhZjhiYThlOTAxYTNjNzI3ODNhL3RleHRyZWdpb246MWQyNzBmMWQ5Mjk0NGFmOGJhOGU5MDFhM2M3Mjc4M2FfNjA0NzMxMzk1Mzc1MA_e5a269ac-acf7-4528-a4a6-9b10f4f61099"
      unitRef="number">0.202</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81NS9mcmFnOjFkMjcwZjFkOTI5NDRhZjhiYThlOTAxYTNjNzI3ODNhL3RleHRyZWdpb246MWQyNzBmMWQ5Mjk0NGFmOGJhOGU5MDFhM2M3Mjc4M2FfNjA0NzMxMzk1Mzc1Nw_e17ae4d4-e448-43bf-a000-cb8e0148cbd6"
      unitRef="number">0.199</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81NS9mcmFnOjFkMjcwZjFkOTI5NDRhZjhiYThlOTAxYTNjNzI3ODNhL3RleHRyZWdpb246MWQyNzBmMWQ5Mjk0NGFmOGJhOGU5MDFhM2M3Mjc4M2FfNjA0NzMxMzk1Mzc2NA_1ec79055-b0f0-4358-81aa-6ede95d72eca"
      unitRef="number">0.231</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81NS9mcmFnOjFkMjcwZjFkOTI5NDRhZjhiYThlOTAxYTNjNzI3ODNhL3RleHRyZWdpb246MWQyNzBmMWQ5Mjk0NGFmOGJhOGU5MDFhM2M3Mjc4M2FfNjA0NzMxMzk1NDE5OA_a03b99e1-dfa2-4328-8cd7-a2b149601b30"
      unitRef="number">0.205</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RleHRyZWdpb246ZWMwM2YxYzY4YTg2NDliOGJiYzJmMDIwMmMyYzhkZDZfNzU4_161e9d94-baac-49ad-b02b-09f66c8d02f2">NET INCOME PER SHARE&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities included outstanding stock options, unvested RSUs, including TSR-based RSUs, PSUs and ESPP contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RleHRyZWdpb246ZWMwM2YxYzY4YTg2NDliOGJiYzJmMDIwMmMyYzhkZDZfNzM3_af2bb77d-413a-45e7-9ea7-c34a25c059f6">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy0xLTEtMS02NjMyNg_881b3da1-ebb2-49c6-9707-9599cab693d2"
      unitRef="usd">70672000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy0xLTEtMS02NjMyNg_8b77dadc-542d-4dc3-b017-3b6f2aad1164"
      unitRef="usd">70672000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy0zLTEtMS02NjMyNg_6908009b-b2da-4422-bc27-444441551caa"
      unitRef="usd">96092000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy0zLTEtMS02NjMyNg_be7a7ce8-a249-4657-8acc-88ad1a987b10"
      unitRef="usd">96092000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy01LTEtMS02NjMyNg_8c92ec01-6ee3-4f85-b5ff-54ecac9ea976"
      unitRef="usd">139245000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy01LTEtMS02NjMyNg_9111fb56-e88d-4a24-b99a-f359b2e1da02"
      unitRef="usd">139245000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy03LTEtMS02NjMyNg_3a27da23-12bd-47d0-a386-7db7a7366258"
      unitRef="usd">97693000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMy03LTEtMS02NjMyNg_91e8988d-0d07-48ba-9a18-942768747cc9"
      unitRef="usd">97693000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNS0xLTEtMS02NjMyNg_3bbc6ab2-4163-4267-84bd-fd362adf9742"
      unitRef="shares">321117000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNS0zLTEtMS02NjMyNg_03cec34f-f2f0-4c05-a74a-845c05870899"
      unitRef="shares">314117000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNS01LTEtMS02NjMyNg_61c237a4-71dc-4217-9549-f6d7dc38c8c9"
      unitRef="shares">320349000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNS03LTEtMS02NjMyNg_0b0bc54c-c39c-4f04-a0fd-f422dc3294cf"
      unitRef="shares">313295000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNi0xLTEtMS02NjMyNg_bd290fb1-1404-4fd4-8df8-03c0278f8ad7"
      unitRef="shares">3787000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNi0zLTEtMS02NjMyNg_f4849350-91a5-4391-b2fb-5e71d810b3ea"
      unitRef="shares">8824000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNi01LTEtMS02NjMyNg_1edd98b5-a1ff-4e1d-bcfb-d8b9b833b147"
      unitRef="shares">3747000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNi03LTEtMS02NjMyNg_ecdc74e3-6f14-4990-a35f-da4029074148"
      unitRef="shares">8819000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNy0xLTEtMS02NjMyNg_64f66061-30c5-43fc-9f9e-8c42bc7db708"
      unitRef="shares">324904000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNy0zLTEtMS02NjMyNg_10185306-4704-4c24-a40a-a2ba63316601"
      unitRef="shares">322941000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNy01LTEtMS02NjMyNg_a6e31f3d-09a7-4b0c-a18e-b1d7b809a93e"
      unitRef="shares">324096000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfNy03LTEtMS02NjMyNg_a396b780-bbde-47fc-92bd-2b34714c99b3"
      unitRef="shares">322114000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfOS0xLTEtMS02NjMyNg_d49676ef-cd91-499c-8cdf-e3f9fee6b6c0"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfOS0zLTEtMS02NjMyNg_23662b5e-28db-4af9-adab-e6919dc2dac0"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfOS01LTEtMS02NjMyNg_438ba54a-127e-4165-bb5b-7100b8b8862b"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfOS03LTEtMS02NjMyNg_e93ffded-50dc-4745-8fb5-680ca55aff4e"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMTAtMS0xLTEtNjYzMjY_35833eaa-6771-441e-9311-6d4b47888a58"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1d983326f02745b09c73cbb715a9a6af_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMTAtMy0xLTEtNjYzMjY_ec10cefd-d609-4a17-852e-558abf511554"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMTAtNS0xLTEtNjYzMjY_29a0e004-045a-424f-838d-1d382d7706a0"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i517d672bf59a4aedace76cb5f7416a17_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjZhY2EyNWI3NWFkMDQzMzE4ZjJhZWJjMGVmNzg0N2E2L3RhYmxlcmFuZ2U6NmFjYTI1Yjc1YWQwNDMzMThmMmFlYmMwZWY3ODQ3YTZfMTAtNy0xLTEtNjYzMjY_777cf0f7-8213-4462-a253-f6b8104c5130"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RleHRyZWdpb246ZWMwM2YxYzY4YTg2NDliOGJiYzJmMDIwMmMyYzhkZDZfNzQ5_6227d32b-038f-4425-988f-f526bdf1a3a7">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie5128decae384f698a9ab00463cbd990_D20220402-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjIzN2I0NTNjN2NmMDRlYjBiMTliN2UzMjYwNjk1OWNlL3RhYmxlcmFuZ2U6MjM3YjQ1M2M3Y2YwNGViMGIxOWI3ZTMyNjA2OTU5Y2VfMi0xLTEtMS02NjMyNg_7295643b-4484-4b41-97a7-f93475a92fec"
      unitRef="shares">14350000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3d22c0ab1ce2424b9a59efba14386e0e_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjIzN2I0NTNjN2NmMDRlYjBiMTliN2UzMjYwNjk1OWNlL3RhYmxlcmFuZ2U6MjM3YjQ1M2M3Y2YwNGViMGIxOWI3ZTMyNjA2OTU5Y2VfMi0zLTEtMS02NjMyNg_7d01f985-d1fa-481d-b5cd-c584453262e5"
      unitRef="shares">12285000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i25b873c8ba6a4c4f960fbb64be80b871_D20220101-20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjIzN2I0NTNjN2NmMDRlYjBiMTliN2UzMjYwNjk1OWNlL3RhYmxlcmFuZ2U6MjM3YjQ1M2M3Y2YwNGViMGIxOWI3ZTMyNjA2OTU5Y2VfMi01LTEtMS02NjMyNg_e052c378-7bb7-40c1-96d9-7affdd3df261"
      unitRef="shares">15436000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i985d03e626eb4a299ec7d942d6a3e0fc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl81OC9mcmFnOmVjMDNmMWM2OGE4NjQ5YjhiYmMyZjAyMDJjMmM4ZGQ2L3RhYmxlOjIzN2I0NTNjN2NmMDRlYjBiMTliN2UzMjYwNjk1OWNlL3RhYmxlcmFuZ2U6MjM3YjQ1M2M3Y2YwNGViMGIxOWI3ZTMyNjA2OTU5Y2VfMi03LTEtMS02NjMyNg_b8d5dc1a-79ea-4488-9d5b-e4b5201de21a"
      unitRef="shares">11146000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i1e85cf3adc3143168c5871013115016c_D20220101-20220701"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfODk2Ng_2fd64099-7150-4900-9a39-aaf23578706b">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Build-to-Suit Lease and Headquarters Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, the office building (New Premises) associated with our October 2019 build-to-suit lease agreement (Build-to-Suit Lease) was substantially completed. The New Premises is 220,517 square feet and is in Alameda, California, adjacent to our existing corporate headquarters. The Build-to-Suit Lease term is 242 months, includes two five-year options to extend the term of the lease and a one-time option to terminate the lease after 180 months. In addition to the monthly lease payments, currently estimated at $0.7&#160;million, subject to an annual increase of 3% during the Term, we are also responsible for paying operating expenses related to the New Premises. On April 15, 2022, the lease commenced for the New Premises. We determined the classification of the lease was an operating lease. Upon commencement of the lease, we recognized a right-of-use asset of $160.9&#160;million inclusive of $44.9&#160;million for the cost of the tenant improvements in excess of the allowance provided by the lessor and an operating lease liability of $116.0&#160;million discounted over 180 months using our estimated incremental borrowing rate of 4.9%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, we entered into the seventh amendment to the lease for our corporate headquarters located on Harbor Bay Parkway, Alameda, California (the Alameda Lease). The May 2022 amendment to the Alameda Lease (the Seventh Lease Amendment) provides, among other things, for the expansion of the premises under the Alameda Lease by 34,745 square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Expansion Space). The term for the 1751 Expansion Space will run coterminous with the term of the Alameda Lease for the existing space. In connection with the Seventh Lease Amendment, we remeasured our lease components under the Alameda Lease relating to the existing premises using an incremental borrowing rate of 5.0%. As of June 1, 2022, we have taken possession of the 1751 Expansion Space, and accordingly we have adjusted our right-of-use asset and liability by $4.3&#160;million.&lt;br/&gt;&lt;br/&gt;For more information about our Leases, see &#x201c;Note 11. Commitments and Contingencies&#x2014;Leases&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#x2019;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#x2019;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#x2019;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#x2019;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#x2019;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. These two lawsuits, numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#x2019;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#x2019;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#x2019;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#x2019;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties have narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN has, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claims 1 and 2 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial occurred in May 2022, and a judgment is expected during the third or fourth quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the February 2022 MSN ANDA Complaint) arising from MSN&#x2019;s further amendment of its ANDA filing with the FDA. In the February 2022 MSN ANDA Complaint, we are seeking, among other remedies, equitable relief enjoining MSN from infringing these patents, as well as an order that the effective date of any FDA approval of MSN&#x2019;s ANDA would be a date no earlier than the expiration of the patents identified in the February 2022 MSN ANDA Complaint, the latest of which expires on January 15, 2030. The February 2022 MSN ANDA Complaint is a new case, numbered Civil Action No. 22-00228, against MSN involving Exelixis patents that are different from those asserted in the consolidated Civil Action Nos. 19-02017 and 20-00633 described above. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patents No. 11,091,439, 11,091,440 and 11,098,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are invalid and not infringed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#x2019;s submission of its ANDA constitutes infringement of certain claims relating to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if those claims are not found to be invalid, and (ii) upon approval, MSN&#x2019;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#x2019;s ANDA product prior to the expiration of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; would also infringe certain claims of each patent, if those claims are not found to be invalid. A bench trial in connection with the February 2022 MSN ANDA Complaint has been scheduled for May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#x2019;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,298,349 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(pharmaceutical composition). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 (the July 2022 MSN ANDA Complaint) arising from MSN&#x2019;s further amendment of its ANDA Filing with the FDA. In the July 2022 MSN ANDA Complaint, we are seeking, among other remedies, equitable relief enjoining MSN from infringing this patent, as well as an order that the effective date of any FDA approval of MSN&#x2019;s ANDA would be a date no earlier than the expiration of the patent identified in the July 2022 MSN ANDA Complaint, which expires on February 10, 2032. The July 2022 MSN ANDA Complaint is a new case against MSN involving an Exelixis patent that is different from those asserted in the consolidated Civil Action Nos. 19-02017, 20-00633 and 22-00228 described above. MSN&#x2019;s response to the complaint is due on August 9, 2022. A trial has not yet been scheduled in connection with the July 2022 MSN ANDA Complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#x2019;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#x2019;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Teva Pharmaceutical Industries Limited (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Teva Parent), asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#x2019;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#x2019;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from infringing these patents. On February 8, 2022, the parties filed a stipulation to stay all proceedings, which was granted by the Delaware District Court on February 9, 2022. On February 11, 2022, this case was administratively closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#x2019;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,298,349 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(pharmaceutical composition). We have 45 days from the receipt of the July 29, 2022 notice to file a patent infringement claim against Teva relating to the newly challenged patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i88887d64754a4f1ebb805302f47aa477_I20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTU2NA_858aadc0-eefd-42fd-8b29-12a85d2f71af"
      unitRef="sqft">220517</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i88887d64754a4f1ebb805302f47aa477_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTU3Mg_fe61f3da-74c3-42f7-a6e1-067d83329d0d">P242M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <exel:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i69d48eac98d64f5887fc5c912672b993_D20220402-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTU5NQ_b8c3d0d5-bd9b-4300-928a-f64dd31bd687"
      unitRef="segment">2</exel:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i88887d64754a4f1ebb805302f47aa477_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNzY5NjU4MTQxMzk4MQ_eb130e80-20b9-4a2f-a9c9-1d4985e6ab80">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod
      contextRef="i69d48eac98d64f5887fc5c912672b993_D20220402-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTU3Mw_b03eb977-a6bb-4c0b-8abf-7210aa8bcfea">P180M</exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment
      contextRef="i69d48eac98d64f5887fc5c912672b993_D20220402-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTU3OQ_d29ac847-26e5-47a5-8a04-5f0d4fb11169"
      unitRef="usd">700000</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage
      contextRef="i69d48eac98d64f5887fc5c912672b993_D20220402-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTU3NQ_413a1595-9699-484e-a692-9ffaf498bbdc"
      unitRef="number">0.03</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ieeb8ed4d7cb445b08584aace5ff56694_I20220415"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNjA0NzMxMzk3MjQxMQ_4bd40645-ffff-417b-ba50-a837c2d1de98"
      unitRef="usd">160900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:TenantImprovements
      contextRef="ieeb8ed4d7cb445b08584aace5ff56694_I20220415"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNjA0NzMxMzk3MjQ0Mg_a57ab080-7e5f-46a7-9a66-02c0748ee308"
      unitRef="usd">44900000</us-gaap:TenantImprovements>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="ieeb8ed4d7cb445b08584aace5ff56694_I20220415"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNjA0NzMxMzk3MjQ3Nw_527fe8cf-03f6-438c-8a30-e73c13ca9036"
      unitRef="usd">116000000</exel:TenantLeaseImprovementsAllowance>
    <exel:OperatingLeaseLiabilityDiscountedPeriod
      contextRef="i95b2c08d83814c348966a2366c0de8a7_D20220415-20220415"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTg0Mw_899c8812-b7e3-47ad-aba7-7898abf61343">P180M</exel:OperatingLeaseLiabilityDiscountedPeriod>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ieeb8ed4d7cb445b08584aace5ff56694_I20220415"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg1NTYzMA_9a4d5853-0786-4318-b457-a608ee14d818"
      unitRef="number">0.049</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ia8db2258b7ae45a995b0f68fabdcd327_I20220531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNzE0NjgyNTYwMzc5NQ_cd07013f-133c-4ed3-827a-3d7ea597f1b4"
      unitRef="sqft">34745</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia312fa6ca0df4ee1be126a7eea55f36f_I20220531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNjA0NzMxMzk3NTU4MQ_2cc4164d-1e04-4e42-a848-85c849a8b7c3"
      unitRef="number">0.050</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib2c7ef7fab7345ebadb2ed3327f9af7d_I20220601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfNjA0NzMxMzk3NTU2Nw_01a8f2e7-5178-43ae-a5c0-d576df5c1ffe"
      unitRef="usd">4300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <exel:LossContingencyNumberOfLawsuitsConsolidated
      contextRef="i188a4a13c6094e2e882585005f7bcf76_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg2Mjc2Nw_980a7e62-3a03-4e5c-ac55-6da4cc9a95ec"
      unitRef="lawsuit">2</exel:LossContingencyNumberOfLawsuitsConsolidated>
    <exel:LossContingencyNumberOfDaysToFilePatentInfringementClaim
      contextRef="ia392f18685aa4066aa68046de26c42a7_D20220729-20220729"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4MTg5NmYxYmJlYzQzZDQ4MDJkY2MxYzVmYTJlMGUyL3NlYzpjODE4OTZmMWJiZWM0M2Q0ODAyZGNjMWM1ZmEyZTBlMl82MS9mcmFnOmU3MjEyNDc2NjBjOTQ1ZGM4YWIxODk4MDFiNTczN2Q0L3RleHRyZWdpb246ZTcyMTI0NzY2MGM5NDVkYzhhYjE4OTgwMWI1NzM3ZDRfOTM0NTg0ODg2Mjc1Mg_e8efba3e-e0f5-454c-b055-734e21c83cdc">P45D</exel:LossContingencyNumberOfDaysToFilePatentInfringementClaim>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M,RUI'48(%TX(F[W,:]*\#T\%?_8C5Y]GLZ8SUH+688]PX8^PV=6\!IWR6-(
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M93%*2#X#Z9(C41JE;ICY 68>A/D';Q^>=89R>RD3DF5SF+8821%"V(T2P8F
MX)DPT#6)4)_[[3=9:6^0>H_2:.UDN6 6XSE<IUP$"?+@/2),%,1[Q[9,;WT)
M%/TT[KX?++)!()+'\_SDE$-)XCEA:*(W%&24]2^<ET]573O!86O2A"19-,=V
M3NP4VL1&*$Q';_J37A^BU'^01D.GZ2=/C]+WB-260P1!Z O1B8Y0F(^&$Q\
M:/,+SC(406LM'8()2C#Q$"::J C%SRIDZHINJKI2%7-7,RA(:5];SGPK:Z=.
M3\2&PLSVJBAXI[,:V-//AH"=#MO<I:D_M4Z@@^(B?'103R%.'(?")*<ABDXG
MBX(WAN7H<'?1F6[#6K:M//%D\U:"HGC.RDZQW%=\H8G?4)C@#ICUBZK0D:]$
MI?\>A983M,UC:9)&%FB'6!I'OG0RL1T*T]T[MM$WEZ&(V#(]*#L&%!_O4$RX
M,3NXCZ2YE5@<W$=2Z*DC\$1].$Q]4W#4-=UP,43'F77&-K'A7!>S,\P.L2S1
MQ8\'\T1_.$Q_;TX*M'-8;5Y+<9S,#Y]#+"8D23Q8CRYW8?8[K=3.8;5YCL H
MQO.:TB5'TCCW1<-$B#A,B%/!MM?7'Q,)?&LZ$D.U(9BNXCL/=)OX4@SG%9%#
M*DM]S(,G<L1A<G3"-B6=CN;V =2,2G9V[6U>1 F"R'+!EHL13CT$CR?VQ.&;
MW+P6.0?7OJ@AO9+SM.$0RR#VG<")]7"8]8:H/@?1YK,HARB:5R0N.1@GV)./
M\41\.$Q\M[QIJN'2,30=>&OB@;6%#W'0GKN6 ,X>R_\W=.KS1)PX"Q9A]XH7
M'W>\+C7=_-#?993STHV#_/O5/:5O9.W4Z8EX<9AX]35^3%'2N+\$+^ EA$C7
M9 (\TKIC2X#@$D((Y(X*P]"=VG%1_:LU3&"T_,N+2DK-ALX%LPG8XKN0R&F_
M;.)G$N9G$\,ZGWG\>@DBZ''LY>C+T-+HE%1ZH*/_"A",EIE6,2\(RI99A %5
MX/>N9<.>$#CT1I>]R!TK6+-A8GPW-CZ7F@WDGO4=\-H98<1F?X+Q;,E<0LC#
M!V0J$$BX0'A5EI6A 9VC3'OGHFI!0?>5SEE.H#;UXRA-$4KG8%V".(T3SX6>
M3%4""5<)N@KKFJ[N^]YC^TD7ZX+MS,>*1\U=7+I;I'8A<)'E-G"'6.J[6)"C
M9FZX6CA&K8N$JJB<'0ABD_Y%FN+$B@6''$9)##U=*#+5!^0YEV?YS-1('#=D
MDB.<6)UGAR!&,$&>IBZ9B@%RIJT[Y]?^)#[;@=AJB;M[ 2Y!9R]@=?1UQWQ:
M^Y.*AZJ5NK+::DUXF6I#8OA:-3PHON\_^&RXTE>??KAC5 ,W OK]EG/UY<%\
M0SI\,US_!U!+ P04    "  -@PE5VVX&Q=,"   2"@  &    'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;*V676^;,!2&_XK%IJF5MF#(9[L$:4TU;9,F18VV
M7;MP$JP:F]DFZ?;K=PR$A99\7"07P3;GO'Y>^P">;I5^,BF )<^9D&;FI=;F
MM[YOXA0R9GHJ!XEW5DIGS&)7KWV3:V!)F90)/Z1TY&>,2R^:EF,+'4U58067
ML-#$%%G&])\[$&H[\P)O-_# UZEU WXTS=D:EF!_Y N-/;]127@&TG EB8;5
MS/L4W,X#ZA+*B)\<MF:O39R51Z6>7.=K,O.H(P(!L742#"\;F(,03@DY?M>B
M7C.G2]QO[]0_E^;1S",S,%?B%T]L.O,F'DE@Q0IA']3V"]2&ADXO5L*4_V1;
MQ8[&'HD+8U56)R-!QF5U9<_U0NPE!(,#"6&=$)Z;T*\3^J71BJRT=<\LBZ9:
M;8EVT:CF&N7:E-GHADNWC4NK\2['/!O-E4QP4R AV#)*\(19[-PQP60,9.F$
M#;E:, W2IF!YS,0U^4#>$I^8%$?-U+?(X=3\N)[SKIHS/##GMT+T" W>DY"&
M84?Z_'CZ/<0]TJ_2@W:ZC^Z;)0B;)0A+O?X!O046#FB-KG&UXZ<N/Y7 H%O
M/6FW)F<QS#Q\E SH#7C1NS?!B'[L<G<AL9;7?N.U?TP]PGTD&R8*(%=<DD0)
MP;0A.>AJ,Z^[S%>*XU+1O14V$>U1BBN_V7=U*JJ%.VAP!T=QEV6%$5;85&G^
M%[?(85=UU\E:R0WW* ):_5[@GA'8(AXVQ,-SB+DQQ6G:X2N(EYC'(EI\HX9O
M=+38YRK+\.UYL-)'EZST"XFUC(X;H^.+5_KXK$H_%=7"G32XD\M6^N1590QH
M=ZF?$]EBOFF8;RY7ZS>O*/IA,.GB[8@,)I-!>) WH/\_=O0<8CS.&,MDPN7Z
M%'8M> YW5^@!<'_O@^U.2]^97G-IB( 5YM+>&$5T=0"I.E;EY3?\45D\$93-
M% ]MH%T WE\I97<==RQHCH'1/U!+ P04    "  -@PE55QN>P<X&   L)@
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M\O?WG(NGB_8&AQ?$%O\!4$L#!!0    (  V#"54TGYES< ,  +D+   8
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M--C6W3;%T0[*"N#[7$JS/5@%U9^%Z ]02P,$%     @ #8,)54"Q83\]"0
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M^C 72^#&57&60-A_1&T,+1UZ63P.Q'PNM4Z7&HQM[C>VR?R>>*\+35[:WUT
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MB#@@YM0(SX12+1@Y<T('L,BG'M2UG(B:T0#L.R[-3".\PVBD@-T@@/ QP%5
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M6UD!A. ;,6U2H1S**O_^N>1M)RA4+#+'H/M@P"=50(,]9[;-Z\>#?HO1[Z^
M9D48=$?=9DW@?50R*+Z E0LZM,G<\:;W.A$:;A8B_XY8[?I!P5'KIR30=>%^
M,&,]K_._*JGOUK_)&?N?HC2O^Q_T_ R]@),L$7,LA5V# ]\%J@^YSMP/4V8Z
MSW7J+I>"HP70"W@^UPA1^8$VJ'^I=/8'4$L#!!0    (  V#"54MU>R>40D
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M:AN+4J*>@^NV4Z4K3<5*S)M2S.]]'KAK"G-4*1K[X$TTF0+\OR*(?<B11HX
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M^SBS9*P7?UPL?7 (CC_WV5R)G.X720ES[ L9J[,>,L(K=Z=ZYS_^,)Z/3EX
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MTP;\OK*HG/4+*6C_J7/^+U!+ P04    "  -@PE5V\B3OMP"   5!@  &0
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MWA_T C!M$VH73E=-X<^UHS;23%?4M]'X!/J^T-H]+_P&W3_!]"]02P,$%
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M/0OKM*:7-Y8NO:7XB*6,?5*571AV716BV-_?@U<[U^*M:Y?QBP8_UF67A5'
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M+@2'J-("/)\I8-'<T &[S]CG_P%02P,$%     @ #8,)5<XPKEP2 P  P 8
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M!LB9'-'KQ#0QOS3@NMCLW;I7%C5O@HZTIQ]3_6R]&H#REFOXC+!F+OQ&+<E
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MMQ7^*QAF)B/-4!0EQ;+BV)J15;M5FL2J:3?M=/H [H(D(NQB V!%,;^^WSD
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M?U)QIQQMP'OZZ)0?Z(+N+S@N_P-02P,$%     @ #8,)5;/5E+9)!P  *A0
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M<4S"+*9AG!&>I#2*0Y(P1F,>@(-5E9AKTYIH)\M'54 NDSM"L"\).8ERRN.
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MY<*[#"^N8CO>#?C,<:OW?+!*5E(^V>#/8N$%EA *S(U%8&0V>(U"6""B\=^
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MSF:)!ZJ_O/O R-9=F"MIZ/IU;D7_.ZCL /I>2FEV@2TP_D$M_P=02P,$%
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M;"]W;W)K<VAE971S+W-H965T,S N>&ULM5A=;]LV%/TKA%8,+;!9(O5E9[:
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M<5UEA%=\AS=D94BGXX3MB1'\_!/TK-_&4JY3+-0I%FD2ZQ7'Z8KC3*D'7ZC
MN?3MY@4>*T+#]VJ^^N>Q#QRX<)"_-/>GZ3V'V7,7^@-8> [S?=>Q!K#H'.:Y
M/5@O6+<+UIT,]GYV-QL+<9+UW'VF4RS4*19I$NNEWNM2[[V2"7@ZBZ-3+-0I
M%FD2ZQ7'[XKCO] $&KY[^G8["P^Z Q,XAZ&Y#Q?6P 3.89YG>_,!+#J'24.!
MS@43F'?!SB>#C2HF#\MC04[RGKO3=(J%.L4B36*]Y"^ZY"]>R086.HNC4RS4
M*19I$NL5!UJ/1WKKA4;0"O3>782<P:N['H$MK(4Z3O:,8 SF^=[P-# "@\CQ
MT04G@">?,' RWH]XA\O1,"=YS]UN6M5"K6J1+K5^!=!C!= K&4(KK*M$.M5"
MK6J1+K5^B1X_W^#D!\A33,$^/]6[/AIZP@C*\KRA)9RCH#QJ#,\&8S#;M>V!
M(Y@G]QL%84E]L<3!AE:E:+Y@N]'N\NI]?64S&+^&5VLX,AZJRZ[Z/N51OKDI
M^XQ9DI4<Y&0KI[)FOK0OUEP^-1U!=_7MR@,5@A9U,R4X)DP!Y/,MI>+841-T
M5X#!#U!+ P04    "  -@PE5 '9Q*,P#  !!%   &0   'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6RU6&MOVS84_2N$5@PML$4B];(R6T!L:5B&I<N2=@\,
M^\!8M"U4$CV2LMM_7U*2%>L1(=F8+[9(G7/(>R]Y;')^I.P3WQ$BP.<\*_C"
MV FQOS1-OMZ1'/,+NB>%?+.A+,="-MG6Y'M&<%*1\LQ$EN69.4X+(YQ7?;<L
MG--29&E!;AG@99YC]F5),GI<&- X==REVYU0'68XW^,MN2?BX_Z6R9;9JB1I
M3@J>T@(PLED85_ RAK8B5(C?4W+D9\] A?) Z2?5N$X6AJ5F1#*R%DH"RZ\#
M69$L4TIR'O\VHD8[IB*>/Y_4?ZR"E\$\8$Y6-/LC3<1N8<P,D) -+C-Q1X\_
MD28@5^FM:<:K3W!LL)8!UB47-&_(<@9Y6M3?^'.3B#."U!DGH(: ^@3G"8+=
M$.SGCN T!.>Y([@-H0K=K&.O$A=A@<,YHT? %%JJJ8<J^Q5;YBLMU$*Y%TR^
M325/A'?D0(J2</ ]>"^7Y2VC2;D6H.V.4HZW6T:V6) $/'QI$6\C(G":\7>2
M^?$^ F_?O -O0%J #SM:<EPD?&X*.4$UC+EN)K.L)X.>F(P-;F@A=AS$14*2
M$7XTS?<F^*9,3)L==,K.$DT*_EQF%\""WP%D(30RG]5SZ*BBP[%P_M_H\7\>
MO9,,NUTJ=J5G/Z%WMA34%J>;TRH!?_\BH>!:D)S_,U;U6M<9UU56>,GW>$T6
MAO0Z3MB!&.&WWT#/^F$LY3K%(IUBL2:Q3G&<MCC.E'JH-N^^V9JLV;QCI:A5
MO$I%_8@<0@<&#O+GYN$\R4.8/7.AWX-%0YCONX[5@\5#F.=V8)V0W39D5TO(
MDRHO77TZQ2*=8K$FL4XIO+84WBM9@Z>S.#K%(IUBL2:Q3G'\MCB^EGU2J[CG
M>][Q+<?I6<,0AF8.<F8]:QC"/->W'=2SAB',A=#QK'%KF+4ASR9#7ETM?[V)
M/_SUYUB<D]27+CF=8I%.L5B36"?_09O_X)7\(-!9')UBD4ZQ6)-8ISC0>OS/
M;VEQA$:F8PEV -V@9PDC..2['NQ91S2"\^3?#Q_V3&$$YP0!LH)Q5X!GAQTX
M[0O*%>ZN?QL-=I+ZTJ6G52W2JA;K4NL6 3T6 ;V2.33"NDJD4RW2JA;K4NN6
MZ/&D!R?/*L\W"'MX )C-W+X]#%$SSQZ8PQ %77OH#2,PA%S8LP;S[$HD)VQ;
MW45QL*9E(>HC;]O;WG==5;<\O?XEO%S!D?Y(W8]55S"/\O7EV@UFV[3@(",;
M.91UX4L?8_5]5=T0=%]=R#Q0(6A>/>X(3@A3 /E^0ZDX-=0 [:UA^!502P,$
M%     @ #8,)528G_1;C!   L!8  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&ULS5A=;]LV%/TKA%8,+1!'(F5+<F8;2)P66X%B@;UV#\,>&(FVB4BB
M1U)V\^]'2K)HUQ*]" VZ/,3ZNO<>'EV>(W*R9_Q); B1X&N6YF+J;*3<WKBN
MB#<DP^*:;4FN[JP8S[!4IWSMBBTG."F#LM1%GA>X&::Y,YN4UQ[X;,(*F=*<
M/' @BBS#_/F.I&P_=:!SN+"@ZXW4%]S99(O79$GDY^T#5V=NDR6A&<D%93G@
M9#5U;N'-G>_K@/*)+Y3LQ=$QT$-Y9.Q)G_R63!U/(R(IB:5.@=7/CLQ)FNI,
M"L<_=5*GJ:D#CX\/V3^4@U>#><2"S%GZ)TWD9NI$#DC("A>I7+#]KZ0>T$CG
MBUDJRO]@7S_K.2 NA&19':P09#2O?O'7FHBC (0Z E =@$K<5:$2Y3V6>#;A
M; ^X?EIETP?E4,MH!8[F^JTL)5=WJ8J3LP79D;P@ @S K2:(2JI.<)Z ]WE"
M\S58$$'XCH [G.(\5O=4)X E7>=T16.<2S#'DJP9UV%L!>ZIB%F1RRK';:K>
M>A7V]IY(3%/Q#KP!- =_;%@AU"-BXDHU# W&C6O(=Q5DU $Y )]8+C="(R3)
M:;RKAM]P@ X<W"%KPH]%>@T\> 60AQ#XO+P';]^\L^3U&V[],J_?D7?Y?@Z6
M:AHE14JN $0#;WREL.^(ZFJI2?B"TP*7S7E$E.:M)EV OQ8L38'JOSWFR=]M
M7%40ANT0])R^$5L<DZFC)FV9U)G]_!,,O%\L QPV QS:LL_JG@!8@GL2D^R1
M\"JW7Y$)VP!7*8,RI=:,W6P8^6@T<7<M2$8-DI&5Z@?.=K16BE0U9 (D P*G
MBL(,)T21?=.&9?0*Y 4-Y,!*WKS@7/?!EG#*DC9T5?SHB"D4HF@<M5,5-G5#
M:]T'58[755MG7WA6%GJAUUXT:HI&]J+X63=]U=V5K!$.8DX2JBY2(8IO9W*%
M)3K#,D"C:.2C=CCC!L[XOS;NQR(G==-ZE0*TX1B?X0C\,(#M**!GQ->S]\ &
M\S5YQ/&3N#J23BVQJJ.SK00U<25OO\L-X:UZ::W2LX_AD87 'Z]S-8;O/$9D
MQHB^O]35.4^FTC#HTCIH? 7:C:6GVL'7\ IHS +:W>*RX-4)3O@*1Z-@V$&8
M<0=H5?++FE?'GU3V8=?\-A(/[1K?5_;@N?0/8 A'?A<31ORA7?U?K'RPQ0[&
MXR#H &(, =H=H10S,#]P,J\X<3^06AKF;+#%S^!6""JDAMP*SEJC;T<;%X'C
M_X'P6:VLYQB1L2ADMZA>PE?G/&Z:* H[= \9HT%VH^FI>^@UK ,9ZT!VZ[BL
M>^C<)]!0_77P97P"617]LNS5\:<Z$W1\8"*C],BN]'UE#YWK_P A&'6(#3+Z
MC^SZ_V+50RU^X(V#K@XVAH#LAK!0'WN2M+\+:V3?+C7&@,(?KV7(:DY]QV@\
M!]D]IY^6G:]!T##J^HA#QCR0W3SZBMEKV(%O[,"_L&*Y*&;^N?;K56O' M(W
MXN];9?JRF-7Q)^H1^AUEC7K[=O7NJV7^N:8/@F$$.U:N_M&FDEW47ZQE=;[C
M'1<?1?ZW+\0]VD140UR76Z4"E$O2:C^QN=ILQ]Y6FY#F\6HO]Y-:U=)<@)2L
M5*AW'2H6>+4]6IU(MBVW)!^95'R6AQNBFI[K!]3]%6/R<*(+-)O4LW\!4$L#
M!!0    (  V#"553@@O%( 0  /\3   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;*U8;8^;.!#^*Q97G5JI7=Z3D$LB[894UU,KK7;;N\\.3!)KP<[9
M)NG=KS\;6/*"%Q$=7P*8>9X9/S,9;,^.C+^('8!$/_.,BKFUDW(_M6V1["#'
MXH[M@:HW&\9S+-4CW]IBSP&G)2C/;,]Q1G:.";46LW+LD2]FK) 9H?#(D2CR
M'/-_'B!CQ[GE6J\#3V2[DWK 7LSV> O/('_L'[EZLAN6E.1 !6$4<=C,K7MW
MNG)]#2@M_B1P%&?W2$]ES=B+?OB2SBU'1P09)%)38'4YP!*R3#.I./ZN2:W&
MIP:>W[^R?RXGKR:SQ@*6+/N+I'(WMR862F&#BTP^L>/O4$\HU'P)RT3YBXZU
MK6.AI!"2Y35819 36EWQSUJ(,X#B,0.\&N#U!?@UP+\&!&\ @AH0] 6$-:"<
MNEW-O10NQA(O9IP=$=?6BDW?E.J7:*47H;I0GB57;XG"R<43'( 6(- GM&14
M<I4X="\$2($P3=%7@M<D(Y(HB_<Q2$PR\4'9_GB.T?MW'] [1"CZOF.%4-9B
M9DL5DB:VD]K]0^7>>\.]C[XIKSN!5C2%U(!?=N-''7A;2='HX;WJ\>!U$OY1
M9'?(<3\BS_$\4SS_#Q[W@7LEW#7 5]WP&)([Y+LF^(48?E,<?LGGO\'75 0N
M*V)JRF_%$)@9=)N;BCU.8&ZI/B: '\!:_/J+.W)^,XD[)%D\)-EJ(+*+- 1-
M&H(N]NLTF+)0$8Q* OUM."S\*)C9AW-Q>]C$G8'<JEG;H3L:A8W'"RW"1HNP
M7TEFI\YDK,MPR+H<DBP>DFPU$-E%+D9-+D;==5EP#E2B/>/ZHV_*0D40GI7
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M_=Z[9T3"K=E"X@L_00U90Q5NQTQWV@WI:3N;'L/;"7_)-%7:@, %I4:]4W)
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MGA!*S)U'X/1:X15*Z8&(QJ\6DW6?](F[]A;]0]!.6N;<XI66WT7AJC%[QZ#
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M^WJ18,9T2VY0T,Q*JHP9ZJJUKS<*V=*!,NY'0=#U,Y8*;]AW8S,U[,NMX:G
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M$94UH/F5E.:F8QV41>?P)U!+ P04    "  -@PE5'3J]W9,#  #/#0  &0
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M;H757Y7-<#DP,G?]Y%(:[$[=:XI_($!9 UQ?2VEV [M!_9=D]C]02P,$%
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M9^/B,@6:@+(&^'PMI7EJV -R_05E_C]02P,$%     @ #8,)52_>RP&\!@
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MKO\:ZW'EXF<9Y^1WF6P5>:]DL<V5SE%9D!=O52GCI/B1O"1?/KTE+W[XD?Q
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MZDK-#!Y *1^O><R;36'K]<-BAUP_.# AQYGP_3:-E_%&^]_:/L 5!N=JC+U
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M@\.:Q2.85[1^2XD 1;NCI_BHT3IRTT5_U/H8+K1&DIF)##YS-N,Y-YR4KM=
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MK -]GTMIM@,[0=/DQO\#4$L#!!0    (  V#"56$,^0=( ,  .,+   9
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M':#>+QF3KQ/=YS5]??@'4$L#!!0    (  V#"57%_$RJQ0,  #01   9
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;,U876_;-A3]*X1:%"V01-^RG=H&
M8DO#.K1 $+?;P[ '1KJVA$BB2])VNE_?2TI6;%DQTDT%^F*)]#F']TM7I,8[
MQA]$"B#)8Y&78F*D4JZO35/$*1147+$UE/C/DO&"2ASRE2G6'&BB245N.I85
MF 7-2F,ZUG.W?#IF&YEG)=QR(C9%0?FW&>1L-S%L8S]QEZU2J2;,Z7A-5[
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M3T_236HI\TH*.B/%!U]8(3<"+(N4I!9\?!D?7L"[RM;&6W3P=HXN$OY19D_
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M;5JGM4)E+Q^F?3#)0:PZ-K,=:/_]SDY(H0JHVOB2^.6>YWQWOO/UME(]Z S
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M[E'8TDKH^]0A83XD+("$A9"P" AF".2T$<CISQI^GD+J!A+F0\("2%@("8N
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M6]'AT.E@B*U;',./6PWS!@PL#V1ZVEKCNXU7R.XZP/9T5X5@,\4K$9LIOM:
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   (  V#"54+%&:L[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    (  V#"5697)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ #8,)
M54EE)9G6!0  UQX  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    (  V#"55&PF@)T 8  #\<   8
M      " @1D.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M"  -@PE5VVX&Q=,"   2"@  &               @($?%0  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ #8,)55<;GL'.!@  +"8  !@
M             ("!*!@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    (  V#"54TGYES< ,  +D+   8              " @2P?  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  -@PE59'>1B=H"   X
M"   &               @('2(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ #8,)54"Q83\]"0  KDP  !@              ("!XB4
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (  V#"57=@LRS
M0 <   T?   8              " @54O  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    "  -@PE5Y'WR'Q@-   J(0  &
M@('+-@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ #8,)
M504&]95Y"P  !B   !D              ("!&40  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    "  -@PE5'7/ O>@,  "U)   &0
M        @(')3P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   (  V#"54MU>R>40D  /$9   9              " @>A<  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ #8,)5>(NKXM&!P  X!$
M !D              ("!<&8  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    "  -@PE5V\B3OMP"   5!@  &0              @('M;0
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (  V#"56M@^26
MVP@  -(6   9              " @0!Q  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ #8,)5<XPKEP2 P  P 8  !D
M ("!$GH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  -
M@PE5/3!C>2P$   4"@  &0              @(%;?0  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  V#"55V?1-5PQ   (\[   9
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M970R,BYX;6Q02P$"% ,4    "  -@PE5MH&9Q,L#  !-"0  &0
M    @(&KL   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M  V#"554DAAQWP(  " &   9              " @:VT  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ #8,)53:MYKQI!   6PH  !D
M             ("!P[<  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    "  -@PE5YN32W;4#  !."0  &0              @(%CO   >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (  V#"55DE.2'&@,
M /$)   9              " @4_   !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ #8,)5?Q?MF'Y!   OR   !D              ("!
MH,,  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  -@PE5
MW(>;^AD&  #\.@  &0              @('0R   >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    (  V#"56K16JDR@,   X4   9
M      " @2#/  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ #8,)50!V<2C, P  010  !D              ("!(=,  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  -@PE5)B?]%N,$  "P%@
M&0              @($DUP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    (  V#"553@@O%( 0  /\3   9              " @3[<  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ #8,)51BVE$^X
M!   +1X  !D              ("!E>   'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    "  -@PE5D,=&A/4"  #&!@  &0
M@(&$Y0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (  V#
M"56NK+3NK@0  "8>   9              " @;#H  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ #8,)58-3+%U5 @  5P4  !D
M         ("!E>T  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    "  -@PE5/"Y8J%H#  " #@  &0              @($A\   >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (  V#"54=.KW=DP,  ,\-
M   9              " @;+S  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ #8,)59G+BPIW P  G@P  !D              ("!?/<
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  -@PE5S7P/
M^!L#   P"@  &0              @($J^P  >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    (  V#"55D>AV=R@,  $T1   9
M  " @7S^  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
M#8,)52_>RP&\!@  K2H  !D              ("!?0(! 'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    "  -@PE5O_AA%B $   9%   &0
M            @(%P"0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    (  V#"56V#E[5Q (  .$&   9              " @<<- 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ #8,)5=+>3L)["
MX%$  !D              ("!PA ! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    "  -@PE5@G]]:U4#  #P"@  &0              @(%T
M&0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (  V#"56$
M,^0=( ,  .,+   9              " @0 = 0!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ #8,)5<7\3*K% P  -!$  !D
M     ("!5R ! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  V#"54+:OO1! 0  ,$0   9              "
M@3XU 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ #8,)
M5>>S0BHD P  ,0H  !D              ("!>3D! 'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    "  -@PE5QH25J!8'  " .0  &0
M        @('4/ $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   (  V#"55S?Q9L60,  "@5   -              "  2%$ 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ #8,)59>*NQS     $P(   L
M ( !I4<! %]R96QS+RYR96QS4$L! A0#%     @ #8,)55:'!S!>!   ="4
M  \              ( !CD@! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M  V#"54,/Y#\Y0$  '\A   :              "  1E- 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  V#"56/X;=ITP$  #8A   3
M              "  39/ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !
- $  =Q$  #I1 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>282</ContextCount>
  <ElementCount>243</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome</Role>
      <ShortName>Condensed Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Collaboration Agreements And Business Development Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities</Role>
      <ShortName>Collaboration Agreements And Business Development Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121104 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2128105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132106 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135107 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2141108 - Disclosure - Provision For Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxes</Role>
      <ShortName>Provision For Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2143109 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2147110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables</Role>
      <ShortName>Collaboration Agreements And Business Development Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2322303 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2329304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2333305 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2336306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2344307 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenues - Revenues Disaggregated by Concentration Risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Concentration Risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenues - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2418412 - Disclosure - Collaboration Agreements And Business Development Activities - GSK Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - GSK Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2419413 - Disclosure - Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2420414 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2424416 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2430420 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2431421 - Disclosure - Fair Value Measurements - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails</Role>
      <ShortName>Fair Value Measurements - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2434422 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438424 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439425 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails</Role>
      <ShortName>Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2442427 - Disclosure - Provision For Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails</Role>
      <ShortName>Provision For Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForIncomeTaxes</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2445428 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2446429 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="exel-20220701.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2448430 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsandContingencies</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exel-20220701.htm">exel-20220701.htm</File>
    <File>exel-20220701.xsd</File>
    <File>exel-20220701_cal.xml</File>
    <File>exel-20220701_def.xml</File>
    <File>exel-20220701_lab.xml</File>
    <File>exel-20220701_pre.xml</File>
    <File>exel20210630exhibit31210q.htm</File>
    <File>exel20220630exhibit31110q.htm</File>
    <File>exel20220630exhibit32110q.htm</File>
    <File>exel2022630exhibit10110q.htm</File>
    <File>exel2022630exhibit10210q.htm</File>
    <File>exel2022630exhibit10310q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20220701_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="729">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>84
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel-20220701.htm": {
   "axisCustom": 2,
   "axisStandard": 20,
   "contextCount": 282,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20220701_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20220701_def.xml"
     ]
    },
    "inline": {
     "local": [
      "exel-20220701.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20220701_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20220701_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20220701.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 422,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 38,
   "keyStandard": 205,
   "memberCustom": 29,
   "memberStandard": 35,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20220701",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Collaboration Agreements And Business Development Activities",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities",
     "shortName": "Collaboration Agreements And Business Development Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121104 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashandInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128105 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132106 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135107 - Disclosure - Stock-Based Compensation",
     "role": "http://www.exelixis.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141108 - Disclosure - Provision For Income Taxes",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxes",
     "shortName": "Provision For Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143109 - Disclosure - Net Income Per Share",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.exelixis.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables",
     "shortName": "Collaboration Agreements And Business Development Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322303 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333305 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344307 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:NumberOfCountriesWithDrugApprovalExcludingTheUS",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:NumberOfCountriesWithDrugApprovalExcludingTheUS",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ia26f483bdcbb41acbef2e9cd23df368f_D20220402-20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i89f773b17954459496fdb8e6635e500c_D20220402-20220701",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Revenues - Revenues Disaggregated by Concentration Risks (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails",
     "shortName": "Revenues - Revenues Disaggregated by Concentration Risks (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i89f773b17954459496fdb8e6635e500c_D20220402-20220701",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i6bde2f537a354fcca14f821547b896d9_D20220402-20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i54050f41270d4c0994179a0b71bcbd09_D20220402-20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ibd88d103ffe54da794c385cd93721ee7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ibd88d103ffe54da794c385cd93721ee7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
     "shortName": "Revenues - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ibd88d103ffe54da794c385cd93721ee7_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "id082ca3812d9497f9a5419f7e2935ef1_D20220402-20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "id082ca3812d9497f9a5419f7e2935ef1_D20220402-20220701",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "id082ca3812d9497f9a5419f7e2935ef1_D20220402-20220701",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ied5cfd9d83994869a3ed269eca638c4a_D20220402-20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i9d122b6fe357426c8ad3468c325f4936_I20220701",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i9d122b6fe357426c8ad3468c325f4936_I20220701",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i37d0046d01764a6a84fff26e8dc7ad8e_D20220101-20220701",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborationAgreementPercentOfRoyaltyOnNetSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418412 - Disclosure - Collaboration Agreements And Business Development Activities - GSK Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - GSK Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i37d0046d01764a6a84fff26e8dc7ad8e_D20220101-20220701",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborationAgreementPercentOfRoyaltyOnNetSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419413 - Disclosure - Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
     "shortName": "Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i9403b468905b44ddb12619327a4d1331_D20220402-20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementIncomeLossFromAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
     "shortName": "Condensed Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i2b5ed8e63d724ab1b37ae2306c7d0aa7_D20220601-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420414 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i2b5ed8e63d724ab1b37ae2306c7d0aa7_D20220601-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424416 - Disclosure - Cash and Investments - Narrative (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430420 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i0fa7e06004bf493583d8ea1de5a444ae_I20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i38408adaba6d4341adb12d55daf8b48e_I20220701",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "forward_contract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431421 - Disclosure - Fair Value Measurements - Narratives (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails",
     "shortName": "Fair Value Measurements - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i38408adaba6d4341adb12d55daf8b48e_I20220701",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "forward_contract",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434422 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "idbb94681ddb446c8ad4b6102bf4f52d2_I20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ic8c8787ab89e4ea8aa9bcbba33a74fb7_D20220402-20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438424 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i7cb92aaea0154533ae9a350686b93d27_D20220402-20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i18d5c27ec4b94608b6a47b96f6900355_D20220525-20220525",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439425 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i18d5c27ec4b94608b6a47b96f6900355_D20220525-20220525",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i73a59494ab85495e95f7a35120b582a9_I20220701",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
     "shortName": "Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i73a59494ab85495e95f7a35120b582a9_I20220701",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442427 - Disclosure - Provision For Income Taxes (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails",
     "shortName": "Provision For Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445428 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ie5128decae384f698a9ab00463cbd990_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446429 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ie5128decae384f698a9ab00463cbd990_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib2c7ef7fab7345ebadb2ed3327f9af7d_I20220601",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448430 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib2c7ef7fab7345ebadb2ed3327f9af7d_I20220601",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "ib6fdff21be674914a8ab028e2e56dbb7_D20220402-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i7915746f5547460f9caa2e4177cfce05_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i7915746f5547460f9caa2e4177cfce05_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220701.htm",
      "contextRef": "i1e85cf3adc3143168c5871013115016c_D20220101-20220701",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 64,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_AccredoHealthIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accredo Health, Incorporated",
        "label": "Accredo Health, Incorporated [Member]",
        "terseLabel": "Accredo Health, Incorporated"
       }
      }
     },
     "localname": "AccredoHealthIncorporatedMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_BuiltToSuitLeaseAndHeadquartersLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Built-To-Suit Lease And Headquarters Lease [Member]",
        "terseLabel": "Built-To-Suit Lease And Headquarters Lease"
       }
      }
     },
     "localname": "BuiltToSuitLeaseAndHeadquartersLeaseMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CardinalHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health",
        "label": "Cardinal Health [Member]",
        "terseLabel": "Cardinal Health"
       }
      }
     },
     "localname": "CardinalHealthMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks, Discounts for Prompt Payment and Other"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationAgreementWithBioInventOptionAndLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement With BioInvent, Option And License",
        "label": "Collaboration Agreement With BioInvent, Option And License [Member]",
        "terseLabel": "Collaboration Agreement with BioInvent, Option And License"
       }
      }
     },
     "localname": "CollaborationAgreementWithBioInventOptionAndLicenseMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementIncomeLossFromAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Income (Loss) from Agreement",
        "label": "Collaborative Arrangement, Income (Loss) From Agreement",
        "terseLabel": "Profits on U.S. commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementIncomeLossFromAgreement",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments",
        "terseLabel": "Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate development milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "terseLabel": "Collaborative arrangement, upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaboration Agreement with GlaxoSmithKline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative Arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "label": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "terseLabel": "Contract revenue recognized, including revenue from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CotellicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cotellic [Member]",
        "label": "Cotellic [Member]",
        "terseLabel": "Cotellic"
       }
      }
     },
     "localname": "CotellicMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_IncreaseDecreaseInAccruedCollaborationLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Collaboration Liabilities",
        "label": "Increase (Decrease) In Accrued Collaboration Liabilities",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedCollaborationLiabilities",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_InvestmentsPurchasesIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments Purchases Incurred But Not Yet Paid",
        "label": "Investments Purchases Incurred But Not Yet Paid",
        "terseLabel": "Unpaid liabilities incurred for unsettled investment purchases"
       }
      }
     },
     "localname": "InvestmentsPurchasesIncurredButNotYetPaid",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen Pharma SAS"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Domain]",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LeaseExpansionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Expansion",
        "label": "Lease Expansion [Member]",
        "terseLabel": "1751 Expansion Space"
       }
      }
     },
     "localname": "LeaseExpansionMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "terseLabel": "Estimated monthly base rent under Build-to-Suite leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage",
        "terseLabel": "Monthly base rent, lease not yet commenced, annual percentage increase"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of options to extend the lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option To Terminate After Period",
        "label": "Lessee, Operating Lease, Option To Terminate After Period",
        "terseLabel": "Option to terminate lease (after period)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminateAfterPeriod",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_LossContingencyNumberOfDaysToFilePatentInfringementClaim": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Days To File Patent Infringement Claim",
        "label": "Loss Contingency, Number Of Days To File Patent Infringement Claim",
        "terseLabel": "Notice period for file a patent infringement claim"
       }
      }
     },
     "localname": "LossContingencyNumberOfDaysToFilePatentInfringementClaim",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_LossContingencyNumberOfLawsuitsConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Lawsuits Consolidated",
        "label": "Loss Contingency, Number Of Lawsuits Consolidated",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfLawsuitsConsolidated",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NumberOfCountriesWithDrugApprovalExcludingTheUS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Countries With Drug Approval, Excluding The U.S.",
        "label": "Number Of Countries With Drug Approval, Excluding The U.S.",
        "terseLabel": "Number of countries with drug approval, excluding the u.s."
       }
      }
     },
     "localname": "NumberOfCountriesWithDrugApprovalExcludingTheUS",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OperatingLeaseLiabilityDiscountedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Liability, Discounted Period",
        "label": "Operating Lease, Liability, Discounted Period",
        "terseLabel": "Operating lease liability discounted period"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityDiscountedPeriod",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductOrServiceAxisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Or Service Axis",
        "label": "Product Or Service Axis [Axis]",
        "terseLabel": "Product Or Service Axis [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxisAxis",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_ProductOrServiceAxisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Or Service Axis [Domain]",
        "label": "Product Or Service Axis [Domain]",
        "terseLabel": "Product Or Service Axis [Domain]"
       }
      }
     },
     "localname": "ProductOrServiceAxisDomain",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products derived from other compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities",
        "label": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member]",
        "terseLabel": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities"
       }
      }
     },
     "localname": "ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting from discovery efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer Regulatory Milestone Probable Of Achievement",
        "label": "Revenue From Contract With Customer Regulatory Milestone Probable Of Achievement",
        "terseLabel": "Revenue from contract with customer, regulatory milestone probable of achievement"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RoyalPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royal Pharma",
        "label": "Royal Pharma [Member]",
        "terseLabel": "Royal Pharma"
       }
      }
     },
     "localname": "RoyalPharmaMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions",
        "label": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "terseLabel": "Reduction in share reserve after all other awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "terseLabel": "Reduction in share reserve after stock option or stock appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "terseLabel": "Maximum potential to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_TSRBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TSR-Based Restricted Stock Units",
        "label": "TSR-Based Restricted Stock Units [Member]",
        "terseLabel": "TSR-Based Restricted Stock Units"
       }
      }
     },
     "localname": "TSRBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TakedaAndIspenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda And Ispen",
        "label": "Takeda And Ispen [Member]",
        "terseLabel": "Takeda And Ispen"
       }
      }
     },
     "localname": "TakedaAndIspenMember",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TenantLeaseImprovementsAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Lease Improvements, Allowance",
        "label": "Tenant Lease Improvements, Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantLeaseImprovementsAllowance",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20220701",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r39",
      "r41",
      "r87",
      "r88",
      "r233",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r167",
      "r265",
      "r271",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r167",
      "r265",
      "r271",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r163",
      "r218",
      "r219",
      "r265",
      "r269",
      "r437",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r163",
      "r218",
      "r219",
      "r265",
      "r269",
      "r437",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r40",
      "r41",
      "r87",
      "r88",
      "r233",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r265",
      "r270",
      "r470",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r265",
      "r270",
      "r470",
      "r485",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Abstract]",
        "terseLabel": "Contract liabilities:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r403"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r45",
      "r47",
      "r48",
      "r457",
      "r476",
      "r477"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r48",
      "r55",
      "r56",
      "r57",
      "r95",
      "r96",
      "r97",
      "r359",
      "r400",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Operating Activities [Abstract]",
        "terseLabel": "Non-cash operating activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r403"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r323",
      "r324",
      "r325",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r286",
      "r327",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "netLabel": "Total stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of lease property (in square feet)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r13",
      "r84",
      "r146",
      "r155",
      "r161",
      "r189",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r355",
      "r360",
      "r385",
      "r401",
      "r403",
      "r440",
      "r455"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r31",
      "r84",
      "r189",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r355",
      "r360",
      "r385",
      "r401",
      "r403"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r170",
      "r196"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Debt securities available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r175",
      "r177",
      "r451"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r175",
      "r176",
      "r450"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r169",
      "r171",
      "r196",
      "r444"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total debt securities available-for-sale",
        "verboseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r365",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid liabilities incurred for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r9",
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r72",
      "r77",
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r72",
      "r386"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r348",
      "r349",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r445",
      "r462"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r220",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r403"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 321,800 and 318,842 at June\u00a030, 2022, and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r51",
      "r53",
      "r54",
      "r59",
      "r447",
      "r465"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r167",
      "r382",
      "r383",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r167",
      "r382",
      "r383",
      "r479",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r167",
      "r382",
      "r383",
      "r479",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r134",
      "r135",
      "r167",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r132",
      "r134",
      "r135",
      "r136",
      "r382",
      "r384",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r167",
      "r382",
      "r383",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Other Assets and Other Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r243",
      "r245",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]",
        "terseLabel": "Contract assets:"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r243",
      "r244",
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r243",
      "r244",
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r243",
      "r244",
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenues",
        "verboseLabel": "Long-term portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amount of revenues recognized included in the beginning contract liability balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r62",
      "r437"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r133",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r172",
      "r196",
      "r203",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r184",
      "r201",
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r181",
      "r197",
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r182",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r180",
      "r200",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r183",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r331",
      "r332"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r75",
      "r144"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r41",
      "r366",
      "r367",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of contract"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r265",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r288",
      "r289",
      "r317",
      "r318",
      "r320",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r60",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r108",
      "r111",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r373",
      "r374",
      "r448",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r60",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r111",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r373",
      "r374",
      "r448",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r55",
      "r56",
      "r57",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r127",
      "r190",
      "r241",
      "r242",
      "r323",
      "r324",
      "r325",
      "r338",
      "r339",
      "r372",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r400",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r375",
      "r376",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets Measured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r234",
      "r236",
      "r237",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r376",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r378",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r234",
      "r277",
      "r278",
      "r283",
      "r284",
      "r376",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r234",
      "r236",
      "r237",
      "r277",
      "r278",
      "r283",
      "r284",
      "r376",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r234",
      "r236",
      "r237",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r186",
      "r187",
      "r188",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r200",
      "r202",
      "r205",
      "r206",
      "r235",
      "r240",
      "r371",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainOnDerivativeInstrumentsPretax": {
     "auth_ref": [
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain on Derivative Instruments, Pretax",
        "terseLabel": "Gain on derivative instruments, pretax"
       }
      }
     },
     "localname": "GainOnDerivativeInstrumentsPretax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r11",
      "r208",
      "r209",
      "r210",
      "r211",
      "r403",
      "r439"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r57",
      "r63"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r335",
      "r336",
      "r337",
      "r340",
      "r342",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "PROVISION FOR INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r106",
      "r107",
      "r145",
      "r333",
      "r341",
      "r343",
      "r467"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r74",
      "r435"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r16"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r29",
      "r403"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "CASH AND INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease option to extend period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r84",
      "r156",
      "r189",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r356",
      "r360",
      "r361",
      "r385",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r84",
      "r189",
      "r385",
      "r403",
      "r441",
      "r459"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Unpaid liabilities incurred in asset acquisition"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r35",
      "r84",
      "r189",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r356",
      "r360",
      "r361",
      "r385",
      "r401",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "netLabel": "License revenues",
        "terseLabel": "License revenues",
        "verboseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds",
        "verboseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r72",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r49",
      "r52",
      "r57",
      "r58",
      "r76",
      "r84",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r116",
      "r146",
      "r154",
      "r157",
      "r160",
      "r162",
      "r189",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r374",
      "r385",
      "r446",
      "r464"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r108",
      "r109",
      "r117",
      "r120",
      "r146",
      "r154",
      "r157",
      "r160",
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income, Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r110",
      "r112",
      "r113",
      "r114",
      "r115",
      "r117",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net income, Diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r146",
      "r154",
      "r157",
      "r160",
      "r162"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Estimate incremental borrowing rate (in percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r94",
      "r140",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r50",
      "r53",
      "r353",
      "r354",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r42",
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized losses on available-for-sale debt securities, net of tax impact of $639, $257, $2,295 and $756, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r43",
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r403"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r70",
      "r322"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "netLabel": "Net product revenues",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r212",
      "r403",
      "r452",
      "r461"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r403",
      "r460",
      "r480"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r330",
      "r436",
      "r498"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r12",
      "r81",
      "r486"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash equivalents included in other long-term assets"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r242",
      "r403",
      "r458",
      "r475",
      "r477"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r190",
      "r323",
      "r324",
      "r325",
      "r338",
      "r339",
      "r372",
      "r472",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r142",
      "r143",
      "r153",
      "r158",
      "r159",
      "r163",
      "r164",
      "r167",
      "r264",
      "r265",
      "r437"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Total revenues",
        "verboseLabel": "Royalty revenues on ex-U.S. sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r134",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r268",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues Disaggregated by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r397",
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "verboseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r315",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r26",
      "r27",
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r81",
      "r438",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r285",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r132",
      "r134",
      "r135",
      "r136",
      "r382",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration Risks"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "netLabel": "Collaboration services revenues",
        "terseLabel": "Collaboration services revenues",
        "verboseLabel": "Collaboration services revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in share reserve under 2017 plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted in the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted in the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of the Company's common stock on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting award percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r30",
      "r442",
      "r443",
      "r454"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r55",
      "r56",
      "r57",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r127",
      "r190",
      "r241",
      "r242",
      "r323",
      "r324",
      "r325",
      "r338",
      "r339",
      "r372",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r400",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r127",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Share-based Payment Arrangement"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive plans and stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r242",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive plans and stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r20",
      "r21",
      "r84",
      "r168",
      "r189",
      "r385",
      "r403"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r393",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r393",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r393",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Inclusive of operating lease liability"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r186",
      "r187",
      "r188",
      "r235",
      "r240",
      "r371",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r277",
      "r449",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government-sponsored enterprises",
        "verboseLabel": "U.S. Treasury and government-sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r137",
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r89",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at June\u00a030, 2022",
        "periodStartLabel": "Balance at December\u00a031, 2021"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r110",
      "r120"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r108",
      "r120"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL108322424-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5291-111683"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r499": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r500": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r501": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r502": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r503": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r504": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r505": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r506": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r507": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r508": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r509": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r510": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r511": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0000939767-22-000097-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-22-000097-xbrl.zip
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M*4CT%3._/WSFU0.2Z+/C$% 1F2:3@EY&&63"A-9R&^^OILW2N.7O*+9S==9
M@//,,3(;&K+V*))B9$[ !4__AZ6!9CYN>58PN>R3E1XBEP"\,%KB4]25S'.?
M<5IC:RE@FKM;GIEF\>P]ST#!9@9A*0#AD4F+Q'^CX(XM#63W[)9GA8\G@\>!
M@<HI@T=$+QR!XX(&P6V0-5CPN7! S7\9*+J4A 1I$GHP5EMM;-8R^*A3YI=E
MU)8(U?D/S,X':)8A6V70Y0#6>JN#212Z&G*1GISD\@%]KQFS]P]H-%IX"!8
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M"8?D,V (1@=@:,>UK$-TX, C-_&:F5[DO?)6(CQW$?XJ*WQE%\'OJ6>C 7,
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M>'G 700F? V\[W#)+#J0C*,A^""YZ,@^<V9-#"E)9F')P%L LWPG,')D/!&
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MDR9=0U0E)V(H'TS1K6Q(/>%<;ANB5C9DX81.KSW9'I?]W.I-ZL[1K5;6HYY
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MC%MU6U08WQF,%_0+FZ2VG!MPFF08T\C!)9V >.:S5*U/UFYM:]E78HTJ-6U
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MRT/OG40[C37PY$[.6RXF_9<RYY6:5DI->\L-0)1W/F0-PWC%LYKA.%BO"<C
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M%.M73?0F)$@DI28F0SQ%DK2Q$KU5+"F-"1VI?HJU(L%G2WX*$BC/_(:@F8B
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M,38JQFBL(5GULZ41F/"@4T"@1E AB6<J-IOKLN)7H;[>4+^]!5DW_?7E@<4
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MD1!+E $B*T#DX"0*-%$XQ)B/BX7(SW0%M]QTNM7O#\M=I]V4;>2<4:6?HQY
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MXWG@2(:<%\,+@G0.R#?"42Z%=B;RE379P&K6*;!4B/ ,*-H2A8-D9O9;&.6
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M^GGOKZ]-^D\:UPG:WL44GGC6//AB&$_,^#(Y;([U\089*R+RUK$DD\98 L3
M%&A@Q1:^6%!=Q^RE I4WDN*@A'<I<DZ]"\G1R$V".U%CPZB.&<?LEK5W:Z!Z
M6J ZGP(J''F4$A,DC!&(FZ"1%HDCRI)WW'@FG5U98QHW0!W50%4#U8("E9-:
M$:X4=4QR39+V HO(P)0A$A2QOG4AV!JH%@.HR"50?3W;/O@BA</>$X(PM@EQ
M81)RT0,_)CIR%S4W-*RL&48:C-R[BG@-5#50/1!08>VH5$%+#D 5I'78,<\-
M%S(P1ZF[=678&J@6 ZC8"*C8-K1OY_T78JG"0AOD4@J(*T&1M80A%A3SP*EH
M$FQE31K>X-@L/% MA'-]X=UWN<!<M2=GG+CCM-S+=Z._G=ZM#ZY%]&O']$E>
M_[<[X!\55E#CI<M9T3SA3GLL/<-,R21%DK=P?>7X5OA4 ^$" 6'S]8P/#.9O
M=,I)Q##\ 6XND*,JH( E#CX8);U>62-,-C"=!<+?;XV!/\",GV/@A;P\R#K+
MRQ7SA".875@2C3$7R6FK,%<VQT\Z;(*XA>.H%O.%%/-I#U*,PF(K(_(PFHCS
M1)"A)@+]88$%:Z45%@PST3!"UE+^O*3<<HF-]Y)'%SA1Q ANI+1:.FFHC.D6
M7I=:RA=2RJ^X7YKK7P+V3A!!$*-6(QXI05K;@&#<8[2$^RC)RAI5K&&DKL7\
M3F+^)"Z+NX@Y5BJDA&7B!O- #/PE(A%FE=.:6GX+GT4MY@LIYM/."QZ]U)Y2
M)!EWB ?ND=.2H.1=]E[DRJ<2.+NF#<.?C+,OH-_B!WX8*E;5HOHMFG'PTZ"C
M6^'?Z/UO%W"ZX,AX!V 4"0/?229ZJSD7QD8:@H[.,X8!)%4=Q[-4>+@[Z\-P
MQEA.,4K.&L23,\AQ+Q OMX!JHYT0*VN,JP;F\UH>OW74]E.N1\T%%9XO,&!G
MH@XL61\2UY([I[PFE/!H;)!)UW$S2P8,TUX/;033ECCDB00XD Z($G,:!6><
MTR8FJA+80YHW*)^UA^8,##4V+!,V)$Y]HA$G"WC@A->8688%A1N+@(VM0U66
M#!O(%#8$FL!8DA%);0+BQ%H@#1(CPX02$FMNL5U9DT(U&)^M9U]CPPO&!J69
MYC1033SA@6@KK-/1*)6<DHG;.CIDR;"!36,#L\0K%U R\(=KBY$3DJ,DF4A)
M!\F(6ED3A#0 ,98;&Q8B=&0AW2ZOKY2AKW=GUHVL=V<N<GC7WRV?L^;-Q47Z
M/'D+4=%'1363W''ON?8<1TRY<URK2$7M"%TJWC*[H5'P2 /S&!%JR]Q\#!DE
M->+<4&RE(]9YX"VJ(>ALE,>B!;4^J-7R/ 5<$&ZX5<1'S;FU, FL$H&): PW
MFM<.S643\&F'IB.*"L,\"+@@"(":("NM1UA0;Y0%HY3GE0[3D/P9;J^I!1SL
M3T^I221AQ8D.6O#@%95),(Z]X[57<LD$?#*""^<BO-%S8D"#^[R>R45.26!4
M0D;;R*BQ,6JRLJ9- U"@%O#G)^!*&FUD-!0(.0@X<R%X'+5).'@O9+WQ;-D$
M?#)V"V^__^(#23"G)0K)@H ;R9&UR2*L)8W*1V857EF3JD&NB=!<- %?".?A
M71P33R+^5QV)<)-O+5_6B[Z'GV+Y0EGO H)8$F)B,M@3CI,V5G)O%4U*\\0=
MKOT4RP2".[.;SG @.5D^1YJ*B#BE$<%$Q@@&/.GHJ,&!K:P1WM!"W1<$'SR(
MM8Y5O[L98Q*8+B(YKW!.XN^2%8)PZHSTP0I:^RF63,!G J^H5\D[ARB7"7&N
M$W*<8V2CE8Q&&T@$,T:2!M7WWEU?"_CB"3A-)-B0M,;2<D5@_!G+"MT:193$
MM9]BV01\TD]!MM>_R* \4]*AD#>>\,@-<LI8Y*SU(/,R2(ES9&6#JWL'3]4"
MOH "[G6P$8.^MIS'*'0RFC!IDTZ"&&=J/\62"?BTGP(DF$EM&$HRY)T4,8"
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MR1K'$(F$(DZ30(92 W\Z[T@&>Y\JEPE?&"%#$?0E$G2F8C*28J<CYB(0&X3
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MEHK%:]Z.?!\X58H*)6.T!@?N'#;4^) T!EAEDFISS4GF#(J.]=@A4>-<!"U
M>1M0[FW!-1^^8N95PC(BG./^00'"R%HK84<S4B4NL-%F;4.;]>M<[:/=-?,,
M+M0[<L=E67$;+I6@G#KX*&2FT59W*!8 [CY>HM. Y\X^QW !C \Y\*9WA(HD
M;!)O*S[*V(VV,\3_D+D%VV<5J&=NU*I/UR'QD!XQU%KM7NT\]L"H@3Z/]T78
M P'[_[__TB#RO^VV>X#ZZ[6W5U![\PBVA\OZY;_WN]";;K>V-=&,S;PS5R[-
MZE'DMQ'?Y<23N[DS5_Q=[QLM:&_#-FN?>O!!]8[1_??P?@T'5G 8^5E7XY P
M:W!^.7'7\) )7]YB'32MW[O^EGE[TR3_TQ-O3H1,#=+$S^/.I3_X*"+7B?8;
MZ.O0R#>V^=V>=]=^O=HUZ-?D.-YA"(:ITM?T.*7[]%C?Q8U<C7?(S*'5&GA3
M<8X.7,7_ML_=A!HH4;"]_E?#:Z*-3,2YZ#D+7&,:O"=>)$LCCO2K6MNH&!FS
MB&13)*_Z?_]J-^9-YM,3#\]?:O,//I.4 ?0(%B*G'#OM%&6P7_EDE71@K:UM
M3'I4_K*=7FU[NU[;!E&OZ=S]#&WO&UD+J-S F=_UM$8P^M\*HO-!QH!G%VX?
MZ!&5_>C:_8IWM19_9),@HV3CM%)FVT-@.Q\RT5X#BNOSSG>G]=&JA[=.)L]4
MWLM%$KV[M_\NH_BC4X^.-XE_XN8EY>\6S&>SW>UWEH5R%.^\':EW!]\/]_\\
MR6K8SLD[>.='>,YAXV#_&%2];YE,_\?>'^\;NZ?OFS/JW0D\ZW1'[)SX<VCK
MC]T_=OCNZ9_'>W]\)J N@KKWCA]\V:8'7_X&]6Z;@DKG%%&@;'/D,0:5CF,P
M>[F)B#(C;*Z)KHB;INGDP; HL+-2*^[ 0L:28BY%XM8)9]4,Y>C>?_ZS^?O>
MQ\W][;W=VN8?']^]VWFWN_^IMKF[5?O]\Z?MW7>?/M6VWOW][C][?^5O:IMO
M][?_WM[??O?I.K[1&R(=;F_>5'>,3SY(1R1EG,5,M*J%9B;!Q9PQN<PT^%_B
M@%5ZDEU\S# ]SXQO1IM=_;6SJZ3&@V._QE#M''" G\*(9[VG<3&$M$QAW^]4
MQ\23VMT0(CV\ZL+F@6VX6@)) ZN^&]=KFV. S#Z1[Z,&9U6D@MR,A_"T#K1B
MK$!>;7GVI*"!,9^;/LG</<'EWP4=NA>/ $0FE.E*G1LU.K:.!R +K87W-,\1
MC-H1 '#CK#K,K1X&<%T]$ZX9GH]4#-&YG@ TLC[J^9!E^G*,(NBN\$T>NXX]
MJYAT\WCGH3QJ0]]@E,XZ[7\:U>BWXG=H9;2]P0">7?HC?&YAIW8&/1_W#Y[1
M@(^.S[L->!?L#+7_:71[[4Z>N>&85M3N5\9T>)S_,TO@K-_I]F$F<\>_'S=@
M/K[G0>L-YR"&\<-/S[+)-&@E].ZH8T^KL^0\>OF\.8$6W;YSG8+G%J8E-3)^
M5CVI5S3.8X'M^D[#P5,<-/5[_2;=!?X/:[!G&ZVQ;%\9!GMU&*X5SKOZSYZZ
M/L4D4+T=B_#5N>XNSYJMGO2FT8/+_1VZ-_ 77%VXR].9FXGHMUNU]]%U^K9S
M#HN9R K;KL":O6XM3OAM?VX/F]R_UFN?1Z4B:CEXIGM9&6/NRRM1 \4SNZ7K
MPT8,BX?D'07DMYOKB,RVIPKY'"+_,/*JPM)V-KCRHDS]'BBI5S=7F"! [ &B
M RSGTA^C]GU>_[1>/>%/"_-6%=JHMMMJ?ZB:&P8%0T;=B)/CUAZ<*-\P,+>W
M=*)QZ[5<I2<71QFB(5&_U6*"1PSK.ASE+;5R?QUWVOVC8YC=DW8C.XQZ,5:>
M_SQBC5YO>/!KSV"3.>LT<K.[?3?^\FIU%>C?43^/2;6/PQNZ,<Y.WK ],()G
MH\(IU=GR6(L(C4ZL=(C?AAMWGMKC]O=8J0'#\WB8Y0HG4R.#:'89=^$.=&J_
M56#8[QW#-@TJ1#7(P].A:@(FQO2R):VC]N <?SS^TWOGXUI+GX8U7O;2=793
MKF>6,SBO^7I_0O-:IH(.SV%=L=T/7TF07,D@D;0Q(4XL0\ZDA*P**DHGI9PM
MZ  6&1A?6.,D#3<:K# MC-6$*>MR3/NT=;6\</YQ=&8YKKMS%_"^M0#%/;:R
M*;_GTQ:/(!BOXX%O\K[5(YA<-T8LOB #6Y>,/DKUB)5I+%GG[!%*73S6R K.
M'Z>Q=W[L4W/YW\K/8%:KUL5^%;BP,PA<>'<E<&$1E3]6;#0^-7[<82P65P[F
M/L4WEW/$[E@BYDX=?2T#1A8A62]L3,HB>H1%M%I5;9Z4[NUJL-_=24YNXU6?
M7D(O)3'_WOU>^>Q[%:@@PK%@-.9,!:V35MP&(ZGD7J?; NUGTO"'!N?[3OMT
M7OCTNQ_#1)=<B@'^'_;MCY5(SO]9]\6H&CM<^PW#.\YWOVS3PY./)[L7S<8N
MO._P9!O:O'VQ]\>[\]VMP]/9:NS^?&__([1WFQR<')[N_K'#]KYLL\.MCZ?P
M3'IPLL,/]K?Q[NEAVFG,L)D$2BW#E"'M)$?<*X.LT!&%8 T/P5$IPMJ&('4B
MKTN->33Q6=4R,P7^7@K\^10=3=8:2BBW0KKH03J4P5AZ+H8.6P+PQ^:G^!7X
M6S+XF^8FX0+6M'8&,<ER.5]'D8E"(^&]=5QPV/1 %62L+H4L\%?@[W7!G[%:
MJABE8S3P@+W500:+I<7.)I[P;1ES!?Z6#/[(-$%[\M1X3E&4$B,.BCVRSFGD
MJ;.,1!9M2FL;2M25?C"778&_ G]+T.%[P!\&1*,V,F69Y%%3[:6R)#&IA&5,
MZ-L('@K\+1G\L6D&Y@QVR8#QZR-!H. 3Y!BQB(*RKY+DBF<&9B'K,+>K#7]/
M[ 1=(<[GJU%XXS2XZWRB=Z*@OVO!H95$11*8PR(&PTSB,5J-'9>!:$NEM\&&
MXA)<*52<+2*F%4PE21)1S03BVG%DK%6(J2 ,DY0E$W+28!UVQR4JV[/H.J:O
M5L!Q5)(Q2T60B@<2#);"4)$"E3;YD(K3:\4$?*8LEQ9<!)=0DM9D+BP0<*8U
MHDPY(84/C(#5)U2=/KP$<Q'PY1-P+94)C',1H^(\2*==H)IPK52B48KBUEDQ
M 9]VZQ@-FS;LTTA*'&$'MPY9!Q:.,$1$4,U"("S'3]2-+@+^ @7<$<FB5TF#
MB',>C4TZ$I!LQD*(CL3BN%@Q 9]V7(@DO90@UL0FFW=PA2PU'G%"E7%!**+=
MVH;4=4GQT@OX4@1H#62?KE.QI'Z*JC;53WJ;YM=!P#>50G@=7NQ%#,S*[Q8!
M:^HMTX0&PXU*Q@I.3%*1&B9B(L6ALTJ[Q>YLS5 PWV%W4 KY0 GBABKDO F(
MFN2BB!K+8&&WH'7*'[Q;+%R^5N,8L"!L0=@;]'&,=;+*4L\8UUAHQY@-^4]O
M<'"T>-16#&&G/6H")C1)'9 *"0QN8@RRT6@474A,$9RT 80U8'#3ZPB*"\(6
MA"T(^],Z+(N,.&H#28ISL'Y9\B"1! QE@CWGQ:6Y8@@[[=+4%H,6:S"R5#C$
MD^;(@'F"G(F..:T3SY%J1M:57'"H1D'8@K %81O269PD!T4VE\PQR7(MN5*4
MV>1M2JSXE%<,8:=]RL$IF[F)D#:YKG6&6:N]1<0:JX+.A3?8V@:AN;#U2X?8
M!;BDQQ5@Q[SCDQ2I/TT(]&PL^#-EGFZJ\_'SE9T>ZHR\4Y&><5VUU:RA]@Q4
M6>,Z$W3G K[?_"JI2(91A7Q,F9281N222(CR9#41S#)CUC:H6+\.*D9U)B8K
M\,#OL!A: TZW(3GK]S9\?]1OVEZ[<SY9>*:7#T3RDGR6Y575[+ME"_LX;O?.
MJ-E_==HNX\)>VKRLJ%,6W;Q%M[>_@W?WCZ ]1WAWR^/=[U\9"SG]/" LE4;<
M)8LL5A0EKG50R0?**2PZM7Z=&WNTZ/IGF=HL4Q7^8YLU5]&\U][U.^VS:%L5
MX6BCVQWQ#?Y/M$U8B6]MRP8[P[9HNQD)VP-.X?,QK^4$=7"JV=!O]BX)@P<4
MO^V*&AB^^R?S"8<:W'@:>[;;@\LRM6%*L5/Q-E;$],?GG39L?=YV?*/5/K6U
M?VWMO_TEE[-*N8M9-N !N39'A%VND??07&_*AD;;5M6N:HUVR 3*__JXN?U+
M[?MQ>\ Z65$"5_K5J))3)IW-]1URD1/XO7O>[<733-D\Z&&IN/1L%9>L \U+
M.Z(IU5P2:SE7 90V E\(8]3KJ[CTO#OA_F<,>C/C#F:"&H2#BZ W4XFTPA@1
MA57$C'"L<CU#LF[N4'&I0HZI.D-#3&ETIZN@V>XC%/CY)UY7X6=Y!+]ZTMWI
MEH<%DJYD>BQ/9VZ$C.U6[4_;&I$MJSN0+<.TCXKJ37%W#H=A <S+?TVPS\]9
MF'/;<)5_>=B68_CL4;F7&ZT!S7)]7/!PR'4\Y%R>2[<\Y%CV,!T5[?Y-9,NC
M%PR(E&\E*AX)^13C\M7Q@P&]EG89]$[?[XU&ZPZ\RU-B6PI@S2N 1:<&J13
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M"OPM08?O8_I*QVPB/@DJ.-/1DA2L4XG:2"QWHG@Y5PS^IKV<5H2$@V4H&<(
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MA&@2&/&(&=*&"H0]-HI0R9C2 $XSR/3?M<Y09F#683V,*&>_MSO-\+T1 "0
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MPPH$@AEG R7JSOGB!?:>&?9F&0V]"Y9AI#V/B+M D=;)(2]A=JVRBEN=*W<
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MKV?T8XJ-#B(1%#P5N4I)1(8ZC@QL+[.>6$;XRCIE:E7JV9CXNC[J8G+V?33
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MZ*]K*2PF8]]'A?N=G%VK< _BY1D5CJD0C20&.9XXXM199*S$R&IBL;5.<B=
MA2-U*87'YL"ZE,+B*6C+9XK? \9Y$I)K[7&BDGNI3.0"2ZXXT3H7QZD5M*4
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MC8$O#0/G%;Y68^#"8.#Y='6IX+3S1J%D,$<@XA2R6&O$ X]4R^ LCQD#B=2
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MZ6MV7CQVYL0$%7#$%&N>%-?41>FCP90;INZ>#%6S\^]@YYD$"NJ5IB8@9T1
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MN,8%_]L1 /O14;_7/9L@5HD! "L5: T[,!X[F/AK[96[2X2JKAO#S35 1L=
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M.P#AE42YPG?M<%@U3,F52^X0C/CK)Q>_\QES<N4N?#WK<4I <=P?5+D+EY*
M.A-Y]! 3^;FH-==-;>DU%THX"#A#<2*6>T4TQ20J8PA.T2M3FV*_6W.9=58'
M;9EAE""!#4=<<YS;D6,D)?6&R<"Q\2OKC*UB.J_ P05R5M?(\TR0AV=W E<I
M84*X%M%R8Y)70-A8"T?O7"RZ1IY'0YZ99J0Y;U%[C<"\=6 S>89,5!(13+C!
M.@23C\FH6N7FP?$TB^IK7V!-[C_]WGY53^TZ7:Y*Z.[^N*:JD5''^\W@$A"S
MIC%2I@BG)C@G*);481F5]HG7&M'OQ:5K&AK&!"I1= F%H'3NI1J1,4Z!6B2\
M\=PR+##@DEAE?%[.Z07R/]<L*VG /()"H:WAA"OM&!=)\$"]4Y'=N9]AS;*/
MQK(S60(X8.:Q1HPQ@7A4'CG))++>)>DHQLGSF@:>-PV8*)1*7L"FY][V4A'D
ML-$H&JV#CE(+90&VZ2HF>@:V%PC'Y^HI- NJ7-XOEN.J:WU<[>$:[_J+.QN=
M_\(LO?2NHT$6'+EG4Y<Y[)D3AB+G&4:YUBHR$K1N'*3@QLO <M#=?*)!YLXQ
M"^[ K#&SQLPZX&3Y,7-:V[4A82N,1XJR?&Q#&=(@TQ#\'SP+D@JKYQ5PLC"8
M>8<N20^I!2GHPM6"+-M7E 4AU:,7A+RH YGK4Q_E$IWE$G[(/8MB>-T?CH8?
MVW80_\R]G-[9L[(JYX+4_2.-'[57][K-5CC</7K3WML\9(V#]W@WO[?U'NYO
MB.;!UNE>*[]OE\S4_3OZ1)KT0V?WRYO#G98_:VY^:.]L'I+FYGO A4/:R.\Z
M?W/0//B<&N?O2>/TJ^#8ZT CBHE0Q+$SR 708AS%S"L,-J=-,V4CD]8B1ND"
M=CQ:K)W,?PIJHC5!QNE2@1];.Z__'_ISX^/69O%ZI_%NJ_EQH[6]T_R5*I*W
MOOKJ4+524DN:L IEQWB7A#0X*JIH$M;$)ZPZN75TW.V?Q?@Q#KYU?+R@Q,NT
MNM$%4BQ_VTD??M2X?@=#ZU<$_(+)%3<VOEJ>N/:2(@6[#ZJVTJ!J"X^L"D%Z
MZW/QH&D:L ZPS6,M@:!YH*"96^D)%<Q;X0@GRU/9\DLL;$4@,50UTT= ":CJ
M3><OD=&D&GS9KB87)X[_/<E5CSN]7,2N\RT6QUT81U4K'KZ>T&;Q,3^P>'<R
M\&UX:/$.KBK^L?7QW;M_YA915?G,X?(6SP3-<@U7VN5]JV<RN6:,F']!2K8F
M&7V4ZIE+,UBRQIE<EL'B-<'YXPSVSH^]QO">< B(LGC_*^]8Z_3&LS;SZ_4S
MYVM;WJU^9JOLOM'HE\TFMJXTFYA'-=$E6XV/G>]W6(N'DLBU[65O-;,6<\7N
M6';V3A-]*0M&YL%9=UB3I5F0A:"@I5FMNY#/H\K ASV\OO))-VNI*PM]B,.8
M6V>5UEG(';;ZQ]E559>[KNO"3AU\>.UUKO?AM(D\6FVM<=XYRYA5/#DU=E#Q
MJI'5'4Z--R;NA>O=4UN56V$I3D9^U455G8P<?.@TCG;YWI</< ^\Y_S#0>/H
MKW;S"\S@RZ?OS<TMMM?:P#NM#T?3)R/-M]MG>P?M[M[;-X<-F%/S;>-L]VB+
M[!WX[WNM+=QHA6YC\[UHOMV[KOI2$H'BZ!4BW%K$;9+(6D]0Y)PPIR211.1"
MV(*;9:D86Q?"K@%O/H!G8_26<1="U!P+I[W,_7495RKRQ.FX<Q_'[/K.?37@
M_7[ FSX*%MJ&1+%'UE")N* 9\)1"C!CFF?"1>5>6FY/+4R/[=R/>BX2[9X9U
M05@7F#.*:<\MUX9( [\RS@C14EU_^EACW4)A'9E6[G#R,46"C-8D=VGTR,#6
M(J:U#A93FZ@$K-.KG,\&><\9ZVJ@JX%N(8 N$8>)8IYK4.*$9(Y:J90*0B<N
M,6&WM6.N@>[W QV;;C8@/."9)(BXW/?$1XH,=@Y%Z@('=3UA0E?6J5S%<E[)
MT;\#Z)[8B[E8A9-^RO\?8Q<^W%\M]F,O#FRW]&;:<)1+ 8\&99?T.MMZ&@F-
MM"I*,(@DUCG=PU!.J29>.1^M&#>FK_UYBXN$U]0*Y:"U>Y48(MA@,&^30@Y[
MCG# $?0]P3U+H/*)5:SJMBO/D*>3P3@IZ:CVAD>OX!\C130D1IVPD[7+:O%Y
M>L9E91-3D6!83R41YT0B2W1 4DNOF;%6.@X\S5>9?+ 95_/TXO&T#2F%D(07
M7G)NF&/)8JX\CZ$LY%2[9A:?IZ==,PQ;#2J70,&XA'BR#!DO6.YZHH,(SO!@
MRK(IIFZ/]BQYFKJ$$V?.4<&3=T;D\U;++ ALKPFNO1"+S]/37HA(*"<"F!@4
M<(VXU!0Y:0S06!0,P^X:#[HWDZN2BH7GZ86(F%KXLF]E98Y;$V/JTAUU&OK\
MT]!E KV0$A>EXH9PJZW#5$<:A0RNCL9:? DR6]N#!2PI$PI9[ +B&H2'8=@C
MHT*DC(-5SW(Q/0X2A#Z;//6ZMD<-JHL"JB08S1B5"5/%A</&*^8!3(FPQDJ;
M:O?9XH/JM/LLP#91[P%%"1>(>V.19KDQN0P^.,V9-?EP4*]B]F"UO ;5&E1K
M4)T&U5\I;%&#ZD*!ZK3_D@;+7(P4$9%!E5F/K -0Y3&"UNH#8TZLK'.^RO3S
MJ:A4@VH-JHL"JH*H(!5U21C+;0S61R6]$TEQ(BU1M0-Y\4%UVH$LA'2>.(N2
M9A%QH@F8_XDC11SAC@CEG5Y9EW15ZCG'ZRX<J,[!_?PKI>_&SQPSI># M<?]
M8:?LMC?(E=TZW^)%=9^_7RW?-%Y$?'&+=;!>)Z.;;[E#S:*G+/E$U-7J2I=_
MMG_TMCRV^Q&Y0;2'R"88Y"O;/;5GPY5_79T:S.OR.MYA"<;=,F^8<4KWF;&^
MPX2K]0;PZ@^JAHK 'W&0KX)1V-\]A*(]R$C_M]M+,:J5]599V:J?BM=92/1R
M<QF[?MUF7EOH[FZ%ZV;ON[78V0*7-_MXTZ%-KF(6K6\7H[/C<DGMJ1V$HMR8
MV\J;Y>)EQ6D<Q+J 65W K"Y@M@ %S'YCL3%@Y+K2V&]:BKK,V%,7B:IKC-4U
MQGXW^2S-4I'[P-!2UY>J:OSVC[-J/=/QLJZQ\N)KK"CO#+5@..)\DL"8C<8R
M@<$<=88%6H<Q_;H?<Y\U#[;/FU_RWW\=P-C.=C;_[#0W_SK:/6H>[;Q]TVF>
M_W78.&C0:3_FSJ:G\#G9>YO;:S0/FIO;O/%V&S>.]CJ[=)?O?MEFC:/W9XWS
MO=3HS(0Q81(#"SHBRD- G)F G"(4)2<%3K"K0HB5=3;'5L7/[.BG!KSG"WA6
MTR!M2I@1SE6R3B5C8!D,L5$&I^L0H\4'O)F.JDPYSJQ"'F,'@.<4<C1B1)P@
M401C8^(KZV+5X#F';3Y?P'N1:/?,H"Y)0;D6(C'..=;.X,2IUD0$!@H"9W7@
MS^)#W73@CPC<"I5KJWC,$4_&(:,9*'C64II ;5=*KZRK5:+F'/=3EY3ZW9Q?
MX]Q-L3@J2))R<*,OBPVYE+3 H!,X)10S=4FI)<"YZ5@<:X-7,61MSDK$"<?(
MD @Z.1/)*FVDS#8LP:O"R*4 NN=<_NE#'(X&'9\;E96YF"6SSG@;ZZQS3:62
M+#"<"QC;@+7TE%J6$C$V4*QK9]NB ]5L!7>AE"514F0= Z"B3",;A$-8"QZ$
M#,D(51;Y-+2N#O,,>9HZ%;7!1%B-N:3,&,P$2U+29"P1HO8G+3Y/SZ2L22ZY
M!;TCF !&EM<XE_"EB%OC)3'<:1K**FZ</-BA5//T O*TUEZ(:(.*AA/!=? R
M1D8I2&U&19TQM00\/>TXD99*K0-%,7""N,8.6<D](H:"1B8U%LJMK#.ZBO&#
M/2<U3R\>3T?OA//41Y[EM.+6$1^==(I@DUN+UTZ"Q>?I&2<!"YP&X5&@@2$N
M,4<:E&]$4_+$Q$!<B"OK5*WBAV=!SI&GGW.\T;LX* F^Y^.#?0'73/OYX!&0
M)U=@*3!0+SGG(I.K#BY(XJ7G2=:^@ 7'HVNJ/PO.81.M1IX$#3J&X,BE%)'B
M*4;E#;&$@-VP*N:6E+U 1S U2QOM?0C:@E4(.J9U+EDO,X='AJEFOG8%+#Y+
MSQ1_9@$39BT*SF:6-@DY+A2*.*;@68@DY$(+J]+,*R6X9ND%8FFJI(Z")4V-
MXLX$*X2.FD?)G0B2DMH3L/@L/1-"D;PQ02J$)3:(6Z*0(U&BY"S7RA.KI,_A
ML=3@FJ6?'TMCS+C3C G0UCC(9QMD)%IXKT!Z8Z%K1\#BL_2T(T!J'K!G"02T
MS%(Z]]RS":2T@VV.(*89L2OKE*Y*/J\:<W5,P,\Y,J?BUQ$ ,R&900KL?-#*
M,FZ"TM([,/Q%THD1%_BC6?TUOMP=7ZXI#&PC!R#A*'$>42ZBARQU!.7Z&TR1
M8$"FY,I #U88ZI.#Q>-9*J5)@4D>-.%@^VDIA?8Z>$,,8Z;NZ;0$##UMUN?*
M.H&KB"+-51.QX<APB9&PWB<B#.<J%Z5=Q;1N__(,65H90Z3"2EL';"T#L+.V
M6#HP[Y6.EM=F_>*S]+19[Q2.5&B)).C[B"<5D)%>(\*35T;H$*7-SG= [9JE
MGQ]+:ZZ(H$[BZ#PW7N7@#L<BS['B-OC:K%\"EIXVZW5TR6O+$?8*S'KX VGA
M R+*:2 XBD6264HS^> <@,4[WJ^;+\U61'W1>5P/6Y*E!_BZX=*R _QLI1+0
MOHV@Q*/D,>AL3BIDO&>(*Y5R4C_H;?(I&RX]JV37&D)K"*W;*STW")WV9"FL
M7=1,("-,0IPPCDRT"1&'K?>:)I&+UC]=>Z4:0FL(?<X06C=36GH(G0D(DB#_
M:*1(!((1YX$ABPU&2N2Z8(((0OU3-E.J(;2&T&<,H77KI.6'T&E/;6!>4B\Q
M"E9$,-]%0,[G,&G*I2',X"324[9.>HIB+K,-CFYL:+18K5=V>D7#GA54K!99
M1UDM[*@8M6/Y1['1@PETBT:,,)7]W'^E+"'=[G=A/8>K90>6X:5/"GM\/.A_
MBZ%\!/!E+\#_H[(=RR .1\"7Y=_PH*WOL=OYWH&';/?\&KR.J&*K:N:R_:.9
MR[LN+,0_[+!Z%#SVTH/"ZGB<<&.^[I]K1>NG+^WT_""6KNE\WS##0_X^#N!%
M54.9*\\KW%EQ(Y"5=P^GU4$=A*<J>NYR_(!VTG+EC$S28#"XQ%@=%%2@R2^7
ML6R[^68:S*['L(W!P/;VRTG]>79QR3M[EC_:R!URFB='+@YVT@:0=[[%=LOK
MAALGHW9_ .01[H: >#D1L!O_[\/9WI=P[ !RFD>?2)-^Z.Q^>7.XT_)GS<T/
M[9W-0]+<?'^^>WY(&_E=YV\.F@>?TTZK@9NM?1C//FX<;']O;'PEGACX#^2/
MYA1Q3Q32B3/$*6$Z"<^$-J5-+3!>!1Z=0;2*U(9KQ<8P$_X$VBXS^8U'4(_-
M_;D31X6X#$\ X'Y$'UPF=DU"<)Q+KVW@3H*X=HDG00/]NGV=Z?,8M#ZF\&^V
MT\U8_*8_> OWCFI"OX[0FP<;N'G>^-XX/R0[K>VSYL97&W1T @<4 ;80C]0@
M3:U"R5,#AD_(9:I6UAD!L:U6"9N-A0)"OXZX'YN&\ZZ/^WQ-]K[L&[:?=_\2
MLM]9XE2"Y*J Z SAUW#B07K<7RX\S$UPB5<B3.'7&>5#GD"^=KM77O"AFMOF
M26SU2[F^4W:&V!F4?VR *(<Q5 _/M[]<7MG<9U^53H$339%P+I].T9Q5P#VR
MR2?%C-;.YS) -Z#_12.[ZL_.<'@"I'1\,AB>9"H=]0L[3I&OVG.4VLOS([,=
M8,1!>=7PY9)3Z[WXZH@)W-.(%,[M9;EER%FED"1.&,R,U1Z#5G&3,E'24SKI
M=HMOMGL2J[:(@&R@XW9/LD53:KZS91B+?WSX^&GXS[4I*^LNW0]_GXFR>3+(
M,RJU]L[WXJA?MA*+5UJ)C767TUC!?OQ]S/-@?:9"X6&IO RW>^]@T?KA[: _
M'-:JS.VJS-9I\_1KPI(;&102VB>4C3!DJ6$(-';)"$O.$. NV.%5):_CL<M]
MDHK3SJ@-Z%R1:+9!O\6!W8\%H.3 =X:Q. 8^*YN3_L_/'%^PC^5^SY?PZ+W)
M;G@ONOLRGO5&->FM\9S?Y2G7%%=2W 9OG'[E3!)+!$%@M7FP$J5#UGCX$QM&
M(W922+ 2B5DSLP''Q3%HJ)5>D*7^-:168EJ%V<&.0)NPG4'U9P7_RT)[#R&]
M\LM-F/T;F/SG/.V:_BK$^U[FL6.;F,-(>\-SYBM!3DB,K*:$>XME-&YE7:^Q
MV>#8A7)(5+SP.\S(3)A+XJ/Y'<M3>EL!H4I#>]E<1&-\V3D9#4< L:!-5DZC
M6J&Z [QDWY!.( 6PT\A& @H5XQII1S7B42E"2<3&Y'P:NLHPZ%1J-KAH2J?J
M7^Q$*?-^*KWF0DY(3%/3UM%QMW\6XT>P3D&;N9ZXFOW>-["D0 J5%E89YG[Y
M^]?]X:C9'^U&&)SO[_?N[EJ7+YJJ-D1C_ZMT*00?'1(Q8L1AVY"1S"-!2(B.
M"&I$+MG(UF[*Z !\ZV9J <@>Q&X^% +"&?S8B&MS$-:6Q.K=S@=S ]^^L&Q+
M(S\?7_4+'P<CVX$YC6EX"%Q4V/W]0=S/^F$68?<S?SFV6B6CF,&< H,I AH%
M283SX)3"8TV0331!QAX-JRN7['9O.!J<E/9*Z3-JM6WO6BVQAO#KS[%VS[X:
M"9NJDZFBF+A3!FD&C.9P[OS)"&B*.B=!8LQ6N;[&#OY'=KF,@"OBJ+!'H/J,
M_EED_Q&H A8^ 45@>.(.HA_[+T=5#E#>U>H\&)AR=#+H%?]H??SPSP+8ZQ >
M!'17G4E6CX>OQ@E#E6>J]+W#A[.7=X9%=6%F^)-!Q?'99Y^O!K6Q=.%W8P'D
M<5AR/HRC8I;\>Z\#3 (<D]_9W/BXN?&^^+/3'T7?[@$C[^<S@!"_%^'"UW1\
MJ7KI<4EKP(7M#G DC.0OVSNQ@[."5!H9W "JX7[[Q^>L_%RL%9L1B+^4<_WJ
MY<!\)]W1\&+X,,+1#7.NCK@GA^O U;,K!O><%='"*I\<YT?=R/>]L<8S3[ZG
MLQYC=SO+NWNS?,-^[QR='+V#_8(]MMU6_S,(Y1_<C>@+8^]&Z_UIX_U7RKST
M$CA::.H0)]$C$WE")#$L:11,F^QTN$8=^_N$F*YP=_YP<EA]/SK2 "Z)!I#:
MFO%@@R6>Z&BTE58+3]Q=Z>B*]/@54BI_9.( CON0I>GP784,=C^^:'HY;^Y_
M!6H)23",<&1 +S&W"G2"(1<]%28ZAA/0BY@-8?A!+N/3AXPW4\=7,\@T/I,H
M3COYE )V9!)9!' X>=QU$)O-@0HGCVRG/+R]](0<7@10 #I.]\<I+)AR<*N?
M T'.28.Y3(.5DD*N:"F@$?I7(&A.^[ ^L??B:/$3;YX"+3(+&C]!B0J1:=$"
M&3J/K,2:8<XML6EEO=^+Q1E0VX0BQWN]7F1E?[!Z6?^8J,+_^S=-B?IC6(P#
M\/HGPV)8F7BE<C&<D: E?;GRC#;%3C8B.A5YSJ@@0,']06%='\2VS3(_#K-P
M+KKQ6^QFM:#7!R+U[4[,,7!WH?>L%4SK#$MBH/R4_W[)M7Q9E_#M&$ZZ<1S6
M<W\K(7N(*X8=#D^.JL]:.3:D!6/\L]OWAR^-[\[?T^;&5TI8TM8P1%4"FSL2
MBZR1 2F*C8K97+!R9<([,6QDR!)6"&8Q\=2[[$QVGEGM @M6<*>]6BDB2-9C
MV#O8#;#8O\3B)'.7+1J9)HK7=M#M%T-0X;J5*7[4#\ O$Z1/_6ZW?UJZ@B[V
M*K-TB,#D1T!XY655/,^/\X_B04<?RC@A><X8EYISPZPAU"GLK/!")B6>[.CC
MGN9N?2ARLUPY_ YRQ1ILN:$!<1,MXLQ09*GDB&&*92"$2PERA;$UHGYV$)?C
M*V:-K5?3<NA>4%T%CV=E%/3G,DGB<HQXM5NWLMKZO\M(\Q^G$E5H.V!]UQX/
MXZO)+W^$SO"X:\]>=7HE<I<W_3$>U3A,/M<2F8IL+\=9??W':2>,VJ^,65.8
MYJ2.<163\8NK;\E:F>\Q%:8_OA.O8<-O_!JOD1N_^]EC%8Q'WNFI3]1:!?9X
MI=S[)Q._1, <WUS!P$RKKTL_Q]DE!>CHJ-^;>-Y[EP#T*MG^2I7;.R=C5:OS
ME MS[TRL^V54/?V$?D6\,2L,-]PZ+;@1T8BD+!.@N#FAJ377GY%<+]7&L1[+
M*$PFF5!B[\M[VCAXTVZ<>[;3>D\:= L^@_\WMT3CP)\VOX! :6V?S69"=;M[
MF[MGC2];Y\US+YJ;G^"Z;A?^/P2!<]8\WR![F\UVX^"OU)CM 4.(95&YA 1S
M$G&K.-(8PV^&>BQEC#3FW $,D/9;*U%7-'T7T%P.;,Q9?F7HX[=^UCB[H&%=
M#WG7E,K[M8IX"X0*USKH'JCO\KGINS\4U4MVV912^_G'IGT 6;7T7KNG!:'9
M>M4I4II@UY%)WB$>C('?,$?"$R:IB5P'T(BY7-/WK GR$*QY2D[Y^Y7Q/V^M
M\$-G>(C2(,:BD\V,[#0=W*CP/7[_CQH6'P"+>2_?P%9NCW>R1L-[H^%LE;F8
M/&>6261"S(?B5"&3DWF<]U)+PKBV<66=K(D'%P:>@T:VL"BY'&"XV?G6"=G]
M?M:)W5!K@ ^!NGF&^%P'=A.5?;)G%=A=CNU)G>\QH/,XZ-<@>"\0/)M5":4)
MN2TE$H%IQ*7PR)I($36),FDP\[G49NE(HG^\&*7P1PV/F>H="WX2ET.F?G[2
MTAWVJ\.5,BAR4,4>E8&X:1RD]2.\J'(7ECE-PSMY%B?'.%?=C:FPQ7&,.0V[
M?W*<_[X(P\IWM#MPX2"3P.4W7C+8+\Y,KWU(%2CV;7+*=WFBY=E3/CFZ%#"6
MG]2-O?U1^R=GL7E<^059BL,?9>T3>/,IW)25Z&*_#\^OC@8NREU?#76[\L)<
M"Z4SG*QS61(EP]^R'/ ^1=XEU=H+$6U0T7 BP!;U,D9&:>264?&4>9=UX.G\
M<P?.2R>HBI* B*%.@+ ).B)#8D+$4&)UBB1XE[OF"BU6)9FM"#6)WK@:LG%]
M3N8C)<H]D$KKT^)%IU/6?/\U$="*N&)(&# /.?<).6<PRMF;7J0DJ":ELU[R
MGYP<UREDCY%"%BGVQ'FC*".<^.@,,P3D$,->4>Z?((7L5L[[D2ETI]2RE\QL
M.(=I*.&ITPIIGL,T?,Y-H#(@H:5TS'CN.5M9)V25&[E*KDO2+^7 I3RRR\4O
M9B,W5N^=9O9K)%>GF2T6K9&=]U]!<#-G1$#148:XU08YZAT*VE.LJ=+>^@SL
M:NVFOA+/.<_LXY7$S,PEU^A;$^7^4ISM\'*NS,_M@Z(-^ED9P9VO_Q%..QP;
M7+U17NUL;'4[WRJCTV8;MM.U V FL*O&23+]8016&_I!Q^4@W5Z1#5**_P#.
MB(5>*R:L5OP9>S%U1F4UKV%Y$?EC8H)=NJ<,,GP- \D%0<M=?=/I@4'8@:%\
MG-2-_'%_!2_5B]_9P:C8WEXMMN&B0N=GYY2D-YW,=7G.I'@#S%D0C/[?LA!"
MJ;=<]>W4RLNURLMXD>YGZ'(F-4Y2)ZJXSEWGA?$1!Z(\BX:EI=-@:L,ARY=<
M^T53L ZYMTCEBB\\LH2L9PJIE)1TU(5HTLHZ&+>2KA)Q?=CIQ!4U!MV;JG>]
MRSF2#\J>_S4ZK-6:Q2([D6LR*&5S!Q\4!,GV*E"<X80@H5PD)% :<UP'(6SM
MIKB.V]2:V]KY@<2M?BG&-Y5?9O]HIM/2(1Q[V8U\VHZ] N1Q9W@1TQ_&6<15
MMLRD+/2T9W:<GP@W'@_Z+OOGU[)D!64C5U'L5:12IN8XX(I2"+\KU?UAC$NI
M'ORT=/A8(@D.(NNX/RS7^]4DD7@<L#TNP7_IKG&X-[ZXQ3J8T\GHYEON$+[^
ME,(W>P6O+-*EGWG4)11X3;21B3@7P7@,7&,:O"=>)$LCCO2K$"N3F]J#B_.J
M?0#=0;2'R":8V2O;/;5GPY5_75T/6(S+BW^'=2/B9QI<2O=9)GV'5:HV"7"R
M/R@)YU59^39?!:.POWL(17N0Q<_?;M\EM;)>YFEEIGF=)1?PV+__9=>OHX ;
M*?;1Z%-=2Y]-@.2,,(^4$3>1N=L]@-38LM\W 4BZ_2$81HN2S=;\.)&';P[S
MP?7>099IVR++M+V#=F>WU>[NM#:^[[::!\WS;;:SV6Q/R\/&E_=GS?,_X7WO
M1>/@$#??OCG:>?M7>^?M)]'8?-,&>0KRU?,&?9.:("^_8EA,HRV8\UHXQ)-U
MR%@<4=22:: E)U6:SF6+#C--(M :MIP2[)( T.8,<YV84FPZE^W=AYW/VQ^W
M=YK%FYT/Q7;S]4YCJVAM_'];'Q^4"_3[S+SK\XYN79;RD#FF%'U5M,)^K\Y$
M)XE2.1FVJE]XK2_@J@%WBPOXVOB5![9\O<:2VIK,Y@=?Y:"3U]7:@&Z] XI(
M=4R^. $G3\YGE_3.QKDGC8VO45@JC?5@Y"2%N* :66XE,H[@Q),DV%1)#;/>
MM+__O*SU]25*YEZ9M][W^^][\_1K),I&'CB*G&O$F0,S%R *>:<C)EQ[%V15
MXO2:?0>#]KA:].[9:F&'5PKTW),@'M:XM":(>1!$3B4GT2N#A4 .YU1R)C32
MQ%HD8XA&!$6CMV7YMMFJ^+\"! ]L%5;O^X/WO;FY)78VOEK,G#&1H  Z.^P[
M" #M@T*6.L*-Q,0Q7 J Z^H.3?2%,@IM>-ROO%A5 -:P-(VKR*Y?5S4NCAWR
M)9<_(47HP&,SZJ1!_ZA\V*>UCVM% HH=E %==O3_L_>M36TCVZ)_194S<PNJ
M)&^];$N3<Z:* )EA[P 9('MVYLM42VJ!$MOREFP(^?5WK=7=>MD&FP"V0:?N
MG1ULN=6]>KV?TTF:W98O!2O$MG[&[#10XT +TZ(I12/XMY#G.3T7"'="7CA1
M9#N<HD$XYJW)AGWU-ICU;F,$ 95-=PF+"N3#GZL-XNM"V#^\334C(U4*6"GV
MQ1I@UER<\PD.*:')5_@+GL]Z%>8$)98THKTW&VE]^4]N?1VR; 2WE:L<H4TQ
MO4[W)4<8_OO+\<$)_.;8/OWMT#WY\D?W,W*$X?'M7U_V;N%]7XYA+W_]]H?=
MY CPCIMC^S.Z*=W/%Y?VR<$@ 8Z0?/[^S^'QP=$-_.[V\_>KKW\=_!6??/_D
M_FWU+.Y'OFL$##1!UV<12 $[,$P_[O5"+S+MV&Z:7L"\ 8>ZW1ZV;.V[IF\"
MKO7]/LZF[GMQT#2]3@XOE,'U\?!,._]][^SP;J-KKFES[VM_?6+$*7O9-%'H
M'<N3<&\4'23HC8LVJC_-\Z/5L?,WBVW0Y/H1SBYG8%OP/@XP[QNAXS*[&YI=
M0*\FFFRNJ7W":>H@J!:5SB(&Y@@#EB&CC\2]ZX*)HTH\I6S&7/;$R;4=:EF9
M3F$;.-\%I<YX4AT80(W[\MU??J03R3-W%/$Z9J_[D(XBKM_I.X_?4<0R.Z#$
M/&C9N[]SEVQ4L@&;M3INS]^6S8)FV?6>9K/]99>=4Q2G" 1$"5_]R24K[IJ3
MMXM'_66*\P3)/^V0:'\II>V"E/ACH;P?UI3W9F71*X#&.1@R]\/B1U&D4N6^
M:"*R.3L4>3,A5LT#^M&#OA: 68]!62\,)BT2/0$2/:DD?*P.'8\+O_M- DH6
M(!N33> =R^#=/>/N?QPA[P/ECZS1;G+3-OG,9"GS@^=5A%O._?0Y3*)HP)^;
M/@N3?>D^'W..N71WQ+7PH.4;),X[VKVU_&LYTPH9L#^82& X3?\>X(P(('U(
M\W+^_$6Z3P7QYV61>"[]?,NEN#K;Z0"4O2W^NOIL']Z>_'GDG/SY_NOQP1_?
MC[\?NG]]^>?57W_"\[_]>WCR_=(\L0_M9F^+D^'[+Y\OCJS/7T+K\Y]_W)P<
M''\_OK@:'@_?#^"=-W_]^=DY/?C#^7SQU[S>%IYG!4[$+(,'@6VX?M@S_+[9
M-_RN[X<LZ/E.9&\+OI!_N,66I\06]#:S*#2Z+O:,CD+'"$RK;SAPZS9CD67U
MW#>_]DV]UY]-9_G1#E%W",@5V.Q*&D7CE4VEH15R+T3(_6"23,NT-HEI?6\P
MK9YO>J;I!T9@1\QP7=LV@M#NP[_@_ZQNUPH9VQ9L:56BI\>7@/=9/^2>P6S7
MQW9??<-C86AX'@@XYGO]P#+?_.KW=--OA5PKY+9'R/U8:G#+MC:+;5E-W3ST
M;1["Y6&O)<.-O:X1=.,85'4>LM#GS._WM@5?6J7HJ;'%MRPK#KH]@WL>6'(@
MZHS ]YD1.UT_L+D5,5!:?K4<7[?=V<345LJU4FY#I=P/YKVW4FZS^);3X%L.
ML_L1LQW#L@/@6_W(-)CC]8Q^%(#6[O1Z-J5<;P6^M%+NJ;'%!QW&1P%G1B88
M_%[ #)]9GN&[=K_G]=U^&/I@RO7UGN]LGY!K\P86R8L#/DJ'R>@Q,P<<N+HH
MG6+J[_]L:+2[W>*:M[A!&0-VQ^YN*'&J-KN&:D.L6J&+:>G5=DVRI[ZH 5A(
MR'?-XUE6?=\"77=NH[1'#[<VFB"+YF9RKG1^6MY-J[P\JO)R,CN)S F"L,<P
M*F_U',.U>]C^%93>.')Z-HMBO^^"B>[8EF[-F<Z[:<K*RA9Y2]Y/$6IJR7M=
MY-T,,YE.R$/'C8W8QGX H=DU6-]E0.-8N>?U30\;@SB6VY+WRR7OQW:QM^2]
M+O)N.MA[5F@[?>8:?2L*07I;F%/G^D;<B_IPW5[HH>O!L4W=<7]X>%Y+WAM)
MWH_N6VS)>UWDW?0LFH$98!MC(W1\(&^<$,S,&)1SU[:!O&W?#6.4WHYN^RL.
M"GZMGL2-=UQ0? =[[.0\G&;)),%6,0_P2?S0C. M8'O/XY.0T;89WK<7?9GF
M$VPVW#+ 1V. LY.!@\CVS3BP#,L%WN?&D6MX4>P98-: K>K%'HOZP #UOO?#
MQLL/C09^F':SK&OY-9/Y\_@F6C)_5C)O>BEBUW-]IVL:OL6ZANOXEA'8<6!T
M.=@UGF4&#F=O?O5TSYX=\]:2^8L@\V?Q4;1D_JQDWO166#P";AYT#6;%L>%R
M*S*",,:A7X$? )</+%=(<[>5YB^3S)_'5]&2^;.2>=-KP<,H[+O<,7JQ!4J[
M[V/V7#<V(@;&F&_"5;L>27/KAUV23T[F;;+%$R5;R#:+/Y)NL73KGA?%0I\K
M%V,1$VU9YZ.QSMG2]YX;]WIFSS(<,T1#* X-/_:YX86N'828?FQZ&,]Q==_\
M85-H53+:HF#/ZV0-SY7'T;*&9V -31\):,5>US%[AMM'5VAHNP;H4PP[_+.>
M R9S#Q@]L 9;]]W9X0XM:WCEK.&9<D!:UO ,K*'I5V$][EBQ$QFFS_J&&YBA
MP2R/&X$5]0,//O0=+K0&T^^UK*%E#6O)'VE9PS.PAJ8OACE^+^A[IA$$$0?5
M 0T*K&FT \?M6V[H^X$CM ;+VG*#XE%<->H114]B8.Q&U0IM1T53N\NU[7(C
M?)8;Z:><._SESO*OMF/#MG9L4/.<'M=]:M\W@4PFQ4JMQ6RUEGNUEM/9HK3(
M]7O]'H^-,/(MC""%.,TP-K@3^S'GO: 7FF]^-3OV;&NT34MZ;7O$O':.\X->
MV9;C/ 7':7I7;6SJ$G2Y87M18+@L]@T6L<#@/=_RH] &JY@XCO-8KM66X[0<
MY\DXSH\Y>UN.\Q0<I^FT=1TO8%V7&9;=YUA]WS6"H!L8<%%FX 6>!_P(.8X[
MVS.HY3@MQ]DLCO.#/N26XSP%QYG)R_.=.(YX9'1-+!8&9=3PXJ!K]#PS9-TN
MBV.7;XF.LQ&EA!O)D.YT<2U(NEO2,RD'"C=;5RW1U>HE\?%'A<F+$0!/[58K
MNIZV(F#Y5I47>\C^R;EV\N7S]^,OG_]VNI[C<,:,7K]O&:YK<<,'L\#H16[@
M]CW/8]C9]#$\:X]))VLNW6CY8\L?-]P)V/+'!_+'VSI_Y*%EACR.C*AG^H8+
MIHOA=6UN=+L@T.*N976[+NG(9LL?6_[8\L=M<5FV_/%A_/&DH3_:/C.Y:;J&
MZ7:9X=IN;'B.%QE6Y'AVU.^;/68^CM>RY8\M?VSYXW,Y6%O^^$#^V- ?^_U^
M&)LQ:(VVY8!]W;,-9G<=(^X%'JCW8==RS)>N/SZ"<_8?$QQG O\;)=?%B(R3
MZ1#H+?SU?^%#M<*099?)B [H*]:7C"(^FOSB](@)/Q-AVPMZMZ$S=C"->%2K
M@LYQ0(N6CO'B<QT8P#7/@?RTL_-/\*?X"3YW<7YF!"POOOD(_]5@#>WP_.-'
MXA!9$DQIE4Z!.02SC871/B 42T;:.)W #A(V:!2+W_",:_R;!%J<I4. 7*8!
M"H;3 2-^F<;:S?(5YX9R>VL!#]DTA]63R17/-/C/K7:33@>1=@7+P'\B@"W\
MOTEB1.HF@<9X.-%@Z=$\SWJJEL%=9QPV".^9I&H?M'VZM,D5FXBG\-9@7W#X
MP:V6Y/D449TN%58JOPUO:4.C= +[YG R.'L>)[ \+(1/<O@%0 +_F?%QFN'/
M<&=)&G6T_ZV1S"/HVG7Q<1Y>\6@ZX*?Q'FQ7 >N\P/I#>7_OX?S[Z7 \G=#-
MG<9-N7,!NWHW &+83GDSX+^?W?[U9S0.;+<'[[@YMF%_WS^[GR\N[9.#07+Z
MVS^3S]__.3P^.+J!W]U^_G[U]:^#O^*3[W]T_^[9=C]R[, P'2_&F<%=P_?@
M7W'7[@51;#&']=](C)CR: ]+9'I=KQM%7AR$3L^UPKYG@TR)71Y'K!L['&Z*
M@P@?PUU-LBDPU0M CQEB641[=Y,=82\#I$X'@_0FUW: BB=7Z12X093O_C+#
MIB4_@D_E$<0R=,_W'@-$!M&%DG]"D %S&K!QSG]1_WBK1$@R(E9#/WHK.9X4
MBM@UHR'&B >*K]_>)-'D"C6SCBFT,QD9E&^67W?HJX94%M]US4[/ZR[\VNQ8
M"[^[:UG+[-BF_Z!E[_ZNZ[K;LED+#,G>MFP6M#K_:=# <I9=]KECY?>6I?@S
MC\XQ4T/@1CQ[6MO,;V@G_;G:R<55QKEV#,]=Y=KA"'GA/Z<CKCFFOL2(KY<&
MC?/DVQ*P^%$4J7A65J@<W$R(H<*TS"RX90[Z6@!F/09EO3"8M$CT!$C49HTM
M\DCNU6S>BO<"S=+Y!FO#9/B1'O6OL^\"[UJV%_&0<<=SXY[O,9\%INGVG#"(
M?-]<N9';#YKB>T.XFE?1&?/H^XE]9)Y<G'PYL>&W!V>#SU_>)<<7@^3$_H1N
MW)N3+U^MTS]/!DWW\/&78^?SES^L8QO^UX;G?OMW<OS;T;?3/X^<ORZ.;T^^
M[-FG%Y^ZG^U_Q\>S[>S[MM_MN4X MK[G&F[@6H;?9WTC]AVWWV6^'?/PS:^6
MJSO=1_8/K[]/RR.VQWV=_,*);#LT66"%W'9M-_!9U^=QP"S7\7K<Y"MW=VOY
MQ:;QBV958C\RK=CWND9DQ<QP/6R8W0V!'+J>ZW8=NV?S+O +6[>]'Q[_T_*+
M%\8O[&[@]9W0"UB/N:$;^STS#H*>&W#/A&^LE5N^M?QBT_A%LZ:0FUT[=/J>
MT0^"ON&:(>@7O<@W^BR.H\B)8KMG ;_HZJ[SPWW@6G[QPO@%R)G(='C/[O'
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M2HW*PS%\>B>V/(A+W,,6!!^X2"_4CO9P&Q\I];N5%8MDQ<W?8$?PP.^CA B
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M '*+&&OR<:F@D$["O;:3P,ZGF&6IM">]=A#*O<S(.S%DHVD,>#;-N [@@O^
M!*!>^&D,5@YI)/0)J@%*B8>=BQ<E0VQ6+\-[*JHEOH;#S^C+8V%PE9J9# =5
MM+.E1;)@FF2/*: WH0W+D3$C-*J5X$C,=Z1C;*U .WL!WO$Q(Z?XHR)@E.2$
M:X K]9NKZ@M-LWRAP"'ENZZO%<G%<[4(0-2$QWJ#(.BZ:(@"IEQ&,A+ 1K?D
MUB@T]7E7'Z!52[\8@4+.,EB>%AW-P0'0W>Y&!;VJFA%62/-'YC*C<3DI;5A:
M'2=)E)?IX5TZIL!BL#42T:%>'!MNXTN:C"3LA>HE<4RF9U-U"&U,U)&,$"Q
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M!6.*.>?D1Q#!(;TR\J7QLJ(S?3Z-52Y+R/(K+4;DQ?-,9=KZG*HO.I-L^T^
M$ /KQ.!*$2Y4"?S5"0.BDHM\'"IG5(UK'*3%2)S9C![A=:],C*!$TW)HG (
MY<A3P^PQGXC)A!A#"^6F\3$1ZT[(C2U<\A0MI+(:(--@())659^4>3^NSY_.
M*Y77 :=QBVH8%R4?58IU!@PX@U&4'31&_>A:$H/TPEX%DW+*%>5AJKN*JB.9
MQ*]P$/H-MD6BJPXQ'P'#S45_HB(RT1PL=,,U59=0KY9'S(+7B3%/**BF(<6.
MY#U70MP1_R\-0:O,02^2D$3HJUX_5P4G()C,.YZ7=JPB9T/V)<VJ* 1LX"M-
MUL 8>B7SN'*;'>T0QW<DL8R*R[:L<Y.;J<0#5ZQ?*K'N^?M&H+#P*N&$-_<#
M$:E=7@G1)16:J.-@94EYAB)V)#N-E(6/@WOA23Q!?:57%J5;2T>R^D_QJJ Z
M^6-P6ZVQ!+B-L^1:S/9(LLC HX@-76+[@)$HT&.W>+IZ,9ML6)E2DRX!F8PG
MPV":Y11Q[&A[%((B=%2C/K%=;J4?T;@6QZS2?!H4TVZQ%2/\6_V]^(V-_'0<
MHH*3:$0HE,:RX.3(V[(P5;(CV5.R5I^9D!T 4F"DL+ !=#&Y!9/X@.I!@[D=
MLJ\\:Q1Z4C)@Y<W G#%A4#:^!*H%WH_S92J+A6FNYH*&:29&ZU'=Z8!?)KF(
M:$@.AF^M]4X@Q:*<)2?'P_)1,?9'QS&*(J.@W)=@IO4=@!C(0-P"!-,,6#6P
MI\95#=EH"C(0Q4Y6;]19SKDN6M3I\JY$0+L8/0Q_\)IP00XJ/DQCO?'&Y7H;
M;H"VL"?XA8J5WR7;*V,=I4B5RD!%<BO4IRYCI:13(:NB(^Q5$A-DL:U?'K*Q
MK!(OFW*IF3D5:[F4J44W9-7,1=;\-IA9E':TTQ%%PL4T7K*$1(FPF-BH] ',
M=$4AR3&^/+,O6=8K>;B*1,L!CX+=-0='54NU!4-3L" 33=26XUDP/EQ7*V2;
MLVJQ7I&;-:*M1VPL5*:J%W$.P.IR V0WW'5>2@55ZE?$%JJCU4,@YXC80&4&
MUBV6WB?QK6HVTI3;E>:?O)RD*=&JA(WH>;-_5)V<5>20TJ#<O!24]!Z9D$Q5
MAR*S:%9!J92\8\B_DHY=5XKF966+,=JJB$0P<1HO#)!<+J^[6&'_;%^7$.7E
M$&J5 %=1:+$LG,2&9-G%G!34,:2&1<D9!8QD^GE56YC"83/9HD HCICQ*=0K
MT$-$@^(K,-U F(XD!8=7*0)(UGA3'7HQ=5C4X9<378IR4<S#D$T$)#*+CC9E
M,6F!125L2+X4=%-3";:$/<J&^F !7"*2<AKO(!L,8*V'Z+U&YE5!X^B40U6X
M3%^LB1\$(2G-P.4PG93@)&E$8 */*I1?;^6 <SVH*^B\%4IE GL <97#HL:
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M"@]A9\YA<$GT?V^6T(_,-YO&%><F%FP.4URQ?.),VM6;<X [.8G:+DU 5BH
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M) USYG4LK0[3X9AE\-4DI1^':9;Q?)R.\%+A'0DL>LM9IHUAZVF4ZZ(H&[X
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M@&38"^EU"/F/H#"&"<]I3>LM7@]<MUBN\IX<OP"$)OV2A-?[9 1[3-A .Y_
M!T/$=+F(^#5<_V :B1U_9-E$.SK2M2-X4O-P/XA4[^'<L  65VGOTVRH6:;Q
MKXZV)5<[HV(LO,;UJ!EQE@ZU*]@PT.5TD@P48DA-P''-=]I!-@4< /E/N)"E
MEQD;;LT%+!K @=!C"!:4W*CL +I=TJS/@O"N0 \J+B_2@*' #25#:IU35[3&
M #3$;?@'ZN,)_@VP B!>XJ]&B/A(V BYG"[N!M0JM4Z)$I>@KPBBS'C D*+&
M+*'+K:[#;GD&JUSA"09YJ1]&':W&E1-8/@/,T6X2>%F8(C%/!6H5+'LA.MX/
MGBK[UJ)IAB>>R^@?@JD;Q+III5^2"3P>UA!N?A7H!]"31P"1LV:P=>T'N9-.
MU+:+Z[WD([ "!@.Z9&32OV@[;%?>, DK8A1PQ_C1.,W4G[ IGD]28%6 J<3R
M":]"9<X0D\M@J[% D00TH,$ 4'8*;!ZP%Q!@<JL-Q'X$7[RY2L(K+9D SD<:
MJ%7ID/ \("U*LBIE, G\$1B.GY?;N4FG _RYQL*K!(X9"9P'/EM*/3Q^EL-&
M8&,%*,0/0;'0TC"<9F^UG6!7R]);-IC<%D^]I=5V0@$BV%T,^TW%WCYUSCM(
M 4.@)Y"&BLFB_G=Z<?CAP]&^8,2_ <P!&N'5!J'_G5AS7 !7@4&7EX4*27GM
M 9_<<&!M@R:6(<Q"; <62(T:#,[L.D$.5%D19=9/=J\C7<=P@('27O!CO_[Q
MZI*T;D<WN-5/EMU\ [W8<CK=^2^^UY+59N%&_=D$ZA9*$:XE>K2A)V@9E'#0
M A:>(P,=1(03-20Q+._9L814OE[A GN^5]=A 1=FVGCX]RLCR+RM+TR)>FIP
M_F1W._T:YCT_9-_\BGRW0-["?"%-'E2-$9(3D,1-@OZAFQ2>N)P"@T[!T"@X
M,AH,*%:!2#8,P/V.N7X 3\=2?+ QB)-K$$K (_#OPRE*2=C)/HB4),\52_J=
M@T2ZTO;9B$4,I4L(;/4[0[TO"81&!TB>PA(9&]^6?!)4N FIEO 3%DT'DU*A
MI?M#+HZ* (NN43D$53C3AGS"<C#JDE [N-A'%AIG+*3[A6]15O)!<IF@@ 8>
MFK$H21EQ6 U87(+2^"H5&C;IQ>B4C)06"0N0ITJRSOPV!XL07B0WOI1P;#GA
M$W!"2P>Q9W6\NMA;GA$P$J8-J3F/,X#(UR(.*#"$<X ! [A;Z'N(I$*!0YS=
M%DWIK*$N5@S+TAHG$@5:0!(DS;CB.#@:YWR$^&/UWPJG$*BI(B90(_-T.LF3
MB"O%G%1/O-A_,CAM1RPCE=<$=5NA6_6;MT(J3M?N6$^K6]EV$YOHQ6ZWXSQ(
MM^HL#2?B/<HH%C9VEM[ <8##-18I-7=:JQX%D>9'#-8T8/A_IRR;*-/7ZNF5
MRXVF@A66Z%[P=0H]W6CPPRR!;Q)4>H46B(=<\ N2!)\J@!D&R4CHT(K#US:*
M@#W]>'#T[U.D4IY<"QH]9AFHZTC<'6T&25>][L(A(138G^R&HB+1JH%5322I
MQ+XNV%<>L?G761QM#EHU\9;>ZW3<ARKL8A\S1M_=6-38?)QD^>1>9"(ZQ7\
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MH98/K0@$NZ?WGH8/M5CTBK#(TTUO*6.KG4FVA$!;=6["*YY)IN*MHY3R%.]
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MW!+K\_EE3&M5Z[^]G><J1%C/S6P:*WWM"9ISK89'3079)J+HNGJ_]\!\@N4
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MUW*C2*OO@]"Y)=BQXPFIS6"<,TU/P/2#'/EFI*S'NP^QHZM9H&^'0C=8N9:
M+V62]O@*0S+@%6S2H"4^M+3+7<T%[BY8+?H='F4=N/(;Z]B5\[<8;M1QT%'V
MLYS'QVR1I,W/3G_^^.'=U__])RWUQT]OS__GHU,_,/F:UWVH-%AI]/GL[&&$
M]^O8$3ZO(CNW1,PZC]LG@P?5D730?M\M?3220M\!)_0C88=I$71=ZSY%KBZ?
MH.UN>+N6TG;YG*=.T64Y7 NU<@"'!Y%(W)@02;1,ORP2&I_/I[^E(&U3D.ZW
MTG5;"M)G0T&Z>1Q=OQ;Y3@&Z@>GGSI'FTCP2;1L./:.ATYVWI=QBRJW]W?V#
M@[O@+SK>NQG3T(.0+3V>P;[>/3J^&47:@U!N/9Z%O=Y@[P*A_\"[!9)U<C4R
MMRV-UY;&:TOC=1<T7G=1Y?-,A6U+#;:E:MH8JJ:MO&WE[8[D[=ZNC*=,-W:.
MFVZJ6B($6T:QY\'I<!@?O7KBG$Q;T7V:HMN+CT^V9"1/CHRD]VK+1O)0V/6M
M#GQD.O!U_.IHRR:V%=U'*+J'(+JK>1$V373OPL_<F@17$97#K45P\Y+_;HJ#
MC9SI1\*1"T;AA8"^7L91;NJE5M'38K XO"LJH%N\L%NO?";<(B]ZO9=/85=^
M3%5LSG[D?TINY"D]3^G=W[LK9IRM8OEAQ;*W29KE?JS<YZZM;BF5Q))]L*'F
M7!?T]$&*II^DY_\4Z\@/X^.]+:?"]BQLSP+EMX[WGNU9N$Z<ZQ$9>[U76_*E
MK6K<JL8?37L='?]8UZG'K!JW9V%[%GR3^?#HR9C,CR[%]HA,CYOB:AZKY?&8
MR)P62(;RKJK=13*AV^?#6.3285:%JID0>4@PRBP$#2MYAC!4V$]A%D*;8S^Q
MA G]9()D))M$7D%/NGIM^*>RN,@JI?C@VO#H:_*]33B^T<(W"R8AVUGC)%@<
MML7BVV+QQSC8;;'X8Y.";6'WMK![0U=F6]C] X7=SU0PMD78VZ+8;1'V1BW?
M5M[N2]Z><L'TIZ4>\[9V^GE4L/2.XN.#'^MYL*V^VHRM?':RNW\<'YT\<=F]
M3A[GJ91*[1S\6%[\:=5*/;02?)8:\#&HOX/#^/#DMGD&-DGW;>_M)WIOOXI[
M/X@*W=[;&[BO!P]"PK0QY_A:)<YW 1+:?G.3OKE& !Y5$=2[X= ,J(E)G7PG
M*,PS*67?W]N]KH5UU>+&C=G<F[D;S[/.=?]@][IT;5MYV,AG=&=G-US\>B>[
MJTO@MU+VB'<7+IO5A57;W?VQ9SPV-+59,+NZFK&NPT^G&3P&P=/#LIC2;_^Q
M^V4W&IJ4.M55=5(W=5'.Z074<:[W?Q:;"9KO VHG"@/IF]P,L[KR.Y3B8\UW
M["57T3.T2V#8 C!M2@1LXY<%J>WZRU'C/.T^J(/#UPU@[!GV-+T<9X.Q(+L3
MD/%D0CV AY6IL;<=3D2REQU ["S]OW^X0NNO@S^LE8P[$X3NW/4OV;^;#!9@
M3DMUELP0U!U]-E71E+ EM]6;^*[E^;3"?4719!7GY//21.,DC?ZXO[L7];/)
M!$4 )&>05..8_C<RL (7R03[L,4(XZ_+;(!RU_Z05LCA\N'+?N' 'WN[)_8%
M"0WGK1F8:=^4,J0>#:FW&_V&)PN4:#8CD1HG-<EH,AJ59B2GA%HI-F6)F"D:
M"#637AAN-2[*>J<VY=0?691<)-F$$.-XH*5* HX(\80ADCUM!C7,]<+DC=0=
M$(:\+XWMW$>7,",X^/2LIL*)8O-(;FG=^(^F-R7:'1)[J-;1Q"15'?7V58$P
M/E[/Z###II91*C.NQQF>>>PVNT&5#BNE[B.L *NR.>]-B9M3&MX$;^EAF@FJ
MVJS.C*=J;)-/6N7;:=3)ZP_;@[(&/RCI>3]%9CJ;%'-CK%HE[KB4VJ-6;R+N
M*>RI7-Q=OQLQ=2?.JD$!!L <!SXJDRG\T,$Z0&W.:>9O>#'TGX+^ ('">^!-
M5!;S9 (*QWY>L"SYHEF!@,-S\*7XT80;$P^3 <@,KN%NY*^]*BL\-W;!^=24
MYB?^+Y1OO.Y(5/&J&C1P>TQ-&<QZ80SWN%EO%@?JC8Q7#:8>F:3,];YM]9,.
M#W%2E@BVY$6F1KSGL\KD<?0U^6;2A%<7^03=/9D,QAELNO9!UGO6$P14D:,&
MAH5W.BL.^WHX6J""BERW;G'AL<-O@?5.)IOVF[*2P5$?3?LV47^^]*F\[5)C
MY#J;XO+A /$-<KGKFBQ;C\J-R8J>'-A49'1GD@U,7I'XA#_5?K*X%<T,WH.#
MDJ?$MO<Y0IT,=4S7E7"OXK5:G#OVZ[U *:;!BTC 6_B_'HLJQ#MM4A5PU\(:
M+>I"3Y '8F/X^L=OD4[FVR3)4<9=6V 4"-MU'@[?I$FY[,]=>B YLF,HFDY7
MT,KC8$B4Z/K5HTQW+QSM=L]DZH .IN\HSX;@[*#ZXP;25N;@2\-&#HW^,EU0
MF%WMTN'W_>)W- #RK+\;G6/C^)0Z$).Q@B6!.2^4-R!8+-6%18Y[.9I;/37+
M9@8W!(WVHAF-^?"4S<C3UV#KP]J2I.K2Z5MA*VP+^E#HX_!$!.K$ZHZ(.E";
M43:(X#_R*I&C3DM+/B*KGF#H/+JK*164$S#'*[,;O<_R)!^(_8#=P^V="C]H
M)BGL(YA";+EGH'BE??8DL'%5_DIKX^)?40)$8L7.@94B)=2'AY3@O:#KX:T9
M[GYEEQS%(*NJ!@LUJ;\Y/*F>PXB;$A=I6I0FCM"FHGK $=TG?=@U^!-;J/#_
MJV8(PI:A[/##R8#P[$ <Y["A?N;NFL.C0A6I+,3CHJC,+0T_XG;S(+6@:[[!
MS3C >XNWM_ W'OY>9:E:@INGLI:X/J:N\>[#/LSD!&X[C+<[C!]L.XQO.XP_
MF$%!6K'HHTUH,$H)^J\_!U_ 'EN.W;2]%G(6X'=P;GR[3XU+NK3\3^EZ@@NG
M3Z^19T[ Q.3K_H^]O5V!'DS5O8?G_;'W>N'/2X(0]/WN8  %'&8<AIO ?;%Q
MJK-[<\!H^5N2-VBU\BS@^B$%9=";@7U(6MOE[1;V58]&\%LP@8R-=;@-L:85
M_ADM0C&;*"QI<C3&X&XOBXM%TY*-Q&R2PCKM5$U6BRPDM3A*Y:R@,.0@F<X:
M<286!IA5467@\H1GPOCQA]U1%G4-T<4N\<1B=#2IUH:09FANY34ME8CCI,A'
M_/RDJ@S;LOAB.+TI$KRG^%^$7*&I_LR,$-&7L3'R4')*^S@0L EY'+ GUUC'
MW6AY#&W5C-B@A$_^>*+);#T/\+1E\:F*3<V:PK#L_=%"+Q,:-86N,(_-.4+T
MI*NS9'SQS-%_5!S..(/EU@D]&@J(5Z]W>R<W*VY?64__:O>H=[,R_0<H_G],
M@T4*B).K/O6!H4SK$I+3+$TGAFW*^ZH"I&/2RJVRC;6^&G"C*QN#7-_=E-1N
M]/S5:(O47GO@-;#"?8]K<&U*ASO5!K=5$'N[*WE%W,)O1?F-4Q,4@MI6P3Z/
MBH1>_.KP*.[U'J3N;%M0LQ7?'Q7?PQ,0WZ?>!/M6:FH>$]KXMEM+_NAF;AJ"
M\)[MF)LU(7P0.^;L^N"IN(V>^A&$^U.Y(+JFMIGG93_>VSN)7_6NJS,VKT7:
M5LXV6<YZ\?&KP_AD[[JF\N;)V1,M47J8C7E6IL'F%9L^EF]N%_8N%W;C2ENZ
MXY5+@FSWF1[_*?*[%6 R]S(<U%*HP )H>!ELX!*^MU!%0ZCZY*(H*5/("+A*
M$^,(;;9(,LXR<\\"')<%$^.W;*L"6TZSK@A(,-(XIH[2F5E3#L:)9#1=JCM(
M""-$LZJS*:?R/3!Y-$U2*9+ 1/M@ F//AAFGN.W#"$=)TR=\7$QS:2\Z N3Z
MNBZ2W<^E]@#AA$/X<U$2MHW3\O*'F*'1@@ EJ+0%(#L(P 5L!:[[!B6@5YZ3
M&SAQ;1_NIX<X7)03[RR'\0X$(1*KVL)U4T,@O"H:FTF*>)!I\B_8YGZ2?^,Z
M'D6;SI(9;+R';D4D"$-,&<8*ADJ6DS#5^L')7I0F<Y*;B:FJ72R?NNH2"GS%
M89?::)E1:3S(+0H:_YKA(QZ^@C&:C!&P@]Z-WF-9CL-]9OFP**=:Y#-*2L("
M$SKF-BJB*F.B__R/X_W]O3>_%C"MPUVW7>?>%^D[O3>*<_%^0OIJ">Y%\+\P
MC2]8C4>/<D\2' H\\A,HH>@\CL[A.U'/%A?]O8&_FQ+$XS.5&2&R%98'OK*W
M\_?=!9U]_059V%P0M-O6\?1*V$5J-.(J'P2IY)=Z.:BW7X*!E5FBR?")82D,
M1VFZ3O52R_ZNC[L;.PT=X7A[NWN18HP6"BUX1E+H\A#ZJ>L&;%4E!9516IBU
MTU68%5^Q#BL.H.W^$S;O.NI>-E(3*-4^JG^AL4YW0YU'@XQZ?;C[^N@.FN,\
M)K 1#?;H":*-6H_8P>\CM&HEBOW!D$A/LJ_&\X22/0D&_6W+@3MH.;"%8BV+
M\OYJA%>!VOJE8D%W5.MO05K/!.5R=!P?'Z[FOWKT&)>M\#Y-X=W?[\5[AZOI
MO39->+?PFK5W4U-Q/(M#2C>\E[:XA@V8TXO]O9/X]7'OY2-&-&PE;*,E[#A^
M=;*W0?*U]3VNY7L,+;?)S7V/IW@"NZ:VF2?P,'Z]?T.,_"-R$;8R]I!S>AWO
M'1UNFHP]$+;H:/]>B_:74$#:D-'IHMI^!!FW=>$O9,, [S"[X*\DZ;\:]D1:
M8"',9,*N[M"]YAZ4U69:156#&!E\T-"4)0-\,+=)]+T[S#*%"7&35PD3H:5F
M5II!)O^R#V8Z#TIO5DQ//*"J5";,<,-G>!-^/LF2OO# *4RI-,,)D;\QB$<(
MC'.D7NB;^M*87 @=!R:;<<)5<\L*)X$7%#@ZDS(J)& ^(SJ.,3]E;ME!1CEL
M3;J&V,/!&O!5Y[2TCX84YLHA5<N9N1I6!D+ 8(ST"DR:90;/G)ND%-[$>!$Y
MD>0+\ [8V(RY'RT]D!VO2)F/DH//4>2;W('L;B!_RV!R7>,C(;Q@$C;B(U6^
M'"'_XY=<CPJT&Q;Q8 "/+IB*#_4(.656X3T> NVQ'%[Q;$GC#K>D<5O2N$VQ
MS\YMZ/36[;,'TY@(5/3NG8$BIX38NBM:[-V&##.K]!YU4.9. *D'9]3'S9=C
MS8B5NY/@MQ.:ZT,E6R2WCE>>8*\#9F:5BY70X$.F5J6O6P);0L<YM-QM@=\>
M;*NOE JP]M1#7("K;;B-LC2L>75;!J6U4)T]61;@;:=R$CV,.+5240.NHPSZ
M/K>,P:(M<S,HTNA@.5QJM0:+L%'[?6MPV(VXR1SY];.YR;IBX@LW&7'E!\?.
MMKK@]D"*D>;*'8P\L-O7:OM0C=%5!ZFN)[;_@?!@)Y=)F=X:DOKA+Y-U>8?M
MA7+%"^5N(Q086AH7$_HYRVUIIEGM]<0:815 3M*Z1IJK!7&^9CC"'C$;DK -
MOWSF>(Q %-J8RQ&[RIOA@3 6;*-!M/4W;Z3U^@]KC^%]E]/!-THX0@U<.!\=
MN_0CB=V]=;6>W/IMX01V]-4*&)\IGH<=#FJPPD'B4I)*^6!B6^6$/,QCDZ3_
MYJHL+.8<D 2#^/PU*?OPY9^3.=9R?;M,YG%T.H''IDD<X83A47F61"_PX?)!
M] N^Y*757>1-5!Y9\ Q/#QHX(-P'A_'1X:NHPI<;[-E"ZK[ !@S&;QVB8P)_
MHW?TJG>]@=$OWMEA?)DE _-2.MA@Q9Z,J^MK&'8?%/BM+"\:J3VL6S\,)N[-
M.V,'H<('/9;RG_,\.@5].!'IPHG(;A"A-\[GQ:_F,OHDF_AR(0:/DO5Q4!=(
MU[F_USOI9@+7<LKHQ<_Z\1?\6(0'E6'5])&'6A0B:O6)@;?PQOECP$W:W]^+
M7_6. DFB*D R:#I$(\8<2C*0PT&Z43>L^USP>SM&R[* 8SC4#FM:](?N_64!
M=_N%V:$K1ULDDI?-#69:PB3K@XX!5D7OU-G4R,_H%),H<K\Z^V4,W$6]XSUY
M>]#,)CSZKE42Z U<*&H6Q-=CE6FC.O@6Q2*Z8O!!+TA_%QZ+A,,NEH8KVO+"
M=JJQYF_1U-A#1;>CP,)<ZBM78*LH_+/7_DC4J+MQ@FX'R]H0R(6-#6*P@G!2
M5"XA]1[^D-#IZ]F:V/_FZF%L7A/4#2=]&"S]JD,J8]NTC0NHEXVR72G<V]N-
MSL!XR#Q& .Z -#)@GQJOT/=.RX7/KU8NS Y]>PZ]*\Y!-KEC'JM'WS%L'?>Q
M9H:Z=_+&EM;)YEE:&%+!*9X.!EC(C(KB$RS;0.,L[X1(XK$87U_9. $CW/8(
M6Y$C[I0+D#(\GR1%B5L6N%'AJS,,.W&I.-YH\+F9"7^ [=>KJ7&*LR+I1IYP
MNI!;?GXST;^:="0Z7)DZ)#@+YO]4[Q?BZ:#&PI)$QY.#!I3KG\9!W#A,C;*#
M$(<]257]LT[1.T!T%P><3_-@OB@&<S:>N"45WQE]\,94:K)A1#UC9*9)\ "=
MF?R(N$=L%RQ_HJP#X:MDNEIZDC%L*RQQDVL^67J[TFU*UIF^(&-F$^%%'%H8
M0NVM+CT6/; "&[#.I<D9M<7I(TP!@\(QTDYX,13NXK@P(6^,W@,GV3<#_P\-
MD0&V"V//%)=I,H]7]E2[AG#N1A^Q90ZLX*C (<%Z9M@BT8F8N4@F#0T2*3K<
MD&UJ.(;+KX9K4_KRT*;^)%>9WR.3A4?Q%@P><?GEU+ 5HYY.GE OM9#0!1$H
MU3"Q:6A8$KKYR+]U]U<LJ8;PB=2_))E@>KHRDXD<0?:,5SY(R6/"5FH6.%.:
M/BY(C!M=C@P&/! ^0_'DTL L<C_"G&"Q?$* %FH#,R&^(=><,[A%EN,$W@2T
M-S"#SK/I.?FSLAAF;/["^:PH!D&!)36ZW]#.7,#LZ.#/-=0LC6%%=$LT%7Q,
MAJ<H_/Z%^$T$#L$RT\&NR9[ROOPF8KE2WHL@_,$9%1 :W4.S H[D813T7/-#
MR//0C PX#MQ5LM"&>; 4?RK*8.M=#[TWKNNJ6V,?(K4$1^*-AE4LR[^=J]M_
MZG79IVY8Z&?8<P7? 0,'%IW6C1HL9@B 8M,M)VE$KY,M.)[+#K:IPFZ8JHOA
MT#*35*C\O<:&K$.MNC$B*A0;R\I!,\7C,C#"K\0PF\J1*N&2T2>D,$@BX"+"
M:=NK2-0P/1%$E[P'7 ?C730+RV<5(>H3&%V*$;@MC*,-XWBUA7$\5QC'/8M:
M,L.XN4*YA'>+FV$QHJ R>4:GWUH,8T23@AW85*3%X?P'W63A\A4@F=+EL,'H
MN-Z<,K2AM=,&";?8?_,ZT_U<@*;'?[P%>Y'XX'8Q ]=P"UE266PHL07GVTN>
MPVW?]UC"%;\Y/4[!!C6?V]9VIM$9NH^6VF!RR<?MZUKN^Q5@8"'5TB[S]#H!
M\(XQ3EW50:/FY;Z)0BCJ'W:W'LL><LC)^0MY$2R5CUU=M\4^06-U'6K(A:S8
M-=[B!ZDD5O+!Z@#\0^_H307GDO2 BLIIGDSF:## OKK-.U.SB[[SV=D:'RW2
M:'EH2&,L1VMB+/T2[CWZGSO-FW:'13X;"BK[09&RR MT14/"_<V66>(K!&U>
M@:#,_%Z/:*82Z9YZH4-*11(NS0MX^%->Y"/LP852CI)<V[&C,'QIIE.,M,(#
MOWBGHR.ZY(4@EX3O[IVU\*9QO>/]-7&]U0;8G4@P3?Q@%V<,ZUZ3A4T[!'^8
MZ+_?NNA/=$K6_P?VM3YGU;='(N-HTXB'6,*H5X3L27>CG\*Z.O7U=VA@\(GI
MLRCA2O*3CD[O)BY\_&I#Y0<91S'E4$SX.OF$N(44Q65SA&,I\JM[7N^<:X\1
M F?-#OR)SNQ$=Q\"MA/]K&%24M;!D(G#<NVPHQ=<(D9MN$&(/S<8S.H=)#N]
M5R_,2XQS]EZE^@^^%+XXH/*[[WQ&T#C'CWLG!X=$M4IH! F4XF_\+[[40#!A
MH8(W]OTW]NT;_5\S.^?9.#-#^#L,A3341\I;,XDP?^9N /V,SC6L@VA_#DE4
M]JK+4PM:H(AL1%$S'B1="AQ7CZ^ZLI1U-!26)YVJP7D;F4$[N:3XU 3]J TR
M<*]Y5G[!^+"&_$06==Z4/"6,$J_2PYR34WU_5,TKT%BQI(,QESXN+BE>NX.B
MP2@K"LG-F.47V8AS1>_!] @#J7L8TSVA8:;8VU*2+DHJ4WP2'FLE+1P*1<6F
MIMZ-?C:#I.&T<Y:/.2\Q\98VHRACZ^<5324\^E8B_9'K(-MC]!^)H#(,#69#
M6 +P&]%-SSB/X!MPSKG!..Z <!IHN1&O-28QKGA"<.9PA<+MRJZ*#O4'UK?[
MS:VEQG&0ED+4W1#.]!ACFA?"8"_Y.PK2JGHI//7B/A]:%5-TJIC8I;%@I%GI
M;]--% _-^6;:IW-U?W0YZ1THNH]6<YTY;SS#>&^>N,. F^!M,6\""/CN@R!T
M0R1+*XIPY;&+" VH)T6J(05\!,5TQ+<;LM4J8"C^#4FV%V;C?+/<\$LSG L_
MB*\WWA5UV,\V1_!Z>8[@&J[$\1^VB87GD5BX1XE=TLS\]//7Z/Q\-_KX]:_O
M/D?GO[[_^/G#Z=?SC[_>U!$^Z6VH(]S;C7XQ(]!@GQBY#RIL@US@=6#@+PA1
MFBJ6EV"CMO @04LL(U^%K&;7QP2&>/KKVU/,Q(>%$N_ACV#"?/CR:TP>G]90
MSM 2P62$2]DS4BH;1' /*'S\[/3GCQ_>??W??T94'XN8%GB4C4!GF.> IX3#
MLK&]!$-[R:A,9N/H_'\(0D A'#*^*/V$0%A!#N"=1(BL3PF=L>C78C<ZCH^/
MCN*CH]?1BRJ9""=),9E/BW(VAJ$2]NME')W$1_N'\<'A?O0"_]1,V%R'3WI[
M\1[XP\='!]$+,)/&1<I&'VA8 BN^I&?2M^ AKXZ6?"OV&AY-LLI#D9W24L*_
MWY8-A9Z9GH*FAP9#,C-@OPZB=]HM!1;*!380!L.(8(4_%&B6XH,_$B(E^KDH
MOL4$ K";<95-2+.4[';K>JS:BV249#G8'@OK?Q2_.CJ)#W'Q,)\A]S473>-K
M*%1P3'VR]X\/EZZ=26#I++X!K.EP";V9$F;*HME/8G<*AMF$1(IPZ3#<6G_]
M%NR-2]R7MQGWIP$UW92U *MQ+@CB12.+4Z@Z65A#0DJ40G'B?06&ZBU%2Q*3
M,JMLZS!_(^@$PC#Q0YM<A0-(<_H59$2.M4X*!\"SRK@G&6+"C:NBDGFBA$S,
MR%J.!)RA<1,(*,FFU;H!4^^D!.EM4=A1+'2Z*0WN0S*/7E'D=2_4.")3.E4>
M0(:6:*KA)1H\31T&+D??;[RT7.P8-T\E6 ,XL27#8;RQV%?0XT5]H1#<5'M)
M,1J7W&<N#8HU [/27"#XAU",=GW=(UB4JI]6'1)<77L:[,KV>M[2/IP8KQSL
M<JD.]J!3NG\U&1,2#)6+AV=6L<-"TDN'?<W0K!(/M':HGNVB8HJ5%_7.CM&Z
M!5M_JI"98?] VUJ% WV?E;![I[JZ>76IH5/,OIE2AO2"UI\IQ51^91=XJ[RU
M>$EYOV^$&TVF!7J5M#$80!KA38-UFQ-,_Q?EW(+)>#G:ZN,D/L;&UX<G*V]>
M+O=QBW!)@!!<BKYQJR$6"".0JZN=5.Z I'<K16%$W):/% ;#4-E5EPM76QW9
M7F-Z)(5.PPJ/?P:NME?(WI;/EZ[^FF7V5K(HERPDE43A\$!?@;; ^BZ,/39X
ML:"RRBZR"57)%WCA@'[MG>R 7/2.:+#[>SM[>Z\/#F)>W(&?J\V\,K3>!L62
M5J<3G:E@>\?-FA*+<FOFJ0!K=R;&H.6X:SA.1R;Q*L6K59X4>4TU!O,B>QF(
M!EG<E<JQO0MQ<>NL;AC-'2H^A=+*"?=!1%?5/A0>YORG/$5QG4,L!Q<$JL@3
M(ZU?9##R9H;6GER?<3 1CT)MFN0-(L&IH6B#I4V(KZ;VH(3TPBN)_B*Q:2VF
M$$S_% -'O.:V0I8_ALDO&$Q"Z.:N9L$\>-?SE74RGQHRJ'71VZN-<&BT1OE*
MO=8ZTNG+8PPE6[';7R)WC+(RMRN :5:1K(&LA#OG7QAMOVJIQB'K*[RP;95B
MYS52(BQN&+<.1)!IBE";$ 0YGY/O:4VUKJWOHUM"O\#T25+"X^FA>8<,8(ID
MI2C$_MU,4B'V+R\R<3_5S@FAIS,D7#?S&/<2$0B$QD+,/,5]>-JP&_\JN."!
M[G$FG"(9$T0857O67/AQ3@D;6!;$K< F5.@-35&#"68;#Q5E&]#Z-6(IY4E9
M%I>,Z\Q*M>K(4+87U['BRW 4N-=I:2Y)[Y",(LY_,$9+!V6_8_OMLGC/[!UZ
MQ>U4M,!7#_FB.(:.I]BEKA70R"*-"-4XI(# ;)0\%9[(8TZ6C;GJ'K35>UYA
MAPA\;X<W_/7.49<?9 5D-SJ%@R?858LRXC4G6:=Z)9Y+"JO*"%NX:3DC]U/T
MHO=R49?+&/B"U1S2TD7GTH<7^R_=S/4AT:MEO_9G &<F'XQEF#:'D(E-S$U6
MJ9396G<P1XL@2WVV@ZPD2V.(NF9L$PTP!GS,H^=\ >'^&UQCB&\3_VO_ZJZM
M4JQUN;AR(G[ PVV/Z_[<7&*X<([NSBI'UR\7N5QN4W?XPS"OO9->?'@ OL.@
MG%=U,B'-1WZ$1NST2X=[T8O9."FGR8#B9)20LI$FB<[A=X_CO=ZK)1&FATD'
M@HB]-_V2]E*\O/V'\/$WBAIHA30$FQ[NZX, 4HBKQ.T@GD1<:#J%9[IU+Y='
M1@(MH9MA545GJ.2<Y6#=2]?985.3NN+A&QHIP55Z:R8=6^#7,>S8"F)YR? :
M >WI-,WZE5ICW%EE^XJM.V856?=8O#63* ?+BDVU92[V;K2_#T[U_OYQ'!Q6
M\!B*R06N^;OOL#/?LVI1K;K"9P_-:O6QS#]PTJ_HWV_S]0OY^J-M3=]S3;W?
MLZ@Y.#K!V<C+<MKFE>^]W7+0>J/,@,=A :R)X3^>,"C5GNU;/^=Q!T$W2I ?
MCSW[O&+"6R&YF<J[ZQ!Y&*$BGI4\EYITYPNM,[^QS)W [=5@;-(&[TD4, ER
M'3R)Z!2J[-=W$9G*KQ:<HG@H!1"II,Y6"RV<1HS_2%2JNOV@5'+%@)0L0W6-
M<!0=Q8<X97#&]^&,'QR>;):>6A5I>[ 8VM\:D+[>\</%S]H2X^T>A8AH@+<=
M'GJ_(CRTZH5W%AJR(8K-"PQUQ(76+%$["F0OG!ZA[P[V.0RTZBEA"&A)= <&
MW@KP6#5UF^&=V,5V*- C,:=HP=GTEWVI4TFC:[".+CIM1@U,ZH0/'][>?&_C
M_8M7_!PIT<-[>,F5OFHI'PN>Y-RFT7J=-S)#:Z79PE=SD70@L.G/73#LV\)?
MXPOL'K<&=HO(ZP=$5'O7N3+N9>2HX\FE/,N!Y%OA/V*="6S49+YZ>6Z$B4;M
MYME3"WDRBO"0,==;!)7=XAV&$\-P4*&WQD99%B3VGT+KXCQ/&YPBJ.!?A+WR
MQ8.4[='8B&GK97P=K.Q5 *GA_1](WTH\N&C>?2LS-$H7$DP<R##$]]P6KO6*
MDUL1((N5-E'G<N#)/WY$4S)^LX0P&'6)]91P++P-(B)ZP3D)P3U2G8"+\*\F
MM5X162L"@&2\@X67@(71)[^4.GG,_??%%A01BU$#1RXU@XRT;8GN#X6Z:(WY
MN'FLFZ@&9C.32)DO_IL? OI#.7@,EHH3>SF37TZ3G,_SOYJ<;28QQOQ#3>+@
MRGZZM$BNXB #ZX9^$>OEG:&W%D7[-N!;5Y'"]3D^M#W(AL'K80UZ"^>Q4:KS
M0?RN-?@U/VEA/3,?KZ;7FW^<"><&]A/N]<S5WOG]=NBL.#SWLKO0M]BM;>J/
MR4%Z2!60A8[/3U(D)89G)6P/1,RC]C3B16A@GZP+&)$N75>F<Y-(D8T/+2J"
M;8#H>02(?A-.Q<-7H/;GE6N$I2WCQ6L/1%6ELRY(:>!V=EBY#('TK\4@)81/
M!5=\X@%%4WG.8W$N?T/JACE'WGGAB!J_X/_?-\3SF9"")?/!(]4.::DG5-SL
M*5@V$J4$16JQ["F!)[DSXWRNC)N;U:L[KNQ&7W!4ECS6?RE) D="U!3$^<E?
M].'#AC-&:KPJ^,6;G==VR/4/L+U#<?#R-[K/TV2:C#K99*]8MGZXJ67KX!<@
ME5_T/B&RW0W*/E^[]?1",R1F^W/$Q692&;+^64X"?AULB81$[F1UXS<X=XB!
M-%D9DB+JS9%H8V"&.G,]@]?$&2,##<.;\"3@,.:QT,_#,YB_F!F?DI#:N$"F
M(",-FE<R'"-_2J+<;6@Y@R>/)/D[$[ANB![?M2OAOAIS3+]CYI3'VS>@TX8<
MD11:1!)\_RBX2%_?P-K8'!P=8.3#HOX&E]3#S<!][:[U94\D<D6;_?D&ER;M
M%H],&>U3 Y*936W3)M)>>,RW$+,VQ.QX"S';0LP>2.,B,W#&O4ALLS3727XW
M.F>77LPSIUY9-Y"Q@00-'"=@?4':$/4*UIC$X:.U?0=UG,"GSIE0JJV(B0([
MU_8]?;0>R^G5O;%[OH6]RU>ID:\RT -4='C?Y:.=B1GR'1Q<RCN]XPV0$6)>
M?OWFCKR=:PTF7*_>P>X>]1E'=F!MD ,W$3A EX$88=K*8$=S%#%"+4D@5#%*
M(,4#H;ITSB'2REFWE"[I5*MSK"!SK[J@J4[05J$T([0BL&K> :7L5[FO6*)]
M9+H'Q&5__>)W"A9F?; @X!=CL<,]-]P;WY4.RE;^;DO^0$M*;KUA7P-S8WU"
M1E$3CBQGE!0U<AH9Z0>43?OH-I'>TT:_,V4!TF@U6(/LV,V2N2FKECZ]S"8H
M*VAC;K?\7K?\4YE1"WA*OH6A#]W#. +C=!ST#.3&'/@C>$'.0?B24!=C;H>N
M'9^DCSAY,C7:%DJ]#\8\O 9T&C:B-]CV;!*SGT ?ZY/S1)2"ZW>._0/-**O$
MJ>D7J>T?@9T0!YHTY+Z;""E!=B@F$PU25>1UV7&@32^5L2CB0FWI6"==GH#[
M#\#2*&NE-CXI2KK?]<_.$,&OS!I&?V[E^U[E^RNW8)06?\QT6Y?:LUZCLM1U
MIL[8MRZ\NY,ZB'G2QAK/W86, ?'I@TDR6%SZ20F'HK09R^!&M5%BRJ6EA>UX
MH6-*RV94!:>.K4@B8Y:@(\L=N:DE#H_;*'GZ-V9*57!UB1/53DSC8%Y?R<1U
M)DY2#%,;VV\C#^0Y]CA2!T%S%:^1FV=\;P7^/@5>,Z NO#@VR:0>#PAFDEQ6
MUIBS!J"G-P/H&W[;EWCZ@1^4GH'0)8-YC#G0A/I)>KVW*%3*7!W< [,B18Y?
M?4/R-$RR"?(YPX,HES]7C #&E.C=6^E\:M)Y9GN "0X,"V$"IP N2X0<>DY
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M)L=U\7W!3SQ*".N.QO2,'<P"R^J)NPK+E!FV53L6T1TZB^[O4 E.+WD@U&I
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M8HC)6B1^AS4* M7U?&;\$T/G"GZ*68'!&+\9^W:9%Y0,3A%*$6=_.A=B@XR
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M%+=>8"*OPB-*94NU1 RG1O PU9AN.2'JY@;?87Q2J?^TWE\"EA3G?6M0,+0
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ML>#,Q5/$]Q,>$#RXMFAP@7VN/^]"Q\<>Q;]4,A )Y<!FIOPWN@,M80(NQ'#
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MV"Z40?U#,A@*A:V3,*E0R_\',X&+LJ0).$5P":K?LGGM:_SM]2ZW66ETH>(
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M,!<7L,&N("1%7_$-';_[O,M=6AD/M*+'7RS$FWY_V:672*OY;<(-+Z3G VI
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M$L(I&XT8%%Z2=.GT1&70Q4DM" P>,!IM,B@+,,SS F]Y#ZJE%4(4PHK#H%T
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M8IG];?7=FO:4:IW5LICAR#4 - O[(2_ZU$D3@53OE(,#1PY:*C 1'I8+3"X
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MOWPPSP64MP3- *DVI=H\<.%4N",7@&14^[$L5D3#,N!(,DU&I75U'RNM'.W
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M6NBPV#?"]H-%2D6UY>TW3(T[)=33@N5J/JOK]7&]SM>FG<>H?%&-TYK@>.
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M>L)YI2+E"V]Q8R8VGG(1]2CQB]Q3J4,].#DX41ICV&9NCGBT11E-2#PS?(<
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M9<I+EM4;F#.E<:D*S)"@]&H76&#BOBN>R!NL.W@U$6SQ\>Z#"ATBR"$?[(+
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M6LG\<=70;SK%5)77ORP7!<T2LY9)@JR;3ZJH +Z$!$)3X&"FE.Q;4\8MQ'P
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M)14#)T,&9I-.AB:XR4_R6M6F_&EQS6H71?60PK!!'F<>G8VTW//"("9I:H1
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MP$2,/FJC$_+^N7D+LF>&#JG:YEVL&@YFE<4<8XHZD*4B%.U#BN4,D2D.18O
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MR'D R\F>4C%:B$)'8$SJPDS,GK?N1W0[DB=,D@:JZ2'4_1+GRW$9T\?JT'_
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M7%5Z_C(.<3PYMUQ6K\NOIV^K-3,GOM('?IM-Y^MO5UTQ+D-DNE8'2LTAA5)
M:27!1^)G*<HRE[26J?5&T'0 @W5^1<5,$"2>5.JUM;CJEZ<M&&V%\2QF@ZTS
M=8ZW\^OA.+ASD]@N^NNC\B'<=A_?;0V:I'$H7;*0)*%5/-6KD<D"""P&E")Y
MJ8>YZ_<HVF\=#]/ZT6 ?3?]7DKJU]Y>)U@JT@-$9F@,Z@N=%0;&.>\5*=J%Y
M=L@F,$^92FTTU(/YWT)$9P<ELJ#E4A@(A199LI(\!#)+(=2V[AH=8FE]R4\S
M\$,=9AX/(0^C]V,_$E7!.YVL!J%, %6XAI Q@?1<%)<M*^Z1]XDX$"^V/#CM
MHI]C/X;:9BS/!Z<=SZ,Z$:3/\ZA=M'OLC'6&Q6@5[3<U7*F,X^"=SZ"+8LBM
M5J*TOL/N^)FZX\'IT1"UBU('.ZR()0IZNP'+$AG%219PEBEP"5,12F3>/!_S
M41Y6=-'M5H<5710S>#>)0A9P]-S3=*J=3).S$%(L(#/2G-(R(GL^9A^*/:T4
M-7@WB:B)XJF>QP7K:EM_ ]XJ!&.=<4IEH7CKD,FC/F;?@T7M%#74P2E3R*3/
M"#PZPL1Y!!]4 M2&*.\4TQD;D^<Q'ISNP9F]U=)#-XD-5>H"@S;%,]"UXD%Q
ME2&H7-="E<@VE('[UHF(C[.!P#YTV5\U?5PP>$=M.HV,*4^N0I21@?)%0,#L
MP!0:9I8ET4+8VLIYO T$]K%Q&BFIAP84%U&\[[]<?/F?8YS32SY^^04_XV3E
MA#IN$G=2 =,2:?1&@R^Z@"C62A:-,[ZU0[\=LB<>_6ROO3Y/CJXFO-S$NYYH
M6X#M*=K9">B!PID]:'P3J7I35P^>6C?0LDBQ2H]#KQ6H4 ($HPSHZ%G!R+4P
MS0O:#L^M^P*0QT:M+EKJDU*OII].EXN5!/@Z<1N]C'7H6F/-KW2*%FUN(6:G
MM!<FA] Z@'0'G /F2[17Y";*[*F%'F*,MT$3Y]"2T3D(H:L>56U@6:_0\ :$
M<]:(8GJPO>^ \]0(LHL6^EQ!OO]R10P_S?%?ISA-7U;+:4&TY#JN N,:%(8"
M,:E:AUZRX%E;HUL?8&P!Z]FL;JFW'@)%M\VO"X#GLVH;B -:TM?@'=Q^;J/:
M+2R<%GH9R&2^#K567!3:6,'**&K5;H*HLH80:0H9X8)4^;%09WOS^&#,Z:*.
MH9RLB[5X?62G--.",])LW<M9O?VB" M9224\"4?)UCW6M\%U'";07@K=QIG:
M1QL;3>3^"\%^"_-Y6(X_8_.2L)M/[JLX[)XQ7"L3\TSJ(+,NV7F5,'G.@T=5
MI$U&D6=]NWIOON/P2=V_7/94HE4NRI3J)>9$-NEKCP=3@)5BE"6F2]';;G$,
M!6,_X'S\>:6>WT[K['M=KIPC_"=.\@BU8XPY"3J1<)2OIT7(R#_QS@2;%&I5
M&DOH7E /O=JB"^MN=O)JJ;%>>FA> )Q5I83)BY/9Z70YDD(ZU)%#J34@BB""
M=P7!1!6R0Z-1],BDK[ \$VA/_?32ZW*-ZSW.3UZ7VG5QU4:1N=IGDQO07!"?
M#1?@N R@[>H<.T3?W*+?A.69-WOJIX>SNGKC^^OI);HKR^&;.9D<?XX\9S)8
M6A!#7@56/ )]:T%&PT0()JO8^NSD7E!/F4EM-=9GJ&KOF)["I!69RX 235U3
M:4C,9J@U;"B%$YA:U]D_\<+!?8AY&+T?2^'@;1/R[7CQ^RI.Q%0QWKH(-M3N
M82XZB,DRB"RA88X'EUI7P-Z%Y^%'^SLQ9.-6O*>F>C7CU@9"S51;!X^VP-93
M?/\N7(<)[+?3XD9Z-%+!T#3A%IW7M'++E2?BZIUH'@,$+652.G.&K8^BAZ?'
M/<'[P["CB^3["-?/YCC^,/WQS_0Q3#_4+CA_A'E>-Y-S5DA:(T'9I$$5<C&B
M+ E22(C:^N18Z^*5N_ ,;\&WT]QUNZ>5V(>)Q]<;GZ9$I"][1-YO/*-!C/UN
M7->BZ='F)(1B(I,WH['$D(L2/$H9I';H1S>>MM_4NGC<I:FLHK!:\0@NN%JG
M*Q&<\AEBUL('+K-RK;NEW42Q[Y)Q\<2WX8]?PY*F2)@L1F1;E: R!Z]K[CNK
M/2<U,C*V)'?$XU1*;T.["F3X16)//5]?&O87;P\AY@M0_YS-?W\U?3.?)5PL
M1MHFHY-&D-*Q6O!0P(GB:QFZ=B4SA[DWI7^%Y/%H?7<!]V =7*#ZB>2Y^(CY
MY]DLTT!EMLX92Q1,]3KEFL*@M 3,)15-@(5O79=X.Y+'H_;=!=Q#@/<"U>H"
MR)',.@>?.&1:@XB$DE8AS!XL)B-"R#DUOQ3P:P2/1\W=!=I#L/4"S<O3^9R^
M.@N/1.F5DEJ3AR-J?V&3P9&H(9$QB];::'GK+LVW ADJ"-J7BG<6ZK%$);\/
MDS!-^.XCXO*7^NDJ_.H#9R5YXDR"Q'IQNJG-!771P+)$0V9^<,WOKM^$Y5#1
MR 9:GO4@[1ZV_MMPG3N^VR#K*::X&=5A(HIMM+<%)?80_;#DD#*AIW42F%2:
M$-I >YL,@(K,6(,\R=CZSN6A27%/''%H3G21>(\^PF5#'JD9JP7OH&L/,E6;
M9'B=$]16!U%FF7CSMB4W0 QO,K;2T :[8C?Q-@P%U.C;Z/7R(\Y_F4T_+'%^
M<G8BMVZ*HJ,03DI:,YV@/3!I\-$*L"9X8Y5BR=X;(KS[%0]>I0TEN'$>-PW[
MOEO.TN_?![(\7\Y./M'RMY+ ^@[567DQ6=$%\X\GGR:S+XBW_\&/?]8O<8_8
M<3] &@2@!Y#0M2BV=MPC\<06*91W-D3N:#5 [86PK*11/Y#VVR,N7K7JL$(3
M*LSQQAO/@=%7K\M;3+,/TWK=\AN<CV?TN<7R2LI)8J+HPFG.><UIJFBDKS+-
M%^&-#BP'4UJ75C<>PMY-^M=:O!W(N?9&(F)&,BR FR!JYYB:X$6K5DQ%,F:*
MPM+Z,HCMD V_F!^2@S<:^+?77@]!_\O+LMO([MQ9]C$DQB-$D4T-:9,5G),$
MSCQFE@ORYK>!]3*0H>)4Q\3;PS/B6()DKZ9D ]#629.X/NXK/\\DSU.V"G2H
M'07('@22*X*P6:,WQKKFZ?-WP#E4J.P(N'+#E6JCLUZ<Z%NAK>_-W@)<3P&W
M.X$=)N;63(W;T6,/'0Q.%.3%(Y,1C#0)E,R"0)H,O&B3DI'*B=;FW@$(<D_\
M[3#\Z"+Z'GCQ%A=8N^6\F.8?:G>;V:>*\=R0/ \PJ)Q+X"5 #LR1.1D"N.0"
MF* 5YRKZ9%JS8PM8ASC<;:;(6;]:Z,.HQPG]ZL//.,5YF!#0%_FDYAXLSVK&
MS[&N8U+6<Z9M8>1R<*RW'F:(T2)$SPM+(B14K1-\.@%\3.3I3S/'$2W<R@SL
M/U:X"XP!(H5[2^=:G-!D17SCUJ,QBJ-==0KQM55PKE4O\MXXX2Z ]ER:;G<,
MYO.:(ETGV_=?+C_R)GQ977]3\Z8OG5N1%!8;/10:=LW)=N 54\!1<8VE6!]:
M]R#>'_5 L< H)-=,2/!:>;)]A($8'(<L2]0.,6+SZ^B.-18X,--V#/]U45BO
MX;][Q;78)*\SI[T8Y9SR%I+(!50I&7Q@"6JN6PK*IQ":6Q&MP \5YCLP)0^C
M[&.)YIW!IP^OG$0N1)&Q-G&1M=8KJ0A!<0=""^:#"@Q5ZW:;7P$X?,1N4 Y<
M7QQWUD4/;O7N@K@<QC2_F83I;^'DHG!LBS'U%,[K8SR'B0+N09/K2]^QZ/BA
M\-=Z3UM)<K46MKJ>24,H-66%J22\1B%%Z]/WA\/;>X*31T[;+JKM@:Y?I:2\
M_E0'=![NJ'>QA2 2L%1K8DW=4;Q1@$HE3DZM*]@Z=KD1S!'Z*[WK>M:'HGIP
M6M[B8CD?I^I;56A_)\TLWK[[^_HB);2)BYQJIU.RD",W$+A#$!R="]QH(UHG
M)]\)Z)E)#176PWKT!N=E-C\Y2P(EH:R#KX:L6*E=)%BVENDK\LP%:N*\MXDP
M68VM^YMM@/+,H"9*ZJ&(\JLE<MW9@;QPR:,!YBP-SJ($)V2$5)C#P(1TNK>\
MQ4L8SYS96SD;JS('.%&YZ._<_)#DQI-[._>X>PS7CC*8B[4.VGHA:IT=QN!8
M8-Q+1\,I7&PXRKCQCH.?3BBR?>PJ-A=4O6HF>S+\ P,I0S!6ZQ!YZ\#2X4\G
M=D:P[K;\(N<5[\+D;'E_<;K\.)O7[+!1,$:RI#@4*QU-V2+ U8LQ==#(>":F
MZ.:!Y?Z&<X3K<EM.=W9A!Z)&'X<G^P[M?$"?:>6J(=6?9O.?Z6^7HY"U\4P)
MB,73KB=T_:K>K\?8ZFX]9D7KMI!]C>69[X<@14,W:570MO.@WF(^3?6SKZ:K
M#]3DJ3GMUJ?X?G8EKO!ZOOKFQ:=/<TSCLX?7/Q]AS517BH$0LK;D*P6BS62T
M.1-2R4;[LEW%X:%&\&3X_W!XTM /[&_0JQ+2U:<6(T<[F^,I@)&!U"%J/CQR
M 2+80"1//&AWN$EP!>DSV0^F]QY:".T\OK.YNEAM6XM7T[/ZCK.N2-;KQ OS
MD"(RDC@-SC,DVTTFD017(J;6(?X>AO%D>'XL5+C);G6X4]-;Q_1/''_XN,3\
MXC/.PP?\\4^<I_$"W\S'"4<^RLB"$!"4YZ!BMA!<\A"C5,Q)XYT8/";0;GC/
ML^%(J'-SENCCV@.NC73URQ_"$B_Z_X\$"\[D;, *,N$4J0%\B?15\"$KB]PW
M/W09>(C/L^6(*'1SQIA#SYC7I\O%,DSS>/KA+"(P"E$7M$*"]C*!LHP<_R 8
MH%$Q6N=2LJU+C9L/XIGU@]+@)J]MLZ/.NTI%?IM-/^.B3L^5!_-^M@R3J[^O
M1=Z_S9;_/RXOR[]'QBJ?2S&0?;U@B#L%T7$.TBO-2LY9B=:MQ'H;S)/C^7'0
MXB;?W<'6\1__=3I>?KER^]K*I7__,4QOW=!&6O*8)%EXSA=76[U%<&@5R!K3
M4EFI&]&=PRWO'<?VY&;#49+FYN3P^\<[X_V#C)T'^6OX<WQR>O)FMJ3?CL/D
M_>P?M&R,L@F8D$D0R0=2"P:@O9 !+]XY*[/FXMIU?W?%/P=$_F3X?_R\N.5$
MK,WY[RX#7OU3AT#6W=OJSRQH6B?Z+7DTHX2>RYH.Z67U6AC7X((GM[\DR5C,
M OLQ]UL/Y,F0_WCH< O)^Z\NN3.K[WQ49[L6'^5@0TJI@%6N)HZC Z?J]8P\
M%>>-XBP,7E72 ?_3I/0AE'\+D_=.UAW*.+L_1(7),E5HX\HLY]J>SX#36H$A
M,;@LLS7A:/)[6@_^>0X]"-K=,@$/=Z!\KR0N @SGL3(>BV5)>O VD67(A2%]
MN0Q,\*2+CSJ:UB&EP0;W/(&.@C:W3)#]SZ2;%>>S5#!J&@E+)M?#=0O>A5(O
MKS%,T%>8FY\X/\%N''O1^B#*/LYN')A4R)$7X!9U[9>G($8=(*6<:D^KH%)K
MO^"1=>/HQ($[NW%TT<5#Z6:PS9B>NW%TZL;1B29#M#781<</A;_,AQ(8;2Q,
M)P_*Q@@N5D.^%D[K8%)H?F_CP^%MIVX<1T?;+JKMIZ?P':7Y*6!A65D06;":
M@1S(OF&F=B&-&#F&U/P.EJ?02Z&3SCOU4NBBL-;WAKU_]W8EA-L0GL,KTDD5
M90!I70%E(MG+SM?V_H'QH(50Y=HZMN$D[_YW#4^5AIJ9]2?603OZ6*.*(-,3
MDM4"5#&U1YPJ$"7++#HA&;9V0Q][1Y]]UHXVBAJP!POSIG!6 A@?:+>.UE>O
MIE[;S+B4R7L=6]]*_KA[L.S#GA9*ZJ$'R_DIT\JZDT;26]$!C]'10I@S!*4\
M8)),1I$24ZU;0U]Y_=..(NRJA_XHL;[&<PLP/3G_7P$YC->^LUIN5^\>,NUA
MW_@:%''4HTP"BJ<E3;E<(&AKP7)BKN>ER-!ZMQA P?>XM_WHMXLHAPNBK!8J
M6LMHO7L]7=^U8K+*T=(H":JK,7A'@\X!>$C&.2<8YZU;WG> -[S=L(<BMXMW
M[*V%C8[G (VU?B3AG(3E+<?CS3MMW?^JWEIO=1SEM5Y<!4LNA<<0M:!%Q 8E
M0_8B6,^5U<5MZ,5U_TL/WIS+,L6M<0JD5HF<<"4A.H= CCF7 5&(H=:*H9MS
MG563<IY9<LF DHK1!B$T>&(>6!=RD=X[P7T?XW^X=<)=&'/K^ME=\,?4J>IB
M"K]8+$Y/SK(FKB4:_6,VH:=-QLLO;VG.CU#EX@1RB*)VY(PUP.ZQWN6IDD?O
M6 J]4&R0T3U-"A\?<0YQ;M=EI&_'B]]_FB.^FBYQ3O;8:H#1"*6#KYV)7 #%
MR+EVLD1(D?965XQ$UKHQ=>^#>IX0!Z5)#[&3I@.LMUS5$XL?QI_'F4S,U0"E
M++QP;X&9S$$I^B<X-%"O3Y0V,>WCX(?9^P[J>1X<E"9]=+]J%E2U-GF=1 !C
M:!HKER20&QY !PPE>5,P-[>(GF NYEYL/HBRCS,7DP6!F(.%%(0'E:H)EE4&
MGZQ%RYEWMOD5DH\K%[,3!^[,Q>RBBP>3R[;%F)YS,3OE8G:BR2!);3OH^*'P
MU]K@?<@"3'+UC-1S\$AV"7=.",\=0SYX/_JCX6VG7,RCHVT7U;9NL;U%FI?T
MUGB^*C2I'3.900B6U90+D5@62J7KC9(>4/;<X17:,>FNBS:&.?'Z#9>OIO0=
MOL'Y6>QYW3#C+%]G5DBT)[/I:BB_S>J')Z<9,VGL(U:IGRY70I^5'\:3TUH6
M=_V!>YR1#0>NP:G:@21Y[1S.<!\SRIQ\=JIH,B2]=HJI+!+:4M1H.)A[.AB$
M*=<WC#_C.TRG<U()DM=_AN8G6@NN@'E=?@SSZ7CZ8;$&<>GC&29"\N3>V: M
M*!,TA! 3>%:;XEDK4FB=W]4*^]Y.VGXX7IS,3J?+D0M<<D8.$5=&@JHWDH;(
M'&1/ ]?.Z*39<0GP#/CP^]%!.'O#&QQ<Z7T</EXXUGL.Y\R[1B%#Y-R!0EWJ
M?;H,HJ_)K/0(+&B9PM997FU',%1,[2@8?$#E'TUX;;^!?__E]@>L7"@C+0^1
MM)*5KY4?04),O( G8\'EQ!63K9M']CB<PX?^AB=IVQ6_&5EZB,;<CNR*M[8-
MOIXB@_=A.U"4[UC(L!5)]]3D(1A7I NB6 3$4LN>4-#.E@/X: QWCKD<6L?R
M#L.T^^)R#Y5H71381X"Y.M97XU4U_G0>'^)8C) &@<D8:>VO*7_:,N#>YY"S
MX#:T=K7N@',L#M2NNKMN5C82_#"!N1J%&2]70<PPS2_)S*39@]-$\M@CHK;%
M4QN$PKIBOWZOLV!29N?1RZB8DLZ0NV PI1B5SCZ,MGC^?G/T%UPL$'_!L, ?
M<)'FXT_G0EA[-UE*-,6 K!TIE66,&"C)60[*)&2>%]':A+X'TM[;WAS#Z_(6
MP^3'!2W9^&8^(V-X^66DE.<\. %2USO40W#@/5-0DLU)99VD:)V!N G+\.M1
M2Q[<V*=:2+R'T,O9F%\3EE"GU6KP[W%^\KK4B38/:3E"EAAZPI6D(80V% BH
M&129F7*$/X5^Z'\7JL?%CL9::'WR>!N\]67$;W&*?X3)>;_$>F++M/0)LA-D
MRT65P!7R;!WF*+13UO!PW[;5\9V/@PI]"KJ').#;D)XCK,0=!68R8SJ#+\[5
MIN35:BL9$BJI<L&05>MKVNZ!]#AHTH?\&^;&;F3Q&6W?SRJX\90VP!=EB?/S
MNTJB32SY9, )[<D!)(O?><(NA9!<!Y&8+#LO&G>]^7%PHG^A-[Q==?,ZM[K>
MJ1K[9-MC_I4VOH^3+S7'XCR58\2%3#)B %F;LJE@ZWVPG)%CF+UP):#3?/>]
MY;[7/W*NM!5_PXM&=T?\8CH]#9-7TS2O'[]R8X:/C$<;:#4TA8.27H.S68 H
MQ3-O="BE1R)M@O74"=9$73W<UWEMDZT5BJ_+WQ>U/ 67(\&YM=8I2(%+4-G1
M@II\AD!.G4>=A7>M&\G?">AQL*B]['NX\/(]3L-T^>KDTWSV^2P!<91$Y-FD
M!)R)>@4G_M_NKF2W;1B(WOLO!+AS>"G0-BE:(+?F;G %!+A1$\5-\_<=RG86
MQXGEF)(17WRP >MQWH@<DF]F&+'*)A*#M1"UC=36SN1YB>*T7.! *U=L_+C4
M??9P^J$^Q?1E/F_O2N&S&1A#51%\,EJ6R9*:YIGS1*KL79 &M^\#-;@[GG0:
M--<W:NUNAL_GH(O&^3XE_:SI0A%/I;@*J!/MK^\5H2FA5VK T<N,X1*C.5-M
MA S#B!_XP!/B?PP3C]'/[SG.C6H%:[0E-W45O<QL5((R;DD(4%8HHW%#'A*A
M2F=EN0XQUSX[W1?C:;C1) S5[)ZWC)/;KGN\T+I?'_5=N+MNT=R6G[IVWD2$
M&V>19J&,UT3E<@ <#"/.:$,4X+O 3<05<>"F9?A#3\,W1C5US3YT;P$]<_?=
M9?N]F>-VJ4CX?U[EFV:5^/)M[IK?)1H&)8U%U^4&MTD9"- D2 J2*Q:MI0D.
M<9"="$[?6^J2,$8'M;Z!U9,;\Y7>D!EEN,9U,].2^8[0G,.-DC4BA@@9 ZK:
M&=M;@4PE;!YUA3G8PL>6':^.:- X3Y/G>BE6%@ J)X>!-8Y%!I6)Y6@=[[17
M/G$K-RNOO'HRMN7OCZ7>K4!96]5T]2]H-Q ]"JAV8MJNEQU*ZS'$K[5(>)/3
M RPX%;O"!A4C &$BE@9S!DIO.4ZT!>V4U#RKH==F$[+ZBM!T2E+W,5QM,K\N
MFOGM9?L+@\XEO*OX([EXO7 WM^FFZ[][: B":'14&(;R<NX-@5@=*.$B,!.%
MHS0-TU(,?^9T(5P]@MKQK5N[$4Z/X_S?']>_$^MT<6G 4Z>(T1)W'<G0TF4T
M$T^E1ZC<^[C'Z[SQ[Q^=V(,M-H:V>^&[=+W X9W_Q8^'JA4B*"-*"PWAE2SR
M8O2LC/,5X/!R*H=4M'KYNNU0/G[ 5=/68]1"? EK[>D#@(U5Q.@U4,?)4:I"
MW6YW.,#NT\P-#UTH(S,49S_#DL4ID /Q N<PKS&6<5Y3X-6SDZ=UB!VI1-/Z
MPS[F'M\/UKT0%&#,6DZ9K0*<"2W@4!T0ZH,.#,"Z4+U"U#8@1RCB4X>HM^E_
MAY7W3?-9?5T^/$8FGS_]!U!+ P04    "  -@PE58=$JD5D1 0#"Q@$ %
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M5]"0;&X%"N1_)>2?:8@'2$/^_L;=3@"-'AA&<\&41V5_1?,Z7!C0X!^QY6P
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M/8P'Y+T&Y045A,]%*( J\+:3'?\<DB%<@$C "8YR,>4 >.,"V-V==!\\ XP
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M%@:K 1_B5PV@X!%"Q4K #C "R,SO14&M$P5[=,5!CDX!KP4*I@B4*"+ !;L
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MC^G:\:AI"LAIAG0-M.\3FJY!W8.'# 5;ZAD) %;L";;?W3T(;';(8)#/=)T
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M]!W)8<HF(0\C+ZQE3AW_3.(\.'"XA#5Q\M#%$SVV#ZXG/]WJ^+6ZJ0/E(#>
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M7IY!'Q[S'KT8GH=H@O'EP76L9BQFRQ(</6KD;@13[D_A!'>]:!=R]8M(S/U
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MZ&@]"F8,^8D!(O5U.539;+'C.OW?C\.9!\X60'G-'HWZ"%4^]=UJS1N+3TL
M\)7:2"O^,;9K4B=XH+?V!+E%]XO[HWO5?7+!KQ<E;L,F(P9/;;'YJ(!:%\V,
MMM@!:VE&BZ[M\O#=;A2A=%O:;ACD0>EX6O25_:W(,2VW4XLPG7HXQ$3QTQQ.
M;#:A&F6;AYVM'M9J)FYP7QO/C2QU,.YH,C]$MZLY44N#V;[; M^G=T!VK&&'
MT+A\?QQ-YGYP^@?5'A=NN^IRYW@S*#*N]=AAERJM"^+5*4%T7/VXW>W,%G:-
M!_5BPK&7HB,AGY0]%6ME. RX7T1%7PYMTUL:\7*>K@\ZE>_WZF>1Z[]-C8#I
M_=)(9"N]A;!^CS=SYW\[,LCTRR('M^T,"P 6D5,%9%UZ@SQR2T5L!PVLK\'5
MYOX]"( # 0)C+A7D2!0B$0;P_1=)M1Q%)5UOST]^@RI"VW32P(2CF[K [V-)
M"40?\A.*EC?EIK2/GS&1BS;\9LKQT0O>"PL?=NW BP=NUN1D*_&H_,E*!"8\
MBBP4BU>RH4#AMRN))B_RC!?JZ/N\I^2[#[1D699U<%Z!!,F"JL(8H!,OC>(Q
M-EP7)9E![H+1JS#J8<BX.V0_P'P[=^\*O;[0>+8];[2< 8I!*S]+AF@; YSX
M\4!W=(>818*&&?"1UZ_]+7Y\8X"*D7AGP@PIOPO1/@EC'9KG/ONNW5?S^!1V
M&%DA31UD3LPX!362VVRAZ *PM0?NB$O("5Y^_K $'>)>O10.K8DXLWXJ8,-+
M_G@4>.S3W1E_='_;Z5?Q)YMD-D>(&_A$HM+X_1710%4PN4'WD(UT>[K>U)N=
M.H=WGVH K>SC/_KM/EUP82NTK<$Y>8'CT^9PQ)#VIT'><R";=PY;5U-RACGP
MG1^6GZ$(>I!0P(E "^DIC"_59(Q43"^;!E#D=\&6[SFF!U">A!< Y@/@M.3C
MX?YT;ICY HI3;K_S4?LO[R-D$]RMNY-OTU8&'X6U'#CTB.LV#-ZETWL_G3,0
MOWB\)^]$65G0.<=Q-7[7YN3K<DP[+O"#F$$LD4&G67X6OL&^@.R#2Q'#+RC"
M@JB05'(P="I0CN]2N:$H.=9%Z<;76T&;G<V "&F@'JM*E4<Z(%GGXP]$WBTC
M.>5)YT-="N,X?4%,P[7Y*8G#3),8=F0=:RW3;-D=W00(EWT;&SRGYF:V8#5B
MSLIYH.313!ULB'D\'(]7)\O4*;(%N'/;#'>SRQ/0R4D7NR/PYC4G@LZ_SGT:
M="KMA[^W0___U4['MLUH98#N=PZ)J]$*:_?!O*&F(\Z>D&[9O$LB<[(C;]F&
MF+.3C&+)T>'J3U7N!('HSO0?X$(#M;O@E_NHHA,.(CWK>4?<=C=J1:OT 8!T
M6/IEVRC+RT<#<@!16X10N0+H^Y90)1D-4+(.5<8> [!M*28^#[7/!?>E.^R1
M(\P2O'2B^ <X>J*OJ3HF]K"ZK/.!KK-:6GQF/"YJ H'YK]MFF_7?8[];D\R7
MOYO2N6Y#W]OPOU.S U+,J2>(T:3%1[K/T '.HLB$:V4:PB-G5>Z^4!-?.#J9
M;8T1JW6V+QM?/@CSUK4L[)-MS\)[2,@#R%_QI$W'^?0/=SV$7M8]/K85%*<Y
MWZ1I;+-6H@$'*.RN 5KU?:0CTF]^H%#-83*</44];UB2\[)V_:@F9O7S%?XG
M&WSB/7:JBT2.B2/A!-2'8?0+935?MH14V])%#R_7XYM6&O2[!!!_Y 5>81.5
M7/Q]@ DNIE)NS"(+,NJ4EKGLFY42ICMJHS*<1T12W=6&_<KU-^*J3JGH@.C[
MJ3!R"1KN08[.]2YJ'.C,=# ?K2LO?T7K^TNC6?[=UY1,TA!CD%+/ HH#U:EB
M8%EY08\9.NJ0;)=>>T/<$>L3 )6_LL=S1G1_8O9;[XR.Q1OU\KW-U__N#@PP
M>T 6CR-Q2:*D:.($>;6I7ZF:>;PJ_&N=M+5'55/=(=RZ_SG)AV?KW6*'W^1E
M2D"3 788@B)<725@+Y62*R9U66N/]1T7;>@WR.C(N*$XN7B&7>?D]8L;IJU+
M4U*S>BS)W$R/%=DOB\=?=QQ-2+^5$B3V"Q'_UQW68JX ;SNJBN+!+ & 4,%"
M_03(UUHGG;5GCAA,QV$H+S.S"-$"G3VG3Z54=#S]DWD\_SW.^R<>Y_WH!74
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MUB=Z3<8VAH+K$4<+HJ[UE[0_<79D66N=J@*/:UPS>TW(3DO:?4R%C\1!"_5
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M@_0H(QOR=IF5'-32+ @NZ"MN?[TL2[N\J[(T269%CR_3^C9>;0_:9 9#/91
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M@UCVO&3N+N\14AFQI)X!JCET0H-J:+*:]ROEW?8J\;,0V\ZYR"#J#K+:=G(
MN8N@DFK!/,$=>+1?>7=QK\A1__>PI< 9-DYDE=\RS(C*PP#Y/:7JI;W.H_KB
M$L7- V^;KVHFYDXSA;]N$5GS7/APZORB 7X(/DLS2*FU(PL /^I(%B VI3R%
M<$GYKXNYT@,F>)I>,/=T"'^ OH]2[5OS]Z<>37_C=:1(W=59.B#,](VB=D;R
M+A>M[J(B#8Z_,SKYIR*85.IO-%I$PW[#W[/0'_S]=MC_G]S BC$$==3F#Z,0
M>H,)=NOHP,3 +__8[R$OF30SR*FO<<O^C_I!P_<#NQ4%K($7X#GA"%\9("YE
MOHPEHG&P$Z0T[Q@TP;A$C5Z\8^/="TT5\[-AF6_IE[=557I@<H-ZA(^^;YP!
M.D";/*\JY*W:TDZ !CI!>A9O04=GR\(>[=BX_7*E)OJ%Y0ZU&P:QFC:GUE7Y
MOCN$R#'XX1_KBYLSAR6+@/'[/2BV\!L4XSS61M4=A*]9DF@7:90C@O=^UW.V
M&?X"YM-O"&9N4\C"9?S !'BX95(R%H=E:PD.GL:ZN<]?4?2MG/R4!"49"B::
M!65.!=&6:$FU.[V]2/?(.FG>"@U',#8][J]+XWC8%5<,VCO%0$X1(Y$/MVOE
M][A%%VMH*B@NBEXN_>*>X\#'YWT?CY\PE<#Y[]3:9;\S^W38SL<@D LHAU/?
ME.]WJ=N_\$3@WW_#/(PDJ&$W5=HQE"/.D#7'&D2KR:0S]: 7'?I@F=Z4T$GC
M<X85&G4:N)D_ K[^VO>A_/^>,/P?GS#\>%&' 4UN1WR$$<(7WE--OCAZ#MG?
MCZFDNN;O4N _8P+6V7.HG.E!UE0%NMN\F<@ /9'%O!ACZ5-6RC//FX[.O:&2
M]TF"JMW __"'^;U3!_?.P<XV\ROH*K>+/LE**_.CFTF@,K2FADAT06(Z@OOS
MW#WW_'%";SC (77[;"=I4Y7@SF]<L[ 2;OQF-N(3A$\N?._\H[0;8LKM2I'E
M-T9LIL]K];I<F&UK*/%91!ZZ0RAQ*<D(0 N:-17WS/:',$!Z#ZB^!YR.)LGL
M/WG:X_ K\Z%W^:\!1O'9\R\:<]22G>B9B@-SS0V/17F<C,E*^WJR+Y>(BA<[
MY"=&;;GZS&1Q!A],T;%C@$J@'T9%FXP1-Q4BI8;6E33.4P2&=TR+4C*.O]HP
ML=SD(EM9QA$X2(5$%'[DK7<.E)"?<C^%:/VR)!$3-%0WX1U.:..L?+Z(43'2
MIG$WU)Z#0X+CT3[Z\1N1V#@I#[1J>"LV!2)(]&O@:BIG<6;I=96-_Q;5=:[T
M5<IP?^NC=E^CV,;.',AV;5H9ABJ\,8!BH8*]L4/]A3Z(X[7^Y,IHJ'R0%D&,
MR8<NPO=0;)2@<BZQ171:HK?'8=H[-K# ;$S5%&_0-QNKW9)FDC&QM(5RK(.#
MGXSG9B>9/#'7,M/-G=J(6O7EOA1I?@R0B0^JN?_3L) !(@ME_%@/K3[1B#U8
MXN"[!?:SWG]' '$C\4)(%GB]21MYS[;3"B8,AQ!$THE*S5LF >X.GI5]<@EI
MQ:6!2(Z*#YTI86EK((YAC!O$!OIDV ;_C6"E3D"\ROXR)S]^[XTDZ]?%55V9
M1T61KH.WV$#H?OC)<>CBF<Z%OKZY:T4K;A3Q;T3(I:09' )"G"%)ZM!B_:-S
M)J+"$II1(XB;6);U*//&)>!MZ460Q[^9:O6?EV)E,@VE<@N1>%_>1-;/$CK>
M3;D*H%_@0A%S/-K.9^=""S#OA,Y]"Z3)9\=/O["9<#RRK-<K<;OF/<9_<<EQ
M^@*QD^]I;@C[KH/:Q[;Z-(V].$P@\; ?R45M]G9O-V3=N1+((+;EP<)#@9JF
MC8;0>VZD_;EQ?%<B*BAG6DK/#[8LGYHWE8/G &][T6OPSQ[I_S-N^F913$@'
MZ MPD>-*!P[#XW#TC/U(?-?)U?M3*@A;L/L5W[:9^%7,CQ\3@T/$TCM@!-B
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M/F;0#IC P%0<73>PS77]!QY4$#LBU-VA-0_)VHDE0U^\?Z,6K=_QWGDT,W_
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M _2LA2XN1;ZTG>E$X:;6([ D=+%O*CU!H\@Y@M[O16J!R #0M06PQ3US:V1
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M@\_*$Y/J$7(@!DA[4D2?_!:]8X!Z/M/;P#"RQ;"@NL?Y]H3NH\RCO ;SN3O
MT4A=N8!)U/,D 7+B.]^ QO@]P1/[59&N669:'F (_F.:T>GP+-7. NK(3Q%
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M% =\Q*:I "=%?]$*X+S0<X4C9>8A\]_S\LT0J'LH22,URHB1!TK2.(B&0HY
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M['Q*S0>B\W\%LFBB*'+I&3DPKQ%O?JVD,?G#5SM$,]<#%1 C:^W^(ER$UW:
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M"#-&5DPC?ZAR=R_W4)F8"HV:JO[V&#9'O\ZZ307L,=,RD;@K:=@!U AAV71
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MRC#27I6(]EX$]Y$B :OCRS?UAK+B7[=QV "9!\:="]O0=)!0&@ ITZ 3V4Q
ME7B="ON8/.W2@)I4&TU8%NCO,D8DS,$2:BXX"VBSHH4"PZ!-T$VAL6-+XUXH
M]ZW.39K1T!^$)P;]4QLT%L<_"=7+UER$#J*.;1B8K[\J&?8=#FJZ%C!:TWD%
MMOP>O+TU;Z:RUQ^S2CIA1;A9WN4@[10^-(IX7?$<G$;T4D=)-I?YIV!\V>YR
MO4*WB3^2/.FAJJ8'??VK3NZ')'6BS0<2!&>Z%>('3AM<-!),!\:[V3Q)?-5\
M1\W]@;/*A:-I^QC.<)'@Y"H8)GR,GR@D,/NBAE/-?Q)]N, B4:OY7?:\W?@1
M^E4L;X[,LU[U@XN;:V%97S]>':%8OO-X#WP=Q:"X9S"W& G??V*ODR?GU_3F
M&:M2 0RP2,$VF)W!]:.>3E0 6&)*%+ZZ#]$MJMP(U8/VPG!@\(OQSZ<WNKQB
M56+6K^DU&*TD<$W6*?LXVN\_Q9OX^(A&QV59^9LV[ZX6>_T\?-!3_]]*9J1B
MJ #Z!?@)A;OF*7,^_F.YM,B-0<Q!S/RRIGSRL_MN%(#^1V@;J! >C;)G8J,"
M+(D@=>_\A\[(A/2.1Y\^ 3>Z;@,3#YP(XT1;\/%#FZ'U,)PV[""E80QXRN!#
MO\)#=]ZV98^9,Y]/^#3O6Y]J7CIL21&T!YS34<]J+'I&F]S'L%H)4=!C1380
MJ]=G>2WPI.+&#4<=_A"5R."C=Y*#KU_UIG^D"S5MI-2EA-56)NYIPIG_TQ+I
MWR^3WN';O4]SI%Q*XGZ6Y#0_E\GV<[.UB^G$<,-R5 D[5T3V^2@-QHO3S">X
MZ3.TG$&X"73D^/H6!D+BHOG#)KN/&AQK19/HGUQJ33<5$'+<SY$*@*/V40&8
M+@A%4HUTU0WK22(3]S)(,50 /L&O1=80;_63#D!LJ(#Z$"49&'K\&0QG(TZ#
MZ:D4'EE\)05*8J0" C5@Q':>_]S^;WA[=AX($P#B0@@-"F;C*+TN26L+G@>A
M<+%*8%?\Y>-Z?EKKOKJKC$1C'3PRU$$JB;=N_7ZO].$#5_KB"J6*M&=3<@HT
MI'?$<;F48PL]Z97!$&[2]<_(9^J7A^8\'$1:Y(,2'#Y",P1W]$<@1?1+XKAN
MPHUN E&^'M^8_148[Y([)C,DS?AJA!,\<N_9ZXAS)^F&$[13C(]=2Z:G @X4
MT-88!%8O.I095>7"PLX+JGF>7O)!A-_GJ+;$%YF;2<$J$E?OW(J8?K%K&R;"
MMK)BM]?O_/1\2F'-&5.[."A#+S^N-S]R*Y1ME HHFJA^6V^_CCT\<SG@^OX
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M"SOJCSEGHRYM]MP59<YSR4DY<R0GE4YY#I#]1CLTJ[[\T*LT(Z*O1LFGPM*
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M/"_;..OYLO7NS5W+H(7G#7\H6ZUA974E]<G+X7K^=77G5TWI[Z(_\21L(D*
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MP3]3DI52]"OU_<_XUPT1\28S\6X2W828IDEO 1M:JTLLK;+B784:CZUA- J
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M[@#@$J3$Z]X7$"2G*,(/YL:^(D28JD"M-))7M6+!VYG-T:Q4P.<LS1#7=U1
M\7U(5<S8>Z-!I=B8[2:YE6[]O5:9#Z"0NG^$-/T_X_\G0U@VP]C+2(/S+K.F
M_*6ZK-,:4G08..XN:N@]M U>5+WY_[5S[U])'VX<P&G3K+S-(6NC!ONFI_7-
MS$/>2:'F,3)%<R*L@Y?U=59JQLP;Y2TM,S2E+&/6TF/?O (24RR\(4J6H3'3
M+)0T1"44%%(1E<NW;[_OY[9S/C^\_H/G>3_/+\_SN/A)V62.W9FAE%]KK<$/
M#%,R(_=?3]$3B(LCO&^^'<7L$30A^AS?8S,>ZNW]M-6D49KVRK +0Q[GXUHE
MQP[2T$X"YJ*HI+SLO7CNX<_HM'88KSCSR"1+Q1B-ZALO=NK]MO)<SIB(Y$A=
M(O&SS4P@_*-LV+B'@- \FTZ(4J)5P\O&Q6N$K'5WX_/1%96?)B9$S2J0&53\
MQ;WSY<D?GP:[KEM=M<KK#\?LY$:;DUUPNJ+)-^@?!O?4#*<FXE-;. \OQ5:G
M>7W^I\W4[Z -CA<VL\2\UR>UR!<F4(P)E&^GF)MZHZ/A-J,X=1N,K4=M=OB]
M$E(=7>J%V[_JJK35[6S,*39,O]R4X#FQ3A\P6D8J[^HXD[$PL##G[# [/ PG
M&VN?XMWRW3IZ/C&M392+-DN!B\>DV30IVH:X"LV^ X,>XM^>#UN9N68"@=E3
MVNV@SRY8Q/A##,4%/4-51]Q./3Z$"'!L"3A]W9@B0Z2RP^440=^SY,2^#B()
M/S;_.M0?PG[^J3=]P-\7Y'V('L+3-GPH9@>UJ]'.=Z=<J(&7V*DH^%75:0PX
M0,5#_:3H\;9PBL:1;PCP4;;J92.S/@(35ZNX]3XR,EAN:76X^B[UP5%L-BS[
M%;S9?T'EKY$1-;&#M_83*2A1S1A7)'8&[]AE*-DW4&+9!EM>)15*P@UE93[.
M%O$<%N0-1H7FBL^U,:D2_<:W(2K)<@P[M!-N';=?]6_#E=59;F5IDX[J5KO#
MK02":T)T@<YB/3IU)E!>D+&+IRX=/Z;':?)OY)P<Y95+Y[ZA%=5O,(&H+18Z
M>P-?'^298MFV2KM,3H?<E<ERNYE1S*6KYQ\:XI54586;S,K6.C;<-2CY!?*0
M[\GOFPDLPF!D!_7_5Z$11G[@.HI\!+V-W" B%7.>HI/,A(NG1OI1,_N#9.:+
MSZY^#T<ML-[=XW'V;:=:WORY*K?;Z1 Z(XLX/Z$WOW?8!'+WHE,TDH/EPP.N
MFZ.2,U(*%5\W4IP[5]+&MNRZUW%1GO?)XQOP]^5T1]>A\0O4.:F%$1H\Q^5&
MS;LT9K*+5]PF:4RT]FYA0\GT!<8</G_W67KH* +;H@V(GW@Z9EM OT*'VO]G
MVMNM]..'M\1WF0DFD'F%X4-_2R'JQ,IN VP.>KF5GL%H3NSWJ.*E;W:X]DNJ
M!!-9ARQ@#4!G46[Z8R]12#WNE0^1&3 3#YT>BO"R<-JR=)AFN'F@SO<F(73=
MT2B\/:$ZJ4D;ZCF/G\OPTJ!JZ^S?P#Y,4W,1'5;(7:4H-SCHFBA-F02PO)%,
MYB:[;TF:>]:RU/E'%IA$A"LP9FJM19Y7E!L[.10W.8NOQ'C07!=;KE/QI2^4
M2RS=3KG2Q5,5K;&:79. _=^&V/;7K!TL,P[^=CR_P?/1=]SM#=>\]M[/[E!H
MOU @,SU:'CPA)21"'ULAZG 4^^/A!]Z"0"";E_GJ.]*H(G68=)PFS;$1,V_=
MN-^](Q_95,&8SZ&(*2=\^]Q?$):W?JY.M8%W[=[]G,&0[UWXPZ@\GSD1IB,]
MMK5#^!!OM_NUGPIKK;81,BJ#X\ZLQVUK;OR0FEGUJW]UI@@ ?$28$>F_*M(V
M(.64TYT0Q58+96M H"'Q^J/2MXW'+ZQ=PH]C'))K4UD\E)MN(E27KF9%C*1D
M04T@ 9)31M_FC'R^\3:Q7B2$JJ+2YK]C*ZNH\?H'ZG0]V%-&4X%E10,Q FB(
MWD'%B.B8GJ]N#&8WM1=S13?;JO><_=4CMV+?_NR0R0I/!/U2";;LQ]_EQ,DD
M;+7Y8 ?-=7SAEP7NNCS7^TR('QSE*$JR5PSU*,R]':=#F</$MFGB,?2Y&D[0
MZH*TH,<Y00:GIO"LR6F]6+^?7LY\<7#+VLH)7XC]9_U/\H\&***;>6RYLO:_
MQJ<FT"9F)KI6V3K<Z"&)7[LL<5_N]495;9V_IX7=9WM-L$5*N!3^>M'OQ!!_
MQ =+ON.22O\MKW^.CQ!P4;AS()59Z0%)\$;?7JJUWL<HN-@K8VB^Q ^%FXM1
MS.6$X*+ %O+ Y,K:0&AL.3&)SQ]?P/P8>&)DUDE9RS3,L&*_+-S%&K'MZO[D
MP0T                  /BGLS6)_P=02P,$%     @ #8,)5<@"^3$\R@
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M\@>RSV)_ERDT?&4_+P >+>/GIV7W8(YU+H=?Y.R^I$\/.:?3^NY0$*(LY&$
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MM[HM/N1<%I6FHNW+S]>%J'>5WRST;V15O97/<CI[JD^ZN2:HFIJ6GWR6Q3C
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M.:B/_/^5534K;F;ETW(G:KD7+&G".$\#2#,F(8I5J/]&]'B/E/97DB0),JN
M9GN18QO^&Z5-?KB5VF!+;Y?"*U:@6VR/>(>R9Z8XCV*G.C96<+I4K?$-ZU U
M:CS ZUB*Q@6I]L(S5BT-6&;&Q;+=HC).;W9,=&6"7!YF4_U&91:Z\Y?U10DD
MI1*QPA!3G&K?+!.0<B)ABF/&$*(X<ZMH?5K4V#AZ6]-_ ;+6U3%=U6E8[1PU
M/V#US,*[.#5J@NOYO,S98EYGT9S/P&=:UFF!>[B:<AXD7\FG3@L:-M?468,/
M4DN=?Z-CX& IGV@NWGTW^:KDZD"QN0YWLRA-GT^B,)$X#3B,),<0<:K,<5P
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M\'0CUGL:NQR5C*H> 18J8+&J37T3Z/PRU/J_=K^8Z'S]8W29&6HYH_6F&8S
MJY,(EMMY53EO_KT3Q?O^S[K$\L]FB2RGS[42?:_?L[5-J=VTW1KW!:1*EB:(
M* P3)"C$.2.0"Y[# B&E:"J4R+P<3?%)G-K]N5N9ZM-J:[Z*.5NTI?7,S[I.
M$O!QM6V2,/?-TSILV^?;:I6V%D'3SO!R,]2Q/@_'\_Q5%WWH@[FSWEWV.HD2
MH&6PSFD_6."6R?VRCE2^+/9BQ,^WB$7@:R5E1 :X)W,C]DP!YM@/:K-1ZMY<
M4LPLRZ\?E#DMC7S[F]I:D:<,=O+7U7+[;?'#GJ/-,3I3C*1(E!JFB@J(5:X@
M):J$92D3Q;'("N)TP(23,+4#Y/UF.W^LO(:/-:V &V)!%3'TO#2+ =X\SQ<2
M;E?PBU$_%%A8-GU,M6$KY6"C'1S_@65Y3;]M<MEP "H6;JISVG !=FS<@(81
M8#EI;UJ#KX&'/7;PM1C)$#O8FOB98*^"L]?V&C;R>$;7JSA_86V];J2P.]'+
M]O2U&GZ["P^;:8DDT0F""B,.,2X0Y,S>=$I$*2FUS)CRLWWV3S@]@^27PY"Y
M\%+K%[!VNRS$PV_@PV)':!OPUB"Y)S:>TNX&2B0%_,)DHRK3;HP?*L:.;P4&
MX[+--_O_]_OF52_[ -4>I,X/.D_.&!(92S"%*J48XC2WT7*(P331N202T4RE
ML]K[_F7+UELWH7,533Y[ZI"R 8-)JY961VW";"SNNJ>-&-MV2L29V[5/ODJ<
M%49)AG"B&&0B+2$F10:YT"E,%$E*<\SDA13-"K]?RDFN;TO7%%=7V4#N5UE7
M5N0,Z00J515=$:FYJ3(!LZ)4"<W2K)1>75Q&6],Q>KJ<7L^;RPNZ,;]^6JVW
M>_LG$V+U^,26/^P.?KLR-]YE[?1:;E:+N:QNQD8 ;9O$3VM2M:/^O%C]X=DB
M\+KOP4V=&6V5!]9VZ@6ND'[?7> ][4T30E;'R'1_V'TC8B) #&1C90U<1<NX
M*08Q8#O*1X@R:'ARU'S;UNFRU0R-X#"7R;G:O)MOQ&*U>>ZZ+ @61" AH<RY
M4< 27D*N,P:I3$1!6%FBTJOWJM_T4S,VOKW_]=>[AU_??WSX FX_O@-O[S\^
MW'W\Y?W'MW?OO_CG,WFL@Z/X' S=H>7EGO!*)+X@'>QI![\/XN4)PRUB#I7'
MY*-G6/D#<RK_*F"4JYO7-$FENW025)9<%P1#EE.CD])$0*YD9AMK%1I1LS!:
M!?:P.9AJ<H*KR:'N]+)Q3*IR@-5--L4!:VB7QI[(3GNLB#DU[FC$[V=S.-%K
MM;4YPW!/=YMS;X1)B(]J6X>&?%AM-KLJ?@^K3IKHM]7"C+=YPS9S,5-YRB7'
M'*I<%! C@B#5RLB./&-4%7F)I5?]4,_YIR9+;&C-O*+_!E0$^@D27_3=I,N
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M8TEQ\8U@87&^@U9CP)EQ1 A/"@UI:=4)F4G()$YAJ@J*L1"%YI[NI,N33DZ
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MXN &-"3ZZ1#^:^"F6 R*[, RQ8+:5!7_R9+_EXX;PR@@-0N@R\-E\+TUD6
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MA,'O%:&ACH47D'KZ%D*!&LN]X(Y1N(OA% :QO0POYG@=1\,I-L_Z&DX^'%!
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M8;Y4R:S,L6*X8%9I).9::WN;:)[ /,$T39F6M' 2W+VS3$U,UX2"AL2;]B_
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M"B,0FLA0SMZ"C]Y#(),Y%Z/H]FF= 7\B;?3C=!4^?%C6AL2;9Z'MLAN>7WL
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MS[\NYND6(PL/VA8?H=1!Y$JR0@?62;",=IK(LF*JM<H[EN8N+]XV>O"DXNP
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M9_+&C1F='H5W+_QA)/F-Z=K-*^XI->YVP3'U[GU[[DK[.F0I"Q/ 6)% V>3
M"9FJI4FP5S**TEJS=*%]WZ6/F,]F^+H\='I7VW#* ]]^3W]:A?-R@XV4K\XX
M)A>,S A)U$Y/"3=GO(#V/HG 6>)AI[RQ/7@ZX':^!>V^#\IO:_=>D/*-W08W
M_ME%.OX9Z<7E^B/>_YF_D4/]ZC,1?42EP8C4CGD/->=V5Y=8,!QS32L4C-=
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MT<JI?;C; 31N5O?$J&WVUD"PG)$^U0:B3P$B*KKD34(>W3]:[=0QT#B<NQU
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M?Y.WKCB+_$Z+RP<OI^N?VYGD#Y'3H@W3.C"5F\9AE0@^86;$/E>?2[,$C]:
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M*ML(41*OK%0)2S2)84\[1R8=(C1(Y#L.$1K"_PY@U/;=EDI9<.ZA".]!.>1
MWZB 2V)*=BE@^7N(T#; -@'4J$.$!DBW V0_,R7$1!9Y*" LMZ"$I2 HH ?A
M"[(<>&(Y-8;J7V7GR""<#!OM,D!H7>Q.?WI.B%$VJ4PGL3K1]5/GM3IN-!C%
MLA9:!?)I&F/P\.$N)S)>Z  ,MA-:%QA\?$Y7G<.%0DJP"A&4U8)<'^G 60S&
M%"-$\V!D_V%J)S)0Z""[=ZB0NL#:HW-JL! #T I@GI$#$^ML:B(?(GJ+,0H;
M<^MI+R]]E- !2#M81%T ;5@FWE!\9WG.$(12=<!-H.-)36&?828:6113C1'X
MPD8C'!(ICR>K#J*,[4=Z;L/$G5IE_>N;/)<2B2F?&6BI:WE&9?!<D<\KK [,
M2X4^'NUYVIZ'.*7!"X, M_.3MF-(OP/X[[-1:,8S6AZC 2,*J^/@%41#9J7.
M?V*L*&=\:X=@'SI[G==P%&@UV!PU2,XGBN4'O)XYF6PQ=#L:+HG'*#-$$3GP
MX+GFTF%QK8?0-2"[U_$.IX+T0U#0^BW%Z(T6-V7J97G0>G+_Y^+7*KXJCXMP
M]DLXW[0KC%/G/X22L8OYS;AT_(J]3*$4HQ)ID*]/.^L\-"T\V(A!.3+BQ;;.
MD1^O8O_T-((K2="?_C4__S1?O%W@OS&L;J0Z8]$$$=$"2N'JG/L 04L):"GZ
M%LZ&9%H;^L,H/IDZ_Q#4#1LQT52H'3@LNY[V5:'OI,-^^+1:7GS\]./\C\VY
M;VW4+$>AC94)=(ZJ3CY$"%P80)6%MY8C5ZT3),V(G]9YZ0S8;47=/<;O=K5&
M9HQU%D0LGH*-Y"$Z5A/F3'KD@671NKVLZ52?T6H<72!T3T'UVGY\HTZ_; J%
MN.'N/D[MXQ_4Q"?=@<9&+N4C;VSO8*I:%1%DE33]XD)].Q@LA&*M,CDQC*WU
M\BEZ#FZ[>^2S/Q ?7],/_4[8UBYXI:!(F^FPTE<%XI!CBMY*U(HWW^#W%$$3
M=S2UPL4WO7?-A-#K!MQ'E7=3BFEG9JX^;CQC\QB]QS YY,B@)AQ!9+5%0Y<"
MWAL)F0GK6-W'HUM/0C^*R7FU7N/Y^HK#^>WB?;U45_/%Q\U3[5L%4,IHI"L<
MF T,5'(,0J(_;H;<&^('EZWSZT-I[-@P#4'/5L,TAJA.RE8=D.A[\O/&LU9C
M)MV>!)R6/%NF&+CD<LU6(T&/(23GN)9),L/Q=,T5Q1MOYB'.SZX:.;_1"/J!
M7Y>+U7T%V30=R(*62XI-0]$6E"&]"+[&JW40K4:'6$:SXX<2W[&!&X*W9PS<
MD83;01YB6W>^"M[I9#4(90*HPC6$C FDYZ(XXG-Q?XF=W1,!8\='.4.DU '8
MVC8+&A:C51Q2[215QG'PSF?013'D5BM16F]F>?F/<@8!:M1'.0.DVP&R'^]S
MCB4*HM: 9<F0%RP+.+JAZ(+"5(02F3?OFGCQF[V'X&*G9O0A0NH":4^])"I:
MR>BY)]6MLY:2LQ1WQ0(R(^FOEA%9?\^_3N3IS4'(:R6T#A#X]#NBJ$F=4GW;
M$:RK\U8->$NNN+'..*6R4+QUF^]?9K/W 0AL)[0.$/CH6P^FD$F?$7AT= ;.
M(_B@$J VI%Y.,9U;IQM>^G.< _!VL(AZ@-GCFWX%!FV*9Z!K[Z7B*D-0N=IL
ME<AWEH'[UM, #EC(?"(;OP^!VN%BZN+MUU,;?HD73'D*Q**,#)0O @)F!Z80
M8[(LB4QV:[_NP)7,)[()_!"OKI' ND#?3:+K]=>;W_YCCBLBZ]/7-_@'GFT2
M!(Z;Q)U4P+1$XI?1X(LN((JUDD7CC&^===F-LFDCC4[2A.UEV,$U_&A5Z]OS
M72FT+%)LGORBU[4/L 0(1AG0T;."D6MAFL^)&D)@)^GLA@C9!L+FXNH)BS\O
MOER<KS<<X]<3--#+6%FE-=;'YDZ1YG(+,3NEO3 YA-:YER?(Z01G[4&P#6X'
M2J13<(FKHR2C<Q!"5PS043C6X;;>@'#.&E'," [@$^1T<ME. JY])-(3N%Y_
MO<.V'U?X/Q>X2%\W9K\@6HJ6-KEO#0I#@9A4?3)>LN!96Z-;URMV(&O:#%YW
MGET3Z?4$R,<.=*6[M7VJD-T&*Z.H,P(IGE)90XC$+R-<D&JT)NOM9'5RM;:"
MP@[^VR%RZ11JZQN-O:["*,VTX(P@4>\)1HKJBK"0E53"$S.5],<('![0U0G8
M6H%AEV#A$,GTA+8#;HPW-V-<=-VI(#6'^H8)E%82?/0>2E&6N:2U3*T'VC4]
MP+3UD,YN[Z,CH@-UV/D!'2IF@J#3I&(C75J;C<O$:Z.M,)[%;) U1GK3EXY=
M]R#N"9]]'T,.D647Z>^K]3,[;-F4QJ%TR4*2:O/*BWPK+QT$%@-*D;S4KC%,
M=R:ND[A\<IR.(\T>C.F&LX\N?S716E%G/$1G2.-T!,^+@F(=]XJ5[$+S\7K;
MB#G]B+V1N6PBK9-Z+/YK6*WHD__ YB^EOOWD\=Y,/7.*8[R>4I)YYXL&Z>H-
M&@R#H%6&& D:)F2>\VB%UJY?3RE,6CFO "6:NGY.DK&V&:HVUODV E-K-_&O
M\'IJ"-[&>STU1+@=7,??XXJ<BVHH;CM+WL_7OV^2<$P5XZV+8$/=ZN"B@Y@L
MJ^]OT3#'@TNMG_D]14\GV#LN1+X9@MA(7EUA[WK2WF9GXF5.CEMT7OL(LGH5
MRDD&SN/EV*^D=.8,6Y<+GZ)GZI59K:2^%4X'BJ #.%%$C_./BQ_^3)_"XF,-
M\/\35OEZ88.S0I*6@;)UY6N1 :(LB7SBA*BM3XZU#BZ>HJ<7.!TJ]8?7:"L1
M] "GID&8*5E$F1+Y)9*X*GW=%68*L#K6RPI69/,A:,=/@G>=ESG\[IT.$1VH
MPZW-^/6BJO/;<J<5^1]XEF>H'6/,2=")SJ)\;5='ID%X9X)-"K4JH]W86X@Z
M?9=Q3\!LO>=;2*\O."ZK.,/9J\_+BT6=7B8=ZLBA;*XO.A)X5Q!,5"$[-!K%
MB"B\1\OIV\SFX-M?5EUA[@.N/K\MU\[3C+FZ,H$;T+PN0#9<@./DWFB[>< 3
MHF_>Y+.-EI>4N&Z#N0-DU0'F?@IU&O9C\=_ZW0K/PY\SSYD,E@QWR)NROD<(
M=8BKC(:)$$Q6L?5S@6>).OV6B38H;"N]7L?,U3G&"X+QUWTJ);?_<Y-BR!9:
M&JYHV'SZ;?[Y)OT<M:LKJ>H[O!@(+%F#LZ4^$O:1(_/UP69C/7R"G$/MSB,?
M?3L;T213A- 4OUMKZI-#!.=C F$]_0V*Q)O[6$_1,_T"A1:8>&@[FDF@>[.Q
M__3<AQ_1UH2,."7W*=#P[!1S61!*8KUUL$ ,,9*;XFQ4=!,IWSKS/:(AN5WY
M=_,EW]$]2[_;L/<6TG2\(#UI2*%(%)1  YYN/T 6HA2:_++FLX%WI:U? S,$
M*]NW?S:43/?&YH"FCF\^HZVY&7NWU#8,Z: RUK8Q9K($95VJRP 9<(U2RU#(
MVQUCF=38CLM=+,^B]$I)K<$&4?<RFPPND[(DF11::Z/EK0=O/TI(OY9D" JV
MNBI[\[R#2/MU. N+A+]]0CQ_4W^Z"J765[.2/%&8!A)U';!1.]UTT<"R1$.V
M(;C8&CO;:.D$/ON+>3D"SSO%SO7C79G0*XKHF52:3F(#>)0!4"6-AC1.QM8+
MO+93,RU^VDA[!PCMP?H.0'2M7K=C%:5FK [Q 5TGV*HZ<LSKG* .?XHRR\2;
M#X3[AHC^(+./=+=<6/NQ>D*L5/=Q]O;\$Z[>+!<?Z?,^7^^SN!Q/IZ,03DK(
MZ"@F<$F#CU: -<$;JQ1+]EDO]^FOF+:FU1@.#;G9D?WX>IN[5E%83:$AN+HQ
M4Q6)X)3/$+,6/G"9B6%CN;UO^F@=:>^T',CGGI#R/OSGET"?.P]GZUG2JE 0
MP,GPU4%R3#IP&AF@E-S9I%,IHX'E+B&=.+E[2G<;6/9F=4]X^==R]?O/BW>K
M9<+U>J9M,IJL*TA9\T+&%7"B^#IY7[N2F<,\&F#N4=*)A6F,F/V9W1-D?IPO
MYNM/F']:+C,Q1F;KG+$$]T2G4'6LAR*?'W-)1=,!A1_+H[U/R?2;7\> S/[,
M[@DR/ZV6!'B9=0X^<<AD*PGPDJPE9@\6DQ$AY)Q\ZX[M^Q1,V\0P%D2&,[?7
MUYN_G2_3[Z_#&O-WR\]?<+'>?.(^B?TMG]0DO;\+E8V2_+=9W=KO=/ME[_&,
M/ _Z_O7Y^K=/A+Y8R7D7OFX:46XRP-9*+UUM=$EU[ZLM2.Z)4( V%\X$Q4"Z
M>1?;010?W,^WZ[>_OOOM=U9$"LU9(%X%'2F(0)\HB/#U#;XBQGEN>&S^1.DP
MDB=^=G(\?'[3#GA$4?=: GW<$NW??/'DYXUH.T=LRS@0H2';FF@2((06H*)6
MY'"Y!%J:S'+@%:DORH+>MA#\0(A9?D6\'&>/M[ITEZA79V=72;NWY3VFY<?%
M_'^)* J*EY>4WBJ<MC9Y7A*$:,E!X?1+B.3P2%5T\)IG;+Z]<;3#G+35'8+I
M[1TF4\)CTNE,FQ3S+1^^N6->U0>2=<+/^=<[S<&;G/2'3V'Q]DMEQ[IV,U^R
M:+V^^'SY=P^:=$1B*FMO0++LZ(8BCL201%V%)+S!$+B-SUGT8Q$[;;YF H7H
M$@6GY:=<<V]9KLP$YANC\NC_\,.?];=X0+_7.(2,Z!DUY5$?+I6-T1:'$:1@
MLC8X6@A8%$B=,5HIHFC>G/;"7*K+>I<G,\!XA"CRIE\\@L\4SG#FD:Q609Y;
M]S"-<I"3=J6&8'ET5VHP++K($),!)%-&S*Z<O==#9,@?3-DJT*$N,]!H(+",
M(&S6Z(VQKOD;S"?(F1:G'8#EF_1S&\GU"\*K-A3DQ2.3$8PT"93,@@YC,O"B
M34I&*B=:SU9]DJ"IB^F-Q+X;G/:000> >D\R(0+JN-?OZWJ6Y9=ZIBO7[*H5
M2>5< B\!<F#DU_L0P"47P 2M.%?1)],:5CN0U26X]@'!<ER)= "RW_",_NGC
M3[C 53BC@[W*GVNQ^/QR2NC5V:X[WZSG3-O"(":.=?AUG:)H$:+GA241$JK6
MG1V#")RZX6,LX(TGI2Y&E+?Q1FX+XHF)H@L/X+WFH)Q&^EW6X(4WFBZ38$KK
MX+#Q$:8%<G]^XI0(Z<!*WZ1M'C_XE?[/1,2,/#C@)HBZFK>.CW"6[$"1C)FB
ML+3V!G:C;%J'8%+P/!R<WEZ2#4WXD3.V.PEF_'SM/F0<)5M[,'_ZR-4&CXH0
MJT$H2?J2N0071(3"N0VZEAY$Z_UCO>1JM]B:U:J.0=U\Y^NOCU=]+N_,8I1S
MREM((A=0I63P@26HO7@I*)]":.YPMR+^I'.R0S"[/2=[3/'WX*9L**<?WB1R
MN!!%QCHO4M;YTTE%"(H[$%HP'U1@J%KO7+U'0"^YUJ."X*&[L;=$.H#3_HR[
M/?8BOSL+BU_#Y^LQUM9[ZT-R=2IZ#8Z3AE#J,SZFDO :A12M8\,QSC$MN ^
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M;2SWQV W7 B]P&<?QMVD9%ZMUQ>?+S-Q#U+?_[6D('1^-C__^IZ"T1FJ7)Q
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M:)Z]9^@. =>S%.R&M)/*W1]/(N,_B+OZA_I+)![]O__S_P%02P,$%     @
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M5NTB";&(J*TS<1W$&8-,Q&[-B47$7:AX3E*XWJ+&HBF.5[#((Z*?3 WD,5?
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M6@9!IFRTUU+B%JD3J0V>VV,DR-(!!/V1(:-"],&.(2%@"YYZTCM7')L/[O;
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MUNS[::/PGRTFSE]=E]VKZXIAFVWMXW*[NKL9Z%FV59QL+Q\6Z)0F[PN-PF)
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MQ7I?J-M5;GNA>^N'FO*_^&IDOE_M_ M02P,$%     @ #8,)5:6W1YBC=0
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M^)7.3T?[2GMOL=.1OTAC;7H%VM6F2-+@C-[F?$\E<W[YJ$KF@5?JZ;W>K:E
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M];FQ^CAV4!@C-M2V 3Q35#Q;">2V;E118DA.8I%5L(YNDW6]#M0"KJFL/2&
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M%6+L7^A['K_[K,P7.HK'7&IO+O7E,9=ZS*5^P[G4(=R\X3.I&H!H[6,*)#O
MN*.']WF1N0:XIT]EVP4X!MWX@6?GXXBXL1(\AMV^@;#;[V.0QY<O2"!K.,)1
M%G?+8I05CRB/*7+D^R7>L4N$ 4#>7\3*A)@/MM,[Y4NPL*V,M>)]"#>/NHW@
M^T4E_M;ZS_0^4\<%[KKA[H3H%] P/,H.?'X#4R.L$3#K^)K4WTK3"%+DC0@S
M=\-L9OAR?]0(%Z#J.)BI1/BE"^_N#E!J]QWOCD0^J'I\T5:/K:G\HKFG[A6^
MEQ:\8_;NUD=^7PZACSTJ.5?)?1Q>R9V?/'_9Q 68 -_@6JZKN,9JOOL':1W,
MS$#N"+:UTMMW;F>Z94WV*()&?#19K]4\X:X>)//VM5WU.WGZ0L"13BZ&((Q.
MU72O04L7$E;(:DXI^]IO2(=^E-/AC[+$#Z@9-G< ,RTIA^K,VI&1<"BZ&3AH
M&G>C[4 ,51F\@?0PT\U:Z:3H%N%:VQ&OPC^B&74=B; S^)QR=_C]V<N+%U1%
M#XHE(Q*EGF2#1,RY4[@+461.\&U?DK&&'9S:/E9E<KO;")".!%T.ZB1*L<1W
MN7*4L@%0&LY00U. Y5"O[H3JXB?_RHN/<!K?Q#D2@<?P6.S\4F=HXE*.$\T8
MS:#>->MD6Y/=LE@H;&?J!4?($"&QXY.@&WJ)#C-$K *B8\=5B5D2X#]=4G;\
MFVM-Y?ZO5L@\QJP+657DJ3@$U]/=QAY6O'.6T>_$:RO#3+?"OELTM(D0/#RX
M(X5=[V$M,KW2.##)4^(#XS@OYCXU2C.C [<T]S,?DI<1UP7U,^:%9?XV3/?@
M\N+ EG6"A0V9*@5H)BP@ID?1P@&!.F7T+;]$F\CDZ,"9X(C-W0=#D*I.I:_>
MS+AC$A 7>(CQ&.0;11V'RIR]'J:.(8#Q'.24E%ET"Q%NNI@)OM7,H]O/0&-M
MNY*I3JVSZ:_H:,2"RACAO_)BFX@ N#W$Z#"'?_[3Y?,?\T*GPG7M;YL#YXYS
M3,Y05M:%>O I">V$%![TPI&,#*&PC"9.9\K.*:/[R_.=<]J:O+!3JGG@Y73J
M,#F0/H$__,Z8:)/ Q& ES&SKM$?B27$;(6D9ZX[?-JTZ)BS[$Y9GI\>,Y3%C
M^6UE++^P@_%LE+T^02*+G/W-QC=[J9 .U+4;4?<W34ZCYIZ6&RI.@PV'NH?T
M);N=^A965Q%CTU">;;%Z,=1]3.G6-JR=LGD1]GM^IFUYU/?Z8ABC?T6\J/"&
MLSS_B/'X8LM3T&CQT '/LGSHXFP27:Y#3U0XK7;Q'CV#(:UI$RA"#:>M0J?W
M:BA^F]N=52^??@U_#85-IY^M3@S[[D*\Q9V[AUV,F)T_MAXQK(3O2R6PVJOJ
MN[]I4'KW@SJ;DIZ,A MZ$(#Y/<[W7JU(&^;\KG:D8^T^^FUSH[WR>*F&ZE:_
M6^1&^ <'=/S"?'2ND9OUL]HNA<1:NJ&('P>NRR:/;4=@A^BR]^-GGMBB_D5=
MH4NOGS,-]N!N[J=\)(XWE-!EF1#9>"84@DY!_T-::M\ZTY@4])\$@XCN]]WE
MW+TVC3XUMASF3KG?+KR'?;U0"6W:-K=S,X 9F<A2"6=Q7O-&IHALMR%Q\'MS
M^,UIR'H:5>#[Y2X'3"+='US4)EBQ1"YLGD3N?C568R"@'=,JDP$L6K#;_H\]
M!XG,Y#9HAF4W=9U$$U/"ZVW4S9ZH2GM,#9/?/F?VX,_08W=<V.L(<6.=!@?T
M0(?C'?Y%)HB@KG8ZK?L)=NWQ>>RR'5N:P%,^ZJ#+>2=VD2;RZ*Y!A+OXI7MM
MG)(;MN!O/U>[<5N:LNFEW^^X?0ZU]-U#[**:WFT;/R3G]($']6:#2Q)3UM]:
MLW]F2:4C>\.8C]V>OQW7%PWOW2=\U#7$QXLA=3^M)Y#4$R[MG]0'CJFTX7#'
MF,HQIL(QE<I#[!FH4H<2LMLU[-?/HI;<?B:,Q@_%QZ,.*ATF!5D3MFFD[$4R
M:7;1SW4J8SM2$2*-1EAV(*94H&-$5!RPUR!V3E:S=0RIWL]KT_58H9XCG.'L
M[ AG.,(9OBTXP_ :>00J>>2QV\A7T_CO^ZMJ5"IN^R<OH<SQ+\?\%87CH"+O
MT+5HSR=5OVYJ6_B';DF.8..:N*ZTC!Q/:JYM 7$3$6/]N<9>=^B*-F]2<*-A
MV_8O;#79J\3YR1^GP]Y>GMO![^8115BOA*<+C&.W*== 4OGJ 81OR-*Q+03#
M.\2R+Y.IJ3D8Y.T3M",Q(<T&V@=INK\30Q?0#-@R+T<UT,!W^6$'?CB&/QNF
MW_.G)? &"B;>C[1@OPC98U 9< 6X+7FY2^I+3J]T4WHZ'"JY1<W=UE=;]-77
M1<;#GYF+DZ=L'#F<_ W<[($*I.$M3QW%=.=V!,CDJZ!G0%Q@ZGXPB7/IY]/1
M:!L/=I(YS;VYAXJ;S=0NVL5D3JTR!:8%S]$(,@?2Y8;UI J6*ZR(Z<(II)M*
M8>12Z:@H2<D*35(2<D(B&7DO^M:P5R""%_,NK3X4)[LFAYL<U98X,]2U:;T"
MC,K5E.7AM!P6EDJC4Q/U>KGX)+!+ELRY@X*Z_8I2+M]JLB$-_N)5HK#JS6E$
MVG4/K1#6U(>0S+J;E:JX6>><^U.0J86JA;5#^Y&$Z9BAON'5<72 ;L5SC>7Y
M;5\#S3/47422);6?U>YB0-,=\=GY9#VUS)YSY;KXTE;*W'_:YXXW^7"KGEI%
MORMJ&MV8J>LG&VK&'-SL $PJ&:%R$NJ2#8$->Z_-_BF=\N10)?8(1+:.<KES
M_ J78T0BVXZ')39MEX@%-O,JS3%\7@3@P]3J$^1TEZ#^4B+7>;FCQ/WF).X'
M3RSRZFTU,&@MM<]=<M YH[I01P0HG0[C$6%4 ?8B4SE+:SETMIC1PD<EYCR;
M^/1\8V#R3E%[]P"$K,%QEW3PK=732E[0R_P2001.#(?JL+,AX?4[7^/P1?[P
M,M\$B.T)P//&J_3:[L[A>LY]N:.)E" $[:/@F7EWW)_PI)I9YU2:",428QG6
M&Y65D08(*TW$P*T9*^J_V*4R.L0IRS"1=LP^PB*1*^E0D41I7.O"OH8@?27-
MXS"*6%*E(HE@;(XAI[LE=9VHSS'7W\[UGQ]S_<=<_S'7_\UFF1I:Y)51,@,I
MPW^V>M(8-YQ*&O?5@?Q]H=#^TCU:Q:%RV)2P#PJ:GV"VH8-Q#C+=*I GW.+4
MU7YTT=F/;.X1KBQL6-9DBB,U["Q-RE6/U^#R?^;6+<"K0/.QMF]HP6B=UQB4
M$%_->3:_598'V(1&."@HC.'0M5XY=*TO3^&_V]+)8<$;KA$JJW5V([+1Y\E@
M*:@MWM&D9^=/_],P!;<=14P7*-(%<A-)58/WA"F*2B?8;C0YL+A6>PR-I]8I
M7$!(;Y5@,V&8+G%/P1IXJQGE"#ML?0W)IUM+1Q,[/>"^X5O*KA4-W&.^-;84
M<Q)LW0"5TT"VS\:R*(!U1(93*C!O'@BY,/QVUJOD7K[H4+M=C]@_X4[!VCOO
MF/R4N<FH;9E,<9+%2 )M@-@<LNCH]S/M*!CQ&PL79I&<"$#7RYM"3R>W*[PL
M8<//$ANVM %IY/G"_[*A3/O,82N31%=C<^1<X5GS5FJV0^[QY,5]9;.[PTL7
M@QJV4U+J5UW41=7JNF[*",QO^Q%(/E;YT+W+X36IR4DW=!$5R'%-Y3MPI]1B
M((7:/%&=%5>M6BK<:@X'H7LI1JBHNH)<KT\7?]U*&RM,L;#.4MK!2)Q\<X,.
M402QZ!+4+<DR$:BX_>YSI'37,#=U@52 MBS.KG5!:VT3_'*H/T2WP:NZ8JG\
MO_,9$[5.\"L9VI<F6ND^4!]>_>^K(?:I3/V4;!_0X76F2P',3+J3'AG<PRSA
M;<U;%^:452*2_V-$?+% Z0^W^34'(P*SF^=A<'YZ]IQKM,RU&&U9YW-#/\]5
MTZ(RM14I*LAV29D3;J(?2=<OA7LH37'ZC>)V[!PD*,4K02G5,'E+BD\R9R3+
M?]99^N'_/'E_$KS&NJW*-9P^%!1W%F;)G^$8%8PN ^.K5J:Z.G?9++F_/=X%
MKHSJ:I47R<,&)8> 9<S'H#:X_)&9XT8 &OC-H$7)V/!H1,EFZPY<>[5VZ,VX
MY74!"UG<\1X:S\< !"KA'$B:9_K>.BM+Z1IW*/HWOI!^*DZ40X_ZS,_Y-"H%
MM8N"*LTB%"09!<(  Z!,TAWJ.Y:4+Z('G4]6TVFK HQL:#KJC* E,U794\,A
M3[=*C!M[E&S*"X6\A5D6]-\2W2*74+JU84S^QYBP>(\6FJ,'$MD$1.I<QE12
M%GK"7?G;-Q 27:C"V7'HJRCM_O5G"I4O+$.>CX>1\A7(Z"S"VEN_U^FA2^D1
M,4]>74=)ZO0E?$]':MB$$:$XZ>A_5&H31#Q$E#X5'4(6'GN) N[2!#_>VIP3
M'G/R8\FFR)[D8+YJ)^*Q,"G?.!6"TX/]']'-\,'8UD8KE?I(+/0SPGIP?Y2(
M>YNC+9H7%)ZATENQEI=@&&Q1->*^^1U>KYPG$ABYUGV64@E96DWI[D*N,VCI
MF2IGJY?^*!6.KH?[I:M[M'N[/__IZ<L?1\)TJ=V=,%CE-V"8%T.L?!A(1[5$
M(H55])%Z=NN.(2Y(1V\02B!CAWM85<LTXVQIHNJ7Y>8(@PN^%*_#6SGQ:C3W
M/K4H=[U ).%O4-9[3;R,6%/H">:%^-\49G:^B_.R\@FSZ+UUR;F[V<TC[]KP
M_G9FS%]>9[!/R<5U'\;E,)E"\%;$]+B,28IN%G5JVP[0/I=>Z3WD1CRU5?/8
M4I Q98B2>0V0+*+/\($+4!["7-<X5;O/4G/^<>(H@X._9]Y>NL3.!<8R9PQ<
M8FA8LP>3<(>84(Z>#UMOE-D]4PE]!S;0RRJO1X..\Q[3__WI_XMC^O^8_O^V
MTO^/9E]VZU)/?#8#QY)9%#$J L[I-'.3U\BG2+FSZR1/(S?KY<0'2ZME'YC'
M]ALOFOHU#WZ;P>08TIQ?<TK#PB+]DF3)&NZ/L7TU5%ENRT(7CLU@7E<TRMP;
M/25+?0!L-+\V37$UR9TA/M!Q*(O.<[HA1@V[ZR=.3:[S0G78(+L'!K?(_,AA
MQ[@([[V1IK1>Z6#1: ;K6@CPDUR8@ 0A;AJTV2.( 4EM=^@BI!/? >)*QY[Q
MK_5FH%F+;BD_2S9)K$IO1#*S]I5L$OZP F OQA, ^R4I8S!5HTSE]<''(T84
M]?HGV_AOBSQ6"DQ[\AW>@PO2<K('$G_^R,@7$ >I)Q8@'J6KA]N1=#R[W(8Q
M &=.%1'X;.!C?6WAU1$%OE[IKG08)$"1^DHO 8KZOVO';]#\F!VC 'MB=XR1
M6&\6Q,-%]K[D;^I?[9UC"$#9E%$O-7;<&$.HO6VK-WM3T85:PG]3J1 S #MN
MM,,EBUXO'-!Q,!8,HTC'' U%-'5I&/BH,[I\KE-_,*Z:('?"-\XJF"C\:$2M
M3L]<A$FPMFNEF<(9C*+?%6Z5X^&<C"-$ITZ60^S DU!RC61:9%6)2TJ!!TV2
M JL.,JN<!O,\IA75*];<-O[6M;$535?+B;MO?KI-G&M34-?P5L<&F/-F:D7*
M*I$L$\EJF\VX<HN#[*#T8/SD7%9#KR+3B.-BUZGP[<0IO%0,>DD5!>?+&<RZ
MX5)^$1W[/R'L.7&&Q+C(T_ZFZ=JT)R9/./H:D\.] RP,-"\*2L;3[KKW+.PJ
MY#D,A3LBO_:]PVG.)/J#P1-W*41&('C^$FD97;@I*A8OH,W&KI:^N%$"$.[J
M9^Z20&F%W8ID8S\[QO(Z0T:_T&*F,?$JV1$^N\2@:P/FH0Y:NY'J74T+7)"_
M:[8BK(Q.DH#QL;5=\[Y-A+7[EA[VNV3HMT)(&.%\Y-!BTSZ> "T1OBX3>$0X
M,#@(;VQ[<M@D I 14-[ A[0%&0X=8*XGO2UTT%J6> #BFJQ$4S@C.*]F]VU[
MUS;N"'^+L2+-#H^)1LQ'-:UJ:A2I=0^S&M24V<)>8G[2LD&"I=\PCC913,DJ
M@R%UV4?MB43LJ!YH7D@W;OZ!$4J-,]-Z)IXUW;B'1 P9P\Y>(!_BC6Y93M.4
M%Z9)1997B60'FU_%48V=+XUL*#7"$X4DNEA@4."$M?#,NLT'"0E[H2%AB!RJ
M?K_):'?_MZ1S!*\3M ?@^^;SN4'I'?,6=@%EVP@_:]0@<8LF":QDL6T<T'D*
M+:_=$J77-MVT9L%R& $R'KH85&,0@T\I$,!M*F!E/N!!XWJ6 3E=/=>TNP\7
M(P'06;Y6W!X+1QZ;D1OKW*G_@:L<D@G32K&)#!!QZNU%72TT8<,BPHA!:$X_
MGGJ"KMJ^ TV3'0EE'''2.&3:R#??K\CYB,VZX-&I)> 6!8LZ39_0"YL?$#P?
MH<'^YU.GX%#'-)R,_M8/CSL#=F&V*SE[+%>[P?74,.1V"D?SH\*1H]=1;G)Q
M27#V*J>FI0V-$X90*;CT[,*M2X_H&%"Z,D4[AO0:EM<,]H(RE9OM6>#(CIG@
MQO81\VX[Q>_21-6!X?AUV7])#C/2PKYD>,0^[, ^7!ZQ#T?LPQ'[\(CZDPJ5
M69\8GN3"U%R;,)I7#N_F0QOZ5Q2%X.^,C-L9DV)-T28#V#:9;AN2/#>*EM0L
M5QP>NIVW&-[.NSQY3H;>SV &9:AK)#+!U=G!/XSM,ABXWB.!--F(:+G$! IH
M[)^BI A^B8J/J@K^FVK9)T[.I=&D@BR<:2NRT]R/[(9TSPFWD)004N0"(A=)
M 28&/0HI*F%/\R\D_*4)^[!D'BM[YF"D;A7\ST2*U^&8@$K*6HZ6]JN,W5E.
MB5L0$ZW_ ?,4PMQ3]1"=1';VR>BTQ!>6VAH+9J<^M&.>"[<LY;NVUH<L:DPM
M<\DA#KUG0OC(Z]E!B<)'N=2E2[QL/&0>) ]OPC67E/3@9>9FYZXC",-!@@-Q
MZELC;XV;I1$-W'8.59$D\7[%1 L8S 04;KQ$UJ[,-A783O%UF_5"SHH)NTS*
MZ:%+IN7PDNG\Y,4SEDRHJTA#795E7:##-H9*'V[BS+C[R'>0V$6S/9P]F!;E
M7_%G^$<';MSX7B$'G_)@B2?.$,N;.;"T%KB9&RW.+6:LRT?^F.4WX!8M.4RE
M;C%/I9LSVA:L^-VLAD%CU'T=8>ZY=*DWX $<%D,'4QI48[IH Y(4"Y1)4CBE
M3+O&>[-"H+L=F*;Y< 8WWV]T+&Q(EH /23XZA@]GC$-16#I+-#ZAK6^M\B6S
M?AK)U_<Z+.K6,"*I72B2\F/96&%COG ABTT'?-I2HL R;-U=T8/NW=1H2,CV
ME%9579LBO[&D*3AFE*PF!BR3P&0/QN56:2I;VI')";8HF-E<=@.7A&?(]AQV
M<S-.!-'.#,Y8UBYV]7]GN[XB22=OO,3R+#5S,!):,!2)-A\D9[,T![>GL,.M
ME#'I&EUN8^EHJ%(OB.NB@''"">#8-1\+O%80DA3^) G75ZC#8=N_3>5<TXK0
M$E*HRYF,$+F(E0O&3/!TS,DDZ:MX87KBQK1ZC6/7RL3-XJ2(ZS7W9RW=UN_X
MJKT8Z/*D)3U#R1;,=01:#\_?_R$:13%2 B\5@;YPOG#V'72,(5SP2V]PM@2G
MPW=NEO;DA=OV!M^0#1#*4UB;HO^MD#EB9ZVZ'K5IH".'0O>^[DH+'KKQL!J#
M\<!9O'_!\J'YC=-N@>-#F0]"I@<;;I7,DLI"PDR"Q^2Z&\3UWK'I[3<OY<'$
M2Z60C"H-6;; /LP1GI(3H00,*B-0](TS.PY^FL..;)2; 8E'DS<;,:]5Q$8_
M7N"%0'4HE:Z@+LUDT& 2S'#)^MAW\NH+S:\N<0E6HJ1 W?'VY.@M\'0GX-33
M6*:8L6TQ=:5$&_(_M)0X)$<[W C.UC9(G;0\W7OM;1R%HM5>@-VGL6"&,I*N
M-J'6BJPSF(/F5*4.:;DP':KYJ.MPPT$ SK+"?;L+(P/.A*+J$'X]=G[UOE]'
MM\FZ7NND!AXJ.(YN.Q:WX-I=)3AEF#=M>/MRG\APV%F63M@ % VG3/AUGC [
M4PH6%NM.QZ5UC1IR81HEJ=;T9BN1^K#7!7:)*Z?FF#;.*1UE*7*5>^N>B\*Q
MKG]Y[?]0AR5-@2R_I,=%*CF<+D\'[XDVTS7UT7;F"DR953YWYLKKR]"!@3MT
M=3P\W[MNR_0&&<*+/$OBX+6T"1RJO4?FTB1AE"KA@BQ-_R8^FJ:@BUQ(C89
MLLAD Y"Q;]V724M$)%8R$X# S!".5$J(&M"],9+LP2UO;D[ QCQ9YM=TR"7
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M08\@=F+<U(^\N#:8D+ZN%:'_[5Z2+X@\#=:IPZ5IY=]DT"7>=^Z,VH C3-;
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M]V5RH4_3T X7.T$:..AGC18G1% 9I5_?27D8*OLPV(J) YAH%J$%573[1"/
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MY=?11S1-4)33!@D,.*]:Y1*P3&/"Y$E(Q;>"]@^P-'N+DIN GLPM-YU&"[T
M.X2A<+!-__RGR^<_FM;/69X5F*JB;^,5&H-&ZWOW,=TDJ1,$]WS@EJANY@!'
MB4P+_SQY?P+KDR)[/RBPG&DEY^WWLNZ%\RS2YOP$FBIZ,!$A+17"Z9#/D:F?
M$; 6Q\B4)&T%LS@!<TK?]G+7;8E$UQ1RNHM%1@)C\ @Y2._L6AU/[[HO"*JU
M]$O!;27JJ\[JLHY2+;IA3U#K9S9[D/?3LM<MB&L[J]*M 1AZSB,C(/>=#I %
M07\,[K'-D0]PYLK@5W43O,MAZ3_7+,G'8):<GH_:+&'9,+A=XK*9HJ) X=MO
M.#^Z"@*_LW#H5'V1Z^K2MOC5@2)Q!^;&A-&]$9S>J"1HN_LUX$1Q$_LY_SK:
MZN?[PMVM>VA)?IN$:YA"O.S&&(*[7D?%5@0_O7X*TIJZK-:%;M[+BK'$4B^D
MYRF,,[JG_CMX/V<S!H$R<C]G7)6*[:HAHQ+WS_<>_L;]X[AQNS=N&HV 1H1:
MY[RY56ERBZ[GSUE\$IR?GCT/WG!0VW*,?!6U:<7PF_'%R<4(L0=4S_26FV1Q
M1'8L8I0<(!2D48\@A>UZ24,/Y<_3T^:?G2S*YDW=B\_.-.!,?_ ,S@"V'2,3
MB"_%& I6?\;(H<,I.@1M.HBSR)1TOB&?"P_0:_#/CIW =V ,GATQ!D>,P;>%
M,1A>(Y;#:\3G)R_&QWWR#D.2"<4 QN56.'C2'OJV!^ WB0[?[ZB&W]@O3B['
M9^IU;^Q1D)Q\"N^;2_41]+S;OG0??;_W*#_NFK]OEO>C'O[ C=+1;VV8?V9)
M-;@Z&<?<#$HH9 +=F@GC\?3I[/#UZ?#]79$D[^DA'>]1*-5QS-(A,H>U5;VS
MM)]N4S@WV6U8=&VD;]:ZN!E>_%R,L>[1=@$9WG"W8^D@\&HRY#.SE-LB&K:R
MO0.A=C#02O%3X:4B7%1._SWX#7T[_(9^?G)V-LX-?7GZ="3;&4;2LYG]1G0G
M V*7'FA';H??D:.D0?87>OA]V=$%$33]V<L+%IK1FJH(0H/?*>I4REZ*'HI%
M1%DJVMD'+U:'[[*,\>SQA?TD5K5QJM_>X==#;N>\&%<CZO=7[XZ.VJ@B,H2
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M7V^YFQ"D%7JP-%[90@8Q/1<ETZFTI?#L)7:OHA2(@=@)9CKLKYZ_<(5S@_&
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MV[O"S:IS/"&TV\,30MN=?5,S<B<[ D0GI=/2E%2!-0?R&2GB0FNJ4M/CN+_
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M':G:<)-SC1:VAIQHP]3P&>D[TL9HQ 0<5.V>Z> "_!6"H[/7:^OX@I*,$-2
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MA[;G*D.&8X8GX8\C7%2[!!SKD_&4!T6?12G$%=[.TG0;B\&T\ZINS"(7D;L
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M,3$P<2YH=&U02P$"% ,4    "  -@PE5>GV7QY %   :&P  '0
M    @ %E<@4 97AE;#(P,C(P-C,P97AH:6)I=#,R,3$P<2YH=&U02P$"% ,4
M    "  -@PE5I;='F*-U  #,L0, '               @ $P> 4 97AE;#(P
M,C(V,S!E>&AI8FET,3 Q,3!Q+FAT;5!+ 0(4 Q0    (  V#"57:BIXOQ00
M $ X   <              "  0WN!0!E>&5L,C R,C8S,&5X:&EB:70Q,#(Q
M,'$N:'1M4$L! A0#%     @ #8,)59O6P1.F-@  .]L! !P
M ( !#/,% &5X96PR,#(R-C,P97AH:6)I=#$P,S$P<2YH=&U02P4&      T
,#0"+ P  ["D&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
